PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Gando, S				Gando, Satoshi			Hemostasis and Thrombosis in Trauma Patients	SEMINARS IN THROMBOSIS AND HEMOSTASIS			English	Article						trauma; traumatic brain injury; coagulopathy; fibrinolysis; disseminated intravascular coagulation; acute coagulopathy trauma shock; fat embolism syndrome	DISSEMINATED INTRAVASCULAR COAGULATION; MULTIPLE ORGAN DYSFUNCTION; SEVERE HEAD-INJURY; SERIAL LABORATORY EXAMINATION; CENTRAL-NERVOUS-SYSTEM; PROTEIN-C PATHWAY; BRAIN-INJURY; FAT-EMBOLISM; ACUTE COAGULOPATHY; TISSUE FACTOR	Hemostasis and thrombosis in trauma patients consist of physiological hemostasis for wound healing and the pathological reaction of disseminated intravascular coagulation (DIC). Whole body trauma, isolated brain injury, and fat embolism syndrome, if extremely severe, can cause DIC and affect a patient's prognosis. Shock-induced hyperfibrinolysis causes DIC with the fibrinolytic phenotype, contributing to oozing-type severe bleeding. If uncontrolled, this phenotype progresses to thrombotic phenotype at the late stage of trauma, followed by microvascular thrombosis, leading to organ dysfunction. Another type of pathological hemostatic change is acute coagulopathy of trauma shock (ACOTS), which gives rise to activated protein C-mediated systemic hypocoagulation, resulting in bleeding. ACOTS occurs only in trauma associated with shock-induced hypoperfusion and there is nothing to suggest DIC in this phenomenon. This review will provide information about the recent advances in hemostasis and thrombosis in trauma and will clarify the pathogeneses of the pathological processes observed in trauma patients.	[Gando, Satoshi] Hokkaido Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Div Acute & Crit Care Med, Sapporo, Hokkaido 0608638, Japan	Gando, S (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Div Acute & Crit Care Med,Kita Ku, N15W7, Sapporo, Hokkaido 0608638, Japan.	gando@med.hokudai.ac.jp	Gando, Satoshi/T-7407-2019	Gando, Satoshi/0000-0002-3525-0750			Abrams ST, 2013, AM J RESP CRIT CARE, V187, P160, DOI 10.1164/rccm.201206-1037OC; Ammollo CT, 2011, J THROMB HAEMOST, V9, P1795, DOI 10.1111/j.1538-7836.2011.04422.x; Arai F, 2007, ANESTHESIOLOGY, V107, P509, DOI 10.1097/01.anes.0000278898.62036.5f; Armstead VE, 1999, ANESTHESIOLOGY, V91, P1844, DOI 10.1097/00000542-199912000-00039; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; BERGENTZ SVEN-ERIK, 1961, ACTA CHIR SCAND, V122, P21; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; Bouillon B, 2010, J TRAUMA, V68, P225, DOI 10.1097/TA.0b013e3181c42815; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chandler WL, 2010, AM J CLIN PATHOL, V134, P90, DOI 10.1309/AJCP3WPOYSKK6BFE; CLARK JA, 1980, J NEUROSURG, V52, P266, DOI 10.3171/jns.1980.52.2.0266; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Davenport R, 2013, TRANSFUSION, V53, p23S, DOI 10.1111/trf.12032; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Dunbar NM, 2009, TRANSFUSION, V49, P2652, DOI 10.1111/j.1537-2995.2009.02335.x; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; Engelman DT, 1996, WORLD J SURG, V20, P5, DOI 10.1007/s002689900001; Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Esmon CT, 1999, BEST PRACT RES CL HA, V12, P343, DOI 10.1053/beha.1999.0029; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Fuchs TA, 2011, BLOOD, V118, P3708, DOI 10.1182/blood-2011-01-332676; GANDO S, 1995, CRIT CARE MED, V23, P1835, DOI 10.1097/00003246-199511000-00009; GANDO S, 1995, J TRAUMA, V39, P660, DOI 10.1097/00005373-199510000-00007; Gando S, 2013, J THROMB HAEMOST, V11, P826, DOI 10.1111/jth.12190; Gando S, 2012, J Thromb Haemost, V10, P2593; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943; Gando S, 1990, Nihon Geka Gakkai Zasshi, V91, P17; Gando S, 1997, THROMB HAEMOSTASIS, V77, P278; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; Gando S, 2001, CRIT CARE MED, V29, P262, DOI 10.1097/00003246-200102000-00006; Gando S, 2011, ANN SURG, V254, P10, DOI 10.1097/SLA.0b013e31821221b1; Gando S, 2010, CRIT CARE MED, V38, pS35, DOI 10.1097/CCM.0b013e3181c9e31d; Gando S, 2009, J TRAUMA, V67, P381, DOI 10.1097/TA.0b013e3181a84f63; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hayakawa M, 2011, SURGERY, V149, P221, DOI 10.1016/j.surg.2010.06.010; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618; Ito T, 2007, J THROMB HAEMOST, V5, P109, DOI 10.1111/j.1538-7836.2006.02255.x; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Kao SJ, 2007, CLIN SCI, V113, P279, DOI 10.1042/CS20070011; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kumar MA, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0391-y; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P1389, DOI 10.1097/TA.0b013e318270d595; Lemarchant S, 2012, NEUROPHARMACOLOGY, V62, P749, DOI 10.1016/j.neuropharm.2011.10.020; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; Levi M, 2007, CRIT CARE MED, V35, P2191, DOI 10.1097/01.CCM.0000281468.94108.4B; Lowenstein CJ, 2005, TRENDS CARDIOVAS MED, V15, P302, DOI 10.1016/j.tcm.2005.09.005; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Maegele M, 2014, SHOCK, V41, P21, DOI 10.1097/SHK.0000000000000088; Manson J, 2012, BRIT J SURG, V99, P12, DOI 10.1002/bjs.7717; MARDER VJ, 2006, HEMOSTASIS THROMBOSI, P1571; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Mellor A, 2001, ANAESTHESIA, V56, P145, DOI 10.1046/j.1365-2044.2001.01724.x; Miller P, 2011, AM J FOREN MED PATH, V32, P291, DOI 10.1097/PAF.0b013e31822a6428; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Noel P, 2013, SEMIN HEMATOL, V50, P259, DOI 10.1053/j.seminhematol.2013.06.009; OKAJIMA K, 1994, AM J HEMATOL, V45, P16, DOI 10.1002/ajh.2830450104; Oshiro A, 2014, CRIT CARE, V18, DOI 10.1186/cc13816; Osterud B, 2006, SEMIN THROMB HEMOST, V32, P11, DOI 10.1055/s-2006-933336; Owings JT, 1997, SEMIN THROMB HEMOST, V23, P17; RISEBOROUGH EJ, 1976, CLIN ORTHOP RELAT R, P248; SALDEEN T, 1970, J TRAUM, V10, P273, DOI 10.1097/00005373-197004000-00001; SALDEEN T, 1970, J TRAUM, V10, P287, DOI 10.1097/00005373-197004000-00002; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schrieber M, 2007, J TRAUMA, V63, P1261; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061; SERCKHANSSEN A, 1965, ACTA PATHOL MIC SC, V65, P31, DOI 10.1111/apm.1965.65.1.31; Shier M R, 1980, Surg Annu, V12, P139; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STUMP DC, 1990, SEMIN THROMB HEMOST, V16, P260, DOI 10.1055/s-2007-1002678; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; TOVI D, 1973, ACTA NEUROL SCAND, V49, P152; Wu Xue-Hai, 2003, Chin J Traumatol, V6, P114; Yanagida Y, 2013, SURGERY, V154, P48, DOI 10.1016/j.surg.2013.02.004; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	99	19	21	1	16	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0094-6176	1098-9064		SEMIN THROMB HEMOST	Semin. Thromb. Hemost.	FEB	2015	41	1					26	34		10.1055/s-0034-1398378			9	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CA9HZ	WOS:000349234700005	25602698				2021-06-18	
J	Greco, T; Hovda, DA; Prins, ML				Greco, Tiffany; Hovda, David A.; Prins, Mayumi L.			Adolescent TBI-Induced Hypopituitarism Causes Sexual Dysfunction in Adult Male Rats	DEVELOPMENTAL NEUROBIOLOGY			English	Article						pituitary; adolescent; hormone; traumatic brain injury; sexual dysfunction	TRAUMATIC BRAIN-INJURY; PITUITARY-FUNCTION; BEHAVIOR; CHILDHOOD; PUBERTY; TESTOSTERONE; CHILDREN; AMYGDALA	Adolescents are at greatest risk for traumatic brain injury (TBI) and repeat TBI (RTBI). TBI-induced hypopituitarism has been documented in both adults and juveniles and despite the necessity of pituitary function for normal physical and brain development, it is still unrecognized and untreated in adolescents following TBI. TBI induced hormonal dysfunction during a critical developmental window has the potential to cause long-term cognitive and behavioral deficits and the topic currently remains unaddressed. The purpose of this study was to determine if four mild TBIs delivered to adolescent male rats disrupts testosterone production and adult behavioral outcomes. Plasma testosterone was quantified from 72 hrs preinjury to 3 months postinjury and pubertal onset, reproductive organ growth, erectile function and reproductive behaviors were assessed at 1 and 2 months postinjury. RTBI resulted in both acute and chronic decreases in testosterone production and delayed onset of puberty. Significant deficits were observed in reproductive organ growth, erectile function and reproductive behaviors in adult rats at both 1 and 2 months postinjury. These data suggest adolescent RTBI-induced hypopituitarism underlies abnormal behavioral changes observed during adulthood. The impact of undiagnosed hypopituitarism following RTBI in adolescence has significance not only for growth and puberty, but also for brain development and neurobehavioral function as adults. (c) 2014 Wiley Periodicals, Inc. Develop Neurobiol 75: 193-202, 2015	[Greco, Tiffany; Hovda, David A.; Prins, Mayumi L.] Semel Inst, Dept Neurosurg, Los Angeles, CA 90095 USA; [Greco, Tiffany; Hovda, David A.; Prins, Mayumi L.] Semel Inst, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hovda, David A.; Prins, Mayumi L.] Semel Inst, Interdept Program Neurosci, Los Angeles, CA 90095 USA; [Hovda, David A.] Semel Inst, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Greco, T (corresponding author), Semel Inst, Dept Neurosurg, Los Angeles, CA 90095 USA.	tgreco@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NFL Charities, UCLA Brain Injury Research Center, Marilyn and Austin Anderson Fellowship	Contract grant sponsor: NFL Charities, UCLA Brain Injury Research Center, Marilyn and Austin Anderson Fellowship.	Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Ahmed EI, 2008, NAT NEUROSCI, V11, P995, DOI 10.1038/nn.2178; Andersen SL, 2003, NEUROSCI BIOBEHAV R, V27, P3, DOI 10.1016/S0149-7634(03)00005-8; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Becu-Villalobos D, 1997, CELL MOL NEUROBIOL, V17, P699, DOI 10.1023/A:1022542221535; BOBROW NA, 1971, ARCH SEX BEHAV, V1, P329, DOI 10.1007/BF01638061; Cunningham RL, 2007, NEUROSCIENCE, V150, P609, DOI 10.1016/j.neuroscience.2007.09.038; De Lorme KC, 2012, BRAIN RES, V1460, P33, DOI 10.1016/j.brainres.2012.04.035; Dyer K, 2013, DISABIL REHABIL, V29, P29; Edelstein RS, 2011, HORM BEHAV, V60, P248, DOI 10.1016/j.yhbeh.2011.05.007; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giuliano F, 2000, NEUROSCI BIOBEHAV R, V24, P517, DOI 10.1016/S0149-7634(00)00020-8; Greco T, 2013, J NEUROTRAUM, V30, P1983, DOI 10.1089/neu.2013.2990; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HART BL, 1983, HORM BEHAV, V17, P274, DOI 10.1016/0018-506X(83)90026-0; Heather NL, 2012, J CLIN ENDOCR METAB, V97, P599, DOI 10.1210/jc.2011-2284; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; HUFFER V, 1964, ANN INTERN MED, V61, P255, DOI 10.7326/0003-4819-61-2-255; Hull EM, 2007, HORM BEHAV, V52, P45, DOI 10.1016/j.yhbeh.2007.03.030; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; Kaulfers AMD, 2010, J PEDIATR-US, V157, P894, DOI 10.1016/j.jpeds.2010.07.004; Khadr SN, 2010, CLIN ENDOCRINOL, V73, P637, DOI 10.1111/j.1365-2265.2010.03857.x; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Lauzier F., 2012, CRIT CARE S1, V16, pP299; LEWIS VG, 1977, ADOLESCENCE, V12, P1; Moon RJ, 2009, ARCH DIS CHILD, V94, P699, DOI 10.1136/adc.2008.145235; Moon RJ, 2010, J NEUROTRAUM, V27, P1827, DOI 10.1089/neu.2010.1408; MORENO J, 2012, INT J PSYCHOL S1, V47, P684; Moreno J, 2012, INT J PSYCHOL, V47, P574; Moreno JA, 2013, NEUROREHABILITATION, V32, P69, DOI 10.3233/NRE-130824; NAZIAN SJ, 1980, ARCH ANDROLOGY, V4, P283, DOI 10.3109/01485018008986974; Newman SW, 1999, ANN NY ACAD SCI, V877, P242, DOI 10.1111/j.1749-6632.1999.tb09271.x; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; PRIMUS RJ, 1989, DEV PSYCHOBIOL, V22, P633, DOI 10.1002/dev.420220608; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Rose SR, 2012, PITUITARY, V15, P267, DOI 10.1007/s11102-011-0360-x; Schneider M, 2013, CELL TISSUE RES, V354, P99, DOI 10.1007/s00441-013-1581-2; Schulz KM, 2004, HORM BEHAV, V45, P242, DOI 10.1016/j.yhbeh.2003.12.007; Sisk CL, 2005, FRONT NEUROENDOCRIN, V26, P163, DOI 10.1016/j.yfrne.2005.10.003; Sisk CL, 2004, NAT NEUROSCI, V7, P1040, DOI 10.1038/nn1326; SIZONENKO P C, 1987, Pediatrician, V14, P191; Somerville LH, 2010, BRAIN COGNITION, V72, P124, DOI 10.1016/j.bandc.2009.07.003; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; vansEden CG, 1990, PROG BRAIN RES, V85, P169; Vetter-O'Hagen CS, 2012, DEV PSYCHOBIOL, V54, P523, DOI 10.1002/dev.20610; Wamstad JB, 2013, BRAIN INJURY, V27, P200, DOI 10.3109/02699052.2012.672786	51	19	20	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8451	1932-846X		DEV NEUROBIOL	Dev. Neurobiol.	FEB	2015	75	2					193	202		10.1002/dneu.22218			10	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	AY8JC	WOS:000347798900006	25066665				2021-06-18	
J	Rabinowitz, AR; Merritt, VC; Arnett, PA				Rabinowitz, Amanda R.; Merritt, Victoria C.; Arnett, Peter A.			The Return-to-Play Incentive and the Effect of Motivation on Neuropsychological Test-Performance: Implications for Baseline Concussion Testing	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							SPORT-RELATED CONCUSSION	Athletes may be less engaged in baseline cognitive testing in the absence of a powerful return-to-play incentive. The present study sought to evaluate whether athletes' level of motivation (1) influences baseline test performance and (2) changes across pre- and post-injury assessments. We found a significant relationship between examiners' ratings of athletes motivation toward testing and baseline cognitive test performance. Athletes, but not controls, demonstrated increased motivation between tests. These findings suggest that baseline test performance may underestimate true premorbid abilities for a subset of athletes.	[Rabinowitz, Amanda R.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Rabinowitz, AR (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Goddard Labs 306, 3710 Hamilton Walk, Philadelphia, PA 19104 USA.	rabinowitz.a@gmail.com		Merritt, Victoria/0000-0001-5683-4168	Benton Meier Neuropsychology Scholarship from the American Psychological Foundation	This work was supported in part by the Benton Meier Neuropsychology Scholarship from the American Psychological Foundation to Amanda R. Rabinowitz. The opinions expressed herein are those of the authors and do not necessarily reflect the opinions of the American Psychological Foundation.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Lovell MR., 2000, IMPACT IMMEDIATE POS; Psychological Corporation, 2001, WECHSLER TEST ADULT; Rabinowitz A. R., 2012, NAT AC NEUR NASHV TE; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d	7	19	19	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JAN 2	2015	40	1			SI		29	33		10.1080/87565641.2014.1001066			5	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CA6IR	WOS:000349015800006	25649777				2021-06-18	
J	Chong, SL; Harjanto, S; Testoni, D; Ng, ZM; Low, CYD; Lee, KP; Lee, JH				Chong, Shu-Ling; Harjanto, Sumitro; Testoni, Daniela; Ng, Zhi Min; Low, Chyi Yeu David; Lee, Khai Pin; Lee, Jan Hau			Early Hyperglycemia in Pediatric Traumatic Brain Injury Predicts for Mortality, Prolonged Duration of Mechanical Ventilation, and Intensive Care Stay	INTERNATIONAL JOURNAL OF ENDOCRINOLOGY			English	Article							RELIABLE OUTCOME PREDICTOR; ADMISSION HYPERGLYCEMIA; CONCOMITANT INJURIES; PROGNOSTIC-FACTORS; BLOOD-GLUCOSE; CHILDREN; HYPOTHERMIA; SEVERITY; INSULIN; MODELS	We aim to study the association between hyperglycemia and in-hospital outcomes among children with moderate and severe traumatic brain injury (TBI). This retrospective cohort study was conducted in a tertiary pediatric hospital between 2003 and 2013. All patients < 16 years old who presented to the Emergency Department within 24 hours of head injury with a Glasgow Coma Scale (GCS) <= 13 were included. Our outcomes of interest were death, 14 ventilation-free, 14 pediatric intensive care unit( PICU-) free, and 28 hospital-free days. Hyperglycemia was defined as glucose > 200mg/dL (11.1 mmol/L). Among the 44 patients analyzed, the median age was 8.6 years (interquartile range (IQR) 5.0-11.0). Median GCS and pediatric trauma scores were 7 (IQR 4-10) and 4 (IQR 3-6), respectively. Initial hyperglycemia was associated with death (37% in the hyperglycemia group versus 8% in the normoglycemia group, p - 0.019), reduced median PICU-free days (6 days versus 11 days, p - 0.006), and reduced median ventilation-free days (8 days versus 12 days, p = 0.008). This association was however not significant in the stratified analysis of patients with GCS <= 8. Conclusion. Our findings demonstrate that early hyperglycemia is associated with increased mortality, prolonged duration of mechanical ventilation, and PICU stay in children with TBI.	[Chong, Shu-Ling; Lee, Khai Pin] KK Womens & Childrens Hosp, Dept Emergency Med, Singapore 229899, Singapore; [Chong, Shu-Ling; Ng, Zhi Min; Lee, Khai Pin; Lee, Jan Hau] SingHealth, Duke NUS Paediat Acad Clin Programme, Singapore 229899, Singapore; [Harjanto, Sumitro] Duke NUS Grad Med Sch, Singapore 169857, Singapore; [Testoni, Daniela] Univ Fed Sao Paulo, Escola Paulista Med, Div Neonatal Med, BR-04020060 Sao Paulo, SP, Brazil; [Ng, Zhi Min] KK Womens & Childrens Hosp, Dept Paediat Med, Singapore 229899, Singapore; [Low, Chyi Yeu David] KK Womens & Childrens Hosp, Dept Neurosurg, Singapore 229899, Singapore; [Lee, Jan Hau] KK Womens & Childrens Hosp, Childrens Intens Care Unit, Singapore 229899, Singapore	Chong, SL (corresponding author), KK Womens & Childrens Hosp, Dept Emergency Med, 100 Bukit Timah Rd, Singapore 229899, Singapore.	chong.shu-ling@kkh.com.sg	NOBRE, DANIELA TESTONI COSTA/D-6657-2017	NOBRE, DANIELA TESTONI COSTA/0000-0001-7629-4904; Lee, Jan Hau/0000-0002-8430-4217			Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; [Anonymous], 2014, INJURY PREVENTION CO; Asilioglu N, 2011, J PEDIAT-BRAZIL, V87, P325, DOI [10.2223/JPED.2097, 10.1590/S0021-75572011000400009]; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Elkon B, 2014, PEDIATR CRIT CARE ME, V15, P623, DOI 10.1097/PCC.0000000000000170; Heather NL, 2012, CLIN ENDOCRINOL, V77, P357, DOI 10.1111/j.1365-2265.2012.04376.x; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kan CH, 2009, MALAYS J MED SCI, V16, P25; KING LR, 1971, ANN SURG, V173, P337, DOI 10.1097/00000658-197103000-00003; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; Macrae D, 2014, NEW ENGL J MED, V370, P107, DOI 10.1056/NEJMoa1302564; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; PARISH RA, 1988, J TRAUMA, V28, P517, DOI 10.1097/00005373-198804000-00017; Pentelenyi T, 1979, Acta Neurochir Suppl (Wien), V28, P103; PENTELENYI T, 1979, INJURY, V10, P201, DOI 10.1016/0020-1383(79)90009-3; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; Rake AJ, 2010, PEDIATR CRIT CARE ME, V11, P707, DOI 10.1097/PCC.0b013e3181e88b1f; Rhine T, 2012, J TRAUMA ACUTE CARE, V73, pS248, DOI 10.1097/TA.0b013e31826b0062; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saadat SMS, 2012, CHILD NERV SYST, V28, P1773, DOI 10.1007/s00381-012-1753-5; Scavarda D, 2010, CHILD NERV SYST, V26, P1555, DOI 10.1007/s00381-010-1150-x; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Stewart TC, 2013, J TRAUMA ACUTE CARE, V75, P836, DOI 10.1097/TA.0b013e3182a685b0; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Yuan F, 2012, J TRAUMA ACUTE CARE, V73, P137, DOI 10.1097/TA.0b013e31824b00ac	37	19	21	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-8337	1687-8345		INT J ENDOCRINOL	Int. J. Endocrinol.		2015	2015								719476	10.1155/2015/719476			8	Endocrinology & Metabolism	Endocrinology & Metabolism	CI9XI	WOS:000355123400001	26074963	DOAJ Gold, Green Published			2021-06-18	
J	Delahunty, SE; Delahunt, E; Condon, B; Toomey, D; Blake, C				Delahunty, Sinead E.; Delahunt, Eamonn; Condon, Brian; Toomey, David; Blake, Catherine			Prevalence of and Attitudes About Concussion in Irish Schools' Rugby Union Players	JOURNAL OF SCHOOL HEALTH			English	Article						health communication; concussion; rugby; adolescents	SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; KNOWLEDGE TRANSFER; FOOTBALL PLAYERS; MANAGEMENT; IMPLEMENTATION; PREVENTION; GUIDELINES; EDUCATION	BACKGROUNDYouth rugby players represent 45.2% (N=69,472) of the Irish rugby union playing population. The risk and consequences of concussion injury are of particular concern in these young athletes, but limited epidemiological data exists. This study investigated annual and lifetime prevalence of concussion in an Irish schoolboy rugby union cohort. METHODSAn anonymous cross-sectional survey of youth rugby players was conducted. Diagnosed concussion was defined as an incident where diagnosis was confirmed by a health professional or coach. Demographics, prevalence, and attitudes to concussion were collated. Data were analyzed with descriptive statistics, chi-square test, t-tests, Mann-Whitney tests, and logistic regression. RESULTSOverall, 304 youth (aged 12-18years) responded. Lifetime prevalence of diagnosed concussion was 19.4%, with annual (2010) prevalence 6.6%. Approximately 25.4% of players with diagnosed concussions returned to play without medical advice. Internal motivation (11.8%) was the predominant factor in feeling pressure to play while concussed. A desire for further concussion education was expressed by 89.5% of participants. CONCLUSIONSReform is required to prevent and manage concussion injuries among youth players in the rugby union, including mandatory education specific to concussion and implementation of return-to-play protocols. These findings have relevance for governing bodies, coaches, clinicians, schools, parents, and rugby union players.	[Delahunty, Sinead E.; Delahunt, Eamonn; Condon, Brian; Toomey, David; Blake, Catherine] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Hlth Sci Ctr, Dublin 4, Ireland	Delahunty, SE (corresponding author), Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Hlth Sci Ctr, Dublin 4, Ireland.	sineaddelahunty@gmail.com; eamonn.delahunt@uccl.ie; bcondon89@gmail.com; cdavidtoomey2@gmail.com; cblake@uccl.ie	Blake, Catherine/M-6728-2016	Blake, Catherine/0000-0002-0600-629X; Delahunt, Eamonn/0000-0001-5449-5932			Ahmed O, 2013, J COMMUNITY INFORM; Australian Rugby, SMARTRUGBY; Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Bramley HP, 2011, CLIN PAEDIAT PHILA, DOI 10.1177/0009922811425233; Chalmers DJ, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80046-X; Covassion T, 2012, J SCH HLTH; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hart E, 2011, FAC SPORTS EX MED AN; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Hollis SJ, 2011, BR J SPORTS MED, DOI 10.1136/bjsm.2011.085332; Immediate Post-concussive Assessment and Cognitive Testing (ImPACT) Applications Inc, IMPACT TEST; International Rugby Board (IRB), IRB CONC POST REC RE; International Rugby Board (IRB), IRB CONC GUID; Irish Rugby Football Union, 2009 2010 LANDM YEAR; Irish Rugby Football Union, GUID CONC RUGB UN; Irish Rugby Football Union, STOP REST INFORM RET; Irish Rugby Football Union, SAFE RUGB; Johnson LSM, 2011, J SCH HLTH, V82, P180; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; New Zealand Rugby Union, RUGBYSMART; O'Rourke KP, 2007, INJURY, V38, P104, DOI 10.1016/j.injury.2006.06.010; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; South African Rugby Union, BOKSMART; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Ulster Rugby, PLAY WELF SEM; US Department of Health and Human Services Centers for Disease Control and Prevention and National Center for Injury Prevention and Control Division of Injury Response, HEADS CONC YOUTH SPO; Viikari-Juntara E, 1996, SCAND J WORK ENV HEA, V22, P259; Viljoen W, 2012, BRIT J SPORT MED, V46, P692, DOI 10.1136/bjsports-2012-091278	44	19	21	0	59	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4391	1746-1561		J SCHOOL HEALTH	J. Sch. Health	JAN	2015	85	1					17	26		10.1111/josh.12219			10	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	AU7DP	WOS:000345761200003	25440449				2021-06-18	
J	Hinson, HE; Puybasset, L; Weiss, N; Perlbarg, V; Benali, H; Galanaud, D; Lasarev, M; Stevens, RD				Hinson, Holly E.; Puybasset, Louis; Weiss, Nicolas; Perlbarg, Vincent; Benali, Habib; Galanaud, Damien; Lasarev, Mike; Stevens, Robert D.		Neuro Imaging Coma Emergence Reco	Neuroanatomical basis of paroxysmal sympathetic hyperactivity: A diffusion tensor imaging analysis	BRAIN INJURY			English	Article						Diffusion tensor imaging; paroxysmal sympathetic hyperactivity; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SUDDEN-DEATH; INSULAR CORTEX; NERVOUS-SYSTEM; STROKE; RAT; ARRHYTHMIAS; TOMOGRAPHY; STRESS; STATE	Primary objective: Paroxysmal sympathetic hyperactivity (PSH) is observed in a sub-set of patients with moderate-to-severe traumatic brain injury (TBI). The neuroanatomical basis of PSH is poorly understood. It is hypothesized that PSH is linked to changes in connectivity within the central autonomic network. Research design: Retrospective analysis in a sub-set of patients from a multi-centre, prospective cohort study Methods and procedures: Adult patients who were <3 weeks after severe TBI were enrolled and screened for PSH using a standard definition. Patients underwent multimodal MRI, which included quantitative diffusion tensor imaging. Main outcomes and results: Principal component analysis (PCA) was used to resolve the set of tracts into components. Ability to predict PSH was evaluated via area under the receiver operating characteristic (AUROC) and tree-based classification analyses. Among 102 enrolled patients, 16 met criteria for PSH. The first principle component was significantly associated (p = 0.024, AUROC = 0.867) with PSH status even after controlling for age and admission GCS. In a classification tree analysis, age, GCS and decreased FA in the splenium of the corpus callosum and in the right posterior limb of the internal capsule discriminated PSH vs no PSH with an AUROC of 0.933. Conclusions: Disconnection involving the posterior corpus callosum and of the posterior limb of the internal capsule may play a role in the pathogenesis or expression of PSH.	[Hinson, Holly E.] Oregon Hlth & Sci Univ, Dept Neurol & Emergency Med, Portland, OR 97239 USA; [Puybasset, Louis] Hop La Pitie Salpetriere, Dept Anesthesiol & Intens Care, Paris, France; [Puybasset, Louis; Perlbarg, Vincent; Benali, Habib] INSERM UPMC, Lab Imagerie Fonct, UMR S 678, Paris, France; [Weiss, Nicolas] Hop La Pitie Salpetriere, Neurol Intens Care Unit, Paris, France; [Galanaud, Damien] Hop La Pitie Salpetriere, Dept Radiol, Paris, France; [Lasarev, Mike] Oregon Hlth & Sci Univ, Oregon Inst Occupat Heath Sci, Portland, OR 97239 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Baltimore, MD USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Crit Care Med, Baltimore, MD USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	Hinson, HE (corresponding author), Oregon Hlth & Sci Univ, Neurol & Neurocrit Care, 3181 SW Sam Jackson Pk Rd,CR 127, Portland, OR 97239 USA.	hinson@ohsu.edu	Hinson, Holly/Q-2268-2019; WEISS, Nicolas/Q-2394-2019; Weiss, Nicolas/E-7345-2011	Hinson, Holly/0000-0003-1598-9782; WEISS, Nicolas/0000-0001-5155-196X; Lasarev, Michael R/0000-0002-1896-2705	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5K12HL108974-03]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000128]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000128] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL108974] Funding Source: NIH RePORTER	The project described was supported in part by Award Number 5K12HL108974-03 from the National Heart, Lung, and Blood Institute. This publication was supported by Oregon Clinical and Translational Research Institute (OCTRI), grant number (UL1TR000128) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).	Ay H, 2006, NEUROLOGY, V66, P1325, DOI 10.1212/01.wnl.0000206077.13705.6d; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; Beissner F, 2013, J NEUROSCI, V33, P10503, DOI 10.1523/JNEUROSCI.1103-13.2013; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Colivicchi F, 2004, STROKE, V35, P2094, DOI 10.1161/01.STR.0000138452.81003.4c; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Gianaros PJ, 2012, HUM BRAIN MAPP, V33, P1700, DOI 10.1002/hbm.21315; HACHINSKI VC, 1992, ARCH NEUROL-CHICAGO, V49, P697, DOI 10.1001/archneur.1992.00530310039010; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; Laowattana S, 2006, NEUROLOGY, V66, P477, DOI 10.1212/01.wnl.0000202684.29640.60; Laxe S, 2013, BRAIN INJURY, V27, P1383, DOI 10.3109/02699052.2013.823648; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; PEREZTREPICHIO AD, 1993, STROKE, V24, P691, DOI 10.1161/01.STR.24.5.691; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Saper CB, 2002, ANNU REV NEUROSCI, V25, P433, DOI 10.1146/annurev.neuro.25.032502.111311; SAPER CB, 1982, J COMP NEUROL, V210, P163, DOI 10.1002/cne.902100207; Seifert F, 2013, HUM BRAIN MAPP, V34, P1768, DOI 10.1002/hbm.22035; Soros P, 2012, LANCET NEUROL, V11, P179, DOI 10.1016/S1474-4422(11)70291-5; Sullivan RM, 1999, J NEUROSCI, V19, P2834; TerHorst GJ, 1996, EUR J NEUROSCI, V8, P2029, DOI 10.1111/j.1460-9568.1996.tb00723.x; Tokgozoglu SL, 1999, STROKE, V30, P1307, DOI 10.1161/01.STR.30.7.1307; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4; Zhang ZH, 1997, BRAIN RES, V760, P243, DOI 10.1016/S0006-8993(97)00284-9	32	19	22	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	4					455	461		10.3109/02699052.2014.995229			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CF8JE	WOS:000352803300006	25565392	Green Accepted			2021-06-18	
J	Muresanu, DF; Ciurea, AV; Gorgan, RM; Gheorghita, E; Florian, SI; Stan, H; Blaga, A; Ianovici, N; Iencean, SM; Turliuc, D; Davidescu, HB; Mihalache, C; Brehar, FM; Mihaescu, AS; Mardare, DC; Anghelescu, A; Chiparus, C; Lapadat, M; Pruna, V; Mohan, D; Costea, C; Costea, D; Palade, C; Bucur, N; Figueroa, J; Alvarez, A				Muresanu, Dafin F.; Ciurea, Alexandru V.; Gorgan, Radu M.; Gheorghita, Eva; Florian, Stefan I.; Stan, Horatiu; Blaga, Alin; Ianovici, Nicolai; Iencean, Stefan M.; Turliuc, Dana; Davidescu, Horia B.; Mihalache, Cornel; Brehar, Felix M.; Mihaescu, Anca S.; Mardare, Dinu C.; Anghelescu, Aurelian; Chiparus, Carmen; Lapadat, Magdalena; Pruna, Viorel; Mohan, Dumitru; Costea, Constantin; Costea, Daniel; Palade, Claudiu; Bucur, Narcisa; Figueroa, Jesus; Alvarez, Anton			A Retrospective, Multi-Center Cohort Study Evaluating the Severity-Related Effects of Cerebrolysin Treatment on Clinical Outcomes in Traumatic Brain Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Cerebrolysin; disability; functional recovery; neuroprotection; clinical outcome; traumatic brain injury	PEPTIDE PREPARATION; CEREBRAL INFARCTION; FUNCTIONAL RECOVERY; NEUROGENESIS; NEURONS; GLUTAMATE; MODERATE; DEATH	Traumatic brain injury (TBI) is a leading cause of death and disability for which there is currently no effective drug therapy available. Because drugs targeting a single TBI pathological pathway have failed to show clinical efficacy to date, pleiotropic agents with effects on multiple mechanisms of secondary brain damage could represent an effective option to improve brain recovery and clinical outcome in TBI patients. In this multicenter retrospective study, we investigated severity-related efficacy and safety of the add-on therapy with two concentrations (20 ml/day or 30 ml/day) of Cerebrolysin (EVER Neuro Pharma, Austria) in TBI patients. Adjunctive treatment with Cerrebrolysin started within 48 hours after TBI and clinical outcomes were ranked according to the Glasgow Outcome Scale and the Modified Rankin Disability Score at 10 and 30 days post-TBI. Analyses of efficacy were performed separately for subgroups of patients with mild, moderate or severe TBI according to Glasgow Coma Scale scores at admission. Compared to standard medical care alone (control group), both doses of Cerebrolysin were associated with improved clinical outcome scores at 10 days post-TBI in mild patients and at 10 and 30 days in moderate and severe cases. A dose-dependent effect of Cerebrolysin on TBI recovery was supported by the dose-related differences and the significant correlations with treatment duration observed for outcome measures. The safety and tolerability of Cerebrolysin in TBI patients was very good. In conclusion, the results of this large retrospective study revealed that early Cerebrolysin treatment is safe and is associated to improved TBI outcome.	[Muresanu, Dafin F.; Palade, Claudiu] Univ Med & Pharm Iuliu Hatieganu, Dept Clin Neurosci, Cluj Napoca 400012, Romania; [Muresanu, Dafin F.] RoNeuro Inst Neurol Res & Diagnost, Cluj Napoca, Romania; [Ciurea, Alexandru V.] Sanador Med Ctr, Dept Neurosurg, Bucharest, Romania; [Gorgan, Radu M.; Brehar, Felix M.] Bagdasar Arseni Emergency Hosp, Dept Neurosurg, Bucharest, Romania; [Gheorghita, Eva; Bucur, Narcisa] Bagdasar Arseni Emergency Hosp, Anesthesiol & Intens Care Dept, Bucharest, Romania; [Florian, Stefan I.; Stan, Horatiu; Blaga, Alin] Univ Med & Pharm Iuliu Hatieganu, Cluj Cty Emergency Hosp, Dept Neurosurg, Cluj Napoca 400012, Romania; [Ianovici, Nicolai; Turliuc, Dana] Prof Dr Nicolae Oblu Emergency Clin Hosp, Dept Neurosurg, Iasi, Romania; [Iencean, Stefan M.] Gr T Popa Univ Med & Pharm, Dept Neurosurg, Iasi, Romania; [Davidescu, Horia B.] Sf Apostol Andrei Emergency Clin Hosp, Dept Neurosurg, Constanta, Romania; [Mihaescu, Anca S.] Sf Apostol Andrei Emergency Clin Hosp, Neurosurg Clin Div, Galati, Romania; [Mihaescu, Anca S.; Mardare, Dinu C.; Anghelescu, Aurelian; Chiparus, Carmen; Lapadat, Magdalena] Bagdasar Arseni Emergency Hosp, Phys Neuralmuscular Rehabil Clin, Bucharest, Romania; [Mohan, Dumitru] Univ Med & Pharm, Dept Neurosurg, Oradea, Romania; [Costea, Constantin; Costea, Daniel] Emergency Clin Hosp, Neurosurg Clin Div, Timisoara, Romania; [Figueroa, Jesus; Alvarez, Anton] Medinova Inst Neurosci, Rehasalud Rehabil Clin, La Coruna, Spain; [Figueroa, Jesus] Hosp Clin Univ, Rehabilitat Dept, Santiago De Compostela, Spain; [Alvarez, Anton] QPS Holdings, Dept Clin Res, La Coruna, Spain	Muresanu, DF (corresponding author), Univ Med & Pharm Iuliu Hatieganu, Dept Clin Neurosci, Victor Babes St 8, Cluj Napoca 400012, Romania.	dafinm@ssnn.ro	Muresanu, Fior-Dafin/AAI-8120-2021; Florian, Ioan Stefan I/D-5934-2016; Brehar, Felix M/B-8095-2011	Florian, Ioan Stefan I/0000-0001-7127-0946; Iencean, Stefan Mircea/0000-0002-6230-8540			AKAI F, 1992, HISTOL HISTOPATHOL, V7, P213; Alvarez XA, 2013, FUTUR NEUROL, V8, P175, DOI 10.2217/FNL.12.95; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281; Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; Alvarez XA, 2008, J NEURAL TRANSM, V115, P683, DOI 10.1007/s00702-008-0024-9; Alvarez XA, 2009, INT J NEUROPSYCHOPH, V12, P867, DOI 10.1017/S1461145709990101; Beattie MS, 2010, EUR J NEUROSCI, V32, P290, DOI 10.1111/j.1460-9568.2010.07343.x; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chen CC, 2013, BRIT J NEUROSURG, V27, P803, DOI 10.3109/02688697.2013.793287; Chen HH, 2007, NEUROBIOL AGING, V28, P1148, DOI 10.1016/j.neurobiolaging.2006.05.036; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Fei Z, 1992, CHINESE J NERV MENTA, V18, P6; Georgy GS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064847; HutterPaier B, 1996, J NEURAL TRANSM-SUPP, P267; Konig P, 2006, J NEUROL NEUROCHIR P, V7, P12; Labiche Lise A, 2004, NeuroRx, V1, P46, DOI 10.1602/neurorx.1.1.46; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Muresanu DF, 2011, CNS NEUROL DISORD-DR, V10, P415; Muresanu DF, 2010, J CELL MOL MED, V14, P455, DOI 10.1111/j.1582-4934.2010.01020.x; Onose G, 2009, J Med Life, V2, P350; Patockova J, 2003, PHYSIOL RES, V52, P455; Popescu BO, 2007, J CELL MOL MED, V11, P1225, DOI 10.1111/j.1582-4934.2007.00149.x; Ren J, 2007, RESTOR NEUROL NEUROS, V25, P25; Riley C, 2006, J NEURAL TRANSM, V113, P103, DOI 10.1007/s00702-005-0302-8; Satou T, 2000, J NEURAL TRANSM, V107, P1253, DOI 10.1007/s007020070015; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Valouskova V, 1998, J NEURAL TRANSM-SUPP, P343; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59; Wronski R, 2000, J NEURAL TRANSM-SUPP, P263; Wronski R, 2000, J NEURAL TRANSM, V107, P145, DOI 10.1007/s007020050013; Xiong HG, 1996, BRAIN RES, V737, P188, DOI 10.1016/0006-8993(96)00731-7; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495; Zhang YL, 2013, J NEUROSURG, V118, P1343, DOI 10.3171/2013.3.JNS122061	38	19	19	0	18	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2015	14	5					587	599		10.2174/1871527314666150430162531			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CI8DM	WOS:000354999100005	25924999				2021-06-18	
J	Yeh, DC; Chan, TM; Harn, HJ; Chiou, TW; Chen, HS; Lin, ZS; Lin, SZ				Yeh, Da-Chum; Chan, Tzu-Min; Harn, Horng-Jyh; Chiou, Tzyy-Wen; Chen, Hsin-Shui; Lin, Zung-Sheng; Lin, Shinn-Zong			Adipose Tissue-Derived Stem Cells in Neural Regenerative Medicine	CELL TRANSPLANTATION			English	Article; Proceedings Paper	7th Pan Pacific Sympsosium on Stem Cells and Cancer Research	APR 12-14, 2014	Taichung, TAIWAN			Adipose tissue-derived stem cells (ADSCs); Stroke; Amyotrophic lateral sclerosis; Parkinson's disease; Alzheimer's disease; Huntington's disease; Cavernous nerve injury	TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; CAVERNOUS NERVE INJURY; ACUTE ISCHEMIC-STROKE; ALZHEIMERS-DISEASE; RAT MODEL; IN-VITRO; NEUROGENIC DIFFERENTIATION; HUNTINGTONS-DISEASE; FUNCTIONAL RECOVERY	Adipose tissue-derived stem cells (ADSCs) have two essential characteristics with regard to regenerative medicine: the convenient and efficient generation of large numbers of multipotent cells and in vitro proliferation without a loss of sternness. The implementation of clinical trials has prompted widespread concern regarding safety issues and has shifted research toward the therapeutic efficacy of stem cells in dealing with neural degeneration in cases such as stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, cavernous nerve injury, and traumatic brain injury. Most existing studies have reported that cell therapies may be able to replenish lost cells and promote neuronal regeneration, protect neuronal survival, and play a role in overcoming permanent paralysis and loss of sensation and the recovery of neurological function. The mechanisms involved in determining therapeutic capacity remain largely unknown; however, this concept can still be classified in a methodical manner by citing current evidence. Possible mechanisms include the following: 1) the promotion of angiogenesis, 2) the induction of neuronal differentiation and neurogenesis, 3) reductions in reactive gliosis, 4) the inhibition of apoptosis, 5) the expression of neurotrophic factors, 6) immunomodulatory function, and 7) facilitating neuronal integration. In this study, several human clinical trials using ADSCs for neuronal disorders were investigated. It is suggested that ADSCs are one of the choices among various stem cells for translating into clinical application in the near future.	[Yeh, Da-Chum] China Med Univ, Dept Internal Med, Beigan Hosp, Yunlin, Taiwan; [Chan, Tzu-Min] China Med Univ, Dept Med Educ & Res, Beigan Hosp, Yunlin, Taiwan; [Chan, Tzu-Min] China Med Univ, Dept Med Educ & Res, An Nan Hosp, Tainan, Taiwan; [Harn, Horng-Jyh] China Med Univ, Dept Med, Taichung, Taiwan; [Harn, Horng-Jyh] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Chiou, Tzyy-Wen] Natl Dong Hwa Univ, Dept Life Sci, Hualien, Taiwan; [Chiou, Tzyy-Wen] Natl Dong Hwa Univ, Grad Inst Biotechnol, Hualien, Taiwan; [Chen, Hsin-Shui] China Med Univ, Sch Med, Taichung, Taiwan; [Chen, Hsin-Shui] China Med Univ, Beigang Hosp, Dept Phys Med & Rehabil, Yunlin, Taiwan; [Lin, Zung-Sheng] China Med Univ, Beigan Hosp, Dept Surg, Yunlin, Taiwan; [Lin, Shinn-Zong] China Med Univ Hosp, Ctr Neuropsychiat, Taichung, Taiwan; [Lin, Shinn-Zong] China Med Univ, Grad Inst Immunol, Taichung, Taiwan; [Lin, Shinn-Zong] China Med Univ, Beigan Hosp, Dept Neurosurg, Yunlin, Taiwan; [Lin, Shinn-Zong] China Med Univ, Tainan Municipal An Nan Hosp, Dept Neurosurg, Tainan, Taiwan	Lin, SZ (corresponding author), China Med Univ Hosp, Ctr Neuropsychiat, Taichung, Taiwan.	shinnzong@yahoo.com.tw	Lin, Shinn-Zong/AAX-2379-2020	Chan, Tzu-Min/0000-0002-0140-5240	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW103-TDU-B-212-113002]; CMUBH [R103-012, R103-007]	This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW103-TDU-B-212-113002), CMUBH R103-012, and CMUBH R103-007. The authors declare no conflicts of interest.	Albersen M, 2010, J SEX MED, V7, P3331, DOI 10.1111/j.1743-6109.2010.01875.x; Bartzokis G, 2011, NEUROBIOL AGING, V32, P1341, DOI 10.1016/j.neurobiolaging.2009.08.007; Beck H, 2008, AM J PATHOL, V173, P77, DOI 10.2353/ajpath.2008.070648; Chan TM, 2014, CELL TRANSPLANT, V23, P541, DOI 10.3727/096368914X678409; Chan TM, 2014, CELL TRANSPLANT, V23, P399, DOI 10.3727/096368914X678292; Chen J, 2012, CNS NEUROSCI THER, V18, P847, DOI 10.1111/j.1755-5949.2012.00382.x; Ching JK, 2013, HUM MOL GENET, V22, P1167, DOI 10.1093/hmg/dds524; Chun W, 2007, FRONT BIOSCI-LANDMRK, V12, P733, DOI 10.2741/2097; Chung JY, 2012, J NEUROL SCI, V317, P40, DOI 10.1016/j.jns.2012.02.035; DU Hou-wei, 2009, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V25, P998; Fang Z, 2010, J HUAZHONG U SCI-MED, V30, P75, DOI 10.1007/s11596-010-0113-5; Ferraiuolo L, 2011, NAT REV NEUROL, V7, P616, DOI 10.1038/nrneurol.2011.152; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Gimble JM, 2013, ORGANOGENESIS, V9, P3, DOI 10.4161/org.24279; Gir P, 2012, PLAST RECONSTR SURG, V129, P1277, DOI 10.1097/PRS.0b013e31824ecae6; Goldstein DS, 2013, ADV PHARMACOL, V68, P235, DOI 10.1016/B978-0-12-411512-5.00012-9; Gu HY, 2013, NEUROSCI LETT, V544, P15, DOI 10.1016/j.neulet.2013.02.057; Gutierrez-Fernandez M, 2013, DISCOV MED, V16, P37; Ikegame Y, 2011, CYTOTHERAPY, V13, P675, DOI 10.3109/14653249.2010.549122; Im W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059438; Im Wooseok, 2010, PLoS Curr, V2, DOI 10.1371/currents.RRN1183; Kalantri A, 2010, JAMA-J AM MED ASSOC, V304, P1327, DOI 10.1001/jama.2010.1341; Kalia LV, 2013, ANN NEUROL, V73, P155, DOI 10.1002/ana.23746; Kato A C, 2006, Rev Med Suisse, V2, P1152; Kato A.C., 2006, REV MED SUISSE, V2, P1156; Kim KS, 2014, CELL TRANSPLANT, V23, P1585, DOI 10.3727/096368913X673450; Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045757; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; Lee HJ, 2012, CELL TRANSPLANT, V21, P959, DOI 10.3727/096368911X627516; Lin G., 2011, UROLOGY, V77; Ma T, 2013, CELL TRANSPLANT, V22, pS113, DOI 10.3727/096368913X672181; Marconi S, 2013, NEUROSCIENCE, V248, P333, DOI 10.1016/j.neuroscience.2013.05.034; Maucksch C, 2013, J CELL BIOCHEM, V114, P754, DOI 10.1002/jcb.24432; Moriyama M, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-21; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ohta Y, 2008, CELL TRANSPLANT, V17, P877, DOI 10.3727/096368908786576516; Perez-Gonzalez R, 2011, J ALZHEIMERS DIS, V24, P17, DOI 10.3233/JAD-2011-102070; Ra JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-181; Ra JC, 2011, STEM CELLS DEV, V20, P1297, DOI 10.1089/scd.2010.0466; Raschzok N, 2013, CELL TRANSPLANT, V22, P1959, DOI 10.3727/096368912X661382; Ribo M, 2010, AM J NEURORADIOL, V31, P1899, DOI 10.3174/ajnr.A2221; Roos RAC, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-40; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Safwani WKZW, 2012, APPL BIOCHEM BIOTECH, V166, P2101, DOI 10.1007/s12010-012-9637-4; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Shyu WC, 2007, STROKE, V38, P367, DOI 10.1161/01.STR.0000254463.24655.14; Su B, 2008, CURR ALZHEIMER RES, V5, P525, DOI 10.2174/156720508786898451; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tanzi RE, 2013, J ALZHEIMERS DIS, V33, pS5, DOI 10.3233/JAD-2012-129044; Thomas J, 2008, J NEUROSCI NURS, V40, P69, DOI 10.1097/01376517-200804000-00002; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Xu YD, 2014, J SEX MED, V11, P2439, DOI 10.1111/jsm.12636; Xue S, 2010, NEUROSCI LETT, V473, P186, DOI 10.1016/j.neulet.2010.02.035; Yang YC, 2011, CURR NEUROVASC RES, V8, P1, DOI 10.2174/156720211794520215; You D, 2013, PROSTATE, V73, P278, DOI 10.1002/pros.22567; Yu JM, 2008, STEM CELLS DEV, V17, P463, DOI 10.1089/scd.2007.0181; Zhang HY, 2011, J SEX MED, V8, P437, DOI 10.1111/j.1743-6109.2010.02128.x; Zhou Y, 2013, CYTOTHERAPY, V15, P467, DOI 10.1016/j.jcyt.2013.01.007; Zuk PA, 2010, MOL BIOL CELL, V21, P1783, DOI 10.1091/mbc.E09-07-0589	62	19	22	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2015	24	3			SI		487	492		10.3727/096368915X686940			6	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	CF7RQ	WOS:000352754400015	25647067	Bronze			2021-06-18	
J	Friesland, A; Weng, ZY; Duenas, M; Massa, SM; Longo, FM; Lu, Q				Friesland, Amy; Weng, Zhiying; Duenas, Maria; Massa, Stephen M.; Longo, Frank M.; Lu, Qun			Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75(NTR)	NEUROTOXICOLOGY			English	Article						Chemotherapeutics; Peripheral neuropathy; Rho GTPases; p75(NTR); Kinases and phosphatases	TRAUMATIC BRAIN-INJURY; RHO-KINASE; INDUCED NEUROTOXICITY; ACTIVATED RHOA; SMALL GTPASES; DOUBLE-BLIND; CHEMOTHERAPY; CANCER; PHOSPHORYLATION; NEUROPROTECTION	Cisplatin is an effective and widely used first-line chemotherapeutic drug for treating cancers. However, many patients sustain cisplatin-induced peripheral neuropathy (CIPN), often leading to a reduction in drug dosages or complete cessation of treatment altogether. Therefore, it is important to understand cisplatin mechanisms in peripheral nerve tissue mediating its toxicity and identify signaling pathways for potential intervention. Rho GTPase activation is increased following trauma in several models of neuronal injury. Thus, we investigated whether components of the Rho signaling pathway represent important neuroprotective targets with the potential to ameliorate CIPN and thereby optimize current chemotherapy treatment regimens. We have developed a novel CIPN model in the mouse. Using this model and primary neuronal culture, we determined whether LM11A-31, a small-molecule, orally bioavailable ligand of the p75 neurotrophin receptor (p75(NTR)), can modulate Rho GTPase signaling and reduce CIPN. Von Frey filament analysis of sural nerve function showed that LM11A-31 treatment prevented decreases in peripheral nerve sensation seen with cisplatin treatment. Morphometric analysis of harvested sural nerves revealed that cisplatin-induced abnormal nerve fiber morphology and the decreases in fiber area were alleviated with concurrent LM11A-31 treatment. Cisplatin treatment increased RhoA activity accompanied by the reduced tyrosine phosphorylation of SHP2, which was reversed by LM11A-31. LM11A-31 also countered the effects of calpeptin, which activated RhoA by inhibiting SHP2 tyrosine phosphatase. Therefore, suppression of RhoA signaling by LM11A-31 that modulates p75(NTR) or activates SHP2 tyrosine phosphatase downstream of the NGF receptor enhances neuroprotection in experimental CIPN in mouse model. (C) 2014 Elsevier Inc. All rights reserved.	[Friesland, Amy; Weng, Zhiying; Duenas, Maria; Lu, Qun] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA; [Friesland, Amy; Lu, Qun] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27834 USA; [Weng, Zhiying] Kunming Med Univ, Sch Pharmaceut Sci, Kunming 650500, Peoples R China; [Weng, Zhiying] Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming 650500, Peoples R China; [Massa, Stephen M.] Vet Adm Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; [Massa, Stephen M.] Univ Calif San Francisco, San Francisco, CA 94121 USA; [Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Lu, Q (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA.	luq@ecu.edu			Jean Perkins Foundation;  [NIH/NCI-CA111891];  [CA165202]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R15CA165202, R01CA111891] Funding Source: NIH RePORTER	Dr. Frank Longo is a founder of PharmatrophiX, a company focused on the development of small molecule ligands for neurotrophin receptors. PharmatrophiX Inc has made an unrestricted gift. The authors also wish to acknowledge the grant supports from NIH/NCI-CA111891 (Lu) and CA165202 (Lu) as well as Jean Perkins Foundation (Longo).	Ahnert-Hilger G, 2004, J NEUROCHEM, V90, P9, DOI 10.1111/j.1471-4159.2004.02475.x; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; CASCINU S, 1995, J CLIN ONCOL, V13, P26, DOI 10.1200/JCO.1995.13.1.26; Cheng C, 2008, EXP NEUROL, V212, P358, DOI 10.1016/j.expneurol.2008.04.023; Chomiak T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007754; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Dergham P, 2002, J NEUROSCI, V22, P6570; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; DOTTI CG, 1988, J NEUROSCI, V8, P1454; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Feng YZ, 2009, J VASC SURG, V50, P675, DOI 10.1016/j.jvs.2009.05.017; GREGG RW, 1992, J CLIN ONCOL, V10, P795, DOI 10.1200/JCO.1992.10.5.795; Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203; Gutierrez-Gutierrez G, 2010, CLIN TRANSL ONCOL, V12, P81, DOI 10.1007/S12094-010-0474-z; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; Jaggi AS, 2012, TOXICOLOGY, V291, P1, DOI 10.1016/j.tox.2011.10.019; James SE, 2008, NEUROTOXICOLOGY, V29, P605, DOI 10.1016/j.neuro.2008.04.008; James SE, 2010, NEUROTOXICOLOGY, V31, P188, DOI 10.1016/j.neuro.2009.12.010; Jones SB, 2004, J NEUROSCI, V24, P8510, DOI 10.1523/JNEUROSCI.1264-04.2004; Kaley TJ, 2009, BRIT J HAEMATOL, V145, P3, DOI 10.1111/j.1365-2141.2008.07558.x; Koeppen S, 2004, J CANCER RES CLIN, V130, P153, DOI 10.1007/s00432-003-0524-9; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Kranenburg O, 1997, J CELL SCI, V110, P2417; Longo FM, 2008, CNS NEUROL DISORD-DR, V7, P63, DOI 10.2174/187152708783885093; Massa SM, 2006, J NEUROSCI, V26, P5288, DOI 10.1523/JNEUROSCI.3547-05.2006; McDonald ES, 2005, NEUROBIOL DIS, V18, P305, DOI 10.1016/j.nbd.2004.09.013; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Pace A, 2007, J CLIN ONCOL, V25; Pace A, 2003, J CLIN ONCOL, V21, P927, DOI 10.1200/JCO.2003.05.139; Pace A, 2010, NEUROLOGY, V74, P762, DOI 10.1212/WNL.0b013e3181d5279e; Park SB, 2008, CURR MED CHEM, V15, P3081, DOI 10.2174/092986708786848569; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; RUSHTON WAH, 1951, J PHYSIOL-LONDON, V115, P101, DOI 10.1113/jphysiol.1951.sp004655; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Smyth JF, 1997, ANN ONCOL, V8, P569, DOI 10.1023/A:1008211226339; Song XY, 2006, J NEUROCHEM, V96, P833, DOI 10.1111/j.1471-4159.2005.03564.x; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Strumberg D, 2002, ANN ONCOL, V13, P229, DOI 10.1093/annonc/mdf058; Ta LE, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-9; Tatsumi S, 2005, NEUROSCIENCE, V131, P491, DOI 10.1016/j.neuroscience.2004.10.022; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; VANDERHOOP RG, 1990, NEW ENGL J MED, V322, P89, DOI 10.1056/NEJM199001113220204; VANDERHOOP RG, 1990, CANCER-AM CANCER SOC, V66, P1697, DOI 10.1002/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO;2-G; Verdu E, 1999, MUSCLE NERVE, V22, P329, DOI 10.1002/(SICI)1097-4598(199903)22:3<329::AID-MUS5>3.0.CO;2-8; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	50	19	19	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	DEC	2014	45						81	90		10.1016/j.neuro.2014.09.005			10	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	AX5GQ	WOS:000346955100009	25277379	Green Accepted			2021-06-18	
J	Larsson, IM; Wallin, E; Kristofferzon, ML; Niessner, M; Zetterberg, H; Rubertsson, S				Larsson, Ing-Marie; Wallin, Ewa; Kristofferzon, Marja-Leena; Niessner, Marion; Zetterberg, Henrik; Rubertsson, Sten			Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome	RESUSCITATION			English	Article						Cardiac arrest; Therapeutic hypothermia; Prognostication; Biomarkers	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; EUROPEAN-RESUSCITATION-COUNCIL; MILD THERAPEUTIC HYPOTHERMIA; AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; COMATOSE SURVIVORS; PRACTICAL SCALE; S-100B; GUIDELINES	Aim of the study: To investigate serum levels of glial fibrillary acidic protein (GFAP) for evaluation of neurological outcome in cardiac arrest (CA) patients and compare GFAP sensitivity and specificity to that of more studied biomarkers neuron-specific enolas (NSE) and S100B. Method: A prospective observational study was performed in three hospitals in Sweden during 2008-2012. The participants were 125 CA patients treated with therapeutic hypothermia (TH) to 32-34 degrees C for 24 hours. Samples were collected from peripheral blood (n = 125) and the jugular bulb (n = 47) up to 108 hours post-CA. GFAP serum levels were quantified using a novel, fully automated immunochemical method. Other biomarkers investigated were NSE and S100B. Neurological outcome was assessed using the Cerebral Performance Categories scale (CPC) and dichotomized into good and poor outcome. Results: GFAP predicted poor neurological outcome with 100% specificity and 14-23% sensitivity at 24, 48 and 72 hours post-CA. The corresponding values for NSE were 27-50% sensitivity and for S100B 21-30% sensitivity when specificity was set to 100%. A logistic regression with stepwise combination of the investigated biomarkers, GFAP, did not increase the ability to predict neurological outcome. No differences were found in GFAP, NSE and S100B levels when peripheral and jugular bulb blood samples were compared. Conclusion: Serum GFAP increase in patients with poor outcome but did not show sufficient sensitivity to predict neurological outcome after CA. Both NSE and S100B were shown to be better predictors. The ability to predict neurological outcome did not increased when combining the three biomarkers. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Larsson, Ing-Marie; Wallin, Ewa; Rubertsson, Sten] Uppsala Univ, Dept Surg Sci Anaesthesiol & Intens Care, SE-75185 Uppsala, Sweden; [Kristofferzon, Marja-Leena] Univ Gavle, Fac Hlth & Occupat Studies, Dept Hlth & Caring Sci, SE-80176 Gavle, Sweden; [Kristofferzon, Marja-Leena] Uppsala Univ, Dept Publ Hlth & Caring Sci, SE-75122 Uppsala, Sweden; [Niessner, Marion] Roche Diagnost GmbH, Penzberg, Germany; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik] Inst Neurol, London WC1N 3BG, England	Larsson, IM (corresponding author), Uppsala Univ, Dept Surg Sci Anaesthesiol & Intens Care, SE-75185 Uppsala, Sweden.	ing-marie.larsson@surgsci.uu.se		Kristofferzon, Marja-Leena/0000-0002-1864-5777	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish State Support for Clinical Research; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation	The authors thank Birgit Klapperich, Roche Diagnostics GmbH, Penzberg, Germany for collaboration. The authors also thank Marie Sellert Rydberg, Dept. of Anaesthesia & Intensive Care Falun for collaboration and data collection and Elisabeth Pettersson, research assistants, Anaesthesiology & Intensive Care, Uppsala University. We also wish to thank the Department of Surgical Sciences, Anaesthesiology & Intensive Care, Uppsala University, for institutional grants, and The Uppsala University Hospital. The study was supported by grants from the Swedish Research Council, Swedish State Support for Clinical Research, the Knut and Alice Wallenberg Foundation.	[Anonymous], 2002, N ENGL J MED, V346, P549; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bouwes A, 2012, ANN NEUROL, V71, P206, DOI 10.1002/ana.22632; Cronberg T, 2013, RESUSCITATION, V84, P867, DOI 10.1016/j.resuscitation.2013.01.019; Cummins RO, 1997, RESUSCITATION, V34, P151, DOI 10.1016/S0300-9572(97)01112-X; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Hayashida H, 2010, NEUROCRIT CARE, V12, P252, DOI 10.1007/s12028-009-9318-5; JENNETT B, 1975, LANCET, V1, P480; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Lu-Emerson C, 2010, NEUROREHABILITATION, V26, P35, DOI 10.3233/NRE-2010-0534; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mlynash M, 2013, NEUROCRIT CARE, V19, P161, DOI 10.1007/s12028-013-9867-5; Mortberg E, 2011, ACTA ANAESTH SCAND, V55, P1132, DOI 10.1111/j.1399-6576.2011.02505.x; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Oddo M, 2014, CRIT CARE MED, V42, P1340, DOI 10.1097/CCM.0000000000000211; Oksanen T, 2009, RESUSCITATION, V80, P165, DOI 10.1016/j.resuscitation.2008.08.017; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Rana OR, 2013, INT J CARDIOL, V168, P1322, DOI 10.1016/j.ijcard.2012.12.016; Rundgren M, 2012, CRIT CARE, V16, DOI 10.1186/cc11244; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Sandroni C, 2013, RESUSCITATION, V84, P1324, DOI 10.1016/j.resuscitation.2013.06.020; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scolletta S, 2012, EXPERT REV CLIN PHAR, V5, P687, DOI [10.1586/ECP.12.64, 10.1586/ecp.12.64]; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; Stammet P, 2013, J AM COLL CARDIOL, V62, P851, DOI 10.1016/j.jacc.2013.04.039; Sun Y, 2013, SCAND J CLIN LAB INV, V73, P601, DOI 10.3109/00365513.2013.830326; TEASDALE G, 1974, LANCET, V2, P81; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Zellner T, 2013, RESUSCITATION, V84, P1382, DOI 10.1016/j.resuscitation.2013.03.021; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263	38	19	22	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	DEC	2014	85	12					1654	1661		10.1016/j.resuscitation.2014.09.007			8	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	AW9UQ	WOS:000346603700010	25260722				2021-06-18	
J	Walcott, BP; Khanna, A; Kwon, CS; Phillips, HW; Nahed, BV; Coumans, JV				Walcott, Brian P.; Khanna, Arjun; Kwon, Churl-Su; Phillips, H. Westley; Nahed, Brian V.; Coumans, Jean-Valery			Time interval to surgery and outcomes following the surgical treatment of acute traumatic subdural hematoma	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Aspirin; Craniectomy; Gastrostomy; Subdural; Surgery; Tracheostomy; Trauma	BRAIN-INJURY; PROGNOSTIC-FACTORS; MORTALITY; RISK; MORBIDITY; THERAPY	Although the pre-surgical management of patients with acute traumatic subdural hematoma prioritizes rapid transport to the operating room, there is conflicting evidence regarding the importance of time interval from injury to surgery with regards to outcomes. We sought to determine the association of surgical timing with outcomes for subdural hematoma. A retrospective review was performed of 522 consecutive patients admitted to a single center from 2006-2012 who underwent emergent craniectomy for acute subdural hematoma. After excluding patients with unknown time of injury, penetrating trauma, concurrent cerebrovascular injury, epidural hematoma, or intraparenchymal hemorrhage greater than 30 mL, there remained 45 patients identified for analysis. Using a multiple regression model, we examined the effect of surgical timing, in addition to other variables on in-hospital mortality (primary outcome), as well as the need for tracheostomy or gastrostomy (secondary outcome). We found that increasing injury severity score (odds ratio [OR] 1.146; 95% confidence interval [CI] 1.035-1.270; p = 0.009) and age (OR1.066; 95%CI 1.006-1.129; p = 0.031) were associated with in-hospital mortality in multivariate analysis. In this model, increasing time to surgery was not associated with mortality, and in fact had a significant effect in decreasing mortality (OR 0.984; 95%CI 0.971-0.997; p = 0.018). Premorbid aspirin use was associated with a paradoxical decrease in mortality (OR 0.019; 95%CI 0.001-0.392; p = 0.010). In this patient sample, shorter time interval from injury to surgery was not associated with better outcomes. While there are potential confounding factors, these findings support the evaluation of rigorous preoperative resuscitation as a priority in future study. (C) 2014 Elsevier Ltd. All rights reserved.	[Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Walcott, BP (corresponding author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.	walcott.brian@mgh.harvard.edu	Nahed, Brian/E-4239-2014	Nahed, Brian/0000-0001-8537-106X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25 NS065743] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Compagnone C, 2007, NEUROSURGERY, V61, P232, DOI [10.1227/01.neu.0000279218.53504.fe, 10.1227/01.NEU.0000186239.10915.09]; Connolly BJ, 2013, J STROKE CEREBROVASC, V22, P444, DOI 10.1016/j.jstrokecerebrovasdis.2013.01.007; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Fang MC, 2012, STROKE, V43, P1795, DOI 10.1161/STROKEAHA.111.630731; Harr JN, 2013, CRIT CARE MED, V41, P399, DOI 10.1097/CCM.0b013e31826ab38b; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	27	19	20	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	DEC	2014	21	12					2107	2111		10.1016/j.jocn.2014.05.016			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AX0DF	WOS:000346622900010	25065950	Green Published, Green Accepted			2021-06-18	
J	Xue, LP; Wang, JK; Wang, WM; Yang, ZY; Hu, ZL; Hu, M; Ding, P				Xue, Liping; Wang, Jinkun; Wang, Weimin; Yang, Zhiyong; Hu, Zhulin; Hu, Min; Ding, Peng			The Effect of Stromal Cell-Derived Factor 1 in the Migration of Neural Stem Cells	CELL BIOCHEMISTRY AND BIOPHYSICS			English	Article						Neural stem cells; Stromal cell-derived factor 1 (SDF-1); Migration	DIFFERENTIAL EXPRESSION; CHEMOKINE RECEPTOR; PERIPHERAL-BLOOD; BONE-MARROW; CXCR4; SDF-1; MOBILIZATION; MUSCLE; INJURY; CXCL12	Neural stem cells (NSCs) have widely been used in the treatment of human neurological disorders as cell therapy via intracerebral or intraventricular infusion. However, the migration mechanism required for NSCs homing and recruitment remains to be elucidated. Recently, SDF-1/CXCR4 axis was shown to be responsible for in cell migration and differentiation during the neural development stage and involved in the pathophysiological process of neurological disorders. In this study, we investigated the effect of SDF-1 in migration of NSCs in vitro and in vivo. The expression of CXCR4 receptor was examined by immunocytochemistry and RT-PCR. The migratory ability of NSCs induced by SDF-1 was assessed by transwell chemotaxis assay. The traumatic brain injury rat model was well established, and the recruitment of NSCs and expression of SDF-1 were investigated in vivo. Our findings demonstrated that SDF-1, in vitro, significantly induced the migratory of NSCs in a dose-dependent manner. An overexpression of neural stem cell marker Nestin in the hippocampus was observed after TBI, and the expressions of SDF-1 surrounding the lesion areas were significantly increased. Our results suggested that the migration of NSCs was activated by chemotactic effect of SDF-1. It was also proved the relevance of SDF-1 in the migration of endogenous NSCs after brain injury. Taken together, these results demonstrated that SDF-1/CXCR4 axis may play crucial role in the migration of Nestin-positive cell after brain injury.	[Xue, Liping; Hu, Zhulin; Hu, Min] Yunnan 2 Prov Peoples Hosp, Dept Ophthalmol, Kunming 650021, Peoples R China; [Wang, Jinkun; Wang, Weimin; Yang, Zhiyong; Ding, Peng] Kunming Med Univ, Dept Neurosurg, Affiliated Hosp 1, Kunming 650032, Peoples R China	Ding, P (corresponding author), Kunming Med Univ, Dept Neurosurg, Affiliated Hosp 1, 295 XiChang Rd, Kunming 650032, Peoples R China.	drpengding@126.com			Grant for High-Level Training of Yun Nan [2013FZ280]; Yunnan Provincial Science and Technology Department [2010CD157]; Kunming Medical University [2010CD157]; Yunnan Province [2013FZ280]; Department of technology, Yunnan province [2010CD157]; Yunnan Medical University [2010CD157]	This study was supported by a special Grant for High-Level Training of Yun Nan (2013FZ280) and a special joint grant of Yunnan Provincial Science and Technology Department and Kunming Medical University (2010CD157). This work is supported by special training funding (No. 2013FZ280) for high-level experts of Yunnan Province, and Joint program (No. 2010CD157) of Department of technology, Yunnan province and Yunnan Medical University.	Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Bellmann-Sickert K, 2011, CHEMMEDCHEM, V6, P193, DOI 10.1002/cmdc.201000403; Comerford I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045095; Durbec Pascale, 2008, V438, P213, DOI 10.1007/978-1-59745-133-8_18; Egawa T, 2001, IMMUNITY, V15, P323, DOI 10.1016/S1074-7613(01)00185-6; Fricker SP, 2006, BIOCHEM PHARMACOL, V72, P588, DOI 10.1016/j.bcp.2006.05.010; Gassmann P, 2009, NEOPLASIA, V11, P651, DOI 10.1593/neo.09272; Gouwy M, 2011, EUR J IMMUNOL, V41, P963, DOI 10.1002/eji.201041178; Heit Bryan, 2003, Sci STKE, V2003, pPL5, DOI 10.1126/stke.2003.170.pl5; Huber BC, 2011, CARDIOVASC RES, V90, P529, DOI 10.1093/cvr/cvr014; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Janssen U, 2002, NEPHRON, V92, P797, DOI 10.1159/000065448; Karin N, 2010, J LEUKOCYTE BIOL, V88, P463, DOI 10.1189/jlb.0909602; Kucia M, 2004, CIRC RES, V95, P1191, DOI 10.1161/01.RES.0000150856.47324.5b; Kucia M, 2004, BLOOD CELL MOL DIS, V32, P52, DOI 10.1016/j.bcmd.2003.09.025; Lapidot T, 2002, LEUKEMIA, V16, P1992, DOI 10.1038/sj.leu.2402684; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Li MZ, 2011, GLIA, V59, P108, DOI 10.1002/glia.21080; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Marquez-Curtis LA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/561098; NELSON RD, 1988, METHOD ENZYMOL, V162, P50; Noda M, 2011, BLOOD, V117, P451, DOI 10.1182/blood-2010-04-277897; Peng H, 2007, J NEUROIMMUNE PHARM, V2, P251, DOI 10.1007/s11481-007-9081-3; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Vasyutina E, 2005, GENE DEV, V19, P2187, DOI 10.1101/gad.346205; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Werner L, 2013, THERANOSTICS, V3, P40, DOI 10.7150/thno.5135; Wong K., 2008, J VISUALIZED EXPT, P12; Woznica David, 2006, V346, P311; Yang SZ, 2013, DEVELOPMENT, V140, P4554, DOI 10.1242/dev.098145; Zhang JX, 2013, DISASTER ADV, V6, P1; Zou Li-Ping, 2011, Zhongguo Dang Dai Er Ke Za Zhi, V13, P321	33	19	20	0	18	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1085-9195	1559-0283		CELL BIOCHEM BIOPHYS	Cell Biochem. Biophys.	DEC	2014	70	3					1609	1616		10.1007/s12013-014-0103-5			8	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	AT2LT	WOS:000344767100018	25241080				2021-06-18	
J	Hartwig, K; Fackler, V; Jaksch-Bogensperger, H; Winter, S; Furtner, T; Couillard-Despres, S; Meier, D; Moessler, H; Aigner, L				Hartwig, Kerstin; Fackler, Viktoria; Jaksch-Bogensperger, Heidi; Winter, Stefan; Furtner, Tanja; Couillard-Despres, Sebastien; Meier, Dieter; Moessler, Herbert; Aigner, Ludwig			Cerebrolysin protects PC12 cells from CoCl2-induced hypoxia employing GSK3 beta signaling	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Neuroprotection; Neurotrophic factors; Cell death	NERVE GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3-BETA; PRESYNAPTIC ADENOSINE RECEPTORS; BRAIN-TISSUE HYDROLYSATE; FIMBRIA-FORNIX LESION; ALZHEIMERS-DISEASE; DRUG CEREBROLYSIN; INDUCED APOPTOSIS; TRANSGENIC MODEL; RAT HIPPOCAMPUS	Cerebrolysin (EVER Neuro Pharma GmbH, Austria) is a peptidergic drug indicated for clinical use in stroke, traumatic brain injury and dementia. The therapeutic effect of Cerebrolysin is thought to ensure from its neurotrophic activity, which shares some properties with naturally occurring neurotrophic factors. However, the exact mechanism of action of Cerebrolysin is yet to be fully deciphered. This study aimed to investigate the neuroprotective effect of Cerebrolysin in a widely used in vitro model of hypoxia-induced neuronal cytotoxicity, namely cobalt chloride (CoCl2)-treatment of PC12 cells. CoCl2-cytotoxicity was indicated by a reduced cell-diameter, cell shrinkage, increased pro-apoptotic Caspase-activities and a decreased metabolic activity. Cerebrolysin maintained the cell-diameter of CoCl2-treated naive PC12 cells, decreased the activation of Caspase 3/7 in CoCl2-stressed naive PC12 cells and restored the cells' metabolic activity in CoCl2-impaired naive and differentiated PC12 cells. Cerebrolysin treatment also decreased the levels of superoxide observed after exposure to CoCl2. Investigating the mechanism of action, we could demonstrate that Cerebrolysin application to CoCl2-stressed PC12 cells increased the phosphorylation of GSK3 beta, resulting in the inhibition of GSK3 beta. This might become clinically relevant for Alzheimer's disease, since GSK3 beta activity has been linked to the production of amyloid beta. Taken together, Cerebrolysin was found to have neuroprotective effects in CoCl2-induced cytotoxicity in PC12 cells. (C) 2014 ISDN. Published by Elsevier Ltd. All rights reserved.	[Jaksch-Bogensperger, Heidi; Furtner, Tanja; Couillard-Despres, Sebastien; Aigner, Ludwig] Paracelsus Med Univ, Inst Mol Regenerat Med, Salzburg, Austria; [Couillard-Despres, Sebastien; Aigner, Ludwig] Paracelsus Med Univ, Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, Salzburg, Austria; [Couillard-Despres, Sebastien] Paracelsus Med Univ, Inst Expt Neuroregenerat, Salzburg, Austria; [Hartwig, Kerstin; Fackler, Viktoria; Winter, Stefan; Meier, Dieter; Moessler, Herbert] EVER Neuro Pharma GmbH, Unterach, Austria	Aigner, L (corresponding author), Paracelsus Med Univ Salzburg, Inst Mol Regenerat Med, Strubergasse 21, A-5020 Salzburg, Austria.	stefan.winter@everpharma.com; ludwig.aigner@pmu.ac.at		Couillard-Despres, Sebastien/0000-0002-8486-6412; Aigner, Ludwig/0000-0002-1653-8046	EVER Neuro Pharma GmbH; European Union's Seventh Framework Program (FP7) [HEALTH-F2-2011-278850 (INMiND), HEALTH-F2-2011-279288 (IDEA)]; State of Salzburg	The present work was supported by a grant from EVER Neuro Pharma GmbH; by the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreements no. HEALTH-F2-2011-278850 (INMiND) and HEALTH-F2-2011-279288 (IDEA); and by the State of Salzburg (to L.A.).	Alvarez XA, 2011, EUR J NEUROL, V18, P59, DOI 10.1111/j.1468-1331.2010.03092.x; Alvarez XA, 2006, EUR J NEUROL, V13, P43, DOI 10.1111/j.1468-1331.2006.01222.x; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; Cole AR, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00004; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; EBEWENeuroPharmaGmbH, 2009, CER SOL INJ SUMM PRO; Ekshyyan O, 2005, CELL DEATH DIFFER, V12, P1066, DOI 10.1038/sj.cdd.4401650; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje; Flugel D, 2007, MOL CELL BIOL, V27, P3253, DOI 10.1128/MCB.00015-07; FrancisTurner L, 1996, NEUROSCI LETT, V202, P193, DOI 10.1016/0304-3940(95)12240-0; FrancisTurner L, 1996, J NEURAL TRANSM-SUPP, P277; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Gutmann B, 2002, NEUROTOX RES, V4, P59, DOI 10.1080/10298420290007637; Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067; HutterPaier B, 1996, J NEURAL TRANSM-SUPP, P267; Jung JY, 2004, NEUROSCI LETT, V371, P85, DOI 10.1016/j.neulet.2004.06.069; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Lan AP, 2013, NEUROCHEM RES, V38, P1454, DOI 10.1007/s11064-013-1044-x; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; Longo FM, 2013, NAT REV DRUG DISCOV, V12, P507, DOI 10.1038/nrd4024; Mallory M, 1999, ACTA NEUROPATHOL, V97, P437, DOI 10.1007/s004010051012; Masliah E, 2012, DRUG TODAY, V48, P3, DOI 10.1358/dot.2012.48(Suppl.A).1739716; Masliah E, 1999, PHARMACOL BIOCHEM BE, V62, P239, DOI 10.1016/S0091-3057(98)00144-0; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Piswanger A., 1990, AMINO ACIDS, P651; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; RUTHER E, 1994, PHARMACOPSYCHIATRY, V27, P32, DOI 10.1055/s-2007-1014271; Ruther E, 2000, J NEURAL TRANSM, V107, P815, DOI 10.1007/s007020070061; Sugita Y, 1993, No To Shinkei, V45, P325; Ubhi K, 2013, J NEUROSCI RES, V91, P167, DOI 10.1002/jnr.23142; Valouskova V, 1996, J NEURAL TRANSM-SUPP, P280; Veinbergs I, 2000, J NEURAL TRANSM-SUPP, P273; Wang GC, 2000, NUCLEIC ACIDS RES, V28, P2135, DOI 10.1093/nar/28.10.2135; WINDISCH VM, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1353; Wojtowicz JM, 1996, J NEURAL TRANSM-SUPP, P281; Wyatt AW, 2006, CELL PHYSIOL BIOCHEM, V17, P137, DOI 10.1159/000092075; XIONG H, 1995, CAN J PHYSIOL PHARM, V73, P1194, DOI 10.1139/y95-170; YOUNG AP, 1983, BIRTH DEFECTS-ORIG, V19, P33; Zhang L, 2013, STROKE, V44, P1965, DOI 10.1161/STROKEAHA.111.000831; Zhang YL, 2013, J NEUROSURG, V118, P1343, DOI 10.3171/2013.3.JNS122061; Zhong XY, 2014, BIOL PHARM BULL, V37, P1199, DOI 10.1248/bpb.b14-00100; Zou WG, 2002, J NEUROSCI RES, V67, P837, DOI 10.1002/jnr.10168; Zou WG, 2001, J NEUROSCI RES, V64, P646, DOI 10.1002/jnr.1118	47	19	21	2	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	NOV	2014	38						52	58		10.1016/j.ijdevneu.2014.07.005			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	AY6FN	WOS:000347662800007	25093704				2021-06-18	
J	Luo, H; Pace, E; Zhang, XG; Zhang, JS				Luo, Hao; Pace, Edward; Zhang, Xueguo; Zhang, Jinsheng			Blast-Induced Tinnitus and Spontaneous Firing Changes in the Rat Dorsal Cochlear Nucleus	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						blast exposure; tinnitus; traumatic brain injury (TBI); dorsal cochlear nucleus; spontaneous activity	NOISE-INDUCED HYPERACTIVITY; SPONTANEOUS NEURAL ACTIVITY; TRAUMATIC BRAIN-INJURY; INFERIOR COLLICULUS; ACOUSTIC TRAUMA; HEARING-LOSS; HOMEOSTATIC PLASTICITY; SOUND; EXPOSURE; DEGENERATION	Exposure to high-pressure blast shock waves is known to cause tinnitus. Although the underlying mechanisms may involve damage to structures in the ear and/or direct brain impact, which triggers a cascade of neuroplastic changes in both auditory and nonauditory centers, it remains unclear how the induced neuroplasticity manifests neuro-physiologically. This study investigates the influence of blast exposure on spontaneous firing rates (SFRs) in the dorsal cochlear nucleus (DCN) and its time course in rats with blast-induced tinnitus. Each rat was exposed to a single blast at 22 psi. Behavioral evidence of tinnitus was measured by using a gap-detection acoustic startle-reflex paradigm. SFRs were measured 1 day, 1 month, and 3 months after blast exposure. The results showed that nine rats with blast-induced tinnitus and hearing loss developed hyperactivity immediately and that the induced hyperactivity persisted in six rats with tinnitus at 1 month after blast exposure. At 3 months after blast exposure, however, the induced hyperactivity of four rats with tinnitus transitioned to hypoactivity. In addition, the 20-30-kHz, and >30-kHz regions in the DCN of rats with and without blast-induced tinnitus were more affected than other frequency regions at different recovery time points after blast exposure. These results demonstrate that the neural mechanisms underlying blast-induced tinnitus are substantially different from those underlying noise-induced tinnitus. (C) 2014 Wiley Periodicals, Inc.	[Luo, Hao; Pace, Edward; Zhang, Xueguo; Zhang, Jinsheng] Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48201 USA; [Zhang, Jinsheng] Wayne State Univ, Coll Liberal Arts & Sci, Dept Commun Sci & Disorders, Detroit, MI 48201 USA	Zhang, JS (corresponding author), Wayne State Univ, Sch Med, 5E-UHC,4201 St Antoine, Detroit, MI 48201 USA.	jinzhang@med.wayne.edu			Department of DefenseUnited States Department of Defense [W81XWH-11-2-0031]	Contract grant sponsor: Department of Defense, contract grant number: W81XWH-11-2-0031	AXELSSON A, 1985, British Journal of Audiology, V19, P271, DOI 10.3109/03005368509078983; Bauer CA, 2008, J NEUROSCI RES, V86, P2564, DOI 10.1002/jnr.21699; Bauer CA, 2007, J NEUROSCI RES, V85, P1489, DOI 10.1002/jnr.21259; Bilak M, 1997, EXP NEUROL, V147, P256, DOI 10.1006/exnr.1997.6636; Brozoski TJ, 2007, JARO-J ASSOC RES OTO, V8, P105, DOI 10.1007/s10162-006-0067-2; Brozoski TJ, 2002, J NEUROSCI, V22, P2383, DOI 10.1523/JNEUROSCI.22-06-02383.2002; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Cho SI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067618; Doiron B, 2011, J NEUROSCI, V31, P10579, DOI 10.1523/JNEUROSCI.1592-11.2011; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Eggermont JJ, 2013, HEARING RES, V295, P140, DOI 10.1016/j.heares.2012.01.005; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Finlayson PG, 2009, HEARING RES, V256, P104, DOI 10.1016/j.heares.2009.07.006; Geckle L., 2004, FORC HLTH PROT C ALB; Gu JW, 2010, J NEUROPHYSIOL, V104, P3361, DOI 10.1152/jn.00226.2010; Heller AJ, 2003, OTOLARYNG CLIN N AM, V36, P239, DOI 10.1016/S0030-6665(02)00160-3; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Kaltenbach JA, 1996, AUDIT NEUROSCI, V3, P57; Kaltenbach JA, 2000, HEARING RES, V147, P282, DOI 10.1016/S0378-5955(00)00138-6; Kaltenbach JA, 2000, HEARING RES, V140, P165, DOI 10.1016/S0378-5955(99)00197-5; Kaltenbach JA, 2006, HEARING RES, V216, P224, DOI 10.1016/j.heares.2006.01.002; Kaltenbach JA, 2011, HEARING RES, V276, P52, DOI 10.1016/j.heares.2010.12.003; Kim JN, 1997, HEARING RES, V103, P169, DOI 10.1016/S0378-5955(96)00173-6; Knipper L, 2013, PROG NEUROBIOL, V111, P17, DOI 10.1016/j.pneurobio.2013.08.002; Kraus KS, 2010, NEUROSCIENCE, V167, P1216, DOI 10.1016/j.neuroscience.2010.02.071; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Langers DRM, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00002; Lepczyk L, 2012, MIDW M ASS RES OT; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Liberman M C, 1978, Acta Otolaryngol Suppl, V358, P1; LIBERMAN MC, 1979, ACTA OTO-LARYNGOL, V88, P161, DOI 10.3109/00016487909137156; LIBERMAN MC, 1984, HEARING RES, V16, P75, DOI 10.1016/0378-5955(84)90026-1; Llano DA, 2012, J NEUROSCI, V32, P16141, DOI 10.1523/JNEUROSCI.2499-12.2012; LOEB M, 1967, J ACOUST SOC AM, V42, P453, DOI 10.1121/1.1910600; Luo L, 2013, ASS RES OTO IN PRESS; Ma WLD, 2006, HEARING RES, V216, P176, DOI 10.1016/j.heares.2006.03.011; Ma WLD, 2006, HEARING RES, V212, P9, DOI 10.1016/j.heares.2005.10.003; Malmierca MS, 2002, J NEUROSCI, V22, P10891; Manzoor NF, 2013, HEARING RES, V295, P114, DOI 10.1016/j.heares.2012.04.003; Manzoor NF, 2012, J NEUROPHYSIOL, V108, P976, DOI 10.1152/jn.00833.2011; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; MCINTOSH AR, 1993, BRAIN RES, V627, P129, DOI 10.1016/0006-8993(93)90756-D; Melcher JR, 2009, HEARING RES, V257, P63, DOI 10.1016/j.heares.2009.08.005; Middleton JW, 2011, P NATL ACAD SCI USA, V108, P7601, DOI 10.1073/pnas.1100223108; Milbrandt JC, 2000, HEARING RES, V147, P251, DOI 10.1016/S0378-5955(00)00135-0; Mrena R, 2002, AUDIOL NEURO-OTOL, V7, P122, DOI 10.1159/000057660; Mulders WHAM, 2013, HEARING RES, V298, P104, DOI 10.1016/j.heares.2012.12.008; Mulders WHAM, 2011, NEUROSCIENCE, V192, P753, DOI 10.1016/j.neuroscience.2011.06.046; Mulders WHAM, 2011, J COMP NEUROL, V519, P2637, DOI 10.1002/cne.22644; Norena AJ, 2003, HEARING RES, V183, P137, DOI 10.1016/S0378-5955(03)00225-9; Pace E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075011; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Richardson BD, 2012, BRAIN RES, V1485, P77, DOI 10.1016/j.brainres.2012.02.014; Roberts LE, 2010, J NEUROSCI, V30, P14972, DOI 10.1523/JNEUROSCI.4028-10.2010; Robertson D, 2013, HEARING RES, V295, P124, DOI 10.1016/j.heares.2012.02.002; Ruttiger L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057247; Salvi RJ, 2000, HEARING RES, V147, P261, DOI 10.1016/S0378-5955(00)00136-2; Sanes DH, 2009, CURR OPIN NEUROBIOL, V19, P188, DOI 10.1016/j.conb.2009.05.014; Schaette R, 2006, EUR J NEUROSCI, V23, P3124, DOI 10.1111/j.1460-9568.2006.04774.x; Schaette R, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00034; Schaette R, 2011, J NEUROSCI, V31, P13452, DOI 10.1523/JNEUROSCI.2156-11.2011; Singer W, 2013, MOL NEUROBIOL, V47, P261, DOI 10.1007/s12035-012-8372-8; Turner JG, 2006, BEHAV NEUROSCI, V120, P188, DOI 10.1037/0735-7044.120.1.188; Vogler DP, 2011, J NEUROSCI, V31, P6639, DOI 10.1523/JNEUROSCI.6538-10.2011; Wallhausser-Franke E, 2003, EXP BRAIN RES, V153, P649, DOI 10.1007/s00221-003-1614-2; Wang H, 2009, NEUROSCIENCE, V164, P747, DOI 10.1016/j.neuroscience.2009.08.026; Whiting B, 2009, NEUROSCIENCE, V163, P1264, DOI 10.1016/j.neuroscience.2009.07.049; Yang SC, 2011, P NATL ACAD SCI USA, V108, P14974, DOI 10.1073/pnas.1107998108; Zhang JS, 2006, J NEUROSCI RES, V84, P819, DOI 10.1002/jnr.20985; Zhang JS, 2013, HEARING RES, V295, P38, DOI 10.1016/j.heares.2012.05.007; Zhang JS, 1998, NEUROSCI LETT, V250, P197, DOI 10.1016/S0304-3940(98)00482-0; Zhang JS, 2013, TINN RES IN INT C 14	73	19	19	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV	2014	92	11					1466	1477		10.1002/jnr.23424			12	Neurosciences	Neurosciences & Neurology	AN4CJ	WOS:000340534900006	24938852				2021-06-18	
J	Wang, HQ; Liao, ZB; Sun, XC; Shi, QH; Huo, G; Xie, YF; Tang, XL; Zhi, XG; Tang, ZH				Wang, Haiquan; Liao, Zhengbu; Sun, Xiaochuan; Shi, Quanhong; Huo, Gang; Xie, Yanfeng; Tang, Xiaolan; Zhi, Xinggang; Tang, Zhaohua			Intravenous administration of Honokiol provides neuroprotection and improves functional recovery after traumatic brain injury through cell cycle inhibition	NEUROPHARMACOLOGY			English	Article						Cell cycle; Honokiol; Neuron; Apoptosis; Neuroprotection; Traumatic brain injury	RETINOBLASTOMA PROTEIN; NEURONAL SURVIVAL; SCAR FORMATION; CDK INHIBITOR; DEATH; APOPTOSIS; ARREST; PROLIFERATION; HIPPOCAMPUS; ACTIVATION	Recently, increasing evidence has shown that cell cycle activation is a key factor of neuronal death and neurological dysfunction after traumatic brain injury (TBI). This study aims to investigate the effects of Honokiol, a cell cycle inhibitor, on attenuating the neuronal damage and facilitating functional recovery after TBI in rats, in an attempt to unveil its underlying molecular mechanisms in TBI. This study suggested that delayed intravenous administration of Honokiol could effectively ameliorate TBI-induced sensorimotor and cognitive dysfunctions. Meanwhile, Honokiol treatment could also reduce the lesion volume and increase the neuronal survival in the cortex and hippocampus. The neuronal degeneration and apoptosis in the cortex and hippocampus were further significantly attenuated by Honokiol treatment. In addition, the expression of cell cycle-related proteins, including cyclin D1, CDK4, pRb and E2F1, was significantly increased and endogenous cell cycle inhibitor p27 was markedly decreased at different time points after TBI. And these changes were significantly reversed by post-injury Honokiol treatment. Furthermore, the expression of some of the key cell cycle proteins such as cyclin D1 and E2F1 and the associated apoptosis in neurons were both remarkably attenuated by Honokiol treatment. These results show that delayed intravenous administration of Honokiol could effectively improve the functional recovery and attenuate the neuronal cell death, which is probably, at least in part, attributed to its role as a cell cycle inhibition This might give clues to developing attractive therapies for future clinical trials. (C) 2014 Elsevier Ltd. All rights reserved.	[Wang, Haiquan; Liao, Zhengbu; Sun, Xiaochuan; Shi, Quanhong; Huo, Gang; Xie, Yanfeng; Zhi, Xinggang; Tang, Zhaohua] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Tang, Xiaolan] Qinghai Univ, Coll Med, Lab Med Mol Biol, Xining 810000, Qinghai Provinc, Peoples R China; [Tang, Xiaolan] Qinghai Univ, Coll Med, Dept Cardiol, Xining 810000, Qinghai Provinc, Peoples R China	Tang, ZH (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Youyi Rd, Chongqing 400016, Peoples R China.	zhaohua_tang@yahoo.com		sun, xiao chuan/0000-0001-6992-332X	National Natural Science Funds of ChinaNational Natural Science Foundation of China (NSFC) [81301630, 30801182]; National key clinical specialist construction Programs of China [[2011]170]	This research was supported by the National Natural Science Funds of China under the award No. 81301630 and 30801182 and the National key clinical specialist construction Programs of China (award no. [2011]170). We would like to thank Xinggang Zhi for his technical assistance.	Akashiba H, 2006, CELL MOL LIFE SCI, V63, P2397, DOI 10.1007/s00018-006-6194-4; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arora S, 2012, CURR MOL MED, V12, P1244, DOI 10.2174/156652412803833508; Arora S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021573; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Curzon P., 2009, METHODS BEHAV ANAL N; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Folch J, 2012, NEUROTOX RES, V22, P195, DOI 10.1007/s12640-011-9277-4; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fried LE, 2009, ANTIOXID REDOX SIGN, V11, P1139, DOI [10.1089/ars.2009.2440, 10.1089/ARS.2009.2440]; Gatson JW, 2012, J NEUROTRAUM, V29, P2209, DOI 10.1089/neu.2011.2274; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hahm ER, 2007, MOL CANCER THER, V6, P2686, DOI 10.1158/1535-7163.MCT-07-0217; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Ino H, 2001, J NEUROSCI, V21, P6086; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishikawa C, 2012, BBA-GEN SUBJECTS, V1820, P879, DOI 10.1016/j.bbagen.2012.03.009; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lee YJ, 2011, PHARMACOL THERAPEUT, V130, P157, DOI 10.1016/j.pharmthera.2011.01.010; Lin JW, 2012, NEURO-ONCOLOGY, V14, P302, DOI 10.1093/neuonc/nor217; Liou KT, 2003, PLANTA MED, V69, P130, DOI 10.1055/s-2003-37707; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Park EJ, 2009, CANCER LETT, V277, P133, DOI 10.1016/j.canlet.2008.11.029; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Vaid M, 2010, CARCINOGENESIS, V31, P2004, DOI 10.1093/carcin/bgq186; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wang W, 2009, PROG NEUROBIOL, V89, P1, DOI 10.1016/j.pneurobio.2009.01.007; Wang XH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018490; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	45	19	21	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	NOV	2014	86						9	21		10.1016/j.neuropharm.2014.06.018			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AR8QN	WOS:000343839800002	24973706				2021-06-18	
J	Shu, IW; Onton, JA; O'Connell, RM; Simmons, AN; Matthews, SC				Shu, I-Wei; Onton, Julie A.; O'Connell, Ryan M.; Simmons, Alan N.; Matthews, Scott C.			Combat veterans with comorbid PTSD and mild TBI exhibit a greater inhibitory processing ERP from the dorsal anterior cingulate cortex	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						N200; P300; Conflict monitoring; Response inhibition; Biomarker	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; EVENT-RELATED POTENTIALS; DEFAULT-MODE NETWORK; RESPONSE-INHIBITION; COGNITIVE CONTROL; CONCUSSED INDIVIDUALS; FUNCTIONAL NETWORKS; DEPRESSION; CONFLICT	Posttraumatic stress disorder (PTSD) is common among combat personnel with mild traumatic brain injury (mTBI). While patients with either PTSD or mTBI share abnormal activation of multiple frontal brain areas, anterior cingulate cortex (ACC) activity during inhibitory processing may be particularly affected by PTSD. To further test this hypothesis, we recorded electroencephalography from 32 combat veterans with mTBI-17 of whom were also comorbid for PTSD (mTBI+PTSD) and 15 without PTSD (mTBI-only). Subjects performed the Stop Task, a validated inhibitory control task requiring inhibition of initiated motor responses. We observed a larger inhibitory processing eventrelated potential (ERP) in veterans with mTBI+PTSD, including greater N200 negativity. Furthermore, greater N200 negativity correlated with greater PTSD severity. This correlation was most dependent on contributions from the dorsal ACC. Support vector machine analysis demonstrated that N200 and P300 amplitudes objectively classified veterans into mTBI-only or mTBI+PTSD groups with 79.4% accuracy. Our results support a model where, in combat veterans with mTBI, larger ERPs from cingulate areas are associated with greater PTSD severity and likely related to difficulty controlling ongoing brain processes, including trauma-related thoughts and feelings. Published by Elsevier Ireland Ltd.	[Shu, I-Wei; Matthews, Scott C.] VISN22 Mental Illness, Res Educ & Clin Ctr, San Diego, CA 92161 USA; [Shu, I-Wei; O'Connell, Ryan M.; Simmons, Alan N.; Matthews, Scott C.] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; [O'Connell, Ryan M.; Matthews, Scott C.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92037 USA; [Simmons, Alan N.; Matthews, Scott C.] Vet Affairs San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Onton, Julie A.] Naval Hlth Res Ctr, San Diego, CA 92106 USA; [Onton, Julie A.] Univ Calif San Diego, Inst Neural Computat, La Jolla, CA 92093 USA	Shu, IW (corresponding author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr,116A, San Diego, CA 92161 USA.	ishu@ucsd.edu	Simmons, Alan N/A-9815-2008	Simmons, Alan N/0000-0003-3963-2112	BUMED under Work Unit 61032; VA Mental Illness Research, Education and Clinical Center; VA Office of Academic AffiliationsUS Department of Veterans Affairs; VA Advanced Fellowship Program in Mental Illness Research Treatment; VA Center of Excellence for Stress and Mental Health; University of California San Diego Academic Senate; U.S. Department of Veterans AffairsUS Department of Veterans Affairs; Congressionally Directed Medical Research ProgramsUnited States Department of Defense; CDA-2 Award from the VA CSRD; Veterans AffairsUS Department of Veterans Affairs [I01CX000292] Funding Source: NIH RePORTER	This work represents Report No. 13-xx and is supported by BUMED under Work Unit 61032. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocols NHRC.2010.0022 and NHRC.2010.0023).; The authors are grateful to Elena Kosheleva and Jenny Marks for their contributions to this research, which was supported by the VA Mental Illness Research, Education and Clinical Center, VA Office of Academic Affiliations, VA Advanced Fellowship Program in Mental Illness Research Treatment, VA Center of Excellence for Stress and Mental Health, and by grants from the University of California San Diego Academic Senate, U.S. Department of Veterans Affairs, and the Congressionally Directed Medical Research Programs. Dr. Matthews is supported by a CDA-2 Award from the VA CSR&D.	Barber AD, 2005, CEREB CORTEX, V15, P899, DOI 10.1093/cercor/bhh189; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Brown MRG, 2008, NEUROIMAGE, V39, P793, DOI 10.1016/j.neuroimage.2007.09.035; Brown MRG, 2007, J NEUROPHYSIOL, V98, P1751, DOI 10.1152/jn.00460.2007; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; Carrion VG, 2008, DEPRESS ANXIETY, V25, P514, DOI 10.1002/da.20346; Clawson A, 2013, PSYCHOPHYSIOLOGY, V50, P711, DOI 10.1111/psyp.12066; Covey TJ, 2013, INT J PSYCHOPHYSIOL, V87, P363, DOI 10.1016/j.ijpsycho.2013.03.009; De Beaumont L, 2013, J CLIN EXP NEUROPSYC, V35, P596, DOI 10.1080/13803395.2013.800023; DeHaan A, 2007, NEUROPSYCHOLOGIA, V45, P406, DOI 10.1016/j.neuropsychologia.2006.06.008; Delorme A, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/130714; Donkers FCL, 2004, BRAIN COGNITION, V56, P165, DOI 10.1016/j.bandc.2004.04.005; Enriquez-Geppert S, 2010, NEUROIMAGE, V51, P877, DOI 10.1016/j.neuroimage.2010.02.043; First MB., 2002, STRUCTURED CLIN INTE; Holmes AJ, 2008, NEUROPSYCHOLOGIA, V46, P2904, DOI 10.1016/j.neuropsychologia.2008.05.028; Huster RJ, 2011, NEUROIMAGE, V56, P1588, DOI 10.1016/j.neuroimage.2011.03.039; Huster RJ, 2010, HUM BRAIN MAPP, V31, P1260, DOI 10.1002/hbm.20933; Huster RJ, 2013, INT J PSYCHOPHYSIOL, V87, P217, DOI 10.1016/j.ijpsycho.2012.08.001; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jovanovic T, 2013, CORTEX, V49, P1884, DOI 10.1016/j.cortex.2012.08.011; Kaiser S, 2003, PSYCHIAT RES-NEUROIM, V122, P169, DOI 10.1016/S0925-4927(03)00004-0; Krompinger JW, 2011, BIOL PSYCHOL, V86, P239, DOI 10.1016/j.biopsycho.2010.12.004; Krompinger JW, 2009, BIOL PSYCHOL, V81, P153, DOI 10.1016/j.biopsycho.2009.03.007; Lanius RA, 2010, AM J PSYCHIAT, V167, P640, DOI 10.1176/appi.ajp.2009.09081168; Larson MJ, 2012, J INT NEUROPSYCH SOC, V18, P323, DOI 10.1017/S1355617711001779; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Matthews SC, 2005, NEUROREPORT, V16, P755, DOI 10.1097/00001756-200505120-00020; Matthews S, 2012, PSYCHOSOM MED, V74, P471, DOI 10.1097/PSY.0b013e31824f888f; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Menon V, 2001, HUM BRAIN MAPP, V12, P131, DOI 10.1002/1097-0193(200103)12:3<131::AID-HBM1010>3.0.CO;2-C; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; OGURA C, 1991, JPN J PSYCHIAT NEUR, V45, P641; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Quinn CR, 2012, AUST NZ J PSYCHIAT, V46, P374, DOI 10.1177/0004867411432073; Ramage AE, 2013, HUM BRAIN MAPP, V34, P3392, DOI 10.1002/hbm.22155; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Ruchsow M, 2008, INT J PSYCHOPHYSIOL, V68, P209, DOI 10.1016/j.ijpsycho.2008.01.010; Sartory G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058150; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Shucard JL, 2008, BIOL PSYCHOL, V79, P223, DOI 10.1016/j.biopsycho.2008.05.005; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Simms LJ, 2002, J ABNORM PSYCHOL, V111, P637, DOI 10.1037//0021-843X.111.4.637; Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Tanelian T., 2008, INVISIBLE WOUNDS WAR; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; THOMAES K, 2012, PSYCHOL MED, V22, P1; Vanderhasselt MA, 2009, BIOL PSYCHOL, V81, P169, DOI 10.1016/j.biopsycho.2009.03.009; Vanderhasselt MA, 2012, J PSYCHIATR NEUROSCI, V37, P250, DOI 10.1503/jpn.110089; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2012, PTSD MILD TRAUMATIC; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wu JH, 2010, NEUROSCI LETT, V486, P117, DOI 10.1016/j.neulet.2010.07.040; Zhang BW, 2007, NEUROSCI LETT, V419, P225, DOI 10.1016/j.neulet.2007.04.013; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhang S, 2012, HUM BRAIN MAPP, V33, P89, DOI 10.1002/hbm.21197; Zhang YY, 2007, NEUROPSYCHOBIOLOGY, V55, P14, DOI 10.1159/000103571; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	66	19	19	0	37	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	OCT 30	2014	224	1					58	66		10.1016/j.pscychresns.2014.07.010			9	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	AQ0MW	WOS:000342478400009	25150386				2021-06-18	
J	Khajeh, L; Blijdorp, K; Neggers, SJCMM; Ribbers, GM; Dippel, DWJ; van Kooten, F				Khajeh, Ladbon; Blijdorp, Karin; Neggers, Sebastian J. C. M. M.; Ribbers, Gerard M.; Dippel, Diederik W. J.; van Kooten, Fop			Hypopituitarism after subarachnoid haemorrhage, do we know enough?	BMC NEUROLOGY			English	Article						Subarachnoid haemorrhage; Hypopituitarism; Neuroendocrine; Functional outcome	TRAUMATIC BRAIN-INJURY; ANTERIOR-PITUITARY FUNCTION; GOOD NEUROLOGICAL RECOVERY; INSULIN TOLERANCE-TEST; QUALITY-OF-LIFE; NEUROENDOCRINE DYSFUNCTION; ACUTE-PHASE; PSYCHOSOCIAL OUTCOMES; GROWTH-HORMONE; GH DEFICIENCY	Background: Fatigue, slowness, apathy and decrease in level of activity are common long-term complaints after a subarachnoid haemorrhage (SAH). They resemble the symptoms frequently found in patients with endocrine dysfunction. Pituitary dysfunction may be the result of SAH or its complications. We therefore hypothesized that it may explain some of the long-term complaints after SAH. We reviewed the literature to clarify the occurrence, pattern and severity of endocrine abnormalities and we attempted to identify risk factors for hypopituitarism after SAH. We also assessed the effect of hypopituitarism on long-term functional recovery after SAH. Methods: In a MEDLINE search for studies published between 1995 and 2014, we used the term subarachnoid haemorrhage in combination with pituitary, hypopituitarism, growth hormone, gonadotropin, testosterone, cortisol function, thyroid function and diabetes insipidus. We selected all case-series and cohort studies reporting endocrine function at least 3 months after SAH and studied their reported prevalence, pathogenesis, risk factors, clinical course and outcome. Results: We identified 16 studies describing pituitary function in the long term after SAH. The reported prevalence of endocrine dysfunction varied from 0 to 55% and the affected pituitary axes differed between studies. Due to methodological issues no inferences on risk factors, course and outcome could be made. Conclusions: Neuroendocrine dysfunction may be an important and modifiable determinant of poor functional outcome after SAH. There is an urgent need for well-designed prospective studies to more precisely assess its incidence, clinical course and effect on mood, behaviour and quality of life.	[Khajeh, Ladbon; Dippel, Diederik W. J.; van Kooten, Fop] Erasmus MC Univ, Med Ctr, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [Blijdorp, Karin; Neggers, Sebastian J. C. M. M.] Erasmus MC Univ, Dept Internal Med, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [Ribbers, Gerard M.] Erasmus MC Univ, Med Ctr, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands; [Ribbers, Gerard M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands	Khajeh, L (corresponding author), Erasmus MC Univ, Med Ctr, Dept Neurol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	l.khajeh@erasmusmc.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019; Dippel, Diederik/AAJ-2192-2020	Ribbers, Gerard M/0000-0002-6114-349X; Dippel, Diederik/0000-0002-9234-3515			Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Arlt W, 2008, CLIN MED, V8, P211, DOI 10.7861/clinmedicine.8-2-211; Bendel S, 2008, CRIT CARE, V12, DOI 10.1186/cc7084; Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; Blijdorp K, 2013, EUR J ENDOCRINOL, V169, P497, DOI 10.1530/EJE-13-0436; Brandt L, 2004, ACTA NEUROL SCAND, V109, P91, DOI 10.1046/j.0001-6314.2003.00189.x; Buchanan KM, 2000, NEUROSURGERY, V46, P831, DOI 10.1097/00006123-200004000-00012; Citerio G, 2007, INTENS CARE MED, V33, P1580, DOI 10.1007/s00134-007-0700-5; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; DOCZI T, 1981, NEUROSURGERY, V9, P394, DOI 10.1227/00006123-198110000-00008; Dutta P, 2012, NEUROL INDIA, V60, P390, DOI 10.4103/0028-3886.100729; Gardner CJ, 2011, BRIT J NEUROSURG, V25, P337, DOI 10.3109/02688697.2010.546900; Gardner CJ, 2013, EUR J ENDOCRINOL, V168, P473, DOI 10.1530/EJE-12-0849; Gasco V, 2013, EUR J ENDOCRINOL, V168, P23, DOI 10.1530/EJE-12-0584; Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9; Hannon MJ, 2014, J CLIN ENDOCR METAB, V99, P291, DOI 10.1210/jc.2013-3032; Hartoft-Nielsen ML, 2004, HORM RES, V61, P53, DOI 10.1159/000075239; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; Jovanovic V, 2010, HORM-INT J ENDOCRINO, V9, P235, DOI 10.14310/horm.2002.1273; Karaca Z, 2013, PITUITARY, V16, P76, DOI 10.1007/s11102-012-0377-9; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Khursheed N, 2013, INT J ENDOCRINOL MET, V11, P179, DOI 10.5812/ijem.8241; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Kreitschmann-Andermahr I, 2008, EXP CLIN ENDOCR DIAB, V116, P276, DOI 10.1055/s-2007-1004552; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kreitschmann-Andermahr I, 2007, CLIN ENDOCRINOL, V66, P833, DOI 10.1111/j.1365-2265.2007.02821.x; Kronvall E, 2014, WORLD NEUROSURG, V81, P529, DOI 10.1016/j.wneu.2013.10.038; Kurokawa Y, 1996, SURG NEUROL, V46, P500, DOI 10.1016/S0090-3019(96)00034-1; Lammert A, 2011, EXP CLIN ENDOCR DIAB, V119, P111, DOI 10.1055/s-0030-1262815; Lanterna LA, 2013, J STROKE CEREBROVASC, V22, pE189, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.002; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; MCKENNA P, 1989, NEUROSURGERY, V24, P361, DOI 10.1227/00006123-198903000-00009; Noble AJ, 2010, NEUROSURGERY, V66, P772, DOI 10.1227/01.NEU.0000367548.63164.B2; Nye EJ, 2001, CLIN ENDOCRINOL, V55, P625, DOI 10.1046/j.1365-2265.2001.01389.x; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; Papavasiliou AK, 2001, SURG NEUROL, V55, P138, DOI 10.1016/S0090-3019(01)00364-0; Parenti G, 2011, J ENDOCRINOL INVEST, V34, P361, DOI [10.1007/BF03347460, 10.3275/7242]; Pfeifer M, 2001, CLIN ENDOCRINOL, V54, P17, DOI 10.1046/j.1365-2265.2001.01179.x; Poll EM, 2010, J NEUROTRAUM, V27, P189, DOI 10.1089/neu.2009.1014; Powell J, 2004, J NEUROL NEUROSUR PS, V75, P1119, DOI 10.1136/jnnp.2002.000414; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P772, DOI 10.1136/jnnp.72.6.772; Rajasekaran S, 2011, CLIN ENDOCRINOL, V74, P9, DOI 10.1111/j.1365-2265.2010.03913.x; Schneider HJ, 2011, J NEUROTRAUM, V28, P1693, DOI 10.1089/neu.2011.1887; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Sherlock M, 2006, CLIN ENDOCRINOL, V64, P250, DOI 10.1111/j.1365-2265.2006.02432.x; SONESSON B, 1987, NEUROSURGERY, V21, P279, DOI 10.1227/00006123-198709000-00001; SONESSON B, 1989, ACTA NEUROL SCAND, V80, P400, DOI 10.1111/j.1600-0404.1989.tb03901.x; Srinivasan L, 2009, BRAIN INJURY, V23, P639, DOI 10.1080/02699050902970778; Tanriverdi F, 2007, CLIN ENDOCRINOL, V67, P931, DOI 10.1111/j.1365-2265.2007.02989.x; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Vaartjes I, 2008, EUR J NEUROL, V15, P1315, DOI 10.1111/j.1468-1331.2008.02309.x; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Vestergaard P, 1997, HORM METAB RES, V29, P106, DOI 10.1055/s-2007-979000; WIJDICKS EFM, 1991, STROKE, V22, P1519, DOI 10.1161/01.STR.22.12.1519; Yee AH, 2010, NEUROSURG CLIN N AM, V21, P339, DOI 10.1016/j.nec.2009.10.011; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	62	19	20	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	OCT 14	2014	14								205	10.1186/s12883-014-0205-0			8	Clinical Neurology	Neurosciences & Neurology	AZ3UM	WOS:000348152100002	25312299	DOAJ Gold, Green Published			2021-06-18	
J	Barbey, AK; Colom, R; Paul, EJ; Chau, A; Solomon, J; Grafman, JH				Barbey, Aron K.; Colom, Roberto; Paul, Erick J.; Chau, Aileen; Solomon, Jeffrey; Grafman, Jordan H.			Lesion mapping of social problem solving	BRAIN			English	Article						social intelligence; latent variable modelling; voxel-based lesion-symptom mapping	TRAUMATIC BRAIN-INJURY; ANTERIOR TEMPORAL-LOBES; HUMAN WORKING-MEMORY; FRONTAL-LOBE; COGNITIVE NEUROSCIENCE; GENERAL INTELLIGENCE; PREFRONTAL CORTEX; OLDER-ADULTS; ORBITOFRONTAL CONTRIBUTIONS; FUNCTIONAL-ORGANIZATION	Accumulating neuroscience evidence indicates that human intelligence is supported by a distributed network of frontal and parietal regions that enable complex, goal-directed behaviour. However, the contributions of this network to social aspects of intellectual function remain to be well characterized. Here, we report a human lesion study (n = 144) that investigates the neural bases of social problem solving (measured by the Everyday Problem Solving Inventory) and examine the degree to which individual differences in performance are predicted by a broad spectrum of psychological variables, including psychometric intelligence (measured by the Wechsler Adult Intelligence Scale), emotional intelligence (measured by the Mayer, Salovey, Caruso Emotional Intelligence Test), and personality traits (measured by the Neuroticism-Extraversion-Openness Personality Inventory). Scores for each variable were obtained, followed by voxel-based lesion-symptom mapping. Stepwise regression analyses revealed that working memory, processing speed, and emotional intelligence predict individual differences in everyday problem solving. A targeted analysis of specific everyday problem solving domains (involving friends, home management, consumerism, work, information management, and family) revealed psychological variables that selectively contribute to each. Lesion mapping results indicated that social problem solving, psychometric intelligence, and emotional intelligence are supported by a shared network of frontal, temporal, and parietal regions, including white matter association tracts that bind these areas into a coordinated system. The results support an integrative framework for understanding social intelligence and make specific recommendations for the application of the Everyday Problem Solving Inventory to the study of social problem solving in health and disease.	[Barbey, Aron K.; Paul, Erick J.] Univ Illinois, Decis Neurosci Lab, Urbana, IL 61801 USA; [Barbey, Aron K.; Paul, Erick J.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Barbey, Aron K.] Univ Illinois, Dept Internal Med, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Dept Psychol, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Neurosci Program, Champaign, IL 61820 USA; [Barbey, Aron K.] Univ Illinois, Inst Genom Biol, Champaign, IL 61820 USA; [Colom, Roberto] Univ Autonoma Madrid, Fdn CIEN, Fdn Reina Sofia, Madrid, Spain; [Chau, Aileen; Grafman, Jordan H.] Rehabil Inst Chicago, Cognit Neurosci Lab, Chicago, IL 60611 USA; [Solomon, Jeffrey] Expert Image Anal LLC, Potomac, MD USA	Barbey, AK (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, Decis Neurosci Lab, Urbana, IL 61801 USA.	barbey@illinois.edu; jgrafman@ric.org	Barbey, Aron/L-7312-2015; Colom, Roberto/F-8779-2010	Barbey, Aron/0000-0002-6092-0912; Colom, Roberto/0000-0001-5865-163X	U.S. National Institute of Neurological Disorders and Stroke intramural research programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]; Ministerio de Ciencia e Innovacion [Ministry of Science and Innovation, Spain] [PSI2010-20364]; Universidad Autonoma de Madrid [CEMU-2012-004]	This work was supported by funding from the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the United States Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study, grant number DAMD17-01-1-0675). R. Colom was supported by grant PSI2010-20364 from Ministerio de Ciencia e Innovacion [Ministry of Science and Innovation, Spain] and CEMU-2012-004 [Universidad Autonoma de Madrid].	Abu-Akel A, 2003, BRAIN RES REV, V43, P29, DOI 10.1016/S0165-0173(03)00190-5; Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Adolphs R, 2003, NEUROPSYCHOLOGIA, V41, P119, DOI 10.1016/S0028-3932(02)00142-2; Adolphs R, 2013, CURR OPIN NEUROBIOL, V23, P291, DOI 10.1016/j.conb.2013.04.011; Adolphs R, 2010, NEURON, V65, P752, DOI 10.1016/j.neuron.2010.03.006; Apperly IA, 2004, J COGNITIVE NEUROSCI, V16, P1773, DOI 10.1162/0898929042947928; Arbuckle JL, 2010, EXP AGING RES, V36, P230; Barbey AK, 2011, OXFORD HDB SOCIAL NE, P349; Barbey AK, 2014, BRAIN STRUCT FUNCT, V219, P485, DOI 10.1007/s00429-013-0512-z; Barbey AK, 2014, BRAIN, V137, P277, DOI 10.1093/brain/awt312; Barbey AK, 2014, SOC COGN AFFECT NEUR, V9, P265, DOI 10.1093/scan/nss124; Barbey AK, 2013, NEUROIMAGE, V82, P547, DOI 10.1016/j.neuroimage.2013.05.087; Barbey AK, 2013, CORTEX, V49, P1195, DOI 10.1016/j.cortex.2012.05.022; Barbey AK, 2012, BRAIN, V135, P1154, DOI 10.1093/brain/aws021; Barbey AK, 2011, CEREB CORTEX, V21, P789, DOI 10.1093/cercor/bhq153; Barbey AK, 2009, TRENDS NEUROSCI, V32, P603, DOI 10.1016/j.tins.2009.09.001; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bennett CM, 2010, ANN NY ACAD SCI, V1191, P133, DOI 10.1111/j.1749-6632.2010.05446.x; BlanchardFields F, 1997, PSYCHOL AGING, V12, P684, DOI 10.1037/0882-7974.12.4.684; Burgaleta M, 2014, HUM BRAIN MAPP, V35, P1957, DOI 10.1002/hbm.22305; Burton CL, 2006, CLIN NEUROPSYCHOL, V20, P432, DOI 10.1080/13854040590967063; Bushara KO, 2001, J NEUROSCI, V21, P300, DOI 10.1523/JNEUROSCI.21-01-00300.2001; CAREY ME, 1982, ACTA CHIR SCAND, P351; Caveness W F, 1979, Adv Neurol, V22, P1; Channon S, 2004, ACTA PSYCHOL, V115, P235, DOI 10.1016/j.actpsy.2003.12.008; Channon S, 2007, NEUROPSYCHOLOGIA, V45, P1725, DOI 10.1016/j.neuropsychologia.2006.12.021; Chiang MC, 2009, J NEUROSCI, V29, P2212, DOI 10.1523/JNEUROSCI.4184-08.2009; Colom R, 2009, INTELLIGENCE, V37, P124, DOI 10.1016/j.intell.2008.07.007; CORNELIUS SW, 1987, PSYCHOL AGING, V2, P144, DOI 10.1037/0882-7974.2.2.144; Costa PT, 2000, ASSESSMENT, V7, P325, DOI 10.1177/107319110000700402; DeYoung CG, 2014, J PERS ASSESS, V96, P46, DOI 10.1080/00223891.2013.806327; DIEHL M, 1995, PSYCHOL AGING, V10, P478, DOI 10.1037/0882-7974.10.3.478; Dimitrov M, 1996, CORTEX, V32, P357, DOI 10.1016/S0010-9452(96)80057-8; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Glascher J, 2010, P NATL ACAD SCI USA, V107, P4705, DOI 10.1073/pnas.0910397107; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Haier RJ, 2005, NEUROIMAGE, V25, P320, DOI 10.1016/j.neuroimage.2004.11.019; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hanten G, 2011, NEUROPSYCHOLOGIA, V49, P486, DOI 10.1016/j.neuropsychologia.2010.12.007; Harlow JM, 1999, J NEUROPSYCH CLIN N, V11, P281, DOI 10.1176/jnp.11.2.281; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jensen A. R., 1998, G FACTOR SCI MENTAL; Jezzini A, 2012, P NATL ACAD SCI USA, V109, P10077, DOI 10.1073/pnas.1200143109; Jung RE, 2007, BEHAV BRAIN SCI, V30, P135, DOI 10.1017/S0140525X07001185; Kennedy DP, 2011, NATURE, V474, P452, DOI 10.1038/474452a; Koenigs M, 2009, J NEUROSCI, V29, P14980, DOI 10.1523/JNEUROSCI.3706-09.2009; Loehlin J. C., 2004, LATENT VARIABLE MODE; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Mar RA, 2007, SOC COGN AFFECT NEUR, V2, P199, DOI 10.1093/scan/nsm011; MARSISKE M, 1995, PSYCHOL AGING, V10, P269, DOI 10.1037/0882-7974.10.2.269; Mayer JD, 2004, PSYCHOL INQ, V15, P197, DOI 10.1207/s15327965pli1503_02; Mayer JD, 2008, AM PSYCHOL, V63, P503, DOI 10.1037/0003-066X.63.6.503; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Mienaltowski A, 2011, ANN NY ACAD SCI, V1235, P75, DOI 10.1111/j.1749-6632.2011.06207.x; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Ochsner KN, 2004, CURR OPIN NEUROBIOL, V14, P254, DOI 10.1016/j.conb.2004.03.011; Ochsner KN, 2001, AM PSYCHOL, V56, P717, DOI 10.1037//0003-066X.56.9.717; Penfield W, 1935, BRAIN, V58, P115, DOI 10.1093/brain/58.1.115; Quilty LC, 2014, J PERS ASSESS, V96, P87, DOI 10.1080/00223891.2013.834440; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; Robertson RH, 2008, NEUROPSYCHOL REHABIL, V18, P236, DOI 10.1080/09602010701734438; Rombouts SARB, 1997, AM J NEURORADIOL, V18, P1317; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; RYLANDER G, 1939, PERSONALITY CHANGES; Sabbagh MA, 2004, BRAIN COGNITION, V55, P209, DOI 10.1016/j.bandc.2003.04.002; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Simmons WK, 2013, HUM BRAIN MAPP, V34, P2944, DOI 10.1002/hbm.22113; Simmons WK, 2010, CEREB CORTEX, V20, P813, DOI 10.1093/cercor/bhp149; Simmons WK, 2009, J INT NEUROPSYCH SOC, V15, P645, DOI 10.1017/S1355617709990348; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; SPSS, 2013, IBM SPSS STAT WIND V; Sternberg RJ, 2000, HDB INTELLIGENCE; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Thornton WL, 2007, PSYCHOL AGING, V22, P470, DOI 10.1037/0882-7974.22.3.470; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whitfield KE, 2003, EXP AGING RES, V29, P1, DOI 10.1080/03610730303703; Woolgar A, 2010, P NATL ACAD SCI USA, V107, P14899, DOI 10.1073/pnas.1007928107	88	19	19	0	26	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2014	137		10				2823	2833		10.1093/brain/awu207			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AR2MG	WOS:000343420900026	25070511	Green Published, Bronze			2021-06-18	
J	Holmes, M; Garver, M; Albrecht, L; Arbabi, S; Pham, TN				Holmes, Meredith; Garver, Matt; Albrecht, Lily; Arbabi, Saman; Pham, Tam N.			Comparison of Two Comorbidity Scoring Systems for Older Adults with Traumatic Injuries	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							SEVERITY SCORE; CO-MORBIDITY; MORTALITY; EMERGENCY; FRAILTY	BACKGROUND: The purpose of this study was to determine the mortality predictive value of two different comorbidity scores, Comorbidity-Polypharmacy Score (CPS) and Charlson scoring system, in a large sample of older trauma patients. STUDY DESIGN: At an urban tertiary care Level I trauma center, trauma patients aged 55 years and older who were initially admitted to critical care were included. This retrospective chart review was conducted at Harborview Medical Center in Seattle, WA. Older trauma patients admitted from January 1, 2010 through December 31, 2010 were screened for inclusion. One-year mortality data were obtained from the Washington State Department of Health. Covariates included age, presence of hypotension, traumatic brain injury, and Injury Severity Score. RESULTS: Records for 667 older trauma patients were reviewed. In multivariate analyses, CPS was an independent predictor of fatal outcomes. Higher CPS was associated with greater mortality, however, it was not superior to Charlson methodology in predicting 1-year mortality in this patient cohort. CONCLUSIONS: The addition of a comorbidity score improves multivariate models predicting long-term mortality in older trauma patients. There was no advantage to using CPS instead of Charlson score, and each was an independent predictor of fatal outcomes. (C) 2014 by the American College of Surgeons	[Holmes, Meredith; Garver, Matt] Univ Washington, Dept Pharm, Harborview Med Ctr, Seattle, WA 98104 USA; [Arbabi, Saman; Pham, Tam N.] Univ Washington, Dept Surg, Harborview Med Ctr, Div Trauma Burns & Crit Care, Seattle, WA 98104 USA; [Albrecht, Lily] Dartmouth Coll, Hanover, NH 03755 USA	Holmes, M (corresponding author), Univ Washington, Dept Pharm, Harborview Med Ctr, 325 Ninth Ave, Seattle, WA 98104 USA.	holmesme@uw.edu					[Anonymous], J TRAUMA S; [Anonymous], J TRAUMA; [Anonymous], J AM COLL SURG; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Englesbe MJ, 2012, ANN SURG, V256, P255, DOI 10.1097/SLA.0b013e31826028b1; Evans DC, 2012, J AM GERIATR SOC, V60, P1465, DOI 10.1111/j.1532-5415.2012.04075.x; Evans David C, 2011, Int J Crit Illn Inj Sci, V1, P104, DOI 10.4103/2229-5151.84793; Jansen JO, 2013, CRIT CARE, V17, DOI 10.1186/cc12499; Justiniano CF, 2013, J SURG RES, V181, P16, DOI 10.1016/j.jss.2012.05.042; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Robinson TN, 2013, AM J SURG, V206, P544, DOI 10.1016/j.amjsurg.2013.03.012; Robinson TN, 2009, ANN SURG, V250, P449, DOI 10.1097/SLA.0b013e3181b45598; Schluter PJ, 2011, INJURY, V42, P83, DOI 10.1016/j.injury.2010.08.036	19	19	19	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2014	219	4					631	637		10.1016/j.jamcollsurg.2014.05.014			7	Surgery	Surgery	AP9TJ	WOS:000342422500006	25154672				2021-06-18	
J	Orfila, JE; Shimizu, K; Garske, AK; Deng, G; Maylie, J; Traystman, RJ; Quillinan, N; Adelman, JP; Herson, PS				Orfila, J. E.; Shimizu, K.; Garske, A. K.; Deng, G.; Maylie, J.; Traystman, R. J.; Quillinan, N.; Adelman, J. P.; Herson, P. S.			Increasing small conductance Ca2+-activated potassium channel activity reverses ischemia-induced impairment of long-term potentiation	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cardiac arrest; global cerebral ischemia; hippocampus long-term potentiation; mouse; small conductance Ca2+-activated potassium channels	TRANSIENT FOREBRAIN ISCHEMIA; HIPPOCAMPAL CA1 NEURONS; TRAUMATIC BRAIN-INJURY; SYNAPTIC PLASTICITY; CEREBRAL-ISCHEMIA; GLOBAL-ISCHEMIA; CLINICAL-TRIALS; NMDA RECEPTORS; CARDIAC-ARREST; SK2 CHANNELS	Global cerebral ischemia following cardiac arrest and cardiopulmonary resuscitation (CA/CPR) causes injury to hippocampal CA1 pyramidal neurons and impairs cognition. Small conductance Ca2+-activated potassium channels type 2 (SK2), expressed in CA1 pyramidal neurons, have been implicated as potential protective targets. Here we showed that, in mice, hippocampal long-term potentiation (LTP) was impaired as early as 3h after recovery from CA/CPR and LTP remained impaired for at least 30days. Treatment with the SK2 channel agonist 1-Ethyl-2-benzimidazolinone (1-EBIO) at 30min after CA provided sustained protection from plasticity deficits, with LTP being maintained at control levels at 30days after recovery from CA/CPR. Minimal changes in glutamate release probability were observed at delayed times after CA/CPR, implicating post-synaptic mechanisms. Real-time quantitative reverse transcriptase-polymerase chain reaction indicated that CA/CPR did not cause a loss of N-methyl-D-aspartate (NMDA) receptor mRNA at 7 or 30days after CA/CPR. Similarly, no change in synaptic NMDA receptor protein levels was observed at 7 or 30days after CA/CPR. Further, patch-clamp experiments demonstrated no change in functional synaptic NMDA receptors at 7 or 30days after CA/CPR. Electrophysiology recordings showed that synaptic SK channel activity was reduced for the duration of experiments performed (up to 30days) and that, surprisingly, treatment with 1-EBIO did not prevent the CA/CPR-induced loss of synaptic SK channel function. We concluded that CA/CPR caused alterations in post-synaptic signaling that were prevented by treatment with the SK2 agonist 1-EBIO, indicating that activators of SK2 channels may be useful therapeutic agents to prevent ischemic injury and cognitive impairments.	[Orfila, J. E.; Shimizu, K.; Garske, A. K.; Traystman, R. J.; Quillinan, N.; Herson, P. S.] Univ Colorado, Sch Med, Dept Anesthesiol, Aurora, CO 80045 USA; [Deng, G.; Traystman, R. J.; Herson, P. S.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO USA; [Maylie, J.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; [Adelman, J. P.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Herson, PS (corresponding author), Univ Colorado, Sch Med, Dept Anesthesiol, Aurora, CO 80045 USA.	paco.herson@ucdenver.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065855, NS080851]; Walter S. and Lucienne Driskill Foundation; AHA-Philips Resuscitation Fellowship [12POST11930031]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065855, R01NS080851] Funding Source: NIH RePORTER	This project was funded by NIH grants (NS065855 and NS080851), a Walter S. and Lucienne Driskill Foundation grant and an AHA-Philips Resuscitation Fellowship (12POST11930031).	Allen D, 2011, J CEREBR BLOOD F MET, V31, P2302, DOI 10.1038/jcbfm.2011.90; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; CREPEL V, 1993, J NEUROPHYSIOL, V69, P1774; Dai XN, 2007, NEUROPHARMACOLOGY, V52, P1124, DOI 10.1016/j.neuropharm.2006.11.012; Davies KD, 2007, BRAIN RES, V1158, P39, DOI 10.1016/j.brainres.2007.05.008; Davies KD, 2008, J BIOL CHEM, V283, P33138, DOI 10.1074/jbc.M803431200; Debanne D, 1996, J PHYSIOL-LONDON, V491, P163, DOI 10.1113/jphysiol.1996.sp021204; Di F. M., 2008, NEUROPHARMACOLOGY, V55, P353; Dos-Anjos S, 2009, NEUROCHEM INT, V54, P180, DOI 10.1016/j.neuint.2008.09.016; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Hammond RS, 2006, J NEUROSCI, V26, P1844, DOI 10.1523/JNEUROSCI.4106-05.2006; HORN M, 1992, ACTA NEUROPATHOL, V85, P79, DOI 10.1007/BF00304636; Hsu JC, 1998, J CEREBR BLOOD F MET, V18, P768, DOI 10.1097/00004647-199807000-00008; Hutchens MP, 2011, JOVE-J VIS EXP, DOI 10.3791/3116; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Khot S, 2006, SEMIN NEUROL, V26, P422, DOI 10.1055/s-2006-948323; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Kofler J, 2004, J NEUROSCI METH, V136, P33, DOI 10.1016/j.jneumeth.2003.12.024; Li JM, 2013, BIOMED RES-TOKYO, V34, P75, DOI 10.2220/biomedres.34.75; Lin MT, 2008, NAT NEUROSCI, V11, P170, DOI 10.1038/nn2041; Lin MT, 2010, J NEUROSCI, V30, P11726, DOI 10.1523/JNEUROSCI.1411-10.2010; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Liu ZA, 2010, BRAIN RES, V1361, P133, DOI 10.1016/j.brainres.2010.09.035; MacDonald John F., 2006, Critical Reviews in Neurobiology, V18, P71; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Mori K, 1998, BRAIN RES, V795, P221, DOI 10.1016/S0006-8993(98)00295-9; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Nagy D, 2011, NEUROPHARMACOLOGY, V61, P1026, DOI 10.1016/j.neuropharm.2011.07.005; Neumann JT, 2013, CURR DRUG TARGETS, V14, P20; Ngo-Anh TJ, 2005, NAT NEUROSCI, V8, P642, DOI 10.1038/nn1449; Nunes B, 2003, RESUSCITATION, V57, P287, DOI 10.1016/S0300-9572(03)00033-9; Peskine A, 2010, BRAIN INJURY, V24, P755, DOI 10.3109/02699051003709581; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Rosenkranz JA, 2009, J PHYSIOL-LONDON, V587, P115, DOI 10.1113/jphysiol.2008.158816; Sanhueza M, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-10; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Stackman RW, 2002, J NEUROSCI, V22, P10163; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Zhang L, 1997, J NEUROCHEM, V69, P1983	45	19	19	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2014	40	8					3179	3188		10.1111/ejn.12683			10	Neurosciences	Neurosciences & Neurology	AS1PL	WOS:000344052500005	25080203	Green Accepted			2021-06-18	
J	Sperry, JL; Zolin, S; Zuckerbraun, BS; Vodovotz, Y; Namas, R; Neal, MD; Ferrell, RE; Rosengart, MR; Peitzman, AB; Billiar, TR				Sperry, Jason L.; Zolin, Samuel; Zuckerbraun, Brian S.; Vodovotz, Yoram; Namas, Rami; Neal, Matthew D.; Ferrell, Robert E.; Rosengart, Matthew R.; Peitzman, Andrew B.; Billiar, Timothy R.			X Chromosome-Linked IRAK-1 Polymorphism Is a Strong Predictor of Multiple Organ Failure and Mortality Postinjury	ANNALS OF SURGERY			English	Article							TOLL-LIKE RECEPTOR-4; CARE RAPID THROMBELASTOGRAPHY; ACUTE TRAUMATIC COAGULOPATHY; KAPPA-B ACTIVATION; GENDER DIMORPHISM; SYSTEMIC INFLAMMATION; SEXUAL-DIMORPHISM; HEMORRHAGIC-SHOCK; SEVERE INJURY; BLUNT TRAUMA	Objective(s): Clinical research characterizing the mechanisms responsible for sex-based outcome differences postinjury remain conflicting. We sought to characterize an X chromosome-linked IRAK-1 (IL-1 receptor-associated kinase) polymorphism as an alternative mechanism responsible for sex differences postinjury. IRAK-1 is key intermediate in the toll-like receptor (TLR) pathway thought to drive inflammation postinjury. Methods: A prospective cohort study was performed over a 24-month period. Bluntly injured patients requiring intensive care unit admission were enrolled, whereas patients with isolated brain and spinal cord injuries were excluded. Outcomes of interest included multiple organ failure (MOF, Marshall MOD score > 5) and mortality. Logistic regression was utilized to determine the independent risk of poor outcome associated with the IRAK-1 variant after controlling for important differences. Results: In an enrolled cohort of 321 patients, the IRAK-1 variant was common (12.5%). Patients with and without the variant were similar in age, injury severity, and 24hr blood transfusion. After controlling for important confounders, the IRAK1 variant was independently associated with more than eightfold (OR = 8.4, P = 0.005, 95% CI: 1.9-37.1) and 11-fold (OR = 11.8, P = 0.037, 95% CI: 1.1-121) greater risk of MOF and mortality, respectively. These differences were most prominent in men, whereas women heterozygous for the variant demonstrated worse outcome in a dose-dependent fashion. Conclusions: The IRAK1 polymorphism is a strong independent predictor of MOF and mortality postinjury and represents a common variant with prognostic potential. These data demonstrate the importance of TLR signaling postinjury and supports that a genetic mechanism may drive sex outcome differences postinjury.	[Sperry, Jason L.; Zolin, Samuel; Zuckerbraun, Brian S.; Vodovotz, Yoram; Namas, Rami; Neal, Matthew D.; Ferrell, Robert E.; Rosengart, Matthew R.; Peitzman, Andrew B.; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Div Trauma & Gen Surg, Pittsburgh, PA 15213 USA	Sperry, JL (corresponding author), Univ Pittsburgh, Dept Surg, Div Trauma & Gen Surg, 200 Lothrop St,Suite F1268, Pittsburgh, PA 15213 USA.	sperryjl@upmc.edu	Namas, Rami/AAD-5793-2020; Namas, Rami/AAD-5796-2020	Namas, Rami/0000-0002-8582-5321; Zolin, Samuel/0000-0001-6347-4260	NIH NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093032]; National Trauma Institute [NTI-NTI-TRA-09-030]; Department of the Army [W81XWH-10-1-0924]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093032] Funding Source: NIH RePORTER	This work was funded by NIH NIGMS K23GM093032 and Award NTI-NTI-TRA-09-030 from the National Trauma Institute and sponsored by the Department of the Army W81XWH-10-1-0924. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. The authors declare no conflicts of interest.	Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001; Arcaroli J, 2006, AM J RESP CRIT CARE, V173, P1335, DOI 10.1164/rccm.200603-341OC; Armant MA, 2002, GENOME BIOL, V3; Baue AE, 1998, SHOCK, V10, P79, DOI 10.1097/00024382-199808000-00001; Bowles BJ, 2003, INJURY, V34, P27; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P1395, DOI 10.1097/TA.0b013e31825b9f05; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; Choudhry MA, 2005, SHOCK, V24, P101, DOI 10.1097/01.shk.0000191341.31530.5e; Choudhry Mashkoor A., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P127; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cotton BA, 2011, J TRAUMA, V71, P407, DOI 10.1097/TA.0b013e31821e1bf0; Croce MA, 2002, J TRAUMA, V53, P889, DOI 10.1097/00005373-200211000-00013; Cuschieri J, 2010, SHOCK, V34, P346, DOI 10.1097/SHK.0b013e3181d8e687; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; Fan J, 2007, J IMMUNOL, V178, P6573, DOI 10.4049/jimmunol.178.10.6573; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; George RL, 2003, SHOCK, V19, P28, DOI 10.1097/00024382-200301000-00006; Gunst Mark, 2010, Proc (Bayl Univ Med Cent), V23, P349; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; Kaczorowski DJ, 2008, J LEUKOCYTE BIOL, V83, P546, DOI 10.1189/jlb.0607374; Kashuk JL, 2012, TRANSFUSION, V52, P23, DOI 10.1111/j.1537-2995.2011.03264.x; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; Kashuk JL, 2009, J SURG RES, V156, P133, DOI 10.1016/j.jss.2009.03.046; Kimbrell DA, 2001, NAT REV GENET, V2, P256, DOI 10.1038/35066006; Levy RM, 2006, AM J PHYSIOL-REG I, V291, pR970, DOI 10.1152/ajpregu.00793.2005; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Liu G, 2008, FASEB J, V22, P2285, DOI 10.1096/fj.07-101816; MacLeod JBA, 2004, AM SURGEON, V70, P805; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; MANSHIP L, 1984, AM SURGEON, V50, P94; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Marshall JC, 1999, EUR J SURG, V163, P62; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Migeon BR, 2008, J AM SOC NEPHROL, V19, P2052, DOI 10.1681/ASN.2008020198; Migeon BR, 2006, JAMA-J AM MED ASSOC, V295, P1428, DOI 10.1001/jama.295.12.1428; MIGEON BR, 1994, TRENDS GENET, V10, P230, DOI 10.1016/0168-9525(94)90169-4; Migeon BR, 2002, CYTOGENET GENOME RES, V99, P8, DOI 10.1159/000071568; Minei JP, 2006, J TRAUMA, V60, P1106, DOI 10.1097/01.ta.0000220424.34835.f1; Mollen KP, 2008, J LEUKOCYTE BIOL, V83, P80, DOI 10.1189/jlb.0407201; Mollen KP, 2006, SHOCK, V26, P430, DOI 10.1097/01.shk.0000228797.41044.08; Nathens AB, 1996, WORLD J SURG, V20, P386, DOI 10.1007/s002689900061; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Offner PJ, 1999, ARCH SURG-CHICAGO, V134, P935, DOI 10.1001/archsurg.134.9.935; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Prince JM, 2006, J AM COLL SURGEONS, V202, P407, DOI 10.1016/j.jamcollsurg.2005.11.021; Rappold JF, 2002, J TRAUMA, V53, P436, DOI 10.1097/00005373-200209000-00007; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Sperry JL, 2008, J LEUKOCYTE BIOL, V83, P499, DOI 10.1189/jlb.0607360; Sperry JL, 2008, CRIT CARE MED, V36, P1838, DOI 10.1097/CCM.0b013e3181760c14; Sperry JL, 2008, J TRAUMA, V64, P572, DOI 10.1097/TA.0b013e3181650fdf; Sperry JL, 2012, J AM COLL SURGEONS, V214, P973, DOI 10.1016/j.jamcollsurg.2012.02.020; Toubiana J, 2010, CRIT CARE MED, V38, P2287, DOI 10.1097/CCM.0b013e3181f9f9c7; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Yang SL, 2009, J LEUKOCYTE BIOL, V85, P1015, DOI 10.1189/jlb.0508288; Yokoyama Y, 2002, IMMUNOL RES, V26, P63, DOI 10.1385/IR:26:1-3:063	65	19	21	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	OCT	2014	260	4					698	705		10.1097/SLA.0000000000000918			8	Surgery	Surgery	AP3LL	WOS:000341977400016	25203887	Green Accepted			2021-06-18	
J	Xu, ZNS; Yao, AN; Chu, SS; Paun, MK; McClintic, AM; Murphy, SP; Mourad, PD				Xu, Zinnia S.; Yao, Anning; Chu, Stephanie S.; Paun, Marla K.; McClintic, Abbi M.; Murphy, Sean P.; Mourad, Pierre D.			Detection of Wild Traumatic Brain Injury in Rodent Models Using Shear Wave Elastography	JOURNAL OF ULTRASOUND IN MEDICINE			English	Article						brain; edema; elastography; traumatic brain injury; ultrasound	CONTROLLED CORTICAL IMPACT; MAGNETIC-RESONANCE ELASTOGRAPHY; VISCOELASTIC PROPERTIES; BLOOD-FLOW; VOLUME; EDEMA	Objectives-Traumatic brain injury (TBI) can cause adverse physiologic changes in fluid content within the brain, which may lead to changes in tissue elasticity (eg, stiffness). This study evaluated the ability of ultrasonic shear wave elastography to observe these changes in the brain after TBI in vivo. Methods-Mice and rats received a mild TBI or sham surgery and were imaged acutely or 24 hours after injury using shear wave elastography, and the hemispheric stiffness values were compared. Results-Stiffness values were consistent across brain hemispheres of sham TBI rodents. By 24 hours after TBI, relative brain tissue stiffness values for mice and rats each decreased ipsilaterally and increased contralaterally, both relative to each other and compared to sham TBI rodents (P < .05). The absolute tissue elasticity value increased for rats (P < .05) but not for mice. Conclusions-Differences between intrahemispheric stiffness values of rodent brains by 24 hours after mild TBI may reflect the observed edema and hemorrhage ipsilateral to TBI and the known reduction of cerebral blood flow in both brain hemispheres. If these hypotheses hold true, ultrasonic shear wave elastography may offer a method for detecting adverse changes in fluid content within the brain after mild TBI.	[Xu, Zinnia S.; Yao, Anning; Chu, Stephanie S.; Mourad, Pierre D.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Paun, Marla K.; Mourad, Pierre D.] Univ Washington, Appl Phys Lab, Seattle, WA 98195 USA; [McClintic, Abbi M.; Murphy, Sean P.; Mourad, Pierre D.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Mourad, PD (corresponding author), Univ Washington, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA.	pierre@apl.washington.edu			Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-11-2-0109]	This work was supported by the Congressionally Directed Medical Research Program (award W81XWH-11-2-0109).	Athanasiou A, 2010, RADIOLOGY, V256, P297, DOI 10.1148/radiol.10090385; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Boulet T, 2013, J NEUROTRAUM, V30, P1512, DOI 10.1089/neu.2012.2788; Boulet T, 2011, J NEUROSCI METH, V201, P296, DOI 10.1016/j.jneumeth.2011.08.019; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Colgan NC, 2010, J NEUROTRAUM, V27, P1265, DOI 10.1089/neu.2009.1267; Deffieux T, 2012, IEEE T ULTRASON FERR, V59, P2390, DOI 10.1109/TUFFC.2012.2472; Derieppe M, 2012, EUR RADIOL, V22, P243, DOI 10.1007/s00330-011-2229-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FRYBACK DG, 1991, MED DECIS MAKING, V11, P88, DOI 10.1177/0272989X9101100203; Garra BS, 2011, ULTRASOUND Q, V27, P177, DOI 10.1097/RUQ.0b013e31822a2138; Gennisson J-L, 2013, Diagn Interv Imaging, V94, P487, DOI 10.1016/j.diii.2013.01.022; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Lee Bruce, 2005, NeuroRx, V2, P372; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Mace E, 2011, IEEE T MED IMAGING, V30, P550, DOI 10.1109/TMI.2010.2079940; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; Meyer Kimberly, 2008, J Trauma Nurs, V15, P185, DOI 10.1097/01.JTN.0000343324.55087.de; Misgeld T, 2007, NAT METHODS, V4, P559, DOI 10.1038/NMETH1055; O'Reilly MA, 2012, INT J HYPERTHER, V28, P386, DOI 10.3109/02656736.2012.666709; Tanter M, 2008, ULTRASOUND MED BIOL, V34, P1373, DOI 10.1016/j.ultrasmedbio.2008.02.002; Xu ZNS, 2013, J ULTRAS MED, V32, P485, DOI 10.7863/jum.2013.32.3.485	27	19	23	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0278-4297	1550-9613		J ULTRAS MED	J. Ultrasound Med.	OCT	2014	33	10					1763	1771		10.7863/ultra.33.10.1763			9	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	AQ0MP	WOS:000342477700006	25253822				2021-06-18	
J	Bazley, FA; Maybhate, A; Tan, CS; Thakor, NV; Kerr, C; All, AH				Bazley, Faith A.; Maybhate, Anil; Tan, Chuen Seng; Thakor, Nitish V.; Kerr, Candace; All, Angelo H.			Enhancement of Bilateral Cortical Somatosensory Evoked Potentials to Intact Forelimb Stimulation Following Thoracic Contusion Spinal Cord Injury in Rats	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Contusion spinal cord injury; cortical plasticity; electrophysiology; somatosensory evoked potentials; unilateral spinal cord injury	INDUCED MOVEMENT THERAPY; PLASTICITY; RECOVERY; DIFFERENTIATION; REORGANIZATION; REGENERATION; MODELS; STROKE	The adult central nervous system is capable of significant reorganization and adaptation following neurotrauma. After a thoracic contusive spinal cord injury (SCI) neuropathways that innervate the cord below the epicenter of injury are damaged, with minimal prospects for functional recovery. In contrast, pathways above the site of injury remain intact and may undergo adaptive changes in response to injury. We used cortical somatosensory evoked potentials (SSEPs) to evaluate changes in intact forelimb pathways. Rats received a midline contusion SCI, unilateral contusion SCI, or laminectomy with no contusion at the T8 level and were monitored for 28 days post-injury. In the midline injury group, SSEPs recorded from the contralateral forelimb region of the primary somatosensory cortex were 59.7% (CI 34.7%, 84.8%; c(2) = 21.9; dof = 1; p = 2.9 x 10(-6)) greater than the laminectomy group; SSEPs from the ipsilateral somatosensory cortex were 47.6% (CI 18.3%, 77%; c(2) = 10.1; dof = 1; p = 0.001) greater. Activation of the ipsilateral somatosensory cortex was further supported by BOLD-fMRI, which showed increased oxygenation at the ipsilateral hemisphere at day seven post-injury. In the unilateral injury group, ipsilesional side was compared to the contralesional side. SSEPs on day 14 (148%; CI 111%, 185%) and day 21 (137%; CI 110%, 163%) for ipsilesional forelimb stimulation were significantly increased over baseline (100%). SSEPs recorded from the hindlimb sensory cortex upon ipsilesional stimulation were 33.9% (CI 14.3%, 53.4%; c(2) = 11.6; dof = 1; p = 0.007) greater than contralesional stimulation. Therefore, these results demonstrate the ability of SSEPs to detect significant enhancements in the activation of forelimb sensory pathways following both midline and unilateral contusive SCI at T8. Reorganization of forelimb pathways may occur after thoracic SCI, which SSEPs can monitor to aid the development of future therapies.	[Bazley, Faith A.; Thakor, Nitish V.; All, Angelo H.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; [Bazley, Faith A.; Thakor, Nitish V.; All, Angelo H.] Natl Univ Singapore, Singapore Inst Neurotechnol, Singapore 117456, Singapore; [Thakor, Nitish V.] Natl Univ Singapore, Dept Elect & Comp Engn Bioengn & Med, Singapore 117456, Singapore; [Maybhate, Anil] Johns Hopkins Univ, Whiting Sch Engn, Baltimore, MD 21218 USA; [Tan, Chuen Seng] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117597, Singapore; [Kerr, Candace] Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [All, Angelo H.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [All, Angelo H.] Natl Univ Singapore, Dept Orthopaed Surg Bioengn & Med, Singapore 117456, Singapore	Bazley, FA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.	fbazley1@jhu.edu; anil.maybhate@jhu.edu; chuen_seng_tan@nuhs.edu.sg; nitish@jhu.edu; ckerr@som.umaryland.edu; hmn@jhu.edu	Tan, Chuen Seng/I-6854-2019; Thakor, Nitish/G-9110-2015; Thakor, Nitish V/A-5878-2008; Tan, Chuen Seng/K-1078-2013	Tan, Chuen Seng/0000-0002-6513-2309; Thakor, Nitish/0000-0002-9981-9395; Tan, Chuen Seng/0000-0002-6513-2309	Maryland Stem Cell Research Fund [2009-MSCRFII-0091-00, 2013-MSCRFII-0109-00]; National University of SingaporeNational University of Singapore [R-175-000-121-133, R-175-000-121-733, R-175-000-122-112, R-711-201-026-133]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01HL071568]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071568] Funding Source: NIH RePORTER	This work was supported in part by Maryland Stem Cell Research Fundunder Grant 2009-MSCRFII-0091-00 and Grant 2013-MSCRFII-0109-00 (PI A. H. All); in part by the National University of Singaporeunder Grant R-175-000-121-133, Grant R-175-000-121-733, Grant R-175-000-122-112, and Grant R-711-201-026-133 (PI A. H. All); and in part by the National Institutes of Healthunder Grant 5R01HL071568 (PI N. V. Thakor).	Agrawal G, 2010, J CLIN NEUROSCI, V17, P1159, DOI 10.1016/j.jocn.2010.02.005; Agrawal G, 2010, SPINE, V35, P1122, DOI 10.1097/BRS.0b013e3181be5fa7; Agrawal G, 2009, J CLIN NEUROSCI, V16, P1052, DOI 10.1016/j.jocn.2008.08.009; Agrawal G, 2008, IEEE ENG MED BIO, P4688, DOI 10.1109/IEMBS.2008.4650259; All AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047645; All AH, 2010, NEUROL SCI, V31, P595, DOI 10.1007/s10072-010-0329-y; All AH, 2009, J NEUROL SCI, V284, P81, DOI 10.1016/j.jns.2009.04.025; Battistuzzo CR, 2012, J NEUROTRAUM, V29, P1600, DOI 10.1089/neu.2011.2199; Bazley FA, 2013, IEEE ENG MED BIO, P6321, DOI 10.1109/EMBC.2013.6610999; Bazley FA, 2012, IEEE ENG MED BIO, P82, DOI 10.1109/EMBC.2012.6345876; Bazley FA, 2012, J NEUROSURG-SPINE, V16, P414, DOI 10.3171/2012.1.SPINE11684; Bazley FA, 2011, IEEE ENG MED BIO, P2005, DOI 10.1109/IEMBS.2011.6090564; Blesch A, 2009, TRENDS NEUROSCI, V32, P41, DOI 10.1016/j.tins.2008.09.008; Boakye M, 2012, J NEUROSURG-SPINE, V17, P141, DOI 10.3171/2012.5.AOSPINE1296; Cafferty WBJ, 2008, TRENDS NEUROSCI, V31, P215, DOI 10.1016/j.tins.2008.02.004; Chaerkady R, 2011, PROTEOMICS, V11, P4007, DOI 10.1002/pmic.201100107; Chen HC, 2012, INTEGR SER INFORM SY, V30, P203, DOI 10.1007/978-1-4614-1557-2_11; Cote MP, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00330; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Dietz V, 2012, EXP NEUROL, V235, P110, DOI 10.1016/j.expneurol.2011.04.007; Edgerton VR, 2004, ANNU REV NEUROSCI, V27, P145, DOI 10.1146/annurev.neuro.27.070203.144308; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Fouad K., 2010, BRAIN RES B; Fuzaro AC, 2012, REV BRAS FISIOTER, V16, P157, DOI 10.1590/S1413-35552012005000010; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Harkema SJ, 2008, BRAIN RES REV, V57, P255, DOI 10.1016/j.brainresrev.2007.07.012; Hodgetts S. I., 2012, CELL TRANSPLANT, V22, P383; Hofstetter CP, 2003, EUR J NEUROSCI, V18, P3061, DOI 10.1111/j.1460-9568.2003.03062.x; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Iyer S, 2010, J NEUROSCI METH, V193, P210, DOI 10.1016/j.jneumeth.2010.08.017; Kerr CL, 2010, INT J NEUROSCI, V120, P305, DOI 10.3109/00207450903585290; Letzen BS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010480; Madhok J, 2010, CRIT CARE MED, V38, P1709, DOI 10.1097/CCM.0b013e3181e7dd29; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; Maybhate A, 2012, CRIT CARE MED, V40, P573, DOI 10.1097/CCM.0b013e318232d97e; Onifer S. M., 2011, NEUROTHERAPEUTICS, P1; Paxinos G., 2006, RAT BRAIN STEREOTAXI; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Ramu J, 2007, EXP NEUROL, V204, P58, DOI 10.1016/j.expneurol.2006.09.015; Ramu J, 2006, J NEUROSCI RES, V84, P1235, DOI 10.1002/jnr.21030; Rao J.-S., BIOMED RES INT, V2013; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Sydekum E, 2009, NEUROIMAGE, V44, P1345, DOI 10.1016/j.neuroimage.2008.10.015; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Yague JG, 2011, EXP NEUROL, V227, P252, DOI 10.1016/j.expneurol.2010.11.011	47	19	20	0	10	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	SEP	2014	22	5					953	964		10.1109/TNSRE.2014.2319313			12	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	AP4WN	WOS:000342080400006	24801738	Bronze			2021-06-18	
J	Dick, AS				Dick, Anthony Steven			The development of cognitive flexibility beyond the preschool period: An investigation using a modified Flexible Item Selection Task	JOURNAL OF EXPERIMENTAL CHILD PSYCHOLOGY			English	Article						Executive function; Cognitive flexibility; Dimensional Change Card Sort; Wisconsin Card Sort; Flexible Item Selection Task; Working memory	CARD SORTING TEST; LATENT VARIABLE ANALYSIS; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; WORKING-MEMORY; YOUNG-CHILDREN; RELATIONAL COMPLEXITY; LIFE-SPAN; AGE; INHIBITION	We explored the development of cognitive flexibility in typically developing 6-, 8-, and 10-year-olds and adults by modifying a common cognitive flexibility task, the Flexible Item Selection Task (FIST). Although performance on the standard FIST reached ceiling by 8 years, FIST performance on other variations continued to improve until 10 years of age. Within a detailed task analysis, we also explored working memory storage and processing components of executive function and how these contribute to the development of cognitive flexibility. The findings reinforce the notion that cognitive flexibility is a multifaceted construct but that the development of working memory contributes in part to age-related change in this ability. (C) 2014 Elsevier Inc. All rights reserved.	Florida Int Univ, Dept Psychol, Miami, FL 33199 USA	Dick, AS (corresponding author), Florida Int Univ, Dept Psychol, Miami, FL 33199 USA.	adick@fiu.edu					Andrews G, 2003, CHILD DEV, V74, P1476, DOI 10.1111/1467-8624.00618; Ashendorf L, 2008, CLIN NEUROPSYCHOL, V22, P262, DOI 10.1080/13854040701218436; Axelrod BN, 2002, CLIN NEUROPSYCHOL, V16, P7, DOI 10.1076/clin.16.1.7.8331; Barcelo F, 2002, NEUROPSYCHOLOGIA, V40, P349, DOI 10.1016/S0028-3932(01)00110-5; Barcelo F, 1999, NEUROREPORT, V10, P1299, DOI 10.1097/00001756-199904260-00027; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Blackwell KA, 2009, J EXP CHILD PSYCHOL, V103, P241, DOI 10.1016/j.jecp.2009.01.002; Blair C, 2004, DEV PSYCHOBIOL, V45, P113, DOI 10.1002/dev.20022; Blair C, 2007, CHILD DEV, V78, P647, DOI 10.1111/j.1467-8624.2007.01019.x; Bond T.G., 2001, APPL RASCH MODEL FUN; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; CARVAJAL HH, 1992, PSYCHOL SCHOOLS, V29, P22, DOI 10.1002/1520-6807(199201)29:1<22::AID-PITS2310290105>3.0.CO;2-P; Cepeda NJ, 2007, PSYCHON B REV, V14, P1058, DOI 10.3758/BF03193091; Cepeda NJ, 2001, DEV PSYCHOL, V37, P715, DOI 10.1037/0012-1649.37.5.715; CHELUNE GJ, 1987, DEV NEUROPSYCHOL, V3, P81, DOI 10.1080/87565648709540365; CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; Chevalier N, 2008, DEVELOPMENTAL SCI, V11, P339, DOI 10.1111/j.1467-7687.2008.00679.x; Chevalier N, 2012, DEV NEUROPSYCHOL, V37, P99, DOI 10.1080/87565641.2011.632458; COHEN JD, 1990, PSYCHOL REV, V97, P332, DOI 10.1037/0033-295X.97.3.332; Cowan N, 2010, DEVELOPMENTAL SCI, V13, P120, DOI 10.1111/j.1467-7687.2009.00864.x; Cragg L, 2012, Q J EXP PSYCHOL, V65, P209, DOI 10.1080/17470210903204618; Cragg L, 2009, DEV PSYCHOL, V45, P1465, DOI 10.1037/a0015360; Crone EA, 2006, DEVELOPMENTAL SCI, V9, P278, DOI 10.1111/j.1467-7687.2006.00490.x; Crone EA, 2004, DEVELOPMENTAL SCI, V7, P443, DOI 10.1111/j.1467-7687.2004.00365.x; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; Dawson TL, 2002, INT J BEHAV DEV, V26, P154, DOI 10.1080/01650250042000645; Deak GO, 2003, ADV CHILD DEV BEHAV, V31, P271; Demetriou A., 2002, MONOGRAPHS SOC RES C, V67; Diamond A, 2005, PSYCHOL SCI, V16, P291, DOI 10.1111/j.0956-7976.2005.01530.x; DIAMOND A, 1994, DEV PSYCHOL, V30, P192, DOI 10.1037/0012-1649.30.2.192; Dick A. S, 2010, SELF SOCIAL REGULATI, P7; Dick AS, 2012, J COGN DEV, V13, P82, DOI 10.1080/15248372.2011.573516; Dunn L. M., 1981, MANUAL PEABODY PICTU; Ellefson MR, 2006, COGNITIVE DEV, V21, P108, DOI 10.1016/j.cogdev.2006.01.002; Espy KA, 2005, DEV NEUROPSYCHOL, V28, P669, DOI 10.1207/s15326942dn2802_6; Fristoe NM, 1997, NEUROPSYCHOLOGY, V11, P428, DOI 10.1037/0894-4105.11.3.428; Frye D, 1995, COGNITIVE DEV, V10, P483, DOI 10.1016/0885-2014(95)90024-1; Gamboz N, 2009, AGING NEUROPSYCHOL C, V16, P260, DOI 10.1080/13825580802573045; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gathercole SE, 2000, J EDUC PSYCHOL, V92, P377, DOI 10.1037//0022-0663.92.2.377; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; Halford GS, 1998, BEHAV BRAIN SCI, V21, P803, DOI 10.1017/S0140525X98001769; HEATON RK, 2000, WCST 64 COMPUTER VER; HODAPP AF, 1993, PSYCHOL REP, V73, P1152, DOI 10.2466/pr0.1993.73.3f.1152; Hughes C., 2002, CHILD ADOL MENT H-UK, V7, P131, DOI DOI 10.1111/1475-3588.00024; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Jacques S, 2001, DEV NEUROPSYCHOL, V20, P573, DOI 10.1207/875656401753549807; Kelly M. A., 1986, J CLIN EXPT NEUROPSY, V7, P604; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Kirkham NZ, 2003, DEVELOPMENTAL SCI, V6, P449, DOI 10.1111/1467-7687.00300; Kloo D, 2005, DEVELOPMENTAL SCI, V8, P44, DOI 10.1111/j.1467-7687.2005.00392.x; Kongs S.K., 2000, WCST 64 WISCONSIN CA; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Maes JHR, 2004, BRAIN COGNITION, V54, P201, DOI 10.1016/j.bandc.2004.01.003; Marcovitch S, 2010, CHILD DEV, V81, P1687, DOI 10.1111/j.1467-8624.2010.01503.x; Marcovitch S, 2009, DEVELOPMENTAL SCI, V12, P1, DOI 10.1111/j.1467-7687.2008.00754.x; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A., 1999, MODELS WORKING MEMOR; Morton JB, 2002, DEV PSYCHOBIOL, V40, P255, DOI 10.1002/dev.10033; Muller U, 2006, CHILD DEV, V77, P395, DOI 10.1111/j.1467-8624.2006.00878.x; Munakata Y, 2001, TRENDS COGN SCI, V5, P309, DOI 10.1016/S1364-6613(00)01682-X; Munakata Y, 2003, DEVELOPMENTAL SCI, V6, P471, DOI 10.1111/1467-7687.00302; Munakata Y, 1998, DEVELOPMENTAL SCI, V1, P161, DOI 10.1111/1467-7687.00021; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; PANIAK C, 1996, CANADIAN J REHABILIT, V9, P233; PARKIN AJ, 1995, NEUROPSYCHOLOGY, V9, P304, DOI DOI 10.1037/0894-4105.9.3.304; Ramscar M, 2013, CHILD DEV, V84, P1308, DOI 10.1111/cdev.12044; ROSSELLI M, 1993, CLIN NEUROPSYCHOL, V7, P145, DOI 10.1080/13854049308401516; Salthouse TA, 2003, J EXP PSYCHOL GEN, V132, P566, DOI 10.1037/0096-3445.132.4.566; Sherer M, 2003, J CLIN EXP NEUROPSYC, V25, P512, DOI 10.1076/jcen.25.4.512.13877; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Willoughby MT, 2013, PSYCHOL ASSESSMENT, V25, P664, DOI 10.1037/a0031747; Willoughby MT, 2010, PSYCHOL ASSESSMENT, V22, P306, DOI 10.1037/a0018708; Wright B., 1979, BEST TEST DESIGN HDB; Wright B. D., 1982, RATING SCALE ANAL RA; Yerys BE, 2012, J AUTISM DEV DISORD, V42, P2013, DOI 10.1007/s10803-012-1443-x; Zelazo P. D., 2003, MONOGRAPHS SOC RES C, V68, pvii; Zelazo PD, 2004, ACTA PSYCHOL, V115, P167, DOI 10.1016/j.actpsy.2003.12.005	81	19	25	3	40	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-0965	1096-0457		J EXP CHILD PSYCHOL	J. Exp. Child Psychol.	SEP	2014	125						13	34		10.1016/j.jecp.2014.01.021			22	Psychology, Developmental; Psychology, Experimental	Psychology	AJ7GA	WOS:000337864000002	24814204				2021-06-18	
J	Elkon, B; Cambrin, JR; Hirshberg, E; Bratton, SL				Elkon, Benjamin; Cambrin, Jay Riva; Hirshberg, Eliotte; Bratton, Susan L.			Hyperglycemia: An Independent Risk Factor for Poor Outcome in Children With Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						hyperglycemia; outcome; traumatic brain injury	TIGHT GLYCEMIC CONTROL; PEDIATRIC INTENSIVE-CARE; CRITICALLY-ILL PATIENTS; BLOOD-GLUCOSE; PERSISTENT HYPERGLYCEMIA; UNITED-STATES; HYPOTHERMIA; TRIAL; ASSOCIATION; RESUSCITATION	Objective: We sought 1) to describe the severity and duration of hyperglycemia among surviving and dying children after traumatic brain injury; 2) to evaluate whether persistent severe hyperglycemia (averaged blood glucose > 200 mg/dL [11 mmol/L] during the first 12 hr after injury) is independently associated with poor Glasgow Outcome Score; and 3) to evaluate different definitions and the prevalence of poor Glasgow Outcome Score to better understand measurement and potential hyperglycemia treatment evaluation. Design: Retrospective cohort. Setting: Level I American College of Surgery verified pediatric trauma center. Patients: Children admitted to intensive care with moderate-to-severe traumatic brain injury. Interventions: None. Measurements and Main Results: Time course for glucose changes was compared by survival and blood glucose groups. Twelve-hour averaged patient blood glucoses were categorized as persistent: severe hyperglycemia (> 200 mg/dL [11 mmol/L]), moderate hyperglycemia (161-200 mg/dL [9-11 mmol/L]), mild hyperglycemia (110-160 mg/dL [6-9 mmol/L]), normal glycemia (80-109 mg/dL [4-6 mmol/L]), or hypoglycemia (< 80 mg/dL [< 4 mmol/L]). Among 271 children, less than 1% had hypoglycemia and were excluded from further analysis. Seven percent had normal, 49% had mild, 24% had moderate, and 20% had severe blood glucose elevation. Among dying children (n = 44, 16%), the mean blood glucose at 20-24 hours after injury was significantly greater compared with survivors (150 vs 113 mg/dL [8 vs 6 mmol/L]) but by 29-32 hours, no longer significantly differed (112 vs 102 mg/dL [6 mmol/L]). Sixty-eight percent of children with severe blood glucose elevation had a poor outcome, whereas good outcomes at discharge occurred in 87% with mild or moderate blood glucose elevation. Severe blood glucose elevation was associated with a 3.5-fold increased adjusted odds ratio of poor outcome (95% CI, 1.2-10.3) compared with mild blood glucose elevation adjusted for injury severity and cardiorespiratory instability. Conclusions: Duration of severe blood glucose elevation (blood glucose > 200 mg/dL [11 mmol/L]) was brief but remained independently associated with poor outcome.	[Elkon, Benjamin; Hirshberg, Eliotte; Bratton, Susan L.] Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA; [Cambrin, Jay Riva] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA; [Hirshberg, Eliotte] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	Bratton, SL (corresponding author), Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA.	susan.bratton@hsc.utah.edu	McMahon, Graham/D-3740-2009	McMahon, Graham/0000-0003-4288-6535; Bratton, Susan/0000-0002-4605-8078	Hydrocephalus Association (Mentored-Young Investigator Award); NREF/AANS (Pediatric Neurosurgery Fellowship Grant) [CDC 1U01 DD000745-01]; AANS/CNS Section on Pediatric Neurological Surgery Research Grant; National Center on Birth Defects and Developmental DisabilitiesUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01DD000745] Funding Source: NIH RePORTER	Dr. Bratton serves as board member for the American Board of Pediatrics Critical Care Subboard (current chair), is employed by the University of Utah, and received support for travel from the Western Regional Pediatric Trauma Conference 2013. Dr. Riva-Cambrin is employed by the University of Utah and received grant support from Hydrocephalus Association (Mentored-Young Investigator Award). His institution received grant support from Hydrocephalus Association (Mentored-Young Investigator Award), NREF/AANS (Pediatric Neurosurgery Fellowship Grant), CDC 1U01 DD000745-01 (Spina Bifida Registry project), and AANS/CNS Section on Pediatric Neurological Surgery Research Grant (Risk Factors of Baclofen Pump Infection: A Multi-Centered Study). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Agus MSD, 2012, NEW ENGL J MED, V367, P1208, DOI 10.1056/NEJMoa1206044; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; Christensen DW, 1997, PEDIATRICS, V99, P715; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; GRAF WD, 1995, ANN EMERG MED, V26, P312, DOI 10.1016/S0196-0644(95)70079-X; Hirshberg E, 2008, CHEST, V133, P1328, DOI 10.1378/chest.07-2702; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobi J, 2012, CRIT CARE MED, V40, P3251, DOI 10.1097/CCM.0b013e3182653269; Legrand M, 2013, CRIT CARE, V17, DOI 10.1186/cc13133; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Macrae D, 2014, NEW ENGL J MED, V370, P107, DOI 10.1056/NEJMoa1302564; Mehari A, 2013, AM J RESP CRIT CARE, V187, P840, DOI 10.1164/rccm.201207-1222OC; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Nadkarni VM, 2010, CIRCULATION, V122, P8276, DOI 10.1161/CIRCULATIONAHA.110.970921; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saadat SMS, 2012, CHILD NERV SYST, V28, P1773, DOI 10.1007/s00381-012-1753-5; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sharma D, 2009, ANESTH ANALG, V108, P81, DOI 10.1213/ane.0b013e31818a6f32; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Traumatic Brain Injury in the United States, 2002, CDC MMWR SURVEILLANC; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	37	19	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2014	15	7					623	631		10.1097/PCC.0000000000000170			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AP3KR	WOS:000341975400013	24849146				2021-06-18	
J	Gao, WM; Lu, CW; Kochanek, PM; Berger, RP				Gao, Weimin; Lu, Chuanwen; Kochanek, Patrick M.; Berger, Rachel P.			Serum amyloid A is increased in children with abusive head trauma: a gel-based proteomic analysis	PEDIATRIC RESEARCH			English	Article							C-REACTIVE PROTEIN; BRAIN-INJURY; BIOMARKER CONCENTRATIONS; PEDIATRIC BRAIN; YOUNG-CHILDREN; A-PROTEIN; COMPONENT; INFANTS; INSIGHT; DISEASE	BACKGROUND: Abusive head trauma (AHT) is the leading cause of death from traumatic brain injury in infants and young children. Identification of mild AHT (Glasgow Coma Scale score: 13-15) is difficult because children can present with nonspecific symptoms and with no history of trauma. METHODS: Two-dimensional difference gel electrophoresis combined with mass spectrometry was used to compare the serum protein profile of children with Mild AHT and age-matched controls. Protein changes were confirmed by western blots. Western blots were performed using serum from children with mild, moderate, and severe AHT to assess the effect of injury severity on protein intensity. The protein identified serum amyloid A (SAA) was then measured by enzyme-linked immunosorbent assay. RESULTS: Using serum from 18 mild AHT cases and 20 controls, there were similar to 1,000 protein spots; 2 were significantly different between groups. Both spots were identified as SAA. There was no relationship between protein levels and injury severity. SAA concentrations measured by enzyme-linked immunosorbent assay were increased in cases vs. controls. CONCLUSION: SAA may be a potential biomarker to identify children with mild AHT who present for medical care without a history of trauma and who might otherwise not be recognized as needing a head computed tomography.	[Gao, Weimin; Lu, Chuanwen] Texas Tech Univ, Inst Environm & Human Hlth, Dept Environm Toxicol, Lubbock, TX 79409 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Kochanek, Patrick M.; Berger, Rachel P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Dept Pediat, Pittsburgh, PA 15213 USA	Gao, WM (corresponding author), Texas Tech Univ, Inst Environm & Human Hlth, Dept Environm Toxicol, Lubbock, TX 79409 USA.	weimin.gao@ttu.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	National Institutes of Health (Bethesda, MD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD055986]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055986] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant 1R01HD055986 (Bethesda, MD).	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Aly H, 2011, J PERINATOL, V31, P263, DOI 10.1038/jp.2010.130; BENSON MD, 1975, ARTHRITIS RHEUM-US, V18, P315, DOI 10.1002/art.1780180404; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, CLIN PEDIATR EMERG M, V7, P186, DOI 10.1016/j.cpem.2006.06.001; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Bruun CF, 1998, ELECTROPHORESIS, V19, P776, DOI 10.1002/elps.1150190529; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Fountas KN, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08311; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Gao WM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-110; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Herman BE, 2011, PEDIATR EMERG CARE, V27, P65, DOI 10.1097/PEC.0b013e31820349db; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; HIJMANS W, 1979, CLIN EXP IMMUNOL, V35, P96; HUSBY G, 1974, J CLIN INVEST, V53, P1054, DOI 10.1172/JCI107642; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Jylhava J, 2009, J INTERN MED, V266, P286, DOI 10.1111/j.1365-2796.2009.02120.x; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kemp PJ, 2003, ANAT REC PART A, V270A, P41, DOI 10.1002/ar.a.10008; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Lu CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038332; Lu CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032895; Murphy S, 2012, NEUROTHERAPEUTICS, V9, P3, DOI 10.1007/s13311-011-0093-6; Rallidis LS, 2006, ATHEROSCLEROSIS, V189, P193, DOI 10.1016/j.atherosclerosis.2005.11.032; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; ROSENTHAL CJ, 1975, J CLIN INVEST, V55, P746, DOI 10.1172/JCI107985; Sieswerda-Hoogendoorn Tessa, 2012, J Pediatr, V160, P880, DOI 10.1016/j.jpeds.2012.01.059; SPAIDE RF, 1990, AM FAM PHYSICIAN, V41, P1145; Takata S, 2011, BIOMARKERS, V16, P530, DOI 10.3109/1354750X.2011.607189; Urieli-Shoval S, 2000, CURR OPIN HEMATOL, V7, P64, DOI 10.1097/00062752-200001000-00012; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	44	19	19	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	SEP	2014	76	3					280	286		10.1038/pr.2014.86			7	Pediatrics	Pediatrics	AO3ZB	WOS:000341274900009	24941216	Bronze			2021-06-18	
J	Harrison, JL; Rowe, RK; O'Hara, BF; Adelson, PD; Lifshitz, J				Harrison, Jordan L.; Rowe, Rachel K.; O'Hara, Bruce F.; Adelson, P. David; Lifshitz, Jonathan			Acute over-the-counter pharmacological intervention does not adversely affect behavioral outcome following diffuse traumatic brain injury in the mouse	EXPERIMENTAL BRAIN RESEARCH			English	Article						TBI Inflammation; NSAID; Sleep; Mouse; Analgesic	ANTIINFLAMMATORY CYTOKINES; INFLAMMATION; MICE; PATHOPHYSIOLOGY; NEUROPROTECTION; EPIDEMIOLOGY; PARACETAMOL; ACTIVATION; EXPRESSION; RECEPTORS	Following mild traumatic brain injury (TBI), patients may self-treat symptoms of concussion, including post-traumatic headache, taking over-the-counter (OTC) analgesics. Administering one dose of OTC analgesics immediately following experimental brain injury mimics the at-home treated population of concussed patients and may accelerate the understanding of the relationship between brain injury and OTC pharmacological intervention. In the current study, we investigate the effect of acute administration of OTC analgesics on neurological function and cortical cytokine levels after experimental diffuse TBI in the mouse. Adult, male C57BL/6 mice were injured using a midline fluid percussion (mFPI) injury model of concussion (6-10 min righting reflex time for brain-injured mice). Experimental groups included mFPI paired with either ibuprofen (60 mg/kg, i.p.; n = 16), acetaminophen (40 mg/kg, i.p.; n = 9), or vehicle (15 % ethanol (v/v) in 0.9 % saline; n = 13) and sham injury paired OTC medicine or vehicle (n = 7-10 per group). At 24 h after injury, functional outcome was assessed using the rotarod task and a modified neurological severity score. Following behavior assessment, cortical cytokine levels were measured by multiplex ELISA at 24 h post-injury. To evaluate efficacy on acute inflammation, cortical cytokine levels were measured also at 6 h post-injury. In the diffuse brain-injured mouse, immediate pharmacological intervention did not attenuate or exacerbate TBI-induced functional deficits. Cortical cytokine levels were affected by injury, time, or their interaction. However, levels were not affected by treatment at 6 or 24 h post-injury. These data indicate that acute administration of OTC analgesics did not exacerbate or attenuate brain-injury deficits which may inform clinical recommendations for the at-home treated mildly concussed patient.	[Harrison, Jordan L.; Rowe, Rachel K.; Adelson, P. David; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Harrison, Jordan L.; Rowe, Rachel K.; Adelson, P. David; Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Harrison, Jordan L.; Adelson, P. David; Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Grad Program Neurosci, Tempe, AZ USA; [Rowe, Rachel K.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Rowe, Rachel K.; O'Hara, Bruce F.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA; [O'Hara, Bruce F.] Univ Kentucky, Coll Arts & Sci, Dept Biol, Lexington, KY USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA	Harrison, JL (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	harrisonj@email.arizona.edu; jlifshitz@email.arizona.edu	Adelson, David/W-2083-2019	Rowe, Rachel/0000-0002-9034-3159	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, R01NS065052-S, R21NS072611, KSCHIRT 10-5A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, R21NS072611] Funding Source: NIH RePORTER	Research reported in this publication was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS065052, R01NS065052-S, R21NS072611, and KSCHIRT 10-5A.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Banchereau J, 2012, NAT IMMUNOL, V13, P925, DOI 10.1038/ni.2406; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Dania M, 2007, EUR J PHARMACOL, V573, P214, DOI 10.1016/j.ejphar.2007.07.012; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Faul M., 2010, CTR DIS CONTROL PREV; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Maiese K, 2008, MERCK MANUAL HOME HL; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Ottani A, 2006, EUR J PHARMACOL, V531, P280, DOI 10.1016/j.ejphar.2005.12.015; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rowe RK, 2014, SLEEP, V37, P743, DOI 10.5665/sleep.3582; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Rowe RK, 2013, LAB ANIMAL, V42, P286, DOI 10.1038/laban.257; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	41	19	19	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	SEP	2014	232	9					2709	2719		10.1007/s00221-014-3948-3			11	Neurosciences	Neurosciences & Neurology	AN4KO	WOS:000340556800001	24760409				2021-06-18	
J	Joseph, B; Pandit, V; Meyer, D; Butvidas, L; Kulvatunyou, N; Khalil, M; Tang, A; Zangbar, B; O'Keeffe, T; Gries, L; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Meyer, David; Butvidas, Lynn; Kulvatunyou, Narong; Khalil, Mazhar; Tang, Andrew; Zangbar, Bardiya; O'Keeffe, Terence; Gries, Lynn; Friese, Randall S.; Rhee, Peter			The significance of platelet count in traumatic brain injury patients on antiplatelet therapy	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Antiplatelet therapy; traumatic brain injury; platelet count; platelet transfusion; neurosurgical intervention	SERIAL LABORATORY EXAMINATION; SEVERE HEAD-INJURY; INTRACRANIAL HEMORRHAGE; SUBSEQUENT DEVELOPMENT; PREINJURY CLOPIDOGREL; THROMBOCYTOPENIA; COAGULOPATHY; PROGRESSION; MANAGEMENT; MODERATE	BACKGROUND: Platelet dysfunction has been attributed to progression of initial intracranial hemorrhage (ICH) on repeat head computed tomographic (RHCT) scans in patients on prehospital antiplatelet therapy. However, there is little emphasis on the effect of platelet count and progression of ICH in patients with traumatic brain injury. The aim of this study was to determine the platelet count cutoff for progression on RHCT and neurosurgical intervention in patients on antiplatelet therapy. METHODS: We performed a prospective cohort analysis of all traumatic brain injury patients with an ICH on prehospital antiplatelet therapy. Antiplatelet therapy was defined as aspirin, clopidogrel, or a combination of both. Admission platelet count was recorded and used for analysis. Receiver operating characteristic curves were plotted to identify the optimal platelet count for progression on RHCT scan and neurosurgical intervention in patients on antiplatelet therapy. RESULTS: A total of 264 patients were enrolled. Platelet count of 135,000/mu L or less (area under the curve, 0.80) and platelet count of 95,000/mu L or less (area under the curve, 0.92) were the optimal threshold points for progression on RHCT scan and neurosurgical intervention, respectively. Patients with platelet count of 135,000/mu L or less were 12.4 times (95% confidence interval, 7.1-18.4) more likely to have progression on RHCT scan and patients with platelet count 95,000/mu L or less were 31.5 times (95% confidence interval, 19.7-96.2) more likely to require neurosurgical intervention. CONCLUSION: A platelet count of less than 135,000/mu L in patients on antiplatelet therapy is predictive of both radiographic and clinical worsening. This is a clinically relevant target intended to help tailor and improve management in patients on antiplatelet therapy. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Pandit, Viraj; Meyer, David; Butvidas, Lynn; Kulvatunyou, Narong; Khalil, Mazhar; Tang, Andrew; Zangbar, Bardiya; O'Keeffe, Terence; Gries, Lynn; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu		Meyer, David/0000-0002-3816-0160			Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; HARKER LA, 1972, NEW ENGL J MED, V287, P155, DOI 10.1056/NEJM197207272870401; Injury Prevention and Control, INJ PREV CONTR TRAUM; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P965, DOI 10.1097/TA.0000000000000161; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P121, DOI 10.1097/TA.0b013e3182a9cc95; Joseph B, 2014, J SURG RES, V186, P287, DOI 10.1016/j.jss.2013.08.009; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P990, DOI 10.1097/TA.0b013e3182a96591; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Stansbury LG, 2013, TRANSFUSION, V53, P783, DOI 10.1111/j.1537-2995.2012.03828.x; Wiles CE, 2005, J TRAUMA, V58, P729; Yuan F, 2012, J NEUROTRAUM, V29, P2137, DOI 10.1089/neu.2011.2233	19	19	19	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2014	77	3					417	421		10.1097/TA.0000000000000372			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AO2BJ	WOS:000341120200006	25159244				2021-06-18	
J	Kreuzer, PM; Landgrebe, M; Vielsmeier, V; Kleinjung, T; De Ridder, D; Langguth, B				Kreuzer, Peter M.; Landgrebe, Michael; Vielsmeier, Veronika; Kleinjung, Tobias; De Ridder, Dirk; Langguth, Berthold			Trauma-Associated Tinnitus	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast; brain injury; chronic tinnitus; noise trauma; trauma; whiplash	OPERATION IRAQI FREEDOM; TEMPORAL BONE-FRACTURES; NOISE-INDUCED TINNITUS; INDUCED HEARING-LOSS; POSTTRAUMATIC-STRESS-DISORDER; PURE-TONE TRAUMA; BRAIN-INJURY; AUDITORY-CORTEX; PERILYMPHATIC FISTULA; WHIPLASH INJURIES	Background: Up to 53% of individuals suffering from traumatic brain injuries develop tinnitus. Objective: To review the current literature on trauma-associated tinnitus in order to provide orientation for the clinical management of patients with trauma-associated tinnitus. Materials: A systematic literature search has been conducted in PubMed database applying the search terms posttraumatic tinnitus and trauma-associated tinnitus. Results have been complemented by related studies, book chapters, and the authors' clinical experience. Results: Not only mechanical, pressure-related, or noise-related head traumata but also neck injuries and emotional trauma can cause tinnitus. Exact diagnosis is essential. Disorders such as ossicular chain disruption, traumatic eardrum perforation, or perilymphatic fistula can be surgically treated. It should also be considered that pulsatile tinnitus can be a sign of life-threatening disorders such as carotid cavernous fistulas, arteriovenous malformations, and carotid dissections. Also, posttraumatic stress disorder should be taken into consideration as a potential contributing factor. Conclusions: There is an evident mismatch between the high incidence of trauma-associated tinnitus and scarce literature on the topic. A consistent and-at best-standardized assessment of tinnitus-and hearing-related sequelae of trauma is recommended both for the improvement of clinical care and for a deeper understanding of the various pathophysiological mechanisms of trauma-associated tinnitus.	[Kreuzer, Peter M.; Landgrebe, Michael; Langguth, Berthold] Univ Regensburg, Dept Psychiat & Psychotherapy, D-93053 Regensburg, Germany; [Vielsmeier, Veronika] Univ Regensburg, Dept Otolaryngol, D-93053 Regensburg, Germany; [Landgrebe, Michael] Social Fdn Bamberg, Dept Psychiat Psychosomat Med & Psychotherapy, Bamberg, Germany; [Kleinjung, Tobias] Univ Zurich, Dept Otolaryngol, Zurich, Switzerland; Brain Res Ctr Antwerp Innovat & Interdisciplinary, Antwerp, Belgium; [De Ridder, Dirk] Univ Otago, Unit Neurosurg, Dept Surg Sci, Dunedin Sch Med, Dunedin, New Zealand	Kreuzer, PM (corresponding author), Univ Regensburg, Dept Psychiat & Psychotherapy, Univ Str 84, D-93053 Regensburg, Germany.	peter.kreuzer@medbo.de	Kleinjung, Tobias/AAJ-3141-2020; Langguth, Berthold/AAP-2638-2021	Kleinjung, Tobias/0000-0003-3867-234X; 	European Psychiatric Association; ServierServier; PfizerPfizer; Astra ZenecaAstraZeneca; LundbeckLundbeck Corporation; LillyEli Lilly; Tinnitus Research Initiative; Tinnitus Research Initiative, Antwerp University TOP Project; SJ Medical Neurodivision; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); American Tinnitus Association	Dr Kreuzer received travel grants by the European Psychiatric Association, Servier, Pfizer, and Astra Zeneca; Dr Landgrebe received travel grants, consultancy, and speaker honoraria from Servier, Lundbeck, and Lilly; Dr Vielsmeier is supported by the Tinnitus Research Initiative; Dr Kleinjung is supported by the Tinnitus Research Initiative; Dr De Ridder is supported by the Tinnitus Research Initiative, Antwerp University TOP Project, and has received consultancy fees from SJ Medical Neurodivision; and Dr Langguth is supported by the Deutsche Forschungsgemeinschaft, the American Tinnitus Association, and the Tinnitus Research Initiative, and he received consultancy and speaker honoraria from Autifony, ANM, Astra Zeneca, Merz, Novartis, Pfizer, Lundbeck, and Servier.	Andersson G, 2009, J AM ACAD AUDIOL, V20, P315, DOI 10.3766/jaaa.20.5.5; Ansell M J, 2010, J R Army Med Corps, V156, P106; ARAN JM, 1995, HEARING RES, V82, P179, DOI 10.1016/0378-5955(94)00175-P; Attias J., 2005, Journal of Basic and Clinical Physiology and Pharmacology, V16, P117; AXELSSON A, 1985, British Journal of Audiology, V19, P271, DOI 10.3109/03005368509078983; AXELSSON A, 1989, British Journal of Audiology, V23, P53, DOI 10.3109/03005368909077819; Axelsson A., 2000, NOISE HEALTH, V2, P47; Baloh R. W, 1998, DIZZINESS HEARING LO; Basura GJ, 2012, BRAIN RES, V1485, P95, DOI 10.1016/j.brainres.2012.08.037; Bauer CA, 2011, EAR HEARING, V32, P145, DOI 10.1097/AUD.0b013e3181f5374f; Becker GD, 2001, EUR ARCH OTO-RHINO-L, V258, P159, DOI 10.1007/s004050100334; Belli S, 2008, EUR ARCH OTO-RHINO-L, V265, P279, DOI 10.1007/s00405-007-0440-8; Rocha CACB, 2007, PROG BRAIN RES, V166, P209, DOI 10.1016/S0079-6123(07)66018-X; Bluvstein I, 2013, J CLIN PSYCHOL MED S, V20, P164, DOI 10.1007/s10880-012-9318-z; Breeze J, 2011, BRIT J ORAL MAX SURG, V49, P607, DOI 10.1016/j.bjoms.2010.10.006; Breeze J, 2011, J LARYNGOL OTOL, V125, P13, DOI 10.1017/S0022215110002215; Brodie HA, 1997, AM J OTOL, V18, P188; BROWN JJ, 1978, ACTA OTO-LARYNGOL, V86, P394, DOI 10.3109/00016487809107518; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; Chae SW, 2001, J LARYNGOL OTOL, V115, P313; Chen J, 2001, Chin J Traumatol, V4, P106; Claussen C, 1995, INT TINNITUS J, V1, P105; CLAUSSEN CF, 1995, ACTA OTO-LARYNGOL, P53; COOPER JC, 1976, ARCH OTOLARYNGOL, V102, P148; Crocetti A, 2009, OTOLARYNG HEAD NECK, V140, P403, DOI 10.1016/j.otohns.2008.11.036; Cronlein T, 2007, PROG BRAIN RES, V166, P227, DOI 10.1016/S0079-6123(07)66021-X; DALISE M, 1997, CEREBROVASC DIS, P1169; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; Demeester K, 2007, B-ENT, P37; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Depauw P, 2001, CLIN NEUROL NEUROSUR, V103, P197, DOI 10.1016/S0303-8467(01)00141-X; Dinh CT, 2009, AUDIOL NEURO-OTOL, V14, P383, DOI 10.1159/000241895; Dobie R, 2004, TINNITUS THEORY MANA, P266; Dobie RA, 2003, OTOLARYNG CLIN N AM, V36, P383, DOI 10.1016/S0030-6665(02)00168-8; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Eggermont JJ, 2000, HEARING RES, V142, P89, DOI 10.1016/S0378-5955(00)00024-1; Fagelson Marc A, 2007, Am J Audiol, V16, P107, DOI 10.1044/1059-0889(2007/015); FAUSTI S, 1994, EAR HEARING, V15, P232, DOI 10.1097/00003446-199406000-00004; FAUSTI SA, 1993, ARCH OTOLARYNGOL, V119, P661; FAUSTI SA, 1992, J INFECT DIS, V165, P1026, DOI 10.1093/infdis/165.6.1026; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fechter LD, 2007, TOXICOL SCI, V98, P510, DOI 10.1093/toxsci/kfm101; FITZGERALD DC, 1995, ARCH PHYS MED REHAB, V76, P1017, DOI 10.1016/S0003-9993(95)81041-2; Folmer RL, 2003, LARYNGOSCOPE, V113, P821, DOI 10.1097/00005537-200305000-00010; Folmer RL, 1999, OTOLARYNG HEAD NECK, V121, P48, DOI 10.1016/S0194-5998(99)70123-3; FRECKMANN N, 1981, ACTA NEUROCHIR, V55, P273, DOI 10.1007/BF01808443; Friedman JA, 2001, J NEUROSURG, V94, P831, DOI 10.3171/jns.2001.94.5.0831; Fukai J, 2001, SURG NEUROL, V55, P353, DOI 10.1016/S0090-3019(01)00469-4; Geckle L, 2004, SOLDIER PERCEPTIONS; Gehr DD, 2000, HEARING RES, V150, P27, DOI 10.1016/S0378-5955(00)00170-2; George MS, 2009, BRAIN STIMUL, V2, P14, DOI 10.1016/j.brs.2008.06.001; Gilles A, 2012, OTOL NEUROTOL, V33, P899, DOI 10.1097/MAO.0b013e31825d640a; GLASSCOCK ME, 1992, AM J OTOL, V13, P333; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Goto F, 2001, AURIS NASUS LARYNX, V28, P29, DOI 10.1016/S0385-8146(00)00089-4; Granier M, 2006, Rev Stomatol Chir Maxillofac, V107, P253, DOI 10.1016/S0035-1768(06)77047-4; Hagberg M, 2005, INT ARCH OCC ENV HEA, V78, P575, DOI 10.1007/s00420-005-0621-y; HALFORD JBS, 1991, J PSYCHOSOM RES, V35, P383, DOI 10.1016/0022-3999(91)90033-K; Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3; Hesser H, 2009, INT J AUDIOL, V48, P295, DOI 10.1080/14992020802635325; Hinton DE, 2006, J TRAUMA STRESS, V19, P541, DOI 10.1002/jts.20138; Jacobson G P, 2001, J Am Acad Audiol, V12, P493; Joos K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040544; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Kaltenbach JA, 2011, HEARING RES, V276, P52, DOI 10.1016/j.heares.2010.12.003; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Khedr EM, 2010, NEUROEPIDEMIOLOGY, V35, P45, DOI 10.1159/000306630; Komiya H, 2000, ACTA OTO-LARYNGOL, V120, P750; Kreuzer PM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045599; Kreuzer PM, 2013, J HEAD TRAUMA REHAB, V28, P386, DOI 10.1097/HTR.0b013e318254736e; KRONENBERG J, 1993, AM J OTOL, V14, P92; Landgrebe M, 2010, BMC MED INFORM DECIS, V10, DOI 10.1186/1472-6947-10-42; Langguth B, 2012, EXPERT OPIN PHARMACO, V13, P2495, DOI 10.1517/14656566.2012.739608; Langguth Berthold, 2011, MMW Fortschr Med, V153, P40; Langguth B, 2011, WORLD J BIOL PSYCHIA, V12, P489, DOI 10.3109/15622975.2011.575178; Leske M C, 1981, ASHA, V23, P229; Levine RA, 1999, AM J OTOLARYNG, V20, P351, DOI 10.1016/S0196-0709(99)90074-1; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lewis J E, 2002, J Am Acad Audiol, V13, P339; LEWIS JE, 1994, CLIN OTOLARYNGOL, V19, P50, DOI 10.1111/j.1365-2273.1994.tb01147.x; Liang Wen, 2007, J Trauma, V63, P1014; Lin CY, 2010, HEARING RES, V269, P42, DOI 10.1016/j.heares.2010.07.005; Lollis SS, 2006, J NEUROSURG, V105, P1, DOI 10.3171/jns.2006.105.1.1; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Malouff JM, 2011, CURR PSYCHIAT REP, V13, P31, DOI 10.1007/s11920-010-0163-1; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; Marciano E, 2003, INT J AUDIOL, V42, P4, DOI 10.3109/14992020309056079; McVeigh K, 2010, J R Army Med Corps, V156, P110; Meenen N M, 1994, Unfallchirurgie, V20, P138, DOI 10.1007/BF02588158; Meenen NM, 1994, UNFALLCHIRURGIE, V20, P149; Mirza S, 2005, J LARYNGOL OTOL, V119, P366, DOI 10.1258/0022215053945723; Mittal MK, 2007, ACCIDENT ANAL PREV, V39, P624, DOI 10.1016/j.aap.2006.10.005; MIZOBUCHI M, 1991, Neurological Surgery, V19, P83; Moller AR, 2011, TEXTBOOK OF TINNITUS, P1; Mrena R, 2004, ACTA OTO-LARYNGOL, V124, P946, DOI 10.1080/00016480310017045; Mrena R, 2004, INT J AUDIOL, V43, P177, DOI 10.1080/14992020400050025; Mrena R, 2002, AUDIOL NEURO-OTOL, V7, P122, DOI 10.1159/000057660; Mrena R, 2009, INT J AUDIOL, V48, P394, DOI 10.1080/14992020902777225; Munjal SK, 2010, BRAIN INJURY, V24, P525, DOI 10.3109/02699050903516872; Nicolas-Puel Cecile, 2006, Int Tinnitus J, V12, P64; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Norena AJ, 2003, J NEUROPHYSIOL, V90, P2387, DOI 10.1152/jn.00139.2003; Norena AJ, 2006, NEUROREPORT, V17, P559, DOI 10.1097/00001756-200604240-00001; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; Ortmann M, 2011, EUR J NEUROSCI, V33, P568, DOI 10.1111/j.1460-9568.2010.07542.x; Persaud R, 2003, CLIN OTOLARYNGOL, V28, P203, DOI 10.1046/j.1365-2273.2003.00688.x; PHOON WH, 1993, OCCUP MED-OXFORD, V43, P35, DOI 10.1093/occmed/43.1.35; Potier M, 2009, EAR HEARING, V30, P291, DOI 10.1097/AUD.0b013e31819769fc; PYYKKO I, 1992, AM J OTOL, V13, P339; Quintanilla-Dieck MD, 2009, J PEDIATR-US, V155, P550, DOI 10.1016/j.jpeds.2009.04.053; Redekop GJ, 2008, CAN J NEUROL SCI, V35, P146, DOI 10.1017/S0317167100008556; Roberts LE, 2010, J NEUROSCI, V30, P14972, DOI 10.1523/JNEUROSCI.4028-10.2010; Rocha CACB, 2008, AUDIOL NEURO-OTOL, V13, P153, DOI 10.1159/000112423; Rosanowski F, 1996, LARYNGO RHINO OTOL, V75, P514, DOI 10.1055/s-2007-997624; Rossiter S, 2006, J SPEECH LANG HEAR R, V49, P150, DOI 10.1044/1092-4388(2006/012); Rowlands RG, 2009, J LARYNGOL OTOL, V123, P182, DOI 10.1017/S0022215108002569; Schaette R, 2011, J NEUROSCI, V31, P13452, DOI 10.1523/JNEUROSCI.2156-11.2011; Schecklmann M, 2013, BRAIN STRUCT FUNCT, V218, P1061, DOI 10.1007/s00429-013-0520-z; Scholten-Peeters GGM, 2002, SPINE, V27, P412, DOI 10.1097/00007632-200202150-00018; SCHUKNECHT H F, 1951, Trans Am Acad Ophthalmol Otolaryngol, V55, P407; SCHUKNECHT HF, 1951, ANN OTO RHINOL LARYN, V60, P273, DOI 10.1177/000348945106000201; Shore SE, 2008, EUR J NEUROSCI, V27, P155, DOI 10.1111/j.1460-9568.2007.05983.x; Shore SE, 2011, HEARING RES, V281, P38, DOI 10.1016/j.heares.2011.05.001; Sindhusake Doungkamol, 2004, J Am Acad Audiol, V15, P269; Snow GW, 2004, TINNITUS THEORY MANA, P16; Stevens C, 2007, INT J AUDIOL, V46, P208, DOI 10.1080/14992020601102329; Taranda J, 2009, PLOS BIOL, V7, P71, DOI 10.1371/journal.pbio.1000018; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tranter RMD, 2009, J FORENSIC LEG MED, V16, P53, DOI 10.1016/j.jflm.2008.09.001; Tungsinmunkong Sunee, 2007, Journal of the Medical Association of Thailand, V90, P2662; Turner Oliver, 2007, Ann Gen Psychiatry, V6, P26, DOI 10.1186/1744-859X-6-26; Ulug T, 2006, J OTOLARYNGOL, V35, P380, DOI 10.2310/7070.2006.0069; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vibert D, 2003, ANN OTO RHINOL LARYN, V112, P246, DOI 10.1177/000348940311200310; Vielsmeier V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038887; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weichbold V, 2003, INT J AUDIOL, V42, P489, DOI 10.3109/14992020309081519; Weichbold V, 2007, INT J AUDIOL, V46, P128, DOI 10.1080/14992020601126849; Weider Dudley J, 2005, Int Tinnitus J, V11, P137; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; WILLIAMS JD, 1980, ANN OTO RHINOL LARYN, V89, P239, DOI 10.1177/000348948008900310; Wysocki J, 2005, SKULL BASE-INTERD AP, V15, P99, DOI 10.1055/s-2005-870593; Wysocki J, 2005, SKULL BASE, V15, P106, DOI DOI 10.1055/S-2005-870593; Yankaskas K, 2013, HEARING RES, V295, P3, DOI 10.1016/j.heares.2012.04.016; Yetiser S, 2008, AM J OTOLARYNG, V29, P31, DOI 10.1016/j.amjoto.2007.01.001; Yoganandan N, 2002, ACCIDENT ANAL PREV, V34, P663, DOI 10.1016/S0001-4575(01)00066-5	154	19	20	0	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					432	442		10.1097/HTR.0b013e31829d3129			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700012	23982788				2021-06-18	
J	Taylor, JM; Kelley, B; Gregory, EJ; Berman, NEJ				Taylor, Jordan M.; Kelley, Brian; Gregory, Eugene J.; Berman, Nancy E. J.			Neuroglobin overexpression improves sensorimotor outcomes in a mouse model of traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Neuroglobin; Traumatic brain injury; Transgenic; Overexpression; Neuroprotective; Sensorimotor	CONTROLLED CORTICAL IMPACT; UP-REGULATION; EXPRESSION; MICE; CELLS; NEUROPROTECTION; PROTECTS; CYTOGLOBIN; RAT	There is a significant need for novel treatments that will improve traumatic brain injury (TBI) outcomes. One potential neuroprotective mechanism is to increase oxygen binding proteins such as neuroglobin. Neuroglobin has a high affinity for oxygen, is an effective free radical scavenger, and is neuroprotective within the brain following hypoxia and ischemia. The purpose of this study was to determine whether neuroglobin overexpression improves sensorimotor outcomes following TBI in transgenic neuroglobin overexpressing (NGB) mice. Additional study aims were to determine if and when an endogenous neuroglobin response occurred following TBI in wild-type (WT) mice, and in what brain regions and cell types the response occurred. Controlled cortical impact (CCI) was performed in adult (5 month) C57/BL6 WT mice, and NGB mice constitutively overexpressing neuroglobin via the chicken beta actin promoter coupled with the cytomegalovirus distal enhancer. The gridwalk task was used for sensorimotor testing of both WT and NGB mice, prior to injury, and at 2, 3, and 7 days post-TBI. NGB mice displayed significant reductions in the average number of foot faults per minute walking at 2,3, and 7 days post-TBI when compared to WT mice at each time point. Neuroglobin mRNA expression was assessed in the injured cortex of WT mice prior to injury, and at 1, 3, 7, and 14 days post-TBI using quantitative real time polymerase chain reaction (qRT-PCR). Neuroglobin mRNA was significantly increased at 7 days post-TBI. Immunostaining showed neuroglobin primarily localized to neurons and glial cells in the injured cortex and ipsilateral hippocampus of WT mice, while neuroglobin was present in all brain regions of NGB mice at 7 days post-TBI. These results showed that overexpression of neuroglobin reduced sensorimotor deficits following TBI, and that an endogenous increase in neuroglobin expression occurs during the subacute period. Increasing neuroglobin expression through novel therapeutic interventions during the acute period after TBI may improve recovery. (C) 2014 Elsevier B.V. All rights reserved.	[Taylor, Jordan M.] Univ Kansas, Med Ctr, Dept Phys Therapy & Rehabil Sci, Kansas City, KS 66160 USA; [Kelley, Brian] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66160 USA; [Gregory, Eugene J.; Berman, Nancy E. J.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA	Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Mailstop 3038,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	NBERMAN@kumc.edu			National Institute of General Medical Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20 GM103418]; University of Kansas Alzheimer's Disease Center [P30 AG035982]; Landon Center on Aging; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG035982] Funding Source: NIH RePORTER	This project was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20 GM103418. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. This work was also supported by an award from the University of Kansas Alzheimer's Disease Center (P30 AG035982) and the Landon Center on Aging.	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Antao ST, 2010, ANTIOXID REDOX SIGN, V13, P769, DOI 10.1089/ars.2009.2977; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chuang PY, 2010, J NEUROTRAUM, V27, P999, DOI 10.1089/neu.2009.1129; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dellavalle B, 2010, GLIA, V58, P1220, DOI 10.1002/glia.21002; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Duong TTH, 2009, J NEUROCHEM, V108, P1143, DOI 10.1111/j.1471-4159.2008.05846.x; Fago A, 2008, IUBMB LIFE, V60, P398, DOI 10.1002/iub.35; Fiocchetti M, 2013, BBA-PROTEINS PROTEOM, V1834, P1744, DOI 10.1016/j.bbapap.2013.01.015; Greenberg DA, 2008, CURR OPIN PHARMACOL, V8, P20, DOI 10.1016/j.coph.2007.09.003; Hundahl CA, 2010, BRAIN RES, V1331, P58, DOI 10.1016/j.brainres.2010.03.056; Jin KL, 2008, NEUROSCI LETT, V430, P135, DOI 10.1016/j.neulet.2007.10.031; Jin KL, 2011, PHARMACOLOGY, V87, P81, DOI 10.1159/000322998; Khan AA, 2008, FASEB J, V22, P1737, DOI 10.1096/fj.07-100784; Li WG, 2011, PROTEINS, V79, P115, DOI 10.1002/prot.22863; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shang AJ, 2012, NEUROL RES, V34, P588, DOI 10.1179/1743132812Y.0000000052; Shang AJ, 2012, NEUROL SCI, V33, P551, DOI 10.1007/s10072-011-0772-4; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Tian SF, 2013, J BIOL CHEM, V288, P15988, DOI 10.1074/jbc.M112.428789; Yu ZY, 2012, INT J MOL SCI, V13, P6995, DOI 10.3390/ijms13066995; Zhao S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-67; Zhu YH, 2002, BLOOD, V100, P2494, DOI 10.1182/blood-2002-01-0280	29	19	23	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 8	2014	577						125	129		10.1016/j.neulet.2014.03.012			5	Neurosciences	Neurosciences & Neurology	AN0XY	WOS:000340308500024	24642455	Green Accepted			2021-06-18	
J	Casella, EM; Thomas, TC; Vanino, DL; Fellows-Mayle, W; Lifshitz, J; Card, JP; Adelson, PD				Casella, Eric M.; Thomas, Theresa Currier; Vanino, Dana L.; Fellows-Mayle, Wendy; Lifshitz, Jonathan; Card, J. Patrick; Adelson, P. David			Traumatic brain injury alters long-term hippocampal neuron morphology in juvenile, but not immature, rats	CHILDS NERVOUS SYSTEM			English	Article						Golgi; Juvenile traumatic brain injury (TBI); Controlledcorticalimpact injury(CCI); Rats; Hippocampus; Dendritic length; Branching points; Soma area	CONTROLLED CORTICAL IMPACT; TEMPORAL-LOBE EPILEPSY; METHYL-D-ASPARTATE; HEAD-INJURY; UNITED-STATES; BEHAVIORAL DEFICITS; EXPERIMENTAL-MODELS; CHILDREN; MICE; NEUROTOXICITY	Pediatric traumatic brain injury (TBI) represents a prominent yet understudied medical condition that can profoundly impact brain development. As the juvenile injured brain matures in the wake of neuropathological cascades during potentially critical periods, circuit alterations may explain neurological consequences, including cognitive deficits. We hypothesize that experimental brain injury in juvenile rats, with behavioral deficits that resolve, will lead to quantifiable structural changes in hippocampal neurons at chronic time points post-injury. Controlled cortical impact (CCI), a model of focal TBI with contusion, was used to induce brain injury on post-natal day (PND) 17 juvenile rats. The histological consequence of TBI was quantified in regions of the hippocampus at post-injury day 28 (PID28) on sections stained using a variation of the Golgi-Cox staining method. Individual neuronal morphologies were digitized from the dentate gyrus (DG), CA3, and CA1 regions. Soma area in the ipsilateral injured DG and CA3 regions of the hippocampus increased significantly at PID28 in comparison to controls. In CA1, dendritic length and dendritic branching decreased significantly in comparison to controls and the contralateral hemisphere, without change in soma area. To extend the study, we examined neuronal morphology in rats with CCI at PND7. On PID28 after CCI on PND7 rats, CA1 neurons showed no injury-induced change in morphology, potentially indicating an age-dependent morphological response to injury. Long-lasting structural alterations in hippocampal neurons of brain-injured PND17 juvenile animals, but not PND7 immature animals, suggest differential plasticity depending on age-at-injury, with potential consequences for later function.	[Casella, Eric M.; Thomas, Theresa Currier; Lifshitz, Jonathan; Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Casella, Eric M.; Thomas, Theresa Currier; Lifshitz, Jonathan; Adelson, P. David] Univ Arizona, Dept Child Hlth, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ 85004 USA; [Thomas, Theresa Currier; Lifshitz, Jonathan] Phoenix VA Healthcare Syst, Phoenix, AZ 85012 USA; [Lifshitz, Jonathan; Adelson, P. David] Arizona State Univ, Neurosci Program, Tempe, AZ 85287 USA; [Adelson, P. David] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85287 USA; [Card, J. Patrick] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; [Fellows-Mayle, Wendy] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Vanino, Dana L.] Med Univ S Carolina, Charleston, SC 29412 USA	Adelson, PD (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Ambulatory Bldg B,4th Floor,1919 East Thomas Rd, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Thomas, Theresa Currier/K-1979-2019; Adelson, David/W-2083-2019	Thomas, Theresa Currier/0000-0002-9619-7666; Card, John/0000-0002-6148-7364	Walter L. Copeland Fund of the Pittsburgh Foundation; Phoenix Children's Hospital	The authors would like to sincerely thank the contributions of Dan Santone for the preliminary studies that made this research possible. Also, Rachel K. Rowe, PhD, Jordan L. Harrison, Jenna M. Ziebell, PhD, and the rest of the Translational Neurotrauma Research Team-Phoenix, AZ, provided thoughtful feedback on early drafts of the manuscript. These experiments were carried out at the University of Pittsburgh and analyzed and prepared for publication at the University of Arizona College of Medicine-Phoenix. This work was supported by the Walter L. Copeland Fund of the Pittsburgh Foundation Funding for Cranial Research and Phoenix Children's Hospital Mission Support Funds.	Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bothwell S, 2001, J NEUROSCI, V21, P4789, DOI 10.1523/JNEUROSCI.21-13-04789.2001; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Card JP, 2005, J NEUROTRAUM, V22, P1209; Card JP, 2005, J NEUROTRAUM, V22, P989, DOI 10.1089/neu.2005.22.989; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fletcher J, 1995, VARIABILITY OUTCOMES; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Iacono D, 2008, J NEUROPATH EXP NEUR, V67, P578, DOI 10.1097/NEN.0b013e3181772794; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 1985, OUTCOME HEAD INJURY; Levin HS, 1995, NEUROBEHAVIORAL OUTC; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mao H., 2013, J NEUROTRAUMA; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; SCHEIBEL ME, 1974, EPILEPSIA, V15, P55, DOI 10.1111/j.1528-1157.1974.tb03997.x; Scheibel ME, 1978, METHODS GOLGI, P89; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Stevenson KL, 2000, J NEUROTRAUM, V17, P997; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497	45	19	20	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	AUG	2014	30	8					1333	1342		10.1007/s00381-014-2446-z			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	AM3CY	WOS:000339730800002	24881033				2021-06-18	
J	Herrell, RK; Edens, EN; Riviere, LA; Thomas, JL; Bliese, PD; Hoge, CW				Herrell, Richard K.; Edens, Edward N.; Riviere, Lyndon A.; Thomas, Jeffrey L.; Bliese, Paul D.; Hoge, Charles W.			Assessing Functional Impairment in a Working Military Population: The Walter Reed Functional Impairment Scale	PSYCHOLOGICAL SERVICES			English	Article						functional impairment; military; scale; validation; Land Combat Study	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; PRIMARY-CARE; PHYSICAL HEALTH; COMBAT; IRAQ; ASSOCIATION; VALIDITY; IMPACT	Measurement of functional impairment is a priority for the military and other professional work groups routinely exposed to stressful traumatic events as part of their occupation. Standard measures of impairment used in general or chronically ill populations contain many items not suitable for these populations, and include mental health symptoms items that are not true measures of functioning. We created a new, 14-item scale-the Walter Reed Functional Impairment Scale-to assess functioning in 4 domains (physical, occupational, social, and personal). We asked 3,380 soldiers how much difficulty they currently have in each of the 4 domains on a 5-point scale. Behaviorally based psychosocial and occupational performance measures and general health questions were used to validate the scale. The utility of the scale was assessed against clinical measures of psychopathology and physical health (depression, posttraumatic stress disorder [PTSD], general health, generalized physical symptoms). We utilized Cronbach's alpha, item response theory, and the score test for trend to establish consistency of items and the validity of the scale. The scale exhibited excellent reliability (Cronbach's alpha = 0.92) and validity. The individual items and quartiles of sum scores were strongly correlated with negative occupational and social performance, and the utility of the scale was demonstrated by strong correlations with depression, PTSD, and high levels of generalized physical symptoms. This scale exhibits excellent psychometric properties in this sample of U. S. soldiers and, pending future research, is likely to have utility for other healthy occupational groups.	[Herrell, Richard K.; Riviere, Lyndon A.; Bliese, Paul D.; Hoge, Charles W.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Edens, Edward N.] US Army Training & Doctrine Command, Ft Eustis, VA USA; [Thomas, Jeffrey L.] US Army Med Res Unit Europe, Walter Reed Army Inst Res, Sembach, Germany	Herrell, RK (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Mil Psychiat Branch, Silver Spring, MD 20910 USA.	richard.k.herrell.ctr@mail.mil		Bliese, paul/0000-0002-5384-8879			Adler AB, 2005, MIL PSYCHOL, V17, P3, DOI 10.1207/s15327876mp1701_2; Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P38; Alonso J, 2011, MOL PSYCHIATR, V16, P1234, DOI 10.1038/mp.2010.101; Amaya-Jackson L, 1999, J TRAUMA STRESS, V12, P709, DOI 10.1023/A:1024781504756; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andersen J, 2010, PSYCHOSOM MED, V72, P498, DOI 10.1097/PSY.0b013e3181d969a1; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Epping-Jordan J. E., 2000, WHO MENTAL HLTH B, V6, P5; Felker B, 2008, MIL MED, V173, P155, DOI 10.7205/MILMED.173.2.155; Garin O, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-51; Grubaugh AL, 2005, J NERV MENT DIS, V193, P658, DOI 10.1097/01.nmd.0000180740.02644.ab; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2011, JAMA-J AM MED ASSOC, V306, P549, DOI 10.1001/jama.2011.1096; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kessler RC, 2009, EPIDEMIOL PSICHIAT S, V18, P23, DOI 10.1017/S1121189X00001421; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; MAHONEY F I, 1958, South Med J, V51, P605, DOI 10.1097/00007611-195805000-00011; Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P1180, DOI 10.1001/archpsyc.64.10.1180; MOSKOWITZ E, 1957, J Chronic Dis, V5, P342, DOI 10.1016/0021-9681(57)90092-9; PATRICK DL, 1981, J EPIDEMIOL COMMUN H, V35, P65, DOI 10.1136/jech.35.1.65; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; R Development Core Team, 2009, R LANG ENV STAT COMP; Rapaport MH, 2005, AM J PSYCHIAT, V162, P1171, DOI 10.1176/appi.ajp.162.6.1171; Reise S. P., 2002, MEASURING ANAL BEHAV; Richardson RD, 2002, PSYCHOSOM MED, V64, P676, DOI 10.1097/01.PSY.0000021941.35402.18; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Samejima F., 1969, PSYCHOMETRIC MONOGRA, V17; SAS Institute Inc, 2008, SAS VERS 9 2; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; StataCorp, 2007, STAT STAT SOFTW REL; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Taft CT, 1999, J TRAUMA STRESS, V12, P3, DOI 10.1023/A:1024786030358; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Toblin RL, 2012, J AFFECT DISORDERS, V136, P469, DOI 10.1016/j.jad.2011.10.048; United States Department of the Army, 1998, PHYS FITN TRAIN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Weathers F. W., 1993, INT SOC TRAUM STRESS; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604	43	19	19	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1541-1559	1939-148X		PSYCHOL SERV	Psychol. Serv.	AUG	2014	11	3					254	264		10.1037/a0037347			11	Psychology, Clinical	Psychology	AN0SS	WOS:000340294900002	25068298				2021-06-18	
J	Lee, SW; Gerdes, L; Tegeler, CL; Shaltout, HA; Tegeler, CH				Lee, Sung W.; Gerdes, Lee; Tegeler, Catherine L.; Shaltout, Hossam A.; Tegeler, Charles H.			A bihemispheric autonomic model for traumatic stress effects on health and behavior	FRONTIERS IN PSYCHOLOGY			English	Article						autonomic nervous system; hemispheric asymmetry; trauma; traumatic brain injury; post-traumatic stress disorder; polyvagal theory; violence; RDoC	BRAIN ELECTRICAL-ACTIVITY; NERVOUS-SYSTEM; HEMISPHERE ASYMMETRY; EEG; AROUSAL; DISORDER; VIOLENCE	A bihemispheric autonomic model (BHAM) may support advanced understanding of traumatic stress effects on physiology and behavior. The model builds on established data showing hemispheric lateralization in management of the autonomic nervous system, and proposes that traumatic stress can produce dominant asymmetry in activity of bilateral homologous brain regions responsible for autonomic management. Rightward and leftward dominant asymmetries are associated with sympathetic high arousal or parasympathetic freeze tendencies, respectively, and return to relative symmetry is associated with improved autonomic regulation. Autonomic auto-calibration for recovery (inverse of Jacksonian dissolution proposed by polyvagal theory) has implications for risk behaviors associated with traumatic life stress. Trauma-induced high arousal may be associated with risk for maladaptive behaviors to attenuate arousal (including abuse of alcohol or sedative-hypnotics). Trauma-induced freeze mode (including callous-unemotional trait) may be associated with low resting heart rate and risk for conduct disorders. The model may explain higher prevalence of leftward hemispheric abnormalities reported in studies of violence. Implications of the BHAM are illustrated through case examples of a military special operations officer with history of traumatic brain injury and post-traumatic stress disorder, and a university student with persisting post-concussion symptoms. Both undertook use of a noninvasive closed-loop neurotechnology high-resolution, relational, resonance-based, electroencephalic mirroring with ensuing decrease in hemispheric asymmetry, improvement in heart rate variability, and symptom reduction. Finally, the BHAM aligns with calls for researchers to use brain-behavioral constructs (research domain criteria or RDoC, proposed by the National Institutes of Mental Health) as building blocks for assessment and intervention in mental health science.	[Lee, Sung W.; Gerdes, Lee] Brain State Technol LLC, 15150 North Hayden Rd,Suite 106, Scottsdale, AZ 85260 USA; [Tegeler, Catherine L.; Tegeler, Charles H.] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC USA; [Shaltout, Hossam A.] Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC USA; [Shaltout, Hossam A.] Wake Forest Sch Med, Dept Obstet & Gynecol, Winston Salem, NC USA	Lee, SW (corresponding author), Brain State Technol LLC, 15150 North Hayden Rd,Suite 106, Scottsdale, AZ 85260 USA.	sung.lee@brainstatetech.com	Tegeler, Charles/R-3623-2019; Shaltout, hossam/F-6903-2013	Shaltout, hossam/0000-0001-7948-3815; Tegeler, Catherine/0000-0002-2943-6719			ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; Avnon Y, 2004, BRAIN, V127, P2099, DOI 10.1093/brain/awh236; Balle M, 2013, BIOL PSYCHOL, V93, P257, DOI 10.1016/j.biopsycho.2013.02.012; Barry RJ, 2007, CLIN NEUROPHYSIOL, V118, P2765, DOI 10.1016/j.clinph.2007.07.028; Britton JW, 2006, EPILEPSIA, V47, P737, DOI 10.1111/j.1528-1167.2006.00509.x; Cechetto DF, 2009, NEUROIMAGE, V47, P795, DOI 10.1016/j.neuroimage.2009.05.024; Chang JS, 2012, PSYCHOSOM MED, V74, P495, DOI 10.1097/PSY.0b013e31824d0da0; CONVIT A, 1991, BIOL PSYCHIAT, V30, P363, DOI 10.1016/0006-3223(91)90292-T; Craig AD, 2005, TRENDS COGN SCI, V9, P566, DOI 10.1016/j.tics.2005.10.005; Cuthbert BN, 2014, WORLD PSYCHIATRY, V13, P28, DOI 10.1002/wps.20087; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126; Daniele Ornella, 2002, J Stroke Cerebrovasc Dis, V11, P28, DOI 10.1053/jscd.2002.123972; Davis Telsie A, 2013, J Psychol Psychother, VSuppl 7, DOI 10.4172/2161-0487.S7-006; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Foster PS, 2008, CLIN NEUROPHYSIOL, V119, P2846, DOI 10.1016/j.clinph.2008.08.021; Gainotti G, 1972, Cortex, V8, P41; Gerdes L, 2013, BRAIN BEHAV, V3, P193, DOI 10.1002/brb3.116; Glenn AL, 2014, NAT REV NEUROSCI, V15, P54, DOI 10.1038/nrn3640; Gray MA, 2007, P NATL ACAD SCI USA, V104, P6818, DOI 10.1073/pnas.0609509104; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Hilz MJ, 2001, ANN NEUROL, V49, P575, DOI 10.1002/ana.1006; Institute of Medicine, 2013, RET HOM IR AFGH ASS; Kerig PK, 2012, J TRAUMA STRESS, V25, P272, DOI 10.1002/jts.21700; Kuhn T., 1962, STRUCTURE SCI REVOLU; Maniglio R, 2015, TRAUMA VIOLENCE ABUS, V16, P241, DOI 10.1177/1524838014526068; McGrath CL, 2013, JAMA PSYCHIAT, V70, P821, DOI 10.1001/jamapsychiatry.2013.143; McMahon RJ, 2010, J ABNORM PSYCHOL, V119, P752, DOI 10.1037/a0020796; Montenegro RA, 2011, NEUROSCI LETT, V497, P32, DOI 10.1016/j.neulet.2011.04.019; Morin CM., 1993, INSOMNIA PSYCHOL ASS; MORROW L, 1981, NEUROPSYCHOLOGIA, V19, P65, DOI 10.1016/0028-3932(81)90045-2; Nachshon I, 1987, CAUSES CRIME NEW BIO, P185; Okano AH, 2015, BRIT J SPORT MED, V49, P1213, DOI 10.1136/bjsports-2012-091658; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Ostrosky-Solis F, 2008, J FORENSIC SCI, V53, P1223, DOI 10.1111/j.1556-4029.2008.00803.x; Pillmann F, 1999, J NEUROPSYCH CLIN N, V11, P454, DOI 10.1176/jnp.11.4.454; Porges S., 2011, POLYVAGAL THEORY; Rabe S, 2008, PSYCHOSOM MED, V70, P13, DOI 10.1097/PSY.0b013e31815aa325; Rabe S, 2006, J ABNORM PSYCHOL, V115, P687, DOI 10.1037/0021-843X.115.4.687; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raine A, 2002, J CHILD PSYCHOL PSYC, V43, P417, DOI 10.1111/1469-7610.00034; Raine A., 1996, NEUROBIOLOGICAL APPR; Rees CA, 2014, ARCH DIS CHILD, V99, P552, DOI 10.1136/archdischild-2012-301863; Saper CB, 2002, ANNU REV NEUROSCI, V25, P433, DOI 10.1146/annurev.neuro.25.032502.111311; Sterling P, 2012, PHYSIOL BEHAV, V106, P5, DOI 10.1016/j.physbeh.2011.06.004; Tegeler C, 2013, NEUROLOGY, V80; Tegeler CH, 2014, JAMA PSYCHIAT, V71, P336, DOI 10.1001/jamapsychiatry.2013.3507; Tegeler CH, 2012, BRAIN BEHAV, V2, P814, DOI 10.1002/brb3.101; VOLKOW ND, 1987, BRIT J PSYCHIAT, V151, P668, DOI 10.1192/bjp.151.5.668; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; WEILER BL, 1996, CRIMINAL BEHAV MENTA, V0006; WITTLING W, 1990, NEUROPSYCHOLOGIA, V28, P457, DOI 10.1016/0028-3932(90)90072-V; Wittling W, 1998, NEUROPSYCHOLOGIA, V36, P461, DOI 10.1016/S0028-3932(97)00129-2; Wittling W, 1998, BRAIN COGNITION, V38, P17, DOI 10.1006/brcg.1998.1000; WONG MTH, 1994, ACTA PSYCHIAT SCAND, V90, P97, DOI 10.1111/j.1600-0447.1994.tb01562.x; Yoon BW, 1997, ARCH NEUROL-CHICAGO, V54, P741, DOI 10.1001/archneur.1997.00550180055012; ZAMRINI EY, 1990, NEUROLOGY, V40, P1408, DOI 10.1212/WNL.40.9.1408	57	19	19	1	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	AUG 1	2014	5								1	10.3389/fpsyg.2014.00843			14	Psychology, Multidisciplinary	Psychology	AN6LE	WOS:000340705200001	25136325	DOAJ Gold, Green Published			2021-06-18	
J	Nielsen, TH; Schalen, W; Stahl, N; Toft, P; Reinstrup, P; Nordstrom, CH				Nielsen, T. H.; Schalen, W.; Stahl, N.; Toft, P.; Reinstrup, P.; Nordstrom, C. H.			Bedside Diagnosis of Mitochondrial Dysfunction After Malignant Middle Cerebral Artery Infarction	NEUROCRITICAL CARE			English	Article						Mitochondrial dysfunction; Cerebral metabolism; Microdialysis; Malignant middle cerebral artery infarction	TRAUMATIC BRAIN-INJURY; CORTICAL SPREADING DEPRESSION; ENERGY-METABOLISM; CYCLOSPORINE-A; INTRACEREBRAL MICRODIALYSIS; GLYCOLYTIC METABOLITES; AMINO-ACIDS; ISCHEMIA; DEPOLARIZATIONS; CYCLE	The study explores whether the cerebral biochemical pattern in patients treated with hemicraniectomy after large middle cerebral artery infarcts reflects ongoing ischemia or non-ischemic mitochondrial dysfunction. The study includes 44 patients treated with decompressive hemicraniectomy (DCH) due to malignant middle cerebral artery infarctions. Chemical variables related to energy metabolism obtained by microdialysis were analyzed in the infarcted tissue and in the contralateral hemisphere from the time of DCH until 96 h after DCH. Reperfusion of the infarcted tissue was documented in a previous report. Cerebral lactate/pyruvate ratio (L/P) and lactate were significantly elevated in the infarcted tissue compared to the non-infarcted hemisphere (p < 0.05). From 12 to 96 h after DCH the pyruvate level was significantly higher in the infarcted tissue than in the non-infarcted hemisphere (p < 0.05). After a prolonged period of ischemia and subsequent reperfusion, cerebral tissue shows signs of protracted mitochondrial dysfunction, characterized by a marked increase in cerebral lactate level with a normal or increased cerebral pyruvate level resulting in an increased LP-ratio. This biochemical pattern contrasts to cerebral ischemia, which is characterized by a marked decrease in cerebral pyruvate. The study supports the hypothesis that it is possible to diagnose cerebral mitochondrial dysfunction and to separate it from cerebral ischemia by microdialysis and bed-side biochemical analysis.	[Nielsen, T. H.; Nordstrom, C. H.] Odense Univ Hosp, Dept Neurosurg, DK-5000 Odense C, Denmark; [Schalen, W.; Stahl, N.] Univ Lund Hosp, Dept Neurosurg, S-22363 Lund, Sweden; [Toft, P.] Odense Univ Hosp, Dept Anesthesiol, DK-5000 Odense C, Denmark; [Reinstrup, P.] Univ Lund Hosp, Dept Anesthesiol, S-22363 Lund, Sweden	Nielsen, TH (corresponding author), Odense Univ Hosp, Dept Neurosurg, Sdr Blvd 29, DK-5000 Odense C, Denmark.	troels.nielsen@ouh.regionsyddanmark.dk	Nielsen, Troels Halfeld/G-3456-2015	Nielsen, Troels Halfeld/0000-0002-3943-8128; Toft, Palle/0000-0002-3188-449X	Lund University Hospital; Odense University Hospital; University of Southern Denmark	We thank Katarina Nielsen, Department of Neurosurgery, Lund University Hospital, for help with the microdialysis equipment and biochemical analyses. The study was supported by Grants from Lund University Hospital, Odense University Hospital and University of Southern Denmark.	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Amer-Wahlin I, 2010, J MATERN-FETAL NEO M, V23, P158, DOI 10.3109/14767050903067360; Bains R, 2006, ACTA ANAESTH SCAND, V50, P572, DOI 10.1111/j.1399-6576.2006.00988.x; Bains R, 2009, ACTA ANAESTH SCAND, V53, P1354, DOI 10.1111/j.1399-6576.2009.02047.x; CHAPMAN AG, 1977, J NEUROCHEM, V28, P1025, DOI 10.1111/j.1471-4159.1977.tb10665.x; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gardenfors A, 2002, ACTA NEUROCHIR, V144, P601, DOI 10.1007/s00701-002-0954-1; Gardenfors A, 2002, ACTA NEUROCHIR WIEN, V144, P8; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hwang JH, 2010, BRAIN RES, V1359, P208, DOI 10.1016/j.brainres.2010.08.047; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Larach DB, 2011, NEUROCRIT CARE, V15, P609, DOI 10.1007/s12028-011-9517-8; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; Nielsen TH, 2012, ACTA NEUROL SCAND, V126, P404, DOI 10.1111/j.1600-0404.2012.01664.x; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; NORBERG K, 1975, BRAIN RES, V86, P31, DOI 10.1016/0006-8993(75)90635-6; Nordstrom CH, 2010, CHILD NERV SYST, V26, P465, DOI 10.1007/s00381-009-1035-z; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; NORDSTROM CH, 1978, STROKE, V9, P327, DOI 10.1161/01.STR.9.4.327; PETTERSEN JC, 1993, J APPL TOXICOL, V13, P9, DOI 10.1002/jat.2550130104; Piilgaard H, 2011, J CEREBR BLOOD F MET, V31, P1588, DOI 10.1038/jcbfm.2011.28; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Reinstrup P, 2011, NEUROCRIT CARE, V14, P441, DOI 10.1007/s12028-010-9486-3; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Vary TC, 1996, SHOCK, V6, P89, DOI 10.1097/00024382-199608000-00002; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x	41	19	19	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2014	21	1					35	42		10.1007/s12028-013-9875-5			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AL7XP	WOS:000339350500006	23860668				2021-06-18	
J	Van Gent, JM; Bandle, J; Calvo, RY; Zander, AL; Olson, EJ; Shackford, SR; Peck, KA; Sise, CB; Sise, MJ				Van Gent, Jan-Michael; Bandle, Jesse; Calvo, Richard Y.; Zander, Ashley L.; Olson, Erik J.; Shackford, Steven R.; Peck, Kimberly A.; Sise, C. Beth; Sise, Michael J.			Isolated traumatic brain injury and venous thromboembolism	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; isolated traumatic brain injury; venous thromboembolism	INTRACRANIAL HEMORRHAGIC INJURIES; ENOXAPARIN PROPHYLAXIS; PLATELET DYSFUNCTION; TISSUE FACTOR; COAGULOPATHY; HYPOPERFUSION; HEMOSTASIS; SAFETY	BACKGROUND: Traumatic brain injury (TBI) is considered an independent risk factor of venous thromboembolism (VTE). However, the role of TBI severity in VTE risk has not been determined. We hypothesized that increased severity of brain injury in patients with isolated TBI (iTBI) is associated with an increased incidence of VTE. METHODS: The records of patients admitted from June 2006 to December 2011 were reviewed for injury data, VTE risk factors, results of lower extremity surveillance ultrasound, and severity of TBI. Patients were identified by DRG International Classification of Diseases-9th Rev. codes for TBI, and only those with a nonhead Abbreviated Injury Scale (AIS) score of 1 or lower, indicating minimal associated injury, were included. The association of iTBI and VTE was determined using a case-control design. Among iTBI patients, those diagnosed with VTE (cases) were matched for age, sex, and admission year to those without VTE (controls). Data were analyzed using conditional logistic regression. RESULTS: There were 345 iTBI patients: 41 cases (12%) and 304 controls (88%). A total of 151 controls could not be matched to an appropriate case and were excluded. Of the remaining 153 controls, 1 to 16 controls were matched to each of the 41 VTE cases. Compared with the controls, the cases had a higher mean head-AIS score (4.4 vs. 3.9, p = 0.001) and overall Injury Severity Score (20.4 vs. 16.8, p = 0.001). Following adjustment for all factors found to be associated with VTE (ventilator days, central line placement, operative time > 2 hours, chemoprophylaxis, history of VTE, and history of cancer), the cases were significantly more likely to have a greater head injury severity (head-AIS score >= 5; odds ratio, 5.25; 95% confidence interval, 1.59-17.30; p = 0.006). CONCLUSION: The incidence of VTE in iTBI patients was significantly associated with the severity of TBI. VTE surveillance protocols may be warranted in these high-risk patients, as early detection of VTE could guide subsequent therapy. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Van Gent, Jan-Michael; Bandle, Jesse; Calvo, Richard Y.; Zander, Ashley L.; Olson, Erik J.; Shackford, Steven R.; Peck, Kimberly A.; Sise, C. Beth; Sise, Michael J.] Scripps Mercy Hosp, Trauma Serv, San Diego, CA 92103 USA	Van Gent, JM (corresponding author), Scripps Mercy Hosp, Trauma Serv MER62, 4077 Fifth Ave, San Diego, CA 92103 USA.	vangent.jan-michael@scrippshealth.org		Calvo, Richard/0000-0001-9147-2668			Brandt MM, 2007, AM J SURG, V193, P383; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Mackman N, 2008, J THROMB HAEMOST, V6, P303, DOI 10.1111/j.1538-7836.2007.02873.x; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Schrieber M, 2007, J TRAUMA, V63, P1261; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Wedzicha JA, 2000, THROMB HAEMOSTASIS, V84, P210	18	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2014	77	2					238	242		10.1097/TA.0000000000000294			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AN0EJ	WOS:000340255700010	25058248				2021-06-18	
J	Liu, DZ; Sharp, FR; Van, KC; Ander, BP; Ghiasvand, R; Zhan, XH; Stamova, B; Jickling, GC; Lyeth, BG				Liu, Da Zhi; Sharp, Frank R.; Van, Ken C.; Ander, Bradley P.; Ghiasvand, Rahil; Zhan, Xinhua; Stamova, Boryana; Jickling, Glen C.; Lyeth, Bruce G.			Inhibition of Src Family Kinases Protects Hippocampal Neurons and Improves Cognitive Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive memory deficits; hemorrhage; Src family kinases (SFKs); thrombin; traumatic brain injury (TBI)	FLUID-PERCUSSION MODEL; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; THROMBIN RECEPTOR REVEALS; CENTRAL-NERVOUS-SYSTEM; TYROSINE KINASE; IN-VIVO; CEREBROSPINAL-FLUID; PROTEOLYTIC MECHANISM; CISTERNA-MAGNA; RAT	Traumatic brain injury (TBI) is often associated with intracerebral and intraventricular hemorrhage. Thrombin is a neurotoxin generated at bleeding sites fater TBI and can lead to cell death and subsequent cognitive dysfunction via activation of Src family kinases (SFKs). We hypothesize that inhibiting SFKs can protect hippocampal neurons and improve cognitive memory function after TBI. To test these hypotheses, we show that moderate lateral fluid percussion (LFP) TBI in adult rats produces bleeding into the cerebrospinal fluid (CSF) in both lateral ventricles, which elevates oxyhemoglobin and thrombin levels in the CSF, activates the SFK family member Fyn, and increases Rho-kinase 1(ROCK1) expression. Systemic administration of the SFK inhibitor, PP2, immediately after moderate TBI blocks ROCK1 expression, protects hippocampal CA2/3 neurons, and improves spatial memory function. These data suggest the possibility that inhibiting SFKs after TBI might improve clinical outcomes.	[Liu, Da Zhi; Sharp, Frank R.; Ander, Bradley P.; Zhan, Xinhua; Stamova, Boryana; Jickling, Glen C.] Univ Calif Davis, Med Ctr, Dept Neurol, Sacramento, CA 95817 USA; [Liu, Da Zhi; Sharp, Frank R.; Ander, Bradley P.; Zhan, Xinhua; Stamova, Boryana; Jickling, Glen C.] Univ Calif Davis, Med Ctr, MIND Inst, Sacramento, CA 95817 USA; [Van, Ken C.; Ghiasvand, Rahil; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Liu, DZ (corresponding author), Univ Calif Davis, Med Ctr, Dept Neurol, 2805 50th St, Sacramento, CA 95817 USA.	dzliu@ucdavis.edu	Jickling, Glen/J-8790-2019; Stamova, Boryana/ABA-2981-2020	Jickling, Glen/0000-0003-3543-0820; Lyeth, Bruce/0000-0003-4811-1474	AHAAmerican Heart Association [12BGIA12060381]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS054652]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089901, R01NS054652] Funding Source: NIH RePORTER	This study was supported by AHA grant 12BGIA12060381 (DZL) and NIH grant NS054652 (FRS).	Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Ardizzone TD, 2004, STROKE, V35, P2587, DOI 10.1161/01.STR.0000143451.14228.ff; Ardizzone TD, 2007, STROKE, V38, P1621, DOI 10.1161/STROKEAHA.106.478966; Atzema C, 2006, J TRAUMA, V60, P1010, DOI 10.1097/01.ta.0000218038.28064.9d; Badjatia N, 2005, NEUROLOGIST, V11, P311, DOI 10.1097/01.nrl.0000178757.68551.26; Chevaleyre V, 2010, NEURON, V66, P560, DOI 10.1016/j.neuron.2010.04.013; Choi UB, 2011, J BIOL CHEM, V286, P29904, DOI 10.1074/jbc.M111.258897; COOKE M P, 1989, New Biologist, V1, P66; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COUGHLIN SR, 1992, SEMIN THROMB HEMOST, V18, P161, DOI 10.1055/s-2007-1002422; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Donovan FM, 1997, J NEUROSCI, V17, P5316; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Faul M., 2010, TRAUMATIC BRAIN INJU, P7; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Flaherty ML, 2006, NEUROLOGY, V66, P1182, DOI 10.1212/01.wnl.0000208400.08722.7c; Fogelholm R, 2005, J NEUROL NEUROSUR PS, V76, P1534, DOI 10.1136/jnnp.2004.055145; Fujimoto S, 2007, NEUROSCIENCE, V144, P694, DOI 10.1016/j.neuroscience.2006.09.049; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Garber ST, 2012, J NEUROSURG, V116, P1093, DOI 10.3171/2012.2.JNS112132; Groveman BR, 2012, FEBS J, V279, P20, DOI 10.1111/j.1742-4658.2011.08413.x; Gurkoff GG, 2013, BRAIN RES, V1515, P98, DOI 10.1016/j.brainres.2013.03.043; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jeon BT, 2013, NEUROTOX RES, V23, P238, DOI 10.1007/s12640-012-9339-2; Joshi A., 2013, AM J RESP CELL MOL B; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kaimachnikov NP, 2009, FEBS J, V276, P4102, DOI 10.1111/j.1742-4658.2009.07117.x; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kubier A, 2012, TOP COMPANION ANIM M, V27, P81, DOI 10.1053/j.tcam.2012.07.003; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Liu D., 2011, J CYTOL HISTOL, V2, P5; Liu DZ, 2008, NEUROBIOL DIS, V30, P201, DOI 10.1016/j.nbd.2008.01.006; Liu DZ, 2012, SCI WORLD J, DOI 10.1100/2012/491737; Liu DZ, 2011, ACTA NEUROCHIR SUPPL, V111, P77, DOI 10.1007/978-3-7091-0693-8_13; Liu DZ, 2010, ANN NEUROL, V67, P526, DOI 10.1002/ana.21924; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Lok J, 2011, ACTA NEUROCHIR SUPPL, V111, P63, DOI 10.1007/978-3-7091-0693-8_11; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Mahat MYA, 2012, J NEUROSCI METH, V211, P272, DOI 10.1016/j.jneumeth.2012.09.013; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Misra A, 2003, J PHARM PHARM SCI, V6, P252; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nakanishi-Matsui M, 2000, NATURE, V404, P609; National Institute of Neurological Disorders and Stroke, 2013, TRAUM BRAIN INJ HOP; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pegg CC, 2010, J NEUROSCI METH, V187, P8, DOI 10.1016/j.jneumeth.2009.12.002; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Place AT, 2011, MOL PHARMACOL, V80, P665, DOI 10.1124/mol.111.073957; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sharma AK, 2006, TOXICOL PATHOL, V34, P393, DOI 10.1080/01926230600798609; Shimizu A, 2005, BIOL REPROD, V73, P1219, DOI 10.1095/biolreprod.105.041616; Tang H, 2005, J BIOL CHEM, V280, P23918, DOI 10.1074/jbc.M503498200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Trepanier CH, 2012, FEBS J, V279, P12, DOI 10.1111/j.1742-4658.2011.08391.x; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; Wang H, 2003, BIOL CHEM, V384, P193, DOI 10.1515/BC.2003.021; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Watkin H, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-6; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xue MZ, 2006, J NEUROSCI, V26, P10281, DOI 10.1523/JNEUROSCI.2806-06.2006; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	66	19	19	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2014	31	14					1268	1276		10.1089/neu.2013.3250			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4CA	WOS:000340534000004	24428562	Green Published			2021-06-18	
J	Bayley, MT; Teasell, RW; Wolfe, DL; Gruen, RL; Eng, JJ; Ghajar, J; Tavender, E; Kua, A; Bragge, P				Bayley, Mark Theodore; Teasell, Robert William; Wolfe, Dalton Louis; Gruen, Russell Lindsay; Eng, Janice Jennifer; Ghajar, Jamshid; Tavender, Emma; Kua, Ailene; Bragge, Peter			Where to Build the Bridge Between Evidence and Practice?: Results of an International Workshop to Prioritize Knowledge Translation Activities in Traumatic Brain Injury Care	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						guidelines; knowledge translation; rehabilitation; therapeutic approaches for the treatment of brain injury; traumatic brain injury	EMERGENCY-MEDICINE; RANDOMIZED-TRIALS; REHABILITATION; IMPLEMENTATION	Introduction: Treatment of patients with traumatic brain injury (TBI) should be based upon the strongest evidence to achieve optimal patient outcomes. Given the challenges, efforts involved, and delays in uptake of evidence into practice, priorities for knowledge translation (KT) should be chosen carefully. An international workshop was convened to identify KT priorities for acute and rehabilitation care of TBI and develop KT projects addressing these priorities. Methods: An expert panel of 25 neurotrauma clinicians, researchers, and KT scientists representing 4 countries examined 66 neurotrauma research topics synthesized from 2 neurotrauma evidence resources: Evidence Based Review of Acquired Brain Injury and Global Evidence Mapping projects. The 2-day workshop combined KT theory presentations with small group activities to prioritize topics using a modified Delphi method. Results: Four acute care topics and 3 topics in the field of rehabilitation were identified. These were focused into 3 KT project proposals: optimization of intracranial pressure and nutrition in the first week following TBI; cognitive rehabilitation following TBI; and vocational rehabilitation following TBI. Conclusion: Three high-priority KT projects were developed: the first combined 2 important topics in acute TBI management of intracranial pressure management and nutrition, and the other projects focused on cognitive rehabilitation and vocational rehabilitation.	[Bayley, Mark Theodore] Univ Hlth Network, Toronto Rehabil Inst, Brain & Spinal Cord Rehabil Program, Toronto, ON M5G 2A2, Canada; [Kua, Ailene] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Bayley, Mark Theodore] Univ Toronto, Fac Med, Toronto, ON, Canada; [Teasell, Robert William] Univ Western Ontario, Schulich Sch Med & Dent, Dept Phys Med & Rehabil, London, ON, Canada; [Teasell, Robert William] Lawson Hlth Res Inst, London, ON, Canada; [Wolfe, Dalton Louis] Lawson Hlth Res Inst, Aging Rehabil & Geriatr Care, London, ON, Canada; [Gruen, Russell Lindsay; Tavender, Emma; Bragge, Peter] Monash Univ, Melbourne, Vic 3004, Australia; [Gruen, Russell Lindsay] Alfred Hlth, Melbourne, Vic, Australia; [Eng, Janice Jennifer] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V5Z 1M9, Canada; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA; [Ghajar, Jamshid] Weill Cornell Med Coll, New York, NY USA; [Tavender, Emma; Bragge, Peter] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Tavender, Emma] Cochrane Effect Practice & Org Care, Australian Satellite, Ottawa, ON, Canada	Bayley, MT (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, Brain & Spinal Cord Rehabil Program, Room 3-131,550 Univ Ave, Toronto, ON M5G 2A2, Canada.	mark.bayley@uhn.ca		Eng, Janice/0000-0002-2093-0788; Bayley, Mark/0000-0001-7860-9463; Tavender, Emma/0000-0002-7230-712X; Bragge, Peter/0000-0003-0745-5131	Victorian Neurotrauma Initiative-a research program of the Transport Accident Commission; Monash UniversityMonash University; Ontario Neurotrauma Foundation	The project described in this article was funded through the Victorian Neurotrauma Initiative-a research program of the Transport Accident Commission and Monash University's Strategic Grants Scheme (lead chief investigator: Peter Bragge) and the Ontario Neurotrauma Foundation (lead chief investigator: Mark Bayley).	Access Economics, 2009, EC COST SPIN CORD IN, P115; Bayley MT, 2007, ARCH PHYS MED REHAB, V88, P526, DOI 10.1016/j.apmr.2007.01.005; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Bragge P, 2012, J NEUROTRAUM, V29, P1539, DOI 10.1089/neu.2011.2193; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Buchan H, 2004, MED J AUSTRALIA, V180, pS48; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; Cranney A, 2008, OSTEOPOROSIS INT, V19, P1733, DOI 10.1007/s00198-008-0669-0; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Grimshaw JM, 2004, MED J AUSTRALIA, V180, pS50; Grimshaw JM, 2001, MED CARE, V39, pII2; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Grol R, 2001, MED CARE, V39, pII46; Grol R, 1997, BRIT MED J, V315, P418, DOI 10.1136/bmj.315.7105.418; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Lang ES, 2007, ACAD EMERG MED, V14, P915, DOI 10.1197/j.aem.2007.07.005; Lang ES, 2007, ACAD EMERG MED, V14, P919, DOI 10.1197/j.aem.2007.07.002; Lang ES, 2007, ANN EMERG MED, V49, P355, DOI 10.1016/j.annemergmed.2006.08.022; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; McKenzie JE, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-86; Priest JL, 2011, POPUL HEALTH MANAG, V14, P43, DOI 10.1089/pop.2010.0019; Ramsay CR, 2003, CLIN RADIOL, V58, P319, DOI 10.1016/S0009-9260(02)00524-X; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Woolf SH, 2008, JAMA-J AM MED ASSOC, V299, P211, DOI 10.1001/jama.2007.26	28	19	20	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					268	276		10.1097/HTR.0000000000000053			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300005	24984091				2021-06-18	
J	Colton, K; Yang, SM; Hu, PF; Chen, HH; Bonds, B; Scalea, TM; Stein, DM				Colton, Katharine; Yang, Shiming; Hu, Peter F.; Chen, Hegang H.; Bonds, Brandon; Scalea, Thomas M.; Stein, Deborah M.			Intracranial pressure response after pharmacologic treatment of intracranial hypertension	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; secondary insults; intracranial pressure; critical care documentation; automated documentation	7.2-PERCENT HYPERTONIC SALINE; CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; INTENSIVE-CARE; MANNITOL; PROPOFOL; FENTANYL; SUFENTANIL; METABOLISM; SEDATION	BACKGROUND: The accepted treatment of increased intracranial pressure (ICP) in patients experiencing severe traumatic brain injury is multimodal and algorithmic, obscuring individual effects of treatment. Using continuous vital signs monitoring, we sought to measure treatment effect and ascertain the accuracy of manual data recording. METHODS: Patients older than 17 years, admitted and requiring ICP monitoring between 2008 and 2010 at a high-volume urban trauma center, were retrospectively evaluated. Timing and dose of ICP-directed therapy were recorded from paper and electronic medical records. ICP data were collected automatically at 6-second intervals and from manual charts. A statistical mixed model was applied to all data to account for multiple sampling. RESULTS: A total of 117 patients met inclusion criteria; 450 treatments were administered when nursing records indicate an ICP greater than 20 mm Hg, While 968 treatments were given when ICP was greater than 20 mm Hg by automated data. Pharmacologic treatments identified include hypertonic saline (HTS), mannitol, barbiturates, and dose escalations of propofol or fentanyl infusions. Treatment with HTS resulted in the largest ICP decrease of the treatments examined, with a 1-hour ICP reduction of 8.8/9.9 mm Hg (for a small/large dose) according to manual data and a reduction of 3.0/2.4 mm Hg according to automated data. Propofol and fentanyl escalations resulted in smaller but significant ICP reductions. Mannitol (n = 8) resulted in statistically insignificant trends down in the first hour but rebounded by the second hour after administration. The average ICP in the hour before medication administration was higher for barbiturates (27 mm Hg) and mannitol (32 mm Hg) than for the other interventions (18-19 mm Hg). CONCLUSION: ICP fell after administration of HTS, mannitol, or barbiturates and showed continued improvement after 2 hours. ICP fell initially after treatment with short-acting propofol and fentanyl but trended back up after 2 hours. Manually recorded data consistently overestimated treatment effectiveness. Automated data collection gives a more accurate assessment of patient status and responsiveness to treatment. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Colton, Katharine; Yang, Shiming; Hu, Peter F.; Chen, Hegang H.; Bonds, Brandon; Scalea, Thomas M.; Stein, Deborah M.] Univ Maryland, Sch Med, Shock Trauma Anesthesia Res Organized Res Ctr, Baltimore, MD USA; [Colton, Katharine; Yang, Shiming; Hu, Peter F.; Chen, Hegang H.; Bonds, Brandon; Scalea, Thomas M.; Stein, Deborah M.] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA; [Colton, Katharine] Duke Univ, Sch Med, Durham, NC USA	Colton, K (corresponding author), Duke Univ, Sch Med, 804 Remington Circle, Durham, NC 27705 USA.	krcolton@gmail.com	Yang, Shiming/I-3695-2015	Yang, Shiming/0000-0003-0338-4268; Stein, Deborah/0000-0003-3683-3963	 [FA8650-11-2-6D06];  [FA8650-12-2-6D09];  [FA8650-13-2-6D15]	This study was funded in part by the grants FA8650-11-2-6D06, FA8650-12-2-6D09, and FA8650-13-2-6D15.	Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; FARLING PA, 1989, ANAESTHESIA, V44, P222, DOI 10.1111/j.1365-2044.1989.tb11228.x; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gugerty B, 2007, CHALLENGES OPPORTUNI; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hravnak M, 2008, ARCH INTERN MED, V168, P1300, DOI 10.1001/archinte.168.12.1300; Hravnak M, 2011, CRIT CARE MED, V39, P65, DOI 10.1097/CCM.0b013e3181fb7b1c; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Lauer KK, 1997, CAN J ANAESTH, V44, P929, DOI 10.1007/BF03011963; LOUGHHEAD MG, 1988, MED J AUSTRALIA, V148, P458, DOI 10.5694/j.1326-5377.1988.tb139571.x; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; Mulligan Alison, 2010, Intensive Crit Care Nurs, V26, P196, DOI 10.1016/j.iccn.2010.03.002; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; PINAUD M, 1990, ANESTHESIOLOGY, V73, P404, DOI 10.1097/00000542-199009000-00007; Schatzmann C, 1998, ACT NEUR S, V71, P31; Schrot RJ, 2002, LANCET, V359, P1633, DOI 10.1016/S0140-6736(02)08545-8; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; Subbe CP, 2007, INTENS CARE MED, V33, P619, DOI 10.1007/s00134-006-0516-8; Turner H B, 1988, J Neurosci Nurs, V20, P236; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WHITE PF, 1982, ANESTHESIOLOGY, V57, P242, DOI 10.1097/00000542-198209000-00019; Wilson SJ, 2013, EMERG MED J, V30, P186, DOI 10.1136/emermed-2011-200499; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	38	19	21	2	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2014	77	1					47	53		10.1097/TA.0000000000000270			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AK4IY	WOS:000338389600012	24977754				2021-06-18	
J	Galvagno, SM; Dubose, JJ; Grissom, TE; Fang, R; Smith, R; Bebarta, VS; Shackelford, S; Scalea, TM				Galvagno, Samuel M.; Dubose, Joseph J.; Grissom, Thomas E.; Fang, Raymond; Smith, Richard; Bebarta, Vikhyat S.; Shackelford, Stacy; Scalea, Thomas M.			The Epidemiology of Critical Care Air Transport Team Operations in Contemporary Warfare	MILITARY MEDICINE			English	Article							SEVERE LUNG INJURY; RESCUE TEAM; MILITARY; FORCE; US	Critical Care Air Transport Teams (CCATTs) have evolved as a vital component of the U.S. Air Force's aeromedical evacuation system. Previous epidemiological research in this area is limited. The objective of this commentary is to highlight the importance of obtaining robust epidemiological data regarding patients transported by CCATTs. A limited epidemiological analysis was performed to describe CCATT patients transported during Operation Enduring Freedom and the waning months of Operation Iraqi Freedom. CCATT transports for the calendar year 2011 were examined as recorded in the U.S. Transportation Command Regulating and Command and Control (C2) Evacuation System database. As many as 290 CCATT primary patient transport records were reviewed. Of these, 58.6% of patients had multiple injuries, 15.9% of patients had traumatic brain injury, 7% had acute coronary syndromes, and 24.8% of all transports were for nonbattle-related injuries. The most common International Classification of Disease, 9th Edition, Clinical Modification coded injury was bilateral lower extremity amputation (40%). Explosive blasts were the top mechanism of injury for patients requiring CCAT. The distribution of injuries and illnesses requiring CCAT appear to have changed compared to previous conventional conflicts. Understanding the epidemiology of casualties evacuated by CCATT during modern warfare is a prerequisite for the development of effective predeployment training to ensure optimal outcomes for critically ill and injured warriors.	[Galvagno, Samuel M.; Grissom, Thomas E.] Univ Maryland, Sch Med, Ctr Shock Trauma, Dept Anesthesiol,Div Trauma Anesthesiol,Program T, Baltimore, MD 21201 USA; [Galvagno, Samuel M.; Grissom, Thomas E.] Univ Maryland, Sch Med, Ctr Shock Trauma, Dept Anesthesiol,Div Crit Care Med,Program Trauma, Baltimore, MD 21201 USA; [Dubose, Joseph J.; Shackelford, Stacy] Univ Maryland, Sch Med, Ctr Shock Trauma, Program Trauma, Baltimore, MD 21201 USA; [Dubose, Joseph J.; Fang, Raymond; Shackelford, Stacy] US Air Force, CSTARS, Baltimore, MD 21201 USA; [Smith, Richard] Air Univ, Maxwell Air Force Base, Montgomery, AL 36112 USA; [Bebarta, Vikhyat S.] US Army, Inst Surg Res, Route Care Res Ctr, Ft Sam Houston, TX 78234 USA	Galvagno, SM (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma, Dept Anesthesiol,Div Trauma Anesthesiol,Program T, T1R83,22 South Greene St, Baltimore, MD 21201 USA.		Bebarta, Vikhyat S/L-9537-2015; Grissom, Thomas E./AAH-5749-2019; Bebarta, Vikhyat S/M-1513-2015	Galvagno, Samuel/0000-0001-5563-4092			Barnes SL, 2008, J TRAUMA, V64, pS144; Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Beninati W, 2008, CRIT CARE MED, V36, pS370, DOI 10.1097/CCM.0b013e31817e3143; Blackbourne LH, 2012, J TRAUMA ACUTE CARE, V73, pS378, DOI 10.1097/TA.0b013e3182754900; Bridges E, 2009, MIL MED, V174, P370, DOI 10.7205/MILMED-D-03-9607; Chung KK, 2009, J TRAUMA, V67, P231, DOI 10.1097/TA.0b013e3181ac68cf; Dorlac GR, 2009, J TRAUMA, V66, pS164, DOI 10.1097/TA.0b013e31819cdf72; DuBose J, 2012, J TRAUMA ACUTE CARE, V73, pS423, DOI 10.1097/TA.0b013e3182754636; Fang R, 2011, J TRAUMA, V71, pS91, DOI 10.1097/TA.0b013e3182218f97; Ficke JR, 2012, J TRAUMA ACUTE CARE, V73, pS520, DOI 10.1097/TA.0b013e31827559da; Galvagno Samuel M Jr, 2011, Air Med J, V30, P258, DOI 10.1016/j.amj.2011.04.006; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Lairet J, 2013, PREHOSP EMERG CARE, V17, P486, DOI 10.3109/10903127.2013.811564; Leland A, 2010, 75700 C RES SERV, P1; Mason PE, 2011, J EMERG MED, V41, P8, DOI 10.1016/j.jemermed.2008.06.032; Maureen M, 2011, MIL MED, V176, P769, DOI 10.7205/MILMED-D-10-00349; Pierce Penny F, 2003, Crit Care Nurs Clin North Am, V15, P221, DOI 10.1016/S0899-5885(02)00082-5; Rice DH, 2008, CRIT CARE, V12, DOI 10.1186/cc6782; Sariego Jack, 2010, Am Surg, V76, pE37; Thorson CM, 2012, J TRAUMA ACUTE CARE, V73, pS483, DOI 10.1097/TA.0b013e31827546fb; United States Air Force, AIR FORC TACT TECHN, P1	21	19	19	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	JUN	2014	179	6					612	618		10.7205/MILMED-D-13-00474			7	Medicine, General & Internal	General & Internal Medicine	AN7UM	WOS:000340806500005	24902127	Bronze			2021-06-18	
J	Hughes, JD; Rabinstein, AA				Hughes, Joshua D.; Rabinstein, Alejandro A.			Early Diagnosis of Paroxysmal Sympathetic Hyperactivity in the ICU	NEUROCRITICAL CARE			English	Article						Paroxysmal sympathetic hyperactivity; ICU; Diagnosis; Sympathetic storm; Dysautonomia	TRAUMATIC BRAIN-INJURY; DYSAUTONOMIA	Paroxysmal sympathetic hyperactivity (PSH) is a complication of acquired brain injury manifesting with episodic tachycardia, tachypnea, hypertension, diaphoresis, hypertonia, and posturing. No universally accepted diagnostic criteria exist and diagnosis is often delayed until the rehabilitation phase. Electronic records were screened to identify consecutive cases of PSH diagnosed in an intensive care unit (ICU) between 1/2006 and 8/2012 and assess the validity of early clinical diagnosis against formal diagnostic criteria. Data collected included patient demographics, brain injury etiology, symptoms noted by the clinician to support the diagnosis of PSH, PSH manifestations, therapeutic interventions, relevant brain imaging, and investigations to exclude alternative diagnoses. An operational set of diagnostic criteria based on previous literature was used for comparison. Fifty-three consecutive patients with PSH were identified. Mean age was 33.6 +/- A 14.5 years (range 16-67). Traumatic brain injury was the most common etiology (30 patients, 56.6 %) but causes were diverse. Mean time to diagnosis was 8.3 +/- A 11.0 days; 31 patients (59 %) were diagnosed within 7 days and 20 patients (38 %) within 3 days of admission. Tachycardia was almost uniformly present, and diaphoresis, fever, hypertension, and tachypnea were also present in most cases. Dystonia and posturing were present in less than half of patients. 89 % of clinically diagnosed cases met formal diagnostic criteria. Paroxysmal sympathetic hyperactivity can be diagnosed early in the ICU. Strict diagnostic criteria supported the clinician's diagnosis in the majority of cases. Diagnosis should not be rejected because of any particular sign's absence, especially dystonia and posturing.	[Hughes, Joshua D.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA; [Rabinstein, Alejandro A.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu		Hughes, Joshua/0000-0003-0362-302X			Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Dolce G, 2011, J NEUROTRAUM, V25, P1079; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Krach LE, 1997, J NEUROL REHABIL, V11, P41; Moussouttas M, 2012, NEUROCRIT CARE, V16, P381, DOI 10.1007/s12028-012-9673-5; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071	14	19	22	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2014	20	3					454	459		10.1007/s12028-013-9877-3			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AI7RH	WOS:000337092900014	23884511				2021-06-18	
J	Tsai, YT; Wang, CC; Leung, PO; Lin, KC; Chio, CC; Hu, CY; Kuo, JR				Tsai, Yin-Tzu; Wang, Che-Chuan; Leung, Pak-On; Lin, Kao-Chang; Chio, Chung-Ching; Hu, Chiao-Ya; Kuo, Jinn-Rung			Extracellular signal-regulated kinase 1/2 is involved in a tamoxifen neuroprotective effect in a lateral fluid percussion injury rat model	JOURNAL OF SURGICAL RESEARCH			English	Article						Fluid percussion injury; Tamoxifen; Extracellular signal-regulated kinases (ERK1/2); Cell apoptosis; Infarction volume; Maximal angle	TRAUMATIC BRAIN-INJURY; ESTROGEN-RECEPTOR MODULATORS; CEREBRAL-ARTERY OCCLUSION; ERK ACTIVATION; PROTEIN; PROGESTERONE; APOPTOSIS; ISCHEMIA; PATHWAY; DAMAGE	Background: The aim of the present study was to determine whether tamoxifen (TMX) causes attenuation of traumatic brain injury (TBI) induced by fluid percussion injury. Materials and methods: Immediately after the onset of fluid percussion TBI, anesthetized male Sprague-Dawley rats were divided into three major groups and intraperitoneally administered the vehicle solution (1 mL/kg), TMX (1 mg/kg), or TMX (1 mg/kg) plus the extracellular signal-regulated kinase 1/2 antagonist SL327 (30 mg/kg). Another group of rats were used as sham-operated controls. The functional outcomes, such as motor outcomes, were evaluated using an incline plane. The cellular infarction volume was evaluated by triphenyltetrazolium chloride staining. Neuronal loss, apoptosis, and p-ERK1/2 and Bcl2 expression in neuronal cortex cells were evaluated by immunofluorescence methods. All the parameters were assessed on day 4 after injury. Results: Compared with the sham-operated controls, the TBI-induced motor deficits and cerebral infarction after TBI were significantly attenuated by TMX therapy. The TBI-induced neuronal loss and apoptosis were also significantly reduced by TMX therapy. The numbers of Bcl2- and phospho-ERK1/2-positive neuronal cells in the ischemic cortex after TBI were significantly increased by TMX therapy. These TMX effects were significantly blocked by SL327 administration. Conclusions: Our results suggest that intravenous injection of TMX may ameliorate TBI in rats by increasing neuronal p-ERK1/2 expression, which might lead to an increase in neuronal Bcl2 expression and a decrease in neuronal apoptosis and cell infarction volume, and it might represent one mechanism by which functional recovery occurred. TMX may be a promising TBI treatment strategy. (C) 2014 Elsevier Inc. All rights reserved.	[Tsai, Yin-Tzu; Leung, Pak-On] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan; [Wang, Che-Chuan; Chio, Chung-Ching; Kuo, Jinn-Rung] Dept Neurosurg, Tainan, Taiwan; [Wang, Che-Chuan] Natl Chiao Tung Univ, Inst Photon Syst, Tainan, Taiwan; [Lin, Kao-Chang; Hu, Chiao-Ya; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Lin, Kao-Chang; Kuo, Jinn-Rung] Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Wang, Che-Chuan] Taiwan Univ Sci & Technol, Dept Child Care, Tainan, Taiwan	Kuo, JR (corresponding author), Chi Mei Med Ctr, 901 Chung Hwa Rd, Tainan, Taiwan.	kuojinnrung@gmail.com			 [CMFHR10110]	The project was supported by CMFHR10110. The authors thank all of the researchers, especially Yung-Te Kuo who participated in this study.	Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Benvenuti S, 2005, J CLIN ENDOCR METAB, V90, P1775, DOI 10.1210/jc.2004-0066; Biegon A, 1996, CANCER RES, V56, P4328; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bourque M, 2007, BIOCHEM PHARMACOL, V74, P1413, DOI 10.1016/j.bcp.2007.07.009; Chesnoy-Marchais D, 2005, ENDOCRINOLOGY, V146, P4302, DOI 10.1210/en.2005-0453; Chuang TJ, 2012, J TRAUMA ACUTE CARE, V73, P1161, DOI 10.1097/TA.0b013e318265d128; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; DonCarlos Lydia L, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS113, DOI 10.1016/j.psyneuen.2009.04.012; Feng Y, 2010, ONCOL REP, V24, P1561, DOI 10.3892/or_00001018; GRILL HJ, 1991, AM J CLIN ONCOL-CANC, V14, pS21; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; JORDAN VC, 1975, EUR J CANCER, V11, P205, DOI 10.1016/0014-2964(75)90119-X; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; Kimelberg HK, 2003, J NEUROSURG, V99, P138, DOI 10.3171/jns.2003.99.1.0138; Kuo JR, 2013, J NEUROTRAUM, V30, P1223, DOI 10.1089/neu.2012.2689; Kuo JR, 2012, NEUROCHEM INT, V60, P105, DOI 10.1016/j.neuint.2011.11.014; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; LIEN EA, 1991, BRIT J CANCER, V63, P641, DOI 10.1038/bjc.1991.147; Liu JL, 2010, BRAIN RES, V1316, P101, DOI 10.1016/j.brainres.2009.12.055; Marshall L F, 2000, Clin Neurosurg, V46, P105; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mehta SH, 2003, NEUROENDOCRINOLOGY, V77, P44, DOI 10.1159/000068332; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Obata T, 2006, TOXICOLOGY, V222, P46, DOI 10.1016/j.tox.2006.01.023; Osuka K, 2001, J NEUROCHEM, V76, P1842, DOI 10.1046/j.1471-4159.2001.00198.x; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Rutledge EM, 1998, AM J PHYSIOL-CELL PH, V274, pC1511; Scherle PA, 2000, J BIOL CHEM, V275, P37086, DOI 10.1074/jbc.M006168200; Sharma K, 2008, BRAIN RES, V1204; Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Suuronen T, 2005, INFLAMM RES, V54, P194, DOI 10.1007/s00011-005-1343-z; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Thurman DJ, 2001, HEAD TRAUMA THERAPEU; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Toborek M, 2007, J CELL BIOCHEM, V100, P279, DOI 10.1002/jcb.21013; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043; Wakade C, 2008, ENDOCRINOLOGY, V149, P367, DOI 10.1210/en.2007-0899; Wang CC, 2013, J SURG RES, V184, P1045, DOI 10.1016/j.jss.2013.04.059; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang Y, 1997, J NEUROSCI, V17, P4341; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zhang YH, 2007, EXP NEUROL, V204, P819, DOI 10.1016/j.expneurol.2007.01.015; Zhao LZ, 2007, BRAIN RES, V1172, P48, DOI 10.1016/j.brainres.2007.06.092; Zhao LQ, 2005, BRAIN RES REV, V49, P472, DOI 10.1016/j.brainresrev.2005.01.009	53	19	20	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUN	2014	189	1					106	116		10.1016/j.jss.2014.02.009			11	Surgery	Surgery	AF6UU	WOS:000334850900014	24636102				2021-06-18	
J	Acker, SN; Partrick, DA; Ross, JT; Nadlonek, NA; Bronsert, M; Bensard, DD				Acker, Shannon N.; Partrick, David A.; Ross, James T.; Nadlonek, Nicole A.; Bronsert, Michael; Bensard, Denis D.			Blood component transfusion increases the risk of death in children with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; blood transfusion; anemia; children	CRITICALLY-ILL; PREDICTIVE FACTORS; CELL TRANSFUSIONS; ANEMIA; PLASMA; SHOCK	BACKGROUND Blood transfusion has been associated with worse outcomes in adult trauma patients with traumatic brain injury (TBI). However, the effects in injured children have not been evaluated. We hypothesize that blood transfusion is also associated with worse outcomes in children with TBI. METHODS A retrospective review of the trauma database at two Level I pediatric trauma centers was performed. We reviewed all patients 18 years and younger with TBI, who survived at least 24 hours, from 2002 to 2011. Exclusion criteria include those who underwent craniotomy, thoracotomy, exploratory laparotomy, and any orthopedic procedure. RESULTS A total of 1,607 children with TBI were included in the study population (mean age, 6.4 [5.7] years; 65% male), 178 of whom received a blood transfusion. Mean Injury Severity Score (ISS) was 16.5 (9.1). Patients who received a transfusion had a higher ISS than those who did not (26.7 vs. 15.3). After controlling for age, sex, ISS, Glasgow Coma Scale (GCS) score on presentation, and mechanism of injury, patients who received a blood transfusion were more likely to be admitted to the intensive care unit (p < 0.0001), less likely to survive to hospital discharge (p = 0.02), more likely to be discharged to a rehabilitation facility (p = 0.01) and be dependent on caretakers at follow-up (p < 0.0001), as well as more likely to develop urinary tract infection (p = 0.02) and bacteremia (p = 0.02) during their hospital stay. These differences in outcomes among those who did and did not receive a blood transfusion began to disappear in patients with a nadir hemoglobin of less than 8.0 g/dL. CONCLUSION Pediatric patients sustaining TBI who receive blood transfusion and do not require operative intervention have worse outcomes compared with patients who do not receive transfusion. This includes an increased risk of death. These data suggest that a transfusion trigger of hemoglobin level at 8.0 g/dL in injured children with TBI may be beneficial. LEVEL OF EVIDENCE Epidemiologic study, level III. Therapeutic study, level IV.	[Acker, Shannon N.; Partrick, David A.; Ross, James T.; Nadlonek, Nicole A.; Bensard, Denis D.] Childrens Hosp Colorado, Dept Pediat Surg, Aurora, CO USA; [Bronsert, Michael] Univ Colorado, Sch Med, Dept Surg Surg Outcomes & Appl Res, Aurora, CO 80045 USA; [Bensard, Denis D.] Denver Hlth & Hosp Author, Dept Surg, Denver, CO USA	Acker, SN (corresponding author), Univ Colorado, Sch Med, 12631 E 17th Ave,C302, Aurora, CO 80045 USA.	shannon.acker@ucdenver.edu					Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Armano R, 2005, CRIT CARE MED, V33, P2637, DOI 10.1097/01.CCM.0000185645.84802.73; Blajchman Morris A, 2002, Am J Ther, V9, P389, DOI 10.1097/00045391-200209000-00005; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Desmet L, 2004, CRIT CARE CLIN, V20, P299, DOI 10.1016/S0749-0704(03)00113-1; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Elterman J, 2013, J TRAUMA ACUTE CARE, V75, P8, DOI 10.1097/TA.0b013e318298492e; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Karam O, 2013, VOX SANG, V104, P342, DOI 10.1111/vox.12009; Lieberman L, 2013, TRANSFUSION, DOI [10.1111/trf.12249, DOI 10.1111/TRF. 12249]; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Morris KP, 2005, ARCH DIS CHILD, V90, P724, DOI 10.1136/adc.2004.062174; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; Pieracci FM, 2012, J PEDIATR SURG, V47, P1587, DOI 10.1016/j.jpedsurg.2012.02.011; Raghavan M, 2005, CHEST, V127, P295, DOI 10.1378/chest.127.1.295; Rouette J, 2010, ANN SURG, V251, P421, DOI 10.1097/SLA.0b013e3181c5dc2e; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Vamvakas EC, 1998, ARCH PATHOL LAB MED, V122, P145; Vincent JL, 2006, CRIT CARE MED, V34, pS96, DOI 10.1097/01.CCM.0000214314.57109.CD; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Winn HR, 2004, YOUMANS NEUROLOGICAL; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1	26	19	21	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					1082	1088		10.1097/TA.0000000000000095			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500034	24662875				2021-06-18	
J	Alexiou, GA; Lianos, G; Fotakopoulos, G; Michos, E; Pachatouridis, D; Voulgaris, S				Alexiou, George A.; Lianos, Georgios; Fotakopoulos, George; Michos, Evaggelos; Pachatouridis, Dimitrios; Voulgaris, Spyridon			Admission glucose and coagulopathy occurrence in patients with traumatic brain injury	BRAIN INJURY			English	Article						Coagulopathy; glucose; traumatic brain injury	HYPERGLYCEMIA	Introduction: Coagulopathy after traumatic brain injury (TBI) is a frequent event and is associated with patients' prognosis. TBI is also associated with a stress response that includes hyperglycemia. This study investigated if coagulopathy occurrence is associated with admission blood glucose levels in patients with TBI. Methods: This study retrospectively evaluated patients with TBI who were admitted to a neurosurgical department over a 4-year period. Coagulopathy was defined as an aPTT >40 seconds and/or INR >1.2 and/or a platelet count <120*10(9) per litre. Results: One-hundred and forty-nine patients were included in the study. Thirty-four patients developed coagulopathy. Patients with coagulopathy had significantly lower haemoglobin levels, increased INR and increased aPTT. Patients with severe TBI had more frequent coagulopathy. Patients with severe TBI had significant higher serum glucose levels compared to patients with mild TBI. Using ROC curves it was found that a serum glucose of 151 mg dl(-1) was the threshold for the discrimination of patients that developed coagulopathy. Logistic regression analysis revealed that serum glucose greater than 151 mg dl(-1) and haemoglobin levels lower than 12.4 mg dL(-1) were significantly associated with coagulopathy occurrence. Conclusion: Coagulopathy frequently occur after TBI. Patients with lower GCS score and lower haemoglobin levels and increased blood glucose levels at admission are at greater risk.	[Alexiou, George A.; Fotakopoulos, George; Michos, Evaggelos; Pachatouridis, Dimitrios; Voulgaris, Spyridon] Univ Hosp Ioannina, Dept Neurosurg, Ioannina, Greece; [Lianos, Georgios] Univ Hosp Ioannina, Dept Surg, Ioannina, Greece	Alexiou, GA (corresponding author), POB 103, Ioannina, Greece.	alexiougrg@yahoo.gr		fotakopoulos, george/0000-0002-2491-2886; Alexiou, George/0000-0003-0257-4481			Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bochicchio GV, 2005, AM SURGEON, V71, P171; Brealey David, 2009, J Diabetes Sci Technol, V3, P1250; Du XL, 1998, DIABETOLOGIA, V41, P249, DOI 10.1007/s001250050900; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Greuters S, 2011, CRITICAL CARE, V15, P1; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Innerhofer P, 2013, INJURY, V44, P209, DOI 10.1016/j.injury.2012.08.047; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Pahatouridis D, 2010, BRAIN INJURY, V24, P1189, DOI 10.3109/02699052.2010.490510; Salim A, 2009, AM SURGEON, V75, P25; Schreiber MA, 2005, J TRAUMA, V58, P475, DOI 10.1097/01.TA.0000153938.77777.26; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vespa PM, 2008, CRIT CARE, V12, DOI 10.1186/cc6986; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; WEISSMAN C, 1990, ANESTHESIOLOGY, V73, P308, DOI 10.1097/00000542-199008000-00020; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72	25	19	20	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2014	28	4					438	441		10.3109/02699052.2014.888769			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AF5GL	WOS:000334741900006	24564221				2021-06-18	
J	Baker, MS				Baker, Michael S.			Casualties of the Global War on Terror and Their Future Impact on Health Care and Society: A Looming Public Health Crisis	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; DAMAGE CONTROL; MILITARY VETERANS; AIR TRANSPORT; IRAQ; EXPERIENCE; RESUSCITATION; TRANSFUSIONS; DIAGNOSES	This article is a primer to understand the medical advances and the future health care consequences of the current conflicts in the Middle East and Southwest Asia, known as the Global War on Terror. There have been significant advances in health care learned in caring for those injured by the conflict-often a polytrauma blast victim, but there are also very high incidence rates of the hidden injuries of war-traumatic brain injury, post-traumatic stress disorder, suicide, and depression. These lead to disruptive behaviors, homelessness, and family violence. Global War on Terror returnees are using medical services and applying for disability at higher rates than in previous conflicts. The costs for veterans' care may peak 30 to 40 years or longer following the conflict, and will inflict an enormous burden on services and resources. The effects of the war will linger for years and impact across generations because of the stress on families and children. We must mobilize government agencies, create public-private partnerships, and invest our resources now to mitigate the approaching tsunami of veterans' health care needs, the impact on our social services, and the devastating costs to society.	[Baker, Michael S.] John Muir Hosp, Dept Surg, Walnut Creek, CA 94598 USA; [Baker, Michael S.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA	Baker, MS (corresponding author), John Muir Hosp, Dept Surg, Walnut Creek, CA 94598 USA.						[Anonymous], 2011, REFERENCE GUIDE ON C; [Anonymous], ITS NOT A CHARITY IT; [Anonymous], 2012, VA BENEFITS ACTIVITY; Baker M, 2013, ARMED FORCES JOURNAL; Barker DE, 2007, J AM COLL SURGEONS, V204, P784, DOI 10.1016/j.jamcollsurg.2006.12.039; Beekley AC, 2008, CRIT CARE MED, V36, pS267, DOI 10.1097/CCM.0b013e31817da7dc; Beekley AC, 2008, J TRAUMA, V64, pS28, DOI 10.1097/TA.0b013e318160937e; Beekley AC, 2007, SURG CLIN N AM, V87, P157, DOI 10.1016/j.suc.2006.09.008; BELLAMY RF, 1984, MIL MED, V149, P55; Beninati W, 2008, CRIT CARE MED, V36, pS370, DOI 10.1097/CCM.0b013e31817e3143; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Bilmes LJ, CURRENT AND PROJECTE; Bilmes LJ, 2008, THE THREE TRILLION D; Blackbourne LH, 2008, CRIT CARE MED, V36, pS304, DOI 10.1097/CCM.0b013e31817e2854; Blimes Lk, 2013, THE FINANCIAL LEGACY; Blumenthal SM, STOPPING THE SURGE O; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Breggin P, MILITARY TO HOLD CON; Brown JL, 2012, JAMA-J AM MED ASSOC, V308, P1869, DOI 10.1001/jama.2012.14254; Cannon JW, ADVANCED EN ROUTE CR; Cassels Caroline, 2009, YOUNG WOMEN VETERANS; Cesur R, 2011, NBER WORKING PAPER S; Clapesattle H, 1941, THE DOCTORS MAYO, P573; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Debusmann B, OUTSOURCED US WARS; Department of Defense, DEFENSE CASUALTY ANA; Dorlac GR, 2009, J TRAUMA, V66, pS164, DOI 10.1097/TA.0b013e31819cdf72; Duchesne JC, 2010, J TRAUMA, V69, P46, DOI 10.1097/TA.0b013e3181df91fa; Faison CF, 2012, PROC US NAV INST, V138, P64; Geiling J, 2012, MIL MED, V177, P1235, DOI 10.7205/MILMED-D-12-00031; Gerlock AA, 2004, MIL MED, V169, P470, DOI 10.7205/MILMED.169.6.470; Girard P, 2007, J SPEC OPER MED, V7, P55; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hildebrand F, 2004, INJURY, V35, P678, DOI 10.1016/j.injury.2004.03.004; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Householder M, 2012, QUADRUPLE AMPUTEE SO; Institute of Medicine, 2010, RETURNING HOME FROM; Jadick R, 2007, ON CALL IN HELL A DO; JORDAN BK, 1992, J CONSULT CLIN PSYCH, V60, P916, DOI 10.1037/0022-006X.60.6.916; Kennedy JF, 1963, 451 PROCLAMATION 356; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lincoln A, 1865, SECOND INAUGURAL ADD; Litz B. T., 2009, PTSD RES Q, V20, P1; Loveland JA, 2004, BRIT J SURG, V91, P1095, DOI 10.1002/bjs.4641; Marshall AD, 2005, CLIN PSYCHOL REV, V25, P862, DOI 10.1016/j.cpr.2005.05.009; Miller CT, 2009, LOS ANGELES TIMES; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pellerin C, 2012, LANDSTUHL MEDICAL CE; Petrakis IL, 2011, AM J ADDICTION, V20, P185, DOI 10.1111/j.1521-0391.2011.00126.x; Purple Heart Homes, QUALITY OF LIFE SOLU; RIZZO J, 2013, NATL GEOGR, V223, P26; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sogomonyan F, 2010, TRAUMA FACED BY CHIL; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Stevens R, THE FORWARD RESUSCIT; Swords to Plowshares, 2011, VETERANS AND THEIR F; Tanielian T, 2008, INVISIBLE WOUNDS SUM; Tanielian T., 2008, INVISIBLE WOUNDS OF; Taylor DM, 2013, MIL MED, V178, P1196, DOI 10.7205/MILMED-D-13-00223; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; US Department of Labor, OFFICE OF WORKERS CO; Walters TJ, 2005, US ARMY MED DEP J, P42; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Wedmore I, 2006, J TRAUMA, V60, P655, DOI 10.1097/01.ta.0000199392.91772.44; Williamson RB, 2009, PRELIMINARY FINDINGS; Yaeger D, 2006, J GEN INTERN MED, V21, pS65, DOI 10.1111/j.1525-1497.2006.00377.x	68	19	19	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	APR	2014	179	4					348	355		10.7205/MILMED-D-13-00471			8	Medicine, General & Internal	General & Internal Medicine	AN7UK	WOS:000340806300001	24690957	Bronze			2021-06-18	
J	Mathias, JL; Harman-Smith, Y; Bowden, SC; Rosenfeld, JV; Bigler, ED				Mathias, Jane L.; Harman-Smith, Yasmin; Bowden, Stephen C.; Rosenfeld, Jeffrey V.; Bigler, Erin D.			Contribution of Psychological Trauma to Outcomes after Traumatic Brain Injury: Assaults versus Sporting Injuries	JOURNAL OF NEUROTRAUMA			English	Article						assault; psychological trauma; sporting injury; post-traumatic stress; outcome; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; HEAD-INJURY; RISK-FACTORS; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE PERFORMANCE; GENDER-DIFFERENCES; PROGNOSTIC VALUE; MODEL SYSTEMS; SYMPTOMS	Clinical research into outcomes after traumatic brain injury (TBI) frequently combines injuries that have been sustained through different causes (e.g., car accidents, assaults, and falls), the effect of which is not well understood. This study examined the contribution of injury-related psychological trauma-which is more commonly associated with specific types of injuries-to outcomes after nonpenetrating TBI in order to determine whether it may be having a differential effect in samples containing mixed injuries. Data from three groups that were prospectively recruited for two larger studies were compared: one that sustained a TBI as a result of physical assaults (i.e., psychologically traumatizing) and another as a result of sporting injuries (i.e., nonpsychologically traumatizing), as well as an orthopedic control group (OC). Psychosocial and emotional (postconcussion symptoms, injury-related stress, and depression), cognitive (memory, abstract reasoning, problem solving, and verbal fluency), and functional (general outcome; resumption of home, social, and work roles) outcomes were all assessed. The TBIassault group reported significantly poorer psychosocial and emotional outcomes and higher rates of litigation (criminal rather than civil) than both the TBIsport and OC groups approximately 6 months postinjury, but there were no differences in the cognitive or functional outcomes of the three groups. The findings suggest that the cause of a TBI may assist in explaining some of the differences in outcomes of people who have seemingly comparable injuries. Involvement in litigation and the cause of an injury may also be confounded, which may lead to the erroneous conclusion that litigants have poorer outcomes.	[Mathias, Jane L.; Harman-Smith, Yasmin] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; [Bowden, Stephen C.] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Div Clin Sci, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3181, Australia; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, N Terrace, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Rosenfeld, Jeffrey V/B-7249-2011	Mathias, Jane/0000-0001-8957-8594; Harman-Smith, Yasmin/0000-0002-9227-8530	National Health and Medical Research Foundation of AustraliaNational Health and Medical Research Council of Australia [207711, 519220]	This research was funded by project grant nos. 207711 and 519220 from the National Health and Medical Research Foundation of Australia.	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Babor T. F., 1989, AUDIT ALCOHOL DISORD; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Blanchard EB, 2003, CRASH PSYCHOL ASSESS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Butler DJ, 1999, AM FAM PHYSICIAN, V60, P524; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; de Oliveira Thais M., 2012, J NEUROPSYCHOL  1120, DOI 10.1111/jnp.12000; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Eid H. O., 2007, SMJ Singapore Medical Journal, V48, P693; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fullerton CS, 2001, AM J PSYCHIAT, V158, P1486, DOI 10.1176/appi.ajp.158.9.1486; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guarino A.J., 2006, APPL MULTIVARIATE RE; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hours M, 2013, ACCIDENT ANAL PREV, V50, P92, DOI 10.1016/j.aap.2012.03.037; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jeon IC, 2008, J KOREAN NEUROSURG S, V44, P295, DOI 10.3340/jkns.2008.44.5.295; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lee SY, 2012, J CLIN NEUROL, V8, P224, DOI 10.3988/jcn.2012.8.3.224; Leon Carrion J., 2001, REV ESPANOLA NEUROPS, V3, P58; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macdonald S, 1999, DRUG ALCOHOL DEPEN, V55, P53, DOI 10.1016/S0376-8716(98)00184-7; Majdan M, 2011, BRAIN INJURY, V25, P797, DOI 10.3109/02699052.2011.581642; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Podell K, 2010, PSYCHIAT CLIN N AM, V33, P855, DOI 10.1016/j.psc.2010.08.003; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Reynolds S, 2011, J INTENSIVE CARE SOC, V12, P196; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; ROSENFIELD S, 1980, J HEALTH SOC BEHAV, V21, P33, DOI 10.2307/2136692; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silver JM, 2012, J NEUROL NEUROSUR PS, V83, P836, DOI 10.1136/jnnp-2011-302078; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Tabachnick BG, 2007, USING MULTIVARIATE S; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weiss DS, 1996, IMPACT EVENTS SCALE, P399; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WHO, 2007, ALC INJ EM DEP SUMM; Willer B., 1994, J HEAD TRAUMA REHAB, V8, P75; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2011, GLOBAL STATUS REPORT; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yoganandan N, 2010, ACCIDENT ANAL PREV, V42, P1370, DOI 10.1016/j.aap.2010.02.017	89	19	20	1	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					658	669		10.1089/neu.2013.3160			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000007	24228916	Green Published			2021-06-18	
J	Metting, Z; Spikman, JM; Rodiger, LA; van der Naalt, J				Metting, Zwany; Spikman, Jacoba M.; Rodiger, Lars A.; van der Naalt, Joukje			Cerebral perfusion and neuropsychological follow up in mild traumatic brain injury: Acute versus chronic disturbances?	BRAIN AND COGNITION			English	Article						Mild traumatic brain injury; Perfusion CT; Neuropsychological testing; Emotion recognition; Executive function	MINOR HEAD-INJURY; DIFFUSE AXONAL INJURY; SOCIAL COGNITION; EMOTION RECOGNITION; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; FUNCTIONAL MRI; FRONTAL LOBES; DYSFUNCTION; DEFICITS	In a subgroup of patients with mild traumatic brain injury (TBI) residual symptoms, interfering with outcome and return to work, are found. With neuropsychological assessment cognitive deficits can be demonstrated although the pathological underpinnings of these cognitive deficits are not fully understood. As the admission computed tomography (CT) often is normal, perfusion CT imaging may be a useful indicator of brain dysfunction in the acute phase after injury in these patients. In the present study, directly after admission perfusion CT imaging was performed in mild TBI patients with follow-up neuropsychological assessment in those with complaints and a normal non-contrast CT. Neuropsychological tests comprised the 15 Words test Immediate Recall, Trailmaking test part B, Zoo Map test and the FEEST, which were dichotomized into normal and abnormal. Perfusion CT results of patients with normal neuropsychological test scores were compared to those with abnormal test scores. In total eighteen patients were included. Those with an abnormal score on the Zoo Map test had a significant lower CBV in the right frontal and the bilateral parieto-temporal white matter. Patients with an abnormal score on the FEEST had a significant higher MTT in the bilateral frontal white matter and a significant decreased CBF in the left parieto-temporal grey matter. No significant relation between the perfusion CT parameters and the 15 Words test and the Trailmaking test part B was present. In conclusion, impairments in executive functioning and emotion perception assessed with neuropsychological tests during follow up were related to differences in cerebral perfusion at admission in mild TBI. The pathophysiological concept of these findings is discussed. (C) 2014 Elsevier Inc. All rights reserved.	[Metting, Zwany; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Rodiger, Lars A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Groningen, Netherlands	Metting, Z (corresponding author), Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	z.meetting@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763	ZonMw, Den Haag, The NetherlandsNetherlands Organization for Health Research and DevelopmentNetherlands Government [39200002]	This study was funded by ZonMw, Den Haag, The Netherlands (Grant number 39200002).	Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Audenaert K., 2003, MED SCI MONITOR, V9, P112; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bisley JW, 2010, ANNU REV NEUROSCI, V33, P1, DOI 10.1146/annurev-neuro-060909-152823; Blair RJR, 2003, PHILOS T R SOC B, V358, P561, DOI 10.1098/rstb.2002.1220; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Deelman B. G., 1980, FUNCTIESTOORNISSEN T; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Duncan J, 2013, NEURON, V80, P35, DOI 10.1016/j.neuron.2013.09.015; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levine B, 2013, NEUROIMAGE-CLIN, V2, P534, DOI 10.1016/j.nicl.2013.03.015; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mehrazin M, 2011, HELL J NUCL MED, V14, P243; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Metting Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064461; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; Young A., 2002, FACIAL EXPRESSIONS E; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	82	19	19	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	APR	2014	86						24	31		10.1016/j.bandc.2014.01.012			8	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	AF2VP	WOS:000334570900004	24556319				2021-06-18	
J	Sharma, B; Bradbury, C; Mikulis, D; Green, R				Sharma, Bhanu; Bradbury, Cheryl; Mikulis, David; Green, Robin			MISSED DIAGNOSIS OF TRAUMATIC BRAIN INJURY IN PATIENTS WITH TRAUMATIC SPINAL CORD INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; traumatic spinal cord injury; diagnosis	HEAD-INJURY	Objective: To determine the frequency of missed acute care traumatic brain injury diagnoses in patients with traumatic spinal cord injury, and to examine risk factors for missed traumatic brain injury diagnosis. Design: Prospective magnetic resonance imaging and neuropsychological assessment plus retrospective medical record review, including computed tomography. Subjects: Ninety-two adults with traumatic spinal cord injury recruited from a large, tertiary spinal cord injury program, initially referred from urban teaching hospitals with neurotrauma facilities. Methods: Diagnosis of traumatic brain injury made with clinical neurological indices (i.e., Glasgow Coma Scale, post-traumatic amnesia, and loss of consciousness), neuroimaging (computed tomography and structural magnetic resonance imaging), and neuropsychological tests of attention and speed of processing, memory, and executive function; all measures were validated on a case-by-case basis to rule out confounds. Missed traumatic brain injury diagnoses were made via acute care medical record review and were corroborated by patient/family report where possible. Results: The frequency of missed traumatic brain injury diagnoses in our sample was 58.5%. Missed traumatic brain injury diagnoses were more frequent in injuries sustained outside of a motor vehicle collision (MVC), with 75.0% of acute care traumatic brain injury diagnoses missed in non-MVC patients vs. 42.9% missed in MVC patients. Among patients with non-MVC injuries, a comparable percentage of missed traumatic brain injury diagnoses were observed in patients with cervical (79%) and sub-cervical injuries (80%). Conclusion: In more than half of the traumatic spinal cord injury patients referred for in-patient rehabilitation, acute care diagnoses of traumatic brain injury were missed. A risk factor for missed diagnosis was an injury caused by a mechanism other than an MVC (e.g., falls, assaults), perhaps due to reduced expectations of traumatic brain injury in non-MVC patients. In our research study, we employed multiple assessments to aid diagnosis, which is particularly important for detecting the milder traumatic brain injuries often associated with spinal cord injury; unfortunately, limited resources may preclude a comprehensive diagnostic approach in clinical settings. Our findings point to the need to examine current acute care diagnostic protocols, and to increase vigilance in patients with traumatic injuries sustained outside of an MVC setting.	[Sharma, Bhanu; Green, Robin] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Sharma, Bhanu; Green, Robin] Toronto Western Hosp, Toronto Rehabil Inst, Toronto, ON M5T 2S8, Canada; [Bradbury, Cheryl] Toronto Western Hosp, Toronto Rehabil Inst, Spinal Cord Rehabil Program, Toronto, ON M5T 2S8, Canada; [Mikulis, David] Toronto Western Hosp, Joint Dept Med Imaging, Div Neuroradiol, Toronto, ON M5T 2S8, Canada	Green, R (corresponding author), Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada.	Robin.Green@uhn.ca	Mikulis, David J/H-5167-2019	Mikulis, David/0000-0003-3956-0892; Green, Robin/0000-0001-9451-3963	Ontario Neurotrauma Foundation; Canada Research Chairs ProgramCanada Research Chairs	The study was supported by funding from the Ontario Neurotrauma Foundation and the Canada Research Chairs Program. The authors have no competing interests to declare.	Arzaga Deborah, 2003, SCI Nurs, V20, P86; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS77, DOI 10.1016/j.apmr.2008.07.008; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chavhan GB, 2009, RADIOGRAPHICS, V29, P1433, DOI 10.1148/rg.295095034; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; Hagen EM, 2010, ACTA NEUROL SCAND, V122, P51, DOI 10.1111/j.1600-0404.2010.01376.x; Heaton R., 1993, WISCONSIN CARD SORTI; Lu D, 2012, ESSENTIALS SPINAL CO, P98; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Macciocchi S, 2012, ARCH PHYS MED REHAB, V93, P1788, DOI 10.1016/j.apmr.2012.01.022; SABOE LA, 1991, J TRAUMA, V31, P43, DOI 10.1097/00005373-199101000-00010; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Smith A., 1982, SYMBOL DIGIT MODALIT; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Wechsler D, 2001, WECHLER TEST ADULT R; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M	17	19	21	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	APR	2014	46	4					370	373		10.2340/16501977-1261			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AE7CR	WOS:000334154800012	24549169	DOAJ Gold			2021-06-18	
J	Patel, TP; Ventre, SC; Geddes-Klein, D; Singh, PK; Meaney, DF				Patel, Tapan P.; Ventre, Scott C.; Geddes-Klein, Donna; Singh, Pallab K.; Meaney, David F.			Single-Neuron NMDA Receptor Phenotype Influences Neuronal Rewiring and Reintegration following Traumatic Injury	JOURNAL OF NEUROSCIENCE			English	Article						functional connectivity; GluN2B; mechanical injury; network activity; synchrony	LONG-TERM POTENTIATION; CA1 PYRAMIDAL NEURONS; D-ASPARTATE RECEPTORS; RAT CORTICAL-NEURONS; BRAIN-INJURY; IN-VITRO; AXONAL INJURY; SYNAPTIC-TRANSMISSION; MECHANICAL STRETCH; NR2B SUBUNIT	Alterations in the activity of neural circuits are a common consequence of traumatic brain injury (TBI), but the relationship between single-neuron properties and the aggregate network behavior is not well understood. We recently reported that the GluN2B-containing NMDA receptors (NMDARs) are key in mediating mechanical forces during TBI, and that TBI produces a complex change in the functional connectivity of neuronal networks. Here, we evaluated whether cell-to-cell heterogeneity in the connectivity and aggregate contribution of GluN2B receptors to [Ca2+](i) before injury influenced the functional rewiring, spontaneous activity, and network plasticity following injury using primary rat cortical dissociated neurons. We found that the functional connectivity of a neuron to its neighbors, combined with the relative influx of calcium through distinct NMDAR subtypes, together contributed to the individual neuronal response to trauma. Specifically, individual neurons whose [Ca2+](i) oscillations were largely due to GluN2B NMDAR activation lost many of their functional targets 1 h following injury. In comparison, neurons with large GluN2A contribution or neurons with high functional connectivity both independently protected against injury-induced loss in connectivity. Mechanistically, we found that traumatic injury resulted in increased uncorrelated network activity, an effect linked to reduction of the voltage-sensitive Mg2+ block of GluN2B-containing NMDARs. This uncorrelated activation of GluN2B subtypes after injury significantly limited the potential for network remodeling in response to a plasticity stimulus. Together, our data suggest that two single-cell characteristics, the aggregate contribution of NMDAR subtypes and the number of functional connections, influence network structure following traumatic injury.	[Patel, Tapan P.; Ventre, Scott C.; Geddes-Klein, Donna; Singh, Pallab K.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Dept Bioengn, 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122; Patel, Tapan/0000-0001-8959-6645	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS35712, HD41699, P01 NS056202]; Department of DefenseUnited States Department of Defense [W911NF-10-1-0526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712, P01NS056202, R01NS088176] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health Grants R01 NS35712, HD41699, and P01 NS056202; and Department of Defense Grant W911NF-10-1-0526.	Akerboom J, 2012, J NEUROSCI, V32, P13819, DOI 10.1523/JNEUROSCI.2601-12.2012; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arnold FJL, 2005, J PHYSIOL-LONDON, V564, P3, DOI 10.1113/jphysiol.2004.077446; Arrondo G, 2009, MULT SCLER J, V15, P509, DOI 10.1177/1352458508101321; Auberson YP, 2002, BIOORG MED CHEM LETT, V12, P1099, DOI 10.1016/S0960-894X(02)00074-4; Babiloni C, 2004, EUR J NEUROSCI, V19, P2583, DOI 10.1111/j.0953-816X.2004.03333.x; Berberich S, 2005, J NEUROSCI, V25, P6907, DOI 10.1523/JNEUROSCI.1905-05.2005; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; Chen G, 1996, J PHYSIOL-LONDON, V494, P451, DOI 10.1113/jphysiol.1996.sp021505; Choo AM, 2013, BRAIN, V136, P65, DOI 10.1093/brain/aws286; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ferrario CR, 2013, J NEUROPHYSIOL, V110, P131, DOI 10.1152/jn.01011.2012; Fetcho JR, 1998, HISTOCHEM J, V30, P153, DOI 10.1023/A:1003243302777; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Franks KM, 2002, BIOPHYS J, V83, P2333, DOI 10.1016/S0006-3495(02)75248-X; Frick A, 2004, NAT NEUROSCI, V7, P126, DOI 10.1038/nn1178; Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011; Fries P, 2009, ANNU REV NEUROSCI, V32, P209, DOI 10.1146/annurev.neuro.051508.135603; Frizelle PA, 2006, MOL PHARMACOL, V70, P1022, DOI 10.1124/mol.106.024042; Furukawa Y, 2000, NEUROSCIENCE, V96, P385, DOI 10.1016/S0306-4522(99)00553-9; Gasparini S, 2004, J NEUROSCI, V24, P11046, DOI 10.1523/JNEUROSCI.2520-04.2004; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hunt DL, 2012, CURR OPIN NEUROBIOL, V22, P496, DOI 10.1016/j.conb.2012.01.007; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Kew JNC, 1998, J NEUROSCI, V18, P1935; Kloda A, 2007, P NATL ACAD SCI USA, V104, P1540, DOI 10.1073/pnas.0609649104; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Liu YY, 2011, NATURE, V473, P167, DOI 10.1038/nature10011; Losonczy A, 2006, NEURON, V50, P291, DOI 10.1016/j.neuron.2006.03.016; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miyashita T, 2012, NEURON, V74, P887, DOI 10.1016/j.neuron.2012.03.039; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Muldoon SF, 2013, P NATL ACAD SCI USA, V110, P3567, DOI 10.1073/pnas.1216958110; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; Pinheiro PS, 2008, NAT REV NEUROSCI, V9, P423, DOI 10.1038/nrn2379; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; Roberts EB, 1999, J NEUROPHYSIOL, V81, P2587; Santucci DM, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000208; Sanz-Clemente A, 2013, NEUROSCIENTIST, V19, P62, DOI 10.1177/1073858411435129; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.ph.55.030193.002025; Singh P, 2012, J BIOL CHEM, V287, P4348, DOI 10.1074/jbc.M111.253740; Singh P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002106; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stocca G, 1998, J PHYSIOL-LONDON, V507, P13, DOI 10.1111/j.1469-7793.1998.013bu.x; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Tovar KR, 1999, J NEUROSCI, V19, P4180; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Volpicelli-Daley LA, 2011, NEURON, V72, P57, DOI 10.1016/j.neuron.2011.08.033; von Engelhardt J, 2009, FRONT MOL NEUROSCI, V2, DOI 10.3389/neuro.02.019.2009; Womelsdorf T, 2007, SCIENCE, V316, P1609, DOI [10.1126/science.1139597, 10.1126/science.1139178]; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	75	19	19	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 19	2014	34	12					4200	4213		10.1523/JNEUROSCI.4172-13.2014			14	Neurosciences	Neurosciences & Neurology	AD4WX	WOS:000333253300009	24647941	Green Published, Bronze			2021-06-18	
J	Gueguen, C; Palmier, B; Plotkine, M; Marchand-Leroux, C; Bessson, VC				Gueguen, Cindy; Palmier, Bruno; Plotkine, Michel; Marchand-Leroux, Catherine; Bessson, Valerie C.			Neurological and Histological Consequences Induced by In Vivo Cerebral Oxidative Stress: Evidence for Beneficial Effects of SRT1720, a Sirtuin 1 Activator, and Sirtuin 1-Mediated Neuroprotective Effects of Poly(ADP-ribose) Polymerase Inhibition	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; PREVENTS NAD(+) DEPLETION; SMALL-MOLECULE ACTIVATORS; PROMOTES CELL-SURVIVAL; DNA-DAMAGE; PARP-1 INHIBITION; ARTERY OCCLUSION; NEURONAL DEATH; RAT; RESVERATROL	Poly(ADP-ribose) polymerase and sirtuin 1 are both NAD+-dependent enzymes. In vitro oxidative stress activates poly(ADPribose) polymerase, decreases NAD(+) level, sirtuin 1 activity and finally leads to cell death. Poly(ADP-ribose) polymerase hyperactivation contributes to cell death. In addition, poly(ADP-ribose) polymerase inhibition restores NAD(+) level and sirtuin 1 activity in vitro. In vitro sirtuin 1 induction protects neurons from cell loss induced by oxidative stress. In this context, the role of sirtuin 1 and its involvement in beneficial effects of poly(ADP-ribose) polymerase inhibition were evaluated in vivo in a model of cerebral oxidative stress induced by intrastriatal infusion of malonate in rat. Malonate promoted a NAD(+) decrease that was not prevented by 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, at 4 and 24 hours. However, 3-aminobenzamide increased nuclear SIRT1 activity/expression ratio after oxidative stress. Malonate induced a neurological deficit associated with a striatal lesion. Both were reduced by 3-aminobenzamide and SRT1720, a sirtuin 1 activator, showing beneficial effects of poly(ADP-ribose) polymerase inhibition and sirtuin 1 activation on oxidative stress consequences. EX527, a sirtuin 1 inhibitor, given alone, modified neither the score nor the lesion, suggesting that endogenous sirtuin 1 was not activated during cerebral oxidative stress. However, its association with 3-aminobenzamide suppressed the neurological improvement and the lesion reduction induced by 3-aminobenzamide. The association of 3-aminobenzamide with SRT1720, the sirtuin 1 activator, did not lead to a better protection than 3-aminobenzamide alone. The present data represent the first demonstration that the sirtuin 1 activator SRT1720 is neuroprotective during in vivo cerebral oxidative stress. Furthermore sirtuin 1 activation is involved in the beneficial effects of poly(ADP-ribose) polymerase inhibition after in vivo cerebral oxidative stress.	[Gueguen, Cindy; Palmier, Bruno; Plotkine, Michel; Marchand-Leroux, Catherine; Bessson, Valerie C.] Univ Paris 05, Fac Sci Pharmaceut & Biol, Pharmacol Circulat Cerebrale EA4475, Paris, France	Bessson, VC (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Pharmacol Circulat Cerebrale EA4475, Paris, France.	valerie.besson@parisdescartes.fr	besson, valerie C/L-7388-2017; MARCHAND-LEROUX, Catherine/L-7453-2017; BESSON, VALERIE/AAZ-9989-2020	besson, valerie C/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380	Universite Paris Descartes; Fondation des Gueules Cassees	This work was supported partly by Universite Paris Descartes and by a grant from the Fondation des Gueules Cassees. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeti R, 2011, BRAIN, V134, P1658, DOI 10.1093/brain/awr104; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Ba XQ, 2011, AM J PATHOL, V178, P946, DOI 10.1016/j.ajpath.2010.12.004; Bai P, 2011, CELL METAB, V13, P461, DOI 10.1016/j.cmet.2011.03.004; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BERNOFSKY C, 1973, ANAL BIOCHEM, V53, P452, DOI 10.1016/0003-2697(73)90094-8; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Caito S, 2010, BIOCHEM BIOPH RES CO, V392, P264, DOI 10.1016/j.bbrc.2009.12.161; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Cosi C, 2000, AMINO ACIDS, V19, P229, DOI 10.1007/s007260070054; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Furukawa A, 2007, CELL PHYSIOL BIOCHEM, V20, P45, DOI 10.1159/000104152; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Gupta YK, 2001, METHOD FIND EXP CLIN, V23, P241, DOI 10.1358/mf.2001.23.5.662120; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hoffmann E, 2013, BRIT J CLIN PHARMACO, V75, P186, DOI 10.1111/j.1365-2125.2012.04340.x; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ichikawa T, 2013, RESPIROLOGY, V18, P332, DOI 10.1111/j.1440-1843.2012.02284.x; Julien C, 2009, J NEUROPATH EXP NEUR, V68, P48, DOI 10.1097/NEN.0b013e3181922348; Kauppinen TM, 2013, BBA-MOL CELL RES, V1833, P1985, DOI 10.1016/j.bbamcr.2013.04.005; Kolthur-Seetharam U, 2006, CELL CYCLE, V5, P873, DOI 10.4161/cc.5.8.2690; Komjati K, 2005, CNS NEUROL DISORD-DR, V4, P179, DOI 10.2174/1568007053544138; Liu D, 2009, NEUROMOL MED, V11, P28, DOI 10.1007/s12017-009-8058-1; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Minor RK, 2011, SCI REP-UK, V1, DOI 10.1038/srep00070; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Paucard A, 2005, FUND CLIN PHARMACOL, V19, P57, DOI 10.1111/j.1472-8206.2004.00297.x; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200; Rajamohan SB, 2009, MOL CELL BIOL, V29, P4116, DOI 10.1128/MCB.00121-09; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shinmura K, 2008, AM J PHYSIOL-HEART C, V295, pH2348, DOI 10.1152/ajpheart.00602.2008; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Strosznajder RP, 2010, MOL NEUROBIOL, V41, P187, DOI 10.1007/s12035-010-8124-6; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Velasquez DA, 2011, DIABETES, V60, P1177, DOI 10.2337/db10-0802; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xie J, 2013, PHARMACOL RES, V67, P60, DOI 10.1016/j.phrs.2012.10.010; Yamazaki Y, 2009, AM J PHYSIOL-ENDOC M, V297, pE1179, DOI 10.1152/ajpendo.90997.2008; Yang HC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046364; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Yoshizaki T, 2010, AM J PHYSIOL-ENDOC M, V298, pE419, DOI 10.1152/ajpendo.00417.2009; Yoshizaki T, 2009, MOL CELL BIOL, V29, P1363, DOI 10.1128/MCB.00705-08; Zhang F, 2010, EUR J PHARMACOL, V636, P1, DOI 10.1016/j.ejphar.2010.03.043	60	19	19	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2014	9	2							e87367	10.1371/journal.pone.0087367			7	Multidisciplinary Sciences	Science & Technology - Other Topics	AB3VI	WOS:000331717900008	24586272	DOAJ Gold, Green Published			2021-06-18	
J	Olson, DM; Batjer, HH; Abdulkadir, K; Hall, CE				Olson, DaiWai M.; Batjer, Hunt H.; Abdulkadir, Kamal; Hall, Christiana E.			Measuring and Monitoring ICP in Neurocritical Care: Results from a National Practice Survey	NEUROCRITICAL CARE			English	Article						Intracranial pressure monitoring; ICP; Documentation; Critical care; Standard practice	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; HEAD-INJURY; INFORMATION-TECHNOLOGY; CLINICAL-PRACTICE; HEALTH-CARE; UNCERTAINTY; HEMORRHAGE; COSTS	The use of intracranial pressure (ICP) monitors is nearly synonymous with Neurocritical Care. Recent studies in nursing literature have report high levels of practice variance associated with ICP monitoring and treatment. There are no recent practice surveys to describe how critical care physicians and nurses who are familiar with ICP management provide care to their patients. A short survey was developed and disseminated electronically to the members of the Neurocritical Care Society. The summary from 241 professionals provides evidence that there is significant practice variation associated with ICP monitoring and management. The results highlight the need to develop standardized approaches to measuring, monitoring, recording, and treating ICP.	[Olson, DaiWai M.; Hall, Christiana E.] Univ Texas Southwestern, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Olson, DaiWai M.; Batjer, Hunt H.; Hall, Christiana E.] Univ Texas Southwestern, Dept Neurosurg, Dallas, TX 75390 USA; [Abdulkadir, Kamal] Univ Texas Southwestern, Dept Nursing, Dallas, TX 75390 USA	Olson, DM (corresponding author), Univ Texas Southwestern, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	DaiWai.Olson@UTsouthwestern.edu; Hunt.Batjer@UTsouthwestern.edu; Kamal.Abdulkadir@UTsouthwestern.edu; Christiana.Hall@UTsouthwestern.edu	Olson, DaiWai/I-5932-2019	Olson, DaiWai/0000-0002-9280-078X			AANN, 2004, AANN COR CURR NEUR N; Abou-Assi S, 2001, POSTGRAD MED, V109, P52, DOI 10.3810/pgm.2001.02.850; ALLAN D, 1989, J ADV NURS, V14, P127, DOI 10.1111/j.1365-2648.1989.tb00910.x; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Dykema J, 2011, EVAL HEALTH PROF, V34, P434, DOI 10.1177/0163278711406113; Greenberg MS, 2001, HDB NEUROSURGERY; Greenberg MS, 2006, HDB NEUROSURGERY; Hunter KM, 2002, HLTH CARE INFORM INT, P209; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kim GS, 2011, NEUROCRIT CARE, V14, P68, DOI 10.1007/s12028-010-9401-y; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Logan RL, 1996, LANCET, V347, P595, DOI 10.1016/S0140-6736(96)91284-2; Low D, 2009, J NEUROTRAUM, V26, P1177, DOI [10.1089/neu.2008.0841, 10.1089/neu.2008-0841]; March K, 2000, Crit Care Nurs Clin North Am, V12, P429; March K, 2009, AACN AANN PROTOCOLS; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; Marmarou A, 1992, J NEUROSURG, V75, pS21; Miriovsky BJ, 2012, J CLIN ONCOL, V30, P4243, DOI 10.1200/JCO.2012.42.8011; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Olson DM, 2013, J NEUROSCI NURS, V45, P186, DOI 10.1097/JNN.0b013e3182986400; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Parashos P, 2005, COMMUNITY DENT ORAL, V33, P9, DOI 10.1111/j.1600-0528.2004.00181.x; Ragauskas A, 2012, NEUROLOGY, V78, P1684, DOI 10.1212/WNL.0b013e3182574f50; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rehman T, 2012, CLIN NEUROL NEUROSUR, V114, P651, DOI 10.1016/j.clineuro.2011.12.040; Shaw M, 2008, ACTA NEUROCHIR SUPPL, V102, P217, DOI 10.1007/978-3-211-85578-2_42; Sinkowitz-Cochran RL, 2013, CLIN INFECT DIS, V56, P1159, DOI 10.1093/cid/cit005; Vaismoradi M, 2011, J ADV NURS, V67, P991, DOI 10.1111/j.1365-2648.2010.05547.x; Watkins P, 2005, CLIN MED, V5, P197, DOI 10.7861/clinmedicine.5-3-197; Wells DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11678	31	19	20	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2014	20	1					15	20		10.1007/s12028-013-9847-9			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AB2RI	WOS:000331639400003	23839709				2021-06-18	
J	Shu, IW; Onton, JA; Prabhakar, N; O'Connell, RM; Simmons, AN; Matthews, SC				Shu, I-Wei; Onton, Julie A.; Prabhakar, Nitin; O'Connell, Ryan M.; Simmons, Alan N.; Matthews, Scott C.			Combat veterans with PTSD after mild TBI exhibit greater ERPs from posterior-medial cortical areas while appraising facial features	JOURNAL OF AFFECTIVE DISORDERS			English	Article						PTSD; Mild TBI; N300; Posterior cingulate cortex; Precuneus; Biomarker	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; DEFAULT-MODE NETWORK; FUNCTIONAL CONNECTIVITY; CONCUSSED INDIVIDUALS; NEURAL MECHANISMS; COGNITIVE CONTROL; TIME-COURSE; DEPRESSION; EMOTION	Posttraumatic stress disorder (PTSD) worsens prognosis following mild traumatic brain injury (mTBI). Combat personnel with histories of mTBI exhibit abnormal activation of distributed brain networks including emotion processing and default mode networks. How developing PTSD further affects these abnormalities has not been directly examined. We recorded electroencephalography in combat veterans with histories of mTBI, but without active PTSD (mTBI only, n=16) and combat veterans who developed PTSD after mTBI (mTBI + PTSD, n = 16) during the Reading the Mind in the Eyes Test (RMET), a validated test of empathy requiring emotional appraisal of facial features. Task-related event related potentials (ERPs) were identified, decomposed using independent component analysis (ICA) and localized anatomically using dipole modeling. We observed larger emotional face processing ERPs in veterans with mTBI + PTSD, including greater N300 negativity. Furthermore, greater N300 negativity correlated with greater PTSD severity, especially avoidance/numbing and hyperarousal symptom clusters. This correlation was dependent on contributions from the precuneus and posterior cingulate cortex (PCC). Our results support a model where, in combat veterans with histories of mTBI, larger ERPs from overactive posterior-medial cortical areas may be specific to PTSD, and is likely related to negative selfreferential activits. Published by Elsevier B.V.	[Shu, I-Wei; Matthews, Scott C.] VISN 22 Mental Illness, Res Educ & Clin Ctr, San Diego, CA 92161 USA; [Shu, I-Wei; O'Connell, Ryan M.; Simmons, Alan N.] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA; [Prabhakar, Nitin; O'Connell, Ryan M.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92037 USA; [Simmons, Alan N.; Matthews, Scott C.] Vet Affairs San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, La Jolla, CA 92161 USA; [Onton, Julie A.] Naval Hlth Res Ctr, San Diego, CA 92106 USA	Shu, IW (corresponding author), VISN 22 Mental Illness, Res Educ & Clin Ctr, 3350 La Jolla Village Dr,116A, San Diego, CA 92161 USA.	ishu@ucsd.edu	Simmons, Alan N/A-9815-2008	Simmons, Alan N/0000-0003-3963-2112	BUMED under Work Unit 61032; VA Mental Illness Research, Education and Clinical Center; VA Office of Academic AffiliationsUS Department of Veterans Affairs; VA Advanced Fellowship Program in Mental Illness Research Treatment; VA Center of Excellence for Stress and Mental Health; University of California San Diego Academic Senate, Department of Veterans Affairs; Congressionally Directed Medical Research ProgramUnited States Department of Defense; CDA-2 from the VA CSRD	This work represents Report No. 12-xx and was supported by BUMED under Work Unit 61032. The views expressed in this article arc those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of Inunan subjects in research (Protocols NHRC.2010.0022 and NHRC.2010.0023).; This research was also supported by the VA Mental Illness Research, Education and Clinical Center, VA Office of Academic Affiliations, VA Advanced Fellowship Program in Mental Illness Research Treatment, and the VA Center of Excellence for Stress and Mental Health, and by grants from the University of California San Diego Academic Senate, Department of Veterans Affairs, and the Congressionally Directed Medical Research Program. Dr. Matthews is supported by a CDA-2 from the VA CSR&D.	Albert J, 2012, HUM BRAIN MAPP, V33, P2147, DOI 10.1002/hbm.21347; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Attias J, 1996, BRIT J PSYCHIAT, V168, P110, DOI 10.1192/bjp.168.1.110; Bae KY, 2011, PROG NEURO-PSYCHOPH, V35, P1908, DOI 10.1016/j.pnpbp.2011.08.002; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Campanella S., 2013, NEUROIMAGE; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delorme A, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/130714; Driessen M, 2004, BIOL PSYCHIAT, V55, P603, DOI 10.1016/j.biopsych.2003.08.018; Ehlers CL, 2006, ANN NY ACAD SCI, V1071, P125, DOI 10.1196/annals.1364.011; Farrow TFD, 2013, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00349; Felmingham KL, 2003, NEUROREPORT, V14, P777, DOI 10.1097/00001756-200304150-00024; First MB., 2002, STRUCTURED CLIN INTE; Fruhholz S, 2011, BIOL PSYCHOL, V87, P265, DOI 10.1016/j.biopsycho.2011.03.008; Hayes JP, 2009, PSYCHIAT RES-NEUROIM, V172, P7, DOI 10.1016/j.pscychresns.2008.05.005; Hermans R. M., 2012, PSYCHOL MED, P1; Javanbakht A, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-5; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Johnson J.D., 2013, CLIN EEG NEUROSCI; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Lanius RA, 2010, ACTA PSYCHIAT SCAND, V121, P33, DOI 10.1111/j.1600-0447.2009.01391.x; Lanius RA, 2007, PSYCHIAT RES-NEUROIM, V155, P45, DOI 10.1016/j.pscychresns.2006.11.006; Lanius RA, 2010, AM J PSYCHIAT, V167, P640, DOI 10.1176/appi.ajp.2009.09081168; Larson MJ, 2012, J INT NEUROPSYCH SOC, V18, P323, DOI 10.1017/S1355617711001779; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Lombardo MV, 2010, J COGNITIVE NEUROSCI, V22, P1623, DOI 10.1162/jocn.2009.21287; Luo WB, 2010, NEUROIMAGE, V49, P1857, DOI 10.1016/j.neuroimage.2009.09.018; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mazza M., 2012, PSYCHIAT RES; Mechias ML, 2010, NEUROIMAGE, V49, P1760, DOI 10.1016/j.neuroimage.2009.09.040; Morey R.A., 2012, HUM BRAIN MAPP; Nardo D, 2011, PSYCHOL MED, V15, P1; Nietlisbach G, 2010, PSYCHOL REP, V106, P832, DOI 10.2466/PR0.106.3.832-844; Pantazatos SP, 2012, NEUROIMAGE, V61, P1355, DOI 10.1016/j.neuroimage.2012.03.051; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Ramage A.E., 2012, HUM BRAIN MAPP; Roy MJ, 2010, ANN NY ACAD SCI, V1208, P142, DOI 10.1111/j.1749-6632.2010.05689.x; Sartory G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058150; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schutter DJLG, 2004, INT J PSYCHOPHYSIOL, V53, P29, DOI 10.1016/j.ijpsycho.2004.01.003; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Shannon BJ, 2004, J NEUROSCI, V24, P10084, DOI 10.1523/JNEUROSCI.2625-04.2004; Simmons AN, 2013, J AFFECT DISORDERS, V146, P426, DOI 10.1016/j.jad.2012.08.006; Simmons AN, 2011, BIOL MOOD ANXIETY DI, V1, DOI 10.1186/2045-5380-1-6; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Stanford MS, 2001, PSYCHIAT RES, V102, P125, DOI 10.1016/S0165-1781(01)00236-0; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Sugiura M, 2005, J COGNITIVE NEUROSCI, V17, P183, DOI 10.1162/0898929053124956; Tanelian T., 2008, INIVISIBLE WOUNDS WA; Tanev Kaloyan, 2003, Curr Psychiatry Rep, V5, P369; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2012, PTSD MILD TRAUMATIC; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Whalley MG, 2009, BRAIN COGNITION, V69, P98, DOI 10.1016/j.bandc.2008.05.008; Wood KH, 2012, NEUROIMAGE, V60, P787, DOI 10.1016/j.neuroimage.2011.12.048; Yin Y, 2011, BRAIN RES, V1411, P98, DOI 10.1016/j.brainres.2011.07.016; Yun XY, 2011, NEUROSCI LETT, V498, P10, DOI 10.1016/j.neulet.2011.04.040; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhang WH, 2012, BIOL PSYCHOL, V89, P444, DOI 10.1016/j.biopsycho.2011.12.011; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	72	19	19	0	29	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	FEB	2014	155						234	240		10.1016/j.jad.2013.06.057			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	287XB	WOS:000329574500033	24342149				2021-06-18	
J	Wei, L; Zhang, YF; Yang, C; Wang, Q; Zhuang, ZW; Sun, ZY				Wei, Liang; Zhang, Yanfei; Yang, Cheng; Wang, Qi; Zhuang, Zhongwei; Sun, Zhiyang			Neuroprotective effects of ebselen in traumatic brain injury model: involvement of nitric oxide and p38 mitogen-activated protein kinase signalling pathway	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						ebselen; inflammation; neuroprotection; traumatic brain injury	LPS-INDUCED INFLAMMATION; CEREBRAL-BLOOD-FLOW; NF-KAPPA-B; HEMORRHAGIC-SHOCK; MAPK; EXPRESSION; ISCHEMIA; DAMAGE; EDEMA; CELLS	1. Previous investigations have found that ebselen is able to treat neurodegenerative diseases caused by radical and acute total cerebral ischaemia. The aim of the present study was to investigate the neuroprotective effects of ebselen in a traumatic brain injury (TBI) model. 2. Ninety Sprague-Dawley rats were randomly divided into five groups (n = 18 in each): (i) sham operation; (ii) an injury model group; (iii) low-dose (3 mg/kg) ebselen-treated group; (iv) a moderate-dose (10 mg/kg) ebselen-treated group; and (v) a high-dose (30 mg/kg) ebselen-treated group. The TBI model was created according using a modified weight-drop model. Neurological severity score (NSS), brain water content and histopathological deficits were assessed as parameters of injury severity. Expression of nitric oxide (NO), inducible NO synthase (iNOS) mRNA, Toll-like receptor (TLR) and phosphorylated (p-) p38 mitogen-activated protein kinase (MAPK) were examined by chemical colorimetry, quantitative polymerase chain reaction and western blotting 24 h after intragastric ebselen administration. 3. Rats in the TBI model group exhibited markedly more severe neurological injury (higher NSS, more brain water content and more histopathological deficits) than those in the sham-operated group. Ebselen treatment significantly ameliorated the neurological injury of TBI rats in a dose-dependent manner. Moreover, ebselen significantly reduced the NO and iNOS mRNA levels and inhibited TLR4 and p-p38 MAPK expression, indicating the involvement of NO and p38 MAPK signalling pathways in the neuroprotection afforded by ebselen. 4. In conclusion, ebselen ameliorated neurological injury, possibly by reducing NO levels and modulating the TLR4-mediated p38 MAPK signalling pathway. Therefore, ebselen may have potential to treat secondary injuries of TBI.	[Wei, Liang; Zhang, Yanfei; Yang, Cheng; Wang, Qi; Zhuang, Zhongwei; Sun, Zhiyang] Tongji Univ, East Hosp, Sch Med, Dept Neurosurg, Shanghai 200120, Peoples R China	Sun, ZY (corresponding author), Tongji Univ, East Hosp, Sch Med, Dept Neurosurg, 150 Jimo Rd,Pudong New Area, Shanghai 200120, Peoples R China.	sunzhiyangtj@hotmail.com					Bowie AG, 2005, MOL IMMUNOL, V42, P859, DOI 10.1016/j.molimm.2004.11.007; Burggraaf S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014561; Byun EB, 2013, INT IMMUNOPHARMACOL, V15, P450, DOI 10.1016/j.intimp.2012.11.021; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Foley LM, 2013, J CEREBR BLOOD F MET, V33, P129, DOI 10.1038/jcbfm.2012.145; Fu YH, 2013, J ETHNOPHARMACOL, V145, P193, DOI 10.1016/j.jep.2012.10.051; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Imai H, 2003, FREE RADICAL BIO MED, V34, P56, DOI 10.1016/S0891-5849(02)01180-2; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kim JP, 2012, ACTA NEUROCHIR, V154, P823, DOI 10.1007/s00701-012-1306-4; Koizumi H, 2011, NEUROL MED-CHIR, V51, P337, DOI 10.2176/nmc.51.337; Kwak HJ, 2005, J PHARMACOL EXP THER, V315, P1188, DOI 10.1124/jpet.105.092056; Lee YJ, 2003, BIOCHEM PHARMACOL, V66, P2281, DOI 10.1016/j.bcp.2003.07.014; Li YB, 2002, NEUROSCI LETT, V330, P69, DOI 10.1016/S0304-3940(02)00444-5; Meng Z, 2013, ACTA PHARMACOL SIN, V34, P901, DOI 10.1038/aps.2013.24; Mozer AB, 2010, CURR NEUROVASC RES, V7, P238; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Nogueira CW, 2011, ARCH TOXICOL, V85, P1313, DOI 10.1007/s00204-011-0720-3; Nozawa R, 1996, J PHARM PHARMACOL, V48, P64, DOI 10.1111/j.2042-7158.1996.tb05879.x; Nurnberger S, 2012, AM J PHYSIOL-GASTR L, V303, pG1373, DOI 10.1152/ajpgi.00056.2012; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Ozgur T, 2012, RENAL FAILURE, V34, P991, DOI 10.3109/0886022X.2012.706880; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; Schallert T, 1997, ADV NEUROL, V73, P229; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Stein DM, 2013, NEUROCRIT CARE, V18, P332, DOI 10.1007/s12028-013-9832-3; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Wang YX, 2010, J SURG RES, V161, P119, DOI 10.1016/j.jss.2008.10.030; Wu JF, 2012, INT IMMUNOPHARMACOL, V12, P74, DOI 10.1016/j.intimp.2011.10.015; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xu JH, 2006, NEUROSCI LETT, V399, P210, DOI 10.1016/j.neulet.2006.02.024	36	19	20	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1870	1440-1681		CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	FEB	2014	41	2					134	138		10.1111/1440-1681.12186			5	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	AR9ON	WOS:000343904500005	24131109				2021-06-18	
J	Suyama, K; Watanabe, M; Sakabe, K; Otomo, A; Okada, Y; Terayama, H; Imai, T; Mochida, J				Suyama, Kaori; Watanabe, Masahiko; Sakabe, Kou; Otomo, Asako; Okada, Yoshinori; Terayama, Hayato; Imai, Takeshi; Mochida, Joji			GRP78 Suppresses Lipid Peroxidation and Promotes Cellular Antioxidant Levels in Glial Cells following Hydrogen Peroxide Exposure	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; SPINAL-CORD-INJURY; UNFOLDED PROTEIN RESPONSE; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; NEUROBLASTOMA-CELLS; EPITHELIAL-CELLS; INDUCTION; NQO1; GLUTATHIONE	Oxidative stress, caused by the over production of reactive oxygen species (ROS), has been shown to contribute to cell damage associated with neurotrauma and neurodegenerative diseases. ROS mediates cell damage either through direct oxidation of lipids, proteins and DNA or by acting as signaling molecules to trigger cellular apoptotic pathways. The 78 kDa glucose-regulated protein (GRP78) is an ER chaperone that has been suggested to protect cells against ROS-induced damage. However, the protective mechanism of GRP78 remains unclear. In this study, we used C6 glioma cells transiently overexpressing GRP78 to investigate the protective effect of GRP78 against oxidative stress (hydrogen peroxide)-induced injury. Our results showed that the overexpression of GRP78 significantly protected cells from ROS-induced cell damage when compared to non-GRP78 overexpressing cells, which was most likely due to GRP78-overexpressing cells having higher levels of glutathione (GSH) and NAD(P)H:quinone oxidoreductase 1 (NQO1), two antioxidants that protect cells against oxidative stress. Although hydrogen peroxide treatment increased lipid peroxidation in non-GRP78 overexpressing cells, this increase was significantly reduced in GRP78-overexpressing cells. Overall, these results indicate that GRP78 plays an important role in protecting glial cells against oxidative stress via regulating the expression of GSH and NQO1.	[Suyama, Kaori; Sakabe, Kou; Terayama, Hayato] Tokai Univ, Sch Med, Dept Anat & Cellular Biol, Isehara, Kanagawa 25911, Japan; [Watanabe, Masahiko; Imai, Takeshi; Mochida, Joji] Tokai Univ, Sch Med, Dept Orthoped Surg, Isehara, Kanagawa 25911, Japan; [Otomo, Asako] Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 25911, Japan; [Okada, Yoshinori] Tokai Univ, Teaching & Res Support Ctr, Isehara, Kanagawa, Japan	Watanabe, M (corresponding author), Tokai Univ, Sch Med, Dept Orthoped Surg, Isehara, Kanagawa 25911, Japan.	masahiko@is.icc.u-tokai.ac.jp	Otomo, Asako/AAA-6374-2019	Otomo, Asako/0000-0002-7849-4309	Research and Study Program of Tokai University Educational System General Research Organization; Tokai University School of Medicine Research Aid; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25830040, 26460809, 25462311] Funding Source: KAKEN	This study was supported in part by the Research and Study Program of Tokai University Educational System General Research Organization and 2012 Tokai University School of Medicine Research Aid. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aragno M, 2000, DIABETES, V49, P1924, DOI 10.2337/diabetes.49.11.1924; Bao F, 2004, NEUROSCIENCE, V126, P285, DOI 10.1016/j.neuroscience.2004.03.054; Bar-Am O, 2009, J MOL NEUROSCI, V37, P135, DOI 10.1007/s12031-008-9139-6; Bhandary B, 2013, INT J MOL SCI, V14, P434, DOI 10.3390/ijms14010434; Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645; Dinkova-Kostova AT, 2010, ARCH BIOCHEM BIOPHYS, V501, P116, DOI 10.1016/j.abb.2010.03.019; Elmann A, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/157598; GOMER CJ, 1991, CANCER RES, V51, P6574; Grant CM, 1998, BIOCHEM BIOPH RES CO, V253, P893, DOI 10.1006/bbrc.1998.9864; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; Higo T, 2010, NEURON, V68, P865, DOI 10.1016/j.neuron.2010.11.010; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Jia ZQ, 2008, BRAIN RES, V1197, P159, DOI 10.1016/j.brainres.2007.12.044; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lim JH, 2008, PHARMACOL RES, V57, P325, DOI 10.1016/j.phrs.2008.03.004; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Long DJ, 2002, CANCER RES, V62, P3030; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Mohammad MK, 2012, TOXICOL APPL PHARM, V265, P73, DOI 10.1016/j.taap.2012.09.021; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Penas C, 2007, J NEUROCHEM, V102, P1242, DOI 10.1111/j.1471-4159.2007.04671.x; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; Suyama K, 2011, NEUROSCI LETT, V504, P271, DOI 10.1016/j.neulet.2011.09.045; Tiffany-Castiglioni E, 2012, NEUROTOXICOLOGY, V33, P545, DOI 10.1016/j.neuro.2012.02.007; Timblin CR, 1998, FREE RADICAL BIO MED, V24, P632, DOI 10.1016/S0891-5849(97)00325-0; Vladykovskaya E, 2012, J BIOL CHEM, V287, P11398, DOI 10.1074/jbc.M111.320416; Yen CC, 2011, ARCH TOXICOL, V85, P565, DOI 10.1007/s00204-011-0709-y; Yokouchi M, 2008, J BIOL CHEM, V283, P4252, DOI 10.1074/jbc.M705951200; Yoshida T, 2008, CANCER CHEMOTH PHARM, V61, P559, DOI 10.1007/s00280-007-0503-y; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507	37	19	21	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2014	9	1							e86951	10.1371/journal.pone.0086951			9	Multidisciplinary Sciences	Science & Technology - Other Topics	298QQ	WOS:000330339800071	24475200	DOAJ Gold, Green Published			2021-06-18	
J	Cha, Y; Kim, Y; Hwang, S; Chung, Y				Cha, Yuri; Kim, Young; Hwang, Sujin; Chung, Yijung			Intensive gait training with rhythmic auditory stimulation in individuals with chronic hemiparetic stroke: A pilot randomized controlled study	NEUROREHABILITATION			English	Article						Gait; rhythmic auditory stimulation; stroke	TRAUMATIC BRAIN-INJURY; BALANCE SCALE; REHABILITATION; RELIABILITY; PERFORMANCE; MODEL	BACKGROUND: Motor relearning protocols should involve task-oriented movement, focused attention, and repetition of desired movements. OBJECTIVES: To investigate the effect of intensive gait training with rhythmic auditory stimulation on postural control and gait performance in individuals with chronic hemiparetic stroke. METHODS: Twenty patients with chronic hemiparetic stroke participated in this study. Subjects in the Rhythmic auditory stimulation training group (10 subjects) underwent intensive gait training with rhythmic auditory stimulation for a period of 6 weeks (30 min/day, five days/week), while those in the control group (10 subjects) underwent intensive gait training for the same duration. Two clinical measures, Berg balance scale and stroke specific quality of life scale, and a 2-demensional gait analysis system, were used as outcome measure. To provide rhythmic auditory stimulation during gait training, the MIDI Cuebase musical instrument digital interface program and a KM Player version 3.3 was utilized for this study. RESULTS: Intensive gait training with rhythmic auditory stimulation resulted in significant improvement in scores on the Berg balance scale, gait velocity, cadence, stride length and double support period in affected side, and stroke specific quality of life scale compared with the control group after training. CONCLUSIONS: Findings of this study suggest that intensive gait training with rhythmic auditory stimulation improves balance and gait performance as well as quality of life, in individuals with chronic hemiparetic stroke.	[Cha, Yuri; Kim, Young] Sahmyook Univ, Dept Phys Therapy, Grad Sch, Seoul 139800, South Korea; [Hwang, Sujin] Baekseok Univ, Div Hlth Sci, Dept Phys Therapy, Cheonan, South Korea; [Chung, Yijung] Sahmyook Univ, Dept Phys Therapy, Coll Hlth & Welfare, Seoul 139800, South Korea	Chung, Y (corresponding author), Sahmyook Univ, Dept Phys Therapy, Coll Hlth & Welfare, POB Hwarangro 815, Seoul 139800, South Korea.	yijung36@syu.ac.kr		Chung, Yijung/0000-0002-2431-8895			BERG K, 1995, SCAND J REHABIL MED, V27, P27; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Conesa L, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-13; Conklyn D, 2010, NEUROREHAB NEURAL RE, V24, P835, DOI 10.1177/1545968310372139; Daly JJ, 2007, THESCIENTIFICWORLDJO, V7, P2031, DOI 10.1100/tsw.2007.299; DeJong G, 2011, PHYS THER, V91, P1826, DOI 10.2522/ptj.20100424; Dobkin B.H., 2003, CLIN SCI NEUROLOGIC; Dy SM, 2012, J GEN INTERN MED, V27, P760, DOI 10.1007/s11606-012-2054-0; Fernandez-Concepcion O, 2005, REV NEUROLOGIA, V41, P391, DOI 10.33588/rn.4107.2005156; Fritz S, 2011, J NEUROL PHYS THER, V35, P141, DOI 10.1097/NPT.0b013e31822a2a09; Hurt CP, 1998, J MUSIC THER, V35, P228, DOI 10.1093/jmt/35.4.228; Kadivar Z, 2011, NEUROREHAB NEURAL RE, V25, P626, DOI 10.1177/1545968311401627; Kim SJ, 2012, CLIN REHABIL, V26, P904, DOI 10.1177/0269215511434648; Kuys SS, 2011, DISABIL REHABIL, V33, P1848, DOI 10.3109/09638288.2010.549895; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Malcolm MP, 2009, TOP STROKE REHABIL, V16, P69, DOI 10.1310/tsr1601-69; Mergner T, 2003, PROG BRAIN RES, V142, P189; Perry J, 2010, GAIT ANALYSIS: NORMAL AND PATHOLOGICAL FUNCTION, SECOND EDITION, P1; Roerdink M, 2007, PHYS THER, V87, P1009, DOI 10.2522/ptj.20050394; Schauer M, 2003, CLIN REHABIL, V17, P713, DOI 10.1191/0269215503cr668oa; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Thaut AH, 2007, NEUROREHAB NEURAL RE, V21, P455, DOI 10.1177/1545968307300523; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Williams LS, 1999, STROKE, V30, P1362, DOI 10.1161/01.STR.30.7.1362	24	19	21	0	21	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2014	35	4					681	688		10.3233/NRE-141182			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AW4HK	WOS:000346241600006	25318784				2021-06-18	
J	Conley, YP; Okonkwo, DO; Deslouches, S; Alexander, S; Puccio, AM; Beers, SR; Ren, DAX				Conley, Yvette P.; Okonkwo, David O.; Deslouches, Sandra; Alexander, Sheila; Puccio, Ava M.; Beers, Sue R.; Ren, Dianxu			Mitochondrial Polymorphisms Impact Outcomes after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; mitochondria; outcome; polymorphism; TBI	PARKINSONS-DISEASE; INCREASED RISK; STRUCTURED INTERVIEWS; ALLELE 4216C; HEAD-INJURY; RAT-BRAIN; DYSFUNCTION; DNA; CELLS; ASSOCIATION	Patient outcomes are variable following severe traumatic brain injury (TBI); however, the biological underpinnings explaining this variability are unclear. Mitochondrial dysfunction after TBI is well documented, particularly in animal studies. The aim of this study was to investigate the role of mitochondrial polymorphisms on mitochondrial function and patient outcomes out to 1 year after a severe TBI in a human adult population. The Human MitoChip V2.0 was used to evaluate mitochondrial variants in an initial set of n=136 subjects. SNPs found to be significantly associated with patient outcomes [Glasgow Outcome Scale (GOS), Neurobehavioral Rating Scale (NRS), Disability Rating Scale (DRS), in-hospital mortality, and hospital length of stay] or neurochemical level (lactate:pyruvate ratio from cerebrospinal fluid) were further evaluated in an expanded sample of n=336 subjects. A10398G was associated with DRS at 6 and 12 months (p=0.02) and a significant time by SNP interaction for DRS was found (p=0.0013). The A10398 allele was associated with greater disability over time. There was a T195C by sex interaction for GOS (p=0.03) with the T195 allele associated with poorer outcomes in females. This is consistent with our findings that the T195 allele was associated with mitochondrial dysfunction (p=0.01), but only in females. This is the first study associating mitochondrial DNA variation with both mitochondrial function and neurobehavioral outcomes after TBI in humans. Our findings indicate that mitochondrial DNA variation may impact patient outcomes after a TBI potentially by influencing mitochondrial function, and that sex of the patient may be important in evaluating these associations in future studies.	[Conley, Yvette P.; Deslouches, Sandra; Alexander, Sheila; Ren, Dianxu] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Beers, Sue R.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA	Conley, YP (corresponding author), Univ Pittsburgh, Sch Nursing, Grad Sch Publ Hlth, 440 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.	yconley@pitt.edu		Conley, Yvette/0000-0002-1784-6067	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR008424, P50NS30318, R01NR013342]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424, R01NR013342] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grant numbers R01NR008424; P50NS30318; and R01NR013342).	Araujo GW, 2008, J NEUROENDOCRINOL, V20, P930, DOI 10.1111/j.1365-2826.2008.01747.x; Arnold S, 2008, J MOL ENDOCRINOL, V41, P289, DOI 10.1677/JME-08-0085; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; BETTINI E, 1992, J NEUROCHEM, V58, P1923, DOI 10.1111/j.1471-4159.1992.tb10070.x; Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; Chen JQ, 1998, CARCINOGENESIS, V19, P2187, DOI 10.1093/carcin/19.12.2187; Chen JQ, 2003, TOXICOL SCI, V75, P271, DOI 10.1093/toxsci/kfg183; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; DITUNNO JF, 1992, J NEUROTRAUM, V9, pS301; Farace E, 2000, Neurosurg Focus, V8, pe6; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gaweda-Walerych K, 2008, J NEURAL TRANSM, V115, P1521, DOI 10.1007/s00702-008-0121-9; Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276; Gomez R, 2009, J TRAUMA, V66, P850, DOI 10.1097/TA.0b013e3181991ac8; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158; Holt I. J, 1994, MITOCHONDRIA DNA PRO, P27; Hoofien D, 2001, BRAIN INJURY, V15, P189; Huebinger RM, 2010, SHOCK, V33, P19, DOI 10.1097/SHK.0b013e3181a99508; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128; Kirchner SC, 2000, NEUROTOXICOLOGY, V21, P441; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lulic D, 2011, NEUROSURGERY, V68, P1172, DOI 10.1227/NEU.0b013e31820c6cdc; Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504; Mattson MP, 1997, NEUROREPORT, V8, P3817, DOI 10.1097/00001756-199712010-00031; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nilsen J, 2007, J NEUROSCI, V27, P14069, DOI 10.1523/JNEUROSCI.4391-07.2007; Nilsen J, 2004, CNS NEUROL DISORD-DR, V3, P297, DOI 10.2174/1568007043337193; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; VANITALLIE CM, 1988, MOL ENDOCRINOL, V2, P332, DOI 10.1210/mend-2-4-332; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Zheng JB, 1999, J STEROID BIOCHEM, V68, P65, DOI 10.1016/S0960-0760(98)00161-7; Zheng JB, 1999, EUR J PHARMACOL, V368, P95, DOI 10.1016/S0014-2999(99)00012-6	55	19	19	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					34	41		10.1089/neu.2013.2855			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500004	23883111	Green Published			2021-06-18	
J	Dell'Anna, AM; Lamanna, I; Vincent, JL; Taccone, FS				Dell'Anna, Antonio Maria; Lamanna, Irene; Vincent, Jean-Louis; Taccone, Fabio Silvio			How much oxygen in adult cardiac arrest?	CRITICAL CARE			English	Article							AMERICAN-HEART-ASSOCIATION; INTENSIVE-CARE-UNIT; EUROPEAN-RESUSCITATION-COUNCIL; EMERGENCY CARDIOVASCULAR CARE; MILD THERAPEUTIC HYPOTHERMIA; TRAUMATIC BRAIN-INJURY; IN-HOSPITAL MORTALITY; CEREBRAL-BLOOD-FLOW; CARDIOPULMONARY-RESUSCITATION; ARTERIAL HYPEROXIA	Although experimental studies have suggested that a high arterial oxygen pressure (PaO2) might aggravate post-anoxic brain injury, clinical studies in patients resuscitated from cardiac arrest (CA) have given conflicting results. Some studies found that a PaO2 of more than 300 mm Hg (hyperoxemia) was an independent predictor of poor outcome, but others reported no association between blood oxygenation and neurological recovery in this setting. In this article, we review the potential mechanisms of oxygen toxicity after CA, animal data available in this field, and key human studies dealing with the impact of oxygen management in CA patients, highlighting some potential confounders and limitations and indicating future areas of research in this field. From the currently available literature, high oxygen concentrations during cardiopulmonary resuscitation seem preferable, whereas hyperoxemia should be avoided in the post-CA care. A specific threshold for oxygen toxicity has not yet been identified. The mechanisms of oxygen toxicity after CA, such as seizure development, reactive oxygen species production, and the development of organ dysfunction, need to be further evaluated in prospective studies.	[Dell'Anna, Antonio Maria; Lamanna, Irene; Vincent, Jean-Louis; Taccone, Fabio Silvio] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, B-1070 Brussels, Belgium	Taccone, FS (corresponding author), Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Route Lennik 808, B-1070 Brussels, Belgium.	ftaccone@ulb.ac.be	Dell'Anna, Antonio Maria/ABD-1945-2020; Dell'Anna, Antonio Maria/K-3980-2018	Dell'Anna, Antonio Maria/0000-0002-8357-504X; Dell'Anna, Antonio Maria/0000-0002-8357-504X; Vincent, Jean-Louis/0000-0001-6011-6951			Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Bellomo R, 2011, CRIT CARE, V15, DOI 10.1186/cc10090; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bisschops LLA, 2012, CRIT CARE MED, V40, P2362, DOI 10.1097/CCM.0b013e318255d983; Cornet AD, 2013, CRIT CARE, V17, DOI 10.1186/cc12554; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Ganga HV, 2013, RESUSCITATION, V84, P1723, DOI 10.1016/j.resuscitation.2013.07.006; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Goto Y, 2013, CRIT CARE, V17, DOI 10.1186/cc13121; Hazelton JL, 2010, J NEUROTRAUM, V27, P753, DOI 10.1089/neu.2009.1186; Holzer M, 2002, NEW ENGL J MED, V346, P549; Ihle JF, 2013, CRIT CARE RESUSC, V15, P186; Janz DR, 2012, CRIT CARE MED, V40, P3135, DOI 10.1097/CCM.0b013e3182656976; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kuisma M, 2006, RESUSCITATION, V69, P199, DOI 10.1016/j.resuscitation.2005.08.010; Lee BK, 2014, AM J EMERG MED, V32, P55, DOI 10.1016/j.ajem.2013.09.044; Lee JK, 2011, CRIT CARE MED, V39, P2337, DOI 10.1097/CCM.0b013e318223b910; Lemiale V, 2013, INTENS CARE MED, V39, P1972, DOI 10.1007/s00134-013-3043-4; Meyhoff CS, 2012, CURR OPIN ANESTHESIO, V25, P363, DOI 10.1097/ACO.0b013e328352b402; Morimoto T, 1996, DEV BRAIN RES, V92, P77, DOI 10.1016/0165-3806(95)00205-7; Nelskyla A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-35; Neumar RW, 2011, CURR OPIN CRIT CARE, V17, P236, DOI 10.1097/MCC.0b013e3283454c8c; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Pilcher J, 2012, RESUSCITATION, V83, P417, DOI 10.1016/j.resuscitation.2011.12.021; Pilla R, 2013, J APPL PHYSIOL, V114, P1009, DOI 10.1152/japplphysiol.01326.2012; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Schneider AG, 2013, RESUSCITATION, V84, P927, DOI 10.1016/j.resuscitation.2013.02.014; Small DL, 1999, PROG CARDIOVASC DIS, V42, P185, DOI 10.1016/S0033-0620(99)70002-2; Spindelboeck W, 2013, RESUSCITATION, V84, P770, DOI 10.1016/j.resuscitation.2013.01.012; Vaahersalo J, 2014, CRIT CARE MED, V42, P1463, DOI 10.1097/CCM.0000000000000228; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147	40	19	21	1	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2014	18	5							555	10.1186/s13054-014-0555-4			7	Critical Care Medicine	General & Internal Medicine	CE5DM	WOS:000351850600071	25636001	DOAJ Gold, Green Published			2021-06-18	
J	Gosseries, O; Charland-Verville, V; Thonnard, M; Bodart, O; Laureys, S; Demertzi, A				Gosseries, Olivia; Charland-Verville, Vanessa; Thonnard, Marie; Bodart, Olivier; Laureys, Steven; Demertzi, Athena			Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness	CURRENT PHARMACEUTICAL DESIGN			English	Article						Amantadine; apomorphine; zolpidem; disorders of consciousness; vegetative state/unresponsive wakefulness syndrom; minimally conscious state; pharmacological treatments; mechanism of action	TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; PLACEBO-CONTROLLED TRIAL; SEVERE HEAD-INJURY; CONTINUOUS SUBCUTANEOUS APOMORPHINE; ADVANCED PARKINSON-DISEASE; DIFFUSE AXONAL INJURY; IMPAIRED CONSCIOUSNESS; CLINICAL PHARMACOKINETICS; UNRESPONSIVE WAKEFULNESS	Survivors of severe brain injuries may end up in a state of 'wakeful unresponsiveness' or in a minimally conscious state. Pharmacological treatments of patients with disorders of consciousness aim to improve arousal levels and recovery of consciousness. We here provide a systematic overview of the therapeutic effects of amantadine, apomorphine and zolpidem in patients recovering from coma. Evidence from clinical trials using these commonly prescribed pharmacological agents suggests positive changes of the patients' neurological status, leading sometimes to dramatic improvements. These findings are discussed in the context of current hypotheses of these agents' therapeutic mechanisms on cerebral function. In order to improve our understanding of the underlying pathophysiological mechanisms of these drugs, we suggest combining sensitive and specific behavioral tools with neuroimaging and electrophysiological measures in large randomized, double-blind, placebo-controlled experimental designs. We conclude that the pharmacokinetics and pharmacodynamics of amantadine, apomorphine and zolpidem need further exploration to determine which treatment would provide a better neurological outcome regarding the patient's etiology, diagnosis, time since injury and overall condition.	[Gosseries, Olivia] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; Univ Liege, Dept Neurol, B-4000 Liege, Belgium; Univ Hosp Liege, Liege, Belgium	Gosseries, O (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, Sart Tilman B30,Allee 6 Aout 8, B-4000 Liege, Belgium.	ogosseries@ulg.ac.be	Demertzi, Athena/I-1251-2019; Laureys, Steven/AAN-2097-2021; Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/A-3349-2011	Demertzi, Athena/0000-0001-8021-3759; Laureys, Steven/0000-0002-3096-3807; Gosseries, Olivia/0000-0001-9011-7496	Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Fonds Leon Fredericq; James S. McDon-nell Foundation; Mind Science Foundation; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Concerted Research Action; Public Utility Foundation "Universite Europeenne du Travail" and "Fondazione Europea di Ricerca Biomedica"	This study was funded by the Belgian National Funds for Scientific Research (FNRS), Fonds Leon Fredericq, James S. McDon-nell Foundation; Mind Science Foundation; European Commission; Concerted Research Action; Public Utility Foundation "Universite Europeenne du Travail" and "Fondazione Europea di Ricerca Biomedica". VCV and OB are research fellows, OG and AD are postdoctoral researchers and SL is research director at FNRS.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; BLEIDNER WE, 1965, J PHARMACOL EXP THER, V150, P484; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; Braver T, 2000, PRINCIPLES FRONTAL L, P428; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86, DOI 10.1017/S1355617700611116; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; Chandler M C, 1988, Brain Inj, V2, P309; Chatelle C, 2013, ZOLPIDEM RECOVERY CO; Chen L, 2004, EXP NEUROL, V186, P212, DOI 10.1016/j.expneurol.2003.11.003; Chen L, 2007, NEUROSCI RES, V58, P77, DOI 10.1016/j.neures.2007.02.002; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Clauss P, 2001, SAMJ S AFR MED J, V91, P788; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss RP, 2000, S AFR MED J, V90, P68; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Cohen SI, 2008, AM J PHYS MED REHAB, V87, P229, DOI 10.1097/PHM.0b013e318161971b; CORSINI GU, 1979, LANCET, V1, P954; Daniele A, 1997, LANCET, V349, P1222, DOI 10.1016/S0140-6736(05)62416-6; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DeMarchi R, 2005, CAN J NEUROL SCI, V32, P4, DOI 10.1017/S0317167100016826; Demertzi A, 2013, CURR OPIN NEUROBIOL, V23, P239, DOI 10.1016/j.conb.2012.12.003; Dewhurst F, 2009, PALLIATIVE MED, V23, P777, DOI 10.1177/0269216309106979; Du B, 2014, AM J MED SCI, V347, P178, DOI 10.1097/MAJ.0b013e318287c79c; ENNA SJ, 1977, ARCH NEUROL-CHICAGO, V34, P683, DOI 10.1001/archneur.1977.00500230053008; FAHN S, 1975, NEUROLOGY, V25, P695, DOI 10.1212/WNL.25.8.695; FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812; Fridman EA, 2010, BRAIN INJURY, V24, P636, DOI 10.3109/02699051003610433; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Gee S, 1869, T CLIN SOC LONDON, V2, P166; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Gosseries O, 2011, NEUROREHABILITATION, V28, P3, DOI 10.3233/NRE-2011-0625; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Hagen C, 1987, LEVELS COGNITIVE FUN; Hall SD, 2010, CLIN NEUROPHYSIOL, V121, P549, DOI 10.1016/j.clinph.2009.11.084; Himeno E, 2011, ANN NEUROL, V69, P248, DOI 10.1002/ana.22319; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Hubsher G, 2012, NEUROLOGY, V78, P1096, DOI 10.1212/WNL.0b013e31824e8f0d; Hughes S, 2005, BRAIN INJURY, V19, P1197, DOI 10.1080/02699050500309296; Jackson CW, 1996, J CLIN PSYCHIAT, V57, P372; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jones BE, 2003, FRONT BIOSCI-LANDMRK, V8, pS438, DOI 10.2741/1074; KARKELA JT, 1993, J FORENSIC SCI, V38, P603; Katzenschlager R, 2005, MOVEMENT DISORD, V20, P151, DOI 10.1002/mds.20276; Kolls BJ, 2006, CLIN NEUROPHARMACOL, V29, P292, DOI 10.1097/01.WNF.0000220824.57769.E5; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2005, LANCET NEUROL, V4, P789, DOI 10.1016/S1474-4422(05)70230-1; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2001, YB INTENSIVE CARE EM; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; LeWitt PA, 2009, CLIN NEUROPHARMACOL, V32, P89, DOI [10.1097/WNF.0B013E31816D91F9, 10.1097/WNF.0b013e31816d91f9]; Lo YL, 2008, ANN NEUROL, V64, P477, DOI 10.1002/ana.21183; Machado C, 2011, CAN J NEUROL SCI, V38, P341, DOI 10.1017/S0317167100011562; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MILLAC P, 1970, LANCET, V2, P720; Mohee A, 2012, EXPERT OPIN DRUG MET, V8, P1447, DOI 10.1517/17425255.2012.727797; Neef C, 1999, CLIN PHARMACOKINET, V37, P257, DOI 10.2165/00003088-199937030-00004; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OCEBM Levels of Evidence Working Group, 2011, OXF LEV EV; Oliveira L, 2011, BRAIN INJURY, V25, P315, DOI 10.3109/02699052.2011.556103; Ossig C, 2013, J NEURAL TRANSM, V120, P523, DOI 10.1007/s00702-013-1008-y; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Patrick PD, 2000, BEHAV INTERVENT, V15, P225, DOI 10.1002/1099-078X(200007/09)15:3<225::AID-BIN58>3.3.CO;2-#; Patrick PD, 2006, J CHILD NEUROL, V21, P879, DOI 10.1177/08830738060210100901; Plum F., 1983, DIAGNOSIS STUPOR COM; Poza J, 2007, P ANN INT IEEE EMBS, P6180; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rappaport M, 2000, COMA NEAR COMA SCALE; Reynolds JC, 2013, RESUSCITATION, V84, P818, DOI 10.1016/j.resuscitation.2012.11.014; Rezak M, 2007, DM-DIS MON, V53, P259, DOI 10.1016/j.disamonth.2007.02.003; Ribaric S, 2012, MOLECULES, V17, P5289, DOI 10.3390/molecules17055289; Riley A, 2010, J SEX MED, V7, P1508, DOI 10.1111/j.1743-6109.2009.01540.x; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7; Saniova B, 2004, J NEURAL TRANSM, V111, P511, DOI 10.1007/s00702-004-0112-4; Sawada H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015298; Sawaguchi T, 2001, NEUROSCI RES, V41, P115, DOI 10.1016/S0168-0102(01)00270-X; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schiff ND, 2009, ANN NY ACAD SCI, V1157, P101, DOI 10.1111/j.1749-6632.2008.04123.x; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Schneider WN, 1999, BRAIN INJURY, V13, P863; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Schwartz JRL, 2008, CURR NEUROPHARMACOL, V6, P367, DOI 10.2174/157015908787386050; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Snyman N, 2010, NEUROPEDIATRICS, V41, P223, DOI 10.1055/s-0030-1269893; Stahl S.M., 2000, ESSENTIAL PSYCHOPHAR; Stern G, 1957, LONDON HOSP GAZATTE, P144; Stern Gerald, 2013, Pract Neurol, V13, P335, DOI 10.1136/practneurol-2012-000432; Struhal W, 2012, WIEN KLIN WOCHENSCHR, V124, P461, DOI 10.1007/s00508-012-0202-5; TEASDALE G, 1974, LANCET, V2, P81; Thonnard M, 2013, FUNCT NEUROL, V28, P259, DOI 10.11138/FNeur/2013.28.4.259; TIMBERLAKE WH, 1978, ANN NEUROL, V3, P119, DOI 10.1002/ana.410030206; U.S. Department Of Health And Human Services, 2010, COMM TERM CRIT ADV E; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; Vargus-Adams JN, 2010, PM&R, V2, P37, DOI 10.1016/j.pmrj.2009.10.010; Weil E., 1884, LYON MED, V48, P411; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wojtecki L, 2012, PARKINSONISM RELAT D, V18, P1002, DOI 10.1016/j.parkreldis.2012.04.012; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zafonte R, 2009, PROG BRAIN RES, V177, P293, DOI 10.1016/S0079-6123(09)17720-8	125	19	21	0	12	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2014	20	26					4167	4184					18	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AK6AA	WOS:000338508000005	24025057				2021-06-18	
J	Hutchison, MG; Comper, P; Meeuwisse, WH; Echemendia, RJ				Hutchison, Michael G.; Comper, Paul; Meeuwisse, Willem H.; Echemendia, Ruben J.			An observational method to code concussions in the National Hockey League (NHL): the heads-up checklist	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Ice hockey; Injury Prevention	YOUTH ICE HOCKEY; PROFESSIONAL FOOTBALL; VIDEO ANALYSIS; INJURY; BIOMECHANICS; RISK; MECHANISMS; AGREEMENT; CHECKING; IMPACTS	Background Development of effective strategies for preventing concussions is a priority in all sports, including ice hockey. Digital video records of sports events contain a rich source of valuable information, and are therefore a promising resource for analysing situational factors and injury mechanisms related to concussion. Aim To determine whether independent raters reliably agreed on the antecedent events and mechanisms of injury when using a standardised observational tool known as the heads-up checklist (HUC) to code digital video records of concussions in the National Hockey League (NHL). Methods The study occurred in two phases. In phase 1, four raters (2 naive and 2 expert) independently viewed and completed HUCs for 25 video records of NHL concussions randomly chosen from the pool of concussion events from the 2006-2007 regular season. Following initial analysis, three additional factors were added to the HUC, resulting in a total of 17 factors of interest. Two expert raters then viewed the remaining concussion events from the 2006-2007 season, as well as all digital video records of concussion events up to 31 December 2009 (n=174). Results For phase 1, the majority of the factors had a value of 0.6 or higher (8 of 15 factors for naive raters; 11 of 15 factors for expert raters). For phase 2, all the factors had a total percent agreement value greater than 0.8 and values of >0.65 for the expert raters. Conclusions HUC is an objective, reliable tool for coding the antecedent events and mechanisms of concussions in the NHL.	[Hutchison, Michael G.; Comper, Paul] Univ Toronto, David L MacIntosh Sport Med Clin, Fac Kinesiol & Phys Educ, Toronto, ON M5S 2W6, Canada; [Hutchison, Michael G.] St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON M5S 2W6, Canada; [Comper, Paul] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 2W6, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Calgary, AB, Canada; [Meeuwisse, Willem H.] Univ Calgary, Hotchkiss Brain Inst, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA	Hutchison, MG (corresponding author), Univ Toronto, David L MacIntosh Sport Med Clin, Fac Kinesiol & Phys Educ, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Echemendia, Ruben/R-6939-2019		Ontario Neurotrauma Foundation (ONF); Pashby Sports Safety Fund	This study received funding by Ontario Neurotrauma Foundation (ONF) and The Pashby Sports Safety Fund. The organisations that contributed funds to the research had no role in the design of the study, the collection, analysis and interpretation of the data.	Andersen TE, 2004, AM J SPORT MED, V32, p69S, DOI 10.1177/0363546503262023; [Anonymous], MAC OS X VERS 10 5 8; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Athiviraham A, 2012, AM J SPORT MED, V40, P2808, DOI 10.1177/0363546512461754; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; ETTLINGER CF, 1995, AM J SPORT MED, V23, P531, DOI 10.1177/036354659502300503; Fleiss J. L., 2004, MEASUREMENT INTERRAT; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2; HARTMANN DP, 1977, J APPL BEHAV ANAL, V10, P103, DOI 10.1901/jaba.1977.10-103; HOUSE AE, 1981, J BEHAV ASSESS, V3, P37, DOI 10.1007/BF01321350; Hutchison MG, 2003, NAT UND RES C MARCH; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pashby T, 2001, CLIN J SPORT MED, V11, P211, DOI 10.1097/00042752-200110000-00001; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pellman EJ, 2003, NEUROSURGERY, V53, P12; Shrout P E, 1998, Stat Methods Med Res, V7, P301, DOI 10.1191/096228098672090967; SILVER JR, 1988, SPORTS MED, V5, P328, DOI 10.2165/00007256-198805050-00005; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Viano DC, 2005, NEUROSURGERY, V56, P66	32	19	19	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					125	U133		10.1136/bjsports-2012-092059			6	Sport Sciences	Sport Sciences	276KK	WOS:000328749000014	23766437				2021-06-18	
J	Levack, WMM; Boland, P; Taylor, WJ; Siegert, RJ; Kayes, NM; Fadyl, JK; McPherson, KM				Levack, William M. M.; Boland, Pauline; Taylor, William J.; Siegert, Richard J.; Kayes, Nicola M.; Fadyl, Joanna K.; McPherson, Kathryn M.			Establishing a person-centred framework of self-identity after traumatic brain injury: a grounded theory study to inform measure development	BMJ OPEN			English	Article							POSTTRAUMATIC GROWTH; YOUNG-PEOPLE; HEAD-INJURY; REHABILITATION; ADJUSTMENT; DISABILITY; ADULTS	Objective: To develop a theoretically sound, client-derived framework to underpin development of a measure reflecting the impact of traumatic brain injury (TBI) on a person's self-identity. Design: Grounded theory, based on transcription of audio recordings from focus group meetings with people who have experienced TBI, analysed with constant comparative methods. Setting: 8 different urban and rural communities in New Zealand. Participants: 49 people (34 men, 15 women), 6 months to 36 years after mild-to-severe TBI. Results: The central concept emerging from the data was that of desiring to be or having lost a sense of being an integrated and valued person. The three main subthemes were: (1) having a coherent, satisfying and complete sense of oneself, (2) respect, validation and acceptance by others and (3) having a valued place in the world. Conclusions: This study reinforces the notion that change in self-identity is an important aspect of life after TBI, and provides information on what this concept means to people with TBI. In order to scientifically evaluate relationships between self-identity and other aspects of health (eg, depression, quality of life), and to test the effect of interventions to address problems with self-identity after TBI, a quantitative tool for evaluation of this construct is required. Themes from this research provide a foundation for the development of a measure of self-identity grounded in the language and experience of people with TBI.	[Levack, William M. M.; Boland, Pauline; Taylor, William J.] Univ Otago, Dept Med, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Siegert, Richard J.] AUT Univ, Fac Hlth & Environm Sci, Dept Psychol, Wellington, New Zealand; [Siegert, Richard J.; Kayes, Nicola M.; Fadyl, Joanna K.; McPherson, Kathryn M.] AUT Univ, Div Rehabil & Occupat Studies, Person Ctr Res Ctr, Auckland, New Zealand	Levack, WMM (corresponding author), Univ Otago, Dept Med, Rehabil Teaching & Res Unit, Wellington, New Zealand.	william.levack@otago.ac.nz	Siegert, Richard J./K-2030-2019; Boland, Pauline/K-2878-2019; Levack, William Mark Magnus/F-9607-2018	Boland, Pauline/0000-0003-0218-327X; Levack, William Mark Magnus/0000-0001-6631-908X; McPherson, Kath/0000-0003-0487-8497; Taylor, William/0000-0001-6075-8479; Siegert, Richard/0000-0002-3074-0929; McPherson, Kathryn/0000-0003-1240-8882	University of Otago; Laura Fergusson Trust Auckland	This work was funded by a research grant from the University of Otago. KMMP's position is partly funded by the Laura Fergusson Trust Auckland.	Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Charmaz K, 2006, CONSTRUCTING GROUNDE; Coetzer R, 2008, NEUROPSYCHOL REHABIL, V18, P766, DOI 10.1080/09602010701860266; Conneeley AL, 2012, BRAIN IMPAIR, V13, P72, DOI 10.1017/BrImp.2012.3; DeWalt DA, 2007, MED CARE, V45, pS12, DOI 10.1097/01.mlr.0000254567.79743.e2; Doering BK, 2011, NEUROPSYCHOL REHABIL, V21, P42, DOI 10.1080/09602011.2010.525947; Douglas J., 2012, SOCIAL CURE IDENTITY; Erikson EH., 1963, CHILDHOOD SOC, V2nd Edn.; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Feigin VL, 2010, BEST PRACT RES-CLIN, V24, P485, DOI 10.1016/j.bpa.2010.10.006; Fotopoulou A, 2008, NEUROPSYCHOL REHABIL, V18, P541, DOI 10.1080/09602010802083545; GLASER B., 1992, EMERGENCE VS FORCING; Gracey F., 2012, SOCIAL CURE IDENTITY, P273, DOI DOI 10.4324/9780203813195; Hammell KW, 2006, PERSPECTIVES DISABIL; Heller W, 2006, J REHABIL, V72, P44; Hogan BA, 1999, NEUROREHABILITATION, V13, P21; Hoogerdijk B, 2011, SCAND J OCCUP THER, V18, P122, DOI 10.3109/11038121003645985; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; McGrath JC, 2011, BRAIN IMPAIR, V12, P82, DOI 10.1375/brim.12.2.82; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; MORRIS SD, 2004, J COGN REHABIL, V22, P15; Morse J., 2002, README 1 USERS GUIDE; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Myles SM, 2004, INT J PSYCHOL PSYCHO, V4, P487; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ownsworth T, 2011, BRAIN IMPAIR, V12, P79; Patterson FL, 2009, J MENT HLTH COUNS, V31, P149; Rogan C, 2013, NEUROPSYCHOL REHABIL, V23, P639, DOI 10.1080/09602011.2013.799076; Strauss A., 1998, BASICS QUALITATIVE R; Sullivan M, 2007, BEING SOCIOLOGICAL; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; Ylvisaker M, 2008, NEUROPSYCHOL REHABIL, V18, P713, DOI 10.1080/09602010802201832	36	19	19	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2014	4	5							e004630	10.1136/bmjopen-2013-004630			9	Medicine, General & Internal	General & Internal Medicine	AI6IQ	WOS:000336976900045	24833684	DOAJ Gold, Green Published			2021-06-18	
S	Maruta, J; Ghajar, J		Niranjan, A; Lunsford, LD		Maruta, Jun; Ghajar, Jamshid			Detecting Eye Movement Abnormalities from Concussion	CONCUSSION	Progress in Neurological Surgery		English	Article; Book Chapter							SYNCHRONIZATION; INJURY	An attention-based biomarker may be useful for concussion screening. A key role of attention is to generate time-based expectancies of specific sensory information, and it is postulated that postconcussion cognitive impairments and symptoms may stem from a primary deficit in this predictive timing mechanism. There is a close relationship between gaze and attention, but in addressing predictive timing, there is a need for an appropriate testing paradigm and methods to quantify oculomotor anomalies. We have utilized a continuous predictive visual tracking paradigm because human visual tracking requires predicting the temporal course of a stimulus and dynamically synchronizing the required action with the stimulus. We have shown that concussion patients often show disrupted gaze-target synchronization characterized by large gaze position error variability and overall phase advancement. Various attention components interact with visual tracking, and thus there is a possibility that different neurological and physiological conditions produce identifiable visual tracking characteristics. Analyzing neuromotor functions, specifically oculomotor synchronization, can provide a fast, accurate, and reliable assessment of cognitive functions. (C) 2014 S. Karger AG, Basel	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Ghajar, Jamshid] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA	Maruta, J (corresponding author), Brain Trauma Fdn, World Trade Ctr 7, 34th Floor,250 Greenwich St, New York, NY 10007 USA.	jmaruta@braintrauma.org		Maruta, Jun/0000-0002-5054-6605			Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; HUGHES A, 1971, DOC OPHTHALMOL, V30, P33, DOI 10.1007/BF00142518; Maruta J, 2012, P SOC PHOTO-OPT INS, V8371; Maruta J, 2013, BEHAV RES METHODS, V45, P289, DOI 10.3758/s13428-012-0248-3; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; UMEDA Y, 1975, ORL J OTO-RHINO-LARY, V37, P290, DOI 10.1159/000275237; VANDERSTEEN J, 1983, VISION RES, V23, P1655, DOI 10.1016/0042-6989(83)90180-3	13	19	19	0	17	KARGER	BASEL	POSTFACH, CH-4009 BASEL, SWITZERLAND	0079-6492		978-3-318-02649-8; 978-3-318-02648-1	PROG NEUROL SURG			2014	28						226	233		10.1159/000358786	10.1159/isbn.978-3-318-02649-8		8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	BC8EJ	WOS:000355566000020	24923406				2021-06-18	
J	Mura, E; Pistoia, F; Sara, M; Sacco, S; Carolei, A; Govoni, S				Mura, Elisa; Pistoia, Francesca; Sara, Marco; Sacco, Simona; Carolei, Antonio; Govoni, Stefano			Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview	CURRENT PHARMACEUTICAL DESIGN			English	Article						Consciousness; vegetative state; coma; minimally conscious state; awakenings; drugs; pharmacology	TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; HISTAMINERGIC TUBEROMAMMILLARY NEURONS; VENTROLATERAL PREOPTIC NUCLEUS; CEREBRAL GLUCOSE-METABOLISM; PLACEBO-CONTROLLED TRIAL; INTRATHECAL BACLOFEN; IMPAIRED CONSCIOUSNESS; TRANSIENT IMPROVEMENT; NEUROTROPHIC FACTOR	The neurobiological approach to consciousness moves from the assumption that all phenomenal experiences are based on neuronal activity in the brain. Consciousness has two main components: wakefulness and awareness. While it may be relatively easy to determine the neuronal correlates of wakefulness, it is not the same for awareness, of which the neural correlates are poorly understood. Knowledge of the circuitry and the neurochemistry of the sleep/wake condition is necessary but not sufficient to understand the circuitry and neurochemistry of consciousness. Disorders of consciousness (DOCs) include coma, vegetative state and minimally conscious state. The study of DOCs and of the electrophysiological changes underlying general anaesthesia-induced loss of consciousness may help in understanding the neuronal correlates of consciousness. In turn, the understanding of the neural bases of consciousness may help in designing interventions aimed at restoring consciousness in DOC patients. Sporadic cases of recovery from a DOC have been reported after the administration of various pharmacological agents (baclofen, zolpidem, amantadine etc.). This review provides an overview of such drugs, which are from various and diverging classes but can be grouped into two main categories: CNS stimulants and CNS depressants. The available data seem to suggest an awakening effect obtained with CNS depressants rather than stimulants, the latter being more effective at improving functional cognitive and behavioral recovery in patients who have spontaneously regained an appreciable level of consciousness. There is a need for more rigorous systematic trials and further investigation of the above treatments, with particular attention paid to their mechanisms of action and the neurotransmitters involved.	[Mura, Elisa; Govoni, Stefano] Univ Pavia, Pharmacol Sect, Dept Drug Sci, I-27100 Pavia, Italy; [Pistoia, Francesca; Sacco, Simona; Carolei, Antonio] Univ Aquila, Neurol Inst, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy; [Pistoia, Francesca; Sara, Marco] IRCCS San Raffaele Pisana, Cassino, Italy	Govoni, S (corresponding author), Univ Pavia, Pharmacol Sect, Dept Drug Sci, Viale Taramelli 14, I-27100 Pavia, Italy.	govonis@unipv.it	Sacco, Simona/I-5253-2012; mura, elisa/ABD-9249-2020; Pistoia, Francesca/AAC-1027-2019; Sara, Marco/AAB-3651-2019	Sacco, Simona/0000-0003-0651-1939; PISTOIA, Francesca/0000-0003-0790-4240			[Anonymous], 2003, Clin Med (Lond), V3, P249; Aquilani R, 2008, ARCH PHYS MED REHAB, V89, P1642, DOI 10.1016/j.apmr.2008.02.023; ASTONJONES G, 1981, J NEUROSCI, V1, P876; Babiloni C, 2010, CLIN NEUROPHYSIOL, V121, P1816, DOI 10.1016/j.clinph.2010.04.027; Barreca S, 2003, BRAIN INJURY, V17, P1065, DOI 10.1080/0269905031000110535; Besser M, 1999, J IMMUNOL, V162, P6303; BOGEN JE, 1995, CONSCIOUS COGN, V4, P52, DOI 10.1006/ccog.1995.1003; Boly M, 2012, J NEUROSCI, V32, P7082, DOI 10.1523/JNEUROSCI.3769-11.2012; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Boutrel B, 2004, SLEEP, V27, P1181, DOI 10.1093/sleep/27.6.1181; Calabresi P, 2003, NEUROBIOL DIS, V12, P82, DOI 10.1016/S0969-9961(02)00016-5; Canedo A, 2002, BRAIN INJURY, V16, P453, DOI 10.1080/02699050110119853; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss R, 2004, NEW ENGL J MED, V351, P511, DOI 10.1056/NEJM200407293510522; Clauss RP, 2010, MED HYPOTHESES, V75, P287, DOI 10.1016/j.mehy.2010.03.005; Clauss RP, 2000, S AFR MED J, V90, P68; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Coulter DA, 1997, J CHILD NEUROL, V12, pS2, DOI 10.1177/0883073897012001031; Crosby NJ, 2003, COCHRANE DB SYST REV, pCD003467, DOI DOI 10.1002/14651858; D'Aleo G, 1994, Funct Neurol, V9, P189; Dario A, 2007, ACTA NEUROCHIR SUPPL, V97, P461; Du B, 2013, AM J MED SCI; Fellerhoff Barbara, 2012, J Med Case Rep, V6, P6, DOI 10.1186/1752-1947-6-6; Formisano R, 2001, Ann Ist Super Sanita, V37, P627; Formisano R, 2011, BRAIN INJURY, V25, P638, DOI 10.3109/02699052.2011.572948; Fridman EA, 2010, BRAIN INJURY, V24, P636, DOI 10.3109/02699051003610433; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Hall SD, 2010, CLIN NEUROPHYSIOL, V121, P549, DOI 10.1016/j.clinph.2009.11.084; HALLANGER AE, 1987, J COMP NEUROL, V262, P105, DOI 10.1002/cne.902620109; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; HASSELMO ME, 1993, TRENDS NEUROSCI, V16, P218, DOI 10.1016/0166-2236(93)90159-J; Hattori N, 2003, J NUCL MED, V44, P1709; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; Hoarau X, 2012, BRAIN INJURY, V26, P1451, DOI 10.3109/02699052.2012.694564; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Huang ZL, 2011, CURR TOP MED CHEM, V11, P1047, DOI 10.2174/156802611795347654; Huang ZL, 2001, P NATL ACAD SCI USA, V98, P9965, DOI 10.1073/pnas.181330998; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Huynh F, 2009, THER DRUG MONIT, V31, P153, DOI 10.1097/FTD.0b013e318196fb9f; Imas OA, 2006, NEUROSCI LETT, V402, P216, DOI 10.1016/j.neulet.2006.04.003; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; Jones EG, 2002, PROG BRAIN RES, V136, P333; Ketter TA, 2003, J CLIN PSYCHOPHARM, V23, P484, DOI 10.1097/01.jcp.0000088915.02635.e8; Kim YW, 2009, CLIN NEUROPHARMACOL, V32, P335, DOI 10.1097/WNF.0b013e3181b40678; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Kroeger D, 2007, J NEUROSCI, V27, P10597, DOI 10.1523/JNEUROSCI.3440-07.2007; Lancioni GE, 2010, RES DEV DISABIL, V31, P1121, DOI 10.1016/j.ridd.2010.06.019; Lanni C, 2009, CELL MOL LIFE SCI, V66, P2985, DOI 10.1007/s00018-009-0055-x; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Liepert J, 2008, CURR OPIN NEUROL, V21, P639, DOI 10.1097/WCO.0b013e32831897a3; Lo YL, 2008, ANN NEUROL, V64, P477, DOI 10.1002/ana.21183; Lombardi F, 2007, FUNCT NEUROL, V22, P47; Lu J, 2000, J NEUROSCI, V20, P3830; Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533; Machado C, 2007, CLIN EEG NEUROSCI, V38, P124, DOI 10.1177/155005940703800306; Machado C, 2011, CAN J NEUROL SCI, V38, P341, DOI 10.1017/S0317167100011562; Magee WL, 2005, NEUROPSYCHOL REHABIL, V15, P522, DOI 10.1080/09602010443000461; Markram K, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00224; Mathiesen C, 2011, J NEUROSCI, V31, P18327, DOI 10.1523/JNEUROSCI.4526-11.2011; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MCGINTY DJ, 1976, BRAIN RES, V101, P569, DOI 10.1016/0006-8993(76)90480-7; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Moein H, 2006, CLIN NEUROL NEUROSUR, V108, P539, DOI 10.1016/j.clineuro.2005.09.003; Monti JM, 2007, SLEEP MED REV, V11, P113, DOI 10.1016/j.smrv.2006.08.003; Monti JM, 2011, SLEEP MED REV, V15, P269, DOI 10.1016/j.smrv.2010.11.003; Murphy M, 2011, SLEEP, V34, P283, DOI 10.1093/sleep/34.3.283; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Okun MS, 2013, NEW ENGL J MED, V368, P483, DOI [10.1056/NEJMct1208070, 10.1056/NEJMc1214078]; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Petit D, 2004, J PSYCHOSOM RES, V56, P487, DOI 10.1016/j.jpsychores.2004.02.001; Peyron C, 1998, J NEUROSCI, V18, P9996; Pistoia F, 2013, ARCH PHYS MED REHABI; Pistoia F, 2012, J NEUROTRAUM, V29, P2328, DOI 10.1089/neu.2009.1257; Pistoia F, 2010, CNS DRUGS, V24, P625, DOI 10.2165/11535940-000000000-00000; Plum F., 1983, DIAGNOSIS STUPOR COM; Prajapati KD, 2011, REV NEUROSCIENCE, V22, P355, DOI 10.1515/RNS.2011.028; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; Rogoz Z, 2008, PHARMACOL REP, V60, P817; Sacco S, 2011, BRAIN INJURY, V25, P488, DOI 10.3109/02699052.2011.558043; Saint-Mleux B, 2004, J NEUROSCI, V24, P63, DOI 10.1523/JNEUROSCI.0232-03.2004; Sakurai T, 2007, NAT REV NEUROSCI, V8, P171, DOI 10.1038/nrn2092; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Sanger DJ, 2004, CNS DRUGS, V18, P9, DOI 10.2165/00023210-200418001-00004; Sanna E, 2002, EUR J PHARMACOL, V451, P103, DOI 10.1016/S0014-2999(02)02191-X; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Sara M, 2008, BRAIN INJURY, V22, P33, DOI 10.1080/02699050701810670; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; Sara M, 2012, LANCET, V379, P1702, DOI 10.1016/S0140-6736(12)60716-8; Sara M, 2011, NEUROREHAB NEURAL RE, V25, P35, DOI 10.1177/1545968310378508; Sara M, 2010, NONLIN DYNAM PSYCHOL, V14, P1; Sara M, 2010, J NEUROTRAUM, V27, P771, DOI [10.1089/neu.2008.0804, 10.1089/neu.2008-0804]; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; SATOH K, 1986, J COMP NEUROL, V253, P277, DOI 10.1002/cne.902530302; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schwartz JRL, 2008, CURR NEUROPHARMACOL, V6, P367, DOI 10.2174/157015908787386050; Seibert PS, 2000, BRAIN INJURY, V14, P295; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; Shirota Y, 2013, NEUROLOGY, V80, P1400, DOI 10.1212/WNL.0b013e31828c2f66; Showalter PEC, 2000, BRAIN INJURY, V14, P997; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Snyman N, 2010, NEUROPEDIATRICS, V41, P223, DOI 10.1055/s-0030-1269893; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; Takahashi K, 2006, J NEUROSCI, V26, P10292, DOI 10.1523/JNEUROSCI.2341-06.2006; Thakkar MM, 2011, SLEEP MED REV, V15, P65, DOI 10.1016/j.smrv.2010.06.004; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; Tononi G, 2001, NEUROPSYCHOPHARMACOL, V25, pS28, DOI 10.1016/S0893-133X(01)00322-0; Treiman DM, 2001, EPILEPSIA, V42, P8, DOI 10.1046/j.1528-1157.2001.042suppl.3008.x; Ugoya SO, 2010, CLIN NEUROPHARMACOL, V33, P279, DOI 10.1097/WNF.0b013e3182011070; Vega JA, 2003, J ANAT, V203, P1, DOI 10.1046/j.1469-7580.2003.00203.x; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; vom Berg J, 2012, NAT MED, V18, P1812, DOI 10.1038/nm.2965; WADA H, 1991, TRENDS NEUROSCI, V14, P415, DOI 10.1016/0166-2236(91)90034-R; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Watson CJ, 2010, SLEEP MED CLIN, V5, DOI 10.1016/j.jsmc.2010.08.003; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Whyte J, 2007, AM J PHYS MED REHAB, V86, P86, DOI 10.1097/PHM.0b013e31802f0434; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wilhelm MJ, 2000, J HEART LUNG TRANSPL, V19, P414, DOI 10.1016/S1053-2498(00)00073-5; Worzniak M, 1997, J FAM PRACTICE, V44, P495; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yamaguchi M, 2005, STROKE, V36, P2212, DOI 10.1161/01.STR.0000182238.08510.c5; Yamamoto T, 2012, WORLD NEUROSURG; Yoshida K, 2006, J COMP NEUROL, V494, P845, DOI 10.1002/cne.20859; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	152	19	20	0	11	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2014	20	26					4121	4139					19	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AK6AA	WOS:000338508000002	24025054				2021-06-18	
J	Ruozi, B; Belletti, D; Forni, F; Sharma, A; Muresanu, D; Mossler, H; Vandelli, MA; Tosi, G; Sharma, HS				Ruozi, Barbara; Belletti, Daniela; Forni, Flavio; Sharma, Aruna; Muresanu, Dafin; Moessler, Herbert; Vandelli, Maria A.; Tosi, Giovanni; Sharma, Hari S.			Poly (D, L-Lactide-co-Glycolide) Nanoparticles Loaded with Cerebrolysin Display Neuroprotective Activity in a Rat Model of Concussive Head Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Blood-brain barrier; brain edema; cerebrolysin; closed head injury; Poly (D,L-lactide-co-glycolide) nanoparticles	BLOOD-BRAIN-BARRIER; WHOLE-BODY HYPERTHERMIA; NEUROTROPHIC FACTORS; SOLVENT EVAPORATION; PLGA NANOPARTICLES; MORBIDITY FACTORS; EDEMA FORMATION; DRUG-DELIVERY; PATHOLOGY; DISRUPTION	Cerebrolysin (CBL) is a neuroprotective agent in central nervous system (CNS) injury and stimulates neurorepair processes. Several studies in our laboratory suggest that CBL administered through nanowired technology may have superior neuroprotective efficacy in CNS trauma. In this investigation, we compared the neuroprotective efficacy of poly-lactide-co-glycolide nanoparticles (NPs) loaded with CBL vs free CBL in a rat model of concussive head injury (CHI). Free CBL or CBL loaded NPs was administered 30 min to 1 h after CHI and animals were sacrificed 5 h later. Changes in blood-brain barrier and brain edema formation were measured as parameters of neuroprotection in CHI after giving CBL alone or as the nanodelivered compound. Our results clearly show that delivery of CBL by NPs has superior neuroprotective effects following CHI as compared to normal CBL. This suggests that CBL delivered by NPs could have robust neuroprotective action in CNS trauma. These findings have potential clinical relevance with regard to nanodelivery of CBL, a feature that requires further investigation.	[Ruozi, Barbara; Belletti, Daniela; Forni, Flavio; Vandelli, Maria A.; Tosi, Giovanni] Univ Modena & Reggio Emilia, Dept Life Sci, Lab Pharmaceut Technol, I-41100 Modena, Italy; [Sharma, Aruna; Sharma, Hari S.] Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75421 Uppsala, Sweden; [Muresanu, Dafin] Univ Hosp, Univ Med Pharm, Dept Clin Neurosci, Cluj Napoca, Romania; [Moessler, Herbert] Ever Neuro Pharma, Oberburgau, Austria	Sharma, HS (corresponding author), Uppsala Univ, Univ Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75421 Uppsala, Sweden.	Sharma@surgsci.uu.se	Tosi, Giovanni/D-4547-2011; Forni, Flavio/D-5492-2015; Ruozi, Barbara/D-5500-2015; Vandelli, Maria Angela/D-5497-2015; Muresanu, Fior-Dafin/AAI-8120-2021; Belletti, Daniela/L-5288-2016	Tosi, Giovanni/0000-0001-8318-667X; Forni, Flavio/0000-0001-5974-6286; Ruozi, Barbara/0000-0002-2400-9910; Vandelli, Maria Angela/0000-0003-1462-8133; Belletti, Daniela/0000-0003-2872-445X	Air Force Office of Scientific Research (EOARD, London, UK)United States Department of DefenseAir Force Office of Scientific Research (AFOSR); Air Force Material Command, USAF [FA8655-05-1-3065]	The work reported here was partially supported by grants from the Air Force Office of Scientific Research (EOARD, London, UK), and Air Force Material Command, USAF, under grant number FA8655-05-1-3065 for studies on biological effects of nanoparticles in the CNS. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Office of Scientific Research or the U. S. Government. The authors declare no conflict of interest with any agency or organization mentioned above.	[Anonymous], 2013, LANCET, V382, P1536; BODMEIER R, 1987, PHARMACEUT RES, V4, P465, DOI 10.1023/A:1016419303727; Bondioli L, 2010, BIOMATERIALS, V31, P3395, DOI 10.1016/j.biomaterials.2010.01.049; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Costantino L, 2006, BIOMATERIALS, V27, P4635, DOI 10.1016/j.biomaterials.2006.04.026; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; DEY P K, 1984, Indian Journal of Physiology and Pharmacology, V28, P177; Feczko T, 2011, CHEM ENG PROCESS, V50, P757, DOI 10.1016/j.cep.2011.06.008; Ghaderi R, 1996, INT J PHARM, V141, P205, DOI 10.1016/0378-5173(96)04639-X; Gromova OA, 2003, ZH NEVROPATOL PSIKH, V103, P59; Guekht AB, 2011, J STROKE CEREBROVASC, V20, P310, DOI 10.1016/j.jstrokecerebrovasdis.2010.01.012; Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067; JOSHI DP, 1979, ANAL CHIM ACTA, V104, P153, DOI 10.1016/S0003-2670(01)83825-3; Liu WM, 2001, SPECTROSC SPECT ANAL, V21, P397; Nguyen T, 2003, ORG LETT, V5, P3245, DOI 10.1021/ol035135z; Park JH, 2005, MOLECULES, V10, P146, DOI 10.3390/10010146; Rosca ID, 2004, J CONTROL RELEASE, V99, P271, DOI 10.1016/j.jconrel.2004.07.007; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Ruozi B, 2012, INT REV NEUROBIOL, V102, P207, DOI 10.1016/B978-0-12-386986-9.00009-0; Ruozi B, 2011, INT J NANOMED, V6, P557, DOI 10.2147/IJN.S14615; Sharma A, 2012, CNS NEUROL DISORD-DR, V11, P7, DOI 10.2174/187152712799960790; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P295, DOI 10.1196/annals.1403.022; Sharma HS, 2010, ACTA NEUROCHIR SUPPL, V106, P301, DOI 10.1007/978-3-211-98811-4_56; Sharma H. S., 2009, HDB NEUROCHEMISTRY M, P363, DOI DOI 10.1007/978-0-387-30375-8_17; Sharma HS, 2013, AMINO ACIDS, V45, P1055, DOI 10.1007/s00726-013-1584-z; Sharma HS, 2011, CURR NEUROPHARMACOL, V9, P223, DOI 10.2174/157015911795017100; Sharma HS, 2009, J NANOSCI NANOTECHNO, V9, P5014, DOI 10.1166/jnn.2009.GR04; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P112, DOI 10.1196/annals.1403.008; Sharma HS, 2012, INT REV NEUROBIOL, V102, P249, DOI 10.1016/B978-0-12-386986-9.00010-7; Sharma HS, 2012, WIRES NANOMED NANOBI, V4, P184, DOI 10.1002/wnan.172; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P138, DOI 10.1111/j.1749-6632.2009.05330.x; Sharma HS, 2010, ACTA NEUROCHIR SUPPL, V106, P321, DOI 10.1007/978-3-211-98811-4_60; Sharma HS., 2009, ACTA U UPSAL, V830, P1; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Vannemreddy P, 2006, ACTA NEUROCHIR SUPPL, V96, P151	36	19	19	0	7	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	8					1475	1482		10.2174/1871527313666140806145540			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AU6BE	WOS:000345686300019	25106629				2021-06-18	
J	Sabati, M; Zhan, JP; Govind, V; Arheart, KL; Maudsley, AA				Sabati, Mohammad; Zhan, Jiping; Govind, Varan; Arheart, Kristopher L.; Maudsley, Andrew A.			Impact of Reduced k-Space Acquisition on Pathologic Detectability for Volumetric MR Spectroscopic Imaging	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						MR spectroscopic imaging; parallel imaging; traumatic brain injury; undersampled acquisition; clinical equivalency	BRAIN; SENSE; RECONSTRUCTION; GRAPPA; PEPSI	PurposeTo assess the impact of accelerated acquisitions on the spectral quality of volumetric magnetic resonance spectroscopic imaging (MRSI) and to evaluate their ability in detecting metabolic changes with mild injury. Materials and MethodsThe implementation of a generalized autocalibrating partially parallel acquisition (GRAPPA) method for a high-resolution whole-brain echo planar SI (3D-EPSI) sequence is first described and the spectral accuracy of the GRAPPA-EPSI method is investigated using lobar and voxel-based analyses for normal subjects and patients with mild traumatic brain injuries (mTBI). The performance of GRAPPA was compared with that of fully encoded EPSI for five datasets collected from normal subjects at the same scanning session, as well as on 45 scans (20 normal subjects and 25 mTBI patients) for which the reduced k-space sampling was simulated. For comparison, a central k-space lower-resolution 3D-EPSI acquisition was also simulated. Differences in individual metabolites and metabolite ratio distributions of the mTBI group relative to those of age-matched control subjects were statistically evaluated using analyses divided into hemispheric brain lobes and tissue types. ResultsGRAPPA-EPSI with 16-minute scan time yielded robust and similar results in terms of MRSI quantitation, spectral fitting, and accuracy with that of fully sampled 3D-EPSI acquisitions and was more accurate than central k-space acquisition. Primary findings included high correlations (accuracy of 92.6%) between the GRAPPA and fully sampled results. ConclusionAlthough the reduced encoding method is associated with lower signal-to-noise ratio (SNR) that impacts the quality of spectral analysis, the use of the parallel imaging method can lead to the same diagnostic outcomes as the fully sampled data when using the sensitivity-limited volumetric MRSI. J. Magn. Reson. Imaging 2014;39:224-234. (c) 2013 Wiley Periodicals, Inc.	[Sabati, Mohammad; Zhan, Jiping; Govind, Varan; Maudsley, Andrew A.] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA; [Arheart, Kristopher L.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA	Sabati, M (corresponding author), Univ Miami, Miller Sch Med, Dept Radiol, 1150 NW 14 St,Ste 713, Miami, FL 33136 USA.	msabati@med.miami.edu		Govind, Varan/0000-0002-1205-5194; Maudsley, Andrew/0000-0001-7653-3063	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS055107, R01EB000822]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055107] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant number: R01NS055107 and R01EB000822.	ADALSTEINSSON E, 1995, MAGNET RESON MED, V33, P461, DOI 10.1002/mrm.1910330402; Adalsteinsson E, 1998, MAGNET RESON MED, V39, P889, DOI 10.1002/mrm.1910390606; Andronesi OC, 2012, RADIOLOGY, V262, P647, DOI 10.1148/radiol.11110277; Bertolino A, 1998, NEUROPSYCHOPHARMACOL, V18, P1; Blaimer M, 2006, MAGN RESON MED, V56, P1359, DOI 10.1002/mrm.21071; Brown MA, 2004, MAGNET RESON MED, V52, P1207, DOI 10.1002/mrm.20244; Collins DL, 1998, IEEE T MED IMAGING, V17, P463, DOI 10.1109/42.712135; Dydak U, 2003, MAGN RESON MED, V50, P196, DOI 10.1002/mrm.10495; Dydak U, 2001, MAGN RESON MED, V46, P713, DOI 10.1002/mrm.1250; Ebel A, 2003, MAGN RESON IMAGING, V21, P113, DOI 10.1016/S0730-725X(02)00645-8; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Griswold MA, 2002, MAGN RESON MED, V47, P1202, DOI 10.1002/mrm.10171; Gu M, 2009, MAGN RESON MED, V61, P267, DOI 10.1002/mrm.21838; Kurhanewicz J, 2000, NEOPLASIA, V2, P166, DOI 10.1038/sj.neo.7900081; Lin FH, 2007, MAGN RESON MED, V57, P249, DOI 10.1002/mrm.21119; Maudsley AA, 2006, NMR BIOMED, V19, P492, DOI 10.1002/nbm.1025; Maudsley AA, 2009, MAGN RESON MED, V61, P548, DOI 10.1002/mrm.21875; Mayer D, 2008, MAGN RESON MED, V59, P891, DOI 10.1002/mrm.21572; Otazo R, 2007, MAGN RESON MED, V58, P1107, DOI 10.1002/mrm.21426; Ozturk-Isik E, 2009, MAGN RESON IMAGING, V27, P1249, DOI 10.1016/j.mri.2009.05.028; POSSE S, 1994, RADIOLOGY, V192, P733, DOI 10.1148/radiology.192.3.8058941; Posse S, 2009, MAGN RESON MED, V61, P541, DOI 10.1002/mrm.21855; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Rueckert M, 2006, P 14 ANN M ISMRM SEA, P296; Signoretti S, 2002, ACT NEUR S, V81, P373; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Sodickson DK, 1997, MAGNET RESON MED, V38, P591, DOI 10.1002/mrm.1910380414; Sodickson DK, 2000, MAGN RESON MED, V44, P243, DOI 10.1002/1522-2594(200008)44:2<243::AID-MRM11>3.0.CO;2-L; TEDESCHI G, 1995, NEUROLOGY, V45, P1384, DOI 10.1212/WNL.45.7.1384; Tsai SY, 2008, MAGN RESON MED, V59, P989, DOI 10.1002/mrm.21545; Zhu XP, 2007, MAGN RESON MED, V57, P815, DOI 10.1002/mrm.21217; Zierhut M, 2009, OCUL IMMUNOL INFLAMM, V17, P3, DOI 10.1080/09273940902797685	33	19	19	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JAN	2014	39	1					224	234		10.1002/jmri.24130			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	268QK	WOS:000328185400028	23559504	Green Accepted			2021-06-18	
J	Strigo, IA; Spadoni, AD; Lohr, J; Simmons, AN				Strigo, I. A.; Spadoni, A. D.; Lohr, J.; Simmons, A. N.			Too hard to control: compromised pain anticipation and modulation in mild traumatic brain injury	TRANSLATIONAL PSYCHIATRY			English	Article						concussion; dorsolateral prefrontal; emotion; imaging; PAG; post-traumatic stress	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MAJOR DEPRESSIVE DISORDER; INSULA ACTIVATION; BLAST EXPOSURE; WAR VETERAN; IRAQ; AFGHANISTAN; EMOTION; PTSD	Mild traumatic brain injury (MTBI) is a vulnerability factor for the development of pain-related conditions above and beyond those related to comorbid traumatic and emotional symptoms. We acquired functional magnetic resonance imaging (fMRI) on a validated pain anticipation task and tested the hypotheses that individuals with a reported history of MTBI, compared with healthy comparison subjects, would show increased brain response to pain anticipation and ineffective pain modulation after controlling for psychiatric symptoms. Eighteen male subjects with a reported history of blast-related MTBI related to combat, and eighteen healthy male subjects with no reported history of MTBI (healthy controls) underwent fMRI during an event-related experimental pain paradigm with cued high or low intensity painful heat stimuli. No subjects in either group met diagnostic criteria for current mood or anxiety disorder. We found that relative to healthy comparison subjects, after controlling for traumatic and depressive symptoms, participants with a reported history of MTBI showed significantly stronger activations within midbrain periaqueductual grey (PAG), right dorsolateral prefrontal cortex and cuneus during pain anticipation. Furthermore, we found that brain injury was a significant moderator of the relationship between anticipatory PAG activation and reported subjective pain. Our results suggest that a potentially disrupted neurocognitive anticipatory network may result from damage to the endogenous pain modulatory system and underlie difficulties with regulatory pain processing following MTBI. In other words, our findings are consistent with a notion that brain injury makes it more difficult to control acute pain. Understanding these mechanisms of dysfunctional acute pain processing following MTBI may help shed light on the underlying causes of increased vulnerability for the development of pain-related conditions in this population.	[Strigo, I. A.; Spadoni, A. D.; Lohr, J.; Simmons, A. N.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Strigo, I. A.; Spadoni, A. D.; Lohr, J.; Simmons, A. N.] Univ Calif San Diego, La Jolla, CA 92161 USA; [Strigo, I. A.] Univ Calif San Diego, BioCircuits Inst, La Jolla, CA 92161 USA	Strigo, IA (corresponding author), Univ Calif San Diego, Dept Psychiat, 3350 La Jolla Village Dr,Bldg 13,MC 9151-B, La Jolla, CA 92161 USA.	istrigo@ucsd.edu	strigo, irina A/L-9882-2016	strigo, irina A/0000-0002-8799-716X; Spadoni, Andrea/0000-0002-8367-6406	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH080003]; Center of Excellence in Stress and Mental Health; Merit Grant; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R00MH080003, K99MH080003] Funding Source: NIH RePORTER	We are grateful to the National Institute of Mental Health (MH080003 to IAS), to the Veterans Administration via Center of Excellence in Stress and Mental Health to ANS and IAS, and Merit Grant to ANS for supporting this work and to Elena Kosheleva and Lindsay E Reinhardt for assisting with data collection.	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brodersen KH, 2012, NEUROIMAGE, V63, P1162, DOI 10.1016/j.neuroimage.2012.08.035; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Craig AD, 1999, MEDULLA THALAMUS TXB, P183; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Fairhurst M, 2007, PAIN, V128, P101, DOI 10.1016/j.pain.2006.09.001; First MB., 1997, STRUCTURED CLIN INTE; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Golkar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048107; Gosselin N, 2012, J NEUROTRAUM, V29, P2625, DOI 10.1089/neu.2012.2312; Hamilton JP, 2012, AM J PSYCHIAT, V169, P693, DOI 10.1176/appi.ajp.2012.11071105; Hayes AF, 2013, INTRO MEDLATION MODE; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jack K, 2010, MANUAL THER, V15, P220, DOI 10.1016/j.math.2009.12.004; Kanske P, 2011, CEREB CORTEX, V21, P1379, DOI 10.1093/cercor/bhq216; Kim SH, 2007, J COGNITIVE NEUROSCI, V19, P776, DOI 10.1162/jocn.2007.19.5.776; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Moeller-Bertram T, 2012, NEUROPHARMACOLOGY, V62, P586, DOI 10.1016/j.neuropharm.2011.04.028; Mohr C, 2008, PAIN, V139, P416, DOI 10.1016/j.pain.2008.05.020; Mutschler I, 2012, NEUROSCI LETT, V520, P204, DOI 10.1016/j.neulet.2012.03.095; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Phan KL, 2005, BIOL PSYCHIAT, V57, P210, DOI 10.1016/j.biopsych.2004.10.030; Ploner M, 2010, P NATL ACAD SCI USA, V107, P355, DOI 10.1073/pnas.0906186106; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Samprit Chatterjee, 2009, SENSITIVITY ANAL LIN, V327; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Simmons A, 2006, BIOL PSYCHIAT, V60, P402, DOI 10.1016/j.biopsych.2006.04.038; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Staud R, 2012, EXPERT REV NEUROTHER, V12, P577, DOI [10.1586/ern.12.41, 10.1586/ERN.12.41]; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Strigo IA, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.15; Strigo IA, 2008, ARCH GEN PSYCHIAT, V65, P1275, DOI 10.1001/archpsyc.65.11.1275; Strigo IA, 2013, INT J EAT DISORDER, V46, P23, DOI 10.1002/eat.22045; Strigo IA, 2010, BIOL PSYCHIAT, V68, P442, DOI 10.1016/j.biopsych.2010.03.034; Taber KH, 2010, PTSD RES Q, V21, P1; Talairach J., 1988, COPLANAR STEREOTAXIC; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Valet M, 2004, PAIN, V109, P399, DOI 10.1016/j.pain.2004.02.033; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Vul E, 2009, PERSPECT PSYCHOL SCI, V4, P274, DOI 10.1111/j.1745-6924.2009.01125.x; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Warden DL, 2005, NEW ENGL J MED, V353, P633; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	70	19	19	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	JAN	2014	4								e340	10.1038/tp.2013.116			8	Psychiatry	Psychiatry	AJ2RL	WOS:000337507500002	24399043	DOAJ Gold, Green Published			2021-06-18	
J	Zamorski, MA; Boulos, D				Zamorski, Mark A.; Boulos, David			The impact of the military mission in Afghanistan on mental health in the Canadian Armed Forces: a summary of research findings	EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY			English	Article						Military personnel; Canada; stress disorders; post-traumatic; combat; epidemiology	SUICIDE ATTEMPTS; DISORDERS; COMBAT; PREVALENCE; VALIDATION; DEPLOYMENT; PERSONNEL; SOLDIERS; SUPPORT; UTILITY	Background: As Canada's mission in Afghanistan winds down, the Canadian Forces (CF) are reflecting on the psychological impact of the mission on more than 40,000 deployed personnel. Methods: All major CF studies of mental health outcomes done before and during the Afghanistan era are summarized, with an eye toward getting the most complete picture of the mental health impact of the mission. Studies on traumatic brain injury (TBI), high-risk drinking, and suicidality are included given their conceptual link to mental health. Results: CF studies on the mental health impact of pre-Afghanistan deployments are few, and they have inadequate detail on deployment experiences. Afghanistan era findings confirm service-related mental health problems (MHPs) in an important minority. The findings of the studies cohere, both as a group and in the context of data from our Allies. Combat exposure is the most important driver of deployment-related MHPs, but meaningful rates will be found in those in low-threat areas. Reserve service and cumulative effects of multiple deployments are not major risk factors in the CF. Many deployed personnel will seek care, but further efforts to decrease the delay are needed. Only a fraction of the overall burden of mental illness is likely deployment attributable. Deployment-related mental disorders do not translate into an overall increase in in-service suicidal behavior in the CF, but there is concerning evidence of increased suicide risk after release. TBI occurred in a distinct minority on this deployment, but severe forms were rare. Most TBI cases do not have persistent "post-concussive'' symptoms; such symptoms are closely associated with MHPs. Conclusion: The mental health impact of the mission in Afghanistan is commensurate with its difficult nature. While ongoing and planned studies will provide additional detail on its impacts, greater research attention is needed on preventive and therapeutic interventions.	[Zamorski, Mark A.; Boulos, David] Canadian Forces Hlth Serv Grp, Ottawa, ON, Canada	Zamorski, MA (corresponding author), Canadian Forces Hlth Serv Grp Headquarters, 1745 Alta Vista Dr, Ottawa, ON K1A 0K6, Canada.	mark.zamorski@forces.gc.ca		Boulos, David/0000-0001-7585-0681			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Armed Forces Health Surveillance Center (AFHSC), 2007, MED SURVEILLANCE MON, V14, P2; Belik SL, 2010, AM J EPIDEMIOL, V172, P1250, DOI 10.1093/aje/kwq290; Belik SL, 2009, CAN J PSYCHIAT, V54, P93, DOI 10.1177/070674370905400207; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Boulos D, 2013, CAN MED ASSOC J, V185, pE545, DOI 10.1503/cmaj.122120; Bryant RA, 2011, DEPRESS ANXIETY, V28, P99, DOI 10.1002/da.20786; Canadian Armed Forces, 2013, ROAD MENT READ R2 M; Department of National Defence, 2010, 2008 2009 HLTH LIF I; Department of National Defence, 2005, HLTH LIF INF SURV 20; Fikretoglu D, 2010, MED CARE, V48, P10, DOI 10.1097/MLR.0b013e3181bd4bf9; Garber B. G., 2008, CANADIAN FORCES HLTH; Garber BG, 2012, CAN J PSYCHIAT, V57, P736, DOI 10.1177/070674371205701205; Goss Gilroy Inc, 1998, HLTH STUD CAN FORC P; Kessler R. C., 1998, INT J METH PSYCH RES, V7, P171, DOI 10.1002/mpr.47.; Kessler RC, 2004, INT J METH PSYCH RES, V13, P122, DOI 10.1002/mpr.169; Lee JEC, 2013, J OCCUP HEALTH PSYCH, V18, P327, DOI 10.1037/a0033059; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; Mendes DD, 2008, INT J PSYCHIAT MED, V38, P241, DOI 10.2190/PM.38.3.b; Office of the Surgeon General U.A.M.C., 2006, FIN REP MENT HLTH AD; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Sareen J, 2008, AM J PUBLIC HEALTH, V98, P2191, DOI 10.2105/AJPH.2008.134205; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238; Sedge P., 2012, PREVALENCE OCCUPATIO; Smith B, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-37; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; *STAT CAN, 2002, CAN COMM HLTH SURV M; *STAT CAN, 2003, DAIL CAN COMM HLTH S; Statistics Canada, 2011, CAN FORC CANC MORT S; Statistics Canada, 2004, CAN COMM HLTH SURV C; Stein DJ, 2009, CNS SPECTRUMS, V14, P25; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Thompson JM, 2011, SURVEY TRANSITION CI; Warden D. L., 2005, WAR NEUROTRAUMA DEFE; Warner CH, 2011, ARCH GEN PSYCHIAT, V68, P1065, DOI 10.1001/archgenpsychiatry.2011.112; Weathers F. W., 1993, PTSD CHECKLIST PCL R; Weathers F. W., 1994, PTSD CHECKLIST PCL C; Zamorski M. A., 2011, REPORT FINDINGS ENHA; Zamorski M. A, 2009, PRELIMINARY REPORT S; Zamorski MA, 2006, CAN PSYCH ASS ANN M; ZAMORSKI MA, 2010, REPORT CANADIAN FORC; Zamorski MA, 2014, CAN J PSYCHIAT, V59, P319; Zamorski MA, 2011, INT REV PSYCHIATR, V23, P173, DOI 10.3109/09540261.2011.562186	47	19	19	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2000-8198	2000-8066		EUR J PSYCHOTRAUMATO	Eur. J. Psychotraumatol.		2014	5								23822	10.3402/ejpt.v5.23822			13	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AO2HG	WOS:000341138800001	25206951	DOAJ Gold, Green Published			2021-06-18	
J	Fife, GP; O'Sullivan, DM; Pieter, W; Cook, DP; Kaminski, TW				Fife, Gabriel P.; O'Sullivan, David M.; Pieter, Willy; Cook, David P.; Kaminski, Thomas W.			Effects of Olympic-style taekwondo kicks on an instrumented head-form and resultant injury measures	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Head injuries; Martial Arts	PROFESSIONAL FOOTBALL; CONCUSSION; IMPACT; BIOMECHANICS	Objective The objective of this study was to assess the effect of taekwondo kicks and peak foot velocity (FVEL) on resultant head linear acceleration (RLA), head injury criterion (HIC15) and head velocity (HVEL). Methods Each subject (n=12) randomly performed five repetitions of the turning kick (TK), clench axe kick (CA), front leg axe kick, jump back kick (JB) and jump spinning hook kick (JH) at the average standing head height for competitors in their weight division. A Hybrid II Crash Test Dummy head was fitted with a protective taekwondo helmet and instrumented with a triaxial accelerometer and fixed to a height-adjustable frame. Resultant head linear acceleration, HVEL, FVEL data were captured and processed using Qualysis Track Manager. Results The TK (130.1151.67g) produced a higher RLA than the CA (54.95 +/- 20.08g, p<0.001, d=1.84) and a higher HIC15 than the JH (672.74 +/- 540.89 vs 300.19 +/- 144.35, p<0.001, ES=0.97). There was no difference in HVEL of the TK (4.73 +/- 1.67m/s) and that of the JB (4.43 +/- 0.78m/s; p=0.977, ES<0.01). Conclusions The TK is of concern because it is the most common technique and cause of concussion in taekwondo. Future studies should aim to understand rotational accelerations of the head.	[Fife, Gabriel P.] Yonsei Univ, Dept Phys Educ, Seoul 120749, South Korea; [Fife, Gabriel P.] Dong A Univ, Dept Phys Educ, Pusan, South Korea; [O'Sullivan, David M.] Chung Ang Univ, Dept Phys Educ, Anseong, South Korea; [O'Sullivan, David M.] Seoul Natl Univ, Dept Phys Educ, Seoul, South Korea; [Pieter, Willy] Keimyung Univ, Dept Taekwondo, Taegu, South Korea; [Cook, David P.] London S Bank Univ, Dept Acad Sport, London, England; [Kaminski, Thomas W.] Univ Delaware, Dept Hlth Nutr & Exercise Sci, Newark, DE USA	O'Sullivan, DM (corresponding author), Chung Ang Univ, Coll Sport Sci, Dept Phys Educ, 72-1 Naeri Daedeokmyeon, Gyeonggido Anseong 456756, South Korea.	tkd4@cau.ac.kr			National Athletic Trainers' Association; University of Delaware GUR Grant	National Athletic Trainers' Association and University of Delaware GUR Grant.	[Anonymous], 2008, WORLD TAEKW HEADQ; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cohen JE, 2010, ISR MED ASSOC J, V12, P509; Foster KJ, 1977, P 21 STAPP CAR CRASH; Greenwald RM, 2001, J APPL BIOMECH, V17, P241, DOI 10.1123/jab.17.3.241; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hertzberg HE., 1969, P 13 STAPP CAR CRASH; Kazemi Mohsen, 2009, J Can Chiropr Assoc, V53, P144; Kim YK, 2011, J SPORT SCI MED, V10, P31; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leopold J., 1999, LOS ANGELES TIM 0111; Luk T.C., 2001, P 19 INT S BIOM SPOR, P166; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Highway Traffic Safety Administration, 2013, THOR ADV CRASH TEST; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; O'Sullivan D, 2009, J SPORT SCI MED, V8, P13; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W., 2009, COMBAT SPORTS MED, P263; PINTAR FA, 1990, 34TH P STAPP CAR CRA, P55; Queck C., 2009, STRAIGHTS TIMES 0711; Scott MW, 1993, 930094 SAE; Society of Automotive Engineers (SAE), 1995, J2111 SAE; Spittle E. K., 1992, HYBRID 2 HYBRID 3 DU; Svenson MY., 1992, P INT IRCOBI C BIOM; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; World Taekwondo Federation News, 2010, WORLD TAEKWONDO FEDR	35	19	19	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2013	47	18					1161	+		10.1136/bjsports-2012-090979			6	Sport Sciences	Sport Sciences	255OK	WOS:000327249500007	22930694				2021-06-18	
J	Zhang, J; Xiong, Y; Lu, LX; Wang, H; Zhang, YF; Fang, F; Song, YL; Jiang, H				Zhang, J.; Xiong, Y.; Lu, L. X.; Wang, H.; Zhang, Y. F.; Fang, F.; Song, Y. L.; Jiang, H.			AQP1 EXPRESSION ALTERATIONS AFFECT MORPHOLOGY AND WATER TRANSPORT IN SCHWANN CELLS AND HYPDXIA-INDUCED UP-REGULATION OF AQP1 OCCURS IN A HIF-1 alpha-DEPENDENT MANNER	NEUROSCIENCE			English	Article						AQP1; Schwann cells; peripheral nerve system; nerve edema; water transport; HIF-1 alpha	PERIPHERAL NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; RAT ASTROCYTES; HYPOXIA; AQUAPORIN-1; MICE; HOMEOSTASIS; INDUCTION; ISCHEMIA; LESSONS	Aquaporin-1 (AQP1) is the principle water channel in the peripheral nervous system (PNS) and is specifically localized to Schwann cells in the PNS. However, the pathophysiological role of AQP1 in peripheral nerves is poorly understood. Here, we utilized RNA interference by lentiviral transduction to specifically down-regulate AQP1 expression and a lentiviral overexpression protocol to up-regulate AQP1 expression, in primary Schwann cell cultures. AQP1 gene silencing resulted in a cell shrinkage phenotype, while AQP1 gene overexpression caused a cell swelling phenotype, as validated by cell volume determinations. Secondly, we utilized an in vitro hypoxia model in Schwann cells to mimic in vivo facial nerve injury. We demonstrated that AQP1 expression was induced within 8 h following hypoxia injury in vitro, and that AQP1 knockdown (KD) caused the cells to resist edema following hypoxia. Finally, we investigated the hypoxic regulation of the AQP1 gene, as well as the involvement of Hypoxia-inducible factor-1 alpha (HIF-1 alpha) in AQP1 modulation and we found that KD of HIF-1 alpha decreased hypoxia-dependent induction of endogenous AQP1 expression at both the mRNA and protein levels. Taken together, these results indicate that (1) AQP1 is an important factor responsible for the fast water transport of cultured Schwann cells and is involved in cell plasticity; (2) AQP1 alterations may be a primary factor in hypoxia-induced peripheral nerve edema; (3) HIF-1 alpha participates in the hypoxic induction of the AQP1 gene; (4) AQP1 inhibition might provide a new therapeutic alternative for the treatment of some forms of peripheral nerve edema. Crown Copyright (C) 2013 Published by Elsevier Ltd. on behalf of IBRO. All rights reserved.	[Zhang, J.; Lu, L. X.; Wang, H.; Zhang, Y. F.; Fang, F.; Song, Y. L.; Jiang, H.] Second Mil Med Univ, Changzheng Hosp, Dept Plast Surg, Shanghai 200003, Peoples R China; [Zhang, J.] Nanchang Univ, Affiliated Hosp 1, Dept Plast Surg, Nanchang 330006, Jiangxi, Peoples R China; [Xiong, Y.] Nanchang Univ, Affiliated Hosp 2, Dept Gastroenterol, Nanchang 330006, Jiangxi, Peoples R China	Jiang, H (corresponding author), Changzheng Hosp, Dept Plast Surg, 415 Fengyang Rd, Shanghai 200003, Peoples R China.	dosjh@126.com					Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.3.CO;2-G; Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Echevarria M, 2007, J BIOL CHEM, V282, P30207, DOI 10.1074/jbc.M702639200; Gao HW, 2006, GLIA, V53, P783, DOI 10.1002/glia.20336; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Kaneko K, 2008, MICROVASC RES, V75, P297, DOI 10.1016/j.mvr.2007.12.003; King LS, 2002, TRENDS ENDOCRIN MET, V13, P355, DOI 10.1016/S1043-2760(02)00665-3; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Ma TH, 2011, ACTA PHARMACOL SIN, V32, P711, DOI 10.1038/aps.2011.63; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mou KJ, 2010, J NEURO-ONCOL, V100, P375, DOI 10.1007/s11060-010-0205-x; Nandasena BGTL, 2007, BRAIN RES, V1157, P32, DOI 10.1016/j.brainres.2007.04.033; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Oshio K, 2006, BIOCHEM BIOPH RES CO, V341, P1022, DOI 10.1016/j.bbrc.2006.01.062; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Semenza G L, 2000, Respir Res, V1, P159, DOI 10.1186/rr27; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2007, SCI STKE, V2007, pcm8, DOI [10.1126/stke.4072007cm8, DOI 10.1126/STKE.4072007CM8]; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shields SD, 2007, PAIN, V131, P8, DOI 10.1016/j.pain.2006.11.018; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; Wang H, 2012, EXP BIOL MED, V237, P1249, DOI 10.1258/ebm.2012.012134; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; Yang M, 2013, J CELL BIOCHEM, V114, P111, DOI 10.1002/jcb.24308; Zhang H, 2010, J BIOL CHEM, V285, P5896, DOI 10.1074/jbc.M109.090233	30	19	19	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 12	2013	252						68	79		10.1016/j.neuroscience.2013.08.006			12	Neurosciences	Neurosciences & Neurology	236YS	WOS:000325836000007	23948641				2021-06-18	
J	Carlozzi, NE; Grech, J; Tulsky, DS				Carlozzi, Noelle E.; Grech, Julie; Tulsky, David S.			Memory functioning in individuals with traumatic brain injury: An examination of the Wechsler Memory Scale-Fourth Edition (WMS-IV)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; TBI; Wechsler Memory Scale-Fourth Edition; WMS-IV; Memory; Assessment	CONFIRMATORY FACTOR-ANALYSIS; MILD HEAD-INJURY; VERBAL-LEARNING TEST; OF-THE-LITERATURE; COGNITIVE REHABILITATION; NEUROPSYCHOLOGICAL RECOVERY; FOLLOW-UP; WAIS-IV; MODERATE; DEFICITS	This study was designed to examine the construct validity of the Wechsler Memory Scale-Fourth Edition (WMS-IV) in individuals with traumatic brain injury (TBI). One hundred individuals with TBI (n = 35 complicated mild/moderate TBI; n = 65 severe TBI) and 100 matched controls from the WMS-IV normative dataset completed the WMS-IV. Multivariate analyses indicated that severe TBI participants had poorer performance than matched controls on all index scores and subtests. Individuals with complicated mild/moderate TBI performed more poorly than controls on all index scores, as well as on tests of visual memory (Designs I and II; Visual Reproduction I and II) and visual working memory (Spatial Addition; Symbol Span), but not on auditory verbal memory tests (Logical Memory I and II; Verbal Paired Associates I and II). After controlling for time since injury, severe TBI participants had significantly lower scores than the complicated mild/moderate TBI on 4 of the 5 WMS-IV index scores (Auditory Memory, Visual Memory, Immediate Memory, Delayed Memory) and 4 of the 10 WMS-IV subtests (Designs I and II, Verbal Pairs II, Logical Memory II). Effect sizes for index and subtest scores were generally moderate for the complicated mild/moderate group and moderate-to-large for the severe TBI group. Findings provide support for the construct validity of the WMS-IV in individuals with TBI.	[Carlozzi, Noelle E.; Grech, Julie; Tulsky, David S.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd,Bldg NC, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu		Tulsky, David/0000-0002-4335-4509	National Institute on Disability and Rehabilitation Research [H133G070138]	This study was supported in part by the National Institute on Disability and Rehabilitation Research [grant number H133G070138].	ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 1977, STAT POWER ANAL BEHA, P1; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Drozdick LW, 2011, ASSESSMENT, V18, P141, DOI 10.1177/1073191110382843; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Hoelzle JB, 2011, J CLIN EXP NEUROPSYC, V33, P283, DOI 10.1080/13803395.2010.511603; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Langeluddecke PM, 2005, J CLIN EXP NEUROPSYC, V27, P576, DOI 10.1080/13803390490918372; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pearson, WMS 3 WMS 4 RAT CHAN; Price LR, 2002, J CLIN EXP NEUROPSYC, V24, P574, DOI 10.1076/jcen.24.5.574.1013; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Traumatic Brain Injury Model Systems National Data Center, 2006, TRAUM BRAIN INJ MOD; Tulsky D.S., 2003, CLIN INTERPRETATION, P147; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vallat-Azouvi C, 2012, NEUROPSYCHOL REHABIL, V22, P634, DOI 10.1080/09602011.2012.681110; Walker AJ, 2009, J INT NEUROPSYCH SOC, V15, P938, DOI 10.1017/S1355617709990610; Wechsler D., 2009, WECHSLER MEMORY SCAL; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	42	19	19	1	42	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV 1	2013	35	9					906	914		10.1080/13803395.2013.833178			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	238PF	WOS:000325959200002	24033318				2021-06-18	
J	Icer, M; Guloglu, C; Orak, M; Ustundag, M				Icer, Mustafa; Guloglu, Cahfer; Orak, Murat; Ustundag, Mehmet			Factors affecting mortality caused by falls from height	ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY			English	Article						Fall from height; height of fall; hemopneumothorax; mortality; subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; PROGNOSTIC-FACTORS; FATAL FALLS; CHILDREN; PATTERN	BACKGROUND: Falls from height are among the most common trauma cases presenting to emergency departments and often cause mortality and morbidity. In the present study, we aimed to determine the factors that effectively reduce mortality caused by falls from height. METHODS: Data from 2252 trauma patients who presented to Dicle University Emergency Service between January 2005 and December 2008 due to falling from height in the Southeastern Anatolia region were retrospectively analyzed. We analyzed the parameters that are considered to have a positive effect on mortality, which included the following: month of fall; age; gender; etiology; place of fall; type of ground on which the patient fell; height of fall; intubation; hypotension; tachycardia; neck, head, thoracal, abdominal, pelvic, and extremity injuries; Glasgow Coma Score (GCS); Injury Severity Score (ISS); and Revised Trauma Score (RTS). RESULTS: There were 1435 males (63.7%) and 817 females (36.3%) included in the study. Two thousand thirty-one (94.6%) patients survived the fall while 121(5.4%) died. The mean age of the surviving patients was 15.55 +/- 18.60 years, while the patients who died had a mean age of 29.59 +/- 28.93 years. The mean height of the fall of the survivors' was 3.09 meters, and the mean height of the fall for those that died was 6.61 +/- 5.73 meters (p<0.001). CONCLUSION: The mean fatal height of the fall in falls from height is 6.61 m. Age, attempted suicide, height of fall, type of ground on which the patient fell, place of fall, and head, thoracic, and abdominal trauma are the primary factors affecting mortality caused by falls from height.	[Icer, Mustafa; Guloglu, Cahfer; Orak, Murat; Ustundag, Mehmet] Dicle Univ, Tip Fak, Acil Tip Anabilim Dali, TR-21280 Diyarbakir, Turkey	Icer, M (corresponding author), Dicle Univ, Tip Fak, Acil Tip Anabilim Dali, TR-21280 Diyarbakir, Turkey.	drmicer@mynet.com					Agalar F, 1999, INT SURG, V84, P271; Al B, 2009, ULUS TRAVMA ACIL CER, V15, P141; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Aufmkolk M, 1999, UNFALLCHIRURG, V102, P525, DOI 10.1007/s001130050445; CEYLAN S, 2002, TURK KLIN TIP BILIM, V22, P156; Chalmers D J, 1996, Inj Prev, V2, P98, DOI 10.1136/ip.2.2.98; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Denninghoff KR, 2008, WEST J EMERG MED, V9, P184; Driscoll TR, 2003, INJ PREV, V9, P15, DOI 10.1136/ip.9.1.15; Goodacre S, 1999, J TRAUMA, V46, P1055, DOI 10.1097/00005373-199906000-00014; Goren S, 2003, FORENSIC SCI INT, V137, P37, DOI 10.1016/S0379-0738(03)00285-8; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Lapostolle F, 2005, CRIT CARE MED, V33, P1239, DOI 10.1097/01.CCM.0000164564.11989.C3; LEHMAN D, 1993, PEDIATRICS, V92, P121; Liu CC, 2009, INJURY, V40, P595, DOI 10.1016/j.injury.2008.11.014; LOWENSTEIN SR, 1989, ANN EMERG MED, V18, P161, DOI 10.1016/S0196-0644(89)80107-6; MATHIS RD, 1993, J TRAUMA, V34, P123, DOI 10.1097/00005373-199301000-00023; McSwaim NE, 2000, TRAUMA, P127; McSwain NE, 1990, POSTGRAD SURG, V2, P140; MELLER JL, 1987, AM J DIS CHILD, V141, P1271, DOI 10.1001/archpedi.1987.04460120033027; Park SH, 2004, YONSEI MED J, V45, P229, DOI 10.3349/ymj.2004.45.2.229; SCALEA T, 1986, J TRAUMA, V26, P706, DOI 10.1097/00005373-198608000-00005; SIEBEN RL, 1971, PEDIATRICS, V47, P886; Spahn DR, 2007, CRIT CARE, V11, DOI 10.1186/cc5686; SPIEGEL CN, 1977, AM J PUBLIC HEALTH, V67, P1143, DOI 10.2105/AJPH.67.12.1143; Taviloglu K, 2001, Ulus Travma Derg, V7, P146; Turk EE, 2004, J TRAUMA, V57, P301, DOI 10.1097/01.TA.0000074554.86172.0E; Venkatesh VT, 2007, MED SCI LAW, V47, P330, DOI 10.1258/rsmmsl.47.4.330; WARNER KG, 1986, ANN EMERG MED, V15, P1088, DOI 10.1016/S0196-0644(86)80134-2; Yagmur Y, 2004, INJURY, V35, P425, DOI 10.1016/S0020-1383(03)00198-0	30	19	21	0	8	TURKISH ASSOC TRAUMA EMERGENCY SURGERY	ISTANBUL	KOPRULU MEHMET PASA SOC, DENIZ ABDAL MAH, DADASOGLU AP, 25-1 SEHREMINI, ISTANBUL, 00000, TURKEY	1306-696X			ULUS TRAVMA ACIL CER	Ulus. Travma Acil Cerrahi Derg.	NOV	2013	19	6					529	535		10.5505/tjtes.2013.77535			7	Emergency Medicine	Emergency Medicine	278IO	WOS:000328883200006	24347212	Bronze			2021-06-18	
J	Jones, A				Jones, Alvin			Victoria Symptom Validity Test: Cutoff Scores for Psychometrically Defined Malingering Groups in a Military Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Victoria Symptom Validity Test; VSVT; Military sample; Malingering	TRAUMATIC BRAIN-INJURY; RESPONSE BIAS; TEST-PERFORMANCE; REPEATABLE BATTERY; EFFORT INDEX; MILD; SPECIFICITY; SENSITIVITY; DYSFUNCTION; VALIDATION	The Victoria Symptom Validity Test (VSVT) is one of the least widely used tests to assess performance validity on tests of neurocognitive functioning, but a meta-analysis has suggested that it is one of the more effective validity tests. The current research examined cutoffs for several different scores derived from the VSVT in an active duty military sample composed primarily of mild TBI patients. The results are consistent with previous research and provide additional evidence that much higher cutoffs scores than originally recommended for the VSVT by the developers based on binomial probability theory can produce excellent classification and diagnostic statistics when a psychometrically defined non-malingering group is compared with two psychometrically defined malingering groups (Probable and Probable to Definite). The utility of the difference score between the Easy and Hard Items is supported by this research. The results also indicate that reaction times have some utility, but they are constrained by a lack of sensitivity.	Womack Army Med Ctr, Dept Brain Injury Med, Ft Bragg, NC 29310 USA	Jones, A (corresponding author), Womack Army Med Ctr, Dept Brain Injury Med, 2817 Riley Rd,Bldg 4-2817, Ft Bragg, NC 29310 USA.	alvin.jones2@us.army.mil					Allen LM, 2001, ARCH CLIN NEUROPSYCH, V16, P846; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Crawford JR, 2009, CLIN NEUROPSYCHOL, V23, P624, DOI 10.1080/13854040802524229; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Egeland J, 2003, J CLIN EXP NEUROPSYC, V25, P79, DOI 10.1076/jcen.25.1.79.13630; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Green P., 2003, GREENS WORD MEMORY T; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Grote C.L., 2007, ASSESSMENT MALINGERE, P44; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Hayden SR, 1999, ANN EMERG MED, V33, P575, DOI 10.1016/S0196-0644(99)70346-X; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P334; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Loring DW, 2007, CLIN NEUROPSYCHOL, V21, P522, DOI 10.1080/13854040600611384; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Macciocchi SN, 2006, ARCH CLIN NEUROPSYCH, V21, P395, DOI 10.1016/j.acn.2006.06.003; Miller E, 1970, Cortex, V6, P121; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Randolph C, 1998, REPEATABLE BATTERY A; Sackett DL., 1991, CLIN EPIDEMIOLOGY BA; Schenk K, 2010, J CLIN EXP NEUROPSYC, V32, P752, DOI 10.1080/13803390903512678; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 2003, CLIN NEUROPSYCHOL, V17, P390, DOI 10.1076/clin.17.3.390.18090; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tombaugh TN, 2007, ARCH CLIN NEUROPSYCH, V22, P25, DOI 10.1016/j.acn.2006.06.013; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	55	19	19	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 1	2013	27	8					1373	1394		10.1080/13854046.2013.851740			22	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	273KW	WOS:000328534700011	24161269				2021-06-18	
J	Larsen, BT; Edwards, WD; Jensen, MH; Johnson, CH; McBane, RD; Harmsen, WS; Maleszewski, JJ				Larsen, Brandon T.; Edwards, William D.; Jensen, Mark H.; Johnson, Craig H.; McBane, Robert D.; Harmsen, William S.; Maleszewski, Joseph J.			Surgical Pathology of Hypothenar Hammer Syndrome With New Pathogenetic Insights A 25-Year Institutional Experience With Clinical and Pathologic Review of 67 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						hypothenar hammer syndrome; ulnar artery; fibromuscular dysplasia; vascular pathology	FIBROMUSCULAR DYSPLASIA; RENOVASCULAR HYPERTENSION; DISEASE; ARTERY; BRAIN	Hypothenar hammer syndrome (HHS) is characterized by digital ischemia after repetitive traumatic injury to the ulnar artery. Some hypothesize that susceptible patients have an intrinsic vasculopathy such as fibromuscular dysplasia (FMD). To investigate this hypothesis, we reviewed our institutional experience with this syndrome over 25 years. Clinical records were reviewed from all patients who underwent surgical treatment for HHS (1987 to 2011), and histologic features of excised ulnar arteries were characterized. A total of 67 patients (mean age 45 y; range, 21 to 75 y; 65 men) were treated for unilateral or bilateral disease. Common symptoms included digital pain (96% of cases), cold intolerance (79%), cyanosis (70%), numbness (54%), tingling (51%), and ulceration (40%). Angiography showed ulnar artery occlusion (89%), irregularity (56%), tortuosity (46%), and digital emboli (89%). Common pathologic features (from 75 specimens) included: luminal thrombosis (87%); intimal thickening (60%) and fibrosis (57%); internal elastic membrane disruption (95%); medial fibrosis (96%), hypertrophy (43%), neovascularization (49%), dilatation (29%), and disruption (25%); and adventitial neovascularization (53%). Specific features of dysplasia were present in 10 cases (15%), including smooth muscle disorganization and additional smooth muscle bundles outside the external elastic membrane, but typical FMD was not identified. Histologic features in HHS most often represent secondary changes consistent with repetitive trauma. Dysplastic features can be found in occasional cases, but FMD does not appear to contribute to HHS in most patients. Angiography should be interpreted with caution in superficial locations, as a string-of-beads appearance may simply reflect a posttraumatic corkscrew deformity of the ulnar artery.	[Larsen, Brandon T.; Edwards, William D.; Maleszewski, Joseph J.] Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA; [McBane, Robert D.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA; [Harmsen, William S.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Jensen, Mark H.; Johnson, Craig H.] Mayo Clin, Dept Plast & Reconstruct Surg, Rochester, MN 55905 USA	Maleszewski, JJ (corresponding author), Mayo Clin, Div Anat Pathol, 200 First St SW, Rochester, MN 55905 USA.	maleszewski.joseph@mayo.edu		McBane, Robert/0000-0001-8727-8029			Begelman SM, 2000, CURR OPIN RHEUMATOL, V12, P41, DOI 10.1097/00002281-200001000-00007; Dethmers RSM, 2005, J HAND SURG-BRIT EUR, V30B, P419, DOI 10.1016/j.jhsb.2005.02.013; Ferris BL, 2000, J VASC SURG, V31, P104, DOI 10.1016/S0741-5214(00)70072-3; HARRISON EG, 1971, MAYO CLIN PROC, V46, P161; HARRISON EG, 1967, AM J MED, V43, P97, DOI 10.1016/0002-9343(67)90151-9; Karimi Kamran M H, 2005, W V Med J, V101, P250; LITTLE JM, 1972, ARCH SURG-CHICAGO, V105, P684; Marie I, 2007, MEDICINE, V86, P334, DOI 10.1097/MD.0b013e31815c95d3; METTINGER KL, 1982, STROKE, V13, P53, DOI 10.1161/01.STR.13.1.53; METTINGER KL, 1982, STROKE, V13, P46, DOI 10.1161/01.STR.13.1.46; Nitecki S, 2008, VASCULAR, V16, P279, DOI 10.2310/6670.2008.00002; Olin JW, 2012, CIRCULATION, V125, P3182, DOI 10.1161/CIRCULATIONAHA.112.091223; Olin JW, 2011, J VASC SURG, V53, P826, DOI 10.1016/j.jvs.2010.10.066; Slovut DP, 2004, NEW ENGL J MED, V350, P1862, DOI 10.1056/NEJMra032393; Stone JR, 2004, CARDIOVASC PATHOL, V13, P20, DOI 10.1016/S1054-8807(03)00110-8; Stroud S D, 1985, Occup Health Nurs, V33, P31; Taylor LM, 2003, J VASC SURG, V37, P697, DOI 10.1067/mva.2003.218	17	19	19	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	NOV	2013	37	11					1700	1708		10.1097/PAS.0b013e318297fa37			9	Pathology; Surgery	Pathology; Surgery	299YF	WOS:000330430900009	23887165				2021-06-18	
J	Chai, RC; Jiang, JH; Wong, AYK; Jiang, F; Gao, K; Vatcher, G; Yu, ACH				Chai, Rui Chao; Jiang, Jiao Hua; Wong, Ann Yuen Kwan; Jiang, Feng; Gao, Kai; Vatcher, Greg; Yu, Albert Cheung Hoi			AQP5 is differentially regulated in astrocytes during metabolic and traumatic injuries	GLIA			English	Article						aquaporin; ischemia; MCAO; scratch-wound; stab-wound	AQUAPORIN WATER CHANNELS; INNER MITOCHONDRIAL-MEMBRANE; CENTRAL-NERVOUS-SYSTEM; BRAIN EDEMA; RAT ASTROCYTES; REACTIVE ASTROCYTES; ISCHEMIC-STROKE; GENE-EXPRESSION; CELL-MIGRATION; PROTEIN	Water movement plays vital roles in both physiological and pathological conditions in the brain. Astrocytes are responsible for regulating this water movement and are the major contributors to brain edema in pathological conditions. Aquaporins (AQPs) in astrocytes play critical roles in the regulation of water movement in the brain. AQP1, 3, 4, 5, 8, and 9 have been reported in the brain. Compared with AQP1, 4, and 9, AQP3, 5, and 8 are less studied. Among the lesser known AQPs, AQP5, which has multiple functions identified outside the central nervous system, is also indicated to be involved in hypoxia injury in astrocytes. In our study, AQP5 expression could be detected both in primary cultures of astrocytes and neurons, and AQP5 expression in astrocytes was confirmed in 1- to 4-week old primary cultures of astrocytes. AQP5 was localized on the cytoplasmic membrane and in the cytoplasm of astrocytes. AQP5 expression was downregulated during ischemia treatment and upregulated after scratch-wound injury, which was also confirmed in a middle cerebral artery occlusion model and a stab-wound injury model in vivo. The AQP5 increased after scratch injury was polarized to the migrating processes and cytoplasmic membrane of astrocytes in the leading edge of the scratch-wound, and AQP5 over-expression facilitated astrocyte process elongation after scratch injury. Taken together, these results indicate that AQP5 might be an important water channel in astrocytes that is differentially expressed during various brain injuries. GLIA 2013;61:1748-1765	[Chai, Rui Chao; Jiang, Jiao Hua; Wong, Ann Yuen Kwan; Jiang, Feng; Gao, Kai; Vatcher, Greg; Yu, Albert Cheung Hoi] Peking Univ, Neurosci Res Inst, Sch Basic Med Sci, Beijing 100191, Peoples R China; [Chai, Rui Chao; Jiang, Jiao Hua; Wong, Ann Yuen Kwan; Jiang, Feng; Gao, Kai; Vatcher, Greg; Yu, Albert Cheung Hoi] Peking Univ, Dept Neurobiol, Sch Basic Med Sci, Beijing 100191, Peoples R China; [Chai, Rui Chao; Jiang, Jiao Hua; Wong, Ann Yuen Kwan; Jiang, Feng; Gao, Kai; Vatcher, Greg; Yu, Albert Cheung Hoi] Peking Univ, Natl Hlth & Family Planning Commiss, Key Lab Neurosci, Minist Educ, Beijing 100191, Peoples R China; [Yu, Albert Cheung Hoi] Peking Univ, Inst Syst Biomed, Lab Translat Med, Beijing 100191, Peoples R China	Yu, ACH (corresponding author), Peking Univ, Neurosci Res Inst, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	achy@hsc.pku.edu.cn	Chai, Ruichao/AAF-3361-2020		Beijing Natural Science FoundationBeijing Natural Science Foundation [7091004]; National Basic Research Program of China (973 program)National Basic Research Program of China [2011CB504400]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30870818, 31070974, 31171009]; Foundation for Innovative Research Groups of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81221002]	Grant sponsor: Beijing Natural Science Foundation; Grant number: 7091004; Grant sponsor: National Basic Research Program of China (973 program); Grant number: 2011CB504400; Grant sponsor: National Natural Science Foundation of China; Grant numbers: 30870818, 31070974, and 31171009; Grant sponsor: Foundation for Innovative Research Groups of the National Natural Science Foundation of China; Grant number: 81221002.	Agre Peter, 2006, Proc Am Thorac Soc, V3, P5, DOI 10.1513/pats.200510-109JH; Amiry-Moghaddam M, 2005, FASEB J, V19, P1459, DOI 10.1096/fj.04-3515com; Anderova M, 2004, GLIA, V48, P311, DOI 10.1002/glia.20076; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Badaut J, 2004, NEUROSCIENCE, V129, P971, DOI 10.1016/j.neuroscience.2004.06.035; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; Butler TL, 2006, AM J PHYSIOL-HEART C, V291, pH705, DOI 10.1152/ajpheart.00090.2006; Calamita G, 2005, J BIOL CHEM, V280, P17149, DOI 10.1074/jbc.C400595200; Chen HH, 2013, ARCH MED RES, V44, P93, DOI 10.1016/j.arcmed.2013.01.004; Chen XQ, 2005, GLIA, V50, P182, DOI 10.1002/glia.20147; Connors NC, 2006, GLIA, V53, P124, DOI 10.1002/glia.20271; Dong Y, 2009, J NEUROCHEM, V109, P182, DOI 10.1111/j.1471-4159.2009.05974.x; Finnie JW, 2011, J CLIN NEUROSCI, V18, P947, DOI 10.1016/j.jocn.2010.11.010; Fort PE, 2008, GLIA, V56, P597, DOI 10.1002/glia.20633; Fu XM, 2007, GLIA, V55, P935, DOI 10.1002/glia.20515; Gunnarson E, 2008, GLIA, V56, P587, DOI 10.1002/glia.20627; Guo JJ, 2012, NEUROSCI BULL, V28, P669, DOI 10.1007/s12264-012-1288-5; Hu Q, 2011, STROKE, V42, P1750, DOI 10.1161/STROKEAHA.110.603142; Ikeshima-Kataoka H, 2013, MOL CELL NEUROSCI, V56, P65, DOI 10.1016/j.mcn.2013.02.002; Jung H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027938; Kawedia JD, 2007, P NATL ACAD SCI USA, V104, P3621, DOI 10.1073/pnas.0608384104; Kawedia JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057541; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Koyama Y, 1999, GLIA, V26, P268, DOI 10.1002/(SICI)1098-1136(199905)26:3<268::AID-GLIA8>3.0.CO;2-G; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Liu HS, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-18; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mccoy E, 2007, GLIA, V55, P1034, DOI 10.1002/glia.20524; Mccoy E, 2010, GLIA, V58, P209, DOI 10.1002/glia.20916; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Miller EW, 2010, P NATL ACAD SCI USA, V107, P15681, DOI 10.1073/pnas.1005776107; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; Musa-Aziz R, 2009, P NATL ACAD SCI USA, V106, P5406, DOI 10.1073/pnas.0813231106; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nito C, 2012, J NEUROTRAUM, V29, P2404, DOI 10.1089/neu.2012.2430; Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Qi LL, 2011, LIFE SCI, V88, P50, DOI 10.1016/j.lfs.2010.10.025; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Roberta A, 2010, CURR NEUROPHARMACOL, V8, P84, DOI 10.2174/157015910791233178; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Serrano-Perez MC, 2011, GLIA, V59, P94, DOI 10.1002/glia.21079; Shi WZ, 2012, NEUROSCI BULL, V28, P680, DOI 10.1007/s12264-012-1281-z; Sidhaye VK, 2008, P NATL ACAD SCI USA, V105, P3345, DOI 10.1073/pnas.0712287105; Sidhaye VK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038717; Sidhaye VK, 2006, P NATL ACAD SCI USA, V103, P4747, DOI 10.1073/pnas.0511211103; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Tang Zhaohua, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P141; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Wang W, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-242; Woo J, 2008, BIOCHEM BIOPH RES CO, V367, P291, DOI 10.1016/j.bbrc.2007.12.073; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Yang CZ, 2011, J NEUROSCI RES, V89, P2041, DOI 10.1002/jnr.22657; Yang CZ, 2012, P NATL ACAD SCI USA, V109, P6963, DOI 10.1073/pnas.1118754109; Yool AJ, 2007, NEUROSCIENTIST, V13, P470, DOI 10.1177/1073858407303081; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Yu ACH, 1995, PROG BRAIN RES, V105, P245; Yu ACH, 2001, GLIA, V35, P121, DOI 10.1002/glia.1077; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zhang QY, 2008, P NATL ACAD SCI USA, V105, P7612, DOI 10.1073/pnas.0802467105; Zhang ZQ, 2010, J PATHOL, V221, P210, DOI 10.1002/path.2702; Zhou Y, 2010, NEUROCHEM RES, V35, P2124, DOI 10.1007/s11064-010-0325-x	76	19	19	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	OCT	2013	61	10					1748	1765		10.1002/glia.22555			18	Neurosciences	Neurosciences & Neurology	205NU	WOS:000323451900015	23922257				2021-06-18	
J	Clark, IA; Vissel, B				Clark, Ian A.; Vissel, Bryce			Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease	BIOCHEMICAL PHARMACOLOGY			English	Article						Alzheimer's disease; Parkinson's disease, alpha-Synuclein; DNA hypomethylation; TNF; Insulin resistance	NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; ONSET ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; CHIMERIC MONOCLONAL-ANTIBODY; APOLIPOPROTEIN-E SUPPRESSES; COLLAGEN-INDUCED ARTHRITIS; TRAUMATIC BRAIN-INJURY; HUMAN PERIPHERAL-BLOOD; AD MOUSE MODELS	The disappointments of a series of large anti-amyloid trials have brought home the point that until the driving force behind Alzheimer's disease, and the way it causes harm, are firmly established and accepted, researchers will remain ill-equipped to find a way to treat patients successfully. The origin of inflammation in neurodegenerative diseases is still an open question. We champion and expand the argument that a shift in intracellular location of et-synuclein, thereby moving a key methylation enzyme from the nucleus, provides global hypomethylation of patients' cerebral DNA that, through being sensed by TLR9, initiates production of the cytokines that drive these cerebral inflammatory states. After providing a background on the relevant inflammatory cytokines, this commentary then discusses many of the known alternatives to the primary amyloid argument of the pathogenesis of Alzheimer's disease, and the treatment approaches they provide. A key point to appreciate is the weight of evidence that inflammatory cytokines, largely through increasing insulin resistance and thereby reducing the strength of the ubiquitously important signaling mediated by insulin, bring together most of these treatments under development for neurodegenerative disease under the one roof. Moreover, the principles involved apply to a wide range of inflammatory diseases on both sides of the blood brain barrier. (c) 2013 Elsevier Inc. All rights reserved.	[Clark, Ian A.; Vissel, Bryce] Australian Natl Univ, Res Sch Biol, Canberra, ACT 0200, Australia; [Vissel, Bryce] Garvan Inst, Neurodegenerat Res Grp, Sydney, NSW, Australia	Clark, IA (corresponding author), Australian Natl Univ, Res Sch Biol, Canberra, ACT 0200, Australia.	ian.clark@anu.edu.au		Vissel, Bryce/0000-0001-8860-8050			Adjou KT, 2007, J COMP PATHOL, V137, P78, DOI 10.1016/j.jcpa.2007.03.007; Adlard PA, 2008, NEURON, V59, P43, DOI 10.1016/j.neuron.2008.06.018; Ahern T, 2013, J EUROPEAN IN PRESS; Ali K, 2005, CIRC RES, V97, P922, DOI 10.1161/01.RES.0000187467.67684.43; Alkam T, 2008, BEHAV BRAIN RES, V189, P100, DOI 10.1016/j.bbr.2007.12.014; Alvarez-Erviti L, 2011, NEUROSCI RES, V69, P337, DOI 10.1016/j.neures.2010.12.020; Amaral PP, 2013, BRIEF FUNCT GENOMICS, V12, P254, DOI 10.1093/bfgp/elt016; Atamaniuk J, 2012, NEPHROL DIAL TRANSPL, V27, P902, DOI 10.1093/ndt/gfr695; Aucan C, 2004, J MED GENET, V41, P21, DOI 10.1136/jmg.2003.011981; Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295; Bakulski KM, 2012, J ALZHEIMERS DIS, V29, P571, DOI 10.3233/JAD-2012-111223; Barbieri M, 2003, AM J PHYSIOL-ENDOC M, V285, pE1064, DOI 10.1152/ajpendo.00296.2003; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Benson JM, 2011, NAT BIOTECHNOL, V29, P615, DOI 10.1038/nbt.1903; Bihaqi SW, 2012, CURR ALZHEIMER RES, V9, P574; Bihaqi SW, 2011, J ALZHEIMERS DIS, V27, P819, DOI 10.3233/JAD-2011-111013; BROOKES AJ, 1994, TRENDS NEUROSCI, V17, P404, DOI 10.1016/0166-2236(94)90013-2; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; Brynskikh A, 2008, BRAIN BEHAV IMMUN, V22, P861, DOI 10.1016/j.bbi.2007.12.008; Butchi NB, 2010, GLIA, V58, P650, DOI 10.1002/glia.20952; Canellada A, 2006, MOL CELL NEUROSCI, V31, P692, DOI 10.1016/j.mcn.2005.12.008; Castellani RJ, 2004, ACTA NEUROBIOL EXP, V64, P11; CAYOTA A, 1992, CLIN EXP IMMUNOL, V88, P478, DOI 10.1111/j.1365-2249.1992.tb06475.x; Chang YH, 2012, INT J OBESITY, V36, P993, DOI 10.1038/ijo.2011.168; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Chen TH, 2012, IMMUNOPHARM IMMUNOT, V34, P484, DOI 10.3109/08923973.2011.630398; Cheng YJ, 2006, ENVIRON HEALTH PERSP, V114, P507, DOI 10.1289/ehp.8550; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clark I, 2012, PHARMACOL REV, V64, P1004, DOI 10.1124/pr.112.005850; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Clarke AW, 2010, MABS-AUSTIN, V2, P539, DOI 10.4161/mabs.2.5.13081; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crabtree GR, 2009, CELL, V138, DOI 10.1016/j.cell.2009.06.026; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Craft S, 1999, ARCH GEN PSYCHIAT, V56, P1135, DOI 10.1001/archpsyc.56.12.1135; Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697; Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003; Crouch PJ, 2011, J NEUROCHEM, V119, P220, DOI 10.1111/j.1471-4159.2011.07402.x; Darsalia V, 2012, CLIN SCI, V122, P473, DOI 10.1042/CS20110374; Das K, 2011, NEURODEGENER DIS, V8, P345, DOI 10.1159/000323797; de Bont N, 1999, J LIPID RES, V40, P680; Deng GM, 2001, J IMMUNOL, V167, P4616, DOI 10.4049/jimmunol.167.8.4616; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Desplats P, 2011, J BIOL CHEM, V286, P9031, DOI 10.1074/jbc.C110.212589; Dineley KT, 2007, NEUROBIOL LEARN MEM, V88, P217, DOI 10.1016/j.nlm.2007.03.010; DONNELLY RJ, 1990, CELL MOL NEUROBIOL, V10, P485, DOI 10.1007/BF00712843; Dore GA, 2009, DIABETOLOGIA, V52, P2551, DOI 10.1007/s00125-009-1497-2; Egecioglu E, 2013, PSYCHONEUROENDOCRINO, V38, P1259, DOI 10.1016/j.psyneuen.2012.11.009; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Eslamboli A, 2007, BRAIN, V130, P799, DOI 10.1093/brain/awl382; Faux NG, 2010, J ALZHEIMERS DIS, V20, P509, DOI 10.3233/JAD-2010-1390; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Franchi L, 2009, J IMMUNOL, V183, P792, DOI 10.4049/jimmunol.0900173; Ge YW, 2002, ANN NY ACAD SCI, V973, P463, DOI 10.1111/j.1749-6632.2002.tb04684.x; Gilman CP, 2003, J NEUROCHEM, V87, P1137, DOI 10.1046/j.1471-4159.2003.02073.x; Goedert M, 1997, NATURE, V388, P232, DOI 10.1038/40767; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Greig NH, 2004, ACTA NEUROBIOL EXP, V64, P1; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Guan QD, 2009, VACCINE, V27, P7096, DOI 10.1016/j.vaccine.2009.09.058; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Guo JJU, 2011, NAT NEUROSCI, V14, P1345, DOI 10.1038/nn.2900; Guo TL, 1996, J LEUKOCYTE BIOL, V59, P932; Gupta VB, 2011, NEUROLOGY, V76, P1091, DOI 10.1212/WNL.0b013e318211c352; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Han XN, 2013, CELL STEM CELL, V12, P342, DOI 10.1016/j.stem.2012.12.015; HARDARDOTTIR I, 1994, J CLIN INVEST, V94, P1304, DOI 10.1172/JCI117449; Harms AS, 2011, MOL THER, V19, P46, DOI 10.1038/mt.2010.217; HART PH, 1991, IMMUNOLOGY, V72, P344; Hayashita-Kinoh H, 2006, BIOCHEM BIOPH RES CO, V341, P1088, DOI 10.1016/j.bbrc.2006.01.057; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Hoyer S, 1994, J Neural Transm Suppl, V44, P259; Iraola-Guzman S, 2011, CLIN GENET, V80, P1, DOI 10.1111/j.1399-0004.2011.01673.x; Jang HM, 2009, P NATL ACAD SCI USA, V106, P14063, DOI 10.1073/pnas.0900096106; Jang H, 2009, BBA-MOL BASIS DIS, V1792, P714, DOI 10.1016/j.bbadis.2008.08.001; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kaul D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037767; Kawasaki T, 2011, IMMUNOL REV, V243, P61, DOI 10.1111/j.1600-065X.2011.01048.x; Kiaei M, 2006, J NEUROSCI, V26, P2467, DOI 10.1523/JNEUROSCI.5253-05.2006; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P8180, DOI 10.1073/pnas.0402268101; Kipnis J, 2008, TRENDS IMMUNOL, V29, P455, DOI 10.1016/j.it.2008.07.007; Kipnis J, 2012, NAT REV IMMUNOL, V12, P662, DOI 10.1038/nri3280; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kivisakk P, 2003, P NATL ACAD SCI USA, V100, P8389, DOI 10.1073/pnas.1433000100; Kiyota T, 2010, FASEB J, V24, P3093, DOI 10.1096/fj.10-155317; Konoeda F, 2010, BIOCHEM BIOPH RES CO, V402, P500, DOI 10.1016/j.bbrc.2010.10.058; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Larson ME, 2012, J NEUROSCI, V32, P10253, DOI 10.1523/JNEUROSCI.0581-12.2012; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laufer BI, 2013, DIS MODEL MECH, V6, P977, DOI 10.1242/dmm.010975; Laurin D, 2009, NEUROBIOL AGING, V30, P1724, DOI 10.1016/j.neurobiolaging.2008.01.008; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Lukiw WJ, 2012, NEUROREPORT, V23, P621, DOI [10.1097/WNR.0b013e32835542b0, 10.1097/00001756-201207110-00009]; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mao X, 2013, DRUG ALCOHO IN PRESS; Margulis L, 1998, TRENDS MICROBIOL, V6, P342, DOI 10.1016/S0966-842X(98)01325-0; MARHAUG G, 1994, BAILLIERE CLIN RHEUM, V8, P553, DOI 10.1016/S0950-3579(05)80115-3; Mariappan N, 2009, FREE RADICAL BIO MED, V46, P462, DOI 10.1016/j.freeradbiomed.2008.10.049; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Mastroeni D, 2011, NEUROBIOL AGING, V32, P1161, DOI 10.1016/j.neurobiolaging.2010.08.017; Mastroeni D, 2010, NEUROBIOL AGING, V31, P2025, DOI 10.1016/j.neurobiolaging.2008.12.005; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; McGonagle D, 2007, SEMIN IMMUNOPATHOL, V29, P303, DOI 10.1007/s00281-007-0084-1; MONK M, 1987, DEVELOPMENT, V99, P371; Moravan MJ, 2011, RADIAT RES, V176, P459, DOI 10.1667/RR2587.1; Mori A, 2012, EUR J IMMUNOL, V42, P2709, DOI 10.1002/eji.201242372; Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200; O'Connor JJ, 2013, IRISH J MED SCI, V182, P157, DOI 10.1007/s11845-013-0911-4; Oka T, 2012, NATURE, V485, P251, DOI 10.1038/nature10992; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; Oliveira AMM, 2012, NAT NEUROSCI, V15, P1111, DOI 10.1038/nn.3151; Ozbay LA, 2012, BRIT J CLIN PHARMACO, V73, P536, DOI 10.1111/j.1365-2125.2011.04118.x; Pardridge William M, 2010, Bioeng Bugs, V1, P231, DOI 10.4161/bbug.1.4.12105; Park JL, 2012, ONCOL LETT, V3, P921, DOI 10.3892/ol.2012.592; Parthsarathy V, 2013, EUR J PHARMACOL, V700, P42, DOI 10.1016/j.ejphar.2012.12.012; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.immunol.5.1.429; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Pottier C, 2013, J ALZHEIMERS DIS, V35, P45, DOI 10.3233/JAD-122311; Price AR, 2013, SCIENCE, V340, DOI 10.1126/science.1234089; PURI RK, 1993, BIOCHEM BIOPH RES CO, V197, P1424, DOI 10.1006/bbrc.1993.2636; Rachmany L, 2013, AGE DORDR IN PRESS; Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572; Sarkar S, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2838; Schmidt J, 2008, BRAIN, V131, P1228, DOI 10.1093/brain/awn053; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schuitemaker A, 2009, NEUROBIOL AGING, V30, P1885, DOI 10.1016/j.neurobiolaging.2008.01.014; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Shapshak P, 2013, BIOINFORMATION, V9, P222, DOI 10.6026/97320630009222; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Shin EC, 2000, MOL CELLS, V10, P65, DOI 10.1007/s10059-000-0065-x; Shirazi RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061965; SIPE JD, 1979, J EXP MED, V150, P597, DOI 10.1084/jem.150.3.597; Sommer G, 2009, J CELL BIOCHEM, V108, P1418, DOI 10.1002/jcb.22382; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tarkowski E, 2003, J NEUROL NEUROSUR PS, V74, P1200, DOI 10.1136/jnnp.74.9.1200; Tauber SC, 2009, J NEUROPATH EXP NEUR, V68, P1116, DOI 10.1097/NEN.0b013e3181b7fde5; Thambisetty M, 2010, ARCH GEN PSYCHIAT, V67, P739, DOI 10.1001/archgenpsychiatry.2010.78; Tobinick Edward, 2006, MedGenMed, V8, P25; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Toperoff G, 2012, HUM MOL GENET, V21, P371, DOI 10.1093/hmg/ddr472; Tsai NW, 2011, CLIN CHIM ACTA, V412, P476, DOI 10.1016/j.cca.2010.11.036; Tukhovskaya EA, 2009, J NEUROSCI RES, V87, P677, DOI 10.1002/jnr.21874; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Vitek MP, 2012, NEURODEGENER DIS, V31, P359; Vom Berg J, 2012, NATURE MED; Wang CSM, 2009, J NEUROL NEUROSUR PS, V80, P562, DOI 10.1136/jnnp.2008.151654; Wang SC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002698; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; Wilson CM, 2009, INT J RADIAT ONCOL, V74, P934, DOI 10.1016/j.ijrobp.2009.02.035; WILSON VL, 1987, J BIOL CHEM, V262, P9948; Wu J, 2008, J NEUROSCI, V28, P3, DOI 10.1523/JNEUROSCI.4405-07.2008; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143; Zhang JB, 2012, INT J BIOL SCI, V8, P935, DOI 10.7150/ijbs.4499; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150; Zhao JY, 2012, DIABETES, V61, P542, DOI 10.2337/db11-1048; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100; Zuckerkandl E, 2002, GENETICA, V115, P105, DOI 10.1023/A:1016080316076; Zuniga LA, 2010, J IMMUNOL, V185, P6947, DOI 10.4049/jimmunol.1001269	182	19	21	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	OCT 1	2013	86	7					862	871		10.1016/j.bcp.2013.07.030			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	225QH	WOS:000324976900003	23939185				2021-06-18	
J	Lovell, MR; Solomon, GS				Lovell, Mark R.; Solomon, Gary S.			Neurocognitive Test Performance and Symptom Reporting in Cheerleaders with Concussions	JOURNAL OF PEDIATRICS			English	Article							SPORTS-RELATED CONCUSSION; UNITED-STATES; HIGH-SCHOOL; INJURIES; EPIDEMIOLOGY; IMPACT; SPECIFICITY; RELIABILITY; SENSITIVITY	Objective To evaluate neurocognitive test results and symptom reporting after sports-related concussion in a group of female cheerleaders. Study design Junior and senior high school female cheerleaders (n = 138) underwent preparticipation baseline testing and repeated the ImPACT (Immediate Postconcussion Assessment and Cognitive Testing) evaluation within 7 days of concussive injury (range, 0-7 days; mean, 3.9 days). Postinjury neurocognitive and symptom scores were compared with preinjury (baseline) scores. "Abnormal" test performance was determined statistically using Reliable Change Index scores and self-reported symptoms. Main outcome variables included the composite scores indices from the ImPACT test, as well as symptoms reported by participants. Preinjury baseline and postinjury test results were compared using MANOVA. Results As a group, cheerleaders with concussion evaluated within 7 days of injury performed poorly on the ImPACT test battery relative to their own baseline (F = 6.5; P = .00). In addition, 61% of the cheerleaders with concussions reported an increase in symptoms compared with baseline. The groups did not differ significantly by position on the squad (F = 0.37; P = .96). Of the group of cheerleaders who did not report increased symptoms at the time of postinjury evaluation, 37% had at least 1 abnormal ImPACT composite score result, suggesting some residual cognitive decline compared with baseline. Conclusion The diagnosis and management of concussion in cheerleaders should not consist solely of self-reported symptoms. Neurocognitive test results represent an important component of the evaluation process and may identify athletes with residual neurocognitive deficits who report being clinically asymptomatic.	[Lovell, Mark R.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Nashville, TN 37212 USA	Solomon, GS (corresponding author), 1506 Village Vanderbilt,1500 21st Ave South, Nashville, TN 37212 USA.	gary.solomon@vanderbilt.edu	Solomon, Gary/K-9011-2019				[Anonymous], 2012, PEDIATRICS, V130, P966; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Mueller FO, 2009, J ATHL TRAINING, V44, P565, DOI 10.4085/1062-6050-44.6.565; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Shields BJ, 2009, J ATHL TRAINING, V44, P586, DOI 10.4085/1062-6050-44.6.586; Shields BJ, 2009, J ATHL TRAINING, V44, P578, DOI 10.4085/1062-6050-44.6.578; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	16	19	19	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR-US	J. Pediatr.	OCT	2013	163	4					1192	+		10.1016/j.jpeds.2013.05.061			5	Pediatrics	Pediatrics	224HM	WOS:000324873700051	23941669				2021-06-18	
J	McMullan, J; Rodriquez, D; Hart, KW; Lindsey, CJ; Vonderschmidt, K; Wayne, B; Branson, R				McMullan, Jason; Rodriquez, Dario; Hart, Kimberly Ward; Lindsey, Christopher J.; Vonderschmidt, Kay; Wayne, Beth; Branson, Richard			Prevalence of Prehospital Hypoxemia and Oxygen Use in Trauma Patients	MILITARY MEDICINE			English	Article							SUPPLEMENTAL OXYGEN; HYPEROXIA	Objective: This study estimates the prevalence of injured patients requiring prehospital supplemental oxygen based on existing recommendations, and determines whether actual use exceeds those recommendations. Patients and Methods: Prehospital oxygen use and continuous peripheral oxygen saturation measurements were prospectively collected on a purposive sample of injured civilians transported to an urban level 1 trauma center by paramedics. Structured chart review determined injury characteristics and outcomes. Supplemental oxygen administration indications were hypoxemia (peripheral oxygen saturation <= 90%), hemorrhagic shock (systolic blood pressure < 100 mmHg), or paramedic suspicion of traumatic brain injury. Results: Paramedics enrolled 224/290 screened subjects. Median (range) age was 34 (18-84) years, 48.7% were nonwhite, 75.4% were male, and Injury Severity Score was 5 (1-75). Half (54.5%) were admitted; 36.2% sustained a penetrating injury. None underwent prehospital endotracheal intubation. Hypoxemia occurred in 86 (38.4%), paramedics suspected traumatic brain injury in 22 (9.8%), and 20 (8.9%) were hypotensive. Any indication for supplemental oxygen (107/224 [47.8%, 95%CI 41.3%-54.3%]) and prehospital administration of oxygen (141/224 [62.9%, 95%CI 56.2%-69.2%]) was common. Many (35/141 [24.8%]) received oxygen without indication. Conclusions: On the basis of current guidelines, less than half of adult trauma patients have an indication for prehospital supplemental oxygen, yet is frequently administered in the absence of clinical indication.	[McMullan, Jason; Hart, Kimberly Ward; Lindsey, Christopher J.; Vonderschmidt, Kay; Wayne, Beth] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH 45267 USA; [Rodriquez, Dario] 88th Med Operat Squadron, Wright Patterson AFB, OH 45433 USA; [Branson, Richard] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA	McMullan, J (corresponding author), Univ Cincinnati, Dept Emergency Med, 231 Albert Sabin Way ML0769, Cincinnati, OH 45267 USA.		McMullan, Jason/ABB-9691-2020; Branson, Richard/K-4567-2019; Branson, Richard/ABD-7229-2020	McMullan, Jason/0000-0002-7656-7447; Branson, Richard/0000-0002-0912-3360; Lindsell, Christopher/0000-0002-3297-2811	U. S. Marine Corps System Command; U. S. Naval Medical Systems; Institutional Clinical and Translational Science Award, NIH/NCRR [5UL1RR026314-03]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314] Funding Source: NIH RePORTER	This study was funded by the U. S. Marine Corps System Command and U. S. Naval Medical Systems and supported in part by an Institutional Clinical and Translational Science Award, NIH/NCRR Grant Number 5UL1RR026314-03.	Adams RJ, 2004, CIRCULATION, V110, P2512, DOI 10.1161/01.CIR.0000134791.68010.FA; Austin MA, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5462; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Branson RD, 2011, INTENS CARE MED, V37, P1, DOI 10.1007/s00134-010-2034-y; Cornet AD, 2012, ARCH INTERN MED, V172, P289, DOI 10.1001/archinternmed.2011.624; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Hale KE, 2008, EMERG MED J, V25, P773, DOI 10.1136/emj.2008.059287; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; *NAT ASS EM MED TE, 2007, PHTLS PREH TRAUM LIF; O'Driscoll BR, 2011, CLIN MED, V11, P372, DOI 10.7861/clinmedicine.11-4-372; Pancioli AM, 2002, ARCH INTERN MED, V162, P49, DOI 10.1001/archinte.162.1.49; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Rubinson L, 2008, CHEST, V133, p32S, DOI 10.1378/chest.07-2691; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Stockinger ZT, 2004, MIL MED, V169, P609, DOI 10.7205/MILMED.169.8.609; Wijesinghe M, 2011, INTERN MED J, V41, P618, DOI 10.1111/j.1445-5994.2010.02207.x	19	19	20	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2013	178	10					1121	1125		10.7205/MILMED-D-13-00126			5	Medicine, General & Internal	General & Internal Medicine	AN7UD	WOS:000340805600013	24083926	Green Accepted, Bronze			2021-06-18	
J	Nakase-Richardson, R; Tran, J; Cifu, D; Barnett, SD; Horn, LJ; Greenwald, BD; Brunner, RC; Whyte, J; Hammond, FM; Yablon, SA; Giacino, JT				Nakase-Richardson, Risa; Tran, Johanna; Cifu, David; Barnett, Scott D.; Horn, Lawrence J.; Greenwald, Brian D.; Brunner, Robert C.; Whyte, John; Hammond, Flora M.; Yablon, Stuart A.; Giacino, Joseph T.			Do Rehospitalization Rates Differ Among Injury Severity Levels in the NIDRR Traumatic Brain Injury Model Systems Program?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Consciousness disorders; Rehabilitation; Traumatic brain injuries	PERSISTENT VEGETATIVE STATE; EARLY INTENSIVE NEUROREHABILITATION; PROLONGED UNCONSCIOUS STATE; POSTTRAUMATIC SEIZURES; MULTICENTER ANALYSIS; YOUNG-ADULTS; CHILDREN; TBI	Objective: To compare the rate and nature of rehospitalization in a cohort of patients enrolled in the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems (TBIMS) who have disorders of consciousness (DOC) at the time of rehabilitation admission with those in persons with moderate or severe traumatic brain injury (TBI) but without DOC at rehabilitation admission. Design: Prospective observational study. Setting: Inpatient rehabilitation within TBIMS with annual follow-up. Participants: Of 9028 persons enrolled from 1988 to 2009 (N=9028), 366 from 20 centers met criteria for DOC at rehabilitation admission and follow-up data, and another 5132 individuals met criteria for moderate (n=769) or severe TBI (n=4363). Interventions: Not applicable. Main Outcome Measures: Participants and/or their family members completed follow-up data collection including questions about frequency and nature of rehospitalizations at 1 year postinjury. For the subset of participants with DOC, additional follow-up was conducted at 2 and 5 years postinjury. Results: The DOC group demonstrated an overall 2-fold increase in rehospitalization in the first year postinjury relative to those with moderate or severe TBI without DOC. Persons with DOC at rehabilitation admission have a higher rate of rehospitalization across several categories than persons with moderate or severe TBI. Conclusions: Although the specific details of rehospitalization are unknown, greater injury severity resulting in DOC status on rehabilitation admission has long-term implications. Data highlight the need for a longitudinal approach to patient management. (c) 2013 by the American Congress of Rehabilitation Medicine	[Nakase-Richardson, Risa] James A Haley Vet Hosp, Div MHBS, Tampa, FL 33612 USA; [Tran, Johanna; Barnett, Scott D.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Nakase-Richardson, Risa; Barnett, Scott D.] Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Tran, Johanna] Univ S Florida, Dept Med, Tampa, FL USA; [Cifu, David] Hunter Holmes McGuire VA Hosp, Div PMRS, Richmond, VA USA; [Cifu, David] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Horn, Lawrence J.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; [Greenwald, Brian D.; Giacino, Joseph T.] Robert Wood Johnson Med Sch, JFK Johnson Rehabil Inst, Ctr Head Injuries, Edison, NJ USA; [Greenwald, Brian D.] Robert Wood Johnson Med Sch, Dept Phys Med & Rehabil, Edison, NJ USA; [Brunner, Robert C.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Yablon, Stuart A.] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Yablon, Stuart A.] Univ Alberta, Div Phys Med & Rehabil, Edmonton, AB, Canada; [Giacino, Joseph T.] Spaulding Rehabil Hosp, Dept Rehabil Neuropsychololgy, Boston, MA USA	Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd 116-B, Tampa, FL 33612 USA.	Risa.Richardson@va.gov	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Cifu, David/0000-0003-1600-9387; Whyte, John/0000-0002-4381-1474; Tran, Johanna/0000-0001-6231-5620	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A060038, H133A070036, H133A-080044, H133A070083, H133A070039, H133A070040, H133A070042, H133A070027, H133A120085]; Health Services Research and Development/Rehabilitation Research and Development Center of Excellence for Maximizing Rehabilitation Outcomes [COE - HFP 09-156]	Supported by the National Institute on Disability and Rehabilitation Research, United States Department of Education (grant nos. H133A060038 [TBI Model System National Data and Statistical Center], H133A070036 [Virginia Commonwealth TBI Model System], H133A-080044 [Southeastern Michigan TBI System], H133A070083 [Mount Sinai School of Medicine], H133A070039 [University of Alabama TBIMS], H133A070040 [Moss TBI Model System], H133A070042 [Carolinas Traumatic Brain Injury Rehabilitation and Research System], H133A070027 [North Texas TBI Model System], H133A120085 [Spaulding-Harvard TBI Model System]). The contents of the article do not necessarily represent the policy of the Department of Education, and endorsement by the Federal Govemment should not be assumed. Statistical support provided by the Health Services Research and Development/Rehabilitation Research and Development Center of Excellence for Maximizing Rehabilitation Outcomes (grant no. COE - HFP 09-156).	BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Eilander HJ, 2007, BRAIN INJURY, V21, P53, DOI 10.1080/02699050601151795; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FIELDS AI, 1993, CRIT CARE MED, V21, P1890, DOI 10.1097/00003246-199312000-00016; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Griffin GD, 2011, MIL MED, V176, P364, DOI 10.7205/MILMED-D-10-00021; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	20	19	19	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1884	1890		10.1016/j.apmr.2012.11.054			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100006	23770278				2021-06-18	
J	Nyberg, J; Aberg, MAI; Toren, K; Nilsson, M; Ben-Menachem, E; Kuhn, HG				Nyberg, Jenny; Aberg, Maria A. I.; Toren, Kjell; Nilsson, Michael; Ben-Menachem, Elinor; Kuhn, H. Georg			Cardiovascular fitness and later risk of epilepsy A Swedish population-based cohort study	NEUROLOGY			English	Article							PHYSICAL-EXERCISE; KINDLING DEVELOPMENT; ADULTHOOD; CHILDHOOD; HEALTH; RATS; SUSCEPTIBILITY; ADOLESCENCE; COMORBIDITY; DEPRESSION	Objective: To analyze the associations between cardiovascular fitness at age 18 years and future risk of epilepsy. Methods: Population-based cohort study of Swedish male conscripts (n = 1,173,079) born in 1950-1987, who were followed for up to 40 years. Data on cardiovascular fitness were collected during conscription exams and linked with hospital registers to calculate later risk of epilepsy using Cox proportional hazard models controlling for several confounders, including familial factors. Results: Epilepsy was recorded in 6,796 individuals during the follow-up time. In fully adjusted models, low and medium cardiovascular fitness (compared with high) at age 18 years was associated with increased risk of future epilepsy (hazard ratio 1.79, 95% confidence interval 1.57-2.03; and hazard ratio 1.36, 95% confidence interval 1.27-1.45, respectively). The associations changed only marginally after adjustment for familial influences and prior severe traumatic brain injury, cerebrovascular disease, or diabetes. Conclusions: Low cardiovascular fitness early in life is associated with an increased risk of epilepsy later in adulthood. These results agree with previous results from animal models. We propose that behaviors that increase cardiovascular fitness may act as positive disease-modifiers for the development of epilepsy.	[Nyberg, Jenny; Aberg, Maria A. I.; Nilsson, Michael; Ben-Menachem, Elinor; Kuhn, H. Georg] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil, Gothenburg, Sweden; [Toren, Kjell] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Gothenburg, Sweden; [Nilsson, Michael] Univ Newcastle, Hunter Med Res Inst, Callaghan, NSW 2308, Australia	Ben-Menachem, E (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil, Gothenburg, Sweden.	Elinor.Ben-Menachem@neuro.gu.se	Aberg, Maria/R-4001-2016; NILSSON, MICHAEL/ABE-7821-2020; Kuhn, Hans-Georg/L-8127-2014	NILSSON, MICHAEL/0000-0002-8826-1621; Kuhn, Hans-Georg/0000-0003-4247-5613; Aberg, Maria/0000-0002-0323-1061	Martha Lundqvists Stiftelse; Wilhelm and Martina Lundgrens Stiftelse; Sten A Olsson Foundation for Research and Culture; Swedish Research Council for Worklife and Social Science (FAS); Swedish government under LUA/ALF; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission	Supported by grants from the Martha Lundqvists Stiftelse, Wilhelm and Martina Lundgrens Stiftelse, Sten A Olsson Foundation for Research and Culture, the Swedish Research Council for Worklife and Social Science (FAS), the Swedish government under the LUA/ALF agreement for biomedical research, and the Swedish Medical Research Council.	Aberg MAI, 2012, BRIT J PSYCHIAT, V201, P352, DOI 10.1192/bjp.bp.111.103416; Aberg MAI, 2009, P NATL ACAD SCI USA, V106, P20906, DOI 10.1073/pnas.0905307106; [Anonymous], 1997, GUID TREATM EP; Arida RM, 2007, PHYSIOL BEHAV, V90, P629, DOI 10.1016/j.physbeh.2006.11.016; Arida RM, 2009, NEUROSCI BIOBEHAV R, V33, P422, DOI 10.1016/j.neubiorev.2008.11.002; Arida RM, 1998, EPILEPSY RES, V30, P127, DOI 10.1016/S0920-1211(97)00102-2; Arida RM, 1999, EPILEPSY RES, V37, P45, DOI 10.1016/S0920-1211(99)00032-7; Ben-Menachem E, 2011, LAKEMEDELSBOKEN 2011; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; da Silva SG, 2011, INT J DEV NEUROSCI, V29, P861, DOI 10.1016/j.ijdevneu.2011.07.011; Daniels ZS, 2009, NEUROLOGY, V73, P658, DOI 10.1212/WNL.0b013e3181ab2b11; ERIKSEN HR, 1994, EPILEPSIA, V35, P1256, DOI 10.1111/j.1528-1157.1994.tb01797.x; Forsgren L, 2005, EUR J NEUROL, V12, P245, DOI 10.1111/j.1468-1331.2004.00992.x; FORSGREN L, 1992, EPILEPSIA, V33, P450, DOI 10.1111/j.1528-1157.1992.tb01690.x; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Kanner AM, 2012, EPILEPSY BEHAV, V24, P156, DOI 10.1016/j.yebeh.2012.01.007; Li XJ, 2008, SEIZURE-EUR J EPILEP, V17, P254, DOI 10.1016/j.seizure.2007.07.011; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Malina RM, 2001, AM J HUM BIOL, V13, P162, DOI 10.1002/1520-6300(200102/03)13:2<162::AID-AJHB1025>3.3.CO;2-K; McAuley JW, 2001, EPILEPSY BEHAV, V2, P592, DOI 10.1006/ebeh.2001.0271; McMurray RG, 2003, MED SCI SPORT EXER, V35, P1914, DOI 10.1249/01.MSS.0000093612.59984.0E; Nakken KO, 1999, EPILEPSIA, V40, P643, DOI 10.1111/j.1528-1157.1999.tb05568.x; Ni H, 2009, TOXICOL LETT, V191, P26, DOI 10.1016/j.toxlet.2009.07.028; Nithianantharajah J, 2009, PROG NEUROBIOL, V89, P369, DOI 10.1016/j.pneurobio.2009.10.001; Nordesjo L, 1974, SWEDISH J DEFENCE ME, P11; Ortega FB, 2008, INT J OBESITY, V32, P1, DOI 10.1038/sj.ijo.0803774; Schober E, 2012, J PEDIAT, V160; Setkowicz Z, 2006, EPILEPSY RES, V71, P142, DOI 10.1016/j.eplepsyres.2006.06.002; Souza MA, 2009, EPILEPSIA, V50, P811, DOI 10.1111/j.1528-1167.2008.01908.x; St Germaine-Smith C, 2011, EPILEPSIA, V52, P2161, DOI 10.1111/j.1528-1167.2011.03292.x; Tutkun E, 2010, ACTA NEUROBIOL EXP, V70, P382; van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351; WHO World Health Organization, 1978, INT STAT CLASS DIS R; World Health Organization, 1992, ICD 10 CLASS MENT BE; World Health Organization, 1967, INTS STAT CLASS DIS	37	19	20	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 17	2013	81	12					1051	1057		10.1212/WNL.0b013e3182a4a4c0			7	Clinical Neurology	Neurosciences & Neurology	AA0EK	WOS:000330767900009	24005340				2021-06-18	
J	Cartagena, CM; Phillips, KL; Williams, GL; Konopko, M; Tortella, FC; Dave, JR; Schmid, KE				Cartagena, Casandra M.; Phillips, Katie L.; Williams, Garry L.; Konopko, Melissa; Tortella, Frank C.; Dave, Jitendra R.; Schmid, Kara E.			Mechanism of Action for NNZ-2566 Anti-inflammatory Effects Following PBBI Involves Upregulation of Immunomodulator ATF3	NEUROMOLECULAR MEDICINE			English	Article						NNZ-2566; Penetrating ballistic-like brain injury; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; NATURAL-KILLER-CELLS; GLY-PRO-GLU; RAT MODEL; IN-VIVO; GLYPROMATE ANALOG; NERVOUS-SYSTEM; EXPRESSION; ASTROCYTES; ENCEPHALOMYELITIS	The tripeptide glycine-proline-glutamate analogue NNZ-2566 (Neuren Pharmaceuticals) demonstrates neuroprotective efficacy in models of traumatic brain injury. In penetrating ballistic-like brain injury (PBBI), it significantly decreases injury-induced upregulation of inflammatory cytokines including TNF-alpha, IFN-gamma, and IL-6. However, the mechanism by which NNZ-2566 acts has yet to be determined. The activating transcription factor-3 (ATF3) is known to repress expression of these inflammatory cytokines and was increased at the mRNA and protein level 24-h post-PBBI. This study investigated whether 12 h of NNZ-2566 treatment following PBBI alters atf3 expression. PBBI alone significantly increased atf3 mRNA levels by 13-fold at 12 h and these levels were increased by an additional fourfold with NNZ-2566 treatment. To confirm that changes in mRNA translated to changes in protein expression, ATF3 expression levels were determined in vivo in microglia/macrophages, T cells, natural killer cells (NKCs), astrocytes, and neurons. PBBI alone significantly increased ATF3 in microglia/macrophages (820 %), NKCs (58 %), and astrocytes (51 %), but decreased levels in T cells (48 %). NNZ-2566 treatment further increased ATF3 protein expression in microglia/macrophages (102 %), NKCs (308 %), and astrocytes (13 %), while reversing ATF3 decreases in T cells. Finally, PBBI increased ATF3 levels by 55 % in neurons and NNZ-2566 treatment further increased these levels an additional 33 %. Since increased ATF3 may be an innate protective mechanism to limit inflammation following injury, these results demonstrating that the anti-inflammatory and neuroprotective drug NNZ-2566 increase both mRNA and protein levels of ATF3 in multiple cell types provide a cellular mechanism for NNZ-2566 modulation of neuroinflammation following PBBI.	[Cartagena, Casandra M.; Phillips, Katie L.; Williams, Garry L.; Konopko, Melissa; Tortella, Frank C.; Dave, Jitendra R.; Schmid, Kara E.] Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA	Cartagena, CM (corresponding author), Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	casandra.cartagena@us.army.mil; katie.phillips1@us.army.mil; garryleejr@hotmail.com; melissa.konopko@gmail.com; frank.c.tortella@us.army.mil; jitendra.ramanlal.dave@us.army.mil; kara.schmid@us.army.mil	Dave, Jitendra R/A-8940-2011	Konopko, Melissa/0000-0001-9515-398X	Neuren Pharmaceuticals Ltd. [W81XWH-05-0074]	We would like to thank Matthew Bombard and Weihong Yang for their excellent assistance with surgical procedures. These studies were supported in part by a cooperative research and development agreement with Neuren Pharmaceuticals Ltd. (W81XWH-05-0074). This material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official, or reflecting true views of the Department of the Army or the Department of Defense.	Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Bickerdike MJ, 2009, J NEUROL SCI, V278, P85, DOI 10.1016/j.jns.2008.12.003; Bienvenu TCM, 2012, NEURON, V74, P1059, DOI 10.1016/j.neuron.2012.04.022; Byram SC, 2003, BRAIN BEHAV IMMUN, V17, P417, DOI 10.1016/S0889-1591(03)00089-8; Cartagena CM, 2008, J NEUROTRAUM, V25, P1087, DOI 10.1089/neu.2007.0444; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Francis JS, 2004, MOL BRAIN RES, V124, P199, DOI 10.1016/j.molbrainres.2003.10.027; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Litvak V, 2009, NAT IMMUNOL, V10, P437, DOI 10.1038/ni.1721; Lu XCM, 2009, J CEREBR BLOOD F MET, V29, P1924, DOI 10.1038/jcbfm.2009.109; Lu XCM, 2011, J NEUROTRAUM, V28, P71, DOI 10.1089/neu.2010.1471; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Massi L, 2012, J NEUROSCI, V32, P16496, DOI 10.1523/JNEUROSCI.3475-12.2012; Matsumoto Y, 1998, EUR J IMMUNOL, V28, P1681, DOI 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Perussia Bice, 1996, Methods (Orlando), V9, P370, DOI 10.1006/meth.1996.0042; Raivich G, 1998, J NEUROSCI, V18, P5804; Rosenberger CM, 2008, P NATL ACAD SCI USA, V105, P2544, DOI 10.1073/pnas.0712182105; Saura J, 1999, NEUROREPORT, V10, P161, DOI 10.1097/00001756-199901180-00031; Schousboe A, 2005, NEUROTOX RES, V8, P221, DOI 10.1007/BF03033975; Schroeter M, 2005, NEUROMOL MED, V7, P183, DOI 10.1385/NMM:7:3:183; Seijffers R, 2006, MOL CELL NEUROSCI, V32, P143, DOI 10.1016/j.mcn.2006.03.005; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; Stow JL, 2009, IMMUNOBIOLOGY, V214, P601, DOI 10.1016/j.imbio.2008.11.005; Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Vianney-Rodrigues P, 2011, EUR J NEUROSCI, V33, P119, DOI 10.1111/j.1460-9568.2010.07487.x; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Whitmore MM, 2007, J IMMUNOL, V179, P3622, DOI 10.4049/jimmunol.179.6.3622; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhang SJ, 2011, J NEUROSCI, V31, P4978, DOI 10.1523/JNEUROSCI.2672-10.2011	43	19	19	0	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1535-1084			NEUROMOL MED	Neuromol. Med.	SEP	2013	15	3					504	514		10.1007/s12017-013-8236-z			11	Neurosciences	Neurosciences & Neurology	195RW	WOS:000322722300006	23765588				2021-06-18	
J	Kouloulas, EJ; Papadeas, AG; Michail, X; Sakas, DE; Boviatsis, EJ				Kouloulas, Efthimios J.; Papadeas, Alexandros G.; Michail, Xanthi; Sakas, Damianos E.; Boviatsis, Efstathios J.			Prognostic value of time-related Glasgow Coma Scale components in severe traumatic brain injury: a prospective evaluation with respect to 1-year survival and functional outcome	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						brain injury; functional independence measure; functional outcome; Glasgow Coma Scale; rehabilitation; survival	INTERNATIONAL CLASSIFICATION; HEAD-INJURY; DISABILITY; LINKING; HEALTH	The severity of traumatic brain injury (TBI) is determined by many variables, the complexity of which has made prediction of functional outcome an elusive target. To evaluate whether the three components of the Glasgow Coma Scale (GCS) and their alterations over time can serve as predictors of functional outcome after a severe TBI at 12 months after the TBI insult, we carried out a prospective study of patients with severe TBI. Seventy patients were initially enrolled. Data were retrieved from the emergency department records and the patients' intensive care unit, neurosurgical, and rehabilitation unit records. All patients underwent follow-up at 3, 6, and 12 months after injury. GCS components were evaluated on the day of injury and 2 weeks after injury. Functional outcome was estimated using the Glasgow Outcome Scale and the Functional Independence Measure motor scale. It was evaluated during rehabilitation and at 12 months after injury. Fifty-one patients were alive and followed up until 12 months. Logistic regression and receiver-operator characteristic curve analyses were carried out. In terms of functional outcome at 12 months, only GCS on day 15 was found to be a prognostic factor, with all its subscales being related to outcome 12 months later, whereas a higher GCS score on day 15 was also related to survival. A higher motor and verbal response on day 15 was strongly associated with a patient's functional independence, whereby the motor response was a better predictor. The GCS motor score 2 weeks after injury was statistically significantly associated with the 12-month functional outcome in TBI survivors. Motor response was the most useful predictor among the GCS components with respect to the long-term functional outcome in patients with severe TBI. (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	[Kouloulas, Efthimios J.; Boviatsis, Efstathios J.] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Neurosurg 2, GR-11527 Athens, Greece; [Papadeas, Alexandros G.] Univ Athens, Sch Med, Epiphany Phys Med & Rehabil Unit, GR-11527 Athens, Greece; [Michail, Xanthi] Univ Athens, Sch Med, Technol Educ Inst Athens, Dept Phys Therapy, GR-11527 Athens, Greece; [Sakas, Damianos E.] Univ Athens, Sch Med, Evangelismos Gen Hosp, Dept Neurosurg 1, GR-11527 Athens, Greece; [Kouloulas, Efthimios J.] Apolloneio Phys Med & Rehabil Ctr, Larisa, Greece	Kouloulas, EJ (corresponding author), 15th,23rd October St, Larisa 21221, Greece.	kouloulas@yahoo.com					Boake C, 2000, PHYS MED REHABILITAT, P1073; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Choi SC, 1996, NEUROTRAUMA, P593; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Hall K, 1977, J REHABIL OUTCOMES M, V1, P63; Hanscom DA, 1987, J HEAD TRAUMA REHAB, V2, P1; Harrell Frank E., 2001, REGRESSION MODELING; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Katz DI, 1998, PROGNOSIS NEUROLOGY, P31; Koskinen S, 2009, INT J REHABIL RES, V32, pS47, DOI 10.1097/00004356-200908001-00064; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MALKMUS D, 1983, PHYS THER, V63, P1952, DOI 10.1093/ptj/63.12.1952; Marion D, 1999, TRAUMATIC BRAIN INJU, P119; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ptyushkin P, 2012, AM J PHYS MED REHAB, V91, pS48, DOI 10.1097/PHM.0b013e31823d4e99; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; Stineman MG, 1997, ARCH PHYS MED REHAB, V78, P636, DOI 10.1016/S0003-9993(97)90430-5; TEASDALE G, 1974, LANCET, V2, P81; Timmons M, 1987, J HEAD TRAUMA REHAB, V2, P64; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	33	19	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0342-5282	1473-5660		INT J REHABIL RES	Int. J. Rehabil. Res.	SEP	2013	36	3					260	267		10.1097/MRR.0b013e32835fd99a			8	Rehabilitation	Rehabilitation	202LZ	WOS:000323219400010	23470551				2021-06-18	
J	McLaughlin, KA; Glang, A; Beaver, SV; Gau, JM; Keen, S				McLaughlin, Karen A.; Glang, Ann; Beaver, Sherry Vondy; Gau, Jeff M.; Keen, Stacie			Web-Based Training in Family Advocacy	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adults; advocacy; caregiver; interactive; online; randomized trial; training; traumatic brain injury; Web-based	TRAUMATIC BRAIN-INJURY; INTERACTIVE MULTIMEDIA; INTERVENTION; REHABILITATION; SATISFACTION; INDIVIDUALS; PREDICTORS; DISTRESS; PROGRAM; SYSTEM	Objective: To examine the efficacy of an interactive multimedia intervention that teaches advocacy skills to people caring for a family member with traumatic brain injury. Participants: A total of 201 individuals (control, n = 97; treatment, n = 104) providing support to a family member with traumatic brain injury. Design: Randomized controlled study. Main Measures: Caregiver knowledge, skill application, behavioral intention, and overall life satisfaction. Intervention: The Brain Injury Partners program, a Web site focused on advocacy, communication skills, and resources for families affected by brain injury. Results: Univariate analyses revealed that compared with the control group, the Brain Injury Partners group reported statistically significant higher adjusted means for application, knowledge, and attitudes scales immediately postintervention and at follow-up. Satisfaction with life, assessed at follow-up but not posttest, was not significant. Discussion: This study demonstrated the effectiveness of a Web-based intervention to teach effective skills to caregivers advocating for a family member with traumatic brain injury.	[McLaughlin, Karen A.] Univ Oregon, Coll Educ, Eugene, OR 97403 USA; [Glang, Ann; Beaver, Sherry Vondy; Keen, Stacie] Oregon Ctr Appl Sci, Eugene, OR USA; [Gau, Jeff M.] Oregon Res Inst, Eugene, OR 97403 USA	McLaughlin, KA (corresponding author), Univ Oregon, Coll Educ, Eugene, OR 97403 USA.	kdurany@uoregon.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD46257]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD046257, R44HD046257] Funding Source: NIH RePORTER	This project was completed with funding from the National Institute of Child Health and Human Development (grant HD46257). The authors thank Donald Hood, John Seeley, PhD, and Carol Dennis, for their contributions to the program and evaluation, and McKay Moore Sohlberg, PhD, and Bonnie Todis, PhD, for their invaluable comments on revisions of this article.	AJZEN I, 1977, PSYCHOL BULL, V84, P888, DOI 10.1037/0033-2909.84.5.888; Albin R.W., 1996, POSITIVE BEHAV SUPPO, P81; Boschen K, 2007, NEUROREHABILITATION, V22, P19; DeNavas-Walt C, 2010, US CENSUS BUREAU CUR; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Glang A, 2007, J HEAD TRAUMA REHAB, V22, P198, DOI 10.1097/01.HTR.0000271121.42523.3a; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Hood D, 2001, FAMILY ADVOCACY SKIL; Hood DR, 1999, C TRAUM BRAIN INJ 21; Horwitz R. C., 1998, FAMILIES SYSTEMS HLT, V16, P71; Irvine AB, 2003, J APPL GERONTOL, V22, P269, DOI 10.1177/0733464803022002006; Kaminski JW, 2008, J ABNORM CHILD PSYCH, V36, P567, DOI 10.1007/s10802-007-9201-9; Kosciulek J.F., 1998, J APPL REHABILITATIO, V29, P8; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; LICHSTEIN KL, 1994, ADV BEHAV RES THER, V16, P1, DOI 10.1016/0146-6402(94)90001-9; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199504000-00003; Malik-Hoegh S., 1994, BRAIN INJURY REHABIL, P393; Man D, 1999, BRAIN INJURY, V13, P433, DOI 10.1080/026990599121485; McLaughlin KA, 2006, J MED SPEECH-LANG PA, V14, pXI; NORM, 1999, MULT IMP INC DAT NOR; Pew Research Center's Internet and American Life Project, HOM BROADB AD 2009; Relyea-Chew A, 2009, ARCH PHYS MED REHAB, V90, P413, DOI 10.1016/j.apmr.2008.07.031; Rempel RG., 1994, BRAIN INJURY REHABIL, P376; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Smith J E, 2000, Care Manag J, V2, P27; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2001, J HEAD TRAUMA REHAB, V16, P498, DOI 10.1097/00001199-200110000-00008; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wills J., 1996, REDEFINING FAMILY SU, P225; Ylvisaker M., 1998, COLLABORATIVE BRAIN	40	19	19	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2013	28	5					341	348		10.1097/HTR.0b013e31824e1d43			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZU	WOS:000330364600080	22688211	Green Accepted			2021-06-18	
J	Peterson, RL; Kirkwood, MW; Taylor, HG; Stancin, T; Brown, TM; Wade, SL				Peterson, Robin L.; Kirkwood, Michael W.; Taylor, H. Gerry; Stancin, Terry; Brown, Tanya M.; Wade, Shari L.			Adolescents' Internalizing Problems Following Traumatic Brain Injury Are Related to Parents' Psychiatric Symptoms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety; closed head injury; depression; neurobehavioral outcomes; pediatrics	CLOSED-HEAD-INJURY; FAMILY ASSESSMENT DEVICE; NEUROBEHAVIORAL SYMPTOMS; ANXIETY DISORDERS; BEHAVIOR PROBLEMS; CHILDREN; VALIDITY; PREVALENCE; OUTCOMES; SYMPTOMATOLOGY	Background: A small body of previous research has demonstrated that pediatric traumatic brain injury (TBI) increases risk for internalizing problems, but findings have varied regarding their predictors and correlates. Methods: We examined the level and correlates of internalizing symptoms in 130 teens who had sustained a complicated mild to severe TBI within the past 1 to 6 months. Internalizing problems were measured via both maternal-and paternal-report Child Behavior Checklist. We also measured family functioning, parent psychiatric symptoms, and postinjury teen neurocognitive function. Results: Mean parental ratings of internalizing problems were within the normal range. Depending on informant, 22% to 26% of the sample demonstrated clinically elevated internalizing problems. In multiple and binary logistic regression models, only parent psychiatric symptoms consistently provided unique prediction of teen internalizing symptoms. For maternal but not paternal report, female gender was associated with greater internalizing problems. Conclusion: Parent and teen emotional problems are associated following adolescent TBI. Possible reasons for this relationship, including the effects of TBI on the family unit, are discussed.	[Peterson, Robin L.] Univ Denver, Dept Psychol, Denver, CO 80208 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado Denver, Sch Med, Aurora, CO USA; [Taylor, H. Gerry] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Cleveland, OH 44109 USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Brown, Tanya M.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Peterson, RL (corresponding author), Univ Denver, Dept Psychol, 2155 South Race St, Denver, CO 80208 USA.	robin.peterson@du.edu	Stancin, Terry/L-7993-2019		NIH from the National Institute of Mental Health [R01-MH073764]; Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER	This work was supported in part by (1) NIH grant R01-MH073764 from the National Institute of Mental Health and (2) a grant from the Colorado Traumatic Brain Injury Trust Fund Research Program, Colorado Department of Human Services, Division of Vocational Rehabilitation, Traumatic Brain Injury Program.	ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; ANGOLD A, 1992, DEV PSYCHOPATHOL, V4, P5, DOI 10.1017/S0954579400005538; [Anonymous], 1999, WECHSL ABR SCAL INT; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Delis D.C., 1994, CVLT C CALIFORNIA VE; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Duhig AM, 2000, CLIN PSYCHOL-SCI PR, V7, P435, DOI 10.1093/clipsy/7.4.435; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Green ML, 1998, J PEDIATR PSYCHOL, V23, P289, DOI 10.1093/jpepsy/23.5.289; Hammen Constance, 1996, P153; Hayman-Abello SE, 2003, J INT NEUROPSYCH SOC, V9, P887, DOI 10.1017/S1355617703960097; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Maruish M.E., 1994, USE PSYCHOL TESTING, P217; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; Noggle CA, 2010, APPL NEUROPSYCHOL, V17, P110, DOI 10.1080/09084281003708977; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Psychological Corporation, 2003, WECHSLER INTELLIGENC; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RICHTERS JE, 1992, PSYCHOL BULL, V112, P485, DOI 10.1037/0033-2909.112.3.485; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; The Psychological Corporation, 2008, WECHSLER ADULT INTEL; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wassenberg R, 2004, BRAIN INJURY, V18, P377, DOI 10.1080/02699050310001617325; Yeates K. O., 2010, PEDIAT NEUROPSYCHOLO, P112; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	52	19	19	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2013	28	5					E1	E12		10.1097/HTR.0b013e318263f5ba			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZU	WOS:000330364600001	22935574	Green Accepted			2021-06-18	
J	Roe, C; Skandsen, T; Anke, A; Ader, T; Vik, A; Lund, SB; Manskow, U; Sollid, S; Sundstrom, T; Hestnes, M; Andelic, N				Roe, Cecilie; Skandsen, Toril; Anke, Audny; Ader, Tiina; Vik, Anne; Lund, Stine Borgen; Manskow, Unn; Sollid, Snorre; Sundstrom, Terje; Hestnes, Morten; Andelic, Nada			SEVERE TRAUMATIC BRAIN INJURY IN NORWAY: IMPACT OF AGE ON OUTCOME	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; aged; treatment; outcome; prognosis	HEAD-INJURY; EPIDEMIOLOGY; MORTALITY; SCALE; HEMATOMA; MODERATE	Objective: The aim of this study was to investigate the influence of age on mortality and 3-month outcome in a Norwegian cohort of patients with severe traumatic brain injury. Methods: Norwegian residents >= 16 years of age who were admitted with a severe traumatic brain injury to the country's 4 major trauma centres in 2009 and 2010 were included, as were adults (16-64 years) and elderly patients (>= 65 years). Results: Half of the adult subjects and 84% of the elderly subjects were injured by falls. One-third of the adults and half of the elderly subjects were admitted to a local hospital before being transported to a regional trauma hospital. Subdural haematomas were more frequent in the elderly subjects. One-quarter of adults and two-thirds of the elderly subjects died within 3 months. At 3 months, 41% of the adult survivors were still in-patients, mainly in rehabilitation units (92%). Of the surviving elderly subjects, 14% were in-patients and none were in rehabilitation units. There was no difference in functional level for survivors at the 3-month follow-up. Conclusion: Old age is associated with fall-induced severe traumatic brain injury and high mortality rates. Less intensive treatment strategies were applied to elderly patients in the present study despite high rates of haemorrhage. Few surviving elderly patients received rehabilitation at 3 months post-injury.	[Roe, Cecilie; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, Trondheim, Norway; [Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Vik, Anne; Lund, Stine Borgen] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Anke, Audny; Manskow, Unn] Univ Hosp North Norway, Dept Rehabil, Tromso, Norway; [Anke, Audny; Manskow, Unn] Univ Tromso, Inst Clin Med, Fac Hlth Sci, Tromso, Norway; [Sollid, Snorre] Univ Hosp North Norway, Dept Neurosurg, Tromso, Norway; [Sundstrom, Terje] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; [Sundstrom, Terje] Univ Bergen, Dept Biomed, Bergen, Norway; [Sundstrom, Terje] Univ Bergen, Dept Surg Sci, Bergen, Norway; [Ader, Tiina] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Hestnes, Morten] Oslo Univ Hosp, Trauma Registry, Oslo, Norway	Roe, C (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway.	e.c.t.roe@medisin.uio.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Sundstrom, Terje/0000-0002-6503-7141; Andelic, Nada/0000-0002-3719-4406; Anke, Audny/0000-0002-2491-2560			Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Czosnyka M, 2005, ACT NEUR S, V95, P341; Depreitere B, 2012, Acta Neurochir Suppl, V114, P289, DOI 10.1007/978-3-7091-0956-4_56; Gerber Linda M, 2009, J Trauma Manag Outcomes, V3, P9, DOI 10.1186/1752-2897-3-9; Gillespie LD., 2003, Cochrane Database Syst Rev, V4, DOI DOI 10.1002/14651858.CD007146.PUB2; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Joosse P, 2012, J TRAUMA ACUTE CARE, V72, P487, DOI 10.1097/TA.0b013e318226ed59; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Magnussen J, 2007, SOC SCI MED, V64, P2129, DOI 10.1016/j.socscimed.2007.02.018; Majdan M, 2011, BRAIN INJURY, V25, P797, DOI 10.3109/02699052.2011.581642; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Protheroe RT, 2011, ANAESTHESIA, V66, P1035, DOI 10.1111/j.1365-2044.2011.06874.x; Sollid Snorre, 2008, Tidsskr Nor Laegeforen, V128, P1524; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Thompson HJ, 2012, RES GERONTOL NURS, V5, P17, DOI 10.3928/19404921-20111206-02; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2007, WHO GLOB REP FALLS P	40	19	19	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					734	740		10.2340/16501977-1198			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500007	24002308	DOAJ Gold, Green Published			2021-06-18	
J	Rosario, ER; Aqeel, R; Brown, MA; Sanchez, G; Moore, C; Patterson, D				Rosario, Emily R.; Aqeel, Rubina; Brown, Meghan A.; Sanchez, Gabriel; Moore, Colleen; Patterson, David			Hypothalamic-Pituitary Dysfunction Following Traumatic Brain Injury Affects Functional Improvement During Acute Inpatient Rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						functional independence measure (FIM); growth hormone; hypogonadism; hypopituitarism; IGF-1; rehabilitation; testosterone	GROWTH-HORMONE DEFICIENCY; QUALITY-OF-LIFE; PROSTATE-CANCER; LONG-TERM; HYPOPITUITARISM; TESTOSTERONE; ADULTS; HYPOGONADISM; PREVALENCE; INSUFFICIENCY	Objective: To evaluate the occurrence of hypothalamic-pituitary dysfunction following a traumatic brain injury (TBI) and to determine its effect on functional improvement in acute inpatient rehabilitation. Methods: A retrospective chart review identified male patients with a primary diagnosis of TBI with or without a skull fracture, an onset date within 6 months prior to admission, and were 16 years of age or older. The percentage of individuals in this population with abnormal hormone levels was determined on the basis of the established normal reference range for each hormone assay. The functional independence measure, which assesses functional outcomes in acute inpatient rehabilitation, was used to examine the relationship between hormone levels and functional improvement. Results: Hypothalamic-pituitary dysfunction was identified in nearly 70% of men following TBI. Hypogonadism, or low testosterone levels, was observed in 66% of the patients, followed by low levels of free T-4 in 46% and low levels of insulin growth factor-1 in 26% of patients. Hypopituitarism associated with impaired functional recovery. Specifically, the functional independence measure change per day was significantly lower in patients with low levels of testosterone and insulin growth factor-1. Conclusions: These findings suggest the importance of testosterone and insulin growth factor-1 activity in the early stages of physical and cognitive rehabilitation.	[Rosario, Emily R.; Aqeel, Rubina; Brown, Meghan A.; Sanchez, Gabriel; Moore, Colleen; Patterson, David] Casa Colina Hosp Rehabil Med, Pomona, CA 91769 USA	Rosario, ER (corresponding author), Casa Colina Hosp Rehabil Med, 255 E Bonita Ave, Pomona, CA 91769 USA.	erosario@casacolina.org	Brown, Meghan/AAM-4944-2020		Casa Colina Centers for Rehabilitation Foundation	The authors thank the Casa Colina Centers for Rehabilitation Foundation for supporting this research.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2005, THESCIENTIFICWORLDJO, V5, P777, DOI 10.1100/tsw.2005.100; Arwert LI, 2005, FRONT HORM RES, V33, P196, DOI 10.1159/000088425; Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485; Bassil Nazem, 2009, Ther Clin Risk Manag, V5, P427; Bassil N, 2010, CLIN GERIATR MED, V26, P197, DOI 10.1016/j.cger.2010.02.003; Bassil N, 2010, CLIN GERIATR MED, V26, P57, DOI 10.1016/j.cger.2009.12.004; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Baumgartner RN, 1999, MECH AGEING DEV, V107, P123, DOI 10.1016/S0047-6374(98)00130-4; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Carlson NE, 2009, BRAIN INJURY, V23, P336, DOI 10.1080/02699050902788535; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Chu LW, 2008, J AM GERIATR SOC, V56, P1286, DOI 10.1111/j.1532-5415.2008.01746.x; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Creyghton Wouter M, 2004, Semin Vasc Med, V4, P167, DOI 10.1055/s-2004-835375; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; Dusick JR, 2008, PITUITARY, V4, P23; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P541, DOI 10.1097/00001199-200311000-00008; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; GOLDENBERG SL, 1995, UROLOGY, V45, P839; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; High WM, 2010, J NEUROTRAUMA; Hohl A, 2009, ARQ BRAS ENDOCRINOL, V53, P1012, DOI 10.1590/S0004-27302009000800016; Janowsky JS, 2000, J COGNITIVE NEUROSCI, V12, P407, DOI 10.1162/089892900562228; Jeong JH, 2010, J NEUROSURG, V113, P532, DOI 10.3171/2009.10.JNS091152; KAUFMAN JM, 2005, ENDOCR REV; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; MacLusky NJ, 2006, NEUROSCIENCE, V138, P957, DOI 10.1016/j.neuroscience.2005.12.054; Maruff P, 2005, HORM RES, V64, P100, DOI 10.1159/000089325; Mauras N, 1998, J CLIN ENDOCR METAB, V83, P1886, DOI 10.1210/jc.83.6.1886; Moffat SD, 2002, J CLIN ENDOCR METAB, V87, P5001, DOI 10.1210/jc.2002-020419; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Mukherjee A, 2004, HORM RES, V62, P35, DOI 10.1159/000080497; Murray RD, 2004, J CLIN ENDOCR METAB, V89, P1586, DOI 10.1210/jc.2003-030761; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Raynaud JP, 2006, J STEROID BIOCHEM, V102, P261, DOI 10.1016/j.jsbmb.2006.09.032; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; van Dam PS, 2005, HORM RES, V64, P109, DOI 10.1159/000089326; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Young TP, 2007, BRAIN INJURY, V21, P645, DOI 10.1080/02699050701210426	63	19	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2013	28	5					390	396		10.1097/HTR.0b013e318250eac6			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZU	WOS:000330364600086	22613945				2021-06-18	
J	Covassin, T; Elbin, RJ; Crutcher, B; Burkhart, S				Covassin, Tracey; Elbin, R. J.; Crutcher, Bryan; Burkhart, Scott			The Management of Sport-Related Concussion: Considerations for Male and Female Athletes	TRANSLATIONAL STROKE RESEARCH			English	Article						Concussions; Sex differences; Neurocognitive function; Clinical assessment	SCHOOL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; SEX-DIFFERENCES; GENDER-DIFFERENCES; HEAD-INJURY; COLLEGIATE; IMPACT; EPIDEMIOLOGY; SPECIFICITY	Sport-related concussion continues to be a centerpiece of attention in the field of sports medicine. The benefit to using neurocognitive testing when managing concussion will be documented in this review. In addition to providing critical objective information on the neurocognitive status of the concussed athlete, research data will be provided on the pre- and post-concussion neurocognitive profiles of concussed male and female athletes. Specifically, an overview of research will be presented on the epidemiology of male and female concussion rates, as well as concussion outcomes including symptoms and cognitive function post-injury. Finally, a clinician's perspective on managing sports-related concussion will be presented focusing on three factors regarding sex differences: risk factors, clinical presentation, and management.	[Covassin, Tracey; Crutcher, Bryan] Michigan State Univ, E Lansing, MI 48824 USA; [Elbin, R. J.; Burkhart, Scott] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15203 USA	Covassin, T (corresponding author), Michigan State Univ, E Lansing, MI 48824 USA.	covassin@msu.edu					Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth JT., 1989, MILD HEAD INJURY, P257; Bernhardt DT, 2000, PEDIATR ANN, V29, P172, DOI 10.3928/0090-4481-20000301-11; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T., 2012, CLIN J SPORT MED; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; de Courten-Myers GM, 1999, J NEUROPATH EXP NEUR, V58, P217; DeHaas DM, 2009, 1981 82 2007 08 NCAA; Ebell MH, 2006, AM FAM PHYSICIAN, V74, P2087; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Esposito G, 1996, J NUCL MED, V37, P559; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halpern D. F., 2000, SEX DIFFERENCES COGN; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Kimura D, 2002, PSYCHOL REP, V91, P1137, DOI 10.2466/PR0.91.7.1137-1142; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; LEWIS RS, 1987, BRAIN COGNITION, V6, P142, DOI 10.1016/0278-2626(87)90115-1; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell M, 2008, NEUROL CLIN, V26, P45, DOI 10.1016/j.ncl.2007.12.001; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan W., PEDIATR, V129, P38; National Federation of State High School Associations, PART HIGH SCH SPORTS; NCAA, 2012, NCAA PART RAT GOING; NFHSA, 2008, PART HIGH SCH SPORTS; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X	41	19	19	0	30	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483			TRANSL STROKE RES	Transl. Stroke Res.	AUG	2013	4	4					420	424		10.1007/s12975-012-0228-z			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	176GD	WOS:000321290900006	24323339				2021-06-18	
J	Calcagnile, O; Holmen, A; Chew, M; Unden, J				Calcagnile, Olga; Holmen, Anders; Chew, Michelle; Unden, Johan			S100B levels are affected by older age but not by alcohol intoxication following mild traumatic brain injury	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; SCANDINAVIAN GUIDELINES; INITIAL MANAGEMENT; PROTEIN S100B; SERUM; S-100B; MARKER; DAMAGE; RULE	Introduction: Biomarkers of brain damage and head injury are potentially useful tools in the management of afflicted patients. Particularly S100B has received much attention and has been adapted into clinical guidelines. Alcohol intoxication and higher age (65 years and over) have been used as risk factors for serious complications following head injury. The effect of these factors on S100B levels has not been fully established in a relevant patient cohort. Methods: We prospectively included 621 adult patients with mild traumatic brain injury (TBI) and S100B sampling. Mild TBI was defined as Glasgow Come Scale 14-15 with loss of consciousness and/or amnesia, but without high-risk factors for intracranial complications. These patients would normally require CT scanning according to local and most international guidelines. S100B was sampled within 3 hours following trauma. Results: 280 patients (45%) were intoxicated by alcohol. Alcohol intoxication had no effect on S100B levels (p = 0.65) and the performance of S100B remained unchanged in these patients. 115 patients (22%) were 65 years or older with elevated S100B levels being more common in this group compared to patients under 65 (p = 0.029). Although the sensitivity of S100B was unchanged in older patients, the specificity was poorer. Conclusion: S100B can be used reliably in mild TBI patients with alcohol intoxication. The clinically utility of S100B in older patients may be limited by very poor specificity leading to only a small decrease in CT scanning.	[Calcagnile, Olga] Hallands Hosp, Dept Pediat Med, S-30185 Halmstad, Sweden; [Holmen, Anders] Hallands Hosp, Dept Res & Dev, S-30185 Halmstad, Sweden; [Chew, Michelle] Lund Univ, Hallands Hosp, Dept Anaesthesia & Intens Care, S-30185 Halmstad, Sweden; [Chew, Michelle] Lund Univ, Hallands Hosp, Inst Clin Sci Malmo, S-30185 Halmstad, Sweden; [Unden, Johan] Lund Univ, Skanes Univ Hosp, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden; [Unden, Johan] Lund Univ, Skanes Univ Hosp, Inst Clin Sci Malmo, S-20502 Malmo, Sweden	Unden, J (corresponding author), Lund Univ, Skanes Univ Hosp, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden.	dr.johan.unden@gmail.com					Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Cervellin G, 2012, CLIN BIOCHEM, V45, P408, DOI 10.1016/j.clinbiochem.2012.01.006; Foerch C, 2007, STROKE, V38, P2491, DOI 10.1161/STROKEAHA.106.480111; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P123, DOI 10.1097/HTR.0b013e31820e6840; Morton MJ, 2012, ANN EMERG MED, V60, P361, DOI 10.1016/j.annemergmed.2011.12.026; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Mussack T, 2000, ACT NEUR S, V76, P393; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Soreide K, 2007, WORLD J SURG, V31, P2092, DOI 10.1007/s00268-007-9226-9; Stein SC, 2000, NEW ENGL J MED, V343, P1570; Stein SC, 2005, J NEUROSURG, V102, P183; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50	22	19	19	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	JUL 6	2013	21								52	10.1186/1757-7241-21-52			6	Emergency Medicine	Emergency Medicine	178MZ	WOS:000321453400001	23830006	DOAJ Gold, Green Published			2021-06-18	
J	Bianchetti, E; Mladinic, M; Nistri, A				Bianchetti, E.; Mladinic, M.; Nistri, A.			Mechanisms underlying cell death in ischemia-like damage to the rat spinal cord in vitro	CELL DEATH & DISEASE			English	Article						magnesium; PAR; AIF; parthanatos; TRPM2; TRPM7	APOPTOSIS-INDUCING FACTOR; TRAUMATIC BRAIN-INJURY; POLY(ADP-RIBOSE) PAR POLYMER; RANDOMIZED CONTROLLED-TRIAL; NEONATAL-RAT; NEURONAL DEATH; LOCOMOTOR NETWORKS; MAGNESIUM-SULFATE; OXIDATIVE STRESS; MG2+ HOMEOSTASIS	New spinal cord injury (SCI) cases are frequently due to non-traumatic causes, including vascular disorders. To develop mechanism-based neuroprotective strategies for acute SCI requires full understanding of the early pathophysiological changes to prevent disability and paralysis. The aim of our study was to identify the molecular and cellular mechanisms of cell death triggered by a pathological medium (PM) mimicking ischemia in the rat spinal cord in vitro. We previously showed that extracellular Mg2+ (1 mM) worsened PM-induced damage and inhibited locomotor function. The present study indicated that 1 h of PM+Mg2+ application induced delayed pyknosis chiefly in the spinal white matter via overactivation of poly (ADP-ribose) polymerase 1 (PARP1), suggesting cell death mediated by the process of parthanatos that was largely suppressed by pharmacological block of PARP-1. Gray matter damage was less intense and concentrated in dorsal horn neurons and motoneurons that became immunoreactive for the mitochondrial apoptosis-inducing factor (the intracellular effector of parthanatos) translocated into the nucleus to induce chromatin condensation and DNA fragmentation. Immunoreactivity to TRPM ion channels believed to be involved in ischemic brain damage was also investigated. TRPM2 channel expression was enhanced 24 h later in dorsal horn and motoneurons, whereas TRPM7 channel expression concomitantly decreased. Conversely, TRPM7 expression was found earlier (3 h) in white matter cells, whereas TRPM2 remained undetectable. Simulating acute ischemic-like damage in vitro in the presence of Mg2+ showed how, during the first 24 h, this divalent cation unveiled differential vulnerability of white matter cells and motoneurons, with distinct changes in their TRPM expression.	[Bianchetti, E.; Mladinic, M.; Nistri, A.] Int Sch Adv Studies SISSA, Dept Neurosci, I-34136 Trieste, Italy; [Mladinic, M.; Nistri, A.] Ist Med Fis & Riabilitaz, SPINAL, Udine, Italy; [Mladinic, M.] Univ Rijeka, Dept Biotechnol, Rijeka, Croatia	Nistri, A (corresponding author), Int Sch Adv Studies SISSA, Dept Neurosci, Via Bonomea 265, I-34136 Trieste, Italy.	nistri@sissa.it	Mladinic, Miranda/A-8288-2015; Pejatovic, Miranda/V-3554-2019	Mladinic, Miranda/0000-0002-3985-6629; bianchetti, elena/0000-0002-6432-6558	government of the Friuli Venezia Giulia Region (SPINAL project)	We thank our colleague Dr. A Kuzhandaivel for her help with the ELISA assay, Dr. Micaela Grandolfo for support with quantitative image analysis and Dr. Andrea Tomicich for software support. This work was supported by a grant from the government of the Friuli Venezia Giulia Region (SPINAL project).	Aarts MM, 2005, PFLUG ARCH EUR J PHY, V451, P243, DOI 10.1007/s00424-005-1439-x; Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Beirowski B, 2009, J NEUROSCI, V29, P653, DOI 10.1523/JNEUROSCI.3814-08.2009; Belrose JC, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-11; Burgoyne LA, 1999, EXP CELL RES, V248, P214, DOI 10.1006/excr.1999.4406; Carrascal L, 2005, BRAIN RES REV, V49, P377, DOI 10.1016/j.brainresrev.2005.02.003; CARRIEDO SG, 1995, NEUROREPORT, V6, P945, DOI 10.1097/00001756-199504190-00030; Chen HC, 2012, BIOCHEM J, V445, P441, DOI 10.1042/BJ20120248; Cifra A, 2012, DEV NEUROBIOL, V72, P1140, DOI 10.1002/dneu.20991; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cook NL, 2009, MAGNESIUM RES, V22, P225, DOI 10.1684/mrh.2009.0189; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Cox B, 2006, NAT PROTOC, V1, P1872, DOI 10.1038/nprot.2006.273; Dent MAR, 2010, FEBS LETT, V584, P2767, DOI 10.1016/j.febslet.2010.04.073; Everaerts W, 2010, AM J PHYSIOL-RENAL, V298, pF692, DOI 10.1152/ajprenal.00599.2009; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Giordano G, 2005, J NEUROCHEM, V94, P808, DOI 10.1111/j.1471-4159.2005.03235.x; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Kuhn FJP, 2005, PFLUG ARCH EUR J PHY, V451, P212, DOI 10.1007/s00424-005-1446-y; Kuzhandaivel A, 2010, NEUROSCIENCE, V169, P325, DOI 10.1016/j.neuroscience.2010.05.011; Kuzhandaivel Anujaianthi, 2011, Front Cell Neurosci, V5, P9, DOI 10.3389/fncel.2011.00009; Kuzhandaivel A, 2010, CELL MOL NEUROBIOL, V30, P1001, DOI 10.1007/s10571-010-9531-y; Lee IH, 2005, J COMP NEUROL, V489, P1, DOI 10.1002/cne.20567; Lees KR, 2004, LANCET, V363, P439; Lin MC, 2004, J AM COLL NUTR, V23, p561S, DOI 10.1080/07315724.2004.10719404; Maas AI, 2007, LANCET NEUROL, V6, P20, DOI 10.1016/S1474-4422(06)70668-8; Margaryan G, 2009, NEUROSCIENCE, V163, P669, DOI 10.1016/j.neuroscience.2009.07.005; McNulty S, 2005, PFLUG ARCH EUR J PHY, V451, P235, DOI 10.1007/s00424-005-1440-4; Miller BA, 2006, J MEMBRANE BIOL, V209, P31, DOI 10.1007/s00232-005-0839-3; Mladinic M., 2013, ANIMAL MODELS SPINAL, P39, DOI [10.1007/978-1-62703-197-4_3, DOI 10.1007/978-1-62703-197-4_3, 10. 1007/978-1-62703-197-4, DOI 10.1007/978-1-62703-197-4]; Nasrabady SE, 2011, EUR J NEUROSCI, V33, P2216, DOI 10.1111/j.1460-9568.2011.07714.x; Nasrabady SE, 2011, CELL MOL NEUROBIOL, V31, P503, DOI 10.1007/s10571-011-9661-x; Nicotera P, 2003, CELL, V115, P768, DOI 10.1016/S0092-8674(03)01019-5; Oh YK, 2006, NEUROSCI LETT, V406, P205, DOI 10.1016/j.neulet.2006.07.044; Palacios-Prado N, 2013, J NEUROSCI, V33, P4741, DOI 10.1523/JNEUROSCI.2825-12.2013; Penas C, 2009, J NEUROTRAUM, V26, P763, DOI [10.1089/neu.2008.0661, 10.1089/neu.2008-0661]; Penner R., 2007, V179, P313; Perlman JM, 2006, CLIN THER, V28, P1353, DOI 10.1016/j.clinthera.2006.09.005; Plesca D, 2008, METHOD ENZYMOL, V446, P107, DOI 10.1016/S0076-6879(08)01606-6; Ryazanova LV, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1108; Saeki H, 2004, ANESTH ANALG, V99, P1805, DOI 10.1213/01.ANE.0000138039.04548.3D; Savitz SI, 2007, ANN NEUROL, V61, P396, DOI 10.1002/ana.21127; Scharenberg AM, 2005, PFLUG ARCH EUR J PHY, V451, P220, DOI 10.1007/s00424-005-1444-0; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Sumoza-Toledo A, 2011, J PHYSIOL-LONDON, V589, P1515, DOI 10.1113/jphysiol.2010.201855; Sun HS, 2009, NAT NEUROSCI, V12, P1300, DOI 10.1038/nn.2395; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Taccola G, 2008, NEUROSCIENCE, V155, P538, DOI 10.1016/j.neuroscience.2008.06.008; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Tresch MC, 2002, J NEUROSCI, V22, P9997; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Vandenabeele Peter, 2006, Sci STKE, V2006, ppe44, DOI 10.1126/stke.3582006pe44; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Wang YF, 2009, EXP NEUROL, V218, P193, DOI 10.1016/j.expneurol.2009.03.020; Xie Yu-Feng, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P95; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	60	19	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	JUL	2013	4								e707	10.1038/cddis.2013.237			11	Cell Biology	Cell Biology	192US	WOS:000322512100008	23828570	DOAJ Gold, Green Published			2021-06-18	
J	De Beaumont, L; Beauchemin, M; Beaulieu, C; Jolicoeur, P				De Beaumont, Louis; Beauchemin, Maude; Beaulieu, Christelle; Jolicoeur, Pierre			Long-term attenuated electrophysiological response to errors following multiple sports concussions	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Sports concussion; Event-related potentials; Error-related negativity; Cognitive control	FOOTBALL PLAYERS; ABNORMALITIES; HISTORY; SYSTEM; CORTEX	This study extracted the error-related negativity (ERN) waveform component recorded from a visual-spatial attention and a visual short-term memory task to assess rigorously the long-term and cumulative effects of concussions on evaluative processes of cognitive control related to performance monitoring. This study demonstrates that, relative to control athletes, multiply concussed athletes show significant ERN amplitude reduction elicited by error generation. These cumulative effects of concussions on ERN amplitude were found in two distinct experimental paradigms designed to solicit concussion-sensitive cognitive abilities such as attention and short-term memory. This suggests that the mechanisms that contribute to the evaluation of cognitive performance may be significantly affected following multiple concussions even in low-conflict situations.	[De Beaumont, Louis; Beaulieu, Christelle] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ G9A 5H7, Canada; [De Beaumont, Louis; Beauchemin, Maude] Montreal Sacred Heart Hosp, Res Ctr, Montreal, PQ, Canada; [Jolicoeur, Pierre] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada	De Beaumont, L (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, CP 5000, Trois Rivieres, PQ G9A 5H7, Canada.	Louis.Debeaumont@uqtr.ca			Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	We wish to thank the Canadian Institute of Health Research (CIHR) for funding this work through grants awarded to P.J. and L.D.B. We also want to recognize the important technical assistance of Pia Amping to this work. Authors' statement: This manuscript has not been published elsewhere, and it has not been submitted simultaneously for publication elsewhere. Statement of authorship: All authors listed have contributed to the original work. Disclosure: The authors have reported no conflicts of interest. Ethical adherence: This study has been approved by the ethics committee of the University of Montreal.	Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M., 1990, PSYCHOPHYSIOLOGICAL, P192; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hewig J, 2011, PSYCHOPHYSIOLOGY, V48, P1390, DOI 10.1111/j.1469-8986.2011.01209.x; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2012, J INT NEUROPSYCH SOC, V18, P323, DOI 10.1017/S1355617711001779; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEZAK MD, 1995, NEUROPSYCHYOLOGICAL; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; Olvet DM, 2009, PSYCHOPHYSIOLOGY, V46, P957, DOI 10.1111/j.1469-8986.2009.00848.x; Olvet DM, 2009, BRAIN RES, V1284, P89, DOI 10.1016/j.brainres.2009.05.079; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Tabachnick BG, 2007, USING MULTIVARIATE S; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vocat R, 2008, NEUROPSYCHOLOGIA, V46, P2545, DOI 10.1016/j.neuropsychologia.2008.04.006; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	39	19	19	1	29	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL 1	2013	35	6					596	607		10.1080/13803395.2013.800023			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	238BH	WOS:000325914900004	23701388				2021-06-18	
J	DiFazio, J; Fletcher, DJ				DiFazio, Jillian; Fletcher, Daniel J.			Updates in the Management of the Small Animal Patient with Neurologic Trauma	VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE			English	Article						Neurotrauma; Traumatic brain injury; Head trauma; Acute spinal cord injury; Resuscitation; Dog; Cat; Cerebral ischemia	SPINAL-CORD-INJURY; INTERVERTEBRAL-DISK DISEASE; 7.5-PERCENT SODIUM-CHLORIDE; CEREBRAL PERFUSION-PRESSURE; PLACEBO-CONTROLLED TRIAL; URINARY-TRACT-INFECTION; SEVERE HEAD-INJURY; BRAIN-INJURY; INTRACRANIAL-PRESSURE; HYPERTONIC SALINE	Neurologic trauma, encompassing traumatic brain injury (TBI) and acute spinal cord injury (SCI), is a cause of significant morbidity and mortality in veterinary patients. Acute SCIs occurring secondary to trauma are also common. Essential to the management of TBI and SCI is a thorough understanding of the pathophysiology of the primary and secondary injury that occurs following trauma. This article reviews the pathophysiology of this primary and secondary injury, as well as recommendations regarding clinical assessment, diagnostics, pharmacologic and nonpharmacologic therapy, and prognosis.	[DiFazio, Jillian] Cornell Univ Hosp Anim, Sect Emergency & Crit Care, Ithaca, NY 14853 USA; [Fletcher, Daniel J.] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA	Fletcher, DJ (corresponding author), Cornell Univ, Coll Vet Med, Dept Clin Sci, DCS Box 31, Ithaca, NY 14853 USA.	djf42@cornell.edu					Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Armitage-Chan EA, 2007, J VET EMERG CRIT CAR, V17, P5, DOI 10.1111/j.1476-4431.2006.00194.x; Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Baltzer WI, 2008, SPINE, V33, P1397, DOI 10.1097/BRS.0b013e3181753c37; Barone G, 2002, J AM VET MED ASSOC, V220, P1499, DOI 10.2460/javma.2002.220.1499; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Boysen SR, 2004, JAVMA-J AM VET MED A, V225, P1198, DOI 10.2460/javma.2004.225.1198; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Brain Trauma Foundation T National Association of State EMS Officials T National Association of EMTs, 2007, PREHOSP EMERG CARE S, V12, P1; Brisson BA, 2010, VET CLIN N AM-SMALL, V40, P829, DOI 10.1016/j.cvsm.2010.06.001; Bubenik L, 2008, VET SURG, V37, P791, DOI 10.1111/j.1532-950X.2008.00452.x; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Caswell JL, 2003, CAN VET J, V44, P137; Cerda-Gonzalez S, 2006, JAVMA-J AM VET MED A, V228, P230, DOI 10.2460/javma.228.2.230; Chan PH, 2000, STROKE, V31, P1952; Chen HSV, 2006, J NEUROCHEM, V97, P1611, DOI 10.1111/j.1471-4159.2006.03991.x; Cherrone KL, 2004, J AM ANIM HOSP ASSOC, V40, P316, DOI 10.5326/0400316; COATES JR, 1995, VET SURG, V24, P128, DOI 10.1111/j.1532-950X.1995.tb01307.x; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Croce MA, 2001, ANN SURG, V233, P851, DOI 10.1097/00000658-200106000-00016; da Silva JC, 2010, NEUROL RES, V32, P139, DOI 10.1179/174313209X405119; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; DENIS F, 1984, CLIN ORTHOP RELAT R, P65; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; Dewey C, 2008, PRACTICAL GUIDE CANI, P221; Dewey C., 2003, PRACTICAL GUIDE CANI, P419; Dewey CW, 2000, VET CLIN N AM-SMALL, V30, P207, DOI 10.1016/S0195-5616(00)50010-2; Dewey CW, 2008, PRACTICAL GUIDE CANI, P323; Dewey CW, 2008, PRACTICAL GUIDE CANI, P323; Dooney Neil, 2011, Int J Crit Illn Inj Sci, V1, P36, DOI 10.4103/2229-5151.79280; Edwards P, 2005, LANCET, V365, P1957; Eminaga S, 2011, J FELINE MED SURG, V13, P850, DOI 10.1016/j.jfms.2011.09.006; Fehlings MG, 2006, SPINE, V31, pS28, DOI 10.1097/01.brs.0000217973.11402.7f; FELTS JF, 1983, J AM ANIM HOSP ASSOC, V19, P755; Fink Matthew E, 2012, Continuum (Minneap Minn), V18, P640, DOI 10.1212/01.CON.0000415432.84147.1e; Fletcher D.J., 2009, SMALL ANIMAL CRITICA, P658; Fluehmann G, 2006, J SMALL ANIM PRACT, V47, P582, DOI 10.1111/j.1748-5827.2006.00106.x; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; GAGE ED, 1968, J AM VET MED ASSOC, V152, P351; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gill PJ, 1996, J AM ANIM HOSP ASSOC, V32, P77, DOI 10.5326/15473317-32-1-77; Green DM, 2010, NEUROCRIT CARE, V13, P299, DOI 10.1007/s12028-010-9417-3; Griffin J, 2009, COMPEND CONTIN ED PR, V31, pE1; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; Hansen B, 2000, VET CLIN N AM-SMALL, V30, P899, DOI 10.1016/S0195-5616(08)70014-7; Hawthorne JC, 1999, J AM ANIM HOSP ASSOC, V35, P135, DOI 10.5326/15473317-35-2-135; Hayes GM, 2009, J VET EMERG CRIT CAR, V19, P629, DOI 10.1111/j.1476-4431.2009.00478.x; Hillman RB, 2009, J AM ANIM HOSP ASSOC, V45, P155, DOI 10.5326/0450155; Hopkins AL, 1996, VET CLIN N AM-SMALL, V26, P875, DOI 10.1016/S0195-5616(96)50110-5; Hopper K, 2009, SMALL ANIMAL CRITICA, P900; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Israel SK, 2009, VET RADIOL ULTRASOUN, V50, P247, DOI 10.1111/j.1740-8261.2009.01528.x; Jeffery ND, 2005, J NEUROTRAUM, V22, P1282, DOI 10.1089/neu.2005.22.1282; Jeffery ND, 2010, VET CLIN N AM-SMALL, V40, P809, DOI 10.1016/j.cvsm.2010.05.004; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Johnson K, 2009, SMALL ANIMAL CRITICA, P419; Johnson P, 2012, VET RADIOL ULTRASOUN, V53, P552, DOI 10.1111/j.1740-8261.2012.01959.x; Kaptanoglu E, 2005, ACTA NEUROCHIR, V147, P405, DOI 10.1007/s00701-004-0447-5; KASSELL NF, 1980, NEUROSURGERY, V7, P598, DOI 10.1227/00006123-198012000-00011; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KEEGAN RD, 1995, AM J VET RES, V56, P193; Kent M, 2010, J AM ANIM HOSP ASSOC, V46, P132, DOI 10.5326/0460132; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kinns J, 2006, VET RADIOL ULTRASOUN, V47, P563, DOI 10.1111/j.1740-8261.2006.00186.x; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; La Rosa G, 2004, SPINAL CORD, V42, P503, DOI 10.1038/sj.sc.3101627; Lamb CR, 2002, VET RADIOL ULTRASOUN, V43, P222, DOI 10.1111/j.1740-8261.2002.tb00994.x; Lauer KK, 1997, CAN J ANAESTH, V44, P929, DOI 10.1007/BF03011963; Leonard SE, 2002, J VET EMERG CRIT CAR, V12, P17, DOI 10.1046/j.1534-6935.2002.00003.x; Levine GJ, 2009, PREV VET MED, V89, P121, DOI 10.1016/j.prevetmed.2009.02.016; Levine JM, 2008, JAVMA-J AM VET MED A, V232, P411, DOI 10.2460/javma.232.3.411; Levine JM, 2007, VET SURG, V36, P482, DOI 10.1111/j.1532-950X.2007.00295.x; LEWIS DD, 1992, J AM VET MED ASSOC, V200, P1381; Ling Geoffrey S F, 2010, Continuum (Minneap Minn), V16, P27, DOI 10.1212/01.CON.0000391451.30299.bc; Lisciandro GR, 2011, J VET EMERG CRIT CAR, V21, P104, DOI 10.1111/j.1476-4431.2011.00626.x; Marioni-Henry K, 2004, J VET INTERN MED, V18, P851, DOI 10.1892/0891-6640(2004)18&lt;851:PODOTS&gt;2.0.CO;2; Mazzaferro E, 2009, SMALL ANIMAL CRITICA, P78, DOI DOI 10.1016/B978-1-4160-2591-7.10019-0; McCarthy P, 2012, PATHOPHYSIOLOGY, P735; McCartney W, 2007, J SMALL ANIM PRACT, V48, P498, DOI 10.1111/j.1748-5827.2006.00309.x; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; McMichael M, 2004, J VET EMERG CRIT CAR, V14, P231, DOI 10.1111/j.1476-4431.2004.04004.x; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Musulin SE, 2011, J VET PHARMACOL THER, V34, P17, DOI 10.1111/j.1365-2885.2010.01186.x; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Nishida H, 2012, VET SURG, V41, P437, DOI 10.1111/j.1532-950X.2011.00959.x; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Olby N, 2003, J AM VET MED ASSOC, V222, P762, DOI 10.2460/javma.2003.222.762; Olby N, 2010, VET CLIN N AM-SMALL, V40, P791, DOI 10.1016/j.cvsm.2010.05.007; Olby NJ, 2001, AM J VET RES, V62, P1624, DOI 10.2460/ajvr.2001.62.1624; OLBY NJ, 1994, J SMALL ANIM PRACT, V35, P345, DOI 10.1111/j.1748-5827.1994.tb01713.x; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Park EH, 2012, J VET EMERG CRIT CAR, V22, P160, DOI 10.1111/j.1476-4431.2012.00723.x; PARKER AJ, 1976, RES VET SCI, V21, P246, DOI 10.1016/S0034-5288(18)33383-6; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Platt SR, 2001, J VET INTERN MED, V15, P581, DOI 10.1892/0891-6640(2001)015&lt;0581:TPVOTM&gt;2.3.CO;2; Proulx J, 1998, COMP CONT EDUC PRACT, V20, P897; Rabinowitz RS, 2008, SPINE, V33, P2260, DOI 10.1097/BRS.0b013e31818786db; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Roberts I, 2004, LANCET, V364, P9442; Ropper AH, 2012, NEW ENGL J MED, V367, P746, DOI 10.1056/NEJMct1206321; Rozanski EA, 2002, VET CLIN N AM-SMALL, V32, P1073, DOI 10.1016/S0195-5616(02)00039-6; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schierhout G, 2012, COCHRANE DB SYST REV; Schwartz G, 2002, PROG BRAIN RES, V137, P177; SEIM HB, 1982, J AM ANIM HOSP ASSOC, V18, P233; Shores A., 1983, CURRENT VET THERAPY, P847; Simpson SA, 2009, J VET EMERG CRIT CAR, V19, P588, DOI 10.1111/j.1476-4431.2009.00468.x; Smarick SD, 2004, JAVMA-J AM VET MED A, V224, P1936, DOI 10.2460/javma.2004.224.1936; Smith PM, 2005, J VET INTERN MED, V19, P788, DOI 10.1892/0891-6640(2005)19[788:SSAACR]2.0.CO;2; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; Sturges B, 2009, SMALL ANIMAL CRITICA, P423; Syring RS, 2001, J AM VET MED ASSOC, V218, P1124, DOI 10.2460/javma.2001.218.1124; Tadie M., 1999, Society for Neuroscience Abstracts, V25, P1090; Tanaka H, 2005, J VET MED SCI, V67, P679, DOI 10.1292/jvms.67.679; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tidwell AS, 2002, VET RADIOL ULTRASOUN, V43, P319, DOI 10.1111/j.1740-8261.2002.tb01011.x; Todd MM, 2006, ANESTHESIOLOGY, V105, P1176, DOI 10.1097/00000542-200612000-00017; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Tsang KKT, 2012, BRIT J ORAL MAX SURG, V50, P298, DOI 10.1016/j.bjoms.2011.03.004; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vitale C, 2007, COMPENDIUM STANDARDS, V9, P1; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Walters MR, 2005, CEREBROVASC DIS, V20, P304, DOI 10.1159/000087929; Weed LH, 1919, AM J PHYSIOL, V48, P512; Wijayatilake DS, 2012, CURR OPIN ANESTHESIO, V25, P540, DOI 10.1097/ACO.0b013e328357960a; Zeng HK, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-153; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023	143	19	19	3	44	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0195-5616	1878-1306		VET CLIN N AM-SMALL	Vet. Clin. N. Am.-Small Anim. Pract.	JUL	2013	43	4					915	+		10.1016/j.cvsm.2013.03.002			27	Veterinary Sciences	Veterinary Sciences	180KI	WOS:000321593700012	23747266				2021-06-18	
J	Green, L; Godfrey, C; Soo, C; Anderson, V; Catroppa, C				Green, L.; Godfrey, C.; Soo, C.; Anderson, V.; Catroppa, C.			A preliminary investigation into psychosocial outcome and quality-of-life in adolescents following childhood traumatic brain injury	BRAIN INJURY			English	Article						Adolescents; psychosocial outcome; quality-of-life; traumatic brain injury	PSYCHOMETRIC PROPERTIES; COMMUNITY INTEGRATION; HEALTH; RECOVERY; CHILDREN; SCALE; SATISFACTION; PREDICTORS; SURVIVORS	Objective: This study investigated the long-term psychosocial outcome and quality-of-life (QoL) of 15-18 year olds, sustaining childhood traumatic brain injury (TBI) between birth and 5 years. Method: Thirty-three participants (17 TBI parent-proxies, 16 control parent-proxies) were involved in the present study which compared parent-ratings for the TBI group and healthy controls on the Sydney Psychosocial Reintegration Scale-Child form (SPRS-C) and the Paediatric Quality of Life Inventory (PedsQL). Results: Despite comparable overall psychosocial reintegration scores, parents reported that their teens with TBI were more likely to experience poor QoL compared to controls. On further analysis, some aspects of psychosocial outcome appear to be compromised following childhood TBI. Conclusions: Interventions targeting childhood TBI must consider QoL in addition to symptom reduction and be extended throughout adolescence. The limitations of the sample size are cause for concern; however, preliminary results do validate the need for future research efforts.	[Green, L.; Anderson, V.; Catroppa, C.] Univ Melbourne, Melbourne, Vic, Australia; [Godfrey, C.; Soo, C.; Anderson, V.; Catroppa, C.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, V.; Catroppa, C.] Royal Childrens Hosp, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au			Murdoch Children's Research Institute; Royal Children's Hospital, Melbourne; Victorian Government's Operational Infrastructure Support Program; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This research was supported by the Murdoch Children's Research Institute, the Royal Children's Hospital, Melbourne and the Victorian Government's Operational Infrastructure Support Program. Funding was also provided from the Australian National Health and Medical Research Council. The research reported in this thesis was conducted in accordance with the principles for the ethical treatment of human subjects as approved for this research by the University of Melbourne Human Research Ethics Committee and the Royal Children's Hospital Human Research Ethics Committee. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bedell Gary M, 2002, Pediatr Rehabil, V5, P107, DOI 10.1080/1363849021000013540; Brown B.B., 1994, PERSONAL RELATIONSHI, P123; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Coghill D, 2009, J CHILD PSYCHOL PSYC, V50, P544, DOI 10.1111/j.1469-7610.2009.02008.x; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Sherer M, 2010, J HEAD TRAUMA REHAB, V25, P92, DOI 10.1097/HTR.0b013e3181c9d887; Soo C, ADAPTING SYDNE UNPUB; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; TEASDALE G, 1974, LANCET, V2, P81; Wallander JL, 1998, J CHILD PSYCHOL PSYC, V39, P29, DOI 10.1111/1469-7610.00302; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zeltzer LK, 2008, CANCER EPIDEM BIOMAR, V17, P435, DOI 10.1158/1055-9965.EPI-07-2541	30	19	19	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					872	877		10.3109/02699052.2013.775506			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200014	23789864				2021-06-18	
J	Kalanuria, A; Nyquist, PA; Armonda, RA; Razumovsky, A				Kalanuria, Atul; Nyquist, Paul A.; Armonda, Rocco A.; Razumovsky, Alexander			Use of Transcranial Doppler (TCD) Ultrasound in the Neurocritical Care Unit	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Transcranial Doppler; Neurocritical care unit; Vasospasm; Stroke; Intracranial hypertension	ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL-BLOOD-FLOW; ACUTE ISCHEMIC-STROKE; PATENT FORAMEN OVALE; CAROTID-ENDARTERECTOMY; HEMODYNAMIC-CHANGES; BRAIN-DEATH; PULSATILITY INDEX; ASYMPTOMATIC EMBOLIZATION; VERTEBROBASILAR VASOSPASM	Transcranial Doppler (TCD) is a portable device that uses a handheld 2-MHz transducer. It is most commonly used in subarachnoid hemorrhage where cerebral blood flow velocities in major intracranial blood vessels are measured to detect vasospasm in the first 2 to 3 weeks. TCD is used to detect vasospasm in traumatic brain injury and post-tumor resection, measurement of cerebral autoregulation and cerebrovascular reactivity, diagnosis of acute arterial occlusions in stroke, screening for patent foramen ovale and monitoring of emboli. It can be used to detect abnormally high intracranial pressure and for confirmation of total cerebral circulatory arrest in brain death.	[Kalanuria, Atul; Nyquist, Paul A.] Johns Hopkins Univ Hosp, Div Neurocrit Care, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Armonda, Rocco A.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20889 USA; [Razumovsky, Alexander] Sentient NeuroCare Serv, Hunt Valley, MD 21031 USA	Razumovsky, A (corresponding author), Sentient NeuroCare Serv, 11011 McCormick Rd,Suite 200, Hunt Valley, MD 21031 USA.	arazumovsky@sentientmedical.com					AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1986, NEURORADIOLOGY, V28, P11, DOI 10.1007/BF00341759; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid Rune, 2002, Eur J Ultrasound, V16, P3, DOI 10.1016/S0929-8266(02)00045-9; Ackerstaff RGA, 2000, STROKE, V31, P1817, DOI 10.1161/01.STR.31.8.1817; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Akopov S, 2002, STROKE, V33, P1274, DOI 10.1161/01.STR.0000013740.62456.A0; Albert A, 1997, J NEUROIMAGING, V7, P159, DOI 10.1111/jon199773159; Alexandrov AV, 2012, J NEUROIMAGING, V22, P215, DOI 10.1111/j.1552-6569.2010.00523.x; Alexandrov AV, 2000, J NEUROIMAGING, V10, P27, DOI 10.1111/jon200010127; Alotaibi NM, 2012, J NEUROINTERV SURG, P1; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Babikian VL, 2000, J NEUROIMAGING, V10, P101, DOI 10.1111/jon2000102101; Baracchini C, 2000, STROKE, V31, P2942, DOI 10.1161/01.STR.31.12.2942; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Bejjani GK, 1999, SURG NEUROL, V52, P577, DOI 10.1016/S0090-3019(99)00108-1; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Belvis R, 2006, J NEUROIMAGING, V16, P133, DOI 10.1111/j.1552-6569.2006.00021.x; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; BRASS LM, 1988, STROKE, V19, P1466, DOI 10.1161/01.STR.19.12.1466; Burch CM, 1996, J NEUROIMAGING, V6, P8, DOI 10.1111/jon1996618; Burgin WS, 2000, STROKE, V31, P1128, DOI 10.1161/01.STR.31.5.1128; Camerlingo M, 1996, ITAL J NEUROL SCI, V17, P215, DOI 10.1007/BF01995686; Cardiol RE, 2011, REV ESP CARDIOL, V64, P12; Carrera E, 2009, NEUROSURGERY, V65, P316, DOI 10.1227/01.NEU.0000349209.69973.88; Cervoni L, 1996, ITAL J NEUROL SCI, V17, P291, DOI 10.1007/BF01997789; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; Conti A, 2009, NEUROCRIT CARE, V10, P326, DOI 10.1007/s12028-009-9199-7; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; Demchuk AM, 2000, J NEUROIMAGING, V10, P1; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Dorsch N W, 1994, J Clin Neurosci, V1, P19, DOI 10.1016/0967-5868(94)90005-1; Dorsch N, 2011, ACTA NEUROCHIR SUPPL, V110, P5, DOI 10.1007/978-3-7091-0353-1_1; Droste DW, 2002, STROKE, V33, P2211, DOI 10.1161/01.STR.0000027884.03365.AC; DROSTE DW, 1989, STROKE, V20, P1005, DOI 10.1161/01.STR.20.8.1005; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; ECKER A, 1951, J NEUROSURG, V8, P660, DOI 10.3171/jns.1951.8.6.0660; FERI M, 1994, CRIT CARE MED, V22, P1120, DOI 10.1097/00003246-199407000-00012; GAUNT ME, 1994, BRIT J SURG, V81, P1435, DOI 10.1002/bjs.1800811009; Goertler M, 2002, J NEUROL NEUROSUR PS, V72, P338, DOI 10.1136/jnnp.72.3.338; Gonzalez NR, 2007, J NEUROSURG, V107, P1101, DOI 10.3171/JNS-07/12/1101; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; GROLIMUND P, 1987, STROKE, V18, P1018, DOI 10.1161/01.STR.18.6.1018; GROSSET DG, 1992, STROKE, V23, P674, DOI 10.1161/01.STR.23.5.674; Hadani M, 1999, INTENS CARE MED, V25, P822, DOI 10.1007/s001340050958; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; HASSLER W, 1988, J NEUROSURG, V68, P745; HASSLER W, 1989, J NEUROSURG, V71, P195, DOI 10.3171/jns.1989.71.2.0195; HOLLERHAGE HG, 1988, J NEUROSURG, V69, P803; Ionita CC, 2008, NEUROCRIT CARE, V9, P8, DOI 10.1007/s12028-007-9029-8; JANSEN C, 1993, STROKE, V24, P665, DOI 10.1161/01.STR.24.5.665; JANSEN C, 1994, STROKE, V25, P992, DOI 10.1161/01.STR.25.5.992; Jo KI, 2012, WORLD NEUROSURG, V77, P316, DOI 10.1016/j.wneu.2011.06.061; JOB FP, 1994, AM J CARDIOL, V74, P381, DOI 10.1016/0002-9149(94)90407-3; Keyrouz SG, 2007, CRIT CARE, V11, DOI 10.1186/cc5958; King A, 2009, STROKE, V40, P3711, DOI 10.1161/STROKEAHA.109.563056; Krejza J, 1999, AM J ROENTGENOL, V172, P213, DOI 10.2214/ajr.172.1.9888770; KUSHNER MJ, 1991, NEUROLOGY, V41, P109, DOI 10.1212/WNL.41.1.109; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; LANGLOIS O, 1992, NEUROCHIRURGIE, V38, P138; Lee MT, 2006, BLOOD, V108, P847, DOI 10.1182/blood-2005-10-009506; Lennard N, 1997, J VASC SURG, V26, P579, DOI 10.1016/S0741-5214(97)70055-7; LENNIHAN L, 1993, J NEUROL NEUROSUR PS, V56, P906, DOI 10.1136/jnnp.56.8.906; Levi CR, 1997, BRAIN, V120, P621, DOI 10.1093/brain/120.4.621; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; Lysakowski C, 2001, STROKE, V32, P2292, DOI 10.1161/hs1001.097108; MAEDA H, 1993, STROKE, V24, P670, DOI 10.1161/01.STR.24.5.670; Markus HS, 2010, LANCET NEUROL, V9, P663, DOI 10.1016/S1474-4422(10)70120-4; Marshall SA, 2010, NEUROSURG CLIN N AM, V21, P291, DOI 10.1016/j.nec.2009.10.010; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN PJ, 1994, STROKE, V25, P390, DOI 10.1161/01.STR.25.2.390; Mascia L, 2003, INTENS CARE MED, V29, P1088, DOI 10.1007/s00134-003-1780-5; MATTLE H, 1988, ARCH NEUROL-CHICAGO, V45, P289, DOI 10.1001/archneur.1988.00520270067022; McGirt Matthew J, 2003, J Stroke Cerebrovasc Dis, V12, P88, DOI 10.1053/jscd.2003.10; Moehring MA, 2002, ULTRASOUND MED BIOL, V28, P49, DOI 10.1016/S0301-5629(01)00486-0; Molina CA, 2001, STROKE, V32, P1079, DOI 10.1161/01.STR.32.5.1079; Molloy J, 1999, STROKE, V30, P1440, DOI 10.1161/01.STR.30.7.1440; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; Nakae R, 2011, NEUROSURGERY, V69, P876, DOI 10.1227/NEU.0b013e318222dc4c; Otten ML, 2008, NEUROL RES, V30, P444, DOI 10.1179/174313208X284089; Patel PM, CEREBRAL PHYSL EFFEC, P305; PETTY GW, 1990, NEUROLOGY, V40, P300, DOI 10.1212/WNL.40.2.300; Rajajee V, 2012, NEUROSURGERY, V70, P1195, DOI 10.1227/NEU.0b013e3182417dca; Rasulo EA, 2008, EUR J ANAESTH, V25, P167, DOI 10.1017/S0265021507003341; Razumovsky A, 2013, ACTA NEUROCHIR SUPPL, V115, P87, DOI 10.1007/978-3-7091-1192-5_19; Razumovsky AY, 1999, ACTA NEUROL SCAND, V99, P65; Rigamonti A, 2008, CAN J ANAESTH, V55, P112, DOI 10.1007/BF03016323; Ringelstein EB, 1998, STROKE, V29, P725; Rowland MJ, 2012, BRIT J ANAESTH; Saqqur M, 2007, CRIT CARE MED, V35, pS216, DOI 10.1097/01.CCM.0000260633.66384.FB; Schwarze JJ, 1999, STROKE, V30, P1234, DOI 10.1161/01.STR.30.6.1234; Serena J, 1998, STROKE, V29, P1322, DOI 10.1161/01.STR.29.7.1322; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Sloan MA, 2004, NEUROLOGY, V62, P1468, DOI 10.1212/WNL.62.9.1468; SLOAN MA, 1994, STROKE, V25, P2187, DOI 10.1161/01.STR.25.11.2187; Smith M, 2007, CURR OPIN ANESTHESIO, V20, P400, DOI 10.1097/ACO.0b013e3282efa686; Soustiel JF, 2002, STROKE, V33, P72, DOI 10.1161/hs0102.100484; Soustiel JF, 1998, NEUROSURGERY, V43, P282, DOI 10.1097/00006123-199808000-00061; Spencer MP, 1997, STROKE, V28, P685, DOI 10.1161/01.STR.28.4.685; Stork JL, 2002, STROKE, V33, P2014, DOI 10.1161/01.STR.0000021002.17394.7F; Sviri GE, 2004, STROKE, V35, P1867, DOI 10.1161/01.STR.0000133397.44528.f8; Sviri GE, 2006, NEUROSURGERY, V59, P360, DOI 10.1227/01.NEU.0000223502.93013.6E; Tegeler CH, 2012, J NEUROIMAGING, P1; Toni D, 1998, STROKE, V29, P1144, DOI 10.1161/01.STR.29.6.1144; Tsivgoulis G, 2007, STROKE, V38, P1245, DOI 10.1161/01.STR.0000259712.64772.85; Ursino M, 1998, J NEUROSURG, V89, P255, DOI 10.3171/jns.1998.89.2.0255; Velat GJ, 2011, WORLD NEUROSURG, V76, P446, DOI 10.1016/j.wneu.2011.02.030; Vora YY, 1999, NEUROSURGERY, V44, P1237, DOI 10.1097/00006123-199906000-00039; Wardlaw JM, 1998, J NEUROSURG, V88, P272, DOI 10.3171/jns.1998.88.2.0272; Washington CW, 2011, NEUROCRIT CARE, V15, P312, DOI 10.1007/s12028-011-9594-8; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1003, DOI 10.1212/WNL.45.5.1003; Wijman CAC, 2001, CEREBROVASC DIS, V11, P317, DOI 10.1159/000047660; Wong KS, 2000, STROKE, V31, P2641, DOI 10.1161/01.STR.31.11.2641; Wozniak MA, 1996, J NEUROIMAGING, V6, P87, DOI 10.1111/jon19966287; YONEDA S, 1974, STROKE, V5, P707, DOI 10.1161/01.STR.5.6.707; ZANETTE EM, 1989, STROKE, V20, P899, DOI 10.1161/01.STR.20.7.899; Zubkov AY, 2009, NEUROL RES, V31, P626, DOI 10.1179/174313209X382331; ZURYNSKI Y, 1991, Neurological Research, V13, P248; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42	125	19	21	1	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	JUL	2013	24	3					441	+		10.1016/j.nec.2013.02.005			17	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	191NY	WOS:000322421100012	23809037				2021-06-18	
J	Lou, MQ; Chen, XZ; Wang, K; Xue, YJ; Cui, DM; Xue, F				Lou, Meiqing; Chen, XianZhen; Wang, Ke; Xue, Yajun; Cui, Daming; Xue, Fei			Increased intracranial pressure is associated with the development of acute lung injury following severe traumatic brain injury	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Traumatic brain injury; Acute lung injury; Systemic inflammatory response syndrome; Intracranial pressure	INFLAMMATORY RESPONSE SYNDROME; SEVERE HEAD-INJURY; MIDLINE SHIFT; HEMORRHAGE	Objective: This study investigated the relationship among intracranial pressure (ICP), the development of acute lung injury (ALI) and systemic inflammatory response syndrome (SIRS) following a severe traumatic brain injury (TBI). Methods: Post-traumatic ICP was continuously monitored for the first week following injury in a series of consecutive patients with isolated severe TBI. The initial ICP and the duration of intracranial hypertension (ICH) were calculated. The risk factors associated with the development of ALI and SIRS were evaluated. Results: Of the 86 patients enrolled, 22 patients developed ALI and 52 patients developed SIRS during the observation period. The patients with ALI presented with a significantly higher initial ICP (31.3 +/- 7.8 mmHgvs. 23.0 +/- 8.8 mmHg,p <0.001) and a longer duration of ICH (16.8 +/- 6.5 h vs. 11.9 +/- 6.0 h, p = 0.002) than those without ALI. The incidence of both ALI and SIRS increased with increasing initial ICI), and the presence of SIRS was associated with a fourfold increase in the risk of developing ALI (odds ratio [OR], 4.0; 95% confidence interval [CI], 1.2-13.0). Conclusions: Increased ICP is associated with increased risks of developing ALI and SIRS following severe TB!. Future studies designed to verify the causative relationship between increased ICP and the systemic responses are warranted. (C) 2012 Elsevier B.V. All rights reserved.	[Lou, Meiqing; Chen, XianZhen; Wang, Ke; Xue, Yajun; Cui, Daming; Xue, Fei] Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Shanghai 200072, Peoples R China	Wang, K (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.	trizzt@gmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81101909, 81201708]	This work is supported by the National Natural Science Foundation of China (No. 81101909 and No. 81201708).	ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Atkinson JLD, 1997, NEUROSURGERY, V41, P1214, DOI 10.1097/00006123-199711000-00052; Azian AA, 2001, ACTA NEUROCHIR, V143, P711, DOI 10.1007/s007010170051; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brown LM, 2011, AM J SURG, V201, P486, DOI 10.1016/j.amjsurg.2010.02.003; Chiewvit Pipat, 2010, Journal of the Medical Association of Thailand, V93, P99; Ciurea AV, 2005, ACT NEUR S, V93, P209; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Fujishima S, 2008, BIOMED PHARMACOTHER, V62, P333, DOI 10.1016/j.biopha.2007.07.003; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hukkanen RR, 2009, TOXICOL PATHOL, V37, P799, DOI 10.1177/0192623309343778; Kitamura Y, 2010, NEUROL MED-CHIR, V50, P456, DOI 10.2176/nmc.50.456; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Lopez-Aguilar J, 2005, CRIT CARE MED, V33, P1077, DOI 10.1097/01.CCM.0000162913.72479.F7; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; Matuschak George M, 2010, Mo Med, V107, P252; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001	21	19	21	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUL	2013	115	7					904	908		10.1016/j.clineuro.2012.09.001			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	177VH	WOS:000321403000012	23010612				2021-06-18	
J	Price, B; Arthur, AO; Brunko, M; Frantz, P; Dickson, JO; Judge, T; Thomas, SH				Price, Brian; Arthur, Annette O.; Brunko, Michael; Frantz, Pam; Dickson, Joshua O.; Judge, Tom; Thomas, Stephen H.			Hemodynamic consequences of ketamine vs etomidate for endotracheal intubation in the air medical setting	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; RAPID-SEQUENCE INTUBATION; EMERGENCY-DEPARTMENT; PROCEDURAL SEDATION; PREHOSPITAL USE; INTRACRANIAL-PRESSURE; INDUCTION AGENT; MANAGEMENT; HYPERTENSION; COMBINATION	Objective: Recent drug shortages have required the occasional replacement of etomidate for endotracheal intubation (ETI) by helicopter emergency medical services (HEMS), with ketamine. The purpose of this study was to assess whether there was an association between ketamine vs etomidate use as the main ETI drug, with hemodynamic or clinical (airway) end points. Methods: This retrospective study used data entered into medical records at the time of HEMS transport. Subjects, 50 ketamine and 50 etomidate, were accrued from 3 US HEMS programs. The study period was from August 2011 through May 2012. Data collection included demographics, diagnostic category, ETI drugs use, ETI success, and complications. Hemodynamic parameters were assessed for up to 2 sets of vital signs before airway management and up to 5 sets of post-ETI vital signs. Significance was defined at the P < .05 level. Results: Patients on ketamine and etomidate were similar (P > .05) with respect to age, sex, scene/interfacility mission type, trauma vs nontrauma, neuromuscular blocking agent use, and rates of coadministration of fentanyl or midazolam. All patients had successful airway placement. Peri-ETI hypoxemia was seen in 10% of etomidate and 16% of ketamine cases (P =. 55). The pre-ETI and post-ETI were similar between the ketamine and etomidate groups with respect to systolic blood pressure and heart rate at every vital signs assessment after ETI. Conclusion: Initial assessment of ETI success and complication rates, as well as peri-ETI hemodynamic changes, suggests no concerning complications associated with large-scale replacement of etomidate with ketamine as the major airway management drug for HEMS. (C) 2013 Elsevier Inc. All rights reserved.	[Price, Brian] Univ Med Ctr Brackenridge, Austin, TX 78701 USA; [Price, Brian] Air Evac Lifeteam, San Marcos, TX 78666 USA; [Arthur, Annette O.; Thomas, Stephen H.] Univ Oklahoma, Sch Community Med, Dept Emergency Med, Tulsa, OK 74146 USA; [Brunko, Michael; Frantz, Pam] Flight Life Colorado, Lakewood, CO 80228 USA; [Dickson, Joshua O.; Judge, Tom] LifeFlight Maine, Bangor, ME 04843 USA; [Thomas, Stephen H.] Air Evac Oklahoma, Muskogee, OK 74401 USA	Arthur, AO (corresponding author), Univ Oklahoma, Dept Emergency Med, Tulsa, OK 74104 USA.	annette-arthur@ouhsc.edu		Thomas, Stephen/0000-0003-4153-3965			Andolfatto G, 2012, ANN EMERG MED, V59, P504, DOI 10.1016/j.annemergmed.2012.01.017; Ballow SL, 2012, J TRAUMA ACUTE CARE, V73, P1401, DOI 10.1097/TA.0b013e318270dcf5; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; Bernhard M, 2011, ANAESTHESIST, V60, P1027, DOI 10.1007/s00101-011-1957-1; Bisanzo M, 2012, ANN EMERG MED, V59, P268, DOI 10.1016/j.annemergmed.2011.11.004; Bozeman WP, 2006, PREHOSP EMERG CARE, V10, P8, DOI 10.1080/10903120500366854; Bozeman William P, 2002, Air Med J, V21, P32, DOI 10.1016/S1067-991X(02)70055-2; Bredmose PP, 2009, EMERG MED J, V26, P62, DOI 10.1136/emj.2007.052753; Bredmose PP, 2009, ACTA ANAESTH SCAND, V53, P543, DOI 10.1111/j.1399-6576.2008.01852.x; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Davis Bradley D, 2002, Curr Opin Crit Care, V8, P571, DOI 10.1097/00075198-200212000-00015; Davis D P, 2001, Prehosp Emerg Care, V5, P163, DOI 10.1080/10903120190940065; Davis DP, 2007, RESUSCITATION, V73, P354, DOI 10.1016/j.resuscitation.2006.09.015; Deitch Sean, 2003, Prehosp Emerg Care, V7, P380, DOI 10.1080/10903120390936617; Filanovsky Y, 2010, CAN J EMERG MED, V12, P154; Gofrit ON, 1997, INJURY, V28, P41, DOI 10.1016/S0020-1383(96)00140-4; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Helm M, 1996, ANAESTHESIST, V45, P1196, DOI 10.1007/s001010050358; Kill C, 2004, ANASTH INTENSIV NOTF, V39, P668, DOI 10.1055/s-2004-826007; Kociszewski C, 2000, AM J EMERG MED, V18, P757, DOI 10.1053/ajem.2000.18033; KUZNETSOVA OY, 1984, VESTN KHIR IM GREKOV, V133, P88; Langrehr D, 1973, Acta Anaesthesiol Belg, V24, P71; Langrehr D, 1967, Anaesthesist, V16, P308; Newton A, 2008, EMERG MED J, V25, P498, DOI 10.1136/emj.2007.053421; Paal P, 2010, RESUSCITATION, V81, P148, DOI 10.1016/j.resuscitation.2009.10.023; Pallin DJ, 2010, INTENS CARE MED, V36, P1268, DOI 10.1007/s00134-010-1880-y; Pasquier M, 2012, INJURY, V43, P1377, DOI 10.1016/j.injury.2011.06.196; Podlesch I, 1967, Anaesthesist, V16, P299; Reid C, 2011, EMERG MED J, V28, P328, DOI 10.1136/emj.2010.092825; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Roberts K, 2009, EMERG MED J, V26, P128, DOI 10.1136/emj.2008.059899; Sibley A, 2011, EMERG MED J, V28, P521, DOI 10.1136/emj.2009.088237; Svenson JE, 2007, AM J EMERG MED, V25, P977, DOI 10.1016/j.ajem.2007.02.040; Swanson Eric R, 2004, Prehosp Emerg Care, V8, P273; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thomas MC, 2011, AM J HEALTH-SYST PH, V68, P2248, DOI 10.2146/ajhp110136; Thomas S, 2010, PREHOSP EMERG CARE, V14, P283, DOI 10.3109/10903127.2010.481758; Tiamfook-Morgan TO, 2006, PREHOSP EMERG CARE, V10, P363, DOI 10.1080/10903120600725835; Walls RM, 2008, ANN EMERG MED, V52, P13, DOI [10.1016/j.annemergmed.2008.01.344, 10.1016/j.annemergmed.2008.01.001]; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Zink BJ, 2004, ANN EMERG MED, V44, P451, DOI 10.1016/j.annemergmed.2004.05.001	42	19	21	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JUL	2013	31	7					1124	1132		10.1016/j.ajem.2013.03.041			9	Emergency Medicine	Emergency Medicine	179VR	WOS:000321550400024	23702065				2021-06-18	
J	Tam, AKH; Kapadia, A; Ilodigwe, D; Li, ZY; Schweizer, TA; Macdonald, RL				Tam, Alan K. H.; Kapadia, Anish; Ilodigwe, Don; Li, Zeyu; Schweizer, Tom A.; Macdonald, R. Loch			Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage Clinical article	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; vasospasm; cerebral infarction; cerebral atrophy; vascular disorders	INFLAMMATORY RESPONSE SYNDROME; FUNCTIONAL STATUS EXAMINATION; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; INFARCTION; VASOSPASM; VOLUME; SCALE; POPULATION	Object. Atrophy in specific brain areas correlates with poor neuropsychological outcome after subarachnoid hemorrhage (SAH). Few studies have compared global atrophy in SAH with outcome. The authors examined the relationship between global brain atrophy, clinical factors, and outcome after SAH. Methods. This study was a post hoc exploratory analysis of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial, a randomized, double-blind, placebo-controlled trial of 413 patients with aneurysmal SAH. Patients with infarctions or areas of encephalomalacia on CT, and those with large clip/coil artifacts, were excluded. The 97 remaining patients underwent CT at baseline and 6 weeks, which was analyzed using voxel-based volumetric measurements. The percentage difference in volume between time points was compared against clinical variables. The relationship with clinical outcome was modeled using univariate and multivariate analysis. Results. Older age, male sex, and systemic inflammatory response syndrome (SIRS) during intensive care stay were significantly associated with brain atrophy. Greater brain atrophy was significantly associated with poor outcome on the modified Rankin scale (mRS), severity of deficits on the National Institutes of Health Stroke Scale (NIHSS), worse executive functioning, and lower EuroQol Group-5D (EQ-5D) score. Adjusted for confounders, brain atrophy was not significantly associated with Mini-Mental State Examination and Functional Status Examination scores. Brain atrophy was not associated with angiographic vasospasm or delayed ischemic neurological deficit. Conclusions. Worse mRS score, NIHSS score, executive functioning, and EQ-5D scores were associated with greater brain atrophy and older age, male sex, and SIRS burden. These data suggest outcome is associated with factors that cause global brain injury independent of focal brain injury.	[Tam, Alan K. H.; Kapadia, Anish; Ilodigwe, Don; Li, Zeyu; Schweizer, Tom A.; Macdonald, R. Loch] St Michaels Hosp, Li Ka Shing Knowledge Inst, Labatt Family Ctr Excellence Brain Injury & Traum, Keenan Res Ctr,Div Neurosurg, Toronto, ON M5B 1W8, Canada; [Schweizer, Tom A.; Macdonald, R. Loch] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada	Macdonald, RL (corresponding author), St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	macdonaldlo@smh.ca	adsa, sdfadf/ABD-7369-2020	Tam, Alan/0000-0001-7155-6768	Physicians Services Incorporated Foundation; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Actelion Pharmaceuticals	R. Loch Macdonald is chief scientific officer of Edge Therapeutics, Inc., and receives grant support from the Physicians Services Incorporated Foundation, the Heart and Stroke Foundation of Canada, and the Canadian Institutes of Health Research. R. Loch Macdonald is a consultant for Actelion Pharmaceuticals, Ltd. Actelion Pharmaceuticals was the sponsor of the CONSCIOUS-1 trial and they provided financial support for the exploratory analysis described in this article. The data analysis and writing are the work of the authors.	BELL BA, 1985, NEUROSURGERY, V16, P498, DOI 10.1227/00006123-198504000-00011; Bendel P, 2006, NEUROLOGY, V67, P575, DOI 10.1212/01.wnl.0000230221.95670.bf; Bendel P, 2010, AM J NEURORADIOL, V31, P370, DOI 10.3174/ajnr.A1804; Bendel P, 2009, NEURORADIOLOGY, V51, P711, DOI 10.1007/s00234-009-0552-5; Biessels GJ, 2006, J NEUROL, V253, P477, DOI 10.1007/s00415-005-0036-4; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; de Bresser J, 2012, STROKE, V43, P2782, DOI 10.1161/STROKEAHA.112.669184; Dhar R, 2008, NEUROCRIT CARE, V8, P404, DOI 10.1007/s12028-008-9054-2; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Firbank MJ, 2007, J NEUROL, V254, P713, DOI 10.1007/s00415-006-0238-4; Fischer U, 2005, STROKE, V36, P2121, DOI 10.1161/01.STR.0000182099.04994.fc; Hadjivassiliou M, 2001, NEUROLOGY, V56, P1672, DOI 10.1212/WNL.56.12.1672; HALE PM, 1992, NEUROSURGERY, V31, P1085, DOI 10.1227/00006123-199212000-00015; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; Lin X, 2001, J NEUROL SCI, V189, P99, DOI 10.1016/S0022-510X(01)00576-7; Lindegaard K F, 1993, Adv Tech Stand Neurosurg, V20, P39; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Miklossy J, 2008, J ALZHEIMERS DIS, V13, P381; OHMAN J, 1991, J NEUROSURG, V74, P14, DOI 10.3171/jns.1991.74.1.0014; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Risselada R, 2010, EUR J EPIDEMIOL, V25, P261, DOI 10.1007/s10654-010-9432-x; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Rosengart AJ, 2007, STROKE, V38, P2315, DOI 10.1161/STROKEAHA.107.484360; SALERNO JA, 1992, HYPERTENSION, V20, P340, DOI 10.1161/01.HYP.20.3.340; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; SOININEN H, 1992, NEUROBIOL AGING, V13, P717, DOI 10.1016/0197-4580(92)90095-F; Staff RT, 2010, J AM GERIATR SOC, V58, P688, DOI 10.1111/j.1532-5415.2010.02765.x; Tam AKH, 2010, NEUROCRIT CARE, V13, P182, DOI 10.1007/s12028-010-9402-x; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; van der Zanden BP, 2006, DRUG ALCOHOL DEPEN, V82, P111, DOI 10.1016/j.drugalcdep.2005.08.012; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646; Zivadinov R, 2009, NEUROLOGY, V73, P504, DOI 10.1212/WNL.0b013e3181b2a706	37	19	21	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2013	119	1					198	206		10.3171/2013.3.JNS121950			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	168WT	WOS:000320739300038	23662822				2021-06-18	
J	Carlson, KF; Barnes, JE; Hagel, EM; Taylor, BC; Cifu, DX; Sayer, NA				Carlson, Kathleen F.; Barnes, Joan E.; Hagel, Emily M.; Taylor, Brent C.; Cifu, David X.; Sayer, Nina A.			Sensitivity and specificity of traumatic brain injury diagnosis codes in United States Department of Veterans Affairs administrative data	BRAIN INJURY			English	Article						Clinical coding; epidemiology; ICD-9-CM; public health surveillance; traumatic brain injury; validity	CASE ASCERTAINMENT; WAR VETERANS; HEAD-INJURY; VALIDITY; ACCURACY; AFGHANISTAN; PREVALENCE; IRAQ; CLAIMS; COSTS	Objective: To examine the validity of using International Classification of Diseases (ICD) diagnosis codes from United States Department of Veterans Affairs (VA) data to describe prevalence of traumatic brain injury (TBI) among military veterans. Methods: VA clinicians complete a standardized TBI evaluation to determine whether veterans' deployment exposures resulted in TBI. Clinician-confirmed cases and non-cases of TBI were used as recorded on the evaluation as the criterion standard against which to evaluate three series of TBI-related ICD diagnosis codes in national VA datasets. Focusing on codes used within VA, measures of validity were calculated and correlates of discordance examined, including patient characteristics, region and time. Secondarily, it was examined whether TBI codes can differentiate mild from more severe TBI cases. Results: Of 49 962 veterans with completed TBI evaluations, 29 534 (59%) received clinician-confirmed TBI diagnoses. Sensitivity of the VA series of codes was 70%, specificity was 82% and concordance was 75%. Concordance varied by region, but not by patient characteristics or time. Codes were not useful for distinguishing mild TBI. Conclusion: Estimates of TBI prevalence in military veterans are important for national programme development and resource distribution. Estimates derived from ICD diagnosis codes in administrative data should take potential misclassification into account.	[Carlson, Kathleen F.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA; [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Barnes, Joan E.; Hagel, Emily M.; Taylor, Brent C.; Sayer, Nina A.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Taylor, Brent C.; Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Cifu, David X.] Vet Hlth Adm, Phys Med & Rehabil Serv, Richmond, VA USA; [Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA	Carlson, KF (corresponding author), Portland VA Med Ctr R&D 66, Portland Ctr Study Chron Comorbid Mental & Phys D, 3715 SW US Vet Hosp Rd, Portland, OR 97239 USA.	kathleen.carlson@va.gov	Sayer, Nina/E-3249-2016; Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377; Cifu, David/0000-0003-1600-9387	United States Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development ServiceUS Department of Veterans Affairs [CDA 08-025]	This work was supported by a career development award from the United States Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (CDA 08-025). The opinions expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. The authors report no conflicts of interest.	Abellera J, 2005, STATES ARE COLLECTIN; [Anonymous], 2009, FED REGISTER, V74, P11; Babcock-Parziale JL, 2012, 08377 SDR HSR D STUD; Bagalman E., 2011, TRAUMATIC BRAIN INJU; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; BIJUR PE, 1990, PEDIATRICS, V86, P337; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; De Coster C, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-77; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Defense and Veterans Brain Injury Center, 2012, DOD NUMB TBI WORLDW; Department of Veterans Affairs Employee Education System, 2010, TRAUM BRAIN INJ IND; Department of Veterans Affairs. Office of Health Data and Informatics, 2010, FACT SHEET INT COD G; Department of Veterans Affairs. Office of Health Data and Informatics, 2009, FACT SHEET INT COD G; Department of Veterans Affairs. Office of Health Data and Informatics, 2008, FACT SHEET INT COD G; Department of Veterans Affairs. Office of Informatics and Analytics, 2011, FACT SHEED COD GUID; Department of Veterans Affairs Office of Rehabilitation Services, 2010, COMPR TBI EV; Department of Veterans Affairs Veterans Health Administration, 2012, VHA HDB; Department of Veterans Affairs VHA Support Services Center, COMPR TBI EV SUMM RE; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gravely AA, 2011, J REHABIL RES DEV, V48, P21, DOI 10.1682/JRRD.2009.08.0116; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hunt JP, 2000, J TRAUMA, V49, P679, DOI 10.1097/00005373-200010000-00016; Iverson G.L., 2007, BRAIN INJURY MED PRI; Ivins BJ, 2006, NEUROEPIDEMIOLOGY, V27, P154, DOI 10.1159/000096127; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kelsey JL, 1996, METHODS OBSERVATIONA, P354; Kostylova A, 2005, INJURY PREV, V11, P186, DOI 10.1136/ip.2004.006585; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Lix LM, 2008, J CLIN EPIDEMIOL, V61, P1250, DOI 10.1016/j.jclinepi.2008.02.002; McNaughton H, 2000, NEW ZEAL MED J, V113, P184; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Sigford B., 2008, NAT POL SYST CAR C E; Surjan G, 1999, INT J MED INFORM, V54, P77, DOI 10.1016/S1386-5056(98)00171-3; Tamblyn R, 2000, J CLIN EPIDEMIOL, V53, P183, DOI 10.1016/S0895-4356(99)00136-5; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; United States Department of Veterans Affairs, 2010, 2 VA IN TRAUM BRAIN; *US DEP HHS, 1989, INT CLASS DIS 9 REV; van Walraven C, 2012, J CLIN EPIDEMIOL, V65, P126, DOI 10.1016/j.jclinepi.2011.08.002; van Walraven C, 2011, J CLIN EPIDEMIOL, V64, P1054, DOI 10.1016/j.jclinepi.2011.01.001; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vose D., 2000, RISK ANAL QUANTITATI; WALTER SD, 1988, J CLIN EPIDEMIOL, V41, P923, DOI 10.1016/0895-4356(88)90110-2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	53	19	19	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2013	27	6					640	650		10.3109/02699052.2013.771795			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	143QO	WOS:000318882500002	23514276				2021-06-18	
J	Conklin, HM; Ashford, JM; Di Pinto, M; Vaughan, CG; Gioia, GA; Merchant, TE; Ogg, RJ; Santana, V; Wu, SJ				Conklin, Heather M.; Ashford, Jason M.; Di Pinto, Marcos; Vaughan, Christopher G.; Gioia, Gerard A.; Merchant, Thomas E.; Ogg, Robert J.; Santana, Victor; Wu, Shengjie			Computerized assessment of cognitive late effects among adolescent brain tumor survivors	JOURNAL OF NEURO-ONCOLOGY			English	Article						Pediatric; Cancer; ImPACT	CONFORMAL RADIATION-THERAPY; WORKING-MEMORY PERFORMANCE; PEDIATRIC-PATIENTS; CHILDHOOD-CANCER; CHILDREN; MEDULLOBLASTOMA; ATTENTION; OUTCOMES	Advantages of computerized assessment of neuropsychological functions include improved standardization and increased reliability of response time variables. Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) is a computerized battery developed for monitoring recovery following mild brain injuries that assesses attention, memory and processing speed. Despite evidence that core areas of deficit among cancer survivors are those assessed by ImPACT, it has not previously been used with this population. Twenty four childhood brain tumor (BT) survivors treated with conformal radiation therapy (mean age = 15.7 +/- A 1.6; mean age at irradiation = 9.8 +/- A 2.5), twenty solid tumor (ST) survivors treated without CNS-directed therapy (mean age = 16.2 +/- A 1.8) and twenty healthy siblings (mean age = 15.1 +/- A 1.6 years) were administered an age modified version of ImPACT. Additional computerized measures of working memory and recognition memory were administered. Univariate ANOVAs revealed group differences (p < 0.05) on measures of recognition memory, spatial working memory, processing speed and reaction time, with BT survivors performing significantly worse than ST survivors and siblings. Pearson correlation coefficients revealed significant associations between ImPACT memory tasks and computerized forced choice recognition tasks (rs = 0.30-0.33, p < 0.05). Multiple surgical resections, hydrocephalus and CSF shunt placement most consistently predicted worse ImPACT performance using linear mixed models (p < 0.05). The ImPACT test battery demonstrated sensitivity to cognitive late effects experienced by some BT survivors with clinical predictors of performance consistent with the pediatric oncology literature. Correlations with measures of similar constructs provide evidence for convergent validity. Findings offer initial support for the utility of ImPACT for monitoring of cognitive late effects.	[Conklin, Heather M.; Ashford, Jason M.] St Jude Childrens Res Hosp, Dept Psychol, Memphis, TN 38105 USA; [Di Pinto, Marcos] Childrens Hosp Orange Cty, Dept Pediat Psychol, Orange, CA 92668 USA; [Vaughan, Christopher G.; Gioia, Gerard A.] Childrens Natl Med Ctr, Ctr Neurosci Res, Washington, DC 20010 USA; [Merchant, Thomas E.] St Jude Childrens Res Hosp, Div Radiat Oncol, Memphis, TN 38105 USA; [Ogg, Robert J.] St Jude Childrens Res Hosp, Div Translat Imaging Res, Memphis, TN 38105 USA; [Santana, Victor] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Wu, Shengjie] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA	Conklin, HM (corresponding author), St Jude Childrens Res Hosp, Dept Psychol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	heather.conklin@stjude.org	Merchant, Thomas E/N-3344-2018; Conklin, Heather M/N-2696-2018	Merchant, Thomas E/0000-0002-0412-6255; 	National Cancer Institute (St. Jude Cancer Center Support [CORE]) [P30 CA21765]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21 CA131616]; International Neuropsychological Society; American Lebanese Syrian Associated Charities (ALSAC)American Lebanese Syrian Associated Charities (ALSAC); Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17 CCU323352]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA131616, P30CA021765] Funding Source: NIH RePORTER	This work was supported in part by the National Cancer Institute (St. Jude Cancer Center Support [CORE] Grant number P30 CA21765), (H.C., grant number R21 CA131616); the International Neuropsychological Society (H.C., Rita Rudel Award); and the American Lebanese Syrian Associated Charities (ALSAC). Research and development of the pediatric and adolescent/midrange version of the ImPACT battery was provided by the Centers for Disease Control and Prevention (G.G., award number U17 CCU323352). We thank the patients and their families who volunteered their time to participate. Portions of this paper were presented at the annual meeting of the International Neuropsychological Society in Boston, Massachusetts, February, 2011. Dr. Gioia is a co-author of Pediatric ImPACT and in the future may receive royalties, but has no financial interest in the adolescent/midrange version presented here. The remaining authors declare that they have no conflict of interest.	Aukema EJ, 2009, INT J RADIAT ONCOL, V74, P837, DOI 10.1016/j.ijrobp.2008.08.060; Conklin HM, 2008, J CLIN ONCOL, V26, P3965, DOI 10.1200/JCO.2007.15.9970; Conklin HM, 2007, DEV NEUROPSYCHOL, V31, P103, DOI 10.1207/s15326942dn3101_6; Conklin HM, 2012, J INT NEUROPSYCH SOC, V18, P996, DOI 10.1017/S1355617712000793; Crom Deborah B, 2007, J Cancer Surviv, V1, P237, DOI 10.1007/s11764-007-0026-x; Dennis M, 1998, MED PEDIATR ONCOL, P25; Di Pinto M, 2012, INT J RADIAT ONCOL, V84, pE363, DOI 10.1016/j.ijrobp.2012.03.066; Filley CM, 2001, NEW ENGL J MED, V345, P425, DOI 10.1056/NEJM200108093450606; Grill J, 1999, INT J RADIAT ONCOL, V45, P137, DOI 10.1016/S0360-3016(99)00177-7; Howarth RA, 2012, J INT NEUROPSYCH SOC, V28, P1; Kahalley LS, 2013, PSYCHO-ONCOLOGY, V22, P447, DOI 10.1002/pon.3021; Kirschen MP, 2008, BEHAV NEUROL, V20, P39, DOI [10.3233/BEN-2008-0216, 10.1155/2008/817253]; Krull KR, 2010, J CANCER SURVIV, V4, P210, DOI 10.1007/s11764-010-0123-0; Lovell MR, 2000, IMPACT; Mabbott DJ, 2008, NEUROPSYCHOLOGY, V22, P159, DOI 10.1037/0894-4105.22.2.159; Mabbott DJ, 2011, CANCER-AM CANCER SOC, V117, P5402, DOI 10.1002/cncr.26127; Maddrey AM, 2005, J NEURO-ONCOL, V72, P245, DOI 10.1007/s11060-004-3009-z; Merchant TE, 2004, J CLIN ONCOL, V22, P3156, DOI 10.1200/JCO.2004.11.142; Merchant TE, 2002, ONCOLOGY-NY, V16, P629; Merchant TE, 2009, J CLIN ONCOL, V27, P3691, DOI 10.1200/JCO.2008.21.2738; Mitby PA, 2003, CANCER, V97, P1115, DOI 10.1002/cncr.11117; Moore BD, 2005, J PEDIATR PSYCHOL, V30, P51, DOI 10.1093/jpepsy/jsi016; Mulhern Raymond K, 2004, Pediatr Rehabil, V7, P1, DOI 10.1080/13638490310001655528; Mulhern RK, 1999, ANN NEUROL, V46, P834, DOI 10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M; Mulhern RK, 2004, LANCET ONCOL, V5, P399, DOI 10.1016/S1470-2045(04)01507-4; Netson KL, 2012, INT J RADIAT ONCOL, V84, P217, DOI 10.1016/j.ijrobp.2011.10.043; Reddick WE, 2000, MAGN RESON IMAGING, V18, P787, DOI 10.1016/S0730-725X(00)00182-X; Reeves CB, 2006, J PEDIATR PSYCHOL, V31, P272, DOI 10.1093/jpepsy/jsj019; RUTTER M, 1976, J CHILD PSYCHOL PSYC, V17, P35, DOI 10.1111/j.1469-7610.1976.tb00372.x; Sands SA, 2012, J CLIN ONCOL, V30, P943, DOI 10.1200/JCO.2011.35.7533; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schultz KAP, 2007, J CLIN ONCOL, V25, P3649, DOI 10.1200/JCO.2006.09.2486; Wechsler D, 1999, ASSESSMENT	33	19	19	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	JUN	2013	113	2					333	340		10.1007/s11060-013-1123-5			8	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	162CD	WOS:000320241100019	23525951	Green Accepted			2021-06-18	
J	Stein, DM; Brenner, M; Hu, PF; Yang, S; Hall, EC; Stansbury, LG; Menaker, J; Scalea, TM				Stein, Deborah M.; Brenner, Megan; Hu, Peter F.; Yang, Shiming; Hall, Erin C.; Stansbury, Lynn G.; Menaker, Jay; Scalea, Thomas M.			Timing of Intracranial Hypertension Following Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article; Proceedings Paper	PROMMTT Symposium held at the 71st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 12-15, 2012	HI	Amer Assoc Surg Trauma		Traumatic brain injury; Intracranial pressure; Intracranial hypertension; Functional outcome	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; EDEMA; ICP; DEXANABINOL; DIAGNOSIS	We asked whether continuous intracranial pressure (ICP) monitoring data could provide objective measures of the degree and timing of intracranial hypertension (ICH) in the first week of neurotrauma critical care and whether such data could be linked to outcome. We enrolled adult (> 17 years old) patients admitted to our Level I trauma center within 6 h of severe TBI. ICP data were automatically captured and ICP 5-minute means were grouped into 12-hour time periods from admission (hour 0) to > 7 days (hour 180). Means, maximum, percent time (% time), and pressure-times-time dose (PTD, mmHg h) of ICP > 20 mmHg and > 30 mmHg were calculated for each time period. From 2008 to 2010, we enrolled 191 patients. Only 2.1 % had no episodes of ICH. The timing of maximum PTD20 was relatively equally distributed across the 15 time periods. Median ICP, PTD20, %time(20), and %time(30) were all significantly higher in the 84-180 h time period than the 0-84 h time period. Stratified by functional outcome, those with poor functional outcome had significantly more ICH in hours 84-180. Multivariate analysis revealed that, after 84 h of monitoring, every 5 % increase in PTD20 was independently associated with 21 % higher odds of having a poor functional outcome (adjusted odds ratio = 1.21, 95 % CI 1.02-1.42, p = 0.03). Although early elevations in ICP occur, ICPs are the highest later in the hospital course than previously understood, and temporal patterns of ICP elevation are associated with functional outcome. Understanding this temporal nature of secondary insults has significant implications for management.	[Stein, Deborah M.; Brenner, Megan; Hall, Erin C.; Menaker, Jay; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma,Div Crit Care, Baltimore, MD 21201 USA; [Stein, Deborah M.; Brenner, Megan; Hu, Peter F.; Yang, Shiming; Stansbury, Lynn G.; Menaker, Jay; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Ctr, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma,Div Crit Care, Baltimore, MD 21201 USA.	dstein@umm.edu; mbrenner@umm.edu; phu@umm.edu; syang@umm.edu; erincarlylehall@gmail.com; lynn.stansbury@gmail.com; jmenaker@umm.edu; tscalea@umm.edu	Yang, Shiming/I-3695-2015	Yang, Shiming/0000-0003-0338-4268; Stein, Deborah/0000-0003-3683-3963			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BUXTON RL, 1970, LANCET, V2, P498; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Lannoo E, 1998, INTENS CARE MED, V24, P236, DOI 10.1007/s001340050556; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Scalea TM, 2007, J TRAUMA, V62, P647, DOI 10.1097/TA.0b013e31802ee542; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	38	19	20	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2013	18	3					332	340		10.1007/s12028-013-9832-3			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	147II	WOS:000319159600007	23494545				2021-06-18	
J	Varsos, GV; de Riva, N; Smielewski, P; Pickard, JD; Brady, KM; Reinhard, M; Avolio, A; Czosnyka, M				Varsos, Georgios V.; de Riva, Nicolas; Smielewski, Peter; Pickard, John D.; Brady, Ken M.; Reinhard, Matthias; Avolio, Alberto; Czosnyka, Marek			Critical Closing Pressure During Intracranial Pressure Plateau Waves	NEUROCRITICAL CARE			English	Article						Critical closing pressure; Plateau waves; Intracranial pressure; Mathematical modeling; Wall tension	CEREBRAL BLOOD-VOLUME; COMMUNICATING HYDROCEPHALUS; ICP PATTERNS; FLOW; CIRCULATION; DEPENDENCE; CSF	Critical closing pressure (CCP) denotes a threshold of arterial blood pressure (ABP) below which brain vessels collapse and cerebral blood flow ceases. Theoretically, CCP is the sum of intracranial pressure (ICP) and arterial wall tension (WT). The aim of this study is to describe the behavior of CCP and WT during spontaneous increases of ICP, termed plateau waves, in order to quantify ischemic risk. To calculate CCP, we used a recently introduced multi-parameter method (CCPm) which is based on the modulus of cerebrovascular impedance. CCP is derived from cerebral perfusion pressure, ABP, transcranial Doppler estimators of cerebrovascular resistance and compliance, and heart rate. Arterial WT was estimated as CCPm-ICP. The clinical data included recordings of ABP, ICP, and transcranial Doppler-based blood flow velocity from 38 events of ICP plateau waves, recorded in 20 patients after head injury. Overall, CCPm increased significantly from 51.89 +/- A 8.76 mmHg at baseline ICP to 63.31 +/- A 10.83 mmHg at the top of the plateau waves (mean +/- A SD; p < 0.001). Cerebral arterial WT decreased significantly during plateau waves by 34.3 % (p < 0.001), confirming their vasodilatatory origin. CCPm did not exhibit the non-physiologic negative values that have been seen with traditional methods for calculation, therefore rendered a more plausible estimation of CCP. Rising CCP during plateau waves increases the probability of cerebral vascular collapse and zero flow when the difference: ABP-CCP (the "collapsing margin") becomes zero or negative.	[Varsos, Georgios V.; de Riva, Nicolas; Smielewski, Peter; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [de Riva, Nicolas] Univ Barcelona, Hosp Clin, Dept Anesthesiol, Barcelona, Spain; [Brady, Ken M.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Reinhard, Matthias] Univ Freiburg, Dept Neurol, D-79106 Freiburg, Germany; [Avolio, Alberto] Macquarie Univ, Australian Sch Adv Med, Sydney, NSW 2109, Australia; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Varsos, GV (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Hills Rd, Cambridge CB2 0QQ, England.	gv249@cam.ac.uk; nderiva@clinic.ub.es; ps10011@cam.ac.uk; jdp1000@medschl.cam.ac.uk; kmbrady@texaschildrens.org; matthias.reinhard@uniklinik-freiburg.de; alberto.avolio@mq.edu.au; mc141@medschl.cam.ac.uk	de Riva, Nicolas/AAN-3347-2020	de Riva, Nicolas/0000-0003-2691-5770; Avolio, Alberto/0000-0002-8311-2010; Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), NIHR Senior Investigator Awards; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0001354, G0001354B, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This study was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), NIHR Senior Investigator Awards (JDP) and the Medical Research Council (Grants G0600986 and G9439390).	Aaslid R, 2003, STROKE, V34, P1645, DOI 10.1161/01.STR.0000077927.63758.B6; Avezaat CJJ, 1984, THESIS; Batorski L, 1989, INTRACRANIAL PRESSUR, VVII, P189; BRUNNER MJ, 1983, AM J PHYSIOL, V245, pH453; Carrera E, 2011, EUR J NEUROL, V18, P711, DOI 10.1111/j.1468-1331.2010.03247.x; Castellani G, 2009, NEUROCRIT CARE, V11, P143, DOI 10.1007/s12028-009-9235-7; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; Czosnyka M, 2012, NEUROL RES, V34, P17, DOI 10.1179/1743132811Y.0000000040; Daley ML, 2005, ACT NEUR S, V95, P327; de Riva N, 2012, NEUROCRIT CARE, V17, P58, DOI 10.1007/s12028-012-9672-6; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; Gazzoli P, 2006, BRIT J NEUROSURG, V20, P348; GJERRIS F, 1982, ACTA NEUROCHIR, V64, P59, DOI 10.1007/BF01405619; HAYASHI M, 1985, J NEUROSURG, V63, P556, DOI 10.3171/jns.1985.63.4.0556; HAYASHI M, 1991, BRAIN, V114, P2681, DOI 10.1093/brain/114.6.2681; HAYASHI M, 1984, J NEUROSURG, V61, P30, DOI 10.3171/jns.1984.61.1.0030; HAYASHI M, 1985, J NEUROSURG, V62, P220, DOI 10.3171/jns.1985.62.2.0220; Kasprowicz M, 2012, NEUROCRIT CARE, V16, P213, DOI 10.1007/s12028-011-9653-1; Kim DJ, 2009, PHYSIOL MEAS, V30, P647, DOI 10.1088/0967-3334/30/7/009; Lopez-Magana JA, 2009, J CEREB BLOOD FLOW M, V29, P1; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MATSUDA M, 1979, J NEUROSURG, V50, P483, DOI 10.3171/jns.1979.50.4.0483; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; NICHOL J, 1951, AM J PHYSIOL, V164, P330; Panerai RB, 2003, MED ENG PHYS, V25, P621, DOI 10.1016/S1350-4533(03)00027-4; Panerai RB, 2011, PHYSIOL MEAS, V32, P1; Puppo Corina, 2012, Acta Neurochir Suppl, V114, P283, DOI 10.1007/978-3-7091-0956-4_55; RENIER D, 1982, J NEUROSURG, V57, P370, DOI 10.3171/jns.1982.57.3.0370; Richards HK, 1999, ACTA NEUROCHIR, V141, P1221, DOI 10.1007/s007010050422; RISBERG J, 1969, J NEUROSURG, V31, P303, DOI 10.3171/jns.1969.31.3.0303; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Rosner MJ, 1999, CARE NEUROSURG INT, P57; Schmidt B, 1999, J CEREBR BLOOD F MET, V19, P990, DOI 10.1097/00004647-199909000-00006; Soehle M, 2004, STROKE, V35, P1393, DOI 10.1161/01.STR.0000128411.07036.a9; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; Varsos GV, 2013, J CEREBR BLOOD F MET, V33, P235, DOI 10.1038/jcbfm.2012.161	38	19	19	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2013	18	3					341	348		10.1007/s12028-013-9830-5			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	147II	WOS:000319159600008	23512327				2021-06-18	
J	Hanks, RA; Sander, AM; Millis, SR; Hammond, FM; Maestas, KL				Hanks, Robin A.; Sander, Angelle M.; Millis, Scott R.; Hammond, Flora M.; Maestas, Kacey L.			Changes in Sexual Functioning From 6 to 12 Months Following Traumatic Brain Injury: A Prospective TBI Model System Multicenter Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; sexual dysfunction; traumatic brain injury	HEAD-INJURY; ADENOCARCINOMA; PRETREATMENT; DYSFUNCTION; BEHAVIOR	Objective: To investigate longitudinal changes in sexual functioning during the first year following moderate to severe traumatic brain injury (TBI). Design: Prospective cohort study. Setting: Community. Participants: 182 persons (53 women and 129 men) with moderate to severe TBI who were admitted to 1 of 6 participating TBI Model System centers and followed in the community at 6 and 12 months after injury. Main Measures: Derogatis Interview for Sexual Functioning-Self-Report (DISF-SR); Global Sexual Satisfaction Index (GSSI). Results: Mean T-scores on the DISF-SR Arousal subscale demonstrated marginal improvement over time, with a 2.59-point increase (P = .05) from 6 to 12 months after injury. There were no significant differences over this 6-month period on the remaining DISF-SR subscales, including sexual cognition/fantasy, sexual behavior/experience, and orgasm. There was no significant change in satisfaction with sexual functioning on the GSSI from 6 months (72% satisfied) to 12 months (71% satisfied). Conclusions and Implications: Sexual function and satisfaction appears to be stable in those with moderate to severe TBI from 6 to 12 months after injury, with the exception of minimal improvement in arousal. These findings, to our knowledge, reflect the first evidence regarding prospective changes in sexual functioning in this population. Future research can go far to assist clinicians in treatment planning and managing patient expectations of recovery of sexual functioning after TBI.	[Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Rehabil Inst Michigan, Detroit, MI 48201 USA; [Sander, Angelle M.; Maestas, Kacey L.] Harris Hlth Syst, Dept Phys Med & Rehabil, Baylor Coll Med, Houston, TX USA; [Sander, Angelle M.; Maestas, Kacey L.] TIRR Mem Hermann Dallas, Brain Injury Res Ctr, Dallas, TX USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Carolinas Rehabil, Carolinas HealthCare Syst, Charlotte, NC USA	Hanks, RA (corresponding author), Wayne State Univ, Sch Med, 261 Mack Ave,Ste 555, Detroit, MI 48201 USA.	rhanks@med.wayne.edu			National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133A080044, H133A070042, H133A070043, H133B031117]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant nos. H133A080044, H133A070042, H133A070043, and H133B031117)	Aloni A, 1999, BRAIN INJURY, V13, P89, DOI 10.1080/026990599121755; Aloni R, 1999, BRAIN INJURY, V13, P269, DOI 10.1080/026990599121647; Derogatis L, 1987, DEROGATIS INTERVIEW; Derogatis L. R., 1975, DEROGATIS SEXUAL FUN; Derogatis LR, 1997, J SEX MARITAL THER, V23, P291; Evans C., 1998, EVID-BASED MENT HEAL, V1, P70, DOI DOI 10.1136/EBMH.1.3.70; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Gervasio AH, 1999, SEXUALITY SEXUAL DYS; Gill CJ, 2011, J HEAD TRAUMA REHAB, V26, P56, DOI 10.1097/HTR.0b013e3182048ee9; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Nicolosi A, 2006, J SEX MARITAL THER, V32, P331, DOI 10.1080/00926230600666469; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; SABHESAN S, 1989, ARCH SEX BEHAV, V18, P349, DOI 10.1007/BF01541953; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; Sandel ME, 2007, SEXUALITY REPROD NEU; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P1331, DOI 10.1016/j.apmr.2012.03.037; Strauss D, 1991, SEX DISABIL, V9, P49; TEASDALE G, 1974, LANCET, V2, P81; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Zasler ND, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P729, DOI 10.1016/0360-3016(90)90503-C; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P1001, DOI 10.1016/0360-3016(90)90025-F	27	19	19	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2013	28	3					179	185		10.1097/HTR.0b013e31828b4fae			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	149PS	WOS:000319334000004	23661069				2021-06-18	
J	Keller, D; Kulp, H; Maher, Z; Santora, TA; Goldberg, AJ; Seamon, MJ				Keller, Deborah; Kulp, Heather; Maher, Zoe; Santora, Thomas A.; Goldberg, Amy J.; Seamon, Mark J.			Life after near death: Long-term outcomes of emergency department thoracotomy survivors	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Emergency department thoracotomy; long-term outcomes; quality of life	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; MAJOR TRAUMA; FUNCTIONAL CONSEQUENCES; ROOM THORACOTOMY; RECOVERY; DETERMINANTS; ADOLESCENTS; POPULATION	BACKGROUND: Predictors of hospital survival after emergency department thoracotomy (EDT) are well established, but little is known of long-term outcomes after hospital survival. Our primary study objective was to analyze the long-term social, cognitive, functional, and psychological outcomes in EDT survivors. METHODS: Review of our Level I trauma center registry (2000-2010) revealed that 37 of 448 patients survived hospitalization after EDT. Demographics and clinical characteristics were analyzed. After attempts to contact survivors, 21 patients or caretakers were invited to an outpatient study evaluation; 16 were unreachable (none of whom were present in the Social Security Death Index). Study evaluation included demographic and social data and an outpatient multidisciplinary assessment with validated scoring instruments (Mini-Mental Status Exam, Glasgow Outcome Scores, Timed Get-Up and Go Test, Functional Independence Measure Scoring, SF-36 Health Survey, and civilian posttraumatic stress disorder checklist). RESULTS: After extended hospitalization (43 +/- 41 days), disposition varied ( home, 62%; rehabilitation, 32%; skilled nursing facility, 6%), but readmission was common (33%) in the 37 EDT hospital survivors. Of the 21 contacted, 16 completed the study evaluation, 2 had died, 1 remained in a comatose state, and 2 were available by telephone only. While unemployment (75%), daily alcohol (50%), and drug use (38%) were common, of the 16 patients who underwent the comprehensive, multidisciplinary outpatient assessment after a median of 59 months following EDT, 75% had normal cognition and returned to normal activities, 81% were freely mobile and functional, and 75% had no evidence of posttraumatic stress disorder upon outpatient screening. CONCLUSION: Despite the common belief that EDT survivors often live with severe neurologic or functional impairment, we have found that most of our sampled EDT survivors had no evidence of long-term impairment. It is our hope that these results are considered by physicians making life or death decisions regarding the "futility'' of EDT in our most severely injured patients. Copyright (c) 2013 by Lippincott Williams & Wilkins	[Keller, Deborah] Univ Hosp Case Med Ctr, Dept Surg, Cleveland, OH USA; [Kulp, Heather] Alfred I duPont Childrens Hosp, Wilmington, DE USA; [Santora, Thomas A.; Goldberg, Amy J.] Temple Univ, Sch Med, Div Trauma & Surg Crit Care, Philadelphia, PA 19122 USA; [Maher, Zoe] Temple Univ, Sch Med, Dept Surg, Philadelphia, PA 19122 USA; [Seamon, Mark J.] Cooper Univ Hosp, Div Trauma & Surg Crit Care, Dept Surg, Camden, NJ 08103 USA	Seamon, MJ (corresponding author), Cooper Univ Hosp, Div Trauma & Surg Crit Care, Dept Surg, 3 Cooper Plaza,Suite 411, Camden, NJ 08103 USA.	seamon-mark@CooperHealth.edu	Keller, Deborah Susan/B-2043-2014; Seamon, Mark/AAM-4713-2021	Keller, Deborah Susan/0000-0002-8645-6206; 			Asensio JA, 2001, J AM COLL SURGEONS, V193, P303; Baker CC, 1980, AM J SURG, V39, P677; BOYD M, 1992, J TRAUMA, V33, P714, DOI 10.1097/00005373-199211000-00021; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; ESPOSITO TJ, 1991, J TRAUMA, V31, P881, DOI 10.1097/00005373-199107000-00001; Gabbe BJ, 2008, ANN SURG, V247, P854, DOI 10.1097/SLA.0b013e3181656d1e; Han PP, 2011, J TRAUMA, V70, P923, DOI 10.1097/TA.0b013e31820cf03e; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 2007, J TRAUMA, V62, P577, DOI 10.1097/TA.0b013e318031aa97; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; LORENZ HP, 1992, J TRAUMA, V32, P780, DOI 10.1097/00005373-199206000-00020; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; MILLHAM FH, 1993, J TRAUMA, V34, P332, DOI 10.1097/00005373-199303000-00004; Mollberg NM, 2011, ANN THORAC SURG, V92, P455, DOI 10.1016/j.athoracsur.2011.04.042; Moore EE, 2011, J TRAUMA, V70, P334, DOI 10.1097/TA.0b013e3182077c35; Oeyen SG, 2010, CRIT CARE MED, V38, P2386, DOI 10.1097/CCM.0b013e3181f3dec5; Passos EM, 2012, J AM COLL SURGEONS, V214, P18, DOI 10.1016/j.jamcollsurg.2011.09.020; Rhee PM, 2000, J AM COLL SURGEONS, V190, P288, DOI 10.1016/S1072-7515(99)00233-1; Seamon MJ, 2008, WORLD J SURG, V32, P604, DOI 10.1007/s00268-007-9392-9; Seamon MJ, 2007, J TRAUMA, V63, P113, DOI 10.1097/TA.0b013e31806842a1; Seamon MJ, 2011, J TRAUMA, V71, P306, DOI 10.1097/TA.0b013e31822178bd; SLOAN EP, 1995, J TRAUMA, V38, P736, DOI 10.1097/00005373-199505000-00010; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Timmers TK, 2011, ARCH SURG-CHICAGO, V146, P412, DOI 10.1001/archsurg.2010.279; Weninger P, 2008, J TRAUMA, V65, P799, DOI 10.1097/TA.0b013e3181820dae	27	19	19	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2013	74	5					1315	1320		10.1097/TA.0b013e31828c3db4			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	149JZ	WOS:000319316600027	23609284				2021-06-18	
J	Cheng, ZG; Zhang, GD; Shi, PQ; Du, BS				Cheng, Zhen-Guo; Zhang, Guo-Dong; Shi, Peng-Qiang; Du, Bao-Shun			Expression and antioxidation of Nrf2/ARE pathway in traumatic brain injury	ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE			English	Article						Traumatic brain injury; Nrf2/ARE pathway; Gene expression; Anti-oxidative stress	TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; NADPH OXIDASE; INHIBITION; MODULATION; PROTECTS; DAMAGE	Objective: To explore the expression of Nrf2/ARE pathway in hindbrain tissue after the traumatic brain injury (TBI) and its anti oxidative stress effect in the secondary nerve injury. Methods: The mice with Nrf2 gene knockout were used for the establishment of brain injury model. The experimental animals were divided into four groups: (Nrf2'/') sham- operation group, (Nrf2(-/-)) brain injury group, (Nrf2(-/-)) sham-operation group and (Nrf2'/') brain injury group. The specimen 24 h after cerebral trauma was selected. Then RT-PCR method was adopted to detect the expression of Nrf2 mRNA in brain; Western blotting method was adopted to detect the levels of Nrf2, HO-1 and NQO1 proteins in brain; ELISA method was adopted to detect the oxidative stress indicators: protein carbonyls, 4- hydroxy-2-nonenal (4-HNE) and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Results: The Nrf2 mRNA and protein of Nrf2(-)/(-) mice were not expressed, and the difference of the relative amount of Nrf2 mRNA between Nrf2(+)/(+) TBI group and Nrf2(+)/(+) sham-operation group was not statistically significant (P>0.05); the level of Nrf2 protein in Nrf2(+)/(+) TBI group increased significantly compared with the Nrf2(+)/(+) sham-operation group (P<0.01); in the sham operation groups, the levels of HO-1 and NQO1 proteins of Nrf2(-)/(-) mice decreased obviously compared with the Nrf2(+)/(-) mice (P<0.01); after brain injury, the levels of HO-1 and NQO1 proteins of Nrf2(-)/(-) mice increased obviously compared with the corresponding sham operation group (P<0.01); the levels of HO-1 and NQO1 proteins of Nrf2(-)/(-) mice in TBI group had no obvious change compared with the corresponding sham-operation group (P>0.05); there was only a little amount of expression of protein carbonyls, 4-HNE and 8-OHdC proteins in brain tissues in the Nrf2(+)/(+) and Nrf2(-)/(-) sham-operation groups, and the difference was not statistically significant (P>0.05); after brain injury, the three oxidative stress indicators were significantly up regulated in the Nrf2(+)/(+) and Nrf2(-)/(-) groups, and the up regulation of the latter group was more significant (P<0.01). Conclusions: After TBI the Nrf2/ARE pathway is activated and the activity of Nrf2 transcription regulation increases. However, the regulation dose not occur in the gene transcription level and only could increase the Nrf2 protein level, while the mRNA expression level has no obvious change. The nerve cell protective effect of Nrf2/ARE pathway in TBI achieves through inhibiting the oxidative stress injuries.	[Cheng, Zhen-Guo; Zhang, Guo-Dong; Shi, Peng-Qiang; Du, Bao-Shun] Xinxiang Cent Hosp, Dept Neurosurg 2, Xinxiang 453000, Henan Province, Peoples R China	Cheng, ZG (corresponding author), Xinxiang Cent Hosp, Dept Neurosurg 2, Xinxiang 453000, Henan Province, Peoples R China.	czg1971@sina.com					Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Calabrese V, 2006, ANTIOXID REDOX SIGN, V8, P444, DOI 10.1089/ars.2006.8.444; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Doverhag C, 2008, NEUROBIOL DIS, V31, P133, DOI 10.1016/j.nbd.2008.04.003; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; Mazur W, 2010, APMIS, V118, P703, DOI 10.1111/j.1600-0463.2010.02646.x; Ni HM, 2012, TOXICOL SCI, V127, P438, DOI 10.1093/toxsci/kfs133; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Otomo E, 2003, CEREBROVASC DIS, V15, P222, DOI 10.1159/000069318; Pan H, 2011, NEUROCHEM RES, V36, P2434, DOI 10.1007/s11064-011-0571-6; Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238; Siow RCM, 2007, REDOX REP, V12, P11, DOI 10.1179/135100007X162167; Stelmasiak Z, 2000, Med Sci Monit, V6, P426; Tang ZS, 2010, J EXP MED, V207, P867, DOI 10.1084/jem.20091704; Vomhof-DeKrey EE, 2012, J NUTR BIOCHEM, V23, P1201, DOI 10.1016/j.jnutbio.2012.03.005; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	22	19	22	0	16	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1995-7645	2352-4146		ASIAN PAC J TROP MED	Asian Pac. J. Trop. Med.	APR	2013	6	4					305	310		10.1016/S1995-7645(13)60061-9			6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	136AS	WOS:000318332400009	23608333	DOAJ Gold			2021-06-18	
J	Goldberg, DS				Goldberg, Daniel S.			Mild Traumatic Brain Injury, the National Football League, and the Manufacture of Doubt: An Ethical, Legal, and Historical Analysis	JOURNAL OF LEGAL MEDICINE			English	Article							SOCIAL CONDITIONS; PUBLIC-HEALTH; FUNDAMENTAL CAUSES; LONG ARM; PLAYERS; RACISM; EPIDEMIOLOGY; INEQUALITIES; CONCUSSION; EDUCATION		E Carolina Univ, Dept Bioeth & Interdisciplinary Studies, Greenville, NC 27858 USA	Goldberg, DS (corresponding author), E Carolina Univ, Dept Bioeth & Interdisciplinary Studies, Greenville, NC 27858 USA.	Goldbergd@ecu.edu					Abrams Douglas E., 2012, MISS SPORTS L REV, V2, P25; Abrams Douglas E., 2012, MISS SPORTS L REV, V2, P1; Abrams HK, 2001, J PUBLIC HEALTH POL, V22, P34, DOI 10.2307/3343553; Al Hazzouri AZ, 2011, J AGING HEALTH, V23, P1027, DOI 10.1177/0898264311421524; ALFRED LORD TENNYSON, 1964, CHARGE LIGHT BRIGADE, V1; [Anonymous], 2009, 111 C, P138; [Anonymous], 2011, BROWNS SAY COLT MCCO; [Anonymous], 2011, COMMUNICATION; Barnes LL, 2012, J INT NEUROPSYCH SOC, V18, P856, DOI 10.1017/S1355617712000628; Bashford Alison, 2007, Med Humanit, V33, P87, DOI 10.1136/jmh.2006.000251; Battista J., 2011, NY TIMES; Baugh Christine M., 2012, BOSTON U CTR STUDY T, P9; Beamon K.K., 2008, J NEGRO EDUC, V77, P352; BEAUCHAMP TL, 1975, AM PHILOS QUART, V12, P119; Birn A. - E., 2009, SOCIAL MED, V4, P166; BRODY HOWARD, 2007, HOOKED; Buchanan Neil H., 2013, RACE EXPLOITATION FO; Caladrone Justin P., 2002, SPORTS LAW J, V9, P131; Cartwright N., 1999, DAPPLED WORLD STUDY; Chang VW, 2009, J HEALTH SOC BEHAV, V50, P245, DOI 10.1177/002214650905000301; CRANOR CF, 1993, REGULATING TOXIC SUB; Ctrs. for Disease Control& Prevention, 2012, CONC ABCS LEARN RESP; De Ville Kenneth, 2002, Account Res, V9, P17; Denner K, 2004, SETON HALL J SPORTS, V14, P209; Denner Keya, 2004, SETON HALL J SPORTS, V14, P217; DeVille Kenneth A., 1992, MED MALPRACTICE 19 C; Edwards H, 2000, SOCIETY, V37, P9, DOI 10.1007/BF02686167; Epstein R., 2004, BROOKLYN LAW R, V69, P1421; Epstein RA, 2003, PERSPECT BIOL MED, V46, pS138, DOI 10.1353/pbm.2003.0051; ESPN.com, 2012, SCOTT FUJ CRIT ROG G; Fainaru-Wada Mark, 2012, NFL REPORTS REAMIN I; Fairchild AL, 2010, AM J PUBLIC HEALTH, V100, P54, DOI 10.2105/AJPH.2009.163956; Family Med. Assocs, 2012, NEW CONC GUID CHILDR; Feigin VL, 2010, BEST PRACT RES-CLIN, V24, P485, DOI 10.1016/j.bpa.2010.10.006; Feinberg Kenneth R., 1987, HOUS L REV, V24, P155; Feinberg Kenneth R., 1987, HOUS L REV, V24, P160; Feyerabend Paul K., 1987, FAREWELL REASON; Galea S, 2010, INT J EPIDEMIOL, V39, P97, DOI 10.1093/ije/dyp296; Gatmen E.J., 2011, SEATTLE J SOC JUST, V10, P509; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gee GC, 2011, DU BOIS REV, V8, P115, DOI 10.1017/S1742058X11000130; Gee GC, 2012, AM J PUBLIC HEALTH, V102, P967, DOI 10.2105/AJPH.2012.300666; Geertz Clifford, 1973, INTERPRETATION CULTU, V412, P449; Gilbert Frederic, 2011, AM J BIOTH NEUROSCI, p[48, 54], DOI DOI 10.1080/21507740.2011.611125; Glymour MM, 2008, NEUROPSYCHOL REV, V18, P194, DOI 10.1007/s11065-008-9066-x; Gol'dshtein D V, 2012, Vestn Ross Akad Med Nauk, P16; Goldberg D. S., 2013, GLOBALIZATION HLTH C, P403; Goldberg DS, 2012, PUBLIC HEALTH ETH-UK, V5, P104, DOI 10.1093/phe/phs013; Goldberg DS, 2012, AM J PUBLIC HEALTH, V102, P44, DOI 10.2105/AJPH.2011.300325; Goldberg DS, 2011, B HIST MED, V85, P1, DOI 10.1353/bhm.2011.0011; Goldberg DS, 2008, HEC FORUM, V20, P337, DOI 10.1007/s10730-008-9079-0; Grant Otis B, 2002, WHITTIER L REV, V24, P645; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gutmann A., 2004, WHY DELIBERATIVE DEM; Gutmann A, 2002, ETHICAL DIMENSIONS H, P77; HAMLIN CHRISTOPHER, 1998, CHRISTOPHER HAMLIN P, P1800; Hayward MD, 2004, DEMOGRAPHY, V41, P87, DOI 10.1353/dem.2004.0005; Hughes K, 2012, LANCET, V379, P1621, DOI 10.1016/S0140-6736(11)61851-5; Imwinkelried EJ, 1995, IOWA LAW REV, V81, P55; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Krimsky Sheldon, 2004, SCI PRIVATE INTEREST; Kuh D, 2003, J EPIDEMIOL COMMUN H, V57, P778, DOI 10.1136/jech.57.10.778; Kuh D, 2004, LIFE COURSE APPROACH; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Levy Alan H., 2003, TACKLING JIM CROW RA; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; Lomax ME, 1999, J SOC HIST, V33, P163, DOI 10.1353/jsh.1999.0017; Lomax ME, 2000, SOCIETY, V37, P21, DOI 10.1007/BF02686169; MacKenzie R, 2004, TOB CONTROL, V13, P79, DOI 10.1136/tc.2004.009233; Markowitz G, 2000, AM J PUBLIC HEALTH, V90, P36, DOI 10.2105/AJPH.90.1.36; Markowitz G., 2002, DECEIT DENIAL DEADLY; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; McCrory P., 2008, CONS STAT CONC SPORT, P43; McKee A, 2012, BRAIN A J NEUROL, V1, P1; Melendez MC, 2008, J BLACK PSYCHOL, V34, P423, DOI 10.1177/0095798408319874; MICHAELS DAVID, 2008, DOUBT IS THEIR PRODU, pX; Miller G, 2009, SCIENCE, V325, P670, DOI 10.1126/science.325_670; Mitten Matthew J., 2005, ST LOUIS U L J, V50, P211; Modin B, 2009, INT J EPIDEMIOL, V38, P733, DOI 10.1093/ije/dyp001; Mortensen Chris, 2011, SOURCE SYSTEM FAILUR; Munthe C, 2011, INT LIBR ETH LAW TEC, V6, P1, DOI 10.1007/978-94-007-1330-7; Najman JM, 2004, SOC SCI MED, V58, P1147, DOI 10.1016/S0277-9536(03)00286-7; NCAA, 2009 2010 STUD ATHL; NCAA, 2011, STUD ATHLET PART, P138; Noone Peter, 2009, Occup Med (Lond), V59, P209; NOWINSKI CHRISTOPHER, 2006, HEAD GAMES; Okasha S, 2001, PHILOS QUART, V51, P307, DOI 10.1111/1467-9213.00231; Overly Kathleen B., 2005, VA SPORTS ENT L J, V5, P31; Parascandola M, 2001, J EPIDEMIOL COMMUN H, V55, P905, DOI 10.1136/jech.55.12.905; Parmet W.E., 2000, ANNU REV PUBL HEALTH, V21, P445; Parmet WE, 2000, ANNU REV PUBL HEALTH, V21, P437, DOI 10.1146/annurev.publhealth.21.1.437; Phelan JC, 2010, J HEALTH SOC BEHAV, V51, pS28, DOI 10.1177/0022146510383498; Podberesky DJ, 2009, PEDIATR RADIOL, V39, P1264, DOI 10.1007/s00247-009-1359-6; Powers M., 2006, SOCIAL JUSTICE MORAL; Quanstrum KH, 2010, NEW ENGL J MED, V363, P1076, DOI 10.1056/NEJMsb1002538; Riis Jacob A., 1890, OTHER HALF LIVES STU; Rosen George, 1993, HIST PUBLIC HLTH; Rosenberg A., 1981, HUME PROBLEM CAUSATI; ROSNER D, 1995, HIVES SICKNESS PUBLI; Rosner D, 2007, AM J IND MED, V50, P740, DOI 10.1002/ajim.20435; Schwarz A, 2007, NY TIMES; Sharek Z, 2012, J LAW MED ETHICS, V40, P368, DOI 10.1111/j.1748-720X.2012.00670.x; Shavers VL, 2006, J NATL MED ASSOC, V98, P386; Sherek Zahariah, 2012, J LAW MED ETHICS, V40, P376; Sloan FA, 2005, J GERONTOL B-PSYCHOL, V60, pP242, DOI 10.1093/geronb/60.5.P242; Smith S., 1911, CITY WAS; Stark A, 2003, CONFLICT INTEREST AM; Starr Paul, 1982, SOCIAL TRANSFORMATIO; SZRETER SIMON, 2004, HLTH WEALTH STUDIES, P3; TAYLOR R, 1985, INT J HEALTH SERV, V15, P547, DOI 10.2190/XX9V-ACD4-KUXD-C0E5; Teplin LA, 2005, ARCH GEN PSYCHIAT, V62, P911, DOI 10.1001/archpsyc.62.8.911; Tesh Sylvia Noble, 2000, UNCERTAIN HAZARDS EN; Wagner WE, 2004, DUKE LAW J, V53, P1619; Weed DL, 2004, J MED PHILOS, V29, P313, DOI 10.1080/03605310490500527; Wiggins David K., 2012, WAKE FOREST J LAW PO, V2, P95; Williams DR, 1999, ANN NY ACAD SCI, V896, P173, DOI 10.1111/j.1749-6632.1999.tb08114.x; Winslade W., 1998, CONFRONTING TRAUMATI; Woodlief Jennifer Lynn, 1991, ENT SPORTS L, V9, P3	118	19	19	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0194-7648	1521-057X		J LEGAL MED	J. Legal Med.	APR 1	2013	34	2					157	191		10.1080/01947648.2013.800792			35	Law; Social Sciences, Biomedical	Government & Law; Biomedical Social Sciences	166QH	WOS:000320571700001	23781860				2021-06-18	
J	Govindarajan, S; McNeil, CJ; Lowry, JP; McMahon, CP; O'Neill, RD				Govindarajan, Sridhar; McNeil, Calum J.; Lowry, John P.; McMahon, Colm P.; O'Neill, Robert D.			Highly selective and stable microdisc biosensors for L-glutamate monitoring	SENSORS AND ACTUATORS B-CHEMICAL			English	Article						Glutamate; Biosensor; o-Phenylenediamine; Nafion; Selectivity; Stability	MODIFIED POLY(PHENYLENEDIAMINE)-COATED ELECTRODES; IN-VIVO; POLY(O-PHENYLENEDIAMINE) FILM; IMPEDANCE SPECTRA; BRUSH MODEL; OXIDASE; CARBON; POLYMER; ENZYME; NEUROTRANSMITTER	Glutamate mediates most of the excitatory synaptic transmission in the brain, and its abnormal regulation is considered a key factor underlying the appearance and progression of many neurodegenerative and psychiatric diseases. In this work, a microdisc-based amperometric biosensor for glutamate detection with highly enhanced selectivity and good stability is proposed. The biosensor utilizes the enzyme glutamate oxidase which was dip-coated onto 125 mu m diameter platinum discs. To improve selectivity, phosphatidylethanolamine was pre-coated prior to enzyme deposition, and electropolymerization of o-phenylenediamine was performed to entrap the enzyme within a polymer matrix. A variety of coating configurations were tested in order to optimize biosensor performance. For stability measurements, biosensors were biased continuously and calibration curves calculated each day for a period of 5-6 days. The optimized biosensors exhibited very high sensitivity (71 +/- 1 mA M-1 cm(-2)), low detection limit of similar to 2.5 mu M glutamate, selectivity (over 87% against ascorbic acid), very good temporal stability during continuous use, and a response time of <5 s. These biosensors are therefore good candidates for further development as devices for continuous monitoring during traumatic brain injury or neurosurgery. (c) 2013 Elsevier B.V. All rights reserved.	[Govindarajan, Sridhar] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [McNeil, Calum J.] Newcastle Univ, Dept Clin Biochem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Lowry, John P.] NUIM, Dept Chem, Maynooth, Kildare, Ireland; [McMahon, Colm P.; O'Neill, Robert D.] Univ Coll Dublin, UCD Sch Chem & Chem Biol, Dublin, Ireland	Govindarajan, S (corresponding author), Swansea Univ, Coll Engn, Swansea SA2 8PP, W Glam, Wales.	sri.govindarajan@gmail.com; calum.mcneil@newcastle.ac.uk	O'Neill, Robert D/D-7290-2014; McNeil, Calum/G-8059-2011	O'Neill, Robert D/0000-0002-9606-5065; McNeil, Calum/0000-0002-8513-087X; Govindarajan, Sridhar/0000-0002-0082-1429; Lowry, John/0000-0002-8957-6799	Northern Brainwave Appeal	The authors would like to thank Prof. A.D. Mendelow and Mr. Patrick Mitchell (Consultant Neurosurgeons, Newcastle General Hospital, Newcastle upon Tyne, UK) for their help and invaluable advice. The authors would also like to thank Northern Brainwave Appeal for funding a part of this research.	Alvarez-Crespo SL, 1997, BIOSENS BIOELECTRON, V12, P739, DOI 10.1016/S0956-5663(97)00041-9; Bartlett PN, 1997, J ELECTROCHEM SOC, V144, P3705, DOI 10.1149/1.1838079; Basu AK, 2006, BIOSENS BIOELECTRON, V21, P1968, DOI 10.1016/j.bios.2005.09.011; BERNERS MOM, 1994, ANAL CHEM, V66, P2017, DOI 10.1021/ac00085a016; Boutelle MG, 1996, J MOL RECOGNIT, V9, P664, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<664::AID-JMR318>3.0.CO;2-U; Brown FO, 2003, ANALYST, V128, P700, DOI 10.1039/b300266g; Burmeister JJ, 2003, TRAC-TREND ANAL CHEM, V22, P498, DOI 10.1016/S0165-9936(03)00904-X; Camurri G, 2005, J ELECTROANAL CHEM, V585, P181, DOI 10.1016/j.jelechem.2005.08.016; Castillo J, 2005, BIOSENS BIOELECTRON, V20, P2116, DOI 10.1016/j.bios.2004.09.013; CENTONZE D, 1994, ELECTROANAL, V6, P423, DOI 10.1002/elan.1140060511; CHIBA K, 1987, J ELECTROANAL CHEM, V219, P117, DOI 10.1016/0022-0728(87)85034-9; Daikhin Y, 2000, J NUTR, V130, p1026S, DOI 10.1093/jn/130.4.1026S; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dingledine Raymond, 1999, P315; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Frost M, 2006, ANAL CHEM, V78, P7370, DOI 10.1021/ac069475k; Govindarajan S, 2009, ANAL LETT, V42, P739, DOI 10.1080/00032710902721972; GOYETTE MA, 1995, J ELECTROANAL CHEM, V382, P17, DOI 10.1016/0022-0728(94)03632-D; Hirano A, 2006, MINI-REV MED CHEM, V6, P1091, DOI 10.2174/138955706778560102; Jeong H, 2011, J NANOSCI NANOTECHNO, V11, P987, DOI 10.1166/jnn.2011.3079; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; Killoran SJ, 2008, ELECTROCHIM ACTA, V53, P7303, DOI 10.1016/j.electacta.2008.03.076; Lancelot E, 1998, PROG BRAIN RES, V116, P331, DOI 10.1016/S0079-6123(08)60446-X; Lang GG, 2006, ELECTROCHIM ACTA, V51, P1680, DOI 10.1016/j.electacta.2005.02.100; Lang GG, 2004, J ELECTROANAL CHEM, V572, P283, DOI 10.1016/j.jelechem.2003.11.052; LOWRY JP, 1994, ELECTROANAL, V6, P369, DOI 10.1002/elan.1140060504; LOWRY JP, 1994, ANAL CHEM, V66, P1754, DOI 10.1021/ac00082a025; MALITESTA C, 1990, ANAL CHEM, V62, P2735, DOI 10.1021/ac00223a016; McAteer K, 1996, ANALYST, V121, P773, DOI 10.1039/an9962100773; McMahon CP, 2007, BIOSENS BIOELECTRON, V22, P1466, DOI 10.1016/j.bios.2006.06.027; McMahon CP, 2006, ANALYST, V131, P68, DOI 10.1039/b511643k; McMahon CP, 2004, CHEM COMMUN, P2128, DOI 10.1039/b408051n; Murphy LJ, 1998, ANAL CHEM, V70, P2928, DOI 10.1021/ac971182r; Nakamura N, 2005, ANAL BIOANAL CHEM, V383, P660, DOI 10.1007/s00216-005-0033-6; O'Neill RD, 1998, CRIT REV NEUROBIOL, V12, P69, DOI 10.1615/CritRevNeurobiol.v12.i1-2.40; O'Neill RD, 2004, BIOSENS BIOELECTRON, V19, P1521, DOI 10.1016/j.bios.2003.12.004; O'Neill RD, 2008, TRAC-TREND ANAL CHEM, V27, P78, DOI 10.1016/j.trac.2007.11.008; Oldenziel WH, 2007, J NEUROSCI METH, V160, P37, DOI 10.1016/j.jneumeth.2006.08.003; Rothwell SA, 2010, ELECTROCHIM ACTA, V55, P1051, DOI 10.1016/j.electacta.2009.09.069; Rothwell SA, 2009, ANAL CHEM, V81, P3911, DOI 10.1021/ac900162c; Ryan MR, 1997, ANALYST, V122, P1419, DOI 10.1039/a704508e; Sanchez CO, 2002, J APPL POLYM SCI, V85, P2564, DOI 10.1002/app.10875; SASSO SV, 1990, ANAL CHEM, V62, P1111, DOI 10.1021/ac00210a004; Shang FJ, 2009, ANALYST, V134, P519, DOI 10.1039/b814317j; Smith Y, 2005, DOPAMINE AND GLUTAMATE IN PSYCHIATRIC DISORDERS, P65, DOI 10.1007/978-1-59259-852-6_3; WANG J, 1994, ANAL CHEM, V66, P1988, DOI 10.1021/ac00085a011; Weinberg RJ, 1999, BRAIN RES BULL, V50, P353, DOI 10.1016/S0361-9230(99)00102-1; Wu CC, 2004, ANAL CHIM ACTA, V505, P239, DOI 10.1016/j.aca.2003.10.073; Yogeswaran U, 2008, SENSOR ACTUAT B-CHEM, V130, P739, DOI 10.1016/j.snb.2007.10.040; Zhu WL, 2011, J NANOSCI NANOTECHNO, V11, P138, DOI 10.1166/jnn.2011.2673	50	19	19	1	55	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND		0925-4005		SENSOR ACTUAT B-CHEM	Sens. Actuator B-Chem.	MAR 1	2013	178						606	614		10.1016/j.snb.2012.12.077			9	Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation	Chemistry; Electrochemistry; Instruments & Instrumentation	101BV	WOS:000315751100080		Green Accepted			2021-06-18	
J	Miltiadous, P; Kouroupi, G; Stamatakis, A; Koutsoudaki, PN; Matsas, R; Stylianopoulou, F				Miltiadous, Panagiota; Kouroupi, Georgia; Stamatakis, Antonios; Koutsoudaki, Paraskevi N.; Matsas, Rebecca; Stylianopoulou, Fotini			Subventricular Zone-Derived Neural Stem Cell Grafts Protect Against Hippocampal Degeneration and Restore Cognitive Function in the Mouse Following Intrahippocampal Kainic Acid Administration	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Stem cell transplantation; Neural stem cell; Insulin-like growth factors; Experimental models; Cellular therapy	TEMPORAL-LOBE EPILEPSY; GROWTH-FACTOR-I; TRAUMATIC BRAIN-INJURY; IGF-I; PRECURSOR CELLS; GABAERGIC INTERNEURONS; NEUROLOGICAL DISORDERS; PROGENITOR CELLS; GENE THERAPIES; SCAR FORMATION	Temporal lobe epilepsy (TLE) is a major neurological disease, often associated with cognitive decline. Since approximately 30% of patients are resistant to antiepileptic drugs, TLE is being considered as a possible clinical target for alternative stem cell-based therapies. Given that insulin-like growth factor I (IGF-I) is neuroprotective following a number of experimental insults to the nervous system, we investigated the therapeutic potential of neural stem/precursor cells (NSCs) transduced, or not, with a lentiviral vector for overexpression of IGF-I after transplantation in a mouse model of kainic acid (KA)-induced hippocampal degeneration, which represents an animal model of TLE. Exposure of mice to the Morris water maze task revealed that unilateral intrahippocampal NSC transplantation significantly prevented the KA-induced cognitive decline. Moreover, NSC grafting protected against neurodegeneration at the cellular level, reduced astrogliosis, and maintained endogenous granule cell proliferation at normal levels. In some cases, as in the reduction of hippocampal cell loss and the reversal of the characteristic KA-induced granule cell dispersal, the beneficial effects of transplanted NSCs were manifested earlier and were more pronounced when these were transduced to express IGF-I. However, differences became less pronounced by 2 months postgrafting, since similar amounts of IGF-I were detected in the hippocampi of both groups of mice that received cell transplants. Grafted NSCs survived, migrated, and differentiated into neurons-including glutamatergic cells-and not glia, in the host hippocampus. Our results demonstrate that transplantation of IGF-I producing NSCs is neuroprotective and restores cognitive function following KA-induced hippocampal degeneration. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:185-198	[Miltiadous, Panagiota; Stamatakis, Antonios; Koutsoudaki, Paraskevi N.; Stylianopoulou, Fotini] Univ Athens, Fac Nursing, Dept Basic Sci, Biol Biochem Lab, Athens 11527, Greece; [Kouroupi, Georgia; Koutsoudaki, Paraskevi N.; Matsas, Rebecca] Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, Athens, Greece	Stylianopoulou, F (corresponding author), Univ Athens, Fac Nursing, Dept Basic Sci, Biol Biochem Lab, 123 Papadiamantopoulou St, Athens 11527, Greece.	rmatsa@pasteur.gr; fstilian@nurs.uoa.gr	STYLIANOPOULOU, FOTINI/B-1403-2008; Stamatakis, A./J-5294-2019	Stamatakis, A./0000-0003-2480-5578; Koutsoudaki, Paraskevi N./0000-0003-4765-3730	framework of the Reinforcement Program of Human Research Manpower (PENED) [03ED82]; National and Community Funds; E.U. FP7 REGPOT Project Neurosign [264083]; Foundation BNP Paribas	The study is part of the 03ED82 research project, implemented within the framework of the Reinforcement Program of Human Research Manpower (PENED) and cofinanced by National and Community Funds (25% from the Greek General Secretariat for Research and Technology and 75% from E.U.-European Social Fund). R.M. acknowledges the support of E.U. FP7 REGPOT Project 264083 Neurosign and the Foundation BNP Paribas.	BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Binder DK, 2006, GLIA, V54, P358, DOI 10.1002/glia.20394; Bjorklund A, 2010, PROG BRAIN RES, V184, P265, DOI 10.1016/S0079-6123(10)84014-2; Bluthe RM, 2005, J NEUROIMMUNOL, V169, P50, DOI 10.1016/j.jneuroim.2005.07.017; Boison D, 2009, NEUROTHERAPEUTICS, V6, P278, DOI 10.1016/j.nurt.2008.12.001; Bondy CA, 2004, EUR J PHARMACOL, V490, P25, DOI 10.1016/j.ejphar.2004.02.042; Bondy CA, 2002, INT REV NEUROBIOL, V51, P189, DOI 10.1016/S0074-7742(02)51006-0; Carpentino JE, 2008, J NEUROSCI RES, V86, P512, DOI 10.1002/jnr.21514; Chesik D, 2007, INT REV NEUROBIOL, V79, P203, DOI 10.1016/S0074-7742(07)79009-8; de Lanerolle NC, 2005, EPILEPSY BEHAV, V7, P190, DOI 10.1016/j.yebeh.2005.06.003; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Fernandez AM, 2005, BRAIN RES REV, V50, P134, DOI 10.1016/j.brainresrev.2005.05.003; Florian C, 2006, LEARN MEMORY, V13, P465, DOI 10.1101/lm.249306; Gluckman PD, 1998, MOL CELL ENDOCRINOL, V140, P95, DOI 10.1016/S0303-7207(98)00035-5; Gold AE, 2005, HIPPOCAMPUS, V15, P808, DOI 10.1002/hipo.20103; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Hartman NW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015856; Hattiangady B, 2008, EXP NEUROL, V212, P468, DOI 10.1016/j.expneurol.2008.04.040; Heinemann U, 2000, EPILEPSIA, V41, pS185, DOI 10.1111/j.1528-1157.2000.tb01579.x; Helmstaedter C, 2002, PROG BRAIN RES, V135, P439; HOLMES GL, 1991, DEV BRAIN RES, V64, P47, DOI 10.1016/0165-3806(91)90208-Z; Hurtado-Chong A, 2009, EUR J NEUROSCI, V30, P742, DOI 10.1111/j.1460-9568.2009.06870.x; INSAUSTI R, 2004, HUMAN NERVOUS SYSTEM; Jessberger S, 2005, EXP NEUROL, V196, P342, DOI 10.1016/j.expneurol.2005.08.010; Kan EM, 2010, CURR MED CHEM, V17, P4492; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Katsimpardi L, 2008, STEM CELLS, V26, P1796, DOI 10.1634/stemcells.2007-0921; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Kazanis I, 2003, BRAIN RES, V991, P34, DOI 10.1016/S0006-8993(03)03525-X; Kesner RP, 2004, REV NEUROSCIENCE, V15, P333; Kouroupi G, 2010, J NEUROCHEM, V115, P460, DOI 10.1111/j.1471-4159.2010.06939.x; Kuruba R, 2009, EPILEPSY BEHAV, V14, P65, DOI 10.1016/j.yebeh.2008.08.020; LAURBERG S, 1979, J COMP NEUROL, V184, P685, DOI 10.1002/cne.901840405; Li TF, 2007, BRAIN, V130, P1276, DOI 10.1093/brain/awm057; Li TF, 2009, EPILEPSY RES, V84, P238, DOI 10.1016/j.eplepsyres.2009.01.002; Liu Xin-Feng, 2004, J Stroke Cerebrovasc Dis, V13, P16, DOI 10.1016/j.jstrokecerebrovasdis.2004.01.005; Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012; LOTHMAN EW, 1981, BRAIN RES, V218, P299, DOI 10.1016/0006-8993(81)91308-1; Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012; Makri G, 2010, STEM CELLS, V28, P127, DOI 10.1002/stem.258; Miltiadous P, 2011, EXP NEUROL, V231, P223, DOI 10.1016/j.expneurol.2011.06.014; Miltiadous P, 2010, CELL MOL NEUROBIOL, V30, P347, DOI 10.1007/s10571-009-9457-4; Naegele JR, 2010, NEUROPHARMACOLOGY, V58, P855, DOI 10.1016/j.neuropharm.2010.01.019; Oberheim NA, 2008, J NEUROSCI, V28, P3264, DOI 10.1523/JNEUROSCI.4980-07.2008; Ohlsson M, 2004, RESTOR NEUROL NEUROS, V22, P1; Parent JM, 2002, PROG BRAIN RES, V135, P121; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; Rao MS, 2007, NEUROBIOL DIS, V27, P117, DOI 10.1016/j.nbd.2007.03.016; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Schwarz SC, 2010, TRANSL RES, V156, P155, DOI 10.1016/j.trsl.2010.07.002; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Sequerra EB, 2010, CEREB CORTEX, V20, P2583, DOI 10.1093/cercor/bhq006; Shetty AK, 1999, EXP NEUROL, V158, P491, DOI 10.1006/exnr.1999.7107; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Shetty AK, 2011, NEUROTHERAPEUTICS, V8, P721, DOI 10.1007/s13311-011-0064-y; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Steiner B, 2008, NEUROSCIENCE, V154, P521, DOI 10.1016/j.neuroscience.2008.04.023; Torres-Aleman I, 2007, EXPERT OPIN THER TAR, V11, P1535, DOI 10.1517/14728222.11.12.1535; Turner RS, 1943, J COMP NEUROL, V79, P73, DOI 10.1002/cne.900790106; VONEIDA TJ, 1981, ANAT REC, V201, P91, DOI 10.1002/ar.1092010112; Waldau B, 2010, STEM CELLS, V28, P1153, DOI 10.1002/stem.446	64	19	22	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	MAR	2013	2	3					185	198		10.5966/sctm.2012-0074			14	Cell & Tissue Engineering	Cell Biology	110FO	WOS:000316428200012	23417642	DOAJ Gold, Green Published			2021-06-18	
J	Kanbak, G; Kartkaya, K; Ozcelik, E; Guvenal, AB; Kabay, SC; Arslan, G; Durmaz, R				Kanbak, Gungor; Kartkaya, Kazim; Ozcelik, Eda; Guvenal, Ahmet Burak; Kabay, Sibel Canbaz; Arslan, Gul; Durmaz, Ramazan			The neuroprotective effect of acute moderate alcohol consumption on caspase-3 mediated neuroapoptosis in traumatic brain injury: The role of lysosomal cathepsin L and nitric oxide	GENE			English	Article						Alcohol; Apoptosis; Caspase-3; Cathepsin L; Nitric oxide; Traumatic brain injury	ACUTE ETHANOL INTOXICATION; NEURONAL DEATH; INHIBITION; APOPTOSIS; PROTEASE; SYNTHASE; MODEL	Our aim in this study was to investigate the effect of moderate acute alcohol administration on cysteine protease mediated neuronal apoptosis and nitric oxide production in the traumatic brain injury. A total of 29 adult Sprague-Dawley male rats weighing 250-300 g were used. The rats were allocated into four groups. The first group was the control (sham-operated) group in which only a craniotomy was performed, the others were alcohol, trauma and trauma + alcohol groups. Caspase-3 enzyme activity in the trauma group increased significantly in comparison with the control group. The alcohol given group showed a decreased caspase-3 enzyme activity compared to the trauma group. The level of caspase-3 enzyme activity in the alcohol + trauma group decreased in comparison to the trauma group. SF/EEL ratio of cathepsin-L enzyme activity in the trauma group was significantly higher than in the control group. Our results indicate that moderate alcohol consumption may have protective effects on apoptotic cell death after traumatic brain injury. Protective effects of moderate ethanol consumption might be related to inhibition of lysosomal protease release and nitric oxide production. Published by Elsevier B.V.	[Kanbak, Gungor; Kartkaya, Kazim; Ozcelik, Eda] Eskisehir Osmangazi Univ, Sch Med, Dept Biochem, Eskisehir, Turkey; [Guvenal, Ahmet Burak; Durmaz, Ramazan] Eskisehir Osmangazi Univ, Sch Med, Dept Neurosurg, Eskisehir, Turkey; [Kabay, Sibel Canbaz] Kutahya Dumlupinar Univ, Sch Med, Dept Neurol, Kutahya, Turkey; [Arslan, Gul] Eskisehir Osmangazi Univ, Vocat High Sch Hlth Serv, Eskisehir, Turkey	Ozcelik, E (corresponding author), Eskisehir Osmangazi Univ, Sch Med, Dept Biochem, Eskisehir, Turkey.	eda_ozcelik@yahoo.com	Dokumacioglu, Eda/AAL-5167-2021	Dokumacioglu, Eda/0000-0001-6779-3082; canbaz kabay, sibel/0000-0003-4808-2191			CHANDLER LJ, 1994, J PHARMACOL EXP THER, V271, P67; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Costa ET, 2003, NEUROSCI LETT, V343, P41, DOI 10.1016/S0304-3940(03)00330-6; Davis RL, 2005, BRAIN RES REV, V49, P494, DOI 10.1016/j.brainresrev.2005.01.008; Durmaz R, 2008, NEUROCHEM RES, V33, P1683, DOI 10.1007/s11064-008-9605-0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; ICHIHARA K, 1987, J PHARMACOL EXP THER, V242, P1109; Is M, 2005, NEUROSURG QUART, V15, P60, DOI 10.1097/01.wnq.0000152407.39871.c7; Islekel H, 1999, BRAIN RES, V843, P18, DOI 10.1016/S0006-8993(99)01845-4; Jang MH, 2002, EUR J PHARMACOL, V449, P39, DOI 10.1016/S0014-2999(02)01973-8; Kavitha G, 2008, ALCOHOL, V42, P47, DOI 10.1016/j.alcohol.2007.10.006; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; KIRSCHKE H, 1983, BIOCHEM J, V214, P871, DOI 10.1042/bj2140871; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lu J, 2003, NEUROSCI LETT, V339, P147, DOI 10.1016/S0304-3940(03)00003-X; Marklund N., 1997, NEUROREPORT, V717, P109; Nabeshima T., 1996, EUR NEUROPSYCHOPHARM, V6, P156; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Savas HA, 2006, WORLD J BIOL PSYCHIA, V7, P51, DOI 10.1080/15622970510029993; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Zhang Yan-bo, 2006, Fa Yi Xue Za Zhi, V22, P404; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zink BJ, 2001, ALCOHOL CLIN EXP RES, V25, P916; Zovein A, 2004, AM J PHYSIOL-REG I, V286, pR273, DOI 10.1152/ajpregu.00160.2003	29	19	19	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-1119	1879-0038		GENE	Gene	JAN 10	2013	512	2					492	495		10.1016/j.gene.2012.10.012			4	Genetics & Heredity	Genetics & Heredity	073UP	WOS:000313768900050	23099040				2021-06-18	
J	Hellmich, HL; Rojo, DR; Micci, MA; Sell, SL; Boone, DR; Crookshanks, JM; DeWitt, DS; Masel, BE; Prough, DS				Hellmich, Helen L.; Rojo, Daniel R.; Micci, Maria-Adelaide; Sell, Stacy L.; Boone, Deborah R.; Crookshanks, Jeanna M.; DeWitt, Douglas S.; Masel, Brent E.; Prough, Donald S.			Pathway Analysis Reveals Common Pro-Survival Mechanisms of Metyrapone and Carbenoxolone after Traumatic Brain Injury	PLOS ONE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GENE-EXPRESSION; OXIDATIVE-PHOSPHORYLATION; COGNITIVE FUNCTION; MESSENGER-RNA; ALZHEIMERS; NEUROPROTECTION; GLUCOCORTICOIDS; IMPAIRMENT; INHIBITOR	Developing new pharmacotherapies for traumatic brain injury (TBI) requires elucidation of the neuroprotective mechanisms of many structurally and functionally diverse compounds. To test our hypothesis that diverse neuroprotective drugs similarly affect common gene targets after TBI, we compared the effects of two drugs, metyrapone (MT) and carbenoxolone (CB), which, though used clinically for noncognitive conditions, improved learning and memory in rats and humans. Although structurally different, both MT and CB inhibit a common molecular target, 11 beta hydroxysteroid dehydrogenase type 1, which converts inactive cortisone to cortisol, thereby effectively reducing glucocorticoid levels. We examined injury-induced signaling pathways to determine how the effects of these two compounds correlate with pro-survival effects in surviving neurons of the injured rat hippocampus. We found that treatment of TBI rats with MT or CB acutely induced in hippocampal neurons transcriptional profiles that were remarkably similar (i.e., a coordinated attenuation of gene expression across multiple injury-induced cell signaling networks). We also found, to a lesser extent, a coordinated increase in cell survival signals. Analysis of injury-induced gene expression altered by MT and CB provided additional insight into the protective effects of each. Both drugs attenuated expression of genes in the apoptosis, death receptor and stress signaling pathways, as well as multiple genes in the oxidative phosphorylation pathway such as subunits of NADH dehydrogenase (Complex1), cytochrome c oxidase (Complex IV) and ATP synthase (Complex V). This suggests an overall inhibition of mitochondrial function. Complex 1 is the primary source of reactive oxygen species in the mitochondrial oxidative phosphorylation pathway, thus linking the protective effects of these drugs to a reduction in oxidative stress. The net effect of the drug-induced transcriptional changes observed here indicates that suppressing expression of potentially harmful genes, and also, surprisingly, reduced expression of pro-survival genes may be a hallmark of neuroprotective therapeutic effects.	[Hellmich, Helen L.; Rojo, Daniel R.; Micci, Maria-Adelaide; Sell, Stacy L.; Boone, Deborah R.; Crookshanks, Jeanna M.; DeWitt, Douglas S.; Masel, Brent E.; Prough, Donald S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Hellmich, HL (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	Department of Anesthesiology; Moody Foundation; Moody Center for Traumatic Brain Injury and Spinal Cord Injury Research	This study was supported by the Department of Anesthesiology, the Moody Foundation and the Moody Center for Traumatic Brain Injury and Spinal Cord Injury Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Aubrecht J, 1996, RES COMMUN MOL PATH, V94, P47; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; BRODY TM, 1955, PHARMACOL REV, V7, P335; CAMPISI D, 1985, PHARMATHERAPEUTICA, V4, P166; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cole GM, 2010, CNS NEUROL DISORD-DR, V9, P140, DOI 10.2174/187152710791011991; Cote S, 2012, ALZHEIMERS DEMENT, V8, P219, DOI 10.1016/j.jalz.2011.03.012; DAVIES GJ, 1974, BRIT MED J, V3, P400, DOI 10.1136/bmj.3.5927.400; De Felice FG, 2006, IUBMB LIFE, V58, P185, DOI 10.1080/15216540600702198; de Quervain DJF, 1998, NATURE, V394, P787, DOI 10.1038/29542; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Du J, 2009, P NATL ACAD SCI USA, V106, P3543, DOI 10.1073/pnas.0812671106; Finkbeiner S, 2006, J NEUROSCI, V26, P10349, DOI 10.1523/JNEUROSCI.3829-06.2006; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Gareri P, 2004, NEUROPHARMACOLOGY, V47, P1205, DOI 10.1016/j.neuropharm.2004.08.021; Gohil M, 2010, NAT BIOTECHNOL, V28, P249; Gomes E, 2007, MOL CELL BIOCHEM, V305, P179, DOI 10.1007/s11010-007-9542-2; Guix FX, 2005, PROG NEUROBIOL, V76, P126, DOI 10.1016/j.pneurobio.2005.06.001; Guzman JN, 2010, NATURE, V468, P696, DOI 10.1038/nature09536; Haines BA, 2010, J CEREBR BLOOD F MET, V30, P1825, DOI 10.1038/jcbfm.2010.52; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Jahn H, 2004, ARCH GEN PSYCHIAT, V61, P1235, DOI 10.1001/archpsyc.61.12.1235; Jahn H, 2003, SLEEP, V26, P823, DOI 10.1093/sleep/26.7.823; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kasarskis A, 2011, PHARMACOGENOMICS, V12, P1695, DOI [10.2217/pgs.11.115, 10.2217/PGS.11.115]; KENNEDY JA, 1990, BRIT J ADDICT, V85, P1133; Khorasani MZ, 2009, PAK J PHARM SCI, V22, P349; Krugers HJ, 2000, STROKE, V31, P1162, DOI 10.1161/01.STR.31.5.1162; Laborie C, 2003, J NEUROENDOCRINOL, V15, P15, DOI 10.1046/j.1365-2826.2003.00859.x; Laborie C, 1995, NEUROENDOCRINOLOGY, V62, P601, DOI 10.1159/000127056; Lui JC, 2010, FASEB J, V24, P3083, DOI 10.1096/fj.09-152835; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; Mahmud T, 1996, ARTHRITIS RHEUM, V39, P1998, DOI 10.1002/art.1780391208; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nagayama S, 2001, LIFE SCI, V69, P2867, DOI 10.1016/S0024-3205(01)01362-5; Nguyen T, 2008, INT J DEV NEUROSCI, V26, P141, DOI 10.1016/j.ijdevneu.2007.10.004; Pilipovic K, 2011, NEUROCHEM RES, V36, P913, DOI 10.1007/s11064-011-0424-3; Pivato LS, 2006, J BIOCHEM MOL TOXIC, V20, P230, DOI 10.1002/jbt.20139; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Pozo K, 2010, NEURON, V66, P337, DOI 10.1016/j.neuron.2010.04.028; Riepe MW, 1997, J CEREBR BLOOD F MET, V17, P257, DOI 10.1097/00004647-199703000-00002; Rogoz Z, 2007, PHARMACOL REP, V59, P588; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Roozendaal B, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn766; Rotllant D, 2002, EUR J NEUROSCI, V16, P693, DOI 10.1046/j.1460-9568.2002.02120.x; Sandeep TC, 2004, P NATL ACAD SCI USA, V101, P6734, DOI 10.1073/pnas.0306996101; SAS Institute, 2004, SAS STAT 9 1 US GUID; Sato H, 2010, J CLIN BIOCHEM NUTR, V47, P224, DOI 10.3164/jcbn.10-58; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; Srivastava S, 2011, CURR PHARM DESIGN, V17, P3418, DOI 10.2174/138161211798072526; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tanaka EM, 2009, NAT REV NEUROSCI, V10, P713, DOI 10.1038/nrn2707; Tovar KR, 2009, J NEUROPHYSIOL, V102, P974, DOI 10.1152/jn.00060.2009; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Whitehead D, 1997, J MOL ENDOCRINOL, V19, P291, DOI 10.1677/jme.0.0190291; YOUNG EA, 1994, ARCH GEN PSYCHIAT, V51, P701; Zhang ZQ, 2010, METHODS MOL BIOL, V662, P317, DOI 10.1007/978-1-60761-800-3_16	72	19	19	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2013	8	1							e53230	10.1371/journal.pone.0053230			12	Multidisciplinary Sciences	Science & Technology - Other Topics	070YR	WOS:000313551500054	23326402	DOAJ Gold, Green Published			2021-06-18	
J	Chen, X; Zhao, ZL; Chai, Y; Luo, LL; Jiang, RC; Dong, JF; Zhang, JN				Chen, Xin; Zhao, Zilong; Chai, Yan; Luo, Lanlan; Jiang, Rongcai; Dong, Jingfei; Zhang, Jianning			Stress-dose hydrocortisone reduces critical illness-related corticosteroid insufficiency associated with severe traumatic brain injury in rats	CRITICAL CARE			English	Article							RANDOMIZED CONTROLLED-TRIAL; SEPTIC SHOCK; RECEPTOR ACTIVATION; CRITICAL-CARE; CELL-DEATH; BARRIER; EXPRESSION; APOPTOSIS; GLUCOCORTICOIDS; THERAPY	Introduction: The spectrum of critical illness-related corticosteroid insufficiency (CIRCI) in severe traumatic brain injury (TBI) is not fully defined and no effective treatments for TBI-induced CIRCI are available to date. Despite growing interest in the use of stress-dose hydrocortisone as a potential therapy for CIRCI, there remains a paucity of data regarding its benefits following severe TBI. This study was designed to investigate the effects of stress-dose hydrocortisone on CIRCI development and neurological outcomes in a rat model of severe traumatic brain injury. Methods: Rats were subjected to lateral fluid percussion injury of 3.2-3.5 atmosphere. These rats were then treated with either a stress-dose hydrocortisone (HC, 3 mg/kg/d for 5 days, 1.5 mg/kg on day 6, and 0.75 mg on day 7), a low-dose methylprednisolone (MP, 1 mg/kg/d for 5 days, 0.5 mg/kg on day 6, and 0.25 mg on day 7) or control saline solution intraperitoneally daily for 7 days after injury. Results: We investigated the effects of stress-dose HC on the mortality, CIRCI occurrence, and neurological deficits using an electrical stimulation test to assess corticosteroid response and modified neurological severity score (mNSS). We also studied pathological changes in the hypothalamus, especially in the paraventricular nuclei (PVN), after stress-dose HC or a low dose of MP was administered, including apoptosis detected by a TUNEL assay, blood-brain barrier (BBB) permeability assessed by brain water content and Evans Blue extravasation into the cerebral parenchyma, and BBB integrity evaluated by CD31 and claudin-5 expression. We made the following observations. First, 70% injured rats developed CIRCI, with a peak incidence on post-injury day 7. The TBI-associated CIRCI was closely correlated with an increased mortality and delayed neurological recovery. Second, post-injury administration of stress-dose HC, but not MP or saline increased corticosteroid response, prevented CIRCI, reduced mortality, and improved neurological function during the first 14 days post injury dosing. Thirdly, these beneficial effects were closely related to improved vascular function by the preservation of tight junctions in surviving endothelial cells, and reduced neural apoptosis in the PVN of hypothalamus. Conclusions: Our findings indicate that post-injury administration of stress-dose HC, but not MP reduces CIRCI and improves neurological recovery. These improvements are associated with reducing the damage to the tight junction of vascular endothelial cells and blocking neuronal apoptosis in the PVN of the hypothalamus.	[Chen, Xin; Zhao, Zilong; Chai, Yan; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Chen, Xin; Zhao, Zilong; Chai, Yan; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Chen, Xin; Zhao, Zilong; Chai, Yan; Jiang, Rongcai; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Chen, Xin; Zhao, Zilong; Chai, Yan; Jiang, Rongcai; Zhang, Jianning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin 300052, Peoples R China; [Luo, Lanlan] Tianjin Huanhu Hosp, Dept Psychol, Tianjin 300060, Peoples R China; [Dong, Jingfei] Univ Washington, Dept Med, Puget Sound Blood Res Inst JD, Div Hematol, Seattle, WA 98104 USA	Chen, X (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	xinchentianjin@me.com; jianningzhang@hotmail.com	Zhao, Zilong/AAZ-2196-2020		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000533]; Project of Tianjin Applied Basic and Cutting-edge Technological Research [13JCQNJC10500]	This work was supported by grants from the National Natural Science Foundation of China (grant no. 81000533), and the Project of Tianjin Applied Basic and Cutting-edge Technological Research (13JCQNJC10500).	Annane D, 2008, EUR RESPIR J, V31, P1150, DOI 10.1183/09031936.00040908; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Arafah BM, 2006, J CLIN ENDOCR METAB, V91, P3725, DOI 10.1210/jc.2006-0674; Asehnoune K, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-228; Aziz MH, 2012, J BIOL CHEM, V287, P29825, DOI 10.1074/jbc.M112.393256; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; Chantong B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-260; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen X, 2011, BRAIN RES, V1382, P298, DOI 10.1016/j.brainres.2011.01.045; Chen X, 2010, NEUROL RES, V32, P1097, DOI 10.1179/016164110X12681290831162; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; Crochemore C, 2005, MOL PSYCHIATR, V10, P790, DOI 10.1038/sj.mp.4001679; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gomes JA, 2005, CRIT CARE MED, V33, P1214, DOI 10.1097/01.CCM.0000166389.85273.38; Gursoy-Ozdemir Y, 2012, J NEUROCHEM, V123, P2, DOI 10.1111/j.1471-4159.2012.07938.x; JAATTELA M, 1991, ENDOCRINOLOGY, V128, P623; Ji RR, 1998, P NATL ACAD SCI USA, V95, P15635, DOI 10.1073/pnas.95.26.15635; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jung B, 2012, CRIT CARE, V16, DOI 10.1186/cc11871; Krugers HJ, 2010, NAT REV NEUROSCI, V11, P675, DOI 10.1038/nrn2913; Kwon YS, 2010, INTENS CARE MED, V36, P1845, DOI 10.1007/s00134-010-1971-9; Laurer H.L., 2002, ENCY HUMAN BRAIN, P93; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Ma B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056580; Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba; Marik PE, 2009, CHEST, V135, P181, DOI 10.1378/chest.08-1149; Martinho A, 2013, MOL CELL BIOCHEM, V376, P41, DOI 10.1007/s11010-012-1547-9; Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100; Miyauchi T, 2009, J ANESTH, V23, P266, DOI 10.1007/s00540-008-0725-0; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Oberleithner H, 2006, J CELL SCI, V119, P1926, DOI 10.1242/jcs.02886; Peng YS, 2009, CRIT CARE, V13, DOI 10.1186/cc7978; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Polito A, 2011, CRIT CARE MED, V39, P597, DOI 10.1097/CCM.0b013e31820b7426; Ramirez SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055972; RINK A, 1995, AM J PATHOL, V147, P1575; Roquilly A, 2011, JAMA-J AM MED ASSOC, V305, P1201, DOI 10.1001/jama.2011.360; Schimmer, 2011, GOODMAN GILMANS PHAR, P1209; Schlossmacher G, 2011, J ENDOCRINOL, V211, P17, DOI 10.1530/JOE-11-0135; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schoknecht K, 2012, EPILEPSIA, V53, P7, DOI 10.1111/j.1528-1167.2012.03697.x; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Triantos CK, 2011, CLIN GASTROENTEROL H, V9, P595, DOI 10.1016/j.cgh.2011.03.033; van Herck H, 1998, LAB ANIM-UK, V32, P377, DOI 10.1258/002367798780599794; Wajanaponsan N, 2007, CRIT CARE, V11, DOI 10.1186/cc5954; Walker ML, 2011, AM SURGEON, V77, P579; Wang T, 2013, J NEUROSURG, V118, P390, DOI 10.3171/2012.8.JNS12736; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao YD, 2001, WORLD J SURG, V25, P1202	57	19	21	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	5							R241	10.1186/cc13067			13	Critical Care Medicine	General & Internal Medicine	AB1HA	WOS:000331540900057	24131855	DOAJ Gold, Green Published			2021-06-18	
J	Huang, YH; Yang, TM; Lee, TC; Chen, WF; Yang, KY				Huang, Yu-Hua; Yang, Tzu-Ming; Lee, Tao-Chen; Chen, Wu-Fu; Yang, Ka-Yen			Acute autologous bone flap infection after cranioplasty for postinjury decompressive craniectomy	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Cranioplasty; Bone flap infection; Traumatic brain injury; Decompressive craniectomy; Risk factor	DELAYED CRANIOPLASTY; GRAFT INFECTION; FROZEN	Background: Acute bone flap infection is a devastating complication after cranioplasty for postinjury decompressive craniectomy. We aim to identify the risk factors of autologous bone flap infection. Methods: We enrolled 151 patients undergoing 153 cranioplasties in the 4-year retrospective study. Autologous bones stored at -75 degrees C were used in the cranioplasties. Acute bone flap infection was defined as the onset of infection <= 14 days after cranioplasty. The epidemiological data of patients and details of the cranioplasty procedure were recorded. Results: Acute bone flap infection was identified in five of the 153 cranioplasties, accounting for 3.3% of all episodes. Three of the 5 infected patients and five of 143 uninfected patients presented with dysfunction of subgaleal drainage comparatively, which was significantly different (p = 0.001). Statistical analysis of the cranioplasty procedures and subsequent results of the two patient groups revealed the following significant findings: the duration of operation (p = 0.03) and the length of hospital stay after cranioplasty (p < 0.001). Conclusions: Dysfunction of subgaleal drainage and long operative duration of cranioplasty are risk factors of acute autologous bone flap infection. Regarding the prolonged hospital stay in complicated patients, better surgical techniques should be implemented in order to eliminate the risks of infection. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.	[Huang, Yu-Hua; Yang, Tzu-Ming; Lee, Tao-Chen; Chen, Wu-Fu; Yang, Ka-Yen] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Hsien, Taiwan	Yang, KY (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, 123 Ta Pei Rd, Kaohsiung, Hsien, Taiwan.	newlupin2002@yahoo.com.tw					ABBOTT KH, 1953, J NEUROSURG, V10, P380, DOI 10.3171/jns.1953.10.4.0380; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Crotti F M, 1979, J Neurosurg Sci, V23, P289; ELLIOTT H, 1951, BRIT J SURG, V39, P31, DOI 10.1002/bjs.18003915305; Fry D.E., 2003, SURG SITE INFECT PAT; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Nagayama K, 2002, NEUROL SURG TOKYO, V30, P165; ODOM GL, 1952, J NEUROSURG, V9, P606, DOI 10.3171/jns.1952.9.6.0606; OSAWA M, 1990, ACTA NEUROCHIR, V102, P38, DOI 10.1007/BF01402184; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Zingale A, 2003, J Neurosurg Sci, V47, P137	13	19	22	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JAN	2013	44	1					44	47		10.1016/j.injury.2011.11.005			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	051MZ	WOS:000312132700008	22154044				2021-06-18	
J	Jonsson, CA; Catroppa, C; Godfrey, C; Smedler, AC; Anderson, V				Jonsson, Catherine Aaro; Catroppa, Cathy; Godfrey, Celia; Smedler, Ann-Charlotte; Anderson, Vicki			Cognitive Recovery and Development after Traumatic Brain Injury in Childhood: A Person-Oriented, Longitudinal Study	JOURNAL OF NEUROTRAUMA			English	Article						childhood; cognition; cluster analysis; follow-up studies; TBI	CHILDREN; PLASTICITY; MEMORY; TERM; PROFILES; OUTCOMES	Influence of childhood traumatic brain injury (TBI) on cognitive recovery and subsequent development is poorly understood. In this longitudinal study we used cluster analysis to explore acute stage individual profiles of injury age and cognition in 118 children with traumatic brain injury. Repeated measures of cognitive function were conducted at 30 months, indicating recovery, and 10 years post-injury, indicating development. Nine clusters were identified. Recovery was evident in three clusters, two of them with low functioning profiles. Developmental gains occurred for three clusters and an acute profile of higher freedom from distractibility (FFD) and lower processing speed (PS) was related to positive differences. One cluster, average low functioning and especially low verbal comprehension, demonstrated a slower development than peers. This suggests that developmental change after TBI in childhood takes place on a continuum, with both chance of long-term catching up, and risk of poor development. An acute profile of higher FFD and lower PS seemed to reflect injury consequences and were followed by developmental gains. These results challenge previous findings, and warrant further investigation.	[Jonsson, Catherine Aaro; Catroppa, Cathy; Godfrey, Celia; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia; [Smedler, Ann-Charlotte] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden	Jonsson, CA (corresponding author), Murdoch Childrens Res Inst, Melbourne, Vic, Australia.	catherine.aaro.jonsson@jll.se			Swedish Council for Working Life and Social ResearchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte) [2010-1390]; Victorian Government; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This article was supported by grants of Swedish Council for Working Life and Social Research (C.A.J., grant number 2010-1390), the Victorian Government's Operational Infrastructure Support Program, and the Australian National Health and Medical Research Council.	Allen DN, 2010, ARCH CLIN NEUROPSYCH, V25, P618, DOI 10.1093/arclin/acq051; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bergman L. R., 2006, DEV PSYCHOPATHOLOGY, P850, DOI [10.1002/9780470939383.ch21, DOI 10.1002/9780470939383.CH21]; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; El Khouri, 2003, STUDYING INDIVIDUAL; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Jonsson CA, 2009, BRAIN INJURY, V23, P1008, DOI 10.3109/02699050903379354; Kamphaus R.W., 2005, CHILD ADOLESCENT INT; Lehnung M, 2003, BRAIN INJURY, V17, P855, DOI 10.1080/0269905031000089369; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Mottram L, 2006, DEV NEUROPSYCHOL, V30, P865, DOI 10.1207/s15326942dn3003_6; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Pressley M., 1997, MEMORY DEV 2 20; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spencer-Smith M, 2009, DEV NEUROREHABIL, V12, P279, DOI 10.3109/17518420903090701; TEASDALE G, 1974, LANCET, V2, P81; Thaler NS, 2010, ARCH CLIN NEUROPSYCH, V25, P781, DOI 10.1093/arclin/acq073; von Eye A, 2006, J ADOLESCENCE, V29, P981, DOI 10.1016/j.adolescence.2006.06.007; Wechsler D, 1991, MANUAL WECHSLER SCAL; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D, 1989, MANUAL PRESCHOOL PRI; Yeates KO, 2005, NEUROPSYCHOLOGY, V19, P618, DOI 10.1037/0894-4105.19.5.618; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	40	19	20	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					76	83		10.1089/neu.2012.2592			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000002	23025803	Green Published			2021-06-18	
J	Majdan, M; Mauritz, W; Wilbacher, I; Brazinova, A; Rusnak, M; Leitgeb, J				Majdan, Marek; Mauritz, Walter; Wilbacher, Ingrid; Brazinova, Alexandra; Rusnak, Martin; Leitgeb, Johannes			Barbiturates Use and Its Effects in Patients with Severe Traumatic Brain Injury in Five European Countries	JOURNAL OF NEUROTRAUMA			English	Article						barbiturates; guidelines; intracranial pressure; medication; traumatic brain injury	REFRACTORY INTRACRANIAL HYPERTENSION; PENTOBARBITAL COMA; MANAGEMENT; EPIDEMIOLOGY; MODERATE; DESIGN	The guidelines for management of traumatic brain injury (TBI) recommend that high-dose barbiturate therapy may be considered to lower intracranial pressure (ICP) that is refractory to other therapeutic options. Lower doses of barbiturates may be used for sedation of patients with TBI, although there is no mention of this in the published guidelines. The goal of this study was to analyze the use of barbiturates in patients with severe TBI in the European centers where the International Neurotrauma Research Organization introduced guideline-based TBI management and to analyze the effects of barbiturates on ICP, use of vasopressors, and short- and long-term outcome of these patients. Data on 1172 patients with severe TBI were collected in 13 centers located in five European countries. Patients were categorized into three groups based on doses of barbiturates administered during treatment. Univariate and multivariate statistical methods were used to analyze the effects of barbiturates on the outcome of patients. Fewer than 20% of all patients with severe TBI were given barbiturates overall, and only 6% was given high doses. High-dose barbiturate treatment caused a decrease in ICP in 69% of patients but also caused hemodynamic instability leading to longer periods of mean arterial pressure <70mm Hg despite increased use of high doses of vasopressors. The adjusted analysis showed no significant effect on outcome on any stage after injury. Thiopental and methohexital were equally effective. Low doses of thiopental and methohexital were used for sedation of patients without side effects. Phenobarbital was probably used for prophylaxis of post-traumatic seizures.	[Majdan, Marek; Brazinova, Alexandra; Rusnak, Martin] Trnava Univ, Dept Publ Hlth, Fac Hlth Care & Social Work, Trnava 91843, Slovakia; [Majdan, Marek; Mauritz, Walter; Wilbacher, Ingrid; Brazinova, Alexandra; Rusnak, Martin] INRO, Vienna, Austria; [Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, Vienna, Austria	Majdan, M (corresponding author), Trnava Univ, Dept Publ Hlth, Fac Hlth Care & Social Work, Hornopotocna 23, Trnava 91843, Slovakia.	mmajdan@igeh.org	Rusnak, Martin/K-9349-2016; Majdan, Marek/K-5017-2012; Brazinova, Alexandra/C-4265-2016	Rusnak, Martin/0000-0003-3321-1042; Majdan, Marek/0000-0001-8037-742X; Brazinova, Alexandra/0000-0003-0625-256X; Mauritz, Walter/0000-0001-9043-3712	European Union grant (Project "Research - Treat - TBI"; 6th Framework Program: INCO-DEV: International Cooperation with Developing Countries) [ICA2-CT-2002-100]; Austrian Worker's Compensation Board (AUVA) [FK 33/2003]; "Jubilee Fund" of the Austrian National Bank [8987]	The data used for this study were collected for a project funded by an European Union grant (Project "Research - Treat - TBI"; 6th Framework Program: INCO-DEV: International Cooperation with Developing Countries 1998-2002; Contract number: ICA2-CT-2002-100), and for another project funded by the Austrian Worker's Compensation Board (AUVA; Contract number FK 33/2003), and by the "Jubilee Fund" of the Austrian National Bank (Project number 8987). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by donations from various sources.	[Anonymous], 2000, J Neurotrauma, V17, P527; Blissitt PA, 2012, AACN ADV CRIT CARE, V23, P186, DOI 10.1097/NCI.0b013e31824db4f3; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock MR, 1996, J NEUROTRAUM, V13, P711; Bullock MR, 2007, J NEUROTRAUMA SUPPL, V24, P1; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kirchberger K, 1998, EPILEPSIA, V39, P1104, DOI 10.1111/j.1528-1157.1998.tb01297.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Majdan M, 2011, BRAIN INJURY, V25, P797, DOI 10.3109/02699052.2011.581642; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; Perez-Barcena J, 2008, CRIT CARE, V12, DOI 10.1186/cc6999; Rangel-Castillo L, 2006, CRIT CARE CLIN, V22, P713, DOI 10.1016/j.ccc.2006.06.003; ROBERTS I, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000033; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WorldBank, 2011, WE CLASS COUNTR	26	19	20	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					23	29		10.1089/neu.2012.2554			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300005	22950895	Green Published			2021-06-18	
J	Ponsford, J; Tweedly, L; Taffe, J				Ponsford, Jennie; Tweedly, Laura; Taffe, John			The relationship between alcohol and cognitive functioning following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Alcohol use; Cognition; Memory; Executive function; Processing speed	SUBSTANCE-ABUSE; CONSUMPTION; DISORDERS; MODERATE; PERFORMANCE; PATTERNS; DRINKING; ATROPHY; MISUSE; DAMAGE	The present study aimed to examine the association between frequency and quantity of alcohol consumption and cognitive functioning following traumatic brain injury (TBI). Sixty moderately to severely injured individuals had completed the Alcohol Use Disorders Identification Test (AUDIT) to measure preinjury alcohol use soon after injury and were recruited and assessed with AUDIT and Time Line Follow-Back (TLFB), as a measure of frequency and quantity of alcohol consumption at 6-9 months post injury. Fifty participants completed both AUDIT and TLFB at a follow-up assessment at 12-15 months post injury. Measures of processing speed/attention, memory, and executive function were also administered. Regression analyses were used to examine the relationships between alcohol use and cognition at the two occasions of measurement. Harmful or hazardous alcohol use pre injury was associated with poorer memory performance on the California Verbal Learning Test (CVLT-II) and slower processing speed on Symbol Digit Modalities Test on average across postinjury measurement occasions, but not with executive functioning, measured by the Modified Six Elements Test (MSET) at 6-9 months post injury. On the other hand, executive functioning on MSET 6-9 months post injury was significantly poorer in participants who were consuming any alcohol at all in the month prior to follow-up assessment. The current study provides evidence showing that pre- and postinjury alcohol use is negatively associated with different aspects of cognitive functioning following TBI. In addition to providing some support for the provision of advice to abstain from alcohol after injury, these findings suggest that interventions to reduce postinjury alcohol use may be useful.	[Ponsford, Jennie; Tweedly, Laura; Taffe, John] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu					Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 1997, REHABIL PSYCHOL, V42, P259; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Estruch R, 1997, J NEUROL SCI, V146, P145, DOI 10.1016/S0022-510X(96)00298-5; Green A, 2010, ALCOHOL CLIN EXP RES, V34, P443, DOI 10.1111/j.1530-0277.2009.01108.x; Harding AJ, 1996, NEUROSCIENCE, V72, P699, DOI 10.1016/0306-4522(95)00577-3; Harper C, 2005, ALCOHOL CLIN EXP RES, V29, P1106, DOI 10.1097/01.ALC.0000171490.09017.A9; Harper C, 2005, CURR OPIN PHARMACOL, V5, P73, DOI 10.1016/j.coph.2004.06.011; HARPER C, 1985, J NEUROL NEUROSUR PS, V48, P211, DOI 10.1136/jnnp.48.3.211; HARPER CG, 1988, BRIT J ADDICT, V83, P613; HAYAKAWA K, 1992, ACTA RADIOL, V33, P201; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kleykamp BA, 2010, EXP CLIN PSYCHOPHARM, V18, P1, DOI 10.1037/a0018407; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kril JJ, 1997, NEUROSCIENCE, V79, P983, DOI 10.1016/S0306-4522(97)00083-3; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; PFEFFERBAUM A, 1988, ALCOHOL CLIN EXP RES, V12, P81, DOI 10.1111/j.1530-0277.1988.tb00137.x; PFEFFERBAUM A, 1995, ALCOHOL CLIN EXP RES, V19, P1177, DOI 10.1111/j.1530-0277.1995.tb01598.x; PHILLIPS SC, 1987, BRAIN, V110, P301, DOI 10.1093/brain/110.2.301; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Ponsford J, 2012, TRAUMATIC BRAIN INJU; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Rochat L, 2009, J NEUROPSYCHOL, V3, P213, DOI 10.1348/174866408X397656; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Searles JS, 2000, PSYCHOL ADDICT BEHAV, V14, P277, DOI 10.1037/0893-164X.14.3.277; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1973, SYMBOL DIGIT MODALIT; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; Strauss E., 2006, COMPEDIUM NEUROPSYCH; Sullivan EV, 2009, ALCOHOL ALCOHOLISM, V44, P155, DOI 10.1093/alcalc/agn103; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Turner AP, 2006, REHABIL PSYCHOL, V51, P78, DOI 10.1037/0090-5550.51.1.78; Verbaten MN, 2009, HUM PSYCHOPHARM CLIN, V24, P199, DOI 10.1002/hup.1022; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Wilson, 1991, NATL ADULT READING T; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2008, BRAIN INJURY, V22, P905, DOI 10.1080/02699050802491271	54	19	20	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN 1	2013	35	1					103	112		10.1080/13803395.2012.752437			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	189YL	WOS:000322304100011	23339581				2021-06-18	
J	Friedenberg, SG; Butler, AL; Wei, L; Moore, SA; Cooper, ES				Friedenberg, Steven G.; Butler, Amy L.; Wei, Lai; Moore, Sarah A.; Cooper, Edward S.			Seizures following head trauma in dogs: 259 cases (1999-2009)	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC EPILEPSY; BRAIN-INJURY; RESPONSE RATES; EPIDEMIOLOGY; RISK	Objective To determine whether dogs with head trauma have a greater incidence of seizures than the general canine patient population. Design Retrospective case series. Animals-259 client-owned dogs. Procedures Medical records of dogs evaluated for head trauma at The Ohio State University Veterinary Medical Center from 1999 to 2009 were reviewed. Data were collected regarding the cause of the head trauma, physical examination and neurologic examination findings, comorbidities, and the development of seizures during hospitalization. A telephone survey was conducted to question owners regarding the development of seizures after discharge. Relationships between the nature of the head trauma and the development of seizures were then examined. Results-3.5% of dogs with head trauma developed in-hospital seizures, and 6.8% of dogs with head trauma for which follow-up information was available developed seizures after hospital discharge, compared with an epilepsy rate of 1.4% in our hospital. Dogs that developed in-hospital seizures were significantly more likely to have been hit by a car or experienced acceleration-deceleration injury. Additionally, 10% of dogs with traumatic brain injury had in-hospital seizures. No visit or patient characteristics were significantly associated with the development of out-of-hospital seizures. Conclusions and Clinical Relevance Dogs with head trauma may develop seizures at a greater rate than dogs in the general canine patient population. Particularly in the immediate to early posttraumatic period, clinicians should remain vigilant for the development of posttraumatic seizures and treat patients accordingly. (J Am Vet Med Assoc 2012;241:1479-1483)	[Friedenberg, Steven G.; Butler, Amy L.; Moore, Sarah A.; Cooper, Edward S.] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA; [Wei, Lai] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA	Friedenberg, SG (corresponding author), Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA.	friedenberg.4@osu.edu	Friedenberg, Steven/L-2681-2019; Moore, Sarah/D-2682-2012	Friedenberg, Steven/0000-0002-7510-2322; Moore, Sarah/0000-0002-4311-6199			Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hocking JS, 2006, J CLIN EPIDEMIOL, V59, P521, DOI 10.1016/j.jclinepi.2005.10.009; Iudice A, 2000, DRUGS, V59, P1091, DOI 10.2165/00003495-200059050-00005; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Keeter S, 2006, PUBLIC OPIN QUART, V70, P759, DOI 10.1093/poq/nfl035; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; O'Toole J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-71; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Platt SR, 2002, VET REC, V151, P243, DOI 10.1136/vr.151.8.243; Platt SR, 2001, J VET INTERN MED, V15, P581, DOI 10.1892/0891-6640(2001)015&lt;0581:TPVOTM&gt;2.3.CO;2; Platt SR, 2007, J VET INT MED, V21, P1145; PODELL M, 1995, J AM VET MED ASSOC, V206, P1721; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Zimmermann R, 2009, J VET INTERN MED, V23, P970, DOI 10.1111/j.1939-1676.2009.0368.x	23	19	19	0	28	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488	1943-569X		JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	DEC 1	2012	241	11					1479	1483		10.2460/javma.241.11.1479			5	Veterinary Sciences	Veterinary Sciences	044XB	WOS:000311657400013	23176240				2021-06-18	
J	Oliva, AA; Kang, Y; Furones, C; Alonso, OF; Bruno, O; Dietrich, WD; Atkins, CM				Oliva, Anthony A., Jr.; Kang, Yuan; Furones, Concepcion; Alonso, Ofelia F.; Bruno, Olga; Dietrich, W. Dalton; Atkins, Coleen M.			Phosphodiesterase isoform-specific expression induced by traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						cAMP; fluid-percussion; inflammation; isoform; phosphodiesterase; traumatic brain injury	CAMP-SPECIFIC PHOSPHODIESTERASES; RAT-BRAIN; DIFFERENTIAL EXPRESSION; FUNCTIONAL RECOVERY; SPLICE VARIANTS; PDE4 INHIBITORS; TNF-ALPHA; ROLIPRAM; IV; LOCALIZATION	Traumatic brain injury (TBI) results in significant inflammation which contributes to the evolving pathology. Previously, we have demonstrated that cyclic AMP (cAMP), a molecule involved in inflammation, is down-regulated after TBI. To determine the mechanism by which cAMP is down-regulated after TBI, we determined whether TBI induces changes in phosphodiesterase (PDE) expression. Adult male Sprague Dawley rats received moderate parasagittal fluid-percussion brain injury (FPI) or sham injury, and the ipsilateral, parietal cortex was analyzed by western blotting. In the ipsilateral parietal cortex, expression of PDE1A, PDE4B2, and PDE4D2, significantly increased from 30 min to 24 h post-injury. PDE10A significantly increased at 6 and 24 h after TBI. Phosphorylation of PDE4A significantly increased from 6 h to 7 days post-injury. In contrast, PDE1B, PD4A5, and PDE4A8 significantly decreased after TBI. No changes were observed with PDE1C, PDE3A, PDE4B1/3, PDE4B4, PDE4D3, PDE4D4, PDE8A, or PDE8B. Co-localization studies showed that PDE1A, PDE4B2, and phospho-PDE4A were neuronally expressed, whereas PDE4D2 was expressed in neither neurons nor glia. These findings suggest that therapies to reduce inflammation after TBI could be facilitated with targeted therapies, in particular for PDE1A, PDE4B2, PDE4D2, or PDE10A.	[Oliva, Anthony A., Jr.; Kang, Yuan; Furones, Concepcion; Alonso, Ofelia F.; Dietrich, W. Dalton; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bruno, Olga] Univ Genoa, Dept Pharm, Med Chem Sect, Genoa, Italy	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14 Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069721, AG033266, NS056072]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS056072, R01NS069721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG033266] Funding Source: NIH RePORTER	This work was supported by The Miami Project to Cure Paralysis, and National Institutes of Health grants NS069721, AG033266, and NS056072. We thank Dr. Beata Frydel and Dayaris Morffi for technical assistance. The authors declare no conflicts of interest.	Ahmed T, 2005, BRAIN RES, V1041, P212, DOI 10.1016/j.brainres.2005.02.023; Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; Atkins CM, 2012, J NEUROSCI RES, V90, P1861, DOI 10.1002/jnr.23069; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Block F, 2001, NEUROREPORT, V12, P1507, DOI 10.1097/00001756-200105250-00041; Bruno O, 2011, BRIT J PHARMACOL, V164, P2054, DOI 10.1111/j.1476-5381.2011.01524.x; Bruno O, 2009, J MED CHEM, V52, P6546, DOI 10.1021/jm900977c; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; D'Sa C, 2002, J NEUROCHEM, V81, P745, DOI 10.1046/j.1471-4159.2002.00878.x; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Fatemi SH, 2008, SCHIZOPHR RES, V101, P36, DOI 10.1016/j.schres.2008.01.029; Fatemi SH, 2008, PSYCHIAT GENET, V18, P282, DOI 10.1097/YPG.0b013e3283060fb8; Giampa C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013417; Grond-Ginsbach C, 2008, J NEUROL, V255, P723, DOI 10.1007/s00415-008-0784-z; Hill EV, 2006, CELL SIGNAL, V18, P2056, DOI 10.1016/j.cellsig.2006.07.018; Iona S, 1998, MOL PHARMACOL, V53, P23; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Lakics V, 2010, NEUROPHARMACOLOGY, V59, P367, DOI 10.1016/j.neuropharm.2010.05.004; Li LX, 2011, METAB BRAIN DIS, V26, P37, DOI 10.1007/s11011-011-9235-0; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Manning CD, 1999, BRIT J PHARMACOL, V128, P1393, DOI 10.1038/sj.bjp.0702911; Medina AE, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00021; Mehats C, 2003, FASEB J, V17, P1831, DOI 10.1096/fj.03-0274com; Michibata H, 2001, BBA-GENE STRUCT EXPR, V1517, P278, DOI 10.1016/S0167-4781(00)00293-1; Miro X, 2002, SYNAPSE, V45, P259, DOI 10.1002/syn.10100; Miwa T, 2009, EUR J PHARMACOL, V602, P112, DOI 10.1016/j.ejphar.2008.10.060; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Reneerkens OAH, 2009, PSYCHOPHARMACOLOGY, V202, P419, DOI 10.1007/s00213-008-1273-x; Reyes-Irisarri E, 2007, J NEUROPATH EXP NEUR, V66, P923, DOI 10.1097/nen.0b013e3181567c31; Robichaud A, 2002, BRIT J PHARMACOL, V135, P113, DOI 10.1038/sj.bjp.0704457; Seeger TF, 2003, BRAIN RES, V985, P113, DOI 10.1016/S0006-8993(03)02754-9; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Suda S, 1998, J NEUROCHEM, V71, P1554; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Temple MD, 2001, J NEUROTRAUM, V18, P47, DOI 10.1089/089771501750055767; Tilley DG, 2002, MOL PHARMACOL, V62, P497, DOI 10.1124/mol.62.3.497; VERGHESE MW, 1995, J PHARMACOL EXP THER, V272, P1313; Willette RN, 1997, J CEREBR BLOOD F MET, V17, P210, DOI 10.1097/00004647-199702000-00011; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; YAN C, 1994, J NEUROSCI, V14, P973; Zhang B, 2002, NEUROPHARMACOLOGY, V42, P262, DOI 10.1016/S0028-3908(01)00174-5; Zhang HT, 2002, NEUROPSYCHOPHARMACOL, V27, P587	50	19	19	2	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	DEC	2012	123	6					1019	1029		10.1111/jnc.12049			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	051WK	WOS:000312158500013	23057870	Green Accepted			2021-06-18	
J	Bonneh-Barkay, D; Wang, GJ; LaFramboise, WA; Wiley, CA; Bissel, SJ				Bonneh-Barkay, Dafna; Wang, Guoji; LaFramboise, William A.; Wiley, Clayton A.; Bissel, Stephanie J.			Exacerbation of Experimental Autoimmune Encephalomyelitis in the Absence of Breast Regression Protein 39/Chitinase 3-Like 1	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						BRP-39; Chitinase-like proteins; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Neuroimmunology; YKL-40	AUTOMATED IMAGE-ANALYSIS; REACTIVE ASTROCYTES; MULTIPLE-SCLEROSIS; YKL-40 EXPRESSION; DIFFERENTIAL EXPRESSION; CEREBROSPINAL-FLUID; SERUM-LEVELS; INFLAMMATION; DISEASE; INJURY	We previously reported that YKL-40, the human analog of mouse breast regression protein 39 ([BRP-39] chitinase 3-like 1), is elevated in the cerebrospinal fluid of patients with a variety of neuroinflammatory conditions, such as multiple sclerosis and traumatic brain injury. Expression of YKL-40 in the CNS was predominantly associated with reactive astrocytes in the vicinity of inflammatory lesions. Because previous studies have shown that reactive astrocytes play a critical role in limiting immune infiltration in the mouse model of experimental autoimmune encephalomyelitis, we explored the role of BRP-39 in regulating neuroinflammation in experimental autoimmune encephalomyelitis. Using BRP-39-deficient (BRP-39(-/-)) mice, we demonstrate the importance of BRP-39 in modulating the severity of clinical experimental autoimmune encephalomyelitis and CNS neuroinflammation. At disease onset, absence of BRP-39 had little effect on clinical disease or lymphocytic infiltrate, but by 14 days after immunization, differences in clinical scores were evident. By 28 days after immunization, BRP-39(-/-) mice showed more severe and persistent clinical disease than BRP-39(+/+) controls. Histopathological evaluation showed that BRP-39(-/-) mice had more marked lymphocytic and macrophage infiltrates and gliosis versus BRP-39(+/+) mice. These findings support the role of BRP-39 expression in limiting immune cell infiltration into the CNS and offer a new target to modulate neuroinflammation.	[Bonneh-Barkay, Dafna; Wang, Guoji; LaFramboise, William A.; Wiley, Clayton A.; Bissel, Stephanie J.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Bonneh-Barkay, D (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA.	dafnabb@yahoo.com			Pittsburgh Foundation;  [P30CA047904]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA047904] Funding Source: NIH RePORTER	This work was supported in part by a grant from The Pittsburgh Foundation John F. & Nancy A. Emmerling Fund for Medical Research to Dafna Bonneh-Barkay. This project used University of Pittsburgh Cancer Institute shared resources that are supported in part by award P30CA047904.	ADAMS CWM, 1989, J NEUROL SCI, V92, P291, DOI 10.1016/0022-510X(89)90144-5; Beers DR, 2011, BRAIN, V134, P1293, DOI 10.1093/brain/awr074; Bonneh-Barkay D, 2010, J BIOL CHEM, V27, P1215; Bonneh-Barkay D, 2008, AM J PATHOL, V173, P130, DOI 10.2353/ajpath.2008.080045; Bonneh-Barkay D, 2012, BRAIN PATHOL, V22, P530, DOI 10.1111/j.1750-3639.2011.00550.x; Bonneh-Barkay D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-34; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Comabella M, 2010, BRAIN, V133, P1082, DOI 10.1093/brain/awq035; Craig-Schapiro R, 2010, BIOL PSYCHIAT, V68, P903, DOI 10.1016/j.biopsych.2010.08.025; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Haroon F, 2011, J IMMUNOL, V186, P6521, DOI 10.4049/jimmunol.1001135; Hung SL, 2002, J LEUKOCYTE BIOL, V72, P72; Hur EM, 2007, NAT IMMUNOL, V8, P74, DOI 10.1038/ni1415; Isse K, 2012, AM J TRANSPLANT, V12, P27, DOI 10.1111/j.1600-6143.2011.03797.x; Isse K, 2010, CLIN LIVER DIS, V14, P669, DOI 10.1016/j.cld.2010.07.004; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; Johansen JS, 1996, BRIT J RHEUMATOL, V35, P553; Johansen JS, 2006, DAN MED BULL, V53, P172; John GR, 2005, GLIA, V49, P161, DOI 10.1002/glia.20109; Kaynar MY, 2005, J CLIN NEUROSCI, V12, P754, DOI 10.1016/j.jocn.2005.06.001; Koutroubakis IE, 2003, INT J COLORECTAL DIS, V18, P254, DOI 10.1007/s00384-002-0446-z; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Matsuura H, 2011, AM J RESP CELL MOL, V44, P777, DOI 10.1165/rcmb.2010-0081OC; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nair A, 2008, CELL MOL LIFE SCI, V65, P2702, DOI 10.1007/s00018-008-8059-5; Nikota JK, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-39; Nojgaard C, 2008, CORONARY ARTERY DIS, V19, P257, DOI 10.1097/MCA.0b013e3282f40dd5; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Raes G, 2002, J LEUKOCYTE BIOL, V71, P597; Rathcke CN, 2010, SCAND CARDIOVASC J, V44, P92, DOI 10.3109/14017430903402218; Singh SK, 2011, J BIOL CHEM, V286, P39893, DOI 10.1074/jbc.M111.257451; Sohn MH, 2010, AM J RESP CRIT CARE, V182, P918, DOI 10.1164/rccm.200912-1793OC; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009; Zhang W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-593	40	19	19	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2012	71	11					948	958		10.1097/NEN.0b013e31826eaee7			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	030CF	WOS:000310544800002	23041842	Green Accepted, Bronze			2021-06-18	
J	Bukur, M; Hadjibashi, AA; Ley, EJ; Malinoski, D; Singer, M; Barmparas, G; Margulies, D; Salim, A				Bukur, Marko; Hadjibashi, Anoushiravan Amini; Ley, Eric J.; Malinoski, Darren; Singer, Matthew; Barmparas, Galinos; Margulies, Daniel; Salim, Ali			Impact of prehospital hypothermia on transfusion requirements and outcomes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Trauma; hypothermia; blood transfusions; complications	RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; EARLY COAGULOPATHY; BLOOD-TRANSFUSION; OXYGEN DELIVERY; POTENTIAL ROLE; DAMAGE CONTROL; RESUSCITATION; COAGULATION; MORTALITY	BACKGROUND: Prehospital hypothermia (PH) is known to increase mortality following traumatic injury. PH relationship with transfusion requirements has not been documented. The purpose of this investigation was to analyze the impact of PH on blood product requirements and subsequent outcomes. METHODS: The Los Angeles County Trauma System Database was queried for all patients admitted between 2005 and 2009. Demographics, physiologic parameters, and transfusion requirements were obtained and dichotomized by admission temperatures with a core temperature of less than 36.5 degrees C considered hypothermic. Multivariate analysis was performed to determine factors contributing to transfusion requirements and to derive adjusted odds ratios (AORs) for mortality and rates of adult respiratory distress syndrome and pneumonia. RESULTS: A total of 21,023 patients were analyzed in our study with 44.6% presenting with PH. Hypothermic patients required 26% more fluid resuscitation (p < 0.001) in the emergency department and 17% more total blood products (p < 0.001) than those who were admitted with a normal temperature. There was a trend toward an increase in emergency department transfusion (8%, p = 0.06). PH was independently associated with the need for a transfusion (AOR, 1.1; p = 0.047), increased mortality (AOR, 2.0; p < 0.01), as well as incidence of adult respiratory distress syndrome (AOR, 1.8; p < 0.05) and pneumonia (AOR, 2.6; p < 0.01). CONCLUSION: PH is associated with increased transfusion and fluid requirements and subsequently worse outcomes. Interventions that correct hypothermia may decrease transfusion requirements and improve outcomes. Prospective studies investigating correction of hypothermia in trauma patients are warranted. (J Trauma Acute Care Surg. 2012;73: 1195-1201. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Bukur, Marko] Cedars Sinai Med Ctr, Div Trauma & Crit Care, Dept Surg, Los Angeles, CA 90048 USA	Bukur, M (corresponding author), Cedars Sinai Med Ctr, Div Trauma & Crit Care, Dept Surg, 8635 W 3rd St,Suite 650, Los Angeles, CA 90048 USA.	bukurm@cshs.org	Barmparas, Galinos/L-6530-2019	Bukur, Marko/0000-0002-1850-7147			BUSH HL, 1995, J VASC SURG, V21, P392, DOI 10.1016/S0741-5214(95)70281-4; COHEN JR, 1995, J VASC SURG, V21, P400; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Fukudome EY, 2009, CRIT CARE MED, V37, pS265, DOI 10.1097/CCM.0b013e3181aa60ac; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; Gong MN, 2005, CRIT CARE MED, V33, P1191, DOI 10.1097/01.CCM.0000165566.82925.14; GREGORY JS, 1991, J TRAUMA, V31, P795, DOI 10.1097/00005373-199106000-00009; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; GUNNING KA, 1995, AUST NZ J SURG, V65, P80, DOI 10.1111/j.1445-2197.1995.tb07265.x; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; HESSEL EA, 1980, J SURG RES, V28, P23, DOI 10.1016/0022-4804(80)90078-5; Hildebrand F, 2004, AM J SURG, V187, P363, DOI 10.1016/j.amjsurg.2003.12.016; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Inaba K, 2009, WORLD J SURG, V33, P864, DOI 10.1007/s00268-009-9936-2; Ireland S, 2011, RESUSCITATION, V82, P300, DOI 10.1016/j.resuscitation.2010.10.016; JOHNSTON TD, 1994, J TRAUMA, V37, P413, DOI 10.1097/00005373-199409000-00014; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Leben J, 1996, Acta Anaesthesiol Scand Suppl, V109, P39; Lewis FR, 1997, ANN SURG, V226, P447; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; Plurad D, 2007, J TRAUMA, V63, P1, DOI 10.1097/TA.0b013e318068b1ed; Rajagopalan S, 2008, ANESTHESIOLOGY, V108, P71, DOI 10.1097/01.anes.0000296719.73450.52; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SHIBUTANI K, 1983, CRIT CARE MED, V11, P640, DOI 10.1097/00003246-198308000-00010; Silverboard H, 2005, J TRAUMA, V59, P717, DOI 10.1097/01.ta.0000174919.35240.21; Spahn DR, 2005, BRIT J ANAESTH, V95, P130, DOI 10.1093/bja/aei169; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VILLALOBOS TJ, 1955, P SOC EXP BIOL MED, V89, P192; WEG JG, 1991, CRIT CARE MED, V19, P650, DOI 10.1097/00003246-199105000-00011; YENARI MA, 1995, THROMB RES, V77, P475, DOI 10.1016/0049-3848(95)93883-2; YOSHIHARA H, 1985, THROMB RES, V37, P503, DOI 10.1016/0049-3848(85)90096-9	38	19	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73	5					1195	1201		10.1097/TA.0b013e31826fc7d9			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	043VF	WOS:000311577100029	23117380				2021-06-18	
J	Chen, J; Weng, JF; Hong, WC; Luo, LF; Yu, W; Luo, SD				Chen, Jun; Weng, Jian-Feng; Hong, Wei-Cong; Luo, Li-Feng; Yu, Wei; Luo, Shi-Da			Change in plasma visfatin level after severe traumatic brain injury	PEPTIDES			English	Article						Visfatin; Traumatic brain injury; Prognosis	COLONY-ENHANCING FACTOR; EXPRESSION; CANCER	Higher plasma visfatin concentration has been associated with ischemic stroke. Thus, we sought to investigate change in plasma visfatin level after traumatic brain injury and to evaluate its relation with disease outcome. Seventy-six healthy controls and 98 patients with acute severe traumatic brain injury were recruited. Twenty-seven patients (27.6%) died and 48 patients (49.0%) suffered from unfavorable outcome (Glasgow outcome scale score of 1-3) in 6 months. On admission, plasma visfatin level was increased in patients than in healthy controls and was highly correlated with Glasgow Coma Scale score. A multivariate analysis identified plasma visfatin level as an independent predictor for 6-month mortality and unfavorable outcome. According to receiver operating characteristic curve analysis, the predictive value of the plasma visfatin concentration was similar to Glasgow Coma Scale score's. In a combined logistic-regression model, visfatin did not improve the predictive value of Glasgow Coma Scale score. Thus, increased plasma visfatin level is associated with 6-month clinical outcomes after severe traumatic brain injury. (C) 2012 Elsevier Inc. All rights reserved.	[Chen, Jun; Weng, Jian-Feng; Hong, Wei-Cong; Luo, Li-Feng; Yu, Wei; Luo, Shi-Da] Second Peoples Hosp Cixi City, Dept Neurosurg, Cixi 315315, Peoples R China	Weng, JF (corresponding author), Second Peoples Hosp Cixi City, Dept Neurosurg, 77 Datong Rd, Cixi 315315, Peoples R China.	cxeycjwjf@163.com			Ningbo Municipal Natural Science Foundation of China [2011A610045]	This work is financially supported by Ningbo Municipal Natural Science Foundation of China (Grant No. 2011A610045).	Berndt J, 2005, DIABETES, V54, P2911, DOI 10.2337/diabetes.54.10.2911; Bi J, 2012, J NEUROCHEM, V120, P334, DOI 10.1111/j.1471-4159.2011.07566.x; Carrero JJ, 2010, NEPHROL DIAL TRANSPL, V25, P901, DOI 10.1093/ndt/gfp587; Imai S, 2009, CURR PHARM DESIGN, V15, P20, DOI 10.2174/138161209787185814; JENNETT B, 1975, LANCET, V1, P480; Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI 10.1172/JCI19930; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kang YS, 2011, NEUROSCI LETT, V504, P121, DOI 10.1016/j.neulet.2011.09.014; Kitani T, 2003, FEBS LETT, V544, P74, DOI 10.1016/S0014-5793(03)00476-9; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lee YC, 2011, CANCER EPIDEM BIOMAR, V20, P1892, DOI 10.1158/1055-9965.EPI-11-0399; Liu P, 2009, J BIOL CHEM, V284, P27344, DOI 10.1074/jbc.M109.002519; Liu P, 2009, CELL BIOL INT, V33, P19, DOI 10.1016/j.cellbi.2008.10.015; Lu LF, 2009, J STROKE CEREBROVASC, V18, P354, DOI 10.1016/j.jstrokecerebrovasdis.2009.01.003; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mercader J, 2008, HORM METAB RES, V40, P467, DOI 10.1055/s-2008-1065324; Nakajima TE, 2009, J GASTROENTEROL, V44, P685, DOI 10.1007/s00535-009-0063-5; Ognjanovic S, 2001, J MOL ENDOCRINOL, V26, P107, DOI 10.1677/jme.0.0260107; Ognjanovic S, 2003, AM J OBSTET GYNECOL, V189, P1187, DOI 10.1067/S0002-9378(03)00591-X; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Xie H, 2007, CALCIFIED TISSUE INT, V80, P201, DOI 10.1007/s00223-006-0155-7; Zhang WP, 2010, J CEREBR BLOOD F MET, V30, P1962, DOI 10.1038/jcbfm.2010.71	23	19	21	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0196-9781	1873-5169		PEPTIDES	Peptides	NOV	2012	38	1					8	12		10.1016/j.peptides.2012.08.016			5	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	073WL	WOS:000313773700002	22960047				2021-06-18	
J	Ettenhofer, ML; Melrose, RJ; Delawalla, Z; Castellon, SA; Okonek, A				Ettenhofer, Mark L.; Melrose, Rebecca J.; Delawalla, Zainab; Castellon, Steven A.; Okonek, Anna			Correlates of Functional Status Among OEF/OIF Veterans With a History of Traumatic Brain Injury	MILITARY MEDICINE			English	Article								This study was conducted to identify factors related to functional status within a clinical sample of Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OFF) with a history of traumatic brain injury (TBI). Medical chart review was conducted for a consecutive group of OEF/OIF Veterans who were referred for neuropsychological evaluation within a Veterans Affairs Medical Center Polytrauma Program related to history of TBI (n = 57). Level of involvement in occupational and academic activity, presence or absence of housing insecurity, and clinician ratings of overall functioning served as indicators of functional status. Reduced functional status was most strongly related to poorer cognitive function, particularly motor function, processing speed, and executive function. Lower levels of functioning were also related to increased severity of postconcussive symptoms, lower levels of education, and ongoing medication treatment for sleep or psychiatric symptoms. Comprehensive evaluation of cognitive, affective, and behavioral functioning among OEF/OIF Veterans with a history of TBI is likely to provide valuable information to inform rehabilitation strategies and identify potential warning signs for poor postdeployment reintegration. Increased awareness of these factors may aid clinicians in identifying patients at risk for poor outcomes and in more effectively targeting symptoms for intervention.	[Ettenhofer, Mark L.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; [Melrose, Rebecca J.; Delawalla, Zainab; Castellon, Steven A.; Okonek, Anna] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA; [Melrose, Rebecca J.; Castellon, Steven A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Okonek, Anna] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA	Ettenhofer, ML (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Ettenhofer, Mark L./J-7171-2019	Ettenhofer, Mark L./0000-0001-9381-7578	VA Greater Los Angeles Healthcare SystemUS Department of Veterans Affairs; Uniformed Services University of the Health Sciences; Department of Veterans AffairsUS Department of Veterans Affairs	Financial support was provided by VA Greater Los Angeles Healthcare System, the Uniformed Services University of the Health Sciences, and the Department of Veterans Affairs (Career Development Award to R. Melrose; Office of Academic Affiliations, Special Fellowship Program in Advanced Geriatrics).	Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bell-McGinty S, 2002, INT J GERIATR PSYCH, V17, P828, DOI 10.1002/gps.646; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cullen NK, 2011, BRAIN INJURY, V25, P35, DOI 10.3109/02699052.2010.531691; Delis DC, 2000, CALIFORNIA VERBAL LE; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kalechstein AD, 2003, J CLIN EXP NEUROPSYC, V25, P1186, DOI 10.1076/jcen.25.8.1186.16723; Kongs SK, 2000, WISCONSIN CARD SORTI; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Larrabee GJ, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P327; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Meyers J., 1995, REY COMPLEX FIGURE T; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Royall DR, 2005, J INT NEUROPSYCH SOC, V11, P899, DOI 10.1017/S135561770505109X; Ruff R. M., 1996, RUFF FIGURAL FLUENCY; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	49	19	19	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	NOV	2012	177	11					1272	1278		10.7205/MILMED-D-12-00095			7	Medicine, General & Internal	General & Internal Medicine	V33OF	WOS:000209027400007	23198501	Bronze			2021-06-18	
J	Konigs, M; de Kieviet, JF; Oosterlaan, J				Konigs, Marsh; de Kieviet, Jorrit F.; Oosterlaan, Jaap			Post-traumatic amnesia predicts intelligence impairment following traumatic brain injury: a meta-analysis	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; OF-THE-LITERATURE; INTELLECTUAL ABILITY; SHORT FORMS; RECOVERY; AGE; CHILDHOOD; SEVERITY; OUTCOMES; MEMORY	Context Worldwide, millions of patients with traumatic brain injury (TBI) suffer from persistent and disabling intelligence impairment. Post-traumatic amnesia (PTA) duration is a promising predictor of intelligence following TBI. Objectives To determine (1) the impact of TBI on intelligence throughout the lifespan and (2) the predictive value of PTA duration for intelligence impairment, using meta-analytic methods. Methods Electronic databases were searched for peer reviewed articles, published until February 2012. Studies reporting intelligence following TBI and injury severity by PTA duration were included. Meta-analytic methods generated effect sizes for full scale IQ (FSIQ), performance IQ (PIQ) and verbal IQ (VIQ), following mild TBI (PTA duration 1-24 h) and severe TBI (PTA duration >7 days), during the subacute phase of recovery (<= 6 months post-injury) and the chronic phase (>6 months post-injury). Meta-regression elucidated the predictive value of PTA duration for intelligence impairment. Results Patients with severe TBI exhibited large depressions in FSIQ in the subacute phase of recovery (d= -1.07, 95% CI to 1.52 to -0.62; p < 0.001), persisting into the chronic phase (d= -0.78, 95% CI -1.06 to -0.51; p < 0.001). PIQ was more severely affected than VIQ in the subacute phase (Q(1) =3.85; p < 0.05) but not in the chronic phase (Q(1) =0.03, p=0.87). Most importantly, longer PTA duration strongly predicted greater depressions of FSIQ and PIQ in the subacute phase (-0.76 <= beta s <= -0.73, Ps < 0.01) and FSIQ, PIQ and VIQ in the chronic phase (-0.80 <= beta s <= -0.61, Ps < 0.05). Conclusions PTA duration is a valuable predictor of intelligence impairment following TBI. Results support the routine assessment of PTA duration in clinical settings.	[Konigs, Marsh; de Kieviet, Jorrit F.; Oosterlaan, Jaap] Vrije Univ Amsterdam, Dept Clin Neuropsychol, NL-1081 BT Amsterdam, Netherlands	Konigs, M (corresponding author), Vrije Univ Amsterdam, FPP Dept Clin Neuropsychol, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.	m.konigs@vu.nl		Konigs, Marsh/0000-0003-0200-0445	Netherlands Organisation for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [022.003.010]	This work was supported by the Netherlands Organisation for Scientific Research (NWO) grant No 022.003.010. The funder had no role in the conductance of this study other than providing financial support.	Ahmed S, 2000, BRAIN INJURY, V14, P765; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; [Anonymous], 2008, SPSS STAT WIND COMP; [Anonymous], 2005, COMP MET VERS 2 COMP; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barker LA, 2010, NEUROPSYCHOLOGIA, V48, P2550, DOI 10.1016/j.neuropsychologia.2010.05.001; Bittner RM, 2007, BRAIN INJURY, V21, P709, DOI 10.1080/02699050701468917; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Ferri J, 2004, NEUROLOGIA, V19, P285; Greenwood R, 1997, LANCET, V349, P1041, DOI 10.1016/S0140-6736(05)62288-X; Guilmette TJ, 1999, ASSESSMENT, V6, P33, DOI 10.1177/107319119900600104; Hedges L.V., 1985, STAT METHODS META AN; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly J A, 1997, AAOHN J, V45, P439; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LUSKIN RC, 1991, AM J POLIT SCI, V35, P1032, DOI 10.2307/2111505; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Persinger MA, 1995, PERCEPT MOTOR SKILL, V81, P1283, DOI 10.2466/pms.1995.81.3f.1283; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P104, DOI 10.1037/0894-4105.18.1.104; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SILVERSTEIN AB, 1967, J CONSULT PSYCHOL, V31, P635, DOI 10.1037/h0025110; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tittle A, 2011, BRAIN INJURY, V25, P933, DOI 10.3109/02699052.2011.597042; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Tremont G, 1997, ARCH CLIN NEUROPSYCH, V12, P757, DOI 10.1016/S0887-6177(97)00049-8; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Verger K, 2000, BRAIN INJURY, V14, P495; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Wechsler, 1949, WECHSLER INTELLIGENC; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 1991, MANUAL WECHSLER INTE; Wechsler D., 1955, MANUAL WECHSLER ADUL; Weddell RA, 2010, ARCH PHYS MED REHAB, V91, P897, DOI 10.1016/j.apmr.2010.01.020; Wells GA., NEWCASTLE OTTAWA SCA; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P90, DOI 10.1017/S1355617707070129; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	61	19	19	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2012	83	11					1048	1055		10.1136/jnnp-2012-302635			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	020MG	WOS:000309813600006	22791900				2021-06-18	
J	Max, JE; Wilde, EA; Bigler, ED; Thompson, WK; MacLeod, M; Vasquez, AC; Merkley, TL; Hunter, JV; Chu, ZD; Yallampalli, R; Hotz, G; Chapman, SB; Yang, TT; Levin, HS				Max, Jeffrey E.; Wilde, Elisabeth A.; Bigler, Erin D.; Thompson, Wesley K.; MacLeod, Marianne; Vasquez, Ana C.; Merkley, Tricia L.; Hunter, Jill V.; Chu, Zili D.; Yallampalli, Ragini; Hotz, Gillian; Chapman, Sandra B.; Yang, Tony T.; Levin, Harvey S.			Neuroimaging Correlates of Novel Psychiatric Disorders After Pediatric Traumatic Brain Injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						TBI; pediatric; psychiatric disorders; prospective; diffusion tensor imaging	1ST 6 MONTHS; HEAD-INJURY; CHILDREN; ADOLESCENTS; ANXIETY; RELIABILITY; MRI; SEGMENTATION; SCHEDULE; VALIDITY	Objective: To study magnetic resonance imaging (MRI) correlates of novel (new-onset) psychiatric disorders (NPD) after traumatic brain injury (TBI) and orthopedic injury (OI). Method: Participants were 7 to 17 years of age at the time of hospitalization for either TBI or OI. The study used a prospective, longitudinal, controlled design with standardized psychiatric assessments conducted at baseline (reflecting pre-injury function) and 3 months post-injury. MRI assessments including diffusion tensor imaging (DTI) derived fractional anisotropy (FA), volumetric measures of gray and white matter regions, volumetric measures of lesions, and cortical thickness were conducted. Injury severity was assessed by standard clinical scales. The outcome measure was the presence of an NPD identified during the first 3 months after injury. Results: There were 88 participants (TBI, 44; 01, 44). NPD occurred more frequently in the TBI (21/44; 48%) versus the OI (6/44; 14%) group (Fisher's exact test, p = .001). NPD in TBI participants was not related to injury severity. Multivariate analysis of covariance of the relationship between FA in hypothesized regions of interest (bilateral frontal and temporal lobes, bilateral centrum semiovale, bilateral uncinate fasciculi) and NPD and group (TBI versus OI) was significant, and both variables (NPD, p < .05; group, p < .001) were jointly significantly related to FA. NPD was not significantly related to volumetric measures of white or gray matter structures, volumetric measures of lesions, or cortical thickness measures. Conclusions: Lowered white matter integrity may be more important in the pathophysiology of NPD than indices of gray matter or white matter atrophic changes, macroscopic lesions, and injury severity. J. Am. Acad. Child Adolesc. Psychiatry, 2012;51(11):1208-1217.	[Max, Jeffrey E.] Rady Childrens Hosp, San Diego, CA 92123 USA; [Max, Jeffrey E.; Thompson, Wesley K.; Yang, Tony T.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Wilde, Elisabeth A.; MacLeod, Marianne; Vasquez, Ana C.; Merkley, Tricia L.; Hunter, Jill V.; Chu, Zili D.; Yallampalli, Ragini; Levin, Harvey S.] Baylor Coll Med, Houston, TX 77030 USA; [Hunter, Jill V.; Chu, Zili D.] Texas Childrens Hosp, Houston, TX 77030 USA; [Bigler, Erin D.; Merkley, Tricia L.] Brigham Young Univ, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Salt Lake City, UT USA; [Bigler, Erin D.] Utah Brain Inst, Salt Lake City, UT USA; [Hotz, Gillian] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Chapman, Sandra B.] Univ Texas Dallas, Richardson, TX 75083 USA	Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800, R01MH085734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research has been supported by the National Institute of Mental Health grant K-08 MH01800 (J.E.M.) and the National Institute of Neurological Disorders and Stroke (NINDS) grant NS-21889 (H.S. L.).	Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gerring J, 2000, BRAIN INJURY, V14, P205; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Juranek J, 2012, BRAIN IMAGING BEHAV, V6, P36, DOI 10.1007/s11682-011-9140-5; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Little R, 2002, STAT ANAL MISSING DA, V2nd; Max J.E., 2011, TXB TRAUMATIC BRAIN, P438; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, J NEUROPSYC IN PRESS; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Moos R, 1994, LIFE STRESSORS SOCIA; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P718, DOI 10.1109/ICCV.2001.937595; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; TEASDALE G, 1974, LANCET, V2, P81; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	41	19	21	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	NOV	2012	51	11					1208	1217		10.1016/j.jaac.2012.08.026			10	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	035IF	WOS:000310939300012	23101746	Green Accepted			2021-06-18	
J	Martens, KM; Vonder Haar, C; Hutsell, BA; Hoane, MR				Martens, Kris M.; Vonder Haar, Cole; Hutsell, Blake A.; Hoane, Michael R.			A Discrimination Task Used as a Novel Method of Testing Decision-Making Behavior following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						animal modeling; behavioral testing; cognitive assessment; traumatic brain injury	RATS; LESIONS; RECOVERY; PERFORMANCE; STIMULI; CORTEX	Traumatic brain injury (TBI) results in a multitude of deficits following injury. Some of the most pervasive in humans are the changes that affect frontally-mediated cognitive functioning, such as decision making. The assessment of decision-making behavior in rodents has been extensively tested in the field of the experimental analysis of behavior. However, due to the narrow therapeutic window following TBI, time-intensive operant paradigms are rarely incorporated into the battery of tests traditionally used, the majority of which assess motor and sensory functioning. The cognitive measures that are used are frequently limited to memory and do not account for changes in decision-making behavior. The purpose of the present study was to develop a simplified discrimination task that can assess deficits in decision-making behavior in rodents. For the task, rats were required to dig in cocoa-scented sand (versus unscented sand) for a reinforcer. Rats were given 12 sessions per day until a criterion level of 80% accuracy for 3 days straight was reached. Once the criterion was achieved, cortical contusion injuries were induced (frontal, parietal, or sham). Following a recovery period, the rats were re-tested on cocoa versus unscented sand. Upon reaching criterion, a reversal discrimination was evaluated in which the reinforcer was placed in unscented sand. Finally, a novel scent discrimination (basil versus coffee with basil reinforced), and a reversal (coffee) were evaluated. The results indicated that the Dig task is a simple experimental preparation that can be used to assess deficits in decision-making behavior following TBI.	[Martens, Kris M.; Vonder Haar, Cole; Hutsell, Blake A.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu	Hutsell, Blake/ABD-8248-2020	Hoane, Michael/0000-0001-7779-2657; Vonder Haar, Cole/0000-0001-7949-2068			*CDC, 2011, INJ PREV CONTR TRAUM; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; EICHENBAUM H, 1986, J NEUROSCI, V6, P1876; Fantino E, 1998, J EXP ANAL BEHAV, V69, P355, DOI 10.1901/jeab.1998.69-355; FINGER S, 1971, J COMP PHYSIOL PSYCH, V77, P221, DOI 10.1037/h0031648; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; HERRNSTEIN RJ, 1964, SCIENCE, V146, P549, DOI 10.1126/science.146.3643.549; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Iversen IH, 2008, J EXP ANAL BEHAV, V90, P113, DOI 10.1901/jeab.2008.90-113; Kaiser DH, 2006, BEHAV PROCESS, V73, P164, DOI 10.1016/j.beproc.2006.05.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li HB, 1999, BRAIN RES BULL, V48, P113, DOI 10.1016/S0361-9230(98)00157-9; Lu XCM, 1998, NEUROSCIENCE, V84, P849, DOI 10.1016/S0306-4522(97)00520-4; NEAFSEY EJ, 1990, CEREBRAL CORTEX RAT, P197; PORTER D, 1984, J EXP PSYCHOL ANIM B, V10, P138; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Slotnick BM, 1997, BRAIN RES, V762, P89, DOI 10.1016/S0006-8993(97)00357-0; SPEAR PD, 1975, BRAIN RES, V94, P337, DOI 10.1016/0006-8993(75)90066-9; SULLIVAN RM, 1991, DEV BRAIN RES, V60, P219, DOI 10.1016/0165-3806(91)90050-S; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WILLIAMS BA, 1994, ANIMAL LEARNING COGN, P81	26	19	19	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2012	29	15					2505	2512		10.1089/neu.2012.2388			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	022NY	WOS:000309967300008	22924664				2021-06-18	
J	Piatt, JH; Neff, DA				Piatt, Joseph H., Jr.; Neff, Daniel A.			Hospital care of childhood traumatic brain injury in the United States, 1997-2009: a neurosurgical perspective Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						children; infant; Kids' Inpatient Database; mortality rate; neurosurgery; traumatic brain injury; epidemiological study	CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; INSURANCE STATUS; PEDIATRIC TRAUMA; HEAD-INJURY; EMERGENCY-DEPARTMENT; RACIAL DISPARITIES; TARGETED THERAPY; SEVERITY SCORES; RISK-FACTORS	Object. The goal in this paper was to study hospital care for childhood traumatic brain injury (TBI) in a nationwide population base. Methods. Data were acquired from the Kids' Inpatient Database (KID) for the years 1997, 2000, 2003, 2006, and 2009. Admission for TBI was defined by any ICD-9-CM diagnostic code for TBI. Admission for severe TBI was defined by a principal diagnostic code for TBI and a procedural code for mechanical ventilation; admissions ending in discharge home alive in less than 4 days were excluded. Results. Estimated raw and population-based rates of admission for all TBI, for severe TBI, for death from severe TBI, and for major and minor neurosurgical procedures fell steadily during the study period. Median hospital charges for severe TBI rose steadily, even after adjustment for inflation, but estimated nationwide hospital charges were stable. Among 14,932 actual admissions for severe TBI captured in the KID, case mortality was stable through the study period, at 23.9%. In a multivariate analysis, commercial insurance (OR 0.86, CI 0.77-0.95; p = 0.004) and white race (OR 0.78, CI 0.70-0.87; p < 0.0005) were associated with lower mortality rates, but there was no association between these factors and commitment of resources, as measured by hospital charges or rates of major procedures. Increasing median income of home ZIP code was associated with higher hospital charges and higher rates of major and minor procedures. Only 46.8% of admissions for severe TBI were coded for a neurosurgical procedure of any kind. Fewer admissions were coded for minor neurosurgical procedures than anticipated, and the state-by-state variance in rates of minor procedures was twice as great as for major procedures. Possible explanations for the "missing ICP monitors" are discussed. Conclusions. Childhood brain trauma is a shrinking sector of neurosurgical hospital practice. Racial and economic disparities in mortality rates were confirmed in this study, but they were not explained by available metrics of resource commitment. Vigilance is required to continue to supply neurosurgical expertise to the multidisciplinary care process. (http://thejns.org/doi/abs/10.3171/2012.7.PEDS11532)	[Piatt, Joseph H., Jr.] Alfred I DuPont Hosp Children, Div Neurosurg, Wilmington, DE 19803 USA; [Neff, Daniel A.] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; [Neff, Daniel A.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA	Piatt, JH (corresponding author), Alfred I DuPont Hosp Children, Div Neurosurg, 1600 Rockland Rd, Wilmington, DE 19803 USA.	jpiatt@nemours.org		Piatt, Joseph/0000-0002-9332-8376			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Alban RF, 2010, AM SURGEON, V76, P1108; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; Epstein D, 2011, PEDIATRICS, V127, pE588, DOI 10.1542/peds.2010-0394; Falcone RA, 2008, J PEDIATR SURG, V43, P1858, DOI 10.1016/j.jpedsurg.2008.01.058; Falcone RA, 2007, J PEDIATR SURG, V42, P1031, DOI 10.1016/j.jpedsurg.2007.01.038; Falcone RA, 2007, J PEDIATR SURG, V42, P172, DOI 10.1016/j.jpedsurg.2006.09.015; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hostetler SG, 2005, PEDIATR EMERG CARE, V21, P420, DOI 10.1097/01.pec.0000169430.68325.a0; Howard I, 2005, ETHNIC DIS, V15, pS5; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; KINGMA J, 1994, PERCEPT MOTOR SKILL, V78, P915, DOI 10.2466/pms.1994.78.3.915; KINGMA J, 1994, PERCEPT MOTOR SKILL, V78, P939, DOI 10.2466/pms.1994.78.3.939; Lopez AM, 2006, PEDIATR CRIT CARE ME, V7, P2, DOI 10.1097/01.PCC.0000192319.55850.81; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Martin CA, 2010, AM J SURG, V199, P210, DOI 10.1016/j.amjsurg.2009.05.001; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Peter JC, 2010, CHILD NERV SYST, V26, P201, DOI 10.1007/s00381-009-1030-4; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; RUTLEDGE R, 1995, J TRAUMA, V38, P590, DOI 10.1097/00005373-199504000-00022; Sabharwal S, 2007, J PEDIATR ORTHOPED, V27, P690, DOI 10.1097/BPO.0b013e3181425653; Salim A, 2008, AM SURGEON, V74, P1088; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Tepas JJ, 2011, J AM COLL SURGEONS, V212, P722, DOI 10.1016/j.jamcollsurg.2010.12.016; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Wall SP, 2005, ACAD EMERG MED, V12, P862, DOI 10.1197/j.aem.2005.05.003	48	19	19	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2012	10	4					257	267		10.3171/2012.7.PEDS11532			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	015YX	WOS:000309485300003	22900487				2021-06-18	
J	Steuer, J; Wanhainen, A; Thelin, S; Nyman, R; Eriksson, MO; Bjorck, M				Steuer, Johnny; Wanhainen, Anders; Thelin, Stefan; Nyman, Rickard; Eriksson, Mats-Ola; Bjorck, Martin			Outcome of endovascular treatment of traumatic aortic transection	JOURNAL OF VASCULAR SURGERY			English	Article							SURGERY-OF-TRAUMA; MULTICENTER TRIAL; SWEDVASC REGISTRY; OPERATIVE REPAIR; STENT GRAFT; INJURY; ASSOCIATION; MANAGEMENT; EXPERIENCE; HEART	Objective: The purpose of this study was to analyze our experience of thoracic endovascular aortic repair (TEVAR) in patients with traumatic aortic transection. Methods: This was a single-center consecutive case series that was conducted at the Uppsala University Hospital, Tertiary Referral Center. There were a total of 17 consecutive patients undergoing TEVAR for traumatic thoracic aortic transection. All patients undergoing TEVAR for aortic transection were registered prospectively and their medical records were reviewed regarding technical details, mechanism of injury, and concomitant injuries. Long-term outcome was analyzed with respect to need for reintervention and survival. Results: Between 2001 and 2010, 17 patients underwent TEVAR for traumatic aortic injury. Median age was 42 years (range, 18-77 years), and 15 of 17 patients (88%) were men. Fourteen patients had been involved in motor vehicle accidents, two had fallen from heights, and one fell off a bicycle on a slope. In all cases, the aortic injury was located in the proximity of the origin of the left subclavian artery. All patients had concomitant injuries. In all patients, a single stent graft was sufficient to exclude the injured part of the aorta. The median cover length was 120 mm (range, 100-200 mm). In-hospital mortality was 24% (4 of 17 patients). One patient died perioperatively and three postoperatively, two from brain injuries and one from multiorgan failure. After a median follow-up of 36 months (range, 10-98 months), three patients underwent reintervention (18%), each patient only once; one for a type I endoleak, and two for pseudocoarctation secondary to stent graft infolding. Two were treated endovascularly, and one had a stent graft explantation. Conclusions: Endovascular repair allows rapid and minimally invasive therapy in patients with traumatic aortic injury with good technical results. The outcome is highly dependent on the severity of other concurrent injuries. (J Vasc Surg 2012;56:973-8.)	[Steuer, Johnny; Wanhainen, Anders; Thelin, Stefan; Bjorck, Martin] Uppsala Univ, Dept Surg Sci, SE-75185 Uppsala, Sweden; [Nyman, Rickard; Eriksson, Mats-Ola] Uppsala Univ, Dept Oncol Radiol & Clin Immunol, SE-75185 Uppsala, Sweden	Steuer, J (corresponding author), Uppsala Univ, Dept Surg Sci, SE-75185 Uppsala, Sweden.	joste@me.com					Acosta S, 2011, BRIT J SURG, V98, P735, DOI 10.1002/bjs.7383; Alsac JM, 2008, J VASC SURG, V48, P1369, DOI 10.1016/j.jvs.2008.07.019; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bent CL, 2007, J VASC SURG, V46, P920, DOI 10.1016/j.jvs.2007.07.032; Bjorck M, 2008, EUR J VASC ENDOVASC, V35, P129, DOI 10.1016/j.ejvs.2007.09.010; Botta L, 2008, J THORAC CARDIOV SUR, V136, P1558, DOI 10.1016/j.jtcvs.2008.07.040; Clancy TV, 2001, J TRAUMA, V51, P346, DOI 10.1097/00005373-200108000-00021; Coady MA, 2010, CIRCULATION, V121, P2780, DOI 10.1161/CIR.0b013e3181e4d033; Demetriades D, 2008, J TRAUMA, V64, P561, DOI 10.1097/TA.0b013e3181641bb3; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Jonker FHW, 2010, J ENDOVASC THER, V17, P725, DOI 10.1583/10-3130.1; Jonker FHW, 2010, J VASC SURG, V52, P39, DOI 10.1016/j.jvs.2010.02.256; Jonker FHW, 2010, J VASC SURG, V51, P565, DOI 10.1016/j.jvs.2009.10.046; Lam RC, 2007, J VASC SURG, V45, P875, DOI 10.1016/j.jvs.2006.12.059; Lee WA, 2011, J VASC SURG, V53, P187, DOI 10.1016/j.jvs.2010.08.027; Madhwal S, 2008, J INVASIVE CARDIOL, V20, P200; Mattox KL, 2008, J TRAUMA, V64, P570; Meredith W, 1997, J TRAUMA, V42, P380; Mitchell RS, 2002, J ENDOVASC THER, V9, P98; Mosquera VX, 2011, J THORAC CARDIOV SUR, V142, P614, DOI 10.1016/j.jtcvs.2010.10.044; Neschis DG, 2009, ANN SURG, V250, P377, DOI 10.1097/SLA.0b013e3181b3b5c9; Pretre R, 1997, NEW ENGL J MED, V336, P626, DOI 10.1056/NEJM199702273360906; Rahimi SA, 2010, J VASC SURG, V52, P891, DOI 10.1016/j.jvs.2010.05.014; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Rotondo MF, 1993, J TRAUMA, V35, P382; Steuer J, 2011, EUR J VASC ENDOVASC, V41, P318, DOI 10.1016/j.ejvs.2010.11.024; Troeng T, 2008, EUR J VASC ENDOVASC, V36, P705, DOI 10.1016/j.ejvs.2008.08.017; Xenos ES, 2008, J VASC SURG, V48, P1343, DOI 10.1016/j.jvs.2008.04.060	28	19	19	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	OCT	2012	56	4					973	978		10.1016/j.jvs.2012.03.259			6	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	016IV	WOS:000309512300012	22608791	Bronze			2021-06-18	
J	Elbin, RJ; Covassin, T; Hakun, J; Kontos, AP; Berger, K; Pfeiffer, K; Ravizza, S				Elbin, R. J.; Covassin, Tracey; Hakun, Jonathan; Kontos, Anthony P.; Berger, Kevin; Pfeiffer, Karin; Ravizza, Susan			Do brain activation changes persist in athletes with a history of multiple concussions who are asymptomatic?	BRAIN INJURY			English	Article						Concussion; functional MRI; neuropsychological	PARIETAL CORTEX; PERFORMANCE; SYMPTOMS; INJURY	Primary objective: To evaluate brain activation patterns of asymptomatic athletes with a history of two or more concussions. Research design: A paired case-control design was used to evaluate brain activation patterns during cognitive performance in 14 athletes with a history of two or more concussions and 14 age-and sex-matched controls with no previous concussion. Methods and procedures: Percentage Blood-Oxygen-Level-Dependent (BOLD) change during an N-back working memory task was assessed in all participants. Performance on the Trail-Making Test Form A and B, Symbol-Digit Modalities Test and the Immediate Post-concussion Assessment and Cognitive Test (ImPACT) was also compared between groups. Main results: As expected, brain regions activated during the performance of the N-back were equivalent between groups. The groups performed similarly on the neurocognitive measures. The history of concussion group was less accurate than controls on the 1-, 2- and 3-back conditions of the N-back. Conclusions: Following the complete resolution of symptoms, a history of two or more concussions is not associated with changes in regional brain activation during the performance of working memory task. Compensatory brain activation may only persist during the typically brief time athletes experience symptoms following concussion.	[Elbin, R. J.; Kontos, Anthony P.] Univ Pittsburgh, Sch Med, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA; [Covassin, Tracey; Pfeiffer, Karin] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Hakun, Jonathan; Ravizza, Susan] Michigan State Univ, Dept Psychol, Cognit Control Lab, E Lansing, MI 48824 USA; [Berger, Kevin] Michigan State Univ, Dept Radiol, Cognit Imaging Res Ctr, E Lansing, MI 48824 USA	Elbin, RJ (corresponding author), Univ Pittsburgh, Sch Med, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA.	rje13@pitt.edu	Pfeiffer, Karin A/D-5252-2018	Pfeiffer, Karin A/0000-0001-6280-9495; Kontos, Anthony/0000-0002-3749-4310	Blue Cross Blue Shield of Michigan Foundation Student-Award Program; Radiology Department and College of Education at Michigan State University	None of the authors declare any financial interests related to this study. The authors would like to acknowledge The Blue Cross Blue Shield of Michigan Foundation Student-Award Program and the Radiology Department and College of Education at Michigan State University for their financial support of this study.	Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jonides J, 1998, J NEUROSCI, V18, P5026; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell M.R., 2006, IMPACT 2006 5 0 CLIN; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2007, IMPACT VERSION 6 0 C; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Ravizza SM, 2004, NEUROIMAGE, V22, P562, DOI 10.1016/j.neuroimage.2004.01.039; Reitan R, 1993, HALSTAD REITAN NEURO; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Smith A., 1968, SYMBOL DIGIT MODALIT; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Wagenmakers EJ, 2008, PSYCHON B REV, V15, P1229, DOI 10.3758/PBR.15.6.1229; Wechsler D., 1955, MANUAL WECHSLER ADUL	35	19	19	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2012	26	10					1217	1225		10.3109/02699052.2012.672788			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	984GR	WOS:000307178600007	22616764				2021-06-18	
J	Yang, CC; Hua, MS; Lin, WC; Tsai, YH; Huang, SJ				Yang, Chi-Cheng; Hua, Mau-Sun; Lin, Wei-Chi; Tsai, Yi-Hsin; Huang, Sheng-Jean			Irritability following traumatic brain injury: Divergent manifestations of annoyance and verbal aggression	BRAIN INJURY			English	Article						Irritability; traumatic brain injury; annoyance; verbal aggression	SCALE	Primary objectives: To evaluate irritability following traumatic brain injury. Research design: A prospective study was conducted at a level I trauma centre. Methods and procedures: One hundred and forty-four participants, which included 80 healthy subjects and 64 patients suffering from TBI, were recruited. Irritability was assessed by the National Taiwan University Irritability Scale (NTUIS) from patients themselves and their families. Main outcomes and results: the results showed 14.8% of patients and 29.4% of their families reported patients' problems of irritability. Meanwhile, both self-reported and family-reported irritability post-injury were significantly higher than those reported by the healthy subjects. When evaluating two sub-components of irritability, respectively, both family- and self-reported post-injury annoyance were significantly higher than the pre-injury one, while the self-reported post-injury verbal aggression was not. Conclusions: TBI patients have remarkable problems of irritability after injuries. Specifically, the results showed that annoyance might be the main characteristic of irritability in TBI patients and patients themselves might be unaware of their verbal aggression post-injury. Hence, it is merited to pay more attention to the annoyance of the patients with TBI and to the reports from significant caregivers when evaluating TBI patients' irritability in clinical settings.	[Yang, Chi-Cheng; Lin, Wei-Chi] Chang Gung Univ, Dept Occupat Therapy, Clin Psychol Program, Tao Yuan, Taiwan; [Hua, Mau-Sun] Natl Taiwan Univ, Dept Psychol, Taipei 10764, Taiwan; [Tsai, Yi-Hsin] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Jin Shan Branch, New Taipei City, Taiwan; [Huang, Sheng-Jean] Natl Taiwan Univ, Coll Med, Dept Surg, Taipei, Taiwan	Yang, CC (corresponding author), Chang Gung Univ, Dept Occupat Therapy, Clin Psychol Program, Tao Yuan, Taiwan.	ccyang@mail.cgu.edu.tw; sjhuang1@ntu.edu.tw			National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC 99-2410-H-182-012-MY2]	This study is supported by the National Science Council of Taiwan (NSC 99-2410-H-182-012-MY2).	Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 2004, SCI PRACT NEUROPSYCH, P269; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BENDIG AW, 1962, J CONSULT PSYCHOL, V26, P200, DOI 10.1037/h0048664; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Craig KJ, 2008, PSYCHIAT RES, V159, P367, DOI 10.1016/j.psychres.2007.03.002; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; HARRIS JA, 1995, BEHAV RES THER, V33, P991, DOI 10.1016/0005-7967(95)00038-Y; JENNETT B, 1975, LANCET, V1, P480; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Marsh NV, 2006, NEUROPSYCHOL REHABIL, V16, P684, DOI 10.1080/09602010500220290; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Spielberger C D, 1995, Issues Compr Pediatr Nurs, V18, P207, DOI 10.3109/01460869509087271; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; VANGOOZEN SHM, 1994, AGGRESSIVE BEHAV, V20, P79, DOI 10.1002/1098-2337(1994)20:2<79::AID-AB2480200202>3.0.CO;2-K; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Yang CC, 2011, BRAIN IMPAIR, V12, P200	26	19	19	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2012	26	10					1185	1191		10.3109/02699052.2012.666374			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	984GR	WOS:000307178600003	22571629				2021-06-18	
J	Tran, MD; Furones-Alonso, O; Sanchez-Molano, J; Bramlett, HM				Minh Dinh Tran; Furones-Alonso, Ofelia; Sanchez-Molano, Juliana; Bramlett, Helen Marie			Trauma-induced expression of astrocytic thrombospondin-1 is regulated by P2 receptors coupled to protein kinase cascades	NEUROREPORT			English	Article						astrocytes; protein kinase signaling; purinergic receptors; thrombospondin; traumatic brain injury	EXTRACELLULAR ATP; CULTURED ASTROCYTES; DNA-SYNTHESIS; INJURY; CELLS; SYNAPTOGENESIS; ACTIVATION; ERK1/2; P2Y(2); CNS	Thrombospondin-1 (TSP-1) is an extracellular matrix protein produced by astrocytes, which can promote synaptogenesis. The regulation of astrocytic TSP-1 involves extracellular ATP through the activation of P2Y receptors coupled to various protein kinase signaling pathways. However, not much is known about the mechanisms regulating TSP-1 expression in primary cortical astrocytes after a traumatic brain injury. Using an in-vitro model of central nervous system trauma that stimulates the release of ATP, we found that trauma-induced expression and release of TSP-1 involved purinergic signaling as both expression and release were significantly attenuated by pyridoxalphosphate-6-azophenyl-2'-4'-disulfonic acid, a P2 receptor antagonist Further antagonist studies with reactive blue 2 point to a role for P2Y4, as reactive blue 2 is a potent antagonist for rat P2Y4 receptors. In addition, the injury-induced expression of TSP-1 was significantly attenuated by the inhibition of extracellular signal-regulated kinase and p38/mitogen-activated protein kinase, whereas injury-induced release of TSP-1 was significantly blocked by the inhibition of extracellular signal-regulated kinase and Akt Using an in-vivo model of a moderate parasagittal fluid-percussion brain injury, we found that TSP-1 levels were increased when compared with those in sham animals in the cortex, thalamus, and hippocampus. We conclude that TSP-1 expression after injury can be regulated by the activation of P2 receptors coupled with protein kinase signaling pathways and suggest that purinergic signaling, by regulating TSP expression, may play an important role in cell-matrix and cell-cell interactions such as those occurring during central nervous system repair. NeuroReport 23:721-726 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	[Minh Dinh Tran; Bramlett, Helen Marie] Miami VA Healthcare Syst, Res Serv, Miami, FL 33125 USA; [Furones-Alonso, Ofelia; Sanchez-Molano, Juliana; Bramlett, Helen Marie] Lois Pope LIFE Ctr, Miami Project Cure Paralysis, Miami, FL USA; [Bramlett, Helen Marie] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA	Tran, MD (corresponding author), Miami VA Healthcare Syst, Res Serv, 1201 NW 16th St, Miami, FL 33125 USA.	minh.tran@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by the Department of Veterans Affairs (to H.M.B.). We are grateful to Joseph T Neary, PhD, for valuable discussions.	Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Bussolati B, 2006, J MOL MED-JMM, V84, P852, DOI 10.1007/s00109-006-0075-z; Chen JK, 2011, J CELL BIOCHEM, V112, P59, DOI 10.1002/jcb.22732; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; El Btaouri H, 2011, BBA-MOL CELL RES, V1813, P695, DOI 10.1016/j.bbamcr.2011.02.004; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Kim MS, 2006, PHOTOCHEM PHOTOBIOL, V82, P645, DOI 10.1562/2005-09-29-RA-702; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Lo FS, 2011, J NEUROPHYSIOL, V106, P2876, DOI 10.1152/jn.00312.2011; Moon Y, 2008, LIFE SCI, V82, P591, DOI 10.1016/j.lfs.2007.11.030; Nakagawa T, 2005, J AM SOC NEPHROL, V16, P899, DOI 10.1681/ASN.2004080689; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; NEARY JT, 1994, J NEUROCHEM, V63, P490; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; ScottDrew S, 1997, J NEUROSCI RES, V50, P202, DOI 10.1002/(SICI)1097-4547(19971015)50:2<202::AID-JNR9>3.0.CO;2-J; Shreiber DI, 1995, INCIDENCE CEREBRAL C, P233; Tran MD, 2006, P NATL ACAD SCI USA, V103, P9321, DOI 10.1073/pnas.0603146103; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Wang XH, 2009, J CLIN NEUROSCI, V16, P818, DOI 10.1016/j.jocn.2008.09.014; Wildman SS, 2003, BRIT J PHARMACOL, V140, P1177, DOI 10.1038/sj.bjp.0705544; Yonezawa T, 2010, GLIA, V58, P755, DOI 10.1002/glia.20959; Yu KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002470	25	19	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	AUG 22	2012	23	12					721	726		10.1097/WNR.0b013e32835688fe			6	Neurosciences	Neurosciences & Neurology	980HV	WOS:000306885100006	22776902				2021-06-18	
J	Binder, LM; Spector, J; Youngjohn, JR				Binder, Laurence M.; Spector, Jack; Youngjohn, James R.			Psychogenic Stuttering and Other Acquired Nonorganic Speech and Language Abnormalities	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Forensic neuropsychology; Head injury; Traumatic brain injury; Malingering; symptom validity testing; Aphasia	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; VALIDITY; SCALE; TESTS	Three cases are presented of peculiar speech and language abnormalities that were evaluated in the context of personal injury lawsuit or workers compensation claims of brain dysfunction after mild traumatic brain injuries. Neuropsychological measures of effort and motivation showed evidence of suboptimal motivation or outright malingering. The speech and language abnormalities of these cases probably were not consistent with neurogenic features of dysfluent speech including stuttering or aphasia. We propose that severe dysfluency or language abnormalities persisting after a single, uncomplicated, mild traumatic brain injury are unusual and should elicit suspicion of a psychogenic origin.	[Binder, Laurence M.] Oregon Hlth & Sci Univ, Dept Neurol, Beaverton, OR 97005 USA	Binder, LM (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 4900 SW Griffith Dr,Ste 244, Beaverton, OR 97005 USA.	pdxlarry@aol.com					Albers J. W., 2007, ASSESSMENT MALINGERE, P312; Arnold G., 2007, ASSESSMENT FEIGNED C, P178; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Baumgartner JM, 1999, STUTTERING RELATED D, P269; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; Boone, 2007, ASSESSMENT FEIGNED C; Boone K., 2003, DOT COUNTING TEST MA; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Cottingham ME, 2010, CLIN NEUROPSYCHOL, V24, P1006, DOI 10.1080/13854046.2010.481636; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; Duffy J. R., 2001, PSYCHOGENIC SPEECH D; FESTA JR, 2008, TXB CLIN NEUROPSYCHO, P363; Gervais RO, 2009, CLIN NEUROPSYCHOL, V23, P996, DOI 10.1080/13854040902748249; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; GREIFFENSTEIN MF, 2007, ASSESSMENT MALINGERE, P100; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Helm-Estabrooks Nancy, 1998, Seminars in Speech and Language, V19, P23, DOI 10.1055/s-2008-1064032; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Larrabee, 2012, FORENSIC NEUROPSYCHO, P116; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu P. H., 2007, ASSESSMENT FEIGNED C, P128; McCrea M, 2008, MILD TRAUMATIC BRAIN; Mohr J., 1976, STUDIES NEUROLINGUIS, V1, P201; Moore DP, 2001, TXB CLIN NEUROPSYCHI; Morgan J. J., 2009, NEUROPSYCHOLOGY MALI, P180; National Center for Injury Prevention, 2003, MILD TRAUM BRAIN INJ; Parrish C., 2009, SIG 2 PERSPECTIVES N, V19, P47, DOI DOI 10.1044/NNS1D19.2.47; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Seery CH, 2005, AM J SPEECH-LANG PAT, V14, P284, DOI 10.1044/1058-0360(2005/028); Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Vossler DG, 2004, NEUROLOGY, V63, P516, DOI 10.1212/01.WNL.0000133208.57562.CB; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]; Youngjohn JR, 1999, ARCH CLIN NEUROPSYCH, V14, P511, DOI 10.1016/S0887-6177(98)00049-3; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	39	19	20	0	31	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2012	27	5					557	568		10.1093/arclin/acs051			12	Psychology, Clinical; Psychology	Psychology	976UN	WOS:000306611300008	22789718	Bronze			2021-06-18	
J	Khalili, MA; Anvari, M; Hekmati-Moghadam, SH; Sadeghian-Nodoushan, F; Fesahat, F; Miresmaeili, SM				Khalili, Mohammad Ali; Anvari, Morteza; Hekmati-Moghadam, Sayyed H.; Sadeghian-Nodoushan, Fatemeh; Fesahat, Farzaneh; Miresmaeili, Sayyed M.			Therapeutic Benefit of Intravenous Transplantation of Mesenchymal Stem Cells After Experimental Subarachnoid Hemorrhage in Rats	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article						Apoptosis; mesenchymal stem cell; rat; subarachnoid hemorrhage; transplantation	MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; STROKE; GROWTH; DIFFERENTIATE; ANGIOGENESIS; REPLACEMENT; ASTROCYTES; EXPRESSION; FOREBRAIN	Background: Subarachnoid hemorrhage (SAH) usually occurs when an aneurysm ruptures and bleeds into the subarachnoid space. However, no information is available regarding the therapeutic potency of transplanted mesenchymal stem cells (MSCs) for SAH. Therefore, our aim was to investigate whether MSC transplantation therapy may cause stem cell activation and improve neurologic functional recovery after induction of SAH. Methods: Female rats were divided into 2 groups of SAH plus phosphate-buffered saline (PBS; control) and SAH plus MSCs (experimental). Both control and experimental groups received PBS or injection of 3 x 10(6) male rat MSCs labeled with bromodeoxyuridine (BrdU) into the tail vein 24 hours after SAH. All animals were killed 14 days after SAH. A behavioral test (Neurological Severity Score) was performed at 1, 7, and 14 days after SAH. Immunohistochemistry was used to identify MSCs and the cells derived from MSCs in brains with SAH. Terminal deoxynucleotidyltransferase mediated dUTP-biotin nick-end labeling was used to identify apoptotic cells. Results: Significant functional recovery (P<.05) was found in SAH animals infused with MSCs compared with other rats. Significantly more BrdU-positive cells were located in the parietal lobe of MSC-treated than in PBS-treated animals. MSCs were also seen to differentiate into glial cells (GFAP), neurons (Neu-N), and endothelial cells (vWF), thereby enhancing neuroplastic effects in the injured brain. Significantly fewer apoptotic cells were found in insulted cerebral tissue in SAH plus MSC rats when compared with other groups. Conclusions: Intravenously transplanted MSCs improve functional recovery, reduce apoptosis, and enhance neuroplastic effects after SAH in animal models. This is a promising novel procedure to repair central nervous system damage after SAH, and may provide a new way to induce plasticity in the injured brain cells.	[Khalili, Mohammad Ali; Anvari, Morteza; Sadeghian-Nodoushan, Fatemeh; Fesahat, Farzaneh] Shahid Sadoughi Univ Med Sci, Res & Clin Ctr Infertil, Yazd, Iran; [Hekmati-Moghadam, Sayyed H.] Shahid Sadoughi Univ Med Sci, Dept Pathol, Yazd, Iran; [Miresmaeili, Sayyed M.] Yazd Acad Ctr Educ, Culture & Res Higher Educ Inst, Yazd, Iran	Khalili, MA (corresponding author), Shahid Sadoughi Univ Med Sci, Res & Clin Ctr Infertil, Yazd, Iran.	khalili59@hotmail.com	fesahat, farzaneh/AAF-4822-2020; anvari, morteza/AAV-3080-2020; Hekmatimoghaddam, Seyedhossein/Q-8258-2017	Hekmatimoghaddam, Seyedhossein/0000-0001-9859-3753	Shahid Sadoughi University of Medical Sciences, Yazd, Iran	This study was supported by a research grant from Shahid Sadoughi University of Medical Sciences, Yazd, Iran. The authors would like to thank Mehrdad Soleimani and Fatemeh Mousavi for their technical assistance and Nasrin Shekrariz for secretarial support.	Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; CLOWER BR, 1994, ANAT REC, V240, P104, DOI 10.1002/ar.1092400110; Dharmasaroja P, 2009, J CLIN NEUROSCI, V16, P12, DOI 10.1016/j.jocn.2008.05.006; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; Hanabusa K, 2005, BRAIN RES, V36, P853; Khalili MA, 1998, MED J IR IRAN, V2, P25; Khalili MA, 2001, MED J IR IRAN, V5, P93; Kondziolka D, 2008, NEUROSURG FOCUS, V24, P1; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2001, CELL TRANSPLANT, V10, P31; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pavlichenko N, 2008, BRAIN RES, V1233, P203, DOI 10.1016/j.brainres.2008.06.123; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x; Romanko MJ, 2004, PROG NEUROBIOL, V74, P77, DOI 10.1016/j.pneurobio.2004.07.001; Sabri M, 2008, BRAIN RES, V1238, P163, DOI 10.1016/j.brainres.2008.08.031; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zhang C, 2006, NEUROSCIENCE, V141, P687, DOI 10.1016/j.neuroscience.2006.04.054	30	19	22	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057			J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	AUG	2012	21	6					445	451		10.1016/j.jstrokecerebrovasdis.2010.10.005			7	Neurosciences; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	977JZ	WOS:000306656600003	21282068				2021-06-18	
J	Obirieze, AC; Gaskin, DJ; Villegas, CV; Bowman, SM; Schneider, EB; Oyetunji, TA; Haut, ER; Efron, DT; Cornwell, EE; Haider, AH				Obirieze, Augustine C.; Gaskin, Darrell J.; Villegas, Cassandra V.; Bowman, Stephen M.; Schneider, Eric B.; Oyetunji, Tolulope A.; Haut, Elliott R.; Efron, David T.; Cornwell, Edward E., III; Haider, Adil H.			Regional variations in cost of trauma care in the United States: Who is paying more?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Cost of trauma care; regional variations; trauma outcomes	HEALTH-CARE; ADMINISTRATIVE DATA; MEDICARE; QUALITY; VALIDATION; REFORM	BACKGROUND: The study of regional variations in costs of care has been used to identify areas of savings for several diseases and conditions. This study investigates similar potential regional differences in the cost of adult trauma care using an all-payer, nationally representative sample. METHODS: Trauma patients aged 18 to 64 years in the 2006-2008 Nationwide Inpatient Sample were identified using International Classification of Diseases, 9th Revision, Clinical Modification codes. Those with isolated diagnoses for five index conditions (ICs): blunt splenic injury, liver injury, tibia fracture, moderate traumatic brain injury, and pneumothorax/hemothorax were selected. Cost was estimated from charges using a cost-to-charge ratio. Generalized linear modeling was used to compare the mean cost for treating these ICs between US regions (Northeast, South, Midwest, and West), adjusting for hospital factors (size, teaching status, and location), patient demographics, injury severity, length of stay, Charlson comorbidity index, local wage index, and payer. Relative mean cost (RC) was calculated using Northeast as the reference, and sampling weights were applied to obtain regional estimates. Differences in adjusted mortality between regions were also assessed. RESULTS: Adjusted relative costs were estimated for 62,678 patients (South: 28,536; West: 12,975; Midwest: 11,450; and Northeast: 9,717). Mean costs for liver injury were 22% higher in the Midwest compared with the Northeast (RC: 1.22; 95% confidence interval [CI]: 1.10-1.35). Similarly higher costs were seen with other regions and ICs (RC for blunt splenic injury in the South: 1.18; 95% CI: 1.07-1.31; RC for pneumothorax/hemothorax in the West: 1.31; 95% CI: 1.22-1.41). No differences in adjusted mortality by region were noted overall. CONCLUSION: Even after controlling for factors known to influence medical care cost, as well as controlling for geographic differences in pricing, significant regional differences exist in the cost of trauma care. Exploring these variations may assist in identifying potential areas for cost savings. (J Trauma Acute Care Surg. 2012; 73: 516-522. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Villegas, Cassandra V.; Schneider, Eric B.; Haut, Elliott R.; Efron, David T.; Haider, Adil H.] Johns Hopkins Sch Med, Ctr Surg Trials & Outcomes Res, Dept Surg, Baltimore, MD 21212 USA; [Obirieze, Augustine C.; Oyetunji, Tolulope A.; Cornwell, Edward E., III] Howard Univ, Coll Med, Outcomes Res Ctr, Dept Surg, Washington, DC USA; [Gaskin, Darrell J.; Bowman, Stephen M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Haider, AH (corresponding author), Johns Hopkins Sch Med, Ctr Surg Trials & Outcomes Res, Dept Surg, 600 N Wolfe St,Halsted 610, Baltimore, MD 21212 USA.	ahaider1@jhmi.edu	Bowman, Stephen/AAF-2154-2019; Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X; Oyetunji, Tolulope/0000-0003-3039-7195	National Institutes of Health/NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112-01]; American College of Surgeons C. James Carrico Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112] Funding Source: NIH RePORTER	Supported by National Institutes of Health/NIGMS K23GM093112-01; American College of Surgeons C. James Carrico Fellowship for the study of Trauma and Critical Care.	[Anonymous], 2006, HEALTHC COST UT PROJ; Briggs A, 1998, J Health Serv Res Policy, V3, P233; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cooper RA, 2009, HEALTH AFFAIR, V28, pW103, DOI 10.1377/hlthaff.28.1.w103; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cutler DM, 1999, AM ECON REV, V89, P228, DOI 10.1257/aer.89.2.228; Deb P., 2010, AM SOC HLTH EC C COR; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2003, PERSPECT BIOL MED, V46, P69, DOI 10.1353/pbm.2003.0004; Gawande A., 2009, NEW YORKER; Glance LG, 2010, ANN SURG, V252, P217, DOI 10.1097/SLA.0b013e3181e623f6; HCUP Nationwide Inpatient Sample (NIS), 2008, HEALTHC COST UT PROJ; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MacKenzie EJ, 2010, J TRAUMA, V69, P1, DOI 10.1097/TA.0b013e3181e03a21; Makarov DV, 2010, J UROLOGY, V183, P1504, DOI 10.1016/j.juro.2009.12.014; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rettenmaier AJ, 2012, HEALTH ECON, V21, P67, DOI 10.1002/hec.1700; Sirovich B, 2008, HEALTH AFFAIR, V27, P813, DOI 10.1377/hlthaff.27.3.813; Skinner J, 2000, NBER FR HLTH POL RES, V3, P69, DOI 10.1162/109623100300091078; Skinner J, 1997, NATL TAX J, V50, P413; Weir S, 2010, EXPERT REV PHARM OUT, V10, P187, DOI [10.1586/erp.10.8, 10.1586/ERP.10.8]; Wennberg J.E., 1998, DARTMOUTH ATLAS HLTH; World Health Organization, 2009, WORLD HLTH STAT 2009; Yasaitis L, 2009, HEALTH AFFAIR, V28, pW566, DOI 10.1377/hlthaff.28.4.w566; Zuckerman S, 2010, NEW ENGL J MED, V363, P54, DOI 10.1056/NEJMsa0909253	28	19	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2012	73	2					516	522		10.1097/TA.0b013e31825132a0			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	992VG	WOS:000307807400056	23019681				2021-06-18	
J	Cai, WK; Carlson, SW; Brelsfoard, JM; Mannon, CE; Moncman, CL; Saatman, KE; Andres, DA				Cai, Weikang; Carlson, Shaun W.; Brelsfoard, Jennifer M.; Mannon, Catherine E.; Moncman, Carole L.; Saatman, Kathryn E.; Andres, Douglas A.			Rit GTPase Signaling Promotes Immature Hippocampal Neuronal Survival	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; PROGRAMMED CELL-DEATH; DENTATE GYRUS; ADULT NEUROGENESIS; OXIDATIVE STRESS; GRANULE NEURONS; MOUSE-BRAIN; P38 MAPK; MICE	The molecular mechanisms governing the spontaneous recovery seen following brain injury remain elusive, but recent studies indicate that injury-induced stimulation of hippocampal neurogenesis contributes to the repair process. The therapeutic potential of endogenous neurogenesis is tempered by the demonstration that traumatic brain injury (TBI) results in the selective death of adult-born immature neurons, compromising the cell population poised to compensate for trauma-induced neuronal loss. Here, we identify the Ras-related GTPase, Rit, as a critical player in the survival of immature hippocampal neurons following brain injury. While Rit knock-out (Rit(-/-)) did not alter hippocampal development, hippocampal neural cultures derived from Rit(-/-) mice display increased cell death and blunted MAPK cascade activation in response to oxidative stress, without affecting BDNF-dependent signaling. When compared with wild-type hippocampal cultures, Rit loss rendered immature (Dcx(+)) neurons susceptible to oxidative damage, without altering the survival of neural progenitor (Nestin(+)) cells. Oxidative stress is a major contributor to neuronal cell death following brain injury. Consistent with the enhanced vulnerability of cultured Rit(-/-) immature neurons, Rit(-/-) mice exhibited a significantly greater loss of adult-born immature neurons within the dentate gyrus after TBI. In addition, post-TBI neuronal remodeling was blunted. Together, these data identify a new and unexpected role for Rit in injury-induced neurogenesis, functioning as a selective survival mechanism for immature hippocampal neurons within the subgranular zone of the dentate gyrus following TBI.	[Cai, Weikang; Mannon, Catherine E.; Moncman, Carole L.; Andres, Douglas A.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; [Carlson, Shaun W.; Brelsfoard, Jennifer M.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA; [Carlson, Shaun W.; Brelsfoard, Jennifer M.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 741 S Limestone St, Lexington, KY 40536 USA.	dandres@uky.edu	Cai, Weikang/K-2394-2019	Cai, Weikang/0000-0001-5638-0805; Carlson, Shaun/0000-0002-1413-5075	Public Health Service from the National Institute of Neurological Disorders and Stroke [NS045103, NS058484, NS072302]; Kentucky Spinal Cord and Head Injury Research Trust [7-20]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [2P20 RR020171]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072302, R01NS045103, R56NS045103, P01NS058484] Funding Source: NIH RePORTER	This work was supported by Public Health Service Grants NS045103 (D. A. A.), NS058484 (K. E. S.), and NS072302 (K. E. S.) from the National Institute of Neurological Disorders and Stroke, Kentucky Spinal Cord and Head Injury Research Trust Grant 7-20 (K. E. S.), and National Center for Research Resources Grant 2P20 RR020171 (D. A. A.). We thank Drs. G.-X. Shi, M. Gentry, and P. Lein for helpful discussions. This manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NCRR.	Amiri A, 2012, J NEUROSCI, V32, P5880, DOI 10.1523/JNEUROSCI.5462-11.2012; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bergami M, 2008, P NATL ACAD SCI USA, V105, P15570, DOI 10.1073/pnas.0803702105; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buss RR, 2006, ANNU REV NEUROSCI, V29, P1, DOI 10.1146/annurev.neuro.29.051605.112800; Cai WK, 2011, MOL BIOL CELL, V22, P3231, DOI 10.1091/mbc.E11-05-0400; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gould E, 1997, J NEUROSCI, V17, P2492; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kuhn HG, 2005, EUR J NEUROSCI, V22, P1907, DOI 10.1111/j.1460-9568.2005.04377.x; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Lein PJ, 2007, J NEUROSCI, V27, P4725, DOI 10.1523/JNEUROSCI.5633-06.2007; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Magavi SS, 2000, NATURE, V405, P951; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; Mu YL, 2010, CURR OPIN NEUROBIOL, V20, P416, DOI 10.1016/j.conb.2010.04.010; Petreanu L, 2002, J NEUROSCI, V22, P6106; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rudolph JL, 2007, BBA-MOL CELL RES, V1773, P1793, DOI 10.1016/j.bbamcr.2007.09.008; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Shi GX, 2011, MOL CELL BIOL, V31, P1938, DOI 10.1128/MCB.01380-10; Shi GX, 2005, MOL CELL BIOL, V25, P830, DOI 10.1128/MCB.25.2.830-846.2005; SHOLL DA, 1953, J ANAT, V87, P387; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Spencer ML, 2002, J BIOL CHEM, V277, P20160, DOI 10.1074/jbc.M201092200; Spencer ML, 2002, J BIOL CHEM, V277, P17605, DOI 10.1074/jbc.M111400200; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Young D, 1999, NAT MED, V5, P448; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	55	19	19	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 18	2012	32	29					9887	9897		10.1523/JNEUROSCI.0375-12.2012			11	Neurosciences	Neurosciences & Neurology	975RI	WOS:000306528200014	22815504	Bronze, Green Accepted, Green Published			2021-06-18	
J	Bagnato, S; Minafra, L; Bravata, V; Boccagni, C; Sant'Angelo, A; Castiglione, A; Andriolo, M; Lucca, LF; De Tanti, A; Pistarini, C; Formisano, R; Dolce, G; Gelfi, C; Galardi, G				Bagnato, Sergio; Minafra, Luigi; Bravata, Valentina; Boccagni, Cristina; Sant'Angelo, Antonino; Castiglione, Alberto; Andriolo, Maria; Lucca, Lucia Francesca; De Tanti, Antonio; Pistarini, Caterina; Formisano, Rita; Dolce, Giuliano; Gelfi, Cecilia; Galardi, Giuseppe			Brain-Derived Neurotrophic Factor (Val66Met) Polymorphism Does Not Influence Recovery from a Post-Traumatic Vegetative State: A Blinded Retrospective Multi-Centric Study	JOURNAL OF NEUROTRAUMA			English	Article						disorders of consciousness; genetic factors; levels of cognitive functioning; traumatic brain injury; vegetative state	MET ALLELE; BDNF; PLASTICITY; ALTERS; MATURATION; SURVIVORS; VOLUME	Brain-derived neurotrophic factor (BDNF) is a neurotrophin that influences neuronal plasticity throughout life. Emergence from a vegetative state (VS) after a traumatic brain injury (TBI) implies that the brain undergoes plastic changes. A common polymorphism in the BDNF gene-BDNF Val66Met (referred to herein as BDNFMet)-impairs cognitive function in healthy subjects. The aim of this study was to determine whether the BDNFMet polymorphism plays a role in the recovery of consciousness and cognitive functions in patients in a VS after a TBI. Fifty-three patients in a VS 1 month after a TBI were included in the study and genotyped for the BDNFMet polymorphism. Scores of levels of cognitive functioning (LCF) at 1, 3, 6, and 12 months post-TBI were retrospectively compared in patients without (Val group), and with (Met group), the BDNFMet polymorphism. The BDNFMet polymorphism was detected in 20 out of the 53 patients. The mean LCF scores in the Val and Met groups were 1.6 +/- 0.5 and 1.4 +/- 0.5 at 1 month, 2.3 +/- 0.7 and 2.5 +/- 1.2 at 3 months, 3.3 +/- 1.7 and 3.5 +/- 1.7 at 6 months, and 4 +/- 1.9 and 3.9 +/- 1.8 at 12 months, respectively (p > 0.05). The percentages of patients in the Val and Met groups who emerged from the VS were 36.4% and 30% at 3 months, 66.3% and 70% at 6 months, and 70% and 87.5% at 12 months (p > 0.05), respectively. These findings provide evidence that the BDNFMet polymorphism is not involved in cognitive improvement in patients with a VS following TBI. Future studies should focus on the role of other BDNF polymorphisms in the recovery from a VS.	[Bagnato, Sergio; Boccagni, Cristina; Sant'Angelo, Antonino; Castiglione, Alberto; Galardi, Giuseppe] Fdn Ist San Raffaele G Giglio, Rehabil Dept, Unit Severe Acquired Brain Injuries, I-90015 Cefalu, PA, Italy; [Bagnato, Sergio; Boccagni, Cristina; Sant'Angelo, Antonino; Galardi, Giuseppe] Fdn Ist San Raffaele G Giglio, Rehabil Dept, Neurophysiol Unit, I-90015 Cefalu, PA, Italy; [Andriolo, Maria] Fdn Ist San Raffaele G Giglio, Clin Pathol & Microbiol Lab, I-90015 Cefalu, PA, Italy; [Minafra, Luigi; Bravata, Valentina] HSR Giglio, Lab Tecnol Oncol LATO, Cefalu, Italy; [Minafra, Luigi; Bravata, Valentina; Gelfi, Cecilia] Natl Council Res CNR, Inst Mol Bioimaging & Physiol IBFM, Cefalu Segrate, Italy; [Lucca, Lucia Francesca; Dolce, Giuliano] St Anna Inst, Crotone, Italy; [De Tanti, Antonio] Cardinal Ferrari Ctr, Fontanellato, Italy; [Pistarini, Caterina] Sci Inst Pavia, IRCCS S Maugeri Fdn, Neurorehabil Unit, Pavia, Italy; [Formisano, Rita] IRCCS Fdn Santa Lucia Roma, Postcoma Unit, Rome, Italy; [Formisano, Rita] IRCCS Fdn Santa Lucia Roma, Headache Ctr, Rome, Italy; [Gelfi, Cecilia] UNIMI, Dept Sci & Biomed Technol, Milan, Italy	Bagnato, S (corresponding author), Fdn Ist San Raffaele G Giglio, Rehabil Dept, Unit Severe Acquired Brain Injuries, I-90015 Cefalu, PA, Italy.	sergiobagnato@gmail.com	Pistarini, CATERINA/K-5234-2018; Gelfi, Cecilia/L-1490-2016; Bagnato, Sergio/H-6842-2013	Pistarini, CATERINA/0000-0001-8925-0484; Gelfi, Cecilia/0000-0002-2996-6912; Bagnato, Sergio/0000-0002-6289-1887; Minafra, Luigi/0000-0003-3112-4519; Boccagni, Cristina/0000-0002-6317-015X			Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bagnato S, 2010, CLIN NEUROPHYSIOL, V121, P274, DOI 10.1016/j.clinph.2009.11.008; Baker-Herman TL, 2004, NAT NEUROSCI, V7, P48, DOI 10.1038/nn1166; Bates D, 2005, NEUROPSYCHOL REHABIL, V15, P175, DOI 10.1080/09602010443000399; Birkenhager TK, 2012, J PSYCHIATR RES, V46, P285, DOI 10.1016/j.jpsychires.2011.12.006; Blesch A, 2007, J NEUROSCI, V27, P10535, DOI 10.1523/JNEUROSCI.1903-07.2007; Boccagni C, 2011, J CLIN NEUROPHYSIOL, V28, P489, DOI 10.1097/WNP.0b013e318231c8c8; Braakman R., 1998, ACTA NEUROCHIR, V95, P49; Bueller JA, 2006, BIOL PSYCHIAT, V59, P812, DOI 10.1016/j.biopsych.2005.09.022; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Fingelkurts A. A., CLIN NEUROPHYSIOLO S, V62; Fingelkurts AA, 2012, CONSCIOUS COGN, V21, P149, DOI 10.1016/j.concog.2011.10.004; Frodl T, 2007, ARCH GEN PSYCHIAT, V64, P410, DOI 10.1001/archpsyc.64.4.410; Hagen C., 1972, LEVELS COGNITIVE FUN; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Hirschberg R, 2011, NEUROL CLIN, V29, P773, DOI 10.1016/j.ncl.2011.07.009; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x; Montag C, 2010, PSYCHIAT RES, V179, P86, DOI 10.1016/j.psychres.2008.08.005; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nemoto K, 2006, NEUROSCI LETT, V397, P25, DOI 10.1016/j.neulet.2005.11.067; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Pivac N, 2009, CROAT MED J, V50, P43, DOI 10.3325/cmj.2009.50.43; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rex CS, 2007, J NEUROSCI, V27, P3017, DOI 10.1523/JNEUROSCI.4037-06.2007; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Royal College of Physicians, 2003, PERM VEG STAT GUID D; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; Shen WH, 2006, NEURON, V50, P401, DOI 10.1016/j.neuron.2006.03.017; Shimizu E, 2004, AM J MED GENET B, V126B, P122, DOI 10.1002/ajmg.b.20118; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Soliman F, 2010, SCIENCE, V327, P863, DOI 10.1126/science.1181886; Szeszko PR, 2005, MOL PSYCHIATR, V10, P631, DOI 10.1038/sj.mp.4001656; Tang S, 2010, BRAIN RES, V1354, P1, DOI 10.1016/j.brainres.2010.07.051; TSUKAHARA T, 1995, NEUROSURGERY, V37, P733, DOI 10.1227/00006123-199510000-00018; Tyler WJ, 2002, LEARN MEMORY, V9, P224, DOI 10.1101/lm.51202; Yano H, 2006, NAT NEUROSCI, V9, P1009, DOI 10.1038/nn1730; Yoshii A, 2010, DEV NEUROBIOL, V70, P304, DOI 10.1002/dneu.20765; Zhang XY, 2012, PSYCHOPHARMACOLOGY, V222, P277, DOI 10.1007/s00213-012-2643-y	47	19	21	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2050	2059		10.1089/neu.2011.2184			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800006	22708958				2021-06-18	
J	Cernich, AN; Chandler, L; Scherdell, T; Kurtz, S				Cernich, Alison N.; Chandler, Lauren; Scherdell, Traci; Kurtz, Shira			Assessment of Co-Occurring Disorders in Veterans Diagnosed With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adult; brain injuries/complications; Iraq war; mental disorders/diagnosis; veterans/psychology	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MILITARY SERVICE MEMBERS; OIF/OEF VETERANS; CHRONIC PAIN; POLYTRAUMA; DEPRESSION; SEQUELAE; IRAQ; REHABILITATION	Aims: The co-occurrence of psychiatric disorders and other somatic disorders poses a significant challenge for the individual clinician working with veterans who report a history of mild traumatic brain injury (mTBI). In this article, common co-occurring symptoms and disorders will be described in relation to the population of veterans with mTBI, using a retrospective analysis of data from initial screening and secondary level evaluation for traumatic brain injury (TBI) in an urban Veteran's Affairs Medical Center. Participants: Four hundred two veterans of the recent conflicts who received secondary level evaluation for TBI following positive TBI screening. Outcomes: Significant differences were detected in symptom reporting between those who screened positive and those who screened negative on psychiatric screening. Those with positive posttraumatic stress disorder and depression screens endorsed more cognitive and affective symptoms; individuals screening positive for alcohol abuse did not report significantly more symptoms. Individuals without positive psychiatric screens reported fewer symptoms than those with positive screens. Consideration of these data in the context of a clinical case will be used to elucidate the challenge this presents to the clinical team. Conclusion: The presence of co-occurring disorders should be considered in the etiology of a veteran's continued symptomatic complaints following TBI.	[Cernich, Alison N.] Dept Vet Affairs, Off Rehabil Serv, Washington, DC USA; [Cernich, Alison N.] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Silver Spring, MD USA; [Cernich, Alison N.; Chandler, Lauren; Scherdell, Traci; Kurtz, Shira] VA Maryland Hlth Care Syst, Baltimore, MD USA; [Cernich, Alison N.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA	Cernich, AN (corresponding author), Def Ctr Excellence, 9th Floor,1355 East West Highway, Silver Spring, MD 20910 USA.	Alison.Cernich@va.gov					Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Herman D., 1993, ANN CONV INT SOC TRA; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Ryan PB, 2011, BRAIN INJURY, V25, P1019, DOI 10.3109/02699052.2011.597044; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271	34	19	19	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2012	27	4					253	260		10.1097/HTR.0b013e3182585cd5			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	975PJ	WOS:000306523000003	22767073				2021-06-18	
J	Hofbauer, M; Jaindl, M; Hochtl, LL; Ostermann, RC; Kdolsky, R; Aldrian, S				Hofbauer, Marcus; Jaindl, Manuela; Hoechtl, Leonard Lee; Ostermann, Roman C.; Kdolsky, R.; Aldrian, Silke			Spine injuries in polytraumatized pediatric patients: Characteristics and experience from a Level I trauma center over two decades	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Spine injuries; polytrauma; pediatric; outcome	CERVICAL-SPINE; BLUNT TRAUMA; CHILDREN; SEVERITY	BACKGROUND: Spine injuries, a common component in polytrauma, are relatively rare in pediatric patients. Previous studies mainly described injuries to the cervical region, whereas information of injury patterns to the thoracic and lumbosacral region lack in the current literature. The aim of this study was to determine the incidence and characteristics of polytraumatized children and associated spine injuries in different pediatric development ages. METHODS: A cohort review of all pediatric patients with the diagnosis of polytrauma and associated spine injury, admitted to a urban Level I trauma center, was conducted over an 18-year period from January 1992 to December 2010. Patients were stratified into four developmental age groups: infants/toddlers (age 0-4 years), preschool/young children (age 5-9 years), preadolescents (age 10-14 years), and adolescents (age 15-17 years). Demographics, clinical injury data, patterns of spine injuries, associated injuries, treatment, and outcome were abstracted and analyzed. RESULTS: From a database of 897 severely (Injury Severity Score >= 16) injured pediatric patients, 28 children met the inclusion criteria. The mean age was 12.7 years (range, 1.3-16.7 years), and there were 18 males and 10 females. Younger children (age 0-9 years) sustained more injuries to the upper spine region, whereas injuries to the lumbar region were only seen in adolescents. Nine (32%) patients received surgical treatment for spine fracture or subluxation, and 15 (54%) were treated by nonoperative means. Four patients (14%) received only palliative treatment due to medical futility. Overall, the most commonly associated injury was thoracic injury (89%) followed by traumatic brain injury (64%). CONCLUSION: The age-related anatomy and physiology predispose younger children to upper spine injuries in contrast to lower spine injuries seen in adolescents. Predictors of mortality include pathologic pupillary light reflex, high Injury Severity Score and Abbreviated Injury Scale score, and a low Glasgow Coma Scale score at admission. Thoracic injuries were the most common associated injuries followed by traumatic brain injury. (J Trauma Acute Care Surg. 2012; 73: 156-161. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Hofbauer, Marcus; Jaindl, Manuela; Hoechtl, Leonard Lee; Ostermann, Roman C.; Kdolsky, R.; Aldrian, Silke] Med Univ Vienna, Dept Trauma Surg, A-1090 Vienna, Austria	Hofbauer, M (corresponding author), Med Univ Vienna, Dept Trauma Surg, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	marcus.hofbauer@medunwien.ac.at					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bederman SS, 2011, J TRAUMA, V71, pE71, DOI 10.1097/TA.0b013e3182092eac; Bliss D, 2002, CRIT CARE MED, V30, pS409, DOI 10.1097/00003246-200211001-00005; Broder J, 2007, EMERG RADIOL, V14, P227, DOI 10.1007/s10140-007-0618-9; Chung S, 2011, J TRAUMA, V70, P873, DOI 10.1097/TA.0b013e3182108823; Cirak B, 2004, J PEDIATR SURG, V39, P607, DOI 10.1016/j.jpedsurg.2003.12.011; Frankel H L, 1969, Paraplegia, V7, P179; Garcia RA, 2002, AM J PHYS MED REHAB, V81, P458, DOI 10.1097/00002060-200206000-00011; Halpern CH, 2010, SPINE, V35, P1721, DOI 10.1097/BRS.0b013e3181e9acb2; Hebert JS, 2000, SPINE, V25, P55, DOI 10.1097/00007632-200001010-00011; Houshian S, 2002, J TRAUMA, V52, P715, DOI 10.1097/00005373-200204000-00018; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Leonard JC, 2011, ANN EMERG MED, V58, P145, DOI 10.1016/j.annemergmed.2010.08.038; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Mahan ST, 2009, J TRAUMA, V67, P537, DOI 10.1097/TA.0b013e3181ad8fc9; Markel TA, 2009, J TRAUMA, V67, P23, DOI 10.1097/TA.0b013e318184ba9a; Mohseni S, 2011, J PEDIATR SURG, V46, P1771, DOI 10.1016/j.jpedsurg.2011.03.007; Mortazavi M, 2011, CHILD NERV SYST, V27, P705, DOI 10.1007/s00381-010-1342-4; Mueller DL, 2011, J TRAUMA, V70, P724, DOI 10.1097/TA.0b013e3182092ff8; NAKAYAMA DK, 1989, ANN SURG, V210, P770, DOI 10.1097/00000658-198912000-00013; Platzer P, 2007, J TRAUMA, V62, P389, DOI 10.1097/01.ta.0000221802.83549.46; Reamy Rebecca R, 2004, J S C Med Assoc, V100, P317; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Salim A, 2006, ARCH SURG-CHICAGO, V141, P468, DOI 10.1001/archsurg.141.5.468; SCHWEIBERER L, 1987, UNFALLCHIRURG, V90, P529; Vogel LC, 2011, J SPINAL CORD MED, V34, P60, DOI 10.1179/107902610X12883422813787	27	19	19	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2012	73	1					156	161		10.1097/TA.0b013e31824e32b5			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	979JU	WOS:000306814100023	22743385				2021-06-18	
J	Pearson, WS; Ovalle, F; Faul, M; Sasser, SM				Pearson, William S.; Ovalle, Fernando, Jr.; Faul, Mark; Sasser, Scott M.			A REVIEW OF TRAUMATIC BRAIN INJURY TRAUMA CENTER VISITS MEETING PHYSIOLOGIC CRITERIA FROM THE AMERICAN COLLEGE OF SURGEONS COMMITTEE ON TRAUMA/CENTERS FOR DISEASE CONTROL AND PREVENTION FIELD TRIAGE GUIDELINES	PREHOSPITAL EMERGENCY CARE			English	Article						traumatic brain injury; trauma centers; triage; criteria	PREHOSPITAL MANAGEMENT; TEAM ACTIVATION; UNITED-STATES; VALIDATION	Background. Traumatic brain injury (TBI) represents a serious subset of injuries among persons in the United States, and prehospital care of these injuries can mitigate both the morbidity and the mortality in patients who suffer from these injuries. Guidelines for triage of injured patients have been set forth by the American College of Surgeons Committee on Trauma (ACS-COT) in cooperation with the Centers for Disease Control and Prevention (CDC). These guidelines include physiologic criteria, such as the Glasgow Coma Scale (GCS) score, systolic blood pressure, and respiratory rate, which should be used in determining triage of an injured patient. Objectives. This study examined the numbers of visits at level I and II trauma centers by patients with a diagnosed TBI to determine the prevalence of those meeting physiologic criteria from the ACS-COT/CDC guidelines and to determine the extent of mortality among this patient population. Methods. The data for this study were taken from the 2007 National Trauma Data Bank (NTDB) National Sample Program (NSP). This data set is a nationally representative sample of visits to level I and II trauma centers across the United States and is funded by the American College of Surgeons. Estimates of demographic characteristics, physiologic measures, and death were made for this study population using both chi-square analyses and adjusted logistic regression modeling. Results. The analyses demonstrated that although many people who sustain a TBI and were taken to a level I or II trauma center did not meet the physiologic criteria, those who did meet the physiologic criteria had significantly higher odds of death than those who did not meet the criteria. After controlling for age, gender, race, Injury Severity Score (ISS), and length of stay in the hospital, persons who had a GCS score <= 13 were 17 times more likely to die than TBI patients who had a higher GCS score (odds ratio [OR] 17.4; 95% confidence interval [CI] 10.7-28.3). Other physiologic criteria also demonstrated significant odds of death. Conclusions. These findings support the validity of the ACS-COT/CDC physiologic criteria in this population and stress the importance of prehospital triage of patients with TBI in the hopes of reducing both the morbidity and the mortality resulting from this injury.	[Pearson, William S.; Ovalle, Fernando, Jr.; Faul, Mark; Sasser, Scott M.] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; [Ovalle, Fernando, Jr.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Sasser, Scott M.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Pearson, WS (corresponding author), Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA.	wpearson@cdc.gov		Faul, Mark/0000-0002-7683-0348	Intramural CDC HHS [CC999999] Funding Source: Medline		[Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Brown JB, 2011, J TRAUMA, V70, P38, DOI 10.1097/TA.0b013e3182077ea8; Center for Disease Control and Prevention, 2010, MMWR-MORBID MORTAL W, V59, P303; Cook CH, 2001, ARCH SURG-CHICAGO, V136, P752, DOI 10.1001/archsurg.136.7.752; Coronado V., 2012, BRAIN INJURY MED; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; ESPOSITO TJ, 1995, ARCH SURG-CHICAGO, V130, P171; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Henry MC, 1996, AM J EMERG MED, V14, P124, DOI 10.1016/S0735-6757(96)90117-5; Henry MC, 1996, ACAD EMERG MED, V3, P992, DOI 10.1111/j.1553-2712.1996.tb03340.x; Lehmann RK, 2007, AM J SURG, V193, P630, DOI 10.1016/j.amjsurg.2007.01.017; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mackersie RC, 2006, PREHOSP EMERG CARE, V10, P287, DOI 10.1080/10903120600721636; Minardi J, 2009, MT SINAI J MED, V76, P138, DOI 10.1002/msj.20105; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; PHILLIPS JA, 1993, J TRAUMA, V34, P127, DOI 10.1097/00005373-199301000-00024; Purtill MA, 2008, J TRAUMA, V65, P1253, DOI 10.1097/TA.0b013e31818bbfc2; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Sasser Scott M., 2009, Morbidity and Mortality Weekly Report, V58, P1; Stiver SI, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E5; Tinkoff GH, 2002, J TRAUMA, V52, P1153, DOI 10.1097/00005373-200206000-00022; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	24	19	19	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	JUL-SEP	2012	16	3					323	328		10.3109/10903127.2012.682701			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	946QD	WOS:000304367100002	22548387	Green Accepted			2021-06-18	
J	Schober, ME; Ke, XR; Xing, BH; Block, BP; Requena, DF; McKnight, R; Lane, RH				Schober, Michelle E.; Ke, Xingrao; Xing, Bohan; Block, Benjamin P.; Requena, Daniela F.; McKnight, Robert; Lane, Robert H.			Traumatic Brain Injury Increased IGF-1B mRNA and Altered IGF-1 Exon 5 and Promoter Region Epigenetic Characteristics in the Rat Pup Hippocampus	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; developmental; epigenetics; neuroprotective; rat	GROWTH-FACTOR-I; HISTONE H3 ACETYLATION; (IGF)-I E-PEPTIDES; METHYLATION; EXPRESSION; IMPROVES; MODEL; TERM; MGF; INFLAMMATION	Traumatic brain injury (TBI) is a major cause of acquired cognitive disability in childhood. Such disability may be blunted by enhancing the brain's endogenous neuroprotective response. An important endogenous neuroprotective response is the insulin-like growth factor-1 (IGF-1) mRNA variant, IGF-1B. IGF-1B mRNA, characterized by exon 5 inclusion, encodes the IGF-1 and Eb peptides. IGF-1A mRNA excludes exon 5 and encodes the IGF-1 and Ea peptides. A region in the human IGF-1B homologue acts as an exon-splicing enhancer (ESE) to increase IGF-1B mRNA. It is not known if TBI is associated with increased brain IGF-1B mRNA. Epigenetic modifications may underlie altered gene expression in the brain after TBI. We hypothesized that TBI would increase hippocampal IGF-1B mRNA in 17-day-old rats, associated with DNA methylation and/or histone modifications at the promoter site 1 (P1) or exon 5/ESE region. Hippocampi from rat pups after controlled cortical impact (CCI) were used to measure IGF-1B mRNA, DNA methylation, and histone modifications at the P1, P2, and exon5/ESE regions. In CCI hippocampi, IGF-1B mRNA peaked at post-injury day (PID) 2 (1700 +/- 320% sham), but normalized by PID 14. IGF-1A peaked at PID 3 (280 +/- 52% sham), and remained elevated at PID 14. Increased IGF-1B mRNA was associated with increased methylation at P1, and increased histone modifications associated with gene activation at P2 and exon5/ESE, together with differential methylation in the exon 5/ESE regions. We report for the first time that hippocampal IGF-1B mRNA increased after developmental TBI. We speculate that epigenetic modifications at the P2 and exon 5/ESE regions are important in the regulation of IGF-1B mRNA expression. The exon 5/ESE region may present a means for future therapies to target IGF-1B transcription after TBI.	[Schober, Michelle E.] Univ Utah, Sch Med, Div Crit Care, Dept Pediat, Salt Lake City, UT 84158 USA; [Ke, Xingrao; Xing, Bohan; Block, Benjamin P.; Requena, Daniela F.; McKnight, Robert; Lane, Robert H.] Univ Utah, Sch Med, Div Neonatol, Salt Lake City, UT 84158 USA	Schober, ME (corresponding author), Univ Utah, Sch Med, Div Crit Care, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	michelle.schober@hsc.utah.edu					Aberg ND, 2010, ENDOCR DEV, V17, P63, DOI 10.1159/000262529; Adelson PD, 1998, ACT NEUR S, V71, P104; Anastasiadou C, 2011, DNA CELL BIOL, V30, P267, DOI 10.1089/dna.2010.1094; Aperghis M, 2004, BRAIN RES, V1009, P213, DOI 10.1016/j.brainres.2004.02.049; Armakolas A, 2010, PROSTATE, V70, P1233, DOI 10.1002/pros.21158; Barton ER, 2010, J APPL PHYSIOL, V108, P1069, DOI 10.1152/japplphysiol.01308.2009; Beresewicz M, 2010, INT J DEV NEUROSCI, V28, P91, DOI 10.1016/j.ijdevneu.2009.09.002; Cai Z, 2011, NEUROSCIENCE, V194, P195, DOI 10.1016/j.neuroscience.2011.08.003; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; D'Ercole AJ, 2002, NEUROPEPTIDES, V36, P209, DOI 10.1054/npep.2002.0893; Dai ZQ, 2010, GROWTH HORM IGF RES, V20, P275, DOI 10.1016/j.ghir.2010.03.005; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dluzniewska J, 2005, FASEB J, V19, P1896, DOI 10.1096/fj.05-3786fje; Fu Q, 2006, FASEB J, V20, P2127, DOI 10.1096/fj.06-6179fje; Fu Q, 2009, FASEB J, V23, P2438, DOI 10.1096/fj.08-124768; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gorecki DC, 2007, NEUROCHEM INT, V51, P451, DOI 10.1016/j.neuint.2007.04.030; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957; Kazanis I, 2003, BRAIN RES, V991, P34, DOI 10.1016/S0006-8993(03)03525-X; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Li R.C., 2011, NEUROSCIENCE; Li XS, 1998, MOL BRAIN RES, V57, P92, DOI 10.1016/S0169-328X(98)00075-8; Lin SY, 2009, EXP NEUROL, V217, P361, DOI 10.1016/j.expneurol.2009.03.021; Lin SY, 2005, BRAIN RES, V1063, P15, DOI 10.1016/j.brainres.2005.09.042; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Lyko F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000506; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; Molfese DL, 2011, DEV NEUROPSYCHOL, V36, P810, DOI 10.1080/87565641.2011.606395; Musaro A, 2007, EXP GERONTOL, V42, P76, DOI 10.1016/j.exger.2006.05.004; Peter CJ, 2011, TRENDS MOL MED, V17, P372, DOI 10.1016/j.molmed.2011.02.003; Pfeffer LA, 2009, MOL BIOL CELL, V20, P3810, DOI 10.1091/mbc.E08-12-1202; Pilch B, 2001, CANCER RES, V61, P6876; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Qureshi IA, 2010, ARCH NEUROL-CHICAGO, V67, P1316, DOI 10.1001/archneurol.2010.275; Riddoch-Contreras J, 2009, EXP NEUROL, V215, P281, DOI 10.1016/j.expneurol.2008.10.014; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; ROTWEIN P, 1993, MOL REPROD DEV, V35, P358, DOI 10.1002/mrd.1080350407; ROTWEIN P, 1986, P NATL ACAD SCI USA, V83, P77, DOI 10.1073/pnas.83.1.77; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Schwartz S, 2010, EMBO J, V29, P1629, DOI 10.1038/emboj.2010.71; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith PJ, 2002, ENDOCRINOLOGY, V143, P146, DOI 10.1210/en.143.1.146; Tremolizzo L, 2002, P NATL ACAD SCI USA, V99, P17095, DOI 10.1073/pnas.262658999; Yan YP, 2006, EUR J NEUROSCI, V24, P45, DOI 10.1111/j.1460-9568.2006.04872.x; Yang SY, 2002, FEBS LETT, V522, P156, DOI 10.1016/S0014-5793(02)02918-6; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061	59	19	19	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2075	2085		10.1089/neu.2011.2276			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800008	22413999				2021-06-18	
J	Wang, JW; Wang, HD; Zhong, WZ; Li, N; Cong, ZX				Wang, Jia-Wei; Wang, Han-Dong; Zhong, Wu-Zhao; Li, Ning; Cong, Zi-Xiang			Expression and cell distribution of metabotropic glutamate receptor 5 in the rat cortex following traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Metabotropic glutamate receptor 5; Rat cortex; Expression; Fluoro-Jade C	GROUP-I; ENDOGENOUS ACTIVATION; SYNAPTIC-TRANSMISSION; MESSENGER-RNAS; AMINO-ACIDS; MGLUR5; GENE; NMDA; LOCALIZATION; INVOLVEMENT	Traumatic brain injury (TBI)-released excessive glutamate resulted in the activation of glutamate receptors including the metabotropic glutamate receptor 5 (mGluR5). To investigate the expression and cell distribution of mGluR5 in the rat cortex following TBI, western blot and quantitative real-time PCR were used to study the protein and mRNA level of mGluR5 respectively while immunohistochemistry analysis and double immunofluorescence with neural cell marker were used to define the cell distribution of mGluR5. Furthermore, we examined the effects of post-TBI administration of (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG), a selective mGluR5 agonist, on the neuronal degeneration in the cortex. In the present study, we found that the protein level of mGluR5 was up-regulated by traumatic brain injury, while TBI-induced mGluR5 mRNA expression displayed biphasic changes with up-regulation in the early time and down-regulation in the late time after TBI. And neuron, astrocyte and microglia in the cortex after TBI all expressed mGluR5. Moreover, CHPG treatment significantly reduced the number of degenerating neurons detected by Fluoro-Jade C staining. These findings demonstrate that expression of mGluR5 differentially changes both spatially and temporally after TBI and may be related to the neuroprotection after TBI. Therefore, understanding the expression and cell distribution of mGluR5 after TBI may give insight into pathophysiology after TBI and provide a new target for the therapy of TBI. (c) 2012 Elsevier B.V. All rights reserved.	[Wang, Jia-Wei; Wang, Han-Dong; Cong, Zi-Xiang] Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070974]; Key Subject of Jiangsu Province [X4200722]	This work was supported by grants from National Natural Science Foundation of China (no. 81070974), and the Key Subject of Jiangsu Province (X4200722).	Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Aronica E, 2001, NEUROSCIENCE, V105, P509, DOI 10.1016/S0306-4522(01)00181-6; Backstrom P, 2007, PSYCHOPHARMACOLOGY, V192, P571, DOI 10.1007/s00213-007-0753-8; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Biber K, 1999, J NEUROCHEM, V72, P1671, DOI 10.1046/j.1471-4159.1999.721671.x; Bruno V, 2001, J CEREBR BLOOD F MET, V21, P1013, DOI 10.1097/00004647-200109000-00001; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, NEUROTHERAPEUTICS, V6, P94, DOI 10.1016/j.nurt.2008.10.038; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Catania MV, 2001, J NEUROSCI, V21, P7664; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Chu ZG, 2005, J NEUROSCI, V25, P5740, DOI 10.1523/JNEUROSCI.0913-05.2005; Ciccarelli R, 1997, GLIA, V21, P390, DOI 10.1002/(SICI)1098-1136(199712)21:4<390::AID-GLIA6>3.0.CO;2-7; Corti C, 2003, J BIOL CHEM, V278, P33105, DOI 10.1074/jbc.M212380200; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Geurts JJG, 2003, BRAIN, V126, P1755, DOI 10.1093/brain/awg179; Gong QZ, 1999, J NEUROTRAUM, V16, P893, DOI 10.1089/neu.1999.16.893; Harney SC, 2006, J NEUROSCI, V26, P1128, DOI 10.1523/JNEUROSCI.2753-05.2006; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hubert GW, 2001, J NEUROSCI, V21, P1838, DOI 10.1523/JNEUROSCI.21-06-01838.2001; Jong YJI, 2009, J BIOL CHEM, V284, P35827, DOI 10.1074/jbc.M109.046276; Kotecha SA, 2003, J BIOL CHEM, V278, P27742, DOI 10.1074/jbc.M301946200; Lea PM, 2005, BRIT J PHARMACOL, V145, P527, DOI 10.1038/sj.bjp.0706219; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Mudo G, 2007, BRAIN RES, V1149, P1, DOI 10.1016/j.brainres.2007.02.041; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Simonyi A, 2010, EUR J PHARMACOL, V639, P17, DOI 10.1016/j.ejphar.2009.12.039; Spillson AB, 2003, EXP NEUROL, V184, pS97, DOI 10.1016/j.expneurol.2003.08.001; Szekeres PG, 1998, J NEUROCHEM, V70, P1694; Wang X, 2012, ADDICT BIOL; Xu X, 2012, NEUROSCIENCE, V202, P474, DOI 10.1016/j.neuroscience.2011.12.008; Yamaguchi S, 1998, J NEUROCHEM, V71, P60; Yanamala N, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-S1-S16; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	43	19	21	0	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 29	2012	1464						73	81		10.1016/j.brainres.2012.05.014			9	Neurosciences	Neurosciences & Neurology	976XI	WOS:000306620300009	22587887				2021-06-18	
J	Rao, V; Mielke, M; Xu, X; Smith, GS; McCann, UD; Bergey, A; Doshi, V; Pham, DL; Yousem, D; Mori, S				Rao, Vani; Mielke, Michelle; Xu, Xin; Smith, Gwenn S.; McCann, Una D.; Bergey, Alyssa; Doshi, Vishal; Pham, Dzung L.; Yousem, David; Mori, Susumi			Diffusion Tensor Imaging Atlas-Based Analyses in Major Depression After Mild Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MRI; ABNORMALITIES; SEQUELAE	There are currently no known early neuroanatomical markers predictive of the development of major depression or depressive symptoms after mild traumatic brain injury (mTBI). The authors conducted a 1-year longitudinal pilot study to determine whether diffusion tensor imaging (DTI) measures collected within 1 month of mTBI could predict incident depression. Of the 14 subjects who met study inclusion criteria, 4 (28.6%) developed major depression over the follow-up period. Compared with the nondepressed group, those who developed depression had white-matter abnormalities in the fronto-temporal regions measured by DTI. These preliminary results highlight the need for additional studies, including studies using a larger sample and appropriate controls. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:309-315)	[Rao, Vani; Smith, Gwenn S.; McCann, Una D.; Bergey, Alyssa; Doshi, Vishal] Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Psychiat, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA; [Mielke, Michelle] Mayo Clin, Coll Med, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN USA; [Xu, Xin; Yousem, David; Mori, Susumi] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA; [Xu, Xin; Yousem, David; Mori, Susumi] Sch Med, Baltimore, MD USA; [Pham, Dzung L.] NIH, Image Proc Core, Ctr Neurosci & Regenerat Med, USUHS, Bethesda, MD 20892 USA	Rao, V (corresponding author), Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Psychiat, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD 21218 USA.	vrao@jhmi.edu	Pham, Dzung/AAR-8263-2020	Mielke, Michelle/0000-0001-7177-1185	National Alliance for Research on Schizophrenia and Depression (NARSAD)French National Research Agency (ANR)NARSAD; Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Forest; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH086881] Funding Source: NIH RePORTER	This study was fully supported by grant from National Alliance for Research on Schizophrenia and Depression (NARSAD) and partially supported by the Department of Defense in the Center for Neuroscience and Regenerative Medicine.; Dr. Rao has a grant from Forest to conduct a clinical trial in post-TBI depression.	Abe O, 2010, PSYCHIAT RES-NEUROIM, V181, P64, DOI 10.1016/j.pscychresns.2009.07.007; BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Ceritoglu C, 2009, NEUROIMAGE, V47, P618, DOI 10.1016/j.neuroimage.2009.04.057; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Diggle P., 2002, ANAL LONGITUDINAL DA; Faria AV, 2011, NEUROIMAGE, V54, P1854, DOI 10.1016/j.neuroimage.2010.09.061; Horsfield MA, 2002, NMR BIOMED, V15, P570, DOI 10.1002/nbm.787; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Miller MI, 2005, P NATL ACAD SCI USA, V102, P9685, DOI 10.1073/pnas.0503892102; Morys Joanna M, 2003, Folia Morphol (Warsz), V62, P347; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P231, DOI 10.1176/appi.neuropsych.22.2.231; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Takahashi T, 2010, PROG NEURO-PSYCHOPH, V34, P98, DOI 10.1016/j.pnpbp.2009.10.005	25	19	20	0	5	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2012	24	3					309	315		10.1176/appi.neuropsych.11080188			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	057VS	WOS:000312592800040	23037644	Green Accepted			2021-06-18	
J	Wu, XM; Jin, W; Liu, XJ; Fu, HR; Gong, PP; Xu, J; Cui, G; Ni, YH; Ke, KF; Gao, ZW; Gao, YL				Wu, Xinmin; Jin, Wei; Liu, Xiaojuan; Fu, Hongran; Gong, Peipei; Xu, Jian; Cui, Gang; Ni, Yaohui; Ke, Kaifu; Gao, Zhiwei; Gao, Yilu			Cyclic AMP Response Element Modulator-1 (CREM-1) Involves in Neuronal Apoptosis after Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						CREM-1; Traumatic brain injury; Apoptosis; Rat; CREB	TRANSCRIPTION FACTORS; BCL-2 EXPRESSION; GENE-EXPRESSION; CELL-DEATH; IN-VITRO; CREB; PROTEINS; BINDING; RAT; PROLIFERATION	The cyclic AMP response element-binding protein (CREB) family can regulate biological functions of various types of cells by forming homo- or heterodimers to bind the target DNA sequences; it plays an essential role in individual neuronal function and entire neuronal circuits. One attractive activity of the CREB family is regulating the transcription of apoptosis-suppressor gene bcl-2. Cyclic AMP response element modulator-1 (CREM-1) is one member of the family with limited acquaintance. To investigate whether CREM-1 is involved in central nervous system injury and repair, we performed an acute traumatic brain injury (TBI) model in adult rats. Western blot analysis and immunohistochemistry showed a significant upregulation of CREM-1 in ipsilateral peritrauma cortex. Immunofluorescent labeling indicated that CREM-1 was localized mainly in the nuclei of neurons; co-localization of CREM-1 and active-caspase-3 in the ipsilateral cortex suggested that CREM-1 might participate in neuronal apoptosis. To further investigate the function of CREM-1, a neuronal cell line PC12 was employed to establish an apoptosis model. We analyzed the association of CREM-1 with p-CREB on PC12 cells by Western blot, immunofluorescent labeling, and co-immunoprecipitation. The result implied that the association of CREM-1 with p-CREB was enhanced in apoptotic cells. Additionally, knocking CREM-1 down with siRNA demonstrated the probable pro-apoptotic role played by CREM-1 in neuronal apoptosis. Together with our data, we hypothesized that CREM-1 might play an important role in regulating neuronal death after TBI by interacting with CREB.	[Wu, Xinmin; Jin, Wei; Fu, Hongran; Gong, Peipei; Cui, Gang; Ni, Yaohui; Ke, Kaifu; Gao, Zhiwei] Nantong Univ, Dept Neurol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China; [Liu, Xiaojuan] Nantong Univ, Dept Immunol, Coll Med, Nantong 226001, Jiangsu, Peoples R China; [Xu, Jian] Nantong Univ, Dept Psychiat, Peoples Hosp 4, Nantong 226001, Jiangsu, Peoples R China; [Gao, Yilu] Nantong Univ, Dept Neurosurg, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China	Gao, ZW (corresponding author), Nantong Univ, Dept Neurol, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China.	gzw1956@163.com; yilugao@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070992]; Nantong University	This study was supported by the National Natural Science Foundation of China (No. 81070992) and funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Nantong University graduate scientific and technological innovation projects.	Allagnat F, 2005, J CELL SCI, V118, P5335, DOI 10.1242/jcs.02600; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Balasubramanian G, 2000, TOXICOL APPL PHARM, V169, P142, DOI 10.1006/taap.2000.9061; Barco A, 2011, MOL NEUROBIOL, V44, P330, DOI 10.1007/s12035-011-8209-x; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Dey S, 2007, NEUROSCIENCE, V144, P509, DOI 10.1016/j.neuroscience.2006.09.047; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Guo Z, 1998, J NEUROSCI, V18, P8163; Haddad JJ, 2007, PROTEIN PEPTIDE LETT, V14, P361, DOI 10.2174/092986607780363925; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; He ZP, 2008, STEM CELLS, V26, P266, DOI 10.1634/stemcells.2007-0436; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Herold S, 2011, MOL CELL NEUROSCI, V46, P79, DOI 10.1016/j.mcn.2010.08.008; Hoh NZ, 2010, J NEUROTRAUM, V27, P1413, DOI 10.1089/neu.2009.1256; Jaworski J, 2003, J NEUROSCI, V23, P4519; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LOGAN A, 1992, J NEUROSCI, V12, P3828; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; RINK A, 1995, AM J PATHOL, V147, P1575; Saggioro D, 2011, VIRUSES-BASEL, V3, P1001, DOI 10.3390/v3071001; Sawka-Verhelle D, 2004, J BIOL CHEM, V279, P17772, DOI 10.1074/jbc.M311991200; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Shankar E, 2010, INT J ONCOL, V36, P883, DOI 10.3892/ijo_00000566; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	38	19	20	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696			J MOL NEUROSCI	J. Mol. Neurosci.	JUN	2012	47	2					357	367		10.1007/s12031-012-9761-1			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	949HQ	WOS:000304567700015	22569987				2021-06-18	
J	Diringer, MN; Scalfani, MT; Zazulia, AR; Videen, TO; Dhar, R; Powers, WJ				Diringer, Michael N.; Scalfani, Michael T.; Zazulia, Allyson R.; Videen, Tom O.; Dhar, Rajat; Powers, William J.			Effect of Mannitol on Cerebral Blood Volume in Patients With Head Injury	NEUROSURGERY			English	Article						Cerebral blood flow; Cerebral blood volume; Mannitol; Osmotic	POSITRON EMISSION TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; INTRAVENOUS (H2O)-O-15; O-15 RADIOTRACERS; WATER-CONTENT; HYPERVENTILATION; FLOW; MANAGEMENT	BACKGROUND: Mannitol has traditionally been the mainstay of medical therapy for intracranial hypertension in patients with head injury. We previously demonstrated that mannitol reduces brain volume in patients with cerebral edema, although whether this occurs because of a reduction in brain water, blood volume, or both remains poorly understood. OBJECTIVE: To test the hypothesis that mannitol acts by lowering blood viscosity leading to reflex vasoconstriction and a fall in cerebral blood volume (CBV). METHODS: We used O-15 positron emission tomography to study 6 patients with traumatic brain injuries requiring treatment for intracranial hypertension. Cerebral blood flow (CBF), CBV, and cerebral metabolic rate for oxygen (CMRO2) were measured before and 1 hour after administration of 1.0 g/kg 20% mannitol. RESULTS: CBV rose from 4.1 +/- 0.4 to 4.2 +/- 0.2 mL/100 g (P = .3), while intracranial pressure fell from 21.5 +/- 4.9 to 13.7 +/- 5.1 mm Hg (P < .003) after mannitol. Blood pressure, PaCO2, oxygen content, CBF, and CMRO2 did not change. CONCLUSION: A single bolus of 1 g/kg of 20% mannitol does not acutely lower CBV. Another mechanism, such as a reduction in brain water, may better explain mannitol's ability to lower intracranial pressure and reduce mass effect.	[Diringer, Michael N.; Scalfani, Michael T.; Zazulia, Allyson R.; Videen, Tom O.; Dhar, Rajat] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Diringer, Michael N.; Scalfani, Michael T.; Zazulia, Allyson R.; Videen, Tom O.; Dhar, Rajat] Washington Univ, Sch Med, Dept Neurol Surg, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA; [Zazulia, Allyson R.; Videen, Tom O.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Powers, William J.] Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA	Diringer, MN (corresponding author), Washington Univ, Sch Med, Dept Neurol, Campus Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	diringerm@wustl.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Dhar, Rajat/0000-0002-5167-5097	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS035966]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966, P50NS035966] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant NS035966. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; CASCINO T, 1983, NEUROLOGY, V33, P898, DOI 10.1212/WNL.33.7.898; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; DONATO T, 1994, ANESTH ANALG, V78, P58; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; INAO S, 1990, ACT NEUR S, V51, P401; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; Lin WL, 1997, MAGNET RESON MED, V38, P420, DOI 10.1002/mrm.1910380311; Manno EM, 1999, NEUROLOGY, V52, P583, DOI 10.1212/WNL.52.3.583; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTIN WRW, 1987, J CEREBR BLOOD F MET, V7, P421, DOI 10.1038/jcbfm.1987.85; MCGRAW CP, 1978, SURG NEUROL, V10, P127; MINTUN MA, 1984, J NUCL MED, V25, P177; Monro Alexander, 1783, OBSERVATIONS STRUCTU; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; RAICHLE ME, 1983, J NUCL MED, V24, P790; RAVUSSIN P, 1985, CAN ANAESTH SOC J, V32, P506, DOI 10.1007/BF03010801; ROBERTS PA, 1987, J NEUROSURG, V66, P440, DOI 10.3171/jns.1987.66.3.0440; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97	26	19	20	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2012	70	5					1215	1218		10.1227/NEU.0b013e3182417bc2			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	933VA	WOS:000303390400044	22089753	Bronze, Green Accepted			2021-06-18	
J	Mustard, CA; Chambers, A; McLeod, C; Bielecky, A; Smith, PM				Mustard, Cameron A.; Chambers, Andrea; McLeod, Christopher; Bielecky, Amber; Smith, Peter M.			Comparison of data sources for the surveillance of work injury	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							CUMULATIVE TRAUMA DISORDERS; UPPER EXTREMITIES; WASHINGTON-STATE; JOB TENURE; COMPENSATION; WORKPLACE; ILLNESS; CLAIMS; MULTIVARIATE; POPULATION	Objective The objective of this study was to compare the incidence of work-related injury and illness presenting to Ontario emergency departments to the incidence of worker's compensation claims reported to the Ontario Workplace Safety & Insurance Board over the period 2004-2008. Methods Records of work-related injury were obtained from two administrative data sources in Ontario for the period 2004-2008: workers' compensation lost-time claims (N = 435 336) and records of non-scheduled emergency department visits where the main problem was attributed to a work-related exposure (N 707 963). Denominator information required to compute the risk of work injury per 2 000 000 work hours, stratified by age and gender was estimated from labour force surveys conducted by Statistics Canada. Results The frequency of emergency department visits for all work-related conditions was approximately 60% greater than the incidence of accepted lost-time compensation claims. When restricted to injuries resulting in fracture or concussion, gender-specific age differences in injury incidence were similar in the two data sources. Between 2004 and 2008, there was a 14.5% reduction in emergency department visits attributed to work-related causes and a 17.8% reduction in lost-time compensation claims. There was evidence that younger workers were more likely than older workers to seek treatment in an emergency department for work-related injury. Conclusions In this setting, emergency department records available for the complete population of Ontario residents are a valid source of surveillance information on the incidence of work-related disorders. Occupational health and safety authorities should give priority to incorporating emergency department records in the routine surveillance of the health of workers.	[Mustard, Cameron A.; Chambers, Andrea; Bielecky, Amber; Smith, Peter M.] Inst Work & Hlth, Toronto, ON M5G 2E9, Canada; [Mustard, Cameron A.; Smith, Peter M.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [McLeod, Christopher] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Mustard, CA (corresponding author), Inst Work & Hlth, 481 Univ Ave,Suite 800, Toronto, ON M5G 2E9, Canada.	cmustard@iwh.on.ca	Smith, Peter/AAE-4293-2021; McLeod, Christopher B/D-7767-2012	Smith, Peter/0000-0001-8286-4563; McLeod, Christopher/0000-0001-9268-3694			Biddle J, 2001, EVIDENCE LEVEL DETER; Boden L, 2010, WORKERS COMPENSATION; Boden LI, 2008, ANN EPIDEMIOL, V18, P500, DOI 10.1016/j.annepidem.2007.11.003; Breslin FC, 2008, ACCIDENT ANAL PREV, V40, P368, DOI 10.1016/j.aap.2007.07.007; Breslin FC, 2006, OCCUP ENVIRON MED, V63, P27, DOI 10.1136/oem.2005.021006; Breslin FC, 2005, AM J IND MED, V48, P50, DOI 10.1002/ajim.20185; Canadian Institute for Health Information, 2008, NAT AMB CAR REP SYST; Canadian Institute for Health Information, 2001, CAN ENH ICD 10; Canadian Standards Association, 1996, Z 795 96 COD WORK IN; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P241; EISENBERG WM, 1988, MON LABOR REV, V111, P58; FINE LJ, 1986, J OCCUP ENVIRON MED, V28, P674, DOI 10.1097/00043764-198608000-00027; Fortuna RJ, 2010, J GEN INTERN MED, V25, P663, DOI 10.1007/s11606-010-1313-1; FRANKLIN GM, 1991, AM J PUBLIC HEALTH, V81, P741, DOI 10.2105/AJPH.81.6.741; Hanrahan LP, 1987, COMPARISON BLS ANN S, P155; Lakdawalla DN, 2007, ECON INQ, V45, P286, DOI 10.1111/j.1465-7295.2006.00011.x; Lippel K, 2003, INT J HEALTH SERV, V33, P253, DOI 10.2190/JPQD-RT1G-QKTK-JF2R; MCCURDY SA, 1991, AM J PUBLIC HEALTH, V81, P85, DOI 10.2105/AJPH.81.1.85; Morse T F, 1998, Int J Occup Environ Health, V4, P209; Mustard C, 2003, AM J PUBLIC HEALTH, V93, P1283, DOI 10.2105/AJPH.93.8.1283; Rosenman KD, 2006, J OCCUP ENVIRON MED, V48, P357, DOI 10.1097/01.jom.0000205864.81970.63; SELIGMAN PJ, 1988, AM J PUBLIC HEALTH, V78, P1218, DOI 10.2105/AJPH.78.9.1218; Shannon HS, 2002, AM J IND MED, V42, P467, DOI 10.1002/ajim.10142; Silverstein B, 1998, AM J PUBLIC HEALTH, V88, P1827, DOI 10.2105/AJPH.88.12.1827; Smith GS, 2005, AM J PUBLIC HEALTH, V95, P1213, DOI 10.2105/AJPH.2004.049338; Smith P, 2011, CAN J PUBLIC HEALTH, V102, P127, DOI 10.1007/BF03404161; Smith Peter M, 2004, Chronic Dis Can, V25, P127; Smith PM, AM J IND MED, DOI [10.1002/ajim.21000, DOI 10.1002/AJIM.21000]; Teutsch S, 2000, PRINCIPLES PRACTICE; Utterback DF, 2010, USE WORKERS COMPENSA; Zakaria D, 2003, AM J IND MED, V43, P507, DOI 10.1002/ajim.10217	31	19	19	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	MAY	2012	69	5					317	324		10.1136/oemed-2011-100222			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	926YO	WOS:000302869600003	22267447	Green Published, Other Gold			2021-06-18	
J	Yan, XX; Cai, Y; Zhang, XM; Luo, XG; Cai, HB; Rose, GM; Patrylo, PR				Yan, Xiao-Xin; Cai, Yan; Zhang, Xue-Mei; Luo, Xue-Gang; Cai, Huaibin; Rose, Gregory M.; Patrylo, Peter R.			BACE1 elevation is associated with aberrant limbic axonal sprouting in epileptic CD1 mice	EXPERIMENTAL NEUROLOGY			English	Article						Aberrant neuroplasticity; Temporal lobe epilepsy; Mossy fiber sprouting; Dystrophic neurites; Beta-secretase; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; TEMPORAL-LOBE EPILEPSY; GATED SODIUM-CHANNELS; ALZHEIMERS-DISEASE PATHOGENESIS; TRAUMATIC BRAIN-INJURY; PILOCARPINE MODEL; BETA-SECRETASE; SYNAPTIC PLASTICITY; MOSSY FIBER; NEURONAL-ACTIVITY	The brain is capable of remarkable synaptic reorganization following stress and injury, often using the same molecular machinery that governs neurodevelopment. This form of plasticity is crucial for restoring and maintaining network function. However, neurodegeneration and subsequent reorganization can also play a role in disease pathogenesis, as is seen in temporal lobe epilepsy and Alzheimer's disease. beta-Secretase-1 (BACE1) is a protease known for cleaving beta-amyloid precursor protein into beta-amyloid (A beta), a major constituent in amyloid plaques. Emerging evidence suggests that BACE1 is also involved with synaptic plasticity and nerve regeneration. Here we examined whether BACE1 immunoreactivity (IR) was altered in pilocarpine-induced epileptic CD1 mice in a manner consistent with the synaptic reorganization seen during epileptogenesis. BACE1-IR increased in the CA3 mossy fiber field and dentate inner molecular layer in pilocarpine-induced epileptic mice, relative to controls (saline-treated mice and mice 24-48 h after pilocarpine-status), and paralleled aberrant expression of neuropeptide Y. Regionally increased BACE1-IR also occurred in neuropil in hippocampal area CA1 and in subregions of the amygdala and temporal cortex in epileptic mice, colocalizing with increased IR for growth associated protein 43 (GAP43) and polysialylated-neural cell adhesion molecule (PSA-NCAM), but reduced IR for microtubule-associated protein 2 (MAP2). These findings suggest that BACE1 is involved in aberrant limbic axonal sprouting in a model of temporal lobe epilepsy, warranting further investigation into the role of BACE1 in physiological vs. pathological neuronal plasticity. Published by Elsevier Inc.	[Yan, Xiao-Xin; Cai, Yan; Luo, Xue-Gang] Cent S Univ, Xiangya Sch Med, Dept Anat & Neurobiol, Changsha 410013, Hunan, Peoples R China; [Cai, Yan; Rose, Gregory M.; Patrylo, Peter R.] So Illinois Univ, Dept Physiol, Carbondale, IL 62901 USA; [Yan, Xiao-Xin; Rose, Gregory M.; Patrylo, Peter R.] So Illinois Univ, Ctr Integrated Res Cognit & Neural Sci, Carbondale, IL 62901 USA; [Zhang, Xue-Mei; Rose, Gregory M.; Patrylo, Peter R.] So Illinois Univ, Dept Anat, Carbondale, IL 62901 USA; [Zhang, Xue-Mei] Harbin Med Univ, Affiliated Hosp 2, Dept Neurol, Harbin 150086, Peoples R China; [Cai, Huaibin] NIA, Neurogenet Lab, Bethesda, MD 20892 USA	Yan, XX (corresponding author), Cent S Univ, Xiangya Sch Med, Dept Anat & Neurobiol, Changsha 410013, Hunan, Peoples R China.	yanxiaoxin@csu.edu.cn; ppatrylo@siumed.edu	Cai, Huaibin/H-3359-2013	Cai, Huaibin/0000-0002-8596-6108	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21NS056371]; Illinois Department of Public Health; Southern Illinois University Center for Alzheimer's disease and related disorders; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Central South University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS056371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000928, ZIAAG000959] Funding Source: NIH RePORTER	This study was supported by the National Institute of Health (1R21NS056371 to P.R.P., X.-X.Y.), the Illinois Department of Public Health (X.-X.Y.), the Southern Illinois University Center for Alzheimer's disease and related disorders (P.R.P., G.M.R, X.-X.Y.), the intramural program of the National Institute on Aging (H.C) and the Central South University (X.-X.Y.).	Akman CI, 2010, EPILEPSY BEHAV, V17, P373, DOI 10.1016/j.yebeh.2009.12.007; Akram A, 2008, NEUROBIOL AGING, V29, P1296, DOI 10.1016/j.neurobiolaging.2007.03.007; Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Arendt T, 2001, NEUROSCIENCE, V102, P723, DOI 10.1016/S0306-4522(00)00516-9; Ben-Ari Yehezkel, 2008, Dialogues Clin Neurosci, V10, P17; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Cai Y, 2012, NEUROTOX RES, V21, P160, DOI 10.1007/s12640-011-9256-9; Cai Y, 2010, EUR J NEUROSCI, V32, P1223, DOI 10.1111/j.1460-9568.2010.07376.x; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chi ZH, 2008, NEUROCHEM INT, V52, P1305, DOI 10.1016/j.neuint.2008.02.008; Claes L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dube C, 2001, EXP NEUROL, V167, P227, DOI 10.1006/exnr.2000.7561; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Fabene PF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001105; Farah MH, 2011, J NEUROSCI, V31, P5744, DOI 10.1523/JNEUROSCI.6810-10.2011; GEDDES JW, 1991, NEUROBIOL AGING, V12, P330, DOI 10.1016/0197-4580(91)90011-8; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gouras GK, 1997, ANN NEUROL, V41, P402, DOI 10.1002/ana.410410317; Hardy J, 2009, J NEUROCHEM, V110, P1129, DOI 10.1111/j.1471-4159.2009.06181.x; Hashimoto M, 2003, NEUROCHEM RES, V28, P1743, DOI 10.1023/A:1026073324672; HENRY TR, 1993, ARCH NEUROL-CHICAGO, V50, P582, DOI 10.1001/archneur.1993.00540060022011; Holtmaat A, 2009, NAT REV NEUROSCI, V10, P647, DOI 10.1038/nrn2699; Howell OW, 2007, NEUROBIOL DIS, V26, P174, DOI 10.1016/j.nbd.2006.12.014; Hu XY, 2010, J NEUROSCI, V30, P8819, DOI 10.1523/JNEUROSCI.1334-10.2010; Huth T, 2011, PFLUG ARCH EUR J PHY, V461, P355, DOI 10.1007/s00424-010-0913-2; Iijima T, 1998, J NEUROTRAUM, V15, P277, DOI 10.1089/neu.1998.15.277; Isokawa M, 2000, EPILEPSIA, V41, pS14, DOI 10.1111/j.1528-1157.2000.tb01550.x; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; Jacobs KM, 2000, EPILEPSIA, V41, pS153, DOI 10.1111/j.1528-1157.2000.tb01574.x; Kim DY, 2007, NAT CELL BIOL, V9, P755, DOI 10.1038/ncb1602; Kim DY, 2011, J BIOL CHEM, V286, P8106, DOI 10.1074/jbc.M110.134692; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KUHL DE, 1980, ANN NEUROL, V8, P348, DOI 10.1002/ana.410080403; Kurz JE, 2008, EPILEPSIA, V49, P1696, DOI 10.1111/j.1528-1167.2008.01616.x; Laird FM, 2005, J NEUROSCI, V25, P11693, DOI 10.1523/JNEUROSCI.2766-05.2005; Li GL, 2000, APMIS, V108, P98; Li SL, 2006, NEUROBIOL DIS, V23, P362, DOI 10.1016/j.nbd.2006.03.011; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Longo T, 2005, EPILEPSIA, V46, P125, DOI 10.1111/j.1528-1167.2005.01019.x; Luan Tian-zhu, 2005, Zhonghua Yi Xue Za Zhi, V85, P1770; Luscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017; Luo XY, 2011, J BIOL CHEM, V286, P23967, DOI 10.1074/jbc.M111.251538; Luo XY, 2010, INT J CLIN EXP PATHO, V3, P618; MACKENZIE IRA, 1994, ACTA NEUROPATHOL, V87, P504; Magloczky Z, 2010, EPILEPSY RES, V89, P52, DOI 10.1016/j.eplepsyres.2010.01.002; Mannix RC, 2011, J NEUROTRAUM, V28, P1855, DOI 10.1089/neu.2011.1759; Marik SA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000395; Mikkonen M, 1998, ANN NEUROL, V44, P923, DOI 10.1002/ana.410440611; Minkeviciene R, 2009, J NEUROSCI, V29, P3453, DOI 10.1523/JNEUROSCI.5215-08.2009; Miyazaki H, 2007, BIOCHEM BIOPH RES CO, V361, P43, DOI 10.1016/j.bbrc.2007.06.170; Moolman DL, 2004, J NEUROCYTOL, V33, P377, DOI 10.1023/B:NEUR.0000044197.83514.64; Nadler JV, 2007, PEPTIDES, V28, P357, DOI 10.1016/j.peptides.2006.07.026; NUKINA N, 1992, GERONTOLOGY, V38, P10; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Patino GA, 2009, J NEUROSCI, V29, P10764, DOI 10.1523/JNEUROSCI.2475-09.2009; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Pereno GI, 2010, BRAIN RES, V1328, P130, DOI 10.1016/j.brainres.2010.01.087; POLLARD H, 1994, NEUROSCIENCE, V61, P773, DOI 10.1016/0306-4522(94)90401-4; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Rao SC, 2009, EPILEPSY BEHAV, V14, P118, DOI 10.1016/j.yebeh.2008.08.012; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; Seeger G, 2009, NEUROBIOL DIS, V35, P258, DOI 10.1016/j.nbd.2009.05.003; SHENG JG, 1994, J NEUROCHEM, V63, P1872; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Shim KS, 2002, NEUROSCI LETT, V324, P209, DOI 10.1016/S0304-3940(02)00210-0; Shrimpton AE, 2007, NEUROPATHOLOGY, V27, P228, DOI 10.1111/j.1440-1789.2007.00766.x; Smith BN, 2001, J NEUROPHYSIOL, V85, P1, DOI 10.1152/jn.2001.85.1.1; Spampanato J, 2001, J NEUROSCI, V21, P7481; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tang FR, 2010, EPILEPSY RES, V89, P43, DOI 10.1016/j.eplepsyres.2009.10.015; Tolner EA, 2003, EUR J NEUROSCI, V17, P2369, DOI 10.1046/j.1460-9568.2003.02687.x; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Uebachs M, 2010, J NEUROSCI, V30, P8489, DOI 10.1523/JNEUROSCI.1534-10.2010; Velliquette RA, 2005, J NEUROSCI, V25, P10874, DOI 10.1523/JNEUROSCI.2350-05.2005; Wang H, 2008, J NEUROSCI, V28, P8677, DOI 10.1523/JNEUROSCI.2440-08.2008; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Weyer SW, 2011, EMBO J, V30, P2266, DOI 10.1038/emboj.2011.119; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Xiong K, 2007, EXP BRAIN RES, V181, P435, DOI 10.1007/s00221-007-0943-y; Yan XX, 2007, J COMP NEUROL, V501, P52, DOI 10.1002/cne.21239; Yan XX, 2004, J NEUROSCI, V24, P2942, DOI 10.1523/JNEUROSCI.0092-04.2004; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang XH, 2010, SCI CHINA LIFE SCI, V53, P322, DOI 10.1007/s11427-010-0062-z; Zhang XM, 2010, EUR J NEUROSCI, V31, P710, DOI 10.1111/j.1460-9568.2010.07103.x; Zhao J, 2007, J NEUROSCI, V27, P3639, DOI 10.1523/JNEUROSCI.4396-06.2007	95	19	20	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2012	235	1					228	237		10.1016/j.expneurol.2012.01.003			10	Neurosciences	Neurosciences & Neurology	934FZ	WOS:000303430400024	22265658	Green Accepted			2021-06-18	
J	Arun, P; Oguntayo, S; Alamneh, Y; Honnold, C; Wang, Y; Valiyaveettil, M; Long, JB; Nambiar, MP				Arun, Peethambaran; Oguntayo, Samuel; Alamneh, Yonas; Honnold, Cary; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Nambiar, Madhusoodana P.			Rapid Release of Tissue Enzymes into Blood after Blast Exposure: Potential Use as Biological Dosimeters	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; LITHOTRIPTER SHOCK-WAVES; EXPLOSIVE BLAST; RATS; DAMAGE; PERMEABILIZATION; OVERPRESSURE; AFGHANISTAN; MEMBRANE; PROTEINS	Explosive blast results in multiple organ injury and polytrauma, the intensity of which varies with the nature of the exposure, orientation, environment and individual resilience. Blast overpressure alone may not precisely indicate the level of body or brain injury after blast exposure. Assessment of the extent of body injury after blast exposure is important, since polytrauma and systemic factors significantly contribute to blast-induced traumatic brain injury. We evaluated the activity of plasma enzymes including aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH) and creatine kinase (CK) at different time points after blast exposure using a mouse model of single and repeated blast exposures to assess the severity of injury. Our data show that activities of all the enzymes in the plasma were significantly increased as early as 1 h after blast exposure. The elevated enzyme activity remained up to 6 h in an overpressure dose-dependent manner and returned close to normal levels at 24 h. Head-only blast exposure with body protection showed no increase in the enzyme activities suggesting that brain injury alone does not contribute to the systemic increase. In contrast to plasma increase, AST, ALT and LDH activity in the liver and CK in the skeletal muscle showed drastic decrease at 6 h after blast exposures. Histopathology showed mild necrosis at 6 h and severe necrosis at 24 h after blast exposures in liver and no changes in the skeletal muscle suggesting that the enzyme release from the tissue to plasma is probably triggered by transient cell membrane disruption from shockwave and not due to necrosis. Overpressure dependent transient release of tissue enzymes and elevation in the plasma after blast exposure suggest that elevated enzyme activities in the blood can be potentially used as a biological dosimeter to assess the severity of blast injury.	[Arun, Peethambaran; Oguntayo, Samuel; Alamneh, Yonas; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Honnold, Cary] Walter Reed Army Inst Res, Vet Serv Program, Div Pathol, Silver Spring, MD USA	Arun, P (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA.	madhusoodana.nambiar@amedd.army.mil			Congressionally Directed Medical Research Programs grant [W81XWH-08-2-0017]	The study was supported by Congressionally Directed Medical Research Programs grant (Award Number W81XWH-08-2-0017) to JBL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Arun P, 2011, NEUROREPORT, V22, P379, DOI 10.1097/WNR.0b013e328346b138; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Bassit RA, 2010, EUR J APPL PHYSIOL, V108, P945, DOI 10.1007/s00421-009-1305-1; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1025; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chavko M, 2008, J TRAUMA, V65, P1140, DOI 10.1097/TA.0b013e3181870a8c; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chavko M, 2009, SHOCK, V32, P325, DOI 10.1097/SHK.0b013e31819c38f1; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Cullen DK, 2011, NEUROIMAGE, V54, pS37, DOI 10.1016/j.neuroimage.2010.10.076; Delius M, 1999, CANCER RES, V59, P5227; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Devarajan P, 2011, CURR OPIN PEDIATR, V23, P194, DOI 10.1097/MOP.0b013e328343f4dd; DOUKAS AG, 1993, ULTRASOUND MED BIOL, V19, P137, DOI 10.1016/0301-5629(93)90006-A; Elsayed NM, 2000, TOXICOLOGY, V155, P91, DOI 10.1016/S0300-483X(00)00281-X; GAMBIHLER S, 1994, J MEMBRANE BIOL, V141, P267; GAMBIHLER S, 1992, NATURWISSENSCHAFTEN, V79, P328, DOI 10.1007/BF01138714; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Gorbunov NV, 2006, EXP MOL PATHOL, V80, P11, DOI 10.1016/j.yexmp.2005.06.007; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reagan WJ, 2010, TOXICOL PATHOL, V38, P1134, DOI 10.1177/0192623310382438; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Shahshahani MM, 2011, J DERMATOL, V38, P1153, DOI 10.1111/j.1346-8138.2011.01278.x; Singab ANB, 2005, ARCH PHARM RES, V28, P791, DOI 10.1007/BF02977344; Sorichter S, 1999, EXERC IMMUNOL REV, V5, P5; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Yamaguchi M, 2002, MOL CELL BIOCHEM, V241, P61, DOI 10.1023/A:1020822610085; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	42	19	19	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2012	7	4							e33798	10.1371/journal.pone.0033798			6	Multidisciplinary Sciences	Science & Technology - Other Topics	955JA	WOS:000305012700016	22493674	DOAJ Gold, Green Published			2021-06-18	
J	Johnson, LSM				Johnson, L. Syd M.			Return to Play Guidelines Cannot Solve the Football-Related Concussion Problem	JOURNAL OF SCHOOL HEALTH			English	Article						injury prevention; physical fitness & sport; health policy	SPORT-RELATED CONCUSSION; 2ND IMPACT SYNDROME; YOUTH ICE HOCKEY; CONTACT SPORTS; BRAIN-INJURIES; HEAD; MANAGEMENT; CHILDREN; TIME	BACKGROUND: High school football players are the single largest cohort of athletes playing tackle football, and account for the majority of sport-related concussions. Return to play guidelines (RTPs) have emerged as the preferred approach for addressing the problem of sport-related concussion in youth athletes. METHODS: This article reviews evidence of the risks and effects of football-related concussion and subconcussive brain trauma, as well as the effectiveness of RTPs as a preventative measure. Literature review utilized PubMed and Google Scholar, using combinations of the search terms "football,'' "sports,'' "concussion, ''Chronic Traumatic Encephalopathy,'' "athlete,'' "youth,'' and "pediatric.'' Literature review emphasized medical journals and primary neuroscientific research on sport-related concussion and concussion recovery, particularly in youth athletes. RESULTS: Sport-related concussion is a significant problem among student athletes. Student athletes are more vulnerable to concussion, and at risk of neurocognitive deficits lasting a year or more, with serious effects on academic and athletic performance. RTPs do little to address the problem of sport-related concussion or the chronic damage caused by subconcussive brain trauma. CONCLUSIONS: Emphasizing RTPs as the solution to the concussion problem in tackle football risks neglecting genuine reforms that would prevent concussions. More effective concussion prevention is needed. Eliminating tackling from school football for youth under 16 is recommended to reduce concussions. Additional modifications to football are recommended to enhance safety and reduce brain trauma at all levels of play.	Michigan Technol Univ, Humanities Dept, Houghton, MI 49931 USA	Johnson, LSM (corresponding author), Michigan Technol Univ, Humanities Dept, 1400 Townsend Dr, Houghton, MI 49931 USA.	lsjohnso@mtu.edu			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [NNF 80045]; States of Mind: Emerging Issues in Neuroethics	Research funded by Canadian Institutes of Health Research, NNF 80045, States of Mind: Emerging Issues in Neuroethics.	Anderson AJ, 2000, PEDIATRICS, V105, P657; Bey T, 2009, WEST J EMERG MED, V10, P6; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Center for the Study of Traumatic Encephalopathy, 2009, 18 YEAR OLD HIGH SCH; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Finn J.D., 1993, SCH ENGAGEMENT STUDE; Gilbert Frederic, 2011, AM J BIOTH NEUROSCI, p[48, 54], DOI DOI 10.1080/21507740.2011.611125; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Heck JF, 2004, J ATHL TRAINING, V39, P101; Johnson LSM, 2011, CAN MED ASSOC J, V183, P921, DOI 10.1503/cmaj.110282; Kissick J, 2007, CANADIAN ACAD SPORT; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lamborn S.D., 1992, STUDENT ENGAGEMENT A, P153; Maloney JL, 2000, CHILD DEV, V71, P502, DOI 10.1111/1467-8624.00160; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Newlin C., 2010, ESTIMATED PROBABILIT; Nowinski C, 2010, NY TIMES; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schwarz A, 2010, NY TIMES; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	37	19	19	2	40	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4391	1746-1561		J SCHOOL HEALTH	J. Sch. Health	APR	2012	82	4					180	185		10.1111/j.1746-1561.2011.00684.x			6	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	901RC	WOS:000300983500005	22385091				2021-06-18	
J	Ley, EJ; Singer, MB; Clond, MA; Ley, HC; Mirocha, J; Bukur, M; Margulies, DR; Salim, A				Ley, Eric J.; Singer, Matt B.; Clond, Morgan A.; Ley, Heidi C.; Mirocha, James; Bukur, Marko; Margulies, Daniel R.; Salim, Ali			Admission heart rate is a predictor of mortality	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Heart rate; trauma; mortality; sympathetic hyperactivity; beta blocker	RELATIVE BRADYCARDIA; TRAUMA	BACKGROUND: The association between admission heart rate (AHR) and mortality after trauma can assist initial emergency department triage and resuscitation. In addition, increased AHR is often associated with sympathetic hyperactivity which may require targeted treatment. We determined whether AHR was a predictor for mortality in trauma patients. METHODS: The Los Angeles County Trauma System Database was queried for all injured patients admitted between 1998 and 2005 (n = 147,788). Traumatic brain injury (TBI) patients (head Abbreviated Injury Scale score >= 3) were excluded. Demographics were compared at various AHR subgroups (<50, 50-59, 60-69, 70-79, 80-89, 90-99, 100-109, and >= 110). Mortality was compared at various AHR ranges, and logistic regression was performed to determine significance. RESULTS: After exclusions, 103,799 trauma patients requiring admission were identified; overall mortality was 1.4%. AHR 80 to 89 demonstrated a statistically significant lower mortality (0.5%) compared with all other AHR ranges, except AHR 70 to 79 (0.6%). In trauma patients who required admission, AHR 70 to 79 and 80 to 89 were predictors of lower mortality. Mortality for 22,232 moderate to severely injured patients was 5.5% and AHR 80 to 89 demonstrated a statistically lower mortality (2.0%) than all other AHR ranges, except AHR 70 to 79 (1.9%). After moderate to severe trauma, AHR <60 and >= 100 were associated with significantly higher mortality. CONCLUSION: Mortality after trauma increases outside the AHR range of 70 to 89 beats per minute. AHR ranges previously considered "normal" were associated with significantly increased mortality. Prospective research is required to evaluate if resuscitation goals should target heart rate at the 70 to 89 range. (J Trauma. 2012;72:943-947. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Ley, Eric J.; Singer, Matt B.; Clond, Morgan A.; Ley, Heidi C.; Mirocha, James; Bukur, Marko; Margulies, Daniel R.; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	eric.ley@cshs.org		Clond, Morgan/0000-0002-3036-4193; Bukur, Marko/0000-0002-1850-7147			Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Benarroch EE, 2009, NEUROLOGY, V73, P236, DOI 10.1212/WNL.0b013e3181aebd43; Brasel KJ, 2007, J TRAUMA, V62, P812, DOI 10.1097/TA.0b013e31803245a1; BRESLOW MJ, 1991, CRIT CARE MED, V19, P1566, DOI 10.1097/00003246-199112000-00021; Cancio LC, 2008, J TRAUMA, V65, P813, DOI 10.1097/TA.0b013e3181848241; Cancio LC, 2008, J TRAUMA, V64, pS51, DOI 10.1097/TA.0b013e3181608c21; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Demetriades D, 1998, J TRAUMA, V45, P534, DOI 10.1097/00005373-199809000-00020; Fleisher LA, 2007, CIRCULATION, V116, pE418, DOI 10.1161/CIRCULATIONAHA.107.185699; Fonseca RB, 2005, J TRAUMA, V59, P884, DOI 10.1097/01.ta.0000187653.64300.f5; Freestone PP, 2002, SHOCK, V18, P465, DOI 10.1097/00024382-200211000-00014; Fujiura Y, 2001, J CLIN EPIDEMIOL, V54, P495, DOI 10.1016/S0895-4356(00)00323-1; Greenland P, 1999, AM J EPIDEMIOL, V149, P853; Jouven X, 2009, AM J CARDIOL, V103, P279, DOI 10.1016/j.amjcard.2008.08.071; Ley EJ, 2011, J TRAUMA, V71, P1689, DOI 10.1097/TA.0b013e31823cc5df; Ley EJ, 2010, J SURG RES, V163, P142, DOI 10.1016/j.jss.2010.04.046; Ley EJ, 2009, J TRAUMA, V67, P1051, DOI 10.1097/TA.0b013e3181bba222; Malhotra A, 2005, J TRAUMA, V59, P889; Pryor JP, 2007, J TRAUMA, V62, P61; Reunanen A, 2000, J INTERN MED, V247, P231, DOI 10.1046/j.1365-2796.2000.00602.x; Thomas I, 2004, BMJ-BRIT MED J, V328, P451, DOI 10.1136/bmj.328.7437.451; van der Poll T., 2000, SEPSIS, V4, P159; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	24	19	19	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2012	72	4					943	947		10.1097/TA.0b013e3182465527			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	925TO	WOS:000302784600032	22491609				2021-06-18	
J	Pacher, P; Mackie, K				Pacher, Pal; Mackie, Ken			Interplay of cannabinoid 2 (CB2) receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration	JOURNAL OF MOLECULAR MEDICINE-JMM			English	Article								Remote neuronal degeneration and death/injury, which often occur in regions remote but functionally connected to the primary lesion site, may play a pivotal role in extending neuronal damage/dysfunction following traumatic brain injury, stroke, or peripheral nerve injury, as well as in chronic neurodegenerative diseases such as multiple sclerosis and amyotrophic lateral sclerosis. Even though the precise mechanisms of remote neuronal injury are poorly understood and no efficacious treatment options are available, it involves glial activation, inflammation, oxidative/nitrative stress, and apoptotic cell death. The newly discovered endocannabinoid signaling system consisting of endocannabinoids (endogenous bioactive lipid mediators), their synthetic and metabolizing enzymes, and their primary G protein-coupled cannabinoid 1 and 2 (CB1 and CB2) receptors has been implicated in the regulation of numerous physiological and pathological processes/functions, including those associated with neurodegeneration. Using a well-characterized rodent model of remote neuronal degeneration, Oddi et al. (J Mol Med 2012, in press, DOI 10.1007/s00109-012-0884-1) have demonstrated that targeting CB2 cannabinoid receptors may represent a promising novel approach to attenuate this pathological process. This editorial discusses the clinical significance of these interesting observations and the mechanisms of the possible interplay of CB2 receptors with nitric oxide synthases, oxidative and nitrative stress, and cell death during remote neurodegeneration.	[Pacher, Pal] NIAAA, Sect Oxidat Stress Tissue Injury, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; [Mackie, Ken] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA	Pacher, P (corresponding author), NIAAA, Sect Oxidat Stress Tissue Injury, Lab Physiol Studies, NIH, 5625 Fishers Lane,MSC-9413, Bethesda, MD 20892 USA.	pacher@mail.nih.gov	Mackie, Ken/E-3715-2013; Pacher, Pal/B-6378-2008	Mackie, Ken/0000-0001-8501-6199; Pacher, Pal/0000-0001-7036-8108	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA AA000375-06, Z99 AA999999, Z01 AA000375-02, ZIA AA000375-05, ZIA AA000375-04, Z01 AA000375-03] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000375] Funding Source: NIH RePORTER		Atwood BK, 2012, PROG NEURO-PSYCHOPH, V38, P16, DOI 10.1016/j.pnpbp.2011.12.001; Atwood BK, 2012, MOL PHARMACOL, V81, P250, DOI 10.1124/mol.111.074013; Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x; Block F, 2005, PROG NEUROBIOL, V75, P342, DOI 10.1016/j.pneurobio.2005.03.004; Carulli D, 2004, PROG NEUROBIOL, V72, P373, DOI 10.1016/j.pneurobio.2004.03.007; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Mukhopadhyay P, 2010, FREE RADICAL BIO MED, V48, P457, DOI 10.1016/j.freeradbiomed.2009.11.022; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Onaivi ES, 2012, J PSYCHOPHARMACOL, V26, P92, DOI 10.1177/0269881111400652; Pacher P, 2011, PROG LIPID RES, V50, P193, DOI 10.1016/j.plipres.2011.01.001; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Viscomi MT, 2009, CEREBELLUM, V8, P184, DOI 10.1007/s12311-009-0107-7; Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786-09.2009; Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874	16	19	20	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0946-2716	1432-1440		J MOL MED	J. Mol. Med.	APR	2012	90	4					347	351		10.1007/s00109-012-0884-1			5	Genetics & Heredity; Medicine, Research & Experimental	Genetics & Heredity; Research & Experimental Medicine	916XM	WOS:000302136500001	22371074				2021-06-18	
J	Sala-Rabanal, M; Wang, SZ; Nichols, CG				Sala-Rabanal, Monica; Wang, Shizhen; Nichols, Colin G.			On Potential Interactions between Non-selective Cation Channel TRPM4 and Sulfonylurea Receptor SUR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; REACTIVE ASTROCYTES; TRAFFICKING; STOICHIOMETRY; SENSITIVITY; ACTIVATION; EXPRESSION; MUTATIONS; PROTEIN; STROKE	The sulfonylurea receptor SUR1 associates with Kir6.2 or Kir6.1 to form K-ATP channels, which link metabolism to excitability in multiple cell types. The strong physical coupling of SUR1 with Kir6 subunits appears exclusive, but recent studies argue that SUR1 also modulates TRPM4, a member of the transient receptor potential family of non-selective cation channels. It has been reported that, following stroke, brain, or spinal cord injury, SUR1 is increased in neurovascular cells at the site of injury. This is accompanied by up-regulation of a non-selective cation conductance with TRPM4-like properties and apparently sensitive to sulfonylureas, leading to the postulation that post-traumatic non-selective cation currents are determined by TRPM4/SUR1 channels. To investigate the mechanistic hypothesis for the coupling between TRPM4 and SUR1, we performed electrophysiological and FRET studies in COSm6 cells expressing TRPM4 channels with or without SUR1. TRPM4-mediated currents were Ca2+-activated, voltage-dependent, underwent desensitization, and were inhibited by ATP but were insensitive to glibenclamide and tolbutamide. These properties were not affected by cotransfection with SUR1. When the same SUR1 was cotransfected with Kir6.2, functional K-ATP channels were formed. In cells cotransfected with Kir6.2, SUR1, and TRPM4, we measured K-ATP-mediated K+ currents and Ca2+-activated, sulfonylurea-insensitive Na+ currents in the same patch, further showing that SUR1 controls K-ATP channel activity but not TRPM4 channels. FRET signal between fluorophore-tagged TRPM4 subunits was similar to that between Kir6.2 and SUR1, whereas there was no detectable FRET efficiency between TRPM4 and SUR1. Our data suggest that functional or structural association of TRPM4 and SUR1 is unlikely.	[Sala-Rabanal, Monica; Wang, Shizhen; Nichols, Colin G.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Sala-Rabanal, Monica; Wang, Shizhen; Nichols, Colin G.] Washington Univ, Sch Med, Ctr Invest Membrane Excitabil Dis, St Louis, MO 63110 USA; [Wang, Shizhen] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63110 USA	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 425 S Euclid Ave, St Louis, MO 63110 USA.	cnichols@wustl.edu	Wang, Shizhen/N-6577-2017; Nichols, Colin/D-6336-2012	Wang, Shizhen/0000-0003-1065-4756; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL95010]; American Heart AssociationAmerican Heart Association [10POST4280056]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL095010] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grant HL95010 (to C. G. N.). This work was also supported by Postdoctoral Fellowship 10POST4280056 from the American Heart Association (to S. W.).	Akrouh A, 2009, IUBMB LIFE, V61, P971, DOI 10.1002/iub.246; Ammala C, 1996, NATURE, V379, P545, DOI 10.1038/379545a0; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512; Crnich R, 2010, AM J PHYSIOL-CELL PH, V299, pC682, DOI 10.1152/ajpcell.00101.2010; Demion M, 2007, CARDIOVASC RES, V73, P531, DOI 10.1016/j.cardiores.2006.11.023; Earley S, 2007, AM J PHYSIOL-HEART C, V292, pH2613, DOI 10.1152/ajpheart.01286.2006; Favilla CG, 2011, STROKE, V42, P710, DOI 10.1161/STROKEAHA.110.599274; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Guinamard R, 2006, HYPERTENSION, V48, P587, DOI 10.1161/01.HYP.0000237864.65019.a5; Guinamard R, 2011, ADV EXP MED BIOL, V704, P147, DOI 10.1007/978-94-007-0265-3_8; Hibino H, 2010, PHYSIOL REV, V90, P291, DOI 10.1152/physrev.00021.2009; Hille B., 2001, ION CHANNELS EXCITAB, P237; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; Kruse M, 2009, J CLIN INVEST, V119, P2737, DOI 10.1172/JCI38292; Kuhner P, 2012, N-S ARCH PHARMACOL, V385, P299, DOI 10.1007/s00210-011-0709-8; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liu H, 2010, CIRC-CARDIOVASC GENE, V3, P374, DOI 10.1161/CIRCGENETICS.109.930867; Locher KP, 2009, PHILOS T R SOC B, V364, P239, DOI 10.1098/rstb.2008.0125; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Makhina EN, 2001, METHOD PHARMACOL TOX, P261; Makhina EN, 1998, J BIOL CHEM, V273, P3369, DOI 10.1074/jbc.273.6.3369; Mikhailov MV, 2005, EMBO J, V24, P4166, DOI 10.1038/sj.emboj.7600877; Morita H, 2007, J PHARMACOL SCI, V103, P417, DOI 10.1254/jphs.FP0061332; Muallem D, 2009, PHILOS T R SOC B, V364, P247, DOI 10.1098/rstb.2008.0191; Murakami M, 2003, BIOCHEM BIOPH RES CO, V307, P522, DOI 10.1016/S0006-291X(03)01186-0; Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711; Nilius B, 2005, J BIOL CHEM, V280, P22899, DOI 10.1074/jbc.M501686200; Nilius B, 2005, J BIOL CHEM, V280, P6423, DOI 10.1074/jbc.M411089200; Nilius B, 2004, PFLUG ARCH EUR J PHY, V448, P70, DOI 10.1007/s00424-003-1221-x; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Popovich P. G., 2010, EXP NEUROL, V232, P615; Pratt EB, 2011, J GEN PHYSIOL, V137, P299, DOI 10.1085/jgp.201010557; Reading SA, 2007, STROKE, V38, P2322, DOI 10.1161/STROKEAHA.107.483404; Sala-Rabanal M, 2010, J BIOL CHEM, V285, P36040, DOI 10.1074/jbc.M110.163170; Shimizu T, 2009, CELL CALCIUM, V45, P226, DOI 10.1016/j.ceca.2008.10.005; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, BBA-MOL BASIS DIS, V1772, P947, DOI 10.1016/j.bbadis.2007.03.004; Simard JM, 2011, STROKE, V42, pE409, DOI 10.1161/STROKEAHA.111.620666; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Simard JM, 2004, J NEUROSURG ANESTH, V16, P98, DOI 10.1097/00008506-200401000-00021; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Vennekens R., 2007, V179, P269; Voets T, 2007, J PHYSIOL-LONDON, V582, P939, DOI 10.1113/jphysiol.2007.132522; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Woo SK, 2012, J CEREBR BLOOD F MET, V32, P525, DOI 10.1038/jcbfm.2011.159; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang Z, 2005, J BIOL CHEM, V280, P39185, DOI 10.1074/jbc.M506965200; Zhu ZM, 2011, PFLUG ARCH EUR J PHY, V461, P211, DOI 10.1007/s00424-010-0902-5	57	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2012	287	12					8746	8756		10.1074/jbc.M111.336131			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	912KV	WOS:000301797800008	22291026	Other Gold, Green Published			2021-06-18	
J	Han, HS; Park, J; Kim, JH; Suk, K				Han, Hyung Soo; Park, Jaechan; Kim, Jong-Heon; Suk, Kyoungho			Molecular and Cellular Pathways as a Target of Therapeutic Hypothermia: Pharmacological Aspect	CURRENT NEUROPHARMACOLOGY			English	Article						Hypothermia; pharmacotherapy; drug target; signal pathway; neuroinflammation	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; GLOBAL CEREBRAL-ISCHEMIA; TRANSIENT FOREBRAIN ISCHEMIA; TO-MODERATE HYPOTHERMIA; NITRIC-OXIDE SYNTHASE; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; EXPERIMENTAL STROKE	Induced therapeutic hypothermia is the one of the most effective tools against brain injury and inflammation. Even though its beneficial effects are well known, there are a lot of pitfalls to overcome, since the potential adverse effects of systemic hypothermia are still troublesome. Without the knowledge of the precise mechanisms of hypothermia, it will be difficult to tackle the application of hypothermia in clinical fields. Better understanding of the characteristics and modes of hypothermic actions may further extend the usage of hypothermia by developing novel drugs based on the hypothermic mechanisms or by combining hypothermia with other therapeutic modalities such as neuroprotective drugs. In this review, we describe the potential therapeutic targets for the development of new drugs, with a focus on signal pathways, gene expression, and structural changes of cells. Theapeutic hypothermia has been shown to attenuate neuroinflammation by reducing the production of reactive oxygen species and proinflammatory mediators in the central nervous system. Along with the mechanism-based drug targets, applications of therapeutic hypothermia in combination with drug treatment will also be discussed in this review.	[Kim, Jong-Heon; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Brain Sci & Engn Inst, Taegu 700422, South Korea; [Park, Jaechan] Kyungpook Natl Univ, Sch Med, Dept Neurosurg, Brain Sci & Engn Inst, Taegu 700422, South Korea; [Han, Hyung Soo] Kyungpook Natl Univ, Sch Med, Dept Physiol, Brain Sci & Engn Inst, Taegu 700422, South Korea	Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Brain Sci & Engn Inst, 101 Dongin 2 Ga, Taegu 700422, South Korea.	ksuk@knu.ac.kr		Park, Jaechan/0000-0001-7572-3260	Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A100870]; Industrial Strategic Technology Development Program [10035197]; Ministry of Knowledge Economy (MKE, Korea)Ministry of Knowledge Economy, Republic of Korea	This work was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100870), and by a grant of the Industrial Strategic Technology Development Program (10035197) funded by the Ministry of Knowledge Economy (MKE, Korea).	Akaji K, 2003, BRAIN RES, V975, P149, DOI 10.1016/S0006-8993(03)02622-2; Ali SS, 2010, J BIOL CHEM, V285, P32522, DOI 10.1074/jbc.M110.155432; Arai Takahiro, 2008, Allergol Int, V57, P331, DOI 10.2332/allergolint.O-08-532; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bartrons M, 2004, CRYOBIOLOGY, V49, P190, DOI 10.1016/j.cryobiol.2004.06.004; Baumann E, 2009, BRAIN RES, V1269, P185, DOI 10.1016/j.brainres.2009.02.062; Belanger M, 2005, J HEPATOL, V42, P694, DOI 10.1016/j.jhep.2004.12.029; Burattini S, 2010, CURR PHARM DESIGN, V16, P1376, DOI 10.2174/138161210791033941; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Capani F, 2009, EXP NEUROL, V219, P404, DOI 10.1016/j.expneurol.2009.06.007; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; Cavaglia M, 2004, ANN THORAC SURG, V78, P1418, DOI 10.1016/j.athoracsur.2004.04.036; Chan EYW, 1999, J CLIN INVEST, V103, P1337, DOI 10.1172/JCI5474; Chen J, 2009, MED HYPOTHESES, V72, P62, DOI 10.1016/j.mehy.2008.07.056; Choi DK, 2010, EXPERT OPIN THER PAT, V20, P1531, DOI 10.1517/13543776.2010.525220; Choi J.S., 2011, STROKE RES IN PRESS; D'Cruz BJ, 2005, BRAIN RES, V1064, P108, DOI 10.1016/j.brainres.2005.09.052; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Dai Da-wei, 2006, Zhonghua Yi Xue Za Zhi, V86, P906; Di Marzo V, 2008, NAT REV DRUG DISCOV, V7, P438, DOI 10.1038/nrd2553; Diestel A, 2010, EUR J NEUROSCI, V31, P779, DOI 10.1111/j.1460-9568.2010.07128.x; Diestel A, 2009, VASC PHARMACOL, V51, P246, DOI 10.1016/j.vph.2009.06.006; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; Dietrichs ES, 2010, ULTRASTRUCT PATHOL, V34, P82, DOI 10.3109/01913120903398753; Duz B, 2007, CRYOBIOLOGY, V55, P279, DOI 10.1016/j.cryobiol.2007.08.009; Fairchild KD, 2005, AM J PHYSIOL-CELL PH, V289, pC1114, DOI 10.1152/ajpcell.00152.2005; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Fang D, 2009, NEUROCHEM INT, V55, P181, DOI 10.1016/j.neuint.2008.12.009; Feng JF, 2010, NEUROSURGERY, V67, P730, DOI 10.1227/01.NEU.0000378023.81727.6E; Florian B, 2008, NEUROSCI LETT, V438, P180, DOI 10.1016/j.neulet.2008.04.020; Fosgerau K, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-51; Gibas M, 2004, MED SCI MONITOR, V10, pBR109; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; Gisselsson LL, 2005, J CEREBR BLOOD F MET, V25, P1346, DOI 10.1038/sj.jcbfm.9600131; Gordan ML, 2010, PERFUSION-UK, V25, P349, DOI 10.1177/0267659110377946; Haddix TL, 1996, J SURG RES, V64, P176, DOI 10.1006/jsre.1996.0325; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Horiguchi T, 2003, J NEUROTRAUM, V20, P511, DOI 10.1089/089771503765355577; Horiuchi T, 2009, ANESTH ANALG, V109, P559, DOI 10.1213/ane.0b013e3181aa96a1; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Hu WW, 2008, HIPPOCAMPUS, V18, P386, DOI 10.1002/hipo.20402; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Imada S, 2010, J NEUROSCI RES, V88, P3457, DOI 10.1002/jnr.22520; Jang J.H., 2009, VASC NEUROL, V1, P53; Ji XM, 2007, FRONT BIOSCI, V12, P1737, DOI 10.2741/2185; Jin JS, 2006, NEUROL MED-CHIR, V46, P321, DOI 10.2176/nmc.46.321; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.3.CO;2-G; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kellermann K, 2009, PERFUSION-UK, V24, P429, DOI 10.1177/0267659109358655; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; Kiyatkin EA, 2009, NEUROSCIENCE, V161, P926, DOI 10.1016/j.neuroscience.2009.04.004; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kobayashi MS, 2008, BRAIN RES REV, V58, P171, DOI 10.1016/j.brainresrev.2008.03.001; Kolomiytseva IK, 2009, DOKL BIOCHEM BIOPHYS, V427, P225, DOI 10.1134/S1607672909040152; Kolomiytseva IK, 2008, COMP BIOCHEM PHYS B, V151, P386, DOI 10.1016/j.cbpb.2008.08.001; Kuboki S, 2007, AM J PHYSIOL-GASTR L, V292, pG201, DOI 10.1152/ajpgi.00186.2006; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lee KM, 2009, GENES GENOM, V31, P89, DOI 10.1007/BF03191142; Lee SM, 2009, J CEREBR BLOOD F MET, V29, P1589, DOI 10.1038/jcbfm.2009.81; Lee Y, 2007, J CEREBR BLOOD F MET, V27, P950, DOI 10.1038/sj.jcbfm.9600395; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Lin H.W., 2011, ANTIOXID REDOX SIGNA; Lopez-Hernandez FJ, 2006, APOPTOSIS, V11, P1339, DOI 10.1007/s10495-006-7689-z; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Matsuda T, 1999, J Anesth, V13, P99, DOI 10.1007/s005400050034; Matsui T, 2008, J NEUROTRAUM, V25, P709, DOI 10.1089/neu.2007.0482; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Ning XH, 2002, J APPL PHYSIOL, V92, P2200, DOI 10.1152/japplphysiol.01035.2001; Oda Y., 2010, J CEREB BLOOD FLOW M; Pabello NG, 2005, BRAIN RES, V1038, P11, DOI 10.1016/j.brainres.2004.12.047; Park WS, 2001, NEUROCHEM RES, V26, P369, DOI 10.1023/A:1010947030587; Parkinson EJ, 2004, J PEDIATR SURG, V39, P696, DOI 10.1016/j.jpedsurg.2004.01.025; Pedersen Trine Funder, 2007, Tidsskr Nor Laegeforen, V127, P163; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Popov VI, 2007, NEUROSCIENCE, V149, P549, DOI 10.1016/j.neuroscience.2007.07.059; Qing M, 2003, CRIT CARE MED, V31, P2769, DOI 10.1097/01.CCM.0000098858.64868.9C; Qing M, 2006, CRIT CARE, V10, DOI 10.1186/cc4886; Rawls SM, 2004, PHARMACOL BIOCHEM BE, V78, P83, DOI 10.1016/j.pbb.2004.02.006; Rawls SM, 2002, J PHARMACOL EXP THER, V301, P963, DOI 10.1124/jpet.301.3.963; Roberts JR, 2002, CRYOBIOLOGY, V44, P161, DOI 10.1016/S0011-2240(02)00018-4; Roelandse M, 2004, J NEUROSCI, V24, P7843, DOI 10.1523/JNEUROSCI.2872-04.2004; Roszer T, 2010, CELL TISSUE RES, V342, P191, DOI 10.1007/s00441-010-1063-8; Sagredo O, 2009, GLIA, V57, P1154, DOI 10.1002/glia.20838; Sakurai T, 2006, BBA-MOL CELL RES, V1763, P290, DOI 10.1016/j.bbamcr.2006.02.007; Sawe N, 2008, J NEUROSCI RES, V86, P1659, DOI 10.1002/jnr.21604; Schmitt KRL, 2007, NEUROSCI RES, V59, P68, DOI 10.1016/j.neures.2007.05.011; Schmitt KRL, 2006, NEUROSCI LETT, V404, P309, DOI 10.1016/j.neulet.2006.05.064; Schmitt KRL, 2010, BRAIN PATHOL, V20, P771, DOI 10.1111/j.1750-3639.2009.00358.x; Schmitt KRL, 2007, J NEUROIMMUNOL, V189, P7, DOI 10.1016/j.jneuroim.2007.06.010; Shao ZH, 2010, AM J PHYSIOL-HEART C, V298, pH2164, DOI 10.1152/ajpheart.00994.2009; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; SHAY J, 1973, AM J PATHOL, V72, P369; Shuja F, 2009, J AM COLL SURGEONS, V209, P89, DOI 10.1016/j.jamcollsurg.2009.03.010; Smart F, 2007, J NEUROCHEM, V101, P1367, DOI 10.1111/j.1471-4159.2007.04521.x; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Suh S.J., 2009, VASC NEUROL, V1, P46; Tanaka T, 2010, AM J PHYSIOL-REG I, V298, pR661, DOI 10.1152/ajpregu.00732.2009; Terao Y, 2009, NEUROSCI RES, V64, P75, DOI 10.1016/j.neures.2009.01.017; Todani M, 2010, FREE RADICAL RES, V44, P462, DOI 10.3109/10715761003610752; Tomimatsu T, 2001, NEUROSCI LETT, V312, P21, DOI 10.1016/S0304-3940(01)02178-4; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vallerand AL, 1999, AVIAT SPACE ENVIR MD, V70, P42; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Viscomi MT, 2010, EXP NEUROL, V224, P56, DOI 10.1016/j.expneurol.2010.03.023; Vosler PS, 2005, MOL BRAIN RES, V135, P21, DOI 10.1016/j.molbrainres.2004.11.006; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Xiong M, 2009, BRAIN RES BULL, V79, P351, DOI 10.1016/j.brainresbull.2009.03.011; Yang D, 2010, CELL PHYSIOL BIOCHEM, V25, P605, DOI 10.1159/000315079; Yang D, 2010, CARDIOVASC RES, V85, P520, DOI 10.1093/cvr/cvp323; Yang D, 2009, FEBS LETT, V583, P2500, DOI 10.1016/j.febslet.2009.07.006; Yenari MA, 2006, NEUROCHEM INT, V49, P164, DOI 10.1016/j.neuint.2006.03.016; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Zhang F, 2007, NEUROBIOL DIS, V25, P45, DOI 10.1016/j.nbd.2006.08.007; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	121	19	19	0	4	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.	MAR	2012	10	1					80	87					8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	897HA	WOS:000300637600008	22942881	Green Published			2021-06-18	
J	Sauerbeck, A; Hunter, R; Bing, GY; Sullivan, PG				Sauerbeck, Andrew; Hunter, Randy; Bing, Guoying; Sullivan, Patrick G.			Traumatic brain injury and trichloroethylene exposure interact and produce functional, histological, and mitochondrial deficits	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Trichloroethylene; Parkinson's disease; Mitochondria; Dual injury; Synergy; Multifactorial	ENVIRONMENTAL RISK-FACTORS; PARKINSONS-DISEASE; HEAD TRAUMA; ENHANCED VULNERABILITY; COMBINED PARAQUAT; COMPLEX I; TOXICITY; NEURONS; DAMAGE; NEUROTOXICITY	Mitochondria play a pivotal role in the development of pathology associated with Parkinson's disease (PD), traumatic brain injury (TBI), and following exposure to the environmental toxin trichloroethylene (TCE). Evidence from humans indicates that both TBI and TCE can play a role in the development of PD and that each of these insults result in significant mitochondrial dysfunction. In the current studies we hypothesized that exposure to both TCE and TBI would result in increased pathology associated with PD. To test this hypothesis, 16 week old male Fischer 344 rats were administered ICE for either one or two weeks by oral gavage. Following exposure to ICE, rats were subjected to either a sham, mild (1.0 mm), or moderate (2.0 mm) controlled cortical impact TBI. Given the strong connection between mitochondrial function and PD, TBI, and TCE, tissue from the striatum and substantia nigra were analyzed 6 h after the TBI. Neither ICE exposure, TBI, nor the combination of the two insults resulted in mitochondrial deficits at 6 h post-TBI in the substantia nigra. Unlike the substantia nigra, the striatum exhibited significant mitochondrial dysfunction. Exposure to TCE alone for two weeks resulted in approximately a 75% reduction in mitochondrial function (p<0.05) in the striatum whereas TBI alone resulted in approximately a 30% reduction in striatal mitochondrial function. Following 1 week exposure to ICE followed by TBI, there was a significant reduction (50%) in mitochondrial function (p<0.05) which required the presence of both insults. Beginning 12 days after the injury significant motor impairment was observed with Rotarod testing. Animals exposed to ICE and a moderate TBI exhibited performance which was approximately 50% of controls (p<0.01). Cylinder testing revealed that at 30 days post-injury animals exposed to ICE and a moderate TBI also had about a 34% reduction in the usage of the contralateral fore paw and this impairment was significantly worse than both control animals and animals exposed to TCE and a mild 181 (p<0.05). At 30 days post-injury there was a 13-17% reduction in the number of tyrosine hydroxylase (TH) positive neurons in the substantia nigra (p<0.05), which was the result of protein loss and not cell death. Loss of TH positive neurons did not result in changes in striatal TH fiber density or levels of the dopamine transporter or type-2 dopamine receptor. Additionally, exposure to TCE prior to the TBI did not increase the loss of cortical tissue, indicating regional specificity for TCE induced deficits. These studies provide further evidence for the connection between ICE, TBI, and PD and lend support to the concept that PD develops from a multifactorial injury scenario. (C) 2012 Elsevier Inc. All rights reserved.	[Sauerbeck, Andrew; Hunter, Randy; Bing, Guoying; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Sauerbeck, Andrew; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), 741 S Limestone St,BBSRB Room 475, Lexington, KY 40536 USA.	Adsaue2@uky.edu; Randy.Hunter@Covance.com; guoying.bing@uky.edu; patsull@uky.edu		Bing, Guoying/0000-0003-0609-8152	National Institutes of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [R01 N548191, R01 NS062993, P30 NS051220, T32 AG000242]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, P30NS051220, R01NS062993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242] Funding Source: NIH RePORTER	The authors would like to thank Dr. Jignesh Pandya and Andrea Sebastian for excellent technical assistance during this project. The authors would also like to thank Dr. Don Gash for assistance throughout the experiments and review of the final manuscript. This research was supported by grants from the National Institutes of Health, U.S. Public Health Service grants R01 N548191, R01 NS062993 (P.G.S.), P30 NS051220, T32 AG000242.	Afonso-Oramas D, 2009, NEUROBIOL DIS, V36, P494, DOI 10.1016/j.nbd.2009.09.002; Akundi RS, 2004, J NEUROCHEM, V91, P263, DOI 10.1111/j.1471-4159.2004.02710.x; [Anonymous], 1998, EOHS ENC OCC HLTH SA; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; *ATSDR, 1997, TOX PROF TRICHL; Bakke B, 2007, J OCCUP ENVIRON HYG, V4, P375, DOI 10.1080/15459620701301763; Bales JW, 2011, EXP NEUROL, V229, P300, DOI 10.1016/j.expneurol.2011.02.013; Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bringmann G, 1995, J NEURAL TRANSM-SUPP, P235; Bringmann G, 1995, J NEURAL TRANSM-SUPP, P245; Brown RC, 2005, ENVIRON HEALTH PERSP, V113, P1250, DOI 10.1289/ehp.7567; Doder M, 1999, J NEUROL NEUROSUR PS, V66, P380, DOI 10.1136/jnnp.66.3.380; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; FACTOR SA, 1988, MOVEMENT DISORD, V3, P30, DOI 10.1002/mds.870030105; Fei QY, 2008, J NEUROCHEM, V105, P2091, DOI 10.1111/j.1471-4159.2008.05293.x; Ferrante RJ, 1997, BRAIN RES, V753, P157, DOI 10.1016/S0006-8993(97)00008-5; Gash DM, 2008, ANN NEUROL, V63, P184, DOI 10.1002/ana.21288; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Janetzky B, 1995, J NEURAL TRANSM-SUPP, P265; Kilburn KH, 2002, ARCH ENVIRON HEALTH, V57, P113, DOI 10.1080/00039890209602925; Kochen W, 2003, ADV EXP MED BIOL, V527, P253; KOUTOUZIS TK, 1994, BRAIN RES, V646, P242, DOI 10.1016/0006-8993(94)90085-X; Landrigan PJ, 2005, ENVIRON HEALTH PERSP, V113, P1230, DOI 10.1289/ehp.7571; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1983, NEW ENGL J MED, V309, P310; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Ling ZD, 2006, EXP NEUROL, V199, P499, DOI 10.1016/j.expneurol.2006.01.010; Ling ZD, 2004, NEUROSCIENCE, V124, P619, DOI 10.1016/j.neuroscience.2003.12.017; Liu M, 2008, J NEUROSCI RES, V86, P2792, DOI 10.1002/jnr.21725; Liu M, 2010, J NEUROCHEM, V112, P773, DOI 10.1111/j.1471-4159.2009.06497.x; MOUTON PR, 2002, PRINCIPLES PRACTICES; Nakamura K, 2000, MOL PHARMACOL, V58, P271; Naoi M, 1999, MECH AGEING DEV, V111, P175, DOI 10.1016/S0047-6374(99)00064-0; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Nilsson GE, 2001, NEWS PHYSIOL SCI, V16, P217; Nuytemans K, 2010, HUM MUTAT, V31, P763, DOI 10.1002/humu.21277; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Paxinos G., 2004, RAT NERVOUS SYSTEM, VThird; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; Riederer P, 2002, EUR J PHARMACOL, V442, P1, DOI 10.1016/S0014-2999(02)01308-0; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; Thiruchelvam M, 2000, BRAIN RES, V873, P225, DOI 10.1016/S0006-8993(00)02496-3; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Veldman BAJ, 1998, CLIN NEUROL NEUROSUR, V100, P15, DOI 10.1016/S0303-8467(98)00009-2; VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x	62	19	19	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2012	234	1					85	94		10.1016/j.expneurol.2011.12.012			10	Neurosciences	Neurosciences & Neurology	910DN	WOS:000301617500010	22201550	Green Accepted			2021-06-18	
J	Honeybul, S; Ho, K; Hanlon, SO				Honeybul, Stephen; Ho, Kwok; Hanlon, Susan O'			Access to Reliable Information about Long-Term Prognosis Influences Clinical Opinion on Use of Lifesaving Intervention	PLOS ONE			English	Article							CEREBRAL-ARTERY INFARCTION; TRAUMATIC BRAIN-INJURY; OF-LIFE DECISIONS; DECOMPRESSIVE CRANIECTOMY; SURGICAL DECOMPRESSION; HEMICRANIECTOMY; ATTITUDES; CARE; MULTICENTER; NEUROTRAUMA	Background: Decompressive craniectomy has been traditionally used as a lifesaving rescue treatment in severe traumatic brain injury (TBI). This study assessed whether objective information on long-term prognosis would influence healthcare workers' opinion about using decompressive craniectomy as a lifesaving procedure for patients with severe TBI. Method: A two-part structured interview was used to assess the participants' opinion to perform decompressive craniectomy for three patients who had very severe TBI. Their opinion was assessed before and after knowing the predicted and observed risks of an unfavourable long-term neurological outcome in various scenarios. Results: Five hundred healthcare workers with a wide variety of clinical backgrounds participated. The participants were significantly more likely to recommend decompressive craniectomy for their patients than for themselves (mean difference in visual analogue scale [VAS] -1.5, 95% confidence interval -1.3 to -1.6), especially when the next of kin of the patients requested intervention. Patients' preferences were more similar to patients who had advance directives. The participants' preferences to perform the procedure for themselves and their patients both significantly reduced after knowing the predicted risks of unfavourable outcomes, and the changes in attitude were consistent across different specialties, amount of experience in caring for similar patients, religious backgrounds, and positions in the specialty of the participants. Conclusions: Access to objective information on risk of an unfavourable long-term outcome influenced healthcare workers' decision to recommend decompressive craniectomy, considered as a lifesaving procedure, for patients with very severe TBI.	[Honeybul, Stephen; Hanlon, Susan O'] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Ho, Kwok] Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia; [Ho, Kwok] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Azoulay E, 2009, AM J RESP CRIT CARE, V180, P853, DOI 10.1164/rccm.200810-1614OC; Barbour KA, 2006, CHEST, V129, P1367, DOI 10.1378/chest.129.5.1367; Burns JP, 2001, CRIT CARE MED, V29, P658, DOI 10.1097/00003246-200103000-00036; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Granja C, 2001, INTENS CARE MED, V27, P555, DOI 10.1007/s001340100852; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2005, INTENS CARE MED, V31, P668, DOI 10.1007/s00134-005-2613-5; Ho KM, 2004, ANAESTH INTENS CARE, V32, P781, DOI 10.1177/0310057X0403200609; Ho KM, 2011, J TRAUMA, V71, P1637, DOI 10.1097/TA.0b013e31823a08f1; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Honeybul S, 2011, J MED ETHICS, V37, P707, DOI 10.1136/medethics-2011-100081; Honeybul S, 2011, ACTA NEUROCHIR, V153, P1105, DOI 10.1007/s00701-011-0974-9; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2011, J NEUROTRAUM, V28, P13, DOI 10.1089/neu.2010.1584; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2010, ACTA NEUROCHIR, V152, P959, DOI 10.1007/s00701-010-0626-5; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koh MS, 2000, SURG NEUROL, V53, P225, DOI 10.1016/S0090-3019(00)00163-4; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pugh EJ, 2009, PALLIATIVE MED, V23, P158, DOI 10.1177/0269216308100248; Pusic A, 2007, OTOLARYNG HEAD NECK, V136, P525, DOI 10.1016/j.otohns.2006.12.006; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sanoff HK, 2007, CLIN COLORECTAL CANC, V6, P700, DOI 10.3816/CCC.2007.n.039; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Uhl E, 2004, J NEUROL NEUROSUR PS, V75, P270; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235	36	19	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2012	7	2							e32375	10.1371/journal.pone.0032375			7	Multidisciplinary Sciences	Science & Technology - Other Topics	927NZ	WOS:000302916100075	22384231	DOAJ Gold, Green Published			2021-06-18	
J	Zhu, J; Aja, S; Kim, EK; Park, MJ; Ramamurthy, S; Jia, JL; Hu, XY; Geng, P; Ronnett, GV				Zhu, Jing; Aja, Susan; Kim, Eun-Kyoung; Park, Min Jung; Ramamurthy, Santosh; Jia, Junling; Hu, Xueying; Geng, Ping; Ronnett, Gabriele V.			Physiological Oxygen Level Is Critical for Modeling Neuronal Metabolism In Vitro	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neuron; culture; oxygen; AMPK; metabolism	ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; OXIDATIVE STRESS; ENERGY-METABOLISM; CORTICAL-NEURONS; NORMOBARIC HYPEROXIA; CEREBRAL-ISCHEMIA; REDOX STATUS; HYPOXIA	In vitro models are important tools for studying the mechanisms that govern neuronal responses to injury. Most neuronal culture methods employ nonphysiological conditions with regard to metabolic parameters. Standard neuronal cell culture is performed at ambient (21%) oxygen levels, whereas actual tissue oxygen levels in the mammalian brain range from 1% to 5%. In this study, we examined the consequences of oxygen level on the viability and metabolism of primary cultures of cortical neurons. Our results indicate that physiological oxygen level (5% O-2) has a beneficial effect on cortical neuronal survival and mitochondrial function in vitro. Moreover, oxygen level affects metabolic fluxes: glucose uptake and glycolysis was enhanced at physiological oxygen level, whereas glucose oxidation and fatty acid oxidation were reduced. Adenosine monophosphate-activated protein kinase (AMPK) was more activated in 5% O-2 and appears to play a role in these metabolic effects. Inhibiting AMPK activity with compound C decreased glucose uptake, intracellular ATP level, and viability in neurons cultured in 5% O-2. These data indicate that oxygen level is an important parameter to consider when modeling neuronal responses to stress in vitro. (C) 2011 Wiley Periodicals, Inc.	[Zhu, Jing; Aja, Susan; Park, Min Jung; Ramamurthy, Santosh; Hu, Xueying; Geng, Ping; Ronnett, Gabriele V.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Kim, Eun-Kyoung; Ronnett, Gabriele V.] Daegu Gyeongbuk Inst Sci & Technol, Dept Brain Sci, Taegu, South Korea; [Jia, Junling] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Embryol,Carnegie Inst Sci, Baltimore, MD 21205 USA; [Ronnett, Gabriele V.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Ronnett, Gabriele V.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Ronnett, GV (corresponding author), Johns Hopkins Sch Med, Dept Neurosci, 725 N Wolfe St,Rangos 480, Baltimore, MD 21205 USA.	gronnett@jhmi.edu		Park, Min Jung/0000-0001-5644-9585	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041079]; Daegu-Gyeongbuk Institute of Science and Technology (DGIST) Convergence Science Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041079] Funding Source: NIH RePORTER	Contract grant sponsor: NINDS; Contract grant number: R01 NS041079 (to G.V.R.); Contract grant sponsor: Research Collaboration Agreement with the Daegu-Gyeongbuk Institute of Science and Technology (DGIST) Convergence Science Center (to S.A.).	Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; AHDABBARMADA M, 1980, PEDIATRICS, V66, P840; Alexander A, 2011, FEBS LETT, V585, P952, DOI 10.1016/j.febslet.2011.03.010; Bickford PC, 1999, FREE RADICAL BIO MED, V26, P817, DOI 10.1016/S0891-5849(98)00260-3; Bitterman H, 2009, CRIT CARE, V13, DOI 10.1186/cc7151; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Burgers HF, 2008, EXP BRAIN RES, V188, P33, DOI 10.1007/s00221-008-1336-6; Carrier RL, 2006, J NEUROSCI METH, V154, P239, DOI 10.1016/j.jneumeth.2005.12.030; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chen HL, 2007, STEM CELLS, V25, P2291, DOI 10.1634/stemcells.2006-0609; Chen PS, 2001, WORLD J GASTROENTERO, V7, P647; COLTON CA, 1995, EXP NEUROL, V132, P54, DOI 10.1016/0014-4886(95)90058-6; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Dean JB, 2004, J APPL PHYSIOL, V96, P784, DOI 10.1152/japplphysiol.00892.2003; Droge W, 2002, PHYSIOL REV, V82, P47; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Genetos DC, 2010, J MOL NEUROSCI, V40, P360, DOI 10.1007/s12031-009-9326-0; Grote J, 1996, J AUTONOM NERV SYST, V57, P168, DOI 10.1016/0165-1838(95)00096-8; Hazelton JL, 2010, J NEUROTRAUM, V27, P753, DOI 10.1089/neu.2009.1186; Hermann Martin, 2008, Cell Commun Signal, V6, P4, DOI 10.1186/1478-811X-6-4; Hinkelbein J, 2010, MOL CELL BIOCHEM, V339, P9, DOI 10.1007/s11010-009-0365-1; Horie N, 2008, CELL MOL NEUROBIOL, V28, P833, DOI 10.1007/s10571-007-9237-y; KAPLAN FS, 1986, BRAIN RES, V384, P199, DOI 10.1016/0006-8993(86)91240-0; Kleman AM, 2008, J NEUROSCI METH, V167, P292, DOI 10.1016/j.jneumeth.2007.08.028; Kumaria A, 2009, BRIT J NEUROSURG, V23, P1; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; La Noce A, 2000, ACTA RADIOL, V41, P394, DOI 10.1034/j.1600-0455.2000.041004394.x; Landree LE, 2004, J BIOL CHEM, V279, P3817, DOI 10.1074/jbc.M310991200; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Levin BE, 2001, NAT NEUROSCI, V4, P459; LIU KJ, 1995, BRAIN RES, V685, P91, DOI 10.1016/0006-8993(95)00413-K; Macri MA, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-14; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Mander P, 2004, BIOCHEM SOC T, V32, P1068, DOI 10.1042/BST0321068; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; METZGER H, 1977, PFLUG ARCH EUR J PHY, V370, P201, DOI 10.1007/BF00581695; Milosevic J, 2005, J NEUROCHEM, V92, P718, DOI 10.1111/j.1471-4159.2004.02893.x; Morgenthaler FD, 2006, NEUROSCIENCE, V141, P157, DOI 10.1016/j.neuroscience.2006.03.065; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; NAIR P, 1975, MICROVASC RES, V9, P158, DOI 10.1016/0026-2862(75)90077-1; Potier E, 2008, J TISSUE ENG REGEN M, V2, P272, DOI 10.1002/term.92; Pouzaud F, 2006, COMP BIOCHEM PHYS C, V143, P232, DOI 10.1016/j.cbpc.2006.02.006; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; Putnam KP, 2002, TOXICOL IN VITRO, V16, P599, DOI 10.1016/S0887-2333(02)00050-4; Ramamurthy S, 2006, J PHYSIOL-LONDON, V574, P85, DOI 10.1113/jphysiol.2006.110122; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Sana TR, 2008, J CHROMATOGR B, V871, P314, DOI 10.1016/j.jchromb.2008.04.030; Schechter M, 2009, ADV EXP MED BIOL, V645, P293, DOI 10.1007/978-0-387-85998-9_44; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Semenza GL, 2009, PHYSIOLOGY, V24, P97, DOI 10.1152/physiol.00045.2008; Severinghaus J W, 1986, J Clin Monit, V2, P174, DOI 10.1007/BF01620550; Shi HL, 2006, NEUROSCI LETT, V410, P57, DOI 10.1016/j.neulet.2006.09.066; SHIBATA M, 1991, BRAIN RES BULL, V26, P467, DOI 10.1016/0361-9230(91)90026-G; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; SMITH RH, 1977, MICROVASC RES, V13, P233, DOI 10.1016/0026-2862(77)90088-7; Studer L, 2000, J NEUROSCI, V20, P7377; Tachtsidis I, 2009, ADV EXP MED BIOL, V645, P315, DOI 10.1007/978-0-387-85998-9_47; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Tolias CM, 2009, J NEUROSURG, V110, P607, DOI 10.3171/JNS.2009.110.3.0607a; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; Vaishnavi SN, 2010, P NATL ACAD SCI USA, V107, P17757, DOI 10.1073/pnas.1010459107; Wagner BK, 2008, NAT BIOTECHNOL, V26, P343, DOI 10.1038/nbt1387; WERNER JC, 1989, AM J PHYSIOL, V256, pE315; White RJ, 1996, J NEUROSCI, V16, P5688; WILSON DF, 1991, J APPL PHYSIOL, V70, P2691; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zhu LL, 2005, MOL NEUROBIOL, V31, P231, DOI 10.1385/MN:31:1-3:231	73	19	19	1	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	FEB	2012	90	2					422	434		10.1002/jnr.22765			13	Neurosciences	Neurosciences & Neurology	875YN	WOS:000299072300009	22002503				2021-06-18	
J	Ohayon, S; Boyko, M; Saad, A; Douvdeyani, A; Gruenbaum, BF; Melamed, I; Shapira, Y; Teichberg, VI; Zlotnik, A				Ohayon, Sharon; Boyko, Matthew; Saad, Amit; Douvdeyani, Amos; Gruenbaum, Benjamin F.; Melamed, Israel; Shapira, Yoram; Teichberg, Vivian I.; Zlotnik, Alexander			Cell-Free DNA as a Marker for Prediction of Brain Damage in Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; brain edema; CFD; neurological performance; TBI	CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; EXPERIMENTAL-MODELS; BLOOD GLUTAMATE; ANIMAL-MODELS; PLASMA DNA; EDEMA; MILD; MICE	Traumatic brain injury (TBI) is a major cause of morbidity and mortality, and early predictors of neurological outcomes are of great clinical importance. Cell free DNA (CFD), a biomarker used for the diagnosis and monitoring of several diseases, has been implicated as a possible prognostic indicator after TBI. The purpose of this study was to determine the pattern and timing of CFD) levels after TBI, and whether a relationship exists between the level of CFD and brain edema and neurological outcomes. Thirty-nine Sprague Dawley rats were randomly assigned to two groups: rats in group 1 (sham group) were anesthetized and had a scalp incision without TBI, and rats in group 2 were anesthetized and had a scalp incision with TBI which was induced by using a weight drop model that causes diffuse brain injury. A neurological severity score (NSS) was assessed at 1, 24, and 48 h after TBI. CFD was measured via blood samples drawn at t=0 (baseline), 12, 24, 48, 72, and 120h after TBI. At 48h after TBI, brain edema was determined in a subgroup of 11 rats by calculating the difference between rats' wet and dry brain weight. The significance of comparisons between and within groups (CFD levels, brain water content, and NSS) were determined using the Kruskal-Wallis, Mann-Whitney and Student t test. The correlation between CFD levels and the NSS, as well as between CFD levels and the extent of brain edema, was calculated using the Spearman and Pearson tests, respectively. Compared with baseline levels, the CFD) levels in rats subjected to TBI were significantly increased at 24 and 48h after TBI (p<0.01 and p<0.05, respectively). A positive correlation was demonstrated between CFD) levels 24 h following TBI and the extent of brain edema (r = 0.63, p<0.05), as well as between CFD levels and the NSS (r = 0.79, p<0.005). In this study, we demonstrated an increase in CFD levels after TBI, as well as a correlation between CFD levels and brain edema and NSS. CFD levels may provide a quick, reliable, and simple prognostic indicator of neurological outcome in animals after TBI. Its role in humans has not been clearly elucidated, but has potentially significant clinical implications.	[Ohayon, Sharon; Boyko, Matthew; Gruenbaum, Benjamin F.; Shapira, Yoram; Zlotnik, Alexander] Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel; [Douvdeyani, Amos] Ben Gurion Univ Negev, Dept Clin Biochem, Div Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel; [Melamed, Israel] Ben Gurion Univ Negev, Soroka Med Ctr, Dept Neurosurg, IL-84105 Beer Sheva, Israel; [Saad, Amit] Univ Haifa, Dept Philosophy, IL-31999 Haifa, Israel; [Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Zlotnik, A (corresponding author), Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel.	zlotnika@bgu.ac.il		Douvdevani, Amos/0000-0002-0197-6481; Boyko, Matthew/0000-0003-3116-1643			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Chang CPY, 2003, CLIN CHIM ACTA, V327, P95, DOI 10.1016/S0009-8981(02)00337-6; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Goldshtein H, 2009, ANN CLIN BIOCHEM, V46, P488, DOI 10.1258/acb.2009.009002; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hayasaki K, 1997, ACT NEUR S, V70, P75; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Kawamata T, 1997, ACT NEUR S, V70, P191; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lo YMD, 2000, CLIN CHEM, V46, P319; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Park DS, 1998, J NEUROSCI, V18, P830; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Povlishock JT, 1999, ACT NEUR S, V73, P15; Prieto R, 2009, NEUROCIRUGIA, V20, P225; Rainer TH, 2003, CLIN CHEM, V49, P562, DOI 10.1373/49.4.562; Sbordone RJ, 2010, PSYCHOL INJ LAW, V3, P63, DOI 10.1007/s12207-010-9066-z; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shimony Avi, 2010, Acute Card Care, V12, P109, DOI 10.3109/17482941.2010.513732; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Swarup V, 2007, FEBS LETT, V581, P795, DOI 10.1016/j.febslet.2007.01.051; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaz R, 1998, ACTA NEUROCHIR, V140, P76, DOI 10.1007/s007010050061; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	46	19	19	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					261	267		10.1089/neu.2011.1938			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300006	22149927				2021-06-18	
J	Cloots, RJH; van Dommelen, JAW; Geers, MGD				Cloots, R. J. H.; van Dommelen, J. A. W.; Geers, M. G. D.			A tissue-level anisotropic criterion for brain injury based on microstructural axonal deformation	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Traumatic brain injury (TBI); Diffuse axonal injury (DAI); Brain injury criterion; Axons; Neurons; Finite element method	PREFRONTAL CORTEX; HEAD-INJURY; PYRAMIDAL NEURONS; WHITE-MATTER; SOMAL SIZE; MODEL; SCHIZOPHRENIA; STRETCH; SYSTEM; MECHANISMS	Different length scales from micrometers to several decimeters play an important role in diffuse axonal injury. The kinematics at the head level result in local impairments at the cellular level. Finite element methods can be used for predicting brain injury caused by a mechanical loading of the head. Because of its oriented microstructure, the sensitivity of brain tissue to a mechanical load can be expected to be orientation dependent. However, the criteria for injury that are currently used at the tissue level in finite element head models are isotropic and therefore do not consider this orientation dependence, which might inhibit a reliable assessment of injury. In this study, an anisotropic brain injury criterion is developed that is able to describe the effects of the oriented microstructure based on micromechanical simulations. The effects of both the main axonal direction and of local deviations from this direction are accounted for. With the anisotropic criterion for brain injury, computational head models will be able to account for aspects of diffuse axonal injury at the cellular level and can therefore more reliably predict injury. (C) 2011 Elsevier Ltd. All rights reserved.	[Cloots, R. J. H.; van Dommelen, J. A. W.; Geers, M. G. D.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands	van Dommelen, JAW (corresponding author), Eindhoven Univ Technol, Mat Technol Inst, POB 513, NL-5600 MB Eindhoven, Netherlands.	j.a.w.v.dommelen@tue.nl	Geers, Marc G.D./E-4385-2014	Geers, Marc G.D./0000-0002-0009-6351	Dutch Technology Foundation STWTechnologiestichting STW; applied science division of NWONetherlands Organization for Scientific Research (NWO); Ministry of Economic Affairs	This work has been supported by the Dutch Technology Foundation STW, applied science division of NWO and the Technology Program of the Ministry of Economic Affairs.	Abaqus, 2010, AB 6 10 MAN; Abolfathi N, 2009, COMPUT METHOD BIOMEC, V12, P249, DOI [10.1080/10255840802430587, 10.1080/10255840903097871]; Alberts B, 1994, MOL BIOL CELL; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Braitenberg V., 1998, CORTEX STAT GEOMETRY; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Cloots R.J.H., 2010, P IRCOBI C, P119; Cloots R.J.H., MULTISCALE MEC UNPUB; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; DRUCKER DC, 1952, Q APPL MATH, V10, P157, DOI 10.1090/qam/48291; FENSTERMACHER JD, 1970, EXP NEUROL, V27, P101, DOI 10.1016/0014-4886(70)90205-0; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Highley JR, 2003, BRIT J PSYCHIAT, V183, P414, DOI 10.1192/bjp.183.5.414; HILL R, 1948, PROC R SOC LON SER-A, V193, P281, DOI 10.1098/rspa.1948.0045; HILL R, 1979, MATH PROC CAMBRIDGE, V85, P179, DOI 10.1017/S0305004100055596; Hutsler JJ, 2003, BRAIN LANG, V86, P226, DOI 10.1016/S0093-934X(02)00531-X; Karami G, 2009, J MECH BEHAV BIOMED, V2, P243, DOI 10.1016/j.jmbbm.2008.08.003; Khoshgoftar Mehdi, 2007, American Journal of Applied Sciences, V4, P918, DOI 10.3844/ajassp.2007.918.924; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kouznetsova V, 2001, COMPUT MECH, V27, P37, DOI 10.1007/s004660000212; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Liu C, 1997, ACTA MATER, V45, P2397, DOI 10.1016/S1359-6454(96)00349-7; Marieb E. N., 1998, HUMAN ANATOMY PHYSL; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; NHTSA, 1972, OCC CRASH PROT HEAD; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; NOLTE J, 2002, HUMAN BRAIN INTRO IT; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; Pierri JN, 2001, ARCH GEN PSYCHIAT, V58, P466, DOI 10.1001/archpsyc.58.5.466; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P307, DOI 10.1093/cercor/5.4.307; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Takhounts EG, 2003, STAPP CAR CRASH J, V47, P51; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	50	19	22	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161			J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	JAN	2012	5	1					41	52		10.1016/j.jmbbm.2011.09.012			12	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	873QX	WOS:000298899200005	22100078				2021-06-18	
J	Gorman, S; Barnes, MA; Swank, PR; Prasad, M; Ewing-Cobbs, L				Gorman, Stephanie; Barnes, Marcia A.; Swank, Paul R.; Prasad, Mary; Ewing-Cobbs, Linda			The Effects of Pediatric Traumatic Brain Injury on Verbal and Visual-Spatial Working Memory	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Pediatric; Working memory; Inhibitory control; Dual-task; Outcome	CLOSED-HEAD-INJURY; POOR COMPREHENDERS; INTRUSION ERRORS; SELECTIVE METAANALYSIS; READING-COMPREHENSION; COGNITIVE-DEVELOPMENT; INHIBITORY CONTROL; SHORT-TERM; CHILDREN; CHILDHOOD	The purpose of this study was to investigate the effects of pediatric traumatic brain injury (TBI) on verbal and visual-spatial working memory (WM). WM tasks examined memory span through recall of the last item of a series of stimuli. Additionally, both verbal and visual-spatial tests had a dual-task condition assessing the effect of increasing demands on the central executive (CE). Inhibitory control processes in verbal WM were examined through intrusion errors. The TBI group (n = 73) performed more poorly on verbal and visual-spatial WM tasks than orthopedic-injured children (n = 30) and non-injured children (n = 40). All groups performed more poorly on the dual-task conditions, reflecting an effect of increasing CE load. This effect was not greater for the TBI group. There were no group differences in intrusion errors on the verbal WM task, suggesting that problems in WM experienced by children with TBI were not primarily due to difficulties in inhibitory control. Finally, injury-related characteristics, namely days to follow commands, accounted for significant variance in WM performance, after controlling for relevant demographic variables. Findings suggest that WM impairments in TBI are general rather than modality-specific and that severity indices measured over time are better predictors of WM performance than those taken at a single time point. (JINS, 2012, 18, 29-38)	[Ewing-Cobbs, Linda] Univ Texas Houston, Hlth Sci Ctr, Dept Pediat, Childrens Learning Inst, Houston, TX 77030 USA; [Gorman, Stephanie] Univ Houston, Dept Psychol, Houston, TX USA	Ewing-Cobbs, L (corresponding author), Univ Texas Houston, Hlth Sci Ctr, Dept Pediat, Childrens Learning Inst, 7000 Fannin UCT 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu			National Institutes of Health-National Institute for Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS046308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308] Funding Source: NIH RePORTER	This work was funded by the National Institutes of Health-National Institute for Neurological Diseases and Stroke grant, R01-NS046308. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the study.	Alloway TP, 2006, CHILD DEV, V77, P1698, DOI 10.1111/j.1467-8624.2006.00968.x; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; Baddeley A.D., 1999, MODELS WORKING MEMOR, P28, DOI DOI 10.1017/CBO9781139174909.005; Barnes M. A., 2010, PEDIAT NEUROPSYCHOLO, P297; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BELL MA, 1992, CHILD DEV, V63, P1142, DOI 10.1111/j.1467-8624.1992.tb01685.x; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; Carretti B, 2005, J EXP CHILD PSYCHOL, V91, P45, DOI 10.1016/j.jecp.2005.01.005; CLAYTON CE, 2006, HDB FUNCTIONAL NEURO, P269; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Cornoldi C, 2006, MEMORY, V14, P176, DOI 10.1080/09658210544000033; Cornoldi C, 2001, CHILD NEUROPSYCHOL, V7, P230, DOI 10.1076/chin.7.4.230.8735; Crone EA, 2006, P NATL ACAD SCI USA, V103, P9315, DOI 10.1073/pnas.0510088103; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; De Beni R, 1998, Q J EXP PSYCHOL-A, V51, P305, DOI 10.1080/713755761; De Beni R, 2000, LEARN INDIVID DIFFER, V12, P131, DOI 10.1016/S1041-6080(01)00033-4; Dempster FN, 1993, EMERGING THEMES COGN, V1, P3; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dennis Maureen, 1988, CLIN NEUROPSYCHOLOGY, P89; DIAMOND A, 1991, BRAIN MATURATION COG; Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FUSTER JM, 1989, PREFRONTAL CORTEX AN; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Holmes J, 2009, DEVELOPMENTAL SCI, V12, pF9, DOI 10.1111/j.1467-7687.2009.00848.x; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KONRAD K, 2000, CHILD NEUROPSYCHOL, V7, P377; Konrad KN, 2000, BRAIN INJURY, V14, P859; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Loose R, 2003, HUM BRAIN MAPP, V18, P249, DOI 10.1002/hbm.10082; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Luria A. R, 1973, WORKING BRAIN; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Milner B., 1964, FRONTAL GRANULAR COR; Miyake A., 1999, MODELS WORKING MEMOR; MRZLIJAK L, 1990, PREFRONTAL CORTEX IT, V85, P185; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Nichelli F, 2001, NEUROL SCI, V22, P377, DOI 10.1007/s100720100068; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Palladino P, 2001, MEM COGNITION, V29, P344, DOI 10.3758/BF03194929; Pimperton H, 2010, J MEM LANG, V62, P380, DOI 10.1016/j.jml.2010.02.005; Posner MI, 2007, COGN AFFECT BEHAV NE, V7, P391, DOI 10.3758/CABN.7.4.391; Raghubar KP, 2010, LEARN INDIVID DIFFER, V20, P110, DOI 10.1016/j.lindif.2009.10.005; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Swanson HL, 2006, REV EDUC RES, V76, P249, DOI 10.3102/00346543076002249; Swanson HL, 2009, J LEARN DISABIL-US, V42, P260, DOI 10.1177/0022219409331958; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940	70	19	19	0	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2012	18	1					29	38		10.1017/S1355617711001251			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	874LL	WOS:000298958800003	22014162	Green Accepted			2021-06-18	
J	Hall, RCW; Hall, RCW				Hall, Ryan C. W.; Hall, Richard C. W.			Compensation Neurosis: A Too Quickly Forgotten Concept?	JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW			English	Article							EXCESSIVE COGNITIVE SYMPTOMS; TRAUMATIC BRAIN-INJURY; ACCIDENT NEUROSIS; HEAD-INJURY; COGNIFORM CONDITION; PROPOSED DIAGNOSES; QUANTITATIVE EEG; BASE RATES; DISORDER; PTSD	There has been great debate concerning the existence and meaning of compensation neurosis. It is included in the International Classification of Diseases (ICD)-9 and -10 but not listed in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). On the eve of publication of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), we re-examine the history and concept of compensation neurosis and conceptually update the condition to reflect current psychiatric thought. We consider its utility as a diagnostic entity for forensic evaluations and its components as they relate to exaggeration in injury claims. We also discuss how compensation neurosis differs from malingering and factitious disorder.	[Hall, Ryan C. W.; Hall, Richard C. W.] Univ Cent Florida, Coll Med, Dept Med Educ, Orlando, FL 32816 USA; [Hall, Ryan C. W.; Hall, Richard C. W.] Univ S Florida, Dept Psychiat, Tampa, FL USA	Hall, RCW (corresponding author), 2500 W Lake Mary Blvd,Suite 219, Lake Mary, FL 32746 USA.	rcwh@live.com					Allaz AF, 1998, GEN HOSP PSYCHIAT, V20, P91, DOI 10.1016/S0163-8343(97)00127-8; American Academy of Psychiatry and the Law, 2005, ETH GUID PRACT FOR P; American Psychiatric Association, 2011, JUST CRIT S IN PRESS; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, DSM 5 DEV J 02 CONV; American Psychiatric Association, DSM 5 DEV; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; American Psychiatric Association, 2010, DSM 5 DEV; American Psychiatric Association, 2011, DSM 5 DEV PERS DIS; American Psychiatric Association, 2012, DSM 5 DEV B 01 DEL D; [Anonymous], FACTITIOUS DISORDER; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bellamy R, 1997, CLIN ORTHOP RELAT R, P94; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P675, DOI 10.1016/j.acn.2007.07.005; Bracha HS, 2008, ARCH GEN PSYCHIAT, V65, P115, DOI 10.1001/archgenpsychiatry.2007.14; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Dunn TM, 2003, ARCH CLIN NEUROPSYCH, V18, P121, DOI 10.1016/S0887-6177(01)00188-3; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; FISHBAIN DA, 1988, PAIN, V32, P197, DOI 10.1016/0304-3959(88)90068-1; Goetz CG, 2007, NEUROLOGY, V69, P103, DOI 10.1212/01.wnl.0000265061.46526.77; Hall R, 2012, NEW PERSPECTIVES FAK, P255; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hall RCW, 2007, J FORENSIC SCI, V52, P717, DOI 10.1111/j.1556-4029.2007.00434.x; Hall RCW, 2006, GEN HOSP PSYCHIAT, V28, P525, DOI 10.1016/j.genhosppsych.2006.08.011; Kennedy F., 1946, COMPENSATION MED, V1, P19; Lees-Haley PR, 2004, ARCH CLIN NEUROPSYCH, V19, P333, DOI 10.1016/j.acn.2003.12.004; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVY A, 1992, Brain Injury, V6, P401, DOI 10.3109/02699059209008136; Mayou R, 1996, BRIT J PSYCHIAT, V168, P399, DOI 10.1192/bjp.168.4.399; McHugh PR, 2007, J ANXIETY DISORD, V21, P211, DOI 10.1016/j.janxdis.2006.09.003; McNally RJ, 2007, J ANXIETY DISORD, V21, P192, DOI 10.1016/j.janxdis.2006.09.005; MENDELSON G, 1995, J PSYCHOSOM RES, V39, P695, DOI 10.1016/0022-3999(94)00154-W; MENDELSON G, 1984, INT J LAW PSYCHIAT, V7, P179, DOI 10.1016/0160-2527(84)90031-1; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Reid WH, 2008, J PSYCHIATR PRACT, V14, P122, DOI 10.1097/01.pra.0000314320.25286.bf; RESNICK PJ, 1995, POSTTRAUMATIC STRESS, P117; Strasburger LH, 1997, AM J PSYCHIAT, V154, P448; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; WESSELY S, 1995, J PSYCHOSOM RES, V39, P659, DOI 10.1016/0022-3999(95)00067-S; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; Winckler P, 1998, Versicherungsmedizin, V50, P219; WOODYARD JE, 1982, ANN ROY COLL SURG, V64, P191; World Health Organization, 1992, ICD 10 CLASS MENT BE, P222; World Health Organization, 2008, COMP NEUR INT CLASS, V1, P80	54	19	20	0	7	AMER ACAD PSYCHIATRY & LAW	BLOOMFIELD	ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA	1093-6793			J AM ACAD PSYCHIATRY	J. Am. Acad. Psychiatry Law		2012	40	3					390	398					9	Law; Psychiatry	Government & Law; Psychiatry	021QE	WOS:000309899600011	22960922				2021-06-18	
J	Hsieh, MY; Ponsford, J; Wong, D; McKay, A				Hsieh, Ming-Yun; Ponsford, Jennie; Wong, Dana; McKay, Adam			Exploring variables associated with change in cognitive behaviour therapy (CBT) for anxiety following traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						anxiety; cognitive behaviour therapy; traumatic brain injury	WORKING ALLIANCE; PANIC DISORDER; REHABILITATION; DEPRESSION; DEFICITS; METAANALYSIS; VALIDATION; PREDICTORS; EXPECTANCY; RETENTION	Purpose: In a pilot randomized controlled trial, we investigated the effectiveness of a 12-weekly anxiety treatment programme adapted for individuals with moderate-severe TBI, based on cognitive behaviour therapy (CBT) and Motivational Interviewing (MI). The current study explored the variables associated with treatment response and group differences in change expectancy and working alliance. Methods: Twenty-seven participants recruited from a brain injury rehabilitation hospital were randomly assigned to MI + CBT, non-directive counselling (NDC) + CBT and treatment-as-usual and assessors were blinded to treatment conditions. Correlation and multiple regression were used to examine the association between reduction in anxiety ratings and a number of clinical, injury and cognitive variables. Random effects regression was used to examine group difference in changes in working alliance and expectancy. Results: There was a trend suggesting that greater injury severity may be predictive of poorer response to CBT and injury severity was significantly related to memory functioning. Participants receiving MI pre-treatment showed a greater increase in change expectancy at the end of CBT and at follow-up, but not at the end of MI. Conclusions: There is a need to further investigate the effectiveness of treatment for individuals with different injury severity and to explore the relationship between change expectancy and treatment outcome.	[Hsieh, Ming-Yun; Ponsford, Jennie; Wong, Dana; McKay, Adam] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Hsieh, Ming-Yun; Ponsford, Jennie; McKay, Adam] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Hsieh, Ming-Yun] Victorian Rehabil Ctr, Melbourne, Vic, Australia	Hsieh, MY (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	ming-yun.hsieh@monash.edu	Wong, Dana/AAD-3410-2020; McKay, Adam JD/M-6003-2017	McKay, Adam JD/0000-0002-0479-7681; Wong, Dana/0000-0001-9619-1929	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Monash UniversityMonash University; Victorian Brain Injury Recovery Association (Australia)	This study was supported in part by grants from the National Health and Medical Research Council and Monash University, and a scholarship from the Victorian Brain Injury Recovery Association (Australia). The funding sources had no role in study design and analysis of data. The authors alone were responsible for the content and writing of the paper.	Aharonovich E, 2006, DRUG ALCOHOL DEPEN, V81, P313, DOI 10.1016/j.drugalcdep.2005.08.003; Aharonovich E, 2003, DRUG ALCOHOL DEPEN, V71, P207, DOI 10.1016/S0376-8716(03)00092-9; Aharonovich E, 2008, DRUG ALCOHOL DEPEN, V95, P279, DOI 10.1016/j.drugalcdep.2008.01.009; [Anonymous], 2009, STAT STAT SOFTW REL; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Boardman T, 2006, J SUBST ABUSE TREAT, V31, P329, DOI 10.1016/j.jsat.2006.05.006; Brabban A, 2009, SCHIZOPHRENIA BULL, V35, P859, DOI 10.1093/schbul/sbp065; Coughlin A, 2007, MEMORY INFORM PROCES; Craighead WE, 2005, CLIN PSYCHOL-SCI PR, V12, P189, DOI 10.1093/clipsy/bpi024; Dow MGT, 2007, PSYCHOL MED, V37, P1493, DOI 10.1017/S0033291707000670; Dozois DJA, 2005, BEHAV RES THER, V43, P1655, DOI 10.1016/j.brat.2004.12.001; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Field A. P, 2009, DISCOVERING STAT USI; First M.B., 2007, STRUCTURED CLIN INTE; Fleming JM, 1996, BRAIN INJURY, V10, P1; Haby MM, 2006, AUST NZ J PSYCHIAT, V40, P9, DOI 10.1080/j.1440-1614.2006.01736.x; Hatcher RL, 2006, PSYCHOTHER RES, V16, P12, DOI 10.1080/10503300500352500; Hox J. J., 2010, MULTILEVEL ANAL TECH; Hsieh M-Y, 2010, MOTIVATIONA IN PRESS; Jumisko E, 2007, DISABIL REHABIL, V29, P1535, DOI 10.1080/09638280601055816; Kazantzis N, 2007, COGN BEHAV PRACT, V14, P317, DOI 10.1016/j.cbpra.2006.08.003; Kazantzis N, 2010, CLIN PSYCHOL-SCI PR, V17, P144, DOI 10.1111/j.1468-2850.2010.01204.x; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Miller W. R., 2002, MOTIVATIONAL INTERVI; Mohlman J, 2005, BEHAV RES THER, V43, P447, DOI 10.1016/j.brat.2004.03.007; Renison B, 2010, CONCURRENT ECOLOGICA; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; SHADISH WR, 1991, J CONSULT CLIN PSYCH, V59, P883, DOI 10.1037/0022-006X.59.6.883; Shallice, 1997, HAYLING BRIXTON TEST; Soo C, 2007, COCHRANE DATABASE SY, P3; Tabachnick BG, 2007, USING MULTIVARIATE S; Westra HA, 2007, MOTIVATIONAL INTERVI, P26; Westra HA, 2007, J CONSULT CLIN PSYCH, V75, P363, DOI 10.1037/0022-006X.75.3.363; Westra HA, 2006, COGNITIVE THER RES, V30, P481, DOI 10.1007/s10608-006-9016-y; Wilson, 1991, NATL ADULT READING T; Wood Angela M, 2004, Clin Trials, V1, P368; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	41	19	19	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2012	34	5					408	415		10.3109/09638288.2011.607219			8	Rehabilitation	Rehabilitation	876CV	WOS:000299085700005	22087644				2021-06-18	
J	Mommsen, P; Bradt, N; Zeckey, C; Andruszkow, H; Petri, M; Frink, M; Hildebrand, F; Krettek, C; Probst, C				Mommsen, Philipp; Bradt, Nikolas; Zeckey, Christian; Andruszkow, Hagen; Petri, Max; Frink, Michael; Hildebrand, Frank; Krettek, Christian; Probst, Christian			Comparison of helicopter and ground Emergency Medical Service: A retrospective analysis of a German rescue helicopter base	TECHNOLOGY AND HEALTH CARE			English	Article						Emergency medical service; air rescue; ground ambulance; mission times; time sensitive diagnosis	TRAUMA PATIENTS; POLYTRAUMATIZED PATIENTS; VENTRICULAR-ARRHYTHMIAS; AMBULANCE TRANSPORT; AIR AMBULANCE; TIME; MORTALITY; IMPACT; ASSOCIATION; SURVIVAL	Background: In consideration of rising cost pressure in the German health care system, the usefulness of helicopter emergency medical service (HEMS) in terms of time- and cost-effectiveness is controversially discussed. The aim of the present study was to investigate whether HEMS is associated with significantly decreased arrival and transportation times compared to ground EMS. Methods: In a retrospective study, we evaluated 1,548 primary emergency missions for time sensitive diagnoses (multiple trauma, traumatic brain and burn injury, heart-attack, stroke, and pediatric emergency) performed by a German HEMS using the medical database, NADIN, of the German Air Rescue Service. Arrival and transportation times were compared to calculated ground EMS times. Results: HEMS showed significantly reduced arrival times at the scene in case of heart-attack, stroke and pediatric emergencies. In contrast, HEMS and ground EMS showed comparable arrival times in patients with multiple trauma, traumatic brain and burn injury due to an increased flight distance. HEMS showed a significantly decreased transportation time to the closest centre capable of specialist care in all diagnosis groups (p < 0.001). Conclusions: The results of the present study indicate the time-effectiveness of German air ambulance services with significantly decreased transportation times.	[Mommsen, Philipp; Bradt, Nikolas; Zeckey, Christian; Andruszkow, Hagen; Petri, Max; Frink, Michael; Hildebrand, Frank; Krettek, Christian; Probst, Christian] Hannover Med Sch, Trauma Dept, D-30625 Hannover, Germany	Mommsen, P (corresponding author), Hannover Med Sch, Trauma Dept, Carl Neuberg Str 1, D-30625 Hannover, Germany.	mommsen.philipp@mh-hannover.de	Mommsen, Philipp/ABC-3510-2020; Hildebrand, Frank/J-3176-2017	Krettek, Christian/0000-0001-9807-0020			Biewener A, 2005, UNFALLCHIRURG, V108, P370, DOI 10.1007/s00113-005-0928-x; Biewener A, 2004, J TRAUMA, V56, P94, DOI 10.1097/01.TA.0000061883.92194.50; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; Clarke JR, 2002, J TRAUMA, V52, P420, DOI 10.1097/00005373-200203000-00002; Cunningham P, 1997, J TRAUMA, V43, P940, DOI 10.1097/00005373-199712000-00013; Diaz MA, 2005, J TRAUMA, V58, P148, DOI 10.1097/01.TA.0000124264.43941.41; Frink M, 2007, UNFALLCHIRURG, V110, P334, DOI 10.1007/s00113-006-1222-2; Gries A, 2008, ANAESTHESIST, V57, P562, DOI 10.1007/s00101-008-1373-3; Gries A, 2006, ANAESTHESIST, V55, P1080, DOI 10.1007/s00101-006-1051-2; Hacke W, 1999, NEUROLOGY, V53, pS3; Hacke W, 2004, LANCET, V363, P768; Hata N, 2006, INTERNAL MED, V45, P45, DOI 10.2169/internalmedicine.45.1399; Hohnloser SH, 2003, CIRCULATION, V107, P941, DOI 10.1161/01.CIR.0000054211.00668.9B; Hotvedt R, 1996, LANCET, V347, P1362, DOI 10.1016/S0140-6736(96)91010-7; Knobloch Karsten, 2009, Air Med J, V28, P146, DOI 10.1016/j.amj.2008.11.004; Kurola J, 2002, ACTA ANAESTH SCAND, V46, P779, DOI 10.1034/j.1399-6576.2002.460704.x; Larson JT, 2004, J TRAUMA, V56, P89, DOI 10.1097/01.TA.0000061163.35582.A5; Lechleuthner A, 1994, Eur J Emerg Med, V1, P159; Milavetz JJ, 1998, J AM COLL CARDIOL, V31, P1246, DOI 10.1016/S0735-1097(98)00088-6; Murphy M S, 1997, Air Med J, V16, P73, DOI 10.1016/S1067-991X(97)90018-3; MYERBURG RJ, 1992, CIRCULATION, V85, P2; Oppe S, 2001, ACCIDENT ANAL PREV, V33, P129, DOI 10.1016/S0001-4575(00)00023-3; Schlechtriemen I, 2002, UNFALLCHIRURG, V105, P974, DOI 10.1007/s00113-002-0515-3; Shatney CH, 2002, J TRAUMA, V53, P817, DOI 10.1097/00005373-200211000-00002; Sollid S, 2003, J NEUROTRAUM, V20, P309, DOI 10.1089/089771503321532897	25	19	20	1	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0928-7329	1878-7401		TECHNOL HEALTH CARE	Technol. Health Care		2012	20	1					49	56		10.3233/THC-2011-0655			8	Health Care Sciences & Services; Engineering, Biomedical	Health Care Sciences & Services; Engineering	068BW	WOS:000313340500005	22297713				2021-06-18	
J	Pardini, M; Krueger, F; Koenigs, M; Raymont, V; Hodgkinson, C; Zoubak, S; Goldman, D; Grafman, J				Pardini, M.; Krueger, F.; Koenigs, M.; Raymont, V.; Hodgkinson, C.; Zoubak, S.; Goldman, D.; Grafman, J.			Fatty-acid amide hydrolase polymorphisms and post-traumatic stress disorder after penetrating brain injury	TRANSLATIONAL PSYCHIATRY			English	Article						endocannabinoids; post-traumatic stress disorder; single-nucleotide polymorphisms	ENDOCANNABINOID SYSTEM; PREFRONTAL CORTEX; COMBAT VETERANS; INVENTORY; LESIONS; TRAUMA; PTSD	The past few years have seen an increase in the clinical awareness of post-traumatic stress disorder (PTSD), one of the most disabling and least understood behavioral disorders. Although the biological bases of PTSD are poorly understood, fatty-acid amide hydrolase (FAAH) activity has been linked with arousability and aversive-memories extinction, that is, two key features of PTSD. In this study, we investigated the association between the FAAH genetic polymorphisms and PTSD development and maintenance. We assessed PTSD frequency in a group of male Vietnam war veterans who suffered combat-related penetrating traumatic brain injury, that is, a relatively homogeneous population regarding the nature of the events that led to PTSD. We showed that rs2295633, a single-nucleotide polymorphism of FAAH, was significantly associated with PTSD diagnosis in subjects without lesions in the ventromedial prefrontal cortex. Moreover, the presence of the C allele was associated with more severe re-experiencing of trauma and more negative reported childhood experiences. In conclusion, our data suggest that FAAH has an important role in PTSD through modulation of aversive memories and point to both a novel therapeutic target and a possible risk marker for this condition. Translational Psychiatry (2012) 2, e75; doi:10.1038/tp.2012.1; published online 31 January 2012	[Grafman, J.] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ 07052 USA; [Pardini, M.; Grafman, J.] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bethesda, MD USA; [Pardini, M.] Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; [Pardini, M.] Univ Genoa, Magnet Resonance Res Ctr Nervous Syst Dis, Genoa, Italy; [Krueger, F.] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Krueger, F.] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Koenigs, M.] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA; [Raymont, V.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Raymont, V.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England; [Hodgkinson, C.; Zoubak, S.; Goldman, D.] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA	Grafman, J (corresponding author), Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	FKruger@gmu.edu; jgrafman@kesslerfoundation.org	Pardini, Matteo/F-8414-2010; Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020	Pardini, Matteo/0000-0002-4740-1982; Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Koenigs, Michael/0000-0002-5799-4881; Grafman, Jordan H./0000-0001-8645-4457	US National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000301] Funding Source: NIH RePORTER	The work was supported by the US National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the US Army Medical Research and Material Command administrated by the Henry M Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bremner JD, 2000, DEPRESS ANXIETY, V12, P1, DOI 10.1002/1520-6394(2000)12:1<1::AID-DA1>3.0.CO;2-W; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Dlugos AM, 2010, NEUROPSYCHOPHARMACOL, V35, P613, DOI 10.1038/npp.2009.166; First MB., 2002, STRUCTURED CLIN INTE; Hill MN, 2009, CNS NEUROL DISORD-DR, V8, P451, DOI 10.2174/187152709789824624; Hodgkinson CA, 2008, ALCOHOL ALCOHOLISM, V43, P505, DOI 10.1093/alcalc/agn032; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Lutz B, 2007, MOL NEUROBIOL, V36, P92, DOI 10.1007/s12035-007-8004-x; Mayer JD., 2002, MAYER SALOVEY CARUSO; Pardini M, 2011, NEUROLOGY, V76, P1038, DOI 10.1212/WNL.0b013e318211c33e; Quirk GJ, 2006, CURR OPIN NEUROBIOL, V16, P723, DOI 10.1016/j.conb.2006.07.004; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Taylor S., 2006, CLIN GUIDE PTSD COGN; Varvel SA, 2007, NEUROPSYCHOPHARMACOL, V32, P1032, DOI 10.1038/sj.npp.1301224; Wechsler D, 1997, WMS 3 ADM SCORING MA	22	19	20	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	JAN	2012	2								e75	10.1038/tp.2012.1			5	Psychiatry	Psychiatry	971PZ	WOS:000306217600011	22832737	DOAJ Gold, Green Published			2021-06-18	
J	Valiyaveettil, M; Alamneh, Y; Miller, SA; Hammamieh, R; Wang, Y; Arun, P; Wei, YL; Oguntayo, S; Nambiar, MP				Valiyaveettil, Manojkumar; Alamneh, Yonas; Miller, Stacy-Ann; Hammamieh, Rasha; Wang, Ying; Arun, Peethambaran; Wei, Yanling; Oguntayo, Samuel; Nambiar, Madhusoodana P.			Preliminary studies on differential expression of auditory functional genes in the brain after repeated blast exposures	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						auditory functional genes; auditory process; blast injury; cadherin; hearing loss; neurotrauma; otoancorin; otoferlin; protocadherin; tinnitus	INDUCED HEARING-LOSS; CU/ZN-SUPEROXIDE-DISMUTASE; GATED CALCIUM-CHANNEL; HEAT-SHOCK PROTEINS; HAIR-CELLS; INNER-EAR; NOISE OVERSTIMULATION; MOUSE COCHLEA; TIP LINK; INJURY	The mechanisms of central auditory processing involved in auditory/vestibular injuries and subsequent tinnitus and hearing loss in Active Duty servicemembers exposed to blast are not currently known. We analyzed the expression of hearing-related genes in different regions of the brain 6 h after repeated blast exposures in mice. Preliminary data showed that the expression of the deafness-related genes otoferlin and otoancorin was significantly changed in the hippocampus after blast exposures. Differential expression of cadherin and protocadherin genes, which are involved in hearing impairment, was observed in the hippocampus, cerebellum, frontal cortex, and midbrain after repeated blasts. A series of calcium-signaling genes that are known to be involved in auditory signal processing were also found to be significantly altered after repeated blast exposures. The hippocampus and midbrain showed significant increase in the gene expression of hearing loss-related antioxidant enzymes. Histopathology of the auditory cortex showed more significant injury in the inner layer compared to the outer layer. In summary, mice exposed to repeated blasts showed injury to the auditory cortex and significant alterations in multiple genes in the brain known to be involved in age- or noise-induced hearing impairment.	[Valiyaveettil, Manojkumar; Alamneh, Yonas; Wang, Ying; Arun, Peethambaran; Wei, Yanling; Oguntayo, Samuel; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Miller, Stacy-Ann; Hammamieh, Rasha] USA, Ctr Environm Hlth Res, Med Res & Mat Command, Ft Detrick, MD USA	Valiyaveettil, M (corresponding author), Walter Reed Army Inst Res, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	m.valiyaveettil@amedd.army.mil; madhusoodana.nambiar@amedd.army.mil					Abaamrane L, 2011, EUR ARCH OTO-RHINO-L, V268, P987, DOI 10.1007/s00405-011-1487-0; Arun P, 2011, NEUROREPORT, V22, P379, DOI 10.1097/WNR.0b013e328346b138; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Elgoyhen AB, 2009, BIOCHEM PHARMACOL, V78, P712, DOI 10.1016/j.bcp.2009.05.023; Beurg M, 2010, J NEUROSCI, V30, P13281, DOI 10.1523/JNEUROSCI.2528-10.2010; Bolz Hanno, 2004, Hum Mutat, V24, P274, DOI 10.1002/humu.9272; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Choi BY, 2009, CLIN GENET, V75, P237, DOI 10.1111/j.1399-0004.2008.01128.x; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; ELSAMMAA M, 1986, AM J OTOL, V7, P241; Fairfield DA, 2005, J NEUROSCI RES, V81, P589, DOI 10.1002/jnr.20417; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fetoni AR, 2009, ACTA OTORHINOLARYNGO, V29, P70; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gong TW, 2012, JARO-J ASSOC RES OTO, V13, P29, DOI 10.1007/s10162-011-0289-9; Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3; Jovine L, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-28; Kathiresan T, 2009, MOL CELL PROTEOMICS, V8, P1972, DOI 10.1074/mcp.M800495-MCP200; Keithley EM, 2005, HEARING RES, V209, P76, DOI 10.1016/j.heares.2005.06.009; Kelley A., 2010, 201016 US ARM AER RE; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Le T, 2007, HEARING RES, V226, P194, DOI 10.1016/j.heares.2006.04.003; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; McFadden SL, 2001, NOISE HEALTH, V3, P49; Momiyama J, 2006, TOHOKU J EXP MED, V209, P89, DOI 10.1620/tjem.209.89; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Mrena R, 2002, AUDIOL NEURO-OTOL, V7, P122, DOI 10.1159/000057660; Noben-Trauth K, 2003, NAT GENET, V35, P21, DOI 10.1038/ng1226; Ohlemiller KK, 2006, BRAIN RES, V1091, P89, DOI 10.1016/j.brainres.2006.03.017; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P237, DOI 10.1159/000013847; Ohlemiller KK, 2000, HEARING RES, V149, P239, DOI 10.1016/S0378-5955(00)00191-X; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P229, DOI 10.1159/000013846; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P219, DOI 10.1159/000013845; Ohlemiller KK, 2000, JARO-J ASSOC RES OTO, V1, P243, DOI 10.1007/s101620010043; Pangrsic T, 2010, NAT NEUROSCI, V13, P869, DOI 10.1038/nn.2578; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Ramakrishnan NA, 2009, J BIOL CHEM, V284, P3227, DOI 10.1074/jbc.M806177200; Ramakrishnan NA, 2009, J BIOL CHEM, V284, P1364, DOI 10.1074/jbc.M803605200; Reisinger E, 2011, J NEUROSCI, V31, P4886, DOI 10.1523/JNEUROSCI.5122-10.2011; Roux I, 2006, CELL, V127, P277, DOI 10.1016/j.cell.2006.08.040; Scherer EQ, 2002, STROKE, V33, P2965, DOI 10.1161/01.STR.0000043673.22993.FD; Schug N, 2006, EUR J NEUROSCI, V24, P3372, DOI 10.1111/j.1460-9568.2006.05225.x; Shen HY, 2011, HEARING RES, V277, P184, DOI 10.1016/j.heares.2011.01.009; Siemens J, 2004, NATURE, V428, P950, DOI 10.1038/nature02483; Sollner C, 2004, NATURE, V428, P955, DOI 10.1038/nature02484; Spencer RF, 2002, HEARING RES, V171, P129, DOI 10.1016/S0378-5955(02)00494-X; Uemaetomari I, 2009, TOHOKU J EXP MED, V218, P41, DOI 10.1620/tjem.218.41; Valiyaveettil M, 2012, NEUROSCI LETT, V506, P141, DOI 10.1016/j.neulet.2011.10.067; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Zheng QY, 2005, HUM MOL GENET, V14, P103, DOI 10.1093/hmg/ddi010; Zwaenepoel I, 2002, P NATL ACAD SCI USA, V99, P6240, DOI 10.1073/pnas.082515999	54	19	21	0	4	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					1153	1162		10.1682/JRRD.2011.09.0182			10	Rehabilitation	Rehabilitation	149EZ	WOS:000319303100016	23341286	Bronze			2021-06-18	
J	Viano, DC; Withnall, C; Wonnacott, M				Viano, David C.; Withnall, Chris; Wonnacott, Michael			Effect of Mouthguards on Head Responses and Mandible Forces in Football Helmet Impacts	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Protective headgear; Recreation and sport; Concussion; Helmets; Sport equipment	PROFESSIONAL FOOTBALL; PROTECTIVE EQUIPMENT; DENTAL INJURIES; CONCUSSION; PREVENTION; PLAYERS; SPORTS	The potential for mouthguards to change the risk of concussion was studied in football helmet impacts. The Hybrid III head was modified with an articulating mandible, dentition, and compliant temporomandibular joints (TMJ). It was instrumented for triaxial head acceleration and triaxial force at the TMJs and upper dentition. Mandible force and displacement were validated against cadaver impacts to the chin. In phase 1, one of five mouthguards significantly lowered HIC in 6.7 m/s impacts (p = 0.025) from the no mouthguard condition but not in 9.5 m/s tests. In phase 2, eight mouthguards increased HIC from +1 to +17% in facemask impacts that loaded the chinstraps and mandible; one was statistically higher (p = 0.018). Peak head acceleration was +1 to +15% higher with six mouthguards and 2-3% lower with two others. The differences were not statistically significant. Five of eight mouthguards significantly reduced forces on the upper dentition by 40.8-63.9%. Mouthguards tested in this study with the Hybrid III articulating mandible lowered forces on the dentition and TMJ, but generally did not influence HIC or concussion risks.	[Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Withnall, Chris; Wonnacott, Michael] Biokinet & Associates Ltd, Ottawa, ON K1H 1E1, Canada	Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net			National Football League	The testing at Biokinetics and Associates Ltd. was funded by the National Football League. Their support of the research on the effects of mouthguards on head responses is appreciated. The opinions presented here are those of the authors and not necessarily those of the NFL. The development of the articulating mandible for the Hybrid III,<SUP>8,41</SUP> cadaver testing and development of biofidelity corridors for impacts to the chin<SUP>6,7,9</SUP> and the series of helmet testing reported here were completed while the lead author was a member of the NFL's MTBI Committee and oversaw the research.	BACKAITIS SH, 1994, HYBRID, V3; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Beachy G, 2004, J ATHL TRAINING, V39, P310; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Chou CC, 1974, SAE T, P398; Craig M., 2006, AM SOC MECH ENG 2006; Craig M. J., 2009, 2009010388 SAE; Craig M. J., 2007, THESIS WAYNE STATE U; Craig M, 2008, J BIOMECH, V41, P2972, DOI 10.1016/j.jbiomech.2008.07.020; DIPIETRO GJ, 1976, J PROSTHET DENT, V36, P624, DOI 10.1016/0022-3913(76)90026-3; Dragulescu D., 2002, 10 C MECH VIBR INT P; Echlin PS, 2005, BRIT J SPORT MED, V39, P254, DOI 10.1136/bjsm.2004.013128; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Goodson J. M., 1975, MONOGRAPHS ORAL SCI, V5; Halstead P. D, 2011, COMPEND CONTIN ED DE, V30, P18; Hubbard R., 1994, HYBRID; Knapik JJ, 2007, SPORTS MED, V37, P117, DOI 10.2165/00007256-200737020-00003; KOOLSTRA JH, 1995, J DENT RES, V74, P1564, DOI 10.1177/00220345950740091001; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Lacrosse U. S, 2003, US POS STAT US MOUTH; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; MERTZ HJ, 1989, 890756 SAE; Mertz HJ, 2001, 45 STAPP CAR CRASH C; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Moore KL, 1999, CLIN ORIENTED ANATOM; Moore KL, 1992, CLIN ORIENTED ANATOM; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Raaii F, 2011, CLIN J SPORT MED, V21, P320, DOI 10.1097/JSM.0b013e31821f5cd7; Roberson T. M., 2001, STURDEVANTS ART SCI; Robin S, 2001, HUMOS HUMAN MODEL SA; Rowson Steven, 2008, Biomed Sci Instrum, V44, P195; Society of Automotive Engineers (SAE), 1995, J2111 SAE; Society of Automotive Engineers (SAE), 1994, J1733 SAE; Stedman T., 1995, STEDMANS MED DICT; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Warnet L, 2001, BRIT J SPORT MED, V35, P257, DOI 10.1136/bjsm.35.4.257; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Wonnacott M., 2010, 2010010136 SAE; Zawawi Khalid H, 2003, J Can Dent Assoc, V69, P737; Zhang FT, 2002, J BIOMECH, V35, P975, DOI 10.1016/S0021-9290(02)00057-X	43	19	19	0	24	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		47	69		10.1007/s10439-011-0399-x			23	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700005	21994059				2021-06-18	
J	Warren, DE; Duff, MC; Magnotta, V; Capizzano, AA; Cassell, MD; Tranel, D				Warren, David E.; Duff, Melissa C.; Magnotta, Vincent; Capizzano, Aristides A.; Cassell, Martin D.; Tranel, Daniel			Long-Term Neuropsychological, Neuroanatomical, and Life Outcome in Hippocampal Amnesia	CLINICAL NEUROPSYCHOLOGIST			English	Article						Amnesia; Hippocampus; Memory; Medial temporal lobe; Anoxia	MEDIAL TEMPORAL-LOBE; TRAUMATIC BRAIN-INJURY; ENDURING MEMORY IMPAIRMENT; DELAYED NEURONAL DEATH; HIGH-RESOLUTION MRI; RETROGRADE-AMNESIA; STATUS EPILEPTICUS; RELATIONAL MEMORY; FOLLOW-UP; DECLARATIVE MEMORY	Focal bilateral hippocampal damage typically causes severe and selective amnesia for new declarative information (facts and events), a cognitive deficit that greatly impacts the ability to live a normal, fully independent life. We describe the case of 1846, a 48-year-old woman with profound hippocampal amnesia following status epilepticus and an associated anoxic episode at age 30. Patient 1846 has undergone extensive neuropsychological testing on many occasions over the 18 years since her injury, and we present data indicating that her memory impairment has remained severe and stable during that time. New, high-resolution, structural MRI studies of 1846's brain reveal substantial bilateral hippocampal atrophy resembling that of other well-known amnesic patients. In spite of severe amnesia 1846 lives a full and mostly independent adult life, facilitated by an extensive social support network of family and friends. Her case provides an example of a rare and unlikely positive outcome in the face of severe memory problems.	[Warren, David E.; Duff, Melissa C.; Tranel, Daniel] Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; [Duff, Melissa C.] Univ Iowa, Dept Commun Sci & Disorders, Iowa City, IA 52242 USA; [Magnotta, Vincent; Capizzano, Aristides A.] Univ Iowa, Coll Med, Dept Radiol, Iowa City, IA 52242 USA; [Cassell, Martin D.] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; [Tranel, Daniel] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA	Warren, DE (corresponding author), Univ Iowa, Coll Med, Dept Neurol, 200 Hawkins Dr,2192 RCP, Iowa City, IA 52242 USA.	davideugenewarren@gmail.com	Capizzano, Aristides A./AAC-5963-2019	Tranel, Daniel/0000-0002-1338-1389; Magnotta, Vincent/0000-0001-8639-5354; Warren, David/0000-0003-0539-2587; Capizzano, Aristides/0000-0003-1950-8499	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS19632]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS019632] Funding Source: NIH RePORTER	This work was supported by the following funding sources: NINDS P50 NS19632 (DT). The authors would like to express their gratitude to 1846, her husband, and her parents for consenting to participate in our research and for the interviews that informed this case report. The authors would also like to thank Dr. Steven W. Anderson, Dr. Sara Cavaco, Kenneth Manzel, and Joel Bruss for their contributions to this report.	Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; ALBERT MS, 1981, ARCH NEUROL-CHICAGO, V38, P495, DOI 10.1001/archneur.1981.00510080057008; ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; Allen JS, 2006, J CLIN EXP NEUROPSYC, V28, P457, DOI 10.1080/13803390590949287; Allen JS, 2005, NEUROBIOL AGING, V26, P1245, DOI 10.1016/j.neurobiolaging.2005.05.023; Auer R., 2002, GREENFIELDS NEUROPAT, V7th, P233; BARR WB, 1990, NEUROPSYCHOLOGIA, V28, P243, DOI 10.1016/0028-3932(90)90018-J; Barrash J, 1997, J INT NEUROPSYCH SOC, V3, P27; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BENTON A, 1994, BENTON LAB TESTS; Benton A., 1994, MULTILINGUAL APHASIA; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Berg, 1993, WISCONSIN CARD SORTI; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; BRIERLEY JB, 1973, ARCH NEUROL-CHICAGO, V29, P367, DOI 10.1001/archneur.1973.00490300029003; Bright P, 2006, LEARN MEMORY, V13, P545, DOI 10.1101/lm.265906; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; Buchanan TW, 2009, HORM BEHAV, V56, P44, DOI 10.1016/j.yhbeh.2009.02.011; Buchanan TW, 2005, J NEUROSCI, V25, P3151, DOI 10.1523/JNEUROSCI.4735-04.2005; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86, DOI 10.1017/S1355617700611116; Cavaco S, 2004, BRAIN, V127, P1853, DOI 10.1093/brain/awh208; Clark E, 2009, ISSUES DIVERS CLIN N, P69, DOI 10.1007/978-0-387-76908-0_4; Cohen N.J., 2001, CONDITIONING CONSCIO; Cohen N.J., 1993, MEMORY AMNESIA HIPPO; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; Corkin S, 1997, J NEUROSCI, V17, P3964; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CORSELLIS JAN, 1983, STATUS EPILEPTICUS M, P129; Damasio A. R., 1989, HDB NEUROPSYCHOLOGY; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P252, DOI 10.1001/archneur.1985.04060030070012; Davachi L, 2008, CURR DIR PSYCHOL SCI, V17, P112, DOI 10.1111/j.1467-8721.2008.00559.x; DeFilippis NA, 1997, BOOKLET CATEGORY TES; DEGIORGIO CM, 1992, EPILEPSIA, V33, P23, DOI 10.1111/j.1528-1157.1992.tb02278.x; Di Paola M, 2008, HIPPOCAMPUS, V18, P719, DOI 10.1002/hipo.20432; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dietl T, 2004, EPILEPSY BEHAV, V5, P394, DOI 10.1016/j.yebeh.2004.01.004; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Duff MC, 2006, NAT NEUROSCI, V9, P140, DOI 10.1038/nn1601; Duff MC, 2008, J CLIN EXP NEUROPSYC, V30, P931, DOI 10.1080/13803390801894681; Duff MC, 2008, APHASIOLOGY, V22, P866, DOI 10.1080/02687030701844196; Duff MC, 2007, APHASIOLOGY, V21, P702, DOI 10.1080/02687030701192265; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Feinstein JS, 2010, P NATL ACAD SCI USA, V107, P7674, DOI 10.1073/pnas.0914054107; Feinstein JS, 2010, J CLIN EXP NEUROPSYC, V32, P88, DOI 10.1080/13803390903066873; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Fujikawa DG, 1996, BRAIN RES, V725, P11, DOI 10.1016/S0006-8993(96)00203-X; GilNagel A, 1997, BRAIN, V120, P183, DOI 10.1093/brain/120.1.183; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; Golden C., 1978, STROOP COLOR WORD TE; Goodglass H., 1972, ASSESSMENT APHASIA R; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; Graham KS, 2010, NEUROPSYCHOLOGIA, V48, P831, DOI 10.1016/j.neuropsychologia.2010.01.001; Grubb NR, 2000, STROKE, V31, P1509, DOI 10.1161/01.STR.31.7.1509; Guerreiro CAM, 2001, EPILEPSY BEHAV, V2, P224, DOI 10.1006/ebeh.2001.0167; Gupta R, 2009, NEUROPSYCHOLOGIA, V47, P1686, DOI 10.1016/j.neuropsychologia.2009.02.007; Hannula DE, 2006, J NEUROSCI, V26, P8352, DOI 10.1523/JNEUROSCI.5222-05.2006; Hannula DE, 2007, J COGNITIVE NEUROSCI, V19, P1690, DOI 10.1162/jocn.2007.19.10.1690; Holdstock JS, 2000, NEUROPSYCHOLOGIA, V38, P410, DOI 10.1016/S0028-3932(99)00099-8; Hooper H.E., 1958, HOOPER VISUAL ORG TE; Horstmann A, 2010, NEUROLOGY, V74, P306, DOI 10.1212/WNL.0b013e3181cbcd6f; Jastak S, 1984, WIDE RANGE ACHIEVEME; Jones RD, 1998, NEUROCASE, V4, P471, DOI 10.1093/neucas/4.6.471; Kaplan E., 1983, BOSTON NAMING TEST; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Knake S, 2009, EPILEPSY BEHAV, V15, P10, DOI 10.1016/j.yebeh.2009.02.027; Konkel A, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.015.2008; KRUMHOLZ A, 1995, NEUROLOGY, V45, P1499, DOI 10.1212/WNL.45.8.1499; Lin JJ, 2007, CEREB CORTEX, V17, P2007, DOI 10.1093/cercor/bhl109; LUCAS E, 1881, RECREATIONS MATH; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Matthews C, 1964, INSTRUCTION MANUAL A; Mayes AR, 2002, HIPPOCAMPUS, V12, P325, DOI 10.1002/hipo.1111; Mayes AR, 2001, COGNITIVE NEUROPSYCH, V18, P97, DOI 10.1080/02643290125897; McCarthy RA, 2005, NEUROPSYCHOLOGIA, V43, P356, DOI 10.1016/j.neuropsychologia.2004.06.024; McKinley JC, 1944, J APPL PSYCHOL, V28, P153, DOI 10.1037/h0059245; Meldrum B. S., 1997, NEUROPATHOL APPL NEU, V23, P201; Meldrum BS, 1997, NEUROPATH APPL NEURO, V23, P185, DOI 10.1111/j.1365-2990.1997.tb01201.x; MEYER A, 1955, J NEUROL NEUROSUR PS, V18, P24, DOI 10.1136/jnnp.18.1.24; Milner B., 1962, PSYCHOL HIPPOCAMPE, P272; Moscovitch M, 1998, CURR OPIN NEUROBIOL, V8, P297, DOI 10.1016/S0959-4388(98)80155-4; Moscovitch M, 2005, J ANAT, V207, P35, DOI 10.1111/j.1469-7580.2005.00421.x; Mueller SG, 2007, NEUROBIOL AGING, V28, P719, DOI 10.1016/j.neurobiolaging.2006.03.007; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; NEVANDER G, 1985, ANN NEUROL, V18, P281, DOI 10.1002/ana.410180303; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; Oxbury S, 1997, NEUROPSYCHOLOGIA, V35, P975, DOI 10.1016/S0028-3932(97)00025-0; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Radovsky A, 1997, TOXICOL PATHOL, V25, P500, DOI 10.1177/019262339702500512; Ranganath C, 2010, HIPPOCAMPUS, V20, P1263, DOI 10.1002/hipo.20852; Reitan RM., 1985, HALSTEAD REITAN NEUR; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ribot T-A., 1881, MALADIES MEMOIRE; Ryan JD, 2000, PSYCHOL SCI, V11, P454, DOI 10.1111/1467-9280.00288; Salat DH, 2006, HIPPOCAMPUS, V16, P936, DOI 10.1002/hipo.20222; SANDERS HI, 1971, BRAIN, V94, P661, DOI 10.1093/brain/94.4.661; SCOVILLE WB, 1954, J NEUROSURG, V11, P64, DOI 10.3171/jns.1954.11.1.0064; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sivan AB., 1992, BENTON VISUAL RETENT; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; SQUIRE LR, 1989, EXP NEUROL, V105, P23, DOI 10.1016/0014-4886(89)90168-4; SQUIRE LR, 1989, J NEUROSCI, V9, P828; Stark SM, 2010, LEARN MEMORY, V17, P284, DOI 10.1101/lm.1768110; Stefanacci L, 2000, J NEUROSCI, V20, P7024, DOI 10.1523/JNEUROSCI.20-18-07024.2000; Suhr J, 1999, NEUROPSYCHOL REHABIL, V9, P31, DOI 10.1080/713755590; Sun HS, 2009, NAT NEUROSCI, V12, P1300, DOI 10.1038/nn.2395; Tate R., 2004, ESSENTIAL HDB MEMORY, P329; Teasdale TW, 2005, BRAIN INJURY, V19, P1049, DOI 10.1080/02699050500110421; Tranel D, 2006, J CLIN EXP NEUROPSYC, V28, P43, DOI 10.1080/13803390490919344; Tranel D, 2006, NEUROPSYCHOLOGY, V20, P1, DOI 10.1037/0894-4105.20.1.1; Tranel D, 2005, J CLIN EXP NEUROPSYC, V27, P102, DOI 10.1080/138033990513663; VOLPE BT, 1985, NEUROLOGY, V35, P1793, DOI 10.1212/WNL.35.12.1793; Voss JL, 2011, P NATL ACAD SCI USA, V108, pE402, DOI 10.1073/pnas.1100225108; Walker M., 2007, HIPPOCAMPUS BOOK, P769; Warren DE, 2012, HIPPOCAMPUS, V22, P1577, DOI 10.1002/hipo.21000; Warren DE, 2011, J COGNITIVE NEUROSCI, V23, P3862, DOI 10.1162/jocn_a_00089; Warren DE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00035; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER ADULT INTEL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wieshmann UC, 1999, J ANAT, V195, P131, DOI 10.1046/j.1469-7580.1999.19510131.x; Wilson, 1991, NATL ADULT READING T; Wilson B. A., 1999, CASE STUDIES NEUROPS, P43; Wilson BA, 1996, BRAIN INJURY, V10, P863, DOI 10.1080/026990596123846; Wilson BA, 1995, BROKEN MEMORIES CASE, P14; Yassa MA, 2010, NEUROIMAGE, V51, P1242, DOI 10.1016/j.neuroimage.2010.03.040; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	135	19	19	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	2					335	369		10.1080/13854046.2012.655781			35	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	936EO	WOS:000303573900011	22401298	Green Accepted			2021-06-18	
J	Zlotnik, A; Leibowitz, A; Gurevich, B; Ohayon, S; Boyko, M; Klein, M; Knyazer, B; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Leibowitz, Akiva; Gurevich, Boris; Ohayon, Sharon; Boyko, Matthew; Klein, Moti; Knyazer, Boris; Shapira, Yoram; Teichberg, Vivian I.			Effect of estrogens on blood glutamate levels in relation to neurological outcome after TBI in male rats	INTENSIVE CARE MEDICINE			English	Article						Traumatic brain injury; Estrogen; Blood glutamate; Neuroprotection	CLOSED-HEAD-INJURY; TRAUMATIC BRAIN-INJURY; CONJUGATED EQUINE ESTROGENS; SCAVENGING ACTIVITY; RECEPTOR; MECHANISMS; ESTRADIOL; WOMEN; NEUROPROTECTION; PROGESTERONE	Estrogen has been shown to possess neuroprotective properties both in vitro and in vivo. Traumatic brain injury (TBI) in ovulating females results in favorable neurological outcomes when compared to males with similar insults. The brain-to-blood glutamate gradient removes excess glutamate from brain extracellular fluids (ECF). Enhancing this gradient leads to improved neurological outcomes following TBI. In this study we investigate the effect of female gonadal steroids on blood glutamate levels and neurological outcomes. Forty male Sprague-Dawley rats were assigned to one of five groups: (1) sham, (2) Premarin treatment, (3) TBI, (4) TBI + Premarin treatment, and (5) TBI + Premarin pretreatment. TBI was induced, and estrogen and glutamate levels were determined at 0, 60, 120, 135, and 150 min. Neurological recovery was evaluated using the Neurological Severity Score (NSS) at 1 h and reassessed at 24 h post TBI. Premarin treatment groups demonstrated a decline in blood glutamate levels by 60 min. This decline was found to be more pronounced in the TBI + Premarin group, which maintained the decline throughout the experiment. At 120 min, the difference between groups was most pronounced (TBI + Premarin 99 +/- A 36 mu M/l vs. control 200 +/- A 46 mu M/l, p < 0.01). Neurological recovery was significantly better in the Premarin treatment group (NSS at 24 h 6 +/- A 1 vs. control 11 +/- A 1). Premarin injected into male rats significantly decreases blood glutamate levels in rats suffering TBI. This decrease is associated with improved neurological outcomes, thus implicating the role of estrogen in neuroprotection.	[Zlotnik, Alexander; Leibowitz, Akiva; Gurevich, Boris; Ohayon, Sharon; Boyko, Matthew; Klein, Moti; Shapira, Yoram] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel; [Knyazer, Boris] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Ophthalmol, IL-84105 Beer Sheva, Israel; [Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Leibowitz, A (corresponding author), Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel.	akival@bgu.ac.il	Knyazer., Boris/D-8969-2014; klein, moti/AAR-6552-2021; Leibowitz, Akiva/F-1397-2012; Knyazer, Boris/AAM-6854-2020	Knyazer., Boris/0000-0002-9246-3226; Knyazer, Boris/0000-0002-9246-3226; Leibowitz, Akiva/0000-0003-4244-1915; Boyko, Matthew/0000-0003-3116-1643			Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Behl C, 2000, J NEUROCYTOL, V29, P351, DOI 10.1023/A:1007109222673; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Cimarosti H, 2005, NEUROSCI LETT, V385, P52, DOI 10.1016/j.neulet.2005.05.006; Cimarosti H, 2006, NEUROCHEM RES, V31, P483, DOI 10.1007/s11064-006-9043-9; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Duckles SP, 2007, CLIN EXP PHARMACOL P, V34, P801, DOI 10.1111/j.1440-1681.2007.04683.x; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Klin Y, 2010, BIOCHEM BIOPH RES CO, V399, P694, DOI 10.1016/j.bbrc.2010.07.144; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Mitrovic AD, 1999, NEUROCHEM INT, V34, P101, DOI 10.1016/S0197-0186(98)00066-7; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patkar S, 2011, NEUROSCI RES, V71, P78, DOI 10.1016/j.neures.2011.05.006; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rocca WA, 2007, NEUROLOGY, V69, P1074, DOI 10.1212/01.wnl.0000276984.19542.e6; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shen KH, 2008, SHOCK, V30, P668, DOI 10.1097/SHK.0b013e31817538cb; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Warren MP, 2004, AM J OBSTET GYNECOL, V190, P1141, DOI 10.1016/j.ajog.2003.09.033; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Zauner A, 1996, ACT NEUR S, V67, P40; Zhao LQ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-24; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2011, BIOL REPROD, V84, P581, DOI 10.1095/biolreprod.110.088120; Zlotnik A, 2011, NEUROCHEM RES, V36, P732, DOI 10.1007/s11064-010-0388-8; Zlotnik A, 2011, J NEUROSURG ANESTH, V23, P45, DOI 10.1097/ANA.0b013e3181f82a8f; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	40	19	19	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JAN	2012	38	1					137	144		10.1007/s00134-011-2401-3			8	Critical Care Medicine	General & Internal Medicine	858YM	WOS:000297839600020	22124768				2021-06-18	
J	Nacci, A; Ferrazzi, M; Berrettini, S; Panicucci, E; Matteucci, J; Bruschini, L; Ursino, F; Fattori, B				Nacci, A.; Ferrazzi, M.; Berrettini, S.; Panicucci, E.; Matteucci, J.; Bruschini, L.; Ursino, F.; Fattori, B.			Vestibular and stabilometric findings in whiplash injury and minor head trauma	ACTA OTORHINOLARYNGOLOGICA ITALICA			English	Article						Whiplash injury; Minor head trauma; Vestibular pathology; Stabilometry; Vestibular-spinal reflex	CERVICAL WHIPLASH; BRAIN-INJURY; NECK; SYMPTOMS; AFFERENTS; EXTENSION; VERTIGO	Vertigo and postural instability following whiplash and/or minor head injuries is very frequent. According to some authors, post-whiplash vertigo cannot be caused by real injury to vestibular structures; other authors maintain that vestibular damage is possible even in the case of isolated whiplash, with vascular or post-traumatic involvement. Furthermore, many of the balance disorders reported after trauma can be justified by post-traumatic modification to the cervical proprioceptive input, with consequent damage to the vestibular spinal reflex. The aim of this study was to evaluate the vestibular condition and postural status in a group of patients (Group A, n = 90) affected with balance disorders following whiplash, and in a second group (Group B, n = 20) with balance disorders after minor head injury associated with whiplash. Both groups were submitted to videonystagmography (VNG) and stabilometric investigation (open eyes - OE, closed eyes - CE, closed eyes with head retroflexed - CER) within 15 days of their injuries and repeated within 10 days after conclusion of cervical physiotherapy treatment. The VNG tests revealed vestibulopathy in 19% of cases in Group A (11% peripheral, 5% central, 3% in an undefined site) and in 60% of subjects in Group B (50% peripheral, 10% central). At the follow-up examination, all cases of non-compensated labyrinth deficit showed signs of compensation, while there were two cases (2%) in Group A and one case (5%) in Group B of PPV. As far as the altered posturographic recordings are concerned, while there was no specific pattern in the two groups, they were clearly pathologic, especially during CER. Both in OE and in CE there was an increase in the surface values and in those pertaining to shifting of the gravity centre on the sagittal plane, which was even more evident during CER. In Group A, the pre-post-physiotherapy comparison of CER results showed that there was a statistically significant improvement in the majority of the parameters after treatment. Moreover, in Group B there was frequent lateral shifting of the centre of gravity that was probably linked with the high percentage of labyrinth deficits. The comparison between the first and second stabilometric examinations was statistically significant only in those parameters referring to gravity centre shifting on the frontal plane, which was probably due to the progressive improvement in the associated vestibulopathy rather than to the physiotherapy treatment performed for the cervical damage. Hence, our study confirms that only in a minority of cases can whiplash cause central or peripheral vestibulopathy, and that this is more probable after minor head injury associated with whiplash. In addition, our data confirm that static stabilometry is fundamental for assessing postural deficits following a cervical proprioceptive disorder. In these cases, in fact, analysis of the different parameters and the indices referring to cervical interference not only permits evaluation of altered postural performance, but also detects and quantifies destabilisation activity within the cervical proprioceptive component.	[Nacci, A.; Ferrazzi, M.; Berrettini, S.; Matteucci, J.; Bruschini, L.; Ursino, F.; Fattori, B.] Univ Pisa, ENT Audiol & Phoniatr Unit, Dept Neurosci, I-56124 Pisa, Italy; [Panicucci, E.] Univ Pisa, Dept Expt Pathol, I-56124 Pisa, Italy	Nacci, A (corresponding author), Univ Pisa, ENT Audiol & Phoniatr Unit, Dept Neurosci, Via Paradisa 2, I-56124 Pisa, Italy.	a.nacci@med.unipi.it	Bruschini, Luca/AAM-8656-2020; Nacci, Andrea/AAF-7207-2019	Bruschini, Luca/0000-0002-6900-1306			ABRAHAMS VC, 1975, J NEUROPHYSIOL, V38, P10; Agostini V, 2011, GAIT POSTURE, V34, P248, DOI 10.1016/j.gaitpost.2011.05.008; Armato E, 2002, CONTROLE POSTURAL PA, P105; BAKER J, 1982, BRAIN RES, V252, P151, DOI 10.1016/0006-8993(82)90989-1; BALLA J, 1988, HEADACHE PROBLEMS DI, P249; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Baloh RW, 2001, CLIN NEUROPHYSIOL, P322; Boniver Raymond, 2002, Int Tinnitus J, V8, P129; Bono G, 1995, 12 GIORN IT OT COLP, P21; BOYLE R, 1981, J NEUROPHYSIOL, V45, P852; BRANDT T, 1981, ANN NY ACAD SCI, V374, P636, DOI 10.1111/j.1749-6632.1981.tb30907.x; Burdo S, 2000, SINDROMI OTONEUROLOG, P41; Casani A, 2000, 17 GIORN IT OT 20 GI, P95; Ciancaglini R, 2000, SINDROMI OTONEUROLOG, P31; CLAUSSEN CF, 1995, ACTA OTO-LARYNGOL, P53; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; Dehail P, 2007, J REHABIL MED, V39, P531, DOI 10.2340/16501977-0096; DICHGANS J, 1974, BRAIN RES, V71, P225, DOI 10.1016/0006-8993(74)90964-0; DIERINGER N, 1984, EXP BRAIN RES, V55, P574; Endo K, 2008, SPINE, V33, pE539, DOI 10.1097/BRS.0b013e31817c55fe; Fattori B, 1992, 4 GIORN VEST PRAT DA, P39; Ferrari Robert, 2006, Aust Fam Physician, V35, P367; Fischer AJEM, 1997, CLIN OTOLARYNGOL, V22, P192, DOI 10.1046/j.1365-2273.1997.00031.x; FISCHER AJEM, 1995, ACTA OTO-LARYNGOL, P49; FRIEDMAN D, 1995, AM J ROENTGENOL, V164, P443, DOI 10.2214/ajr.164.2.7839986; Gagey PM, 1986, HUIT LECONS POSTUROL; Garcia R, 1996, CRANIO, V14, P233, DOI 10.1080/08869634.1996.11745973; GAY JR, 1953, JAMA-J AM MED ASSOC, V152, P1698, DOI 10.1001/jama.1953.03690180020006; Ghilardi PL, 2003, VESTIBOLOMETRIA CLIN, P135; Ghilardi PL, 1995, 12 GIORN IT OT COLP, P85; Ghilardi PL, 1989, ATT 76 C NAZ SIO RIE, P383; Giordano C, 2003, AUDIOMETRIA CLIN APP; Giordano C, 1995, 12 GIORN IT OT COLP, P103; GUIDETTI G, 1989, VESTIBULAR COMPENSATION, P145; GUIDETTI G, 1988, Agressologie, V29, P653; Guidetti G, 1996, DIAGNOSI TERAPIA DIS, P381; Guidetti G, 1996, DIAGNOSI TERAPIA DIS, P615; Guidetti G, 1990, DIAGNOSI TRATTAMENTO, P129; Honrubia V, 2001, CLIN NEUROPHYSIOL, P152; JONGKEES L B, 1962, Pract Otorhinolaryngol (Basel), V24, P65; Klobas L, 2004, SWED DENT J, V28, P29; MacNab I, 2002, J BONE JOINT SURG BR, V84, P807; MAGNUSSON T, 1994, CEPHALALGIA, V14, P223, DOI 10.1046/j.1468-2982.1994.014003223.x; Manfrin M, 2008, TRATTATO VESTIBOLOGI, V3, P331; Mira E, 1995, 12 GIORN IT OT COLP, P9; Nomura Y, 1998, EQUILIB RES, V57, P608; NORRE M E, 1987, Acta Oto-Rhino-Laryngologica Belgica, V41, P574; Nuti D, 1992, 12 GIORN IT NIST CLI, P25; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; Palmgren Per J, 2009, Chiropr Osteopat, V17, P6, DOI 10.1186/1746-1340-17-6; PEARCE JMS, 1993, J NEUROL NEUROSUR PS, V56, P1328, DOI 10.1136/jnnp.56.12.1328-a; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; PETERSON BW, 1988, PROG BRAIN RES, V76, P163; Pignataro O, 2000, SINDROMI OTONEUROLOG, P23; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; Richmond F J, 1979, Prog Brain Res, V50, P245; Rowlands RG, 2009, J LARYNGOL OTOL, V123, P182, DOI 10.1017/S0022215108002569; Schuknecht HF, 1969, ARCH OTOLARYNGOL, V90, P113; SINFORIANI E, 1993, CONFIN CEPHALALGICA, V2, P71; Skovron ML, 1998, WHIPLASH INJURIES CU, P61; SPITZER WO, 1995, SPINE, V20, pS1; TEASDALE G, 1974, LANCET, V2, P81; TOGLIA JU, 1976, NEUROLOGY, V26, P808, DOI 10.1212/WNL.26.9.808; Tranter RMD, 2009, J FORENSIC LEG MED, V16, P53, DOI 10.1016/j.jflm.2008.09.001; Yoganandan N, 1999, SPINE, V24, P83, DOI 10.1097/00007632-199901010-00021; Zappal G, 1988, RIABILITAZIONE APPRE, V8, P337	66	19	19	0	15	PACINI EDITORE	PISA	VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY	0392-100X	1827-675X		ACTA OTORHINOLARYNGO	Acta Otorhinolaryngol. Ital.	DEC	2011	31	6					378	389					12	Otorhinolaryngology	Otorhinolaryngology	884GB	WOS:000299691800005	22323849				2021-06-18	
J	Bennett, S; Ward, M; Moreau, K; Fortin, G; King, J; MacKay, M; Plint, A				Bennett, Susan; Ward, Michelle; Moreau, Katherine; Fortin, Gilles; King, Jim; MacKay, Morag; Plint, Amy			Head injury secondary to suspected child maltreatment: Results of a prospective Canadian national surveillance program	CHILD ABUSE & NEGLECT			English	Article						Child maltreatment; Head injury; Surveillance; Abuse; Incidence	SHAKEN-BABY-SYNDROME; TRAUMATIC BRAIN-INJURY; CHANGE KNOWLEDGE; ABUSE	Objective: We sought to determine the incidence, clinical features, and demographic profile of head injury secondary to suspected child maltreatment (abuse or neglect) in Canada to help inform the development and evaluation of prevention programs for abusive head injuries. Methods: From March 1, 2005 to February 28, 2008, an average of 2,545 paediatricians and paediatric subspecialists were surveyed monthly through the established network of the Canadian Paediatric Surveillance Program. We calculated incidence rates using the number of confirmed cases over the product of the duration of the study (3 years) and population estimates by age group. Results: There were 220 confirmed cases of head injury from suspected child maltreatment. The annual incidence rate was 14.1 per 100,000 for children less than 1 year of age and 1.4 per 100,000 for those less than 15 years. Seventy three percent (141) of cases involved infants less than 12 months of age and 52% (100) of cases involved infants less than 6 months of age. Seventy-five percent (165) of cases presented to the emergency room. With regard to outcome, 12% (27) of cases resulted in death and 45% (75) of survivors had neurological sequelae at discharge. Thirty percent (67) of all cases, as well as, 30% (8) of deaths were previously known to child welfare authorities. Conclusion: This study provides an estimate of the rate of head injury secondary to suspected child maltreatment in Canada. The young age and poor medical outcomes of those involved highlights the need for prevention efforts that are implemented early in life. Given that a significant percentage of injured infants and children were already known to child welfare authorities, the study also highlights the need to establish and evaluate additional preventive efforts for parents and caregivers already in the child welfare system. (C) 2011 Elsevier Ltd. All rights reserved.	[Bennett, Susan] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Psychiat, Ottawa, ON K1H 8L1, Canada; [Bennett, Susan; Ward, Michelle; King, Jim; Plint, Amy] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON K1H 8L1, Canada; [Moreau, Katherine] Childrens Hosp Eastern Ontario, Clin Res Unit, Res Inst, Ottawa, ON K1H 8L1, Canada; [Fortin, Gilles] Univ Montreal, Dept Pediat Neurol, Montreal, PQ H3C 3J7, Canada; [MacKay, Morag] European Child Safety Alliance, Birmingham B15 1RP, W Midlands, England	Bennett, S (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Psychiat, Ottawa, ON K1H 8L1, Canada.		Plint, Amy/AAE-2250-2020				Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2008, AM J PREV MED, V34, pS106, DOI 10.1016/j.amepre.2008.01.021; Barr RG, 2009, CAN MED ASSOC J, V180, P727, DOI 10.1503/cmaj.081419; Barr RG, 2009, PEDIATRICS, V123, P972, DOI 10.1542/peds.2008-0908; Dias Mark S, 2005, Pediatrics, V115, pe470, DOI 10.1542/peds.2004-1896; Fanconi M, 2010, EUR J PEDIATR, V169, P1023, DOI 10.1007/s00431-010-1175-x; Flaherty EG, 2008, PEDIATRICS, V122, P611, DOI 10.1542/peds.2007-2311; Goulet C, 2009, JOGNN-J OBST GYN NEO, V38, P7, DOI 10.1111/j.1552-6909.2008.00301.x; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kelly P, 2008, J PAEDIATR CHILD H, V44, P99, DOI 10.1111/j.1440-1754.2007.01234.x; King WJ, 2003, CAN MED ASSOC J, V168, P155; Public Health Agency of Canada, 2010, CAN INC STUD REP CHI; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; REECE RM, 2003, INFLICTED CHILDHOOD; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; *STAT CAN, 2003, CAN SOC INF MAN SYST; Tolliday F., 2010, COMMUNITIES CHILDREN, V5, P31	21	19	19	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	NOV	2011	35	11					930	936		10.1016/j.chiabu.2011.05.018			7	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	859XV	WOS:000297910000004	22099143				2021-06-18	
J	Cameron, RP; Mona, LR; Syme, ML; Cordes, CC; Fraley, SS; Chen, SS; Klein, LS; Welsh, E; Smith, K; Lemos, L				Cameron, Rebecca P.; Mona, Linda R.; Syme, Maggie L.; Cordes, Colleen Clemency; Fraley, Sarah S.; Chen, Suzie S.; Klein, Leslie S.; Welsh, Elizabeth; Smith, Kimberly; Lemos, Larry			Sexuality Among Wounded Veterans of Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND): Implications for Rehabilitation Psychologists	REHABILITATION PSYCHOLOGY			English	Article						sex; veterans; disability; PTSD; TBI	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE-PROCESSING THERAPY; COMBAT VETERANS; MILITARY SERVICE; HEALTH; WOMEN; SCALE; PEOPLE; DYSFUNCTION	Objective: The sexual lives of returning Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) veterans have only been discussed minimally in the psychological literature. Given the nature of military social and cultural contexts, the potential for exposure to combat-related stressors that may lead to posttraumatic stress disorder (PTSD), and the risk of traumatic brain injury secondary to physical injury, the potential for significant psychological and relational ramifications exists. This article focuses on the intimate relationships and sexuality of returning OIF/OEF/OND veterans within the context of their personal cultural variables and the diverse experience of being a part of military life. Conclusions: Culturally competent assessment and evidenced-based treatment approaches are highlighted to offer clinicians initial strategies to begin treatment of sexuality issues within the returning Veteran population. These clinical tools are discussed within a positive psychology approach that emphasizes healthy sexuality as a part of overall satisfactory quality of life.	[Cameron, Rebecca P.] Calif State Univ Sacramento, Dept Psychol, Sacramento, CA 95819 USA; [Fraley, Sarah S.] VA Long Beach Healthcare Syst, Behav Hlth, Long Beach, CA USA; [Syme, Maggie L.] SDSU UCSD Canc Ctr Comprehens Partnership, San Diego, CA USA; [Cordes, Colleen Clemency] Arizona State Univ, Nicholas A Cummings Behav Hlth Program, Tempe, AZ 85287 USA; [Chen, Suzie S.] VA Long Beach Healthcare Syst, Spinal Cord Injury Disorders Serv, Long Beach, CA USA; [Klein, Leslie S.] Gallaudet Univ, Dept Psychol, Washington, DC 20002 USA; [Welsh, Elizabeth] VA Los Angeles Ambulatory Care Ctr, Los Angeles, CA USA; [Smith, Kimberly] Pepperdine Univ, Grad Sch Educ & Psychol, Malibu, CA USA; [Lemos, Larry] VA Long Beach Healthcare Syst, Geriatr & Extended Care, Long Beach, CA USA	Cameron, RP (corresponding author), Calif State Univ Sacramento, Dept Psychol, 6000 J St, Sacramento, CA 95819 USA.	Cameron@csus.edu		Syme, Maggie/0000-0003-3260-5568; Brindle, Sarah/0000-0002-7529-394X			Allen ES, 2010, J FAM PSYCHOL, V24, P280, DOI 10.1037/a0019405; Aloni R., 2003, SEXUAL DIFFICULTIES; Apa Pesidential Task Force, 2006, AM PSYCHOL, V61, P271, DOI 10.1037/0003-066X.61.4.271; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V78, P711, DOI 10.1210/jc.78.3.711; BARLOW DH, 1986, J CONSULT CLIN PSYCH, V54, P140, DOI 10.1037/0022-006X.54.2.140; Becker CB, 2001, COGN BEHAV PRACT, V8, P107, DOI 10.1016/S1077-7229(01)80017-1; Belfield T, 2007, J ROY SOC MED, V100, P499, DOI 10.1258/jrsm.100.11.499; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Bormann JE, 2008, J HOLIST NURS, V26, P109, DOI 10.1177/0898010107311276; Bowling KL, 2005, ARMED FORCES SOC, V31, P411, DOI 10.1177/0095327X0503100305; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Brown D., 2008, BAN SEX SOLDIERS AFG; Calhoun PS, 2002, J TRAUMA STRESS, V15, P205, DOI 10.1023/A:1015251210928; Chambless DL, 2001, ANNU REV PSYCHOL, V52, P685, DOI 10.1146/annurev.psych.52.1.685; Chance RS, 2002, J PSYCHOL THEOL, V30, P195; Cook JM, 2004, J FAM PSYCHOL, V18, P36, DOI 10.1037/0893-3200.18.1.36; Cooper TV, 2008, AM J HEALTH PROMOT, V22, P164, DOI 10.4278/ajhp.22.3.164; Cosgrove DJ, 2002, UROLOGY, V60, P881, DOI 10.1016/S0090-4295(02)01899-X; Csoka A, 2008, J SEX MED, V5, P2977, DOI 10.1111/j.1743-6109.2008.01073.x; Cukor J, 2009, CLIN PSYCHOL REV, V29, P715, DOI 10.1016/j.cpr.2009.09.001; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Davis L., 1990, COURAGE HEAL WORKBOO; Department of Veterans Affairs, 2004, IR WAR CLIN GUID; Department of Veterans Affairs, 2009, MIL HLTH HIST POCK C; DeRogatis L, 2008, J SEX MED, V5, P357, DOI 10.1111/j.1743-6109.2007.00672.x; Dialmy A, 2010, EUR J CONTRACEP REPR, V15, P160, DOI 10.3109/13625181003793339; Duke MR, 2008, QUAL HEALTH RES, V18, P244, DOI 10.1177/1049732307312305; Erbes CR, 2008, J CLIN PSYCHOL, V64, P972, DOI 10.1002/jclp.20521; Ferguson Cynthia T, 2008, J Forensic Nurs, V4, P190; Fraley SS., 2007, SEXUALITY RES SOCIAL, V4, P15, DOI [10.1525/srsp.2007.4.1.15, DOI 10.1525/SRSP.2007.4.1.15]; Galovski T, 2004, AGGRESS VIOLENT BEH, V9, P477, DOI 10.1016/S1359-1789(03)00045-4; Gates G. J., 2010, LESBIAN GAY BISEXUAL; Gates R. M., 2010, MEMORANDUM COMMANDER; Gill C. J., 1991, RES URBAN PLANNING A; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Gosling J, 1999, BRAIN INJURY, V13, P785; Guldin A, 2000, SEX DISABIL, V18, P233, DOI 10.1023/A:1005690009575; Hanna W. J., 1991, DISABILITY HANDICAP, V6, P49, DOI DOI 10.1080/02674649166780041; Harrington Ellen F, 2006, Cultur Divers Ethnic Minor Psychol, V12, P212, DOI 10.1037/1099-9809.12.2.212; Harrison D, 2006, SOCIOL REV, V54, P546, DOI 10.1111/j.1467-954X.2006.00629.x; Hays P. A., 2008, ADDRESSING CULTURAL, DOI [10.1037/11650-000, DOI 10.1037/11650-000]; Henry N, 2004, AGGRESS VIOLENT BEH, V9, P535, DOI 10.1016/S1359-1789(03)00048-X; Hepburn C., 1988, ALIVE WELL; Hibbard Buffington AL, 1996, J APPL REHABILITATIO, V27, P45; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Howard MD, 2007, SEX ADDICT COMPULS, V14, P77, DOI 10.1080/10720160701310443; Hoyt T, 2011, J TRAUMA DISSOCIATIO, V12, P244, DOI 10.1080/15299732.2011.542612; HUDSON WW, 1981, J SEX RES, V17, P157, DOI 10.1080/00224498109551110; Hunter C. L., 2009, INTEGRATED BEHAV HLT, DOI [10.1037/11871-000, DOI 10.1037/11871-000]; Hutchinson JW, 2008, MIL MED, V173, P1164, DOI 10.7205/MILMED.173.12.1164; Hyun J, 2009, PTSD RES Q, V20, P1; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kane T, 2006, WHO ARE RECRUITS DEM; Kang H, 2005, ANN EPIDEMIOL, V15, P191, DOI 10.1016/j.annepidem.2004.05.009; KAUFMAN M., 2003, ULTIMATE GUIDE SEX D; Kennedy CH, 2011, LIVING AND SURVIVING IN HARMS WAY: A PSYCHOLOGICAL TREATMENT HANDBOOK FOR PRE- AND POST-DEPLOYMENT OF MILITARY PERSONNEL, P67; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Knapp DE, 2008, EMPLOY RESPONSIB RIG, V20, P227, DOI 10.1007/s10672-008-9089-8; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Lessing J., 1984, LESBIAN SEX, P151; Letourneau EJ, 1997, J TRAUMA STRESS, V10, P125, DOI 10.1023/A:1024868632543; Linehan MM., 1993, COGNITIVE BEHAV TREA; Litz BT, 2002, AUST NZ J PSYCHIAT, V36, P198, DOI 10.1046/j.1440-1614.2002.01002.x; Maguen S, 2005, COGN BEHAV PRACT, V12, P479, DOI 10.1016/S1077-7229(05)80075-6; Martin L, 2000, BEHAV MED, V26, P23, DOI 10.1080/08964280009595750; McFarlane A.C., 2001, SEX RELATSH THER, V16, P261, DOI [10.1080/14681990124457, DOI 10.1080/14681990124457]; McGahuey CA, 2000, J SEX MARITAL THER, V26, P25, DOI 10.1080/009262300278623; Mercer B, 2008, J CLIN NURS, V17, P341, DOI 10.1111/j.1365-2702.2008.02582.x; Meyers S. L., 2009, NY TIMES; Military Acceptance Project, FREQ ASK QUEST; Miller W. R., 1979, J SEX MARITAL THER, P5282; Mills B., 2004, SEX RELATSH THER, V19, P265, DOI [DOI 10.1080/14681990410001715418, 10.1080/14681990410001715418]; Mohamed S, 2008, J CLIN PSYCHIAT, V69, P959, DOI 10.4088/JCP.v69n0611; Mona L. R., 2011, IMPLEMENTING CBT OLD, P263; Mona LR, 2010, HANDBOOK OF ASSESSMENT IN CLINICAL GERONTOLOGY, 2ND EDITION, P331, DOI 10.1016/B978-0-12-374961-1.10013-2; Mona LR, 2003, WOMEN THER, V26, P211, DOI 10.1300/J015v26n03_03; Monson CM, 2008, J CLIN PSYCHOL, V64, P958, DOI 10.1002/jclp.20511; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Monson CM, 2009, CLIN PSYCHOL REV, V29, P707, DOI 10.1016/j.cpr.2009.09.002; Moradi B, 2009, MIL PSYCHOL, V21, P513, DOI 10.1080/08995600903206453; Murdoch M, 2009, MIL MED, V174, P1100, DOI 10.7205/MILMED-D-04-2308; National Center for Posttraumatic Stress Disorder, 2007, TRAUM BRAIN INJ PTSD; National Defense Research Institute, 2010, SEX OR US MIL PERS P; National Institute of Disability and Rehabilitation Research, 1999, NIDRR LONG RANG PLAN; Nunnink SE, 2010, MIL MED, V175, P424, DOI 10.7205/MILMED-D-09-00085; O'Brien C, 2008, J NERV MENT DIS, V196, P252, DOI 10.1097/NMD.0b013e318166397d; Oddy M, 2001, SEX RELATSH THER, V16, P247, DOI [10.1080/14681990125256, DOI 10.1080/14681990125256]; Olkin R., 1999, WHAT PSYCHOTHERAPIST; Orsillo SM, 2005, BEHAV MODIF, V29, P95, DOI 10.1177/0145445504270876; PRICE JL, 2007, PARTNERS VETERANS PT; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Rowe EL, 2009, MIL PSYCHOL, V21, P387, DOI 10.1080/08995600902914768; Rubio-Aurioles E, 2009, J SEX MED, V6, P2255, DOI 10.1111/j.1743-6109.2009.01348.x; Santelli J, 2006, J ADOLESCENT HEALTH, V38, P72, DOI 10.1016/j.jadohealth.2005.10.006; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Schnurr PP, 2010, EPIDEMIOLOGY PTSD; Schnurr PP, 2008, PTSD RES QTLY, V19, P1; Shafer MA, 2002, MIL MED, V167, P496; Shawver L., 1995, FLAG WAS STILL THERE; Sherman MD, 2005, PROF PSYCHOL-RES PR, V36, P626, DOI 10.1037/0735-7028.36.6.626; Sinclair GD, 2009, J HOMOSEXUAL, V56, P701, DOI 10.1080/00918360903054137; Solomon Z, 2008, J FAM PSYCHOL, V22, P659, DOI 10.1037/a0013596; Spivak B, 2003, NEUROPSYCHOBIOLOGY, V47, P57, DOI 10.1159/000070009; Street AE, 2008, J REHABIL RES DEV, V45, P409, DOI 10.1682/JRRD.2007.06.0088; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tsimtsiou Z, 2006, J SEX MED, V3, P583, DOI 10.1111/j.1743-6109.2006.00271.x; Turchik JA, 2010, AGGRESS VIOLENT BEH, V15, P267, DOI 10.1016/j.avb.2010.01.005; Turna B, 2005, INT J IMPOT RES, V17, P148, DOI 10.1038/sj.ijir.3901294; United States Census, 2010, STAT ABSTR US 2010; Uomoto JM, 2009, REHABIL PSYCHOL, V54, P259, DOI 10.1037/a0016907; VA/DoD Clinical Practice Guideline Working Group, 2010, MAN POSTTR STRESS; VA/DoD Management of Concussion/mTBI Working Group, 2009, MAN CONC MILD TRAUM; von Sadovszky V, 2008, WOMEN HEALTH ISS, V18, P174, DOI 10.1016/j.whi.2008.01.004; von Sadovszky V, 2007, JOGNN-J OBST GYN NEO, V36, P348, DOI 10.1111/J.1552-6909.2007.00153.x; Weber J. P., 2000, MIL MED, V165, P297; Weber JP, 2000, MIL MED, V165, pIII; Whitehead T. L., 1993, Journal of Burn Care and Rehabilitation, V14, P221, DOI 10.1097/00004630-199303000-00018; Yaeger D, 2006, J GEN INTERN MED, V21, pS65, DOI 10.1111/j.1525-1497.2006.00377.x; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004; Zeiss A. M., 1999, HDB ASSESSMENT CLIN, P270	126	19	19	0	21	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2011	56	4					289	301		10.1037/a0025513			13	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	862AQ	WOS:000298062600003	22121937				2021-06-18	
J	Meares, S; Shores, EA; Taylor, AJ; Lammel, A; Batchelor, J				Meares, Susanne; Shores, E. Arthur; Taylor, Alan J.; Lammel, Andrea; Batchelor, Jennifer			Validation of the Abbreviated Westmead Post-traumatic Amnesia Scale: A brief measure to identify acute cognitive impairment in mild traumatic brain injury	BRAIN INJURY			English	Article						Glasgow Coma Scale; mild traumatic brain injury; post-traumatic amnesia; PTA; Westmead Post-Traumatic Amnesia Scale	GLASGOW COMA SCALE; HEAD-INJURY; EMERGENCY-DEPARTMENT; UNITED-STATES; PTA SCALE; MEMORY; ANALGESIA; ACCURACY; RECOVERY	Objective: To validate the use of the Abbreviated Westmead Post-traumatic Amnesia Scale (A-WPTAS) in the assessment of acute cognitive impairment in mild traumatic brain injury (mTBI). Methods: Data previously collected from 82 mTBI and 88 control participants using the Revised Westmead Post-traumatic Amnesia Scale (R-WPTAS) was converted to A-WPTAS scores and pass/fail classifications were calculated for both scales. Results: The proportion of failures on the R-WPTAS and the A-WPTAS did not differ and a similar number of mTBIs were classified on each. For mTBIs the relationship between the independent memory test and a pass/fail classification was the same for both scales. Bivariate logistic regressions revealed that mTBIs, relative to controls, were around 8 times more likely to fail the assessment (R-WPTAS: 95%% CI: 3.70-18.87; A-WPTAS: 95%% CI: 3.70-20.14). As verbal learning improved the likelihood of failure was reduced. Greater education was associated with a decreased likelihood of failure. The relationship between education and a fail performance was not sustained when education was adjusted for the effect of age, prior mTBI, blood alcohol level, injury status, verbal learning, and morphine administration. Conclusions: The A-WPTAS is a valid measure. The A-WPTAS may reduce the risk of failing to classify patients with mTBI by identifying and documenting acute cognitive impairment.	[Meares, Susanne; Shores, E. Arthur; Taylor, Alan J.; Lammel, Andrea; Batchelor, Jennifer] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia	Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	arthur.shores@mq.edu.au		Shores, Edwin A/0000-0003-1553-5131; Meares, Susanne/0000-0002-3859-9974; Batchelor, Jennifer/0000-0003-4438-4993	Motor Accidents Authority of New South Wales [04/239]; Macquarie University, Sydney, Australia [A006079]	This study was funded by the Motor Accidents Authority of New South Wales (Grant Ref: 04/239) and a Collaborative Research Grant from Macquarie University, Sydney, Australia (Grant Ref: A006079).	Andriessen TMJC, 2009, BRAIN INJURY, V23, P345, DOI 10.1080/02699050902791414; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dawson KS, 2007, BRAIN INJURY, V21, P943, DOI 10.1080/02699050701553171; De Guise E, BRAIN INJURY, V19, P1087; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kemp S, 2010, J NEUROPSYCHOL, V4, P231, DOI 10.1348/174866409X482614; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; McCarter RJ, 2007, BRAIN INJURY, V21, P1393, DOI 10.1080/02699050701793793; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reed D, 2007, ADULT TRAUMA CLIN PR; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Shores EA, 2008, GLASGOW COMA SCALE G; Sosin DM, 1996, BRAIN INJURY, V10, P47; Symonds CP, 1943, LANCET, V1, P7; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198	40	19	19	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2011	25	12					1198	1205		10.3109/02699052.2011.608213			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	829WF	WOS:000295615200006	21902551				2021-06-18	
J	Ross, KA; McMillan, T; Kelly, T; Sumpter, R; Dorris, L				Ross, Kimberley A.; McMillan, Tom; Kelly, Tom; Sumpter, Ruth; Dorris, Liam			Friendship, loneliness and psychosocial functioning in children with traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; paediatric; social; friendship	CLOSED-HEAD-INJURY; DIFFICULTIES QUESTIONNAIRE; ADOLESCENTS; STRENGTHS; QUALITY	Objective: This study compares friendship quality, rates of loneliness and general psychosocial functioning in children who have sustained a traumatic brain injury (TBI) with non-injured controls. Methods: A between-subjects design with 14 participants in the TBI group and 14 in the non-injured control group, aged between 7-13 years and matched for age, gender, receptive vocabulary and socio-economic status. Children completed measures of receptive vocabulary (BPVS II), friendship quality (FQQ-R) and loneliness (LSDS). The main caregiver was asked to assess social skills and social withdrawal (PIC-2) and general psychosocial and behavioural functioning (SDQ). Results: Significant differences were not found on measures completed by children or on the PIC-2. On the SDQ, total difficulties were rated as much greater by caregivers in the TBI group (z == -2.6, p == 0.009) and these were mainly associated with sub-scales relating to emotional problems and hyperactivity. Conclusions: Whilst evidence for friendship problems was not found in children with TBI, evidence for emotional and behavioural difficulties that may lead to social vulnerabilities later in life were found. This indicates a need for prospective longitudinal research to explore the complex relationship between TBI and poorer social outcomes that may not become evident until adolescence.	[Dorris, Liam] Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland; [Ross, Kimberley A.; McMillan, Tom; Sumpter, Ruth; Dorris, Liam] Univ Glasgow, Acad Unit Mental Hlth & Wellbeing, Gartnavel Royal Hosp, Glasgow, Lanark, Scotland; [Kelly, Tom] Royal Victoria Infirm, Dept Neuropsychol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Dorris, L (corresponding author), Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland.	liamdorris@gmail.com	Dorris, Liam/AAK-2273-2021	Dorris, Liam/0000-0002-9502-3154	NHS Education Scotland	This research was part funded by NHS Education Scotland.	Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Asher S.R., 1990, PEER REJECTION CHILD; ASHER SR, 1985, J CONSULT CLIN PSYCH, V53, P500, DOI 10.1037/0022-006X.53.4.500; Biggs BK, 2010, ANXIETY STRESS COPIN, V23, P431, DOI 10.1080/10615800903406543; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Communities and Local Government, 2007, IND DEPR; Dunn L.M., 1997, BRIT PICTURE VOCABUL; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FONAGY P, 1997, BRIT J DEV PSYCHOL, V15, P56; Gauvin-Lepage J, 2010, BRAIN INJURY, V24, P1087, DOI 10.3109/02699052.2010.494593; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; HAPPE F, 1995, CHILD DEV, V60, P843; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; LACHAR D, 2004, INSTRUMENTS CHILDREN, V2, P141; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; PARKER JG, 1993, DEV PSYCHOL, V29, P611, DOI 10.1037/0012-1649.29.4.611; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Rosenthal R., 1991, META ANAL PROCEDURES, V1st; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; *SCOTT EX NAT STAT, 2009, SCOTT IND MULT DEPR; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; WINDSOR J, 1995, LANGUAGE INTERVENTIO, P213; Wirt RD, 1990, MULTIDIMENSIONAL DES	34	19	19	0	15	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2011	25	12					1206	1211		10.3109/02699052.2011.609519			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	829WF	WOS:000295615200007	21961568				2021-06-18	
J	van Pelt, ED; de Kloet, A; Hilberink, SR; Lambregts, SAM; Peeters, E; Roebroeck, ME; Catsman-Berrevoets, CE				van Pelt, E. Danielle; de Kloet, Arend; Hilberink, Sander R.; Lambregts, Susanne A. M.; Peeters, Els; Roebroeck, Marije E.; Catsman-Berrevoets, Coriene E.			The incidence of traumatic brain injury in young people in the catchment area of the University Hospital Rotterdam, The Netherlands	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						Brain injury; Trauma; Children; Adolescents; Incidence; Netherlands	GLASGOW COMA SCALE; MINOR HEAD TRAUMA; CHILDREN; EPIDEMIOLOGY; ADOLESCENTS	Background: Traumatic brain injuiy (TBI) is in the developed countries the most common cause of death and disability in childhood. Aim: The purpose of this study is to estimate the incidence of TBI for children and young people in an urbanised region of the Netherlands and to describe relevant characteristics of this group. Methods: Patients, aged 1 month - 24 years who presented with traumatic brain injury at the Erasmus University Hospital (including the Sophia Children's Hospital) in 2007 and 2008 were included in a retrospective study. Data were collected by means of diagnosis codes and search terms for TBI in patient records. The incidence of TBI in the different referral areas of the hospital for standard, specialised and intensive patient care was estimated. Results: 472 patients met the inclusion criteria. The severity of the Injury was classified as mild in 342 patients, moderate in 50 patients and severe in 80 patients. The total incidence of traumatic brain injury in the referral area of the Erasmus University Hospital was estimated at 113.9 young people per 100.000. The incidence for mild traumatic brain injury was estimated at 104.4 young people, for moderate 6.1 and for severe 3.4 young people per 100.000. Conclusion: The ratio for mild, moderate and severe traumatic brain injury in children and young people was 33.7-1.8-1.In the mild TBI group almost 17% of the patients reported sequelae. The finding that 42% of them had a normal brain CT scan at admission underwrites the necessity of careful follow up of children and young people with mild TBI. (C) 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[van Pelt, E. Danielle; Catsman-Berrevoets, Coriene E.] Erasmus Univ Hosp, Sophia Childrens Hosp, Dept Paediat Neurol, NL-3015 GJ Rotterdam, Netherlands; [de Kloet, Arend] Sophia Rehabil & Hague Univ, The Hague, Netherlands; [Hilberink, Sander R.; Lambregts, Susanne A. M.; Roebroeck, Marije E.] Erasmus Univ Hosp, Dept Rehabil Med & Physiotherapy, Rotterdam, Netherlands; [Peeters, Els] Haga Hosp, The Hague, Netherlands; [Peeters, Els] Med Ctr Haaglanden, Dept Neurol, The Hague, Netherlands	Catsman-Berrevoets, CE (corresponding author), Erasmus Univ Hosp, Sophia Childrens Hosp, Dept Paediat Neurol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.	c.catsman@erasmusmc.nl					Aarsen FK, 2006, CANCER-AM CANCER SOC, V106, P396, DOI 10.1002/cncr.21612; Cnossen MH, 2010, DEV MED CHILD NEUROL, V52, P394, DOI 10.1111/j.1469-8749.2009.03580.x; Curtain RP, 2006, PEDIATR NEUROL, V34, P329, DOI 10.1016/j.pediatrneurol.2005.08.033; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Dunning J, 2004, ARCH DIS CHILD, V89, P763, DOI 10.1136/adc.2003.042523; Dutch Healthcare Authority, 2010, DUTCH HEALTHC AUTH; Dutch Society of Neurology, 2010, GUID ASS TREATM PAT; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Erasmus University Medical Centre Rotterdam, 2007, ER U MED CTR ROTT AN; Gillett J, 2004, NEUROREHABILITATION, V19, P207; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Johnston MV, 2003, EUR J PAEDIATR NEURO, V7, P105, DOI 10.1016/S1090-3798(03)00039-4; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; McDougall J, 2006, BRAIN INJURY, V20, P1189, DOI 10.1080/02699050600975541; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Statistics Netherlands, 2010, POP BAS FIG; TEASDALE G, 1974, LANCET, V2, P81; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Ventsel G, 2008, NEUROEPIDEMIOLOGY, V30, P20, DOI 10.1159/000113302; Vermunt LCAC, 2009, BRIT J CLIN PSYCHOL, V48, P195, DOI 10.1348/014466508X391094; YOSHIDA M, 1979, SURG NEUROL, V12, P115	36	19	19	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	NOV	2011	15	6					519	526		10.1016/j.ejpn.2011.05.005			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	862YB	WOS:000298128900008	21855375				2021-06-18	
J	Yu, GX; Dymond, M; Yuan, LS; Chaturvedi, LS; Shiratsuchi, H; Durairaj, S; Marsh, HM; Basson, MD				Yu, Guangxiang; Dymond, Michael; Yuan, Lisi; Chaturvedi, Lakshmi S.; Shiratsuchi, Hiroe; Durairaj, Srinivasan; Marsh, H. Michael; Basson, Marc D.			Propofol's effects on phagocytosis, proliferation, nitrate production, and cytokine secretion in pressure-stimulated microglial cells	SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; INTESTINAL EPITHELIAL-CELLS; SEVERE HEAD-INJURY; EXTRACELLULAR PRESSURE; MACROPHAGE PHAGOCYTOSIS; REPETITIVE DEFORMATION; INTRACRANIAL-PRESSURE; NERVOUS-SYSTEM; NITRIC-OXIDE; RAT-BRAIN	Background. Intracranial hypertension complicates severe traumatic brain injury frequently and might be associated with poor outcomes. Traumatic brain injury induces a neuroinflammatory response by microglial activation and upregulation of proinflammatory cytokines, such as interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6. To elucidate the effect of increased intracranial pressure on microglial function, we studied the effects of increased extracellular pressure on primary human. microglial cell phagocytosis, proliferation, cytokine secretion, and total nitrate production. In addition, because many patients receive propofol during anesthesia or intensive care unit sedation, we evaluated whether propofol alters the effects of pressure. Methods. Human microglial cells were pretreated with (2.5-20 mu g/mL) propofol or Intralipid as a vehicle control were incubated at ambient atmospheric pressure or at 15 or 30 mm fig increased pressure far 2 h for phagocytosis assays or 24 h for proliferation, cytokine secretion, and total nitrate production studies. Phagocytosis was determined by incorporation of intracellular fluorescent latex beads. Tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 were assayed by sandwich enzyme-linked immunosorbent assay and total nitrate by Greiss reagent. Results. Increased extracellular pressure stimulated phagocytosis versus untreated microglial cells or cells treated with an Intralipid vehicle control. Propofol also stimulated microglial phagocytosis at ambient pressure. Increased pressure, however; decreased phagocytosis in the presence of propofol. Pressure also increased microglial tumor necrosis factor-alpha and interleukin-1 beta secretion and propofol pretreatment blocked the pressure-stimulated effect. Interleukin-6 production was not altered either by pressure or by propofol. Pressure also induced total nitrate secretion, and propofol pretreatment decreased basal as well as pressure-induced microglial nitrate production. Conclusion. Extracellular pressures consistent with increased intracranial pressure after a head injury activate inflammatory signals in human primary microglial cells in vitro, stimulating phagocytosis, proliferation, tumor necrosis factor-alpha, interleukin-1 beta, and total nitrate secretion but not affecting interleukin-6. Such inflammatory) events may contribute to the worsened prognosis of traumatic brain injury after increased intracranial pressure. Because propofol alleviated these potentially proinflammatory effects, these results suggest that the inflammatory cascade activated by intracranial pressure might be targeted by propofol in patients with increased intracranial pressure after traumatic brain injury. (Surgery 2011;150:887-96.)	[Basson, Marc D.] Michigan State Univ, Coll Human Med, Dept Surg, Lansing, MI 48912 USA; [Yu, Guangxiang; Dymond, Michael; Chaturvedi, Lakshmi S.; Marsh, H. Michael; Basson, Marc D.] Wayne State Univ, Dept Anesthesiol, Detroit, MI USA; [Dymond, Michael; Chaturvedi, Lakshmi S.; Shiratsuchi, Hiroe; Marsh, H. Michael; Basson, Marc D.] John D Dingell VA Med Ctr, Detroit, MI USA	Basson, MD (corresponding author), Michigan State Univ, Coll Human Med, Dept Surg, 1200 E Michigan Ave,Suite 655, Lansing, MI 48912 USA.	marc.basson@hc.msu.edu	Yuan, Lisi/G-1615-2013; /AAL-3363-2020		NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK060771-09, R01 DK060771] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK060771] Funding Source: NIH RePORTER		Abdul-Sater AA, 2009, J BIOL CHEM, V284, P26789, DOI 10.1074/jbc.M109.026823; Basson MD, 2000, J CELL BIOCHEM, V78, P47, DOI 10.1002/(SICI)1097-4644(20000701)78:1<47::AID-JCB5>3.0.CO;2-M; Bhalla S, 2009, AM J SURG, V198, P611, DOI 10.1016/j.amjsurg.2009.07.006; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Chaturvedi LS, 2007, J BIOL CHEM, V282, P14, DOI 10.1074/jbc.M605817200; Chen RM, 2005, ANN NY ACAD SCI, V1042, P262, DOI 10.1196/annals.1338.030; Chen RM, 2003, ANESTHESIOLOGY, V98, P1178, DOI 10.1097/00000542-200305000-00021; Chiu WT, 2009, CHEM-BIOL INTERACT, V181, P430, DOI 10.1016/j.cbi.2009.06.011; Craig DH, 2008, CELL MOL BIOL LETT, V13, P260, DOI 10.2478/s11658-007-0054-6; Craig DH, 2007, AM J SURG, V194, P618, DOI 10.1016/j.amjsurg.2007.08.001; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Engdahl O, 1998, BRIT J ANAESTH, V81, P957; Farber K, 2006, PFLUG ARCH EUR J PHY, V452, P615, DOI 10.1007/s00424-006-0064-7; Flanigan TL, 2008, AM J SURG, V196, P683, DOI 10.1016/j.amjsurg.2008.07.016; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Hall NG, 2006, AM J RESP CELL MOL, V34, P719, DOI 10.1165/rcmb.2005-0463OC; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Honsho S, 2009, CIRC RES, V105, P1149, DOI 10.1161/CIRCRESAHA.109.208199; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Lee CJ, 2010, SHOCK, V33, P93, DOI 10.1097/SHK.0b013e3181a6eaf5; Luo D, 2009, BIOCH BIOPH IN PRESS; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mattana J, 1996, PATHOBIOLOGY, V64, P40, DOI 10.1159/000164004; Mikawa K, 1998, ANESTH ANALG, V87, P695, DOI 10.1097/00000539-199809000-00039; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nagai A, 2001, NEUROBIOL DIS, V8, P1057, DOI 10.1006/nbdi.2001.0437; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Pugin J, 1998, AM J PHYSIOL-LUNG C, V275, pL1040; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Shiratsuch H, 2005, AM J SURG, V190, P757, DOI 10.1016/j.amjsurg.2005.07.016; Shiratsuchi H, 2005, AM J PHYSIOL-CELL PH, V288, pC1083, DOI 10.1152/ajpcell.00543.2004; Shiratsuchi H, 2004, AM J PHYSIOL-CELL PH, V286, pC1358, DOI 10.1152/ajpcell.00553.2003; Shiratsuchi H, 2007, J CELL BIOCHEM, V102, P353, DOI 10.1002/jcb.21295; Shiratsuchi H, 2009, AM J PHYSIOL-CELL PH, V296, pC1400, DOI 10.1152/ajpcell.00345.2008; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SHYR MH, 1995, NEUROSCI LETT, V184, P212, DOI 10.1016/0304-3940(94)11209-2; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; Terpolilli NA, 2009, J NEUROTRAUM, V26, P1963, DOI 10.1089/neu.2008.0853; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Tomkins O, 2011, CARDIOVASC PSYCHIAT, V2011; VASS K, 1993, LAB INVEST, V69, P275; Vouyouka AG, 2004, SURGERY, V136, P282, DOI 10.1016/j.surg.2004.04.033; Walsh MF, 2004, CELL PROLIFERAT, V37, P427, DOI 10.1111/j.1365-2184.2004.00324.x; WHITTEMORE ER, 1993, BRAIN RES, V621, P59, DOI 10.1016/0006-8993(93)90297-Z; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Wu GJ, 2009, CHEM-BIOL INTERACT, V180, P465, DOI 10.1016/j.cbi.2009.05.003	60	19	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2011	150	5					887	896		10.1016/j.surg.2011.04.002			10	Surgery	Surgery	845NC	WOS:000296828600002	21676422	Green Accepted			2021-06-18	
J	FitzGerald, DB; Crosson, BA				FitzGerald, David B.; Crosson, Bruce A.			Diffusion weighted imaging and neuropsychological correlates in adults with mild traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Diffusion tensor imaging; Mild traumatic brain injury; Neuropsychological testing; Neurophysiological testing	COMMON DATA ELEMENTS; WHITE-MATTER INJURY; AXONAL INJURY; ABNORMALITIES; DYSFUNCTION; INTEGRITY	Diffusion Tensor Imaging (DTI) is increasingly being used as a research tool in mild Traumatic Brain Injury (mTBI). This article reviews the concepts of diffusion tensor imaging, neuropsychological testing and results to date when applied to mTBI in adults. DTI is being used in conjunction with neuropsychological and electrophysiological measures to provide improved structural/functional correlations of mTBI. Future directions and applications of DTI in mTBI research are suggested. Published by Elsevier B.V.	[FitzGerald, David B.] N Florida S Georgia Vet Hlth Syst, Neurol Serv 127, Gainesville, FL 32608 USA; [FitzGerald, David B.; Crosson, Bruce A.] Brain Rehabil Res Ctr, Rehabil Res & Dev Serv RR&D, Off Res & Dev, Dept Vet Affairs, Gainesville, FL USA; [FitzGerald, David B.] Univ Florida, Dept Neurol, Gainesville, FL 32610 USA; [Crosson, Bruce A.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA	FitzGerald, DB (corresponding author), N Florida S Georgia Vet Hlth Syst, Neurol Serv 127, 1601 SW Archer Rd, Gainesville, FL 32608 USA.	dfitzger@massmed.org	Crosson, Bruce A/L-3128-2013		Veterans Health AdministrationUS Department of Veterans Affairs [B6698W, B6364S]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21-DC009247, R01-DC007387]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC007387, R21DC009247] Funding Source: NIH RePORTER	Dr. FitzGerald is sponsored by Veterans Health Administration RR&D Career Development award B6698W.; Dr. Crosson is sponsored by Veterans Health Administration RR&D grant B6364S and NIH grants R21-DC009247 and R01-DC007387.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Centers for Disease Control, 2010, INJ PREV CONTR TRAUM; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P37, DOI 10.1016/B978-0-12-374709-9.00003-1; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	41	19	21	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		79	85		10.1016/j.ijpsycho.2011.02.011			7	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600009	21338633				2021-06-18	
J	Ross, EH; Hoaken, PNS				Ross, Erin H.; Hoaken, Peter N. S.			Executive Cognitive Functioning Abilities of Male First Time and Return Canadian Federal Inmates	CANADIAN JOURNAL OF CRIMINOLOGY AND CRIMINAL JUSTICE			English	Article						executive cognitive functioning; adult male inmates; forensic rehabilitation; recidivism	FRONTAL-LOBE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; CORRECTIONAL TREATMENT; AGGRESSIVE-BEHAVIOR; NEUROPSYCHOLOGICAL FUNCTION; ANTISOCIAL-BEHAVIOR; PASSIVE-AVOIDANCE; VIOLENT BEHAVIOR; DECISION-MAKING; REHABILITATION	A primary goal of forensic rehabilitation programming for incarcerated offenders is to eliminate or, at the very least, decrease rates of recidivism. However, repeat offending continues to occur, and studies suggest that reductions in recidivism brought about by programs are modest. Indeed, a series of studies suggests decreases in recidivism ranging between only 7% and 14%. While several factors have been identified as potential contributors to criminal behaviour, one notion that has garnered much attention is that an individual may be predisposed to criminality if s/he has deficits in executive cognitive functioning. At this time, the link between executive functioning and antisocial behaviour is largely unquestioned. However, it remains uncertain whether executive deficits may be even more profound in offenders who have served multiple terms of imprisonment. Using a cross sectional design, 93 Canadian federal inmates, categorized as either first timers (n = 56) or return inmates (n = 37) were tested on a battery of executive cognitive-functioning measures. In keeping with our hypotheses, return inmates showed more severe and pervasive patterns of executive dysfunction. These results suggest that improved focus on ameliorating ECF deficits of offenders may further assist in decreasing recidivism.	[Ross, Erin H.; Hoaken, Peter N. S.] Univ Western Ontario, Dept Psychol, London, ON N6A 3K7, Canada	Ross, EH (corresponding author), Univ Western Ontario, Dept Psychol, London, ON N6A 3K7, Canada.						ANDREWS DA, 1990, CRIMINOLOGY, V28, P369, DOI 10.1111/j.1745-9125.1990.tb01330.x; Anstiss B, 2003, NEW ZEAL J PSYCHOL, V32, P84; Antonio R.Damasio, 1995, HDB MEMORY DISORDERS; Aos S., 2006, EVIDENCE BASED PUBLI; Bechara A, 1998, J NEUROSCI, V18, P428; Bergeron T.K, 2001, J OFFENDER REHABIL, DOI [10.1300/J076v33n03_02, DOI 10.1300/J076V33N03_02]; Blud L, 2003, LEGAL CRIMINOL PSYCH, V8, P69, DOI 10.1348/135532503762871255; Broomhall L., 2005, PSYCHIAT PSYCHOL LAW, V12, P367, DOI [DOI 10.1375/PPLT.12.2.367, 10.1375/pplt.12.2.367]; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Bufkin JL, 2005, TRAUMA VIOLENCE ABUS, V6, P176, DOI 10.1177/1524838005275089; Chen CY, 2005, NEUROREPORT, V16, P1213, DOI 10.1097/00001756-200508010-00016; Chen M.K., 2007, AM LAW ECON REV, V9, P1, DOI DOI 10.1093/ALER/AHM006; Clarke R. V. G., 1993, ADV CRIMINOLOGICAL T; Cohen R A, 1999, Violence Vict, V14, P397; Cohen RA, 2003, J INT NEUROPSYCH SOC, V9, P760, DOI 10.1017/S1355617703950090; Correctional Service Canada, 2004, PROGR DESCR REINT PR; Correctional Service Canada, 2007, AB IN; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dowden C, 2000, CAN J CRIMINOL, V42, P449, DOI 10.3138/cjcrim.42.4.449; Enns RA, 2006, J OFFENDER REHABIL, V44, P43, DOI 10.1300/J076v44n04_04; Fillmore MT, 2004, ADDICTION, V99, P1237, DOI 10.1111/j.1360-0443.2004.00805.x; Fishbein D, 2000, CRIM JUSTICE BEHAV, V27, P139, DOI 10.1177/0093854800027002001; Friendship C, 2003, LEGAL CRIMINOL PSYCH, V8, P103, DOI 10.1348/135532503762871273; Gendreau P, 1999, EFFECTS PRISON SENTE; Giancola PR, 2006, J PSYCHOPATHOL BEHAV, V28, P211, DOI 10.1007/s10862-005-9015-4; Giancola PR, 1998, J ABNORM PSYCHOL, V107, P629, DOI 10.1037/0021-843X.107.4.629; Giancola PR, 2004, J ABNORM PSYCHOL, V113, P541, DOI 10.1037/0021-843X.113.4.541; GIANCOLA PR, 1994, J ABNORM PSYCHOL, V103, P832, DOI 10.1037/0021-843X.103.4.832; Grigsby J, 2002, NEUROEPIDEMIOLOGY, V21, P213, DOI 10.1159/000065638; Hawkins KA, 2000, AGGRESS VIOLENT BEH, V5, P147, DOI 10.1016/S1359-1789(98)00033-0; Heaton R., 1981, MANUAL WISCONSIN CAR; Heaton R., 1993, WISCONSIN CARD SORTI; HEATON RK, 2005, WISCONSIN CARD SORTI; HELMERS KF, 1995, PERS INDIV DIFFER, V19, P927, DOI 10.1016/S0191-8869(95)00107-7; Hoaken PNS, 2007, AGGRESSIVE BEHAV, V33, P412, DOI 10.1002/ab.20194; Hollin CR, 2008, CRIM JUSTICE BEHAV, V35, P269, DOI 10.1177/0093854807312234; Ishikawa SS, 2001, J ABNORM PSYCHOL, V110, P423, DOI 10.1037/0021-843X.110.3.423; Jackson D. N., 2003, MULTIDIMENSIONAL APT; Kahokehr A, 2004, J GERIATR PSYCH NEUR, V17, P68, DOI 10.1177/0891988704264536; Kiehl KA, 2000, BIOL PSYCHIAT, V48, P210, DOI 10.1016/S0006-3223(00)00834-9; Koechlin E, 2000, P NATL ACAD SCI USA, V97, P7651, DOI 10.1073/pnas.130177397; Koski L, 2001, NEUROPSYCHOLOGIA, V39, P268, DOI 10.1016/S0028-3932(00)00110-X; KRIESHOK TS, 1985, J COUNS DEV, V64, P87, DOI 10.1002/j.1556-6676.1985.tb01016.x; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lindman H. R., 1974, ANAL VARIANCE COMPLE; Lipsey MW, 2007, ANNU REV LAW SOC SCI, V3, P297, DOI 10.1146/annurev.lawsocsci.3.081806.112833; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Marceau R, 2008, J OFFENDER REHABIL, V47, P41, DOI 10.1080/10509670801940409; Marsh NV, 2006, BRAIN INJURY, V20, P61, DOI 10.1080/02699050500110645; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; McGuire J, 2002, OFFENDER REHABILITAT; Monchi O, 2001, J NEUROSCI, V21, P7733; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Motiuk Larry, 1993, FORUM CORRECTIONAL R, V5; Nagin DS, 2004, J QUANT CRIMINOL, V20, P295, DOI 10.1007/s10940-004-5866-1; NEWMAN JP, 1990, PERS INDIV DIFFER, V11, P1101, DOI 10.1016/0191-8869(90)90021-I; Olvera RL, 2005, BIPOLAR DISORD, V7, P57, DOI 10.1111/j.1399-5618.2004.00167.x; Osterman Karin, 2006, CONT RES AGGRESSION; Paschall MJ, 2002, AGGRESS VIOLENT BEH, V7, P215, DOI 10.1016/S1359-1789(00)00044-6; PATTERSON CM, 1987, J PERS SOC PSYCHOL, V52, P565, DOI 10.1037/0022-3514.52.3.565; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; PETRIDES M, 1990, NEUROPSYCHOLOGIA, V28, P137, DOI 10.1016/0028-3932(90)90096-7; Phillips L.H., 2008, EXECUTIVE FUNCTION F; Proctor A, 2008, NEUROREHABILITATION, V23, P529; Raaijmakers MAJ, 2008, J ABNORM CHILD PSYCH, V36, P1097, DOI 10.1007/s10802-008-9235-7; Robert O.Pail, 1997, NEUROCOGNITIVE BATTE; Roberts A.C., 1998, PREFRONTAL CORTEX EX; Romero J., 2003, PSYCHOL SPAIN, V7, P77; Ross EH, 2010, CRIM JUSTICE BEHAV, V37, P656, DOI 10.1177/0093854810363104; Royall DR, 2000, NEUROEPIDEMIOLOGY, V19, P293, DOI 10.1159/000026268; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Seguin JR, 2004, J ABNORM PSYCHOL, V113, P603, DOI 10.1037/0021-843X.113.4.603; SEGUIN JR, 1995, J ABNORM PSYCHOL, V104, P614, DOI 10.1037/0021-843X.104.4.614; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tong LSJ, 2008, PSICOTHEMA, V20, P20; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; UCHIYAMA CL, 1994, ARCH CLIN NEUROPSYCH, V9, P215, DOI 10.1016/0887-6177(94)90027-2; Valliant PM, 2003, PSYCHOL REP, V92, P299, DOI 10.2466/PR0.92.1.299-306; VERNON PA, 1985, INTELLIGENCE, V9, P357, DOI 10.1016/0160-2896(85)90020-0; West R, 1999, J GERONTOL B-PSYCHOL, V54, pP34, DOI 10.1093/geronb/54B.1.P34; WILKINSON J, 2005, HOWARD J, V44, P70, DOI DOI 10.1111/J.1468-2311.2005.00356.X; Wilson S, 2003, LEGAL CRIMINOL PSYCH, V8, P83, DOI 10.1348/135532503762871264; Wood Jacqueline N, 2003, Behav Cogn Neurosci Rev, V2, P97; Wormith JS, 2007, CRIM JUSTICE BEHAV, V34, P879, DOI 10.1177/0093854807301552; Wykes T, 1999, SCHIZOPHRENIA BULL, V25, P291, DOI 10.1093/oxfordjournals.schbul.a033379; Yechiam E, 2008, PSYCHON B REV, V15, P44, DOI 10.3758/PBR.15.1.44	88	19	19	2	21	UNIV TORONTO PRESS INC	TORONTO	JOURNALS DIVISION, 5201 DUFFERIN ST, DOWNSVIEW, TORONTO, ON M3H 5T8, CANADA	1707-7753	1911-0219		CAN J CRIMINOL CRIM	Can. J. Criminol. Crim. Justice	OCT	2011	53	4					377	403		10.3138/cjccj.53.4.377			27	Criminology & Penology	Criminology & Penology	871ZM	WOS:000298776200001					2021-06-18	
J	Wu, X; Sha, HY; Sun, YR; Gao, L; Liu, H; Yuan, Q; Zhang, T; Zhu, JH; Zhou, LF; Hu, J				Wu, Xing; Sha, Hongying; Sun, Yirui; Gao, Liang; Liu, Hua; Yuan, Qiang; Zhang, Tao; Zhu, Jianhong; Zhou, Liangfu; Hu, Jin			N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Isolated Traumatic Brain Injury: A Prospective Cohort Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						NT-proBNP; Traumatic brain injury; Hyponatremia; Intracranial pressure	PLASMA-CONCENTRATIONS; ISCHEMIC-STROKE; HYPONATREMIA	Background: The role of brain natriuretic peptide (BNP) after traumatic brain injury (TBI) remains unclear, and its relationship with hyponatremia is still controversial. The aim of this study is to investigate the secretion pattern of N-terminal (NT)-proBNP in patients with TBI and to assess the relationship between NT-proBNP, sodium balance, and intracranial pressure (ICP). Methods: We measured serum NT-proBNP levels of 84 patients with isolated TBI on a daily basis from day 1 to day 14 after injury. Results: In average, the peak of BNP level was measured at 703.9 pg/mL +/- 179.1 pg/mL on day 3 after injury, which was correlated to the severity of TBI. Among patients with severe TBI, plasma NT-proBNP concentrations in patients with hyponatremia were statistically higher than those without hyponatremia (p < 0.05). In the hyponatremic group, the plasma NT-proBNP increased to a peak of 1001.16 pg/mL +/- 131.52 pg/mL within 48 hours after injury and maintained at a high level for 3 days. In the normonatremic group, the plasma NT-proBNP reached a peak of 826.43 pg/mL +/- 337.43 pg/mL on day 5 and quickly decreased thereafter. In addition, we found plasma NT-proBNP concentrations in patients with ICP > 15 mm Hg were significantly higher than those in patients with ICP <= 15 mm Hg (p < 0.01). Conclusions: This study provides evidence that BNP plasma concentrations increase rapidly after TBI. Plasma BNP concentrations are correlated with hyponatremia in severe TBI patients but not in mild and moderate TBI patients. Furthermore, patients with elevated ICP have a higher serum BNP level in first 4 days after injury.	[Wu, Xing; Sha, Hongying; Sun, Yirui; Gao, Liang; Zhu, Jianhong; Zhou, Liangfu; Hu, Jin] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China; [Zhang, Tao] Fudan Univ, Huashan Hosp, Dept Lab Med, Shanghai 200433, Peoples R China; [Liu, Hua; Yuan, Qiang] Jiao Tong Univ, Dept Neurosurg, Hosp 6, Shanghai 200030, Peoples R China	Hu, J (corresponding author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Wulumuqizhong Rd 12, Shanghai 200433, Peoples R China.	xggbtt@gmail.com			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [30600640, 30870805, 90919002, 30770824, 81000518]; National Basic Research ProgramNational Basic Research Program of China [2007CB947902, 2009CB941100, 2010CB945500]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [10JC1402300]; Shanghai Nature Science Foundation [08411952000]; Young Backbone Foundation of Fudan University; Open Foundation of State Key Laboratory of Medical Neurobiology	Supported by National Natural Science Foundation of China (NSFC Grants 30600640, 30870805, 90919002, 30770824, and 81000518), National Basic Research Program (2007CB947902, 2009CB941100, and 2010CB945500), The Science and Technology Commission of Shanghai Municipality Project (10JC1402300), Shanghai Nature Science Foundation (08411952000), Young Backbone Foundation of Fudan University, and Open Foundation of State Key Laboratory of Medical Neurobiology.	Al-Najjar Y, 2009, EUR J HEART FAIL, V11, P1155, DOI 10.1093/eurjhf/hfp147; Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang TP, 2010, J TRAUMA, V68, P1401, DOI 10.1097/TA.0b013e3181bb9a87; Di Angelantonlo E, 2007, J NEUROL SCI, V260, P139, DOI 10.1016/j.jns.2007.04.018; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Kirchhoff C, 2008, CRIT CARE, V12, DOI 10.1186/cc7013; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; Lu DC, 2008, SURG NEUROL, V69, P226, DOI 10.1016/j.surneu.2007.02.051; McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50; Montaner J, 2008, STROKE, V39, P2280, DOI 10.1161/STROKEAHA.107.505354; Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; Nakagawa K, 2005, CEREBROVASC DIS, V19, P157, DOI 10.1159/000083249; Powner DJ, 2007, NEUROCRIT CARE, V7, P119, DOI 10.1007/s12028-007-0079-8; Rubattu S, 2008, AM J HYPERTENS, V21, P733, DOI 10.1038/ajh.2008.174; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; Sherlock M, 2009, POSTGRAD MED J, V85, P171, DOI 10.1136/pgmj.2008.072819; SUDOH T, 1988, BIOCHEM BIOPH RES CO, V155, P726, DOI 10.1016/S0006-291X(88)80555-2; Sviri GE, 2006, ACTA NEUROCHIR, V148, P529, DOI 10.1007/s00701-005-0666-4; TAKAHASHI T, 1992, CIRC RES, V71, P9, DOI 10.1161/01.RES.71.1.9; Tomida M, 1998, STROKE, V29, P1584, DOI 10.1161/01.STR.29.8.1584	22	19	20	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					820	825		10.1097/TA.0b013e3182277b69			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	833ZT	WOS:000295925700014	21808206				2021-06-18	
J	Sutton, GP; Barchard, KA; Bello, DT; Thaler, NS; Ringdahl, E; Mayfield, J; Allen, DN				Sutton, Griffin P.; Barchard, Kimberly A.; Bello, Danielle T.; Thaler, Nicholas S.; Ringdahl, Erik; Mayfield, Joan; Allen, Daniel N.			Beery-Buktenica Developmental Test of Visual-Motor Integration Performance in Children With Traumatic Brain Injury and Attention-Deficit/Hyperactivity Disorder	PSYCHOLOGICAL ASSESSMENT			English	Article						Beery; Beery-Buktenica Developmental Test of Visual-Motor Integration; traumatic brain injury; attention-deficit/hyperactivity disorder; ADHD	TERM; RECOVERY	Evaluation of visuoconstructional abilities is a common part of clinical neuropsychological assessment, and the Beery-Buktenica Developmental Test of Visual-Motor Integration (VMI; K. E. Beery & N. A. Beery, 2004) is often used for this purpose. However, few studies have examined its psychometric properties when used to assess children and adolescents with traumatic brain injury (TBI) or attention-deficit/hyperactivity disorder (ADHD), even though these are among the most common acquired and neurodevelopmental forms of brain dysfunction in children. This study examined the validity of VMI scores in 123 children with TBI and 65 with ADHD. The TBI and ADHD groups performed significantly worse than the standardization sample, obtaining VMI mean scores of 87.2 (SD = 13.7) and 93.5 (SD = 11.27). Previous research has noted decrements in visuoconstructional abilities in TBI but relative sparing in ADHD. To examine the criterion validity of VMI scores, the authors therefore compared these 2 groups. As anticipated, the TBI group performed significantly worse than the ADHD group, but receiver operator characteristic analysis indicated that VMI scores were poor at discriminating between groups. Nonetheless, convergent validity evidence supported interpretation of VMI scores as measuring perceptual organization in both groups. In particular, principal components analysis indicated that VMI total scores loaded with perceptual organization tests from the Wechsler Intelligence Scale for Children, 3rd ed. (WISC-III; D. Wechsler, 1997), and its highest correlation was with the WISC-III Perceptual Organization Index. Also, the VMI correlated significantly with the Grooved Pegboard test for the group with TBI. These findings suggest that VMI scores are sensitive to visuoconstructional and motor deficits in children with developmental and acquired brain dysfunction.	[Sutton, Griffin P.; Barchard, Kimberly A.; Bello, Danielle T.; Thaler, Nicholas S.; Ringdahl, Erik; Allen, Daniel N.] Univ Nevada, Dept Psychol, Neuropsychol Res Program, Las Vegas, NV 89154 USA; [Mayfield, Joan] Our Childrens House Baylor, Dallas, TX USA	Allen, DN (corresponding author), Univ Nevada, Dept Psychol, Neuropsychol Res Program, Las Vegas, NV 89154 USA.	daniel.allen@unlv.edu		Allen, Daniel/0000-0003-4868-2242			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beery K.E., 2004, BEERY BUKTENICA DEV, V5th; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; GOLDSTEIN DJ, 1986, J CLIN PSYCHOL, V42, P890, DOI 10.1002/1097-4679(198611)42:6<890::AID-JCLP2270420611>3.0.CO;2-Y; Goldstein S, 2008, NEUROPSYCHOLOGY HDB, P651; Hall S, 1996, J CLIN PSYCHOL, V52, P449, DOI 10.1002/(SICI)1097-4679(199607)52:4<449::AID-JCLP10>3.0.CO;2-G; Hosmer D. W., 2000, APPL LOGISTIC REGRES, DOI [10. 1002/0471722146, DOI 10.1002/0471722146, 10.1002/0471722146]; Kaplan BJ, 1998, HUM MOVEMENT SCI, V17, P471, DOI 10.1016/S0167-9457(98)00010-4; Kooistra L, 2005, J LEARN DISABIL-US, V38, P195, DOI 10.1177/00222194050380030201; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Piek JP, 1999, DEV MED CHILD NEUROL, V41, P159, DOI 10.1017/S0012162299000341; Pitcher TM, 2003, DEV MED CHILD NEUROL, V45, P525, DOI 10.1111/j.1469-8749.2003.tb00952.x; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS J, 1994, DEV NEUROPSYCHOL, V10, P19, DOI 10.1080/87565649409540563; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	20	19	20	0	54	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	SEP	2011	23	3					805	809		10.1037/a0023370			5	Psychology, Clinical	Psychology	816TD	WOS:000294624100021	21875221				2021-06-18	
J	Holfelder, K; Schittenhelm, J; Trautmann, K; Haybaeck, J; Meyermann, R; Beschorner, R				Holfelder, K.; Schittenhelm, J.; Trautmann, K.; Haybaeck, J.; Meyermann, R.; Beschorner, R.			De novo expression of the hemoglobin scavenger receptor CD163 by activated microglia is not associated with hemorrhages in human brain lesions	HISTOLOGY AND HISTOPATHOLOGY			English	Article						Microglia; Ischemia; Hypoxia; Trauma; Hemorrhage	CENTRAL-NERVOUS-SYSTEM; PERIVASCULAR MACROPHAGES; REACTIVE ASTROCYTES; CEREBRAL-ISCHEMIA; HUMAN MONOCYTES; HEME UPTAKE; IDENTIFICATION; PROTEIN; INJURY; CELLS	The main function of CD163 (hemoglobin scavenger receptor) is to bind the hemoglobin-haptoglobin complex, thereby mediating extravasal hemolysis. However, CD163 also has an antiinflammatory function. After CD163-mediated endocytosis, hemoglobin is catabolized further by hemeoxygenase 1 (HO-1). Previously, we found expression of HO-1 to be restricted to microglia/macrophages at sites of hemorrhages in human traumatic and ischemic brain lesions. We now investigated if CD163 expression is also correlated with hemorrhages in brain lesions. Methods. Autopsy brain tissue from 44 cases with hemorrhagic brain lesions (32 traumatic brain injuries/TBI, 12 intracerebral bleedings/ICB), 56 non-hemorrhagic brain lesions (30 ischemias, 26 hypoxias) and 6 control brains were investigated. The post injury survival times ranged from a few minutes to 60 months. Results. In controls, single perivascular monocytes expressed CD163, but only single CD163+ microglia were found in 3/6 cases. CD163+ cells in the parenchyma (activated microglia/macrophages) increased significantly within 24 hours after trauma and ischemia and within 1-7 days following ICB or hypoxia. Overall, significantly lower and higher levels of parenchymal CD163+ cells occurred in hypoxia and ischemia, respectively. Perivascular CD163+ cells also increased significantly in all pathological conditions. In areas remote from circumscribed brain lesions (TBI, ICB, ischemia), significant changes were only found in ICB and ischemia. Conclusions. De novo expression of CD163 by activated microglia/macrophages and CD163+ infiltrating monocytes are neither restricted to nor predominant in hemorrhagic brain lesions. Thus, the antiinflammatory function of CD163 probably predominates, both in hemorrhagic and non-hemorrhagic brain lesions and points to possible immunomodulatory treatment strategies targeting CD163	[Holfelder, K.; Schittenhelm, J.; Trautmann, K.; Meyermann, R.; Beschorner, R.] Univ Tubingen, Dept Neuropathol, Inst Pathol & Neuropathol, D-72074 Tubingen, Germany; [Haybaeck, J.] Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; [Haybaeck, J.] Med Univ Graz, Inst Pathol, Graz, Austria	Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwerstr 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X			Abraham NG, 2006, CIRC RES, V99, P911, DOI 10.1161/01.RES.0000249616.10603.d6; Beschorner R, 2007, HISTOPATHOLOGY, V50, P897, DOI 10.1111/j.1365-2559.2007.02703.x; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; Bover LC, 2007, J IMMUNOL, V178, P8183, DOI 10.4049/jimmunol.178.12.8183; Fabriek BO, 2007, J NEUROIMMUNOL, V187, P179, DOI 10.1016/j.jneuroim.2007.04.016; Fabriek BO, 2005, GLIA, V51, P297, DOI 10.1002/glia.20208; Ferrer I., 2008, GREENFIELDS NEUROPAT, P121; Fischer-Smith T, 2008, J NEUROVIROL, V14, P318, DOI 10.1080/13550280802132857; Graversen JH, 2002, INT J BIOCHEM CELL B, V34, P309, DOI 10.1016/S1357-2725(01)00144-3; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hogger P, 1998, J IMMUNOL, V161, P1883; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Onofre Gabriela, 2009, Acta Medica (Hradec Kralove), V52, P57, DOI 10.14712/18059694.2016.105; Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9; Schaer CA, 2007, J LEUKOCYTE BIOL, V82, P106, DOI 10.1189/jlb.0706453; Schaer CA, 2006, CIRC RES, V99, P943, DOI 10.1161/01.RES.0000247067.34173.1b; Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014; Schaer DJ, 2007, ANTIOXID REDOX SIGN, V9, P991, DOI 10.1089/ars.2007.1576; Sulahian TH, 2001, J IMMUNOL METHODS, V252, P25, DOI 10.1016/S0022-1759(01)00328-3; Suttner DM, 1999, FASEB J, V13, P1800; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858; Wenzel I, 1996, EUR J IMMUNOL, V26, P2758, DOI 10.1002/eji.1830261131; Yepes M, 2005, AM J PATHOL, V166, P511, DOI 10.1016/S0002-9440(10)62273-0; Yepes M, 2007, MOL NEUROBIOL, V35, P255, DOI 10.1007/s12035-007-0024-z; Zhang XH, 2007, J CEREBR BLOOD F MET, V27, P534, DOI 10.1038/sj.jcbfm.9600368	34	19	20	0	2	F HERNANDEZ	MURCIA	PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN	0213-3911			HISTOL HISTOPATHOL	Histol. Histopath.	AUG	2011	26	8					1007	1017					11	Cell Biology; Pathology	Cell Biology; Pathology	780WP	WOS:000291890500005	21692033				2021-06-18	
J	Legarda, SB; McMahon, D; Othmer, S; Othmer, S				Legarda, Stella B.; McMahon, Doreen; Othmer, Siegfried; Othmer, Sue			Clinical Neurofeedback: Case Studies, Proposed Mechanism, and Implications for Pediatric Neurology Practice	JOURNAL OF CHILD NEUROLOGY			English	Article						neurology; epilepsy; neurofeedback; electroencephalogram	OSCILLATIONS; EEG; STIMULATION; BIOFEEDBACK; CHILDREN	Trends in alternative medicine use by American health care consumers are rising substantially. Extensive literature exists reporting on the effectiveness of neurofeedback in the treatment of autism, closed head injury, insomnia, migraine, depression, attention deficit hyperactivity disorder, epilepsy, and posttraumatic stress disorder. We speculated that neurofeedback might serve as a therapeutic modality for patients with medically refractory neurological disorders and have begun referring patients to train with clinical neurofeedback practitioners. The modality is not always covered by insurance. Confident their child's medical and neurological needs would continue to be met, the parents of 3 children with epilepsy spectrum disorder decided to have their child train in the modality. The children's individual progress following neurofeedback are each presented here. A proposed mechanism and practice implications are discussed.	[Legarda, Stella B.] Georgetown Univ, Med Ctr, Dept Pediat, Washington, DC 20007 USA; [Legarda, Stella B.] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA; [McMahon, Doreen] NOVA Neurointegrat Med, Maclean, VA USA; [Othmer, Siegfried; Othmer, Sue] BCIAC, EEG Inst, Biofeedback Certificat Inst Amer, Woodland Hills, CA USA	Legarda, SB (corresponding author), Georgetown Univ Hosp, Pasquerilla Healthcare Ctr, 3800 Reservoir Rd NW,2nd Floor, Washington, DC USA.	m.stella.legarda@gunet.georgetown.edu					ALADJALOVA NA, 1957, NATURE           MAY, P957; Arns M, 2009, CLIN EEG NEUROSCI, V40, P180, DOI 10.1177/155005940904000311; Boison D, 2010, EPILEPSIA, V51, P97, DOI 10.1111/j.1528-1167.2010.02883.x; Boulet SL, 2009, ARCH PEDIAT ADOL MED, V163, P19, DOI 10.1001/archpediatrics.2008.506; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; FEINSTEIN B, 1974, SLEEP RES, V3, P134; Fernandez T, 2003, CLIN ELECTROENCEPHAL, V34, P145, DOI 10.1177/155005940303400308; Gevensleben H, 2009, J CHILD PSYCHOL PSYC, V50, P780, DOI 10.1111/j.1469-7610.2008.02033.x; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; Kwon JS, 1996, J AFFECT DISORDERS, V40, P169, DOI 10.1016/0165-0327(96)00057-2; LEGARDA S, 2010, AM EP SOC 64 ANN M; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Lorincz ML, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004447; LUDERS HO, 2004, DEEP BRAIN STIMULATI; Lundgren J, 1998, EPILEPSIA, V39, P809, DOI 10.1111/j.1528-1157.1998.tb01173.x; Mantini D, 2007, P NATL ACAD SCI USA, V104, P13170, DOI 10.1073/pnas.0700668104; Monto S, 2008, J NEUROSCI, V28, P8268, DOI 10.1523/JNEUROSCI.1910-08.2008; OTHMER S, 2008, PROTOCOL GUIDE NEURO; Parri HR, 2001, NEUROREPORT, V12, P3897, DOI 10.1097/00001756-200112210-00008; Parri HR, 2001, NAT NEUROSCI, V4, P803, DOI 10.1038/90507; Peniston EG, 1991, MED PSYCHOTHERAPY, V4, P47; Price J, 2009, INTRODUCTION TO QUANTITATIVE EEG AND NEUROFEEDBACK: ADVANCED THEORY AND APPLICATIONS, 2ND EDITION, P453, DOI 10.1016/B978-0-12-374534-7.00017-4; Robbins Jim, 2008, SYMPHONY BRAIN EVOLU; Schrader LM, 2006, CLIN NEUROPHYSIOL, V117, P781, DOI 10.1016/j.clinph.2005.12.010; Sterman MB, 2006, APPL PSYCHOPHYS BIOF, V31, P21, DOI 10.1007/s10484-006-9002-x; STERMAN MB, 1974, EPILEPSIA, V15, P395, DOI 10.1111/j.1528-1157.1974.tb04016.x; STERMAN MB, 1969, ANN NY ACAD SCI, V157, P723, DOI 10.1111/j.1749-6632.1969.tb12916.x; STERMAN MB, 1978, EPILEPSIA, V19, P207, DOI 10.1111/j.1528-1157.1978.tb04483.x; Strehl U, 2006, PEDIATRICS, V118, pE1530, DOI 10.1542/peds.2005-2478; Tan G, 2009, CLIN EEG NEUROSCI, V40, P173, DOI 10.1177/155005940904000310; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Vanhatalo S, 2004, P NATL ACAD SCI USA, V101, P5053, DOI 10.1073/pnas.0305375101; Walker J.E., 2002, J NEUROTHER, V6, P31, DOI [10.1300/J184v06n02_05, DOI 10.1300/J184v06n02_05, DOI 10.1300/J184V06N02_]; WALKER JE, 2005, CHILD ADOLESC PSYCHI, V14, P153; Walker JE, 2011, CLIN EEG NEUROSCI, V42, P59, DOI 10.1177/155005941104200112; 2009, DYESS D HLTH NE 0731	36	19	20	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	AUG	2011	26	8					1045	1051		10.1177/0883073811405052			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	796WY	WOS:000293085400021	21576401				2021-06-18	
J	Pan, Y; Zhang, HB; Acharya, AB; Cruz-Flores, S; Panneton, WM				Pan, Yi; Zhang, Haibo; Acharya, Aninda B.; Cruz-Flores, Salvador; Panneton, W. Michael			The effect of heliox treatment in a rat model of focal transient cerebral ischemia	NEUROSCIENCE LETTERS			English	Article						Helium; Heliox; Acute stroke; Transient focal ischemia; Rat model	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; NORMOBARIC HYPEROXIA; IN-VIVO; ARTERY OCCLUSION; INFARCT VOLUME; STROKE; CARDIOPROTECTION; NEUROPROTECTION; THERAPY	Manipulation of inhaled gases during ischemia/reperfusion is a potential novel therapy for acute stroke. We previously found that treatment with a mixture of 70%/30% helium/oxygen (heliox) or 100% oxygen protects the brain against acute focal ischemia-reperfusion injury. This study evaluates the potential neuro-protective effects of delayed heliox treatment and its dose response effects in a rat transient focal cerebral ischemia model. Adult male rats were subjected to 2-h middle cerebral artery occlusion and then assigned to 1 of 4 inhaled gas exposure groups: I: 70%/30% nitrogen/oxygen (control); II: 70%/30% helium/oxygen administered immediately after occlusion; III: 70%/30% helium/oxygen administered after a 30-60 min delay; or, IV: 40%/30%/30% nitrogen/helium/oxygen administered immediately after occlusion. Outcome measurements included infarct size and neurological deficit score. Mean infarct sizes from groups I to IV were 228, 35, 109, and 124 mm(3) respectively (p = 0.012). Only group II had significantly smaller infarct size compared to the control group (p = 0.008). In addition, only Group II had a significantly lower neurological deficit score at 24h post ischemia when compared to the control group (p < 0.001). Since heliox reduced infarct size and improved neurological deficit scores if initiated immediately after onset of ischemia, it may be a useful adjuvant to other stroke therapies. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Pan, Yi; Zhang, Haibo; Acharya, Aninda B.; Cruz-Flores, Salvador] St Louis Univ, Dept Neurol & Psychiat, St Louis, MO 63104 USA; [Panneton, W. Michael] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Pan, Y (corresponding author), St Louis Univ, Dept Neurol & Psychiat, 1438 S Grand Blvd, St Louis, MO 63104 USA.	pany@slu.edu	Cruz-Flores, Salvador/AAR-1233-2020	Cruz-Flores, Salvador/0000-0003-4998-1471	Department of Neurology & Psychiatry, School of Medicine, Saint Louis University; Souers Stroke Institute	The Souers Stroke Institute, Department of Neurology & Psychiatry, School of Medicine, Saint Louis University provided support for this study.	Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; David HN, 2008, FASEB J, V22, P1275, DOI 10.1096/fj.07-9420com; David HN, 2009, J CEREBR BLOOD F MET, V29, P1159, DOI 10.1038/jcbfm.2009.40; Fujiwara N, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-79; Goldlust EJ, 1996, STROKE, V27, P1657, DOI 10.1161/01.STR.27.9.1657; Heinen A, 2008, ANESTHESIOLOGY, V109, P830, DOI 10.1097/ALN.0b013e3181895aa0; Henninger N, 2007, J CEREBR BLOOD F MET, V27, P1632, DOI 10.1038/sj.jcbfm.9600463; Henninger N, 2009, J CEREBR BLOOD F MET, V29, P119, DOI 10.1038/jcbfm.2008.104; Hess DR, 2006, RESPIR CARE, V51, P608; Huhn R, 2009, BRIT J ANAESTH, V102, P614, DOI 10.1093/bja/aep042; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Kim HY, 2005, ANN NEUROL, V57, P571, DOI 10.1002/ana.20430; Liu SM, 2006, J CEREBR BLOOD F MET, V26, P1274, DOI 10.1038/sj.jcbfm.9600277; Liu WL, 2009, J NEUROCHEM, V108, P811, DOI 10.1111/j.1471-4159.2008.05821.x; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lucchinetti E, 2009, ANESTH ANALG, V109, P101, DOI 10.1213/ane.0b013e3181a27e4b; Pagel PS, 2008, ANESTH ANALG, V107, P762, DOI 10.1213/ane.0b013e3181815995; Pagel PS, 2008, ANESTH ANALG, V107, P769, DOI 10.1213/ane.0b013e3181815b84; Pagel PS, 2008, J CARDIOTHOR VASC AN, V22, P554, DOI 10.1053/j.jvca.2008.04.005; Pagel PS, 2007, ANESTH ANALG, V105, P562, DOI 10.1213/01.ane.0000278083.31991.36; Pagel PS, 2009, J CARDIOTHOR VASC AN, V23, P619, DOI 10.1053/j.jvca.2008.12.020; Pagel PS, 2009, ANESTH ANALG, V108, P1076, DOI 10.1213/ane.0b013e318193e934; Pan Y, 2007, EXP NEUROL, V205, P587, DOI 10.1016/j.expneurol.2007.03.023; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; VanDeripe DR, 2004, MED HYPOTHESES, V62, P294, DOI 10.1016/S0306-9877(03)00304-9; Yamamoto H, 2003, EXP NEUROL, V182, P261, DOI 10.1016/S0014-4886(03)00116-X	28	19	19	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 22	2011	497	2					144	147		10.1016/j.neulet.2011.04.048			4	Neurosciences	Neurosciences & Neurology	787VI	WOS:000292404400015	21539894				2021-06-18	
J	Allan, CL; Ebmeier, KP				Allan, Charlotte L.; Ebmeier, Klaus P.			The influence of ApoE4 on clinical progression of dementia: a meta-analysis	INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY			English	Article						apolipoproteins; cognition; dementia; genetics; systematic review; meta-analysis	ONSET ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E EPSILON-4; TRAUMATIC BRAIN-INJURY; COGNITIVE DECLINE; AMYLOID DEPOSITION; E GENOTYPE; TYPE-4 ALLELE; MOUSE MODEL; ASSOCIATION; PROTEIN	Objective: ApoE4 is a risk factor for the development of Alzheimer's disease, and has a functional role suggesting its importance in the neuropathology of dementia. We present a meta-analysis to investigate whether ApoE4 also affects the clinical progression of dementia in terms of cognitive decline or mortality. Methods: We searched Medline, Embase and PsychINFO from 1990 until April 2009, for case control or cohort studies which investigated the effect of ApoE4 on progression of dementia. We identified 427 studies; 17 were suitable for inclusion. In total, there were 1733 participants with dementia at baseline, of whom 975 were heterozygous or homozygous for ApoE4. Results: There was no significant difference in cognitive decline (random-model effect size = 0.02; 95% C.-I.: -0.09 to 0.14; p = 0.67) or mortality (random-model pooled odds ratio = 0.74; 95% C.-I.: 0.36 to 1.53; p = 0.41) based on the presence of ApoE4. There was no significant heterogeneity between studies using cognitive decline as an outcome. In meta-regressions of cognitive decline, duration of symptoms, age, gender and frequency of participants with ApoE4 in the samples did not contribute to outcome. Conclusion: Different ApoE alleles do not modify the speed of clinical progression of dementia in a way that would be detectable in a sample of 1700 patients. Copyright (c) 2010 John Wiley & Sons, Ltd.	[Allan, Charlotte L.; Ebmeier, Klaus P.] Univ Oxford, Dept Psychiat, Oxford OX1 2JD, England	Allan, CL (corresponding author), Univ Oxford, Dept Psychiat, Oxford OX1 2JD, England.	Charlotte.allan@psych.ox.ac.uk	Ebmeier, Klaus P./B-4789-2008	Ebmeier, Klaus P./0000-0002-5190-7038; Allan, Charlotte/0000-0001-6827-5420	Oxford University Clinical Academic Graduate School; Gordon Edward Small's Charitable Trust [SC008962]	CLA is supported by Oxford University Clinical Academic Graduate School (OUCAGS@medsci.ox.ac.uk). Funding was also provided by the Gordon Edward Small's Charitable Trust (Scottish Charity Register No. SC008962).	Avramopoulos D, 2009, GENOME MED, V1, DOI 10.1186/gm34; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; BASUN H, 1995, NEUROSCI LETT, V183, P32, DOI 10.1016/0304-3940(94)11107-T; Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934; *BIOST, 2006, COMPR MET 2 2 048; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Chai Chen K, 2007, Am J Alzheimers Dis Other Demen, V22, P37, DOI 10.1177/1533317506295655; Chalmers K, 2003, NEUROPATH APPL NEURO, V29, P231, DOI 10.1046/j.1365-2990.2003.00457.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Craft S, 1998, NEUROLOGY, V51, P149, DOI 10.1212/WNL.51.1.149; Dal Forno G, 2002, NEUROLOGY, V58, P1045, DOI 10.1212/WNL.58.7.1045; DalForno G, 1996, ARCH NEUROL-CHICAGO, V53, P345; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Forstl H, 1996, NERVENARZT, V67, P730, DOI 10.1007/s001150050047; FRISONI GB, 1995, ANN NEUROL, V37, P596, DOI 10.1002/ana.410370509; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hawi Z, 2003, IRISH J MED SCI, V172, P74, DOI 10.1007/BF02915251; Herholz K, 1999, DEMENT GERIATR COGN, V10, P494, DOI 10.1159/000017196; Hirono N, 2003, J NEUROPSYCH CLIN N, V15, P354, DOI 10.1176/appi.neuropsych.15.3.354; Holmes C, 1996, J NEUROL NEUROSUR PS, V61, P580, DOI 10.1136/jnnp.61.6.580; Jonker C, 1998, ARCH NEUROL-CHICAGO, V55, P1065, DOI 10.1001/archneur.55.8.1065; Juva K, 2000, NEUROLOGY, V54, P412, DOI 10.1212/WNL.54.2.412; Kanai M, 1999, NEUROSCI LETT, V267, P65, DOI 10.1016/S0304-3940(99)00323-7; Kim JM, 2002, DEMENT GERIATR COGN, V13, P119, DOI 10.1159/000048643; Kleiman T, 2006, DEMENT GERIATR COGN, V22, P73, DOI 10.1159/000093316; Kurz A, 1996, NEUROLOGY, V47, P440, DOI 10.1212/WNL.47.2.440; Lanterna LA, 2007, NEUROLOGY, V69, P766, DOI 10.1212/01.wnl.0000267640.03300.6b; Lehtovirta M, 1998, J NEUROL NEUROSUR PS, V64, P742, DOI 10.1136/jnnp.64.6.742; Mori E, 2002, ANN NEUROL, V51, P209, DOI 10.1002/ana.10093; NAGY Z, 1995, NEUROSCIENCE, V69, P757, DOI 10.1016/0306-4522(95)00331-C; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	35	19	19	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-6230	1099-1166		INT J GERIATR PSYCH	Int. J. Geriatr. Psychiatr.	MAY	2011	26	5					520	526		10.1002/gps.2559			7	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	743DL	WOS:000288997400010	20845403				2021-06-18	
J	Batchelor, PE; Kerr, NF; Gatt, AM; Cox, SF; Ghasem-Zadeh, A; Wills, TE; Sidon, TK; Howells, DW				Batchelor, Peter E.; Kerr, Nicole F.; Gatt, Amy M.; Cox, Susan F.; Ghasem-Zadeh, Ali; Wills, Taryn E.; Sidon, Tara K.; Howells, David W.			Intracanal Pressure in Compressive Spinal Cord Injury: Reduction with Hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						decompression; hypothermia; intracanal pressure; neuroprotection; spinal cord injury	SEVERE HEAD-INJURY; HOSPITAL CARDIAC-ARREST; TRAUMATIC BRAIN-INJURY; 4-DEGREES-C NORMAL SALINE; INTRACRANIAL-PRESSURE; CERVICAL-SPINE; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; COMATOSE SURVIVORS; CRANICAL PRESSURE	Most cases of human spinal cord injury (SCI) are accompanied by continuing cord compression. Experimentally, compression results in rapid neurological decline over hours, suggesting a rise in intracanal pressure local to the site of injury. The aim of this study was to measure the rise in local intracanal pressure accompanying progressive canal occlusion and to determine the relationship between raised intracanal pressure and neurological outcome. We also aimed to establish whether hypothermia was able to reduce raised intracanal pressure. We demonstrate that, following SCI in F344 rats, local intracanal pressure remains near normal until canal occlusion exceeds 30% of diameter, whereupon a rapid increase in pressure occurs. Intracanal pressure appears to be an important determinant of neurological recovery, with poor long-term behavioural and histological outcomes in animals subject to 8 h of 45% canal occlusion, in which intracanal pressure is significantly elevated. In contrast, good neurological recovery occurs in animals with near normal intracanal pressure (animals undergoing 8 h of 30% canal occlusion or those undergoing immediate decompression). We further demonstrate that hypothermia is an effective therapy to control raised intracanal pressure, rapidly reducing elevated intracanal pressure accompanying critical (45%) canal occlusion to near normal. Overall these data indicate that following SCI only limited canal narrowing is tolerated before local intracanal pressure rapidly rises, inducing a sharp decline in neurological outcome. Raised intracanal pressure can be controlled with hypothermia, which may be a useful therapy to emergently decompress the spinal cord prior to surgical decompression.	[Batchelor, Peter E.; Kerr, Nicole F.; Gatt, Amy M.; Cox, Susan F.; Wills, Taryn E.; Sidon, Tara K.; Howells, David W.] Natl Stroke Res Inst, Dept Med, Heidelberg, Vic, Australia; [Ghasem-Zadeh, Ali] Natl Stroke Res Inst, Endocrinol Ctr Excellence, Heidelberg, Vic, Australia; Univ Melbourne, Austin Hlth, Heidelberg, Vic, Australia	Batchelor, PE (corresponding author), Austin Hlth, Dept Med, Studley Rd, Heidelberg, Vic 3084, Australia.	batch@bigpond.net.au		Howells, David/0000-0002-2512-7724	National Stroke Research Institute	This study was supported by the National Stroke Research Institute.	ALBECK MJ, 1991, J NEUROSURG, V74, P597, DOI 10.3171/jns.1991.74.4.0597; Anderson RE, 2003, J TRAUMA, V54, P550, DOI 10.1097/01.TA.0000047049.64695.69; Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Batchelor PE, 2010, J NEUROTRAUM, V27, P1357, DOI 10.1089/neu.2010.1360; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2010, CIRCULATION, V122, P737, DOI 10.1161/CIRCULATIONAHA.109.906859; Botel U, 1997, SPINAL CORD, V35, P420, DOI 10.1038/sj.sc.3100407; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Carlson GD, 1997, SPINE, V22, P1285, DOI 10.1097/00007632-199706150-00002; Carlson GD, 2003, J BONE JOINT SURG AM, V85A, P86, DOI 10.2106/00004623-200301000-00014; Carlson GD, 2000, SPINE, V25, P1218, DOI 10.1097/00007632-200005150-00004; Dahlqvist Mats B, 2010, J Med Case Rep, V4, P297, DOI 10.1186/1752-1947-4-297; DELAMARTER RB, 1995, J BONE JOINT SURG AM, V77A, P1042, DOI 10.2106/00004623-199507000-00010; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dimar JR, 1999, SPINE, V24, P1623, DOI 10.1097/00007632-199908150-00002; DOWNEY JA, 1969, J APPL PHYSIOL, V27, P209; DOWNEY JA, 1967, J APPL PHYSIOL, V22, P91; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FEHLINGS M, 2009, CAN J SURG S, V52, P10; Fehlings MG, 1999, SPINE, V24, P605, DOI 10.1097/00007632-199903150-00023; Fraidakis M, 1998, EXP NEUROL, V153, P299, DOI 10.1006/exnr.1998.6897; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kakulas BA, 1992, HDB CLIN NEUROLOGY, P21; Khan S, 2007, J SPINAL CORD MED, V30, P27, DOI 10.1080/10790268.2007.11753910; Kim F, 2005, CIRCULATION, V112, P715, DOI 10.1161/CIRCULATIONAHA.105.544528; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LEECH P, 1974, J NEUROL NEUROSUR PS, V37, P1093, DOI 10.1136/jnnp.37.10.1093; Levi AD, 2010, NEUROSURGERY, V66, P670, DOI 10.1227/01.NEU.0000367557.77973.5F; Levi AD, 2009, J NEUROTRAUM, V26, P407, DOI 10.1089/neu.2008.0745; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P575; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Morishita Y, 2009, EUR SPINE J, V18, P877, DOI 10.1007/s00586-009-0968-y; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Ng W. P., 1999, NEUROSURG FOCUS, V6, pe3; Norman G, 2008, BIOSTATISTICS BARE E, P46; Papadopoulos SM, 2002, J TRAUMA, V52, P323, DOI 10.1097/00005373-200202000-00019; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Prasad SS, 2003, SPINE, V28, P1263, DOI 10.1097/00007632-200306150-00009; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rabinowitz RS, 2008, SPINE, V33, P2260, DOI 10.1097/BRS.0b013e31818786db; Rajek A, 2000, ANESTHESIOLOGY, V93, P629, DOI 10.1097/00000542-200009000-00010; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SCHMIDT KD, 1992, MAYO CLIN PROC, V67, P469, DOI 10.1016/S0025-6196(12)60394-2; Schreckinger M, 2009, NEUROCRIT CARE, V11, P427, DOI 10.1007/s12028-009-9256-2; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shields CB, 2005, J NEUROSURG-SPINE, V3, P302, DOI 10.3171/spi.2005.3.4.0302; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Tator CH, 1999, J NEUROSURG, V91, P12, DOI 10.3171/spi.1999.91.1.0012; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vroemen M, 2006, AM J NEURORADIOL, V27, P598; Wolfla CE, 1996, J NEUROSURG, V84, P642, DOI 10.3171/jns.1996.84.4.0642; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046	67	19	20	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					809	820		10.1089/neu.2010.1622			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100281	21250916				2021-06-18	
J	Griffin, GD				Griffin, Gerald Dieter			The Injured Brain: TBI, mTBI, the Immune System, and Infection: Connecting the Dots	MILITARY MEDICINE			English	Article							BACTERIAL TRANSLOCATION; BARRIER; STROKE; PERMEABILITY; ACTIVATION	Traumatic brain injury or stroke causes profound suppression of the cellular immune system and short- and long-term psychological sequelae. Infection is also a common result and is likely caused by bacterial translocation from the gut. Both the bacterial translocation from the gut and the ensuing pneumonia and sepsis are ameliorated by adoptive immune therapy. Huge health care costs are incurred by brain trauma and its sequelae in our soldiers, athletes, and general population. Diffusion tensor imaging and adoptive immune therapy should become standards of care to follow the injured brain serially as it heals and as the immune suppression and infections are overcome. Brain infrastructure healing is retarded by a suppressed immune system, and the blood brain barrier's response to trauma offers opportunity for adoptive immune therapy to enhance microglial-directed neuronal repair and maintenance.	BiobancUSA, Monterey, CA 93940 USA	Griffin, GD (corresponding author), BiobancUSA, 5 Lower Ragsdale,Suite 100, Monterey, CA 93940 USA.		Griffin, Gerald Dieter/R-7186-2019				Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; BRATHWAITE CEM, 1993, J TRAUMA, V34, P586, DOI 10.1097/00005373-199304000-00017; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; GAUTREAUX MD, 1994, INFECT IMMUN, V62, P2874, DOI 10.1128/IAI.62.7.2874-2884.1994; GAUTREAUX MD, 1995, INFECT IMMUN, V63, P3827, DOI 10.1128/IAI.63.10.3827-3834.1995; Hartl R, 1997, ACT NEUR S, V70, P240; Huber JD, 2006, AM J PHYSIOL-HEART C, V290, pH732, DOI 10.1152/ajpheart.00747.2005; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; MacFie J, 2004, BRIT MED BULL, V71, P1, DOI 10.1093/bmb/ldh029; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; O'Boyle CJ, 1998, GUT, V42, P29, DOI 10.1136/gut.42.1.29; Oztuna V, 2004, J ORTHOP TRAUMA, V18, P92; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1222; TANIELIAN T, 2008, MG7201CCF RAND CORP; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Tuosto L, 1994, EUR J IMMUNOL, V24, P1061, DOI 10.1002/eji.1830240508; Vogelgesang A, 2008, STROKE, V39, P237, DOI 10.1161/STROKEAHA.107.493635; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; Witt KA, 2008, MICROVASC RES, V75, P91, DOI 10.1016/j.mvr.2007.06.004; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706	26	19	21	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	APR	2011	176	4					364	368		10.7205/MILMED-D-10-00021			5	Medicine, General & Internal	General & Internal Medicine	825BO	WOS:000295246100004	21539156	Bronze			2021-06-18	
J	Malmivaara, K; Kivisaari, R; Hernesniemi, J; Siironen, J				Malmivaara, K.; Kivisaari, R.; Hernesniemi, J.; Siironen, J.			Cost-effectiveness of decompressive craniectomy in traumatic brain injuries	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						cost-effectiveness; decompressive craniectomy; health-related quality of life; quality-adjusted life year; traumatic brain injury	SEVERE HEAD-INJURY; MANAGEMENT	Background and purpose: Decompressive craniectomy (DC) is used regularly in traumatic brain injury (TBI). There are, however, no cost-effectiveness studies of the procedure. Methods: We evaluated the outcomes and treatment costs of all decompressive craniectomies performed between the 2000 and 2006 in a single institution to lower intractable intracranial pressure after TBI. The health-related quality of life was evaluated on the Euroqol (EQ-5D) questionnaire and on the visual-analogue scale (VAS), and cost of a quality-adjusted life year (QALY) was calculated. Results: In this study of 54 patients, the median follow-up time was 5.6 years. Overall mortality rate was 41%. Of the 22 non-survivors, 73% died within 30 days. For 32 survivors, the median EQ-5D index value was 0.85, which is equal to the normal population. The median VAS value was 73, whilst normal population's value is 80. Of the survivors, 81% (26/32) were able to live at home and 31% (10/32) returned to work. The cost of neurosurgical treatment for one QALY was 2400euro. Estimation for all medical costs, including rehabilitation and anticipated future costs, resulted cost of a QALY 17 900 euro. Conclusion Mortality after severe TBI leading to DC was high, but amongst the survivors, the health-related quality of life was equal to normal population. Most survivors were able to live at home and were almost as satisfied with their health as in general people are. Cost of neurosurgical treatment was low, and also including all evaluated costs, cost of a QALY gained was acceptable.	[Kivisaari, R.; Hernesniemi, J.; Siironen, J.] Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland; [Malmivaara, K.] Paijat Hame Cent Hosp, Dept Pediat, Lahti, Finland	Malmivaara, K (corresponding author), Dept Neurosurg, Topeliuksenkatu 5,PB 266, Helsinki 00029, Finland.	malmivaara@helsinki.fi			Maire Taponen Foundation; Paijat-Hame Central hospital	The research was supported by the Maire Taponen Foundation (KM, JS) and Paijat-Hame Central hospital research grant (KM).	Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Daboussi A, 2009, J NEUROSURG ANESTH, V21, P339, DOI 10.1097/ANA.0b013e3181b1dbba; Danish SF, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS945; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Kakar V, 2009, BRIT J NEUROSURG, V23, P147, DOI 10.1080/02688690902756702; Lemcke J, 2010, ACTA NEUROCHIR SUPPL, V106, P231, DOI 10.1007/978-3-211-98811-4_43; MALMIVAARA K, 2010, EUR J NEUROL, DOI DOI 10.1111/J.1468-1331-2010.03162.X; Malmivaara K, 2009, NEUROSURGERY, V65, P530, DOI 10.1227/01.NEU.0000350861.97585.CE; Meier U, 2008, ACTA NEUROCHIR SUPPL, V102, P29, DOI 10.1007/978-3-211-85578-2_6; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Munch E, 2000, NEUROSURGERY, V47, P315; PICKARD JD, 1990, BRIT MED J, V301, P629, DOI 10.1136/bmj.301.6753.629; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Soustiel JF, 2010, NEUROSURGERY, V67, P65, DOI 10.1227/01.NEU.0000370604.30037.F5; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Weinstein MC, 2009, VALUE HEALTH, V12, pS5, DOI 10.1111/j.1524-4733.2009.00515.x; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4	27	19	20	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	APR	2011	18	4					656	662		10.1111/j.1468-1331.2010.03294.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	736OI	WOS:000288503600023	21175999				2021-06-18	
J	Swan, AA; Chandrashekar, R; Beare, J; Hoane, MR				Swan, Alicia A.; Chandrashekar, Rupa; Beare, Jason; Hoane, Michael R.			Preclinical Efficacy Testing in Middle-Aged Rats: Nicotinamide, a Novel Neuroprotectant, Demonstrates Diminished Preclinical Efficacy after Controlled Cortical Impact	JOURNAL OF NEUROTRAUMA			English	Article						aging; CCI; nicotinamide; recovery of function; therapy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; IMPROVES FUNCTIONAL RECOVERY; FLUID PERCUSSION INJURY; COGNITIVE DEFICITS; OXIDATIVE STRESS; CONTUSION INJURY; SENSORIMOTOR; PROGESTERONE; PATHWAYS; NEURONS	Age is a consistent predictor of poor outcome following traumatic brain injury (TBI). Although the elderly population has one of the highest rates of TBI-related hospitalization and death, few preclinical studies have attempted to model and treat TBI in the aged population. Recent studies have indicated that nicotinamide (NAM), a soluble B-group vitamin, improved functional recovery in experimental models of TBI in young animals. The purpose of the present study was to examine the preclinical efficacy of NAM in middle-aged rats. Groups of middle-aged (14-month-old) rats were assigned to NAM (500 mg/kg or 50 mg/kg) or saline alone (1 mL/kg) treatment conditions, and received unilateral cortical contusion injuries (CCI) and injections at 1 h and 24 h following injury. The animals were tested on a variety of tasks to assess vestibulomotor (tapered beam) and cognitive performance (reference and working memory in the Morris water maze), and were evaluated for lesion size, blood-brain barrier compromise, astrocytic activation, and edema formation. In summary, the preclinical efficacy of NAM as a treatment following CCI in middle-aged rats differs from that previously documented in younger rats; while treatment with 50 mg/kg NAM appeared to have no effect, the 500-mg/kg dose worsened performance in middle-aged animals. Histological indicators demonstrated more nuanced group differences, indicating that NAM may positively impact some of the cellular cascades following injury, but were not substantial enough to improve functional recovery. These findings emphasize the need to examine potential treatments for TBI utilizing non-standard populations, and may explain why so many treatments have failed in clinical trials.	[Swan, Alicia A.; Chandrashekar, Rupa; Beare, Jason; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu	Beare, Jason E/D-2870-2016; Swan, Alicia A/O-3536-2018	Beare, Jason E/0000-0003-3988-1223; Swan, Alicia A/0000-0003-2412-0499; Hoane, Michael/0000-0001-7779-2657	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	Funding provided by NIH grant NS045647.	Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; BARNES CA, 1998, NEUROBIOL AGING, P563; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Centers for Disease Control and Prevention, 2010, INJ PREV CONTR TRAUM; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P271, DOI 10.2174/156720205774322584; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; KATSURI SB, 2009, RESTOR NEUROL NEUROS, V27, P265; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; RUTLANDBROWN W, 2006, J HEAD TRAUMA REHAB, P456; Sandhu SK, 2002, BIOGERONTOLOGY, V3, P161, DOI 10.1023/A:1015643107449; SCHALLERT T, 2005, ORIENTING PLACING BE, P129; SHAO C, 2006, FREE RADIC BIOL MED, P77; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; Xu P, 2010, MECH AGEING DEV, V131, P287, DOI 10.1016/j.mad.2010.03.006; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4	41	19	19	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					431	440		10.1089/neu.2010.1519			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600008	21083416	Green Published			2021-06-18	
J	Zhao, JA; Zhang, SW; Wu, XJ; Huan, WP; Liu, ZQ; Wei, HX; Shen, AG; Teng, HL				Zhao, Jian; Zhang, Shuangwei; Wu, Xiujie; Huan, Weipeng; Liu, Zhiqiang; Wei, Haixiang; Shen, Aiguo; Teng, Honglin			KPC1 Expression and Essential Role After Acute Spinal Cord Injury in Adult Rat	NEUROCHEMICAL RESEARCH			English	Article						SCI; Astrocyte; Proliferation; KPC1; p27(kip1)	UBIQUITIN-MEDIATED DEGRADATION; CDK INHIBITOR P27; CELL-CYCLE; REGULATES PROTEOLYSIS; REACTIVE ASTROCYTES; GLIAL PROLIFERATION; TRAUMATIC BRAIN; P27(KIP1); REGENERATION; MECHANISMS	KPC1 (Kip1 ubiquitylation-promoting complex 1) is the catalytic subunit of the ubiquitin ligase KPC, which regulates the degradation of the cyclin-dependent kinase inhibitor p27(kip1) at the G1 phase of the cell cycle. To elucidate the expression and role of KPC1 in nervous system lesion and repair, we performed an acute spinal cord contusion injury (SCI) model in adult rats. Western blot analysis showed a significant up-regulation of KPC1 and a concomitant down-regulation of p27(kip1) following spinal injury. Immunohistochemistry and immunofluorescence revealed wide expression of KPC1 in the spinal cord, including expression in neurons and astrocytes. After injury, KPC1 expression was increased predominantly in astrocytes, which highly expressed PCNA, a marker for proliferating cells. Co-immunoprecipitation demonstrated increased interactions between p27(kip1) and KPC1 4 days after injury. To understand whether KPC1 plays a role in astrocyte proliferation, we applied LPS to induce astrocyte proliferation in vitro. Western blot analysis demonstrated that p27(kip1) expression was negatively correlated with KPC1 expression following LPS stimulation. Immunofluorescence analysis showed subcellular localizations of p27(kip1) and KPC1 were also changed following the stimulation of astrocytes with LPS. These results suggest that KPC1 is related to the down-regulation of p27(kip1); this event may be involved in the proliferation of astrocytes after SCI.	[Zhao, Jian; Zhang, Shuangwei; Wu, Xiujie; Huan, Weipeng; Liu, Zhiqiang; Wei, Haixiang; Shen, Aiguo] Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong 226001, Peoples R China; [Zhao, Jian; Zhang, Shuangwei; Wu, Xiujie; Huan, Weipeng; Liu, Zhiqiang; Wei, Haixiang; Shen, Aiguo] Nantong Univ, Jiangsu Prov Key Lab Neuroregenerat, Nantong 226001, Peoples R China; [Teng, Honglin] Affiliated Hosp 1, Wenzhou Med Coll, Dept Spine Surg, Wenzhou 325000, Zhejiang, Peoples R China	Shen, AG (corresponding author), Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong 226001, Peoples R China.	shen_aiguo@yahoo.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30770488, 30870320, 31070723, 81071487, 81070275]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK2009156, BK2009157, BK2009161, BK2009169]; 333 high-level personnel training project of Jiangsu Province [BRA2010137]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [Y2090545]	This work was supported by the National Natural Science Foundation of China (No. 30770488, No. 30870320, No. 31070723, No. 81071487 and No. 81070275), Natural Science Foundation of Jiangsu Province (No. BK2009156, No. BK2009157 and No. BK2009161; BK2009169), the 333 high-level personnel training project of Jiangsu Province (No. BRA2010137) and the Natural Science Foundation of Zhejiang Province (Y2090545).	Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Brahmachari S, 2006, J NEUROSCI, V26, P4930, DOI 10.1523/JNEUROSCI.5480-05.2006; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Codeluppi S, 2009, J NEUROSCI, V29, P1093, DOI 10.1523/JNEUROSCI.4103-08.2009; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fillies T, 2007, ONCOL REP, V17, P355; Go HS, 2009, NEUROIMMUNOMODULAT, V16, P365, DOI 10.1159/000228911; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; GRUNER JA, 1992, J NEUROTRAUM, V9, P126; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kotoshiba S, 2005, J BIOL CHEM, V280, P17694, DOI 10.1074/jbc.M500866200; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Minamishima YA, 2002, CANCER RES, V62, P995; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nieto-Sampedro M, 1999, ADV EXP MED BIOL, V468, P207; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Shen AU, 2008, NEUROCHEM INT, V52, P1266, DOI 10.1016/j.neuint.2008.01.011; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sun LL, 2007, J MOL NEUROSCI, V32, P16, DOI 10.1007/s12031-007-0003-x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tawfik VL, 2006, GLIA, V54, P193, DOI 10.1002/glia.20365; Tomoda K, 1999, NATURE, V398, P160; Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	43	19	22	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAR	2011	36	3					549	558		10.1007/s11064-010-0377-y			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	716RB	WOS:000286990100024	21229311				2021-06-18	
J	McLeod, TCV; Register-Mihalik, JK				McLeod, Tamara C. Valovich; Register-Mihalik, Johna K.			Clinical Outcomes Assessment for the Management of Sport-Related Concussion	JOURNAL OF SPORT REHABILITATION			English	Article						patient report; mild traumatic brain injury; health-related quality of life	QUALITY-OF-LIFE; GENERIC CORE SCALES; MULTIDIMENSIONAL FATIGUE SCALE; TRAUMATIC BRAIN-INJURY; MIGRAINE DISABILITY; PSYCHOMETRIC PROPERTIES; HEAD-INJURY; SYMPTOMS QUESTIONNAIRE; EMOTIONAL RESPONSES; CONSTRUCT-VALIDITY	Patient Scenario: An adolescent female youth soccer athlete, with a previous concussion history, suffered a second concussion 4 wk ago. Her postconcussive symptoms are affecting her school performance and social and family life. Clinical Outcomes Assessment: Concussion is typically evaluated via symptoms, cognition, and balance. There is no specific patient-oriented outcomes measure for concussion. Clinicians can choose from a variety of generic and specific outcomes instruments aimed at assessing general health-related quality of life or various concussion symptoms and comorbidities such as headache, migraine, fatigue, mood disturbances, depression, anxiety, and concussion-related symptoms. Clinical Decision Making: The data obtained from patient self-report instruments may not actively help clinicians make return-to-play decisions; however, these scales may be useful in providing information that may help the athlete return to school, work, and social activities. The instruments may also serve to identify issues that may lead to problems down the road, including depression or anxiety, or serve to further explore the nature of an athlete's symptoms. Clinical Bottom Line: Concussion results in numerous symptoms that have the potential to linger and has been associated with depression and anxiety. The use of outcomes scales to assess health-related quality of life and the effect of other symptoms that present with a concussion may allow clinicians to better evaluate the effects of concussion on physical, cognitive, emotional, social, school, and family issues, leading to better and more complete management.	[McLeod, Tamara C. Valovich] AT Still Univ, Athlet Training Program, Mesa, AZ 85206 USA; [Register-Mihalik, Johna K.] Univ N Carolina, Chapel Hill, NC USA	McLeod, TCV (corresponding author), AT Still Univ, Athlet Training Program, Mesa, AZ 85206 USA.		McLeod, Tamara/AAU-9435-2020				Andrasik F, 2005, HEADACHE, V45, P429, DOI 10.1111/j.1526-4610.2005.05094.x; Bayliss MS, 2002, HIT 6 USERS GUIDE; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Connelly M, 2006, J PEDIATR PSYCHOL, V31, P698, DOI 10.1093/jpepsy/jsj063; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Harris CA, 2008, PAIN, V137, P609, DOI 10.1016/j.pain.2007.10.022; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hershey AD, 2001, NEUROLOGY, V57, P2034, DOI 10.1212/WNL.57.11.2034; Himanen L, 2009, BRAIN INJURY, V23, P220, DOI 10.1080/02699050902748323; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kawata AK, 2005, HEADACHE, V45, P638, DOI 10.1111/j.1526-4610.2005.05130.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MCLEOD TCV, ATHL TRAIN IN PRESS; Osman A, 2008, J CLIN PSYCHOL, V64, P83, DOI 10.1002/jclp.20433; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Parsons JT, 2011, J SPORT REHABIL, V20, P17, DOI 10.1123/jsr.20.1.17; Piebes SK, 2011, J SPORT REHABIL, V20, P129, DOI 10.1123/jsr.20.1.129; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Powers SW, 2004, CEPHALALGIA, V24, P120, DOI 10.1111/j.1468-2982.2004.00652.x; Register-Mihalik JK, 2009, ATHL TRAIN SPORTS HL, V1, P227; Rozen W. M., 2007, INDIVIDUAL DIFFERENC, V5, P73, DOI DOI 10.1136/BJSP0RTS-2017-097791; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; Snyder AR, 2008, J ATHL TRAINING, V43, P428, DOI 10.4085/1062-6050-43.4.428; Snyder AR, 2010, J SPORT REHABIL, V19, P237, DOI 10.1123/jsr.19.3.237; Stalnacke BM, 2009, J REHABIL MED, V41, P353, DOI 10.2340/16501977-0349; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Stewart WF, 2000, PAIN, V88, P41, DOI 10.1016/S0304-3959(00)00305-5; Stewart WF, 2001, NEUROLOGY, V56, pS20, DOI 10.1212/WNL.56.suppl_1.S20; Stewart WF, 1999, CEPHALALGIA, V19, P107, DOI 10.1046/j.1468-2982.1999.019002107.x; Valovich McLeod TC, 2008, J ATHL TRAINING, V43, P437, DOI DOI 10.404/1062-6050-43.4.437; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Varni JW, 2008, QUAL LIFE RES, V17, P105, DOI 10.1007/s11136-007-9282-5; Varni JW, 2009, J HEALTH PSYCHOL, V14, P611, DOI 10.1177/1359105309103580; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2004, J RHEUMATOL, V31, P2494; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Varni JW, 2002, J BEHAV MED, V25, P175, DOI 10.1023/A:1014836921812; Ware J. E., 2008, USERS MANUAL SF 36V2; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008	60	19	19	2	23	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1056-6716	1543-3072		J SPORT REHABIL	J. Sport Rehabil.	FEB	2011	20	1			SI		46	60		10.1123/jsr.20.1.46			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	719AX	WOS:000287172700006	21411822				2021-06-18	
J	Stringer, AY				Stringer, Anthony Y.			Ecologically-oriented neurorehabilitation of memory: Robustness of outcome across diagnosis and severity	BRAIN INJURY			English	Article						Cognitive rehabilitation; traumatic brain injury; stroke; memory	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; IMAGERY; IMPAIRMENT; PROGRAMS	Primary objective: The current study looked for a differential response to memory rehabilitation, testing the hypotheses that outcome would vary significantly as a function of patient diagnosis and severity of memory impairment. Research design: Unblinded, open-label, pre/post-treatment comparison of memory rehabilitation in patients stratified by diagnosis (brain injury, n = 15; stroke, n = 12; other neurological condition, n = 6) and memory impairment severity. Methods and procedures: Patients underwent an ecologically-oriented, strategy-based intervention for memory impairment and were evaluated pre- and post-treatment on seven simulations (four with alternate forms, randomized to the pre- or post-test) of everyday declarative or prospective memory tasks. Main outcomes and results: Patients at all levels of severity and in all three diagnostic groups showed equivalent, statistically significant improvement in memory performance. Neither practice effects from repeat test administration nor spontaneous recovery accounted for the improvement in memory performance. Conclusions: The current study provided evidence of improved performance in everyday memory content domains with compensatory-based cognitive rehabilitation. Comparable improvement was seen across diagnostic groups and severity ranges. Additional case series and randomized clinical trials are needed to evaluate further the efficacy of compensation-based approaches to cognitive rehabilitation.	Emory Univ, Dept Rehabil Med, Div Neuropsychol & Behav Hlth, Atlanta, GA 30322 USA	Stringer, AY (corresponding author), Emory Univ, Dept Rehabil Med, Div Neuropsychol & Behav Hlth, 1441 Clifton Rd NE, Atlanta, GA 30322 USA.	astring@emory.edu					Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; Cappa SF, 2005, EUR J NEUROL, V12, P665; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Delis DC, 1987, CALIFORNIA VERBAL LE; Downes JJ, 1997, NEUROPSYCHOL REHABIL, V7, P195, DOI 10.1080/713755535; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Hampstead BM, 2008, J INT NEUROPSYCH SOC, V14, P883, DOI 10.1017/S1355617708081009; HAMPSTEAD BM, 2008, J INT NEUROPSYCH SOC, V14, P178; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mazmanian Paul E., 1993, Brain Injury, V7, P319, DOI 10.3109/02699059309034958; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Nadolne MJ, 2001, J INT NEUROPSYCH SOC, V7, P675, DOI 10.1017/S1355617701766039; Patel M, 2003, CLIN REHABIL, V17, P158, DOI 10.1191/0269215503cr596oa; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Stringer A. Y., 2007, ECOLOGICAL ORIENTED; Stringer AY, 2003, CLIN NEUROPSYCHOL, V17, P34, DOI 10.1076/clin.17.1.34.15625; TOMBAUGH TN, 1992, CLIN NEUROPSYCHOL, V6, P63; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; Wechsler D., 1987, WECHSLER MEMORY SCAL; Winocur G, 2007, J INT NEUROPSYCH SOC, V13, P166, DOI 10.1017/S1355617707070191	27	19	19	1	14	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2011	25	2					169	178		10.3109/02699052.2010.541894			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800004	21219089				2021-06-18	
J	Winkler, D; Farnworth, L; Sloan, S; Brown, T				Winkler, Dianne; Farnworth, Louise; Sloan, Sue; Brown, Ted			Moving from aged care facilities to community-based accommodation: Outcomes and environmental factors	BRAIN INJURY			English	Article						Acquired brain injury; young adults; aged care	TRAUMATIC BRAIN-INJURY; SUPPORT NEEDS; INTEGRATION; PEOPLE; INCONTINENCE; SATISFACTION; ABI	Objective: Nearly 3500 people under 60 years of age are living in residential aged care in Australia, a situation which is generally recognized as incompatible with optimum quality of life. The objective of the current study is to explore the transition experiences of young people with acquired brain injury who have lived in aged care facilities and moved into community-based settings. Research design: Grounded theory, qualitative design. Methods and procedures: Semi-structured interviews were conducted with seven individuals with very severe ABI, seven family caregivers and two disability support workers. Each interview was recorded and transcribed verbatim. Results: Participants identified a range of positive outcomes that resulted from the transition from aged care settings to community living environments including increased independence in everyday activities, improved well-being and a greater degree of social inclusion. Participants also identified environmental factors that they deemed as crucial to facilitating positive outcomes. Conclusions: People with very severe ABI have the potential to increase their level of independence in community-based accommodation settings; a potential that is not fostered in most aged care environments. The findings inform the outcome variables and environmental factors that should be measured in studies of transition from aged care to the community.	[Winkler, Dianne] Summer Fdn Ltd, Blackburn 3130, Lancs, England; [Farnworth, Louise; Brown, Ted] Monash Univ, Dept Occupat Therapy, Frankston, Vic, Australia; [Sloan, Sue] Osborn Sloan & Associates, Occupat Therapist & Neuropsychol, Melbourne, Vic, Australia	Winkler, D (corresponding author), Summer Fdn Ltd, POB 208, Blackburn 3130, Lancs, England.	di.winkler@summerfoundation.org.au		Winkler, Di/0000-0003-3899-6248; Brown, Ted/0000-0001-9403-5877			ABELLO D, 2008, QUALITY LIFE OUTCOME; *ACIL TASM PTY LTD, 2003, FF WORKF STRUCT AUST; *ACT GOV DEP DIS H, 2006, ACQ BRAIN INJ PROJ R; *AG CAR PRIC REV T, 2004, REV PRIC ARR RES AG; *AUSTR GOV DEP FAM, 2008, YOUNG PEOPL DIS RES; *AUSTR GOV DEP FAM, YOUNG PEOPL DIS RES; *AUSTR I HLTH WELF, 2006, RES AG CAR AUSTR 200; *AUSTR I HLTH WELF, 2007, TABL 30 JUN 2006 STA; Ball Kathleen, 2001, LINK MAGAZINE, V10, P14; Barreca S, 2003, BRAIN INJURY, V17, P1065, DOI 10.1080/0269905031000110535; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; CALLAWAY L, 2005, AUSTR OCCUPATIONAL T, V52, P262; Cameron C, 2001, AUST NZ J PUBL HEAL, V25, P261, DOI 10.1111/j.1467-842X.2001.tb00574.x; Chou SC, 2003, GERONTOLOGIST, V43, P459, DOI 10.1093/geront/43.4.459; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; *CONT FDN AUSTR, FUND SCH CONT PROD; Cummins R., 2005, PERSONAL WELLBEING I; Cummins R. A., 1997, COMPREHENSIVE QUALIT; Department of Human Services, 2005, CREAT NEW OPP RESP N; Department of Human Services Victoria, 2001, ACQ BRAIN INJ STRAT; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Felce D., 1996, DEINSTITUTIONALISATI, P81; Fleminger S, 2005, PSYCHIATR BULL, V29, P53, DOI 10.1192/pb.29.2.53; Foxx-Orenstein A, 2003, ARCH PHYS MED REHAB, V84, P231, DOI 10.1053/apmr.2003.50095; Fyffe C, 2003, YOUNG PEOPLE ABI LES; GALLOP J, 2001, BOARD INQUIRY DISA 1; Glaser BG, 1965, AWARENESS DYING; Goffman E., 1961, ASYLUMS ESSAYS SOCIA; Jones G, 1999, YOUNG PEOPLE NURSING; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; KELLY G, 2007, BRAIN IMPAIR, V8, P262, DOI DOI 10.1375/BRIM.8.3.262; Lanno E., 2008, BRAIN INJURY S1, V22, P49; Mansell J., 1996, DEINSTITUTIONALISATI, P242; Martin B., 2008, WHO CARES OLDER AUST; MASON T, 2008, J PSYCHIATR MENT HLT, V3, P303; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McKnight J., 1995, CARELESS SOC COMMUNI; McMillan TM, 2004, CLIN REHABIL, V18, P132, DOI 10.1191/0269215504cr712oa; *MIN HLTH LONG TER, 2005, REP STUD REV LEV SER; Moylan M, 1995, NATL RES PROJECT EXA; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PAPASTRAT LA, 1992, J HEAD TRAUMA REHAB, V7, P11; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; *QSR INT PTY LTD, 2002, NVIVO 2 0; Regnier V, 2009, NEUROREHABILITATION, V25, P169, DOI 10.3233/NRE-2009-0514; Richards L, 2005, HANDLING QUALITATIVE; Roberts K, 1998, NURSING RES PROCESSE; SCHOFIELD M, 2004, RES METHODS NURSING; Senate Community Affairs References Committee, 2005, COMM AFF REF COMM QU; Shimada H, 2009, AM J PHYS MED REHAB, V88, P823, DOI 10.1097/PHM.0b013e3181b71ec2; SHORTEN B, 2008, PARLIAMENTARY SECRET; SLOAN S, 2007, BRAIN IMPAIR, V8, P251, DOI DOI 10.1375/BRIM.8.3.251; Sloan S, 2008, ACQUIRED BRAIN INJUR; Sloan S., 2004, BRAIN IMPAIR, V5, P12, DOI DOI 10.1375/BRIM.5.1.12.35399; Sloan S, 2009, BRAIN IMPAIR, V10, P282, DOI 10.1375/brim.10.3.282; Sloan S, 2009, BRAIN IMPAIR, V10, P295, DOI 10.1375/brim.10.3.295; Soulsby G, 2008, BRAIN INJURY, V22, P155; Strettles B, 2005, ACCOMMODATION NSW AD; Stringer K, 1999, STUDY ACCOMMODATION; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; TATE RL, 2003, FROM HOSP TO WHERE, P12; UDS Data Management Service, 1990, GUID US UN DAT SET M; VicHealth, 2005, SOC INCL DET MENT HL; Willer B., 1993, J HEAD TRAUMA REHABI, V8, P11; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Winkler D., 2007, YOUNGER PEOPLE RESID; WINKLER D, 2008, YOUNG PEOPLE RESIDEN; Winkler Dianne, 2006, Aust Health Rev, V30, P100; World Health Organization, 2001, INT CLASS FUNCT DIS; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408	71	19	19	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2011	25	2					153	168		10.3109/02699052.2010.541403			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800003	21219088				2021-06-18	
J	Alderman, N; Wood, RL; Williams, C				Alderman, Nick; Wood, Rodger Li; Williams, Claire			The development of the St Andrew's-Swansea Neurobehavioural Outcome Scale: Validity and reliability of a new measure of neurobehavioural disability and social handicap	BRAIN INJURY			English	Article						Acquired brain injury; neurorehabilitation; outcome measurement	OVERT AGGRESSION SCALE; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; NEUROPSYCHOLOGY BEHAVIOR; AFFECT PROFILE; RATING-SCALE; REHABILITATION; INSTRUMENT; INVENTORY; HEALTH	Primary objective: Neurobehavioural disability (NBD) has a major impact on long-term psychosocial outcome following acquired brain injury (ABI). A recent review highlighted that a reliable and valid measure that can adequately capture the subtle and varied characteristics of NBD has yet to be developed. In this paper, the work underpinning the 'St Andrews-Swansea Neurobehavioural Outcome Scale' (SASNOS) is described using a conceptual framework underpinned by the WHO ICF. The intention is that SASNOS will provide a reliable and valid means of measuring NBD. Methods and procedures: Three hundred and thirty-six sets of ratings were made regarding ABI and neurologically healthy samples. The initial pool of 117 items was subjected to exploratory factor analysis and Rasch analysis. Reliability and validity of the new measure were determined using a range of appropriate statistical methods. Main outcomes: Forty-nine items were retained, falling into five principal factors. Content and construct validity are calculated. SASNOS has excellent discriminant/diagnostic validity. Inter-rater and test re-test reliability are good. Conclusions: SASNOS has a range of clinical and research applications and can be employed when measuring outcome. This new measure will enable neurorehabilitation services to directly compare the clinical populations they serve using the same frame of reference for NBD.	[Alderman, Nick] St Andrews Healthcare, Natl Brain Injury Ctr, Kemsley Unit, Northampton NN1 5DG, England; [Wood, Rodger Li; Williams, Claire] Swansea Univ, Swansea, W Glam, Wales	Alderman, N (corresponding author), St Andrews Healthcare, Natl Brain Injury Ctr, Kemsley Unit, Billing Rd, Northampton NN1 5DG, England.	nalderman@standrew.co.uk		Williams, Claire/0000-0002-0791-744X; Alderman, Nick/0000-0002-8523-4142			Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Dickens G, 2007, J FORENSIC PSYCHI PS, V18, P507, DOI 10.1080/14789940701492279; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Fleminger S, 2005, PSYCHIATR BULL, V29, P53, DOI 10.1192/pb.29.2.53; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Knight C, 2008, NEUROPSYCHOL REHABIL, V18, P129, DOI 10.1080/09602010701822381; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KREUTZER JS, 1999, QUAL LIFE RES, V8, P17; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Linacre J. M, 2009, WINSTEPS RASCH MEASU; LINACRE JM, 1998, USERS GUIDE BIGSTEPS; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; NELSON LD, 1989, PSYCHOL ASSESSMENT, V1, P266; RUFF RM, 2003, RUFF NEUROBEHAVIOURA; Satz P, 1996, PSYCHOL ASSESSMENT, V8, P115; SIMBLETT S, 2010, 7 S NEUR REH SPEC IN, V11, P204; SPSS, 2007, SPSS WIND VERS 16 0; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Turner-Stokes L, 1999, NEUROPSYCHOL REHABIL, V9, P329, DOI 10.1080/096020199389419; TurnerStokes L, 1997, CLIN REHABIL, V11, P306, DOI 10.1177/026921559701100407; Urbina S., 2004, ESSENTIALS PSYCHOL T; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Wade D. T., 2005, EFFECTIVENESS REHABI; Wade DT, 2003, CLIN REHABIL, V17, P349, DOI 10.1191/0269215503cr619ed; Wing JK, 1998, BRIT J PSYCHIAT, V172, P11, DOI 10.1192/bjp.172.1.11; Wood R. L1., 1990, NEUROBEHAVIOURAL SEQ; Wood RL, 2008, BRAIN INJURY, V22, P905, DOI 10.1080/02699050802491271; Wood RL, 2001, BRAIN DAM B, P3; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; WOOD RLI, 2009, C 30 YEARS NEUR REH; World Health Organization, INT CLASS FUNCT DIS; Worthington AD, 2006, BRAIN INJURY, V20, P947, DOI 10.1080/02699050600888314; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	41	19	19	1	11	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2011	25	1					83	100		10.3109/02699052.2010.532849			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700010	21117921				2021-06-18	
J	Baldwin, VN; Powell, T; Lorenc, L				Baldwin, Victoria N.; Powell, Theresa; Lorenc, Louise			Factors influencing the uptake of memory compensations: A qualitative analysis	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Memory compensations; Acquired brain injury (ABI)	TRAUMATIC BRAIN-INJURY; ASSISTIVE DEVICES; EVERYDAY MEMORY; POCKET-COMPUTER; SELF-EFFICACY; PEOPLE; AWARENESS; TECHNOLOGY; AIDS	In 1996, Wilson and Watson stated that it is not always easy to persuade people with memory impairments to use memory strategies, despite the value of using them. To date, there has been no in-depth exploration of what motivates people to use memory compensations from the perspective of the individual with an acquired brain injury. In this study eight people attending an out-patient brain injury rehabilitation service were interviewed. Transcripts were analysed using interpretative phenomenological analysis. Four master themes emerged from the analysis: emotional barriers that need to be overcome before memory compensations are used; factors that may have a reverse effect on motivation, such as the strategy being an unpleasant reminder that one is different; beliefs about memory, such as it is better to use your own memory rather than relying on memory aids otherwise it will become lazy; and the final master theme "It's not in my nature", i.e., it does not fit with the person's lifestyle. The results show that motivation for strategy use depends on complex processes that include social, emotional and practical factors. This study demonstrates the importance of adhering to a biopsychosocial approach within rehabilitation.	[Powell, Theresa] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England; [Lorenc, Louise] Moor Green, W Midlands Rehabil Serv, Birmingham, W Midlands, England	Powell, T (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	t.powell@bham.ac.uk	Powell, Theresa/AAE-4249-2020	Powell, Theresa/0000-0002-3351-9453			Aben L, 2008, J REHABIL MED, V40, P681, DOI 10.2340/16501977-0227; Caprani N., 2007, SUPP HUM MEM INT SYS, P17; Coughlan AK, 1986, ADULT MEMORY INFORM; Department of Health, 2008, HIGH QUAL CAR ALL NH; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Gartland D, 2004, NEUROPSYCHOL REHABIL, V14, P61, DOI 10.1080/09602010343000165; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kit KA, 2007, REHABIL PSYCHOL, V52, P25, DOI 10.1037/0090-5550.52.1.25; Lazarous R. S., 1984, STRESS APPRAISAL COP; Leventhal H, 1984, HDB PSYCHOL HLTH, V4, P219; Leventhal H., 1980, MED PSYCHOL, V2, P7; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lund ML, 2003, OTJR-OCCUP PART HEAL, V23, P67, DOI 10.1177/153944920302300204; McDougall GJ, 2004, NURS RES, V53, P323, DOI 10.1097/00006199-200409000-00007; McDougall GJ, 2003, NURS RES, V52, P42, DOI 10.1097/00006199-200301000-00006; Moore A. D., 1995, BRAIN INJURY, V6, P89; O'Callaghan C, 2006, NEUROPSYCHOL REHABIL, V16, P579, DOI 10.1080/09602010500368834; Palmer P., 2007, TECHNOLOGY DISABILIT, V19, P17; Pape TLB, 2002, DISABIL REHABIL, V24, P5, DOI 10.1080/09638280110066235; Parette P, 2004, EDUC TRAIN DEV DISAB, V39, P217; Patel D., 2008, THESIS U BIRMINGHAM; Riley GA, 2004, BRAIN INJURY, V18, P871, DOI 10.1080/02699050410001671829; Roelands M, 2002, SOC SCI MED, V54, P1441, DOI 10.1016/S0277-9536(01)00126-5; Roulstone A., 2007, WHAT CAN ASSISTIVE T; Royle J, 2008, DISABIL REHABIL, V30, P114, DOI 10.1080/09638280701223876; Smith J. A., 2008, QUALITATIVE PSYCHOL, P53, DOI DOI 10.4135/9781848607927.N11; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; van Hooren SAH, 2007, PATIENT EDUC COUNS, V65, P205, DOI 10.1016/j.pec.2006.07.010; Verhaeghen P, 2000, GERONTOLOGIST, V40, P540, DOI 10.1093/geront/40.5.540; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Wright P, 2001, INT J REHABIL RES, V24, P299, DOI 10.1097/00004356-200112000-00006; Yardley L., 2008, QUALITATIVE PSYCHOL, P53	35	19	19	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	4					484	501		10.1080/09602011.2011.582378			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	885OO	WOS:000299788700003	21707468				2021-06-18	
J	Chevignard, MP; Brooks, N; Truelle, JL				Chevignard, Mathilde P.; Brooks, Neil; Truelle, Jean-Luc			Community integration following severe childhood traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article						childhood traumatic brain injury; community integration; intervention; outcome; quality of life	QUALITY-OF-LIFE; PEDIATRIC TBI; FAMILY INTERVENTION; FUNCTIONAL RECOVERY; EXECUTIVE FUNCTIONS; COGNITIVE SEQUELAE; YOUNG-CHILDREN; OUTCOMES; TERM; REHABILITATION	Purpose of review Severe childhood traumatic brain injury (TBI) is the leading cause of death and acquired disability in children, causing impairments in children's sensory-motor, cognitive and behavioural functioning, with devastating consequences on community integration. Community integration is the ultimate goal of rehabilitation; it is a complex outcome, with many variables contributing to it. Recent findings Community integration and quality of life (QOL) are lower in children who sustained severe TBI at a younger age. Further, a wide range of injury-related, demographic and postinjury factors influence outcomes, and should serve as targets for specific interventions. An increasing number of interventions targeting cognitive, behavioural or family-related issues have been developed, with promising results. Summary Children should benefit from early integrated patient and family-centred specific care, and receive long-term follow-up until early adulthood, with regular assessments, enabling detection and treatment of any emerging problem, and to ensure the acquisition of independent living skills and stable vocational outcome when this is possible. So far, few well conducted intervention studies are available, but their number is increasing with positive results on the trained skills. Well designed studies using large samples and looking at generalization of the skills in everyday life are needed.	[Chevignard, Mathilde P.] Hop Natl St Maurice, Rehabil Dept Children Acquired Brain Injury, St Maurice, France; [Chevignard, Mathilde P.] Univ Paris 06, Paris, France; [Brooks, Neil] Rehab Walls, Milton Keynes, Bucks, England; [Truelle, Jean-Luc] Univ Hosp, Neurorehabil Dept, Garches, France	Chevignard, MP (corresponding author), Hop Natl St Maurice, INR A, 14 Rue Val dOsne, F-94410 St Maurice, France.	m.chevignard@hopital-saint-maurice.fr			Hopital National de Saint Maurice; France Traumatisme Cranien - SOFMER; 'Societe Francophone d'Etudes et de Recherche sur les Handicaps de l'Enfance' (SFERHE)	Research from the author as described in the study has been supported by the Hopital National de Saint Maurice, as well as by grants from 'France Traumatisme Cranien - SOFMER' and the 'Societe Francophone d'Etudes et de Recherche sur les Handicaps de l'Enfance' (SFERHE). We thank Associate Professor Cathy Catroppa, Professor Pascale Pradat-Diehl, Doctor Anne Laurent-Vannier and Frederique Poncet for their helpful advice about the article and for the English corrections.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Badge H, 2010, CHILD CARE HLTH DEV, V36, P54, DOI 10.1111/j.1365-2214.2009.01005.x; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Carney J, 2009, DEV DISABIL RES REV, V15, P152, DOI 10.1002/ddrr.57; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chevignard M, 2010, CHILD CARE HLTH DEV, V36, P31, DOI 10.1111/j.1365-2214.2009.00949.x; Chevignard MP, 2010, BRAIN IMPAIR, V11, P125, DOI 10.1375/brim.11.2.125; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Cole WR, 2009, DEV DISABIL RES REV, V15, P159, DOI 10.1002/ddrr.58; Davis AS, 2010, APPL NEUROPSYCHOL, V17, P104, DOI 10.1080/09084281003708951; Dise-Lewis JE, 2009, J HEAD TRAUMA REHAB, V24, P166, DOI 10.1097/HTR.0b013e3181a7ecb0; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; Erickson SJ, 2010, DEV NEUROREHABIL, V13, P175, DOI 10.3109/17518420903479867; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Horton AM, 2010, APPL NEUROPSYCHOL, V17, P99, DOI 10.1080/09084281003708944; Javouhey E, 2006, EUR J PEDIATR, V165, P519, DOI 10.1007/s00431-006-0118-z; Johnson AR, 2009, DEV DISABIL RES REV, V15, P124, DOI 10.1002/ddrr.63; Kapapa T, 2010, J CHILD NEUROL, V25, P409, DOI 10.1177/0883073809340697; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kumar R, 2009, CHILD NERV SYST, V25, P813, DOI 10.1007/s00381-009-0820-z; Lajiness-O'Neill R, 2010, APPL NEUROPSYCHOL, V17, P83, DOI 10.1080/09084281003708837; Laurent-Vannier A, 2009, Ann Phys Rehabil Med, V52, P436, DOI 10.1016/j.rehab.2009.03.001; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; Martin C, 2008, CURR OPIN PEDIATR, V20, P294, DOI 10.1097/MOP.0b013e3282ff0dfa; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Noggle CA, 2010, APPL NEUROPSYCHOL, V17, P110, DOI 10.1080/09084281003708977; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Semrud-Clikeman M, 2010, APPL NEUROPSYCHOL, V17, P116, DOI 10.1080/09084281003708985; Sharples PM, 1998, INJURY YOUNG, V263-299; Slifer KJ, 2009, DEV DISABIL RES REV, V15, P144, DOI 10.1002/ddrr.60; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Stipanicic A, 2008, CHILD ABUSE NEGLECT, V32, P415, DOI 10.1016/j.chiabu.2007.07.008; Sullivan JR, 2010, APPL NEUROPSYCHOL, V17, P93, DOI 10.1080/09084281003708852; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Winthrop AL, 2010, CURR OPIN PEDIATR, V22, P346, DOI 10.1097/MOP.0b013e3283394351; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	59	19	19	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2010	23	6					695	700		10.1097/WCO.0b013e328340296f			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	675SJ	WOS:000283852400023	20962640				2021-06-18	
J	Torres, BBJ; Caldeira, FMC; Gomes, MG; Serakides, R; Viott, AD; Bertagnolli, AC; Fukushima, FB; de Oliveira, KM; Gomes, MV; de Melo, EG				Junta Torres, Bruno Benetti; Caetano Caldeira, Fatima Maria; Gomes, Mardelene Geisa; Serakides, Rogeria; Viott, Aline de Marco; Bertagnolli, Angelica Cavalheiro; Fukushima, Fabiola Bono; de Oliveira, Karen Maciel; Gomes, Marcus Vinicius; de Melo, Eliane Goncalves			Effects of dantrolene on apoptosis and immunohistochemical expression of NeuN in the spinal cord after traumatic injury in rats	INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY			English	Article						apoptosis; caspase-3; dantrolene; immunochemistry; NeuN; spinal cord injury; TUNEL-staining	NEURONAL CELL-DEATH; CA2+ RELEASE; IN-VITRO; CASPASE-3; ACTIVATION; IMPROVEMENT; CONTUSION	P>Dantrolene has been shown to be neuroprotective by reducing neuronal apoptosis after brain injury in several animal models of neurological disorders. In this study, we investigated the effects of dantrolene on experimental spinal cord injury (SCI). Forty-six male Wistar rats were laminectomized at T13 and divided in six groups: GI (n = 7) underwent SCI with placebo and was euthanized after 32 h; GII (n = 7) underwent laminectomy alone with placebo and was euthanized after 32 h; GIII (n = 8) underwent SCI with dantrolene and was euthanized after 32 h; GIV (n = 8) underwent SCI with placebo and was euthanized after 8 days; GV (n = 8) underwent laminectomy alone with placebo and was euthanized after 8 days; and GVI (n = 8) underwent SCI with dantrolene and was euthanized after 8 days. A compressive trauma was performed to induce SCI. After euthanasia, the spinal cord was evaluated using light microscopy, TUNEL staining and immunochemistry with anti-Caspase-3 and anti-NeuN. Animals treated with dantrolene showed a smaller number of TUNEL-positive and caspase-3-positive cells and a larger number of NeuN-positive neurons, both at 32 h and 8 days (P < 0.05). These results showed that dantrolene protects spinal cord tissue after traumatic SCI by decreasing apoptotic cell death.	[Junta Torres, Bruno Benetti; Caetano Caldeira, Fatima Maria; Gomes, Mardelene Geisa; Serakides, Rogeria; Viott, Aline de Marco; Fukushima, Fabiola Bono; de Oliveira, Karen Maciel; de Melo, Eliane Goncalves] Univ Fed Minas Gerais, Sch Vet, Dept Vet Med & Surg, BR-30123970 Belo Horizonte, MG, Brazil; [Gomes, Mardelene Geisa; Serakides, Rogeria; Viott, Aline de Marco] Univ Fed Minas Gerais, Sch Vet, Lab Histopathol, BR-30123970 Belo Horizonte, MG, Brazil; [Bertagnolli, Angelica Cavalheiro] Univ Fed Minas Gerais, Inst Biol Sci, Lab Comparat Pathol, BR-30123970 Belo Horizonte, MG, Brazil; [Gomes, Marcus Vinicius] Univ Fed Minas Gerais, Fac Med, Neurosci Lab, BR-30123970 Belo Horizonte, MG, Brazil	Serakides, R (corresponding author), Univ Fed Minas Gerais, Sch Vet, Dept Vet Med & Surg, Ave Antonio Carlos 6627,Caixa Postal 567,Campus U, BR-30123970 Belo Horizonte, MG, Brazil.	serakide@netuno.lcc.ufmg.br	de Marco Viott, Aline/AAK-9553-2021; Fukushima, Fabiola Bono/ABG-2548-2020; Torres, Bruno Benetti Junta/AAX-9672-2020; Serakides, Rogeria/C-7571-2016; bertagnolli, angelica/U-4762-2019; DE LAVOR, MARIO SERGIO LIMA/Y-4138-2019	de Marco Viott, Aline/0000-0003-1097-2359; Fukushima, Fabiola Bono/0000-0001-9843-8374; Torres, Bruno Benetti Junta/0000-0002-6400-046X; Serakides, Rogeria/0000-0001-5374-6242; bertagnolli, angelica/0000-0002-4956-2085; DE LAVOR, MARIO SERGIO LIMA/0000-0003-0795-5320	Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Cristalia Lab	The study was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Cristalia Lab.	Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Aslan A, 2009, EUR SPINE J, V18, P1442, DOI 10.1007/s00586-009-1033-6; Ayar A, 2002, PHYSIOL RES, V51, P341; Barut S, 2005, SURG NEUROL, V64, P213, DOI 10.1016/j.surneu.2005.03.042; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Buyukokuroglu ME, 2002, PHARMACOL RES, V45, P455, DOI 10.1006/phrs.2002.0970; Buyukokuroglu ME, 2001, PHARMACOL RES, V44, P491, DOI 10.1006/phrs.2001.0890; Cherednichenko G, 2008, MOL PHARMACOL, V73, P1203, DOI 10.1124/mol.107.043299; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; Gwak M, 2008, ANESTH ANALG, V106, P227, DOI 10.1213/01.ane.0000287663.81050.38; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; Kobayashi S, 2005, J BIOL CHEM, V280, P6580, DOI 10.1074/jbc.M408375200; Kocogullari CU, 2008, THORAC CARDIOV SURG, V56, P406, DOI 10.1055/s-2008-1038731; Krause T, 2004, ANAESTHESIA, V59, P364, DOI 10.1111/j.1365-2044.2004.03658.x; Li F, 2005, BRAIN RES, V1048, P59, DOI 10.1016/j.brainres.2005.04.058; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McEwen ML, 2005, J HISTOCHEM CYTOCHEM, V53, P809, DOI 10.1369/jhc.4A6467.2005; Mori F, 2005, EPILEPSY RES, V65, P59, DOI 10.1016/j.eplepsyres.2005.04.006; Muehlschlegel S, 2009, NEUROCRIT CARE, V10, P103, DOI 10.1007/s12028-008-9133-4; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nakayama R, 2002, ANESTHESIOLOGY, V96, P705, DOI 10.1097/00000542-200203000-00029; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Popescu BO, 2002, J CELL MOL MED, V6, P555, DOI 10.1111/j.1582-4934.2002.tb00454.x; Shields LBE, 2008, SURG NEUROL, V69, P568, DOI 10.1016/j.surneu.2008.02.009; Solaroglu I, 2005, SURG NEUROL, V64, P17, DOI 10.1016/j.surneu.2005.07.058; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; Takagi T, 2003, NEUROL MED-CHIR, V43, P20, DOI 10.2176/nmc.43.20; Thorell WE, 2002, J NEUROTRAUM, V19, P335, DOI 10.1089/089771502753594909; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Ucuncu H, 2005, HUM EXP TOXICOL, V24, P567, DOI 10.1191/0960327105ht569oa; Wei HF, 2000, J NEUROCHEM, V75, P81, DOI 10.1046/j.1471-4159.2000.0750081.x; Wei HF, 1996, J NEUROCHEM, V67, P2390; Xu GY, 2008, NEUROSCIENCE, V153, P1034, DOI 10.1016/j.neuroscience.2008.02.065; Xu GP, 2002, BRAIN RES, V952, P153, DOI 10.1016/S0006-8993(02)02988-8; Yano T, 2001, RESUSCITATION, V50, P117, DOI 10.1016/S0300-9572(00)00369-5; ZHANG L, 1993, NEUROSCI LETT, V158, P105, DOI 10.1016/0304-3940(93)90623-S; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	46	19	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-9673	1365-2613		INT J EXP PATHOL	Int. J. Exp. Pathol.	DEC	2010	91	6					530	536		10.1111/j.1365-2613.2010.00738.x			7	Pathology	Pathology	684XV	WOS:000284589500081	21039984	Green Published			2021-06-18	
J	Evans, HL; Zonies, DH; Warner, KJ; Bulger, EM; Sharar, SR; Maier, RV; Cuschieri, J				Evans, Heather L.; Zonies, David H.; Warner, Keir J.; Bulger, Eileen M.; Sharar, Sam R.; Maier, Ronald V.; Cuschieri, Joseph			Timing of Intubation and Ventilator-Associated Pneumonia Following Injury	ARCHIVES OF SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; RAPID-SEQUENCE INTUBATION; ENDOTRACHEAL INTUBATION; POSTTRAUMATIC PNEUMONIA; NOSOCOMIAL PNEUMONIA; RISK-FACTORS; COMPLICATIONS; OUTCOMES; FIELD; RESUSCITATION	Hypothesis: In an emergency medical system with established rapid-sequence intubation protocols, prehospital (PH) intubation of patients with trauma is not associated with a higher rate of ventilator-associated pneumonia (VAP) than emergency department (ED) intubation. Design: Retrospective observational cohort. Setting: Level I trauma center. Patients: Adult patients with trauma intubated in a PH or an ED setting from July 1, 2007, through July 31, 2008. Main Outcome Measures: Diagnosis of VAP by means of bronchoscopic alveolar lavage or clinical assessment when bronchoscopic alveolar lavage was impossible. Secondary outcomes included time to VAP, length of hospitalization, and in-hospital mortality. Results: Of 572 patients, 412 (72.0%) underwent PH intubation. The ED group was older than the PH group (mean ages, 46.4 vs 39.1 years; P < .001) and had a higher incidence of blunt injury (142 [88.8%] vs 322 [78.2%]; P = .002). The mean (SD) lowest recorded ED systolic blood pressure was lower in the ED group (102.8 [1.9] vs 111.4 [1.2] mm Hg; P < .001), despite similar mean injury severity scores in both groups (27.2 [0.7] vs 27.0 [1.1]; P = .94). There was no difference in the mean rate of VAP (30 [18.8%] vs 71 [17.2%]; P = .66) or mean time to diagnosis (8.1 [1.2] vs 7.8 [1.0] days; P = .89). Logistic regression analysis identified history of drug abuse, lowest recorded ED systolic blood pressure, and injury severity score as 3 independent factors predictive of VAP. Conclusions: Prehospital intubation of patients with trauma is not associated with higher risk of VAP. Further investigation of intubation factors and the incidence and timing of aspiration is required to identify potentially modifiable factors to prevent VAP.	[Evans, Heather L.; Zonies, David H.; Warner, Keir J.; Bulger, Eileen M.; Maier, Ronald V.; Cuschieri, Joseph] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [Sharar, Sam R.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA	Evans, HL (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Campus Box 359796,325 9th Ave, Seattle, WA 98104 USA.	hlevans@uw.edu	Evans, Heather L/B-7620-2008; Evans, Heather/F-9113-2014; Zonies, David/B-6497-2011	Evans, Heather/0000-0002-3661-0666; 			Bard MR, 2006, J TRAUMA, V61, P1441, DOI 10.1097/01.ta.0000245981.22931.43; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Brown DL, 2001, J TRAUMA, V51, P1207, DOI 10.1097/00005373-200112000-00034; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; COBB LA, 1975, CIRCULATION, V52, P223; Cook DJ, 1998, JAMA-J AM MED ASSOC, V279, P1605, DOI 10.1001/jama.279.20.1605; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; Croce MA, 1995, J TRAUMA, V39, P1134, DOI 10.1097/00005373-199512000-00022; Croce MA, 2003, J TRAUMA, V54, P724, DOI 10.1097/01.TA.0000054643.54218.C5; Croce MA, 2001, AM SURGEON, V67, P105; Davis DP, 2007, PREHOSP EMERG CARE, V11, P1, DOI 10.1080/10903120601021093; DEMLING RH, 1988, CRIT CARE MED, V16, P573, DOI 10.1097/00003246-198806000-00001; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; Eckert MJ, 2004, J TRAUMA, V57, P750, DOI 10.1097/01.TA.0000147499.73570.12; Griffin R, 2009, J BURN CARE RES, V30, P395, DOI 10.1097/BCR.0b013e3181a28966; Hadjizacharia P, 2009, J TRAUMA, V66, P491, DOI 10.1097/TA.0b013e3181622b9b; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Li J, 1999, AM J EMERG MED, V17, P141, DOI 10.1016/S0735-6757(99)90046-3; Melsen WG, 2009, CRIT CARE MED, V37, P2709, DOI 10.1097/CCM.0b013e3181ab8655; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Warner KJ, 2010, PREHOSP EMERG CARE, V14, P103, DOI 10.3109/10903120903144858	28	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	NOV	2010	145	11					1041	1046		10.1001/archsurg.2010.239			6	Surgery	Surgery	680KK	WOS:000284230600009	21079091	Bronze			2021-06-18	
J	Pantaleo, N; Chadwick, W; Park, SS; Wang, LY; Zhou, Y; Martin, B; Maudsley, S				Pantaleo, Nick; Chadwick, Wayne; Park, Sung-Soo; Wang, Liyun; Zhou, Yu; Martin, Bronwen; Maudsley, Stuart			The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Central neurological disorders; substance P; neurokinin A; neurokinin B; neurotherapeutics; receptor-ligand systems; tachykinin	SUBSTANCE-P-LIKE; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID LEVELS; MESENCEPHALIC DOPAMINERGIC-NEURONS; AMYOTROPHIC-LATERAL-SCLEROSIS; FREE MAGNESIUM CONCENTRATION; DISEASE CEREBRAL-CORTEX; PRIMARY SENSORY NEURONS; CENTRAL-NERVOUS-SYSTEM; IN-SITU HYBRIDIZATION	Our understanding of the complex signaling neurophysiology of the central nervous system has facilitated the exploration of potential novel receptor-ligand system targets for disorders of this most complex organ. In recent years, many relatively neglected receptor-ligand systems have been re-evaluated with respect to their ability to potently modulate discrete tracts in the central nervous system. One such system is the tachykinin (previously neurokinin) system. The multiple heptahelical G protein-coupled receptors and neuropeptide ligands that comprise this system may be significantly involved in more central nervous systems actions than previously thought, including sleep disorders, amyotrophic lateral sclerosis, Alzheimer's disease and Machado-Joseph disease. The development of our understanding of the role of the tachykinin receptor-ligand system in higher order central functions is likely to allow the creation of more specific and selective tachykinin-related neurotherapeutics.	[Maudsley, Stuart] NIA, Receptor Pharmacol Unit, Biomed Res Ctr, Neurosci Lab,NIH, Baltimore, MD 21224 USA; [Martin, Bronwen] NIA, Metab Unit, Clin Invest Lab, NIH, Baltimore, MD 21224 USA	Maudsley, S (corresponding author), NIA, Receptor Pharmacol Unit, Biomed Res Ctr, Neurosci Lab,NIH, Baltimore, MD 21224 USA.	maudsleyst@mail.nih.gov	Maudsley, Stuart/Q-4782-2019; Zhou, Yu/M-7975-2014; Pantaleo, Nick/AAE-4452-2021	Martin, Bronwen/0000-0002-9185-6925	NIH, National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000917, ZIAAG000325, ZIAAG000318, ZIAAG000319, ZIAAG000915] Funding Source: NIH RePORTER	This research was supported by the Intramural Research Program of the NIH, National Institute on Aging. The authors have no conflicts of scientific interest with respect to the manuscript.	Ahmed MM, 2004, NEUROSCIENCE, V126, P639, DOI 10.1016/j.neuroscience.2004.04.024; Almeida TA, 2004, CURR MED CHEM, V11, P2045, DOI 10.2174/0929867043364748; Amadoro G, 2007, NEUROPHARMACOLOGY, V52, P1366, DOI 10.1016/j.neuropharm.2007.01.020; ARMSTRONG DM, 1989, NEUROSCIENCE, V31, P663, DOI 10.1016/0306-4522(89)90431-4; Augood SJ, 1996, NEUROSCIENCE, V72, P1023, DOI 10.1016/0306-4522(95)00595-1; Barker R, 1996, REV NEUROSCIENCE, V7, P187; BEAL MF, 1987, NEUROLOGY, V37, P1205, DOI 10.1212/WNL.37.7.1205; Bondy B, 2003, BIOL PSYCHIAT, V53, P538, DOI 10.1016/S0006-3223(02)01544-5; BONNER TI, 1987, MOL BRAIN RES, V2, P243, DOI 10.1016/0169-328X(87)90031-3; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; BURGUNDER JM, 1989, NEUROSCIENCE, V32, P323, DOI 10.1016/0306-4522(89)90081-X; CADIEUX A, 1986, NEUROSCIENCE, V19, P605, DOI 10.1016/0306-4522(86)90285-X; Calvo N, 1996, BRAIN RES, V740, P323, DOI 10.1016/S0006-8993(96)00879-7; Chadwick W, 2008, TRENDS NEUROSCI, V31, P504, DOI 10.1016/j.tins.2008.07.005; CHANG MM, 1971, NATURE-NEW BIOL, V232, P86; Chen LW, 1998, BRAIN RES, V780, P150, DOI 10.1016/S0006-8993(97)01062-7; Chen LW, 2004, CURR DRUG TARGETS, V5, P197, DOI 10.2174/1389450043490596; COOPER PE, 1981, BRAIN RES, V218, P219, DOI 10.1016/0006-8993(81)91302-0; CRAMER H, 1989, EUR NEUROL, V29, P1, DOI 10.1159/000116366; CRYSTAL HA, 1982, J NEUROCHEM, V38, P1781, DOI 10.1111/j.1471-4159.1982.tb06665.x; Cui QL, 2008, NEUROSCI RES, V60, P162, DOI 10.1016/j.neures.2007.10.007; Dawson LA, 2008, NEUROPSYCHOPHARMACOL, V33, P1642, DOI 10.1038/sj.npp.1301549; De Laurentiis A, 2003, REGUL PEPTIDES, V111, P91, DOI 10.1016/S0167-0115(02)00258-6; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; ERSPAMER V, 1962, BRIT J PHARM CHEMOTH, V19, P337, DOI 10.1111/j.1476-5381.1962.tb01198.x; FERRANTE RJ, 1986, NEUROSCI LETT, V71, P283, DOI 10.1016/0304-3940(86)90634-8; Fiebich BL, 2000, J IMMUNOL, V165, P5606, DOI 10.4049/jimmunol.165.10.5606; Furuta T, 2000, J COMP NEUROL, V426, P279, DOI 10.1002/1096-9861(20001016)426:2<279::AID-CNE9>3.0.CO;2-F; Furuta T, 2004, J COMP NEUROL, V473, P43, DOI 10.1002/cne.20087; GAI WP, 1991, BRAIN, V114, P2253, DOI 10.1093/brain/114.5.2253; GARCIARILL E, 1987, BRAIN RES BULL, V18, P731, DOI 10.1016/0361-9230(87)90208-5; GERARD NP, 1993, REGUL PEPTIDES, V43, P21, DOI 10.1016/0167-0115(93)90404-V; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GILLBERG PG, 1982, BRAIN RES, V250, P394, DOI 10.1016/0006-8993(82)90439-5; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; HALLIDAY GM, 1990, NEUROSCIENCE, V39, P81, DOI 10.1016/0306-4522(90)90223-Q; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Herpter I, 2003, WORLD J BIOL PSYCHIA, V4, P56, DOI 10.3109/15622970309167952; ITO H, 1995, ACTA NEUROPATHOL, V89, P513; KAGE R, 1988, J NEUROCHEM, V50, P1412, DOI 10.1111/j.1471-4159.1988.tb03024.x; KALRA PS, 1994, BRAIN RES, V662, P178, DOI 10.1016/0006-8993(94)90810-9; KANGAWA K, 1983, BIOCHEM BIOPH RES CO, V114, P533, DOI 10.1016/0006-291X(83)90813-6; Kart E, 2004, PEPTIDES, V25, P1959, DOI 10.1016/j.peptides.2004.07.003; Kashiba H, 1997, NEUROSCIENCE, V76, P299; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KIMURA S, 1983, P JPN ACAD B-PHYS, V59, P101, DOI 10.2183/pjab.59.101; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; KOWALL NW, 1993, REGUL PEPTIDES, V46, P174, DOI 10.1016/0167-0115(93)90028-7; Kramer JH, 2003, EXP BIOL MED, V228, P665; Kramer MS, 2004, NEUROPSYCHOPHARMACOL, V29, P385, DOI 10.1038/sj.npp.1300260; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Krasnova IN, 2000, NEUROSCIENCE, V95, P113; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; Kurtz MM, 2002, GENE, V296, P205, DOI 10.1016/S0378-1119(02)00861-2; Lallemend F, 2003, J NEUROCHEM, V87, P508, DOI 10.1046/j.1471-4159.2003.02014.x; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Lieb K, 1997, J IMMUNOL, V159, P4952; Lieb K, 2002, NEUROPSYCHOPHARMACOL, V27, P1041, DOI 10.1016/S0893-133X(02)00369-X; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; Liu HT, 1999, P NATL ACAD SCI USA, V96, P5286, DOI 10.1073/pnas.96.9.5286; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; MAI JK, 1986, NEUROSCIENCE, V17, P709, DOI 10.1016/0306-4522(86)90041-2; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; Mantyh PW, 2002, J CLIN PSYCHIAT, V63, P6; MARKSTEINER J, 1992, NEUROSCIENCE, V51, P107, DOI 10.1016/0306-4522(92)90475-H; MARKSTEINER J, 1992, J COMP NEUROL, V317, P341, DOI 10.1002/cne.903170403; Marriott I, 2000, J IMMUNOL, V165, P182, DOI 10.4049/jimmunol.165.1.182; Marriott I, 2001, J NEUROIMMUNOL, V114, P131, DOI 10.1016/S0165-5728(00)00466-5; Martin B, 2008, HISTOL HISTOPATHOL, V23, P237, DOI 10.14670/HH-23.237; Martin B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002398; Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799; MARTIN FC, 1993, J NEUROIMMUNOL, V42, P53, DOI 10.1016/0165-5728(93)90212-H; MARTIN JB, 1984, NEUROLOGY, V34, P1059, DOI 10.1212/WNL.34.8.1059; Matsuishi T, 1999, J NEURAL TRANSM, V106, P943, DOI 10.1007/s007020050214; Matsuishi T, 1996, J NEUROL SCI, V142, P107, DOI 10.1016/0022-510X(96)00159-1; MAUBORGNE A, 1983, BRAIN RES, V268, P167, DOI 10.1016/0006-8993(83)90403-1; Maudsley S, 2006, NAT MED, V12, P392, DOI 10.1038/nm0406-392; Maudsley S, 2005, J PHARMACOL EXP THER, V314, P485, DOI 10.1124/jpet.105.083121; Maudsley S, 1998, BRIT J PHARMACOL, V124, P675, DOI 10.1038/sj.bjp.0701889; MAUDSLEY S, 1995, BRIT J PHARMACOL, V116, pP444; MAUDSLEY S, 1993, BRIT J PHARMACOL, V110, pP175; Maudsley S, 2007, CURR ALZHEIMER RES, V4, P3, DOI 10.2174/156720507779939850; McCluskey LP, 2001, J NEUROIMMUNOL, V116, P136, DOI 10.1016/S0165-5728(01)00295-8; McCutcheon JE, 2008, EUR J NEUROSCI, V27, P683, DOI 10.1111/j.1460-9568.2008.06043.x; McIntosh TK, 1996, LAB INVEST, V74, P315; Morcuende S, 2003, EUR J NEUROSCI, V18, P1828, DOI 10.1046/j.1460-9568.2003.02911.x; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; OHKUBO H, 1991, ANN NY ACAD SCI, V632, P53, DOI 10.1111/j.1749-6632.1991.tb33094.x; Pae CU, 2009, EXPERT OPIN PHARMACO, V10, P1561, DOI 10.1517/14656560902988510; Park SW, 2007, J NEUROSURG, V107, P593, DOI 10.3171/JNS-07/09/0593; Phenna S, 1996, BRIT J PHARMACOL, V119, P315, DOI 10.1111/j.1476-5381.1996.tb15988.x; Pieri M, 2010, NEUROPHARMACOLOGY, V58, P268, DOI 10.1016/j.neuropharm.2009.06.029; Pompei P, 2001, J HISTOCHEM CYTOCHEM, V49, P1469, DOI 10.1177/002215540104901114; Preston Z, 2000, NEUROSCI LETT, V284, P89, DOI 10.1016/S0304-3940(00)00968-X; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; QUIGLEY BJ, 1991, NEUROSCIENCE, V41, P41, DOI 10.1016/0306-4522(91)90199-X; REGOLI D, 1994, PHARMACOL REV, V46, P551; Richfield EK, 2002, MOVEMENT DISORD, V17, P327, DOI 10.1002/mds.10032; RIMON R, 1984, BIOL PSYCHIAT, V19, P509; Rosler N, 2001, J NEURAL TRANSM, V108, P231, DOI 10.1007/s007020170091; Rupniak NMJ, 2000, NEUROPHARMACOLOGY, V39, P1413, DOI 10.1016/S0028-3908(00)00052-6; RUSSELL IJ, 1994, ARTHRITIS RHEUM-US, V37, P1593, DOI 10.1002/art.1780371106; Russell IJ, 2002, RHEUM DIS CLIN N AM, V28, P329, DOI 10.1016/S0889-857X(01)00006-0; Salthun-Lassalle B, 2005, MOL PHARMACOL, V68, P1214, DOI 10.1124/mol.105.015453; Sankhala KK, 2009, EXPERT OPIN DRUG MET, V5, P1607, DOI 10.1517/17425250903451675; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SCHEDLOWSKI M, 1995, PSYCHONEUROENDOCRINO, V20, P103, DOI 10.1016/0306-4530(94)00048-4; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; Shughrue PJ, 1996, J COMP NEUROL, V372, P395; Silva RAD, 2000, SYNAPSE, V38, P243, DOI 10.1002/1098-2396(20001201)38:3<243::AID-SYN3>3.0.CO;2-G; SIVAM SP, 1992, J NEUROCHEM, V59, P2278; Sonomura T, 2007, EUR J NEUROSCI, V26, P3093, DOI 10.1111/j.1460-9568.2007.05923.x; Spooren W, 2005, NAT REV DRUG DISCOV, V4, P967, DOI 10.1038/nrd1905; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; TATEMOTO K, 1985, BIOCHEM BIOPH RES CO, V128, P947, DOI 10.1016/0006-291X(85)90138-X; TENOVUO O, 1984, BRAIN RES, V303, P113, DOI 10.1016/0006-8993(84)90217-8; VAEROY H, 1988, PAIN, V32, P21, DOI 10.1016/0304-3959(88)90019-X; Van Belle S, 2002, CANCER-AM CANCER SOC, V94, P3032, DOI 10.1002/cncr.10516; Vink R, 2004, J AM COLL NUTR, V23, p538S, DOI 10.1080/07315724.2004.10719398; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74; Weiss DW, 1996, BEHAV MED, V22, P5, DOI 10.1080/08964289.1996.9933760; Whitty CJ, 1997, J COMP NEUROL, V382, P394; Willis M, 2007, BRAIN RES, V1143, P199, DOI 10.1016/j.brainres.2007.01.080; WOIE K, 1993, CIRC RES, V73, P839, DOI 10.1161/01.RES.73.5.839; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yew DT, 1999, EXP GERONTOL, V34, P117, DOI 10.1016/S0531-5565(98)00017-5; Yu ZF, 1997, NEUROREPORT, V8, P2117, DOI 10.1097/00001756-199707070-00006; Zachrisson O, 1998, MOL BRAIN RES, V60, P291, DOI 10.1016/S0169-328X(98)00191-0; Zhang X, 2008, NEUROPHARMACOLOGY, V54, P1143, DOI 10.1016/j.neuropharm.2008.03.005; Zhang Y, 2000, NAT IMMUNOL, V1, P392, DOI 10.1038/80826	135	19	19	0	7	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	NOV	2010	9	5					627	635		10.2174/187152710793361504			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	685HW	WOS:000284620800011	20632965	Green Accepted			2021-06-18	
J	Ritz, MF; Graumann, U; Gutierrez, B; Hausmann, O				Ritz, Marie-Francoise; Graumann, Ursula; Gutierrez, Bertha; Hausmann, Oliver			Traumatic Spinal Cord Injury Alters Angiogenic Factors and TGF-Beta1 that may Affect Vascular Recovery	CURRENT NEUROVASCULAR RESEARCH			English	Article						Angiogenic factors; gene expression; rat model; revascularization; spinal cord injury; vessel regression	ENDOTHELIAL GROWTH-FACTOR; BLOOD-BRAIN-BARRIER; VON-WILLEBRAND-FACTOR; CCN FAMILY; FACTOR-B; FUNCTIONAL RECOVERY; COMPRESSION INJURY; CEREBRAL-ISCHEMIA; CONTUSION INJURY; NERVOUS-SYSTEM	Traumatic spinal cord injury (SCI) disrupts the blood-spinal cord barrier and reduces the blood supply caused by microvascular changes. Vessel regression and neovascularization have been observed in the course of secondary injury contributing to microvascular remodeling after trauma. Spatio-temporal distribution of blood vessels and modulation of gene expression of several angiogenic factors have been investigated in rats after spinal cord compression injury. Rarefaction of vessels was detectable at the injury site 2 days after SCI before they disappeared in the developing cavity after 2 and 4 weeks, whereas no changes were observed in the penumbra. Investigation of the temporal expression of angiogenic genes using quantitative RT-PCR disclosed a constant down-regulation of the vascular endothelial growth factor (VEGF), and transient decreases of angiopoietin-1 (Ang-1), platelet-derived growth factor-BB (PDGF-BB), as well as placental growth factor (PlGF), with the lowest values obtained 3 days after injury, when compared to the expression levels obtained in sham-operated rats. Hepatocyte growth factor (HGF) was the only angiogenic factor with a constant increased gene expression when compared with controls, starting at day 3 post-SCI. mRNA levels of transforming growth factor-beta 1 (TGF-beta 1) were elevated at every time point following SCI, whereas those encoding for the cysteine-rich protein CCN1/CYR61 were upregulated after 2 h, 6 h, and 1 week only. Our data provide an overview of the temporal modulated expression of the major angiogenic factors, hampering revascularization in the lesion during the phase of secondary injury. These findings should be considered in order to improve therapeutic interventions.	[Ritz, Marie-Francoise] Pharmactr, Dept Biomed, CH-4056 Basel, Switzerland; [Graumann, Ursula; Gutierrez, Bertha; Hausmann, Oliver] Spinal Injury Res, Swiss Parapleg Res, CH-6207 Nottwil, Switzerland; [Hausmann, Oliver] Neuro & Spine Ctr Hirslanden Clin St Anna, CH-6006 Luzern, Switzerland	Ritz, MF (corresponding author), Pharmactr, Dept Biomed, Klingelbergstr 50, CH-4056 Basel, Switzerland.	marie-francoise.ritz@unibas.ch			Swiss Paraplegic Foundation, Nottwil, Switzerland; Swiss Neuro Institute, Hirslanden, Zurich, Switzerland	This work was supported by the Swiss Paraplegic Foundation, Nottwil, Switzerland, and by the Swiss Neuro Institute, Hirslanden, Zurich, Switzerland.	Aigner L, 2008, CELL TISSUE RES, V331, P225, DOI 10.1007/s00441-007-0466-7; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Bai T, 2010, J IMMUNOL, V184, P3223, DOI 10.4049/jimmunol.0902792; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Beck H, 2002, J NEUROPATH EXP NEUR, V61, P339, DOI 10.1093/jnen/61.4.339; Benton RL, 2009, CURR NEUROVASC RES, V6, P124, DOI 10.2174/156720209788185678; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; BLIGHT AR, 1991, J NEUROL SCI, V106, P158, DOI 10.1016/0022-510X(91)90253-4; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; Buss A, 2008, SPINAL CORD, V46, P364, DOI 10.1038/sj.sc.3102148; Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Chen XH, 2007, J CARD FAIL, V13, P874, DOI 10.1016/j.cardfail.2007.07.004; Chow J, 2001, DEV BRAIN RES, V130, P123, DOI 10.1016/S0165-3806(01)00220-6; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; De Paula EV, 2009, TRANSL RES, V153, P232, DOI 10.1016/j.trsl.2009.02.002; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Fataccioli V, 2002, HUM GENE THER, V13, P1461, DOI 10.1089/10430340260185094; Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570; Graumann U, 2010, CURR NEUROVASC RES, V7, P144, DOI 10.2174/156720210791184907; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Grote K, 2007, BLOOD, V110, P877, DOI 10.1182/blood-2006-07-036202; Han S, 2010, BRAIN, V133, P1026, DOI 10.1093/brain/awq034; Herrera JJ, 2009, J NEUROTRAUM, V26, P995, DOI [10.1089/neu.2008.0779, 10.1089/neu.2008-0779]; Higgins Stephen P, 2009, Cell Commun Insights, V2, P1; Hughes JM, 2007, DIABETOLOGIA, V50, P1089, DOI 10.1007/s00125-007-0621-4; Ieda Y, 2007, J MOL CELL CARDIOL, V42, P540, DOI 10.1016/j.yjmcc.2006.11.015; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; ImperatoKalmar EL, 1997, EXP NEUROL, V145, P322, DOI 10.1006/exnr.1997.6449; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Kaneko M, 1998, ACTA NEUROPATHOL, V95, P471, DOI 10.1007/s004010050827; Kitamura K, 2007, J NEUROSCI RES, V85, P2332, DOI 10.1002/jnr.21372; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lehti K, 2005, GENE DEV, V19, P979, DOI 10.1101/gad.1294605; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li J, 2010, MICROVASC RES, V80, P10, DOI 10.1016/j.mvr.2009.12.002; Li W, 1996, DIABETOLOGIA, V39, P537; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu HB, 2008, ENDOCRINOLOGY, V149, P1666, DOI 10.1210/en.2007-1415; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Ma H, 2002, ATHEROSCLEROSIS, V164, P79, DOI 10.1016/S0021-9150(02)00062-X; Meyuhas R, 2008, MOL CANCER RES, V6, P1397, DOI 10.1158/1541-7786.MCR-07-2086; Montesinos MC, 2004, AM J PATHOL, V164, P1887, DOI 10.1016/S0002-9440(10)63749-2; Mueller CA, 2003, J NEUROIMMUNOL, V135, P1, DOI 10.1016/S0165-5728(02)00427-7; Mueller CA, 2007, J NEUROSURG-SPINE, V7, P205, DOI 10.3171/SPI-07/08/205; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Niimi H, 2003, CLIN HEMORHEOL MICRO, V29, P149; Noubade R, 2008, AM J PATHOL, V173, P892, DOI 10.2353/ajpath.2008.080001; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Ramsauer M, 2007, J CELL SCI, V120, P1810, DOI 10.1242/jcs.003533; Renner O, 2003, MOL BRAIN RES, V113, P44, DOI 10.1016/S0169-328X(03)00085-8; Risau W, 1998, PATHOL BIOL, V46, P171; Roncal C, 2008, J PATHOL, V216, P236, DOI 10.1002/path.2408; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Ruggeri ZM, 2003, CURR OPIN HEMATOL, V10, P142, DOI 10.1097/00062752-200303000-00008; Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0293; Shimamura M, 2007, BRAIN RES, V1151, P188, DOI 10.1016/j.brainres.2007.03.022; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; Van Belle E, 1998, CIRCULATION, V97, P381; Vincent L, 2004, CANCER CELL, V6, P307, DOI 10.1016/j.ccr.2004.09.024; Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Xiyang YB, 2009, J NEUROTRAUM, V26, P275, DOI 10.1089/neu.2007.0374; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; You JJ, 2009, INVEST OPHTH VIS SCI, V50, P3447, DOI 10.1167/iovs.08-2603; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zhang ZC, 2010, ACTA CRYSTALLOGR C, V66, pI9, DOI 10.1107/S0108270109054316; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	84	19	22	0	9	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2026			CURR NEUROVASC RES	Curr. Neurovasc. Res.	NOV	2010	7	4					301	310		10.2174/156720210793180756			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	685IY	WOS:000284623600004	20860549				2021-06-18	
J	Zhang, XM; Du, F; Yang, D; Yu, CJ; Huang, XN; Liu, W; Fu, J				Zhang, Xue-mei; Du, Fang; Yang, Dan; Yu, Chun-jiang; Huang, Xiang-nan; Liu, Wei; Fu, Jin			Transplanted bone marrow stem cells relocate to infarct penumbra and co-express endogenous proliferative and immature neuronal markers in a mouse model of ischemic cerebral stroke	BMC NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; PROGENITOR CELLS; STROMAL CELLS; IN-VIVO; EXPRESSING CELLS; NEUROGENESIS; DOUBLECORTIN; MANIPULATION; WIDESPREAD; INDUCTION	Background: Several studies demonstrate that neurogenesis may be induced or activated following vascular insults, which may be important for neuronal regeneration and functional recovery. Understanding the cellular mechanism underlying stroke-associated neurogenesis is of neurobiological as well as neurological/clinical relevance. The present study attempted to explore potential homing and early development of transplanted bone marrow stem cells in mouse forebrain after focal occlusion of the middle cerebral artery, an experimental model of ischemic stroke. Results: Bone marrow stem cells isolated from donor mice were confirmed by analysis of surface antigen profile, and were pre-labeled with a lipophilic fluorescent dye PKH26, and subsequently transfused into recipient mice with middle cerebral artery coagulation. A large number of PKH26-labeled cells were detected surrounding the infarct site, most of which colocalized with immunolabelings for the proliferating cell nuclear antigen (PCNA) and some also colocalized with the immature neuronal marker doublecortin (DCX) during 1-2 weeks after the bone marrow cells transfusion. Conclusions: The present study shows that transplanted bone morrow cells largely relocate to the infarct penumbra in ischemic mouse cerebrum. These transplanted bone marrow cells appear to undergo a process of in situ proliferation and develop into putative cortical interneurons during the early phase of experimental vascular injury.	[Zhang, Xue-mei; Du, Fang; Yang, Dan; Yu, Chun-jiang; Huang, Xiang-nan; Fu, Jin] Harbin Med Univ, Affiliated Hosp 2, Dept Neurol, Harbin 150086, Peoples R China; [Liu, Wei] Harbin Med Univ, Affiliated Hosp 2, Ctr Res & Expt, Harbin 150086, Peoples R China	Fu, J (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Neurol, Harbin 150086, Peoples R China.	fujin198@126.com					Arlotta P, 2003, EXP GERONTOL, V38, P173, DOI 10.1016/S0531-5565(02)00156-0; Atala A, 2004, ANNU REV BIOMED ENG, V6, P27, DOI 10.1146/annurev.bioeng.6.012204.115707; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Crain BJ, 2005, J NEUROL SCI, V233, P121, DOI 10.1016/j.jns.2005.03.017; Fotheringham AP, 2000, NEUROPATH APPL NEURO, V26, P412, DOI 10.1046/j.1365-2990.2000.00265.x; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Grove JE, 2004, STEM CELLS, V22, P487, DOI 10.1634/stemcells.22-4-487; Gu WG, 2010, STEM CELL RES, V4, P148, DOI 10.1016/j.scr.2009.12.001; Hess DC, 2002, TRENDS MOL MED, V8, P452, DOI 10.1016/S1471-4914(02)02404-8; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Ji KH, 2009, J DERMATOL, V36, P403, DOI 10.1111/j.1346-8138.2009.00666.x; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Jin SZ, 2009, WORLD J GASTROENTERO, V15, P2657, DOI 10.3748/wjg.15.2657; JIN SZ, 2010, DIG DIS SCI; Kawada H, 2006, CIRCULATION, V113, P701, DOI 10.1161/CIRCULATIONAHA.105.563668; Koh LP, 2004, ANN HEMATOL, V83, P286, DOI 10.1007/s00277-003-0810-2; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Magavi SS, 2002, DEV BRAIN RES, V134, P57, DOI 10.1016/S0165-3806(01)00316-9; Mattiesen WRC, 2009, ACTA NEUROPATHOL, V117, P525, DOI 10.1007/s00401-009-0509-0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Nadri S, 2007, INT J DEV BIOL, V51, P723, DOI 10.1387/ijdb.072352ns; Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88; OKADA S, 1992, BLOOD, V80, P3044; Perin EC, 2004, CIRCULATION, V110, pII213, DOI 10.1161/01.CIR.0000138398.77550.62; Shen CC, 2010, CURR NEUROVASC RES, V7, P6, DOI 10.2174/156720210790820208; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Terai S, 2003, J BIOCHEM, V134, P551, DOI 10.1093/jb/mvg173; Tomita T, 1999, RHEUMATOLOGY, V38, P854, DOI 10.1093/rheumatology/38.9.854; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Wang YM, 2007, BRAIN RES, V1167, P118, DOI 10.1016/j.brainres.2007.06.065; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yau TM, 2003, ANN THORAC SURG, V75, P169, DOI 10.1016/S0003-4975(02)04290-X; Zhang XM, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.017.2009; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	42	19	22	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	OCT 25	2010	11								138	10.1186/1471-2202-11-138			9	Neurosciences	Neurosciences & Neurology	675VS	WOS:000283868800001	20973978	DOAJ Gold, Green Published			2021-06-18	
J	Arango-Lasprilla, JC; Ketchum, JM; Cifu, D; Hammond, F; Castillo, C; Nicholls, E; Watanabe, T; Lequerica, A; Deng, XY				Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Cifu, David; Hammond, Flora; Castillo, Camilo; Nicholls, Elizabeth; Watanabe, Thomas; Lequerica, Anthony; Deng, Xiaoyan			Predictors of Extended Rehabilitation Length of Stay After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Length of stay; Prognosis; Rehabilitation	FUNCTIONAL INDEPENDENCE MEASURE; INPATIENT REHABILITATION; VIOLENCE; COMPLICATIONS; OUTCOMES; MODEL	Objective: To develop a prediction rule for acutely identifying patients at risk for extended rehabilitation length of stay (LOS) after traumatic brain injury (TBI) by using demographic and injury characteristics. Design: Retrospective cohort study. Setting: Traumatic Brain Injury Model Systems. Participants: Sample of TBI survivors (N=7284) with injuries occurring between 1999 and 2009. Interventions: Not applicable. Main Outcome Measures: Extended rehabilitation LOS defined as 67 days or longer. Results: A multivariable model was built containing FIM motor and cognitive scores at admission, preinjury level of education, cause of injury, punctate/petechial hemorrhage, acute-care LOS, and primary payor source. The model had good calibration, excellent discrimination (area under the receiver operating characteristic curve = .875). and validated well. Based on this model, a formula for determining the probability of extended rehabilitation LOS and a prediction rule that classifies patients with predicted probabilities greater than 4.9% as at risk for extended rehabilitation LOS were developed. Conclusions: The current predictor model for TBI survivors who require extended inpatient rehabilitation may allow for enhanced rehabilitation team planning, improved patient and family education, and better use of health care resources. Cross-validation of this model with other TBI populations is recommended.	[Arango-Lasprilla, Juan Carlos; Cifu, David; Castillo, Camilo; Nicholls, Elizabeth] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Ketchum, Jessica M.; Deng, Xiaoyan] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Cifu, David; Castillo, Camilo; Nicholls, Elizabeth; Deng, Xiaoyan] Virginia Commonwealth Univ, Ctr Rehabil Sci & Engn, Richmond, VA 23298 USA; [Hammond, Flora] Indiana Univ Sch Med, Indianapolis, IN USA; [Hammond, Flora] Carolinas Rehabil, Charlotte, NC USA; [Watanabe, Thomas] Moss Rehab Albert Einstein Med Ctr, Philadelphia, PA USA; [Lequerica, Anthony] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; [Lequerica, Anthony] Kessler Fdn, W Orange, NJ USA; [Cifu, David] Richmond Vet Adm Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, VCU W Hosp, 3rd Fl,Rm 3-102,1200 E Broad St, Richmond, VA 23298 USA.	jcarangolasp@vcu.edu	Ketchum, Jessica/AAE-8200-2020	Cifu, David/0000-0003-1600-9387; Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education [HI33A070036, HI33A21943-16, HI33A07003]	Supported by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. HI33A070036, HI33A21943-16 and HI33A07003).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; Esselman PC, 2004, ARCH PHYS MED REHAB, V85, P1445, DOI 10.1016/j.apmr.2003.10.018; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Highhouse S, 1996, J BUS PSYCHOL, V11, P85, DOI 10.1007/BF02278258; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; Lew HL, 2002, AM J PHYS MED REHAB, V81, P830, DOI 10.1097/00002060-200211000-00005; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Ottenbacher KJ, 2000, AM J PUBLIC HEALTH, V90, P1920, DOI 10.2105/AJPH.90.12.1920; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Valach L, 2004, INT J REHABIL RES, V27, P135, DOI 10.1097/01.mrr.0000131577.55940.80	20	19	22	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2010	91	10					1495	1504		10.1016/j.apmr.2010.07.010			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	661IT	WOS:000282720300002	20875505				2021-06-18	
J	Hall, BJ; Lally, JE; Vukmanic, EV; Armstrong, JE; Fell, JD; Gupta, DS; Hubscher, CH				Hall, Bradley J.; Lally, Jason E.; Vukmanic, Eric V.; Armstrong, James E.; Fell, Jason D.; Gupta, Daya S.; Hubscher, Charles H.			Spinal Cord Injuries Containing Asymmetrical Damage in the Ventrolateral Funiculus Is Associated With a Higher Incidence of At-Level Allodynia	JOURNAL OF PAIN			English	Article						Allodynia; neuropathic pain; spinal cord injury; neurotrauma; monofilaments; segmental pain	CHRONIC CENTRAL PAIN; CENTRAL NEUROPATHIC PAIN; VON-FREY MONOFILAMENTS; MU-OPIOID RECEPTOR; THALAMIC NEURONS; RODENT MODEL; DORSAL-HORN; RAT; ACTIVATION; INHIBITION	Approximately 70% of male rats receiving severe T8 spinal contusions develop allodynia in T5-7 dermatomes (at-level) beginning 2 weeks after injury. In contrast, rats having either complete transections or dorsal hemisections do not develop allodynia at-level after chronic spinal cord injury (SCI). In the present study, incomplete laceration and contusion injuries were made to test for neuroanatomical correlates between areas of white matter damage/sparing at the lesion epicenter and the presence/absence of allodynia. After incomplete laceration lesions and 6 weeks of behavioral testing, histological reconstruction and analysis of the lesion epicenters revealed a significant difference (P<.001) in the amount of ventrolateral funiculus (VLF) asymmetry between rats showing pain-like responses evoked by touch (74.5% +/- 8.4% side-to-side difference in VLF damage) versus those not responding to touch (11.3% +/- 4.4% side-to-side difference in VLF damage). A 5-week mean allodynia score for each rat that incorporates a full range of forces that are all innocuous in intact controls revealed that the degree of hypersensitivity at level is related to the extent of VLF asymmetry after SCI. No other damaged spinal white matter or gray matter area was correlated with sensitivity to touch. Similar findings were obtained for rats receiving 18 contusions, a more clinically relevant injury. These data suggest that different extents of damage/sparing between the 2 sides of VLF probably are a requisite for the development of allodynia after SCI. Perspective: A side-to-side lesion asymmetry after chronic SCI in a rodent model was found to be highly correlated with the presence and degree of allodynia. Greater insight of key factors contributing to the development and maintenance of chronic neuropathic pain is important for improving quality of life. (C) 2010 by the American Pain Society	[Hall, Bradley J.; Lally, Jason E.; Vukmanic, Eric V.; Armstrong, James E.; Fell, Jason D.; Gupta, Daya S.; Hubscher, Charles H.] Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA	Hubscher, CH (corresponding author), Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.	chhubs01@louisville.edu		Gupta, Daya/0000-0003-1084-9932	National Center for Research Resources (NCRR), NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR015576]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER	Supported by grant No. RR015576 from the National Center for Research Resources (NCRR), a component of the NIH.	Abraham KE, 2001, PAIN, V90, P181, DOI 10.1016/S0304-3959(00)00402-4; BERKLEY KJ, 1995, NAT MED, V1, P766, DOI 10.1038/nm0895-766; BOIVIE J, 1992, SYMP PAIN R, P363; Campbell JN, 2006, NEURON, V52, P77, DOI 10.1016/j.neuron.2006.09.021; Carson F.L., 1990, HISTOTECHNOLOGY SELF; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; CLIFFER KD, 1991, J NEUROSCI, V11, P852; Crown ED, 2006, EXP NEUROL, V199, P397, DOI 10.1016/j.expneurol.2006.01.003; DAVIDOFF G, 1991, SYMP PAIN R, P77; DONOVAN WH, 1982, PARAPLEGIA, V20, P135, DOI 10.1038/sc.1982.27; Eaton MJ, 2006, J NEUROTRAUM, V23, P549, DOI 10.1089/neu.2006.23.549; Finnerup NB, 2007, EXP NEUROL, V207, P139, DOI 10.1016/j.expneurol.2007.06.001; Finnerup NB, 2003, NEUROLOGY, V61, P1569, DOI 10.1212/01.WNL.0000096016.29134.FA; Garcia R, 1998, NEUROSCIENCE, V82, P139; Gerke MB, 2003, NEUROSCIENCE, V117, P715, DOI 10.1016/S0306-4522(02)00961-2; Hains BC, 2003, J NEUROSCI, V23, P8881; HATEM SM, 2007, 2007 NEUR M PLANN SA; HOSOBUCHI Y, 1986, J NEUROSURG, V64, P543, DOI 10.3171/jns.1986.64.4.0543; Hubbard DT, 2007, NEUROSCIENCE, V150, P818, DOI 10.1016/j.neuroscience.2007.10.001; Hubscher CH, 2006, EXP NEUROL, V197, P177, DOI 10.1016/j.expneurol.2005.09.007; Hubscher CH, 2003, J NEUROPHYSIOL, V89, P2, DOI 10.1152/jn.00294.2002; Hubscher CH, 2002, BRAIN RES, V947, P234, DOI 10.1016/S0006-8993(02)02930-X; Hubscher CH, 2001, NEUROREPORT, V12, P2995, DOI 10.1097/00001756-200109170-00048; Hubscher CH, 2008, J NEUROTRAUM, V25, P1241, DOI 10.1089/neu.2008.0515; Hugues S, 2003, J NEUROPHYSIOL, V90, P3224, DOI 10.1152/jn.00895.2002; Hulsebosch CE, 2000, J NEUROTRAUM, V17, P1205, DOI 10.1089/neu.2000.17.1205; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Keizer D, 2007, EUR J ANAESTH, V24, P658, DOI 10.1017/S0265021507000221; Keizer D, 2007, CLIN J PAIN, V23, P85, DOI 10.1097/01.ajp.0000210950.01503.72; Kloos AD, 2005, EXP NEUROL, V191, P251, DOI 10.1016/j.expneurol.2004.09.016; Kohno T, 2005, PAIN, V117, P77, DOI 10.1016/j.pain.2005.05.035; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570; Luna L. G, 1968, MANUAL HISTOLOGIC ST; Markenson Joseph A., 1996, American Journal of Medicine, V101, p6S; MELZACK R, 1982, PAIN, V14, P33, DOI 10.1016/0304-3959(82)90078-1; Merskey H, 1994, CLASSIFICATION CHRON; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Niv David, 2006, Pain Pract, V6, P3, DOI 10.1111/j.1533-2500.2006.00052.x; Oatway MA, 2004, PAIN, V110, P259, DOI 10.1016/j.pain.2004.03.040; Pattany PM, 2002, AM J NEURORADIOL, V23, P901; Porreca F, 2001, J NEUROSCI, V21, P5281, DOI 10.1523/JNEUROSCI.21-14-05281.2001; Reed WR, 2009, J NEUROPHYSIOL, V102, P1062, DOI 10.1152/jn.00165.2009; RICHARDSON RR, 1980, PAIN, V8, P75, DOI 10.1016/0304-3959(80)90091-3; Saade NE, 2006, EXP NEUROL, V197, P157, DOI 10.1016/j.expneurol.2005.09.005; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SIDDALL P, 1995, NEUROREPORT, V6, P1241, DOI 10.1097/00001756-199506090-00003; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Spennato G, 2008, PSYCHOPHARMACOLOGY, V196, P583, DOI 10.1007/s00213-007-0993-7; Sun H, 2001, PAIN, V90, P105, DOI 10.1016/S0304-3959(00)00392-4; Sved P, 1997, SPINAL CORD, V35, P526, DOI 10.1038/sj.sc.3100443; Villanueva L, 2000, PROG PAIN RES MANAG, V16, P371; Wang GX, 2008, J NEUROSCI, V28, P11959, DOI 10.1523/JNEUROSCI.3296-08.2008; Wasner G, 2008, BRAIN, V131, P2387, DOI 10.1093/brain/awn169; WOOLF CJ, 1984, PAIN, V18, P325, DOI 10.1016/0304-3959(84)90045-9; WOOLF CJ, 1984, BRAIN RES, V303, P299, DOI 10.1016/0006-8993(84)91216-2; YAKSH TL, 1989, PAIN, V37, P111, DOI 10.1016/0304-3959(89)90160-7; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; Yu CG, 2005, MOL BRAIN RES, V138, P244, DOI 10.1016/j.molbrainres.2005.04.013; Zhang HJ, 2005, BRAIN RES, V1055, P103, DOI 10.1016/j.brainres.2005.06.072; Zhang YP, 2004, J NEUROSURG, V100, P343, DOI 10.3171/spi.2004.100.4.0343; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007	63	19	19	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	SEP	2010	11	9					864	875		10.1016/j.jpain.2009.12.008			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	652TW	WOS:000282033900007	20338826	Green Accepted			2021-06-18	
J	Jeong, JH; Kim, YZ; Cho, YW; Kim, JS				Jeong, Jae Hyun; Kim, Young Zoon; Cho, Yong Woon; Kim, Joon Soo			Negative effect of hypopituitarism following brain trauma in patients with diffuse axonal injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; diffuse axonal injury; hypopituitarism; functional outcome	HEAD-INJURY; POSTTRAUMATIC HYPOPITUITARISM; COMA	Object. The aim of this prospective observational study was to assess the incidence and pattern of hypopituitarism after diffuse axonal injury (DAI) and to identify its effect on these patients in terms of functional outcome. Methods. Of 1307 patients with traumatic brain injury treated at the authors' institution between March 2005 and June 2008, 65 patients with DAI were enrolled in the present study. The authors determined basal hormone levels, initial Glasgow Coma Scale scores, the Marshall CT grades, the presence of abnormal signal intensity indicating lesions on MR images, and duration of unconsciousness. At the 6-month follow-up visits, functional outcomes were estimated using the Modified Barthel Index. Univariate and multivariate analyses were performed to identify factors that influenced functional outcomes. Results. Twenty-one patients with hypopituitarism (Group A) had more lesions in the body of the corpus callosum, basal ganglia, thalamus, and the gray white matter junction than those without hypopituitarism (Group B). In Group A, growth hormone deficiency (17 patients, 80.9%) was the most common, and multiple pituitary hormone deficiencies were found in 12 patients (57.1%). The mean Modified Barthel Index score at the 6-month follow-up was 64.7 in Group A and 88.5 in Group B (p = 0.027). Duration of unconsciousness (p = 0.035), the Marshall CT grade (p = 0.021), hypopituitarism (p = 0.044), and abnormal signal intensities on MR imaging in midline or deep structures of the brain (p = 0.001) were found to be associated with functional outcome. Conclusions. The findings in this prospective observational study suggest that hypopituitarism in patients with DAI has a relationship not only with injuries in the midline or deep structures of the brain, but also with a poor outcome. (DOI: 10.3171/2009.10.JNS091152)	[Jeong, Jae Hyun; Kim, Young Zoon; Cho, Yong Woon; Kim, Joon Soo] Sungkyunkwan Univ, Sch Med, Masan Samsung Hosp, Dept Neurosurg, Masan 630723, South Korea	Kim, YZ (corresponding author), Sungkyunkwan Univ, Sch Med, Masan Samsung Hosp, Dept Neurosurg, 50,Hapsung 2 Dong, Masan 630723, South Korea.	youngzoon.kim@samsung.com					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1992, GREENFIELDS NEUROPAT, P123; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; Daniel PM, 1961, MOD TRENDS ENDOCR, P55; EDWARDS OM, 1986, MEDICINE, V65, P281; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hernberg-Stahl E, 2001, J CLIN ENDOCR METAB, V86, P5277, DOI 10.1210/jc.86.11.5277; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kusanagi Hiroaki, 2000, Journal of Nippon Medical School, V67, P130, DOI 10.1272/jnms.67.130; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; MAHONEY F I, 1965, Md State Med J, V14, P61; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; TEASDALE G, 1974, LANCET, V2, P81; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807	30	19	19	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					532	538		10.3171/2009.10.JNS091152			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100016	19943735				2021-06-18	
J	Sogut, O; Guloglu, C; Orak, M; Sayhan, MB; Gokdemir, MT; Ustundag, M; Akkus, Z				Sogut, O.; Guloglu, C.; Orak, M.; Sayhan, M. B.; Gokdemir, M. T.; Ustundag, M.; Akkus, Z.			Trauma Scores and Neuron-specific Enolase, Cytokine and C-reactive Protein Levels as Predictors of Mortality in Patients with Blunt Head Trauma	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						BLUNT HEAD TRAUMA; NEURON-SPECIFIC ENOLASE; CYTOKINES; C-REACTIVE PROTEIN; GLASGOW COMA SCALE; REVISED TRAUMA SCORE	ACUTE-PHASE RESPONSE; BRAIN-INJURY; CEREBROSPINAL-FLUID; UNITED-STATES; INTERLEUKIN-6; SERUM; EPIDEMIOLOGY; BIOMARKERS; DIAGNOSIS; EMERGENCY	This study evaluated serum neuron-specific enolase (NSE), cytokine and high-sensitivity C-reactive-protein (hs-CRP) levels, along with the Glasgow Coma Scale (GCS) and Revised Trauma Score (RTS), as predictors of mortality in the early post-traumatic period, in 100 Turkish patients with blunt head trauma. Overall patient mortality was 27%. There was a significant association between age and mortality, and mortality was negatively correlated with GCS and RTS. Head injury severity (GCS) was significantly related to NSE, hs-CRP, interleukin (IL)-6, IL-8 and tumour necrosis factor (TNF)-alpha levels. Mortality correlated positively with IL-6, IL-8, TNF-alpha and hs-CRP levels. NSE, hs-CRP, IL-6, IL-8 and TNF-alpha levels were significantly higher in non-survivors compared with survivors. GCS score <= 8, younger age and NSE levels were significant independent predictors of mortality. During the early post-traumatic period, NSE may be an objective alternative criterion to the GCS, in the management of patients with blunt head trauma.	[Sogut, O.] Harran Univ, Fac Med, Dept Emergency Med, TR-63300 Sanliurfa, Turkey; [Guloglu, C.; Orak, M.; Ustundag, M.] Dicle Univ, Fac Med, Dept Emergency Med, Diyarbakir, Turkey; [Akkus, Z.] Dicle Univ, Fac Med, Dept Biostat, Diyarbakir, Turkey; [Sayhan, M. B.] Edirne Publ Hosp, Emergency Serv, Edirne, Turkey; [Gokdemir, M. T.] Sanliurfa Res & Training Hosp, Dept Emergency Med, Sanliurfa, Turkey	Sogut, O (corresponding author), Harran Univ, Fac Med, Dept Emergency Med, Yenisehir Kampusu, TR-63300 Sanliurfa, Turkey.	drosogut@harran.edu.tr			Scientific Research Projects Committee of Dicle University, Diyarbakir, TurkeyDicle University	The study was financially supported by the Scientific Research Projects Committee of Dicle University, Diyarbakir, Turkey and we should like to thank them for their contribution.	ANASTASIADES KD, 1987, AM J CLIN PATHOL, V87, P245, DOI 10.1093/ajcp/87.2.245; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; Faist E, 1996, WORLD J SURG, V20, P454, DOI 10.1007/s002689900071; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Gabbe BJ, 2003, ANZ J SURG, V73, P944, DOI 10.1046/j.1445-1433.2003.02833.x; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Is M, 2007, J CLIN NEUROSCI, V14, P1163, DOI 10.1016/j.jocn.2006.05.020; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kuhls DA, 2002, J AM COLL SURGEONS, V194, P695, DOI 10.1016/S1072-7515(02)01211-5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Ning, 2004, Chin J Traumatol, V7, P156; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Luk SS, 1999, J TRAUMA, V46, P122, DOI 10.1097/00005373-199901000-00020; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Peden M, 2002, INJURY CHART BOOK GR; PULLICINO EA, 1990, LYMPHOKINE RES, V9, P231; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; ROYDS JA, 1981, J NEUROL NEUROSUR PS, V44, P1129, DOI 10.1136/jnnp.44.12.1129; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055	40	19	19	1	9	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	SEP-OCT	2010	38	5					1708	1720		10.1177/147323001003800516			13	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	695WT	WOS:000285404000016	21309485				2021-06-18	
J	Wei, G; Lu, XCM; Yang, XF; Tortella, FC				Wei, Guo; Lu, Xi-Chun M.; Yang, Xiaofang; Tortella, Frank C.			Intracranial Pressure following Penetrating Ballistic-Like Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral perfusion pressure; intracranial pressure; mean arterial blood pressure; penetrating ballistic-like brain injury; rat	TRAUMATIC BRAIN; GUNSHOT WOUNDS; HEAD-INJURY; ISCHEMIA; NNZ-2566; ANALOG; EDEMA; MODEL	Penetrating ballistic brain injury involves a leading shockwave producing a temporary cavity causing substantial secondary injury. In response to the prevalence of this type of brain trauma in the military, a rat model of penetrating ballistic-like brain injury (PBBI) was established. This study focuses on cerebral physiological responses resulting from a PBBI, specifically the immediate and delayed changes in intracranial pressure (ICP) and cerebral perfusion pressure (CPP). ICP/CPP was measured continuously in rats subjected to PBBI, probe insertion alone, or sham injury. Immediately following the PBBI, a transient (<0.1 sec) and dramatic elevation of ICP reaching 280.0 +/- 86.0 mm Hg occurred, accompanied by a profound decrease in CPP to -180.2 +/- 90.1 mm Hg. This emergent ICP/CPP response resolved spontaneously within seconds, but was followed by a slowly-developing and sustained secondary phase, which peaked at 24 h post-injury, reaching 37.2 +/- 10.4 mm Hg, and remained elevated until 72 h post-injury. The measured decrease in CPP reached 85.3 +/- 17.2 mm Hg at 3 h post-injury. By comparison, probe insertion alone did not produce the immediate ICP crisis (28.6 +/- 9.1 mm Hg), and only a mild and sustained increase in ICP (13.5 +/- 2.1 mm Hg) was observed in the following 3 h post-injury. Injury severity, as measured by lesion volume, brain swelling, and neurological deficits at 1, 3, and 7 days post-injury, also reflected the distinctive differences between the dynamics of the PBBI versus controls. These results not only reinforced the severe nature of this model in mimicking the ballistic effect of PBBI, but also established cerebral pathophysiological targets for neuroprotective therapies.	[Wei, Guo; Lu, Xi-Chun M.; Yang, Xiaofang; Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA	Wei, G (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Guo.Wei@US.ARMY.MIL					Abadal-Centellas JM, 2007, J TRAUMA, V62, P282, DOI 10.1097/01.ta.0000199422.01949.78; BARACH E, 1986, J TRAUMA, V26, P225, DOI 10.1097/00005373-198603000-00003; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Chen ZY, 2009, J NEUROTRAUM, V26, P1987, DOI 10.1089/neu.2008.0863; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Lu XCM, 2009, J CEREBR BLOOD F MET, V29, P1924, DOI 10.1038/jcbfm.2009.109; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Pintar F A, 2001, Biomed Sci Instrum, V37, P429; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Shear DA, 2009, PHARMACOL BIOCHEM BE, V94, P56, DOI 10.1016/j.pbb.2009.07.006; SOBLOSKY JS, 1992, J NEUROSURG, V76, P119, DOI 10.3171/jns.1992.76.1.0119; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; Volgas DA, 2005, INJURY, V36, P380, DOI 10.1016/j.injury.2004.08.038; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2005, PHARMACOL BIOCHEM BE, V81, P182, DOI 10.1016/j.pbb.2005.03.011; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Yoganandan N, 1997, J TRAUMA, V42, P266, DOI 10.1097/00005373-199702000-00014; Zhang JY, 2007, J BIOMECH, V40, P2341, DOI 10.1016/j.jbiomech.2006.10.021; Zhang JY, 2005, J NEUROTRAUM, V22, P1335, DOI 10.1089/neu.2005.22.1335	26	19	19	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1635	1641		10.1089/neu.2010.1378			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500010	20568960				2021-06-18	
J	Klimo, P; Ragel, BT; Scott, WH; McCafferty, R				Klimo, Paul, Jr.; Ragel, Brian T.; Scott, William H., Jr.; McCafferty, Randall			Pediatric neurosurgery during Operation Enduring Freedom Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						pediatric neurosurgery; Operation Enduring Freedom; Afghanistan; penetrating brain injury; humanitarian service	COMBAT SUPPORT HOSPITALS; SURGICAL-TEAM; TRAUMATIC BRAIN; IRAQI FREEDOM; AFGHANISTAN; EXPERIENCE; BLAST; MISSION; INJURY	Object. Operation Enduring Freedom (OEF) is the current US military conflict against terrorist elements in Afghanistan. Deepening US involvement in this conflict and increasing coalition casualties prompted the establishment of continuous neurosurgical assets at Craig Joint Theater Hospital (CJTH) at Bagram Airfield, Afghanistan, in September 2007. As part of the military's medical mission, children with battlefield-related injuries and, on a selective case-by-case basis, non war-related pathological conditions are treated at CJTH. Methods. A prospectively maintained record was created in which all rotating neurosurgeons at CJTH recorded their personal procedures:From this record, the authors were able to extract all cases involving patients 18 years of age or younger. Variables recorded included: age, sex, and category of patient (for example, local national, enemy combatant), date, indication and description of the neurosurgical procedure, mechanism of injury, and in-hospital morbidity and mortality data. Results. From September 2007 to October 2009, 296 neurosurgical procedures were performed at CJTH. Fifty-seven (19%) were performed in 43 pediatric patients (16 girls and 27 boys) with an average age of 7.5 years (range 11 days-18 years). Thirty-one of the 57 procedures (54%) were for battlefield-related trauma and 26 for humanitarian reasons (46%). The vast majority of cases were cranial (49/57, 86%) compared with spinal (7/54, 13%), with one peripheral nerve case. Craniotomies or craniectomies for penetrating brain injuries were the most common procedures. There were 5 complications (11.6%) and 4 in-hospital deaths (9.3%). Conclusions. As in previous military conflicts, children are the unfortunate victims of the current Afghanistan campaign. Extremely limited pediatric neurosurgical service and care is rendered under challenging conditions and Air Force neurosurgeons provide valuable, life-saving pediatric treatment for both war-related injuries and humanitarian needs. As the conflict in Afghanistan continues, military neurosurgeons will continue to care for injured children to the best of their abilities. (DOI:10.317112010.3.PEDS109)	[Klimo, Paul, Jr.] 88th Med Grp, Wright Patterson AFB, OH 45433 USA; [Ragel, Brian T.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; [Scott, William H., Jr.] 99th Med Operat Squadron, Nellis AFB, NV USA; [McCafferty, Randall] Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA	Klimo, P (corresponding author), 88th Med Grp, 4881 Sugar Maple Dr, Wright Patterson AFB, OH 45433 USA.	atomkpnk@yahoo.com					Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Beekley AC, 2004, AM J SURG, V187, P652, DOI 10.1016/j.amjsurg.2004.02.001; Beekley AC, 2009, J TRAUMA, V66, pS129, DOI 10.1097/TA.0b013e31819d85e7; Beitler AL, 2006, MIL MED, V171, P189, DOI 10.7205/MILMED.171.3.189; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bono Christopher M, 2004, Spine J, V4, P230, DOI 10.1016/S1529-9430(03)00178-5; Burnett MW, 2008, PEDIATRICS, V121, P261, DOI 10.1542/peds.2006-3666; Coppola CP, 2006, ARCH PEDIAT ADOL MED, V160, P972, DOI 10.1001/archpedi.160.9.972; Creamer KM, 2009, J TRAUMA, V67, P762, DOI 10.1097/TA.0b013e31818b1e15; Djientcheu VD, 2008, J NEUROL SCI, V275, P29, DOI 10.1016/j.jns.2008.07.003; Eastridge BJ, 2009, J TRAUMA, V66, pS48, DOI 10.1097/TA.0b013e31819ce315; Fuenfer MM, 2009, MIL MED, V174, P887, DOI 10.7205/MILMED-D-02-2308; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; KLIMO P, 2009, YOUNG NEUROSURGE SPR, P3; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Martin M, 2009, J TRAUMA, V66, pS51, DOI 10.1097/TA.0b013e31819d86ad; Matos RI, 2008, PEDIATRICS, V122, pE959, DOI 10.1542/peds.2008-1244; McGuigan R, 2007, J PEDIATR SURG, V42, P207, DOI 10.1016/j.jpedsurg.2006.09.020; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Nessen SC, 2009, J TRAUMA, V66, pS37, DOI 10.1097/TA.0b013e31819ce302; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peoples GE, 2005, MIL MED, V170, P462, DOI 10.7205/MILMED.170.6.462; Spinella PC, 2008, CRIT CARE MED, V36, pS293, DOI 10.1097/CCM.0b013e31817da99f; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warf BC, 2005, J NEUROSURG, V103, P475, DOI 10.3171/ped.2005.103.6.0475	25	19	19	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2010	6	2					107	114		10.3171/2010.3.PEDS109			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	632ES	WOS:000280404400001	20672929				2021-06-18	
J	Shen, YC; Hsia, RY				Shen, Yu-Chu; Hsia, Renee Y.			Changes in Emergency Department Access Between 2001 and 2005 Among General and Vulnerable Populations	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; SAFETY-NET HOSPITALS; RACIAL DISPARITIES; PRIMARY-CARE; HEALTH-INSURANCE; UNITED-STATES; FINANCIAL-PRESSURE; RISK-FACTORS; MORTALITY; TRENDS	Objectives. We analyzed how ease of geographic access to emergency departments (EDs), defined as driving time to the closest ED, changed between 2001 and 2005, and whether access deterioration was more likely to occur in vulnerable communities. Methods. We classified communities on the basis of American Hospital Association and Census data into 3 categories according to driving time to the nearest ED: no increase, less than a 10-minute increase, and a 10-minute or more increase. We estimated a multinomial logit model to examine the relative risk ratio (RRR) of various community characteristics. Results. More than 95% of communities experienced no ED access deterioration. However, 11.4 million people experienced increased driving time to their nearest ED. Low-income communities had a higher risk of facing deteriorating access compared with high-income communities (urban: RRR=3.67; P<.01; rural: RRR= 1.75; P<.10), and communities with higher shares of Hispanics also had higher risks of facing declines (urban: RRR=3.41; P<.10; rural: RRR=2.67; P<.01). Conclusions. Deteriorating access to EDs is more likely to occur in communities with economic hardship and high shares of Hispanic populations. The uneven access to critical services warrants increased attention from policy-making bodies. (Am J Public Health. 2010;100:1462-1469. doi:10.2105/AJPH.2009.175828)	[Shen, Yu-Chu] USN, Grad Sch Business & Publ Policy, Postgrad Sch, Monterey, CA 93943 USA; [Shen, Yu-Chu] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Hsia, Renee Y.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Hsia, Renee Y.] San Francisco Gen Hosp, Emergency Dept, San Francisco, CA 94110 USA	Shen, YC (corresponding author), USN, Grad Sch Business & Publ Policy, Postgrad Sch, 555 Dyer Rd,Code GB, Monterey, CA 93943 USA.	yshen@nps.edu			Robert Wood Johnson Foundation's Changes in Health Care Financing and Organization initiativeRobert Wood Johnson Foundation (RWJF) [63974]; Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); National Institutes of Health/National Center for Research Resources, University of California, San Francisco Clinical and Translational ScienceUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)University of California System [KL2 RR024130]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024130] Funding Source: NIH RePORTER	This project was supported by the Robert Wood Johnson Foundation's Changes in Health Care Financing and Organization initiative (grant 63974). In addition, R.Y. Hsia was supported in part by a grant under the Robert Wood Johnson Foundation's Physician Faculty Scholars Program and the National Institutes of Health/National Center for Research Resources, University of California, San Francisco Clinical and Translational Science (KL2 RR024130).	*AM HOSP ASS, 2001, AHA TREND WATCH, V3, P1; *AM HOSP ASS, 2005, AHA ANN SURV DAT FIS; Arthur M, 2008, MED CARE, V46, P192, DOI 10.1097/MLR.0b013e31815b9d8e; Bazzoll GJ, 2005, HEALTH AFFAIR, V24, P1047, DOI 10.1377/hlthaff.24.4.1047; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Burt Catharine W, 2006, Adv Data, P1; Carr BG, 2009, ANN EMERG MED, V54, P261, DOI 10.1016/j.annemergmed.2008.11.016; Chang DC, 2005, MED CLIN N AM, V89, P945, DOI 10.1016/j.mcna.2005.05.005; Committee on the Future of Emergency Care in the United States Health System Institute of Medicine, 2007, HOSP BAS EM CAR BREA; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; Derlet RW, 2001, ACAD EMERG MED, V8, P151, DOI 10.1111/j.1553-2712.2001.tb01280.x; Gaskin DJ, 1999, J URBAN HEALTH, V76, P351, DOI 10.1007/BF02345673; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; *HLTH RES SERV ADM, 2005, AR RES FIL; Hunt KA, 2006, ANN EMERG MED, V48, P1, DOI 10.1016/j.annemergmed.2005.12.030; Krause JS, 2006, J SPINAL CORD MED, V29, P17, DOI 10.1080/10790268.2006.11753852; Lambe S, 2002, ANN EMERG MED, V39, P389, DOI 10.1067/mem.2002.122433; LOVE RF, 1979, MANAGE SCI, V25, P130, DOI 10.1287/mnsc.25.2.130; Lucas Jacqueline W, 2005, Vital Health Stat 10, P1; McConnel C E, 1999, Prehosp Disaster Med, V14, P232; McConnel CE, 1998, SOC SCI MED, V46, P1027, DOI 10.1016/S0277-9536(97)10029-6; MELNICK GA, 2004, HLTH AFF MILLWOOD S; Nawar Eric W, 2007, Adv Data, P1; O'Toole TP, 2002, J URBAN HEALTH, V79, P200, DOI 10.1093/jurban/79.2.200; OHARE WP, 1985, POPUL BULL, V40, P1; PHIBBS C, 2010, PAT INC COST EST TRA; Phibbs CS, 1995, MED CARE RES REV, V52, P532, DOI 10.1177/107755879505200406; Pitts Stephen R, 2008, Natl Health Stat Report, P1; Rust G, 2008, ARCH INTERN MED, V168, P1705, DOI 10.1001/archinte.168.15.1705; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shen YC, 2003, J HEALTH ECON, V22, P243, DOI 10.1016/S0167-6296(02)00124-8; Shen YC, 2009, INT J HEALTH CARE FI, V9, P211, DOI 10.1007/s10754-009-9066-2; Shen YC, 2009, MED CARE, V47, P968, DOI 10.1097/MLR.0b013e31819c9415; Shermer CR, 2007, J TRAUMA, V63, P1268; Sinay UT, 1998, J RURAL HEALTH, V14, P357, DOI 10.1111/j.1748-0361.1998.tb00641.x; Singh GK, 2006, INT J EPIDEMIOL, V35, P903, DOI 10.1093/ije/dyl089; Suruda A, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-29; Thamer M, 1997, AM J PUBLIC HEALTH, V87, P96, DOI 10.2105/AJPH.87.1.96; U.S. Census Bureau, 2002, CENS 2000 SUMM FIL 3; U.S. Government Accountability Office, 2009, HOSP EM DEP CROWD CO; Weber EJ, 2005, ANN EMERG MED, V45, P4, DOI 10.1016/j.annemergmed.2004.06.023; WILNER D, 1977, J MAINE MED ASSOC, V68, P401	43	19	19	0	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	AUG	2010	100	8					1462	1469		10.2105/AJPH.2009.175828			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	656RR	WOS:000282354800025	20558800	Green Published, Green Accepted			2021-06-18	
J	Wang, GS; Zhou, DS; Wang, CZ; Gao, YQ; Zhou, QQ; Qian, GS; DeCoster, MA				Wang, Guansong; Zhou, Deshan; Wang, Changzheng; Gao, Yuqi; Zhou, Qiquan; Qian, Guisheng; DeCoster, Mark A.			Hypoxic preconditioning suppresses group III secreted phospholipase A2-induced apoptosis via JAK2-STAT3 activation in cortical neurons	JOURNAL OF NEUROCHEMISTRY			English	Article						anoxia; cortical neurons; JAK2; pre-conditioning; secreted phospholipase A2; STAT3	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; M-TYPE RECEPTOR; NF-KAPPA-B; UP-REGULATION; SEQUENTIAL ACTIVATION; INTRAVENOUS-INFUSION; GENE-EXPRESSION; CEREBRAL-CORTEX; GROWTH-FACTOR	Our previous studies show that group III secreted phospholipases A(2) (sPLA(2)s III) induces extensive neuronal apoptosis in brain cortical cultures. However, the molecular mechanisms underlying sPLA(2) III-induced neuronal injury/death are still unknown. Also it is not clear whether hypoxic pre-conditioning (HPC) is able to protect neurons from the sPLA(2) III insult. In this report, we demonstrate that sPLA(2) III significantly decreased production of Bcl-xl and the ratio of Bcl-xl/Bax, and increased expression of Bax, cleaved caspase 3, and cleaved alpha-Fodrin in primary neuronal culture. HPC prevented the sPLA(2) III-induced decreases in production of Bcl-xl and the ratio of Bcl-xl/Bax, and increases in expression of Bax, cleaved caspase 3, and alpha-Fodrin. However, the HPC-produced neuronal protection was eliminated or attenuated by AG490, rapamycin, and STAT3 shRNA. Our results suggest that sPLA(2) III-induced neuronal apoptosis is likely because of its alterations in expression and activity of Bcl-xl, Bax, caspase 3, and its target gene fodrin; and that HPC-produced neuroprotection against the sPLA(2) III toxicity is mediated via JAK-STAT signal pathways that regulate the expression of Bcl-xl, Bax, and cleaved caspase 3 in cultured cortical neurons.	[Wang, Guansong; Wang, Changzheng; Qian, Guisheng] Third Mil Med Univ China, Inst Resp Dis, Affiliated Hosp 2, Chongqing 400037, Peoples R China; [Zhou, Deshan; Gao, Yuqi; Zhou, Qiquan] Third Mil Med Univ China, Dept Neurosci Histol & Altitude Mil Med, Chongqing, Peoples R China; [DeCoster, Mark A.] Louisiana Tech Univ, Inst MicroMfg, Ruston, LA 71270 USA	Qian, GS (corresponding author), Third Mil Med Univ China, Inst Resp Dis, Affiliated Hosp 2, Chongqing 400037, Peoples R China.	wanggs2003@hotmail.com; qiangs@mail.tmmu.com.cn; decoster@latech.edu	DeCoster, Mark/AAF-5224-2020		National Natural Scientific Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30770928, 30971309]; PLA [080093, 06G083]; 973 program of ChinaNational Basic Research Program of China [2006CB504100]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20RR016456]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016456] Funding Source: NIH RePORTER	This work was supported by the National Natural Scientific Foundation of China Grants 30770928 and 30971309 (to G. Wang), the PLA Grants 080093 (to G. Wang) and 06G083 (G. Qian), 973 program of China Grant 2006CB504100 (to Y. Gao), and National Institutes of Health Grant P20RR016456 (M. DeCoster). We are grateful to Dr. Chu Chen from Neuroscience Center, Louisiana State University Health Sciences Center for the critical comments and good suggestions on this manuscript.	Ayala-Grosso C, 2006, NEUROSCIENCE, V141, P863, DOI 10.1016/j.neuroscience.2006.04.041; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Cao GD, 2002, J NEUROSCI, V22, P5423; Chan SL, 2004, CLIN EXP PHARMACOL P, V31, P119, DOI 10.1111/j.1440-1681.2004.03975.x; Chang AY, 2005, EXP NEUROL, V195, P40, DOI 10.1016/j.expneurol.2004.09.014; CHCNG A, 2007, J NEUROSCI, V27, P1519; Chen HH, 2007, EXP CELL RES, V313, P3106, DOI 10.1016/j.yexcr.2007.04.026; Chong ZZ, 2007, BRIT J PHARMACOL, V150, P839, DOI 10.1038/sj.bjp.0707161; Cunha-Oliveira T, 2007, J NEUROCHEM, V101, P543, DOI 10.1111/j.1471-4159.2006.04406.x; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Daniel B, 2004, BRAIN RES PROTOC, V13, P144, DOI 10.1016/j.brainresprot.2004.04.001; DeCoster MA, 2003, BRAIN RES, V988, P20, DOI 10.1016/S0006-8993(03)03326-2; DeCoster MA, 2002, J NEUROSCI RES, V67, P634, DOI 10.1002/jnr.10131; Dey S, 2007, NEUROSCIENCE, V144, P509, DOI 10.1016/j.neuroscience.2006.09.047; Dhandapani KM, 2005, J NEUROCHEM, V95, P9, DOI 10.1111/j.1471-4159.2005.03319.x; Dudley AC, 2005, BIOCHEM J, V390, P427, DOI 10.1042/BJ20050351; Geocadin RG, 2005, BRAIN RES, V1064, P146, DOI 10.1016/j.brainres.2005.04.046; Guaiquil VH, 2004, FREE RADICAL BIO MED, V37, P1419, DOI 10.1016/j.freeradbiomed.2004.06.041; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Kumar A, 2006, ENDOCRINOLOGY, V147, P4893, DOI 10.1210/en.2006-0027; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Li GH, 2009, J NEURO-ONCOL, V91, P165, DOI 10.1007/s11060-008-9696-0; Liang Zhang, 2007, Genomics Proteomics & Bioinformatics, V5, P25, DOI 10.1016/S1672-0229(07)60011-4; Lin AMY, 2003, ANN NY ACAD SCI, V993, P168, DOI 10.1111/j.1749-6632.2003.tb07527.x; Liu J, 2005, STROKE, V36, P1264, DOI 10.1161/01.STR.0000166180.91042.02; Lu Y, 2006, J BIOL CHEM, V281, P36683, DOI 10.1074/jbc.M607374200; Ma FY, 2005, ENDOCRINOLOGY, V146, P5112, DOI 10.1210/en.2005-0770; Ma MC, 2005, J BIOL CHEM, V280, P16208, DOI 10.1074/jbc.M408055200; Mascareno E, 2005, VASC PHARMACOL, V43, P327, DOI 10.1016/j.vph.2005.08.023; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; Panzeri C, 2006, BRAIN, V129, P1710, DOI 10.1093/brain/awl104; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Rouault M, 2007, BIOCHEMISTRY-US, V46, P1647, DOI 10.1021/bi062119b; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakanaka M, 2007, J NEUROTRAUM, V24, P1037, DOI 10.1089/neu.2006.0182; Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009; Shou Y, 2002, J NEUROCHEM, V81, P842, DOI 10.1046/j.1471-4159.2002.00880.x; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; Terui K, 2004, J HEPATOL, V41, P957, DOI 10.1016/j.jhep.2004.08.019; Titsworth WL, 2007, EXP NEUROL, V207, P150, DOI 10.1016/j.expneurol.2007.06.010; Titsworth WL, 2008, CNS NEUROL DISORD-DR, V7, P254, DOI 10.2174/187152708784936671; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Wang GS, 2005, CELL BIOL INT, V29, P598, DOI 10.1016/j.cellbi.2005.03.014; Wang GS, 2005, NEUROREPORT, V16, P1345, DOI 10.1097/01.wnr.0000174403.79020.65; Wang G, 2008, INT J BIOCHEM CELL B, V40, P461, DOI 10.1016/j.biocel.2007.08.008; Wick A, 2002, J NEUROSCI, V22, P6401; Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yap YW, 2006, J NEUROCHEM, V98, P1597, DOI 10.1111/j.1471-4159.2006.03996.x; Yata K, 2007, BRAIN RES, V1145, P227, DOI 10.1016/j.brainres.2007.01.144; Yin W, 2007, STROKE, V38, P1017, DOI 10.1161/01.STR.0000258102.18836.ca; Zhang B, 2006, J CEREBR BLOOD F MET, V26, P708, DOI 10.1038/sj.jcbfm.9600225; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	57	19	21	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2010	114	4					1039	1048		10.1111/j.1471-4159.2010.00817.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	636EC	WOS:000280710100010	20492356				2021-06-18	
J	Wang, T; Zheng, W; Xu, H; Zhou, JM; Wang, ZY				Wang, Tao; Zheng, Wei; Xu, He; Zhou, Jia-Min; Wang, Zhan-You			Clioquinol Inhibits Zinc-Triggered Caspase Activation in the Hippocampal CA1 Region of a Global Ischemic Gerbil Model	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; NEURONAL DEATH; TRANSIENT ISCHEMIA; TRANSGENIC MICE; CANCER-CELLS; IN-VITRO; APOPTOSIS; CHELATOR	Background: Excessive release of chelatable zinc from excitatory synaptic vesicles is involved in the pathogenesis of selective neuronal cell death following transient forebrain ischemia. The present study was designed to examine the neuroprotective effect of a membrane-permeable zinc chelator, clioquinol (CQ), in the CA1 region of the gerbil hippocampus after transient global ischemia. Methodology/Principal Findings: The common carotid arteries were occluded bilaterally, and CQ (10 mg/kg, i.p.) was injected into gerbils once a day. The zinc chelating effect of CQ was examined with TSQ fluorescence and autometallography. Neuronal death, the expression levels of caspases and apoptosis inducing factor (AIF) were evaluated using TUNEL, in situ hybridization and Western blotting, respectively. We were able to show for the first time that CQ treatment attenuates the ischemia-induced zinc accumulation in the CA1 pyramidal neurons, accompanied by less neuronal loss in the CA1 field of the hippocampus after ischemia. Furthermore, the expression levels of caspase-3, -9, and AIF were significantly decreased in the hippocampus of CQ-treated gerbils. Conclusions/Significance: The present study indicates that the neuroprotective effect of CQ is related to downregulation of zinc-triggered caspase activation in the hippocampal CA1 region of gerbils with global ischemia.	[Wang, Tao; Zheng, Wei; Xu, He; Zhou, Jia-Min; Wang, Zhan-You] China Med Univ, Coll Basic Med Sci, Minist Educ China, Key Lab Med Cell Biol, Shenyang, Peoples R China	Wang, T (corresponding author), China Med Univ, Coll Basic Med Sci, Minist Educ China, Key Lab Med Cell Biol, Shenyang, Peoples R China.	zhanyouw@hotmail.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30370452, 30770680]; Program for New Century Excellent Talents in UniversityProgram for New Century Excellent Talents in University (NCET) [NCET-04-0288]; Department of Education of Liaoning Province [20060948]	The study was supported by the Natural Science Foundation of China (30370452, 30770680), the Program for New Century Excellent Talents in University (NCET-04-0288), and the Research Project for Universities of the Department of Education of Liaoning Province (20060948). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adlard PA, 2008, NEURON, V59, P43, DOI 10.1016/j.neuron.2008.06.018; ARAKI T, 1989, ACTA NEUROL SCAND, V80, P548, DOI 10.1111/j.1600-0404.1989.tb03925.x; BarKalifa R, 2009, EUR J PHARMACOL, V618, P15, DOI 10.1016/j.ejphar.2009.07.019; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Carboni S, 2005, J NEUROCHEM, V92, P1054, DOI 10.1111/j.1471-4159.2004.02925.x; Chen D, 2007, CANCER RES, V67, P1636, DOI 10.1158/0008-5472.CAN-06-3546; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; DANSCHER G, 1982, HISTOCHEMISTRY, V76, P281, DOI 10.1007/BF00543951; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001; Diener HC, 2008, STROKE, V39, P1774, DOI 10.1161/STROKEAHA.107.506378; Doering P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010131; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Gao HL, 2009, NEUROTOX RES, V16, P416, DOI 10.1007/s12640-009-9072-7; Gupta S, 2006, BIOL PHARM BULL, V29, P957, DOI 10.1248/bpb.29.957; Hegde ML, 2009, J ALZHEIMERS DIS, V17, P457, DOI 10.3233/JAD-2009-1068; Hetz C, 2005, J BIOL CHEM, V280, P42960, DOI 10.1074/jbc.M505843200; Ibach B, 2005, PHARMACOPSYCHIATRY, V38, P178, DOI 10.1055/s-2005-871241; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Medvedeva YV, 2009, J NEUROSCI, V29, P1105, DOI 10.1523/JNEUROSCI.4604-08.2009; Nguyen T, 2005, P NATL ACAD SCI USA, V102, P11840, DOI 10.1073/pnas.0502177102; Nitzan YB, 2003, J MOL MED-JMM, V81, P637, DOI 10.1007/s00109-003-0462-7; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Park JA, 2000, J NEUROSCI, V20, P9096; Regland B, 2001, DEMENT GERIATR COGN, V12, P408, DOI 10.1159/000051288; Ritchie CW, 2004, EXPERT OPIN INV DRUG, V13, P1585, DOI 10.1517/13543784.13.12.1585; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Strosznajder R, 2006, ACTA NEUROBIOL EXP, V66, P15; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; White AR, 2006, J BIOL CHEM, V281, P17670, DOI 10.1074/jbc.M602487200; Xu H, 2011, HIPPOCAMPUS, V21, P495, DOI 10.1002/hipo.20767; Yu HJ, 2009, BIOCHEM J, V417, P133, DOI 10.1042/BJ20081421; Zhang LH, 2010, NEUROBIOL AGING, V31, P74, DOI 10.1016/j.neurobiolaging.2008.02.018	42	19	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2010	5	7							e11888	10.1371/journal.pone.0011888			9	Multidisciplinary Sciences	Science & Technology - Other Topics	633QY	WOS:000280520200047	20686690	DOAJ Gold, Green Published			2021-06-18	
J	Gervasi, O; Magni, R; Zampolini, M				Gervasi, Osvaldo; Magni, Riccardo; Zampolini, Mauro			Nu!RehaVR: virtual reality in neuro tele-rehabilitation of patients with traumatic brain injury and stroke	VIRTUAL REALITY			English	Article						Nu!RehaVR; Virtual reality; Tele-rehabilitation; Neurological disease; Nu!Reha desk; Traumatic brain Injury; Stroke patients; X3D; Ajax3D	UPPER EXTREMITY; TELEREHABILITATION; NEEDS; INTERNET; GLOVE	The availability of virtual environments on the Web is fostering new applications of virtual reality in several fields, including some therapeutical applications. We present an application of virtual reality applied to the tele-rehabilitation of patients with traumatic brain injury and stroke. Our system, based on X3D and Ajax3D technologies, enhances the possibility of making tele-rehabilitation exercises aimed at the recovery of the neurological disease. The system, called Nu!RehaVR, has been designed to integrate the activity carried out on a tele-rehabilitation system, Nu!Reha (Nu!Reha is a trademark of Pragma Engineering srl. See http://www.nureha.eu) desk, with the activities performed in the virtual worlds, through some rehabilitation exercises in contexts incompatible with the patients' impairments (not able to move or forced in static positions because of therapies, etc.). The architecture of Nu!RehaVR and the environments associated to two exercises, "Utilising an elevator to reach a given floor" and "Crossing a road using a traffic light", are illustrated. These exercises can be considered as prototypes of a series of tele-rehabilitation exercises which help to stimulate the patients performing actions in relatively dangerous scenarios. The system is designed to allow the remote monitoring and assessment of the patient's activities by the medical staff at the hospital using the communication facilities of the tele-rehabilitation system.	[Gervasi, Osvaldo] Univ Perugia, Dept Math & Comp Sci, I-06123 Perugia, Italy; [Magni, Riccardo] Pragma Engn Srl, I-06100 Perugia, Italy; [Zampolini, Mauro] Foligno Hosp, Reg Umbria ASL3, Dept Rehabil, I-06034 Foligno, PG, Italy	Gervasi, O (corresponding author), Univ Perugia, Dept Math & Comp Sci, Via Vanvitelli 1, I-06123 Perugia, Italy.	osvaldo@unipg.it; riccardo.magni@pragmaeng.it; m.zampolini@als3.umbria.it	Gervasi, Osvaldo/AAH-2792-2019; Gervasi, Osvaldo/B-9234-2013	Gervasi, Osvaldo/0000-0003-4327-520X	EUEuropean Commission	EU projects IST H-CAD and eTen Hellodoc are acknowledged for having promoted the concept of tele-rehabilitation applied to neuro-rehabilitation practice and for the support provided. The Working Group "ELAMS" of the COST D37 Action is acknowledged for the useful knowledge and technology contribution provided to the present research.	Burdea G, 2000, IEEE T REHABIL ENG, V8, P430, DOI 10.1109/86.867886; Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381; Hauber RP, 2002, J HEAD TRAUMA REHAB, V17, P535, DOI 10.1097/00001199-200212000-00005; Heuser A, 2007, IEEE T NEUR SYS REH, V15, P43, DOI 10.1109/TNSRE.2007.891393; Hill AJ, 2006, AM J SPEECH-LANG PAT, V15, P45, DOI 10.1044/1058-0360(2006/006); Holden MK, 2007, IEEE T NEUR SYS REH, V15, P36, DOI 10.1109/TNSRE.2007.891388; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; HUMBLER NR, 2004, TELEMED J E-HEALTH, V10, P129; HUYGENS B, 2008, J TELEMED TELECARE, V14, P249, DOI DOI 10.1258/JET.2008.080104; IRON L, 2004, MED INFORM INTERNET, V29, P119; IRON L, 2001, STUD HLTH TECHNOL IN, V81, P386; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Nakanishi J, 2004, NEURAL NETWORKS, V17, P1453, DOI 10.1016/j.neunet.2004.05.003; Page SJ, 2007, ARCH PHYS MED REHAB, V88, P922, DOI 10.1016/j.apmr.2007.03.038; Placidi G, 2007, COMPUT BIOL MED, V37, P1100, DOI 10.1016/j.compbiomed.2006.09.011; PRINTABLE DH, 2004, J REHABIL RES DEV, V41, P481; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Riva G, 2005, CYBERPSYCHOL BEHAV, V8, P220, DOI 10.1089/cpb.2005.8.220; Riva G, 2007, LECT NOTES COMPUT SC, V4563, P699; Rizzo AA, 2004, TELEMED J E-HEALTH, V10, P184, DOI 10.1089/1530562041641336; Robinson SS, 2003, TELEMED J E-HEALTH, V9, P57, DOI 10.1089/153056203763317657; Russell TG, 2002, J TELEMED TELECARE, V8, P50, DOI 10.1258/13576330260440853; Sanford JA, 2004, ASSIST TECHNOL, V16, P43, DOI 10.1080/10400435.2004.10132073; Sanford JA, 2006, J AM GERIATR SOC, V54, P1641, DOI 10.1111/j.1532-5415.2006.00913.x; Torsney K, 2003, NEUROREHABILITATION, V18, P183; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; ZAMPOLINI M, 2007, IEEE VIRTUAL RE 0927, P83; Zampolini M, 2008, LECT NOTES COMPUT SC, V5073, P78	29	19	19	1	22	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338			VIRTUAL REAL-LONDON	Virtual Real.	JUN	2010	14	2					131	141		10.1007/s10055-009-0149-7			11	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	838HV	WOS:000296279600004					2021-06-18	
J	Cao, Y; He, W				Cao, Yu; He, Wei			Synthesis and Characterization of Glucocorticoid Functionalized Poly(N-vinyl pyrrolidone): A Versatile Prodrug for Neural Interface	BIOMACROMOLECULES			English	Article							SILICON MICROELECTRODE ARRAYS; ALTERNATING MULTILAYER FILM; TRAUMATIC BRAIN-INJURY; DRUG-DELIVERY; IN-VIVO; TISSUE-RESPONSE; NERVOUS-SYSTEM; POLYMER-FILMS; PH; DEVICES	A poly(N-vinyl pyrrolidone)-based glucocorticoid prodrug was synthesized via a hydrazone linkage and characterized by H-1 NMR and UV-vis spectroscopy. pH sensitivity of drug release from the prodrug was observed under conditions mimicking inflammation-induced tissue acidosis. Multi layers of poly(acrylic acid)/prodrug were successfully deposited onto silicon substrates via hydrogen bond-driven layer-by-layer (LBL) assembly. The layers were destructible when incubated in physiological pH, which could be beneficial for biosensors such as neural electrodes. Bioactivity of the prodrug and its released free drug were studied with RAW264.7 macrophages in vitro, where inhibition of nitric oxide production was observed, suggesting the desired anti-inflammatory effect. Neural culture showed that both the prodrug and its precursor polymer were nontoxic to neurons and did not alter the ability of neurons to maintain neurite extensions, reassuring further application of this prodrug to mitigate inflammation at the neural interface. This system allows localized pharmacological interventions that deliver anti-inflammatory drugs based on the extent of inflammation without interfering with the electrical properties of Me neural electrodes.	[Cao, Yu; He, Wei] Univ Tennessee, Dept Mat Sci & Engn, Knoxville, TN 37996 USA; [He, Wei] Univ Tennessee, Dept Mech Aerosp & Biomed Engn, Knoxville, TN 37996 USA	He, W (corresponding author), Univ Tennessee, Dept Mat Sci & Engn, Knoxville, TN 37996 USA.	whe5@utk.edu	He, Wei/K-7218-2013	He, Wei/0000-0002-6638-9691	University of Tennessee	The research was supported by the startup fund from the University of Tennessee. We thank Dr. Tim Sparer (Department of Microbiology, the University of Tennessee) for kindly providing macrophages, Dr. Bin Zhao's group (Department of Chemistry, the University of Tennessee) for use of the ellipsometer and GPC, and Dr. Fang Cheng (Department of Bioengineering, University of Washington) for helpful suggestions. We also appreciate Zheng Cao and Jonathan Page for their help with cell culture and insightful discussions.	Abidian MR, 2008, BIOMATERIALS, V29, P1273, DOI 10.1016/j.biomaterials.2007.11.022; Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; Basu A, 2006, BIOCONJUGATE CHEM, V17, P618, DOI 10.1021/bc050322y; Bencini M, 2005, MACROMOLECULES, V38, P8211, DOI 10.1021/ma050422z; Bencini M, 2006, MACROMOL RAPID COMM, V27, P1060, DOI 10.1002/marc.200600194; Berna M, 2006, BIOMACROMOLECULES, V7, P146, DOI 10.1021/bm050480s; Biran R, 2005, EXP NEUROL, V195, P115, DOI 10.1016/j.expneurol.2005.04.020; Brunot C, 2007, BIOMATERIALS, V28, P632, DOI 10.1016/j.biomaterials.2006.09.026; Buhler V, 2005, POLYVINYLPYRROLIDONE; Buttgereit F, 1998, ARTHRITIS RHEUM, V41, P761, DOI 10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M; Capadona JR, 2008, SCIENCE, V319, P1370, DOI 10.1126/science.1153307; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Coessens V, 1996, J CONTROL RELEASE, V38, P141, DOI 10.1016/0168-3659(95)00111-5; D'Souza AJM, 2004, J PHARM SCI-US, V93, P1962, DOI 10.1002/jps.20096; Engstrom JUA, 2006, MACROMOL CHEM PHYS, V207, P536, DOI 10.1002/macp.200500479; Frunder H., 1949, PHARMAZIE, V4, P345; Gao ZG, 2005, J DRUG TARGET, V13, P391, DOI 10.1080/10611860500376741; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Halthur TJ, 2004, LANGMUIR, V20, P1739, DOI 10.1021/la035475t; Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002; HANSON GR, 1982, DEV BRAIN RES, V3, P529, DOI 10.1016/0165-3806(82)90052-9; He W, 2003, BIOMACROMOLECULES, V4, P75, DOI 10.1021/bm0256505; He W, 2007, ADV MATER, V19, P3529, DOI 10.1002/adma.200700943; He W, 2006, J NEURAL ENG, V3, P316, DOI 10.1088/1741-2560/3/4/009; He XH, 1999, LIFE SCI, V65, P355, DOI 10.1016/S0024-3205(99)00257-X; HENSON PM, 1971, J IMMUNOL, V107, P1547; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hickey T, 2002, J BIOMED MATER RES, V61, P180, DOI 10.1002/jbm.10016; Ignatius MJ, 1998, J BIOMED MATER RES, V40, P264, DOI 10.1002/(SICI)1097-4636(199805)40:2<264::AID-JBM11>3.3.CO;2-N; Ihre HR, 2002, BIOCONJUGATE CHEM, V13, P443, DOI 10.1021/bc010102u; Johnson MD, 2007, J NEUROSCI METH, V160, P276, DOI 10.1016/j.jneumeth.2006.09.023; Kaal ECA, 2004, CURR OPIN ONCOL, V16, P593, DOI 10.1097/01.cco.0000142076.52721.b3; Kaila K., 1998, PH BRAIN FUNCTION; KENNEDY PR, 1989, J NEUROSCI METH, V29, P181, DOI 10.1016/0165-0270(89)90142-8; Kharlampieva E, 2006, POLYM REV, V46, P377, DOI 10.1080/15583720600945386; Kipke DR, 2003, IEEE T NEUR SYS REH, V11, P151, DOI 10.1109/TNSRE.2003.814443; KIRSH YE, 1998, WATER SOLUBLE POLYNV; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; Lakard S, 2004, BIOELECTROCHEMISTRY, V62, P19, DOI 10.1016/j.bioelechem.2003.09.009; Lee ES, 2007, J CONTROL RELEASE, V123, P19, DOI 10.1016/j.jconrel.2007.08.006; Lee HY, 2007, MACROMOL RES, V15, P547, DOI 10.1007/BF03218829; Lu DX, 2009, J BIOMED MATER RES B, V89B, P177, DOI 10.1002/jbm.b.31203; Maynard EM, 2000, J NEUROSCI METH, V97, P93, DOI 10.1016/S0165-0270(00)00159-X; Nicolelis MAL, 2003, P NATL ACAD SCI USA, V100, P11041, DOI 10.1073/pnas.1934665100; Park KK, 2006, STEROIDS, V71, P183, DOI 10.1016/j.steroids.2005.10.003; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Quinn JF, 2007, CHEM SOC REV, V36, P707, DOI 10.1039/b610778h; Rousche PJ, 2001, IEEE T BIO-MED ENG, V48, P361, DOI 10.1109/10.914800; Shain W, 2003, IEEE T NEUR SYS REH, V11, P186, DOI 10.1109/TNSRE.2003.814800; SILVER IA, 1975, PHILOS T ROY SOC B, V271, P261, DOI 10.1098/rstb.1975.0050; Singh A, 2003, BIOMATERIALS, V24, P5083, DOI 10.1016/S0142-9612(03)00424-1; Spataro L, 2005, EXP NEUROL, V194, P289, DOI 10.1016/j.expneurol.2004.08.037; Spireas S, 1998, INT J PHARM, V166, P177, DOI 10.1016/S0378-5173(98)00046-5; STEENBERGEN C, 1977, CIRC RES, V41, P849, DOI 10.1161/01.RES.41.6.849; Stockton WB, 1997, MACROMOLECULES, V30, P2717, DOI 10.1021/ma9700486; Sukhishvili SA, 2000, J AM CHEM SOC, V122, P9550, DOI 10.1021/ja002410t; Sukhishvili SA, 2002, MACROMOLECULES, V35, P301, DOI 10.1021/ma011346c; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; Tang ZY, 2006, ADV MATER, V18, P3203, DOI 10.1002/adma.200600113; Thierry B, 2005, J AM CHEM SOC, V127, P1626, DOI 10.1021/ja045077s; Thomas M, 2005, PHARM RES-DORDR, V22, P373, DOI 10.1007/s11095-004-1874-y; TWYCROSS R, 1994, DRUG SAFETY, V11, P163, DOI 10.2165/00002018-199411030-00003; Vleggeert-Lankamp CLAM, 2004, BIOMATERIALS, V25, P2741, DOI 10.1016/j.biomaterials.2003.09.067; Wang D, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2106; Wang LY, 1997, MACROMOL RAPID COMM, V18, P509, DOI 10.1002/marc.1997.030180609; Wang LY, 1999, LANGMUIR, V15, P1360, DOI 10.1021/la981181+; Wuts P. G. M., 2007, GREENES PROTECTIVE G; YAMAOKA T, 1995, J PHARM SCI, V84, P349, DOI 10.1002/jps.2600840316; Yang JY, 2004, SENSOR ACTUAT A-PHYS, V113, P204, DOI 10.1016/j.sna.2004.02.029; Yang SG, 2006, LANGMUIR, V22, P338, DOI 10.1021/la051581e; Yoon JJ, 2003, BIOMATERIALS, V24, P2323, DOI 10.1016/S0142-9612(03)00024-3; Zhong YH, 2007, BRAIN RES, V1148, P15, DOI 10.1016/j.brainres.2007.02.024	74	19	20	1	27	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1525-7797	1526-4602		BIOMACROMOLECULES	Biomacromolecules	MAY	2010	11	5					1298	1307		10.1021/bm100095t			10	Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science	Biochemistry & Molecular Biology; Chemistry; Polymer Science	592DO	WOS:000277355800022	20411929				2021-06-18	
J	Dulou, R; Dagain, A; Delmas, JM; Lambert, E; Blondet, E; Goasguen, O; Pouit, B; Dutertre, G; De Soultrait, F; Pernot, P				Dulou, Renaud; Dagain, Arnaud; Delmas, Jean-Marc; Lambert, Evelyne; Blondet, Eric; Goasguen, Olivier; Pouit, Bruno; Dutertre, Guillaume; De Soultrait, Francois; Pernot, Philippe			The French mobile neurosurgical unit	NEUROSURGICAL FOCUS			English	Article						mobile team; French neurosurgery; war surgery	SURGICAL-TREATMENT; INJURIES; MEDICINE; SURGERY; MISSION; ARMY	The authors present the French concept of a mobile neurosurgical unit (MNSU) as used to provide specific support to remote military medicosurgical units deployed in Africa, South America, Central Europe, and Afghanistan. From 2001 to 2009, 15 missions were performed, for 16 patients. All but 3 of these missions (those in Kosovo, French Guyana, and Afghanistan) concerned Africa. Eleven patients were French soldiers, 3 were civilians, and 2 were Djiboutian soldiers. The conditions that MNSUs were requested for included craniocerebral wounds (2 cases), closed head trauma (7 cases), spinal trauma (5 cases), and spontaneous intracranial hemorrhage (2 cases). In 5 of the 16 cases, neurosurgical treatment was provided on site. All French soldiers and 2 civilians were evacuated to France. The MNSU can be deployed for timely treatment when some delay in neurosurgical management is acceptable. (DOI: 10.3171/2010.2.FOCUS1016)	[Dulou, Renaud; Dagain, Arnaud; Delmas, Jean-Marc; Blondet, Eric; Goasguen, Olivier; Pouit, Bruno; Dutertre, Guillaume; De Soultrait, Francois; Pernot, Philippe] Hop Instruct Armees du Val de Grace, Serv Neurochirurg, F-75230 Paris 05, France; [Lambert, Evelyne] Hop Instruct Armees Percy, Serv Anesthesie Reanimat, Clamart, France	Dulou, R (corresponding author), Hop Instruct Armees du Val de Grace, Serv Neurochirurg, F-75230 Paris 05, France.	renaud.dulou@gmail.com		dagain, arnaud/0000-0001-8416-1976			Amirjamshidi A, 2003, SURG NEUROL, V60, P105, DOI 10.1016/S0090-3019(03)00358-6; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; Cushing H, 1918, BRIT J SURG, V5, P558; Department of Defense United States of America, 2004, EM WAR SURG, P121; Donovan DJ, 2006, MIL MED, V171, P12, DOI 10.7205/MILMED.171.1.12; Hughes J T, 2004, J Med Biogr, V12, P18; King B, 2005, J NATL MED ASSOC, V97, P648; Madei WF, 2000, MIL MED, V165, P445; MEIROWSKY AM, 1953, ANN SURG, V138, P178, DOI 10.1097/00000658-195308000-00003; PERNOT P, 1992, MED ARMEES, V20, P115; PERRIN J, 1950, ONE YEAR WAR NEUROSU; Pitlyk PJ, 1996, MIL MED, V161, P462; RIGNAULT DP, 1990, MIL MED, V155, P143; Rosenfeld JV, 1997, MIL MED, V162, P311; Schurr PH, 2005, J ROY SOC MED, V98, P423, DOI 10.1258/jrsm.98.9.423; SEBESTA D, 1990, MIL MED, V155, P227; Seet B, 1999, MIL MED, V164, P451; 1982, MED ARMEES, V10, P873	18	19	21	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E13	10.3171/2010.2.FOCUS1016			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600013	20568929				2021-06-18	
J	Kesmezacar, H; Sarikaya, IA				Kesmezacar, Hayrettin; Sarikaya, Ilker Abdulah			The results of conservatively treated simple elbow dislocations	ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA			English	Article						Dislocations/therapy/complications; elbow joint/injuries; joint instability	MEDIAL COLLATERAL LIGAMENT; RADIAL HEAD; INSTABILITY; JOINT; FRACTURE; EXCISION; SUBLUXATION; STABILITY; REPAIR; ADULT	Objectives: Closed reduction followed by short-time immobilization is the generally accepted treatment for simple elbow dislocations. However, the number of studies concerning the results of this method is limited. In this study, the clinical and radiographic results of conservatively treated simple elbow dislocations were retrospectively evaluated. Methods: The study included 21 patients (16 males, 5 females) who underwent closed reduction and immobilization for simple elbow dislocations. Simple dislocations were defined as non-fracture dislocations and dislocations accompanied by minor avulsion fractures that did not require additional surgery or immobilization. The mean age of the patients at the time of injury was 35 years (range 16 to 59 years). All the patients had posterior dislocations. Eleven patients (52.4%) had minor avulsion fractures. Following closed reduction, a plaster splint and hinged brace were used in four (19.1%) and 17 (81%) patients, respectively. Incremental active and passive motions were started at the end of the first week in patients in whom a brace was used. The mean duration of brace use was 27 +/- 16 days. Patients using a plaster splint were immobilized for three weeks. The patients were assessed clinically with respect to range of motion, instability, and neurologic findings after a mean follow-up period of 34 months (range 12 to 99 months). Functional assessments included the Mayo Elbow Performance Score (MEPS) and the Broberg-Morrey Functional Rating Index (BMFRI). Standard elbow anteroposterior and lateral radiographs were examined for concentric reduction and signs of degeneration and heterotopic ossification. Results: Compared to the normal side, the degrees of flexion, extension, flexion arc, and pronation were significantly decreased in dislocated elbows (p<0.05), while the degrees of supination and rotational arc were similar. There was no muscular atrophy. Four patients (19.1%) had residual instability and six patients (28.6%) had mild to moderate neurological complaints that were primarily related to the ulnar nerve. Three patients complained of mild pain, and one patient complained of moderate pain at ::est. Radiographic assessment showed mild degeneration in three patients (14.3%), and mild to moderate heterotopic ossification in 14 patients (66.7%). Patients with and without heterotopic ossification did not differ significantly with respect to the values of joint ranee of motion. The mean MEPS and BMFRI scores were 96.9 and 97.7, respectively. The scores of both systems were excellent in 20 patients (95.2%) and moderate in one patient (4.8%). The majority of the patients (81%) reported complaints about their elbows including sensation of stiffness in the elbow, pain during strenuous work or sports activities, and limitation of movement. Only four patients (19.1%) reported a feeling of full recovery. Conclusion: Although closed reduction with short-term immobilization is a universally accepted method for simple elbow dislocations with excellent functional scores, it is associated with significant limitations in joint movements and a great majority of patients do not consider themselves fully recovered.	[Kesmezacar, Hayrettin; Sarikaya, Ilker Abdulah] Istanbul Univ, Cerrahpasa Med Fac, Dept Orthoped & Traumatol, TR-34303 Istanbul, Turkey	Kesmezacar, H (corresponding author), Istanbul Univ, Cerrahpasa Tip Fak, Ortopedi & Travmatol Anabilim Dali, TR-34303 Istanbul, Turkey.	hkesmezacar@yahoo.com					Ahmad CS, 2004, AM J SPORT MED, V32, P1607, DOI 10.1177/0363546503263149; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; CROMACK P I, 1961, Aust N Z J Surg, V30, P212, DOI 10.1111/j.1445-2197.1961.tb03112.x; Duckworth AD, 2008, J SHOULDER ELB SURG, V17, P276, DOI 10.1016/j.jse.2007.06.006; DURIG M, 1979, J BONE JOINT SURG AM, V61, P239, DOI 10.2106/00004623-197961020-00012; Eygendaal D, 2000, J BONE JOINT SURG AM, V82A, P555, DOI 10.2106/00004623-200004000-00010; HABERNEK H, 1992, CLIN ORTHOP RELAT R, P226; Jensen SL, 2003, J BONE JOINT SURG BR, V85B, P1006, DOI 10.1302/0301-620X.85B7.14405; Jeon In-Ho, 2008, Keio Journal of Medicine, V57, P99, DOI 10.2302/kjm.57.99; JOHANSSON O, 1962, Acta Chir Scand Suppl, VSuppl 287, P1; JOSEFSSON PO, 1987, J BONE JOINT SURG AM, V69A, P605, DOI 10.2106/00004623-198769040-00018; JOSEFSSON PO, 1984, J BONE JOINT SURG AM, V66A, P927, DOI 10.2106/00004623-198466060-00014; JOSEFSSON PO, 1989, CLIN ORTHOP RELAT R, P126; JOSEFSSON PO, 1986, ACTA ORTHOP SCAND, V57, P537, DOI 10.3109/17453678609014788; KING T, 1953, J BONE JOINT SURG BR, V35, P50; Kini MC, 1940, J BONE JOINT SURG, V22, P107; LANSINGER K, 1984, ARCH ORTHOP TRAUMA S, V102, P183; LINSCHEI.RL, 1965, J AMER MED ASSOC, V194, P1171, DOI 10.1001/jama.194.11.1171; LINSCHEID RL, 1993, ELBOW ITS DISORDERS, P441; Maripuri SN, 2007, INJURY, V38, P1254, DOI 10.1016/j.injury.2007.02.040; McKee MD, 2003, J SHOULDER ELB SURG, V12, P391, DOI 10.1016/S1058-2746(03)00027-2; MEHLHOFF TL, 1988, J BONE JOINT SURG AM, V70A, P244, DOI 10.2106/00004623-198870020-00013; Micic I, 2009, INT ORTHOP, V33, P1141, DOI 10.1007/s00264-008-0624-x; MORREY BF, 1991, CLIN ORTHOP RELAT R, P187; MORREY BF, 1983, AM J SPORT MED, V11, P315, DOI 10.1177/036354658301100506; MORREY BF, 1993, ELBOW ITS DISORDERS, V2, P86; NEVIASER JS, 1977, SOUTHERN MED J, V70, P172, DOI 10.1097/00007611-197702000-00013; O'Driscoll S W, 2001, Instr Course Lect, V50, P89; ODRISCOLL SW, 1991, J BONE JOINT SURG AM, V73A, P440, DOI 10.2106/00004623-199173030-00015; ODRISCOLL SW, 1992, CLIN ORTHOP RELAT R, P186; Osborne G, 1966, J Bone Joint Surg Br, V48, P340; PROTZMAN RR, 1978, J BONE JOINT SURG AM, V60, P539, DOI 10.2106/00004623-197860040-00019; Ring D, 2000, CLIN ORTHOP RELAT R, P44; Ross G, 1999, AM J SPORT MED, V27, P308, DOI 10.1177/03635465990270030701; ROYLE SG, 1991, CLIN ORTHOP RELAT R, P201; SCHWAB GH, 1980, CLIN ORTHOP RELAT R, P42	36	19	19	0	14	TURKISH ASSOC ORTHOPAEDICS TRAUMATOLOGY	ISTANBUL	TIP FAKULTESI ORTOPEDI VE TRAVMATOLOJI KLINIGI, ISTANBUL, TOPKAPI 34390, TURKEY	1017-995X			ACTA ORTHOP TRAUMATO	Acta Orthop. Traumatol. Turc.	MAY-JUN	2010	44	3					199	205		10.3944/AOTT.2010.2400			7	Orthopedics	Orthopedics	690WB	WOS:000285038400006	21088460	DOAJ Gold			2021-06-18	
J	Kinoshita, Y; Kamitani, H; Mamun, MH; Wasita, B; Kazuki, Y; Hiratsuka, M; Oshimura, M; Watanabe, T				Kinoshita, Yusuke; Kamitani, Hideki; Mamun, Mahabub Hasan; Wasita, Brian; Kazuki, Yasuhiro; Hiratsuka, Masaharu; Oshimura, Mitsuo; Watanabe, Takashi			A gene delivery system with a human artificial chromosome vector based on migration of mesenchymal stem cells towards human glioblastoma HTB14 cells	NEUROLOGICAL RESEARCH			English	Article						Mesenchymal stem cell; human artificial chromosome vector; migration; herpes simplex virus thymidine kinase gene; gene delivery system; glioblastoma	TRAUMATIC BRAIN-INJURY; THERAPY; GLIOMA; TUMOR; MODEL; DIFFERENTIATION; EXPRESSION; TROPISM; MSC	Mesenchymal stem cells (MSCs) have been expected to become useful gene delivery vehicles against human malignant gliomas when coupled with an appropriate vector system, because they migrate towards the lesion. Human artificial chromosomes (HACs) are non-integrating vectors with several advantages for gene therapy, namely, no limitations on the size and number of genes that can be inserted. We investigated the migration of human immortalized MSCs bearing a HAC vector containing the herpes simplex virus thymidine kinase gene (HAC-tk-hiMSCs) towards malignant gliomas in vivo. Red fluorescence protein-labeled human glioblastoma HTB14 cells were implanted into a subcortical region in nude mice. Four days later, green fluorescence protein-labeled HAC-tk-hiMSCs were injected into a contralateral subcortical region (the HTB14/HAC-tk-hiMSC injection model). Tropism to the glioma mass and the route of migration were visualized by fluorescence microscopy and immunohistochemical staining. HAC-tk-hiMSCs began to migrate toward the HTB14 glioma area via the corpus callosum on day 4, and gathered around the HTB14 glioma mass on day 7. To test whether the delivered gene could effectively treat glioblastoma in vivo, HTB14/HAC-tk-hiMSC injected mice were treated with ganciclovir (GCV) or PBS. The HTB14 glioma mass was significantly reduced by GCV treatment in mice injected with HAC-tk-hiMSCs. It was confirmed that gene delivery by our HAC-hiMSC system was effective after migration of MSCs to the glioma mass in vivo. Therefore, MSCs containing HACs carrying an anticancer gene or genes may provide a new tool for the treatment of malignant gliomas and possibly of other tumor types.	[Kinoshita, Yusuke; Kamitani, Hideki; Mamun, Mahabub Hasan; Wasita, Brian; Watanabe, Takashi] Tottori Univ, Fac Med, Dept Neurosurg, Tottori 6838504, Japan; [Kazuki, Yasuhiro; Oshimura, Mitsuo] Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct, Tottori 6838504, Japan; [Hiratsuka, Masaharu] Tottori Univ, Sch Life Sci, Dept Mol & Cellular Biol, Tottori 6838504, Japan	Kinoshita, Y (corresponding author), Tottori Univ, Fac Med, Dept Neurosurg, 36-1 Nishi Cho, Tottori 6838504, Japan.	yuusuke.kinoshita@hospital.tottori.tottori.jp		Wasita, Brian/0000-0002-5501-3541			Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Buhring HJ, 2007, ANN NY ACAD SCI, V1106, P262, DOI 10.1196/annals.1392.000; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; Ehtesham M, 2002, CANCER RES, V62, P5657; Hamada H, 2005, CANCER SCI, V96, P149, DOI 10.1111/j.1349-7006.2005.00032.x; Katoh M, 2004, BIOCHEM BIOPH RES CO, V321, P280, DOI 10.1016/j.bbrc.2004.06.145; Kazuki Y, 2008, GENE THER, V15, P617, DOI 10.1038/sj.gt.3303091; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Li SY, 2005, CANCER GENE THER, V12, P600, DOI 10.1038/sj.cgt.7700826; Mageed AS, 2007, TRANSPLANTATION, V83, P1019, DOI 10.1097/01.tp.0000259752.13304.0b; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276; Namba H, 1998, HUM GENE THER, V9, P5, DOI 10.1089/hum.1998.9.1-5; Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006-291X(02)00661-7; Rainov NG, 2000, HUM GENE THER, V11, P2389, DOI 10.1089/104303400750038499; Ren XY, 2006, STEM CELL REV, V2, P43, DOI 10.1385/SCR:2:1:43; Ren XY, 2005, STEM CELLS, V23, P1608, DOI 10.1634/stemcells.2005-0021; Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a; Schmidt NO, 2005, NEOPLASIA, V7, P623, DOI 10.1593/neo.04781; Shah K, 2005, ANN NEUROL, V57, P34, DOI 10.1002/ana.20306; Shitara S, 2008, BIOCHEM BIOPH RES CO, V369, P807, DOI 10.1016/j.bbrc.2008.02.119; Soling Ariane, 2004, Genet Vaccines Ther, V2, P7, DOI 10.1186/1479-0556-2-7; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088	24	19	20	3	10	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	MAY	2010	32	4					429	437		10.1179/174313209X455718			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	593IJ	WOS:000277446600017	19589205				2021-06-18	
J	Mumford, N; Duckworth, J; Thomas, PR; Shum, D; Williams, G; Wilson, PH				Mumford, Nick; Duckworth, Jonathan; Thomas, Patrick R.; Shum, David; Williams, Gavin; Wilson, Peter H.			Upper limb virtual rehabilitation for traumatic brain injury: Initial evaluation of the elements system	BRAIN INJURY			English	Article						Traumatic brain injury; virtual reality; rehabilitation; motor learning; motor control; augmented feedback	COGNITIVE FUNCTION; REALITY; STROKE; FEEDBACK; HAND; ARM; EXERCISE	Primary objective: To evaluate the effectiveness of a tabletop virtual-reality (VR) based upper-limb rehabilitation system (called Elements) for promoting movement skill in patients with TBI. Research design: An ABA case study design with multiple baselines was employed. Baseline performance in this design is contrasted against the results during the treatment phase. Research methods: Three patients with TBI participated in 12 1-hour sessions of VR-based training. The VR system consisted of a 42-inch tabletop LCD, camera tracking system and tangible user interface. The system requires participants to move an object to cued locations while receiving augmented movement feedback to reinforce speed, trajectory and placement. Upper limb performance was assessed using these three system-measured variables and standardized tests. Trends in the time-sequence plots for each patient were assessed by sight inspection of smoothed data and then by statistical analyses. Results: Participants demonstrated improvements on movement accuracy, efficiency and bimanual dexterity and mixed improvement on speed and other measures of movement skill. Conclusion: Taken together, the findings demonstrate that the Elements system shows promise in facilitating motor learning in these TBI patients. Larger scale trials are now deemed a viable step in further validating the system.	[Wilson, Peter H.] RMIT Univ, Sch Hlth Sci, Discipline Psychol, Div Psychol, Melbourne, Vic 3000, Australia; [Mumford, Nick] RMIT Univ, Dept Psychol, Melbourne, Vic 3000, Australia; [Duckworth, Jonathan] RMIT Univ, Sch Creat Media, Melbourne, Vic 3000, Australia; [Thomas, Patrick R.] Griffith Univ, Sch Educ & Profess Studies, Brisbane, Qld 4111, Australia; [Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Williams, Gavin] Epworth Med Fdn, Melbourne, Vic, Australia	Wilson, PH (corresponding author), RMIT Univ, Sch Hlth Sci, Discipline Psychol, Div Psychol, POB 2476V, Melbourne, Vic 3000, Australia.	peter.h.wilson@rmit.edu.au	Shum, David/A-3914-2008; Wilson, Peter H./E-2881-2018	Shum, David/0000-0002-4810-9262; Wilson, Peter H./0000-0003-3747-0287; Williams, Gavin/0000-0003-2758-7473	Australian Research Council (ARC)Australian Research Council [LP0562622]; Australia Council for the Arts	This work was supported in part by an Australian Research Council (ARC) Linkage Grant LP0562622, and Synapse Grant awarded by the Australia Council for the Arts. We wish to acknowledge the contributions of other members of the broader Elements project; Ross Eldridge and Dr Heiko Rudolph from the School of Electrical and Computer Engineering, RMIT University, and Mark Guglielmetti, an artist and Lecturer with the School of Art and Design, Monash University.	Armagan O, 2003, AM J PHYS MED REHAB, V82, P856, DOI [10.1097/01.PHM.0000091984.72486.E0, 10.1097/01.PHM.0000091984.72486.EO]; Backman CL, 1999, AM J PHYS MED REHAB, V78, P170, DOI 10.1097/00002060-199903000-00022; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Boian R, 2002, STUD HEALTH TECHNOL, V85, P64; BRAVO G., 1997, CANADIAN J OCCUPATIO, V64, P270, DOI DOI 10.1177/000841749706400504; DAVID D, 2007, COGNITION BRAIN BEHA, V11, P299; Eastridge D, 2005, BEHAV INTERVENT, V20, P77, DOI 10.1002/bin.175; EDMANS JA, 2004, 5 INT C DIS VIRT REA, P3; Fischer HC, 2007, TOP STROKE REHABIL, V14, P1, DOI 10.1310/tsr1401-1; Fisher I, 2004, AUST OCCUP THER J, V51, P185, DOI DOI 10.1111/J.1440-1630.2004.00446.X; Gentleman D, 2001, TRAUMA, V3, P193; Gibson JJ., 1966, SENSES CONSIDERED PE; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Henderson A, 2007, TOP STROKE REHABIL, V14, P52, DOI 10.1310/tsr1402-52; HOLDEN MK, 2001, NEUROLOGY REPORT, V25, P129; Hubert V, 2007, HUM BRAIN MAPP, V28, P1415, DOI 10.1002/hbm.20354; Jeannerod M, 2006, CR BIOL, V329, P354, DOI 10.1016/j.crvi.2006.03.017; Jeannerod Marc, 2006, MOTOR COGNITION WHAT; Kinugasa T, 2004, SPORTS MED, V34, P1035, DOI 10.2165/00007256-200434150-00003; Law M., 1996, CANADIAN J OCCUPATIO, V63, P9, DOI [10.1177/000841749606300103, DOI 10.1177/000841749606300103]; Laycock J, 1992, THESIS U BRADFORD BR; Mastos M, 2007, CLIN REHABIL, V21, P47, DOI 10.1177/0269215506073494; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Maulucci RA, 2001, NEUROREHABILITATION, V16, P171; McCarron L., 1997, MCCARRON ASSESSMENT; McCrea PH, 2002, DISABIL REHABIL, V24, P534, DOI 10.1080/09638280110115393; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Morgan DL, 2001, AM PSYCHOL, V56, P119, DOI 10.1037/0003-066X.56.2.119; NOURBAKHSH MR, 1994, PHYS THER, V74, P768, DOI 10.1093/ptj/74.8.768; Piron L, 2004, MED INFORM INTERNET, V29, P119, DOI 10.1080/14639230410001723428; Piron L, 2003, ST HEAL T, V94, P265; Piron L, 2007, 2007 VIRTUAL REHABILITATION, P119; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; Platz T, 1999, RESTOR NEUROL NEUROS, V14, P161; Platz T., 2005, ARM ARM REHABILITATI; PRIDMORE T, 2004, 5 INT C DIS VIRT REA, P11; RADOMSKI MV, 2000, OCCUPATIONAL THERAPY; Riva G, 2007, 2007 VIRTUAL REHABILITATION, P157; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rose Dorian K, 2004, Top Stroke Rehabil, V11, P20, DOI 10.1310/XAUM-LPBM-0RXD-RLDK; Rosenbaum D. A., 2004, INT J SPORT EXERCISE, V2, P439, DOI DOI 10.1080/1612197X.2004.9671754; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; Seidler RD, 2004, NEUROIMAGE, V22, P1775, DOI 10.1016/j.neuroimage.2004.05.003; Shumway-Cook A, 2007, MOTOR CONTROL TRANSL; Sideridis GD, 1997, J BEHAV EDUC, V7, P191, DOI DOI 10.1023/a:1022841108508; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Stewart JC, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-21; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Todorov E, 1997, J MOTOR BEHAV, V29, P147, DOI 10.1080/00222899709600829; Turolla A, 2007, 2007 VIRTUAL REHABILITATION, P47; TURVEY MT, 1980, PRELIMINARIES THEORY; Van Vliet PM, 2006, DISABIL REHABIL, V28, P831, DOI 10.1080/09638280500534937; Vaz DV, 2008, CLIN REHABIL, V22, P234, DOI 10.1177/0269215507081578; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; WILSON BA, 1998, COMPREHENSIVE CLIN P, P463; WILSON PH, 2006, P 5 INT WOR IN PRESS; WILSON PH, 2007, P ANN C VIRT REH VEN, DOI DOI 10.1109/ICVR.2007.4362122; Winstein C., 2003, MOTOR CONTROL, V9, P77; Wulf G, 2001, PSYCHON B REV, V8, P648, DOI 10.3758/BF03196201; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	60	19	19	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2010	24	5					780	791		10.3109/02699051003652807			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	592PJ	WOS:000277391300011	20353283				2021-06-18	
J	Srinivas, R; Brown, SD; Chang, YF; Garcia-Fillion, P; Adelson, PD				Srinivas, Ravi; Brown, S. Danielle; Chang, Yue-Fang; Garcia-Fillion, Pamela; Adelson, P. David			Endocrine function in children acutely following severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Endocrine; Pediatric; Traumatic brain injury; Acute	NEUROENDOCRINE DYSFUNCTION; ABNORMALITIES	Despite the prevalence of frontal injury following traumatic brain injury (TBI) in adults and children with potentially concomitant hypothalamic and pituitary involvement, endocrine dysfunction acutely following TBI has not been well studied in children. To study the acute pediatric endocrine response after severe TBI (Glasgow Coma Scale a parts per thousand currency signaEuro parts per thousand 8), an endocrine panel, including cortisol, ACTH, TSH, T3, T4, free T4, GH, and prolactin levels, were obtained in 37 children (1-17 years) on the day of injury and post-injury days (PID) 3 and 7. Outcome was determined at 6-month follow-up using the Glasgow Outcome Score (GOS) extended modified for pediatric patients (GOS-E Peds) to compare "good" (GOS-E Peds 1-2) to "poor" (GOS-E Peds 3-5) outcomes. Our results showed that following severe TBI in children, cortisol was significantly elevated (24.46 +/- 13.41 mu g/dL) on PID 1 along with ACTH but then returned to normal (10.14-19.92 mu g/dL) by PID 3; 46% and 14% of children had a low cortisol and ACTH (< 10.14 and < 2, respectively) in the acute period. In summary, the cortisol response to trauma and stress in the acute period following severe TBI in the majority of children was altered, though seemingly appropriate cortisol was abnormally low in a significant percentage of children. Further study as to the significance of these findings is needed, but this study provides preliminary insight into the potential impact of severe TBI on the acute response of the hypothalamic-pituitary axis in children.	[Adelson, P. David] Phoenix Childrens Neurosci Inst, Dept Pediat Neurosurg, Phoenix, AZ 85016 USA; [Brown, S. Danielle; Garcia-Fillion, Pamela; Adelson, P. David] Phoenix Childrens Hosp, Childrens Neurosci Inst, Phoenix, AZ USA; [Srinivas, Ravi; Brown, S. Danielle; Chang, Yue-Fang; Adelson, P. David] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA	Adelson, PD (corresponding author), Phoenix Childrens Neurosci Inst, Dept Pediat Neurosurg, Bldg B,4th Floor,1919 E Thomas Rd, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Adelson, David/W-2083-2019		Center for Injury and Research Control (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR323155]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052478]	We would like to thank the Center for Injury and Research Control (CDC no. R49/CCR323155) for funding this project through their Student Grants section (RS) and the NIH ( no. R01 NS052478) (PDA) for their support in this project.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Beers SR, 2005, J NEUROTRAUM, V22, P1224; Bettendorf M, 2002, EUR J NUCL MED MOL I, V29, pS439, DOI 10.1007/s00259-002-0905-3; Cernak I, 1999, BRAIN INJURY, V13, P1005; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JENNETT B, 1975, LANCET, V1, P480; KAPTEIN EM, 1981, J CLIN ENDOCR METAB, V53, P764, DOI 10.1210/jcem-53-4-764; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Radovick S, 2003, PEDIAT ENDOCRINOLOGY; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	16	19	21	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAY	2010	26	5					647	653		10.1007/s00381-009-1038-9			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	582NV	WOS:000276605600011	19937245				2021-06-18	
J	Thackeray, JD; Scribano, PV; Lindberg, DM				Thackeray, Jonathan D.; Scribano, Philip V.; Lindberg, Daniel M.			Yield of Retinal Examination in Suspected Physical Abuse With Normal Neuroimaging	PEDIATRICS			English	Article						retinal hemorrhages; child physical abuse; abusive head trauma; traumatic brain injury	SHAKEN BABY SYNDROME; TRAUMATIC BRAIN-INJURY; HEAD TRAUMA; YOUNG-CHILDREN; HEMORRHAGES	OBJECTIVE: In some centers, dedicated ophthalmologic examination is performed for all children who are evaluated for potential physical abuse. Although retinal hemorrhages have been reported in rare cases of abused children with normal neuroimaging results, the utility of ophthalmologic examination in this group is currently unknown. The objective of this study was to determine the prevalence of retinal hemorrhages in children younger than 2 years who were evaluated for physical abuse and who had no evidence of traumatic brain injury (TBI) on neuroimaging. PATIENTS AND METHODS: We performed retrospective analysis of data obtained from 1676 children younger than 5 years who were evaluated for potential physical abuse as a part of the Using Liver Transaminases to Recognize Abuse research network. We reviewed results of dedicated ophthalmologic examination in all children younger than 2 years with no evidence of TBI on neuroimaging. RESULTS: Among 282 children who met inclusion criteria, only 2 (0.7% [95% confidence interval: 0.1%-2.5%]) had retinal hemorrhages considered "characteristic" of abuse. Seven other children (2.5% [95% confidence interval: 1.0%-5.1%]) had a nonspecific pattern of retinal hemorrhages. Both children with characteristic retinal hemorrhages in the absence of TBI showed evidence of head or facial injury on physical examination and/or altered mental status. CONCLUSIONS: In children younger than 2 years being evaluated for physical abuse without radiographic evidence of brain injury, retinal hemorrhages are rare. Dedicated ophthalmologic examination should not be considered mandatory in this population. Pediatrics 2010; 125: e1066-e1071	[Thackeray, Jonathan D.; Scribano, Philip V.] Nationwide Childrens Hosp, Ctr Child & Family Advocacy, Columbus, OH 43205 USA; [Lindberg, Daniel M.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA	Thackeray, JD (corresponding author), Nationwide Childrens Hosp, Ctr Child & Family Advocacy, 655 E Livingston Ave, Columbus, OH 43205 USA.	jonathan.thackeray@nationwidechildrens.org					Aryan HE, 2005, J CLIN NEUROSCI, V12, P624, DOI 10.1016/j.jocn.2005.05.005; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CAFFEY J, 1974, PEDIATRICS, V54, P396; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; HOLLENHORST RW, 1958, ARCH OPHTHALMOL-CHIC, V60, P187; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Johnson DL, 1993, NEUROSURGERY, V33, P234; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kelly P, 2008, J PAEDIATR CHILD H, V44, P99, DOI 10.1111/j.1440-1754.2007.01234.x; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2008, ARCH OPHTHALMOL-CHIC, V126, P800, DOI 10.1001/archopht.126.6.800; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Laskey AL, 2007, CHILD ABUSE NEGLECT, V31, P329, DOI 10.1016/j.chiabu.2006.02.017; Levin AV, 2002, NEUROSURG CLIN N AM, V13, P201, DOI 10.1016/S1042-3680(02)00004-9; Levin AV, 2009, CHILD ABUSE MED DIAG, P211; Lindberg D, 2009, PEDIATRICS, V124, P509, DOI 10.1542/peds.2008-2348; Morad Y, 2004, J AAPOS, V8, P445, DOI 10.1016/j.jaapos.2004.06.007; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Reece RM, 2009, CHILD ABUSE MED DIAG; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Trenchs V, 2008, CHILD NERV SYST, V24, P815, DOI 10.1007/s00381-008-0583-y	28	19	19	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAY	2010	125	5					E1066	E1071		10.1542/peds.2009-2184			6	Pediatrics	Pediatrics	590NI	WOS:000277232800038	20385633				2021-06-18	
J	Wang, F; Luo, YM; Ling, F; Wu, H; Chen, J; Yan, F; He, ZY; Goel, GJ; Ji, XM; Ding, YC				Wang, Fei; Luo, Yumin; Ling, Feng; Wu, Hao; Chen, Jian; Yan, Feng; He, Zhongyi; Goel, Gunjan; Ji, Xunming; Ding, Yuchuan			Comparison of neuroprotective effects in ischemic rats with different hypothermia procedures	NEUROLOGICAL RESEARCH			English	Article						Cerebral ischemia; reperfusion damage; hypothermia; infarct; motor behavior	CEREBRAL-ARTERY OCCLUSION; TRANSIENT FOCAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; COLD SALINE INFUSION; ACUTE STROKE; MODERATE HYPOTHERMIA; REPERFUSION INJURY; THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; TERRITORY	Objective: The neuroprotective effect of hypothermia has long been recognized. The aim of this work was to compare the neuroprotective effect of systemic, head and local vascular cooling hypothermia procedures in ischemic rats. Methods: Stroke in Sprague-Dawley rats (n=64) was induced by a 3 hour right middle cerebral artery occlusion using an intraluminal filament. Before reperfusion, ischemic animals (n=16 in each group) received hypothermia (systemic, head or local vascular) or no treatment. Brain temperature, infarction volume (n=8 in each group) and functional outcome (n=8 in each group) were compared. Results: Regarding brain temperature, vascular cooling significantly reduced the temperature of ischemic territory in cortex from 37.2 +/- 0.1 to 33.4 +/- 0.4 degrees C and in striatum from 37.5 +/- 0.2 to 33.9 +/- 0.4 degrees C within 5 minutes. This hypothermic condition remained for up to 60 minutes after reperfusion. However, systemic cooling reduced brain temperature at a similar level for six times longer. In the head cooling group, the target temperature was reached in 15 minutes, but returned to normal within 5 minutes. Although all hypothermia procedures induced neuroprotection, ischemic rats with vascular cooling showed significantly (p<0.001) better neuroprotection with 10.7 +/- 2.6% infarction, compared to 54.2 +/- 1.9% (no treatment), 37.1 +/- 1.0% (head cooling) and 29.1 +/- 3.4% (systemic cooling). Significantly (p<0.001) better effects on motor function were also detected in vascular cooling groups at 14 and 28 days. Conclusion: Vascular cooling appears to be the most effective in reducing infarct volume and improving functional outcome than the other two hypothermia methods in a rat ischemia/reperfusion model.	[Wang, Fei; Luo, Yumin; Wu, Hao; Yan, Feng; Ji, Xunming; Ding, Yuchuan] Capital Med Univ, Xuanwu Hosp, Key Lab Neurodegenerat Dis, Cerebral Vasc Dis Inst,Minist Educ, Beijing, Peoples R China; [Wang, Fei; He, Zhongyi] Ningxia Med Univ, Yinchuan, Peoples R China; [Ling, Feng; Chen, Jian; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China; [Goel, Gunjan; Ding, Yuchuan] Wayne State Univ, Sch Med, Detroit, MI USA	Ji, XM (corresponding author), 45 Changchun St, Beijing 100053, Peoples R China.	jixm70@hotmail.com	Ji, Xunming/AAN-3370-2021				Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; Balousek PA, 1996, CURR OPIN CARDIOL, V11, P550, DOI 10.1097/00001573-199609000-00015; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Becker KJ, 2005, STROKE, V36, P400, DOI 10.1161/01.STR.0000153056.25397.ff; CLARK RK, 1994, BRAIN RES BULL, V35, P387, DOI 10.1016/0361-9230(94)90119-8; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Corbett D, 2000, BRAIN PATHOL, V10, P145; Corbett R, 1998, J NEUROCHEM, V71, P1205; Diao CG, 2003, ANN BIOMED ENG, V31, P346, DOI 10.1114/1.1554924; Ding YC, 2002, STROKE, V33, P2492, DOI 10.1161/01.STR.0000028237.15541.CC; Ding YC, 2002, J NEUROSURG, V96, P310, DOI 10.3171/jns.2002.96.2.0310; Ding YC, 2002, BEHAV BRAIN RES, V132, P29, DOI 10.1016/S0166-4328(01)00405-3; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; Ding YC, 2004, NEUROSURGERY, V54, P956, DOI 10.1227/01.NEU.0000114513.96704.29; Ding YH, 2004, NEUROSCI LETT, V372, P35, DOI 10.1016/j.neulet.2004.09.010; Feigin V, 2003, LANCET NEUROL, V2, P529, DOI 10.1016/S1474-4422(03)00500-3; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kataoka K, 1998, NEUROSCI RES, V32, P103, DOI 10.1016/S0168-0102(98)00076-5; Konstas AA, 2007, J APPL PHYSIOL, V102, P1329, DOI 10.1152/japplphysiol.00805.2006; KULUZ JW, 1992, STROKE, V23, P1792, DOI 10.1161/01.STR.23.12.1792; Lee SM, 2009, J CEREBR BLOOD F MET, V29, P1589, DOI 10.1038/jcbfm.2009.81; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Luan XD, 2004, ACTA NEUROPATHOL, V107, P227, DOI 10.1007/s00401-003-0802-2; Lyden PD, 2006, INT J STROKE, V1, P9, DOI 10.1111/j.1747-4949.2005.00011.x; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Slotboom J, 2004, NEURORADIOLOGY, V46, P923, DOI 10.1007/s00234-004-1286-z; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Zhao H, 2003, J NEUROCHEM, V85, P1026, DOI 10.1046/j.1471-4159.2003.01756.x; Zhao WH, 2009, NEUROL RES, V31, P43, DOI 10.1179/174313208X327982	33	19	21	0	2	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	MAY	2010	32	4					378	383		10.1179/016164110X12670144526183			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	593IJ	WOS:000277446600008	20483004				2021-06-18	
J	Wang, L; Li, ZQ; Shi, ZBA; Zhang, YQ; Shen, JH				Wang, Li; Li, Zhongquan; Shi, Zhanbiao; Zhang, Yuqing; Shen, Jianhuan			Factor structure of acute stress disorder symptoms in Chinese earthquake victims: A confirmatory factor analysis of the acute stress disorder scale	PERSONALITY AND INDIVIDUAL DIFFERENCES			English	Article						Acute stress disorder scale; Factor structure; Confirmatory factor analyses; Earthquake; China	TRAUMATIC BRAIN-INJURY; 2-YEAR PROSPECTIVE EVALUATION; PTSD; PREDICTORS; DISSOCIATION; INTERVIEW; THERAPY; ISSUES	This study examined the factor structure of the acute stress disorder scale (ASDS; Bryant, Moulds, & Guthrie, 2000), a self-report measure for acute stress disorder (ASD). The study was completed 6 to 10 days following an earthquake; it included 353 Chinese earthquake victims (173 women, 180 men; mean age = 29.36, SD = 11.45 years). The results of confirmatory factor analyses indicate that a 4-factor model (dissociation, reexperiencing, avoidance and arousal) is consistent with the conceptualization of ASD, which is defined in the Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-IV). Implications and limitations for the results are discussed. (C) 2010 Elsevier Ltd. All rights reserved.	[Li, Zhongquan] Nanjing Univ, Sch Social & Behav Sci, Dept Psychol, Nanjing 210093, Jiangsu, Peoples R China; [Wang, Li] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China; [Shi, Zhanbiao] Chinese Acad Sci, Inst Psychol, Psychol Crisis Intervent Ctr, Beijing 100101, Peoples R China; [Zhang, Yuqing] Chinese Acad Sci, Inst Psychol, Ctr Social & Econ Behav, Beijing 100101, Peoples R China; [Shen, Jianhuan] Univ Toronto, Dept Psychiat, Toronto, ON, Canada	Li, ZQ (corresponding author), Nanjing Univ, Sch Social & Behav Sci, Dept Psychol, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China.	zhongquanl@hotmail.com		wang, li/0000-0002-1459-3412; li, zhongquan/0000-0002-8480-4166			AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Briere J, 2005, AM J PSYCHIAT, V162, P2295, DOI 10.1176/appi.ajp.162.12.2295; Brooks R, 2008, J TRAUMA STRESS, V21, P352, DOI 10.1002/jts.20333; Bryant R. A., 1999, AUSTR J EMERGENCY MA, V14, P9; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 2005, J CONSULT CLIN PSYCH, V73, P334, DOI 10.1037/0022-006X.73.2.334; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2003, BEHAV RES THER, V41, P489, DOI 10.1016/S0005-7967(02)00179-1; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2007, J ANXIETY DISORD, V21, P183, DOI 10.1016/j.janxdis.2006.09.012; Byrne B. M, 2001, STRUCTURAL EQUATION; Ehlers A, 2003, BEHAV RES THER, V41, P1, DOI 10.1016/S0005-7967(01)00126-7; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Holeva V, 2001, BEHAV THER, V32, P65, DOI 10.1016/S0005-7894(01)80044-7; Joreskog K. G., 2005, LISREL 8 72 INTERACT; Kleindorfer S. O., 2006, J TRAUMA PRACTICE, V4, P81, DOI [10.1300/J189v04n01_06, DOI 10.1300/J189V04N01_06]; Marsella AJ, 2004, PSYCHIAT CLIN N AM, V27, P521, DOI 10.1016/j.psc.2004.03.011; McDonald RP, 2002, PSYCHOL METHODS, V7, P64, DOI 10.1037//1082-989X.7.1.64; MERENDA P. F., 1994, CROSS CULTURAL TOPIC, P53; Merenda PF, 2006, PSYCHOL REP, V99, P307, DOI 10.2466/PR0.99.2.307-314; Orsillo S. M., 2001, PRACTITIONERS GUIDE, P255, DOI DOI 10.1007/0-306-47628-2_20; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Pole Nnamdi, 2005, Cultur Divers Ethnic Minor Psychol, V11, P144, DOI 10.1037/1099-9809.11.2.144; Rhoades Jr G.F., 2006, J TRAUMA PRACTICE, V4, P21; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; Satorra A., 1988, ASA 1988 P BUSINESS, P308; TANG CS, 2007, CROSS CULTURAL ASSES, P135; Wang XD, 2000, AM J PSYCHIAT, V157, P1260, DOI 10.1176/appi.ajp.157.8.1260	33	19	24	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0191-8869			PERS INDIV DIFFER	Pers. Individ. Differ.	MAY	2010	48	7					798	802		10.1016/j.paid.2010.01.027			5	Psychology, Social	Psychology	591JE	WOS:000277295700004					2021-06-18	
J	Weeks, SR; McAuliffe, CL; DuRussel, D; Pasquina, PF				Weeks, Sharon R.; McAuliffe, Caitlin L.; DuRussel, David; Pasquina, Paul F.			Physiological and Psychological Fatigue in Extreme Conditions: The Military Example	PM&R			English	Article							PROLONGED PHYSICAL STRESS; SLEEP; RESPONSES; HORMONES; ENERGY; EXERCISE; BRAIN	The extreme conditions causing fatigue in military service members in combat and combat training deserve special consideration. The collective effects of severe exertion, limited caloric intake, and sleep deprivation, combined with the inherent stressors of combat, lead to both physiological and psychological fatigue that may significantly impair performance. Studies of combat training have revealed a myriad of endocrine, cognitive, and neurological changes that occur as a result of exposure to extreme conditions. Further contributory effects of multiple military deployments, post-traumatic stress disorder, and traumatic brain injury may also influence both the susceptibility to and expression of fatigue states. Further research is needed to explore these effects to enhance military readiness and performance as well as prevent injuries. PM R 2010;2:438-441	[Weeks, Sharon R.; McAuliffe, Caitlin L.; DuRussel, David; Pasquina, Paul F.] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA	Pasquina, PF (corresponding author), Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, 6900 Georgia Ave NW, Washington, DC 20307 USA.	paul.pasquina@us.army.mil		Weeks, Sharon/0000-0002-9952-9136	Military Amputee Research Program; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Center for Neuroscience and Regenerative Medicine (CNRM) at the Uniformed Services University of the Health Sciences	Funded by the Military Amputee Research Program; Funded by the Center for Neuroscience and Regenerative Medicine; The views expressed in this article are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense, or the United States Government. The authors would also like to acknowledge the support of the Center for Neuroscience and Regenerative Medicine (CNRM) at the Uniformed Services University of the Health Sciences	Armentrout JJ, 2006, AVIAT SPACE ENVIR MD, V77, P963; BAHR R, 1991, ACTA PHYSIOL SCAND, V141, P555, DOI 10.1111/j.1748-1716.1991.tb09117.x; Belasco A., 2007, COST IRAQ AFGHANISTA; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; BELYAVIN A, 1987, ELECTROEN CLIN NEURO, V66, P137, DOI 10.1016/0013-4694(87)90183-0; Bruner E. F., 2006, MILITARY FORCES WHAT; CA Morgan, 2000, ASSESSMENT HUMANS EX, P612; Caldwell J A, 2001, Air Med J, V20, P25; Caldwell JA, 2002, INT J AVIAT PSYCHOL, V12, P19, DOI 10.1207/S15327108IJAP1201_3; Friedl KE, 2000, J APPL PHYSIOL, V88, P1820; Gomez-Merino D, 2003, MIL MED, V168, P1034; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hosek J., 2006, DEPLOYMENTS AFFECT S; LeDuc PA, 2005, AVIAT SPACE ENVIR MD, V76, pC86; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Morgan CA, 2000, BIOL PSYCHIAT, V47, P891, DOI 10.1016/S0006-3223(99)00307-8; Nindl BC, 2003, J APPL PHYSIOL, V95, P1083, DOI 10.1152/japplphysiol.01148.2002; OGILVIE RD, 1992, SLEEP, AROUSAL, AND PERFORMANCE, P73; OPSTAD PK, 1992, J CLIN ENDOCR METAB, V74, P1176, DOI 10.1210/jc.74.5.1176; OPSTAD PK, 1994, EUR J ENDOCRINOL, V131, P56, DOI 10.1530/eje.0.1310056; OPSTAD PK, 1991, ACTA ENDOCRINOL-COP, V125, P14, DOI 10.1530/acta.0.1250014; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Rabinowitz YG, 2009, MIL MED, V174, P358, DOI 10.7205/MILMED-D-01-5008; RAY WJ, 1990, PRINCIPLES PSYCHOPHY, P385; Reger MA, 2009, J CLIN PSYCHIAT, V70, P1266, DOI 10.4088/JCP.08m04361; Roy-Byrne P, 2004, PSYCHOL MED, V34, P363, DOI 10.1017/S0033291703008894; van Zuiden M, 2009, BRAIN BEHAV IMMUN, V23, P1132, DOI 10.1016/j.bbi.2009.07.004	29	19	20	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	MAY	2010	2	5					438	441		10.1016/j.pmrj.2010.03.023			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V23SB	WOS:000208361400015	20656625				2021-06-18	
J	Luccichenti, G; Giugni, E; Peran, P; Cherubini, A; Barba, C; Bivona, U; Formisano, R; Sabatini, U				Luccichenti, Giacomo; Giugni, Elisabetta; Peran, Patrice; Cherubini, Andrea; Barba, Carmen; Bivona, Umberto; Formisano, Rita; Sabatini, Umberto			3 Tesla is twice as sensitive as 1.5 Tesla magnetic resonance imaging in the assessment of diffuse axonal injury in traumatic brain injury patients	FUNCTIONAL NEUROLOGY			English	Article						diffuse axonal injury; gradient echo sequences; high-field magnetic resonance; traumatic brain injury	MILD HEAD-INJURY; PRACTICAL SCALE; SEQUELAE; ECHO; LESIONS; COMA; MICROBLEEDS; TECHNOLOGY; SEQUENCES; DAMAGE	Diffuse axonal injury (DAI), associated with deafferentation and functional rearrangement, probably plays a role in the chronic phase of traumatic brain injury (TBI). DAI with a haemorrhagic component can be quantified using magnetic resonance imaging (MRI) thanks to the iron-based susceptibility effect of haemosiderin, which increases with magnetic field strength. The aim of this work was to compare conventional 1.5 Tesla and 3 Tesla MRI in the assessment of DAI in TBI patients. Eighteen TBI patients were submitted, in random order, to a 1.5T and a 3T MRI examination using standard gradient echo sequences. Both scans were always performed on the same day. DAI lesions with a haemorrhagic component were manually segmented and classified by anatomical location. The Wilcoxon and ANOVA tests were used for statistical analysis, significance being set at p<0.05. The results of this study showed that 3T MRI is almost twice as sensitive as 1.5T MRI in assessing DAI in terms of lesion number and volume. Differences between the two scanners were not significant in the posterior cranial fossa. High-field MRI enhances the assessment of DAI and may help to increase understanding of the mechanisms underlying subacute and chronic clinical, cognitive and behavioural changes in TBI patients.	[Luccichenti, Giacomo] IRCCS Fdn Santa Lucia, Dept Radiol, I-00179 Rome, Italy	Luccichenti, G (corresponding author), IRCCS Fdn Santa Lucia, Dept Radiol, Via Ardeatina 306, I-00179 Rome, Italy.	g.luccichenti@yahoo.it	; Cherubini, Andrea/D-1327-2009; SABATINI, Umberto/K-4659-2016; Peran, Patrice/N-7561-2015	barba, carmen/0000-0001-5445-5842; Cherubini, Andrea/0000-0002-5946-4390; SABATINI, Umberto/0000-0001-5321-8626; Peran, Patrice/0000-0001-7200-0139			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Allkemper T, 2004, EUR RADIOL, V14, P1000, DOI 10.1007/s00330-004-2241-4; Bastianello S, 2009, FUNCT NEUROL, V24, P69; Caltagirone C, 2008, FUNCT NEUROL, V23, P195; Cherubini A, 2007, NEUROIMAGE, V34, P1331, DOI 10.1016/j.neuroimage.2006.11.024; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; JENNETT B, 1975, LANCET, V1, P480; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	26	19	19	0	6	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264			FUNCT NEUROL	Funct. Neurol.	APR-JUN	2010	25	2					109	114					6	Clinical Neurology	Neurosciences & Neurology	726ZM	WOS:000287766900008	20923609				2021-06-18	
J	Cartagena, CM; Burns, MP; Rebeck, GW				Cartagena, Casandra M.; Burns, Mark P.; Rebeck, G. William			24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury	BRAIN RESEARCH			English	Article						Cyp46; 24S-hydroxycholesterol; Lipid metabolism; Traumatic brain injury	LIVER-X-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; STEROL-REGULATED TRANSPORT; EVANS BLUE EXTRAVASATION; FATTY-ACID SYNTHESIS; CHOLESTEROL HOMEOSTASIS; CEREBROSPINAL-FLUID; TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; ENDOPLASMIC-RETICULUM	Membrane damage during traumatic brain injury (TBI) alters the brain homeostasis of cholesterol and other lipids. Cholesterol 24S-hydroxylase (Cyp46) is a cholesterol metabolic enzyme that is increased after TBI. Here, we systematically examined the effects of the enzymatic product of Cyp46, 24S-hydroxycholesterol, on the cholesterol regulatory genes, SREBP-1 and 2, their posttranslational regulation, and their effects on gene transcription. 24S-hydroxycholesterol increased levels of SREBP-1 mRNA and full-length protein but did not change levels of cleaved SREBP-1, consistent with the role of 24-hydroxycholesterol as an LXR agonist. In contrast, 24S-hydroxycholesterol decreased levels of LXR-independent SREBP-2 mRNA, full-length protein, and SREBP-2 active cleavage product. We examined the downstream effects of changes to these lipid regulatory factors by studying cholesterol and fatty acid synthesis genes. In neuroblastoma cells, 24S-hydroxycholesterol decreased mRNA levels of the cholesterol synthesis genes HMG CoA reductase, squalene synthase, and FPP synthase but did not alter levels of the mRNA of fatty acid synthesis genes acetyl CoA carboxylase or fatty acid synthase. After TB!, as after 24S-hydroxycholesterol treatment in vitro, SREBP-1 mRNA levels were increased while SREBP-2 mRNA levels were decreased. Also similar to the in vitro results with 24S-hydroxycholesterol, HMG CoA reductase and squalene synthase mRNA levels were significantly decreased. Fatty acid synthase mRNA levels were not altered but acetyl CoA carboxylase mRNA levels were significantly decreased. Thus, changes to transcription of cholesterol synthesis genes after TBI were consistent with increases in Cyp46 activity, but changes to fatty acid synthesis genes must be regulated by other mechanisms. (C) 2010 Elsevier B.V. All rights reserved.	[Cartagena, Casandra M.; Burns, Mark P.; Rebeck, G. William] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA	Rebeck, GW (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	casandra.cartagena@us.army.mil; mpb37@georgetown.edu; gwr2@georgetown.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Burns, Mark P/0000-0003-4750-2000	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AG14473, F31-AG025676]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F31AG025676, P01AG030128, R01AG014473] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (R01-AG14473, F31-AG025676).	Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200; Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x; Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Cartagena CM, 2008, J NEUROTRAUM, V25, P1087, DOI 10.1089/neu.2007.0444; Costet P, 2000, J BIOL CHEM, V275, P28240; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Du XM, 2004, J BIOL CHEM, V279, P47010, DOI 10.1074/jbc.M408690200; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fagan AM, 1998, EXP NEUROL, V151, P314, DOI 10.1006/exnr.1998.6818; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Fujiyoshi M, 2007, J NEUROCHEM, V100, P968, DOI 10.1111/j.1471-4159.2006.04240.x; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Gasparovic C, 2001, NEUROSCI LETT, V301, P87, DOI 10.1016/S0304-3940(01)01616-0; Gilardi F, 2009, NEUROSCIENCE, V164, P530, DOI 10.1016/j.neuroscience.2009.08.003; Gill S, 2008, PROG LIPID RES, V47, P391, DOI 10.1016/j.plipres.2008.04.002; Gimpl G, 2002, TRENDS BIOCHEM SCI, V27, P596, DOI 10.1016/S0968-0004(02)02224-7; He X, 2006, J NEUROPATH EXP NEUR, V65, P652, DOI 10.1097/01.jnen.0000225906.82428.69; Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Huang ZH, 2001, ARTERIOSCL THROM VAS, V21, P2019, DOI 10.1161/hq1201.100242; Hudry E, 2010, MOL THER, V18, P44, DOI 10.1038/mt.2009.175; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Johanson CE, 2008, FLUIDS BARRIERS CNS, V5, DOI 10.1186/1743-8454-5-10; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Kamada H, 2003, NEUROSCI RES, V45, P91, DOI 10.1016/S0168-0102(02)00203-1; Karu K, 2007, J LIPID RES, V48, P976, DOI 10.1194/jlr.M600497-JLR200; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Levin-Allerhand J A, 2002, J Nutr Health Aging, V6, P315; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Meir K, 2002, J BIOL CHEM, V277, P34036, DOI 10.1074/jbc.M201122200; Natali F, 2007, J LIPID RES, V48, P1966, DOI 10.1194/jlr.M700051-JLR200; NIKAWA J, 1979, FEBS LETT, V102, P223, DOI 10.1016/0014-5793(79)80005-8; Ohyama Y, 2006, J BIOL CHEM, V281, P3810, DOI 10.1074/jbc.M505179200; Olkkonen VM, 2009, MOL ASPECTS MED, V30, P123, DOI 10.1016/j.mam.2009.02.004; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Radhakrishnan A, 2007, P NATL ACAD SCI USA, V104, P6511, DOI 10.1073/pnas.0700899104; Raghow R, 2008, TRENDS ENDOCRIN MET, V19, P65, DOI 10.1016/j.tem.2007.10.009; Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605; Rebeck GW, 2004, J MOL NEUROSCI, V23, P219, DOI 10.1385/JMN:23:3:219; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rubink DS, 2005, J APPL PHYSIOL, V98, P1221, DOI 10.1152/japplphysiol.00621.2004; Sabol SL, 2005, J LIPID RES, V46, P2151, DOI 10.1194/jlr.M500080-JLR200; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; Shafaati M, 2007, NEUROSCI LETT, V425, P78, DOI 10.1016/j.neulet.2007.08.014; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Sun LP, 2007, P NATL ACAD SCI USA, V104, P6519, DOI 10.1073/pnas.0700907104; Tall AR, 2008, J INTERN MED, V263, P256, DOI 10.1111/j.1365-2796.2007.01898.x; Teunissen CE, 2007, J NEUROSCI RES, V85, P1499, DOI 10.1002/jnr.21266; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; Turley SD, 1996, J LIPID RES, V37, P1953; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099; Vaya J, 2007, J NEUROCHEM, V102, P1727, DOI 10.1111/j.1471-4159.2007.04689.x; Wang YQ, 2008, J PROTEOME RES, V7, P1606, DOI 10.1021/pr7006076; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200	78	19	20	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 10	2010	1319						1	12		10.1016/j.brainres.2009.12.080			12	Neurosciences	Neurosciences & Neurology	569TI	WOS:000275624100001	20053345	Green Accepted			2021-06-18	
J	Kreipke, CW; Schafer, PC; Rossi, NF; Rafols, JA				Kreipke, Christian W.; Schafer, Patrick C.; Rossi, Noreen F.; Rafols, Jose A.			Differential effects of endothelin receptor A and B antagonism on cerebral hypoperfusion following traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						Brain trauma; endothelin; vascular regulation	RESPONSES; ISCHEMIA; DAMAGE; MODEL; RATS	Objectives: Our laboratory has previously shown that endothelin 1 (ET-1), a powerful vasoconstrictor, and its receptors, A (ETrA) and B (ETrB), are up-regulated following trauma. This up-regulation coincides temporally with enhanced vasoreactivity in cerebral cortical microvessels, which leads to a state of chronic hypoperfusion for up to 48 hours following traumatic brain injury (TBI). However, the direct contribution of either receptor up-regulation to decreased cerebral blood flow (CBF) after closed head trauma has not been determined. Furthermore, how ET-1 blockade may affect histological outcome following TBI has not been explored. Therefore, the effects of ETrA and B antagonism on TBI induced hypoperfusion of CBF and cell injury in sensorimotor cortex (smCx) and hippocampus (Hipp) were assessed by arterial spin labeling magnetic resonance imaging and Fluoro-Jade staining, respectively. Methods: Adult male rats were given intracerebroventricular injections of ETrA (BQ123) or ETrB antagonist (BQ788) before being subjected to TBI using a closed head acceleration impact model. Following TBI, CBF was measured and histological examination of cell integrity was carried out. Results: ETrA blockade ameliorated TBI induced hypoperfusion in smCx and Hipp at 4 and 24 hours after TBI and caused a mild hyperemia in both centers by 48 hours after injury. Furthermore, ETrA antagonism reduced the extent of Fluoro-Jade labeled cells within smCx and Hipp as compared with TBI only. ETrB blockade had little effect on TBI induced hypoperfusion and did not change the extent of cell injury following TBI. Discussion: These results suggest that decreased CBF following TBI may be caused by ETrA, but not ETrB, up-regulation. Furthermore, these results suggest that TBI induced hypoperfusion may contribute to poor neurologic outcome following TBI. In this work, we provide a rationale for studying the clinical relevancy of use of ETrA antagonists following TBI.	[Kreipke, Christian W.; Schafer, Patrick C.; Rafols, Jose A.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Rossi, Noreen F.] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Room 9312 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS039860]; International Conference on endothelin [ET-10]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER	This work was supported by the National Institute of Health (grant no. NS039860). A partial report of these findings was presented at the International Conference on endothelin (ET-10) in Bergamo, Italy.	Andersson KE, 2001, UROL CLIN N AM, V28, P233, DOI 10.1016/S0094-0143(05)70134-8; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; BEGNINI A, 2007, P ET 10 BERG IT; EHRENREICH H, 2005, SCIENCE, V309, P392; ISHIKAWA K, 1992, J MED CHEM, V35, P2139, DOI 10.1021/jm00089a028; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; Jacobs A, 2006, CURR MED RES OPIN, V22, P2567, DOI 10.1185/030079906X158020; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pollock DM, 2006, HYPERTENSION, V48, P211, DOI 10.1161/01.HYP.0000229908.62191.6e; Rafols JA, 2007, NEUROL RES, V29, P337, DOI 10.1179/016164107X204639; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Siren AL, 2002, BRAIN RES, V945, P144, DOI 10.1016/S0006-8993(02)02911-6; Touzani O, 1997, J CEREBR BLOOD F MET, V17, P1157, DOI 10.1097/00004647-199711000-00004; Zhao P, 2007, ANESTHESIOLOGY, V107, P963, DOI 10.1097/01.anes.0000291447.21046.4d	18	19	20	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2010	32	2					209	214		10.1179/174313209X414515			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	558XJ	WOS:000274781900017	19570328				2021-06-18	
J	Finnie, JW; Manavis, J; Blumbergs, PC				Finnie, John W.; Manavis, Jim; Blumbergs, Peter C.			Diffuse neuronal perikaryal amyloid precursor protein immunoreactivity in an ovine model of non-accidental head injury (the shaken baby syndrome)	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Animal model; Neuronal and axonal reactions; Shaken baby syndrome	TRAUMATIC AXONAL INJURY; PERMANENT BRAIN-DAMAGE; INFANT SYNDROME; NEUROPATHOLOGY; CHILDREN; IMPACT; SHAKING	Non-accidental head injury ("shaken baby syndrome") is a major cause if death and disability in infants and young children, but it is uncertain whether shaking alone is sufficient to cause brain damage or an additional head impact is required. Accordingly, we used manual shaking in an ovine model in an attempt to answer this question since lambs have a relatively large gyrencephalic brain and weak neck muscles resembling a human infant. Neuronal perikaryal and axonal reactions were quantified 6 hours after shaking using amyloid precursor protein (APP) immunohistochemistry. Neuronal perikaryal APP was widely distributed in the brain and spinal cord, the first time such a diffuse neuronal stress response after shaking has been demonstrated, but axonal immunoreactivity was minimal a id largely confined to the rostral cervical spinal cord at the site of maximal loading. No ischaemic-hypoxic damage was found in haematoxylin and eosin-stained sections. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.	[Finnie, John W.; Manavis, Jim; Blumbergs, Peter C.] Inst Med & Vet Sci, Hanson Inst Ctr Neurol Dis, Adelaide, SA 5000, Australia	Blumbergs, PC (corresponding author), Inst Med & Vet Sci, Hanson Inst Ctr Neurol Dis, POB 14 Rundle Mall, Adelaide, SA 5000, Australia.	peter.blumbergs@imvs.sa.gov.au					BLUMBERGS PC, 2008, GREENFIELDS NEUROPAT, P792; Bonnier C, 2002, BRAIN PATHOL, V12, P320; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; Dobbing J, 1981, SCI F PAEDIATRICS, P744; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Finnie JW, 2001, J COMP PATHOL, V124, P159, DOI 10.1053/jcpa.2000.0446; Geddes JF, 2004, FORENSIC SCI INT, V146, P83, DOI 10.1016/S0379-0738(03)00283-4; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; Ghahreman A, 2005, J NEUROSURG, V103, P213, DOI 10.3171/ped.2005.103.3.0213; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Hymel KP, 2006, PEDIATRICS, V118, P421, DOI 10.1542/peds.2006-1245; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Krous HF, 1999, PEDIATR DEVEL PATHOL, V2, P497, DOI 10.1007/s100249900156; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Oehmichen M, 2008, ACTA NEUROPATHOL, V116, P317, DOI 10.1007/s00401-008-0356-4; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reichard RR, 2003, J NEUROTRAUM, V20, P347, DOI 10.1089/089771503765172309; Richards PG, 2006, ARCH DIS CHILD, V91, P205, DOI 10.1136/adc.2005.090761; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Ward JD, 1996, NEUROTRAUMA, P859	37	19	19	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	FEB	2010	17	2					237	240		10.1016/j.jocn.2009.07.001			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	554PC	WOS:000274445900020	20036546				2021-06-18	
J	Jacobs, B; Beems, T; van der Vliet, TM; Borm, GF; Vos, PE				Jacobs, Bram; Beems, Tjemme; van der Vliet, Ton M.; Borm, George F.; Vos, Pieter E.			The Status of the Fourth Ventricle and Ambient Cisterns Predict Outcome in Moderate and Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cisterns; computed tomography scan; head injury; outcome; severe traumatic brain injury; ventricles	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; BASAL CISTERNS; CT SCAN; VALIDATION; CLASSIFICATION; SURVIVAL; MODELS; IMPACT	Computed tomography (CT) of the head has become the diagnostic tool of choice, particularly for moderate and severe traumatic brain injury (TBI). Various CT characteristics are associated with outcome, and may therefore be used as outcome predictors. One of the most prominent predictors appears to be the status of the basal cisterns. This study describes the prognostic value of the appearance of individual cisterns and ventricles in relation to that of the basal cisterns. Further, we determine the interrater and intrarater reliability in the evaluation of the cisterns and ventricles. All consecutive moderate and severe adult TBI patients admitted to our hospital were included in this study as part of the prospective Radboud University Brain Injury Cohort Study (RUBICS). Outcome was assessed at 6 months post-trauma using the Glasgow Outcome Scale-Extended (GOS-E). The predictive value of cisterns and ventricles was determined using multivariate binary logistic regression analysis. We included 126 moderate and 574 severe TBI patients. Absence (complete obliteration), but also compression of the ambient cisterns and/or the fourth ventricle were strongly related to unfavorable outcome and death and emerged as the only significant outcome predictors after multivariate analysis. The assessment of the ambient cisterns and the fourth ventricle had a satisfactory inter-and intrarater reliability (kappa coefficients: 0.80-0.95). We conclude that, because obliteration of the ambient cisterns and the fourth ventricle both are better than the status of the basal cisterns as outcome predictors, they might be used in CT prediction models in cases of moderate and severe TBI.	[Jacobs, Bram; Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Beems, Tjemme] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; [van der Vliet, Ton M.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; [Borm, George F.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6500 HB Nijmegen, Netherlands	Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dep Neurol 935, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012				*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P597; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Chen R, 2009, SURG RADIOL ANAT, V31, P129, DOI 10.1007/s00276-008-0417-3; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COLQUHOUN IR, 1989, CLIN RADIOL, V40, P13, DOI 10.1016/S0009-9260(89)80006-6; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Edwards P, 2005, LANCET, V365, P1957; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JACOBS B, 2009, J NEUROTRAUMA; LANDIS JR, 1977, BIOMETRICS, V33, P174; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LIU HM, 1995, J TRAUMA, V38, P330, DOI 10.1097/00005373-199503000-00003; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; Servadei F, 2000, NEUROSURGERY, V46, P70; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stranjalis G, 2008, J TRAUMA, V65, P789, DOI 10.1097/TA.0b013e3181469e26; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	45	19	19	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					331	340		10.1089/neu.2009.1105			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800006	19852584				2021-06-18	
J	Lopez-Aguilar, J; Quilez, ME; Marti-Sistac, O; Garcia-Martin, C; Fuster, G; Puig, F; Flores, C; Villar, J; Artigas, A; Blanch, L				Lopez-Aguilar, Josefina; Elisa Quilez, Maria; Marti-Sistac, Octavi; Garcia-Martin, Carolina; Fuster, Gemma; Puig, Ferranda; Flores, Carlos; Villar, Jesus; Artigas, Antonio; Blanch, Lluis			Early physiological and biological features in three animal models of induced acute lung injury	INTENSIVE CARE MEDICINE			English	Article						Ventilator-induced lung injury; Endotoxemia; Lipopolysaccharide; Brain injury; Inflammation; Metalloproteinases	TRAUMATIC BRAIN-INJURY; ULTRASTRUCTURAL-CHANGES; MECHANICAL VENTILATION; PULMONARY; DEATH; DYSFUNCTION; EXPRESSION; CYTOKINES; PRESSURE; RATS	Critically ill patients often develop acute lung injury (ALI) in the context of different clinical conditions. We aimed to explore differences in early local and systemic features in three experimental animal models of ALI. Mechanically ventilated male Sprague-Dawley rats were randomized to high tidal volume (VT) ventilation (HVT) (n = 8, VT 24 ml/kg), massive brain injury (MBI) (n = 8, VT 8 ml/kg) or endotoxemia (LPS) (n = 8, VT 8 ml/kg). Each experimental group had its own control group of eight rats (VT 8 ml/kg). We measured arterial blood gases, mean arterial pressure, lung compliance, inflammatory mediators in plasma and their expression and gelatinase activity in the lungs after 3 h of injury. Despite maintaining relatively normal lung function without evidence of important structural changes, we observed altered lung and systemic inflammatory responses in all three experimental models. LPS triggered the most robust inflammatory response and HVT the lowest systemic proinflammatory response. The HVT group had higher Il6, Tnf and Cxcl2 mRNA in lungs than MBI animals. Metalloproteinase activity/expression and neutrophilic recruitment in the lungs were higher in HVT than in LPS or MBI. The early responses to direct or remote lung insult in our three models of ALI captured different physiological and biological features that could lead to respiratory and/or multiorgan failure.	[Lopez-Aguilar, Josefina; Elisa Quilez, Maria; Marti-Sistac, Octavi; Garcia-Martin, Carolina; Fuster, Gemma; Puig, Ferranda; Artigas, Antonio; Blanch, Lluis] Esfera UAB, Inst Univ, Corp Parc Tauli, Hosp Sabadell,Crit Care Ctr, Sabadell 08208, Spain; [Lopez-Aguilar, Josefina; Elisa Quilez, Maria; Marti-Sistac, Octavi; Fuster, Gemma; Puig, Ferranda; Flores, Carlos; Villar, Jesus; Artigas, Antonio; Blanch, Lluis] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain	Lopez-Aguilar, J (corresponding author), Esfera UAB, Inst Univ, Corp Parc Tauli, Hosp Sabadell,Crit Care Ctr, Parc Tauli S-N, Sabadell 08208, Spain.	jlopeza@tauli.cat	Fuster, Gemma/B-5468-2019; Flores, Carlos/R-1159-2019; Villar, Jesus/R-4526-2019	Fuster, Gemma/0000-0002-4501-2422; Villar, Jesus/0000-0001-5687-3562; antonio, artigas/0000-0002-8029-1017	FISInstituto de Salud Carlos III [CA 05/0138]; Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica and Instituto de Salud Carlos [III-FIS PI-04/2365]; Ministerio de Educacion y CienciaSpanish GovernmentEuropean Commission [BFU2006-07124/BFI]; Fundacio Parc Tauli CIR; Programa de Estabilizacion FIS and Health Department of the Generalitat de Catalunya; Instituto de Salud Carlos III and FUNCISInstituto de Salud Carlos III [EMER07/001]	The authors would like to thank Neus Gomez (supported by FIS CA 05/0138) and Milagros Martinez for their technical assistance. The study was supported by Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica and Instituto de Salud Carlos III-FIS PI-04/2365, Ministerio de Educacion y Ciencia BFU2006-07124/BFI, Fundacio Parc Tauli CIR. JLA received support from the Programa de Estabilizacion FIS and Health Department of the Generalitat de Catalunya. CF was supported by a specific agreement between the Instituto de Salud Carlos III and FUNCIS (EMER07/001) under the ENCYT 2015 framework.	Altemeier WA, 2005, J IMMUNOL, V175, P3369, DOI 10.4049/jimmunol.175.5.3369; Altemeier WA, 2004, AM J PHYSIOL-LUNG C, V287, pL533, DOI 10.1152/ajplung.00004.2004; Avlonitis VS, 2007, AM J TRANSPLANT, V7, P83, DOI 10.1111/j.1600-6143.2006.01593.x; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; Bregeon F, 2005, ANESTHESIOLOGY, V102, P331; Chiari P, 2000, J HEART LUNG TRANSPL, V19, P675, DOI 10.1016/S1053-2498(00)00127-3; dos Santos CC, 2006, ANNU REV PHYSIOL, V68, P585, DOI 10.1146/annurev.physiol.68.072304.113443; Dreyfuss D, 2003, AM J RESP CRIT CARE, V167, P1467, DOI 10.1164/rccm.200206-611CP; Fisher AJ, 2001, AM J RESP CRIT CARE, V163, P259, DOI 10.1164/ajrccm.163.1.2005093; Foda HD, 2001, AM J RESP CELL MOL, V25, P717, DOI 10.1165/ajrcmb.25.6.4558f; Gonzalvo R, 2007, CRIT CARE, V11, DOI 10.1186/cc5930; Haitsma JJ, 2000, INTENS CARE MED, V26, P1515, DOI 10.1007/s001340000648; Herrera MT, 2003, INTENS CARE MED, V29, P1345, DOI 10.1007/s00134-003-1756-5; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Isowa N, 2001, AM J PHYSIOL-LUNG C, V280, pL762; Kim JH, 2006, AM J PHYSIOL-LUNG C, V291, pL580, DOI 10.1152/ajplung.00270.2005; Lanchou J, 2003, CRIT CARE MED, V31, P536, DOI 10.1097/01.CCM.0000048626.02184.F8; Lewis CC, 2008, AM J RESP CRIT CARE, V177, P376, DOI 10.1164/rccm.200702-333OC; Lopez-Aguilar J, 2006, CRIT CARE MED, V34, P1106, DOI 10.1097/01.CCM.0000205757.66971.DA; Lopez-Aguilar J, 2005, CRIT CARE MED, V33, P1077, DOI 10.1097/01.CCM.0000162913.72479.F7; Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008; Menezes SLS, 2005, J APPL PHYSIOL, V98, P1777, DOI 10.1152/japplphysiol.01182.2004; Nonas SA, 2007, AM J PHYSIOL-LUNG C, V293, pL292, DOI 10.1152/ajplung.00481.2006; Pugin J, 2003, CRIT CARE MED, V31, pS200, DOI 10.1097/01.CCM.0000057844.31307.ED; Skrabal CA, 2005, J SURG RES, V123, P118, DOI 10.1016/j.jss.2004.07.245; Slutsky Arthur S, 2005, Respir Care, V50, P646; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; Tremblay LN, 2005, AM J PHYSIOL-LUNG C, V288, pL596, DOI 10.1152/ajplung.00438.2004; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Villar J, 2009, ANESTHESIOLOGY, V110, P1341, DOI 10.1097/ALN.0b013e31819fcba9; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Yildirim E, 2004, J HEART LUNG TRANSPL, V23, P1423, DOI 10.1016/j.healun.2003.10.006; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021	34	19	23	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	FEB	2010	36	2					347	355		10.1007/s00134-009-1695-x			9	Critical Care Medicine	General & Internal Medicine	546KU	WOS:000273810500023	19841895				2021-06-18	
J	Demakis, GJ; Hammond, FM; Knotts, A				Demakis, George J.; Hammond, Flora M.; Knotts, Allison			Prediction of Depression and Anxiety 1 Year After Moderate-Severe Traumatic Brain Injury	APPLIED NEUROPSYCHOLOGY			English	Article						anxiety; depression; Personality Assessment Inventory; traumatic brain injury	DISABILITY RATING-SCALE; PERSONALITY-ASSESSMENT INVENTORY; HEAD-INJURY; IMPAIRED AWARENESS; POPULATION; DISORDERS; COMMUNITY; PEOPLE	This study examined three scales of the Personality Assessment Inventory (PAI; Anxiety, Anxiety-Related Disorders, and Depression) in 88 participants 1 year after they suffered a moderate-severe traumatic brain injury (TBI). Participants were all enrolled in the federally funded Traumatic Brain Injury Model System project at Carolinas Rehabilitation. The following variables were assessed at the time of injury: age, sex, employment and marital status, and length of loss of consciousness. Disability status, using the Disability Rating Scale (DRS), was assessed at the time of discharge from the rehabilitation hospital. A series of three linear regression analyses found that these variables significantly predicted scores on the Anxiety and Anxiety-Related Disorders scales, which accounted for 14% and 17.7% of the variance, respectively. The variables did not significantly predict scores on the Depression scale. Within each regression analysis, DRS was consistently and negatively related to each PAI scale, such that greater disability was associated with better psychological functioning. Such seemingly paradoxical findings are discussed in terms of anosognosia or poor awareness of psychological functioning among those with greater disability 1 year after TBI.	[Demakis, George J.] Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA; [Hammond, Flora M.; Knotts, Allison] Carolinas HealthCare Syst, Carolinas Rehabil, Charlotte, NC USA	Demakis, GJ (corresponding author), Univ N Carolina, Dept Psychol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	gdemakis@uncc.edu					Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Corcoran C, 2005, TXB TRAUMATIC BRAIN, P213; Deb S, 1999, AM J PSYCHIAT, V156, P374; Demakis GJ, 2007, ARCH CLIN NEUROPSYCH, V22, P123, DOI 10.1016/j.acn.2006.09.004; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Flashman L., 2005, TXB TRAUMATIC BRAIN, P353; Fleming J, 1999, BRAIN INJURY, V13, P417; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kurtz JE, 2007, J PERS ASSESS, V88, P66, DOI 10.1207/s15327752jpa8801_09; Leung K L, 2005, Work, V25, P333; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Morey L. C., 1991, PERSONALITY ASSESSME; Morey LC, 2006, DIFFERENTIATING NORM, P451; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	35	19	21	0	6	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	3					183	189	PII 926372433	10.1080/09084282.2010.499752			7	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	643VQ	WOS:000281328100004	20799109				2021-06-18	
J	Drake, AI; Meyer, KS; Cessante, LM; Cheung, CR; Cullen, MA; McDonald, EC; Holland, MC				Drake, Angela I.; Meyer, Kimberly S.; Cessante, Lynne M.; Cheung, Catherine R.; Cullen, Maren A.; McDonald, Eric C.; Holland, Martin C.			Routine TBI screening following combat deployments	NEUROREHABILITATION			English	Article						Blast; combat veteran; injury mechanism; Iraq; Afghanistan; Marines; military; post-deployment; prevalence; screening; traumatic brain injury	TRAUMATIC BRAIN-INJURY; WAR; IRAQ; VETERANS; CARE	A precise estimate of the rates of traumatic brain injury (TBI) in returning combat troops is difficult to establish given the challenges of screening large numbers of military personnel returning from combat deployments. The Brief Traumatic Brain Injury Screen (BTBIS) was implemented in the First Marine Expeditionary Force between 2004 and 2006. Nine percent of the 7909 marines who completed the BTBIS were considered having a positive screen; that is, they endorsed at least one injury mechanism and indicated a change in mental status at the time of injury. The majority of combat-related TBI's were due to multiple injury agents with the next largest group related to blast exposure only. Most importantly, of those who screened positive for TBI 70.5% (n = 500) were first identified by the screen. Service members who endorsed items on the BTBIS were contacted for follow-up assessment of persistent symptoms related to TBI and clinical referrals were made as needed. Given the rate of positive TBI screens in this non-referred sample of military personnel returning from a combat deployment, routine TBI screening appears valuable in screening individuals who might not be identified otherwise. Furthermore, this study appears to refute the contention that routine TBI screening will result in an over-identification of TBI in this population.	[Drake, Angela I.; Meyer, Kimberly S.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Cessante, Lynne M.; Cheung, Catherine R.; Cullen, Maren A.] USN, Def & Vet Brain Injury Ctr, Med Ctr, San Diego, CA 92152 USA	Drake, AI (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Bldg 1,Room B209,6900 Georgia Ave NW, Washington, DC 20307 USA.	adrake@dvbic.org	Meyer, Kimberly/L-5430-2019				Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Institute of Medicine, 2008, GULF WAR HLTH, V7; KENNEDY JE, 2010, NEUROREHABILITATION; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; SCHWAB KA, 2006, NEUROLOGY S2, V66; STAHURA B, 2005, YEAR VETERANS AFFAIR, P78; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; ENHANCED POSTDEPLOYM	17	19	21	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2010	26	3					183	189		10.3233/NRE-2010-0554			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300002	20448308				2021-06-18	
J	Gale, SD; Prigatano, GP				Gale, Shawn D.; Prigatano, George P.			Deep White Matter Volume Loss and Social Reintegration After Traumatic Brain Injury in Children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							VOXEL-BASED MORPHOMETRY; CHILDHOOD HEAD-INJURY; RECOVERY; OUTCOMES; PREDICTORS	Objective: To explore whether children judged by their parents as showing an "excellent" or "complete" social reintegration after pediatric traumatic brain injury have less white matter volume (WMV) loss and better neuropsychological test scores than children who do not achieve this same level of reintegration. Setting: Primary-care hospital/medical center. Participants: Twenty-eight children with post-acute traumatic brain injury evaluated as outpatients. Measures: Parental ratings of overall social reintegration, neuropsychological test performance, and voxel-based morphometry analysis of brain WMV loss. Results: In addition to showing worse neuropsychological test performance, children judged not to make a complete or excellent social reintegration had greater WNW loss, particularly within the corpus callosum. WMV loss in the corpus callosum correlated with the child's Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV) Full Scale IQ (rho = .677, P = .000) and parental ratings of level of social integration (rho = .415, P = .028). Admitting Glasgow Coma Scale scores, mother's level of education, WISC-IV Processing Speed Index scores, and WMV loss in the region of the corpus callosum significantly contributed to parental ratings of a child's level of social reintegration. Conclusions: Preliminary findings suggested that diffuse WMV loss, particularly in deep brain regions (eg, corpus callosum), may relate to the child's long-term psychosocial outcome as viewed from the parents' perspective.	[Gale, Shawn D.; Prigatano, George P.] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 222 W Thomas Rd,Ste 315, Phoenix, AZ 85013 USA.	gprigat@chw.edu	Gale, Shawn/M-3144-2013	Gale, Shawn/0000-0002-8989-0964	Barrow Neurological Foundation	Funding for the study was made possible by the Barrow Neurological Foundation.	Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bigler ED, 2005, TXB TRAUMATIC BRAIN; Birch HG, 1964, BRAIN DAMAGE CHILDRE; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Broman S. H., 1995, TRAUMATIC HEAD INJUR; Delis D, 1994, CALIFORNIA VERBAL LE; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gennarelli TA, 2005, TXB TRAUMATIC BRAIN; Good CD, 2001, NEUROIMAGE, V14, P685, DOI 10.1006/nimg.2001.0857; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEVIN HS, 1997, NEUROSURGERY, V40, P440; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; MAZZIOTTA JC, 1995, NEUROIMAGE, V2, P89, DOI 10.1006/nimg.1995.1012; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Prigatano GP, 2008, J INT NEUROPSYCH SOC, V14, P143, DOI 10.1017/S1355617708080089; Prigatano GP, 2008, BRAIN INJURY, V22, P491, DOI 10.1080/02699050802084902; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P414, DOI 10.1097/01.HTR.0000341438.97745.ee; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Shaffer D, 1975, Ciba Found Symp, P191; SPSS, 2008, SPSS WIND REL 16 0 2; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Wechsler D., 2003, WECHSLER INTELLIGENC; Wilke M, 2002, HUM BRAIN MAPP, V17, P48, DOI 10.1002/hbm.10053; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	37	19	20	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					15	22		10.1097/HTR.0b013e3181c39960			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800003	20051899				2021-06-18	
J	Hawley, LA; Newman, JK				Hawley, Lenore A.; Newman, Jody K.			Group interactive structured treatment (GIST): A social competence intervention for individuals with brain injury	BRAIN INJURY			English	Article						Social skills; brain injury; group therapy; social communication skills; social competence	TRIAL	Background: Impairments in social competence are among the most prevalent sequelae of traumatic brain injury and present a major barrier to a person returning to a productive life. The recent increased incidence of TBI among military personnel and the subsequent difficulties these individuals face reintegrating into society accentuates the need for efficacious social competence treatment interventions for the TBI population. Method and results: This paper outlines the theoretical model and clinical application of Group Interactive Structured Treatment (GIST) for Social Competence. GIST-Social Competence is a structured cognitive-behavioural group therapy model addressing the underlying cognitive, communicative and emotional impairments impeding social competence after TBI. A recent randomized control trial (RCT) funded by the National Institute on Disability and Rehabilitation Research demonstrated the efficacy of this programme. GIST integrates the principles of established cognitive-behavioural therapy, group therapy and holistic neuro-rehabilitation in a manualized 13 week intervention combining a structured curriculum with a group therapy format. The structured cognitive-behavioural approach allows even those with significant underlying deficits (including self-awareness, memory, problem-solving, etc.) to benefit from this intervention. Conclusion: The GIST model can be applied to other treatment areas in TBI rehabilitation. Clinical observations from application of GIST with military personnel are reviewed.	[Hawley, Lenore A.] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Newman, Jody K.] Univ Colorado, Dept Psychiat, Neurobehav Disorders Program, Sch Med, Aurora, CO USA	Hawley, LA (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	lhawley@craighospital.org; jnewman@craighospital.org			National Institute on Disability and Rehabilitation Research; Colorado TBI Trust	We are grateful to the many clients and families we have worked with through the years who have given us the knowledge and insight to develop this programme. We would like to thank Craig Hospital, especially Cynthia Harrison-Felix, PhD, Gale Whiteneck, PhD, Cynthia Braden, MA, CCC CPHQ, and the entire research team, for believing in the GIST programme and for providing the opportunity to demonstrate its efficacy. The National Institute on Disability and Rehabilitation Research supported the treatment efficacy RCT at Craig Hospital, as part of a TBI Model Systems grant. The Colorado TBI Trust Fund funded the feasibility study, providing further information regarding the application of GIST to individuals with TBI and co-existing diagnoses. Special acknowledgement is given to Don Gerber, PhD, for sharing his expertise and encouraging the authors to further develop the GIST theoretical model, and to Clare Morey, MA, CCC, for her valuable clinical observations, feedback and review. Denver Options is currently supporting the GIST intervention for active duty soldiers and veterans and we would like to acknowledge Jennifer Anderson, Christen Mason and John Lenz of Denver Options for their support in that effort.	[Anonymous], 2008, GULF WAR HLTH, V7; BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497; Beck A., 1979, COGNITIVE THERAPY EM; Bellack A., 2004, SOCIAL SKILLS TRAINI; BENYISHAY Y, 1985, SEMINARS NEUROLOGY, V5; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Brabender VA, 2004, ESSENTIALS GROUP THE; BURLINGAME GM, 2003, BERGIN GARFIELDS HDB; CICERONE KD, 2000, TRAUMATIC BRAIN INJU, P95; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dobson K.S., 2002, HDB COGNITIVE BEHAV; DZURILLA T, 2002, HDB COGNITIVE BEHAV, P211; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Hawley L., 2008, GROUP INTERACTIVE ST; LEZAK M, 1978, AM J PHYS MED, V58, P9; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Meichenbaum D., 1977, COGNITIVE BEHAV MODI; PRIGATANO G, 1999, PRINCIPLES NEUROPSYC, P252; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; Rose S. D., 1998, GROUP THERAPY TROUBL; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; WELSH J, 1998, ENCY CHILDHOOD ADOLE; Yalom I. D., 2005, THEORY PRACTICE GROU; Ylvisaker M., 1998, COLLABORATIVE BRAIN	26	19	19	0	20	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	11					1292	1297		10.3109/02699052.2010.506866			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800003	20735320				2021-06-18	
J	Klonoff, PS; Olson, KC; Talley, MC; Husk, KL; Myles, SM; Gehrels, JA; Dawson, LK				Klonoff, Pamela S.; Olson, Karen C.; Talley, Melanie C.; Husk, Kristi L.; Myles, Stephen M.; Gehrels, Jo-Ann; Dawson, Lauren K.			The relationship of cognitive retraining to neurological patients' driving status: The role of process variables and compensation training	BRAIN INJURY			English	Article						Driving; cognitive rehabilitation; community integration; outcome	TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; CEREBRAL INJURY; REHABILITATION; NEUROREHABILITATION; OUTCOMES; FITNESS; STROKE; PERFORMANCE; PREDICTION	Primary objective: To explore the relationship of cognitive retraining performance to discharge driving status. Methods and procedures: One hundred and three brain-injured patients from a holistic milieu-oriented work/school re-entry programme. Experimental interventions: Initial, last, mean, and best cognitive retraining scores; Behavioural Checklist ratings; Working Alliance (WA) scores. Main outcomes and results: At the time of discharge, 50.5% of the sample were cleared to drive. Better performance on a cognitive retraining task addressing information processing and motor speed, focused attention, visual scanning and memory was associated with clearance to drive. Patients' behavioural approach to cognitive retraining tasks (use of compensations, organizational and procedural skills) and higher mean and discharge WA scores with staff were associated with driving clearance. Higher mean WA scores were also related to an enhanced behavioural approach to cognitive retraining tasks, including timeliness to sessions, compensation use, better communication pragmatics, decreased distractibility and the ability to apply the 'big picture' benefits of cognitive retraining to the 'real world'. Conclusions: Cognitive retraining exercises that incorporate skill remediation, 'process' variables and metacognitive skills, as well as a better WA with patients, positively related to clearance to drive at the time of discharge from a holistic milieu-oriented programme.	[Klonoff, Pamela S.; Husk, Kristi L.; Myles, Stephen M.; Gehrels, Jo-Ann] Barrow Neurol Inst, Ctr Transit NeuroRehabil, Phoenix, AZ 85013 USA; [Olson, Karen C.] Gentiva Rehab Walls, Phoenix, AZ USA; [Talley, Melanie C.] Moore Counseling Ctr, Moore, OK USA; [Dawson, Lauren K.] Private Practice, Honolulu, HI USA	Klonoff, PS (corresponding author), Barrow Neurol Inst, Ctr Transit NeuroRehabil, 222 W Thomas Rd,Suite 401, Phoenix, AZ 85013 USA.	pamela.klonoff@chw.edu					Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Bordin E. S., 1994, WORKING ALLIANCE THE, P13, DOI DOI 10.1037/H0085885; Brenner LA, 2008, REHABIL PSYCHOL, V53, P18, DOI 10.1037/0090-5550.53.1.18; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Elkin-Frankston S, 2007, ARCH CLIN NEUROPSYCH, V22, P631, DOI 10.1016/j.acn.2007.04.004; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Galski T, 1997, AM J OCCUP THER, V51, P352, DOI 10.5014/ajot.51.5.352; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; HOPEWELL CA, 1990, NEUROPSYCHOLOGY EVER, P307; Klonoff PS, 2007, BRAIN INJURY, V21, P1097, DOI 10.1080/02699050701687342; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; KLONOFF PS, 1996, THEORETICAL FDN CLIN, P219; Klonoff PS, 2000, INT HDB NEUROPSYCHOL, P195; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; Lundqvist A, 2007, BRAIN INJURY, V21, P1109, DOI 10.1080/02699050701651660; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; McKenna P, 2004, BRIT J CLIN PSYCHOL, V43, P325, DOI 10.1348/0144665031752952; McKenna P, 2007, J NEUROPSYCHOL, V1, P85, DOI 10.1348/174866407X180837; PERNA RB, 2000, J COGNITIVE REHABILI, V7, P16; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Radford KA, 2004, BRAIN INJURY, V18, P775, DOI 10.1080/02699050310001657394; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; SCOTT CA, 2008, J CLIN EXPT NEUROPSY, V1, P1; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Soderstrom ST, 2006, SCAND J PSYCHOL, V47, P419, DOI 10.1111/j.1467-9450.2006.00550.x; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yale Steven H, 2003, Clin Med Res, V1, P177	45	19	19	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	2					63	73		10.3109/02699050903512863			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	597BF	WOS:000277729500001	20085443				2021-06-18	
J	Prieto, G; Delgado, AR; Perea, MV; Ladera, V				Prieto, Gerardo; Delgado, Ana R.; Perea, Maria V.; Ladera, Valentina			Scoring Neuropsychological Tests Using the Rasch Model: An Illustrative Example With the Rey-Osterrieth Complex Figure	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuropsychological testing; Rasch Rating Scale Model; ROCF		Parametric statistical methods are typically used for analyzing test scores, even though they are ordinal at best. The Meyers and Meyers' Rey-Osterrieth Complex Figure four-category scoring system has been evaluated with the Rasch Rating Scale Model, and disordered thresholds have been found. However, Rasch-modeling dichotomized data led to good fit for both normal (n = 219) and Traumatic Brain Injury (n = 54) samples and generalized validity for these groups, as well as for male and female groups. The logarithmic transformation of the item and person data performed by the model converts the ordinal data to yield interval scaled data. This is desirable not only from a scientific perspective, but also from the point of view of interpretability and communicability.	[Prieto, Gerardo; Delgado, Ana R.; Perea, Maria V.; Ladera, Valentina] Univ Salamanca, E-37008 Salamanca, Spain	Delgado, AR (corresponding author), Univ Salamanca, E-37008 Salamanca, Spain.	adelgado@usal.es	Ladera, Valentina/Q-6132-2017; Delgado, Ana R./A-3846-2012; Perea, M. Victoria/B-2904-2018; Prieto, Gerardo/F-3397-2012	Ladera, Valentina/0000-0003-4075-4483; Delgado, Ana R./0000-0003-0380-8999; Perea, M. Victoria/0000-0002-0258-8480; Prieto, Gerardo/0000-0001-8187-7784			ANDERSEN EB, 1970, J ROY STAT SOC B, V32, P283; ANDERSEN EB, 1973, PSYCHOMETRIKA, V38, P123, DOI 10.1007/BF02291180; ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814; Bond T. G., 2007, APPL RASCH MODEL, V2nd; Delgado AR, 2007, BEHAV RES METHODS, V39, P570, DOI 10.3758/BF03193027; Embretson SE, 2006, AM PSYCHOL, V61, P50, DOI 10.1037/0003-066X.61.1.50; Fernando K, 2003, NEW ZEAL J PSYCHOL, V32, P33; LEZAK K, 1995, NEUROPSYCHOLOGICAL A; LINACRE JM, 2000, WINSTEPS MULTIPLE CH; Linacre JM, 2006, USERS GUIDE WINSTEPS; Linacre John M, 2002, J Appl Meas, V3, P85; Long JD, 2003, HDB PSYCHOL, P635; LUCE RD, 1964, J MATH PSYCHOL, V1, P1, DOI 10.1016/0022-2496(64)90015-X; Meyers J, 1995, REY COMPLEX FIGURE R; Michell J., 1999, MEASUREMENT PSYCHOL; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PEREA V, 2000, PSICOTHEMA, V12, P353; Perez G, 1995, WSS NONLIN SCI SER B, V7, P105; PRIETO G, 2003, ENCY PSYCHOL ASSESSM, V2, P975; Rasch G., 1960, PROBABILISTIC MODELS; Rasch G., 1968, MATH THEORY OBJECTIV; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Shin MS, 2006, NAT PROTOC, V1, P892, DOI 10.1038/nprot.2006.115; STERN RA, 1994, CLIN NEUROPSYCHOL, V8, P309, DOI 10.1080/13854049408404137; WABER DP, 1985, J CLIN EXP NEUROPSYC, V7, P264, DOI 10.1080/01688638508401259	25	19	22	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	1					45	56	PII 913604714	10.1080/13854040903074645			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535MK	WOS:000272972300004	19658034				2021-06-18	
J	Schroeter, ML; Ettrich, B; Menz, M; Zysset, S				Schroeter, Matthias L.; Ettrich, Barbara; Menz, Mareike; Zysset, Stefan			Traumatic brain injury affects the frontomedian cortex-An event-related fMRI study on evaluative judgments	NEUROPSYCHOLOGIA			English	Article						Diffuse axonal injury; Evaluative judgment; fMRI; Social cognition; Theory of mind; Traumatic head injury	DIFFUSE AXONAL INJURY; MEDIAL PREFRONTAL CORTEX; HEAD-INJURY; NEUROPSYCHIATRIC INVENTORY; EMOTION RECOGNITION; EMPIRICAL ANALYSES; NULL-HYPOTHESIS; FOCAL LESIONS; ACTIVATION; DEFICITS	Traumatic brain injuries represent the leading cause of death and disability in young adults in industrialized countries. Recently, it has been suggested that dysfunctions of the frontomedian cortex, which enables social cognition, are responsible for clinical deficits in the long-term. To validate this hypothesis, we examined brain activation in seven young adults suffering from diffuse axonal injury during a cognitive task that specifically depends on frontomedian structures, namely evaluative judgments, contrasted with semantic memory retrieval. Brain activation in patients was compared with healthy age and gender matched control subjects using event-related functional magnetic resonance imaging. Evaluative judgments were related to a neural network discussed in the context of self-referential processing and theory of mind. More precisely, the neural network consisted of frontomedian regions, the temporal pole, and the posterior superior temporal gyrus and sulcus/angular gyrus. Patients showed higher activations in this network and the inferior frontal gyrus, whereas healthy control subjects activated more dopaminergic structures, namely the ventral tegmental area, during evaluative judgments. One possible interpretation of the data is that deficits in the ventral tegmental area, and consequently the mesocorticolimbic projection system, have to be compensated for by higher brain activations in the frontomedian and anterior cingulate cortex in patients with diffuse axonal injury. In conclusion, our study supports the hypothesis that traumatic brain injury is characterized by frontomedian dysfunctions, which may be responsible for clinical deficits in the long-term and which might be modified by rehabilitative strategies in the future. (C) 2009 Elsevier Ltd. All rights reserved.	[Schroeter, Matthias L.; Ettrich, Barbara; Menz, Mareike; Zysset, Stefan] Max Planck Inst Human Cognit & Brain Sci, D-04103 Leipzig, Germany; [Schroeter, Matthias L.] Univ Leipzig, Day Clin Cognit Neurol, D-04103 Leipzig, Germany; [Menz, Mareike] UKE Hamburg, D-20246 Hamburg, Germany; [Menz, Mareike] Univ Hosp Schleswig Holstein, Dept Neurol, D-23538 Lubeck, Germany	Schroeter, ML (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1A, D-04103 Leipzig, Germany.	schroet@cbs.mpg.de					Abu-Akel A, 2003, MED HYPOTHESES, V60, P382, DOI 10.1016/S0306-9877(02)00406-1; Aguirre GK, 1997, NEUROIMAGE, V5, P199, DOI 10.1006/nimg.1997.0264; Al-Adawi S, 2000, MED HYPOTHESES, V54, P523, DOI 10.1054/mehy.1999.0890; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Bachevalier J, 1997, EXP BRAIN RES, V115, P430, DOI 10.1007/PL00005713; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Barbas H, 1999, J COMP NEUROL, V410, P343, DOI 10.1002/(SICI)1096-9861(19990802)410:3<343::AID-CNE1>3.0.CO;2-1; BARNES CL, 1992, J COMP NEUROL, V318, P222, DOI 10.1002/cne.903180207; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006; Brass M, 2005, NEUROPSYCHOLOGIA, V43, P89, DOI 10.1016/j.neuropsychologia.2004.06.018; Brass M, 2005, TRENDS COGN SCI, V9, P314, DOI 10.1016/j.tics.2005.05.001; Christoff K, 2000, PSYCHOBIOLOGY, V28, P168; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; D'Ardenne K, 2008, SCIENCE, V319, P1264, DOI 10.1126/science.1150605; DANNEMILLER E, 1231, EUROPEAN J NUCL MED, V27, P1410; Delis DC, 1987, CALIFORNIA VERBAL LE; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gouick J, 2004, TRAUMA, V6, P285, DOI DOI 10.1191/1460408604TA3230A; HAERTING C, 2000, WMS R DTSCH ADAPTATI; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI DOI 10.1016/S1053-8119(18)31587-8; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Lammel S, 2008, NEURON, V57, P760, DOI 10.1016/j.neuron.2008.01.022; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lohmann G, 2001, COMPUT MED IMAG GRAP, V25, P449, DOI 10.1016/S0895-6111(01)00008-8; LUCAS JA, 1999, CLIN NEUROPSYCHOLOGY, P243; Marit RS, 2005, J HEAD TRAUMA REHAB, V20, P377, DOI 10.1097/00001199-200507000-00009; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Miezin FM, 2000, NEUROIMAGE, V11, P735, DOI 10.1006/nimg.2000.0568; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; MORAN MA, 1987, J COMP NEUROL, V256, P88, DOI 10.1002/cne.902560108; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nichols T, 2005, NEUROIMAGE, V25, P653, DOI 10.1016/j.neuroimage.2004.12.005; Norris DG, 2000, JMRI-J MAGN RESON IM, V11, P445, DOI 10.1002/(SICI)1522-2586(200004)11:4<445::AID-JMRI13>3.0.CO;2-T; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ochsner KN, 2004, J COGNITIVE NEUROSCI, V16, P1746, DOI 10.1162/0898929042947829; Okamoto T, 2007, EUR J NEUROL, V14, P540, DOI 10.1111/j.1468-1331.2007.01742.x; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schroeter ML, 2008, NEUROBIOL AGING, V29, P418, DOI 10.1016/j.neurobiolaging.2006.10.023; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Schroeter ML, 2007, NEUROIMAGE, V36, P497, DOI 10.1016/j.neuroimage.2007.03.024; Schroeter ML, 2007, NEUROIMAGE, V34, P26, DOI 10.1016/j.neuroimage.2006.09.001; Schroeter ML, 2004, NEUROIMAGE, V22, P341, DOI 10.1016/j.neuroimage.2003.12.041; Schroeter ML, 2004, NEUROIMAGE, V23, P1317, DOI 10.1016/j.neuroimage.2004.08.001; Schroeter ML, 2005, J CEREBR BLOOD F MET, V25, P1675, DOI 10.1038/sj.jcbfm.9600159; Schroeter ML, 2002, HUM BRAIN MAPP, V17, P61, DOI 10.1002/hbm.10052; Stamatakis EA, 2002, J NUCL MED, V43, P476; Svoboda E, 2006, NEUROPSYCHOLOGIA, V44, P2189, DOI 10.1016/j.neuropsychologia.2006.05.023; Talairach J., 1988, COPLANAR STEREOTAXIC; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; UGURBIL K, 1993, MAGN RESON QUART, V9, P259; Vogeley K, 1999, CONSCIOUS COGN, V8, P343, DOI 10.1006/ccog.1999.0394; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson JTL, 2005, ACTA NEUROCHIR SUPPL, V93, P75; WOLFRAM H, 1986, PSYCHOL LEISTUNGSTES; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Zarahn E, 1997, NEUROIMAGE, V5, P179, DOI 10.1006/nimg.1997.0263; Zimmermann P, 1993, TESTBATTERIE AUFMERK; Zysset S, 2003, NEUROSCI LETT, V335, P183, DOI 10.1016/S0304-3940(02)01196-5; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	87	19	20	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JAN	2010	48	1					185	193		10.1016/j.neuropsychologia.2009.09.004			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	550NU	WOS:000274135500021	19747929				2021-06-18	
J	Schwartz, ES; Edgar, JC; Gaetz, WC; Roberts, TPL				Schwartz, Erin Simon; Edgar, J. Christopher; Gaetz, William C.; Roberts, Timothy P. L.			Magnetoencephalography	PEDIATRIC RADIOLOGY			English	Article						Magnetoencephalography; Epilepsy; Functional imaging; Children	HUMAN SOMATOSENSORY CORTEX; EPILEPSY SURGERY; MEG; PERFORMANCE; STIMULATION; RECORDINGS; CEREBELLUM; ACTIVATION; SIGNALS; FIELDS	Although magnetoencephalography (MEG) may not be familiar to many pediatric radiologists, it is an increasingly available neuroimaging technique both for evaluating normal and abnormal intracranial neural activity and for functional mapping. By providing spatial, temporal, and time-frequency spectral information, MEG affords patients with epilepsy, intracranial neoplasia, and vascular malformations an opportunity for a sensitive and accurate non-invasive preoperative evaluation. This technique can optimize selection of surgical candidates as well as increase confidence in preoperative counseling and prognosis. Research applications that appear promising for near-future clinical translation include the evaluation of children with autism spectrum disorder, traumatic brain injury, and schizophrenia.	[Schwartz, Erin Simon] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA; [Schwartz, Erin Simon; Edgar, J. Christopher; Gaetz, William C.; Roberts, Timothy P. L.] Childrens Hosp Philadelphia, Lurie Family Fdn MEG Imaging Ctr, Dept Radiol, Philadelphia, PA 19104 USA	Schwartz, ES (corresponding author), Childrens Hosp Philadelphia, Dept Radiol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	simon@email.chop.edu		Roberts, Timothy/0000-0001-7320-4870	Pennsylvania Department of Health	This work has been funded, in part, by a grant from the Pennsylvania Department of Health. The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions. Dr. Roberts gratefully acknowledges the Oberkircher Family for the Oberkircher Family Chair in Pediatric Radiology at the Children's Hospital of Philadelphia.	Alberstone CD, 2000, J NEUROSURG, V92, P79, DOI 10.3171/jns.2000.92.1.0079; ALLISON T, 1991, BRAIN, V114, P2465, DOI 10.1093/brain/114.6.2465; Cheyne D, 2006, HUM BRAIN MAPP, V27, P213, DOI 10.1002/hbm.20178; Cheyne D, 2007, CLIN NEUROPHYSIOL, V118, P1691, DOI 10.1016/j.clinph.2007.05.064; Cornwell BR, 2008, J NEUROSCI, V28, P5983, DOI 10.1523/JNEUROSCI.5001-07.2008; DEECKE L, 1978, ELECTROENCEPHALOGR S, V34, P225; ENGEL J, 1988, ACTA NEUROL SCAND, V78, P84, DOI 10.1111/j.1600-0404.1988.tb08008.x; Gaetz W, 2008, CLIN NEUROPHYSIOL, V119, P1923, DOI 10.1016/j.clinph.2008.04.291; Gaetz W, 2009, NEUROSURGERY, V64, pS177, DOI 10.1227/01.NEU.0000316433.10913.32; Garolera M, 2007, NEUROREPORT, V18, P1449, DOI 10.1097/WNR.0b013e3282efa253; HARI R, 1985, PROG NEUROBIOL, V24, P233, DOI 10.1016/0301-0082(85)90007-3; Ioannides AA, 2005, PROG BRAIN RES, V148, P139, DOI 10.1016/S0079-6123(04)48012-1; Knowlton RC, 2006, ANN NEUROL, V59, P835, DOI 10.1002/ana.20857; Knowlton Robert C, 2008, Epilepsy Curr, V8, P1, DOI 10.1111/j.1535-7511.2007.00215.x; Knowlton Robert C, 2003, Curr Neurol Neurosci Rep, V3, P341, DOI 10.1007/s11910-003-0012-2; Knowlton RC, 2009, ANN NEUROL, V65, P716, DOI 10.1002/ana.21660; Lee D, 2006, EPILEPSY BEHAV, V8, P742, DOI 10.1016/j.yebeh.2006.02.012; LEMON RN, 1979, BRAIN RES, V161, P150, DOI 10.1016/0006-8993(79)90202-6; Lewine J D, 1995, Neuroimaging Clin N Am, V5, P575; Luo Q, 2009, CEREB CORTEX, V19, P1896, DOI 10.1093/cercor/bhn216; Mamelak AN, 2002, J NEUROSURG, V97, P865, DOI 10.3171/jns.2002.97.4.0865; Martin T, 2006, HUM BRAIN MAPP, V27, P552, DOI 10.1002/hbm.20200; Merrifield WS, 2007, EPILEPSY BEHAV, V10, P120, DOI 10.1016/j.yebeh.2006.10.012; Moses SN, 2009, NEUROIMAGE, V46, P863, DOI 10.1016/j.neuroimage.2009.02.042; Nakasato N, 2000, J CLIN NEUROPHYSIOL, V17, P201, DOI 10.1097/00004691-200003000-00009; Okada Y, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2168672; Okada Y, 1999, CLIN NEUROPHYSIOL, V110, P214, DOI 10.1016/S0013-4694(98)00111-4; Okada YC, 1999, CLIN NEUROPHYSIOL, V110, P230, DOI 10.1016/S0013-4694(98)00099-6; Okada YC, 1997, ELECTROEN CLIN NEURO, V103, P474, DOI 10.1016/S0013-4694(97)00043-6; OKADA YC, 1984, EXP BRAIN RES, V56, P197; Papanicolaou AC, 2004, J NEUROSURG, V100, P867, DOI 10.3171/jns.2004.100.5.0867; Papanicolaou AC, 1999, J NEUROSURG, V90, P85, DOI 10.3171/jns.1999.90.1.0085; Roberson KD, 2000, J APPL ANIM RES, V17, P57, DOI 10.1080/09712119.2000.9706291; Roberts T P, 1995, J Image Guid Surg, V1, P339, DOI 10.1002/(SICI)1522-712X(1995)1:6<339::AID-IGS5>3.0.CO;2-B; ROBINSON SE, 1999, BIOMAG 2000, P302; ROBINSON SE, 2004, NEUROL CLIN NEUROPHY, V74; ROMANI G L, 1988, Brain Topography, V1, P5, DOI 10.1007/BF01129335; Rowley H A, 1995, Neuroimaging Clin N Am, V5, P695; Scherg M, 1996, Electroencephalogr Clin Neurophysiol Suppl, V46, P127; Schiffbauer H, 2002, J NEUROSURG, V97, P1333, DOI 10.3171/jns.2002.97.6.1333; Schiffbauer Hagen, 2003, Neurosurg Focus, V15, pE7; Schwartz ES, 2008, AM J NEURORADIOL, V29, P832, DOI 10.3174/ajnr.A1029; SOBEL DF, 1993, AM J NEURORADIOL, V14, P915; Wada J, 2007, J NEUROSURG, V106, P1117, DOI 10.3171/jns.2007.106.6.1117; Williamson J. S, 1990, ADV AUDIOL, P1, DOI DOI 10.1016/J.IDAIRYJ.2009.07.008; WOOD CC, 1985, SCIENCE, V227, P1051, DOI 10.1126/science.3975600	46	19	19	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	JAN	2010	40	1					50	58		10.1007/s00247-009-1451-y			9	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	527RD	WOS:000272383300004	19937237				2021-06-18	
J	Svestkova, O; Angerova, Y; Sladkova, P; Bickenbach, JE; Raggi, A				Svestkova, Olga; Angerova, Yvona; Sladkova, Petra; Bickenbach, Jerome Edmond; Raggi, Alberto			Functioning and disability in traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; disability; ICF classification; ICF checklist; WHO-DAS II; FIM	LONG-TERM DISABILITY; UNITED-STATES; RATING-SCALE; FOLLOW-UP; ICF; EPIDEMIOLOGY; REHABILITATION; QUESTIONNAIRE; HEALTH	Purpose. To describe functioning and disability in patients with traumatic brain injury (TBI) according to the model endorsed by the International Classification of Functioning Disability and Health (ICF). Methods. Adult patients with acquired TBI were consecutively enrolled. The Functional Independence Measure (FIM), the WHO Disability Assessment Schedule II (WHO-DAS II) and the ICF checklist were administered in individual sessions. Descriptive analyses were performed to report on FIM and WHO-DAS II scores. ICF categories reported as a problem by more than 20% of patients were described in detail. Results. One hundred patients (66 males, mean age 36.1) were enrolled. Mean WHO-DAS II score was 16.8, mean FIM was 116.5 and 87 ICF categories were selected: 27 Body Functions (mainly mental and movement-related) and Structures, 43 Activities and Participation (mainly connected with mobility) and 17 Environmental Factors. Negligible difference between capacity and performance qualifiers was observed. Conclusions. The ICF can be successfully implemented in clinical and rehabilitation of patients with TBI, because it enables to describe the variety of problems they encounter: ICF-derived data provide a holistic view of disability and enable the impact of service interventions on functioning and participation, and enable clinicians to tailor intervention according to patient's actual needs.	[Svestkova, Olga; Angerova, Yvona; Sladkova, Petra] Charles Univ Prague, Dept Rehabil Med, Prague 12800, Czech Republic; [Bickenbach, Jerome Edmond] Swiss Parapleg Fdn, Notwill, Switzerland; [Raggi, Alberto] Neurol Inst C Besta IRCCS Fdn, Neurol Publ Hlth & Disabil Unit, Sci Directorate, Milan, Italy	Svestkova, O (corresponding author), Charles Univ Prague, Dept Rehabil Med, Albertov 7, Prague 12800, Czech Republic.		Raggi, Alberto/K-5787-2016; Svetkova, Olga/O-1062-2017; Angerova, Yvona/AAL-8925-2021	Raggi, Alberto/0000-0002-7433-7779; Svetkova, Olga/0000-0002-4271-4795; 	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [SP-24-CT-2004-513708]	MHADIE project was funded by the European Commission, Sixth Framework Programme. Contract Number: SP-24-CT-2004-513708, thematic priority 'Scientific Support to Policies'.	Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andlin-Sobocki P, 2005, EUR J NEUROL, V12, pVIII, DOI 10.1111/j.1468-1331.2005.01201.x; AYUSO JL, 2010, DISABIL REHABIL, V32, pS17; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Cieza Alarcos, 2006, BMC Med Res Methodol, V6, P36, DOI 10.1186/1471-2288-6-36; *CRAIG HOSP, TRAUM BRAIN INJ MOD; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Ewert T, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410015362; Francescutti C, 2009, DISABIL REHABIL, V31, pS46, DOI 10.3109/09638280903317757; Garin O, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-51; Hamilton B., 1987, REHABILITATION OUTCO; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Kuipers P, 2009, DISABIL REHABIL, V31, P144, DOI 10.1080/01674820701817938; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; O'Donovan MA, 2009, DISABIL REHABIL, V31, P2073, DOI 10.3109/09638280902918738; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Scarponi F, 2009, DISABIL REHABIL, V31, pS134, DOI 10.3109/09638280903317906; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; Steiner WA, 2002, PHYS THER, V82, P1098, DOI 10.1093/ptj/82.11.1098; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tempest S, 2006, DISABIL REHABIL, V28, P663, DOI 10.1080/09638280500276992; Ustun TB, 2010, MEASURING HLTH DISAB; von Holst H, 2009, NEUROEPIDEMIOLOGY, V33, P314; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 2001, INT CLASS FUNCT DIS; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	31	19	19	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2010	32			1			S68	S77		10.3109/09638288.2010.511690			10	Rehabilitation	Rehabilitation	671HR	WOS:000283492200009	20929314				2021-06-18	
J	Zgaljardic, DJ; Temple, RO				Zgaljardic, Dennis J.; Temple, Richard O.			Neuropsychological Assessment Battery (NAB): Performance in a Sample of Patients with Moderate-to-Severe Traumatic Brain Injury	APPLIED NEUROPSYCHOLOGY			English	Article						neuropsychological assessment; postacute; rehabilitation; traumatic brain injury	SCREENING MODULE; COGNITIVE IMPAIRMENT; REHABILITATION; VALIDITY; SCORES	The Neuropsychological Assessment Battery (NAB; Stern White, 2003) is a comprehensive test battery that assesses five cognitive domains (Attention, Language, Memory, Spatial, and Executive Functions). The purpose of the current descriptive study was to present data on the index and primary test scores from the five main NAB cognitive modules in a sample of patients with moderate-to-severe traumatic brain injury (TBI) admitted to a residential postacute rehabilitation program. Twenty patients were administered all five main NAB modules upon recommendation from the NAB Screening module. The sample performed significantly worse than normal on tests that assess selective and divided attention, psychomotor speed, verbal memory, and cognitive flexibility. The largest proportion of patients performing below an established impairment cutoff (10th percentile) occurred on the Numbers and Letters, List Learning, Story Learning, Daily Living Memory, and Categories Tests. Significant performance decrements were not observed on any indices or tests from the Language or Spatial cognitive domain modules. The pattern of performance on the NAB demonstrated by the current sample is consistent with the neuropsychological profile observed in postacute patients with moderate-to-severe TBI without focal deficits (e.g., aphasia), demonstrating its relative sensitivity in this patient population. A comparison between the current study sample and a related clinical sample from the NAB standardization data is discussed.	[Zgaljardic, Dennis J.] Transit Learning Ctr, Dept Neuropsychol, Galveston, TX 77550 USA; [Zgaljardic, Dennis J.] Univ Texas Med Branch, Galveston, TX USA; [Temple, Richard O.] CORE Hlth Care, Dripping Springs, TX USA	Zgaljardic, DJ (corresponding author), Transit Learning Ctr, Dept Neuropsychol, 1528 Postoff St, Galveston, TX 77550 USA.	dzgaljardic@tlc-galveston.org			Moody Endowment	This work was supported by the Moody Endowment. We gratefully acknowledge Jason Levinson, MA, for assistance with data collection, and Kimberly Wildes, DrPH, MA, and Renee Pearcy for editorial assistance.	BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brown LB, 2005, ARCH CLIN NEUROPSYCH, V20, P209, DOI 10.1016/j.acn.2004.06.003; Cahn-Weiner DA, 2009, EPILEPTIC DISORD, V11, P222, DOI 10.1684/epd.2009.0265; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Gavett BE, 2009, J INT NEUROPSYCH SOC, V15, P121, DOI 10.1017/S1355617708090176; Grohman K, 2004, EXP CLIN PSYCHOPHARM, V12, P200, DOI 10.1037/1064-1297.12.3.200; Iverson GL, 2007, APPL NEUROPSYCHOL, V14, P178, DOI 10.1080/09084280701508952; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lynch WJ, 2004, J HEAD TRAUMA REHAB, V19, P180, DOI 10.1097/00001199-200403000-00009; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Temple RO, 2009, BRAIN INJURY, V23, P45, DOI 10.1080/02699050802590361; Wechsler, 1981, WAIS R MANUAL; Zgaljardic DJ, 2010, APPL NEUROPSYCHOL, V17, P27, DOI 10.1080/09084280903297909	16	19	21	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	4					283	288	PII 930971379	10.1080/09084282.2010.525118			6	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	693AE	WOS:000285196200007	21154042				2021-06-18	
J	Cullen, NK; Crescini, C; Bayley, MT				Cullen, Nora K.; Crescini, Charmagne; Bayley, Mark T.			Rehabilitation Outcomes After Anoxic Brain Injury: A Case-Controlled Comparison With Traumatic Brain Injury	PM&R			English	Article								Objective: To investigate the functional outcomes of patients with anoxic brain injury (AnBI) compared with control patients with traumatic brain injury (TBI) during inpatient rehabilitation. Design: Matched case-controlled design. Setting: Inpatient neurorehabilitation program. Participants: Fifteen patients with AnBI and 15 patients with TBI. Methods: Data of 15 patients with a primary diagnosis of AnBI were retrospectively reviewed and matched to 15 patients with TBI admitted within the same time frame on age, acute care length of stay, and functional status at admission. Main Outcome Measure: Functional outcome was assessed by the use of the Functional Independence Measure (FIM). Results: Compared with the control patients with TBI, patients with AnBI achieved significantly tower FIM motor gain (16.3 +/- 15.6 versus 5.7 +/- 10.7, respectively) and efficiency scores (0.27 +/- 0.28 versus 0.06 +/- 0.13), discharge FIM cognition scores (25.9 +/- 5.9 versus 21.7 +/- 7.3), total FIM gain (22.5 +/- 19.6 versus 9.1 +/- 12.1), and total FIM efficiency scores (0.39 +/- 0.38 versus 0.10 +/- 0.16; all P < .05). Conclusions: Results suggest a slower rate of recovery for patients with AnBI compared with TBI, with physical recovery being slower than cognitive recovery as measured by the FM during inpatient rehabilitation when matched according to preinjury characteristics and functional status at rehabilitation admission. Future studies on larger samples of patients with AnBI and TBI that use a case-controlled design and longer-term outcome measurement are warranted to further clarify the differences in functional outcomes between these groups and to assess whether optimal rehabilitation interventions dale: for these groups.	[Cullen, Nora K.; Crescini, Charmagne; Bayley, Mark T.] Toronto Rehabil Inst, Neuro Rehabil Program, Toronto, ON M5G 2A2, Canada; [Cullen, Nora K.; Bayley, Mark T.] Univ Toronto, Div Physiatry, Toronto, ON M5G 2A2, Canada	Cullen, NK (corresponding author), Toronto Rehabil Inst, Neuro Rehabil Program, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	cullen.nora@torontorehab.on.co		Bayley, Mark/0000-0001-7860-9463; Cullen, Nora/0000-0001-6359-9418	Physicians' Services Foundation Inc.; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Province of Ontario	This research was supported by the Physicians' Services Foundation Inc. Equipment and space were funded with grants from the Canada Foundation for Innovation and the Province of Ontario. The views expressed here do not necessarily reflect those of the Ontario Ministry of Health and Long-Term Care.	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; AUER RN, 1997, GREENFIELDS NEUROPAT, P263; Bachman D., 1997, NEUROLOGIC REHABILIT, P145; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P383, DOI 10.1016/0887-6177(88)90052-2; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Cullen N, 2007, J HEAD TRAUMA REHAB, V22, P214, DOI 10.1097/01.HTR.0000281836.54602.6d; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Fertl E, 2000, RESUSCITATION, V47, P231, DOI 10.1016/S0300-9572(00)00239-2; Fiedler RC, 1996, AM J PHYS MED REHAB, V75, P125, DOI 10.1097/00002060-199603000-00010; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Green REA, 2006, BRAIN COGNITION, V60, P199; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; Gualtieri CT, 2002, BRAIN INJURY MENTAL; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; Hofgren C, 2008, BRAIN INJURY, V22, P972, DOI 10.1080/02699050802491289; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; National Data and Statistical Center, TRAUM BRAIN INJ MOD; PARKIN AJ, 1987, CORTEX, V23, P655, DOI 10.1016/S0010-9452(87)80055-2; Ravaud JF, 1999, SCAND J REHABIL MED, V31, P31; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; Schmidt JG, 1997, J NEUROL REHABIL, V11, P189; Shah MK, 2004, BRAIN INJURY, V18, P111, DOI 10.1080/0269905031000149551; Shah MK, 2007, J NEUROL SCI, V260, P95, DOI 10.1016/j.jns.2007.04.012; Stewart DG, 1998, NEUROREHABILITATION, V10, P13, DOI 10.3233/NRE-1998-10103; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; UDS Data Management Service, 1995, GUID UN DAT SYST MED; Wade D T, 1988, Int Disabil Stud, V10, P64; Walker WC, 1996, BRAIN INJURY, V10, P65	33	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482			PM&R	PM&R	DEC	2009	1	12					1069	1076		10.1016/j.pmrj.2009.09.013			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LP	WOS:000208412200004	19926548				2021-06-18	
J	Niven, DJ; Laupland, KB; Gregson, DB; Church, DL				Niven, Daniel J.; Laupland, Kevin B.; Gregson, Daniel B.; Church, Deirdre L.		S Aureus Screening Initiative Grp	Epidemiology of Staphylococcus aureus nasal colonization and influence on outcome in the critically ill	JOURNAL OF CRITICAL CARE			English	Article						Staphylococcus aureus; Nasal colonization; Critically ill	VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE UNIT; TRAUMATIC BRAIN-INJURY; MAJOR RISK-FACTOR; METHICILLIN-RESISTANT; NOSOCOMIAL INFECTIONS; CARRIAGE; BACTEREMIA; SURVEILLANCE; HOSPITALS	Purpose: To determine the rate of Staphylococcus aureus nasal colonization at admission to intensive care units (ICU) and assess its effect on the development of an ICU-acquired S aureus infection. Materials and Methods: We screened all ICU admissions for nasal colonization within the Calgary Health Region from October 2005 to September 2006 and followed up patients to hospital discharge or death or S aureus infection to 30 days. Results: One thousand three hundred eight patients were admitted to ICU for more than 48 hours and screened for nasal colonization. Fifty (4%) were methicillin-resistant S aureus (MRSA)-positive, 311 (24%) were methicillin-sensitive S aureus (MSSA)-positive, and 947 (72%) were nasal screen-negative. Overall, 5% (63/1239) of patients uninfected at ICU admission developed an ICU-acquired S aureus infection. The rate of ICU-acquired infection was 5% in MRSA colonized patients, 12% in MSSA colonized patients, and 3% in noncolonized patients. A positive nasal screen (odds ratio [OR], 4.7; 95% confidence interval [CI] 2.7-7.9), neuro/trauma patients (OR, 3.1; 95% CI, 1.8-5.2), and higher first Therapeutic Intervention Scoring System score (OR, 1.03 per point; 95% CI, 1.01-1.05) were independent predictors for developing an ICU-acquired S aureus infection. Conclusions: Nasal colonization with S aureus is a significant risk factor for ICU-acquired S aureus infections, and strategies to control these infections should target both MSSA and MRSA colonization. (C) 2009 Elsevier Inc. All rights reserved.	[Niven, Daniel J.; Laupland, Kevin B.; Gregson, Daniel B.; Church, Deirdre L.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Niven, Daniel J.; Laupland, Kevin B.; Gregson, Daniel B.; Church, Deirdre L.] Calgary Lab Serv, Calgary, AB, Canada; [Laupland, Kevin B.; Gregson, Daniel B.; Church, Deirdre L.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; [Laupland, Kevin B.] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Laupland, Kevin B.] Univ Calgary, Ctr Antimicrobial Resistance, Calgary, AB, Canada	Laupland, KB (corresponding author), Foothills Med Ctr Calgary, Calgary, AB T2N 2T9, Canada.	kevin.laupland@calgaryhealthregion.ca	Laupland, kevin/AAJ-6339-2020; Laupland, Kevin/AAG-3656-2020; Viani, Rafael/V-1196-2018	Laupland, kevin/0000-0002-1205-5354; 	Department of Critical Care Medicine; Calgary Health Region	We thank all members and intensive care unit staff of the Department of Critical Care Medicine, Calgary Health Region, for their support of this initiative.	BRAWLEY RL, 1989, AM J EPIDEMIOL, V130, P769, DOI 10.1093/oxfordjournals.aje.a115398; BROWN RB, 1985, CRIT CARE MED, V13, P472, DOI 10.1097/00003246-198506000-00006; CHANDRASEKAR PH, 1986, CRIT CARE MED, V14, P508, DOI 10.1097/00003246-198605000-00017; Corbella X, 1997, EUR J CLIN MICROBIOL, V16, P351, DOI 10.1007/BF01726362; Cosgrove SE, 2005, INFECT CONT HOSP EP, V26, P166, DOI 10.1086/502522; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; DONOWITZ LG, 1982, CRIT CARE MED, V10, P355, DOI 10.1097/00003246-198206000-00001; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Haddadin AS, 2002, POSTGRAD MED J, V78, P385, DOI 10.1136/pmj.78.921.385; Kalmeijer MD, 2000, INFECT CONT HOSP EP, V21, P319, DOI 10.1086/501763; KLUYTMANS JAJW, 1995, J INFECT DIS, V171, P216, DOI 10.1093/infdis/171.1.216; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Laupland KB, 2006, J HOSP INFECT, V63, P124, DOI 10.1016/j.jhin.2005.12.016; Porter R, 2003, INTENS CARE MED, V29, P655, DOI 10.1007/s00134-003-1679-1; Pujol M, 1996, AM J MED, V100, P509, DOI 10.1016/S0002-9343(96)00014-9; Robicsek A, 2008, ANN INTERN MED, V148, P409, DOI 10.7326/0003-4819-148-6-200803180-00003; Safdar N, 2008, AM J MED, V121, P310, DOI 10.1016/j.amjmed.2007.07.034; Shorr AF, 2006, CRIT CARE, V10, DOI 10.1186/cc4934; Simor AE, 2001, CAN MED ASSOC J, V165, P21; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; Weber DJ, 1999, CHEST, V115, p34S, DOI 10.1378/chest.115.suppl_1.34S; WEINSTEIN HJ, 1959, NEW ENGL J MED, V260, P1303, DOI 10.1056/NEJM195906252602601; Wood GC, 2002, PHARMACOTHERAPY, V22, P972, DOI 10.1592/phco.22.12.972.33596; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	26	19	21	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	DEC	2009	24	4					583	589		10.1016/j.jcrc.2008.10.004			7	Critical Care Medicine	General & Internal Medicine	527XJ	WOS:000272404200018	19327313				2021-06-18	
J	Ochalski, PG; Spiro, RM; Fabio, A; Kassam, AB; Okonkwo, DO				Ochalski, Pawel G.; Spiro, Richard M.; Fabio, Anthony; Kassam, Amin B.; Okonkwo, David O.			FRACTURES OF THE CLIVUS: A CONTEMPORARY SERIES IN THE COMPUTED TOMOGRAPHY ERA	NEUROSURGERY			English	Article						Clivus; Cranial base; Traumatic brain injury	BASILAR ARTERY; LONGITUDINAL FRACTURE; NASOSEPTAL FLAP; SKULL BASE; OCCLUSION; INCARCERATION; INJURY; TRAUMA; CT	OBJECTIVE: We report the morbidity and mortality associated with fractures of the clivus and discuss management approaches specific to this unique diagnostic entity. METHODS: We performed a boolean search of our electronic medical record database to identify patients with fractures of the clivus that were diagnosed using computed tomography of the head. A retrospective imaging and chart analysis was completed to further characterize the fractures and to analyze outcomes. RESULTS: Between January 1999 and December 2007, 41 patients were identified with fractures of the clivus. We found a 0.21% overall incidence among all head-injured patients presenting to our institution and a 2.3% incidence among those patients with a cranial fracture. Ten of 41 patients (24.4%) died, and neurological and vascular complications associated with central cranial base fractures were observed in 19 of 41 patients (46%). Furthermore, associated cranial fractures remote from the central cranial base and associated intracranial hemorrhages were observed in 40 of 41 (97.6%) and 33 of 41 (80.5%) patients, respectively. In terms of outcomes, 26 of 41 patients (63.5%) had a Glasgow Coma Scale score of 12 or greater at the time of discharge from the hospital. CONCLUSION: We demonstrate a lower than previously reported mortality rate in patients with clival fractures. Nevertheless, as a result of location, fractures of the clivus were frequently associated with a high rate of complications and neurological sequelae.	[Ochalski, Pawel G.; Spiro, Richard M.; Fabio, Anthony; Kassam, Amin B.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Dept Neurosurg, Med Ctr, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	Okonkwodo@upmc.edu		Fabio, Anthony/0000-0002-6808-4939	NCIPC CDC HHS [R49 CE323155] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER		ANTHONY DC, 1987, J NEUROSURG, V66, P929, DOI 10.3171/jns.1987.66.6.0929; Bala A, 2004, J CLIN NEUROSCI, V11, P660, DOI 10.1016/j.jocn.2003.11.008; Bonilha L, 2002, ARQ NEURO-PSIQUIAT, V60, P636, DOI 10.1590/S0004-282X2002000400023; Carter DA, 1998, J TRAUMA, V44, P230, DOI 10.1097/00005373-199801000-00039; Cho J, 2008, J KOREAN MED SCI, V23, P747, DOI 10.3346/jkms.2008.23.4.747; CORRADINO G, 1990, NEUROSURGERY, V27, P592, DOI 10.1227/00006123-199010000-00015; Feiz-Erfan I, 2007, J NEUROSURG, V107, P364, DOI 10.3171/JNS-07/08/0364; GUHA A, 1989, CAN J NEUROL SCI, V16, P81, DOI 10.1017/S0317167100028560; Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; JOSLYN JN, 1988, RADIOLOGY, V166, P817, DOI 10.1148/radiology.166.3.3340778; KAPILA A, 1985, J COMPUT ASSIST TOMO, V9, P1142, DOI 10.1097/00004728-198511000-00033; Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5; Katsuno M, 2007, NEUROL MED-CHIR, V47, P307, DOI 10.2176/nmc.47.307; Khan N, 2000, SURG NEUROL, V54, P171, DOI 10.1016/S0090-3019(00)00284-6; LINDENBERG R, 1966, J NEUROSURG, V24, P908, DOI 10.3171/jns.1966.24.5.0908; LOOP JW, 1964, RADIOLOGY, V83, P36, DOI 10.1148/83.1.36; MEGURO K, 1985, NEUROSURGERY, V16, P666, DOI 10.1227/00006123-198505000-00015; Menku A, 2004, NEUROSURG REV, V27, P194, DOI 10.1007/s10143-004-0320-2; Mizushima H, 1998, J NEUROSURG, V88, P590, DOI 10.3171/jns.1998.88.3.0590; RUSSELL WR, 1949, J NEUROL NEUROSUR PS, V12, P52, DOI 10.1136/jnnp.12.1.52; SANDERS BB, 1973, J NEUROSURG, V39, P610, DOI 10.3171/jns.1973.39.5.0610; Sato S, 2001, NEUROL MED-CHIR, V41, P541, DOI 10.2176/nmc.41.541; SHAW CM, 1972, J NEUROL NEUROSUR PS, V35, P247, DOI 10.1136/jnnp.35.2.247; SIGHTS WP, 1968, J NEUROSURG, V28, P588, DOI 10.3171/jns.1968.28.6.0588; Taguchi Y, 2000, J TRAUMA, V48, P1148, DOI 10.1097/00005373-200006000-00023	26	19	19	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2009	65	6					1063	1069		10.1227/01.NEU.0000360154.18604.28			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	522SQ	WOS:000272019400021	19934965				2021-06-18	
J	Rousseau, P; Post, A; Hoshizaki, TB				Rousseau, P.; Post, A.; Hoshizaki, T. B.			The effects of impact management materials in ice hockey helmets on head injury criteria	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART P-JOURNAL OF SPORTS ENGINEERING AND TECHNOLOGY			English	Article						hockey; helmet; mild traumatic brain injury; linear acceleration; angular acceleration; head injury criterion		The objective of this study was to compare the capacity of vinyl nitrile and expanded polypropylene, two materials commonly used in ice hockey helmets, to reduce the peak linear acceleration, peak angular acceleration, and head injury criterion values during a direct impact to a hybrid III headform. Six different ice hockey helmets were tested using a pneumatic linear impactor at velocities similar to those in hockey. The results showed that helmets using expanded polypropylene foam liners are significantly better at reducing linear acceleration; however, helmets using vinyl nitrile foam liners are significantly better at reducing angular acceleration. Furthermore, the impact location influenced the performance of the liner.	[Rousseau, P.; Post, A.; Hoshizaki, T. B.] Univ Ottawa, Dept Human Kinet, Neurotrauma Impact Sci Lab, Ottawa, ON K1N 6N5, Canada	Rousseau, P (corresponding author), Univ Ottawa, Dept Human Kinet, Neurotrauma Impact Sci Lab, 125 Univ St, Ottawa, ON K1N 6N5, Canada.	prous83@yahoo.ca		Post, Andrew/0000-0002-5960-5552	Xenith	The authors would like to thank Itech Mission, Nike Bauer, and Reebok CCM for kindly providing us with helmets. They would also like to thank Xenith for supporting in part the laboratory.	[Anonymous], 1997, CANCSAZ2621M90; [Anonymous], 2006, 83SC5N ISO TC; ASTM International, 2007, F104507 ASTM; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; Holbourn AHS, 1943, LANCET, V2, P438; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; LOWENHIELM P, 1975, J BIOMECH, V8, P351, DOI 10.1016/0021-9290(75)90069-X; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Ono K, 1980, P 24 STAPP CAR CRASH, P103; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Patrick L. M., 1965, P 7 STAPP CAR CRASH, P483; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	30	19	19	0	14	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1754-3371	1754-338X		P I MECH ENG P-J SPO	Proc. Inst. Mech. Eng. Part P-J. Sport. Eng. Technol.	DEC	2009	223	P4					159	165		10.1243/17543371JSET36			7	Engineering, Mechanical; Sport Sciences	Engineering; Sport Sciences	V23QG	WOS:000208356700004					2021-06-18	
J	Zhang, HT; Luo, J; Sui, LS; Ma, X; Yan, ZJ; Lin, JH; Wang, YS; Chen, YZ; Jiang, XD; Xu, RX				Zhang, Hong-Tian; Luo, Jie; Sui, Li-Sen; Ma, Xu; Yan, Zhong-Jie; Lin, Jian-Hao; Wang, Yu-Sheng; Chen, Yi-Zhao; Jiang, Xiao-Dan; Xu, Ru-Xiang			Effects of Differentiated Versus Undifferentiated Adipose Tissue-derived Stromal Cell Grafts on Functional Recovery After Spinal Cord Contusion	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Adipose tissue-derived stromal cells; Spinal cord injury; Neural differentiation; Neurogenesis; Functional recovery	TRAUMATIC BRAIN-INJURY; BONE-MARROW; STEM-CELLS; ADULT-RAT; TRANSPLANTATION; NEURONS; GROWTH; REPAIR; TRANSDIFFERENTIATION; ARTIFACT	Controversies exist concerning the need for mesenchymal stromal cells (MSCs) to be transdifferentiated prior to their transplantation. In the present study, we compared the results of grafting into the rat contused spinal cord undifferentiated, adipose tissue-derived stromal cells (uADSCs) versus ADSCs induced by two different protocols to form differentiated nervous tissue. Using Basso, Beattie, and Bresnahan scores and grid tests, we found that three cell-treated groups, including uADSCs-treated, dADSCs induced by Protocol 1 (dADSC-P1)-treated, and dADSCs induced by Protocol 2 (dADSC-P2)-treated groups, significantly improved locomotor functional recovery in SCI rats, compared with the saline-treated group. Furthermore, functional recovery was better in the uADSC-treated and dADSC-P2-treated groups than in the dADSC-P1-treated group at week 12 postinjury (P < 0.05 for dADSC-P1 group vs. uADSCs or dADSC-P2 groups). Although both protocols could induce high percentages of cells expressing neural markers in vitro, few BrdU-labeled cells survived at the injury sites in the three cell-treated groups, and only a small percentage of BrdU-positive cells expressed neural markers. On the other hand, the number of NF200-positive axons in the uADSC-treated and dADSC-P2-treated groups was significantly larger than those in the dADSC-P1-treated and saline-treated control groups. Our results indicate that ADSCs are able to differentiate into neural-like cells in vitro and in vivo. However, neural differentiated ADSCs did not result in better functional recovery than undifferentiated ones, following SCI. In vitro neural transdifferentiation of ADSCs might therefore not be a necessary pretransplantation step. Furthermore, cellular replacement or integration might not contribute to the functional recovery of the injured spinal cord.	[Zhang, Hong-Tian; Luo, Jie; Ma, Xu; Yan, Zhong-Jie; Lin, Jian-Hao; Wang, Yu-Sheng; Chen, Yi-Zhao; Jiang, Xiao-Dan; Xu, Ru-Xiang] So Med Univ, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China; [Zhang, Hong-Tian; Luo, Jie; Ma, Xu; Yan, Zhong-Jie; Lin, Jian-Hao; Wang, Yu-Sheng; Chen, Yi-Zhao; Jiang, Xiao-Dan; Xu, Ru-Xiang] So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China; [Xu, Ru-Xiang] Mil Gen Hosp Beijing PLA, Dept Neurosurg, Beijing 100700, Peoples R China; [Sui, Li-Sen] Guangdong Hosp Tradit Chinese Med, Dept Neurosurg, Guangzhou 510120, Guangdong, Peoples R China	Jiang, XD (corresponding author), So Med Univ, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China.	jiangxiao_dan@163.com; zhanghongtian007@126.com			Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [U0632008, 30772232, 30801184, 30500526]; Funds for Key Sci-Tech Research Projects of Guangdong Province [2006Z3-E522, 05/06-7005206, 05/067005213, 258-2008A030201019]; Funds for Key Sci-Tech Research Projects of Guangzhou [3-2008A1-E4011-6]	We thank Associate Professor Rang-ke Wu, Associate Director of the School of Foreign Studies, Southern Medical University, for his diligent revision and proofreading of this article. This research was supported by the Natural Science Foundation of China (NSFC; U0632008, 30772232, 30801184, 30500526), Funds for Key Sci-Tech Research Projects of Guangdong Province [2006Z3-E522, YUE KEJIBAN (2007) 05/06-7005206, 05/067005213, YUECAIJIAO (2008) 258-2008A030201019], and Funds for Key Sci-Tech Research Projects of Guangzhou [YUEKETIAOZI (2008) 3-2008A1-E4011-6].	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Croft AP, 2006, STEM CELLS, V24, P1841, DOI 10.1634/stemcells.2005-0609; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Kamada T, 2005, J NEUROPATH EXP NEUR, V64, P37, DOI 10.1093/jnen/64.1.37; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Vaquero J, 2009, HISTOL HISTOPATHOL, V24, P107, DOI 10.14670/HH-24.107; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yano S, 2005, J NEUROTRAUM, V22, P907, DOI 10.1089/neu.2005.22.907; Ye M, 2007, PARKINSONISM RELAT D, V13, P44, DOI 10.1016/j.parkreldis.2006.07.013; Yoshihara H, 2006, BRAIN RES, V1119, P65, DOI 10.1016/j.brainres.2006.08.080; Yoshimura H, 2007, CELL TISSUE RES, V327, P449, DOI 10.1007/s00441-006-0308-z; Zhu RS, 2007, J NEUROSCI RES, V85, P3064, DOI 10.1002/jnr.21426; Zurita M, 2008, NEUROSCI RES, V60, P275, DOI 10.1016/j.neures.2007.11.006	23	19	20	0	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	DEC	2009	29	8					1283	1292		10.1007/s10571-009-9424-0			10	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	532WM	WOS:000272781000023	19533335				2021-06-18	
J	Katada, R; Nishitani, Y; Honmou, O; Okazaki, S; Houkin, K; Matsumoto, H				Katada, Ryuichi; Nishitani, Yoko; Honmou, Osamu; Okazaki, Shunichiro; Houkin, Kiyohiro; Matsumoto, Hiroshi			Prior Ethanol Injection Promotes Brain Edema after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						alcohol consumption; brain contusion; brain edema; oxidative stress; rats	TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVITY; OXIDATIVE STRESS; HEAD-INJURY; INFLAMMATORY CYTOKINES; CEREBRAL-ISCHEMIA; N-ACETYLCYSTEINE; FACTOR-ALPHA; RATS; PATHOPHYSIOLOGY	Alcohol consumption prior to traumatic brain injury (TBI) promotes morbidity and mortality although the mechanisms involved remain unclear. The morbidity and mortality caused by TBI, especially brain contusion, are known to be closely associated with brain edema. Here we examined the effects of ethanol pretreatment on brain edema, inflammatory responses, and oxidative stress after brain contusion. Male Wistar rats were given 3g/kg ethanol intraperitoneally and 1 h later were subjected to brain contusion. The ethanol-pretreated group had a significantly decreased survival rate. Magnetic resonance imaging showed ethanol pretreatment significantly augmented the volume of cytotoxic brain edema after contusion. In the ethanol-pretreated rat, the activities of NF-kappa B and AP-1 were reduced 6 h after contusion and COX-2 mRNA expression was increased 24 h after contusion. These findings suggest that ethanol augmented cerebral edema and mortality in rats with brain contusion, possibly through actions on cell survival pathways or COX-2 expression. In addition, antioxidant treatment at 3 h post-injury significantly attenuated some markers of oxidative stress, mortality, and volume of edema at 24 h after ethanol treatment and contusion.	[Matsumoto, Hiroshi] Sapporo Med Univ, Sch Med, Dept Legal Med & Mol Alcohol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; [Katada, Ryuichi; Honmou, Osamu; Houkin, Kiyohiro] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 0608556, Japan	Matsumoto, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Legal Med & Mol Alcohol, Chuo Ku, S-1 W-17, Sapporo, Hokkaido 0608556, Japan.	hmatsumo@sapmed.ac.jp	Houkin, Kiyohiro/G-5364-2012	honmou, Osamu/0000-0001-8697-7530	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science	This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.	ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; Allansson L, 2001, J NEUROCHEM, V76, P472, DOI 10.1046/j.1471-4159.2001.00097.x; Aschner M, 2001, BRAIN RES, V900, P219, DOI 10.1016/S0006-8993(01)02314-9; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; El-Guindy NBD, 2007, ALCOHOL, V41, P335, DOI 10.1016/j.alcohol.2007.07.002; Emanuele N, 2005, ENDOCR RES, V31, P9, DOI 10.1080/07435800500228930; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fitzgerald DJ, 2007, ALCOHOL CLIN EXP RES, V31, P317, DOI 10.1111/j.1530-0277.2006.00307.x; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kelly G S, 1998, Altern Med Rev, V3, P114; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mascalchi M, 2005, RADIOL MED, V109, P155; Matsumoto H, 2000, ALCOHOL ALCOHOLISM, V35, P31, DOI 10.1093/alcalc/35.1.31; Matsumoto H, 2002, ALCOHOL CLIN EXP RES, V26, p6S, DOI 10.1097/01.ALC.0000026827.79925.C9; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Nishitani Y, 2006, FEBS LETT, V580, P9, DOI 10.1016/j.febslet.2005.11.030; Nordmann R, 1987, Alcohol Alcohol Suppl, V1, P75; Onda T, 2008, J CEREBR BLOOD F MET, V28, P329, DOI 10.1038/sj.jcbfm.9600527; RATAN RR, 1994, J NEUROSCI, V14, P4385; Ringel F, 2006, J NEUROTRAUM, V23, P1693, DOI 10.1089/neu.2006.23.1693; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; WORLEY PF, 1993, J NEUROSCI, V13, P4776; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055	44	19	24	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					2015	2025		10.1089/neu.2008.0552			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600016	19558208				2021-06-18	
J	Lundblad, C; Grande, PO; Bentzer, P				Lundblad, Cornelia; Grande, Per-Olof; Bentzer, Peter			Hemodynamic and Histological Effects of Traumatic Brain Injury in eNOS-Deficient Mice	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; brain trauma; edema; endothelial nitric oxide synthase; permeability	NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; L-ARGININE; HEAD-INJURY; MICROVASCULAR PERMEABILITY; MOUSE; RAT; ISCHEMIA; INHIBITION	Microvascular dysfunction in the brain, characterized by vasoconstriction, vascular occlusion, and disruption of the blood brain barrier, may adversely affect outcome following traumatic brain injury (TBI). Because of its vasodilating and antiaggregative properties, nitric oxide (NO) produced by nitric oxide synthase in the endothelium (eNOS) is a key regulator of vascular homeostasis. The objective of the present study was to evaluate the role of eNOS in vascular disturbances and histological outcome in the brain following TBI. Cortical blood flow ([C-14]-iodoantipyrine technique), number of perfused capillaries (FITC-dextran technique), brain water content (wet vs. dry weight), and the transfer constant (K-i) for [Cr-51]-EDTA, reflecting permeability, were analyzed 3 h and 24 h after a controlled cortical impact injury (CCI) in eNOS-deficient (eNOS-KO) and wild-type (WT) mice. Cortical contusion volume and cell count in the hippocampus were evaluated 3 weeks after injury. Blood flow in the injured cortex decreased in both groups following trauma. There were no significant differences between the groups at 3 h, but blood flow was lower in eNOS-KO mice than in WT mice 24 h after trauma. Brain water content was higher in the WT mice than in eNOS-KO mice at 24 h. Number of perfused capillaries, K-i, and histological outcome were similar in both groups. We conclude that eNOS is important for maintenance of cerebral blood flow after trauma and that eNOS promotes edema formation by mechanisms other than increased permeability. The vascular effects of eNOS do not, however, influence histological outcome.	[Bentzer, Peter] Univ Lund Hosp, Dept Anesthesiol & Intens Care, SE-22185 Lund, Sweden; Lund Univ, Dept Anesthesiol & Intens Care, S-22100 Lund, Sweden	Bentzer, P (corresponding author), Univ Lund Hosp, Dept Anesthesiol & Intens Care, SE-22185 Lund, Sweden.	peter.bentzer@med.lu.se		Lundblad, Cornelia/0000-0001-9686-2112	Swedish Research CouncilSwedish Research CouncilEuropean Commission [11581]; Medical Faculty of Lund University; Region Skane (ALF)	We would like to thank Assoc. Prof. Bo Holmqvist (Dept. of Experimental Oncology, Lund University) for his generous help with the PCR experiments. The skillful technical assistance by Helen Davidsson is gratefully acknowledged. This study was supported by grants from the Swedish Research Council (grant no. 11581), from the Medical Faculty of Lund University, and from Region Skane (ALF).	Al-Shabrawey M, 2003, MOL VIS, V9, P549; Atochin DN, 2003, J CEREBR BLOOD F MET, V23, P1219, DOI 10.1097/01.WCB.0000089601.87125.E4; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P8, DOI 10.1038/jcbfm.1983.2; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Cherian L, 2003, J PHARMACOL EXP THER, V304, P617, DOI 10.1124/JPET.102.043430; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Han F, 2006, J NEUROCHEM, V99, P97, DOI 10.1111/j.1471-4159.2006.04048.x; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hlatky R, 2003, J CEREBR BLOOD F MET, V23, P582, DOI 10.1097/01.WCB.0000059586.71206.F3; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; JAY TM, 1988, J CEREBR BLOOD F MET, V8, P121, DOI 10.1038/jcbfm.1988.16; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lundblad C, 2007, MICROVASC RES, V74, P1, DOI 10.1016/j.mvr.2007.03.001; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Maeda K, 2000, J CEREBR BLOOD F MET, V20, P10, DOI 10.1097/00004647-200001000-00003; Mayhan WG, 2000, BRAIN RES, V855, P143, DOI 10.1016/S0006-8993(99)02389-6; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MONCADA S, 1991, PHARMACOL REV, V43, P109; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stefanovic B, 2007, J CEREBR BLOOD F MET, V27, P741, DOI 10.1038/sj.jcbfm.9600377; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WANIEWSKI J, 1992, NEPHROL DIAL TRANSPL, V7, P50; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4	35	19	23	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1953	1962		10.1089/neu.2009.0955			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600011	19929218				2021-06-18	
J	Uswatte, G; Qadri, LH				Uswatte, Gitendra; Qadri, Laura Hobbs			A Behavioral Observation System for Quantifying Arm Activity in Daily Life After Stroke	REHABILITATION PSYCHOLOGY			English	Article						arm; observation; rehabilitation; treatment outcome; stroke	INDUCED MOVEMENT THERAPY; UPPER-EXTREMITY; REHABILITATION; ACCELEROMETRY; VALIDITY	Objective: Evaluate psychometric properties of the Functional Arm Activity Behavioral Observation System (FAABOS) for measuring hemiparetic arm use. Participants and Measures: All participants acquired their brain injury > 1 year prior to study entry; most had mild-to-moderate upper-extremity hemiparesis. In Study 1, 9 stroke survivors wore accelerometers and were videotaped for 15 min in the hospital or at home after they were asked to behave as usual. In Study 2, 1 traumatic brain injury and 8 stroke survivors wore accelerometers and were videotaped at home for 3 days with a motion-triggered camera. Observers independently rated 15-min segments of the Study I and 2 videotapes in 2-s blocks with a 4-step arm-activity coding scheme. Results: Interrater reliability was excellent; the mean Cohen's K in each study was >= .84. For data from both studies combined, validity was supported by a strong correlation between amount of hemiparetic arm functional activity, as determined by the observers, and the ratio of hemiparetic to other arm movement, as determined by accelerometry. Conclusion: FAABOS reliably and validly quantifies amount of spontaneous hemiparetic arm activity outside the laboratory.	[Uswatte, Gitendra; Qadri, Laura Hobbs] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; [Uswatte, Gitendra] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35294 USA	Uswatte, G (corresponding author), Univ Alabama Birmingham, Dept Psychol, 1530 3rd Ave S,CH415, Birmingham, AL 35294 USA.	guswatte@uab.edu	Uswatte, Gitendra/C-4913-2009		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD034273, R01 HD053750-01A2, HD053750, HD34273, R01 HD053750, R01 HD053750-02] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133G050222] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD053750] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD034273] Funding Source: NIH RePORTER		BAKEMAN R, 1986, OBSERVING INTERACTIO; Bowman MH, 2006, NEUROREHABILITATION, V21, P167; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Elliott TR, 2002, REHABIL PSYCHOL, V47, P131, DOI 10.1037//0090-5550.47.2.131; Merbitz C, 1996, Assist Technol, V8, P121; Schasfoort FC, 2003, PAIN, V101, P79, DOI 10.1016/S0304-3959(02)00298-1; Smith E.E., 1981, CATEGORIES CONCEPTS; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 2006, NEUROREHABILITATION, V21, P93; Uswatte G, 2006, NEUROLOGY, V67, P1189, DOI 10.1212/01.wnl.0000238164.90657.c2; Uswatte G, 2005, ARCH PHYS MED REHAB, V86, P1498, DOI 10.1016/j.apmr.2005.01.010; Uswatte G, 2005, REHABIL PSYCHOL, V50, P34, DOI 10.1037/0090-5550.50.1.34; Uswatte G, 2000, STROKE, V31, P662, DOI 10.1161/01.STR.31.3.662; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; USWATTE G, NEW FRONTIE IN PRESS; USWATTE G, 2009, ASSESSMENT REHABILIT, P121; Uswatte G, 2006, ARCH PHYS MED REHAB, V87, P1340, DOI 10.1016/j.apmr.2006.06.006; van der Lee JH, 2004, STROKE, V35, P1410, DOI 10.1161/01.STR.0000126900.24964.7e; World Health Organization, 2001, INT CLASS FUNCT DIS	22	19	19	0	28	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2009	54	4					398	403		10.1037/a0017501			6	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	526YF	WOS:000272331600006	19929121	Green Accepted			2021-06-18	
J	Datta, SGS; Pillai, SV; Rao, SL; Kovoor, JME; Chandramouli, BA				Datta, S. G. S.; Pillai, S. V.; Rao, S. L.; Kovoor, J. M. E.; Chandramouli, B. A.			Post-concussion syndrome: Correlation of neuropsychological deficits, structural lesions on magnetic resonance imaging and symptoms	NEUROLOGY INDIA			English	Article						Minimal traumatic brain injury; post-concussion syndrome; magnetic resonance imaging; neuropsychological deficits	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; MILD; MODERATE; SCALE; MRI; TOMOGRAPHY; RECOVERY	Background : Post-concussion syndrome (PCS) associated with mild traumatic brain injury (MTBI) can cause long-lasting disabilities. Magnetic resonance imaging (MRI) evaluation in these patients may demonstrate structural lesions that correlate with functional deficits on neuropsychological testing. However, little is known about the significance of the relationship between structureal lesions on MRI, functional deficits on neuropsychological evaluation and outcome in patients with MTBI. Aims: To assess neuropsychological deficits and structural lesions on MRI in patients with PCS following MTBI, and to find correlation between these findings and PCS. Settings and Design : Prospective, observational, cohort study in a tertiary hospital. Materials and Methods : The study cohort included consecutive patients with MTBI (three months or more duration) and PCS. All the patients in the cohort had neuropsychological testing using the National Institute of Mental Health and Neurological Sciences Neuropsychological Battery for head injury and also MRI using T1, T2 and FLAIR sequences. Statistical analysis was done using Fishers Exact test of significance. Results : All the 20 patients evaluated had neuropsychological deficits. Eleven patients had lesions on MRI. Disturbances of sleep, behavior and memory and abnormalties in tests for mental speed were more frequent in patients with lesions on MRI, but were not statically significant (P=0.08). Both the test modalities localized lesions predominantly to the frontal and temporal lobes. All the symptoms observed in the patients were associated with prefrontal dysfunction on neuropsychological testing. Conclusions : Prefrontal dysfunction is invariably associated with PCS following MTBI. Structural lesions on MRI may not always be present but when present may influence the degree or severity of the symptoms.	[Datta, S. G. S.; Pillai, S. V.; Chandramouli, B. A.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India; [Rao, S. L.] Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Bangalore 560029, Karnataka, India; [Kovoor, J. M. E.] Natl Inst Mental Hlth & Neurosci, Dept Neuroimaging & Intervent Radiol, Bangalore 560029, Karnataka, India	Pillai, SV (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India.	drshibupillai@hotmail.com					Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Flanagan S, 1999, MT SINAI J MED, V66, P152; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; JENNETT B, 1975, LANCET, V1, P480; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KURTZKE JF, 1993, CLIN NEUROLOGY; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rao S.L., 2004, NIMHANS NEUROPSYCHOL; Ruchinskas R A, 1997, Appl Neuropsychol, V4, P43, DOI 10.1207/s15324826an0401_5; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	20	19	19	0	9	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	SEP-OCT	2009	57	5					594	598		10.4103/0028-3886.57810			5	Neurosciences	Neurosciences & Neurology	531OU	WOS:000272678200011	19934558				2021-06-18	
J	Drabek, T; Tisherman, SA; Beuke, L; Stezoski, J; Janesko-Feldman, K; Lahoud-Rahme, M; Kochanek, PM				Drabek, Tomas; Tisherman, Samuel A.; Beuke, Lauren; Stezoski, Jason; Janesko-Feldman, Keri; Lahoud-Rahme, Manuella; Kochanek, Patrick M.			Deep Hypothermia Attenuates Microglial Proliferation Independent of Neuronal Death After Prolonged Cardiac Arrest in Rats	ANESTHESIA AND ANALGESIA			English	Article							FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; DELAYED RESUSCITATION; MINOCYCLINE TREATMENT; NEUROLOGICAL DYSFUNCTION; SUSPENDED ANIMATION; FUNCTIONAL DEFICITS; MILD HYPOTHERMIA; TISSUE-DAMAGE	INTRODUCTION: Conventional resuscitation of exsanguination cardiac arrest (CA) victims is generally unsuccessful. Emergency preservation and resuscitation is a novel approach that uses an aortic flush to induce deep hypothermia during CA, followed by delayed resuscitation with cardiopulmonary bypass. Minocycline has been shown to be neuroprotective across a number of brain injury models via attenuating microglial activation. We hypothesized that deep hypothermia and minocycline would attenuate neuronal death and microglial activation and improve outcome after exsanguination CA in rats. METHODS: Using isofluxane anesthesia, rats were subjected to a lethal hemorrhagic shock. After 5 min of no flow, hypothermia was induced with an aortic flush. Three groups were studied: ice-cold (IC) flush, room-temperature (RT) flush, and RT flush followed by minocycline treatment (RT-M). After 20 min of CA, resuscitation was achieved via cardiopulmonary bypass. Survival, Overall Performance Category (1 = normal, 5 = death), Neurologic Deficit Score (0-10% = normal, 100% = max deficit), neuronal death (Fluoro-jade C), and microglial proliferation (Iba1 immunostaining) in hippocampus were assessed at 72 h. RESULTS: Rats in the IC group had lower tympanic temperature during CA versus other groups (IC, 20.9 degrees C +/- 1.3 degrees C; RT, 28.4 degrees C +/- 0.6 degrees C; RT-M, 28.3 degrees C +/- 0.7 degrees C; P < 0.001). Although survival was similar in all groups (RT, 6/9; IC, 6/7; RT-M, 6/11), neurological outcome was better in the IC group versus other groups (Overall Performance Category: IC, 1 +/- 1; RT, 3 1; RT-M, 2 1; P < 0.05; Neurologic Deficit Score: IC, 8% +/- 9%; RT, 55% +/- 19%; RT-M, 27% +/- 16%; P < 0.05). Histological damage assessed in survivors showed selective neuronal death in CA1 and dentate gyrus, similar in all groups (P = 0.15). In contrast, microglial proliferation was attenuated in the IC group versus all other groups (P < 0.01). CONCLUSIONS: Deeper levels of hypothermia induced by the IC versus RT flush resulted in better neurological outcome in survivors. Surprisingly, deep hypothermia attenuated microglial activation but not hippocampal neuronal death. Mino-cycline had modest benefit on neurologic outcome in survivors but did not attenuate microglial activation in brain. Our findings suggest a novel effect of deep hypothermia on microglial proliferation during exsanguination CA. (Anesth Analg 2009;109:914-23)	[Drabek, Tomas; Tisherman, Samuel A.; Beuke, Lauren; Stezoski, Jason; Janesko-Feldman, Keri; Lahoud-Rahme, Manuella; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Drabek, Tomas] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; [Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; [Tisherman, Samuel A.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA; [Lahoud-Rahme, Manuella] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Drabek, T (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	drabekt@anes.upmc.edu	Tisherman, Samuel A./AAK-9377-2020; Kochanek, Patrick M/D-2371-2015; Drabek, Tomas/AAJ-1595-2021	Tisherman, Samuel A./0000-0003-3810-3729; Kochanek, Patrick M/0000-0002-2627-913X; Drabek, Tomas/0000-0002-5702-4498	Society of Cardiovascular Anesthesiologists; Laerdal Foundation for Acute Medicine; Department of Anesthesiology, University of PittsburghUniversity of Pittsburgh	Supported by a Starter Grant from the Society of Cardiovascular Anesthesiologists (to TD), the Laerdal Foundation for Acute Medicine (to TD), and a Seed Grant from the Department of Anesthesiology, University of Pittsburgh (to TD).	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; Bellamy R, 1996, CRIT CARE MED, V24, pS24; BREGMAN D, 1980, AM J CARDIOL, V46, P261, DOI 10.1016/0002-9149(80)90067-3; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Drabek T, 2007, RESUSCITATION, V75, P114, DOI 10.1016/j.resuscitation.2007.03.012; Drabek T, 2007, LIFE SCI, V81, P543, DOI 10.1016/j.lfs.2007.06.015; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Fan LW, 2005, NEUROSCIENCE, V133, P159, DOI 10.1016/j.neuroscience.2005.02.016; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fukui O, 2006, BRAIN RES, V1121, P35, DOI 10.1016/j.brainres.2006.08.121; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; Hayashi Y, 2006, NEUROSCIENCE, V142, P87, DOI 10.1016/j.neuroscience.2006.06.003; Hewlett KA, 2006, NEUROSCIENCE, V141, P27, DOI 10.1016/j.neuroscience.2006.03.071; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Maekawa S, 2002, CRIT CARE MED, V30, P2700, DOI 10.1097/00003246-200212000-00014; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; NEUMAR RW, 1995, RESUSCITATION, V29, P249, DOI 10.1016/0300-9572(94)00827-3; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Rhee PM, 2000, J AM COLL SURGEONS, V190, P288, DOI 10.1016/S1072-7515(99)00233-1; Safar P, 2000, CRIT CARE MED, V28, pN214, DOI 10.1097/00003246-200011001-00012; SAIVIN S, 1988, CLIN PHARMACOKINET, V15, P355, DOI 10.2165/00003088-198815060-00001; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shoemaker WC, 1996, CRIT CARE MED, V24, pS12; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; TRUNKEY D, 1991, NEW ENGL J MED, V324, P1259; Wang CX, 2002, BMC NEUROL, V2, DOI 10.1186/1471-2377-2-2; Wang CX, 2003, BRAIN RES, V963, P327, DOI 10.1016/S0006-8993(02)04045-3; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	42	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2009	109	3					914	923		10.1213/ane.0b013e3181b0511e			10	Anesthesiology	Anesthesiology	488EB	WOS:000269330800036	19690267				2021-06-18	
J	Duncan, CC; Mirsky, AF; Lovelace, CT; Theodore, WH				Duncan, Connie C.; Mirsky, Allan F.; Lovelace, Christopher T.; Theodore, William H.			Assessment of the attention impairment in absence epilepsy: Comparison of visual and auditory P300	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article; Proceedings Paper	14th World Congress of Psychophysiology the Olympics of the Brain	SEP 08-13, 2008	St Petersburg, RUSSIA	Int Org Psychophysiol		Event-related potentials; P300; Absence epilepsy; Complex partial epilepsy; Attention; CPT	EVENT-RELATED POTENTIALS; JUVENILE MYOCLONIC EPILEPSY; CENTRENCEPHALIC EPILEPSY; TEMPORAL-LOBE; PERFORMANCE; INFORMATION; DEFICITS	We report an investigation of P300 measures of information processing in patients with generalized epilepsy of the absence type and those with complex partial epilepsy. Studies have demonstrated that absence patients perform more poorly than complex partial patients on behavioral tests of sustained attention (the Continuous Performance Test, or CPT). Duncan (Duncan, C.C., 1988. Application of event-related brain potentials to the analysis of interictal attention in absence epilepsy. In: Myslobodsky, M.S., Mirsky A.F. (Eds.), Elements of Petit Mal Epilepsy. Peter Lang, New York, pp. 341-364] reported that P300 was significantly reduced in a group of absence patients as compared with healthy controls. The present investigation was undertaken to compare the attention deficit in absence patients to that in complex partial seizure patients. Thus, ERPs were recorded while participants with absence seizure disorder, complex partial seizure disorder, and healthy controls performed auditory and visual versions of the CPT. A significant reduction in the amplitude of P300 on the visual CPT was observed in both groups of seizure patients as compared to controls. In contrast, P300 on the auditory CPT was reduced only in the group with absence seizures. These ERP data support and amplify previous behavioral findings of the impaired capacity of absence patients to mobilize and sustain attentional resources. Auditory sustained attention seems to be more affected by the pathophysiology of absence epilepsy than visual attention. Two possible factors may be involved: (a) There are separate visual and auditory attention systems in the brain, and the latter is more vulnerable than the former [Duncan, C.C., Kosmidis, M.H., Mirsky, A.F., 2005. Closed head injury-related information processing deficits: An event-related potential analysis. Int. J. Psychophysiol. 58, 133-157]; and (b) Auditory processing depends on intact mechanisms in the brainstem, which are dysfunctional in patients with absence seizures. (C) 2009 Elsevier B.V. All rights reserved.	[Duncan, Connie C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Clin Psychophysiol & Psychopharmacol Lab, Bethesda, MD 20814 USA; [Mirsky, Allan F.] NIMH, NIH, Bethesda, MD 20892 USA; [Lovelace, Christopher T.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Theodore, William H.] NINDS, Clin Epilepsy Sect, NIH, Bethesda, MD 20892 USA	Duncan, CC (corresponding author), USU, Dept Psychiat, CPPL, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	cduncan@usuhs.mil		Lovelace, Christopher/0000-0003-1741-0017	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 NS002858-16] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002858, ZIANS002236] Funding Source: NIH RePORTER		BOCQUILLON P, 2008, HUM BRAIN MAPP  1125; Chayasirisobhon WV, 2007, CLIN EEG NEUROSCI, V38, P168, DOI 10.1177/155005940703800314; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Duncan CC, 1988, ELEMENTS PETIT MAL E, P341; DUNCAN CC, 2003, ANN M SOC PSYCH RES; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; FEDIO P, 1969, NEUROPSYCHOLOGIA, V7, P287, DOI 10.1016/0028-3932(69)90054-2; FUKAI M, 1990, ACTA NEUROL SCAND, V82, P197, DOI 10.1111/j.1600-0404.1990.tb04488.x; GLOOR P, 1988, ELEMENTS PETIT MAL E, P159; Kim SY, 2007, J CLIN NEUROL, V3, P86, DOI 10.3988/jcn.2007.3.2.86; LANSDELL H, 1964, EXP NEUROL, V9, P463, DOI 10.1016/0014-4886(64)90054-8; Levav M, 2002, J CLIN EXP NEUROPSYC, V24, P311, DOI 10.1076/jcen.24.3.311.985; Lindsley DB, 1960, HDB PHYSIOLOGY, P1553; MIRSKY AF, 1965, ELECTROEN CLIN NEURO, V18, P334, DOI 10.1016/0013-4694(65)90053-2; MIRSKY AF, 1986, J CLIN NEUROPHYSIOL, V3, P179; MIRSKY AF, 1960, EXP NEUROL, V2, P75, DOI 10.1016/0014-4886(60)90049-2; MIRSKY AF, 1988, ELEMENTS PETIT MAL E, P311; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; ORREN MM, 1974, THESIS BOSTON U BOST; ORREN MM, 1978, CONT CLIN NEUROPHY S, V34, P251; Penfield W, 1954, EPILEPSY FUNCTIONAL; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Schwab RS, 1939, J NERV MENT DIS, V89, P690; Sonmez F, 2004, EPILEPSY BEHAV, V5, P329, DOI 10.1016/j.yebeh.2004.01.007; Spitzer R.L., 1978, SCHEDULE AFFECTIVE D; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Zgorzalewicz M, 2000, Neurol Neurochir Pol, V34 Suppl 1, P109; Zgorzalewicz Malgorzata, 2006, Przegl Lek, V63 Suppl 1, P8	30	19	20	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	AUG	2009	73	2			SI		118	122		10.1016/j.ijpsycho.2009.03.005			5	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	478YW	WOS:000268625700010	19414047	Green Accepted			2021-06-18	
J	Uomoto, JM; Williams, RM				Uomoto, Jay M.; Williams, Rhonda M.			Post-Acute Polytrauma Rehabilitation and Integrated Care of Returning Veterans: Toward a Holistic Approach	REHABILITATION PSYCHOLOGY			English	Article						Operation Enduring Freedom; Operation Iraqi Freedom; war; rehabilitation; brain injuries; stress disorders	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; OPERATION IRAQI FREEDOM; MENTAL-HEALTH PROBLEMS; MEDICALLY UNEXPLAINED SYMPTOMS; PEER SUPPORT; GULF-WAR; COGNITIVE REHABILITATION; PSYCHOLOGICAL SYMPTOMS; MARITAL SATISFACTION	Throughout the history of war, exposure to combat has been associated with clusters of physical and psychological symptoms labeled in various ways, from "hysteria" to "shell shock" in World War I to "polytrauma" in Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF). Objective: To describe the historical conceptualizations of combat injury and the ways they are relevant to developing current rehabilitation strategies, discuss the symptom complex presented by OEF/OIF veterans, and describe key elements and principles of holistic, integrated care for post-acute OEF/OIF veterans. Conclusions: A conceptualization of rehabilitation recognizing a final common pathway of functional disability and suffering is proposed, and both systematic and treatment-specific aspects at the core of a veteran-centered holistic approach are discussed.	[Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, VISN VHA Polytrauma Network Site 20, Ctr Polytrauma Care, Rehabil Care Serv, Seattle, WA USA; [Williams, Rhonda M.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA	Uomoto, JM (corresponding author), VA Puget Sound Hlth Care Syst, VISN VHA Polytrauma Network Site 20, Ctr Polytrauma Care, Rehabil Care Serv, Seattle, WA USA.	jay.uomoto@va.gov	Uomoto, Jay/AAF-4809-2019				Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Anger WK, 1999, J INT NEUROPSYCH SOC, V5, P203, DOI 10.1017/S1355617799533031; Ashbury FD, 1998, PATIENT EDUC COUNS, V35, P89, DOI 10.1016/S0738-3991(98)00035-4; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Ben Arzi N, 2000, BRAIN INJURY, V14, P725; Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cassell EJ, 1999, ANN INTERN MED, V131, P531, DOI 10.7326/0003-4819-131-7-199910050-00009; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 2005, ARCH PHYS MED REHAB, V86, P1861; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Davison KP, 2000, AM PSYCHOL, V55, P205, DOI 10.1037/0003-066X.55.2.205; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; *DEP VET AFF, 2009, VET HLTH ADM DIR 200; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Department of Veterans Affairs Department of Defense (VA/DoD), 2004, VA DOD CLIN PRACT GU; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; Dunn J, 1999, J COMMUNITY APPL SOC, V9, P13, DOI 10.1002/(SICI)1099-1298(199901/02)9:1<13::AID-CASP488>3.0.CO;2-F; Dunn J, 2003, J PSYCHOSOC ONCOL, V21, P55, DOI 10.1300/J077v21n02_04; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; Ehde DM, 2006, TRAUMA REHABILITATION, P245; Ford JD, 2001, PSYCHOSOM MED, V63, P842, DOI 10.1097/00006842-200109000-00019; FORDYCE WE, 1988, AM PSYCHOL, V43, P276, DOI 10.1037/0003-066X.43.4.276; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Gosling J, 1999, BRAIN INJURY, V13, P785; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Howorth PW, 2000, PSYCHIAT B, V24, P225, DOI DOI 10.1192/PB.24.6.225; Jones E, 2003, J TRAUMA STRESS, V16, P411, DOI 10.1023/A:1024426321072; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kipen HM, 2002, ENVIRON HEALTH PERSP, V110, P591, DOI 10.1289/ehp.02110s4591; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Levy BS, 2009, ANNU REV PUBL HEALTH, V30, P123, DOI 10.1146/annurev.publhealth.031308.100147; LOESER JD, 1980, P 1 WORLD C CLIN PHA, P313; Loughran T, 2008, HIST PSYCHIATR, V19, P25, DOI 10.1177/0957154X07077749; Manguno-Mire G, 2007, J NERV MENT DIS, V195, P144, DOI 10.1097/01.nmd.0000254755.53549.69; Marshall AD, 2005, CLIN PSYCHOL REV, V25, P862, DOI 10.1016/j.cpr.2005.05.009; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Myers CS, 1915, LANCET, V1, P316; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Ozakinci G, 2006, ENVIRON HEALTH PERSP, V114, P1553, DOI 10.1289/ehp.9251; Pasquina PF, 2008, J REHABIL RES DEV, V45, P953, DOI 10.1682/JRRD.2007.10.0163; Pols H, 2006, ENDEAVOUR, V30, P144, DOI 10.1016/j.endeavour.2006.10.002; Prigatano G., 1985, NEUROPSYCHOLOGICAL R; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Renshaw KD, 2008, J FAM PSYCHOL, V22, P586, DOI 10.1037/0893-3200.22.3.586; Renshaw KD, 2009, ANXIETY STRESS COPIN, V22, P101, DOI 10.1080/10615800802354000; Rentz ED, 2006, TRAUMA VIOLENCE ABUS, V7, P93, DOI 10.1177/1524838005285916; ROMANO JM, 1985, PSYCHOL BULL, V97, P18, DOI 10.1037/0033-2909.97.1.18; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sharp D, 2006, LANCET, V368, P975, DOI 10.1016/S0140-6736(06)69395-1; Sherman MD, 2005, PSYCHIAT SERV, V56, P1150, DOI 10.1176/appi.ps.56.9.1150; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Smith RC, 2006, J GEN INTERN MED, V21, P671, DOI 10.1111/j.1525-1497.2006.00460.x; Soetekouw PMMB, 2000, EUR J CLIN INVEST, V30, P630; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Taft CT, 2008, J CONSULT CLIN PSYCH, V76, P648, DOI 10.1037/a0012576; Toomey R, 2007, BRIT J PSYCHIAT, V190, P385, DOI 10.1192/bjp.bp.105.019539; UOMOTO JM, TRAUMATIC B IN PRESS; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vasterling JJ, 2008, J REHABIL RES DEV, V45, P347, DOI 10.1682/JRRD.2007.05.0077; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Veith EM, 2006, REHABIL PSYCHOL, V51, P289, DOI 10.1037/0090-5550.51.4.289; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wells L M, 1993, Health Soc Work, V18, P221; Williams RM, 2002, J BURN CARE REHABIL, V23, P449, DOI 10.1097/00004630-200211000-00012; WILLIAMS RM, 2009, PEER VISITATION OIF; Wilson BA, 2002, NEUROREHAB NEURAL RE, V16, P207, DOI 10.1177/0888439002016002003; World Health Organization, 2001, INT CLASS FUNCT DIS	84	19	19	0	4	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					259	269		10.1037/a0016907			11	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	488SW	WOS:000269371100003	19702424				2021-06-18	
J	Wanger, AK; Sokoloski, JE; Chen, XB; Harun, R; Clossin, DP; Khan, AS; Andes-Koback, M; Michael, AC; Dixon, CE				Wanger, Amy K.; Sokoloski, Joshua E.; Chen, Xiangbei; Harun, Rashed; Clossin, Damian P.; Khan, Amina S.; Andes-Koback, Meghan; Michael, Adrian C.; Dixon, C. Edward			Controlled cortical impact injury influences methylphenidate-induced changes in striatal dopamine neurotransmission	JOURNAL OF NEUROCHEMISTRY			English	Article						controlled cortical impact; dopamine transporter; electrochemistry; methylphenidate; microdialysis; voltammetry	TRAUMATIC BRAIN-INJURY; C-FOS; EXTRACELLULAR DOPAMINE; NUCLEUS-ACCUMBENS; GENE-EXPRESSION; TISSUE-LEVELS; RAT STRIATUM; COCAINE; MICRODIALYSIS; RELEASE	Traumatic brain injury features deficits are often ameliorated by dopamine (DA) agonists. We have previously shown deficits in striatal DA neurotransmission using fast scan cyclic voltammetry after controlled cortical impact (CCI) injury that are reversed after daily treatment with the DA uptake inhibitor methylphenidate (MPH). The goal of this study was to determine how a single dose of MPH (5 mg/kg) induces changes in basal DA and metabolite levels and with electrically evoked overflow (EO) DA in the striatum of CCI rats. MPH-induced changes in EO DA after a 2-week daily pre-treatment regime with MPH was also assessed. There were no baseline differences in basal DA or metabolite levels. MPH injection significantly increased basal [DA] output in dialysates for control but not injured rats. Also, MPH injection increased striatal peak EO [DA] to a lesser degree in CCI (176% of baseline) versus control rats (233% of baseline). However, daily pre-treatment with MPH resulted in CCI rats having a comparable increase in EO [DA] after MPH injection when compared with controls. The findings further support the concept that daily MPH therapy restores striatal DA neurotransmission after CCI.	[Wanger, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wanger, Amy K.; Sokoloski, Joshua E.; Chen, Xiangbei; Harun, Rashed; Clossin, Damian P.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wanger, Amy K.; Harun, Rashed] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Khan, Amina S.; Andes-Koback, Meghan; Michael, Adrian C.] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA	Wanger, AK (corresponding author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu		Harun, Rashed/0000-0003-1843-6710	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08HD40833, R01NS40125, R21 NS057348]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125, R21NS057348] Funding Source: NIH RePORTER	This work was supported by NIH K08HD40833 (AKW), R01NS40125 (CED), and R21 NS057348 (AKW & ACM). Special thanks to Xiecheng Ma for her technical support on this study.	Abin-Carriquiry JA, 2008, EUR J PHARMACOL, V589, P80, DOI 10.1016/j.ejphar.2008.05.013; Arnsten AFT, 2006, NEUROPSYCHOPHARMACOL, V31, P2376, DOI 10.1038/sj.npp.1301164; Borland LM, 2005, J NEUROSCI METH, V146, P149, DOI 10.1016/j.jneumeth.2005.02.002; Borland LM, 2004, J NEUROCHEM, V91, P220, DOI 10.1111/j.1471-4159.2004.02708.x; Brandon CL, 2003, EUR J NEUROSCI, V18, P1584, DOI 10.1046/j.1460-9568.2003.02892.x; BUTCHER SP, 1991, NEUROSCI LETT, V122, P245, DOI 10.1016/0304-3940(91)90869-U; Chase TD, 2003, NEUROREPORT, V14, P769, DOI 10.1097/00001756-200304150-00022; DASH PK, 1995, J NEUROSCI, V15, P2030; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fleckenstein AE, 2009, NEUROPHARMACOLOGY, V56, P133, DOI 10.1016/j.neuropharm.2008.07.002; Gagnaire F, 2006, ARCH TOXICOL, V80, P703, DOI 10.1007/s00204-006-0083-3; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Greco PG, 2003, EUR J PHARMACOL, V479, P117, DOI 10.1016/j.ejphar.2003.08.062; Hawken CM, 2004, NEUROREPORT, V15, P1045, DOI 10.1097/00001756-200404290-00022; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; Hope BT, 2006, EUR J NEUROSCI, V24, P867, DOI 10.1111/j.1460-9568.2006.04969.x; Huff JK, 2002, J PHARMACEUT BIOMED, V29, P767, DOI 10.1016/S0731-7085(02)00196-6; Jedynak JP, 2002, J NEUROCHEM, V82, P382, DOI 10.1046/j.1471-4159.2002.00982.x; KAAKKOLA S, 1987, J NEURAL TRANSM, V69, P221, DOI 10.1007/BF01244343; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kuczenski R, 2005, BIOL PSYCHIAT, V57, P1391, DOI 10.1016/j.biopsych.2004.12.036; Kuczenski R, 1997, J NEUROCHEM, V68, P2032; Kulagina NV, 2001, NEUROSCIENCE, V102, P121, DOI 10.1016/S0306-4522(00)00480-2; Lin JS, 1996, P NATL ACAD SCI USA, V93, P14128, DOI 10.1073/pnas.93.24.14128; Lonjon M, 2004, NEUROSCI LETT, V354, P131, DOI 10.1016/j.neulet.2003.10.005; Lu Y, 1998, J NEUROCHEM, V70, P584; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Oechsner M, 2002, J NEURAL TRANSM, V109, P69, DOI 10.1007/s702-002-8237-z; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Sadri-Vakili G, 2008, J PHARMACOL EXP THER, V327, P840, DOI 10.1124/jpet.108.143958; Shaham Y, 2005, NAT NEUROSCI, V8, P1437, DOI 10.1038/nn1105-1437; Smith AD, 2005, EXP NEUROL, V193, P420, DOI 10.1016/j.expneurol.2005.01.010; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Volz TJ, 2008, J PHARMACOL EXP THER, V327, P161, DOI 10.1124/jpet.108.139386; Volz TJ, 2007, J PHARMACOL EXP THER, V323, P738, DOI 10.1124/jpet.107.126888; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yano M, 2005, NEUROPSYCHOPHARMACOL, V30, P901, DOI 10.1038/sj.npp.1300613; Youdim MBH, 2004, NEUROLOGY, V63, pS32, DOI 10.1212/WNL.63.7_suppl_2.S32; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZETTERSTROM T, 1988, EUR J PHARMACOL, V148, P327, DOI 10.1016/0014-2999(88)90110-0	50	19	20	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2009	110	3					801	810		10.1111/j.1471-4159.2009.06155.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	470IP	WOS:000267968700003	19457094	Green Accepted			2021-06-18	
J	Gioia, GA; Isquith, PK; Schneider, JC; Vaughan, CG				Gioia, Gerard A.; Isquith, Peter K.; Schneider, Jillian C.; Vaughan, Christopher G.			New Approaches to Assessment and Monitoring of Concussion in Children	TOPICS IN LANGUAGE DISORDERS			English	Article						assessment; children; concussion; management; mild TBI; pediatric	TRAUMATIC BRAIN-INJURY; SPORTS; MILD; MANAGEMENT; EPIDEMIOLOGY; FOOTBALL; RELIABILITY; SYMPTOMS; RECOVERY	A "mild" traumatic brain injury (TBI) constitutes the overwhelming majority of brain injury cases in children and adolescents. This article focuses on cerebral concussion, which can be viewed as a subset of mild TBI, which, until recently; has received limited attention in the pediatric assessment literature. Few extant measures appropriate to this condition in the developing child are available. A "broadband" approach to the assessment and management of concussion in children is presented, stressing the unique goals of the pediatric postinjury evaluation and treatment process in returning to home life, school, and sports/recreation. This approach calls for standardized assessment using diverse methods that tap multiple domains of the child's functioning, gathering input from key respondents across settings. Neuropsychological testing, together with structured symptom rating scales, provides a multilevel view of the effects of the concussion on the child. Structured data obtained with standardized methods from multiple sources provide more reliable and ecologically valid information to facilitate interventions in the child's key home and school environments. New pediatric assessment measures are presented, providing clinicians with tools to assess and manage this injury effectively. Two clinical cases highlight the use of the battery in guiding recovery. Continued research on the broadband concussion assessment model is needed.	[Gioia, Gerard A.; Schneider, Jillian C.; Vaughan, Christopher G.] Childrens Natl Med Ctr, Div Pediat Neuropsychol, Washington, DC 20010 USA; [Isquith, Peter K.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA	Gioia, GA (corresponding author), Childrens Natl Med Ctr, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	ggioia@cnmc.org	Isquith, Peter/AAY-4851-2020				Almquist J, 2001, ATHLET THER TODAY, V6, P13, DOI 10.1123/att.6.1.13; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bernhardt DT, 2000, PEDIATR ANN, V29, P172, DOI 10.3928/0090-4481-20000301-11; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; *CDCP NAT CTR INJ, 2003, C MILD TRAUM BRAIN I; *CDCP NAT CTR INJ, 2007, HEADS BRAIN INJ YOUR; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gioia G, 2006, J INT NEUROPSYCHO S1, V12, P39; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2008, J INT NEUROPSYCH SOC, V14, P204; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LOVE S, 2002, GREENFIELDS NEUROPAT, V2, P1; Lovell M.R., 2004, TRAUMATIC BRAIN INJU; Lovell M, 2008, NEUROL CLIN, V26, P45, DOI 10.1016/j.ncl.2007.12.001; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Parsons SK, 1999, INT J CANCER, P46; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TURKIBENALI Y, 2005, PHYSICA E, V26, P222; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2004, J RHEUMATOL, V31, P2494; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	66	19	19	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-8294	1550-3259		TOP LANG DISORD	Top. Lang. Disord.	JUL-SEP	2009	29	3					266	281		10.1097/TLD.0b013e3181b5322b			16	Linguistics; Rehabilitation	Linguistics; Rehabilitation	488HT	WOS:000269340700007					2021-06-18	
J	Kochanek, PM; Tasker, RC				Kochanek, Patrick M.; Tasker, Robert C.			Pediatric Neurointensive Care: 2008 Update for the Rogers' Textbook of Pediatric Intensive Care	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; cardiac arrest; asphyxia; hypoxic ischemic encephalopathy; stroke; status epilepticus; children; infant; hypothermia	TRAUMATIC-BRAIN-INJURY; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; STATUS EPILEPTICUS; INSULIN THERAPY; CLINICAL-TRIAL; HEAD-INJURY; CHILDREN; STROKE; HYPERGLYCEMIA	Objective: To review important articles, in the field of pediatric neurointensive care, that were published subsequent to the fourth edition of the Rogers' Textbook of Pediatric Intensive Care. Data Sources: The U.S. National Library of Medicine (http://www.ncbi.nlm.nih.gov/sites/entrezPubMed) was searched for the term pediatric and the following individual terms, cardiac arrest, asphyxia, traumatic brain injury, status epilepticus, stroke, cerebral ischemia, and cerebral hemorrhage, to generate abstracts of additional citations that were then screened for potential inclusion. The authors were also aware of a number of key recent articles in both pediatric and adult neurointensive care and these were also screened. Study Selection and Data Extraction: Promising articles were reviewed and the decision as to whether they were included was made at the discretion of the section editors. Data Synthesis: Articles in four categories were included based on selected chapters in the neurointensive care section of the textbook, using the specific chapter heading in the textbook, namely, head and spinal cord trauma, hypoxic-ischemic encephalopathy, status epilepticus, and cerebrovascular disease and stroke. Conclusion: Developments in the field and practice of pediatric neurocritical care continue with significant additions to the literature and practice recommendations concerning care following traumatic brain injury, cardiac arrest, status epilepticus, and cerebrovascular events. Importantly, the continued progression in knowledge raises the health services issue of whether, in certain settings of high clinical volume, it is time for specialized pediatric neurointensive care services or units. (Pediatr Crit Care Med 2009; 10:517-523)	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Tasker, Robert C.] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Sch Clin, Cambridge CB2 2QQ, England	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpccm@anes.upmc.edu	Tasker, Robert C/R-5837-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Tasker, Robert/0000-0003-3647-8113	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087, 3730318]; DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); United States ArmyUnited States Department of Defense [PR-054755 W81, WH06-1-0247]; The Evelyn Trust, Cambridge, U.K.; Sparks, U.K.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038087] Funding Source: NIH RePORTER	Supported, in part, by grants from NINDS (NS38087, 3730318), the CDC (University of Pittsburgh Center for Injury Research and Control/CIRCL), DARPA, and the United States Army PR-054755 W81 x WH06-1-0247 (to PMK) and from The Evelyn Trust, Cambridge, U.K., and Sparks, U.K. (to RCT).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Appleton R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001905.pub2; Beardsall K, 2008, NEW ENGL J MED, V359, P1873, DOI 10.1056/NEJMoa0803725; Bell MJ, 2009, NEUROCRIT CARE, V10, P4, DOI 10.1007/s12028-008-9061-3; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Burns CM, 2008, PEDIATRICS, V122, P65, DOI 10.1542/peds.2007-2822; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Curry R, 2008, PEDIATR CRIT CARE ME, V9, P141, DOI 10.1097/PCC.0B013e318166870e; DeVeber G, 2008, LANCET NEUROL, V7, P983, DOI 10.1016/S1474-4422(08)70231-X; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Forsyth RJ, 2008, PEDIATR CRIT CARE ME, V9, P8, DOI 10.1097/01.PCC.0000298759.78616.3A; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Hattori H, 2008, BRAIN DEV-JPN, V30, P504, DOI 10.1016/j.braindev.2007.12.016; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Hirshberg E, 2008, PEDIATR CRIT CARE ME, V9, P361, DOI 10.1097/PCC.0b013e318172d401; Holzer M, 2002, NEW ENGL J MED, V346, P549; Huang SC, 2008, CRIT CARE MED, V36, P1607, DOI 10.1097/CCM.0b013e318170b82b; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Klein GW, 2008, J PEDIATR-US, V153, P379, DOI 10.1016/j.jpeds.2008.04.012; Kollmar R, 2009, NEUROCRIT CARE, V10, P173, DOI 10.1007/s12028-008-9162-z; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Monagle P, 2008, CHEST, V133, p887S, DOI 10.1378/chest.08-0762; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; Polderman KH, 2002, NEW ENGL J MED, V347, P64; Preissig CM, 2008, PEDIATR CRIT CARE ME, V9, P581, DOI 10.1097/PCC.0b013e31818d36cb; Rafaat KT, 2008, PEDIATR CRIT CARE ME, V9, P567, DOI 10.1097/PCC.0b013e31818c8955; Roach ES, 2008, STROKE, V39, P2644, DOI 10.1161/STROKEAHA.108.189696; ROGERS MC, 2008, ROGERS TXB PEDIAT IN, P810; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; Schrader DV, 2009, EUR J PAEDIATR NEURO, V13, P10, DOI 10.1016/j.ejpn.2008.01.011; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shany E, 2007, J CHILD NEUROL, V22, P255, DOI 10.1177/0883073807299858; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Tobias JD, 2008, SOUTH MED J, V101, P268, DOI 10.1097/SMJ.0b013e318164e3f0; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Zamponi N, 2008, NEUROSURG REV, V31, P291, DOI 10.1007/s10143-008-0134-8	46	19	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2009	10	4					517	523		10.1097/PCC.0b013e3181ab88cd			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	468SI	WOS:000267840500014	19584637				2021-06-18	
J	Love, PF; Tepas, JJ; Wludyka, PS; Masnita-Iusan, C				Love, Pamela F.; Tepas, Joseph J., III; Wludyka, Peter S.; Masnita-Iusan, Carmen			Fall-Related Pediatric Brain Injuries: The Role of Race, Age, and Sex	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	13th Annual Conference of the Injury Free Coalition for Kids	DEC 12-14, 2008	Ft Lauderdale, FL			Fall related; Traumatic brain injury; Pediatric falls; Pediatric traumatic brain injury; Traumatic brain injury from falls	EPIDEMIOLOGY; PREVENTION	Background: Falls remain a major cause of childhood morbidity and mortality. To improve effectiveness of our prevention program, we used our electronic injury surveillance database to analyze patient variables and the incidence of fall-related brain injury. Methods: The database was queried for all injuries treated in the pediatric emergency department for which the word "fall" was listed as part of the chief complaint. Age, sex, and mechanism variables were cross tabulated for analysis with traumatic brain injury (TBI) codes. Results: Between June 2005 and June 2008, the electronic surveillance system reported 39,718 injury-related visits to the pediatric emergency department. Falls were reported in 3,436 patients (2,107 males, 1,329 females). TBI occurred from falls in 171 patients. Although black children had a higher fall rate (69.24%) than white children (23.75%) and non-black non-white children (7.01%), white children had the highest TBI rate from falls (9.47%). TBI from falls occurred at a lower mean age for females (5.40 +/- 4.45) than males (6.6 +/- 5.15) and for non-whites (5.98 +/- 4.88) than whites (6.21 +/- 4.93). Multiple logistic regression demonstrated a significant influence of age, race, and sex on the likelihood that a fall results in TBI. Females have a higher risk of TBI from falls than males from ages 0 to 11.5. This runs contrary to previous studies suggesting that toddler males are at highest risk for TBI. Conclusion: A disproportionate number of infants, toddlers, and adolescents sustain brain injury from falls. Race and sex group differences mandate enhanced focus on environmental safety and risk-taking behaviors.	[Love, Pamela F.] Univ Florida, Coll Med, Dept Pediat Emergency Med, Jacksonville, FL 32209 USA; [Tepas, Joseph J., III] Univ Florida, Coll Med, Dept Surg Pediat Surg & Pediat, Jacksonville, FL 32209 USA; [Wludyka, Peter S.] Dept Math & Stat, Jacksonville, FL USA; [Masnita-Iusan, Carmen] Univ N Florida, Jacksonville, FL USA	Love, PF (corresponding author), Univ Florida, Coll Med, Dept Pediat Emergency Med, Jacksonville, FL 32209 USA.	jjt@jax.ufl.edu					BERNEY J, CHILDS NERV SYST, V10, P517; Bull MJ, 2001, PEDIATRICS, V107, P1188; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Goldstein B, 1994, Pediatr Rev, V15, P213, DOI 10.1542/pir.15-6-213; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Mathers LJ, 1998, ACAD EMERG MED, V5, P1064, DOI 10.1111/j.1553-2712.1998.tb02663.x; MOSENTHAL AC, 1995, J TRAUMA, V38, P753, DOI 10.1097/00005373-199505000-00013; Park SH, 2004, YONSEI MED J, V45, P229, DOI 10.3349/ymj.2004.45.2.229; Pitone ML, 2006, PEDIATR EMERG CARE, V22, P470, DOI 10.1097/01.pec.0000226869.41803.50; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037	12	19	21	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2009	67	1		S			S12	S15		10.1097/TA.0b013e3181ac7f22			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	470DA	WOS:000267953200004	19590346				2021-06-18	
J	Salvarani, CP; Colli, BO; Carlotti, CG				Salvarani, Carmine Porcelli; Colli, Benedicto Oscar; Carlotti Junior, Carlos Gilberto			Impact of a program for the prevention of traffic accidents in a Southern Brazilian city: a model for implementation in a developing country	SURGICAL NEUROLOGY			English	Article						Accidents; Traffic; Prevention; Trauma; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MOTORCYCLE HELMET USE; HEAD-INJURY; MORTALITY; EPIDEMIOLOGY; CALIFORNIA; RIDERS; LAW	Background: Traffic accidents constitute the main cause of death in the first decades of life. Traumatic brain injury is the event most responsible for the severity of these accidents. The SBN started an educational program for the prevention of traffic accidents, adapted from the American model "Think First" to the Brazilian environment, since 1995, with special effort devoted to the prevention of TBI by using seat belts and motorcycle helmets. The objective of the present study was to set up a traffic accident prevention program based on the adapted Think First and to evaluate its impact by comparing epidemiological variables before and after the beginning of the program. Methods: The program was executed in Maringa city, from September 2004 to August 2005, with educational actions targeting the entire population, especially teenagers and young adults. The program was implemented by building a network of information facilitators and multipliers inside the organized civil society, with widespread population dissemination. To measure the impact of the program, a specific software was developed for the storage and processing of the epidemiological variables. Results: The results showed a reduction of trauma severity due to traffic accidents after the execution of the program, mainly TBI. Conclusions: The adapted Think First was systematically implemented and its impact measured for the first time in Brazil, revealing the usefulness of the program for reducing trauma and TBI severity in traffic accidents through public education and representing a standardized model of implementation in a developing country. (C) 2009 Elsevier Inc. All rights reserved.	[Salvarani, Carmine Porcelli] State Univ Maringa Parana, Maringa Med Sch, Div Neurosurg, Maringa, Parana, Brazil; [Colli, Benedicto Oscar; Carlotti Junior, Carlos Gilberto] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Div Neurosurg, BR-05508 Sao Paulo, Brazil	Salvarani, CP (corresponding author), State Univ Maringa Parana, Maringa Med Sch, Div Neurosurg, Maringa, Parana, Brazil.	cinnmaringa@wnet.com.br	Carlotti, Carlos G/C-1608-2012; Colli, Benedicto/A-2833-2016	Carlotti, Carlos G/0000-0002-7055-0564; Colli, Benedicto/0000-0002-0222-6770			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; *AM COLL SURG, 2004, INF ATLS PROGR COURS; Amatuzzi M M, 1998, Rev Hosp Clin Fac Med Sao Paulo, V53, P299; Auman KM, 2002, AM J PUBLIC HEALTH, V92, P1352, DOI 10.2105/AJPH.92.8.1352; Bastos Yara Gerber Lima, 2005, Cad. Saúde Pública, V21, P815, DOI 10.1590/S0102-311X2005000300015; Brandt MM, 2002, J TRAUMA, V53, P469, DOI 10.1097/00005373-200209000-00012; *BRAZ ASS TRAFF ME, 2004, MORT BRAS IMP AC TRA; *BRAZ I GEOGR STAT, 2005, EST POP RES MUN 2005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; Coben JH, 2007, ACCIDENT ANAL PREV, V39, P190, DOI 10.1016/j.aap.2006.06.018; Colli BO, 1997, ARQ NEURO-PSIQUIAT, V55, P91, DOI 10.1590/S0004-282X1997000100015; Oliveira Nelson Luiz Batista de, 2003, Rev. Latino-Am. Enfermagem, V11, P749, DOI 10.1590/S0104-11692003000600008; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Gericke CA, 2004, J PUBLIC HEALTH-UK, V26, P230, DOI 10.1093/pubmed/fdh149; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hijar M, 2000, INT J EPIDEMIOL, V29, P715, DOI 10.1093/ije/29.4.715; HONSSON B, 2007, TRAFFIC INJ PREV, V8, P87; Hundley JC, 2004, J TRAUMA, V57, P944, DOI 10.1097/01.TA.0000149497.20065.F4; *I APPL EC RES IPE, 2002, CAR TEND RED URB BRA; *I APPL EC RES IPE, 2003, IMP SOC EC AC TRANS; Jorge Maria Helena Prado de Mello, 2004, Rev. bras. epidemiol., V7, P228; Jorge Maria Helena Prado de Mello, 2002, Rev. bras. epidemiol., V5, P212, DOI 10.1590/S1415-790X2002000200008; KRAUS JF, 1995, J NEUROTRAUM, V12, P873, DOI 10.1089/neu.1995.12.873; Leitao FBP, 1997, REV SAUDE PUBL, V31, P47, DOI 10.1590/S0034-89101997000500005; Liberatti C L, 2001, Inj Prev, V7, P190, DOI 10.1136/ip.7.3.190; LIMA RAC, 2001, TRAUMA DOENCA SECULO, P2849; Lindqvist K, 2001, ACCIDENT ANAL PREV, V33, P599, DOI 10.1016/S0001-4575(00)00071-3; Minayo MCS, 1994, A violencia social sob a perspectiva da saude publica, V10, P7, DOI [10. 1590/ S0102- 311X1994000500002, DOI 10.1590/S0102-311X1994000500002]; Minayo MCS, 1997, HIST CIENC SAUDE-MAN, V6, P513; Montazeri A, 2004, PUBLIC HEALTH, V118, P110, DOI 10.1016/S0033-3506(03)00173-2; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Nakamura N, 2002, NEUROL RES, V24, P45, DOI 10.1179/016164102101199530; *NAT DEP TRAFF ROA, IMP USO EST AC TRANS; Pikoulis E, 2006, Int J Inj Contr Saf Promot, V13, P190, DOI 10.1080/17457300500294547; Posada J, 2000, Rev Panam Salud Publica, V7, P88, DOI 10.1590/S1020-49892000000200003; Regidor Poyatos E, 1992, Gac Sanit, V6, P245; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Scalassara MB, 1998, REV SAUDE PUBL, V32, P125, DOI 10.1590/S0034-89101998000200004; SELECKI BR, 1982, AUST NZ J SURG, V52, P93, DOI 10.1111/j.1445-2197.1982.tb05297.x; Senserrick TM, 2006, INJURY PREV, V12, P56, DOI 10.1136/ip.2006.012773; Servadei F, 2003, INJURY PREV, V9, P257, DOI 10.1136/ip.9.3.257; Silveira Renata, 2002, Rev. Latino-Am. Enfermagem, V10, P765, DOI 10.1590/S0104-11692002000600003; SILVERBERG D, 1992, EUR J EPIDEMIOL, V8, P826, DOI 10.1007/BF00145327; Soares Dorotéia Fátima Pelissari de Paula, 2006, Rev. bras. epidemiol., V9, P193, DOI 10.1590/S1415-790X2006000200006; Solagberu BA, 2006, INJURY PREV, V12, P266, DOI 10.1136/ip.2005.011221; TEASDALE G, 1974, LANCET, V2, P81; *THINK 1 FDN, THINK 1 VAL; *THINK 1 FDN, MISS HIST; *THINK WELL MAR, 2004, EST TRANS URB MAR; *THINK WELL MAR, 2003, EST TRANS URB MAR; *THINK WELL MAR, 2005, EST TRANS URB MAR; *THINK WELL PROGR, 2003, BAS PROGR PENS BEM; *TRAFF ROAD DEP PA, 2003, FROT VEIC MAR; *TRAFF ROAD DEP PA, 2005, FROT VEIC MAR; *TRAFF ROAD DEP PA, 2004, FROT VEIC MAR; WHO. Geneva: World Health Organisation, 2004, WORLD REP ROAD TRAFF; WYATT G B, 1980, Papua New Guinea Medical Journal, V23, P60; Yan-Hong Li, 2006, Int J Inj Contr Saf Promot, V13, P217, DOI 10.1080/17457300600580779	60	19	19	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUL	2009	72	1					6	14		10.1016/j.surneu.2007.10.008			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	467XG	WOS:000267775800002	18328548				2021-06-18	
J	de Leon, MB; Kirsch, NL; Maio, RF; Tan-Schriner, CU; Millis, SR; Frederiksen, S; Tanner, CL; Breer, L				de Leon, Marita B.; Kirsch, Ned L.; Maio, Ronald F.; Tan-Schriner, Cheribeth U.; Millis, Scott R.; Frederiksen, Shirley; Tanner, Clare L.; Breer, Lynn			Baseline Predictors of Fatigue 1 Year After Mild Head Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	James W Rae Scientific Day Conference 2008	MAY09, 2008	Univ Michigan, Dept Phys Med & Rehabilitat, Ann Arbor, MI		Univ Michigan, Dept Phys Med & Rehabilitat	Fatigue; Rehabilitation	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; CONCUSSION SYMPTOMS; RECOVERY; ADULTS; PARTICIPATION; DISABILITY; SF-36; INDIVIDUALS; POPULATION	Objective: To compare reports of fatigue 12 months after minor trauma by participants with mild head injury (MHI) with those with other injury, and identify injury and baseline predictors of fatigue. Design: An inception cohort study of participants with MHI and other nonhead injuries recruited from and interviewed at the emergency department (ED), with a follow-up telephone interview at 12 months. Setting: Level II Community hospital ED. Participants: Participants (n=58) with MHI and loss of consciousness (LOC) of 30 minutes or less and/or posttraumatic amnesia (PTA) less than 24 hours, 173 with MHI but no PTA/LOC, and 128 with other mild nonhead injuries. Inclusion criteria: age 18 years or older. within 24 hours of injury, Glasgow Coma Scale score of 13 or higher, and discharge from the ED. Interventions: Not applicable. Main Outcome Measure: Medical Outcomes Study 36-Item Short-Form Health Survey Vitality subscale. Results: Significant predictors of fatigue severity at 12 months were baseline fatigue, having seen a Counselor for a mental health issue, medical disability, marital status, and in some stage of litigation. Injury type was not a significant predictor. Conclusions: Fatigue severity 12 months after injury is associated with baseline characteristics and not MHI. Clinicians should be cautious about attributing persisting fatigue to MHI without comprehensive consideration of other possible etiologic factors.	[de Leon, Marita B.; Kirsch, Ned L.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Maio, Ronald F.; Frederiksen, Shirley] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Maio, Ronald F.] Univ Michigan, Injury Res Ctr, Ann Arbor, MI 48109 USA; [Millis, Scott R.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; [Tan-Schriner, Cheribeth U.; Tanner, Clare L.; Breer, Lynn] Michigan Publ Hlth Inst, Okemos, MI USA	Kirsch, NL (corresponding author), Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, 355 Briarwood Circle, Ann Arbor, MI 48109 USA.	nlkirsch@umich.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007422] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5-T32-HD007422-17] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR523223-01] Funding Source: Medline		Andersson AL, 1997, INJURY, V28, P539, DOI 10.1016/S0020-1383(97)00083-1; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; O'Connor PJ, 2004, J PSYCHOSOM RES, V57, P435, DOI 10.1016/j.jpsychores.2003.12.006; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Sluis CK, 1998, INJURY, V29, P277, DOI 10.1016/S0020-1383(97)00198-8; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Ware JE., 2000, SCORE VERSION 2 SF 3; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	52	19	19	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2009	90	6					956	965		10.1016/j.apmr.2008.12.016			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	455SW	WOS:000266787000009	19480871				2021-06-18	
J	Kassner, SS; Kollmar, R; Bonaterra, GA; Hildebrandt, W; Schwab, S; Kinscherf, R				Kassner, S. S.; Kollmar, R.; Bonaterra, G. A.; Hildebrandt, W.; Schwab, S.; Kinscherf, R.			THE EARLY IMMUNOLOGICAL RESPONSE TO ACUTE ISCHEMIC STROKE: DIFFERENTIAL GENE EXPRESSION IN SUBPOPULATIONS OF MONONUCLEAR CELLS	NEUROSCIENCE			English	Article						lymphocytes; lymphopenia; macrophages; monocytes; oxLDL; PBMC	LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; ACTIVATED PARENCHYMAL MICROGLIA/MACROPHAGES; MANGANESE SUPEROXIDE-DISMUTASE; HUMAN ENDOTHELIAL-CELLS; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; PLASMA OXIDIZED LDL; CEREBRAL-ISCHEMIA; CD40 LIGAND	Peripheral blood mononuclear cells (PBMCs), i.e. lymphocytes, monocytes and macrophages are key players in the development of innate and adaptive immune responses. However, little is known about their properties in patients with acute stroke. Experimental procedures: We presently characterized the early time course of PBMC subpopulations in 19 patients with acute ischemic stroke and symptom onset below 6 h compared to 19 age-matched healthy subjects. Immediately after acute ischemic stroke, as well as 1 and 3 days thereafter, PBMC subpopulations (cluster of differentiation [CD]3+, CD14+, CD19+, CD68+) were isolated by magnetic bead system and the expression of proinflammatory (CD40, tumor necrosis factor-alpha [TNF alpha]), proapoptotic (caspase-3 [CPP32], poly(ADP-ribose) polymerase [PARP]) and adhesion relevant (CD38) genes was measured by quantitative polymerase chain reaction (PCR). Furthermore, besides routine parameters, plasma levels of oxidized low-density lipoproteins (oxLDL) were studied. Results: In comparison to healthy subjects, patients revealed (i) twofold elevated plasma oxLDL concentrations, (ii) decreased (15%) blood cholesterol levels, and (iii) a 40% decrease in total number of lymphocytes. Furthermore, the majority of PBMC subpopulations revealed an increased expression of proinflammatory, proapoptotic or adhesion-relevant genes. Significant positive correlations were observed between expression of most of these genes in PBMCs and individual plasma oxLDL concentrations. Conclusion: Elevated expression of proinflammatory, proapoptotic and adhesion genes in subsets of PBMCs after ischemic stroke may contribute to an immunodepressive syndrome, possibly due to increased plasma oxLDL levels. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Bonaterra, G. A.; Kinscherf, R.] TRIDOMUS C, Ctr Biomed & Med Technol Mannheim, Sect Macroscop Anat, D-68167 Mannheim, Germany; [Kassner, S. S.] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, D-68167 Mannheim, Germany; [Kollmar, R.; Schwab, S.] Univ Erlangen Nurnberg, Dept Neurol, D-91054 Erlangen, Germany; [Hildebrandt, W.] German Canc Res Ctr, D-69120 Heidelberg, Germany	Kinscherf, R (corresponding author), TRIDOMUS C, Ctr Biomed & Med Technol Mannheim, Sect Macroscop Anat, Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.	Ralf.Kinscherf@medma.uni-heidelberg.de					Berard M, 1999, IMMUNOLOGY, V98, P47; Berard R, 1999, J IMMUNOL, V163, P4655; Beschorner R, 2002, J NEUROIMMUNOL, V126, P107, DOI 10.1016/S0165-5728(02)00046-2; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Bonaterra GA, 2005, FREE RADICAL BIO MED, V38, P235, DOI 10.1016/j.freeradbiomed.2004.10.021; Bonaterra GA, 2007, J MOL MED, V85, P181, DOI 10.1007/s00109-006-0117-6; Braun JS, 2007, EXP NEUROL, V206, P183, DOI 10.1016/j.expneurol.2007.03.032; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Di Napoli M, 2002, STROKE, V33, P1763, DOI 10.1161/01.STR.0000019124.54361.08; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; Du XL, 2006, GENOMICS, V87, P693, DOI 10.1016/j.ygeno.2006.02.003; Endres M, 2006, ATHEROSCLEROSIS SUPP, V7, P31, DOI 10.1016/j.atherosclerosissup.2006.01.005; Fujita E, 1998, CELL DEATH DIFFER, V5, P289, DOI 10.1038/sj.cdd.4400355; GARCIA JH, 1974, J NEUROPATH EXP NEUR, V33, P408, DOI 10.1097/00005072-197407000-00007; Garlichs CD, 2001, CIRCULATION, V104, P2395, DOI 10.1161/hc4501.099312; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Haeusler KG, 2008, CEREBROVASC DIS, V25, P50, DOI 10.1159/000111499; Hakkinen T, 2000, VIRCHOWS ARCH, V437, P396, DOI 10.1007/s004280000239; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Holvoet P, 2006, CLIN CHEM, V52, P760, DOI 10.1373/clinchem.2005.064337; Ishikawa M, 2005, CIRCULATION, V111, P1690, DOI 10.1161/01.CIR.0000160349.42665.0C; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; Jeong YJ, 2005, BRIT J NUTR, V93, P581, DOI 10.1079/BJN20041397; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; Kinscherf R, 2003, FREE RADICAL BIO MED, V35, P1286, DOI 10.1016/j.freeradbiomed.2003.07.001; Kinscherf R, 1998, FASEB J, V12, P461; Kinscherf R, 1997, FASEB J, V11, P1317; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Krupinski J, 1996, FOLIA NEUROPATHOL, V34, P17; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Love S, 2000, NEUROREPORT, V11, P2495, DOI 10.1097/00001756-200008030-00030; Luo YK, 2004, J CARDIOVASC PHARM, V44, P381, DOI 10.1097/01.fjc.0000138164.88740.f8; Meier P, 2007, J AM SOC NEPHROL, V18, P331, DOI 10.1681/ASN.2006050514; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Offner H, 2009, NEUROSCIENCE, V158, P1098, DOI 10.1016/j.neuroscience.2008.05.033; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Omari KM, 2003, J NEUROIMMUNOL, V134, P166, DOI 10.1016/S0165-5728(02)00423-X; Pasceri V, 2001, CIRCULATION, V103, P2531; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Prass K, 2006, STROKE, V37, P2607, DOI 10.1161/01.STR.0000240409.68739.2b; Qing Z, 2001, J NEUROPATH EXP NEUR, V60, P798, DOI 10.1093/jnen/60.8.798; Qizilbash N, 1995, LANCET, V346, P1647; Schlittenhardt D, 2005, CELL TISSUE RES, V322, P425, DOI 10.1007/s00441-005-0024-0; Schulte-Herbruggen O, 2006, NEUROIMMUNOMODULAT, V13, P13, DOI 10.1159/000092109; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SILVESTRINI M, 1994, STROKE, V25, P1390, DOI 10.1161/01.STR.25.7.1390; SORNAS R, 1972, ARCH NEUROL-CHICAGO, V26, P489, DOI 10.1001/archneur.1972.00490120029002; Sotgiu S, 2006, EUR J NEUROL, V13, P505, DOI 10.1111/j.1468-1331.2006.01280.x; Tanne D, 2006, INT J CARDIOL, V107, P322, DOI 10.1016/j.ijcard.2005.03.051; Thienel U, 1999, CELL IMMUNOL, V198, P87, DOI 10.1006/cimm.1999.1583; Uno M, 2005, NEUROL RES, V27, P94, DOI 10.1179/016164105X18395; Uno M, 2003, J NEUROL NEUROSUR PS, V74, P312, DOI 10.1136/jnnp.74.3.312; Urbich C, 2002, CIRCULATION, V106, P981, DOI 10.1161/01.CIR.0000027107.54614.1A; Urra X, 2009, NEUROSCIENCE, V158, P1174, DOI 10.1016/j.neuroscience.2008.06.014; Virag Laszlo, 2005, Current Vascular Pharmacology, V3, P209, DOI 10.2174/1570161054368625; Vogelgesang A, 2008, STROKE, V39, P237, DOI 10.1161/STROKEAHA.107.493635; Yin L, 2003, ACT NEUR S, V86, P93	59	19	20	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 5	2009	160	2					394	401		10.1016/j.neuroscience.2009.02.050			8	Neurosciences	Neurosciences & Neurology	436PQ	WOS:000265426700014	19258025				2021-06-18	
J	Broglio, SP; Monk, A; Sopiarz, K; Cooper, ER				Broglio, Steven P.; Monk, Annette; Sopiarz, Kay; Cooper, Earl R.			The influence of ankle support on postural control	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Postural balance; Sports injuries; Cerebral concussion	MILD HEAD-INJURY; ATHLETIC TAPE; CONCUSSION; STABILITY; EXERCISE; METAANALYSIS; PERFORMANCE; INVERSION; MOTION	Postural control assessments are commonly administered to athletes as part of a pre-season screening. Establishing a baseline level of function permits the clinician to compare post-injury results to normal functioning during the return to play decision-making process. In the athletic setting, follow-Lip tests may be completed on the sideline immediately following injury. We sought to examine the effect of commonly administered external ankle joint support on postural control using the balance error scoring system (BESS) and the NeuroCom sensory organization test (SOT). Nineteen volunteers free from balance issues completed three sessions with varied ankle support: bilateral prophylactic ankle taping, laced bracing device, or barefoot. Each session included an initial balance assessment on the BESS and SOT, a 20 min treadmill walk, and post-walk balance test. Fewer errors, indicating improved balance, were committed on the BESS during the barefoot condition than the braced ankle condition (p = 0.044) at the pre-walk assessment. During the post-walk assessment, fewer errors were committed during the barefoot condition compared to the braced ankle condition (p = 0.034) and the taped ankle condition (p = 0.037). All ankle support conditions showed similar improvements in balance between the pre and post-walk assessments on the BESS (p<0.001) and SOT composite balance score (p = 0.009). These findings indicate that ankle support devices may influence postural control on the BESS, but not on the NeuroCom SOT. Clinicians using the BESS as a balance assessment device at multiple time points should be consistent in the application of ankle support devices. Published by All rights reserved.	[Broglio, Steven P.; Monk, Annette; Sopiarz, Kay] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Cooper, Earl R.] Georgia Coll, Dept Kinesiol, Milledgeville, GA 31061 USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA.	broglio@uiuc.edu		Cooper, Earl/0000-0003-1132-4644			BENNELL KL, 1994, J ORTHOP SPORT PHYS, V20, P287, DOI 10.2519/jospt.1994.20.6.287; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Cordova ML, 2000, J ORTHOP SPORT PHYS, V30, P170, DOI 10.2519/jospt.2000.30.4.170; Cordova ML, 2002, J ATHL TRAINING, V37, P446; Dickin DC, 2007, CLIN J SPORT MED, V17, P109, DOI 10.1097/JSM.0b013e31803bf647; FEUERBACH JW, 1993, J ORTHOP SPORT PHYS, V17, P149, DOI 10.2519/jospt.1993.17.3.149; Gravlee JR, 2007, AM FAM PHYSICIAN, V75, P342; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HEIT EJ, 1996, J SPORT REHABIL, V5, P206; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; Kinzey SJ, 1997, J ATHL TRAINING, V32, P300; Manfroy PP, 1997, AM J SPORT MED, V25, P156, DOI 10.1177/036354659702500203; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; MYBURGH KH, 1984, AM J SPORT MED, V12, P441, DOI 10.1177/036354658401200607; Pederson TS, 1997, J ATHL TRAINING, V32, P29; PERRIN DH, 1995, ATHLETIC TAPING BRAC; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Riemann BL, 2000, J ATHL TRAINING, V35, P19; ROVERE GD, 1988, AM J SPORT MED, V16, P228, DOI 10.1177/036354658801600305; Simoneau GG, 1997, J ATHL TRAINING, V32, P141; TROPP H, 1984, AM J SPORT MED, V12, P185, DOI 10.1177/036354658401200302; VALOVICH TC, 2002, USE STANDARDIZED ASS; Wilkerson GB, 2002, J ATHL TRAINING, V37, P436; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	29	19	21	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2009	12	3					388	392		10.1016/j.jsams.2007.12.010			5	Sport Sciences	Sport Sciences	448IN	WOS:000266256400010	18550434				2021-06-18	
J	Fleming, J; Kennedy, S; Fisher, R; Gill, H; Gullo, M; Shum, D				Fleming, Jennifer; Kennedy, Sahra; Fisher, Rebecca; Gill, Hannah; Gullo, Matthew; Shum, David			Validity of the Comprehensive Assessment of Prospective Memory (CAPM) for Use With Adults With Traumatic Brain Injury	BRAIN IMPAIRMENT			English	Article						neuropsychological assessment; psychosocial integration; self-report; test validity	HEAD-INJURY; QUESTIONNAIRE; REHABILITATION; PERFORMANCE; FAILURES	Objective: To expand upon the existing psychometric properties of the Comprehensive Assessment of Prospective Memory (CAPM) for use with adults with traumatic brain injury by examining concurrent and criterion validity. Method: Participants were 45 adults with a traumatic brain injury. Participants and their relatives completed Section A of the CAPM and a measure of psychosocial integration. Participants were also administered two neuropsychological tests of prospective memory, the Cambridge Prospective Memory Test (CAM-PROMPT) and the Memory Intentions Screening Test (MIST). Concurrent validity was measured by comparing scores on the CAPM with scores on the CAM-PROMPT and MIST. Criterion validity was examined by correlating CAPM scores with level of psychosocial integration. Results: Participant self-reports on the CAPM were not significantly correlated with the CAM-PROMPT or MIST, but were significantly correlated with level of psychosocial integration. Relative reports on the CAPM were correlated significantly with total score on the MIST and CAM-PROMPT and level of psychological integration. Conclusions: The findings indicate that the concurrent validity of the self-report version of CAPM is low suggesting that self-reports alone do not provide an objective measure for assessing prospective memory function. The relative report version however, demonstrated reasonable concurrent and criterion validity, suggesting that the relative report version of the Section A of the CAPM is a useful means of evaluating frequency of prospective memory failure in adults with traumatic brain injury.	[Fleming, Jennifer; Kennedy, Sahra; Fisher, Rebecca; Gill, Hannah] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Gill, Hannah; Gullo, Matthew; Shum, David] Griffith Univ, Griffith Inst Hlth & Med Res, Nathan, Qld 4111, Australia; [Gullo, Matthew; Shum, David] Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia	Fleming, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	j.fleming@uq.edu.au	Gullo, Hannah/C-5011-2008; Fleming, Jennifer M/B-4436-2011; Shum, David/A-3914-2008; Gullo, Matthew/C-3850-2008	Shum, David/0000-0002-4810-9262; Gullo, Matthew/0000-0003-3657-5191; GULLO, Hannah/0000-0003-4238-4033	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia;  [113 277002]	This research was funded by a National Health and Medical Research Council (NHMRC) Project grant (113 No. 277002).	Andrewes DG, 1998, NEUROPSYCHOL REHABIL, V8, P377, DOI 10.1080/713755582; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; CHAU IT, 2007, NEUROPSYCHOL REHABIL, V5, P1; CICERONE KD, 1990, J CLIN EXP NEUROPSYC, V12, P92; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Fleming J, 2000, BRAIN IMPAIR, V1, P141, DOI DOI 10.1375/brim.1.2.141; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; GILWESKI MJ, 1988, PSYCHOPHARMACOLOGY B, V24, P665; GOLDSTEIN LH, 1992, BRIT J CLIN PSYCHOL, V31, P75, DOI 10.1111/j.2044-8260.1992.tb00969.x; Gravetter F. J., 2000, STAT BEHAV SCI; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; HERRMANN DJ, 1983, BRAIN IMPAIRMENT, V3, P1; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MAYLOR EA, 2002, NEUROPSYCHOLOGY, V20, P144; RASKIN S, 2000, MEMORY INTENTI UNPUB; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Waugh N., 1999, THESIS GRIFFITH U BR; WEITEN W, 1998, PSYCHOL THEMES VARIA; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; Wilson B., 2005, CAMBRIDGE PROSPECTIV; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348	31	19	20	0	14	AUSTRALIAN ACAD PRESS	BOWEN HILLS	32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA	1443-9646			BRAIN IMPAIR	Brain Impair.	MAY	2009	10	1					34	44		10.1375/brim.10.1.34			11	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	443CQ	WOS:000265888200006		Green Published			2021-06-18	
J	Honeybul, S				Honeybul, S.			Decompressive craniectomy: A new complication	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Decompressive craniectomy; Complications; Head injury	TRAUMATIC BRAIN-INJURY; INFARCTION; CHILDREN; TRIAL	There is an increasing amount of published literature Supporting the use of decompressive craniectomy in the management of raised intracranial pressure and it appears that this procedure will become established as a method by which intracranial hypertension can be treated. While technically fairly straightforward, a decompressive craniectomy is not without complications. A further complication is presented here, which has not been previously reported. A 56-year-old male fell backwards from a bar stool and struck his occiput. He had a decompressive craniectomy and was making an excellent recovery when he fell and injured the unprotected craniectomy site. He Suffered further cerebral injury and subsequently died. Following a detailed review of the case a number of recommendations were made and a specific post-decompressive craniectomy operational policy for the assessment and management of these patients was implemented. While we accept that these particular guidelines are specific to a particular institution, this case highlights the need to view these patients as a particularly high risk and recommend that institutions review or establish a specific policy regarding their management. (C) 2008 Elsevier Ltd. All rights reserved.	Sir Charles Gairdner Hosp, Dept Neurosurg, Nedlands, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Nedlands, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4; Hutchinson Peter, 2007, Neurosurg Focus, V22, pE14; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235	9	19	19	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	MAY	2009	16	5					727	729		10.1016/j.jocn.2008.06.015			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	433RQ	WOS:000265223900032	19261473				2021-06-18	
J	Weireter, LJ; Collins, JN; Britt, RC; Reed, SF; Novosel, TJ; Britt, LD				Weireter, Leonard J., Jr.; Collins, J. N.; Britt, Rebecca C.; Reed, Scott F.; Novosel, T. J.; Britt, L. D.			Impact of a Monitored Program of Care on Incidence of Ventilator-Associated Pneumonia: Results of a Longterm Performance-Improvement Project	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	120th Annual Meeting of the Southern-Surgical-Association	DEC, 2008	Palm Beach, FL	SE Surg Assoc			SYSTEMS	BACKGROUND: Ventilator-associated Pneumonia (VAP) remains a major source of morbidity, mortality, and expense in the ICU despite therapies directed against it. STUDY DESIGN: A retrospective review of a prospectively developed performance-improvement project monitoring the incidence of VAP in two adjacent ICUs was conducted. In response to an excessive VAP rate, weekly multidisciplinary team meetings were instituted to review data, develop care protocols, and modify care routines. Protocol compliance was monitored daily and feedback provided weekly to the care teams. VAP rates were determined by the institutional Infection Control Committee and reviewed monthly with the ICU multidisciplinary team. Duration of the investigational period was 10 years. RESULTS: A standardized ventilator-weaning protocol was instituted with confirmed 95% use. Additional modifications of care, such as patient positioning, use of specific endotracheal tubes to minimize aspiration of supraglottic secretions, an oral-care regimen, and aggressive antibiotic stewardship were standardized, with a compliance rate >90%. VAP rates dropped from 12.8 per 1,000 patient-days in 1998 to 1.1 in 2007 in the burn trauma ICU and from 21.2 to <1 in the neurotrauma ICU in the same time frame. Also, mean ventilator length of stay decreased from 6 days to 4.2 and from 5.8 days to 4.75 simultaneously in the respective ICUs. Such performance improvement has been sustained since implementation of the program. CONCLUSION: A systematic, monitored program of standardized care protocols can markedly reduce VAP rate in the ICU. (J Am Coll Surg 2009;208:700-705. (C) 2009 by the American College of Surgeons)	[Weireter, Leonard J., Jr.; Collins, J. N.; Britt, Rebecca C.; Reed, Scott F.; Novosel, T. J.; Britt, L. D.] Eastern Virginia Med Sch, Dept Surg, Norfolk, VA 23507 USA	Weireter, LJ (corresponding author), Eastern Virginia Med Sch, Dept Surg, 825 Fairfax Ave,Ste 610, Norfolk, VA 23507 USA.	weiretlj@evms.edu					[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Berwick DM, 1998, ANN INTERN MED, V128, P289, DOI 10.7326/0003-4819-128-4-199802150-00008; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; Langley GJ, 1996, IMPROVEMENT GUIDE PR; Nolan TW, 1998, ANN INTERN MED, V128, P293, DOI 10.7326/0003-4819-128-4-199802150-00009; WEIRETER LJ, 1999, AM ASS SURG TRAUM AN	7	19	19	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	MAY	2009	208	5					700	704		10.1016/j.jamcollsurg.2009.01.041			5	Surgery	Surgery	441WP	WOS:000265801500010	19476819				2021-06-18	
J	Terre, R; Mearin, F				Terre, R.; Mearin, F.			Evolution of tracheal aspiration in severe traumatic brain injury-related oropharyngeal dysphagia: 1-year longitudinal follow-up study	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						aspiration; deglutition; dysphagia; outcome; traumatic brain injury; videofluoroscopy	DISABILITY RATING-SCALE; ACUTE STROKE; INTERRATER RELIABILITY; SWALLOWING DISORDERS; HEAD TRAUMA; PROGRESSION; PREDICTORS	The aims of the article were to ascertain the clinical evolution and prognostic factors of aspiration recovery and feeding outcome in patients with severe traumatic brain injury (TBI) and a videofluoroscopic (VFS) diagnosis of tracheal aspiration. Twenty-six patients with severe TBI and VFS diagnosis of tracheal aspiration were prospectively evaluated. Clinical evaluation of oropharyngeal dysphagia and VFS examination were performed at admission and repeated at 1, 3, 6 and 12 months of follow-up. At admission, all patients had VFS aspiration. During follow-up, an improvement was observed in both oral and pharyngeal function, with the number of patients with aspiration decreasing progressively. The most significant change occurred in the examination made at 3 months. At 1 year, only 23% of patients had aspiration. No patient had clinically significant respiratory infections during the follow-up period. Persistent aspiration at 1 year of follow-up correlated with baseline variables: Rancho Los Amigos Level Cognitive Function Scale score, Disability Rating Scale score, tongue control alteration, velopharyngeal reflex abolition and delay in triggering swallowing reflex. Swallowing physiology in severe TBI greatly improved during follow-up and the number of aspirations decreased progressively, with the most significant reduction at between 3 and 6 months of evolution. This study revealed several prognostic factors for persisting aspiration: neurological involvement (evaluated with the Rancho Los Amigos Level Cognitive Function Scale and Disability Rating Scale), tongue control alteration, oropharyngeal reflex abolition and delay in triggering swallowing reflex at baseline.	[Terre, R.; Mearin, F.] Univ Barcelona, Univ Inst Affiliated Autonomous, Neurorehabil Hosp, Inst Guttmann,Funct Digest Rehabil, Badalona, Spain	Terre, R (corresponding author), Inst Guttmann, Funct Digest Rehabil, Cami Can Ruti S-N, Badalona 08916, Spain.	rterre@gutmann.com					COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Daniels SK, 1998, ARCH PHYS MED REHAB, V79, P14, DOI 10.1016/S0003-9993(98)90200-3; Ekberg O, 1988, Dysphagia, V3, P46, DOI 10.1007/BF02406279; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Hagen C, 1981, TOP LANG DIS, V1, P73; Hagen C, 1979, REHABILITATION HEAD, P87; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; HORNER J, 1993, NEUROLOGY, V43, P430, DOI 10.1212/WNL.43.2.430; HORNER J, 1988, NEUROLOGY, V38, P317, DOI 10.1212/WNL.38.2.317; Kim Y, 2005, DYSPHAGIA, V20, P290, DOI 10.1007/s00455-005-0029-6; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; LINDEN P, 1983, ARCH PHYS MED REHAB, V64, P281; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; Logemann J., 1993, MANUAL VIDEOFLUOROGR, P115; Logemann JA, 2000, J SPEECH LANG HEAR R, V43, P1264, DOI 10.1044/jslhr.4305.1264; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Logemann JA, 1998, EVALUATION TREATMENT, P307; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; McCullough GH, 2005, J SPEECH LANG HEAR R, V48, P1280, DOI 10.1044/1092-4388(2005/089); Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Perlman Adrienne L., 1994, Dysphagia, V9, P90, DOI 10.1007/BF00714593; Ramsey D, 2005, DYSPHAGIA, V20, P105, DOI 10.1007/s00455-004-0024-3; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; Scott A, 1998, DYSPHAGIA, V13, P223, DOI 10.1007/PL00009576; Smithard DG, 1998, AGE AGEING, V27, P99, DOI 10.1093/ageing/27.2.99; Spechler SJ, 1999, GASTROENTEROLOGY, V117, P233, DOI 10.1016/S0016-5085(99)70573-1; STANNERS JAB, 1993, AGE AGEING, V2, P47; Stoeckli SJ, 2003, DYSPHAGIA, V18, P53, DOI 10.1007/s00455-002-0085-0; Terre R, 2006, NEUROGASTROENT MOTIL, V18, P200, DOI 10.1111/j.1365-2982.2005.00729.x; Terrte R, 2007, BRAIN INJURY, V21, P1411, DOI 10.1080/02699050701785096; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Ward EC, 2007, J HEAD TRAUMA REHAB, V22, P184, DOI 10.1097/01.HTR.0000271119.96780.f5; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	36	19	23	0	12	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1350-1925			NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	APR	2009	21	4					361	369		10.1111/j.1365-2982.2008.01208.x			9	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	418RD	WOS:000264165200003	19019014				2021-06-18	
J	Ackery, A; Provvidenza, C; Tator, CH				Ackery, Alun; Provvidenza, Christine; Tator, Charles H.			Concussion in Hockey: Compliance with Return to Play Advice and Follow-up Status	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SPORT-RELATED CONCUSSION; ICE HOCKEY; MANAGEMENT; INJURY; PREVENTION; SCIENCE	Objectives: To determine the compliance rate among hockey players with Concussion of other head injuries who were advised by a physician about return to play. To assess compliance of hockey players with return to play advice and to assess the incidence of long-term post-concussion symptoms. Methods: A retrospective chart review, telephone questionnaire and follow-up analysis of income. level of education and professional aspirations. The study examined 40 hockey players with concussion or other head injury treated at a neurosurgical ambulatory clinic, who had initial visits between 1995 and 2003, and had been seen at least two years prior to completing the questionnaire. Results: There was a 58% (23 of 40) participation rate in the Study. Fifteen (65%) of the 23 participants were advised to never return to play, and 5 (33%) were non-compliant and returned to play. Four (80%) of the five noncompliant players continued to suffer from post concussion Symptoms. Overall, 15 (65%) of the 23 players participating in the Study continued to suffer post concussion symptoms at least two years after the clinic visit. Conclusions: Five (33%) of 15 hockey players advised to never return to play were non-compliant and returned to play, and four continued 10 suffer from post concussion Symptoms two or more years later. After repeated concussions, 65% of hockey players had long-term sequelae that prevented return to play and produced long-term post-concussion symptoms.	[Ackery, Alun; Provvidenza, Christine; Tator, Charles H.] Univ Toronto, ThinFirst Canada, Toronto, ON, Canada; [Ackery, Alun] Univ Toronto, Fac Med, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada	Tator, CH (corresponding author), Toronto Western Hosp, 399 Bathurst St 4W-433, Toronto, ON M5T 2S8, Canada.		Ackery, Alun/B-6634-2016		Dr. Tom Pashby Sport Safety Fund; Tridel Corporation the Ontario Neurotrauma Foundation; Krembil Family Foundation	ThinkFirst gratefully acknowledges support for its injury prevention programs from the Dr. Tom Pashby Sport Safety Fund, Tridel Corporation the Ontario Neurotrauma Foundation and the Krembil Family Foundation.	Bailes JE, 2001, J ATHL TRAINING, V36, P236; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory Paul, 2005, Clin J Sport Med, V15, P48; *MED CAOS, 2000, CAN J SPORT MED, P10; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Tator CH, 2001, NEUROLOGICAL SPORTS, P261; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	23	19	19	1	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAR	2009	36	2					207	212		10.1017/S0317167100120281			6	Clinical Neurology	Neurosciences & Neurology	421OB	WOS:000264367100015	19378716	Bronze			2021-06-18	
J	Berger, R; Richichi, R				Berger, Rachel; Richichi, Rudolph			Derivation and validation of an equation for adjustment of neuron-specific enolase concentrations in hemolyzed serum	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						neuron-specific enolase; hemolysis; brain injury; children; derivation and validation	TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; MARKERS; PROTEINS; DAMAGE; NSE	Objective: To derive and validate a formula to allow for adjustment of serum neuron-specific enolase (NSE) concentrations based on the amount of hemolysis in the sample. To compare the accuracy of qualitative and quantitative assessment of hemolysis. Design: Derivation and validation of a formula. Subjects: Eighty-three children <11 years of age were used for the derivation. Twenty-three children <11 years without brain injury and 30 with brain injury were used for the validation. Interventions: We evaluated the amount of hemolysis quantitatively using a hemocue and qualitatively by visualization. We measured NSE concentrations by enzyme-linked immunosorbent assay. Using a subset of subjects, we used linear regression analysis to derive an equation to adjust serum NSE concentrations based on the degree of hemolysis. We prospectively validated the formula in a different group. NSE <= 11.5 ng/mL was considered normal. Results: The formula derived was as follow: Adjusted NSE = Unadjusted NSE - (1.659) (square root of the hemocue). In the validation, 96% of children without brain injury had a normal adjusted NSE; 93% of children with brain injury had an abnormal adjusted NSE. Qualitative analysis of hemolysis was inconsistent and both overassessed and under-assessed hemolysis as quantified by hemocue. Conclusions: We retrospectively derived and prospectively validated an equation for adjusting serum NSE concentrations based on the amount of hemolysis in the sample. Use of this formula will allow for accurate measurement of NSE even in hemolyzed sample and may improve its usefulness as a marker of brain injury in children. Qualitative assessment of the degree of hemolysis is not accurate and should not be used. (Pediatr Crit Care Med 2009; 10:260-263)	[Berger, Rachel] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Richichi, Rudolph] Stat Anal & Measurement Consultants, Lanexa, VA USA	Berger, R (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.	rberger@pitt.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K23HD43843-01]; Children's Hospital of Pittsburgh General Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084]; University of Pittsburgh Center for Injury Research and Control (CIRCL)University of Pittsburgh; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER	Supported by grant 1K23HD43843-01 from the National Institutes of Health, by grant M01 RR00084 from the Children's Hospital of Pittsburgh General Clinical Research Center, and the University of Pittsburgh Center for Injury Research and Control (CIRCL) (RB).	Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; Amer-Wahlin I, 2001, CLIN CHIM ACTA, V304, P57, DOI 10.1016/S0009-8981(00)00408-3; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Burns ER, 2002, LAB MED, V33, P378, DOI 10.1309/PGM4-4F8L-2P1M-LKPB; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Lemery L., 1998, ADV MED LAB PROFESSI, V2, P24; *NAT COMM CLIN LAB, 2007, PROC COLL DIAGN BLOO; NOTOMI T, 1985, TUMOUR BIOL, V6, P57; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Sharp MK, 1998, ANN BIOMED ENG, V26, P788, DOI 10.1114/1.65; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	16	19	19	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2009	10	2					260	263		10.1097/PCC.0b013e31819a376d			4	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	419VK	WOS:000264247600020	19188872				2021-06-18	
J	Kochanek, PM; Fink, EL; Bell, MJ; Bayir, H; Clark, RSB				Kochanek, Patrick M.; Fink, Ericka L.; Bell, Michael J.; Bayir, Huelya; Clark, Robert S. B.			Therapeutic Hypothermia: Applications in Pediatric Cardiac Arrest	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			asphyxia; cooling; drowning; neonate; newborn; resuscitation	WHOLE-BODY HYPOTHERMIA; MILD SYSTEMIC HYPOTHERMIA; TRAUMATIC BRAIN-INJURY; PERINATAL ASPHYXIA; NEONATAL ENCEPHALOPATHY; CEREBRAL RESUSCITATION; RAT-BRAIN; CHILDREN; INFANTS; TEMPERATURE	There is a rich history for the use of therapeutic hypothermia after cardiac arrest in neonatology and pediatrics. Laboratory reports date back to 1824 in experimental perinatal asphyxia. Similarly, clinical reports in pediatric cold water drowning victims represented key initiating work in the field. The application of therapeutic hypothermia in pediatric drowning victims represented some of the seminal clinical use of this modality in modern neurointensive care. Uncontrolled application (too deep and too long) and unique facets of asphyxial cardiac arrest in children (a very difficult insult to affect any benefit) likely combined to result in abandonment of therapeutic hypothermia in the mid to late 1980s. Important studies in perinatal medicine have built upon the landmark clinical trials in adults, and are once again bringing therapeutic hypothermia into standard care for pediatrics. Although more work is needed, particularly in the use of mild therapeutic hypothermia in children, there is a strong possibility that this important therapy will ultimately have broad applications after cardiac arrest and central nervous system (CNS) insults in the pediatric arena.	[Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.] Dept Pediat, Pittsburgh, PA USA; [Bayir, Huelya] Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Bayir, Huelya] Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA USA; [Kochanek, Patrick M.; Fink, Ericka L.; Bell, Michael J.; Bayir, Huelya; Clark, Robert S. B.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, R01NS038087, P01NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD047349-02, K12 HD047349, 5K12HD047349-02] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38087, R01 NS038087-01A1, R01 NS038087, R01 NS038087-09, P01 NS030318-160010, P01 NS030318-169003, P01 NS030318, NS30318] Funding Source: Medline		Atkins DL, 2006, PEDIATRICS, V117, pE1005, DOI 10.1542/peds.2006-0346; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CONN AW, 1979, PEDIATR CLIN N AM, V26, P691; CONN AW, 1979, CAN MED ASSOC J, V120, P397; DANIEL SS, 1966, J PEDIATR-US, V68, P45, DOI 10.1016/S0022-3476(66)80421-3; Debillon T, 2003, DEV MED CHILD NEUROL, V45, P17, DOI 10.1017/S0012162203000045; EDWARDS WF, 1824, INFLUENCE AGENTS PHY; Fink EL, 2005, DEV NEUROSCI-BASEL, V27, P191, DOI 10.1159/000085992; Fink EL, 2007, CRIT CARE MED, V35, pA97; FREWEN TC, 1982, J PEDIATR-US, V100, P663, DOI 10.1016/S0022-3476(82)80782-8; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Haque IU, 2006, PEDIATR CRIT CARE ME, V7, P7, DOI 10.1097/01.PCC.0000192322.45123.80; Higgins RD, 2006, J PEDIATR-US, V148, P170, DOI 10.1016/j.jpeds.2005.12.009; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; JENKINS LW, 2008, ROGERS TXB PEDIAT IN, P810; Johnston MV, 2005, BRAIN PATHOL, V15, P234; KOCHANEK PM, 1988, CRIT CARE CLIN, V4, P661; LANSKY LL, 1977, J PEDIATR-US, V90, P639, DOI 10.1016/S0022-3476(77)80390-9; LEVENE MI, 1986, LANCET, V1, P67, DOI 10.1016/S0140-6736(86)90718-X; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McDonald J W, 1993, NIDA Res Monogr, V133, P185; MCDONALD JW, 1991, NEUROSCI LETT, V126, P83, DOI 10.1016/0304-3940(91)90377-6; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Nehlig A, 1997, DIABETES METAB, V23, P18; Nishisaki A, 2007, PEDIATR CRIT CARE ME, V8, P10, DOI 10.1097/01.pcc.0000256621.63135.4b; NUSSBAUM E, 1988, PEDIATRICS, V81, P630; OATES RK, 1976, ARCH DIS CHILD, V51, P512, DOI 10.1136/adc.51.7.512; Ohmura A, 2005, BRAIN DEV-JPN, V27, P517, DOI 10.1016/j.braindev.2005.01.004; OROURKE PP, 1986, CRIT CARE MED, V14, P466, DOI 10.1097/00003246-198605000-00006; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shimohama S, 2001, BIOCHEM BIOPH RES CO, V289, P1063, DOI 10.1006/bbrc.2001.6108; SIEBKE H, 1975, LANCET, V1, P1275; SILVERMAN WA, 1958, PEDIATRICS, V22, P876; Topjian AA, 2007, CIRCULATION, V116, P945; Vaagenes P, 1997, RESUSCITATION, V35, P41, DOI 10.1016/S0300-9572(97)01108-8; VANNUCCI RC, 1990, PEDIATRICS, V85, P961; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; WESTIN B, 1962, ACTA PAEDIATR SCAND, V51, P5; YAGER J, 1993, PEDIATR RES, V34, P525, DOI 10.1203/00006450-199310000-00029; YASUDA T, 1995, J NEUROSCI RES, V40, P306, DOI 10.1002/jnr.490400304; Young KD, 1999, ANN EMERG MED, V33, P195, DOI 10.1016/S0196-0644(99)70394-X; Young KD, 2004, PEDIATRICS, V114, P157, DOI 10.1542/peds.114.1.157	54	19	20	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					421	427		10.1089/neu.2008.0587			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900017	19271968	Green Published, Green Accepted			2021-06-18	
J	Lasarzik, I; Winkelheide, U; Stallmann, S; Orth, C; Schneider, A; Tresch, A; Werner, C; Engelhard, K				Lasarzik, Irina; Winkelheide, Uta; Stallmann, Sonja; Orth, Christian; Schneider, Astrid; Tresch, Achim; Werner, Christian; Engelhard, Kristin			Assessment of Postischemic Neurogenesis in Rats with Cerebral Ischemia and Propofol Anesthesia	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 13-17, 2007	San Francisco, CA	Amer Soc Anesthesiologists			TRAUMATIC BRAIN-INJURY; FOREBRAIN ISCHEMIA; NEURONAL DIFFERENTIATION; ADULT NEUROGENESIS; MEMORY IMPAIRMENT; HIPPOCAMPUS; DAMAGE; CELLS; ISOFLURANE; STROKE	Background: Postischemic endogenous neurogenesis can be dose-dependently modulated by volatile anesthetics. The intravenous anesthetic propofol is used during operations with a risk of cerebral ischemia, such as neurosurgery, cardiac surgery, and vascular surgery. The effects of propofol on neurogenesis are unknown and, therefore, the object of this study. Methods: Eighty male Sprague-Dawley rats were randomly assigned to treatment groups with propofol administration for 3 h: 36 mg . kg(-1) . h(-1) propofol with or without cerebral ischemia and 72 mg . kg(-1) . h(-1) propofol with or without cerebral ischemia. In addition, 7 rats with propofol administration for 6 h and 14 treatment-naive rats were investigated. Forebrain ischemia was induced by bilateral carotid artery occlusion and hemorrhagic hypotension. Animals received 5-bromo-2-deoxyuridine for 7 days. 5-Bromo-2-deoxyuridine-positive neurons were counted in the dentate gyrus after 9 and 28 days. Spatial learning in the Barnes maze and histopathologic damage of the hippocampus were analyzed. Results: Propodol revealed no impact on basal neurogenesis. Cerebral ischemia increased the amount of new neurons. After 28 days, neurogenesis significantly increased in animals with low-dose propofol administered during cerebral ischemia compared with naive animals, whereas no significant difference was observed in animals with high-dose propofol during ischemia. Neuronal damage in the CA3 region was increased at 28 days with high-dose propofol. Postischemic deficits in spatial learning were not affected by propofol. Conclusions: Independent effects of propofol are difficult to ascertain. Peri-ischemic propofol administration may exert secondary effects on neurogenesis by modulating the severity of histopathologic	[Lasarzik, Irina; Winkelheide, Uta; Stallmann, Sonja; Orth, Christian; Werner, Christian; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Anasthesiol Klin, D-55131 Mainz, Germany	Lasarzik, I (corresponding author), Johannes Gutenberg Univ Mainz, Anasthesiol Klin, Langenbeckstr 1, D-55131 Mainz, Germany.	lasarzik@uni-mainz.de					ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Bailey JM, 1997, ANESTH ANALG, V85, P681, DOI 10.1097/00000539-199709000-00036; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x; Cipolla MJ, 2002, STROKE, V33, P2094, DOI 10.1161/01.STR.0000020712.84444.8D; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Eberspacher E, 2006, ANESTH ANALG, V103, P1527, DOI 10.1213/01.ane.0000247803.30582.2d; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Engelhard K, 2007, ANESTH ANALG, V104, P898, DOI 10.1213/01.ane.0000255730.73018.31; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Harburg GC, 2007, NEUROSCIENCE, V144, P77, DOI 10.1016/j.neuroscience.2006.09.018; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kawaguchi Masahiko, 2005, J Anesth, V19, P150, DOI 10.1007/s00540-005-0305-5; Kawai T, 2004, J CEREBR BLOOD F MET, V24, P548, DOI 10.1097/00004647-200405000-00009; Liu SH, 2003, J NEUROSCI, V23, P732; Nasu I, 2006, ANESTH ANALG, V103, P413, DOI 10.1213/01.ane.0000223686.50202.38; Ng KP, 2006, ANESTH ANALG, V103, P1453, DOI 10.1213/01.ane.0000247732.33602.f5; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sakai H, 2007, ANESTHESIOLOGY, V106, P92, DOI 10.1097/00000542-200701000-00017; Salazar-Colocho P, 2008, NEUROSCI RES, V61, P27, DOI 10.1016/j.neures.2008.01.008; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Squire LR, 1996, HIPPOCAMPUS, V6, P546; Steckler T, 1998, PROG NEUROBIOL, V54, P313, DOI 10.1016/S0301-0082(97)00061-0; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Taupin P, 2006, CR BIOL, V329, P465, DOI 10.1016/j.crvi.2006.04.001; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tozuka Y, 2005, NEURON, V47, P803, DOI 10.1016/j.neuron.2005.08.023; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; WARNER DS, 1990, BRAIN RES, V536, P176, DOI 10.1016/0006-8993(90)90023-5; Werner C, 1995, ANAESTHESIST, V44, pS566; ZOLAMORGAN S, 1992, J NEUROSCI, V12, P2582	35	19	22	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAR	2009	110	3					529	537		10.1097/ALN.0b013e318195b4fe			9	Anesthesiology	Anesthesiology	412OU	WOS:000263734900014	19212268	Bronze			2021-06-18	
J	Minardi, J; Crocco, TJ				Minardi, Joseph; Crocco, Todd J.			Management of Traumatic Brain Injury: First Link in Chain of Survival	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						clinical management; prehospital; review; traumatic brain injury	7.5-PERCENT SODIUM-CHLORIDE; RAPID-SEQUENCE INTUBATION; ENDOTRACHEAL INTUBATION; HYPERTONIC SALINE; RESUSCITATION; IMPACT; MORTALITY; HYPOXIA; DEXTRAN; FIELD	Traumatic brain injury is a significant cause of morbidity and mortality. The prehospital care of the patients with a traumatic brain injury is critical to maximizing the chances for a good outcome. Prehospital management of the traumatic brain injury patient is directed toward preventing and limiting secondary brain injury while facilitating rapid transport to an appropriate facility capable of providing definitive neurocritical care. Key points in management include the assessment of oxygenation, blood pressure, and mental status (as measured with the Glasgow Coma Scale) and the pupillary examination. Treatment strategies are directed toward maintaining adequate oxygenation and perfusion and treating herniation. Judicious use of temporary hyperventilation and hypertonic saline are considerations. This review provides saline are considerations. This review provides the most recent evidence regarding the treatment of traumatic brain injury in the prehospital setting and introduces areas in need of future research. St. Sinai J Med. 76:138-144, 2009 (C) 2009 Mount Sinai School of Medicine	[Minardi, Joseph; Crocco, Todd J.] W Virginia Univ, Dept Emergency Med, Morgantown, WV 26506 USA	Crocco, TJ (corresponding author), W Virginia Univ, Dept Emergency Med, Morgantown, WV 26506 USA.	tcrocco@hsc.wvu.edu					Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P3204; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Lane Peter L, 2002, Prehosp Disaster Med, V17, P142; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Myburgh J, 2007, NEW ENGL J MED, V357, P874; *NAT CTR INJ PREV, TRAUM BRAIN INJ; Perel P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub3; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Silverboard H, 2005, J TRAUMA, V59, P717, DOI 10.1097/01.ta.0000174919.35240.21; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	32	19	20	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					138	144		10.1002/msj.20105			7	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800007	19306368				2021-06-18	
J	Ruchelsman, DE; Tejwani, NC; Kwon, YW; Egol, KA				Ruchelsman, David E.; Tejwani, Nirmal C.; Kwon, Young W.; Egol, Kenneth A.			Open Reduction and Internal Fixation of Capitellar Fractures with Headless Screws	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							CORONAL SHEAR FRACTURES; HUMERAL CAPITELLUM; CAPITULUM HUMERI; DISTAL END	BACKGROUND: The outcome of operatively treated capitellar fractures has not been reported frequently. The purpose of the present study was to evaluate the clinical, radiographic, and functional outcomes following open reduction and internal fixation of capitellar fractures that were treated with a uniform surgical approach in order to further define the impact on the outcome of fracture type and concomitant lateral column osseous and/or ligamentous injuries. METHODS: A retrospective evaluation of the upper extremity database at our institution identified sixteen skeletally mature patients (mean age, 40 17 years) with a closed capitellar fracture. In all cases, an extensile lateral exposure and articular fixation with buried cannulated variable-pitch headless compression screws was performed at a mean of ten days after the injury. Clinical, radiographic, and elbow-specific outcomes, including the Mayo Elbow Performance Index, were evaluated at a mean of 27 19 months postoperatively. RESULTS: Six Typed, two Type-III, and eight Type-IV fractures were identified with use of the Bryan and Morrey classification system. Four of five ipsilateral radial head fractures occurred in association with a Type-IV fracture. The lateral collateral ligament was intact in fifteen of the sixteen elbows. Metaphyseal comminution was observed in association with five fractures (including four Type-IV fractures and one Type-III fracture). Supplemental mini-fragment screws were used for four of eight Type-IV fractures and one of two Type-III fractures. All fractures healed, and no elbow had instability or weakness. Overall, the mean ulnohumeral motion was 123 degrees (range, 70 degrees to 150 degrees). Fourteen of the sixteen patients achieved a functional arc of elbow motion, and all patients had full forearm rotation. The mean Mayo Elbow Performance Index score was 92 10 points, with nine excellent results, six good results, and one fair result. Patients with a Type-IV fracture had a greater magnitude of flexion contracture (p = 0.04), reduced terminal flexion (p = 0.02), and a reduced net ulnohumeral arc (p = 0.01). An ipsilateral radial head fracture did not appear to affect ulnohumeral motion or the functional outcome. CONCLUSIONS: Despite the presence of greater flexion contractures at the time of follow-up in elbows with Type-IV fractures or fractures with an ipsilateral radial head fracture, good to excellent outcomes with functional ulnohumeral motion can be achieved following internal fixation of these complex fractures. Type-IV injuries may be more common than previously thought; such fractures often are associated with metaphyseal comminution or a radial head fracture and may require supplemental fixation. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.	[Ruchelsman, David E.; Tejwani, Nirmal C.; Kwon, Young W.; Egol, Kenneth A.] NYU, Hosp Joint Dis, Dept Orthopaed Surg, New York, NY 10003 USA	Ruchelsman, DE (corresponding author), NYU, Hosp Joint Dis, Dept Orthopaed Surg, 301 E 17th St,14th Floor, New York, NY 10003 USA.	man@nyumc.org; Nirmal.Tejwani@nyumc.org; Young.Kwon@nyumc.org; Kenneth.Egol@nyumc.org		Kwon, Young/0000-0003-2465-9945; Tejwani, Nirmal/0000-0001-8578-6556			ALVAREZ E, 1975, J BONE JOINT SURG AM, V57, P1093, DOI 10.2106/00004623-197557080-00010; Bryan R.S, 1985, ELBOW ITS DISORDERS, P325; Dubberley JH, 2006, J BONE JOINT SURG AM, V88A, P46, DOI 10.2106/JBJS.D.02954; DUSHUTTLE RP, 1985, J TRAUMA, V25, P317, DOI 10.1097/00005373-198504000-00006; FOWLES JV, 1974, J BONE JOINT SURG AM, VA 56, P794, DOI 10.2106/00004623-197456040-00013; Goodman HJ, 2005, BULL HOSP JT DIS, V62, P85; GRANTHAM SA, 1981, CLIN ORTHOP RELAT R, P262; Imatani J, 2001, J SHOULDER ELB SURG, V10, P554, DOI 10.1067/mse.2001.118005; MA YZ, 1984, CLIN ORTHOP RELAT R, P17; Mahirogullari M, 2006, J HAND SURG-BRIT EUR, V31B, P320, DOI 10.1016/j.jhsb.2006.02.002; McKee MD, 1996, J BONE JOINT SURG AM, V78A, P49, DOI 10.2106/00004623-199601000-00007; Mighell MA, 2006, J ORTHOP TRAUMA, V20, P699, DOI 10.1097/01.bot.0000246411.33047.80; Ochner RS, 1996, J TRAUMA, V40, P199, DOI 10.1097/00005373-199602000-00005; Ring D, 2003, J BONE JOINT SURG AM, V85A, P232, DOI 10.2106/00004623-200302000-00008; Ruchelsman DE, 2008, J BONE JOINT SURG AM, V90A, P1321, DOI 10.2106/JBJS.G.00940; Sano S, 2005, J SHOULDER ELB SURG, V14, P307, DOI 10.1016/j.jse.2004.09.005; Stamatis E, 2003, J ORTHOP TRAUMA, V17, P279, DOI 10.1097/00005131-200304000-00006	17	19	21	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	MAR	2009	91A		1	2			38	49		10.2106/JBJS.H.01195			12	Orthopedics; Surgery	Orthopedics; Surgery	419GZ	WOS:000264208900005	19255199				2021-06-18	
J	Arvanitidis, AP; Corbett, D; Colbourne, F				Arvanitidis, Anastasia P.; Corbett, Dale; Colbourne, Frederick			A high fat diet does not exacerbate CA1 injury and cognitive deficits following global ischemia in rats	BRAIN RESEARCH			English	Article						High fat western diet; Hippocampus; Morris water maze; Global ischemia; Stroke	NEUROTROPHIC FACTOR; BRAIN-DAMAGE; POSTISCHEMIC HYPOTHERMIA; FOREBRAIN ISCHEMIA; MEMORY IMPAIRMENT; RISK; STROKE; PLASTICITY; CHOLESTEROL; HIPPOCAMPUS	A diet high in saturated fat and similar in composition to western diets (WD) has been shown to exacerbate injury following traumatic brain injury. Thus, we investigated the effects of a WD on cell death and functional outcome following global ischemia. First we assessed the effects of a 60-day WD regimen on temperature, activity and glucose levels in normal rats (Experiment 1). Second, we evaluated the influence of a 60-day WD regimen on hippocampal CA1 injury and learning and memory impairments following global ischemia in rats (Experiment 2). Male Sprague-Dawley rats, obtained at similar to 50 g, were randomly assigned to either the WD or the low-fat control diet (CD). Animals were fed for 30 days, then subjected to surgery (body temperature probe implantation in experiment 1; forebrain ischemia in experiment 2), and then they stayed on the same diet for another 30 days. Two and 4 weeks following surgery, learning and memory were assessed using the Morris Water Maze. At 60 days, rats were killed and viable hippocampal CA1 cells were quantified. Results from experiment 1 revealed no differences in glucose or temperature profiles between animals fed the WD and CD; however, WD animals were significantly less active than CD animals. Eight minutes of ischemia in experiment 2 induced severe hippocampal CA1 cell loss (similar to 90%) and learning and memory impairments relative to non-ischemic controls. However, the WD did not exacerbate CA1 injury or behavioural deficits. These findings suggest that a 60-day WD regimen does not significantly influence recovery following global ischemia. (C) 2008 Elsevier B.V. All rights reserved.	[Arvanitidis, Anastasia P.; Colbourne, Frederick] Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; [Corbett, Dale] Mem Univ Newfoundland, St John, NF, Canada; [Colbourne, Frederick] Univ Alberta, Ctr Neurosci, Edmonton, AB T6G 2E9, Canada	Colbourne, F (corresponding author), Univ Alberta, Dept Psychol, P217 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.	fcolbour@ualberta.ca	Colbourne, Frederick/ABB-7774-2020; Corbett, Dale/D-6625-2011	Colbourne, Frederick/0000-0002-9567-2082; Corbett, Dale/0000-0003-0217-4576	Canadian Stroke Network (CSN); Alberta Heritage Foundation for Medical Research (AHFMR)Alberta Heritage Foundation for Medical Research	Research supported by a grant from the Canadian Stroke Network (CSN) to FC who is an Alberta Heritage Foundation for Medical Research (AHFMR) Senior Medical Scholar. APA is supported by the department of Psychology at the University of Alberta. The authors gratefully acknowledge M. Penner and L. Tong for their technical assistance.	Bobyn PJ, 2005, EXP NEUROL, V196, P308, DOI 10.1016/j.expneurol.2005.08.006; Brown RW, 2000, DEV PSYCHOBIOL, V37, P238, DOI 10.1002/1098-2302(2000)37:4<238::AID-DEV4>3.0.CO;2-J; COLBOURNE F, 1993, BRAIN RES, V602, P264, DOI 10.1016/0006-8993(93)90691-F; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Ding EL, 2006, SEMIN NEUROL, V26, P11, DOI 10.1055/s-2006-933305; GERHARDT SC, 1988, BEHAV NEUROSCI, V102, P301, DOI 10.1037/0735-7044.102.2.301; Gillman MW, 1997, JAMA-J AM MED ASSOC, V278, P2145, DOI 10.1001/jama.278.24.2145; Greenwood CE, 1996, BEHAV NEUROSCI, V110, P451, DOI 10.1037/0735-7044.110.3.451; GREENWOOD CE, 1990, BEHAV NEURAL BIOL, V53, P74, DOI 10.1016/0163-1047(90)90831-P; He K, 2003, BRIT MED J, V327, P777, DOI 10.1136/bmj.327.7418.777; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Li PA, 1997, ACTA PHYSIOL SCAND, V161, P567, DOI 10.1046/j.1365-201X.1997.00264.x; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Morris MC, 2004, NEUROLOGY, V62, P1573, DOI 10.1212/01.WNL.0000123250.82849.B6; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P194, DOI 10.1001/archneur.60.2.194; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Myers RE, 1979, ADV PERINATAL NEUROL, V1, P85; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; REED DM, 1988, STROKE, V19, P820, DOI 10.1161/01.STR.19.7.820; Sauvaget C, 2004, STROKE, V35, P1531, DOI 10.1161/01.STR.0000130426.52064.09; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; WEBER KO, 1989, CEREBRAL ISCHEMIA CA, P79; WINOCUR G, 1993, PSYCHOBIOLOGY, V21, P286; Winocur G, 1999, BEHAV BRAIN RES, V101, P153, DOI 10.1016/S0166-4328(98)00147-8; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	35	19	20	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 3	2009	1252						192	200		10.1016/j.brainres.2008.11.058			9	Neurosciences	Neurosciences & Neurology	407WK	WOS:000263394800018	19071094				2021-06-18	
J	Grip, H; Jull, G; Treleaven, J				Grip, Helena; Jull, Gwendolen; Treleaven, Julia			HEAD EYE CO-ORDINATION USING SIMULTANEOUS MEASUREMENT OF EYE IN HEAD AND HEAD IN SPACE MOVEMENTS: POTENTIAL FOR USE IN SUBJECTS WITH A WHIPLASH INJURY	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						whiplash; head eye coordination; head movement; gaze stability; eye disturbances; monitoring		Objective. Describe reproducibility of a measurement method to investigate deficits in eye-head co-ordination. Methods. Combined recordings of head and eye rotation using wireless motion sensors and electrooculography (EOG) were used as an initial step towards a method to quantify eye-head co-ordination deficits. Head rotation to the side during gaze fixation and sequential head and eye movements were studied on 20 asymptomatic control subjects and six subjects with chronic whiplash disorders. All included whiplash subjects reported eye disturbances according to a vision symptom questionnaire. Results. The trial-to-trial reproducibility was moderate to high for 24 of 28 variables (Intraclass Correlation Coefficient 0.44 to 0.87). Velocity gain (ratio of eye and head velocities) was on average close to unity in both groups. Head stability was high in control subjects, while three of six whiplash subjects demonstrated head instability during eye movement. Whiplash subjects also demonstrated a decreased range of head movement during gaze fixation and lower head velocities as compared with the asymptomatics. Conclusions. The method of combined head and eye motion appears to give accurate, repeatable measurements. Case studies of whiplash subjects indicated deficits in head eye co-ordination. The method could be useful in further clinical research into eye and head movement in those with neck disorders.	[Grip, Helena; Treleaven, Julia] Umea Univ Hosp, Dept Biomed Engn & Informat, S-90185 Umea, Sweden; [Jull, Gwendolen] Univ Queensland, Whiplash Res Unit, Div Physiotherapy, Brisbane, Qld 4072, Australia	Grip, H (corresponding author), Umea Univ Hosp, Dept Biomed Engn & Informat, S-90185 Umea, Sweden.	helena.grip@vll.se	Treleaven, Julia/N-1379-2019; Jull, Gwendolen/F-4233-2010; Treleaven, Julia M/F-8734-2010	Treleaven, Julia/0000-0002-6258-3972; Jull, Gwendolen/0000-0003-2670-1318; Treleaven, Julia M/0000-0002-6258-3972; Grip, Helena/0000-0003-1635-122X			Allison RS, 1996, IEEE T BIO-MED ENG, V43, P1073, DOI 10.1109/10.541249; Brown M, 2006, DOC OPHTHALMOL, V113, P205, DOI 10.1007/s10633-006-9030-0; COLE GK, 1993, J BIOMECH ENG-T ASME, V115, P344, DOI 10.1115/1.2895496; Collewijn H, 2000, J NEUROPHYSIOL, V84, P376; Corneil BD, 2002, J NEUROPHYSIOL, V88, P1980, DOI 10.1152/jn.2002.88.4.1980; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Grip H, 2003, IEEE T INF TECHNOL B, V7, P412, DOI 10.1109/TITB.2003.821322; Grip H, 2007, CLIN BIOMECH, V22, P865, DOI 10.1016/j.clinbiomech.2007.05.008; Hansson EE, 2006, J REHABIL MED, V38, P387, DOI 10.1080/16501970600768992; Hirvonen M, 2007, ARCH OTOLARYNGOL, V133, P157, DOI 10.1001/archotol.133.2.157; Hulse M, 2000, HNO, V48, P295, DOI 10.1007/s001060050569; Humphreys BK, 2002, J WHIPLASH RELATED D, V1, P99, DOI DOI 10.3109/J180V0LN01_09; Jasiewicz JM, 2007, MANUAL THER, V12, P380, DOI 10.1016/j.math.2006.07.005; Joyce CA, 2002, PSYCHOPHYSIOLOGY, V39, P607, DOI 10.1017/S0048577202394113; Jull G, 2007, J ORTHOP RES, V25, P404, DOI 10.1002/jor.20220; JURGENS R, 1989, EXP BRAIN RES, V77, P381, DOI 10.1007/BF00274995; Kelders WPA, 2005, J NEUROTRAUM, V22, P133, DOI 10.1089/neu.2005.22.133; Kimpo RR, 2005, J NEUROPHYSIOL, V94, P3092, DOI 10.1152/jn.00048.2005; Land MF, 2006, PROG RETIN EYE RES, V25, P296, DOI 10.1016/j.preteyeres.2006.01.002; Mergner T, 1998, EXP BRAIN RES, V120, P450, DOI 10.1007/s002210050418; Migliaccio AA, 2006, VISION RES, V46, P2475, DOI 10.1016/j.visres.2006.02.008; Montfoort I, 2006, INVEST OPHTH VIS SCI, V47, P2881, DOI 10.1167/iovs.05-1561; NORTH ALVIN W., 1965, INVEST OPHTHALMOL, V4, P343; Pereira MJ, 2008, ARCH PHYS MED REHAB, V89, P1097, DOI 10.1016/j.apmr.2007.10.044; Proudlock FA, 2003, INVEST OPHTH VIS SCI, V44, P2991, DOI 10.1167/iovs.02-1315; REVEL M, 1994, ARCH PHYS MED REHAB, V75, P895, DOI 10.1016/0003-9993(94)90115-5; Ronsse R, 2007, J NEUROSCI METH, V159, P158, DOI 10.1016/j.jneumeth.2006.06.016; SPITZER WO, 1995, SPINE, V20, pS1; Stahl JS, 2001, EXP BRAIN RES, V136, P200, DOI 10.1007/s002210000593; Storaci R, 2006, EUR SPINE J, V15, P1811, DOI 10.1007/s00586-006-0085-0; Tjell C, 1998, AM J OTOL, V19, P76; Treleaven J, 2005, J REHABIL MED, V37, P219, DOI 10.1080/16501970410024299; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; WERNER J, 1980, NEUROSCIENCE CLIN PE; Yakushin SB, 2005, J NEUROPHYSIOL, V93, P3693, DOI 10.1152/jn.01269.2004; YOUNG LR, 1975, AM PSYCHOL, V30, P315, DOI 10.1037/0003-066X.30.3.315	37	19	19	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307			J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	FEB	2009	23	1					31	40		10.1007/s10877-009-9160-5			10	Anesthesiology	Anesthesiology	V20OZ	WOS:000208150600004	19199060				2021-06-18	
J	Tong, M; Holmes, GM				Tong, M.; Holmes, G. M.			Gastric dysreflexia after acute experimental spinal cord injury in rats	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						gastric motility; neurotrauma; receptive relaxation reflex; vagovagal reflex	VAGO-VAGAL REFLEX; GASTROINTESTINAL TRANSIT; AUTONOMIC DYSREFLEXIA; AFFERENT-FIBERS; RELAXATION; NEURONS; TRANSECTION; PATHWAYS; MOTILITY; NUCLEUS	Gastric reflexes are mediated mainly by vago-vagal reflex circuits in the caudal medulla. Despite the fact that brainstem vago-vagal circuitry remains intact after spinal cord injury (SCI), patients with SCI at the cervical level most often present gastric stasis with an increased risk of reflux and aspiration of gastric contents. Using a miniature strain gauge sutured to the gastric surface; we tested gastric motility and reflexive gastric relaxation following oesophageal distension (oesophageal-gastric relaxation reflex) in animals 3 days after a severe spinal contusion at either the third or ninth thoracic spinal segment (acute T3- or T9 SCI, respectively). Both basal gastric motility and the oesophageal-gastric relaxation reflex were significantly diminished in animals with T3 SCI. Conversely, both basal gastric motility and the oesophageal-gastric relaxation reflex were not significantly reduced in T9 SCI animals compared to controls. The reduced gastric motility and oesophageal-gastric reflex in T3 SCI rats was not ameliorated by celiac sympathectomy. Our results show that gastric stasis following acute SCI is independent of altered spinal sympathetic input to the stomach caudal to the lesion. Our data suggest that SCI may alter the sensitivity of vagal reflex function, perhaps by interrupting ascending spinosolitary input to brainstem vagal nuclei.	[Tong, M.; Holmes, G. M.] Louisiana State Univ, Pennington Biomed Res Ctr, Neurotrauma & Nutr Lab, Baton Rouge, LA 70808 USA	Holmes, GM (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Neurotrauma & Nutr Lab, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	holmesgm@pbrc.edu			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [49177]; Pennington Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK072476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049177] Funding Source: NIH RePORTER	The authors extend a special note of thanks to Drs R. Alberto Travagli, Kirsteen Browning and Stefany Primeaux for their commentary during the preparation of the manuscript. We thank Emily Creekmore for her assistance with data collection and analysis. We thank Dr Barry Robert, Cynthia Kloster, Hsin (Frank) Hsu and Shannon Sterba for their technical assistance. Grants: This work was supported by NINDS grant #49177 and the Pennington Foundation.	ABRAHAMSSON H, 1973, ACTA PHYSIOL SCAND, P1; ABRAHAMSSON H, 1969, ACTA PHYSIOL SCAND, V77, P172, DOI 10.1111/j.1748-1716.1969.tb04561.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BERLLY MH, 1984, ARCH PHYS MED REHAB, V65, P687; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; BUELKESAM J, 1978, LAB ANIM SCI, V28, P157; Cannon WB, 1911, AM J PHYSIOL, V29, P267; Cosman B C, 1991, J Am Paraplegia Soc, V14, P175; Dwyer KM, 2002, J TRAUMA, V52, P26, DOI 10.1097/00005373-200201000-00007; EUCHNERWAMSER I, 1993, J NEUROPHYSIOL, V69, P868; FEALEY RD, 1984, GASTROENTEROLOGY, V87, P69; Fukuda H, 2005, NEUROGASTROENT MOTIL, V17, P245, DOI 10.1111/j.1365-2982.2004.00602.x; Gamboa-Esteves FO, 2001, BRAIN RES, V921, P195, DOI 10.1016/S0006-8993(01)03118-3; Gillis R. A., 1989, HDB PHYSL 6, P621; Gondim FAA, 1999, SPINAL CORD, V37, P793, DOI 10.1038/sj.sc.3100923; Gondim FDA, 2001, AUTON NEUROSCI-BASIC, V87, P52; HERMANN G, 1995, NEUROIMMUNOMODULAT, V2, P74, DOI 10.1159/000096874; Hermann GE, 2006, AM J PHYSIOL-REG I, V290, pR1570, DOI 10.1152/ajpregu.00717.2005; Holmes GM, 2005, EXP NEUROL, V193, P29, DOI 10.1016/j.expneurol.2005.01.002; JANSSON G, 1969, ACTA PHYSIOL SCAND, V75, P245, DOI 10.1111/j.1748-1716.1969.tb04376.x; Kabatas S, 2008, NEUROSCIENCE, V154, P1627, DOI 10.1016/j.neuroscience.2008.04.071; Kao CH, 1999, DIGEST DIS SCI, V44, P1512, DOI 10.1023/A:1026690305537; KEWALRAMANI LS, 1979, J TRAUMA, V19, P259, DOI 10.1097/00005373-197904000-00008; Kirshblum SC, 2002, ARCH PHYS MED REHAB, V83, pS50, DOI 10.1053/apmr.2002.32156; Krantis A, 1998, AM J PHYSIOL-GASTR L, V275, pG897; Krowicki ZK, 1999, J AUTONOM NERV SYST, V77, P83, DOI 10.1016/S0165-1838(99)00033-8; Laird AS, 2006, J PHYSIOL-LONDON, V577, P539, DOI 10.1113/jphysiol.2006.116301; Leal P. R., 2007, Autonomic & Autacoid Pharmacology, V27, P167, DOI 10.1111/j.1474-8673.2007.00408.x; Leal PRL, 2008, AUTON NEUROSCI-BASIC, V141, P66, DOI 10.1016/j.autneu.2008.05.006; Lu WY, 1998, AM J PHYSIOL-REG I, V274, pR1436; Lu WY, 1998, AM J PHYSIOL-REG I, V274, pR1425; Maiorov DN, 1997, AM J PHYSIOL-HEART C, V272, pH625; MCCANN MJ, 1992, J PHYSIOL-LONDON, V453, P401, DOI 10.1113/jphysiol.1992.sp019235; MCCANN MJ, 1994, INNERVATION OF THE GUT, P81; Medeiros BA, 2008, AUTON NEUROSCI-BASIC, V139, P24, DOI 10.1016/j.autneu.2007.12.003; MENETREY D, 1991, EUR J NEUROSCI, V3, P249, DOI 10.1111/j.1460-9568.1991.tb00087.x; MENETREY D, 1987, J COMP NEUROL, V255, P439, DOI 10.1002/cne.902550310; NEUHUBER W, 1979, ANAT EMBRYOL, V155, P355, DOI 10.1007/BF00317648; NINOMURCIA M, 1992, AM J ROENTGENOL, V158, P279, DOI 10.2214/ajr.158.2.1729781; Oakley PA, 2001, RESUSCITATION, V48, P37, DOI 10.1016/S0300-9572(00)00316-6; ORMSBEE HS, 1976, AM J PHYSIOL, V230, P389; Ozaki N, 2001, AM J PHYSIOL-GASTR L, V281, pG1449; Powley TL, 2004, PHYSIOL BEHAV, V82, P69, DOI 10.1016/j.physbeh.2004.04.037; Primeaux SD, 2007, AM J PHYSIOL-REG I, V293, pR1102, DOI 10.1152/ajpregu.00224.2007; Qin C, 2003, AUTON NEUROSCI-BASIC, V109, P10, DOI 10.1016/j.autneu.2003.08.005; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rabchevsky AG, 2006, PROG BRAIN RES, V152, P265, DOI 10.1016/S0079-6123(05)52017-X; RAJENDRAN SK, 1992, AM J GASTROENTEROL, V87, P1614; RENEHAN WE, 1995, AM J PHYSIOL-GASTR L, V268, pG780; Rogers RC, 1999, J PHYSIOL-LONDON, V514, P369, DOI 10.1111/j.1469-7793.1999.369ae.x; Rogers RC, 2003, AM J PHYSIOL-REG I, V285, pR479, DOI 10.1152/ajpregu.00155.2003; Rogers RC, 1996, NEUROSCI BIOBEHAV R, V20, P57, DOI 10.1016/0149-7634(95)00040-L; Roman C., 1987, PHYSL GASTROINTESTIN, P507; SEGAL JL, 1995, AM J GASTROENTEROL, V90, P466; Sengupta J. N., 2000, American Journal of Medicine, V108, p87S; SENGUPTA JN, 1989, J NEUROPHYSIOL, V61, P1001; STINNEFORD JG, 1993, PARAPLEGIA, V31, P384, DOI 10.1038/sc.1993.64; TAKAHASHI T, 1995, J PHYSIOL-LONDON, V484, P481, DOI 10.1113/jphysiol.1995.sp020680; Takahashi T, 1997, J PHYSIOL-LONDON, V504, P479, DOI 10.1111/j.1469-7793.1997.479be.x; Travagli RA, 2006, ANNU REV PHYSIOL, V68, P279, DOI 10.1146/annurev.physiol.68.040504.094635; TRAVAGLI RA, 2004, NEUROGASTROENTEROLOG; Weaver LC, 2006, PROG BRAIN RES, V152, P245, DOI 10.1016/S0079-6123(05)52016-8; Wolf C, 2003, SPINAL CORD, V41, P347, DOI 10.1038/sj.sc.3101440; Yamada M, 2006, NEUROSCI RES, V54, P261, DOI 10.1016/j.neures.2005.12.007; ZAGON A, 1993, NEUROSCIENCE, V54, P729, DOI 10.1016/0306-4522(93)90243-9	66	19	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1350-1925	1365-2982		NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	FEB	2009	21	2					197	206		10.1111/j.1365-2982.2008.01215.x			10	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	397UT	WOS:000262688300013	19126185	Green Accepted			2021-06-18	
J	Aghakhani, N; Durand, P; Chevret, L; Parker, F; Devictor, D; Tardieu, M; Tadie, M				Aghakhani, Nozar; Durand, Philippe; Chevret, Laurent; Parker, Fabrice; Devictor, Denis; Tardieu, Marc; Tadie, Marc			Decompressive craniectomy in children with nontraumatic refractory high intracranial pressure Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						craniectomy; intracranial hypertension; outcome; pediatric neurosurgery	HERPES-SIMPLEX ENCEPHALITIS; TRAUMATIC BRAIN-INJURY; SCORE	Object. In this study, the authors investigated the clinical efficacy of decompressive craniectomy treatments for nontraumatic intracranial hypertension in children. Methods. Seven patients with nontraumatic refractory high intracranial pressure (ICP) were enrolled in the study between 1995 and 2005; there were 2 boys and 5 girls with a mean age of 9 years (range 4-14). Decompressive craniectomy was performed in all patients after standard medical therapy had proven insufficient and ICP remained > 50 mm Hg. All patients had a Glasgow Coma Scale score < 8 at admission and a mean Pediatric Risk of Mortality Scale score of 20 (range 10-27). Results. One patient died of persistent high ICP and circulatory failure 48 hours after surgery. Six months later, according to their Glasgow Outcome Scale scores, 3 patients had adequate recoveries, 2 patients recovered with moderate disabilities, and 1 patient had severe disabilities. According to the Pediatric Overall Performance Category Scale, 4 patients received a score of 2 (mild disability), 1 a score of 3 (moderate disability), and 1 a score of 4 (severe disability). Five patients returned to school and normal life. Conclusions. The authors found decompressive craniectomy to be an effective and lifesaving technique in children. This procedure should be included in the arsenal of treatments for nontraumatic intracranial hypertension.	[Aghakhani, Nozar; Parker, Fabrice; Tadie, Marc] Bicetre Univ Hosp, Dept Neurosurg, F-94275 Le Kremlin Bicetre, France; [Tardieu, Marc] Bicetre Univ Hosp, Dept Pediat Neurol, F-94275 Le Kremlin Bicetre, France; [Durand, Philippe; Chevret, Laurent; Devictor, Denis] Bicetre Univ Hosp, Pediat Intens Care Unit, F-94275 Le Kremlin Bicetre, France	Aghakhani, N (corresponding author), Bicetre Univ Hosp, Dept Neurosurg, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	nozar.aghakhani@bct.aphp.fr		aghakhani, nozar/0000-0001-8389-8167			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Ausman J I, 1976, Surg Neurol, V6, P97; Bayram N, 2008, EUR J PEDIATR, V167, P821, DOI 10.1007/s00431-007-0566-0; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHI C-S, 1990, Acta Paediatrica Japonica, V32, P426; Ebel H, 1999, CHILD NERV SYST, V15, P84, DOI 10.1007/s003810050337; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; GREENGARD J, 1962, JAMA-J AM MED ASSOC, V180, P660, DOI 10.1001/jama.1962.03050210022005; JENNETT B, 1975, LANCET, V1, P480; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; Simma B, 2002, INTENS CARE MED, V28, P1000, DOI 10.1007/s00134-002-1333-3; Taferner E, 2001, INTENS CARE MED, V27, P1426, DOI 10.1007/s001340101027; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Yan HJ, 2002, SURG NEUROL, V57, P20, DOI 10.1016/S0090-3019(01)00688-7	19	19	19	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROS-PEDIATR	J. Neurosurg.-Pediatr.	JAN	2009	3	1					66	69		10.3171/2008.10.PEDS08116			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	388LA	WOS:000262020100013	19119908				2021-06-18	
J	Blanchet, S; Paradis-Giroux, AA; Pepin, M; Mckerral, M				Blanchet, Sophie; Paradis-Giroux, Andree-Anne; Pepin, Michel; Mckerral, Michelle			Impact of divided attention during verbal learning in young adults following mild traumatic brain injury	BRAIN INJURY			English	Article						Episodic memory; attention; executive processes; mild head injury	EVENT-RELATED POTENTIALS; HEAD-INJURY; EPISODIC MEMORY; OLDER-ADULTS; RETRIEVAL; SYMPTOMS; PERFORMANCE; TOMOGRAPHY; CONCUSSION; STRATEGY	Primary objective: The goal of the present study was to assess the impact of mild traumatic brain injury (MTBI) on episodic memory performance in relation to attentional and executive control processes in young adults. Research design/methods: A verbal memory paradigm manipulating attentional load (full attention or divided attention) and semantic congruency between pairs of category-target words during encoding was administrated to 13 individuals with MTBI and 12 normal control participants. Environmental supports during retrieval (free recall, cued recall and recognition modes) were also manipulated. Main outcomes and results: Results show that recall performances of individuals with MTBI were similar to those of controls when words were encoded under full attention. In contrast, individuals with MTBI performed worse than control participants when encoding under divided attention, whatever the semantic link between pairs of words. Conclusions: By using a sensitive test, one was able to objectively measure subtle impairments in memory performance, suggesting a diminished availability of attentional resources after MTBI. Young adults' learning of verbal material under divided attention might be compromised by the reduction of cognitive resources following MTBI. These findings are also discussed in light of different factors that can influence cognitive performance.	[Blanchet, Sophie; Paradis-Giroux, Andree-Anne; Pepin, Michel] Inst Readaptat Deficience Phys Quebec, Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ G1M 2S8, Canada; [Blanchet, Sophie; Paradis-Giroux, Andree-Anne; Pepin, Michel] Univ Laval, Sch Psychol, Quebec City, PQ, Canada; [Mckerral, Michelle] Ctr Readaptat Lucie Bruneau, Ctr Interdisciplinary Res Rehabil Greater Montrea, Montreal, PQ, Canada; [Mckerral, Michelle] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada	Blanchet, S (corresponding author), Inst Readaptat Deficience Phys Quebec, Ctr Interdisciplinary Res Rehabil & Social Integr, 525 Blvd Hamel Est, Quebec City, PQ G1M 2S8, Canada.	sophie.blanchet@rea.ulaval.ca		Paradis-Giroux, Andree-Anne/0000-0003-0527-6439			Anderson ND, 2000, J COGNITIVE NEUROSCI, V12, P775, DOI 10.1162/089892900562598; Anderson ND, 1998, PSYCHOL AGING, V13, P405, DOI 10.1037/0882-7974.13.3.405; BADDELEY A, 1984, J EXP PSYCHOL GEN, V113, P518, DOI 10.1037/0096-3445.113.4.518; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1996, J EXPT PSYCHOL A, V49, P5, DOI DOI 10.1080/713755608; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BERSTAIN M, 2002, J INT NEUROPSYCH SOC, V8, P673; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bouchard S, 1996, CAN J AGING, V15, P500, DOI 10.1017/S0714980800009387; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Conners C. K., 1995, CONNERS CONTINUOUS P; Craik FIM, 1996, J EXP PSYCHOL GEN, V125, P159, DOI 10.1037/0096-3445.125.2.159; Desrochers A, 2000, CAN J EXP PSYCHOL, V54, P274, DOI 10.1037/h0087347; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DUBORD S, 2000, B PSYCHOL, V53, P185; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; FAVREAU M, 1980, SEMANTIC CATEGORY NO; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Guerin F, 2006, NEUROREHABILITATION, V21, P295; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Iidaka T, 2000, J COGNITIVE NEUROSCI, V12, P267, DOI 10.1162/089892900562093; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCauley S. R., 2007, J CLIN EXPT NEUROPSY, V25, P1; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; MOSCOVITCH M, 1992, J COGNITIVE NEUROSCI, V4, P257, DOI 10.1162/jocn.1992.4.3.257; Moscovitch M, 1990, MODULAR DEFICITS ALZ, P1; Moscovitch M., 1994, NEUROPSYCHOLOGY, V8, P524, DOI DOI 10.1037/0894-4105.8.4.524; Naveh-Benjamin M, 2004, PSYCHON B REV, V11, P1067, DOI 10.3758/BF03196738; Naveh-Benjamin M, 2003, MEM COGNITION, V31, P1021, DOI 10.3758/BF03196123; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; PAIVIO A, 1973, COGNITIVE PSYCHOL, V5, P176, DOI 10.1016/0010-0285(73)90032-7; PAIVIO A, 1991, CAN J PSYCHOL, V45, P255, DOI 10.1037/h0084295; PAIVIO A, 1975, PSYCHOL LEARN MOTIV, P179; PEPIN M, 2004, TIFA VERSION EXPT 1; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Raskin SA, 1997, BRAIN INJURY, V11, P587, DOI 10.1080/026990597123287; Regard M, 1981, THESIS U VICTORIA; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A., 1958, LEXAMEN CLINIQUE PSY; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Signoret J. L, 1991, BATTERIE EFFICIENCE, V144; Toglia MP, 1997, PERCEPT MOTOR SKILL, V84, P976, DOI 10.2466/pms.1997.84.3.976; Tulving E, 1983, ELEMENTS EPISODIC ME; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANDERLINDEN M, 1987, QUESTIONNAIRE AUTO; WECHSLER D, 1997, MEM 3 ECHELLE CLIN M, V3; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	63	19	19	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	2					111	122	PII 908462980	10.1080/02699050802649688			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403LD	WOS:000263083200005	19191090				2021-06-18	
S	Kawase, M; Sakagami, H; Motohashi, N		Motohashi, N		Kawase, Masami; Sakagami, Hiroshi; Motohashi, Noboru			The Chemistry of Bioactive Mesoionic Heterocycles	BIOACTIVE HETEROCYCLES VII: FLAVONOIDS AND ANTHOCYANINS IN PLANTS, AND LATEST BIOACTIVE HETEROCYCLES II	Topics in Heterocyclic Chemistry		English	Article; Book Chapter						Mesoionic; Sydnones; Sydnonimines; 1,2,3,4-Oxatriazolium-5-aminates; 1,3,4-Thiadiazolium-2-aminides	NITRIC-OXIDE DONORS; SUBSTITUTED OXATRIAZOLE-5-IMINE DERIVATIVES; HUMAN LYMPHOCYTE-PROLIFERATION; ENERGY-LINKED FUNCTIONS; TRAUMATIC BRAIN-INJURY; RAT-LIVER MITOCHONDRIA; INDUCED CELL-DEATH; COMPOUND MI-D; BIOLOGICAL EVALUATION; ANTIOXIDANT ACTIVITY	This review focuses on the latest developments in biologically interesting mesoionic compounds, such as sydnones, sydnonimines, 1,2,3,4-oxatriazolium-5-aminates, and 1,3,4-thiadiazolium-2-aminides, mainly since 2000.	[Kawase, Masami] Matsuyama Univ, Fac Pharmaceut Sci, Matsuyama, Ehime 7908578, Japan; [Sakagami, Hiroshi] Meikai Univ, Sch Dent, Saitama 3500238, Japan; [Motohashi, Noboru] Meiji Pharmaceut Univ, Tokyo 2048588, Japan	Kawase, M (corresponding author), Matsuyama Univ, Fac Pharmaceut Sci, 4-2 Bunkyo Cho, Matsuyama, Ehime 7908578, Japan.	kawase@cc.matsuyama-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20590114] Funding Source: KAKEN		Anderzhanova EA, 2000, ANN NY ACAD SCI, V914, P137, DOI 10.1111/j.1749-6632.2000.tb05191.x; Azarifar D, 2006, SYNTHESIS-STUTTGART, P1123, DOI 10.1055/s-2006-926380; BIEBER TI, 1955, CHEM IND-LONDON, P910; BROOKES P, 1957, J CHEM SOC, P4409, DOI 10.1039/jr9570004409; Bryan-Lluka LJ, 2004, BRIT J PHARMACOL, V143, P63, DOI 10.1038/sj.bjp.0705904; Cadena SMSC, 2002, CELL BIOCHEM FUNCT, V20, P31, DOI 10.1002/cbf.932; Cadena SMSC, 1998, FEBS LETT, V440, P46, DOI 10.1016/S0014-5793(98)01427-6; Cai TB, 2005, J ORG CHEM, V70, P3518, DOI 10.1021/jo050010o; Cardoso JC, 2004, DRUG DEVELOP RES, V61, P207, DOI 10.1002/ddr.10354; Choi KM, 2007, NEUROGASTROENT MOTIL, V19, P585, DOI 10.1111/j.1365-2982.2007.00936.x; Corell Tim, 1994, Polish Journal of Pharmacology, V46, P553; da Silva EF, 2002, EUR J MED CHEM, V37, P979, DOI 10.1016/S0223-5234(02)01401-0; Dunkley CS, 2003, BIOORG MED CHEM LETT, V13, P2899, DOI 10.1016/S0960-894X(03)00487-6; Ferry-Dumazet H, 2002, LEUKEMIA, V16, P708, DOI 10.1038/sj.leu.2402404; FINNEGAN WG, 1965, J ORG CHEM, V30, P567, DOI 10.1021/jo01013a066; Fischer E., 1882, LIEBIGS ANN CHEM, V212, P316, DOI DOI 10.1002/JLAC.18822120303; Gasco A, 2005, NITRIC OXIDE DONORS: FOR PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS, P131, DOI 10.1002/3527603751.ch6; Gryglewski RJ, 2002, CURR PHARM DESIGN, V8, P167, DOI 10.2174/1381612023396311; GRYNBERG N, 1992, ANTICANCER RES, V12, P1025; Grynberg N, 1997, ANTI-CANCER DRUG, V8, P88, DOI 10.1097/00001813-199701000-00012; Halila GC, 2007, CHEM-BIOL INTERACT, V169, P160, DOI 10.1016/j.cbi.2007.06.003; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Herman AG, 2005, EUR HEART J, V26, P1945, DOI 10.1093/eurheartj/ehi333; Holm P, 1998, EUR J PHARMACOL, V346, P97, DOI 10.1016/S0014-2999(98)00009-0; Hsu MF, 2006, EUR J PHARMACOL, V535, P43, DOI 10.1016/j.ejphar.2006.02.013; Kankaanranta H, 1997, MOL PHARMACOL, V51, P882; Kankaanranta H, 1996, BRIT J PHARMACOL, V117, P401, DOI 10.1111/j.1476-5381.1996.tb15204.x; Kato H, 1957, NIPPON KAGAKU ZASSHI, V78, P707; KIER LB, 1967, J PHARM SCI, V56, P149, DOI 10.1002/jps.2600560202; Kojima S, 2006, EUR J PHARMACOL, V550, P162, DOI 10.1016/j.ejphar.2006.08.047; Kosonen O, 1997, EUR J PHARMACOL, V337, P55, DOI 10.1016/S0014-2999(97)01266-1; Kosonen O, 1998, BRIT J PHARMACOL, V125, P247, DOI 10.1038/sj.bjp.0702042; Kosonen O, 1998, J PHARMACOL EXP THER, V286, P215; Lahteenmaki T, 1998, BRIT J PHARMACOL, V125, P402, DOI 10.1038/sj.bjp.0702076; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Laursen BE, 2006, CARDIOVASC DRUG REV, V24, P247, DOI 10.1111/j.1527-3466.2006.00247.x; Lee CS, 2007, LIFE SCI, V80, P1759, DOI 10.1016/j.lfs.2007.02.003; Lee CS, 2005, BRAIN RES, V1036, P18, DOI 10.1016/j.brainres.2004.12.036; Luchowski P, 2007, EUR J PHARMACOL, V563, P130, DOI 10.1016/j.ejphar.2007.02.044; Marcos E, 2003, AM J RESP CRIT CARE, V168, P487, DOI 10.1164/rccm.200210-1212OC; Martinet W, 2007, BRIT J PHARMACOL, V152, P493, DOI 10.1038/sj.bjp.0707426; MASUDA K, 1971, CHEM PHARM BULL, V19, P559; McGrowder D., 2006, INT J PHARMACEUT, V2, P366, DOI DOI 10.3923/IJP.2006.366.373; Meij JTA, 2004, MOL PHARMACOL, V66, P1043, DOI 10.1124/mol.104.001354; Miller MR, 2007, BRIT J PHARMACOL, V151, P305, DOI 10.1038/sj.bjp.0707224; MONCADA S, 1995, FASEB J, V9, P1319; Moustafa MA, 2004, ARCH PHARM, V337, P427, DOI 10.1002/ardp.200300847; Moustafa MA, 2004, ARCH PHARM, V337, P164, DOI 10.1002/ardp.200300814; NEWTON CG, 1982, TETRAHEDRON, V38, P2965, DOI 10.1016/0040-4020(82)80186-5; Ollis W. D., 1976, ADV HETEROCYCL CHEM, V19, P1, DOI [DOI 10.1016/S0065-2725(08)60230-5, 10.1016/s0065-2725(08)60230-5]; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Patel KP, 2001, EXP BIOL MED, V226, P814; Pitsikas N, 2005, NEUROBIOL AGING, V26, P259, DOI 10.1016/j.neurobiolaging.2004.04.003; Pitsikas N, 2007, EUR J PHARMACOL, V571, P174, DOI 10.1016/j.ejphar.2007.06.019; Rabkin SW, 2007, AUTOPHAGY, V3, P347, DOI 10.4161/auto.4054; Rabkin SW, 2007, NITRIC OXIDE-BIOL CH, V16, P339, DOI 10.1016/j.niox.2006.10.007; Rodrigues RF, 2007, EUR J MED CHEM, V42, P1039, DOI 10.1016/j.ejmech.2006.12.026; Schrammel A, 1998, MOL PHARMACOL, V54, P207; Schwenke DO, 2007, CLIN EXP PHARMACOL P, V34, P88, DOI 10.1111/j.1440-1681.2007.04544.x; Schwenke DO, 2005, CLIN EXP PHARMACOL P, V32, P952, DOI 10.1111/j.1440-1681.2005.4290.x; Senff-Ribeiro A, 2004, BRIT J CANCER, V91, P297, DOI 10.1038/sj.bjc.6601946; Senff-Ribeiro A, 2004, ANTI-CANCER DRUG, V15, P269, DOI 10.1097/00001813-200403000-00012; Senff-Ribeiro A, 2003, MELANOMA RES, V13, P465, DOI 10.1097/00008390-200310000-00005; Shih MH, 2007, TETRAHEDRON, V63, P2990, DOI 10.1016/j.tet.2007.01.066; Shih MH, 2007, CHEM PHARM BULL, V55, P1126, DOI 10.1248/cpb.55.1126; Shih MH, 2005, TETRAHEDRON, V61, P10917, DOI 10.1016/j.tet.2005.08.107; Shih MH, 2004, BIOORGAN MED CHEM, V12, P4633, DOI 10.1016/j.bmc.2004.06.033; Shih MH, 2003, TETRAHEDRON, V59, P4103, DOI 10.1016/S0040-4020(03)00574-X; Shpak AV, 2005, J CHROMATOGR SCI, V43, P11, DOI 10.1093/chromsci/43.1.11; Siegemund M, 2007, ACTA ANAESTH SCAND, V51, P693, DOI 10.1111/j.1399-6576.2007.01334.x; Sitmo M, 2007, AM J PHYSIOL-GASTR L, V293, pG886, DOI 10.1152/ajpgi.00124.2007; Taylor EL, 2004, BRIT J PHARMACOL, V143, P179, DOI 10.1038/sj.bjp.0705909; Taylor EL, 2007, BIOCHEM PHARMACOL, V74, P1039, DOI 10.1016/j.bcp.2007.06.028; Vilpo JA, 1997, ANTI-CANCER DRUG DES, V12, P75; Vinatier V, 2006, NITRIC OXIDE-BIOL CH, V15, P363, DOI 10.1016/j.niox.2006.03.006; Wang JP, 2003, EUR J PHARMACOL, V458, P243, DOI 10.1016/S0014-2999(02)02790-5; Wang PG, 2002, CHEM REV, V102, P1091, DOI 10.1021/cr000040l; Wiley JW, 2007, NEUROGASTROENT MOTIL, V19, P541, DOI 10.1111/j.1365-2982.2007.00958.x	78	19	19	0	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	1861-9282		978-3-642-00335-6	TOP HETEROCYCL CHEM			2009	16						135	152		10.1007/7081_2007_096	10.1007/978-3-642-00336-3		18	Biochemistry & Molecular Biology; Chemistry, Organic; Food Science & Technology	Biochemistry & Molecular Biology; Chemistry; Food Science & Technology	BKC41	WOS:000267752400004					2021-06-18	
J	Wahlstrom, MR; Olivecrona, M; Nystrom, F; Koskinen, LOD; Naredi, S				Wahlstrom, M. Rodling; Olivecrona, M.; Nystrom, F.; Koskinen, L. -O. D.; Naredi, S.			Fluid therapy and the use of albumin in the treatment of severe traumatic brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							RESPIRATORY-DISTRESS-SYNDROME; SEVERE HEAD-INJURY; ACUTE LUNG INJURY; INTRACRANIAL-PRESSURE; ONCOTIC THERAPY; ORGAN FAILURE; CARE; HYPERTENSION; METAANALYSIS; TRANSFUSION	Evidence-based guidelines for severe traumatic brain injury (TBI) do not include strategies for fluid administration. The protocol used in this study includes albumin administration to maintain normal colloid osmotic pressure and advocates a neutral to slightly negative fluid balance. The aim of this study was to analyze the occurrence of organ failure and the mortality in patients with severe TBI treated by a protocol that includes defined strategies for fluid therapy. Ninety-three patients with severe TBI and Glasgow Coma Score <= 8 were included during 1998-2001. Medical records of the first 10 days were retrieved. Organ dysfunction was evaluated with the Sequential Organ Failure Assessment (SOFA) score. Mortality was assessed after 10 and 28 days, 6 and 18 months. The total fluid balance was positive on days 1-3, and negative on days 4-10. The crystalloid balance was negative from day 2. The mean serum albumin was 38 +/- 6 g/l. Colloids constituted 40-60% of the total fluids given per day. Furosemide was administered to 94% of all patients. Severe organ failure defined as SOFA >= 3 was evident only for respiratory failure, which was observed in 29%. None developed renal failure. After 28 days, mortality was 11% and, after 18 months, it was 14%. A protocol including albumin administration in combination with a neutral to a slightly negative fluid balance was associated with low mortality in patients with severe TBI in spite of a relatively high frequency (29%) of respiratory failure, assessed with the SOFA score.	[Wahlstrom, M. Rodling; Nystrom, F.; Naredi, S.] Umea Univ Hosp, Dept Anesthesia & Intens Care, S-90185 Umea, Sweden; [Olivecrona, M.; Koskinen, L. -O. D.] Umea Univ Hosp, Dept Neurosurg, S-90185 Umea, Sweden	Wahlstrom, MR (corresponding author), Umea Univ Hosp, Dept Anesthesia & Intens Care, S-90185 Umea, Sweden.	marie.rodling@anestesi.umu.se	Koskinen, Lars-Owe/AAQ-8957-2020	Koskinen, Lars-Owe/0000-0003-3528-8502; Naredi, Silvana/0000-0002-4409-6089	Faculty of Medicine; Umea University, Sweden; Vasterbotten Country Council, Sweden	This study was financially supported by the Faculty of Medicine, Umea University, Sweden, and the Vasterbotten Country Council, Sweden.	Abid O, 2000, CRIT CARE MED, V28, P947, DOI 10.1097/00003246-200004000-00006; ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; Dubois MJ, 2006, CRIT CARE MED, V34, P2536, DOI 10.1097/01.CCM.0000239119.57544.0C; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Grande PO, 2008, ACTA ANAESTH SCAND, V52, P738, DOI 10.1111/j.1399-6576.2008.01688.x; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hebert PC, 2007, CHEST, V131, P1583, DOI 10.1378/chest.06-1055; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Mangialardi RJ, 2000, CRIT CARE MED, V28, P3137, DOI 10.1097/00003246-200009000-00001; Martin GS, 2005, CRIT CARE MED, V33, P1681, DOI 10.1097/01.CCM.0000171539.47006.02; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NAREDI S, 2001, ACTA ANAESTH SCAND, V45, P1; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Persson J, 2006, CRIT CARE MED, V34, P2456, DOI 10.1097/01.CCM.0000233876.87978.AB; Powers KA, 2003, CRIT CARE MED, V31, P2355, DOI 10.1097/01.CCM.0000084846.45830.AA; Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; TOMITA H, 1994, ACTA NEUROCHIR, P547; Vincent JL, 2004, CRIT CARE MED, V32, P2029, DOI 10.1097/01.CCM.0000142574.00425.E9; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	41	19	19	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2009	53	1					18	25		10.1111/j.1399-6576.2008.01798.x			8	Anesthesiology	Anesthesiology	384YO	WOS:000261780300003	18945246	Green Published			2021-06-18	
J	Jalali, R; Dutta, D; Kamble, R; Gupta, T; Munshi, A; Sarin, R; Dinshaw, K				Jalali, Rakesh; Dutta, Debnarayan; Kamble, Rashmi; Gupta, Tejpal; Munshi, Anusheel; Sarin, Rajiv; Dinshaw, Ketayun			Prospective assessment of activities of daily living using Modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy	JOURNAL OF NEURO-ONCOLOGY			English	Article						Modified Barthel's Index; Activities of daily living; Low-grade gliomas; Stereotactic conformal radiotherapy	TRAUMATIC BRAIN-INJURY; FUNCTIONAL ASSESSMENT; TUMORS; METASTASES; CHILDHOOD; BENIGN	Purpose To report prospective evaluations of activities of daily living (ADL) in young patients with low-grade gliomas treated with stereotactic conformal radiotherapy (SCRT). Materials and methods Between April 2001 and February 2008, 38 children and young adults (age 5-25 years, median 12.5 years) with low-grade gliomas with residual/progressive disease and treated with SCRT were accrued in a prospective protocol. Patients underwent baseline and follow-up ADL assessments by the modified Barthel's battery, which comprises domains of personal hygiene, bathing self, feeding, toilet, stair climbing, dressing, bowel control, bladder control, ambulation, and chair-bed transfer. Result The patient population consisted of 38 patients (male 29, female 9) with a diagnosis of residual or progressive low-grade glioma (pilocytic astrocytoma in 27, fibrillary astrocytoma in 5, ependymoma in 4, and oligodendroglioma and pleomorphic xanthoastrocytoma in 1 each). Three patients were visually handicapped. Mean of total modified Barthel's ADL score (Barthel' Index, BI) at baseline before staring SCRT was 94.5 (standard deviation 14.8, range 45-100). At 2-year and 3-year follow-up, mean BI was 97.1 and 99, respectively. At baseline pre-radiotherapy assessment, patients with impaired visual function and with low performance status (Karnofsky performance score, KPS < 70) had significantly lower BI than those with normal vision (P = 0.001) and with good performance status (P = 0.001). On follow-up, maximum improvement in individual BI was seen in the ambulation-related domain in patients with impaired visual function (P = 0.027), low KPS (P = 0.015), and age less than 13 years (P = 0.103). The mean pre-radiotherapy baseline BI of three patients, who eventually developed local recurrence, was only 64 (SD 32.1) as compared with a baseline score of 97.18 seen in patients whose tumor remained controlled at follow-up (P = 0.001). Conclusions Young patients with low-grade gliomas after surgical intervention had a lower than normal BI before starting radiotherapy, suggesting a decrease in ADL possibly due to tumor- and surgery-related factors. At 2-year and 3-year follow-up after SCRT, there was no further decrease in mean BI. A significant improvement in BI was seen in visually handicapped patients, patients with poor performance status, and younger patients. Patients who developed tumor recurrence at follow-up had a significantly lower BI at baseline than patients with controlled disease (P = 0.001).	[Jalali, Rakesh] Tata Mem Hosp Parel, Mumbai 400012, Maharashtra, India; [Jalali, Rakesh; Dutta, Debnarayan; Gupta, Tejpal; Munshi, Anusheel; Sarin, Rajiv; Dinshaw, Ketayun] Dept Radiat Oncol, Mumbai, Maharashtra, India; [Kamble, Rashmi] Dept Brain Tumor Fdn India, Mumbai, Maharashtra, India	Jalali, R (corresponding author), Tata Mem Hosp Parel, Radiat Oncol & NeuroOncol 125, Mumbai 400012, Maharashtra, India.	rjalali@tmc.gov.in		Sarin, Rajiv/0000-0002-6405-8282			Arthanat S, 2004, DISABIL REHABIL, V26, P235, DOI 10.1080/09638280310001644889; Brazil L, 1997, J NEURO-ONCOL, V34, P187, DOI 10.1023/A:1005710729748; Carpentieri SC, 2003, NEUROSURGERY, V52, P1348, DOI 10.1227/01.NEU.0000064804.00766.62; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chan KH, 2003, QJM-INT J MED, V96, P643, DOI 10.1093/qjmed/hcg108; DESIREE D, 2000, NEUROSURG FOCUS, V8, P1; Gerrard GE, 2003, CLIN ONCOL-UK, V15, P422, DOI 10.1016/S0936-6555(03)00148-1; Herman MA, 2003, AM J CLIN ONCOL-CANC, V26, P273, DOI 10.1097/00000421-200306000-00014; Jalali R, 2005, RADIOTHER ONCOL, V74, P37, DOI 10.1016/j.radonc.2004.09.014; Jalali R, 2007, PEDIATR BLOOD CANCER, V49, P430; Jalali R, 2006, INT J RADIAT ONCOL, V66, pS14, DOI 10.1016/j.ijrobp.2005.11.025; JANNOUN L, 1990, INT J RADIAT ONCOL, V18, P747, DOI 10.1016/0360-3016(90)90393-X; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; LEON J, 1989, FUNCTIONAL STATUS EL; Makris A, 1995, Clin Oncol (R Coll Radiol), V7, P82, DOI 10.1016/S0936-6555(05)80806-4; Marcinkevicius Egidijus, 2006, Medicina (Kaunas), V42, P130; Merchant TE, 2004, J CLIN ONCOL, V22, P3156, DOI 10.1200/JCO.2004.11.142; Nitta O., 2005, J PHYS THER SCI, V17, P103, DOI DOI 10.1589/JPTS.17.103; Pace A, 2003, ANN ONCOL, V14, P1722, DOI 10.1093/annonc/mdg502; Perks JR, 1999, INT J RADIAT ONCOL, V45, P507, DOI 10.1016/S0360-3016(99)00156-X; *ROYAL COLL PHYS B, 1992, STAND ASS SCAL ELD P; Sardell S, 2000, CLIN ONCOL-UK, V12, P36, DOI 10.1053/clon.2000.9108; SCAND J, 1990, CARING SCI, V4, P99; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Thomas R, 1995, Eur J Cancer Care (Engl), V4, P63, DOI 10.1111/j.1365-2354.1995.tb00058.x; Wade DT, 1992, MEASUREMENT NEUROLOG	27	19	20	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X			J NEURO-ONCOL	J. Neuro-Oncol.	DEC	2008	90	3					321	328		10.1007/s11060-008-9666-6			8	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	370NG	WOS:000260768300012	18704269				2021-06-18	
J	Lemon, JA; Rollo, CD; McFarlane, NM; Boreham, DR				Lemon, Jennifer A.; Rollo, C. David; McFarlane, Nicole M.; Boreham, Douglas R.			Radiation-induced apoptosis in mouse lymphocytes is modified by a complex dietary supplement: the effect of genotype and gender	MUTAGENESIS			English	Article							ACETYL-L-CARNITINE; MITOCHONDRIAL OXIDATIVE STRESS; HORMONE INHIBITS APOPTOSIS; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; FREE-RADICAL PROCESSES; GIANT TRANSGENIC MICE; ALPHA-LIPOIC ACID; GROWTH-HORMONE; VITAMIN-E	This study examined whether radiation sensitivity measured by lymphocyte apoptosis could be ameliorated by a complex anti-oxidant/anti-ageing dietary supplement. We also examined lymphocytes from both genders of normal (Nr) mice as well as transgenic growth hormone (Tg) mice that express strongly elevated reactive oxygen species processes and a progeroid syndrome of accelerated ageing. We introduce Tg mice as a potentially valuable new model to study radiation sensitivity. Isolated lymphocytes from all experimental groups were exposed to gamma radiation and the time course of apoptosis was measured in vitro. Kinetics of radiation-induced apoptosis was similar among groups, which peaked at 8 h, but maximal levels differed significantly between groups. Nr male mice had 60% lower levels of radiation-induced apoptosis than Tg males, supporting our hypothesis that Tg mice would be radiation sensitive. The dietary supplement protected lymphocytes in male mice of both strains, with proportionally greater reductions in Tg mice. Lymphocytes from female mice (both Nr and Tg) were highly radiation resistant compared to males and the supplement provided no additional benefit at the doses used in this study. These results highlight that radiation-induced apoptosis is complex and is modified by genotype, dietary supplements and gender.	[Lemon, Jennifer A.; McFarlane, Nicole M.; Boreham, Douglas R.] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON L8S 4K1, Canada; [Rollo, C. David] McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	Lemon, JA (corresponding author), McMaster Univ, Dept Med Phys & Appl Radiat Sci, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	lemonja@mcmaster.ca			CANDU Owners Group [03.014]; Chemical Biological Radiological Nuclear Research and Technology Initiative [015ssH1021-021608]; National Science and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada (NSERC) [238495]	CANDU Owners Group (03.014), the Chemical Biological Radiological Nuclear Research and Technology Initiative (015ssH1021-021608) and the National Science and Engineering Research Council (238495).	AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078; Bartke A, 2004, CURR TOP DEV BIOL, V63, P189, DOI 10.1016/S0070-2153(04)63006-7; Beckman KB, 1998, PHYSIOL REV, V78, P547; Behl C, 1997, MOL PHARMACOL, V51, P535; Blacker D, 2005, NEW ENGL J MED, V352, P2439, DOI 10.1056/NEJMe058086; Boddaert J, 2005, MECH AGEING DEV, V126, P678, DOI 10.1016/j.mad.2005.01.001; Bogazzi F, 2004, ENDOCRINOLOGY, V145, P3353, DOI 10.1210/en.2004-0225; Bolognesi C, 1997, CANCER EPIDEM BIOMAR, V6, P249; Bramlett Helen M, 2005, Pathophysiology, V12, P17, DOI 10.1016/j.pathophys.2005.02.009; Bridger JM, 2004, EXP GERONTOL, V39, P717, DOI 10.1016/j.exger.2004.02.002; Calder WA., 1984, SIZE FUNCTION LIFE H, P431; Carlson JC, 1999, AGE, V22, P181, DOI 10.1007/s11357-999-0021-4; Chen DX, 2002, J NEUROCHEM, V81, P1273, DOI 10.1046/j.1471-4159.2002.00916.x; Clutter AC, 1996, GENETICS, V143, P1753; Cui Yu-fang, 1999, Journal of Environmental Pathology Toxicology and Oncology, V18, P185; CUTOLO M, 1995, CLIN EXP RHEUMATOL, V13, P217; Cuzzorcrea S, 2004, CURR MED CHEM, V11, P1147, DOI 10.2174/0929867043365396; Dhitavat S, 2005, BRAIN RES, V1061, P114, DOI 10.1016/j.brainres.2005.05.074; Dulos GJ, 2001, INT IMMUNOPHARMACOL, V1, P321, DOI 10.1016/S1567-5769(00)00029-1; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Evans MJ, 1997, CLIN IMMUNOL IMMUNOP, V82, P258, DOI 10.1006/clin.1996.4300; Garaj-Vrhovac V, 2003, MUTAGENESIS, V18, P265, DOI 10.1093/mutage/18.3.265; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Geracitano LA, 2004, MAR ENVIRON RES, V58, P1, DOI 10.1016/j.marenvres.2003.09.001; Ginaldi L, 2004, IMMUNOL RES, V30, P81, DOI 10.1385/IR:30:1:081; Gonzalez-Juanatey JR, 2004, J ENDOCRINOL, V180, P325; Haddad JJ, 2004, INT IMMUNOPHARMACOL, V4, P475, DOI 10.1016/j.intimp.2004.02.002; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P1870, DOI 10.1073/pnas.261708898; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; HAUKE SJ, 2001, J GERONTOL BIOL SCI, V56, pB153; Hofmann-Lehmann R, 1998, VET IMMUNOL IMMUNOP, V65, P151, DOI 10.1016/S0165-2427(98)00150-0; Huber SA, 1999, LUPUS, V8, P384, DOI 10.1177/096120339900800511; Joksic G, 2004, BRAZ J MED BIOL RES, V37, P1111, DOI 10.1590/S0100-879X2004000800002; JOKSIC G, 2000, J ENVIRON PATHOL TOX, V23, P195; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Kumari M, 2000, J GERONTOL A-BIOL, V55, pB228, DOI 10.1093/gerona/55.5.B228; Kuo HW, 2003, OCCUP ENVIRON MED, V60, P590, DOI 10.1136/oem.60.8.590; Lang F, 2004, J MOL RECOGNIT, V17, P473, DOI 10.1002/jmr.705; Lee CK, 2004, FREE RADICAL BIO MED, V36, P1043, DOI 10.1016/j.freeradbiomed.2004.01.015; Lemon JA, 2005, J GERONTOL A-BIOL, V60, P275, DOI 10.1093/gerona/60.3.275; Lemon JA, 2003, EXP BIOL MED, V228, P800, DOI 10.1177/15353702-0322807-05; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Lu AG, 2002, J CEREBR BLOOD F MET, V22, P183, DOI 10.1097/00004647-200202000-00006; Ludwig DS, 2003, ASIA PAC J CLIN NU S, V12, pS4; Matsuda T, 1998, JPEN-PARENTER ENTER, V22, P368, DOI 10.1177/0148607198022006368; Meliska CJ, 1997, NEUROBIOL LEARN MEM, V68, P1, DOI 10.1006/nlme.1997.3772; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Monget AL, 1996, EUR J CLIN NUTR, V50, P443; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Murata M, 2004, BIOCHEM BIOPH RES CO, V316, P123, DOI 10.1016/j.bbrc.2004.02.022; Ogueta S, 2000, J ENDOCRINOL, V165, P321, DOI 10.1677/joe.0.1650321; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; Palmon SC, 1998, J CEREBR BLOOD F MET, V18, P1248, DOI 10.1097/00004647-199811000-00011; PATINO JAG, 2000, EUR J IMMUNOL, V30, P2586; Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89; Pieters RS, 2006, INT J RADIAT ONCOL, V64, P251, DOI 10.1016/j.ijrobp.2005.04.019; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; Qin XJ, 2008, J APPL TOXICOL, V28, P271, DOI 10.1002/jat.1276; Rafique R, 2004, FREE RADICAL RES, V38, P157, DOI 10.1080/10715760310001643311; Rinaldi P, 2003, NEUROBIOL AGING, V24, P915, DOI 10.1016/S0197-4580(03)00031-9; Rollo CD, 1996, CAN J ZOOL, V74, P606, DOI 10.1139/z96-070; Rollo CD, 1999, CAN J ZOOL, V77, P1874, DOI 10.1139/cjz-77-12-1874; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Satoh M, 2007, CIRCULATION, V115, P3197, DOI 10.1161/CIRCULATIONAHA.106.657981; Sener G, 2003, LIFE SCI, V72, P2707, DOI 10.1016/S0024-3205(03)00187-5; Shin DH, 2004, NEUROSCI LETT, V354, P64, DOI 10.1016/j.neulet.2003.09.070; SHIRSHEV SV, 2003, BIOKHIMIYA, V68, P577; Singh M, 2000, J NEUROSCI, V20, P1694; Sonta T, 2004, FREE RADICAL BIO MED, V37, P115, DOI 10.1016/j.freeradbiomed.2004.04.001; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; Steger R W, 1993, J Reprod Fertil Suppl, V46, P61; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Verzola D, 2004, KIDNEY INT, V65, P1252, DOI 10.1111/j.1523-1755.2004.00497.x; Vilatoba M, 2005, TRANSPL P, V37, P399, DOI 10.1016/j.transproceed.2004.12.053; WOLF E, 1993, MECH AGEING DEV, V68, P71, DOI 10.1016/0047-6374(93)90141-D; Wu LY, 2004, P NATL ACAD SCI USA, V101, P7094, DOI 10.1073/pnas.0402004101; Yaffe K, 2004, NEUROLOGY, V63, P1705; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	80	19	20	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0267-8357			MUTAGENESIS	Mutagenesis	NOV	2008	23	6					465	472		10.1093/mutage/gen038			8	Genetics & Heredity; Toxicology	Genetics & Heredity; Toxicology	367NE	WOS:000260557900006	18644835	Bronze			2021-06-18	
J	Hosalkar, H; Goebel, J; Reddy, S; Pandya, NK; Keenan, MA				Hosalkar, Harish; Goebel, Jennifer; Reddy, Sudheer; Pandya, Nirav K.; Keenan, Mary Ann			Fixation techniques for split anterior tibialis transfer in spastic equinovarus feet	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							EQUINUS DEFORMITY; TOE FLEXORS; ADULT; FOOT; MANAGEMENT; GAIT	Equinovarus of the foot is the most common lower extremity deformity following traumatic brain injury. We evaluated outcomes of the split anterior tibialis tendon transfer (SPLATT) for correction of equinovarus in 47 patients with hemiplegic traumatic brain injury and specifically studied differences in outcomes with two tendon fixation techniques. Seventeen patients constituting Group I underwent fixation with one technique and 30 constituting Group II had another technique. Patients in both groups had appropriate procedures based on dynamic electromyography and gait analyses. Both groups were demographically comparable. All 47 feet were corrected to plantigrade position. Thirty-six of 47 patients became brace-free at final followup. There was a notable decrease in the use of ambulatory aids and ambulatory status improved in both groups. There were three fixation-related complications in Group I and none in Group II. Surgical correction of the spastic equinovarus with SPLATT, in the appropriate patient, with or without associated tendon procedures helps to achieve and maintain correction, improves the ambulatory status of the patient, and eliminates the need for bracing in as much as 77% of patients. We recommend the Group II construct owing to the considerably lower complication rate.	[Hosalkar, Harish; Goebel, Jennifer; Reddy, Sudheer; Pandya, Nirav K.; Keenan, Mary Ann] Hosp Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	Keenan, MA (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 3400 Spruce St,2 Silverstein, Philadelphia, PA 19104 USA.	maryann.keenan@uphs.upenn.edu	Keenan, Mary Ann/ABB-1551-2020				Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; BANKS HH, 1977, CLIN ORTHOP RELAT R, P70; EDWARDS P, 1993, FOOT ANKLE, V14, P335, DOI 10.1177/107110079301400605; Fuller DA, 2004, ORTHOPEDICS, V27, P372; HOFFER MM, 1974, ORTHOP CLIN N AM, V5, P31; Hosalkar HS, 2007, J BONE JOINT SURG AM, V89A, P2316, DOI 10.2106/JBJS.G.00285; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; KEENAN MA, 1984, FOOT ANKLE, V5, P35, DOI 10.1177/107110078400500105; Keenan MAE, 1999, J HEAD TRAUMA REHAB, V14, P163, DOI 10.1097/00001199-199904000-00006; LAWRENCE SJ, 1994, FOOT ANKLE INT, V15, P340, DOI 10.1177/107110079401500610; LEMPERG R, 1969, ACTA ORTHOP SCAND, V40, P507, DOI 10.3109/17453676909046536; ONO K, 1980, INT ORTHOP, V4, P225, DOI 10.1007/BF00268160; Perry J., 1992, GAIT ANAL NORMAL PAT, P381; PINZUR MS, 1986, J BONE JOINT SURG AM, V68A, P1249, DOI 10.2106/00004623-198668080-00016; ROPER BA, 1978, J BONE JOINT SURG BR, V60, P533; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Viosca E, 2005, ARCH PHYS MED REHAB, V86, P1234, DOI 10.1016/j.apmr.2004.11.016; WATERS RL, 1982, J BONE JOINT SURG AM, V64, P284, DOI 10.2106/00004623-198264020-00022	18	19	19	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	OCT	2008	466	10					2500	2506		10.1007/s11999-008-0395-0			7	Orthopedics; Surgery	Orthopedics; Surgery	347KX	WOS:000259141600027	18648897	Green Published			2021-06-18	
J	Grandhi, R; Duane, TM; Dechert, T; Malhotra, AK; Aboutanos, MB; Wolfe, LG; Ivatury, RR				Grandhi, Ramesh; Duane, Therese M.; Dechert, Tracey; Malhotra, Ajai K.; Aboutanos, Michel B.; Wolfe, Luke G.; Ivatury, Rao R.			Anticoagulation and the elderly head trauma patient	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Scientific Meeting and Postgraduate Course Program of the Southeastern-Surgical-Congress	FEB 09-12, 2008	Birmingham, AL	SE Surg Congress			PREINJURY WARFARIN USE; ATRIAL-FIBRILLATION; BRAIN-INJURY; BLEEDING COMPLICATIONS; ANTITHROMBOTIC THERAPY; RISK-FACTORS; MORTALITY; STROKE; AGE; SEVERITY	We sought to determine the effect of anticoagulation therapy on outcomes in elderly patients with closed head injury. We retrospectively reviewed elderly closed head injury patients (>= 65 years) comparing 52 patients on warfarin (AC) with 439 patients not on warfarin (NAC) with subsequent 1:3 propensity matching used to analyze comparable groups. The overall AC group had a higher head abbreviated injury score (AIS) (4.0 +/- 0.7 vs 3.8 +/- 0.7, P = 0.04) compared with the NAC group. After propensity matching, 49 AC patients were compared with 147 NAC patients who were similar for age, gender, injury severity score, and head AIS. Admission INR was higher in the AC group compared to the NAC group (2.5 +/- 1.3 vs 1.1 +/- 0.3, P < 0.0001) and the AC group had a higher mortality rate (38.8% AC (19/49) vs 23.1% NAC (34/147), P = 0.04). In the AC group, survivors and nonsurvivors had similar repeat International Normalized Ratio (INR) values (1.57 +/- 0.65 survivors vs 1.8 +/- 0.72 nonsurvivors, P = 0.31). The AC group experienced greater morbidity after trauma and had higher mortality rates than their NAC counterparts. Prevention of injury and more selective use of warfarin in this patient population are essential to decrease mortality.	[Grandhi, Ramesh; Duane, Therese M.; Dechert, Tracey; Malhotra, Ajai K.; Aboutanos, Michel B.; Wolfe, Luke G.; Ivatury, Rao R.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA	Duane, TM (corresponding author), West Hosp, 1200 E Broad St,15th Floor,POB 980454, Richmond, VA 23298 USA.	tmduane@vcn.edu	Ivatury, Rao R./H-2922-2019	Dechert, Tracey/0000-0003-4712-883X			CANNEGIETER SC, 1994, CIRCULATION, V89, P635, DOI 10.1161/01.CIR.89.2.635; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; Fleming B, 2001, CAN FAM PHYSICIAN, V47, P727; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; He W., 2005, US CENSUS BUREAU CUR, VP23-209, 65; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Karni A, 2001, AM SURGEON, V67, P1098; Kauder D.R., 2004, TRAUMA, P1041; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Schwab C.W., 1990, EARLY CARE INJURED P, P328; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	27	19	20	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	SEP	2008	74	9					802	805					4	Surgery	Surgery	344NC	WOS:000258933400005	18807665				2021-06-18	
J	Klose, M; Feldt-Rasmussen, U				Klose, M.; Feldt-Rasmussen, U.			Does the type and severity of brain injury predict hypothalamo-pituitary dysfunction? Does post-traumatic hypopituitarism predict worse outcome?	PITUITARY			English	Article						hypopituitarism; traumatic brain injury; predictors; outcome	GROWTH-HORMONE DEFICIENCY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY INSUFFICIENCY; CRITICALLY-ILL PATIENTS; SEPTIC SHOCK; LONG-TERM; CONSENSUS GUIDELINES; ANTIEPILEPTIC DRUGS; CORTISOL RESPONSE; CRITICAL ILLNESS	Several studies have reported a close association between traumatic brain injury (TBI) and pituitary dysfunction, and expert panels have recently proposed recommendations for hormone assessment and replacement for pituitary insufficiency after TBI. Given the high incidence of TBI, identification of reliable predictors is of utmost importance in order to secure a cost-effective screening strategy. It has not yet been possible to identify early hormone alterations as a useful tool for the prediction of long-term post-traumatic hypopituitarism, whereas indicators of increased trauma severity have been reported as predictive in an increasing number of studies. Outcome studies have moreover indicated that post-traumatic hypopituitarism is of clinical significance, which may justify introduction of neuroendocrine screening in TBI. Much larger cohorts are, however, still needed for further evaluation and confirmation of reliable screening markers, and future studies should be designed to ensure a high diagnostic robustness for proper identification of reliable predictors, as the results may be highly dependent on diagnostic pitfalls.	[Klose, M.; Feldt-Rasmussen, U.] Copenhagen Univ Hosp, Dept Med Endocrinol, Rigshosp, DK-2100 Copenhagen, Denmark	Feldt-Rasmussen, U (corresponding author), Copenhagen Univ Hosp, Dept Med Endocrinol, Rigshosp, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	ulla.feldt-rasmussen@rh.regionh.dk					Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Beishuizen A, 2001, INTENS CARE MED, V27, P1584, DOI 10.1007/s001340101073; Benedetti MS, 2005, EUR J CLIN PHARMACOL, V61, P863, DOI 10.1007/s00228-005-0056-0; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Bonert VS, 2004, J CLIN ENDOCR METAB, V89, P3397, DOI 10.1210/jc.2003-032213; Bonnefont X, 2005, P NATL ACAD SCI USA, V102, P16880, DOI 10.1073/pnas.0508202102; Cansu A, 2006, EPILEPSIA, V47, P1855, DOI 10.1111/j.1528-1167.2006.00821.x; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; Herzog AG, 2005, CURR OPIN NEUROL, V18, P167, DOI 10.1097/01.wco.0000162859.42218.fd; HERZOG AG, 1986, ARCH NEUROL-CHICAGO, V43, P347, DOI 10.1001/archneur.1986.00520040035015; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Isojarvi JIT, 2005, CNS DRUGS, V19, P207, DOI 10.2165/00023210-200519030-00003; Isojarvi JIT, 2001, EPILEPSIA, V42, P930, DOI 10.1046/j.1528-1157.2001.042007930.x; Jochberger S, 2006, J CLIN ENDOCR METAB, V91, P4381, DOI 10.1210/jc.2005-2830; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; Miller KK, 2005, J CLIN ENDOCR METAB, V90, P768, DOI 10.1210/jc.2004-0894; MOLIJN GJ, 1995, J CLIN ENDOCR METAB, V80, P1799, DOI 10.1210/jc.80.6.1799; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Vanhorebeek I, 2006, J CLIN ENDOCR METAB, V91, P3803, DOI 10.1210/jc.2005-2089	50	19	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	SEP	2008	11	3					255	261		10.1007/s11102-008-0102-x			7	Endocrinology & Metabolism	Endocrinology & Metabolism	322NN	WOS:000257382700003	18404391				2021-06-18	
J	Zhang, H; Zheng, XS; Yang, XF; Fang, SW; Shen, G; Zhao, CL; Tian, M				Zhang, Hong; Zheng, Xuesheng; Yang, Xiaofeng; Fang, Shengwei; Shen, Gang; Zhao, Chunlei; Tian, Mei			C-11-NMSP/F-18-FDG microPET to monitor neural stem cell transplantation in a rat model of traumatic brain injury	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING			English	Article						neural stem cell; transplantation; microPET; assessment	POSITRON-EMISSION-TOMOGRAPHY; REPORTER GENE-EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DOPAMINE-RECEPTORS; LIVING ANIMALS; IN-VIVO; STROKE; REPLACEMENT; LIGAND; PET	Purpose To investigate whether C-11-N-methylspiperone (C-11-NMSP) microPET could be used for imaging neural stem cells (NSCs) transplantation in a rat model of traumatic brain injury. Methods NSCs were induced to express dopamine receptor type 2 (DRD2), then confirmed by RT-PCR, Western blotting and immunocytochemistry. Eighteen rats were subjected to focal traumatic brain injury in the right parietal lobe and then assigned randomly to the transplantation group and the control group. NSCs labeled with 5-bromo-2-deoxyuridine (BrdU) were transplanted into the cerebral lesion of the transplatation group. MicroPET scan using C-11-NMSP and F-18-FDG were performed to detect the DRD2 expression of transplanted NSCs and the regional glucose metabolism in the cerebral lesion, respectively. Behavioral neurological function of rats were also tested. Results Histological analysis identified viable NSCs. Western blotting and immunofluorescence showed high level of NSCs-induced DRD2 expression. Immunostaining demonstrated high levels of survived BrdU+ and DRD2+ donor cells in the cerebral lesion 2 weeks after transplantation. The lesion-to-normal contralateral ratio (L/N ratio) of C-11-NMSP in the cerebral lesion decreased significantly from 97% to 68% after injury and increased dramatically to 137% 1 day after the transplantation and then decreased gradually. Glucose metabolism showed a decrease of 35% in the cerebral lesion 1 day after injury and recovered to 87% 2 weeks after transplantation. The behavioral neurological function of the transplantation group was significantly improved compared with the control group. Conclusions This study verified that C-11-NMSP microPET can be used to assess the NSCs-induced DRD2 expression in rat model.	[Zhang, Hong; Fang, Shengwei; Zhao, Chunlei; Tian, Mei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Nucl Med, Hangzhou 310009, Zhejiang, Peoples R China; [Zhang, Hong; Zheng, Xuesheng; Fang, Shengwei; Zhao, Chunlei] Zhejiang Univ, Med PET Ctr, Hangzhou 310009, Zhejiang, Peoples R China; [Zhang, Hong; Fang, Shengwei; Zhao, Chunlei] Zhejiang Univ, Inst Nucl Med & Mol Imaging, Hangzhou 310009, Zhejiang, Peoples R China; [Zhang, Hong; Fang, Shengwei; Zhao, Chunlei] Key Lab Med Mol Imaging Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China	Tian, M (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Nucl Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	meitian@gmail.com	Tian, Mei/E-3751-2012		National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30672396]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [R205066]; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China [2006DFB32940]	This study was supported by the grants from the National Science Foundation of China (NSFC) (No. 30672396), the Natural Science Foundation of Zhejiang Province (No. R205066), and a key project grant from the Ministry of Science and Technology of China (MOST; No. 2006DFB32940).	Arbab AS, 2006, EXPERT REV MED DEVIC, V3, P427, DOI 10.1586/17434440.3.4.427; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Blasberg Ronald G, 2002, Mol Imaging, V1, P280; DONALDBURNS H, 1984, J NUCI MED, V25, P1222; Findlay M, 1996, J CLIN ONCOL, V14, P700, DOI 10.1200/JCO.1996.14.3.700; Gambhir SS, 2000, NEOPLASIA, V2, P118, DOI 10.1038/sj.neo.7900083; Gambhir SS, 1999, NUCL MED BIOL, V26, P481, DOI 10.1016/S0969-8051(99)00021-9; Jacobs A, 2001, J NUCL MED, V42, P467; Liang Q, 2001, GENE THER, V8, P1490, DOI 10.1038/sj.gt.3301542; Liang QW, 2002, MOL THER, V6, P73, DOI 10.1006/mthe.2002.0626; Limke TL, 2003, DEV NEUROSCI-BASEL, V25, P257, DOI 10.1159/000072273; Luan Zuo, 2005, Zhonghua Er Ke Za Zhi, V43, P580; LYON RA, 1986, J NEUROSCI, V6, P2941; MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877; MARTRES MP, 1985, SCIENCE, V228, P752, DOI 10.1126/science.3838821; Mayhall EA, 2004, CURR OPIN CELL BIOL, V16, P713, DOI 10.1016/j.ceb.2004.09.007; Modo M, 2004, NEUROIMAGE, V21, P311, DOI 10.1016/j.neuroimage.2003.08.030; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; Phelps ME, 2000, J NUCL MED, V41, P661; Price J, 2001, CURR OPIN NEUROBIOL, V11, P564, DOI 10.1016/S0959-4388(00)00250-6; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Su H, 2004, MOL IMAGING BIOL, V6, P139, DOI 10.1016/j.mibio.2004.02.001; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Tian M, 2004, EUR J NUCL MED MOL I, V31, P5, DOI 10.1007/s00259-003-1316-9; Tonchev AB, 2003, MOL CELL NEUROSCI, V23, P292, DOI 10.1016/S1044-7431(03)00058-7; WAGNER H, 1986, SCIENCE, V221, P1264; Wu JC, 2002, CIRCULATION, V106, P180, DOI 10.1161/01.CIR.0000023620.59633.53; Zheng XS, 2007, BRAIN INJURY, V21, P275, DOI 10.1080/02699050701225754; Zheng XS, 2007, CANCER RES, V67, P3691, DOI 10.1158/0008-5472.CAN-06-3912; Zhu JH, 2006, NEW ENGL J MED, V355, P2376, DOI 10.1056/NEJMc055304	32	19	22	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1619-7070	1619-7089		EUR J NUCL MED MOL I	Eur. J. Nucl. Med. Mol. Imaging	SEP	2008	35	9					1699	1708		10.1007/s00259-008-0835-9			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	340VT	WOS:000258673800016	18509630				2021-06-18	
J	Abe, C; Tanaka, K; Awazu, C; Morita, H				Abe, Chikara; Tanaka, Kunihiko; Awazu, Chihiro; Morita, Hironobu			Impairment of vestibular-mediated cardiovascular response and motor coordination in rats born and reared under hypergravity	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						vestibular system; renal sympathetic nerve activity; arterial pressure; rotarod; linear acceleration	TRAUMATIC BRAIN-INJURY; CONSCIOUS RATS; VESTIBULOSYMPATHETIC REFLEX; PRESSOR-RESPONSE; BLOOD-PRESSURE; MICROGRAVITY; SYSTEM; PLASTICITY; LOCOMOTION; CORTEX	It is well known that environmental stimulation is important for the proper development of sensory function. The vestibular system senses gravitational acceleration and then alters cardiovascular and motor functions through reflex pathways. The development of vestibular-mediated cardiovascular and motor functions may depend on the gravitational environment present at birth and during subsequent growth. To examine this hypothesis, arterial pressure (AP) and renal sympathetic nerve activity (RSNA) were monitored during horizontal linear acceleration and performance in a motor coordination task in rats born and reared in 1-G or 2-G environments. Linear acceleration of +/- 1 G increased AP and RSNA. These responses were attenuated in rats with a vestibular lesion, suggesting that the vestibular system mediated AP and RSNA responses. These responses were also attenuated in rats born in a 2-G environment. AP and RSNA responses were partially restored in these rats when the hypergravity load was removed, and the rats were maintained in a 1-G environment for 1 wk. The AP response to compressed air, which is mediated independently of the vestibular system, did not change in the 2-G environment. Motor coordination was also impaired in the 2-G environment and remained impaired even after 1 wk of unloading. These results indicate that hypergravity impaired both the vestibulo-cardiovascular reflex and motor coordination. The vestibulo-cardiovascular reflex was only impaired temporarily and partially recovered following 1 wk of unloading. In contrast, motor coordination did not return to normal in response to unloading.	[Abe, Chikara; Tanaka, Kunihiko; Awazu, Chihiro; Morita, Hironobu] Gifu Univ, Grad Sch Med, Dept Physiol, Gifu 5011194, Japan	Morita, H (corresponding author), Gifu Univ, Grad Sch Med, Dept Physiol, 1-1 Yanagido, Gifu 5011194, Japan.	zunzunmorita@gmail.com	Abe, Chikara/V-6174-2019	Abe, Chikara/0000-0003-3856-7494	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [08J00200] Funding Source: KAKEN		Abe C, 2007, EXP BRAIN RES, V181, P639, DOI 10.1007/s00221-007-0961-9; BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; Buitrago MM, 2004, NEUROBIOL LEARN MEM, V81, P211, DOI 10.1016/j.nlm.2004.01.001; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Clarac F, 1998, BRAIN RES REV, V28, P35, DOI 10.1016/S0165-0173(98)00024-1; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gotoh TM, 2004, AM J PHYSIOL-REG I, V286, pR25, DOI 10.1152/ajpregu.00458.2003; Hajjar H, 2005, DRUG AGING, V22, P55; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hess BJM, 2003, J NEUROPHYSIOL, V90, P1996, DOI 10.1152/jn.00302.2003; Holley DC, 2003, J APPL PHYSIOL, V95, P1266, DOI 10.1152/japplphysiol.00707.2002; HUBEL DH, 1967, J NEUROPHYSIOL, V30, P1561; Iossa S, 1999, J NUTR, V129, P1593; Jian BJ, 1999, J APPL PHYSIOL, V86, P1552; KARHUNEN E, 1973, ACTA OTO-LARYNGOL, V1974, P1; Kerman IA, 1999, AM J PHYSIOL-REG I, V277, pR716; Kihara M, 1998, AGE AGEING, V27, P551, DOI 10.1093/ageing/27.5.551; Kita S, 2006, AVIAT SPACE ENVIR MD, V77, P842; Matsuda T, 2004, BRAIN RES, V1028, P140, DOI 10.1016/j.brainres.2004.09.004; Morita H, 2007, NEUROSCI LETT, V412, P201, DOI 10.1016/j.neulet.2006.11.014; Poo C, 2007, J NEUROSCI, V27, P7553, DOI 10.1523/JNEUROSCI.1786-07.2007; Reschke MF, 1998, BRAIN RES REV, V28, P102, DOI 10.1016/S0165-0173(98)00031-9; RICHARDSON DR, 1977, AVIAT SPACE ENVIR MD, V48, P195; ROYET JP, 1989, J COMP NEUROL, V289, P586, DOI 10.1002/cne.902890405; SIMONS DJ, 1987, NATURE, V326, P694, DOI 10.1038/326694a0; Smith PF, 1997, HIPPOCAMPUS, V7, P465, DOI 10.1002/(SICI)1098-1063(1997)7:5<465::AID-HIPO3>3.0.CO;2-G; Takahashi E, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-19; Takei Y, 1997, EXP BRAIN RES, V115, P361, DOI 10.1007/PL00005705; Tanaka K, 2006, NEUROSCI LETT, V397, P40, DOI 10.1016/j.neulet.2005.11.052; Uno Y, 2002, J NEUROCHEM, V81, P1308, DOI 10.1046/j.1471-4159.2002.00933.x; Wade CE, 2002, AVIAT SPACE ENVIR MD, V73, P859; Walton KD, 2005, J PHYSIOL-LONDON, V565, P609, DOI 10.1113/jphysiol.2004.074393; Walton KD, 2005, J PHYSIOL-LONDON, V565, P593, DOI 10.1113/jphysiol.2004.074385; Yamamoto K, 2004, AM J PHYSIOL-HEART C, V286, pH1382, DOI 10.1152/ajpheart.00801.2003; Yates BJ, 2005, J VESTIBUL RES-EQUIL, V15, P119; Yates BJ, 1998, BRAIN RES REV, V28, P73, DOI 10.1016/S0165-0173(98)00028-9	36	19	19	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	JUL 1	2008	295	1					R173	R180		10.1152/ajpregu.00120.2008			8	Physiology	Physiology	323VY	WOS:000257477700021	18495837				2021-06-18	
J	Mittrach, R; Grill, E; Walchner-Bonjean, M; Scheuringer, M; Boldt, C; Huber, EO; Stucki, G				Mittrach, Rene; Grill, Eva; Walchner-Bonjean, Monika; Scheuringer, Monika; Boldt, Christine; Huber, Erika Omega; Stucki, Gerold			Goals of physiotherapy interventions can be described using the International Classification of Functioning, Disability and Health	PHYSIOTHERAPY			English	Article						physical therapy (speciality); documentation; rehabilitation; treatment outcome; goals; lCF	ICF CORE SET; EARLY INPATIENT REHABILITATION; TRAUMATIC BRAIN-INJURY; PHYSICAL-THERAPY; MENTAL PRACTICE; STROKE; IDENTIFICATION; ARTHROPLASTY; FACILITIES; CATEGORIES	Objective To provide an example of how goals of physiotherapy interventions and their typical patterns can be described using the International Classification of Functioning, Disability and Health (ICF). Design Cross-sectional study. Setting Acute hospital. Participants One hundred patients with neurological, musculoskeletal or cardiopulmonary conditions requiring physiotherapy interventions in University Hospital Zurich between January 2003 and October 2003. Main outcome measures The case record form consisted of two parts: a standardised questionnaire for functioning and health of the patient; and a standardised record form for physiotherapy interventions. Both parts were based on the ICF Results The mean age of the subjects was 58.2 years (standard deviation 15.9), the median age was 60.5 years and 44% were female. The most frequent intervention goals in patients with neurological conditions were: muscle power functions; muscle tone functions; control of voluntary movement functions; changing basic body position; maintaining a body position; and transferring oneself. The most frequent intervention goals for cardiopulmonary patients were: functions of the cardiovascular system; and respiration functions. The most frequent intervention goals in patients with musculoskeletal conditions were: sensation of pain; stability of joint functions; muscle power functions; muscle tone functions; and muscle endurance functions. Conclusion By using the lCF as a framework and linguistic support, intervention goals can serve as standardised documentation for physiotherapy interventions, their evaluation and planning. (C) 2007 Chartered Society of Physiotherapy. Published by Elsevier Ltd. All rights reserved.	[Stucki, Gerold] Univ Munich, Dept Phys Med & Rehabil, D-81377 Munich, Germany; [Mittrach, Rene; Grill, Eva; Walchner-Bonjean, Monika; Scheuringer, Monika; Boldt, Christine; Stucki, Gerold] Univ Munich, IHRS, WHO FIC Collaborating Ctr DIMDI, ICF Res Branch, Munich, Germany; [Huber, Erika Omega] Univ Zurich Hosp, Dept Rheumatol, Zurich, Switzerland; [Huber, Erika Omega] Univ Zurich Hosp, Inst Med Phys, Zurich, Switzerland; [Stucki, Gerold] Swiss Parapleg Res, Nottwil, Switzerland	Stucki, G (corresponding author), Univ Munich, Dept Phys Med & Rehabil, Marchioninistr 15, D-81377 Munich, Germany.	gerold.stucki@med.uni-muenchen.de	Grill, Eva/AAF-8104-2020; Grill, Eva/D-1875-2010; Scheuringer, Monika/C-2306-2013	Grill, Eva/0000-0002-0273-7984; Grill, Eva/0000-0002-0273-7984; Scheuringer, Monika/0000-0001-7196-3419			Bitar AA, 2005, ARCH PHYS MED REHAB, V86, pS56, DOI 10.1016/j.apmr.2004.12.015; Boldt C, 2005, DISABIL REHABIL, V27, P375, DOI 10.1080/09638280400013982; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Edwards MJ, 2003, DISABIL REHABIL, V25, P405, DOI 10.1080/0963828031000062642; Ewert T, 2005, DISABIL REHABIL, V27, P367, DOI 10.1080/09638280400014014; Finger ME, 2006, PHYS THER, V86, P1203, DOI 10.2522/ptj.20050134; Grill E, 2005, DISABIL REHABIL, V27, P447, DOI 10.1080/09638280400014048; Grill E, 2005, DISABIL REHABIL, V27, P361, DOI 10.1080/09638280400013974; HAYES SH, 1986, ARCH PHYS MED REHAB, V67, P319; Higgs J, 2001, J Interprof Care, V15, P79; Jette DU, 2005, PHYS THER, V85, P238, DOI 10.1093/ptj/85.3.238; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Munin MC, 1998, JAMA-J AM MED ASSOC, V279, P847, DOI 10.1001/jama.279.11.847; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Page SJ, 2005, ARCH PHYS MED REHAB, V86, P399, DOI 10.1016/j.apmr.2004.10.002; Page SJ, 2001, PHYS THER, V81, P1455, DOI 10.1093/ptj/81.8.1455; Pomeroy VM, 2001, CLIN REHABIL, V15, P67, DOI 10.1191/026921501675454995; Stoll T, 2005, DISABIL REHABIL, V27, P381, DOI 10.1080/09638280400013990; Stucki G, 2005, DISABIL REHABIL, V27, P353, DOI 10.1080/09638280400014105; STUCKI G, 1997, RHEUMATOLOGY; van der Peijl ID, 2004, ANN THORAC SURG, V77, P1535, DOI 10.1016/j.athoracsur.2003.10.091; Wade DT, 2003, CLIN REHABIL, V17, P1, DOI 10.1191/0269215503cr578ed; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; WHO, 2007, INT STAT CLASS DIS H; World Health Organization, 2001, INT CLASS FUNCT DIS; ZIMMERMAN JR, 1998, REHABILITATION MED P, P1677	27	19	22	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0031-9406			PHYSIOTHERAPY	Physiotherapy	JUN	2008	94	2					150	157		10.1016/j.physio.2007.08.006			8	Rehabilitation	Rehabilitation	313MO	WOS:000256744900009					2021-06-18	
J	Morgan, AT; Sell, D; Ryan, M; Raynsford, E; Hayward, R				Morgan, Angela Tamsin; Sell, Deborah; Ryan, Martina; Raynsford, Elizabeth; Hayward, Richard			Pre and post-surgical dysphagia outcome associated with posterior fossa tumour in children	JOURNAL OF NEURO-ONCOLOGY			English	Article						infratentorial neoplasm; posterior fossa tumour; brain tumour; cerebellum; child; dysphagia	TRAUMATIC BRAIN-INJURY; PEDIATRIC-PATIENTS; DYSARTHRIA; RESECTION; MUTISM	Background Swallowing impairment (dysphagia) has been reported as a possible sequela following surgical removal of posterior fossa tumours (PFT). Dysphagia may result in aspiration of food/fluid leading to respiratory tract infection, placing the patient at considerable health risk. No prospective studies have investigated dysphagia pre and post-surgical removal of PFT. The present study aimed to document the presence, severity and characteristics of dysphagia pre and post-surgical resection of PFT, and to determine whether children were managing a normal oral diet (i.e. a measure of functional swallowing ability) at two months post-surgery. Methods Dysphagia was assessed using a clinical bedside evaluation in 11 participants (8 M; aged 3 years 6 months to 13 years 5 months) pre (within 3-5 days) and post-surgery (within 1-2 weeks). Return to normal oral feeding was documented at two months post-surgery via a parent telephone interview. Results and conclusion No participant had dysphagia pre-surgically. Seventy three percent (8/11) had dysphagia at 1-2 weeks post-surgery, primarily characterized by impaired lip closure (8/8), poor mastication (8/8), and inefficient oral transit (8/8). Whilst dysphagia severity was largely mild (6/8) in presentation, data suggest that assessment and monitoring of this disorder may be required in the acute phase post-surgery. Overall however, prognosis appeared positive, with 75% (6/8) of participants managing a full oral diet at 2 months post-surgery.	[Morgan, Angela Tamsin] Murdoch Childrens Res Inst, Language & Literacy Grp, Parkville, Vic 3052, Australia; [Sell, Deborah; Ryan, Martina; Raynsford, Elizabeth] Great Ormond St Hosp Sick Children, Speech Pathol Dept, London WC1N 3JH, England	Morgan, AT (corresponding author), Murdoch Childrens Res Inst, Language & Literacy Grp, 50 Flemington Rd, Parkville, Vic 3052, Australia.	angela.morgan@mcri.edu.au	Morgan, Angela/J-5235-2017	Morgan, Angela/0000-0003-1147-7405; Sell, Debbie/0000-0002-2488-5881			Aarsen FK, 2004, NEUROLOGY, V62, P1311, DOI 10.1212/01.WNL.0000120549.77188.36; Catsman-Berrevoets CE, 1999, J NEUROL NEUROSUR PS, V67, P755, DOI 10.1136/jnnp.67.6.755; Cornwell Petrea L, 2003, Pediatr Rehabil, V6, P67; Cornwell PL, 2003, J CLIN NEUROSCI, V10, P506, DOI 10.1016/S0967-5868(03)00077-8; Hanif Ghazala, 2004, J Coll Physicians Surg Pak, V14, P150; Huber JF, 2007, J CHILD NEUROL, V22, P848, DOI 10.1177/0883073807303995; Ibrahim K, 2004, SEIZURE-EUR J EPILEP, V13, P108, DOI 10.1016/S1059-1311(03)00083-9; Martin Bonnie J. W., 1994, Dysphagia, V9, P1; Morgan A, 2005, J MED SPEECH-LANG PA, V13, P109; Morgan A, 2004, J HEAD TRAUMA REHAB, V19, P226, DOI 10.1097/00001199-200405000-00004; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Morgan A, 2003, J HEAD TRAUMA REHAB, V18, P239, DOI 10.1097/00001199-200305000-00002; MORGAN AT, 2007, DEV NEUROREHABIL, V15, P1; Newman LA, 2006, CHILD NERV SYST, V22, P1296, DOI 10.1007/s00381-006-0065-z; POLLACK IF, 1995, NEUROSURGERY, V37, P885, DOI 10.1227/00006123-199511000-00006; Reilly S, 1996, J PEDIATR-US, V129, P877, DOI 10.1016/S0022-3476(96)70032-X	16	19	20	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	MAY	2008	87	3					347	354		10.1007/s11060-008-9524-6			8	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	285VU	WOS:000254805100014	18209951				2021-06-18	
J	Spaeth, DM; Mahajan, H; Karmarkar, A; Collins, D; Cooper, RA; Boninger, ML				Spaeth, Donald M.; Mahajan, Harshal; Karmarkar, Amol; Collins, Diane; Cooper, Rory A.; Boninger, Michael L.			Development of a wheelchair virtual driving environment: Trials with subjects with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; wheelchairs	ELECTRIC-POWERED WHEELCHAIRS; ISOMETRIC JOYSTICKS; AMNESIA; TECHNOLOGY; POSITION; STATES	Objective: To develop and test a wheelchair virtual driving environment that can provide quantifiable measures of driving ability, offer driver training, and measure the performance of alternative controls. Design: A virtual driving environment was developed. The wheelchair icon is displayed in a 2-dimensional, bird's eye view and has realistic steering and inertial properties. Eight subjects were recruited to test the virtual driving environment. They were clinically evaluated for range of motion, muscle strength, and visual field function. Driving capacity was assessed by a brief trial with an actual wheelchair. During virtual trials, subjects were seated in a stationary wheelchair: a standard motion sensing joystick (MSJ) was compared with an experimental isometric joystick by using a repeated-measures design. Setting: Subjects made 2 laboratory visits. The first visit included clinical evaluation, tuning the isometric joystick. familiarization with virtual driving environment, and 4 driving tasks. The second visit included 40 trials with each joystick. Participants: Subjects (n=8; 7 men, I woman) with a mean age of 22.65 +/- 2y and traumatic brain injury, both ambulatory and nonambulatory, were recruited. Interventions: The MSJ used factory settings. A tuning program customized the isometric joystick transfer functions during visit 1. During the second visit, subjects performed 40 trials with each joystick. Main Outcome Measure: The root mean square error (RMSE) was defined as the average deviation from track centerline (in meters) and speed (in m/s). Results: Data analysis from the first 8 subjects showed no statistically significant differences between joysticks. RMSE averaged.12 to .21m; speed averaged.75 m/s. For all tasks and joysticks, driving in reverse resulted in a higher RMSE and more virtual collisions than forward driving. RMSE rates were greater in left and right turns than straight and docking tasks. Conclusions: Testing with instrumented real wheelchairs can validate the virtual driving environment and assess whether virtual driving skills transfer to actual driving.	[Spaeth, Donald M.] VA Pittsburgh HealthCare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA; [Spaeth, Donald M.; Mahajan, Harshal; Karmarkar, Amol; Collins, Diane; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA USA; [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Spaeth, Donald M.; Mahajan, Harshal; Karmarkar, Amol; Collins, Diane; Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA; [Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA	Spaeth, DM (corresponding author), VA Pittsburgh HealthCare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, 7180 Highland Dr,Bldg 4,2nd F1 E,151R1-H, Pittsburgh, PA 15206 USA.	spaethd@herlpitt.org	Karmarkar, Amol/E-6030-2011	Karmarkar, Amol/0000-0001-8355-1585; Collins, Diane/0000-0003-0646-0457; Boninger, Michael/0000-0001-6966-919X	National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education [H133A020502]; Human Engineering Research Laboratories	Supported by the National Institute on Disability and Rehabilitation Research. U.S. Department of Education (grant no. H133A020502) and supported with resources and facilities by the Human Engineering Research Laboratories. VA Pittsburgh Healthcare System.	BEVLY A, P 28 ANN RESNA C 200; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; COOPER R, 2005, Patent No. 20050195166; Cooper RA, 2000, IEEE T CONTR SYST T, V8, P112, DOI 10.1109/87.817696; Cooper RA, 2000, IEEE T BIO-MED ENG, V47, P902, DOI 10.1109/10.846684; Cooper RA, 2002, MED ENG PHYS, V24, P703, DOI 10.1016/S1350-4533(02)00111-X; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Dicianno BE, 2007, IEEE T NEUR SYS REH, V15, P144, DOI 10.1109/TNSRE.2007.891394; Dicianno BE, 2006, AM J PHYS MED REHAB, V85, P631, DOI 10.1097/01.phm.0000228519.54763.b4; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Fehr L, 2000, J REHABIL RES DEV, V37, P353; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; Harrison A, 2002, DISABIL REHABIL, V24, P599, DOI 10.1080/09638280110111360; Kanyer B., 1992, J HEAD TRAUMA REHAB, V7, P81; KAYE HS, 2000, DISABILITY STAT REPO; MAUGUS P, 2006, FACETS MAGAZINE  FAL, P26; NINISS H, 2000, P 3 INT C DIS VIRT R, P9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Spaeth D, 2002, THESIS U PITTSBURGH; SPAETH DM, P 29 ANN RESNA C 200; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VICTORIEN C, 2007, INT J REHABIL RES, V30, P91; Webster JS, 2001, ARCH PHYS MED REHAB, V82, P769, DOI 10.1053/apmr.2001.23201; WU HS, 2006, Patent No. 7004885; ZHAI S, P IEEE VIRT REAL C 2	25	19	21	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					996	1003		10.1016/j.apmr.2007.11.030			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900028	18452751				2021-06-18	
J	Baytan, SH; Alkanat, M; Okuyan, M; Ekinci, M; Gedikli, E; Ozeren, M; Akgun, A				Baytan, Sukrucan H.; Alkanat, Mehmet; Okuyan, Mukadder; Ekinci, Murat; Gedikli, Eyup; Ozeren, Mehmet; Akgun, Ahmet			Simvastatin impairs spatial memory in rats at a specific dose level	TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						Barnes maze; behavior; statins; brain; locomotor	TRAUMATIC BRAIN-INJURY; D-2 RECEPTOR EXPRESSION; PREFRONTAL CORTEX; DOPAMINE D-1; CHOLESTEROL-SYNTHESIS; REDUCTASE INHIBITORS; COGNITIVE FUNCTION; PYRAMIDAL CELLS; LOWERING DRUGS; ACETYLCHOLINE	Statins, inhibitors of cholesterol synthesis, are used to prevent cardiovascular complications. Moreover, statins have been shown to influence some cognitive functions. The modulating effects of simvastatin, one member of the statin family, on memory-related neurotransmitters and neuronal structures have also been reported. We aimed to investigate the behavioral effects of long-term simvastatin application on daily activity, psychomotor performance and spatial memory using Sprague-Dawley rats. Simvastatin (10 or 30 mg/kg/day) was administered orally to rats, in parallel with a vehicle-treated group. Daily activity test results of both simvastatin groups were found similar to the vehicle group after five weeks of simvastatin or vehicle application. Psychomotor performance was measured with the rotarod test. After 6 weeks of simvastatin or vehicle application, the vehicle-treated group stayed on the rotarod device for a shorter time compared with both simvastatin-treated groups. Spatial memory was evaluated by the Barnes maze test. Four weeks of 10 mg/kg/day simvastatin application led to poorer scores on spatial memory compared to the vehicle group, but surprisingly, this effect was not seen in the 30 mg/kg/day group. Our results revealed that simvastatin administration had no significant effect on daily activity. Psychomotor performance test results suggested that simvastatin alters psychomotor behavior at higher nervous system levels. Spatial memory test results indicate that long-term simvastatin usage impairs spatial memory only at 10 mg/kg/day dose.	[Baytan, Sukrucan H.; Alkanat, Mehmet; Okuyan, Mukadder; Akgun, Ahmet] Karadeniz Tech Univ, Sch Med, Dept Physiol, Trabzon, Turkey; [Ekinci, Murat; Gedikli, Eyup] Karadeniz Tech Univ, Sch Engn, Dept Comp Engn, Trabzon, Turkey; [Ozeren, Mehmet] Karadeniz Tech Univ, Sch Med, Dept Obstet & Gynecol, Trabzon, Turkey	Baytan, SH (corresponding author), KTU Tip Fak, Fizyoloji ABD, TR-61080 Trabzon, Turkey.	cbaytan@gmail.com	OZEREN, MEHMET/ABI-7832-2020; Ekinci, Murat/A-9653-2012; Gedikli, Eyup/U-5309-2017; Karahan, Suleyman Caner/AAL-5846-2021; ALKANAT, MEHMET/ABF-3833-2020	OZEREN, MEHMET/0000-0002-4552-9042; ALKANAT, MEHMET/0000-0001-8079-3749			Ardevol A, 1998, PFLUG ARCH EUR J PHY, V435, P454, DOI 10.1007/s004240050539; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Baytan SH, 2006, TOHOKU J EXP MED, V209, P311, DOI 10.1620/tjem.209.311; BORER KT, 1977, PHYSIOL BEHAV, V18, P29, DOI 10.1016/0031-9384(77)90089-0; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Cibickova L, 2007, PHYSIOL RES, V56, P765; COLE AE, 1983, SCIENCE, V221, P1299, DOI 10.1126/science.6612345; Darvesh S, 2004, CLIN BIOCHEM, V37, P42, DOI 10.1016/j.clinbiochem.2003.09.004; Duriez P, 2003, THERAPIE, V58, P5, DOI 10.2515/therapie:2003002; Fujishiro H, 2005, PSYCHOPHARMACOLOGY, V182, P253, DOI 10.1007/s00213-005-0072-x; Golomb BA, 2004, QJM-INT J MED, V97, P229, DOI 10.1093/qjmed/hch035; Gray JA, 1991, NEUROBIOLOGY LEARNIN, P273; Greig NH, 2005, P NATL ACAD SCI USA, V102, P17213, DOI 10.1073/pnas.0508575102; GUILLOT F, 1993, J CARDIOVASC PHARM, V21, P339, DOI 10.1097/00005344-199302000-00022; Hoebel BG, 2007, CURR OPIN PHARMACOL, V7, P617, DOI 10.1016/j.coph.2007.10.014; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; Lee RS, 1998, BRAIN RES, V799, P317, DOI 10.1016/S0006-8993(98)00477-6; Li WD, 2005, CURR BIOL, V15, P1961, DOI 10.1016/j.cub.2005.09.043; Lindberg C, 2005, J NEUROSCI RES, V82, P10, DOI 10.1002/jnr.20615; Lutjohann D, 2004, STEROIDS, V69, P431, DOI 10.1016/j.steroids.2004.03.012; Marz P, 2007, GLIA, V55, P1, DOI 10.1002/glia.20422; Mohapel P, 2005, NEUROBIOL AGING, V26, P939, DOI 10.1016/j.neurobiolaging.2004.07.015; Muldoon MF, 2000, AM J MED, V108, P538, DOI 10.1016/S0002-9343(00)00353-3; Muldoon MF, 2004, AM J MED, V117, P823, DOI 10.1016/j.amjmed.2004.07.041; Pahan K, 2006, CELL MOL LIFE SCI, V63, P1165, DOI 10.1007/s00018-005-5406-7; Parle M, 2007, YAKUGAKU ZASSHI, V127, P1125, DOI 10.1248/yakushi.127.1125; Pooler AM, 2006, J NEUROCHEM, V97, P716, DOI 10.1111/j.1471-4159.2006.03763.x; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; Schulz JG, 2004, J NEUROCHEM, V89, P24, DOI 10.1046/j.1471-4159.2003.02305.x; Snipes G J, 1997, Subcell Biochem, V28, P173; Steffenach HA, 2002, P NATL ACAD SCI USA, V99, P3194, DOI 10.1073/pnas.042700999; Summers MJ, 2007, PHARMACOTHERAPY, V27, P183, DOI 10.1592/phco.27.2.183; Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136; Thiel CM, 1998, NEUROSCIENCE, V85, P1253, DOI 10.1016/S0306-4522(98)00030-X; TSUJI A, 1993, J PHARMACOL EXP THER, V267, P1085; Turner RJ, 2004, J AM COLL NUTR, V23, p534S, DOI 10.1080/07315724.2004.10719397; Vecka M, 2004, TOHOKU J EXP MED, V204, P299, DOI 10.1620/tjem.204.299; Wagstaff LR, 2003, PHARMACOTHERAPY, V23, P871, DOI 10.1592/phco.23.7.871.32720; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang Q, 2005, BRAIN RES, V1045, P229, DOI 10.1016/j.brainres.2005.03.016; Wang Q, 2005, BRIT J PHARMACOL, V144, P933, DOI 10.1038/sj.bjp.0706106; Wang Q, 2006, NEUROSCI LETT, V408, P189, DOI 10.1016/j.neulet.2006.09.009; Wilkerson A, 1999, NEUROSCIENCE, V89, P743, DOI 10.1016/S0306-4522(98)00346-7	45	19	22	1	5	TOHOKU UNIV MEDICAL PRESS	SENDAI	2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN	0040-8727	1349-3329		TOHOKU J EXP MED	Tohoku J. Exp. Med.	APR	2008	214	4					341	349		10.1620/tjem.214.341			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	296ZN	WOS:000255584600008	18441510	Bronze			2021-06-18	
J	Hartzfeld, P; Elisevich, K; Pace, M; Smith, B; Gutierrez, JA				Hartzfeld, P.; Elisevich, K.; Pace, M.; Smith, B.; Gutierrez, J. A.			Characteristics and surgical outcomes for medial temporal post-traumatic epilepsy	BRITISH JOURNAL OF NEUROSURGERY			English	Article						closed head injury; hippocampal sclerosis; magnetic resonance imaging; medial temporal epilepsy	TRAUMATIC BRAIN-INJURY; HUMAN HEAD-INJURY; HIPPOCAMPAL PATHOLOGY; ISCHEMIA; RECEPTOR; NEURONS; DAMAGE; RAT	A common post-traumatic location of epileptogenesis is the medial temporal lobe despite evidence of associated diffuse or remote cerebral injury. We undertook a review of post-traumatic medial temporal lobe epilepsy (MTLE) patients as part of an overall post-traumatic epilepsy population to assess the extent of cerebral injury sustained by this subpopulation and to establish whether surgical outcome differed from that of a non-traumatically-induced epilepsy population. A retrospective review of 57 patients operated for post-traumatic epilepsy (PTE) over a 10-year period (1993-2003) was undertaken with particular attention to those undergoing medial temporal resection. Preoperative magnetic resonance imaging (MRI) was assessed for the type and location of abnormalities. Postoperative outcomes were compared with those of patients with MTLE of non-traumatic origin operated by the same surgeon. Of the 57 patients operated, 30 cases underwent medial temporal lobe resection. The most common mechanism of injury was blunt trauma attributable to motor vehicle accidents with imaging abnormalities characterized by medial temporal sclerosis (MTS; 16 cases), T2/FLAIR hyperintensities (nine cases), periventricular gliosis (seven cases), diffuse cerebral atrophy (five cases) and focal encephalomalacia (three cases). Six patients had normal MRI studies. No significant differences in postoperative outcomes were found between post- and non-traumatic MTLE epilepsy groups. The presence of histopathological change in the medial temporal lobe varied greatly and provided no indication of a favourable postoperative outcome. Patients with post-traumatic medial temporal lobe epilepsy respond favourably to surgical treatment. In the case of medial temporal sclerosis, there is substantial variation of histopathological findings which correlate poorly with current imaging applications. The favourable outcomes obtained following surgery in this group attest to a commonality with other risk factors in the genesis of epilepsy in this location.	[Hartzfeld, P.; Elisevich, K.] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Pace, M.] Henry Ford Hlth Syst, Dept Radiol, Detroit, MI 48202 USA; [Smith, B.] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Gutierrez, J. A.] Henry Ford Hlth Syst, Dept Pathol, Detroit, MI 48202 USA	Elisevich, K (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nskoe@neuro.hfh.edu	Elisevich, Kost/AAF-8260-2020	Elisevich, Kost/0000-0002-2695-7500			Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; de Jong EK, 2005, J NEUROSCI, V25, P7548, DOI 10.1523/JNEUROSCI.1019-05.2005; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Mitrasinovic OM, 2005, J NEUROSCI, V25, P4442, DOI 10.1523/JNEUROSCI.0514-05.2005; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAMPIGLIONE G, 1975, CIBA F SYMP, V34, P263; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SEISJO BK, 1988, ANN NY ACAD SCI, V522, P638; Soares HD, 1995, J NEUROSCI, V15, P8223; Tellez-Zenteno JF, 2005, BRAIN, V128, P1188, DOI 10.1093/brain/awh449; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	22	19	19	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	APR	2008	22	2					224	230		10.1080/02688690701818901			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	275KX	WOS:000254071400009	18348018				2021-06-18	
J	Kovesdi, E; Tamas, A; Reglodi, D; Farkas, O; Pal, J; Toth, G; Bukovics, P; Doczi, T; Buki, A				Kovesdi, Erzsebet; Tamas, Andrea; Reglodi, Dora; Farkas, Orsolya; Pal, Jozsef; Toth, Gabor; Bukovics, Peter; Doczi, Tamas; Buki, Andras			Posttraumatic administration of pituitary adenylate cyclase activating polypeptide in central fluid percussion injury in rats	NEUROTOXICITY RESEARCH			English	Article						traumatic brain injury; PACAP; axonoprotection; APP; RMO	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; VASOACTIVE-INTESTINAL-PEPTIDE; INTRAAXONAL NEUROFILAMENT COMPACTION; INDUCED RETINAL LESION; AXONAL DAMAGE; SPINAL-CORD; HIPPOCAMPAL-NEURONS; SUBSTANTIA-NIGRA; CYCLOSPORINE-A	Several in vitro and in vivo experiments have demonstrated the neuroprotective effects of pituitary adenylate cyclase activating polypeptide (PACAP) in focal cerebral ischemia, Parkinson's disease and traumatic brain injury (TBI). The aim of the present study was to analyze the effect of PACAP administration on diffuse axonal injury (DAI), an important contributor to morbidity and mortality associated with TBI, in a central fluid percussion (CFP) model of TBI. Rats were subjected to moderate (2 Atm) CFP injury. Thirty min after injury, 100 mu g PACAP was administered intracerebroventricularly. DAI was assessed by immunohistochemical detection of beta-amyloid precursor protein, indicating impaired axoplasmic transport, and RMO-14 antibody, representing foci of cytoskeletal alterations (neurofilament compaction), both considered classical markers of axonal damage. Analysis of damaged, immunoreactive axonal profiles revealed significant axonal protection in the PACAP-treated versus vehicle-treated animals in the corticospinal tract, as far as traumatically induced disturbance of axoplasmic transport and cytoskeletal alteration were considered. Similarly to our former observations in an impact acceleration model of diffuse TBI, the present study demonstrated that PACAP also inhibits DAI in the CFP injury model. The finding indicates that PACAP and derivates can be considered potential candidates for further experimental studies, or purportedly for clinical trials in the therapy of TBI.	[Kovesdi, Erzsebet; Pal, Jozsef; Bukovics, Peter; Doczi, Tamas; Buki, Andras] Univ Pecs, Fac Med, Dept Neurosurg, Pecs, Hungary; [Tamas, Andrea; Reglodi, Dora] Univ Pecs, Fac Med, Dept Anat, Pecs, Hungary; [Farkas, Orsolya] Univ Pecs, Fac Med, Dept Radiol, Pecs, Hungary; [Toth, Gabor] Univ Szeged, Dept Med Chem, Szeged, Hungary; [Bukovics, Peter] Hungarian Acad Sci, Clin Neurosci Res Grp, Pecs, Hungary	Buki, A (corresponding author), Univ Pecs, Fac Med, Dept Neurosurg, Pecs, Hungary.	andras.buki@aok.pte.hu	Buki, Andras/B-1960-2010; Pal, Jozsef/C-4073-2009; Pal, Jozsef/I-3416-2013	Pal, Jozsef/0000-0001-6468-6409			Atlasz T, 2007, GEN COMP ENDOCR, V153, P108, DOI 10.1016/j.ygcen.2006.12.022; Aubert N, 2006, J NEUROCHEM, V99, P1237, DOI 10.1111/j.1471-4159.2006.04148.x; Babai N, 2005, NEUROTOX RES, V8, P227, DOI 10.1007/BF03033976; Beal MF, 2000, NEUROTOX RES, V2, P71, DOI 10.1007/BF03033786; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brenneman DE, 2007, PEPTIDES, V28, P1720, DOI 10.1016/j.peptides.2007.04.002; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; Dejda A, 2005, PHARMACOL REP, V57, P307; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; DEYEBENES JG, 2000, NEUROTOX RES, V2, P115, DOI DOI 10.1007/BF03033789; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doberer D, 2007, EUR J CLIN INVEST, V37, P665, DOI 10.1111/j.1365-2362.2007.01832.x; Dohi K, 2002, REGUL PEPTIDES, V109, P83, DOI 10.1016/S0167-0115(02)00190-8; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Feng SQ, 2005, NEUROTOX RES, V7, P169, DOI 10.1007/BF03033785; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gasz B, 2006, PEPTIDES, V27, P87, DOI 10.1016/j.peptides.2005.06.022; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gerlach M, 2000, NEUROTOX RES, V2, P99, DOI 10.1007/BF03033788; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Katahira M., 2003, Regulatory Peptides, V115, P49; Kim WK, 2000, J NEUROSCI, V20, P3622; Li M, 2007, PEPTIDES, V28, P1891, DOI 10.1016/j.peptides.2007.05.002; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; POVISHLOK J, 1996, ACTA NEUROCHIR SUPP, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; RACZ B, 2006, INT J NEUROPROT NEUR, V2, P80; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Racz B, 2007, NEUROTOX RES, V12, P95, DOI 10.1007/BF03033918; Ravni A, 2006, J NEUROCHEM, V98, P321, DOI 10.1111/J.1471-4159.2006.03884.X; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reglodi D, 2006, NEUROPEPTIDES, V40, P265, DOI 10.1016/j.npep.2006.06.001; Reglodi D, 2004, REGUL PEPTIDES, V123, P85, DOI 10.1016/j.regpep.2004.05.016; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Reglodi D, 2005, NEUROTOX RES, V8, P317; Segura-Aguilar J, 2006, NEUROTOX RES, V10, P263, DOI 10.1007/BF03033362; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Tamas A, 2006, ANN NY ACAD SCI, V1070, P570, DOI 10.1196/annals.1317.083; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; van Landeghem FKH, 2007, ACTA NEUROPATHOL, V113, P683, DOI 10.1007/s00401-007-0208-7	60	19	21	0	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	APR	2008	13	2					71	78		10.1007/BF03033558			8	Neurosciences	Neurosciences & Neurology	313LH	WOS:000256741600001	18515209				2021-06-18	
J	Rivas, S; Douds, GL; Ostdahl, RH; Harbaugh, KS				Rivas, Sharon; Douds, G. Logan; Ostdahl, Roger H.; Harbaugh, Kimberly S.			Fulminant Guillain-Barre syndrome after closed head injury: a potentially reversible cause of an ominous examination - Case report	JOURNAL OF NEUROSURGERY			English	Article						brainstem encephalitis; fulminant Guillain-Barre syndrome; head injury; Miller Fisher syndrome	BRAIN-STEM ENCEPHALITIS; MILLER-FISHER-SYNDROME; CENTRAL PONTINE MYELINOLYSIS; ACUTE AXONAL POLYNEUROPATHY; CRITICAL ILLNESS; ELECTROPHYSIOLOGICAL FINDINGS; CHRONIC-ALCOHOLISM; DEATH; TRAUMA; OPHTHALMOPLEGIA	Fulminant Guillain-Barre syndrome (GBS) is a rapidly progressive form of polyneuropathy in which patients demonstrate eventual flaccid quadriplegia and an absence of brainstem function. Most patients present after a mild upper respiratory or gastrointestinal illness and have nondiagnostic cerebral imaging studies. The authors present a case of fulminant GBS that developed in a 55-year-old alcoholic man 1 week after admission for a closed head injury. The details of this case and a discussion of GBS will be presented. This case provides evidence for combined central and peripheral nervous system involvement in severe cases of GBS. Recognition of fulminant GBS is important to prevent inappropriate declaration of brain death or withdrawal of support in the face of a potentially reversible process.	[Rivas, Sharon; Douds, G. Logan; Harbaugh, Kimberly S.] Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA 17033 USA; [Ostdahl, Roger H.] Neurol Surg LTD, Mechanicsburg, PA USA	Harbaugh, KS (corresponding author), Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA 17033 USA.	kharbaugh@psu.edu					ALDIN AN, 1982, BRAIN, V105, P481, DOI 10.1093/brain/105.3.481; ALDIN ASN, 1987, ACTA NEUROL SCAND, V75, P287, DOI 10.1111/j.1600-0404.1987.tb05449.x; AMIT R, 1992, CHILD NERV SYST, V8, P354, DOI 10.1007/BF00296569; Arai M, 2002, EUR J NEUROL, V9, P115, DOI 10.1046/j.1468-1331.2002.00321.x; Berciano J, 1997, MUSCLE NERVE, V20, P846; BERLIT P, 1992, J CLIN NEURO-OPHTHAL, V12, P57; BICKERSTAFF ER, 1957, BRIT MED J, V1, P1384, DOI 10.1136/bmj.1.5032.1384; Bohlega SA, 1997, MUSCLE NERVE, V20, P514, DOI 10.1002/(SICI)1097-4598(199704)20:4<514::AID-MUS19>3.3.CO;2-U; Bolton CF, 2005, MUSCLE NERVE, V32, P140, DOI 10.1002/mus.20304; BOLTON CF, 1995, NEW ENGL J MED, V333, P1415, DOI 10.1056/NEJM199511233332110; COAD NR, 1990, ANAESTHESIA, V45, P456, DOI 10.1111/j.1365-2044.1990.tb14333.x; DeFreitas GR, 1997, ARQ NEURO-PSIQUIAT, V55, P315, DOI 10.1590/S0004-282X1997000200022; DUNCAN R, 1987, POSTGRAD MED J, V63, P479, DOI 10.1136/pgmj.63.740.479; FEASBY TE, 1986, BRAIN, V109, P1115, DOI 10.1093/brain/109.6.1115; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; Friedman Y, 2003, CAN J NEUROL SCI, V30, P397, DOI 10.1017/S0317167100003152; Hughes RAC, 2003, J ROY SOC MED, V96, P432, DOI 10.1258/jrsm.96.9.432; Hughes RAC, 1999, J NEUROIMMUNOL, V100, P74, DOI 10.1016/S0165-5728(99)00195-2; Hund E, 2001, CURR OPIN NEUROL, V14, P649, DOI 10.1097/00019052-200110000-00015; Lin TM, 2006, J PLAST RECONSTR AES, V59, P543, DOI 10.1016/j.bjps.2005.10.017; Matsumoto H, 2002, BRAIN DEV-JPN, V24, P98, DOI 10.1016/S0387-7604(01)00409-0; Mochizuki H, 2003, J NEUROL, V250, P1077, DOI 10.1007/s00415-003-0157-6; Mondejar RR, 2002, NEURORADIOLOGY, V44, P411, DOI 10.1007/s00234-001-0733-3; Nishimoto Y, 2004, J NEUROIMMUNOL, V148, P200, DOI 10.1016/j.jneuroim.2003.11.017; Odaka M, 2003, BRAIN, V126, P2279, DOI 10.1093/brain/awg233; Odaka M, 2001, J NEUROL NEUROSUR PS, V70, P50, DOI 10.1136/jnnp.70.1.50; Okumura A, 2002, ARCH DIS CHILD, V86, P304, DOI 10.1136/adc.86.4.304; PASTENA L, 1988, DRUG ALCOHOL DEPEN, V21, P153, DOI 10.1016/0376-8716(88)90062-2; Pulitano S, 2005, CHILD NERV SYST, V21, P473, DOI 10.1007/s00381-005-1144-2; Ragazzoni A, 2000, INT J PSYCHOPHYSIOL, V37, P99, DOI 10.1016/S0167-8760(00)00098-2; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; Ruzek KA, 2004, AM J NEURORADIOL, V25, P210; Sartucci F, 2005, NEUROL SCI, V26, P125, DOI 10.1007/s10072-005-0445-2; Sharma V, 2006, J CLIN NEUROSCI, V13, P277, DOI 10.1016/j.jocn.2005.01.011; SHUERT GT, 1972, J ORAL SURG, V30, P913; Stevenson VL, 2003, EUR J NEUROL, V10, P187, DOI 10.1046/j.1468-1331.2003.00502_1.x; Stojkovic T, 2001, J NEUROL, V248, P430, DOI 10.1007/s004150170190; Susuki K, 2003, J NEUROL SCI, V211, P89, DOI 10.1016/S0022-510X(03)00058-3; TABARAUD F, 1990, J NEUROL SCI, V97, P195, DOI 10.1016/0022-510X(90)90218-C; Tatsumoto M, 2006, J NEUROIMMUNOL, V177, P201, DOI 10.1016/j.jneuroim.2006.04.005; THOMAS PK, 1992, J NEUROL, V239, P361; THOMPSON D, 2000, DRUG DELIV TECHNOL, V2, P34; Vandenbulcke M, 1999, ACTA NEUROL BELG, V99, P198; Vargas F, 2000, INTENS CARE MED, V26, P623, DOI 10.1007/s001340051213; Vega-Basulto S, 2004, REV NEUROLOGIA, V39, P1194, DOI 10.33588/rn.3912.2003444; Wang De-sheng, 2006, J Zhejiang Univ Sci B, V7, P138, DOI 10.1631/jzus.2006.B0138; Wohrle JC, 1998, ARCH NEUROL-CHICAGO, V55, P1329, DOI 10.1001/archneur.55.10.1329; Yuki N, 1997, J NEUROL SCI, V145, P119, DOI 10.1016/S0022-510X(96)00251-1; Zifko UA, 1998, J NEUROL SCI, V159, P186, DOI 10.1016/S0022-510X(98)00164-6	49	19	20	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2008	108	3					595	600		10.3171/JNS/2008/108/3/0595			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	270PM	WOS:000253732700024	18312109				2021-06-18	
J	Casson, IR; Pellman, EJ; Viano, DC				Casson, Ira R.; Pellman, Elliot J.; Viano, David C.			Concussion in the national football league: an overview for neurologists	NEUROLOGIC CLINICS			English	Article							PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; GAME IMPACTS; INJURIES; BIOMECHANICS; PERFORMANCE; PLAYER	The authors' studies have yielded a great deal of data regarding the biomechanics of head injury and the clinical picture of mild traumatic brain injury (MTBI) in the National Football League (NFL). The research has demonstrated the link between the effects of biomechanical forces on the brain and the clinical symptomatology of the concussed players. New insights into the mechanisms of injury are leading to new ways of protecting football players from the effects of MTBI. The clinical data validate the effectiveness of the current NFL physician approach to the evaluation and treatment of the player who sustains MTBI. There are still many more questions to answer and much more knowledge to be gained from continuing research in this area.	[Viano, David C.] ProBiomech LLC, Bloomfield Hills, MI 48304 USA; [Casson, Ira R.; Pellman, Elliot J.; Viano, David C.] Natl Football League, Mild Traumat Brain Injury Comm, New York, NY 10017 USA; [Casson, Ira R.] Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Neurol, Bronx, NY 10467 USA; [Pellman, Elliot J.] LLP, ProHEALTH Care Associates, New Hyde Pk, NY 11042 USA; [Pellman, Elliot J.] Mt Sinai Hosp, Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Pellman, Elliot J.] Mt Sinai Hosp, Dept Orthopaed, New York, NY 10029 USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					*C NEUR SURG, 1996, CLIN NEUROSURG, V16, P386; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Casson Ira R, 2006, Neurosurgery, V59, pE1152; Casson Ira R, 2006, Neurosurgery, V58, pE1003, DOI 10.1227/01.NEY.0000217313.15590.C5; *COL MED SOC, 1991, REP SPORTS MED COMM; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Kelly JP, 1997, NEUROLOGY, V48, P581; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	30	19	19	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2008	26	1					217	+		10.1016/j.ncl.2007.11.005			27	Clinical Neurology; Neurosciences	Neurosciences & Neurology	281ID	WOS:000254489200013	18295092				2021-06-18	
J	Good, GE; Schopp, LH; Thomson, D; Hathaway, SL; Mazurek, MO; Sanford-Martens, TC				Good, Glenn E.; Schopp, Laura H.; Thomson, Doug; Hathaway, Stefani L.; Mazurek, Micah O.; Sanford-Martens, Tiffany C.			Men with serious injuries: Relations among masculinity, age, and alcohol use	REHABILITATION PSYCHOLOGY			English	Article						men; masculinity; alcohol abuse; traumatic brain injury; spinal cord injury	SPINAL-CORD-INJURY; GENDER-ROLE CONFLICT; TRAUMATIC BRAIN-INJURY; SUBSTANCE-ABUSE; SEXUAL ADJUSTMENT; HELP-SEEKING; PREDICTORS; DRINKING; REHABILITATION; STRESS	Objective: To increase understanding of masculine role attitudes and conflicts associated with alcohol use among men with serious injuries. Participants and Measures: Fifty-two Midwestern adult men with spinal cord injury or traumatic brain injury completed masculine role attitudes and conflicts and alcohol consumption instruments. Age and blood alcohol content at injury were obtained from records. Results: Younger men reported greater pursuit of status, drive for dominance, and risk taking but less self-reliance and overall masculine role conflict. Earlier age of injury was associated with greater pursuit of status and drive for dominance but less self-reliance, restrictive emotionality, and overall masculine role conflict. Endorsement of dominance correlated positively with number of alcoholic drinks per drinking episode (r(s) = .43) and binge drinking (r(s) = .47). Masculine role conflict associated with success, power, and competition correlated with number of drinks per drinking episode (r(s) = .46). Implications: Greater awareness and sensitivity to masculinity-related attitudes and conflicts may (a) reduce psychological barriers to accepting assistance, (b) promote active engagement in rehabilitation activities, (c) avoid counterproductive ambivalence and resistance, and (d) improve the therapeutic working alliance associated with favorable outcomes among men with serious injuries.	[Good, Glenn E.; Thomson, Doug; Hathaway, Stefani L.; Sanford-Martens, Tiffany C.] Univ Missouri, Dept Educ Sch & Counseling Psychol, Columbia, MO 65211 USA; [Schopp, Laura H.; Mazurek, Micah O.] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65211 USA	Good, GE (corresponding author), Univ Missouri, Dept Educ Sch & Counseling Psychol, 16 Hill Hall, Columbia, MO 65211 USA.	goodg@missouri.edu	Mazurek, Micah/ABE-8748-2020; Mazurek, Micah/AAR-6192-2020	Mazurek, Micah/0000-0001-7715-6538			Abreu J. M., 2000, PSYCHOL MEN MASCULIN, V1, P75, DOI DOI 10.1037/1524-9220.1.2.75; Addis ME, 2003, AM PSYCHOL, V58, P5, DOI 10.1037/0003-066X.58.1.5; Baumeister R. F., 1998, PSYCHOL BULL, V104, P3; Baumeister R. F., 1997, REV GEN PSYCHOL, V1, P145, DOI [10.1037//1089-2680.1.2.145, DOI 10.1037/1089-2680.1.2.145, 10.1037/1089-2680.1.2.145.]; Berger JM, 2005, PSYCHOL MEN MASCULIN, V6, P73, DOI DOI 10.1037/1524-9220.6.1.73; Blazina C, 1996, J COUNS PSYCHOL, V43, P461, DOI 10.1037/0022-0167.43.4.461; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Bray RM, 1999, AM J DRUG ALCOHOL AB, V25, P239, DOI 10.1081/ADA-100101858; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Conroy L, 1999, SPINAL CORD, V37, P624, DOI 10.1038/sj.sc.3100904; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; COURNOYER RJ, 1995, J COUNS PSYCHOL, V42, P11, DOI 10.1037/0022-0167.42.1.11; Courtenay WH, 1998, J AM COLL HEALTH, V46, P279, DOI 10.1080/07448489809596004; Dawson DA, 2005, ALCOHOL ALCOHOLISM, V40, P453, DOI 10.1093/alcalc/agh176; Good G. E., 2006, PSYCHOL MEN MASCULIN, V7, P165, DOI DOI 10.1037/1524-9220.7.3.165; GOOD GE, 1995, J COUNS PSYCHOL, V42, P3, DOI 10.1037/0022-0167.42.1.3; Grady Denise, 2006, N Y Times Web, pA30; HARRISON J, 1978, J SOC ISSUES, V34, P65, DOI 10.1111/j.1540-4560.1978.tb02541.x; HULL JG, 1983, J PERS SOC PSYCHOL, V44, P1097, DOI 10.1037/0022-3514.44.6.1097; ISENHART C, 2005, NEW HDB PSYCHOTHERAP, P134; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEMLE R, 1989, J SUBST ABUSE TREAT, V6, P213, DOI 10.1016/0740-5472(89)90045-7; LO CC, 1995, J DRUG ISSUES, V25, P817, DOI 10.1177/002204269502500411; Locke BD, 2005, J COUNS PSYCHOL, V52, P279, DOI 10.1037/0022-0167.52.3.279; MAHALIK JR, 2003, PSYCHOL MEN MASCULIN, V4, P3, DOI DOI 10.1037/1524-9220.4.1.3; Marini I. D., 2005, NEW HDB PSYCHOTHERAP, P88; MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.psych.39.1.223; McCreary DR, 1999, J COUNS PSYCHOL, V46, P109, DOI 10.1037/0022-0167.46.1.109; Middleton JW, 1998, ARCH PHYS MED REHAB, V79, P1428, DOI 10.1016/S0003-9993(98)90239-8; Miller W. R., 2002, MOTIVATIONAL INTERVI; *NAT SPIN CORD INJ, 2005, SPIN CORD INJ FACTS; Nolen-Hoeksema S, 2006, J GEN PSYCHOL, V133, P357, DOI 10.3200/GENP.133.4.357-374; O'Neil JM., 1995, NEW PSYCHOL MEN, P164; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; ONEIL JM, 1986, SEX ROLES, V14, P335; Phelps J, 2001, ARCH SEX BEHAV, V30, P591, DOI 10.1023/A:1011910900508; STILLSON RW, 1991, J COUNS PSYCHOL, V38, P458, DOI 10.1037/0022-0167.38.4.458; *SUBST AB MENT HLT, 2005, 2005 NATL SURV DRUG; Substance Abuse and Mental Health Services Administration OoAS, 2007, NSDUH REP GEND DIFF; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; Tokar DM, 2000, J COUNS PSYCHOL, V47, P380, DOI 10.1037//0022-0167.47.3.380; WATANABE ME, 2005, APPL NEUROLOGY, V1, P10; Williams RJ, 1999, J PSYCHOL, V133, P323, DOI 10.1080/00223989909599745; Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0; Zoroya G, 2005, US TODAY, pA1	51	19	19	0	11	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2008	53	1					39	45		10.1037/0090-5550.53.1.39			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	266JR	WOS:000253431900005					2021-06-18	
J	Lundblad, C; Grande, PO; Bentzer, P				Lundblad, Cornelia; Grande, Per-Olof; Bentzer, Peter			Increased cortical cell loss and prolonged hemodynamic depression after traumatic brain injury in mice lacking the IP receptor for prostacyclin	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; brain edema; microvascular permeability; microvascular perfusion; prostacyclin	LOW-DOSE PROSTACYCLIN; CEREBRAL BLOOD-FLOW; THROMBOXANE A(2); CAPILLARY PERFUSION; HEAD-INJURY; RAT; PERMEABILITY; INHIBITOR; ISCHEMIA; MOUSE	Prostacyclin is the major arachidonic acid metabolite of the vascular endothelium and is produced mainly via the cyclooxygenase-2 pathway. By acting on the prostacyclin (IP) receptor on platelets and vascular smooth muscle cells, prostacyclin exerts vasodilatory and antiaggregative/antiadhesive effects. Previous studies have shown that prostacyclin production increases after brain trauma, but the importance of prostacyclin for posttraumatic hemodynamic alterations and neuron survival has not been investigated. This study evaluated if endogenous prostacyclin plays a role in the pathophysiologic process in the brain after brain trauma. This was performed by comparing prostacyclin (IP) receptor-deficient (IP-/-) mice and mice with functional IP receptor (IP+/+) after a controlled cortical injury regarding contusion volume, cerebral blood flow ([C-14] iodoantipyrine autoradiography), number of perfused capillaries (fluorescein isothiocyanate-dextran fluorescence technique), the transfer constant (K-i) for [Cr-51] EDTA, and brain water content (wet vs dry weight) in the injured and contralateral cortex. Contusion volume was increased in IP-/- mice compared with IP+/+ mice. Three hours after trauma, cortical blood flow was decreased in the injured cortex of both groups and the reduction in blood flow in the cortex of the IP-/- mice persisted from 3 to 24 h, whereas blood flow approached normal values in the IP+/+ mice after 24 h. No differences could be detected between the two genotypes regarding other hemodynamic parameters. We conclude that the prostacyclin IP receptor is beneficial for neuron survival after brain trauma in mice, an effect that may be mediated by improved cortical perfusion.	[Lundblad, Cornelia; Grande, Per-Olof; Bentzer, Peter] Univ Lund Hosp, Dept Anesthesiol & Intens Care, Univ Lund, SE-22185 Lund, Sweden	Bentzer, P (corresponding author), Univ Lund Hosp, Dept Anesthesiol & Intens Care, Univ Lund, SE-22185 Lund, Sweden.	peter.bentzer@med.lu.se		Lundblad, Cornelia/0000-0001-9686-2112			Bentzer P, 2004, J TRAUMA, V56, P385, DOI 10.1097/01.TA.0000057238.75632.7F; Bentzer P, 2003, J NEUROTRAUM, V20, P447, DOI 10.1089/089771503765355522; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; ERLANSSON M, 1991, PROSTAGLANDINS, V41, P157, DOI 10.1016/0090-6980(91)90028-E; FENSTERMACHER JD, 1981, PHARMACOL THERAPEUT, V14, P217, DOI 10.1016/0163-7258(81)90062-0; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Liu D, 2002, J CEREBR BLOOD F MET, V22, P431, DOI 10.1097/00004647-200204000-00007; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MCCALDEN TA, 1984, LIFE SCI, V34, P1801, DOI 10.1016/0024-3205(84)90672-6; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; Rudic RD, 2005, CIRC RES, V96, P1240, DOI 10.1161/01.RES.0000170888.11669.28; SAKURADA O, 1978, AM J PHYSIOL, V234, P59; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; WANIEWSKI J, 1992, NEPHROL DIAL TRANSPL, V7, P50; WEISS HR, 1988, MICROVASC RES, V36, P172, DOI 10.1016/0026-2862(88)90017-9; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; Xiao CY, 2001, CIRCULATION, V104, P2210, DOI 10.1161/hc4301.098058; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	36	19	20	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2008	28	2					367	376		10.1038/sj.jcbfm.9600533			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	255MS	WOS:000252662700014	17713464	Bronze			2021-06-18	
J	Salim, A; Martin, M; Brown, C; Inaba, K; Browder, T; Rhee, P; Teixeira, PGR; Demetriades, D				Salim, Ali; Martin, Matthew; Brown, Carlos; Inaba, Kenji; Browder, Timothy; Rhee, Peter; Teixeira, Pedro G. R.; Demetriades, Demetrios			The presence of the adult respiratory distress syndrome does not worsen mortality or discharge disability in blunt trauma patients with severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						adult respiratory distress syndrome; traumatic brain injury; trauma; morbidity; mortality; disability	ACUTE LUNG INJURY; NEUROGENIC PULMONARY-EDEMA; SEVERE HEAD-INJURY; COMBAT CASUALTIES; RISK-FACTORS; INSUFFICIENCY; IDENTIFICATION; COMPLICATIONS; CARE	Purpose: To evaluate the prevalence of the acute respiratory distress syndrome (ARDS) among blunt trauma patients with severe traumatic brain injury (TBI) and to determine if ARDS is associated with higher mortality, morbidity and worse discharge outcome. Methods: Blunt trauma patients with TBI (head abbreviated injury score {AIS} >= 4) who developed predefined ARDS criteria between January 2000 and December 2004 were prospectively collected as part of an ongoing ARDS database. Each patient in the TBI + ARDS group was matched with two control TBI patients based on age, injury severity score (ISS) and head AIS. Outcomes including complications, mortality and discharge disability were compared between the two groups. Results: Among 362 TBI patients, 28 (7.7%) developed ARDS. There were no differences between the two groups with respect to age, sex, ISS, Glasgow coma score (GCS), head, abdomen and extremity AIS. The TBI + ARDS group had significantly more patients with chest AIS >= 3 (57.1% versus 32.1%, p = 0. 03). There was no difference with respect to overall mortality between the TBI + ARDS group (50.0%) and the TBI group (51.8%) (OR 0.79: 95% Cl 0.31-2.03, p=0.63). There was no significant difference with respect to discharge functional capacity between the two groups. There were significantly more overall complications in the TBI + ARDS group (42.9%) compared to the TBI group (16.1%) (OR 3.66: 95% CI 1.19-11.24, p=0.02). The TBI + ARDS group had an overall mean intensive care unit (ICU) length of stay of 15.6 days, versus 8.4 days in the TBI group (p < 0.01). The TBI + ARDS group had significantly higher hospital charges than the TBI group ($210,097 versus $115,342, P < 0.01). Conclusion: The presence of ARDS was not associated with higher mortality or worse discharge disability. It was, however, associated with higher hospital morbidity, longer ICU and hospital length of stay. (c) 2007 Elsevier Ltd. All rights reserved.	[Salim, Ali; Martin, Matthew; Brown, Carlos; Inaba, Kenji; Browder, Timothy; Rhee, Peter; Teixeira, Pedro G. R.; Demetriades, Demetrios] Univ So Calif, Los Angeles Cty Med Ctr, Univ So Calif Keck Sch Med, Div Trauma & Crit Ctr,Dept Surg, Los Angeles, CA 90033 USA	Salim, A (corresponding author), LAC USC, Med Ctr, 1200 N State St,Rm 9900, Los Angeles, CA 90033 USA.	asalim@surgery.usc.edu	Teixeira, Pedro/H-2239-2011; INABA, KENJI/AAC-8532-2020; Martin, Matthew/B-2676-2014	Teixeira, Pedro/0000-0002-7258-7977; Martin, Matthew/0000-0002-9169-9069			BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BRATTON SL, 1997, NEUROSURGERY, V41, P1214; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742; Eberhard LW, 2000, CRIT CARE MED, V28, P125, DOI 10.1097/00003246-200001000-00021; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; GARCIAURIA J, 1981, J NEUROSURG, V54, P632, DOI 10.3171/jns.1981.54.5.0632; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; KATSURADA K, 1973, SURGERY, V73, P191; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; MARTIN AM, 1969, ANN SURG, V170, P30, DOI 10.1097/00000658-196907000-00004; Martin M, 2005, J TRAUMA, V59, P1107, DOI 10.1097/01.ta.0000188633.94766.d0; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; MCCLELLAN MD, 1989, J APPL PHYSIOL, V67, P1185; Miller PR, 2002, AM SURGEON, V68, P845; Navarrete-Navarro P, 2001, INTENS CARE MED, V27, P1133, DOI 10.1007/s001340100955; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Salim A, 2006, ARCH SURG-CHICAGO, V141, P655, DOI 10.1001/archsurg.141.7.655; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; Treggiari MM, 2004, CRIT CARE MED, V32, P327, DOI 10.1097/01.CCM.0000108870.09693.42; Valta P, 1999, CRIT CARE MED, V27, P2367, DOI 10.1097/00003246-199911000-00008; Weisman SJ, 1939, SURGERY, V6, P722	26	19	22	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	JAN	2008	39	1					30	35		10.1016/j.injury.2007.06.015			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	264GE	WOS:000253274700004	17920066				2021-06-18	
J	Salorio, CF; Slomine, BS; Guerguerian, AM; Christensen, JR; White, JRM; Natale, JE; Shaffner, DH; Grados, MA; Vasa, RA; Gerring, JP				Salorio, Cynthia F.; Slomine, Beth S.; Guerguerian, Anne-Marie; Christensen, James R.; White, Jeanette R. M.; Natale, JoAnne E.; Shaffner, Donald H.; Grados, Marco A.; Vasa, Roma A.; Gerring, Joan P.			Intensive care unit variables and outcome after pediatric traumatic brain injury: A retrospective study of survivors	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; critical care; outcome predictors; blood pressure; children	CEREBRAL PERFUSION-PRESSURE; DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; BLOOD-PRESSURE; AUTOREGULATION; CHILDREN; HYPOTENSION; PREDICTORS; COMA	Objective: Traumatic brain injury is a leading cause of death and disability in children. Hypotension has been associated with poor survival and outcome in children after traumatic brain injury, but the effect of acute hypertension is less certain. The objective was to obtain acute physiologic variables during the early hospitalization period in a cohort of children prospectively enrolled in another study. Design. Retrospective chart reviews. Setting: University-affiliated pediatric rehabilitation center. Patients. Fifty-seven survivors, 5-17 yrs of age, admitted for rehabilitation between 1992 and 1995 after sustaining a traumatic brain injury. Interventions: Standard of care. Measurements and Main Results. Outcomes were assessed at 1 yr postinjury through cognitive testing of the child and parent interview of the child's global functional skills. Cognitive outcome was measured using the Performance 10 from the Wechsler Intelligence Scale for Children, Third Edition. Overall functional outcome was assessed using the Disability Rating Scale. Conclusions. This study suggests that early markers of secondary injury after moderate to severe traumatic brain injury in children may be predictive of long-term outcome. This study reinforces the need for longer term, systematic, and more precise measurements of outcomes in children with traumatic brain injury and prospective studies to examine the predictive value of acute management variables on multiple types of outcomes after traumatic brain injury in children.	[Slomine, Beth S.] Kennedy Krieger Inst, Neuropsychol Rehabil Serv, Baltimore, MD 21205 USA; [Salorio, Cynthia F.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21205 USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Grados, Marco A.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Guerguerian, Anne-Marie] Univ Toronto, Hosp Sick Children, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Guerguerian, Anne-Marie] Univ Toronto, Res Inst, Toronto, ON, Canada; [White, Jeanette R. M.] Medicalliance, Sci Affairs, Columbia, MD USA; [Natale, JoAnne E.] Univ Calif Davis, Dept Pediat, Sacramento, CA 95817 USA; [Gerring, Joan P.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA	Salorio, CF (corresponding author), Kennedy Krieger Inst, Neuropsychol Rehabil Serv, Baltimore, MD 21205 USA.	salorio@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264; SHAFFNER, DONALD/0000-0001-5530-0746	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007414] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5-T32-HD0741410] Funding Source: Medline		ADELSON PD, 2004, PEDIATR CRIT CARE ME, V4, pS12; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; *BRAIN TRAUM FDN, 2003, GUID MAN SEV TRAUM B; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Heath D L, 1999, J Neurosci Nurs, V31, P97; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; Immink RV, 2004, CIRCULATION, V110, P2241, DOI 10.1161/01.CIR.0000144472.08647.40; Jackson S, 2000, ACTA NEUROCHIR SUPPL, V76, P453; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jones PA, 2003, PHYSIOL MEAS, V24, P201, DOI 10.1088/0967-3334/24/1/315; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kirkness CJ, 2005, ACTA NEUROCHIR SUPPL, V95, P13; Lannoo E, 1998, INTENS CARE MED, V24, P236, DOI 10.1007/s001340050556; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Wechsler D., 1991, WECHSLER INTELLIGENC; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; WILSON J T L, 1990, Brain Injury, V4, P349; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	48	19	19	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2008	9	1					47	53		10.1097/01.PCC.0000298638.66240.0E			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	252QR	WOS:000252462200009	18477913				2021-06-18	
J	Nicholson, KL; Mansbach, RS; Menniti, FS; Balster, RL				Nicholson, Katherine L.; Mansbach, Robert S.; Menniti, Frank S.; Balster, Robert L.			The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys	BEHAVIOURAL PHARMACOLOGY			English	Article						CP-101 606; drug discrimination; monkey; N-methyl-D-aspartate; phencyclidine; rat self-ad ministration; traxprodil	RECEPTOR NR2B SUBUNIT; TRAUMATIC BRAIN-INJURY; NMDA RECEPTORS; IN-VITRO; CHANNEL; KETAMINE; DRUG; STEREOISOMERS; PHARMACOLOGY; BLOCKER	Development of N-methyl-D-aspartate (NMDA) antagonists for a variety of disorders has been hindered by their production of phencyclidine (PCP)-like psychological effects and abuse potential. There is, however, evidence to suggest that this problem might be mitigated by targeting NMDA receptors subtypes, in particular, those containing the NR2B subunit. To further test this hypothesis, the NR2B selective antagonist CP-101 606 (traxoprodil) was evaluated in two animal models: drug discrimination, a model of the subjective effects of drugs in humans, and self-administration, which evaluates the reinforcing properties of the drug. In the first study, CP-101 606 (3-300 mu g/kg/infusion) was tested for intravenous self-administration in rhesus monkeys experienced in PCP (5.6pg/kg/infusion, intravenously) self-administration. In the second study, CP-1 01 606 was tested for production of PCP-like discriminative stimulus effects in rats (3-56 mg/ kg, intraperitoneally) and rhesus monkeys (0.3-5.6 mg/kg intravenously). Evidence was obtained for reinforcing effects of at least one dose of CP-1 01 606 in all four monkeys. In rats, CP-101 606 produced more than 80% mean PCP-lever selection (2.0 mg/kg, intraperitoneally) but, unlike PCP itself, the dose producing the highest level of substitution was accompanied by more than 50% suppression of response rates. In monkeys, CP-101 606 produced more than 90% PCP-lever selection (0.1 mg/kg intramuscularly) in three of four animals at doses that did not significantly decrease rates of responding. The data show that CP-101606 has some PCP-like discriminative stimulus effects in rats and monkeys and functions as a positive reinforcer in monkeys. These results suggest that inhibition of NR2B subunit containing NMDA receptors plays a role in the production of the subjective effects and abuse potential associated with many subtype-nonselective NMDA receptor antagonists such as PCR.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Somaxon Pharmaceut, San Diego, CA USA; CNS Discovery, Pfizer Global Res & Dev, Groton, CT USA	Nicholson, KL (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, PO Box 980613, Richmond, VA 23298 USA.			Menniti, Frank/0000-0003-2612-9534	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA001442-30, R01 DA001442, DA-01442] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA001442] Funding Source: NIH RePORTER		ATOR NA, 1987, PHARMACOL BIOCHEM BE, V27, P391, DOI 10.1016/0091-3057(87)90588-0; BALSTER RL, 1995, BEHAV PHARMACOL, V6, P577; BALSTER RL, 1994, DRUG ALCOHOL DEPEN, V35, P211, DOI 10.1016/0376-8716(94)90076-0; BALSTER RL, 1991, BRIT J ADDICT, V86, P1549; BALSTER RL, 1990, COMP PERCEPTION, V1, P127; BALSTER RL, 1996, HANDB EXP PHARM, V118, P233; Bandyopadhyay S, 2006, EPILEPSY RES, V72, P127, DOI 10.1016/j.eplepsyres.2006.07.013; Bath CP, 1996, EUR J PHARMACOL, V299, P103, DOI 10.1016/0014-2999(95)00846-2; Beardsley PM, 2002, BEHAV PHARMACOL, V13, P583, DOI 10.1097/00008877-200211000-00007; Boyce S, 1999, NEUROPHARMACOLOGY, V38, P611, DOI 10.1016/S0028-3908(98)00218-4; Brackett RL, 2000, NEUROPHARMACOLOGY, V39, P407, DOI 10.1016/S0028-3908(99)00151-3; BRADY KT, 1982, PHARMACOL BIOCHEM BE, V17, P291, DOI 10.1016/0091-3057(82)90083-1; BRADY KT, 1982, SCIENCE, V215, P178, DOI 10.1126/science.6274022; BRADY KT, 1982, J PHARMACOL EXP THER, V220, P56; Brimecombe JC, 1997, P NATL ACAD SCI USA, V94, P11019, DOI 10.1073/pnas.94.20.11019; BULLOCK R, 1999, ANN NY ACAD SCI, V890, P551; Chaperon F, 2003, BEHAV PHARMACOL, V14, P477, DOI 10.1097/01.fbp.0000091471.79060.ed; Chazot PL, 2004, CURR MED CHEM, V11, P389, DOI 10.2174/0929867043456061; Chazot PL, 2002, NEUROPHARMACOLOGY, V42, P319, DOI 10.1016/S0028-3908(01)00191-5; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; Chenard BL, 1999, CURR PHARM DESIGN, V5, P381; CHENARD BL, 1991, J MED CHEM, V34, P3085, DOI 10.1021/jm00114a018; De Vry J, 2003, BEHAV PHARMACOL, V14, P229, DOI 10.1097/00008877-200305000-00007; DERLET RW, 1990, PHARMACOL BIOCHEM BE, V36, P745, DOI 10.1016/0091-3057(90)90071-O; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; Dravid SM, 2007, J PHYSIOL-LONDON, V581, P107, DOI 10.1113/jphysiol.2006.124958; Dyker AG, 1999, STROKE, V30, P986, DOI 10.1161/01.STR.30.5.986; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Furukawa H, 2005, NATURE, V438, P185, DOI 10.1038/nature04089; GRIFFITHS RR, 1979, CLIN PHARMACOL THER, V25, P611; Guscott MR, 2003, EUR J PHARMACOL, V476, P193, DOI 10.1016/S0014-2999(03)02182-4; Hallett PJ, 2004, PHARMACOL THERAPEUT, V102, P155, DOI 10.1016/j.pharmthera.2004.04.001; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; HOLTZMAN SG, 1990, MODERN METHODS PHARM, V6, P193; JACKSON A, 1988, PSYCHOPHARMACOLOGY, V96, P87, DOI 10.1007/BF02431538; KEW JN, 1996, J PHYSL, V15, P761; Klein M, 1999, ANN NY ACAD SCI, V890, P515, DOI 10.1111/j.1749-6632.1999.tb08033.x; Koek W, 1999, PHARMACOL BIOCHEM BE, V64, P275, DOI 10.1016/S0091-3057(99)00055-6; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; Kundrotiene J, 2004, J NEUROTRAUM, V21, P83, DOI 10.1089/089771504772695977; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LANNES B, 1991, NEUROSCI LETT, V128, P177, DOI 10.1016/0304-3940(91)90255-R; Luo JH, 1997, MOL PHARMACOL, V51, P79; McAllister KH, 1996, EUR J PHARMACOL, V314, P307, DOI 10.1016/S0014-2999(96)00576-6; Menniti F, 1997, EUR J PHARMACOL, V331, P117, DOI 10.1016/S0014-2999(97)10092-9; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; Monaghan DT, 1997, J PHARMACOL EXP THER, V280, P614; MONYER H, 1992, NATURE, V256, P1217; Mott DD, 1998, NAT NEUROSCI, V1, P659, DOI 10.1038/3661; Nankai M, 1998, PROG NEURO-PSYCHOPH, V22, P35, DOI 10.1016/S0278-5846(97)00180-2; Nicholson KL, 1997, BEHAV PHARMACOL, V8, P396; Nicholson KL, 1999, PSYCHOPHARMACOLOGY, V146, P49, DOI 10.1007/s002130051087; Nicholson KL, 1998, BEHAV PHARMACOL, V9, P231; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; PARSONS CG, 1995, NEUROPHARMACOLOGY, V34, P1239, DOI 10.1016/0028-3908(95)00092-K; Parsons CG, 1998, DRUG NEWS PERSPECT, V11, P523, DOI 10.1358/dnp.1998.11.9.863689; ROGAWSKI MA, 1993, TRENDS PHARMACOL SCI, V14, P325, DOI 10.1016/0165-6147(93)90005-5; Sharma TA, 1999, J PHARMACOL EXP THER, V289, P1041; SLIFER BL, 1983, J PHARMACOL EXP THER, V225, P522; SLIFER BL, 1985, SUBST ALCOHOL ACTION, V5, P273; Smith Paul F, 2003, Curr Opin Investig Drugs, V4, P826; Steece-Collier K, 2000, EXP NEUROL, V163, P239, DOI 10.1006/exnr.2000.7374; Taniguchi K, 1997, BRIT J PHARMACOL, V122, P809, DOI 10.1038/sj.bjp.0701445; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409; Wessell RH, 2004, NEUROPHARMACOLOGY, V47, P184, DOI 10.1016/j.neuropharm.2004.03.011; WILLETTS J, 1988, EUR J PHARMACOL, V146, P167, DOI 10.1016/0014-2999(88)90498-0; Witkin JM, 1997, J PHARMACOL EXP THER, V280, P46; YAMAKURA T, 1993, NEUROREPORT, V4, P687, DOI 10.1097/00001756-199306000-00021; Young AM, 1986, BEHAVIORAL ANAL DRUG, P9; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428	70	19	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0955-8810			BEHAV PHARMACOL	Behav. Pharmacol.	DEC	2007	18	8					731	743		10.1097/FBP.0b013e3282f14ed6			13	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	236DM	WOS:000251283200004	17989511				2021-06-18	
J	Dirette, DK; Plaisier, BR				Dirette, Diane K.; Plaisier, Brian R.			The development of self-awareness of deficits from 1 week to 1 year after traumatic brain injury: Preliminary findings	BRAIN INJURY			English	Article						self-awareness; time post-injury; severity of injury; deficit factors	IMPAIRED AWARENESS; REHABILITATION; SEVERITY	Primary objective: To examine the process of recovery of self- awareness with consideration for the variables of severity of injury and deficit factors. Research design: A longitudinal, descriptive design was used. Methods and procedures: Eighteen participants and their significant others were interviewed using the Awareness Questionnaire at 1 week, 1 month, 4 months and 1 year post- injury. Main outcomes and results: Participants differed in self- awareness according to severity of injury, deficit factors and time post- injury. Overall, participants with mild TBI demonstrated better self- awareness. There was a significant interaction effect between severity of injury and time post- injury. Reduced self- awareness of cognitive deficits was noted for the participants with moderate and severe TBI. Conclusions: Time post- injury, severity of injury and deficit factors are confounding variables in the study of self- awareness.	Western Michigan Univ, Dept Occupat Therapy, Kalamazoo, MI 49008 USA; Bronson Methodist Hosp, Kalamazoo, MI USA	Dirette, DK (corresponding author), Western Michigan Univ, Dept Occupat Therapy, 1903 W Michigan Ave, Kalamazoo, MI 49008 USA.	diane.dirette@wmich.edu					BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; COETZER BR, 2002, J COGNITIVE REHABILI, V4, P46; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Garmoe W, 2005, J HEAD TRAUMA REHAB, V20, P348, DOI 10.1097/00001199-200507000-00006; Golden Z, 2003, INT J NEUROSCI, V113, P733, DOI 10.1080/00207450390200044; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LAATSCH L, 2001, J COGNITIVE REHA SPR, P10; MCWILLIAMS S, 1991, BRIT J OCCUPATIONAL, V54, P246; Munro B., 2005, STAT METHODS HLTH RE; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rimel RW, 1990, REHABILITATION ADULT, P8; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505	25	19	20	0	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2007	21	11					1131	1136		10.1080/02699050701687326			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WX	WOS:000250329900004	17952713				2021-06-18	
J	Klonoff, PS; Talley, MC; Dawson, LK; Myles, SM; Watt, LM; Gehrels, JA; Henderson, SW				Klonoff, Pamela S.; Talley, Melanie C.; Dawson, Lauren K.; Myles, Stephen M.; Watt, Lisa M.; Gehrels, Jo-Ann; Henderson, Steven W.			The relationship of cognitive retraining to neurological patients' work and school status	BRAIN INJURY			English	Article						cognitive retraining; work; outcome; vocational rehabilitation; brain injury	TRAUMATIC BRAIN-INJURY; MILIEU-BASED NEUROREHABILITATION; 11 YEARS POSTDISCHARGE; REHABILITATION; OUTCOMES; AWARENESS; PROGRAM	Primary objective: To explore the relationship of cognitive retraining performance to discharge productivity status. Methods and procedures: One hundred and one brain-injured patients from a holistic milieu-oriented work/school re-entry programme. Experimental interventions: Initial, last, mean and best cognitive retraining scores; cognitive retraining behavioural checklist ratings; and working alliance scores. Main outcomes and results: Most (82.2%) of the sample returned to paid work or school. Better performance on two cognitive retraining tasks addressing information processing speed, visual scanning, visuospatial skills and memory were associated with return to the same level of work/school with and without modifications. Selected process variables related to the patients' behavioural approach to cognitive retraining tasks (e. g. their use of compensations, organizational and abstraction skills, procedural skills and unassisted task recall) were associated with better work/school outcomes. Patients' positive working alliance ratings related to their behavioural approach to cognitive retraining tasks. This highlights the importance of combining interventions targeting both the therapeutic interactive process and skill remediation to maximize work/ school reintegration. Conclusions: Cognitive Retraining exercises that incorporate both process variables and metacognitive skills, as well as a better working alliance with patients, positively related to return to work and school at the time of discharge from a holistic milieu-oriented programme.	Ctr Transit Neurorehabil, Barrow Neurol Inst, Phoenix, AZ USA	Klonoff, PS (corresponding author), St Josephs Hosp, Barrow Neurol Inst, CTN, 222 W Thomas Rd,Suite 401, Phoenix, AZ 85013 USA.	pamela.klonoff@chw.edu					BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bordin E. S., 1994, WORKING ALLIANCE THE, P13, DOI DOI 10.1037/H0085885; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CHRISTENSEN AL, 1992, SCAND J REHABIL MED, P34; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; FRYER LJ, 1989, J HEAD TRAUMA REHAB, V4, P20; Goverover Y, 2004, J CLIN EXP NEUROPSYC, V26, P737, DOI 10.1080/13803390490509321; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; KLONOFF PS, 2005, CRITICAL TREATMENT I; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; KLONOFF PS, 1996, THEORETICAL FDN CLIN, P219; Klonoff PS, 2000, INT HDB NEUROPSYCHOL, P195; MALEC J, 1992, NEUROREHABILITATION, V2, P1; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Mateer C A, 1999, Semin Clin Neuropsychiatry, V4, P50; PERNA RB, 2000, J COGNITIVE REHABILI, V7, P18; Petrella L, 2005, BRAIN INJURY, V19, P643, DOI 10.1080/02699050410001671874; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; Spreen O., 1991, COMPENDIUM NEUROPSYC; STERN JM, 1985, SCAND J REHABIL MED, P53; TEASDALE TW, 1993, BRAIN INJURY, V7, P535, DOI 10.3109/02699059309008181; Wechsler D, 1997, WAIS 3 ADM SCORING M	31	19	19	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2007	21	11					1097	1107		10.1080/02699050701687342			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WX	WOS:000250329900001	17952711				2021-06-18	
J	Simpson, GK; Tate, RL				Simpson, Grahame K.; Tate, Robyn L.			Preventing suicide after traumatic brain injury: implications for general practice	MEDICAL JOURNAL OF AUSTRALIA			English	Article							REHABILITATION; ASSOCIATION; DEPRESSION	People with traumatic brain injury (TBI) have an increased risk of suicide, suicide attempts and suicide ideation compared with the general population. Most suicide deaths and attempts involve self-poisoning. General practitioners are strategically placed to make a significant contribution to preventing suicide in this group. Assessment approaches need to take into account the chronic nature of suicide risk in people with TBI. The assessment of post-TBI,depression is complicated by the confounding effect of post-TBI motor-sensory and cognitive impairments, but psychological symptoms (feelings of hopelessness, worthlessness, and anhedonia, in particular) suggest the diagnosis of depression after TBI. Management includes close attention to how medications are prescribed, dispensed and administered. Family and community brain injury agencies can be enlisted to provide emotional support and monitoring of people with TBI. GPs can facilitate access to needed mental health services for people with TBI during times of suicidal crisis. Clinical practice guidelines for the care of people living with traumatic brain injury in the community, recently published for general practice, may be of use in managing people with TBI (http://www.maa.nsw.gov.au/default.aspx?MenulD=188).	Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia	Simpson, GK (corresponding author), Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia.	grahame.simpson@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060			ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Beautrais AL, 2005, CRISIS, V26, P1, DOI 10.1027/0227-5910.26.1.1; *COMM DEP HLTH AG, 2000, LIFE FRAM PREV SUIC; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORTUNE N, 1999, DEFINITION INCIDNENC; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Haste F, 1998, BRIT J GEN PRACT, V48, P1759; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; McKelvey RS, 2001, MED J AUSTRALIA, V175, P550, DOI 10.5694/j.1326-5377.2001.tb143718.x; MRAZEK PJ, 1994, COMMITTE PREVENTION; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SIMPSON GK, 2001, SUICIDE PREVENTION T; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; TREVENA L, 2004, CLIN PRACTICE GUIDEL; Williams WH, 2003, STUD NEUROPSYCHOL DE, P115	24	19	20	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0025-729X	1326-5377		MED J AUSTRALIA	Med. J. Aust.	AUG 20	2007	187	4					229	232		10.5694/j.1326-5377.2007.tb01206.x			4	Medicine, General & Internal	General & Internal Medicine	206CB	WOS:000249160400009	17708726				2021-06-18	
J	Barrett, AM; Eslinger, PJ				Barrett, Anna M.; Eslinger, Paul J.			Amantadine for adynamic speech - Possible benefit for aphasia?	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						amantadine; aphasia; rehabilitation	TRAUMATIC BRAIN-INJURY; OPEN-LABEL TRIAL; NONFLUENT APHASIA; REHABILITATION; BROMOCRIPTINE	Objective: Dopaminergic agents may stimulate behavior and verbal expression after frontal lobe dysfunction. Although amantadine is used in neurorehabilitation of motivational disorders and head injury, it is not commonly prescribed to improve aphasia. This pilot study examined verbal fluency on and off amantadine for nonfluent speech. Design: Four participants undergoing inpatient rehabilitation, meeting criteria for transcortical motor aphasia had stroke (2), stroke postaneurysm surgery (1), or brain tumor resection (1). We administered 100 mg of amantadine twice a day in an open-label, on- off protocol, with multiple assessments per on-off period. Results: Off medication, subjects generated a mean 12.62 of words (abnormally few) on the Controlled Oral Word Association test. On medication, word generation significantly improved to 17.7 1 words (P = 0.04), although scores remained psychometrically in the abnormal range. Conclusions: Further research on amantadine, specifically for nonfluent speech and nonfluent aphasia, including effects on functional communication and control conditions, may be warranted.	Kessler Med Rehabilitat REs & Educ Cor, Stroke Rehabilitat Res Program, W Orange, NJ 07052 USA; Penn State Coll Med, Dept Neurol Neural & Behav Sci & Radiol, Hershey, PA USA	Barrett, AM (corresponding author), Kessler Med Rehabilitat REs & Educ Cor, Stroke Rehabilitat Res Program, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.			Barrett, A.M./0000-0002-0789-2887	NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB00454, R01 EB000454] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02 NS047099-01, K02 NS047099-04, K02 NS 47099, K08 NS 002085, K08 NS002085-06, K02 NS047099] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS047099, K08NS002085] Funding Source: NIH RePORTER		ALBERT ML, 1981, CLIN ASPECTS DYSPHAS; Arciniegas DB, 2004, BRAIN INJURY, V18, P1309, DOI 10.1080/02699050410001720130; BENSON DF, 1996, APHASIA CLIN PERSPEC, P15; Benton A, 1989, MULTILINGUAL APHASIA; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; DeMarchi R, 2005, CAN J NEUROL SCI, V32, P4, DOI 10.1017/S0317167100016826; DOTY L, 1990, GERONTOLOGIST, V30, P20; Drayton SJ, 2004, PSYCHOSOMATICS, V45, P205, DOI 10.1176/appi.psy.45.3.205; Gold M, 2000, BRAIN LANG, V74, P141, DOI 10.1006/brln.2000.2332; Greener J, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858, DOI 10.1002/14651858.CD000424]; HERRMANN M, 1989, APHASIOLOGY, V3, P513, DOI 10.1080/02687038908249019; Imamura T, 1994, No To Shinkei, V46, P556; Klein Reva B., 2004, Seminars in Speech and Language, V25, P193; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; KRUPP LB, 1995, NEUROLOGY, V45, P19956; MAZZONI M, 1995, APHASIOLOGY, V9, P553, DOI 10.1080/02687039508248714; MAZZONI M, 1992, APHASIOLOGY, V6, P387, DOI 10.1080/02687039208248609; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MILLET VM, 1982, ANTIMICROB AGENTS CH, V21, P1; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Patrick PD, 2003, BRAIN INJURY, V17, P497, DOI 10.1080/0269905031000070279; Pfeiffer RF, 1996, MOVEMENT DISORD, V11, P104, DOI 10.1002/mds.870110123; POSTMA JU, 1975, J AM GERIATR SOC, V23, P212, DOI 10.1111/j.1532-5415.1975.tb00187.x; Raymer AM, 2003, FRONT BIOSCI-LANDMRK, V8, pS845, DOI 10.2741/1142; Rothberg MB, 2003, ANN INTERN MED, V139, P321, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00007; SABE L, 1992, NEUROLOGY, V42, P1637, DOI 10.1212/WNL.42.8.1637; Sarno JE, 1998, ACQUIRED APHASIA, V569-94; Schneider WN, 1999, BRAIN INJURY, V13, P863; SILVER DE, 1972, NEUROLOGY, V22, P665, DOI 10.1212/WNL.22.7.665; Taus C, 2003, COCHRANE DB SYST REV; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Zafonte RD, 1998, BRAIN INJURY, V12, P617; 2002, MOV DISORD S4, V17, pS13	33	19	20	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2007	86	8					605	612		10.1097/PHM.0b013e31811473b3			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	194ZX	WOS:000248383400002	17667190	Green Accepted			2021-06-18	
J	Biegon, A; Gibbs, A; Alvarado, M; Ono, M; Taylor, S				Biegon, Anat; Gibbs, Andrew; Alvarado, Maritza; Ono, Michele; Taylor, Scott			In vitro and in vivo characterization of [H-3]CNS-5161 - A use-dependent ligand for the N-methyl-D-aspartate receptor in rat brain	SYNAPSE			English	Article						glutamate; brain; autoradiography; radiopharmaceutical; PET	EXCITATORY AMINO-ACIDS; CANDIDATE PET TRACER; NMDA ION-CHANNEL; HEAD-INJURY; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; SPECT AGENT; PCP SITE; GLUTAMATE; BINDING	Glutamate is the major excitatory neurotransmitter in the brain. Glutamate activation of the N-methyl-D-aspartate (NMDA) receptor subtype is thought to mediate important physiological and pathological processes, including memory formation and excitotoxicity. The goal of the present work was to characterize and validate a candidate agent for noninvasive positron emission tomography (PET) imaging of this receptor. [H-3]-labeled N-[3-H-3]-methyl-3-(thiomethylphenyl)cyanamide (CNS-5161) was incubated with rat brain homogenates at increasing concentrations, temperatures, and times to establish the binding kinetics and affinity of the ligand in vitro. Nonspecific binding was measured with 100 mu M MK-801. The compound was also injected i.v. in rats pretreated with saline, NMDA, MK801, or a combination, and organ and brain regional uptake was assessed at various times after injection by autoradiography or dissection. Blood and brain samples were assayed for metabolites by high-performance liquid chromatography. CNS-5161 binds brain membranes with high affinity (K-d < 4 nM) and fast association and dissociation kinetics. Specific binding increased in the presence of glutamate and glycine. Intravenous administration in control rats resulted in a heterogeneous brain distribution with hippocampus and cortex > thalamus > striatum > cerebellum, and a cortex/cerebellum ratio of 1.4. Pretreatment with NMDA increased the hippocampus-to-cerebellum ratio to 1.6-1.9 while MK801 abolished this increase, resulting in ratios close to 1. Thus, CNS-5161 binds preferentially to the activated state of the NMDA receptor channel in vitro and in vivo. The high affinity and fast kinetics make it compatible with PET imaging of a carbon-11 labeled CNS-5161.	Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Funct Imaging, Berkeley, CA 94720 USA	Biegon, A (corresponding author), Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA.	Biegon@bnl.gov					Ametamey SM, 2002, NUCL MED BIOL, V29, P227, DOI 10.1016/S0969-8051(01)00293-1; Ametamey SM, 1999, J RECEPT SIGNAL TR R, V19, P129, DOI 10.3109/10799899909036640; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bisaga A, 2000, DRUG ALCOHOL DEPEN, V59, P1, DOI 10.1016/S0376-8716(99)00107-6; Bressan RA, 2005, BIOL PSYCHIAT, V58, P41, DOI 10.1016/j.biopsych.2005.03.016; Bressan RA, 2004, NUCL MED BIOL, V31, P155, DOI 10.1016/j.nucmedbio.2003.08.008; Brown DRP, 1997, J PSYCHIAT RES, V31, P605, DOI 10.1016/S0022-3956(97)00031-9; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; Gibbs AR, 2002, J LABELLED COMPD RAD, V45, P395, DOI 10.1002/jlcr.561; GIBSON RE, 1992, NUCL MED BIOL, V19, P319; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; Hu LY, 1997, J MED CHEM, V40, P4281, DOI 10.1021/jm970459c; JEZOVA D, 1992, Endocrine Regulations, V26, P73; Kiesewetter D O, 1990, Int J Rad Appl Instrum A, V41, P139, DOI 10.1016/0883-2889(90)90098-2; KLOOG Y, 1988, BIOCHEMISTRY-US, V27, P843, DOI 10.1021/bi00403a001; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Kumlien E, 1999, EPILEPSIA, V40, P30, DOI 10.1111/j.1528-1157.1999.tb01985.x; Lees KR, 1997, NEUROLOGY, V49, pS66, DOI 10.1212/WNL.49.5_Suppl_4.S66; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MINICK DJ, 1988, J MED CHEM, V31, P1923, DOI 10.1021/jm00118a010; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MUIR KW, 1994, BRIT J CLIN PHARMACO, V38, P33, DOI 10.1111/j.1365-2125.1994.tb04318.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; OLNEY JW, 1985, INT REV NEUROBIOL, V27, P337, DOI 10.1016/S0074-7742(08)60561-9; Ouyang XH, 1996, NUCL MED BIOL, V23, P315, DOI 10.1016/0969-8051(95)02086-1; Owens J, 2000, NUCL MED BIOL, V27, P557, DOI 10.1016/S0969-8051(00)00102-5; Owens J, 1997, NUCL MED COMMUN, V18, P149, DOI 10.1097/00006231-199702000-00010; Paxinos G, 1998, RAT BRAIN STEREOTACT; PRICE GW, 1988, EUR J PHARMACOL, V158, P279, DOI 10.1016/0014-2999(88)90080-5; SCHIFFER WK, 2005, DYNAMIC CHANGES NMDA; SMITH DJ, 1980, LIFE SCI, V26, P789, DOI 10.1016/0024-3205(80)90285-4; Tamminga C, 1999, BRIT J PSYCHIAT, V174, P12, DOI 10.1192/S0007125000293598; WALLACE MC, 1992, J NEUROSURG, V76, P127, DOI 10.3171/jns.1992.76.1.0127; Waterhouse RN, 2004, NUCL MED BIOL, V31, P939, DOI 10.1016/j.nucmedbio.2004.03.012; Waterhouse RN, 2003, NUCL MED BIOL, V30, P869, DOI 10.1016/S0969-8051(03)00127-6; Waterhouse RN, 2002, J LABELLED COMPD RAD, V45, P955, DOI 10.1002/jlcr.622; WIELAND DM, 1988, APPL RADIAT ISOTOPES, V39, P1219; Zhao YJ, 2006, J LABELLED COMPD RAD, V49, P163, DOI 10.1002/jlcr.1033	46	19	19	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	AUG	2007	61	8					577	586		10.1002/syn.20400			10	Neurosciences	Neurosciences & Neurology	178CO	WOS:000247199000001	17455246				2021-06-18	
J	Cullen, N				Cullen, Nora			Canadian Healthcare Perspective in Traumatic Brain Injury Rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury rehabilitation; Canadian healthcare; universal access		Brain injury rehabilitation is based on principles of universal access to healthcare in a publicly funded system and is available to all residents in Canada. However, a variability of resources exists because of the vastness of the country and differences in provincial funding. Rehabilitation is typically provided by an interprofessional team and is client centered, goal directed, evidence based, and aimed at improving quality of life for survivors of brain injury. Work is being done exploring different models of care including community treatment and the use of rehabilitation therapists. Patient education is an ongoing priority. Data collection is considered mandatory in many centers for program evaluation and quality improvement. There is a clear need for coordinated standards of care across the country.	[Cullen, Nora] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Cullen, Nora] Univ Toronto, Toronto, ON, Canada	Cullen, N (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	Cullen.Nora@TorontoRehab.on.ca		Cullen, Nora/0000-0001-6359-9418			Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; MAHABIR M, 2003, WORLD C BRAIN INJ MA; RYU A, 2006, 54 ANN M AAPM R NOV; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0	7	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2007	22	4					214	220		10.1097/01.HTR.0000281836.54602.6d			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V87BQ	WOS:000205885400004	17667063				2021-06-18	
J	Davis, DP; Douglas, DJ; Koenig, W; Carrison, D; Buono, C; Dunford, JV				Davis, Daniel P.; Douglas, Danielle J.; Koenig, William; Carrison, Dale; Buono, Colleen; Dunford, James V.			Hyperventilation following aero-medical rapid sequence intubation may be a deliberate response to hypoxemia	RESUSCITATION			English	Article						hyperventilation; aero-medical; hypoxemia	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; ENDOTRACHEAL INTUBATION; INTRAHOSPITAL TRANSPORT; BLOOD-GASES; HYPOXIA; HYPOTENSION; MODERATE; OUTCOMES; IMPACT	Background: Recent studies document a high incidence of hyperventilation by prehospital providers, with a potentially detrimental effect on outcome in traumatic brain injury (TBI). Purpose: To document the incidence of hyperventilation by aero-medical providers and explore a possible relationship between hyperventilation episodes and desaturations or impending hypoxemia. Methods: This was a prospective, descriptive study using TBI patients undergoing prehospital RSI by aero-medical crews. Continuous data regarding end-tidal CO2 (EtCO2), ventilatory rate, and oxygen saturation (SPO2) were downloaded from hand-held oximeter-capnometer devices. Two investigators independently assessed oximetry/capnometry data to identify the following occurrences: desaturation during RSI (SpO(2) < 90%), impending hypoxemia (SpO(2) decrease by >= 3% to a value <95%) following intubation, loss Of SpO(2) signal, hyperventilation (EtCO2 < 30 mmHg), and severe hyperventilation (EtCO2 < 25 mmHg). Covariate analysis was used to explore the possible association between hyperventilation episodes and either desaturation, impending hypoxemia, or loss of SpO(2) signal. Results: A total of 32 aero-medical patients were enrolled with a mean duration of ventilation monitoring of 14.8 min. The incidence of hyperventilation or severe hyperventitation was substantially tower than previously documented with ground paramedics. A total of 28 hyperventilation episodes were identified in 16 patients; 13 of these were associated with impending hypoxemia following intubation, five were associated with desaturation during RSI, and seven were associated with loss Of SpO(2) signal. The remaining three occurred immediately following intubation without desaturation during RSI. Desaturation was observed in 62% of patients; of note, desaturation was recorded on the quality improvement document in only 23% of these. Covariate analysis revealed an association between hyperventilation episodes and either desaturatios during RSI, impending hypoxemia following intubation, or toss of SpO(2) signal. Conclusions: The incidence of hyperventilation by aeromedical crews was lower than reported for ground paramedics and appears to occur in response to desaturation, impending hypoxemia, or toss of SpO(2) signal. (c) 2006 Elsevier Ireland Ltd. AR rights reserved.	Univ Calif San Diego, Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA	Davis, DP (corresponding author), Univ Calif San Diego, Med Ctr, Dept Emergency Med, 200 W Arbor Dr,Mailcode 8676, San Diego, CA 92103 USA.	davismd@cox.net					Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHUGANI HT, 1991, J CEREBR BLOOD F MET, V11, P35, DOI 10.1038/jcbfm.1991.4; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J TRAUMA, V59, P794; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DOBERSTEIN C, 1994, ACTA NEUROCHIR, P41; Douzinas EE, 2001, INTENS CARE MED, V27, P269, DOI 10.1007/s001340000796; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Falcone R E, 1996, Air Med J, V15, P163, DOI 10.1016/S1067-991X(96)90024-3; Feng ZC, 1998, RESUSCITATION, V37, P33, DOI 10.1016/S0300-9572(98)00031-8; GABIG TG, 1979, BLOOD, V53, P1133; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; OUYANG YB, 1994, BRAIN RES, V646, P65, DOI 10.1016/0006-8993(94)90058-2; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; Vadeboncoeur TF, 2006, J EMERG MED, V30, P131, DOI 10.1016/j.jemermed.2005.04.019; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916	49	19	19	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUN	2007	73	3					354	361		10.1016/j.resuscitation.2006.09.015			8	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	180UW	WOS:000247392700006	17291673				2021-06-18	
J	Hamani, D; Charrueau, C; Butel, MJ; Besson, V; Belabed, L; Nicolis, I; Le Plenier, S; Marchand-Leromp, C; Chaumeil, JC; Cynober, L; Moinard, C				Hamani, Djamel; Charrueau, Christine; Butel, Marie-Jose; Besson, Valerie; Belabed, Linda; Nicolis, Ioannis; Le Plenier, Servane; Marchand-Leromp, Catherine; Chaumeil, Jean-Claude; Cynober, Luc; Moinard, Christophe			Effect of an immune-enhancing diet on lymphocyte in head-injured rats: What is the role of arginine?	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	Clinical Nutrition Week 2005	JAN, 2005	Orlando, FL			arginine; head injury; immune-enhancing diet; dysimmunity; enteral nutrition; bacterial translocation	TRAUMATIC BRAIN-INJURY; ORNITHINE ALPHA-KETOGLUTARATE; CRITICALLY-ILL PATIENTS; BACTERIAL TRANSLOCATION; NITRIC-OXIDE; NOSOCOMIAL INFECTIONS; PROTEIN-METABOLISM; IN-VIVO; IMMUNONUTRITION; NUTRITION	Objective: The benefit of immune-enhancing diets (IEDs) in the intensive care unit remains controversial. Considering their complexity, the role of each component, in particular arginine (Arg), in their properties is largely unknown. The aim of this study was to determine the role of arginine in the immunomodulatory effects of an IED (Crucial(R)) in head-injured rats. Design: Thirty-four rats were randomized into five groups: AL (ad libitum), HI (head-injured), HI-STD (HI + standard enteral nutrition, EN), HI-STD-Arg (HI + standard EN + Arg in equimolar concentration to Arg in IED), and HI-IED (HI + IED). These isocaloric and isonitrogenous diets were administered over 4 days. After death, the thymus was removed and weighed. The density of CD25, CD4 and CD8 on lymphocytes from blood and from Peyer patches was evaluated. Mesenteric lymph nodes, liver and spleen were cultured for analysis of enterobacterial translocation and dissemination. Measurements and results: HI induced an atrophy of the thymus which was not corrected by the standard diet (HI 0.27 +/- 0.03, HI-STD 0.35 +/- 0.03 vs. AL 0.49 +/- 0.02 g; p < 0.05). However, the standard diet supplemented with arginine limited the thymic atrophy and the IED restored thymus weight. CD25 density and interleukin-2 production were increased only in the HI-STD-Arg and HI-IED groups (p < 0.05). Head injury induced enterobacterial translocation and dissemination which were blunted only in the HI-STD-Arg group (p < 0.05). Conclusions: In this rat HI model, arginine appears to be safe, contributes to a large extent to the immunomodulatory effects of the IED, and seems to limit enterobacterial translocation and dissemination more efficiently alone than in an IED.	Univ Paris 05, Fac Pharm, Lab Biol Nutr EA2498, F-75270 Paris 06, France; Univ Paris 05, Fac Pharm, Lab Pharm Galen EA2498, F-75270 Paris, France; Univ Paris 05, Fac Pharm, Microbiol Lab, F-75270 Paris 06, France; Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale EA2510, F-75270 Paris 06, France; Univ Paris 05, Fac Pharm, Lab Biomath EA2498, F-75270 Paris 06, France; Hop Hotel Dieu, AP HP, Serv Biochim, Paris, France	Hamani, D (corresponding author), Univ Paris 05, Fac Pharm, Lab Biol Nutr EA2498, 4 Ave Observ, F-75270 Paris 06, France.	djamel.hamani@nutrition-paris5.org	Cynober, Luc/ABB-2368-2020; BESSON, VALERIE/AAZ-9989-2020; MARCHAND-LEROUX, Catherine/L-7453-2017; Nicolis, Ioannis/C-3302-2012; besson, valerie C/L-7388-2017	BESSON, VALERIE/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Nicolis, Ioannis/0000-0001-7207-7689; besson, valerie C/0000-0002-1491-2380			BARBUL A, 1984, J SURG RES, V36, P620, DOI 10.1016/0022-4804(84)90149-5; Belabed L, 2006, CLIN NUTR, V25, P832, DOI 10.1016/j.clnu.2006.02.003; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Breuille D, 1998, CLIN SCI, V94, P413, DOI 10.1042/cs0940413; Bronte V, 2003, TRENDS IMMUNOL, V24, P302, DOI 10.1016/S1471-4906(03)00132-7; Calder P C, 2004, METABOLIC THERAPEUTI, P305; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Correa L, 2000, J HOSP INFECT, V46, P89, DOI 10.1053/jhin.2000.0803; CYNOBER L, 1995, J NUTR BIOCHEM, V6, P402, DOI 10.1016/0955-2863(95)00066-9; Cynober L, 2003, CURR OPIN CLIN NUTR, V6, P189, DOI 10.1097/00075197-200303000-00007; ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Heyland DK, 2001, JAMA-J AM MED ASSOC, V286, P944, DOI 10.1001/jama.286.8.944; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; KANG W, 2005, J PARENTER ENTERAL N, V29, pS4; LeBoucher J, 1997, AM J PHYSIOL-ENDOC M, V273, pE557; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; MacFie J, 2006, BRIT J SURG, V93, P87, DOI 10.1002/bjs.5184; MAHONEY EJ, 2004, METABOLIC THERAPEUTI, P211; McCowen Karen C, 2002, Nutr Clin Pract, V17, P265, DOI 10.1177/0115426502017005265; Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001; Moinard C, 2005, INTENS CARE MED, V31, P281, DOI 10.1007/s00134-004-2489-9; Moinard C, 2002, CLIN SCI, V102, P287, DOI 10.1042/CS20010162; Nitenberg Gerard, 2000, Curr Opin Crit Care, V6, P253, DOI 10.1097/00075198-200008000-00004; PRASAD AS, 1991, AM J CLIN NUTR, V53, P403; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; Radrizzani D, 2006, INTENS CARE MED, V32, P1191, DOI 10.1007/s00134-006-0238-y; Schneider SM, 2004, BRIT J NUTR, V92, P105, DOI 10.1079/BJN20041152; Singer P, 2005, NUTRITION, V21, P282, DOI 10.1016/j.nut.2004.10.001; Ulusoy H, 2003, J CLIN NEUROSCI, V10, P596, DOI 10.1016/S0967-5868(03)00142-5; VAUBOURDOLLE M, 1991, JPEN-PARENTER ENTER, V15, P517, DOI 10.1177/0148607191015005517; Wallace JL, 2000, GASTROENTEROLOGY, V119, P512, DOI 10.1053/gast.2000.9304; Walrand S, 2004, AM J PHYSIOL-CELL PH, V286, pC1474, DOI 10.1152/ajpcell.00563.2002; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; Zulfikaroglu B, 2003, CLIN NUTR, V22, P277, DOI 10.1016/S0261-5614(02)00211-X	42	19	19	0	5	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2007	33	6					1076	1084		10.1007/s00134-007-0624-0			9	Critical Care Medicine	General & Internal Medicine	177LV	WOS:000247155500023	17429607				2021-06-18	
J	Stanford, RE; Soden, R; Bartrop, R; Mikk, M; Taylor, TKF				Stanford, R. E.; Soden, R.; Bartrop, R.; Mikk, M.; Taylor, T. K. F.			Spinal cord and related injuries after attempted suicide: psychiatric diagnosis and long-term follow-up	SPINAL CORD			English	Article						acute spinal cord injury; fall from height; suicide; mental-illness; long-term outcome; drug abuse	TRAUMATIC BRAIN-INJURY; VERTICAL DECELERATION INJURIES; DRUG-USE; PSYCHOTIC DISORDERS; MENTAL-ILLNESS; RIVER BRIDGES; MORTALITY; SCHIZOPHRENIA; FALLS; AUTOKABALESIS	Study Design: Retrospective analysis of acute spinal cord injuries (ASCI). Objectives: Determine incidence of ASCI due to suicide attempt from 1970 to 2000. Describe demographics, injuries, mental illness, functional outcomes and nature of subsequent deaths. Setting: State spinal cord injury services, New South Wales, Australia. Methods: Retrospective record review and follow-up interview. Results: Of 2752 ASCI admissions, 56 were because of attempted suicide (55 falls, one gunshot wound). Thirty-six males and 20 females. Median age 30 years (15-74). Most common levels of vertebral injury were C5 and L1. Twenty-three had complete spinal cord injury. Thirty-two had an Injury Severity Score of > 415. Forty had more than one major injury. There was a significant rise in the incidence of ASCI following self-harm over time (Poisson regression, P = 0.004). There was a significant change in scene of injury away from hospitals over time (w 2 test, df = 1, P = 0.0001). Psychiatric diagnoses were personality disorder 27; schizophrenia 16; depression 14; chronic alcohol abuse 10; mood disorder 10; chronic substance abuse 10; other four. Follow-up was available in 47 cases (84%) at an average of 8 years. Four subsequent deaths were by suicide. Domiciliary arrangements were: home 28; hospital five; nursing home three; group home/hostel four. Conclusions: Community placement outcomes for survivors were good. Subsequent death by suicide was high. There was a significant rise in cases and a change in injury scene away from hospitals over time.	Prince Wales Hosp, Dept Orthopaed, Sydney, NSW, Australia; Univ New S Wales, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Royal N Shore Hosp, Dept Rehabil Med, Spinal Injuries Unit, Spinal Injuries Res Off, Sydney, NSW, Australia; Royal N Shore Hosp, Dept Psychol Med, Sydney, NSW, Australia; Prince Henry Hosp, Dept Rehabil Med, Spinal Cord Injury Unit, Sydney, NSW, Australia; Royal N Shore Hosp, Dept Traumat & Orthopaed Surg, Sydney, NSW, Australia; SpineCare Fdn, Parramatta, NSW, Australia	Stanford, RE (corresponding author), Prince Wales Hosp, Dept Orthopaed, Sydney, NSW, Australia.		Stanford, Ralph/AAV-2726-2020	Stanford, Ralph/0000-0002-4547-8927			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Babidge NC, 2001, ACTA PSYCHIAT SCAND, V103, P105, DOI 10.1034/j.1600-0447.2001.00192.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIERINGSORENSEN F, 1992, PARAPLEGIA, V30, P139, DOI 10.1038/sc.1992.43; Bostman O M, 1987, Scand J Soc Med, V15, P119; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Burdekin B., 1993, HUMAN RIGHTS MENTAL; CANTOR CH, 1990, AUST NZ J PSYCHIAT, V24, P377, DOI 10.3109/00048679009077705; Cantor CH, 1999, MED J AUSTRALIA, V171, P137, DOI 10.5694/j.1326-5377.1999.tb123565.x; CANTOR CH, 1989, BRIT J PSYCHIAT, V155, P829, DOI 10.1192/bjp.155.6.829; Daigle MS, 2005, ACCIDENT ANAL PREV, V37, P625, DOI 10.1016/j.aap.2005.03.004; Degenhardt L, 2001, PSYCHOL MED, V31, P659, DOI 10.1017/S0033291701003865; Drake RE, 1998, RECENT DEV ALCOHOL, V14, P285, DOI 10.1007/0-306-47148-5_12; Gibb SJ, 2005, AUST NZ J PSYCHIAT, V39, P95, DOI 10.1111/j.1440-1614.2005.01514.x; GIRARD R, 1980, PARAPLEGIA, V18, P381, DOI 10.1038/sc.1980.66; Glass C A, 1992, J Am Paraplegia Soc, V15, P187; Hall W, 2004, DRUG ALCOHOL REV, V23, P433, DOI 10.1080/09595230412331324554; Hoff J, 1971, Proc Veterans Adm Spinal Cord Inj Conf, V18, P53; Hunt GE, 2002, SCHIZOPHR RES, V54, P253, DOI 10.1016/S0920-9964(01)00261-4; ISBISTER ES, 1992, INJURY, V23, P119, DOI 10.1016/0020-1383(92)90046-U; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; KATZ K, 1988, INJURY, V19, P371, DOI 10.1016/0020-1383(88)90124-6; Kavanagh DJ, 2004, SCHIZOPHR RES, V66, P115, DOI 10.1016/S0920-9964(03)00130-0; Kennedy P, 1999, SPINAL CORD, V37, P847, DOI 10.1038/sj.sc.3100932; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; KRAUSE JS, 1992, CURR OPIN NEUROL NEU, V5, P669; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; MARINO RJ, 2000, INT STANDARDS NEUROL; Maxwell JC, 2003, DRUG ALCOHOL REV, V22, P347, DOI 10.1080/0959523031000154490; MCLENNAN W, 2000, SUICIDES AUSTR 1921; Montross Lori P, 2005, Ann Clin Psychiatry, V17, P173, DOI 10.1080/10401230591002156; Newton L, 2000, AUST NZ J PSYCHIAT, V34, P484, DOI 10.1046/j.1440-1614.2000.00733.x; Palmer DD, 1999, J CLIN PSYCHIAT, V60, P100; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Richter D, 1996, INJURY, V27, P655, DOI 10.1016/S0020-1383(96)00083-6; SCALEA T, 1986, J TRAUMA, V26, P706, DOI 10.1097/00005373-198608000-00005; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SIMS A, 1979, MED SCI LAW, V19, P195, DOI 10.1177/002580247901900310; Soden RJ, 2000, SPINAL CORD, V38, P604, DOI 10.1038/sj.sc.3101080; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Wirbel RJ, 1998, EUR J SURG, V164, P109; Wyatt JP, 2000, J CLIN FORENSIC MED, V7, P1; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628	44	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	JUN	2007	45	6					437	443		10.1038/sj.sc.3102043			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	176JH	WOS:000247080500007	17339888	Bronze			2021-06-18	
J	Frumberg, DB; Fernando, MS; Lee, DE; Biegon, A; Schiffer, WK				Frumberg, David B.; Fernando, Marion S.; Lee, Dianne E.; Biegon, Anat; Schiffer, Wynne K.			Metabolic and behavioral deficits following a routine surgical procedure in rats	BRAIN RESEARCH			English	Article						glucose metabolism; brain injury; behavior; surgery; microdialysis; functional neuroimaging; parametric mapping	TRAUMATIC BRAIN-INJURY; CEREBRAL GLUCOSE-UTILIZATION; ONE-TRIAL TEST; COGNITIVE DEFICITS; SPATIAL NORMALIZATION; DYNAMIC CHANGES; MICROPET R4; CELL LOSS; MEMORY; CORTEX	To test the hypothesis that functional metabolic deficits observed following surgical brain injury are associated with changes in cognitive performance in rodents, we performed serial imaging studies in parallel with behavioral measures in control animals and in animals with surgical implants. Memory function was assessed using the novel object recognition (NOR) test, administered 3 days prior to and 3, 7, 14 and 56 days after surgery. At each time point, general locomotion was also measured. Metabolic imaging with F-18-fluorodeoxyglucose ([F-18]FDG) occurred 28 and 58 days after surgery. Animals with surgical implants performed significantly worse on tests of object recognition, while general locomotion was unaffected by the implant. There was a significant decrease in glucose uptake after surgery in most of the hemisphere ipsilateral to the implant relative to the contralateral hemisphere. At both time points, the most significant metabolic deficits occurred in the primary motor cortex (-25%; p<0.001), sensory cortex (-15%, p<0.001) and frontal cortex (-12%; p<0.001). Ipsilateral areas further from the site of insertion became progressively worse, including the sensory cortex, dorsal striatum and thalamus. These data was supported by a voxel-based analysis of the PET data, which revealed again a unilateral decrease in [F-18]FDG uptake that extended throughout the ipsilateral cortex and persisted for the duration of the 58-day study. Probe implantation in the striatum results in a widespread and long-lasting decline in cortical glucose metabolism together with a persistent, injury-related deficit in the performance of a cognitive (object recognition) task in rats. (c) 2007 Elsevier B.V. All rights reserved.	Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; Cornell Univ, Ithaca, NY 14853 USA	Schiffer, WK (corresponding author), Brookhaven Natl Lab, Dept Med, Bldg 555, Upton, NY 11973 USA.	wynne@bnl.gov			NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [F31DA015874, R01DA015082] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F31 DA015874, F31 DA015874-02, R01 DA015082, DA15082] Funding Source: Medline		Alexoff DL, 2003, J NUCL MED, V44, P815; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Baker KB, 2002, LEARN MEMORY, V9, P58, DOI 10.1101/lm.46102; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biran R, 2005, EXP NEUROL, V195, P115, DOI 10.1016/j.expneurol.2005.04.020; Broersen LM, 2000, PROG BRAIN RES, V126, P79; Chang Q, 2004, BEHAV NEUROSCI, V118, P383, DOI 10.1037/0735-7044.118.2.383; Chang Q, 2003, J NEUROSCI, V23, P3001; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; Courtiere A, 2005, EUR J NEUROSCI, V21, P1973, DOI 10.1111/j.1460-9568.2005.04015.x; Csicsvari J, 2003, J NEUROPHYSIOL, V90, P1314, DOI 10.1152/jn.00116.2003; Engstad T, 2003, NEUROEPIDEMIOLOGY, V22, P326, DOI 10.1159/000072921; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; ENNACEUR A, 1992, BEHAV BRAIN RES, V51, P83, DOI 10.1016/S0166-4328(05)80315-8; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Funkiewiez A, 2004, J NEUROL NEUROSUR PS, V75, P834, DOI 10.1136/jnnp.2002.009803; GILMAN S, 1987, ANN NEUROL, V22, P370, DOI 10.1002/ana.410220314; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; Hauss-Wegrzyniak B, 2002, EXP NEUROL, V176, P336, DOI 10.1006/exnr.2002.7966; Hauss-Wegrzyniak B, 2000, NEUROREPORT, V11, P1759, DOI 10.1097/00001756-200006050-00032; Helmstaedter C, 2004, J NEUROL NEUROSUR PS, V75, P323; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Knoess C, 2003, EUR J NUCL MED MOL I, V30, P737, DOI 10.1007/s00259-002-1052-6; Kossel AH, 1997, J NEUROSCI, V17, P9634; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Mostafa RM, 2002, PHYSIOL BEHAV, V76, P589, DOI 10.1016/S0031-9384(02)00730-8; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Rousche PJ, 2001, IEEE T BIO-MED ENG, V48, P361, DOI 10.1109/10.914800; SANBERG PR, 1978, BRAIN RES, V149, P546, DOI 10.1016/0006-8993(78)90502-4; Schiffer WK, 2005, J NEUROSCI METH, V144, P25, DOI 10.1016/j.jneumeth.2004.10.016; Schiffer WK, 2000, LIFE SCI, V66, pPL169, DOI 10.1016/S0024-3205(00)00432-X; Schiffer WK, 2006, J NEUROSCI METH, V155, P272, DOI 10.1016/j.jneumeth.2006.01.027; Schweinhardt P, 2003, J NEUROSCI METH, V129, P105, DOI 10.1016/S0165-0270(03)00192-4; STENSAAS SS, 1976, ACTA NEUROPATHOL, V35, P187; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; TSABARI R, 2005, 95012 SOC NEUR; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; WAGNER KR, 1990, J CEREBR BLOOD F MET, V10, P417, DOI 10.1038/jcbfm.1990.72; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YUEN TGH, 1995, BIOMATERIALS, V16, P951, DOI 10.1016/0142-9612(95)93121-S; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	47	19	20	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 4	2007	1144						209	218		10.1016/j.brainres.2007.01.134			10	Neurosciences	Neurosciences & Neurology	161RT	WOS:000246034100025	17346680	Green Accepted			2021-06-18	
J	Bonnier, C; Marique, P; Van Hout, A; Potelle, D				Bonnier, Christine; Marique, Patricia; Van Hout, Anne; Potelle, Dominique			Neurodevelopmental outcome after severe traumatic brain injury in very young children: Role for subcortical lesions	JOURNAL OF CHILD NEUROLOGY			English	Article						pediatric brain injuries; neurodevelopmental outcome; subcortical lesions	SHAKEN BABY SYNDROME; HEAD-INJURY; COMA; EXPERIENCE; INFANTS; AGE	Traumatic brain injury is a major cause of mortality and morbiditv in children younger than 15 years of age. To evaluate the role of subcortical lesions on neurodevelopmental outcomes, longterm outcomes of 50 children with severe traumatic brain injury before 4 years of age (accidental injury, n = 21, nonaccidental injury, n = 29) were reviewed retrospectively and compared with late magnetic resonance imaging (MRI) findings: no visible lesions, cortical lesions, or subcortical lesions. Subcortical lesions occurred in both accidental and nonaccidental traumatic brain injuries. Traumatic brain injury severity (initial Glasgow Coma Scale or coma duration) was significantly associated with subcortical lesions. Long-term motor or visual deficiencies occurred in one third of patients and cognitive deficiencies in 52.1%. Although deficiencies occurred without visible MRI lesions, global outcome scores, motor delay, visual impairment, head growth slowing, global intellectual quotients, and planning performances were significantly worse in patients with subcortical lesions. An alarming deterioration in intellectual quotient over time was noted. It was concluded that neurodevelopmental outcomes are worrisome after severe traumatic brain injury in young children, and subcortical lesions affect the prognosis.	Clin Univ St Luc, Pediat Neurol Serv, B-1200 Brussels, Belgium; Ctr Neurol William Lennox, Louvain, Belgium	Bonnier, C (corresponding author), Clin Univ St Luc, Pediat Neurol Serv, Ave Hippocrate,10-1067, B-1200 Brussels, Belgium.	bonnier@nepe.ucl.ac.be					Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; AUDENAERT K, 2003, MED SCI MONITOR, V10, P112; BANICH MT, 1990, NEUROPSYCHOLOGIA, V28, P35, DOI 10.1016/0028-3932(90)90084-2; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; Bonnier C, 2002, BRAIN PATHOL, V12, P320; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; BRENNER SL, 1989, J NATL MED ASSOC, V81, P183; BRUNET O, 1978, ECHELLE DEV PSYCHOMO; CHEVRIEMULLER C, 1981, EPREUVRES EXAMEN LAN; CHEVRIEMULLER C, 1988, BATTERIE EVALUATION; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; Forsyth RJ, 2001, ARCH DIS CHILD, V84, P200, DOI 10.1136/adc.84.3.200; Gennarelli TA, 1985, NEUROSURGERY, V2, P1531; Gil AM, 2003, J SCHOOL PSYCHOL, V41, P337, DOI 10.1016/S0022-4405(03)00085-2; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; JENNETT B, 1975, LANCET, V1, P480; Kaufman A.S., 1983, K ABC KAUFMAN ASSESS; Korkman M, 1998, NEPSY DEV NEUROPSYCH; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MEADOWS AT, 1981, LANCET, V2, P1015; MULHERN RK, 1992, MED PEDIATR ONCOL, V20, P181, DOI 10.1002/mpo.2950200302; MULHERN RK, 1992, J CLIN ONCOL, V10, P1095, DOI 10.1200/JCO.1992.10.7.1095; OSERETSKY L, 1984, ECHELLE DEV MOTEUR L; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; TEASDALE G, 1974, LANCET, V2, P81; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wechsler D, 1995, ECHELLE INTELLIGENCE; WECHSLER D, 1992, MANUAL EWCHSLER INTE; ZIMMERMAN P, 1994, TEA TEST EVALUATION	46	19	20	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	MAY	2007	22	5					519	529		10.1177/0883073807302604			11	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	179IV	WOS:000247283900001	17690056				2021-06-18	
J	Donohue, JT; Clark, DE; DeLorenzo, MA				Donohue, Joseph T.; Clark, David E.; DeLorenzo, Michael A.			Long-term survival of medicare patients with head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	132nd Annual Meeting of the American-Public-Health-Association	NOV 06-10, 2004	Washington, DC	Amer Public Hlth Assoc		traumatic brain injury; survival; aged	GERIATRIC-PATIENTS; TRAUMA PATIENTS; MAJOR TRAUMA; BRAIN-INJURY; MORTALITY; VALIDATION; SEVERITY; DEATH; OLD	Background: An increasing number of older patients are being hospitalized with traumatic brain injury (TBI). Knowledge of their expected long-term survival may be useful in making clinical decisions. Methods: Patients age 65 or older admitted for the first time with head injury (ICD-9 800-804 or 850-854) during 1999 were identified in a complete national sample of fee-for-service Medicare hospitalization and denominator data. Cases were categorized by age, sex, maximum Abbreviated Injury Score (AISmax), and Charlson comorbidity score. Survival was determined at hospital discharge, and (using the denominator file) at 1, 6, 12, and 24 months after the initial hospital admission. Results: For all cases (n = 30,684), the hospital mortality was 14.3%, but was cumulatively 19.75%, 30.5%, 36.1%, and 44.9% at successive times up to 24 months. Long-term mortality was higher with increased age, comorbidity, or AISmax, and higher in men. These effects persisted with multivariate logistic regression analysis and were used to construct a simplified prediction score for clinical use. Conclusions: The mortality for older patients with TBI is much higher than for an uninjured control population. The relative risk for death remains elevated after hospital discharge and for at least 2 years. Awareness of the expected prognosis may help family members and health care providers make appropriate clinical decisions during acute hospitalization.	Maine Med Ctr, Portland, ME 04102 USA; Harvard Univ, Injury Control Res Ctr, Boston, MA 02115 USA	Clark, DE (corresponding author), 887 Congress St, Portland, ME 04102 USA.	clarkd@mmc.org			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR115279-04] Funding Source: Medline		ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AMACHER AL, 1987, NEUROSURGERY, V20, P954; [Anonymous], 1971, JAMA-J AM MED ASSOC, V215, P277; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clark DE, 2005, AM J PUBLIC HEALTH, V95, P273, DOI 10.2105/AJPH.2003.036871; Clark DE, 2004, J AM GERIATR SOC, V52, P2023, DOI 10.1111/j.1532-5415.2004.52560.x; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Hannan EL, 2004, J TRAUMA, V56, P1297, DOI 10.1097/01.TA.0000075350.66739.53; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; PELLICANE JV, 1992, J TRAUMA, V33, P440, DOI 10.1097/00005373-199209000-00018; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; SMITH DP, 1990, SOUTHERN MED J, V83, P171, DOI 10.1097/00007611-199002000-00010; VANAALST JA, 1991, J TRAUMA, V31, P1096; vanderSluis CK, 1996, J TRAUMA, V40, P78, DOI 10.1097/00005373-199601000-00015	26	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2007	62	2					419	423		10.1097/01.ta.0000219286.88179.18			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	137ZY	WOS:000244333300037	17297334				2021-06-18	
J	Chang, TTL; Ciuffreda, KJ; Kapoor, N				Chang, Tina Ting-Li; Ciuffreda, Kenneth Joseph; Kapoor, Neera			Critical flicker frequency and related symptoms in mild traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; mild brain injury; critical flicker frequency; light sensitivity; motion sensitivity; temporal; processing	HEAD-INJURY; LIGHT-SENSE; SENSITIVITY; PERIMETRY; LUMINANCE; MIGRAINE; SOUND	Primary objective: To determine whether critical flicker frequency (CFF) thresholds are abnormal in individuals with mild traumatic brain injury (TBI) and, if so, if they are correlated with the degree of reported motion and light sensitivity. Methods and procedures: The foveal CFF threshold was assessed in individuals with mild TBI ( n = 18) having varying degrees of reported light and motion sensitivity. Mean CFF values were obtained using the ascending and descending psychophysical method of limits with binocular viewing at 40 cm. A 7-item, rating-scale questionnaire was used to assess the degree of light and motion sensitivity. These parameters were also assessed in a large visually-normal, non-TBI cohort. Main outcomes and results: CFF in the mild TBI group was not significantly different across age groups from the visually-normal, non-TBI cohort. However, mean CFF among the mild TBI subjects was significantly higher for the ` light sensitive' and ` motion sensitive' sub-groups when compared to the ` not light sensitive' and ` not motion sensitive' sub-groups. The majority of TBI subjects manifested both light and motion sensitivity. Conclusion: CFF was found to be related to the reported degree of light and motion sensitivity in individuals with mild TBI. Neurological disinhibition as a result of brain injury may be causal of the subjective hypersensitivity to light and motion in the presence of normal CFF.	SUNY Coll Optometry, Raymond J Greenwald Rehabil Ctr, Dept Clin Sci, New York, NY 10036 USA; SUNY Coll Optometry, Raymond J Greenwald Rehabil Ctr, Dept Vis Sci, New York, NY 10036 USA	Ciuffreda, KJ (corresponding author), SUNY Coll Optometry, Raymond J Greenwald Rehabil Ctr, Dept Clin Sci, 33 W 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu			NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [T35EY007079] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [T35 EY07079] Funding Source: Medline		BATTERSBY WS, 1951, J EXP PSYCHOL, V42, P135, DOI 10.1037/h0057037; BATTERSBY WS, 1951, J EXP PSYCHOL, V42, P59, DOI 10.1037/h0063538; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Carmel D, 2006, CURR BIOL, V16, P907, DOI 10.1016/j.cub.2006.03.055; Ceranic BJ, 1998, J NEUROL NEUROSUR PS, V65, P523, DOI 10.1136/jnnp.65.4.523; Chen PC, 2000, J FORMOS MED ASSOC, V99, P45; COIFFREDA KC, 2001, VISUAL VESTIBULAR CO, P77; COLESTON DM, 1995, CEPHALALGIA, V15, P396, DOI 10.1046/j.1468-2982.1995.1505396.x; del Romo GB, 2005, INVEST OPHTH VIS SCI, V46, P1107, DOI 10.1167/iovs.04-1138; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; HARVEY LO, 1970, VISION RES, V10, P55, DOI 10.1016/0042-6989(70)90062-3; HATCH SW, 1998, OPHTHALMIC RES EPIDE, V24, P187; Jackowski MM, 1996, NEUROREHABILITATION, V6, P193, DOI 10.3233/NRE-1996-6305; JACKOWSKI MM, 2001, VISUAL VESTIBULAR CO, P145; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; KOERNER F, 1973, EXP BRAIN RES, V18, P88; KOOI KA, 1958, NEUROLOGY, V8, P764, DOI 10.1212/WNL.8.10.764; Kowacs PA, 2005, CEPHALALGIA, V25, P339, DOI 10.1111/j.1468-2982.2004.00861.x; KUYK TK, 1991, OPTOMETRY VISION SCI, V68, P786, DOI 10.1097/00006324-199110000-00005; LACHENMAYR BJ, 1991, GRAEF ARCH CLIN EXP, V229, P246, DOI 10.1007/BF00167877; LACHENMAYR BJ, 1994, INVEST OPHTH VIS SCI, V35, P2741; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; McKendrick A.M., 2003, ADLERS PHYSL EYE, P511; MISIAK H, 1951, SCIENCE, V113, P551, DOI 10.1126/science.113.2941.551; SCHWARTZ SH, 1999, VISUAL PERCEPTION CL, P205; SNELGAR RS, 1985, DOC OPHTHALMOL, V60, P79, DOI 10.1007/BF00164571; Suter P. S., 2004, TRAUMATIC BRAIN INJU, P209; Talcott JB, 1998, NEURO-OPHTHALMOLOGY, V20, P187, DOI 10.1076/noph.20.4.187.3931; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x	29	19	19	1	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1055	1062		10.1080/02699050701591437			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600008	17891568				2021-06-18	
J	Coetzer, R				Coetzer, Rudi			Psychotherapy following traumatic brain injury: Integrating theory and practice	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						psychotherapy; traumatic brain injury	PERSONALITY PATHOLOGY; SELF-AWARENESS; REHABILITATION; INTERVENTIONS; DYSFUNCTION; DEPRESSION; DISTRESS; FEEDBACK; PEOPLE; MODEL	Psychotherapy is now an approach used within several models of neurorehabilitation. However, a core theoretical model to guide psychotherapeutic practice is lacking. This article attempts to illustrate how the Generic Model of Psychotherapy of Orlinsky and Howard, which emphasizes the common factors shared by many psychotherapies, can be applied in neurorehabilitation settings. A case report is presented to illustrate how this model can potentially inform psychotherapeutic practice. The use of a theoretical model to underpin psychotherapeutic interventions in neurorehabilitation settings has the potential to facilitate our understanding of the psychotherapeutic process following traumatic brain injury in this evolving area of professional practice.	Conwy & Denbighshire NHS Trust, Colwyn Bay Hosp, N Wales Brain Injury Serv, Colwyn Bay LL29 8AY, Wales; Univ Wales, Sch Psychol, Bangor, Gwynedd, Wales	Coetzer, R (corresponding author), Conwy & Denbighshire NHS Trust, Colwyn Bay Hosp, N Wales Brain Injury Serv, Hesketh Rd, Colwyn Bay LL29 8AY, Wales.	Rudi.Coetzer@cd-tr.wales.nhs.uk		Coetzer, Rudi/0000-0003-4505-7230			Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Ben-Yishay Y., 2000, INT HDB NEUROPSYCHOL, P127, DOI [10.1007/978-1-4757-5569-5_8, DOI 10.1007/978-1-4757-5569-5_8]; Beutler LE, 2002, J CLIN PSYCHOL, V58, P1199, DOI 10.1002/jclp.10106; BRACY OL, 1994, J COGN REHAB, V12, P8; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Caetano C., 1997, NEUROPSYCHOL REHABIL, P63; CHRISTENSEN AL, 1991, J HEAD TRAUMA REHAB, V6, P56; CICERONE KD, 1989, REHABIL PSYCHOL, V34, P105, DOI 10.1037//0090-5550.34.2.105; Coetzer B. R, 2004, ILLNESS CRISIS LOSS, V12, P171, DOI DOI 10.1177/1054137303262216; Coetzer BR, 2001, J COGN REHABIL, V19, P8; Coetzer R., 2006, TRAUMATIC BRAIN INJU; Davis CG, 2001, AM BEHAV SCI, V44, P726, DOI 10.1177/0002764201044005003; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Howes H, 2005, PSYCHOL HEALTH, V20, P129, DOI 10.1080/0887044042000272903; Judd D, 2005, BRAIN INJURY, V19, P437, DOI 10.1080/02699050400010994; Kolden G G, 1992, J Psychother Pract Res, V1, P225; Kolden G. G, 1991, PSYCHOTHER RES, V1, P62, DOI [10.1080/10503309112331334071, DOI 10.1080/10503309112331334071]; Kolden GG, 2005, PSYCHOTHER RES, V15, P165, DOI 10.1080/10503300512331387825; Kolden GG, 1996, J PERS DISORD, V10, P107, DOI 10.1521/pedi.1996.10.2.107; Kolden GG, 2000, J CLIN PSYCHOL, V56, P1207, DOI 10.1002/1097-4679(200009)56:9<1207::AID-JCLP7>3.0.CO;2-Z; Larry E, 2002, J CONTEMP PSYCHOTHER, V32, P25, DOI DOI 10.1023/A:1015579111666; LEZAK MD, 2004, NEUROPSYCHOL ASSESSM; Mateer C. A., 1997, NEUROPSYCHOL REHABIL, P285; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McGrath J, 2004, CLIN REHABIL, V18, P767, DOI 10.1191/0269215504cr802oa; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Orlinsky D. E., 1995, COMPREHENSIVE TXB PS, V1, P3; Orlinsky D. E., 1986, HDB PSYCHOTHERAPY BE, P311; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1; Prigatano GP, 1997, J INT NEUROPSYCH SOC, V3, P497, DOI 10.1017/S1355617797004979; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 2000, INT HDB NEUROPSYCHOL, P115, DOI DOI 10.1007/978-1-4757-5569-5_7; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P88, DOI 10.1097/00001199-199608000-00011; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Schlund MW, 1999, BRAIN INJURY, V13, P375, DOI 10.1080/026990599121566; Schlund MW, 1999, BRAIN INJURY, V13, P889; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sprenkle DH, 2004, J MARITAL FAM THER, V30, P113, DOI 10.1111/j.1752-0606.2004.tb01228.x; TEASDALE T, 1997, NEUROPSYCHOL REHAB F, P469; Wallace CA, 2000, BRAIN INJURY, V14, P549; WAMPLOD BE, 2001, GREAT PSYHCOTHERAPY; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876	46	19	21	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2007	22	1					39	47		10.1097/00001199-200701000-00005			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130SX	WOS:000243820400005	17235230				2021-06-18	
J	Gardner, HB				Gardner, Horace B.			A witnessed short fall mimicking presumed shaken baby syndrome (inflicted childhood neurotrauma)	PEDIATRIC NEUROSURGERY			English	Article						shaken baby syndrome; inflicted childhood neurotrauma; fall; trauma; subdural hematoma; retinal hemorrhage	ACUTE SUBDURAL-HEMATOMA	A witnessed fall backwards of an infant from a sitting position resulted in the subdural hematoma and retinal hemorrhages characteristic of presumed shaken baby syndrome. Violent shaking is not necessary to produce these findings. Copyright (c) 2007 S. Karger AG, Basel.		Gardner, HB (corresponding author), 318 Oklahoma Rd, Manitou Springs, CO 80829 USA.	horacebgardner@yahoo.com					AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; IKEDA A, 1987, CHILD NERV SYST, V3, P19, DOI 10.1007/BF00707188; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Piatt J H Jr, 1999, Neurosurg Focus, V7, pe4; Pittman T, 2003, PEDIATR NEUROSURG, V39, P57, DOI 10.1159/000071315; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001	6	19	19	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.		2007	43	5					433	435		10.1159/000106399			3	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	208FQ	WOS:000249305600019	17786015				2021-06-18	
J	Nayak, C; Nayak, D; Bhat, S; Raja, A; Rao, A				Nayak, Chandrika; Nayak, Dinesh; Bhat, Surekha; Raja, Annaswamy; Rao, Anjali			Relationship between neurological outcome and early oxidative changes in erythrocytes in head injury patients	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						erythrocytes; glutathione; lipid peroxidation; outcome; reactive oxygen species	TRAUMATIC BRAIN INJURY; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; FREE-RADICALS; METABOLISM; STRESS; DAMAGE; ISCHEMIA	Background: Experimental data indicate that destructive oxidative events reach their peak within the first 24 h after trauma in head injury (HI) and that brain damage occurring due to this impact can be the cause of death or irreversible permanent disabilities in affected patients. Methods: Venous blood samples were obtained from 50 HI patients within 24 h of trauma onset and from 30 age- and sex-matched normal controls (NC). Patients were divided into three different neurological outcome groups: those who died within 10 days of trauma (D), and those with severe neurological deficits (SD) or mild/no neurological deficits (MD) at 90 days after trauma. Early oxidative changes in erythrocytes were assessed by estimating an indicator of lipid peroxidative damage - thiobarbituric acid-reactive substances (TBARS) - and antioxidants [reduced glutathione (GSH) levels and superoxide dismutase (SOD) activity]. Results: In the D group, erythrocyte TBARS levels were significantly higher compared to the NC, SD and MD groups (p < 0.001); GSH levels were significantly lower compared to the NC (P < 0.061) and MD (p < 0.01) groups and SOD activity was significantly higher than in the NC (p < 0.01) and MD (p < 0.01) groups. In the SD group, TBARS levels were significantly higher than in the NC (p < 0.001) and MD (p < 0.05) groups; GSH levels were significantly lower than in the NC (p < 0.001) and MD (p < 0.01) groups and SOD activity was higher compared to the NC and MD (p < 0.01) groups. In the MD group, TBARS levels were significantly higher and GSH levels significantly lower compared to the NC group (p < 0.001). However,we did not observe any significant change in SOD activity compared to the NC group. Conclusions: These findings indicate that early oxidative changes may reflect the severity of neurological insult and provide an early indication of patient outcome in traumatic HI.	Int Ctr Hlth Sci, Melaka Manipal Med Coll, Dept Biochem, Manipal 576104, Karnataka, India; Kasturba Med Coll & Hosp, Dept Pediat, Manipal 576119, India; Melaka Manipal Med Coll, Dept Biochem, Manipal, India; Kasturba Med Coll & Hosp, Dept Neurosurg, Manipal 576119, India; Kasturba Med Coll & Hosp, Dept Biochem, Manipal 576119, India	Nayak, C (corresponding author), Int Ctr Hlth Sci, Melaka Manipal Med Coll, Dept Biochem, Manipal Campus, Manipal 576104, Karnataka, India.	chandrikadinesh@yahoo.com	Bhat, Malpe Surekha/F-8674-2010	Rao, Anjali/0000-0002-2676-2762; Nayak, Dinesh M/0000-0001-7384-8916; Nayak, Chandrika D/0000-0002-4674-7359			Beauchamp C., 1971, ANAL BIOCHEM, V44, P276, DOI DOI 10.1016/0003-2697(71)90370-8; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHERUBINI A, 2001, 2 VIRT C CARD SEP 1; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DISILVESTRO RA, 1989, ARCH BIOCHEM BIOPHYS, V274, P298, DOI 10.1016/0003-9861(89)90442-6; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Giustarini D, 2003, CLIN CHEM, V49, P327, DOI 10.1373/49.2.327; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; IKEDA Y, 1994, ACTA NEUROCHIR, P136; JAIN SK, 1989, DIABETES, V38, P1539, DOI 10.2337/diabetes.38.12.1539; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1994, ADV EXP MED BIOL, V366, P389; Nayak C, 2006, CLIN CHEM LAB MED, V44, P460, DOI 10.1515/CCLM.2006.068; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Polidori MC, 2001, STROKE, V32, P898, DOI 10.1161/01.STR.32.4.898; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; REITER RJ, 1995, FASEB J, V9, P526; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Said SI, 2000, FREE RADICAL BIO MED, V28, P1300, DOI 10.1016/S0891-5849(00)00289-6; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SHOHAMI E, 1989, J NEUROTRAUM, V16, P365; Siems WG, 2000, CLIN NEPHROL, V53, pS9; SUDHA K, 1998, THESIS MANIPAL ACAD; Tentori L, 1981, Methods Enzymol, V76, P707, DOI 10.1016/0076-6879(81)76152-4; Yamamoto T, 1999, ACT NEUR S, V75, P17	36	19	21	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621	1437-4331		CLIN CHEM LAB MED	Clin. Chem. Lab. Med.		2007	45	5					629	633		10.1515/CCLM.2007.123			5	Medical Laboratory Technology	Medical Laboratory Technology	175HY	WOS:000247005900010	17484625				2021-06-18	
J	Conn, JM; Annest, JL; Bossarte, RM; Gilchrist, J				Conn, Judith M.; Annest, Joseph L.; Bossarte, Robert M.; Gilchrist, Julie			Non-fatal sports and recreational violent injuries among children and teenagers, United States, 2001-2003	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						violence; injury; sports; child; adolescent; epidemiology	AFRICAN-AMERICAN BOYS; PREVENTION PROGRAMS; CARE-CENTERS; SCHOOL; EPIDEMIOLOGY; INTERVENTION; AGGRESSION; TRIAL	Background: An estimated 2.7 million non-fatat unintentional sports and recreational injuries are treated in U.S. hospital emergency departments (EDs) annually. However, little is known about the number of sports and recreational injuries resulting from violent behavior. Methods: Data for 2001-2003 on sports and recreational injuries were obtained from the National Electronic Injury Surveillance Systern-All Injury Program (NEISS-AIP)-a national sample of 66 U.S. EDs. National estimates and rates of persons treated for violence-related sports and recreational injuries in EDs are compared to those treated for unintentional sports and recreational injuries. Types of injuries and injury circumstances are described. Results: During the study period, an estimated 6705 (8.3 per 100,000; 95% confidence intervals (CI), 6.3-10.3) children and teenagers with violence-related sports and recreational injuries were treated in U.S. EDs annually, compared to 2,698,634 children and teenagers with unintentional sports and recreational injuries. Thus, violent behavior accounted for 0.25% of sports and recreational injuries. The highest incidence rate (13.6 per 100,000) for violence-related sports and recreational injuries was for children aged 10-14 years. Most patients with violence-related sports and recreational injuries were treated and released from the ED. A majority of those with violence-related sports and recreational injuries were injured to the head/neck region (52.2%), of which 24.1% were treated for traumatic brain injuries. Most violent injuries resulted from being pushed or hit (65.6%); the most common sports and recreational activity varied by age: playground (65.2%) for children <=9 years; bicycling (26.7%) for 10-14-year-olds; basketball (45.3%) for 15-19-year-otds. Conclusions: National ED surveillance systems can provide useful information pertaining to prevention programs designed to reduce sports and recreational injuries resulting from violent behavior and unintentional causes. Sports Medicine Australia. Published by Elsevier Ltd.	Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA USA; Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA	Conn, JM (corresponding author), Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,MS-K59, Atlanta, GA 30341 USA.	jconn@cdc.gov	Bossarte, Robert/AAF-8571-2019				Alkon A, 1999, ARCH PEDIAT ADOL MED, V153, P1248, DOI 10.1001/archpedi.153.12.1248; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Boden Barry P, 2005, Curr Sports Med Rep, V4, P45; Boulton MJ, 1999, CHILD DEV, V70, P944, DOI 10.1111/1467-8624.00068; *CDCP, EST 1 JUL 2001 1 JUL; Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; CHANG A, 1989, PEDIATRICS, V83, P272; Cohen L R, 1999, Adolesc Med, V10, P125; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; *CONS PROD SAF COM, 2002, NAT EL INJ SURV SYST; Cooper WO, 2000, ARCH PEDIAT ADOL MED, V154, P1134, DOI 10.1001/archpedi.154.11.1134; Craig WM, 2000, SCHOOL PSYCHOL INT, V21, P22, DOI 10.1177/0143034300211002; DAHLBERG L, 2005, VIOLENCE GLOBAL HLTH; Dusenbury L, 1997, J SCHOOL HEALTH, V67, P409, DOI 10.1111/j.1746-1561.1997.tb01286.x; Farrell AD, 2001, J CLIN CHILD PSYCHOL, V30, P451, DOI 10.1207/S15374424JCCP3004_02; FOX B, 2005, TEEN KILLED BASEBALL; Greenberg M. T., 1998, BLUEPRINTS VIOLENCE; Grossman DC, 1997, JAMA-J AM MED ASSOC, V277, P1605, DOI 10.1001/jama.277.20.1605; HAMMARSTROM A, 1994, SCAND J SOC MED, V22, P120, DOI 10.1177/140349489402200207; HUDLEY C, 1993, CHILD DEV, V64, P124, DOI 10.2307/1131441; Hudley C, 1996, AM J PREV MED, V12, P75; HUDLEY C, 1995, APPL PREV PSYCHOL, V4, P185, DOI 10.1016/S0962-1849(05)80057-5; Leff SS, 2003, SCHOOL PSYCHOL REV, V32, P418; LENAWAY DD, 1992, AM J PREV MED, V8, P193; LEVIN DS, 1995, PEDIATR EXERC SCI, V7, P379; Limbos MAP, 2003, J SCHOOL HEALTH, V73, P101, DOI 10.1111/j.1746-1561.2003.tb03582.x; Mattila VM, 2005, SCAND J PUBLIC HEALT, V33, P307, DOI 10.1080/14034940510005851; McCaig LF, 2004, NATL HOSP AMBULATORY; MCCARTHY B, 2004, PHILADELPHIA IN 0702; *NIH, 1992, C SPORTS INJ YOUTH S; Ranalli Dennis N, 2005, Curr Sports Med Rep, V4, P12; ROSINSKI J, 2004, BOSTON HERALD   0819, pO32; Ryan G, 2005, J INTERPERS VIOLENCE, V20, P132, DOI 10.1177/0886260504268605; Scala CD, 1997, J SCH HLTH, V6, P384; SEYMOUR A, 2004, ATLANTA J CONST 0612, pC1; Spoth RL, 2000, ARCH PEDIAT ADOL MED, V154, P1248, DOI 10.1001/archpedi.154.12.1248; *STAT REG, 2005, POL HOLD CHOCT 14 YE; Tenenbaum G, 1997, SPORT PSYCHOL, V11, P1, DOI 10.1123/tsp.11.1.1; TERRY RC, 1985, QUEST, V37, P27; THORTON T, 2002, BEST PRACTICES YOUTH; 2005, CHICAGO TRIBUNE 0223, P3; 2005, SUSPECTS SOUGHT TEEN	43	19	19	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	DEC	2006	9	6					479	489		10.1016/j.jsams.2006.03.004			11	Sport Sciences	Sport Sciences	119TY	WOS:000243037800009	16621700				2021-06-18	
J	Hart, T; Dijkers, M; Fraser, R; Cicerone, K; Bogner, JA; Whyte, J; Malec, J; Waldron, B				Hart, Tessa; Dijkers, Marcel; Fraser, Robert; Cicerone, Keith; Bogner, Jennifer A.; Whyte, John; Malec, James; Waldron, Brigid			Vocational services for traumatic brain injury - Treatment definition and diversity within model systems of care	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						measurement of treatment; traumatic brain injury; vocational rebabilitation	SUPPORTED EMPLOYMENT; BLACK-BOX; REHABILITATION; WORK; RETURN; SATISFACTION; INDIVIDUALS; LIFE	Objective: To examine characteristics and diversity among vocational treatment services in model programs for traumatic brain injury (TBI) rehabilitation. Setting: Vocational or postacute treatment components of 16 TBI Model System (TBIMS) centers. Participants: Vocational director/coordinator from each TBIMS surveyed in semistructured phone interview. Measure: Survey of vocational services for people with TBI, with about 100 closed and open-ended questions on vocational assessments; pre- and postjob placement treatments; program philosophies; funding; and integration of cognitive, behavioral, family, and medical rehabilitation interventions. Results: Great diversity was found among the vocational services of the 16 TBIMS. Programs fell into 3 clusters emphasizing medical rehabilitation services, supported employment, or a combination of these with an emphasis on case management. job coaching was identified as a key intervention, but there was great variability in intensity, availability, and funding of coaching services. Conclusion: Diversity in vocational services appears related to funding differences and "parallel evolution" rather than strong treatment philosophy or scientific evidence base. Multicenter research on effectiveness or establishment of best practices in vocational rehabilitation after TBI must deal with substantial existing variability in treatment models and specific interventions, and must examine the relationship of treatment variations to case-mix factors.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; JFK Johnson Rehabil Inst, Dept Phys Med & Rehabil, Edison, NJ USA; Ohio State Univ, Coll Med, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu	Bogner, Jennifer/E-2773-2011; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Whyte, John/0000-0002-4381-1474; Dijkers, Marcel/0000-0002-8362-5596			ABRAMS D, 1993, J HEAD TRAUMA REHAB, V84, P59; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bode RK, 2004, ARCH PHYS MED REHAB, V85, P1901, DOI 10.1016/j.apmr.2004.02.023; Bond GR, 1997, REHABIL COUNS BULL, V40, P265; Bond GR, 1997, PSYCHIATR SERV, V48, P335; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; *COMM ACCR REH FAC, 2002, COMM ACCR REH FAC ST; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Crowther R., 2001, COCHRANE DB SYST REV, V2001, DOI [DOI 10.1002/14651858.CD003080, 10.1002/14651858.CD003080]; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DeJong G, 2004, ARCH PHYS MED REHAB, V85, P678, DOI 10.1016/j.apmr.2003.06.033; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; FRASER R, 1997, VOCAT REHABIL, V8, P371; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Keith RA, 1997, ARCH PHYS MED REHAB, V78, P1298, DOI 10.1016/S0003-9993(97)90300-2; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF, 2005, REHABILITATION TRAUM, P176; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Prigatano G., 1985, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wall JR, 1998, BRAIN INJURY, V12, P215; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Wehman P, 1999, REHABILITATION ADULT, P326; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D	34	19	19	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					467	482		10.1097/00001199-200611000-00002			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400002	17122678				2021-06-18	
J	Ivashkova, Y; Svetnitsky, A; Mayzler, O; Pruneau, D; Benifla, M; Fuxman, Y; Cohen, A; Artru, AA; Shapira, Y				Ivashkova, Yulia; Svetnitsky, Albert; Mayzler, Olga; Pruneau, Didier; Benifla, Mony; Fuxman, Yulia; Cohen, Avi; Artru, Alan A.; Shapira, Yoram			Bradykinin B2 receptor antagonism with LF 18-1505T reduces brain edema and improves neurological outcome after closed head trauma in rats	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						bradykinin antagonist; brain edema; head injury; neurologic outcome; rat	NITRIC-OXIDE SYNTHASE; B-2 RECEPTOR; KININ RECEPTORS; GUINEA-PIG; INJURY; PERMEABILITY; INHIBITION; MODEL; RELAXATION; REDUCTION	Background: We evaluated the effect of LF 18-1505T, a novel nonpeptide bradykinin type-2 receptor antagonist, on brain edema and neurologic severity score (NSS) after closed head trauma (CHT). Methods: There were 132 rats anesthetized and assigned for sham or CHT; infusion of saline or LF 18-1505T (0.3, 1, 3, 10, or 30 mu g center dot kg(-1) center dot min(-1)); and determination of neurologic outcome (brain water content anti NSS) or physiologic variables (blood pressure, glucose concentration, etc.). Results: Post-CHT brain water content was less with LF 18-1505T doses of 3 and 10 mu g center dot kg(-1) center dot min(-1) (80.1 +/- 3.8 through 81.6 +/- 2.6%, mean +/- SD) than in the untreated group (84.6 +/- 1.9%, p < 0.01). Post-CHT NSS improved with doses of 3, 10, and 30 mu g center dot kg(-1) center dot min(-1) (median, 7; range, 0-12 through median, 10; range, 8-18) as compared with that in the untreated group (median, 17; range, 14-23; p < 0.05). LF 18-1505T with or without CHT did not significantly alter physiologic variables. Conclusions: LF 18-1505T decreased brain edema and improved neurologic status after CTH in rats without significantly altering physiologic. values.	Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA; Labs Fournier, Res Ctr, Daix, France; Barzilay Med Ctr, Dept Surg, Askelon, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Div Anesthesiol, Dept Surg, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Dept Neurol Surg, IL-84105 Beer Sheva, Israel	Artru, AA (corresponding author), Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA.	artruaa@u.washington.edu					Bastian S, 1997, BRIT J PHARMACOL, V122, P393, DOI 10.1038/sj.bjp.0701380; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; Dixon CE, 1996, NEUROTRAUMA, P1337; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1990, NEW TRENDS LIPID MED, P129; Feldman Z, 1997, J TRAUMA, V43, P667, DOI 10.1097/00005373-199710000-00017; FRANCEL PC, 1992, J NEUROTRAUMA S1, V9, P27; Gecse A, 1989, Adv Exp Med Biol, V247A, P249; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Gorlach C, 1996, PEPTIDES, V17, P1373, DOI 10.1016/S0196-9781(96)00223-9; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Hsu CY, 1996, NEUROTRAUMA, P1433; Jeftinija SD, 1996, J NEUROCHEM, V66, P676; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; Kaplanski J, 2003, RESUSCITATION, V56, P207, DOI 10.1016/S0300-9572(02)00371-4; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; KATUSIC ZS, 1993, STROKE, V24, P392, DOI 10.1161/01.STR.24.3.392; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Lehmberg J, 2003, J CEREBR BLOOD F MET, V23, P441, DOI 10.1097/01.WCB.0000052280.23292.35; Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MULLERESTERL W, 1989, THROMB HAEMOSTASIS, V61, P2; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; Paquet JL, 1999, BRIT J PHARMACOL, V126, P1083, DOI 10.1038/sj.bjp.0702403; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Perez M., 2001, J CLIN BASIC CARDIOL, V4, P39; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, FUND CLIN PHARMACOL, V13, P75, DOI 10.1111/j.1472-8206.1999.tb00323.x; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; PRUNEAU D, 1995, BRIT J PHARMACOL, V116, P2106, DOI 10.1111/j.1476-5381.1995.tb16418.x; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; Sharma HS, 2000, ACTA NEUROCHIR SUPPL, V76, P159; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; Wang Q, 1997, J CELL PHYSIOL, V172, P171, DOI 10.1002/(SICI)1097-4652(199708)172:2<171::AID-JCP4>3.0.CO;2-L; WARD PE, 1991, BRADYKININ ANTAGONIS, P147; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V323, P66, DOI 10.1007/BF00498830; Xing MZ, 1997, AM J PHYSIOL-CELL PH, V272, pC1380	54	19	20	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2006	61	4					879	885		10.1097/01.ta.0000234722.98537.01			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	096YU	WOS:000241413700022	17033555				2021-06-18	
J	Swann, IJ; Bauza-Rodriguez, B; Currans, R; Riley, J; Shukla, V				Swann, I. J.; Bauza-Rodriguez, B.; Currans, R.; Riley, J.; Shukla, V.			The significance of post-traumatic amnesia as a risk factor in the development of olfactory dysfunction following head injury	EMERGENCY MEDICINE JOURNAL			English	Article							RECOVERY	Objective: To test the following hypothesis in the assessment of head injury patients: only patients with 5 min or more of post-traumatic amnesia ( PTA) are at risk of acute olfactory dysfunction ( OD). Methods: This was a retrospective comparative study of olfactory status in head injury patients seen at a head injury clinic at Glasgow Royal Infirmary from 1985 to 2003. Of 828 clinic attenders, 101 had acute OD. These subjects were compared with a randomly selected control group of 102 patients with head injury but normal olfactory function. The main outcome measure was a significant likelihood of patients with PTA lasting for 5 or more minutes having acute OD compared with those with PTA of less than 5 min. Results: The likelihood of patients with a PTA of 5 min or more having acute OD compared to those with PTA of less than 5 min is clinically significant with an odds ratio of 9.6 ( p< 0.01). Conclusion: Examination of patients with 5 min or more of PTA should include a simple test of sense of smell. Patients with impaired smell sensation should be aware of their condition prior to discharge from hospital. In addition, the need for a CT brain scan and appropriate follow up should be considered.	Glasgow Royal Infirm, Dept Emergency Med, Glasgow G4 0SF, Lanark, Scotland; Greater Glasgow Hlth Board, N Glasgow Div, Glasgow, Lanark, Scotland; Glasgow Caledonian Univ, Div Math, Glasgow G4 0BA, Lanark, Scotland; Hull Royal Infirm, Kingston Upon Hull HU3 2JZ, N Humberside, England	Swann, IJ (corresponding author), Glasgow Royal Infirm, Dept Emergency Med, 84 Castle St, Glasgow G4 0SF, Lanark, Scotland.	Ian.Swann@northglasgow.scot.nhs.uk					Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Jackson JH, 1864, LOND HOSP REP, V1, P470; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; Mann Norman M, 2003, Conn Med, V67, P545; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; McFarland K, 2001, CLIN NEUROPSYCHOL, V15, P59, DOI 10.1076/clin.15.1.59.1916; Miwa T, 2001, ARCH OTOLARYNGOL, V127, P497, DOI 10.1001/archotol.127.5.497; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; *SCOTT INT GUID NE, 2000, EARLY MAN PAT HEAD I; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; SWANN IJ, 1981, INJURY, V12, P274, DOI 10.1016/0020-1383(81)90200-X; Swann IJ, 2001, EMERG MED J, V18, P352, DOI 10.1136/emj.18.5.352; SWANN IJ, 1993, J NEUROTRAUM, V10, P176; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171	15	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	AUG	2006	23	8					618	621		10.1136/emj.2005.029017			4	Emergency Medicine	Emergency Medicine	065NT	WOS:000239167300013	16858094	Green Published			2021-06-18	
J	Takeuchi, N; Ikoma, K; Chuma, T; Matsuo, Y				Takeuchi, Naoyuki; Ikoma, Katsunori; Chuma, Takayo; Matsuo, Yuichiro			Measurement of transcallosal inhibition in traumatic brain injury by transcranial magnetic stimulation	BRAIN INJURY			English	Article						traumatic brain injury; transcranial magnetic stimulation; corpus callosum; diffuse axonal injury	DIFFUSE AXONAL INJURY; HEAD-INJURY; CORPUS-CALLOSUM; MULTIPLE-SCLEROSIS; MOTOR CORTEX; HUMANS; FIBERS; COMA	Primary objective: To study whether transcallosal inhibition (TCI) can evaluate the severity of traumatic brain injury (TBI). Research design: Case-control study. Methods and procedures: Twenty patients with a chronic TBI and 20 control subjects were studied. The following transcranial magnetic stimulation parameters were checked; resting motor threshold, central motor latency times, onset latency of TCI, duration of TCI, transcallosal conduction times and amount of TCI. The severity of TBI was evaluated using the Glasgow Coma Scale (GCS). Main outcome and results: The amount of TCI was significantly lower in the patients than the control subjects (p < 0.001). The amount of TO was highly correlated with the GCS (r = 0.787, p < 0.001). Conclusion: An assessment of TCI was found to be a more sensitive and useful method for an evaluation of the severity of TBI.	Hokkaido Univ, Grad Sch Med, Dept Rehabil Med, Sapporo, Hokkaido 0600814, Japan	Takeuchi, N (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Rehabil Med, North 14 West 5, Sapporo, Hokkaido 0600814, Japan.	naoyuki@med.hokudai.ac.jp	Ikoma, Katsunori/D-8158-2012		Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17300179] Funding Source: KAKEN		Aranyi Z, 2002, EXP BRAIN RES, V145, P76, DOI 10.1007/s00221-002-1101-1; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; JANE JA, 1984, CLIN NEUROSURG, V29, P346; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Meyer BU, 1998, ANN NEUROL, V43, P360, DOI 10.1002/ana.410430314; Meyer BU, 1996, J PHYSIOL-LONDON, V497P, pP34; MEYER BU, 1995, BRAIN, V118, P429, DOI 10.1093/brain/118.2.429; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmierer K, 2000, J NEUROL NEUROSUR PS, V68, P633, DOI 10.1136/jnnp.68.5.633; Schmierer K, 2002, NEUROLOGY, V59, P1218, DOI 10.1212/WNL.59.8.1218; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Whyte J, 1998, REHABILITATION MED P, P1191; Wolters A, 2004, MOVEMENT DISORD, V19, P518, DOI 10.1002/mds.20064	24	19	19	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2006	20	9					991	996		10.1080/02699050600909771			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100011	17046801				2021-06-18	
J	Engstrom, M; Schott, U; Nordstrom, CH; Romner, B; Reinstrup, P				Engstrom, Martin; Schott, Ulf; Nordstrom, Carl-Henrik; Romner, Bertil; Reinstrup, Peter			Increased lactate levels impair the coagulation system - A potential contributing factor to progressive hemorrhage after traumatic brain injury	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						acidosis; coagulation; lactate; thromboelastography; trauma	CEREBRAL PERFUSION-PRESSURE; ACTIVATED FACTOR-VII; HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; COAGULOPATHY; HYPOTHERMIA; TIME; THROMBOELASTOGRAPHY; THROMBELASTOGRAPHY; PREDICTORS	Progressive intracerebral contusions are a major problem in the management of patients with severe traumatic brain injury that is also linked to worse outcome. Microdialysis studies have revealed that lactate levels are very high inside contusions, corresponding to significant acidosis. The current study was performed in an effort to investigate whether the lactate accumulation inside cerebral contusions may be a contributing factor to the prolonged bleeding inside contusions. We have investigated the effects of lactic acidosis on the coagulation system with rotational thromboelastometry. It was a laboratory study involving 6 healthy volunteers. Blood was drawn and the pH was adjusted by addition of lactic acid in vitro. The pH levels studied were 7.4, 7.2, 7.0, and 6.8. The pH was also readjusted to 7.4 by addition the buffer THAM to blood initially adjusted to a pH of 6.8 to study the reversibility of potential adverse effects induced by the lactic acidosis. We found the coagulation to be significantly impaired by lactic acidosis (P = 0.0001). The impairment found was reversible after correction of the acidosis by a buffer. In conclusion, we found that lactic acidosis impaired the coagulation system. The impairment caused by lactic acidosis may be one factor causing the progressive hemorrhage in postraumatic cerebral contusions, known to have high levels of lactate and correspondingly low pH. It may also be important to consider in bleeding trauma patients.	Univ Lund Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden; Halmstad Cty Hosp, Dept Anaesthesia & Intens Care, Halmstad, Sweden	Engstrom, M (corresponding author), Lund Univ, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden.	martin.engstrom@med.lu.se	Schott, Ulf/AAY-6982-2020				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Armand R, 2003, TRANSFUS MED REV, V17, P223, DOI 10.1016/S0887-7963(03)00022-1; Bowbrick VA, 2003, PLATELETS, V14, P219, DOI 10.1080/0953710031000118849; Caprini JA, 1995, SEMIN THROMB HEMOST, V21, P91; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; Eddy VA, 2000, SURG CLIN N AM, V80, P845, DOI 10.1016/S0039-6109(05)70099-2; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Engstrom Martin, 2005, BMC Blood Disord, V5, P3, DOI 10.1186/1471-2326-5-3; Gentilello LM, 2001, AM J RESP CRIT CARE, V163, P604, DOI 10.1164/ajrccm.163.3.2004106; Goh KYC, 1997, J NEUROL NEUROSUR PS, V63, P334, DOI 10.1136/jnnp.63.3.334; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; Hendriks HGD, 2002, BLOOD COAGUL FIBRIN, V13, P309, DOI 10.1097/00001721-200206000-00006; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Hutchinson PJA, 2002, ACT NEUR S, V81, P359; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; Kettner SC, 2003, ANESTH ANALG, V96, P1772, DOI 10.1213/01.ANE.0000062520.65192.C9; Krishna G, 1998, AUST NZ J SURG, V68, P826, DOI 10.1111/j.1445-2197.1998.tb04696.x; Lynn M, 2002, INTENS CARE MED, V28, pS241, DOI 10.1007/s00134-002-1471-7; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2005, STROKE, V36, P74, DOI 10.1161/01.STR.0000149628.80251.b8; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Metcalf K, 1990, Nurse Anesth, V1, P33; Mikhail J, 1999, AACN Clin Issues, V10, P85, DOI 10.1097/00044067-199902000-00008; Murray DJ, 1997, J CARDIOTHOR VASC AN, V11, P24, DOI 10.1016/S1053-0770(97)90247-0; Nielsen VG, 2002, ANESTH ANALG, V95, P1503, DOI 10.1097/00000539-200212000-00008; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Rixen D, 2001, SHOCK, V15, P83, DOI 10.1097/00024382-200115020-00001; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; TUMAN KJ, 1987, ANESTH ANALG, V66, P856; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; WONG CA, 1995, REGION ANESTH, V20, P521	42	19	21	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2006	18	3					200	204		10.1097/01.ana.0000211002.63774.8a			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	059FQ	WOS:000238719100007	16799348				2021-06-18	
J	Sonna, LA; Kuhlmeier, MM; Carter, HC; Hasday, JD; Lilly, CM; Fairchild, KD				Sonna, Larry A.; Kuhlmeier, Matthew M.; Carter, Heather C.; Hasday, Jeffrey D.; Lilly, Craig M.; Fairchild, Karen D.			Effect of moderate hypothermia on gene expression by THP-1 cells: a DNA microarray study	PHYSIOLOGICAL GENOMICS			English	Article; Proceedings Paper	101st International Conference of the American-Thoracic-Society	MAY 20-25, 2005	San Diego, CA	Amer Thorac Soc, Fogarty AIDS Int Training & Res Program		cold stress; thermal stress; heat shock; mononuclear cells	TRAUMATIC BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; CARDIAC-ARREST; COLD STRESS; HEAT; DIFFERENTIATION; ADULTS	The mechanisms by which moderate hypothermia (32 C for 12-72 h) affect human cellular function are unclear. We tested the hypothesis that it produces broad changes in mRNA expression in vitro. Acute monocytic leukemia (THP-1) cells were incubated under control conditions (37 C) or moderate hypothermia (32 C) for 24 h. RNA was extracted, and the hypothermic response was confirmed by examining the expression of the cold-induced RNA-binding protein (CIRBP) gene by RT-PCR. Gene expression analysis was performed on seven sets of paired samples with Affymetrix U133A chips using established statistical methods. Sequences were considered affected by cold if they showed statistically significant changes in expression and also met published post hoc filter criteria (changes in geometric mean expression of >= 2-fold and expression calls of "present" or "marginal" in at least half of the experiments). Changes in the expression of selected sequences were further confirmed by PCR. Sixty-seven sequences met the criteria for increased expression ( including cold-inducible genes CIRBP and RNA binding motif 3), and 100 sequences showed decreased expression as a result of hypothermia. Functional categories affected by hypothermia included genes involved in immune responses; cell growth, proliferation, and differentiation; and metabolism and biosynthesis. Several heat shock proteins (HSPs) showed decreases in expression. Moderate hypothermia produces substantial changes in gene expression, in categories potentially of systemic importance. Cold exposure without rewarming decreased the expression of several HSPs. These in vitro findings suggest that prolonged hypothermia in vivo might be capable of producing physiologically relevant changes in gene expression by circulating leukocytes.	USA, Thermal & Mt Med Div, Res Inst Environm Med, Natick, MA USA; Univ Maryland, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA USA; Univ Virginia Hosp, Div Neonatol, Charlottesville, VA USA	Sonna, LA (corresponding author), USA, Thermal & Mt Med Div, Res Inst Environm Med, 42 Kansas St, Natick, MA USA.	larry_sonna@yahoo.com					Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Castellani JW, 2002, MED SCI SPORT EXER, V34, P2013, DOI 10.1097/00005768-200212000-00023; Chen C, 2000, CANCER RES, V60, P4377; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; FARRELL RE, 1998, RNA METHODOLOGIES, P94; Hayden JM, 2002, J LIPID RES, V43, P26; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kaminski N, 2002, AM J RESP CELL MOL, V27, P125, DOI 10.1165/ajrcmb.27.2.f247; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Nishiyama H, 1997, GENE, V204, P115, DOI 10.1016/S0378-1119(97)00530-1; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Safar PJ, 2002, NEW ENGL J MED, V346, P612, DOI 10.1056/NEJM200202213460811; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sonna LA, 2004, J APPL PHYSIOL, V96, P1943, DOI 10.1152/japplphysiol.00886.2003; Sonna LA, 2003, PHYSIOL GENOMICS, V12, P195, DOI 10.1152/physiolgenomics.00104.2002; Sonna LA, 2002, J APPL PHYSIOL, V92, P2208, DOI 10.1152/japplphysiol.01002.2001; Sonna LA, 2002, J APPL PHYSIOL, V92, P1725, DOI 10.1152/japplphysiol.01143.2001; Wood RJ, 2004, PHYSIOL GENOMICS, V17, P122, DOI 10.1152/physiolgenomics.00002.2003	22	19	19	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1094-8341			PHYSIOL GENOMICS	Physiol. Genomics	JUN 16	2006	26	1					91	98		10.1152/physiolgenomics.00296.2005			8	Cell Biology; Genetics & Heredity; Physiology	Cell Biology; Genetics & Heredity; Physiology	062AC	WOS:000238915500009	16595739				2021-06-18	
J	Ates, O; Yucel, N; Cayli, SR; Altinoz, E; Yologlu, S; Kocak, A; Cakir, CO; Turkoz, Y				Ates, Ozkan; Yucel, Neslihan; Cayli, Suleyman R.; Altinoz, Eyup; Yologlu, Sairn; Kocak, Ayhan; Cakir, Celal Ozbek; Turkoz, Yusuf			Neuroprotective effect of etomidate in the central nervous system of streptozotocin-induced diabetic rats	NEUROCHEMICAL RESEARCH			English	Article						central nervous system; diabetes mellitus; etomidate; malondialdehide; oxidative damage; streptozotocin	TRAUMATIC BRAIN-INJURY; INCOMPLETE FOREBRAIN ISCHEMIA; GLUTAMATE RELEASE INHIBITOR; NITRIC-OXIDE FORMATION; OXIDATIVE STRESS; XANTHINE-OXIDASE; ALZHEIMERS-DISEASE; RADICAL PRODUCTION; MELLITUS; NEURONS	It is well known that hyperglycaemia due to diabetes mellitus leads to oxidative stress in the central nervous system. Oxidative stress plays important role in the pathogenesis of neurodegenerative changes. In the present study we investigated the possible neuroprotective effect of etomidate against streptozotocin-induced (STZ-induced) hyperglycaemia in the rat brain and spinal cord. A total of 40 rats were used in this study. Rats were divided into four groups: sham-control, diabetic, diabetic-etomidate treated and vehicle for etomidate treatment group. Diabetes mellitus was induced by a single injection of streptozotocin (60 mg/kg body weight). Three days after streptoztocin injection, etomidate (2 mg/kg) was injected intraperitoneally for etomidate group and lipid emulsion (10%) for vehicle group was injected with corresponding amount intraperitoneally every day for 6 weeks. Six weeks after streptozotocin injection, seven rats from each group were killed and brain, brain stem and cervical spinal cord were removed. The hippocampus, cortex, cerebellum, brain stem and spinal cord were dissected for the biochemical analysis (the level of malondialdehyde [MDA], total nitrite, reduced glutathione [GSH], and xanthine oxidase [XO] activity). STZ-induced diabetes resulted in significantly elevation of MDA, XO and nitrite levels in the hippocampus, cortex, cerebellum,, brain stem and spinal cord of the rats (P < 0.05) while etomidate treatment provided significantly lower values (P < 0.05). This study demonstrated that etomidate have neuroprotective effect on the neuronal tissue against the diabetic oxidative damage.	Inonu Univ, Sch Med, Dept Neurosurg, Turgut Ozal Med Ctr, TR-44069 Malatya, Turkey; Inonu Univ, Sch Med, Dept Emergency Med, TR-44069 Malatya, Turkey; Inonu Univ, Sch Med, Dept Biochem, TR-44069 Malatya, Turkey; Inonu Univ, Sch Med, Dept Biostat, TR-44069 Malatya, Turkey	Ates, O (corresponding author), Inonu Univ, Sch Med, Dept Neurosurg, Turgut Ozal Med Ctr, TR-44069 Malatya, Turkey.	atesozkan@hotmail.com	Turkoz, Yusuf/ABG-7931-2020; Yologlu, Saim/ABI-8014-2020; Yucel, Neslihan/ABI-3412-2020	Turkoz, Yusuf/0000-0001-5401-0720; Yologlu, Saim/0000-0002-9619-3462; Yucel, Neslihan/0000-0001-5845-2614; Altinoz, Eyup/0000-0002-3991-9773			Asgary S, 1999, Pharm Acta Helv, V73, P223, DOI 10.1016/S0031-6865(98)00025-9; Baydas G, 2002, J PINEAL RES, V32, P225, DOI 10.1034/j.1600-079X.2002.01856.x; Baydas G, 2003, FREE RADICAL BIO MED, V35, P797, DOI 10.1016/S0891-5849(03)00408-8; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; BIESSELS GJ, 1994, DIABETOLOGIA, V37, P643, DOI 10.1007/BF00417687; Bonnefont-Rousselot D, 2000, DIABETES METAB, V26, P163; Bramwell KJ, 2006, PEDIATR EMERG CARE, V22, P90, DOI 10.1097/01.pec.0000199563.64264.3a; Cerutti SM, 2000, CELL BIOL INT, V24, P35, DOI 10.1006/cbir.1999.0451; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; Desco MC, 2002, DIABETES, V51, P1118, DOI 10.2337/diabetes.51.4.1118; Dincer Y, 2002, METABOLISM, V51, P1360, DOI 10.1053/meta.2002.35192; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Ercel Ergul, 1999, Biomedical Research (Aligarh), V10, P95; Greene DA, 1999, EUR J PHARMACOL, V375, P217, DOI 10.1016/S0014-2999(99)00356-8; Guyot LL, 2000, BRAIN RES, V872, P29, DOI 10.1016/S0006-8993(00)02426-4; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8; Hill R. A., 1995, COMPREHENSIVE ORGANI, V4; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Jungersten L, 1996, CLIN PHYSIOL, V16, P369, DOI 10.1111/j.1475-097X.1996.tb00726.x; Kapoor R, 2003, ANN NEUROL, V53, P174, DOI 10.1002/ana.10443; Karelson E, 2001, NEUROCHEM RES, V26, P353, DOI 10.1023/A:1010942929678; Kristal BS, 1997, FREE RADICAL BIO MED, V22, P813, DOI 10.1016/S0891-5849(96)00429-7; Low PA, 1997, DIABETES, V46, pS38, DOI 10.2337/diab.46.2.S38; Luxford C, 2000, CHEM RES TOXICOL, V13, P665, DOI 10.1021/tx000053u; LYSKO PG, 1994, STROKE, V25, P2476, DOI 10.1161/01.STR.25.12.2476; Malcangio M, 1998, PAIN, V76, P151, DOI 10.1016/S0304-3959(98)00037-2; MARSHAK DR, 1992, NEUROBIOL AGING, V13, P1, DOI 10.1016/0197-4580(92)90002-F; Matsumoto S, 2003, FREE RADICAL RES, V37, P767, DOI 10.1080/1071576031000107344; Mendez-Alvarez E, 2001, FREE RADICAL BIO MED, V31, P986, DOI 10.1016/S0891-5849(01)00679-7; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moosmann B, 2002, EXPERT OPIN INV DRUG, V11, P1407, DOI 10.1517/13543784.11.10.1407; Mu XJ, 2000, BRAIN RES, V870, P66, DOI 10.1016/S0006-8993(00)02402-1; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; Murugaiah KD, 1998, ANESTHESIOLOGY, V89, P919, DOI 10.1097/00000542-199810000-00017; Nakagawa T, 2005, J NUTR SCI VITAMINOL, V51, P278, DOI 10.3177/jnsv.51.278; Nishikawa T, 2000, NATURE, V404, P787; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Ovtscharoff W, 2002, ACTA HISTOCHEM, V104, P23, DOI 10.1078/0065-1281-00634; Ozbek E, 2000, EUR UROL, V37, P172, DOI 10.1159/000020135; PARKS D, 1988, J APPL PHYSIOL, V254, P768; PATEL PM, 1995, ANESTH ANALG, V80, P933, DOI 10.1097/00000539-199505000-00013; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PRAJDA N, 1975, FEBS LETT, V59, P245, DOI 10.1016/0014-5793(75)80385-1; PUIL E, 1994, NEUROSCI LETT, V176, P63, DOI 10.1016/0304-3940(94)90872-9; Revsin Y, 2005, BRAIN RES, V1038, P22, DOI 10.1016/j.brainres.2004.12.032; Sano T, 1998, DIABETOLOGIA, V41, P1355, DOI 10.1007/s001250051076; Schulz-Stubner S, 2005, CRIT CARE MED, V33, P2723, DOI 10.1097/01.CCM.0000187093.71107.A8; Slatter DA, 2000, DIABETOLOGIA, V43, P550, DOI 10.1007/s001250051342; Somani SM, 1996, ALCOHOL, V13, P603, DOI 10.1016/S0741-8329(96)00075-4; Tachi Y, 2001, LIFE SCI, V69, P1039, DOI 10.1016/S0024-3205(01)01183-3; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; WATSON JC, 1992, NEUROSURGERY, V30, P540; ZEBALLOS GA, 1995, CIRCULATION, V91, P2982, DOI 10.1161/01.CIR.91.12.2982	60	19	24	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUN	2006	31	6					777	783		10.1007/s11064-006-9076-0			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	071VC	WOS:000239631000008	16794861				2021-06-18	
J	Lefebvre, H; Levert, MJ				Lefebvre, Helene; Levert, Marie Josee			Breaking the news of traumatic brain injury and incapacities	BRAIN INJURY			English	Article						traumatic brain injury (TBI); breaking the news; disclosure; information	BAD-NEWS; PHYSICIANS; FAMILIES; PARENTS; CANCER; CARE	Primary objective: This paper presents research results regarding disclosure of traumatic brain injury (TBI) diagnosis and resulting deficits of a study aiming to investigate the experiences of individuals who had sustained a TBI, their families, the physicians and health professionals involved, from the critical care episodes and subsequent rehabilitation. Research design: Semi-structured interviews were conducted with individuals who had sustained a TBI (n = 8) and their families (n = 8) as well as with the health professionals (or service providers) (n = 22) and physicians (n = 9) who provided them care. Main outcomes and results: Results revealed that the quality of the disclosure is strongly influenced by the medical uncertainty surrounding the TBI and the difficulties of healthcare professionals in dealing with the family's emotions. Conclusions: Delivering bad news is always difficult, but it is possible to make this harrowing experience easier and, in so doing, enhance patient and family resilience.	Univ Montreal, Fac Nursing, Montreal, PQ H3C 3J7, Canada; Montreal Ctr Interdisciplinary Res Rehabil, CRIR, Montreal, PQ, Canada; Hop Sacre Coeur, Res Ctr, Montreal, PQ H4J 1C5, Canada; GIRAFE, Montreal, PQ, Canada	Lefebvre, H (corresponding author), Univ Montreal, Fac Nursing, Downtown Stn,POB 6128, Montreal, PQ H3C 3J7, Canada.	helene.lefebvre@umontreal.ca					Ahmann E, 1998, Pediatr Nurs, V24, P554; Baile W F, 2000, Oncologist, V5, P302, DOI 10.1634/theoncologist.5-4-302; BOLDUC M, 1996, THESIS U MONTREAL QU; BOUCHARD JM, 1994, DEFICIENCE INCAPACIT; BOUCHARD JM, 1999, APPRENTISSAGE SOCIAL, V19, P48; BOUCHARD JM, 1995, LINTEGRATION PERSONN, P379; Boule R, 2005, COMMUNICATION PROFES, P267; BRIERE N, 1996, THESIS U MONTREAL QU; BRZUSTOWSKI M, LANNONCE HANDICAP GR; BURY JA, 1988, ED SANTE CONCEPT ENJ; Campbell EM, 1998, BEHAV MED, V24, P73, DOI 10.1080/08964289809596383; COHADON F, 2002, TRAUMATISES CRANIENS; Cohen M H, 1993, West J Nurs Res, V15, P77, DOI 10.1177/019394599301500106; COHEN MH, 1995, QUAL HEALTH RES, V5, P63, DOI 10.1177/104973239500500105; CYRULNIK B, 2002, MERVEILLEUX MALHEUR; Davies R, 2003, CHILD CARE HLTH DEV, V29, P77, DOI 10.1046/j.1365-2214.2003.00316.x; DELLORTO AE, 2000, HEAD INJURY FAMILY L; DENORMANDIE P, 1999, ESPACE ETHIQUE MISSI; Fallowfield L, 2004, LANCET, V363, P312, DOI 10.1016/S0140-6736(03)15392-5; Farrell M, 2001, J ADV NURS, V36, P765, DOI 10.1046/j.1365-2648.2001.02042.x; FISHER GN, 1994, RESSORT INVISIBLE; Frenisy MC, 1999, ANN MED-PSYCHOL, V157, P159; Frosch S, 1997, BRAIN INJURY, V11, P891; GADOURY M, 1999, CADRE REFERENCE CLIN; GENDRON S, 2000, THESIS U MONTREAL QU; Girgis A, 1998, BEHAV MED, V24, P53, DOI 10.1080/08964289809596381; Girgis A, 1999, BEHAV MED, V25, P69, DOI 10.1080/08964289909595739; Glasser B., 1967, DISCOVERY GROUNDED T; GUBA LG, 1989, FOURTH GENERATION EV; Habermas J., 1987, THEORIE LAGIR COMMUN, VI et II; Horowitz R., 1998, FAMILIES SYSTEMS HLT, V16, P71; KALUBI JC, 1998, INNOVATIONS APPRENTI, P97; Kim MK, 1999, LARYNGOSCOPE, V109, P1064, DOI 10.1097/00005537-199907000-00010; Klein S, 2000, EUR J CANCER, V36, P273; KRIER M, 1997, HANDICAPS INADAPTATI, V75, P33; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; LEFEBVRE H, 2005, PARTENARIAT FAMILLES; Lefebvre H., 2002, FAMILLE SITUATION HA, P27; Lefebvre H., 2005, FRONTIERES, V17, P77; LUCYSHYN JM, 1996, CHILDREN ACQUIRED BR, P99; Maguire P, 1998, EUR J SURG ONCOL, V24, P188, DOI 10.1016/S0748-7983(98)92929-8; Merton R.K., 1990, FOCUSED INTERVIEW MA; Mishel M H, 1997, Annu Rev Nurs Res, V15, P57; MUCCHIELLI A, 2004, DICT METHODES QUALIT; Nolte ML, 1999, DISSERTATION ABSTR I, V60, P4900; Pearson D, 1999, CHILD CARE HLTH DEV, V25, P3, DOI 10.1046/j.1365-2214.1999.00086.x; Pelchat D, 2001, Paediatr Child Health, V6, P365; PELCHAT D, 1996, THESIS U MONTREAL QU; PELCHAT D, 2001, REV INFIRMIERE QUEBE, V9, P26; PELCHAT D, 1994, CAHIERS LAFREE, V6, P81; PELCHAT D, 2002, PRAT PSYCHOL, V1, P41; PELCHAT D, 2000, PROCESSUS LANNOUNCE; Pires A., 1997, RECHERCHE QUALITATIV, P113, DOI DOI 10.1522/030022877; PIRES A. P, 1997, RECHERCHE QUALITATIV, P3; POUPART J., 1997, RECHERCHE QUALITATIV, P173; POURTOIS JP, 1999, LEDUCATION POSTMODER; Ptacek J T, 2000, Crit Care Nurs Q, V23, P51; Ptacek JT, 1999, SUPPORT CARE CANCER, V7, P113, DOI 10.1007/s005200050240; SAINTCHARLES D, 1998, INNOVATIONS APPRENTI, P97; SANDRINEBERTHON B, 2000, LEDUCATION PATIENT S, P7; SCHERZER BP, 1995, LEVEIL, V1, P3; SCHUMACKER KL, 1994, IMAGE J NURSING SCHO, V26, P72; Sohlberg MM, 2001, J HEAD TRAUMA REHAB, V16, P498, DOI 10.1097/00001199-200110000-00008; Sohlberg MM, 1998, BRAIN INJURY, V12, P333; TEASDALE G, 1974, LANCET, V2, P81; TOCHON FV, 1996, REV SCI ED, V22, P467, DOI DOI 10.7202/031889AR; VANDERMAREN JM, 1995, METHODES RECHERCHE L	67	19	20	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					711	718		10.1080/02699050600744244			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200005	16809203				2021-06-18	
J	Morales, D; McIntosh, T; Conte, V; Fujimoto, S; Graham, D; Grady, MS; Stein, SC				Morales, Diego; McIntosh, Tracy; Conte, Valeria; Fujimoto, Scott; Graham, David; Grady, M. Sean; Stein, Sherman C.			Impaired fibrinolysis and traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						fibrinolysis; mice; plasminogen; traumatic brain injury; uPA	TISSUE-PLASMINOGEN ACTIVATOR; CONTROLLED CORTICAL IMPACT; DISSEMINATED INTRAVASCULAR COAGULATION; CENTRAL-NERVOUS-SYSTEM; HEAD-INJURY; HIPPOCAMPAL CA3-REGION; MEMORY CONSOLIDATION; TRANSGENIC MOUSE; RATS; DEFICITS	Traumatic brain injury (TBI) has been associated with intravascular coagulation, which may be a result of thromboplastin released following brain injury. Clots thus formed are lysed by plasmin, which is activated by tissue-type and urokinase-type plasminogen activators (uPA). To evaluate the association between traumatic intravascular coagulation and post-traumatic outcome, uPA knockout (uPA -/-) transgenic mice (n = 12) or wild-type littermates (WT; n = 12) were anesthetized and subjected to controlled cortical impact (CCI) brain injury. A second group of uPA -/- (n = 12) and WT mice (n = 12) were subjected to sham injury. Motor function was assessed over 2 weeks using the composite neuroscore test and cognition (learning) was assessed with the Morris Water Maze (MWM) at 2 weeks post-injury, whereupon the animals were sacrificed for cortical lesion volume analysis. Motor function was significantly worse in the brain-injured uPA -/- mice when compared to brain-injured WT mice at 48 h (p < 0.05) and one week post-injury (p < 0.65). These differences resolved by 2 weeks post-injury. There was no significant difference in post-injury cognitive function between uPA -/- mice and WT mice. However, at 2 weeks post-injury, the brain-injured uPA -/- had a significantly larger volume of cortical tissue loss than their WT counterparts (P < 0.05). These results demonstrate that the absence of uPA in mice aggravates acute motor deficit and exacerbates cortical tissue loss following CCI brain injury, and suggests a neuroprotective role of the fibrinolytic process following TBI.	Univ Penn, Sch Med, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA USA; Osped Maggiore Policlin, Neurosurg Intens Care Unit, Dept Anesthesia & Crit Care Med, Fdn IRCCS, Milan, Italy; So Gen Hosp, Dept Neuropathol, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland	Stein, SC (corresponding author), 310 Spruce St, Philadelphia, PA 19106 USA.	sherman.stein@uphs.upenn.edu		Morales, Diego/0000-0001-6672-9046	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40978, NS 008803] Funding Source: Medline		Asakura H, 2001, CRIT CARE MED, V29, P1164, DOI 10.1097/00003246-200106000-00015; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eilertsen KE, 2004, BLOOD COAGUL FIBRIN, V15, P521, DOI 10.1097/00001721-200409000-00001; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FLECK RA, 1990, THROMB RES, V57, P765, DOI 10.1016/0049-3848(90)90034-A; Florian C, 2004, BEHAV BRAIN RES, V154, P365, DOI 10.1016/j.bbr.2004.03.003; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, MILD MODERATE HEAD I, P63; Hayes RL, 1989, MILD HEAD INJURY, P54; Hogan KA, 2002, THROMB HAEMOSTASIS, V87, P563; HOOTS WK, 1993, NEUROTRAUMA, P673; Hoover-Plow J, 2001, BRAIN RES, V898, P256, DOI 10.1016/S0006-8993(01)02191-6; Horwood JM, 2001, BEHAV PHARMACOL, V12, P487, DOI 10.1097/00008877-200111000-00010; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kataoka K, 2000, BRAIN RES, V887, P187, DOI 10.1016/S0006-8993(00)03042-0; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KAUFMAN HH, 1985, CENTRAL NERVOUS SYST, P187; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Levi M, 1999, THROMB HAEMOSTASIS, V82, P695; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Pawlak R, 2002, NEUROSCIENCE, V113, P995, DOI 10.1016/S0306-4522(02)00166-5; Ploplis VA, 2002, THROMB HAEMOSTASIS, V87, P22; Ripley TL, 2001, BEHAV BRAIN RES, V125, P215, DOI 10.1016/S0166-4328(01)00303-5; Rogove AD, 1999, J CELL SCI, V112, P4007; Seeds NW, 2003, J NEUROSCI, V23, P7368; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Stupien G, 2003, NEUROBIOL LEARN MEM, V80, P32, DOI 10.1016/S1074-7427(03)00022-4; Tsirka SE, 2002, BIOCHEM SOC T, V30, P222, DOI 10.1042/bst0300222; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; VINK R, 1987, SOC MAGNET RESON MED, V1, P525; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yepes M, 2004, EXP BIOL MED, V229, P1097	54	19	20	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2006	23	6					976	984		10.1089/neu.2006.23.976			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	056TW	WOS:000238549000013	16774481				2021-06-18	
J	Shin, YB; Kim, SJ; Kim, IJ; Kim, YK; Kim, DS; Park, JH; Yeom, SR				Shin, Yong Beom; Kim, Seong-Jang; Kim, In-Ju; Kim, Yong-Ki; Kim, Dong-Soo; Park, Jae Heung; Yeom, Seok-Ran			Voxel-based statistical analysis of cerebral blood flow using Tc-99m ECD brain SPECT in patients with traumatic brain injury: Group and individual analyses	BRAIN INJURY			English	Article						statistical parametric mapping; brain SPECT; traumatic brain injury	CLOSED-HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; LOBE EPILEPSY; MILD; CT; PERFORMANCE; MRI	Purpose: Statistical parametric mapping (SPM)was applied to brain perfusion single photon emission computed tomography ( SPECT) images in patients with traumatic brain injury ( TBI) to investigate regional cerebral abnormalities compared to age-matched normal controls. Method: Thirteen patients with TBI underwent brain perfusion SPECT were included in this study (10 males, three females, mean age 39.8 +/- 18.2, range 21 similar to 74). SPM2 software implemented in MATLAB 5.3 was used for spatial preprocessing and analysis and to determine the quantitative differences between TBI patients and age-matched normal controls. Results: Three large voxel clusters of significantly decreased cerebral blood perfusion were found in patients with TBI. The largest clusters were area including medial frontal gyrus ( voxel number 3642, peak Z-value 4.31, 4.27, p = 0.000) in both hemispheres. The second largest clusters were areas including cingulated gyrus and anterior cingulate gyrus of left hemisphere ( voxel number 381, peak Z-value = 3.67, 3.62, p = 0.000). Other clusters were parahippocampal gyrus ( voxel number 173, peak Z-value 3.40, p 0.000) and hippocampus ( voxel number 173, peak Z-value 3.23, p = 0.001) in the left hemisphere. The false discovery rate (FDR) was less than 0.04. Conclusion: From this study, group and individual analyses of SPM2 could clearly identify the perfusion abnormalities of brain SPECT in patients with TBI. Group analysis of SPM2 showed hypoperfusion pattern in the areas including medial frontal gyrus of both hemispheres, cingulate gyrus, anterior cingulate gyrus, parahippocampal gyrus and hippocampus in the left hemisphere compared to age-matched normal controls. Also, left parahippocampal gyrus and left hippocampus were additional hypoperfusion areas. However, these findings deserve further investigation on a larger number of patients to be performed to allow a better validation of objective SPM analysis in patients with TBI.	Pusan Natl Univ Hosp, Dept Nucl Med, Pusan 602739, South Korea; Pusan Natl Univ Hosp, Dept Rehabil Med, Pusan 602739, South Korea; Pusan Natl Univ Hosp, Dept Emergency Med, Pusan 602739, South Korea	Kim, SJ (corresponding author), Pusan Natl Univ Hosp, Dept Nucl Med, 1-10 Ami Dong, Pusan 602739, South Korea.	growthkim@daum.net					Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ahmadi J, 1989, Top Magn Reson Imaging, V2, P17; Davalos Deana B, 2002, Appl Neuropsychol, V9, P92, DOI 10.1207/S15324826AN0902_4; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; HADLEY DM, 1988, CLIN RADIOL, V39, P131; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; HUSSEIN MAD, 1998, CLIN NUCL MED, V23, P309; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kim SK, 2001, EPILEPSIA, V42, P1531, DOI 10.1046/j.1528-1157.2001.21901.x; Kim YK, 2002, J NUCL MED, V43, P1167; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Masdeu J C, 1994, J Neuroimaging, V4, P177; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Parker RS, 1996, NEUROPSYCHOL REV, V6, P135, DOI 10.1007/BF01874895; PRAYER L, 1993, ACTA RADIOL, V34, P593; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Stamatakis EA, 2002, J NUCL MED, V43, P476; Talairach J., 1998, COPLANAR STEREOTAXIC; Umile EM, 1998, BRAIN INJURY, V12, P577; Van Laere KJ, 2002, J NUCL MED, V43, P458; YEALY D M, 1991, Emergency Medicine Clinics of North America, V9, P707	28	19	19	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	6					661	667		10.1080/02699050600677071			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100011	16754291				2021-06-18	
J	Chahine, LM; Chemali, Z				Chahine, L. M.; Chemali, Z.			Du rire aux larmes: Pathological laughing and crying in patients with traumatic brain injury and treatment with lamotrigine	EPILEPSY & BEHAVIOR			English	Article						traumatic brain injury; pathological laughter and crying; lamotrigine	LAUGHTER	Pathologic laughter and crying (PLC) is the involuntary occurrence of laughter and crying in the absence of a corresponding change in affect. PLC resulting from structural brain damage in patients with traumatic brain injury can be the cause of substantial social dysfunction in these patients. The use of lamotrigine as an antiepileptic drug and mood stabilizer is well established; its use in PLC has been reported only once during treatment following a stroke. We present here four young patients with pathological laughter and/or pathological crying following traumatic brain injury who were successfully treated with lamotrigine. Data supporting the use of lamotrigine in the treatment of PLC following traumatic brain injury and the neuroanatomy of pathological laughing are briefly reviewed. (c) 2006 Elsevier Inc. All rights reserved.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cognit & Behav Neurol, Boston, MA 02115 USA; Amer Univ Beirut, Med Ctr, Dept Psychiat, Beirut, Lebanon; Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon	Chemali, Z (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cognit & Behav Neurol, Boston, MA 02115 USA.	zelchemali@partners.org		Chahine, Lana/0000-0003-2521-7196			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Blackburn-Munro G, 2005, CURR PHARM DESIGN, V11, P2961, DOI 10.2174/1381612054865000; CRAWFORD C, 1983, NEW ZEAL MED J, V96, P972; Derex L, 1997, STROKE, V28, P1464, DOI 10.1161/01.STR.28.7.1464; Gao KM, 2005, BIPOLAR DISORD, V7, P13, DOI 10.1111/j.1399-5618.2005.00250.x; Green B, 2003, CURR MED RES OPIN, V19, P272, DOI 10.1185/030079903125001703; Karceski S, 2005, EPILEPSY BEHAV, V7, pS1, DOI 10.1016/j.yebeh.2005.06.001; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; McCullagh S, 2000, J NEUROPSYCH CLIN N, V12, P100, DOI 10.1176/jnp.12.1.100; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mild Traumatic Brain Injury Committee of the Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHABI, V8, P86; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; Patsalos PN, 2005, EPILEPSIA, V46, P140, DOI 10.1111/j.1528-1167.2005.00326.x; Poeck K., 1969, HDB CLIN NEUROLOGY, P343; Ramasubbu R, 2003, CLIN NEUROPHARMACOL, V26, P233, DOI 10.1097/00002826-200309000-00006; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; Schlienger RG, 1998, NEUROLOGY, V51, P1172, DOI 10.1212/WNL.51.4.1172; SELIGER G M, 1992, Brain Injury, V6, P267, DOI 10.3109/02699059209029668; Southam E, 1998, EUR J PHARMACOL, V358, P19, DOI 10.1016/S0014-2999(98)00580-9; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tidwell A, 2003, AM J MANAG CARE, V9, P253; UDAKA F, 1984, ARCH NEUROL-CHICAGO, V41, P1095, DOI 10.1001/archneur.1984.04050210093023; VARDI J, 1994, BEHAV MED, V20, P44, DOI 10.1080/08964289.1994.9934615; Vinod KY, 2002, NEUROCHEM INT, V40, P315, DOI 10.1016/S0197-0186(01)00088-2; Wild B, 2003, BRAIN, V126, P2121, DOI 10.1093/brain/awg226; 1974, THOMSON MICROMEDEX H	28	19	20	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	MAY	2006	8	3					610	615		10.1016/j.yebeh.2006.01.017			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	045BD	WOS:000237716700022	16504590				2021-06-18	
J	Rogers, E; Wagner, AK				Rogers, Emily; Wagner, Amy K.			Gender, sex steroids, and neuroprotection following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; MEMORY; RATS; ALLOPREGNANOLONE; STROKE; TRIAL		Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Kaufmann Bldg,3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu					Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Duka T, 2000, PSYCHOPHARMACOLOGY, V149, P129, DOI 10.1007/s002139900324; Gibbs RB, 2000, NEUROBIOL AGING, V21, P107, DOI 10.1016/S0197-4580(00)00103-2; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sherwin BB, 2005, HORM BEHAV, V47, P371, DOI 10.1016/j.yhbeh.2004.12.002; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Simpkins JW, 2005, CELL MOL LIFE SCI, V62, P271, DOI 10.1007/s00018-004-4382-2; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673	16	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					279	281		10.1097/00001199-200605000-00008			3	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600008	16717505				2021-06-18	
J	Rosenbek, JC; Rodriguez, AD; Hieber, B; Leon, SA; Crucian, GP; Ketterson, TU; Ciampitti, M; Singletary, F; Heilman, KM; Rothi, LJG				Rosenbek, John C.; Rodriguez, Amy D.; Hieber, Bethany; Leon, Susan A.; Crucian, Gregory P.; Ketterson, Timothy U.; Ciampitti, Maribel; Singletary, Floris; Heilman, Kenneth M.; Rothi, Leslie J. Gonzalez			Effects of two treatments for aprosodia secondary to acquired brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						aprosodia; cognitive-linguistic treatment; dysarthria; emotional prosody; expressive; imitative treatment; memory; receptive; rehabilitation; right-hemisphere damage; traumatic brain injury	RIGHT-HEMISPHERE; INTERVENTIONS; STROKE	Expressive aprosodia is an impaired ability to change one's voice to express common emotions such as joy, anger, and sadness. Individuals with aprosodia speak in a flat, unemotional voice that often results in miscommunicated emotional messages. This study investigated two conceptually based treatments for expressive aprosodia: imitative treatment and copitive-linguistic treatment. Five women and nine men with expressive aprosodia following right-hemisphere brain damage received the treatments in two phases I month apart in random order. Treatment was received 3 to 4 days a week for a total of 20 sessions each phase. As the outcome measure, sentences that elicited treated (happy, angry, sad, neutral) and untreated (fear) emotional tones of voice were administered during baseline, prior to treatment sessions, following treatment termination, and at 1- and 3-month followups. Effect sizes indicated that treatment effects were modest to substantial and that 12 participants responded to at least one treatment. Four responsive participants who were available for follow-up showed benefit at I and 3 months posttreatment. Most visual and statistical analyses were congruent.	Univ Florida, Dept Commun Disorders, Gainesville, FL 32611 USA; Malcom Randall VA Med Ctr, Dept Vet Affairs Rehabil Res, Gainesville, FL USA; Malcom Randall VA Med Ctr, Dev Brain Rehabil Res Ctr, Gainesville, FL USA; VAMC, Neurol Serv, Gainesville, FL USA; Univ Florida, Dept Commuicat Sci & Disorders, Gainesville, FL USA; Univ Florida, Dept Neurol, Gainesville, FL USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Florida, Hlth Sci Ctr, Jacksonville, FL 32209 USA; Univ Florida, Brooks Ctr Rehabil Studies, Gainesville, FL USA; VAMC, Ctr Geriatr Res Educ & Clin, Gainesville, FL USA	Rosenbek, JC (corresponding author), Univ Florida, Dept Commun Disorders, POB 100174,101 S Newell Dr,Room 2150, Gainesville, FL 32611 USA.	jrosenbe@phhp.ufl.edu	Rodriguez, Amy/ABH-8007-2020; Rodriguez, Amy/F-8332-2011		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P50 DCO3888] Funding Source: Medline		Anderson J. M., 1999, J INT NEUROPSYCH SOC, V5, P157; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BOWERS D, 1993, NEUROPSYCHOLOGY, V7, P433; Bowers D, 1998, FLORIDA AFFECT BATTE; Boyd LA, 2001, NEUROSCI LETT, V298, P65, DOI 10.1016/S0304-3940(00)01734-1; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Leon SA, 2005, J REHABIL RES DEV, V42, P93, DOI 10.1682/JRRD.2003.12.0182; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Robey RR, 1999, APHASIOLOGY, V13, P445, DOI 10.1080/026870399402028; Rosenbek JC, 2004, J INT NEUROPSYCH SOC, V10, P786, DOI 10.1017/S135561770410502X; ROSS ED, 1981, ARCH NEUROL-CHICAGO, V38, P561, DOI 10.1001/archneur.1981.00510090055006; Stringer AY, 1996, BRAIN INJURY, V10, P583, DOI 10.1080/026990596124151; TRYON WW, 1982, J APPL BEHAV ANAL, V15, P423, DOI 10.1901/jaba.1982.15-423; TUCKER DM, 1977, NEUROLOGY, V27, P947, DOI 10.1212/WNL.27.10.947; van der Merwe A, 1997, COMSIG '97 - PROCEEDINGS OF THE 1997 SOUTH AFRICAN SYMPOSIUM ON COMMUNICATIONS AND SIGNAL PROCESSING, P1, DOI 10.1109/COMSIG.1997.629970; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	17	19	19	0	9	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.	MAY-JUN	2006	43	3					379	390		10.1682/JRRD.2005.01.0029			12	Rehabilitation	Rehabilitation	090CR	WOS:000240928700009	17041823	Bronze			2021-06-18	
J	Beni, SM; Tsenter, J; Alexandrovich, AG; Galron-Krool, N; Barzilai, A; Kohen, R; Grigoriadis, N; Simeonidou, C; Shohami, E				Beni, SM; Tsenter, J; Alexandrovich, AG; Galron-Krool, N; Barzilai, A; Kohen, R; Grigoriadis, N; Simeonidou, C; Shohami, E			CuZn-SOD deficiency, rather than overexpression, is associated with enhanced recovery and attenuated activation of NF-kappa B after brain trauma in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						antioxidants; NF-kappa B; neuroprotection; oxidative stress; superoxide dismutase; traumatic brain injury	CLOSED-HEAD INJURY; CU/ZN-SUPEROXIDE-DISMUTASE; MITOCHONDRIAL CYTOCHROME-C; TRANSGENIC MICE; TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; LIPID-PEROXIDATION; GLOBAL-ISCHEMIA; INDUCED NEUROPROTECTION	Superoxide-dismutases (SOD) catalyze O-2(-) conversion to hydrogen peroxide (H2O2) and with other antioxidant enzymes and low molecular weight antioxidants (LMWA) constitute endogenous defense mechanisms. We first assessed the effects of SOD1 levels on outcome after closed head injury (CHI) and later, based on these results, the effects of SOD1 deficiency on cellular redox homeostasis. Superoxide-dismutase 1-deficient (SOD1(-/-)) and - overexpressing (transgenic (Tg)) mice and matched wild-type (WT) controls were subjected to CHI and outcome ( neurobehavioral and memory functions) was assessed during 14 days. Brain edema, LMWA, and SOD2 activity were measured along with histopathological analysis. Transactivation of nuclear factor-kappa B (NF-kappa B) was evaluated by electromobility shift assay. Mortality, motor, and cognitive outcome of Tg and WT mice were comparable. Mortality and edema were similar in SOD1(-/-) and WT mice, yet, unexpectedly, SOD1(-/-) displayed better neurobehavioral recovery (P<0.05) at 14 days after CHI. Basal LMWA were higher in the cortex and liver of SOD1(-/-) mice (P<0.05) and similar to WT in the cerebellum. Five minutes after CHI, cortical LMWA decreased only in SOD1(-/-) mice. One week after CHI, SOD2 activity decreased fourfold in WT cortex (P<0.001), but was preserved in the SOD1(-/-). Constitutive NF-kappa B transactivation was comparably low in SOD1(-/-) and WT; however, CHI induced a robust NF-kappa B activation that was absent in SOD1(-/-) cortices (P<0.005 versus WT). At the same time, immunohistochemical analysis of brain sections revealed that astrogliosis and neurodegeneration were of lesser severity in SOD1(-/-) mice. We suggest that SOD1 deficiency impairs H2O2-mediated activation of NF-kappa B, decreasing death-promoting signals, and leading to better outcome.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Phys Med & Rehabil, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; Aristotle Univ Thessaloniki, Fac Med, Dept Physiol, GR-54006 Thessaloniki, Greece; Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, IL-91905 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il					ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; BarPeled O, 1996, P NATL ACAD SCI USA, V93, P8530, DOI 10.1073/pnas.93.16.8530; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bethea JR, 1998, J NEUROSCI, V18, P3251; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Carballo M, 1999, J BIOL CHEM, V274, P93, DOI 10.1074/jbc.274.1.93; CEBALLOSPICOT I, 1992, MUTAT RES, V275, P281, DOI 10.1016/0921-8734(92)90032-K; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Combs CK, 2001, J NEUROSCI, V21, P1179; de Haan JB, 2003, REDOX REP, V8, P69, DOI 10.1179/135100003125001378; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Dopp JM, 2002, NEUROCHEM RES, V27, P1535, DOI 10.1023/A:1021608724117; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; Fujimura M, 2001, BRAIN RES, V889, P208, DOI 10.1016/S0006-8993(00)03134-6; Fujimura M, 2000, J NEUROSCI, V20, P2817; Gahtan E, 1998, EUR J NEUROSCI, V10, P538, DOI 10.1046/j.1460-9568.1998.00058.x; Halliwell B., 1989, FREE RADICAL BIO MED, P160; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kamata H, 2002, ANN NY ACAD SCI, V973, P419, DOI 10.1111/j.1749-6632.2002.tb04675.x; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawase M, 1999, STROKE, V30, P1962, DOI 10.1161/01.STR.30.9.1962; KELNER MJ, 1995, FREE RADICAL BIO MED, V18, P497, DOI 10.1016/0891-5849(94)00167-I; Khan JY, 2003, PEDIATR RES, V54, P77, DOI 10.1203/01.PDR.0000065736.69214.20; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kondo T, 1997, J NEUROSCI, V17, P4180; Lerner-Natoli M, 2000, EPILEPSY RES, V41, P141, DOI 10.1016/S0920-1211(00)00132-7; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Litchfield S, 2001, ACTA NEUROPATHOL, V101, P17; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McDonald RPA, 1999, NEUROREPORT, V10, P1875, DOI 10.1097/00001756-199906230-00014; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; Muller A, 2001, J MICROMECH MICROENG, V11, P301, DOI 10.1088/0960-1317/11/4/302; Murakami K, 1997, STROKE, V28, P1797, DOI 10.1161/01.STR.28.9.1797; Nishio S, 1997, ACT NEUR S, V70, P84; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; PeledKamar M, 1997, P NATL ACAD SCI USA, V94, P3883, DOI 10.1073/pnas.94.8.3883; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; XIE QW, 1994, J BIOL CHEM, V269, P4705; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; Yoshida T, 2000, CIRC RES, V86, P264, DOI 10.1161/01.RES.86.3.264	74	19	19	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2006	26	4					478	490		10.1038/sj.jcbfm.9600209			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	026LM	WOS:000236340400004	16094314	Bronze			2021-06-18	
J	Lotze, M; Grodd, W; Rodden, FA; Gut, E; Schonle, PW; Kardatzki, B; Cohen, LG				Lotze, M; Grodd, W; Rodden, FA; Gut, E; Schonle, PW; Kardatzki, B; Cohen, LG			Neuroimaging patterns associated with motor control in traumatic brain injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						TBI; fMRI; primary motor cortex; outcome	HEAD-INJURY; STROKE; RECOVERY; FMRI; METABOLISM; ACTIVATION; MODERATE; ARM	Objective. To determine if patients with traumatic brain injury (TBI) and motor deficits show differences in functional activation maps during repetitive hand movements relative to healthy controls. Are there predictors for motor Outcome in the functional maps of these patients? Methods. In an exploratory.. cross-sectional study, functional magnetic resonance imaging (fMRI) was used to study the blood-oxygenation-level-dependent (BOLD) response in cortical motor areas of 34 patients suffering from moderate motor deficits after TBI as they performed unilateral fist-clenching motions. Twelve of these patients with unilateral motor deficits were studied 3 months after TBI and a 2nd time approximately 4 months later. Results. Compared to age-matched, healthy controls performing the same task, TB patients showed diminished fMRI-signal change in the primary sensorimotor cortex contralateral to the moving hand (cSM1), the contralateral dorsal premotor cortex, and bilaterally in the supplementary motor areas (SMAs). Clinical impairment and the magnitude of the fMRI-signal change in cSM1 and SMA were negatively correlated. Patients with poor and good motor recovery showed comparable motor impairment at baseline. Only patients who evolved to "poor clinical outcome's had decreased fMRI-signal change in the cSM1 during baseline. Conclusions. These observations raise the hypothesis that the magnitude of the fMRI-signal change in the cSM1 region could have prognostic value in the evaluation of patients with TBI.	Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72074 Tubingen, Germany; Univ Tubingen, Dept Neuroradiol, CNS, Sect MR, D-7400 Tubingen, Germany; Univ Konstanz, Kliniken Schmieder, Lurija Inst Rehabil Sci & Hlth Res, Allenbach, Germany; NINDS, Human Cort Physiol Sect, NIH, Bethesda, MD 20892 USA	Lotze, M (corresponding author), Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Gartenstr 29, D-72074 Tubingen, Germany.	martin.lotze@uni-tuebingen.de	Lotze, Martin/D-2964-2012	Lotze, Martin/0000-0003-4519-4956	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003030, Z01NS003030] Funding Source: NIH RePORTER		ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Bobath B, 1977, Physiotherapy, V63, P310; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; JANDA V, 1993, MUSKELFUNKTIONSDIAGN; Kastrup A, 2002, NEUROIMAGE, V15, P74, DOI 10.1006/nimg.2001.0916; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Nelles G, 1999, ANN NEUROL, V46, P901, DOI 10.1002/1531-8249(199912)46:6<901::AID-ANA13>3.0.CO;2-7; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pariente J, 2001, ANN NEUROL, V50, P718, DOI 10.1002/ana.1257; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Shelton FDAP, 2001, STROKE, V32, P107, DOI 10.1161/01.STR.32.1.107; Talairach J., 1988, COPLANAR STEREOTAXIC; Turton A, 1996, ELECTROMYOGR MOTOR C, V101, P316, DOI 10.1016/0924-980X(96)95560-5; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Waldvogel D, 2000, NEUROREPORT, V11, P3843, DOI 10.1097/00001756-200011270-00048; Ward NS, 2003, BRAIN, V126, P1430, DOI 10.1093/brain/awg145; Ward NS, 2003, BRAIN, V126, P2476, DOI 10.1093/brain/awg245; Weiller C, 1998, EXP BRAIN RES, V123, P13, DOI 10.1007/s002210050539; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; Wexler BE, 1997, MAGN RESON IMAGING, V15, P385, DOI 10.1016/S0730-725X(96)00232-9	27	19	19	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAR	2006	20	1					14	23		10.1177/1545968305282919			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	011PG	WOS:000235280000003	16467275				2021-06-18	
J	Trovato, M; Slomine, B; Pidcock, F; Christensen, J				Trovato, M; Slomine, B; Pidcock, F; Christensen, J			The efficacy of donepezil hydrochloride on memory functioning in three adolescents with severe traumatic brain injury	BRAIN INJURY			English	Article						brain injury; donepezil; adolescents; memory; cognition; drug therapy		Objective: To explore efficacy of donepezil on memory in adolescents with severe traumatic brain injury (TBI). Design: Single subject, unblinded, multiple baseline design. Methods and procedures: Memory functioning was examined in three adolescents with TBI on and off medication ( 5 and 10 mg) using the Selective Reminding Test. Four variables were examined: Total recall (TR) number of words total words recalled, Long Term Storage (LTS) words recalled on two trials in a row, Consistency of Long Term Retrieval (CLTR) words continuously recalled, Delay number of words recalled after delay. Results: On medication, three out of three participants demonstrated better memory. Two showed greatest improvement on 10 mg. All participants demonstrated improvement in TR and LTS. Two participants demonstrated improved CLTR. No participants displayed improvement in Delay. No adverse side effects were reported. Conclusions: Results suggests that donepezil may be effective in improving memory in adolescents with severe TBI and warrant further examination.	Kennedy Krieger Inst, Baltimore, MD 21205 USA	Trovato, M (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	trovato@kennedykrieger.org					[Anonymous], 2003, J NEUROPSYCH CLIN N, V15, P383, DOI 10.1176/appi.neuropsych.15.3.383; Bourgeois JA, 2002, J NEUROPSYCH CLIN N, V14, P463, DOI 10.1176/appi.neuropsych.14.4.463; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fisher RS, 2001, EPILEPSY BEHAV, V2, P330, DOI 10.1006/ebeh.2001.0221; Greene YM, 2000, J CLIN PSYCHOPHARM, V20, P350, DOI 10.1097/00004714-200006000-00010; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HAYES RL, 1989, MILD HEAD INJURY, P69; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; Spreen O., 1998, COMPENDIUM NEUROPSYC; Taverni JP, 1998, BRAIN INJURY, V12, P77; THAL LJ, 1992, NEUROPSYCHOLOGY MEMO, P277; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	19	19	19	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					339	343		10.1080/02699050500487811			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400014	16537276				2021-06-18	
J	Anzai, K; Young, J; McCallum, J; Miller, B; Jongbloed, L				Anzai, K; Young, J; McCallum, J; Miller, B; Jongbloed, L			Factors influencing discharge location following high lesion spinal cord injury rehabilitation in British Columbia, Canada	SPINAL CORD			English	Article						high lesion spinal cord injury; social policy; discharge location; discharge planning	LENGTH-OF-STAY; LIFE SATISFACTION; SYSTEM	Study design: Retrospective chart review. Objective: To identify and describe factors that influence discharge location - extended care unit (nursing home) or other (private home, group home, or acute care) - following rehabilitation for individuals with a new high lesion spinal cord injury (SCI) (C1-C4) in British Columbia, Canada. Setting: GF Strong Rehabilitation Centre, Vancouver, British Columbia, Canada. Methods: Eligible clients were adults admitted to the GF Strong Rehabilitation Centre Spinal Cord Program between 1994 and 2003, with a new C1-4 lesion (traumatic or nontraumatic), and an ASIA score of A-C at time of discharge. Medical charts of 52 individuals were reviewed and data regarding individual characteristics, health-related characteristics, personal context, hospitalization factors, health resources, and other contextual factors were extracted. Results: In total, 40% of clients were discharged to extended care units post rehabilitation. Seven variables were associated at a univariate level: age, employment at the time of injury, preexisting medical conditions, social support, preinjury living situation, and insurance (worker's compensation or motor vehicle) or private funding for equipment. Four variables were associated at the multivariate level: age, preinjury living situation, and insurance or private funding for equipment. Conclusion: A range of individual, health-related, family and social policy variables influence discharge location following rehabilitation for high lesion SCI in British Columbia. The unique combination of variables presented by each individual should be considered by the rehabilitation team in the discharge planning process. Sponsorship: This study was funded by the BC Neurotrauma Fund.	GF Strong Rehabil Ctr, Vancouver, BC V5Z 2G9, Canada; Parkwood Hosp, Geriatr Rebabil Program, London, ON, Canada; Univ British Columbia, Sch Rehabil Sci, Vancouver, BC V5Z 1M9, Canada	Anzai, K (corresponding author), GF Strong Rehabil Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.						BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P785, DOI 10.1016/S0003-9993(99)90228-9; DIJKERS M, 1996, AM REHABILITATION, V22, P18; Dijkers Marcel P., 1995, P185; Fiedler RC, 1997, AM J PHYS MED REHAB, V76, P76, DOI 10.1097/00002060-199701000-00017; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1507, DOI 10.1016/S0003-9993(99)90265-4; HAMMELL KR, 1998, THESIS U BRIT COLUMB; Hammell KW, 2004, SPINAL CORD, V42, P607, DOI 10.1038/sj.sc.3101662; Hammell KW, 2004, SPINAL CORD, V42, P491, DOI 10.1038/sj.sc.3101636; Inman C, 1999, CLIN REHABIL, V13, P25, DOI 10.1191/026921599674943310; Nieves C C, 1991, Rehabil Nurs, V16, P129; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Tooth L, 2003, SPINAL CORD, V41, P220, DOI 10.1038/sj.sc.3101433; World Health Organization, 2001, INT CLASS FUNCT DIS	15	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	JAN	2006	44	1					11	18		10.1038/sj.sc.3101778			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	000WJ	WOS:000234492800003	16030516	Bronze			2021-06-18	
J	Kunz, T; Marklund, N; Hillered, L; Oliw, EH				Kunz, Tina; Marklund, Niklas; Hillered, Lars; Oliw, Ernst H.			Effects of the selective cyclooxygenase-2 inhibitor rofecoxib on cell death following traumatic brain injury in the rat	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						COX-2 inhibitor; fluid percussion brain injury; Fluoro-Jade B; neuroinflammation; prostaglandins; TUNEL staining	GENE-EXPRESSION; FUNCTIONAL RECOVERY; INDUCED SEIZURES; NEURONAL DEATH; METABOLISM; ISCHEMIA; DAMAGE; NEUROPROTECTION; POSTTREATMENT; DEGENERATION	Purpose: Lateral fluid percussion brain injury (FPI) increases cyclooxygenase-2 (COX-2) expression in the cortex and hippocampus. The objective was to investigate whether the selective COX-2 inhibitor rofecoxib (10 mg/kg twice daily) reduces neuronal cell death after FPI in rats, since rofecoxib has been shown to be neuroprotective in other models of CNS injury. Methods: Rofecoxib (n = 23) or vehicle (n = 20) were administered after FPI and for up to 3 days. Cell death was evaluated by Fluoro-Jade B staining and by the TdT-mediated dUTP nick end labelling (TUNEL) assay. Results: COX-2 immunoreactivity increased in the ipsilateral cortex and hippocampus (CA1) and bilaterally in the dentate gyri. Fluoro-Jade B- and TUNEL-positive cells were detected 12-72 It after FPI in the ipsilateral cortex and bilaterally in the dentate gyri. Fluoro-Jade B staining did not indicate a significant neuroprotective effect of rofecoxib (12-72 h) and neither did TUNEL staining. Quantificaton of the TUNEL staining in the ipsilateral cortex was similar to 50% lower in the rofecoxib group at 12 and 24 h, but this did not reach statistical significance (p = 0.06), and appeared unchanged at 72 It. Conclusions: Rofecoxib lacked significant protective effect on early neuronal cell death in the FPI model of traumatic brain injury.	Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden	Oliw, EH (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, POB 591, SE-75124 Uppsala, Sweden.	ernst.oliw@farmbio.uu.se		Marklund, Niklas/0000-0002-9797-5626; Oliw, Ernst/0000-0002-7986-8130			Baillie TA, 2001, DRUG METAB DISPOS, V29, P1614; Bareyre FM, 2002, J NEUROSCI, V22, P7097; Bauer MKA, 1997, EUR J BIOCHEM, V243, P726, DOI 10.1111/j.1432-1033.1997.00726.x; Burnier Michel, 2005, Expert Opin Drug Saf, V4, P491; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CHEN J, 1995, NEUROREPORT, V6, P245; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Gobbo OL, 2005, BRAIN RES, V1046, P224, DOI 10.1016/j.brainres.2005.03.046; Gobbo OL, 2004, NEUROSCIENCE, V125, P317, DOI 10.1016/j.neuroscience.2004.01.045; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Halpin RA, 2000, DRUG METAB DISPOS, V28, P1244; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Kawaguchi K, 2005, BRAIN RES, V1050, P130, DOI 10.1016/j.brainres.2005.05.038; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Kunz T, 2005, COGNITIVE BRAIN RES, V25, P826, DOI 10.1016/j.cogbrainres.2005.09.017; Kunz T, 2001, PHARMACOL TOXICOL, V88, P271, DOI 10.1034/j.1600-0773.2001.d01-116.x; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Dell DM, 2000, J NEUROSCI, V20, P4821; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RINK A, 1995, AM J PATHOL, V147, P1575; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sandrini M, 2002, INFLAMM RES, V51, P154, DOI 10.1007/PL00000287; Sasaki T, 2004, J CEREBR BLOOD F MET, V24, P107, DOI 10.1097/01.WCB.0000100065.36077.4A; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shaftel SS, 2003, MOL BRAIN RES, V119, P213, DOI 10.1016/j.molbrainres.2003.09.006; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Soares HD, 1995, J NEUROSCI, V15, P8223; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436	49	19	19	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2006	24	1					55	63					9	Neurosciences	Neurosciences & Neurology	047PU	WOS:000237892000007	16518028				2021-06-18	
J	Vinchon, M; Pierrat, V; Tchofo, PJ; Soto-Ares, G; Dhellemmes, P				Vinchon, M; Pierrat, V; Tchofo, PJ; Soto-Ares, G; Dhellemmes, P			Traumatic intracranial hemorrhage in newborns	CHILDS NERVOUS SYSTEM			English	Article						head injury; birth trauma; subdural hematoma; newborn	SUBDURAL-HEMATOMA; MANAGEMENT; DELIVERY; INFANTS; INJURY	Introduction: Neonatal traumatic head injuries (NTHI) can be life-threatening and require aggressive treatment. The indications, techniques, and results of brain decompression are not well defined in the literature. Methods: We studied prospectively cases of NTHI with intracranial traumatic lesions; skull fractures without underlying lesions were not included. We treated 17 cases of NTHI: 7 patients had a subdural hematoma, 3 had an extradural hematoma, and the others had subarachnoid hemorrhage. Surgical evacuation of intracranial clots was performed in 7 cases, by needle aspiration in 5 and by craniotomy in 2 patients with extradural hematomas. Results: The outcome was favorable in all but one patient, who had hemophilia A, and died of rebleeding at the age of 2 months. Conclusion: Surgical decompression of intracranial hematomas due to NTHI is often unnecessary; however, it may be required in emergency because of poor clinical tolerance. Whenever possible, percutaneous needle aspiration is the treatment of choice.	Ctr Hosp Reg & Univ Lille, Serv Neurochirurg Pediat, F-59037 Lille, France; Lille Univ Hosp, Dept Pediat Neurosurg, Lille, France; Lille Univ Hosp, Dept Neonatal Intens Care, Lille, France; Lille Univ Hosp, Dept Neuroradiol, Lille, France	Vinchon, M (corresponding author), Ctr Hosp Reg & Univ Lille, Serv Neurochirurg Pediat, Pl Verdun, F-59037 Lille, France.	m-vinchon@chru-lille.fr	Vinchon, Matthieu/AAH-6845-2021	Vinchon, Matthieu/0000-0002-9122-6165			AOKI N, 1990, ACTA NEUROCHIR, V106, P65, DOI 10.1007/BF01809334; AVRAHAMI E, 1993, NEURORADIOLOGY, V35, P107, DOI 10.1007/BF00593964; CASTILLO M, 1995, AM J NEURORADIOL, V16, P816; Chamnanvanakij S, 2002, PEDIATR NEUROL, V26, P301, DOI 10.1016/S0887-8994(01)00420-9; GOVAERT P, 1990, ACTA NEUROCHIR, V106, P52, DOI 10.1007/BF01809333; GOVAERT P, 1993, CLIN DEV MED, V129; Harpold TL, 1998, NEUROSURG CLIN N AM, V9, P141; HAYASHI T, 1987, CHILD NERV SYST, V3, P23, DOI 10.1007/BF00707189; HOLLAND E, 1922, J OBSTET GYN BR COMM, V29, P549; Hoskote A, 2002, CHILD NERV SYST, V18, P311, DOI 10.1007/s00381-002-0616-x; Hovind KH, 1986, HEAD INJURIES NEWBOR, P87; LEESTMA JE, 1995, PEDIAT NEUROPATHOLOG, P243; Levene M. I., 1995, P335; Myles LM, 2001, PEDIATR NEUROSURG, V34, P94, DOI 10.1159/000056001; Perrin RG, 1997, NEUROSURGERY, V40, P1190, DOI 10.1097/00006123-199706000-00016; PIERREKAHN A, 1970, ANN PEDIAT, V32, P419; Sorensen N., 1986, HEAD INJURIES NEWBOR, P83; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; WILLIAMS B, 1977, LANCET, V2, P51	19	19	19	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	DEC	2005	21	12					1042	1048		10.1007/s00381-004-1131-z			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	985HQ	WOS:000233368600010	15928969				2021-06-18	
J	Lins, H; Wallesch, CW; Wunderlich, MT				Lins, H; Wallesch, CW; Wunderlich, MT			Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections	ACTA NEUROLOGICA SCANDINAVICA			English	Article						cerebrospinal fluid; serum; neurochemistry; central nervous system infection; protein S100B; neuron-specific enolase	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; MYELIN BASIC-PROTEIN; S-100 PROTEIN; PRACTICAL SCALE; INFARCTION; RELEASE; S100B; MENINGITIS	Objective - To elucidate the relation between release patterns and cerebrospinal fluid/serum concentrations of neurobiochemical markers of cerebral damage and their potential value as monitoring parameters in central nervous system infections. Methods - We investigated protein S-100B and neuron-specific enolase (NSE) in 102 sequential cerebrospinal fluid (CSF)-serum-pairs in patients with bacterial (n = 11) or viral (n = 13) meningitis/meningoencephalitis and neuroborreliosis (n = 8) in comparison with controls (n = 13). Results - Highest S-100B values in CSF and serum were found on admission and showed a significant decrease afterwards. Comparison between disease groups revealed significant differences between bacterial and viral meningitis and neuroborreliosis for S-100B and also when compared with controls. NSE was not significantly elevated. Conclusions - S-100B is altered in CNS infection but does not provide additional benefit in the differential diagnosis when compared with standard CSF parameters. Nevertheless, S-100B values might be used as an additional monitoring parameter especially when sequential lumbar punctures are contraindicated.	Univ Magdeburg, Dept Neurol, D-39120 Magdeburg, Germany	Wunderlich, MT (corresponding author), Univ Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	michael.wunderlich@medizin.uni-magdeburg.de					Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Dotevall L, 1999, EUR J NEUROL, V6, P169, DOI 10.1111/j.1468-1331.1999.tb00010.x; Gazzolo D, 2004, CLIN CHEM, V50, P941, DOI 10.1373/clinchem.2003.021048; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Infante JR, 2000, TUMOR BIOL, V21, P38, DOI 10.1159/000030109; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JENNETT B, 1975, LANCET, V1, P480; Koedel U, 2002, LANCET INFECT DIS, V2, P721, DOI 10.1016/S1473-3099(02)00450-4; LAMERS KJB, 1995, ACTA NEUROL SCAND, V92, P247; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Nygaard O, 1997, CLIN CHEM, V43, P541; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; Otto M, 1998, BRIT MED J, V316, P577, DOI 10.1136/bmj.316.7131.577; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79; TEASDALE G, 1974, LANCET, V2, P81; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; VANENGELEN BGM, 1992, CLIN CHEM, V38, P813; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005	22	19	24	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	NOV	2005	112	5					303	308		10.1111/j.1600-0404.2005.00484.x			6	Clinical Neurology	Neurosciences & Neurology	972ZH	WOS:000232491900005	16218912				2021-06-18	
J	Nguyen, MP; Bittner, GD; Fishman, HM				Nguyen, MP; Bittner, GD; Fishman, HM			Critical interval of somal calcium transient after neurite transection determines B104 cell survival	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						plasmalemmal injury; calcium-initiated cell degeneration; injury-induced apoptosis; injured cell mortality; cell death prevention	EXCITOTOXIC NEURONAL DEATH; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; SPINAL-CORD; NEUROBLASTOMA-CELLS; NITRIC-OXIDE; ADULT-RATS; IN-VIVO; APOPTOSIS; AXOTOMY	Nerve cells may survive or die after axohal or dendritic transection. After neurite transection near (< 50 mu m) the cell body of Fura-2-loaded B104 neuroblastoma (rat brain-derived) cells, the somal calcium concentration (SCC) undergoes a three-phase transient change: a rapid (0-0.15-min posttransection [PT]) rise phase, followed by an early (0.15-1.5-min PT) rapid decay phase, and succeeded by a late (1.5-60-min PT) slower decay phase that, restores SCC to preinjury levels. The SCC in a critical interval (1.5-12.5 min PT) of the third transient phase correlates with cell fate, i.e., most transected cells that exclude dye (restore a barrier) and die have a significantly higher (P < 0.005) SCC in this critical interval than do transected cells that exclude dye and survive at 24-hr PT Loading BAPTA (chelation of somal Ca2+) before, but not after, the critical interval increases the percentage of cells that survive compared to that of cells transected without BAPTA loading. Furthermore, most transected cells that die despite successful barrier restoration exhibit characteristics consistent with apoptosis initiated during the critical interval of the SCC, including caspase activation and plasmalemmal phosphaticlylserine translocation. These data suggest that decreased cell survival for injuries near the soma is due to Ca2+-initiated apoptosis during the critical interval of the third phase of the SCC transient. (c) 2005 Wiley-Liss, Inc.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Neurobiol Sect, Sch Biol Sci, Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Coll Pharm, Austin, TX 78712 USA	Fishman, HM (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.	hfishman@utmb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031256] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS031256-12, R01 NS031256, NS31256] Funding Source: Medline		Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; BALENTINE JD, 1982, LAB INVEST, V47, P286; BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chan YM, 2001, NEUROREPORT, V12, P541, DOI 10.1097/00001756-200103050-00022; Chaudhary P, 1999, MOL BRAIN RES, V67, P36, DOI 10.1016/S0169-328X(99)00032-7; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; DibHajj SD, 1996, FEBS LETT, V384, P78, DOI 10.1016/0014-5793(96)00273-6; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Fishman HM, 2003, NEWS PHYSIOL SCI, V18, P115, DOI 10.1152/nips.01429.2002; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu XQ, 1996, BRAIN RES, V735, P50; HIMES BT, 1989, J COMP NEUROL, V284, P215, DOI 10.1002/cne.902840206; Hyrc K, 1997, J NEUROSCI, V17, P6669; INGOGLIA NA, 2001, AXONAL REGENERATION; Kermer P, 2000, MOL BRAIN RES, V85, P144, DOI 10.1016/S0169-328X(00)00256-4; Kermer P, 1998, J NEUROSCI, V18, P4656; Ko HW, 1998, J NEUROCHEM, V71, P1390; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; Luo J, 1999, J NEUROCHEM, V72, P2286, DOI 10.1046/j.1471-4159.1999.0722286.x; Luo J, 1997, BRAIN RES, V770, P139, DOI 10.1016/S0006-8993(97)00762-2; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.0.CO;2-#; Montgomery, 2001, DESIGN ANAL EXPT; Namura S, 1998, J NEUROSCI, V18, P3659; OCONNOR TM, 1974, J CELL BIOL, V60, P448, DOI 10.1083/jcb.60.2.448; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; SANNER CA, 1993, EXP NEUROL, V123, P81, DOI 10.1006/exnr.1993.1142; SCHUBERT D, 1975, NATURE, V254, P341, DOI 10.1038/254341a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; SNIDER WD, 1989, J COMP NEUROL, V279, P489, DOI 10.1002/cne.902790312; STYS PK, 1990, MUSCLE NERVE, V13, P750, DOI 10.1002/mus.880130814; Tan ZY, 2003, NEUROSCI LETT, V340, P123, DOI 10.1016/S0304-3940(03)00094-6; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSIEN RY, 1985, CELL CALCIUM, V6, P145, DOI 10.1016/0143-4160(85)90041-7; TYMIANSKI M, 1994, J NEUROPHYSIOL, V72, P1973; TYNDALE RF, 1994, J NEUROSCI, V14, P5417; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Volbracht C, 2001, NEUROREPORT, V12, P3645, DOI 10.1097/00001756-200112040-00008; XIE XY, 1991, J NEUROSCI, V11, P3257; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yoo S, 2004, J NEUROBIOL, V60, P137, DOI 10.1002/neu.20005	53	19	20	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	SEP 15	2005	81	6					805	816		10.1002/jnr.20606			12	Neurosciences	Neurosciences & Neurology	961BZ	WOS:000231638200006	16049977	Green Accepted			2021-06-18	
J	McCrory, P; Makdissi, M; Davis, G; Collie, A				McCrory, P; Makdissi, M; Davis, G; Collie, A			Value of neuropsychological testing after head injuries in football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; COMPUTERIZED COGNITIVE ASSESSMENT; AUSTRALIAN RULES FOOTBALLERS; PROFESSIONAL SOCCER PLAYERS; TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; TEST PROTOCOL; REACTION-TIME; IMPAIRMENT; RECOVERY	This paper reviews the pros and cons of the traditional paper and pencil and the newer computerised neuropsychological tests in the management of sports concussion. The differences between diagnosing concussion on the field and neuropsychological assessment at follow up and decision making with regard to return to play are described. The authors also discuss the issues involved in interpreting the results of neuropsychological testing (comparison with population norms versus player's own baseline test results) and potential problems of such testing in football. Finally, suggested recommendations for neuropsychological testing in football are given.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; Cabrini Med Ctr, Malvern, Vic, Australia; CogState Ltd, Melbourne, Vic, Australia	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	Collie, Alex/0000-0003-2617-9339			Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J ATHL TRAINING, V36, P297; Barth J T, 2000, Dent Clin North Am, V44, P67; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT, 2001, J ATHL TRAINING, V36, P253; Barth JT., 1989, MILD HEAD INJURY, P257; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BRUCE DA, 1984, PRIMARY CARE, V11, P175; Chan K M, 1984, Br J Sports Med, V18, P195; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; DAILEY SW, 1992, PHYSICIAN SPORTSMED, V20, P79, DOI 10.1080/00913847.1992.11947468; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FAULKNER C, 1985, AUST J PHYSIOTHER, V31, P242; FIELDS KB, 1989, PHYSICIAN SPORTSMED, V17, P69, DOI 10.1080/00913847.1989.11709682; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; Gronwall D, 1989, MILD HEAD INJURY, P153; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; *HLTH COUNC NETH, 2003, BRAIN DAM BOX SOCC P, P1; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; Juma A H, 1998, Indian J Med Sci, V52, P433; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; KUJALA UM, 1995, BRIT MED J, V311, P1465, DOI 10.1136/bmj.311.7018.1465; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LURIA AR, 1962, HIGHER CONTROL FUNCT; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; Maddocks DL, 1993, INFORMATION PROCESSI, P1; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; MCGRATH A, 1997, HEADING INJURIES OUT; MCKEAG D, 1996, AM MED SOC SPORTS ME, P1; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SOCIETY CM, 1991, REPORT SPORTS MED CO; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Turner M., 1998, JOCK CLUB C HEAD INJ; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Walsh K. W, 1991, UNDERSTANDING BRAIN; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	80	19	19	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I58	I63		10.1136/bjsm.2005.020776			6	Sport Sciences	Sport Sciences	954KI	WOS:000231153600008	16046357	Green Published, Bronze			2021-06-18	
J	Ojha, BK; Jha, DK; Kale, SS; Mehta, VS				Ojha, BK; Jha, DK; Kale, SS; Mehta, VS			Trans-cranial Doppler in severe head injury: Evaluation of pattern of changes in cerebral blood flow velocity and its impact on outcome	SURGICAL NEUROLOGY			English	Article						TCD; severe head injury; hyperemia; oligemia; vasospasm; outcome	INTRACRANIAL HYPERTENSION; ANGIOGRAPHIC FINDINGS; ARTERIAL SPASM; BRAIN INJURY; ULTRASOUND; HYPEREMIA; METABOLISM; VASOSPASM; ISCHEMIA; TRAUMA	Background: Trans-cranial Doppler (TCD) studies after head injury have been done in the first 24 hours after injury and do not specify the exact interval between injury and time of recordings. We have studied cerebral blood flow changes in patients with severe head injury using serial TCD starting within 6 hours after trauma, and present our findings and its correlation with clinical outcome. Methods: Thirty-two patients with closed severe brain injuries formed the study group. Six-hourly serial TCD studies were done starting within 6 hours after trauma until 48 hours after trauma or death of the patient, whichever was earlier. Flow velocities of the extracranial internal carotid (VEC-ICA) and middle cerebral artery (V-MCA) were recorded to identify vasospasm, hyperemia, or oligemia. Serial changes in flow velocities were correlated with the clinical outcome of the patients at 12 months' follow-up after injury. Result: Oligemia (n = 30) and vasospasm (n = 2) were the earliest changes observed within 6 hours of trauma. In the oligemia group, persistent oligemia (n = 14), hyperemia (n = 6), normal flow velocity (n = 5), and vasospasm developing within 24 hours (n = 5) were observed. Eight patients developed vasospasm after 24 hours. All patients with persistent oligemia and vasospasm developing within 24 hours had poor outcome. Conclusion: Oligemia is the most common change within 6 hours of head injury. Persistence of oligemia beyond 24 hours is associated with poor outcome. Early (within 24 hours posttrauma) onset of vasospasm is associated with poor outcome; however, delayed (> 24 hours after trauma) vasospasm is not associated with poor outcome. (c) 2005 Published by Elsevier Inc.	King Georges Med Univ, Dept Neurosurg, Lucknow 226003, Uttar Pradesh, India; All India Inst Med Sci, Dept Neurosurg, New Delhi 110027, India	Ojha, BK (corresponding author), King Georges Med Univ, Dept Neurosurg, Lucknow 226003, Uttar Pradesh, India.	bkojha@rediffmail.com					AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BARIE PS, 1993, J TRAUMA, V35, P88, DOI 10.1097/00005373-199307000-00015; BARZO P, 1991, NEUROSURGERY, V28, P821, DOI 10.1227/00006123-199106000-00006; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KIRKPATRICK PJ, 1995, J NEUROSURG, V83, P963, DOI 10.3171/jns.1995.83.6.0963; KOSHU K, 1987, NEUROSURGERY, V21, P693, DOI 10.1227/00006123-198711000-00016; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TEASDALE G, 1974, LANCET, V2, P81; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X	39	19	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	AUG	2005	64	2					174	179		10.1016/j.surneu.2004.11.030			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	952UN	WOS:000231031100015	16051018				2021-06-18	
J	Zaltzman, R; Alexandrovich, A; Trembovler, V; Shohami, E; Gozes, I				Zaltzman, R; Alexandrovich, A; Trembovler, V; Shohami, E; Gozes, I			The influence of the peptide NAP on Mac-1-deficient mice following closed head injury	PEPTIDES			English	Article; Proceedings Paper	4th Peptide Receptors Symposium	JUL 31-AUG 04, 2004	Montreal, CANADA			activity-dependent neuroprotective protein (ADNP); NAP; Mac-1; closed head injury (CHI); neurological severity score (NSS)	DEPENDENT NEUROPROTECTIVE PROTEIN; TRAUMATIC BRAIN-INJURY; INTERCELLULAR-ADHESION MOLECULE-1; NITRIC-OXIDE PRODUCTION; MAC-1 CD11B CD18; TRANSENDOTHELIAL MIGRATION; INFLAMMATORY RESPONSE; MEDIATES ADHERENCE; HUMAN MONOCYTES; RECEPTOR	A single administration of the neuroprotective peptide NAP was previously shown to protect against death associated with closed head injury (CHI) and enhance recovery of the surviving mice. The protective effect was accompanied by down-regulation of the relative mRNA content of the complement receptor 3 (Mac-1, a marker for inflammation) as measured about a month after the injury. In contrast, the mRNA transcripts for activity-dependent neuroprotective protein (ADNP, the NAP containing protein) were shown to increase 29 days post CHI in the injured hemisphere of Mac-1 expressing mice. The present study was set out to investigate: (1) are Mac-l-deficient mice less susceptible to the adverse outcome of traumatic head injury; (2) does NAP treatment affect Mac-l-deficient mice subjected to head injury; and (3) is Mac-1 expression associated with ADNP expression. Results showed that (1) Mac-l-deficient mice were partially protected against death associated with severe head injury as compared to Mac-1 expressing mice. (2) Significant protection against death was observed in NAP-treated mice and an increase in recovery was observed in the NAP-treated Mac-1 mice 4 weeks after injury. (3) ADNP expression did not change in the Mac-1-deficient mice following head injury. Our working hypothesis is that a month following injury, gene expression in the injured brain is altered and competing proteins are expressed such as Mac-1 that is associated with inflammation and ADNP that is associated with neuroprotection. Obviously, this plasticity in gene expression is intimately interwoven with the genetic background of the animal. NAP treatment tilts the balance toward neuroprotection. (c) 2005 Elsevier Inc. All rights reserved.	Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91905 Jerusalem, Israel	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il					ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ANDERSON DC, 1990, BLOOD, V76, P2613; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Benimetskaya L, 1997, NAT MED, V3, P414, DOI 10.1038/nm0497-414; Benirschke SK, 2004, J ORTHOP TRAUMA, V18, P1, DOI 10.1097/00005131-200401000-00001; Brenneman DE, 2000, BIOCHEM SOC T, V28, P983; CAMPBELL MJ, 1995, MED STAT; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Delgado M, 2003, FASEB J, V17, P1922, DOI 10.1096/fj.02-1029fje; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Divinski I, 2004, J BIOL CHEM, V279, P28531, DOI 10.1074/jbc.M403197200; FAN ST, 1991, J CLIN INVEST, V87, P50, DOI 10.1172/JCI115000; FURMAN S, 2005, IN PRESS NEURON GLIA; GLADWIN AM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P166, DOI 10.1016/0167-4889(90)90072-L; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; GOODRUM KJ, 1994, INFECT IMMUN, V62, P3102, DOI 10.1128/IAI.62.8.3102-3107.1994; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; GOZES I, IN PRESS CURR ALZHEI; Hailer NP, 2001, NEUROSCI LETT, V298, P33, DOI 10.1016/S0304-3940(00)01711-0; Hama H, 2004, NEURON, V41, P405, DOI 10.1016/S0896-6273(04)00007-8; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Ilschner S, 1996, GLIA, V18, P129, DOI 10.1002/(SICI)1098-1136(199610)18:2<129::AID-GLIA5>3.3.CO;2-G; Kipnis J, 2003, J NEUROTRAUM, V20, P559, DOI 10.1089/089771503767168483; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Matsuno R, 1998, BIOCHEM BIOPH RES CO, V244, P115, DOI 10.1006/bbrc.1998.8231; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Penkowa M, 1999, GLIA, V25, P343; Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7; Reichert F, 2001, NEUROBIOL DIS, V8, P504, DOI 10.1006/nbdi.2001.0383; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Salimi K, 2002, BRAIN RES, V946, P283, DOI 10.1016/S0006-8993(02)02896-2; SCHOLZ KH, 1990, ORG SYNTH, V7, P4; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITHSWINTOSKY VL, 2000, SOC NEUR ABST, V26, P843; Soriano SG, 1999, STROKE, V30, P134, DOI 10.1161/01.STR.30.1.134; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Ugarova TP, 2001, ANN NY ACAD SCI, V936, P368; van Spriel AB, 2001, BLOOD, V97, P2478, DOI 10.1182/blood.V97.8.2478; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; Zaltzman R, 2004, J MOL NEUROSCI, V24, P181, DOI 10.1385/JMN:24:2:181; Zaltzman R, 2003, NEUROREPORT, V14, P481, DOI 10.1097/01.wnr.0000058036.29600.ff; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1	59	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781	1873-5169		PEPTIDES	Peptides	AUG	2005	26	8					1520	1527		10.1016/j.peptides.2005.03.014			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	954UX	WOS:000231181700032	16042992				2021-06-18	
J	Baker, F; Wigram, T; Gold, C				Baker, F; Wigram, T; Gold, C			The effects of a song-singing programme on the affective speaking intonation of people with traumatic brain injury	BRAIN INJURY			English	Article						intonation; song singing; music therapy; mood	PARKINSONS-DISEASE; ACOUSTIC MEASURES; MUSIC-THERAPY; VOCAL FATIGUE; SPEECH; DEPRESSION; MOOD; INDIVIDUALS; RELAXATION; EMOTION	Primary objective: To examine changes in the relationship between intonation, voice range and mood following music therapy programmes in people with traumatic brain injury. Research design: Data from four case studies were pooled and effect size, ANOVA and correlation calculations were performed to evaluate the effectiveness of treatment. Methods and procedures: Subjects sang three self-selected songs for 15 sessions. Speaking fundamental frequency, fundamental frequency variability, slope, voice range and mood were analysed pre- and post-session. Results: Immediate treatment effects were not found. Long-term improvements in affective intonation were found in three subjects, especially in fundamental frequency. Voice range improved over time and was positively correlated with the three intonation components. Mood scale data showed that immediate effects were in the negative direction whereas there weres increases in positive mood state in the longer-term. Conclusions: Findings suggest that, in the long-term, song singing can improve vocal range and mood and enhance the affective intonation styles of people with TBI.	Univ Queensland, Brisbane, Qld, Australia; Univ Aalborg, Aalborg, Denmark; Sogn & Fjordane Univ Coll, Sandane, Norway	Baker, F (corresponding author), Univ Queensland, Brisbane, Qld, Australia.	f.bakr1@mailbox.uq.edu.au	Gold, Christian/K-1774-2015				Alpert M, 2001, J AFFECT DISORDERS, V66, P59, DOI 10.1016/S0165-0327(00)00335-9; APPLE W, 1979, J PERS SOC PSYCHOL, V37, P715, DOI 10.1037/0022-3514.37.5.715; Aronson A. E., 1990, CLIN VOICE DISORDERS; AUSTIN D, 1998, DYNAMICS MUSIC PSYCH, P315; Bachorowski JA, 1999, CURR DIR PSYCHOL SCI, V8, P53, DOI 10.1111/1467-8721.00013; Baker C, 2004, AIRL BUS, V20, P32; BAKER F, UNPUB BRIT J MUSIC T; Baumann B, 1999, COGNITIVE NEUROPSYCH, V4, P333, DOI DOI 10.1080/135468099395864; Benke T, 1998, BRAIN COGNITION, V38, P36, DOI 10.1006/brcg.1998.1013; Brown S, 2000, ORIGINS OF MUSIC, P271; BUNCH M, 1997, DYNAMICS SINGING VOI; Cohen N. S., 1995, MUSIC THERAPY PERSPE, V13, P70; COHEN NS, 1992, J MUSIC THER, V29, P87, DOI 10.1093/jmt/29.2.102; Darrow A. A., 1991, CASE STUDIES MUSIC T, P193; DARROW AA, 1986, J MUSIC THER, V23, P194, DOI 10.1093/jmt/23.4.194; Davis P., 1998, AUSTR VOICE, V4, P13; DAVITZ JR, 1959, J COMMUN, V9, P6, DOI 10.1111/j.1460-2466.1959.tb00286.x; Fairbanks G., 1960, VOICE ARTICULATION D, V, 2nd ed; Fricchione C., 1986, BRAIN LANG, V71, P75; Frolov M. V., 1999, HUM PHYSL, V25, P42; Garcia-Toro M, 2000, J NERV MENT DIS, V188, P824, DOI 10.1097/00005053-200012000-00006; Haneishi E, 2001, J MUSIC THER, V38, P273, DOI 10.1093/jmt/38.4.273; Husain G, 2002, MUSIC PERCEPT, V20, P151, DOI 10.1525/mp.2002.20.2.151; Iwanaga M, 1996, J MUSIC THER, V33, P219, DOI 10.1093/jmt/33.3.219; KATSCH S, 1985, MUSIC YOU; Kent RD, 1999, AM J SPEECH-LANG PAT, V8, P129, DOI 10.1044/1058-0360.0802.129; KITCH JA, 1994, J VOICE, V8, P207, DOI 10.1016/S0892-1997(05)80291-7; Kolb B., 1999, COGNITIVE NEUROREHAB, P9; KUNY S, 1995, PSYCHOPATHOLOGY, V28, P190, DOI 10.1159/000284922; LEONARD RJ, 1988, J SPEECH HEAR RES, V31, P54, DOI 10.1044/jshr.3101.54; Livingston F., 1996, AUSTR J NEUROSCI, V9, P12; Morris RJ, 1996, J VOICE, V10, P159, DOI 10.1016/S0892-1997(96)80043-9; Mozziconacci S. J., 1997, IPO ANN PROGR REPORT, V32, P154; MURRAY IR, 1993, J ACOUST SOC AM, V93, P1097, DOI 10.1121/1.405558; Naarding P, 2003, J NEUROLINGUIST, V16, P37, DOI 10.1016/S0911-6044(01)00043-4; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; NEWHAM P, 1998, FDN EXPRESSIVE ARTS, P89; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Patel AD, 1998, BRAIN LANG, V61, P123, DOI 10.1006/brln.1997.1862; Pittman J, 1994, VOICE SOCIAL INTERAC; Robb SL, 2000, J MUSIC THER, V37, P2, DOI 10.1093/jmt/37.1.2; Scherer K., 1991, MUSIC LANGUAGE SPEEC, P146; Stern R. A., 1997, VISUAL ANALOG MOOD S; THAUT MH, 1993, J MUSIC THER, V30, P210, DOI 10.1093/jmt/30.4.210; TURRY A, 1999, CLIN APPL MUSIC THER, P13; Welham NV, 2003, J VOICE, V17, P21, DOI 10.1016/S0892-1997(03)00033-X; Wigram T., 1993, HDB INQUIRY ARTS THE, P177; ZHANG SP, 1994, J NEUROPHYSIOL, V72, P1337	48	19	20	1	20	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2005	19	7					519	528		10.1080/02699050400005150			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	933IQ	WOS:000229622500006	16134740				2021-06-18	
J	Casas, F; Alam, H; Reeves, A; Chen, Z; Smith, WA				Casas, F; Alam, H; Reeves, A; Chen, Z; Smith, WA			A portable cardiopulmonary bypass/extracorporeal membrane oxygenation system for the induction and reversal of profound hypothermia: Feasibility study in a swine model of lethal injuries	ARTIFICIAL ORGANS			English	Article; Proceedings Paper	12th Congress of the International-Society-for-Rotary-Blood-Pumps	OCT 07-10, 2004	Cleveland, OH	Int Soc Rotary Blood Pump		hypothermia; suspended animation; rotary blood pump	UNCONTROLLED HEMORRHAGIC-SHOCK; PROLONGS SURVIVAL-TIME; CARDIAC-ARREST; CIRCULATORY ARREST; MILD HYPOTHERMIA; BRAIN-DAMAGE; RESUSCITATION; RATS; DOGS; EPIDEMIOLOGY	The Cleveland Clinic Foundation's (CCF) cardiopulmonary bypass/extracorporeal membrane oxygenation (CPB/ECMO) system capabilities were tested in a hypothermia trauma management feasibility study in a porcine animal model at the Uniformed Services University of the Health Sciences (USUHS, Bethesda, MD, U.S.A.). In this survival series, the CCF system was used in a simulated forward lines combat casualty application where lethal uncontrolled hemorrhage from major vascular injuries was repaired under a state of profound hypothermic arrest (suspended animation), followed by recovery and monitoring in an intensive care unit (ICU) setting. The animals were monitored for survival, neurological impact, cognitive functions, organ damage, and delayed complications over 3 weeks. A survival rate of 83% matched rates previously found using conventional equipment. Neurological findings, organ dysfunction, and complication rates also were no different from previous studies using standard equipment. Successful survival results demonstrated that the CCF CPB/ECMO system could be used to induce a period of profound hypothermic arrest for the repair of lethal traumatic injuries. The logistical advantages of this system make it an attractive choice for use in austere settings and during transport.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; Uniformed Serv Univ Hlth Sci, Trauma Res & Readiness Inst Surg, Bethesda, MD 20814 USA	Casas, F (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	casasf@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K01HL073076] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K01HL073076] Funding Source: Medline		Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ALAM H, IN PRESS J TRAUMA; Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; Alam HB, 2002, J TRAUMA, V52, P18, DOI 10.1097/00005373-200201000-00006; APRAHAMIAN C, 1985, ANN EMERG MED, V14, P583, DOI 10.1016/S0196-0644(85)80785-X; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Behringer W, 2003, CRIT CARE MED, V31, P1523, DOI 10.1097/01.CCM.0000063450.73967.40; Behringer W, 2000, ANESTHESIOLOGY, V93, P1491, DOI 10.1097/00000542-200012000-00022; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; COLE SL, 1956, JAMA-J AM MED ASSOC, V161, P1454, DOI 10.1001/jama.1956.02970150022005; *COMM FLUID RES CO, 1999, JFLUID RES STAT SCI, P1; JENNINGS RB, 1988, CRIT CARE MED, V16, P988, DOI 10.1097/00003246-198810000-00010; Kim SH, 1998, J TRAUMA, V44, P485, DOI 10.1097/00005373-199803000-00010; Leonov Y, 2002, RESUSCITATION, V52, P193, DOI 10.1016/S0300-9572(01)00453-1; MATTOX KL, 1982, J TRAUMA, V22, P934, DOI 10.1097/00005373-198211000-00008; Norio H, 2002, J TRAUMA, V52, P1056, DOI 10.1097/00005373-200206000-00006; RADOVSKY A, 1995, STROKE, V26, P2127, DOI 10.1161/01.STR.26.11.2127; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Safar Peter J, 2002, Curr Opin Anaesthesiol, V15, P203, DOI 10.1097/00001503-200204000-00010; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Shoemaker WC, 1996, CRIT CARE MED, V24, pS12; Takasu A, 1999, CRIT CARE MED, V27, P1557, DOI 10.1097/00003246-199908000-00025; Takasu A, 2003, RESUSCITATION, V56, P319, DOI 10.1016/S0300-9572(02)00405-7; Takasu A, 2002, RESUSCITATION, V54, P303, DOI 10.1016/S0300-9572(02)00148-X; Talbott JH, 1941, NEW ENGL J MED, V224, P281, DOI 10.1056/NEJM194102132240705; Taylor MJ, 2005, TRANSPL P, V37, P303, DOI 10.1016/j.transproceed.2004.12.024; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; TISHERMAN SA, 1990, J TRAUMA, V30, P836, DOI 10.1097/00005373-199007000-00014; VANDAM LD, 1959, NEW ENGL J MED, V261, P595, DOI 10.1056/NEJM195909172611206; VANDAM LD, 1959, NEW ENGL J MED, V261, P546, DOI 10.1056/NEJM195909102611106; Wu XR, 2003, CRIT CARE MED, V31, P195, DOI 10.1097/00003246-200301000-00030	31	19	21	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0160-564X	1525-1594		ARTIF ORGANS	Artif. Organs	JUL	2005	29	7					557	563		10.1111/j.1525-1594.2005.29092.x			7	Engineering, Biomedical; Transplantation	Engineering; Transplantation	939EX	WOS:000230056300008	15982284				2021-06-18	
J	Kompanje, EJO; Maas, AIR; Hilhorst, MT; Slieker, FJA; Teasdale, GM				Kompanje, EJO; Maas, AIR; Hilhorst, MT; Slieker, FJA; Teasdale, GM			Ethical considerations on consent procedures for emergency research in severe and moderate traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; proxy consent; waiver of consent; randomised controlled trails; European Union	SPINAL-CORD INJURY; INFORMED-CONSENT; CLINICAL-TRIALS; EUROPEAN-UNION; HEAD-INJURY; TIRILAZAD MESYLATE; METHYLPREDNISOLONE; RESUSCITATION; MORTALITY; EFFICACY	Therapeutic trials in TBI are subject to principles of Good Clinical Practice (GCP), to national legislation, and to international and European ethical concepts and regulations [e.g. 13]. The guiding principles underlying these investigations of treatment are respect for autonomy of research subjects, protection against discomfort, risk, harm and exploitation and the prospect of some benefit. Patients with significant TBI are mentally incapacitated, thus prohibiting obtaining consent directly from the subject. Various approaches to consent procedures are used as surrogate to subject consent: proxy consent, consent by an independent physician and waiver of consent. These approaches are reviewed. A questionnaire soliciting opinions was mailed to 148 EBIC (European Brain Injury Consortium) associated neuro-trauma centers in 19 European countries. 48% respondents believe that relatives were not able to make a balanced decision, 72% believed that consent procedures are a significant factor causing decrease in enrollment rate and 83% stated that consent procedures delay initiation of study treatment, resulting in possible harm if the agent has shown to be effective. 64% of the respondents considered TBI an emergency situation in which clinical research could be initiated under the emergency exception for consent. In new European legislation, emergency research under waiver of consent is not permitted. Nevertheless, we consider that randomising patients with TBI into carefully evaluated trial protocols without prior consent may be considered ethically justified.	Erasmus MC Univ Med Ctr Rotterdam, Dept Neurosurg, Rotterdam, Netherlands; Erasmus MC Univ Med Ctr Rotterdam, Dept Intens Care, Rotterdam, Netherlands; Erasmus MC Univ Med Ctr Rotterdam, Dept Med Eth, Rotterdam, Netherlands; Inst Neurol Sci, Dept Neurosurg, Glasgow, Lanark, Scotland	Kompanje, EJO (corresponding author), Erasmus Med Ctr Rotterdam, Dept Neurosurg, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.j.o.kompanje@erasmusmc.nl	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264			Agard A, 2001, HEART, V86, P632, DOI 10.1136/heart.86.6.632; Annane D, 2004, INTENS CARE MED, V30, P321, DOI 10.1007/s00134-003-2065-8; Arnold RM, 2003, CRIT CARE MED, V31, pS347, DOI 10.1097/01.CCM.0000065123.23736.12; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Clifton GL, 2002, J NEUROTRAUM, V19, P1121, DOI 10.1089/08977150260337930; Coppolino M, 2001, CHEST, V119, P603, DOI 10.1378/chest.119.2.603; CORTBUS F, 2002, NEUROTRAUMA, P69; DRUML C, 2003, EUROPEAN DIRECTIVE F; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Foex BA, 2001, EMERG MED J, V18, P198, DOI 10.1136/emj.18.3.198; Freeman BD, 2001, AM J RESP CRIT CARE, V164, P190, DOI 10.1164/ajrccm.164.2.2011028; Kompanje EJO, 2004, INTENS CARE MED, V30, P168, DOI 10.1007/s00134-003-2044-0; Kowey P, 2000, RESUSCITATION, V47, P307, DOI 10.1016/S0300-9572(00)00247-1; Lemaire F, 2002, INTENS CARE MED, V28, P660, DOI 10.1007/s00134-002-1280-z; Lindley RI, 1998, BRIT MED J, V316, P1005, DOI 10.1136/bmj.316.7136.1005; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PLOMER A, 2001, EUROPEAN J HLTH LAW, V8, P333; Roupie E, 2000, INTENS CARE MED, V26, P52, DOI 10.1007/s001340050011; Schats R, 2003, J NEUROL NEUROSUR PS, V74, P988, DOI 10.1136/jnnp.74.7.988; Sterz F, 2002, RESUSCITATION, V53, P237, DOI 10.1016/S0300-9572(02)00103-X; Stocchetti N, 2004, INTENS CARE MED, V30, P517, DOI 10.1007/s00134-003-2142-z; SULMASY DP, 1994, AM J MED, V96, P432, DOI 10.1016/0002-9343(94)90170-8; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; VALADKA AB, 2001, CONTEMP NEUROSURG, V23, P1; van Olden GDJ, 2003, INJURY, V34, P191, DOI 10.1016/S0020-1383(02)00202-4; WRIGHT DW, 2001, ACAD EMERG MED, V8, P419	32	19	19	0	1	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUN	2005	147	6					633	640		10.1007/s00701-005-0525-3			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	933FM	WOS:000229614300019	15806325				2021-06-18	
J	Lobato, RD; Alen, JF; Perez-Nunez, A; Alday, R; Gomez, PA; Pascual, B; Lagares, A; Miranda, P; Arrese, I; Kaen, A				Lobato, RD; Alen, JF; Perez-Nunez, A; Alday, R; Gomez, PA; Pascual, B; Lagares, A; Miranda, P; Arrese, I; Kaen, A			Value of serial CT scanning and intracranial pressure monitoring for detecting new intracranial mass effect in severe head injury patients showing lesions type I-II in the initial CT scan	NEUROCIRUGIA			Spanish	Article						head injury; postraumatic coma; brain contusion epidural hematoma; axonal injury; computerized tomography; intracranial pressure	TRAUMATIC INTRACEREBRAL HEMATOMA; COMPUTERIZED-TOMOGRAPHY; BRAIN-INJURY; HEMORRHAGE; COAGULATION; MANAGEMENT; FIBRINOLYSIS; COMA	Objective. To determine the incidence of pathological and intracranial pressure (ICP) changes during the acute posttraumatic period in severe head injury patients presenting with lesions Types I-II (TCDB classification) in the admission CT scan with the aim of defining the most appropriate strategy of sequential CT scanning and ICP monitoring for detecting new intracranial mass effect and improving the final outcome. Material and methods. 56 patients (ages 15-80 years) consecutively admitted during a 2 years period were included. All had the initial CT scan < 24 hours after injury (mean interval = 150 min), several CT controls within the first days of the course and ICP monitoring after admission. Different epidemiological, clinical and radiological variables were recorded and deterioration defined as the development of sustained ICP over 20 mmHg requiring aggressive medical and/or surgical treatment was considered the dependent variable. Uni and multivariate analyses were made for determining the correlation between different parameters and the occurrence of deterioration and the final outcome as assessed with the GOS. Results. The mean GCS score was 5 and 37% of the patients showed pupillary changes; 52.3% had peritraumatic hypotension-hypoxemia, 16.1% anemia and 12.3% coagulation changes. 50% of the patients showed petechial hemorrhages in the white matter or the brainstem, 66% SAH, 40% HIV, 39.3% brain contusion and 21.4% small extraxial hematomas. 57.1% of the patients showed CT changes through the acute posttraumatic period consisting of new contusion (26.8% of the cases), growing of previous contusion (68.2%) or previous extraaxial hematoma (10.7%), and generalized brain swelling (10.7%). 64.9% of the patients made a favourable and 35.7% an unfavourable outcome. Overall, 27 (48.9%) patients developed deterioration, 21 (37.5%) with concurrent CT changes and 6 (10,7%) without new pathology as seen by the CT control. The remaining 29 (51.7%) patients in this series did not develop deterioration in spite that 11(19.6%) showed CT changes. The age, the initial score, the occurrence of peritraumatic hypotension-hypoxemia and coagulation disorders did not correlate with the risk of deterioration. By contrast, the presence of contusion at the initial CT scan (p= 0.01) and the occurrence of CT change (only generalized brain swelling, p= 0.003) significantly correlated with the risk of deterioration; in his turn deterioration increased by a factor of 10 (OR = 9,8) the risk of death and 7 out of the 8 patients who died developed intractable intracranial hypertension. The 8 (14.2%) patients requiring surgery showed simultaneous ICP deterioration and CT changes, but another 11 patients in a similar condition could be managed without surgery. With or without ICP deterioration, patients showing CT changes had a worse outcome than those without new pathologies, but the difference did not reach statistical significance, Discussion and conclusions. Over 50% of the patients with initial Type I-II lesions developed new CT changes and nearly 50% showed intracranial hypertension during the acute posttraumatic period. Considering the high incidences of ICP and CT deterioration through the course, along with the absence of strong predictors and the discordances between CT and ICP changes (which were seen in 30.3% of the cases) we recommend ICP monitoring after admission in all patients and serial CT scanning at 2-4, 12, 24, 48 and 72 hours after injury with additional controls as indicated by clinical or ICP changes in all cases. Though it is clear that the presence of severe intracranial hypertension significantly increased the risk of death, the small size of the sample in this series prevented to assess to what extent the occurrence of new mass effect and/or raised ICP contributed to the development of moderate and severe disability in the survivors which were mainly due to the occurrence of diffuse axonal injury. Finally, demonstrating that sequential CT scanning and ICP monitoring improve the final outcome in this type of patients would require a prospective randomized trial which is impracticable for different reasons, among them the ethical ones.	Hosp 12 Octubre, Serv Neurocirugia, E-28041 Madrid, Spain	Lobato, RD (corresponding author), Hosp 12 Octubre, Serv Neurocirugia, Avda Cordoba SN, E-28041 Madrid, Spain.		kaen, ariel/G-3786-2015; KAEN, ARIEL/F-1338-2015; Perez-Nunez, Angel/AAG-4422-2020; Lagares, Alfonso/B-2969-2011; Gomez, Pedro/N-5051-2019; ALEN, JOSE A FERNANDEZ/G-4990-2018	Perez-Nunez, Angel/0000-0002-2391-6586; Lagares, Alfonso/0000-0003-3996-0554; Gomez, Pedro/0000-0002-4185-5238; ALEN, JOSE A FERNANDEZ/0000-0002-3321-983X			BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; LAGARES A, 2005, PATOLOGIA APARATO LO, V3, P41; LEE ST, 1991, ACTA NEUROCHIR, V113, P121, DOI 10.1007/BF01403196; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V46, P77; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; ROBERSON FC, 1979, SURG NEUROL, V12, P161; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; SAWADA Y, 1984, J NEUROL NEUROSUR PS, V47, P1125, DOI 10.1136/jnnp.47.10.1125; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2000, NEUROSURGERY, V46, P70; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TEASDALE G, 1974, LANCET, V2, P81; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021	32	19	29	0	5	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	1130-1473	2340-6305		NEUROCIRUGIA	Neurocirugia	JUN	2005	16	3					217	234					18	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	943JG	WOS:000230349100001	16007322				2021-06-18	
J	Yidirim, E; Ozisik, K; Solaroglu, I; Kaptanoglu, E; Beskonakli, E; Sargon, MF; Kilinc, K; Sakinci, U				Yidirim, E; Ozisik, K; Solaroglu, I; Kaptanoglu, E; Beskonakli, E; Sargon, MF; Kilinc, K; Sakinci, U			Protective effect of erythropoietin on type II pneumocyte cells after traumatic brain injury in rats	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Tbi traumatic brain injury; lung; erythropoietin; ultrastructure	NEUROGENIC PULMONARY-EDEMA; CENTRAL-NERVOUS-SYSTEM; ACUTE LUNG INJURY; SPINAL-CORD-INJURY; LIPID-PEROXIDATION; NITRIC-OXIDE; GRANULOCYTE DEPLETION; ANTIOXIDANT; DAMAGE; METHYLPREDNISOLONE	Background: The main objective was to evaluate the protective effect of erythropoietin on lung ultrastructure against damage in rats after traumatic brain injury. Methods: We used forty Wistar-Albino female rats weighing 170-200 gr. The rats were allocated into five groups. The first group was the control and the second was the craniotomy without trauma. The third group was the trauma group. The fourth and fifth groups were erythropoietin (1000 IU/kg) and vehicle (0,4 mL/rat) groups, respectively. A weight-drop method was used for achieving head trauma. Samples were obtained from pulmonary lobes 24-hour post injury. Lipid peroxidation levels were determined and electron microscopic scoring model was used to reveal the ultrastructural changes. Results: Ultrastructural evaluation revealed pathologic changes in the trauma group compared with the control group (p < 0.05). Lipid peroxidation levels were found to be higher in the trauma group (p < 0.05). Erythropoietin significantly reduced both the ultrastructural pathologic changes and the lipid peroxidation levels in the treatment group (p < 0.05). Conclusions. Erythropoietin protects the ultrastructure of pneumocyte type II cells against damage after traumatic brain injury.	Ankara Numune Educ & Res Hosp, Dept Thorac Surg, Ankara, Turkey; Ankara Numune Educ & Res Hosp, Dept Neurosurg, Ankara, Turkey; Univ Hacettepe, Fac Med, Dept Anat, TR-06100 Ankara, Turkey; Univ Hacettepe, Fac Med, Dept Biochem, TR-06100 Ankara, Turkey	Yidirim, E (corresponding author), Asagiovecler Mh 79 Sk 8-3, TR-06460 Ankara, Turkey.	erseyda@yahoo.com	Solaroglu, Ihsan/ABE-8816-2020; Solaroglu, Ihsan/ABF-7606-2020	Solaroglu, Ihsan/0000-0002-9472-1735; Sargon, Mustafa Fevzi/0000-0001-6360-6008			Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Atkinson JLD, 1997, NEUROSURGERY, V41, P1214, DOI 10.1097/00006123-199711000-00052; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BanyMohammed FM, 1996, PEDIATR RES, V40, P381, DOI 10.1203/00006450-199609000-00003; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BODENHAM A, 1989, BRIT MED J, V299, P1009, DOI 10.1136/bmj.299.6706.1009; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; BUERNI M, 2002, CLIN SCI, V103, P275; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Cecka J M, 1988, Clin Transpl, P399; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; CORMAN J, 1991, ANN CHIR, V45, P791; Deehan SC, 1996, INTENS CARE MED, V22, P672, DOI 10.1007/BF01709745; DETTBARN CL, 1989, HEART LUNG, V18, P583; EDMONDS HL, 1986, NEUROSURGERY, V19, P36, DOI 10.1227/00006123-198607000-00005; Eid Tore, 2002, Clin Breast Cancer, V3 Suppl 3, pS109, DOI 10.3816/CBC.2002.s.021; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hall SRR, 2002, ANESTH ANALG, V94, P948; HEFLIN AC, 1981, J CLIN INVEST, V68, P1253, DOI 10.1172/JCI110371; HINSON JM, 1983, J APPL PHYSIOL, V55, P92; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Holt AW, 1999, MED J AUSTRALIA, V170, P479, DOI 10.5694/j.1326-5377.1999.tb127848.x; JELKMANN W, 1992, PHYSIOL REV, V72, P449; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kaptanoglu E, 2002, J NEUROSURG ANESTH, V14, P114, DOI 10.1097/00008506-200204000-00005; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; MARK L, 1999, AM J PHYSIOL, V276, P494; MARON MB, 1989, J APPL PHYSIOL, V67, P305; MARTIN N, 1997, HDB ORGANIC CONDUCTI, V1, P2; MIHARA M, 1981, YAKUGAKU ZASSHI, V101, P221, DOI 10.1248/yakushi1947.101.3_221; Piper IR, 1998, BRIT J ANAESTH, V80, P639; Pyeron A M, 2001, J Neurosci Nurs, V33, P203; RICHARD JN, 1996, ANN THORAC SURG, V62, P302; SAID SI, 1995, NEUROSCIENCE, V65, P943, DOI 10.1016/0306-4522(95)00021-A; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schwarz S, 1997, NERVENARZT, V68, P956, DOI 10.1007/s001150050222; SHELLEY S, 1994, J FLA MED ASSOC, V8, P49; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SINGBARTL G, 1989, ANAESTHESIST, V38, P360; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; WAUCHOB TD, 1984, ANAESTHESIA, V39, P529, DOI 10.1111/j.1365-2044.1984.tb07355.x; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	47	19	21	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2005	58	6					1252	1258		10.1097/01.TA.0000169803.09482.F8			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	943EU	WOS:000230336100027	15995478				2021-06-18	
J	Krave, U; Hojer, S; Hansson, HA				Krave, U; Hojer, S; Hansson, HA			Transient, powerful pressures are generated in the brain by a rotational acceleration impulse to the head	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						DAI; diffuse brain injury; fibre optic pressure transducer; injury mechanism	MISSILE EXTREMITY IMPACT; NERVOUS-SYSTEM; WAVE INJURIES; BIOMECHANICS; MODEL; PIGS; TRAUMA; LIGHT; MILD; NECK	A rotational acceleration impulse to a head, as occurs at traffic accidents, sport injuries, assaults and falls, induces a diffuse brain damage that eventually could result in persistent neuropsychiatric deficits and neurodegeneration. Emphasis has been concentrated on the relative motion of the brain inside the skull during head impact, whereas less attention has been paid to whether intracranial pressure changes are generated and, if so, the implications thereof. In the present experimental study we investigated in an animal model system, based on rabbits, if a sagittal, anterior-posterior rotational acceleration of a head generated intracranial pressure changes, recorded by fibre optic pressure sensors, inserted ipsilaterally in the parieto-temporal and the occipital lobes. Two levels of rotational acceleration were used in the experiments; one higher, corresponding to the threshold limit for moderate diffuse brain injury, and one lower, close to being noninjurious. Several pressure recordings were performed in each rabbit at the two acceleration levels. The pressure recordings invariably revealed the same general characteristics of rapid, positive and negative pressures within the brain, with variations in amplitude and duration, lasting for up to 10 ms. A major finding was the generation of powerful negative pressures, as low as 0.3 bars in absolute pressure. The most prominent difference in amplitudes of the negative peak pressures between the two applied acceleration levels was demonstrated at the parieto-temporal location. The presented pressure recordings are the first to disclose the generation of transient, powerful intracerebral pressures at rotational acceleration of the head, which must be considered in studies of brain injury generation and distribution as well as prevention.	Gothenburg Univ, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, Dept Appl Mech, SE-41296 Gothenburg, Sweden; Samba Sensors AB, SE-41328 Gothenburg, Sweden	Hansson, HA (corresponding author), Gothenburg Univ, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden.	hans-arne.hansson@anatcell.gu.se					CLAUSEN F, 2002, 20 ANN NAT NEUR SOC, P529; Eichberger A, 2000, ACCIDENT ANAL PREV, V32, P251, DOI 10.1016/S0001-4575(99)00097-4; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOSCH HH, 1970, J TRAUM, V10, P370, DOI 10.1097/00005373-197005000-00002; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; HANSSON HA, 2003, 21 ANN NAT NEUR SOC, P200; HARDY WN, 2001, 45 STAPP CAR CRASH C; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; KRAUS FJ, 1997, NEUROEPIDEMIOLOGY, V14, P435; MEANEY DF, 1993, ASME AMD, V169; NAHUM AM, 1977, 21 STAPP CAR CRASH; NUSHOLTZ GS, 1984, 28 STAPP CAR CRASH C; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Ortengren T, 1996, J NEUROTRAUM, V13, P171, DOI 10.1089/neu.1996.13.171; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Reilly P, 1997, HEAD INJURY PATHOPHY; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sosin DM, 1996, BRAIN INJURY, V10, P47; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1990, J TRAUMA, V30, P281, DOI 10.1097/00005373-199003000-00006; SVENSSON MY, 1993, 1993 INT IRCOBI C BI, P189; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trosseille X, 1992, 36 STAPP CAR CRASH C; VALLFORS B, 1976, NEUROSURGICAL SUCTIO; Ward C., 1980, 24 STAPP CAR CRASH C; Wisniewski H. M, 1986, ATLAS RABBIT BRAIN S; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	37	19	21	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2005	21	10					2876	2882		10.1111/j.1460-9568.2005.04115.x			7	Neurosciences	Neurosciences & Neurology	929TQ	WOS:000229369700026	15926935				2021-06-18	
J	Marson, DC; Dreer, LE; Krzywanski, S; Huthwaite, JS; DeVivo, MJ; Novack, TA				Marson, DC; Dreer, LE; Krzywanski, S; Huthwaite, JS; DeVivo, MJ; Novack, TA			Impairment and partial recovery of medical decision-making capacity in traumatic brain injury: A 6-month longitudinal study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; decision making; mental competency; rehabilitation	MACARTHUR TREATMENT COMPETENCE; PHYSICIANS LEGAL STANDARD; MILD ALZHEIMERS-DISEASE; PROTOTYPE-INSTRUMENT; PERSONAL JUDGMENTS; COGNITIVE MODELS; CONSENT; ABILITIES; REHABILITATION; CONSISTENCY	Objective: To investigate empirically change in medical decision-making capacity (MDC) in patients with traumatic brain injury (TBI). Design: Longitudinal study comparing control and TBI groups at hospitalization and at 6 months postinjury. Setting: Inpatient brain injury rehabilitation unit. Participants: Twenty healthy controls and 24 patients with moderate to severe TBI. Interventions: Not applicable. Main Outcome Measures: MDC was measured by using the Capacity to Consent to Treatment Instrument (CCTI). The CCTI evaluates performance on a series of 4 accepted consent abilities, or standards: S1 (evidencing/communicating choice), S3 (appreciating consequences), S4 (reasoning about treatment), and S5 (understanding the treatment situation and choices), and I experimental standard [S2] (making the reasonable treatment choice when the alternative choice is unreasonable). In addition, TBI patients were assigned I of 3 capacity outcomes (capable, marginally capable, incapable) for each standard. Results: At hospitalization, TBI patients performed equivalently with controls on standards SI and [S2] but significantly below controls on S3 (P < .001), S4 (P < .02), and S5 (P < .001). At 6-month follow-up, TBI patients showed significant within-group improvement on these 3 standards (S3, S4, S5) but continued to fall significantly below controls on S3 (P < .006) and S5 (P < .001). A group by time interaction emerged on S5 (P < .02). The TBI group showed increasing proportions of capable outcomes on all standards over the 6 months. Conclusions: Patients with TBI showed initial impairment and subsequent partial recovery of MDC over a 6-month period. Complex consent abilities of appreciation, reasoning, and understanding were significantly impaired in hospitalized acute TBI patients. At follow-up, TBI patients showed substantial recovery of reasoning and partial recovery of appreciation and understanding consent abilities. The study suggests the importance in the rehabilitation setting of serial evaluations of MDC in patients with TBI.	Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Alzheimers Dis Res Ctr, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35233 USA	Marson, DC (corresponding author), Univ Alabama Birmingham, Dept Neurol, Rm JT1216, Birmingham, AL 35233 USA.	dmarson@uab.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG 10483-12, 1P50 AG16582-01] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD07420] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG010483, P50AG016582] Funding Source: NIH RePORTER		APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; BANJA JD, 1986, ARCH PHYS MED REHAB, V67, P790; *CDCP, 1997, MMWR-MORBID MORTAL W, V48, P8; CHRISTENSEN K, 1995, B AM ACAD PSYCH LAW, V18, P221; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1995, J INT NEUROPSYCH SOC, V1, P66; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dymek MP, 2001, NEUROLOGY, V56, P17, DOI 10.1212/WNL.56.1.17; Dymek MP, 1999, J FORENSIC NEUROPSYC, V1, P27, DOI DOI 10.1300/J151V01N01_; Earnst KS, 2000, J AM GERIATR SOC, V48, P919, DOI 10.1111/j.1532-5415.2000.tb06888.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; FITTEN LJ, 1990, ARCH INTERN MED, V150, P1717, DOI 10.1001/archinte.150.8.1717; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Griffith HR, 2003, NEUROLOGY, V60, P449, DOI 10.1212/WNL.60.3.449; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P127, DOI 10.1007/BF01499322; GRISSO T, 1986, EVALUATINIG COMPETEN; Hillier SL, 1997, BRAIN INJURY, V11, P661; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; KAPP M, 1992, GERIATRICS LAW PATIE; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Levin H, 1979, J NERV MENT DIS, V20, P694; Marson D, 2001, ARCH CLIN NEUROPSYCH, V16, P754; Marson D., 2001, ALZHEIMERS DIS RELAT, P165; Marson DC, 2000, ARCH NEUROL-CHICAGO, V57, P877, DOI 10.1001/archneur.57.6.877; Marson DC, 2000, J AM GERIATR SOC, V48, P911, DOI 10.1111/j.1532-5415.2000.tb06887.x; Marson DC, 1999, NEUROLOGY, V53, P1983, DOI 10.1212/WNL.53.9.1983; MARSON DC, 1994, ALZ DIS ASSOC DIS, V8, P5, DOI 10.1097/00002093-199424003-00002; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P949, DOI 10.1001/archneur.1995.00540340029010; Marson DC, 1997, J AM GERIATR SOC, V45, P458, DOI 10.1111/j.1532-5415.1997.tb05171.x; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P955, DOI 10.1001/archneur.1995.00540340035011; Marson DC, 1996, NEUROLOGY, V46, P666, DOI 10.1212/WNL.46.3.666; Marson DC, 1997, J AM GERIATR SOC, V45, P453, DOI 10.1111/j.1532-5415.1997.tb05170.x; MCNEMAR Q, 1975, PSYCHOLOGICAL STAT; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Reid-Proctor GM, 2001, BRAIN INJURY, V15, P377, DOI 10.1080/02699050010005977; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; ROTH LH, 1977, AM J PSYCHIAT, V134, P279; Simon Robert I., 1994, P569; *SPSS INC, 2000, SPSS BAS 10 0 APPL G; Stuss D.T., 1986, FRONTAL LOBES; TEASDALE G, 1974, LANCET, V2, P81; TEPPER AM, 1984, LAW HUMAN BEHAV, V8, P205, DOI 10.1007/BF01044693; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Wong JG, 1999, PSYCHOL MED, V29, P437, DOI 10.1017/S0033291798008113; WONG T, 1998, ETHICAL ISSUES EVALU, P187; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100	52	19	19	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					889	895		10.1016/j.apmr.2004.09.020			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	928NM	WOS:000229278500007	15895333				2021-06-18	
J	Helgeland, MI; Torgersen, S				Helgeland, MI; Torgersen, S			Stability and prediction of schizophrenia from adolescence to adulthood	EUROPEAN CHILD & ADOLESCENT PSYCHIATRY			English	Article						schizophrenia; adolescent psychiatry; long-term follow-up	CHILDHOOD-ONSET SCHIZOPHRENIA; LONG-TERM COURSE; FOLLOW-UP; HIGH-RISK; 1ST-DEGREE RELATIVES; BIRTH COHORT; DISORDERS; DIAGNOSIS; CHILDREN; AGE	Stability of schizophrenia diagnosis from adolescence to adulthood, antecedents of schizophrenia, and differences in developmental and behavioural histories between subjects with early onset schizophrenia (EOS) and with adult onset schizophrenia (AOS) were investigated in 145 adult subjects diagnosed with mental disorders in adolescence and rediagnosed on the basis of medical records according to DSM-IV. A very high diagnostic stability schizophrenia was demonstrated at the 28-year follow-up. Several factors, including neurological adversities, delayed language development, low IQ, and congenital functional disability, differentiated significantly between schizophrenic subjects and nonschizophrenic subjects. Histories of concussion, physical abuse, parental divorce, and unstable familial context differentiated significantly between EOS and AOS subjects. Our findings support earlier evidence of schizophrenia being a chronic disorder with high diagnostic stability, and confirm the importance of neurological adversities, delayed language development, and low IQ as factors predictive of schizophrenia. Exploration of four case histories of AOS subjects delineates "pre-schizophrenic warning cluster" where combination of neurological adversities, temperamental problems, antisocial behaviour, preference for solitary play, and unstable family system constitute main factors.	Univ Oslo, Inst Psychol, N-0317 Oslo, Norway; Sogn Ctr Child & Adolescent Psychiat, Oslo, Norway	Helgeland, MI (corresponding author), Bjerkelundgaten 5, N-0553 Oslo, Norway.						AMBELAS A, 1992, BRIT J PSYCHIAT, V160, P401, DOI 10.1192/bjp.160.3.401; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANGST J, 1988, SCHIZOPHRENIA BULL, V14, P501, DOI 10.1093/schbul/14.4.501; ASARNOW JR, 1994, SCHIZOPHRENIA BULL, V20, P599, DOI 10.1093/schbul/20.4.599; AYLWARD E, 1984, SCHIZOPHRENIA BULL, V10, P430, DOI 10.1093/schbul/10.3.430; BLAND RC, 1976, ARCH GEN PSYCHIAT, V33, P949; Bleuler E., 1911, DEMENTIA PRAECOX GRO; Bleuler M., 1978, SCHIZOPHRENIC DISORD; Cannon M, 2002, ARCH GEN PSYCHIAT, V59, P449, DOI 10.1001/archpsyc.59.5.449; CAWTHRON P, 1994, J CHILD PSYCHOL PSYC, V35, P1321, DOI 10.1111/j.1469-7610.1994.tb01237.x; Chen YR, 1996, AM J PSYCHIAT, V153, P682; CIOMPI L, 1980, SCHIZOPHRENIA BULL, V6, P606, DOI 10.1093/schbul/6.4.606; Davidson L, 1997, CAN J PSYCHIAT, V42, P34, DOI 10.1177/070674379704200105; Davidson M, 2000, ACTA PSYCHIAT SCAND, V101, P7, DOI 10.1111/j.0065-1591.2000.007s021[dash]2.x; DELISI LE, 1992, SCHIZOPHRENIA BULL, V18, P209, DOI 10.1093/schbul/18.2.209; EATON WW, 1992, SCHIZOPHRENIA BULL, V18, P229, DOI 10.1093/schbul/18.2.229; Ericson E. H., 1968, IDENTITY YOUTH CRISI; Falloon IRH, 1998, BRIT J PSYCHIAT, V172, P33, DOI 10.1192/S0007125000297638; First M.B., 1996, STRUCTURED CLIN INTE; FISH B, 1992, ARCH GEN PSYCHIAT, V49, P221; HAAS GL, 1990, BIOL PSYCHIAT, V27, P179; HARDING CM, 1987, AM J PSYCHIAT, V144, P718; HARTMANN E, 1984, ARCH GEN PSYCHIAT, V41, P1050; HEGARTY JD, 1994, AM J PSYCHIAT, V151, P1409; Hollis C, 2000, AM J PSYCHIAT, V157, P1652, DOI 10.1176/appi.ajp.157.10.1652; HOLLIS C, 1995, BRIT J PSYCHIAT, V166, P489, DOI 10.1192/bjp.166.4.489; JANES CL, 1994, CHILDREN RISK SCHIZO, P160; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; KENDLER KS, 1985, ARCH GEN PSYCHIAT, V42, P770; KRAUSZ M, 1993, SCHIZOPHRENIA BULL, V19, P831, DOI 10.1093/schbul/19.4.831; Lewis S., 1989, SCHIZOPHRENIA SCI PR, P56; Malmberg A, 1998, BRIT J PSYCHIAT, V172, P308, DOI 10.1192/bjp.172.4.308; MARCUS J, 1985, SCHIZOPHRENIA BULL, V11, P85, DOI 10.1093/schbul/11.1.85; MARENGO J, 1991, AM J PSYCHIAT, V148, P606; MARNEROS A, 1991, EUR ARCH PSY CLIN N, V241, P187, DOI 10.1007/BF02219720; MASON P, 1995, BRIT J PSYCHIAT, V167, P596, DOI 10.1192/bjp.167.5.596; Maziade M, 1996, BRIT J PSYCHIAT, V169, P361, DOI 10.1192/bjp.169.3.361; MCGLASHAN TH, 1988, SCHIZOPHRENIA BULL, V14, P515, DOI 10.1093/schbul/14.4.515; MCGLASHAN TH, 1990, SCHIZOPHR B, V14, P515; Miller PM, 2002, PSYCHOL MED, V32, P173, DOI 10.1017/S0033291701004779; MURRAY RM, 1992, SCHIZOPHRENIA BULL, V18, P319, DOI 10.1093/schbul/18.2.319; ONSTAD S, 1991, ACTA PSYCHIAT SCAND, V83, P463, DOI 10.1111/j.1600-0447.1991.tb05577.x; ONSTAD S, 1993, PSYCHOL MED, V23, P335, DOI 10.1017/S0033291700028439; PARNAS J, 1982, ARCH GEN PSYCHIAT, V39, P658; Pfohl B., 1994, STRUCTURED INTERVIEW; RAM R, 1992, SCHIZOPHRENIA BULL, V18, P185, DOI 10.1093/schbul/18.2.185; Robins L.N., 1966, DEVIANT CHILDREN GRO; SALOKANGAS RKR, 1990, SCHIZOPHR RES, V3, P333, DOI 10.1016/0920-9964(90)90019-4; Schaeffer JL, 2002, J AM ACAD CHILD PSY, V41, P538, DOI 10.1097/00004583-200205000-00011; SCHMIDT M, 1995, EUR ARCH PSY CLIN N, V245, P93, DOI 10.1007/BF02190735; SEEMAN MV, 1983, COMPR PSYCHIAT, V24, P125, DOI 10.1016/0010-440X(83)90100-1; SHAPIRO R, 1979, WHO SCHIZOPHRENIA IN; TRAINOR D, 1979, PSYCHIATR NEWS  0406, P30; TSUANG MT, 1981, ARCH GEN PSYCHIAT, V38, P535; VAILLANT GE, 1978, SCHIZOPHRENIA BULL, V4, P78, DOI 10.1093/schbul/4.1.78; VETTER P, 1993, PSYCHOPATHOLOGY, V26, P173, DOI 10.1159/000284819; WALKER E, 1990, AM J PSYCHIAT, V147, P1052; WATKINS JM, 1988, J CHILD PSYCHOL PSYC, V29, P865, DOI 10.1111/j.1469-7610.1988.tb00759.x; WATT NF, 1982, J CONSULT CLIN PSYCH, V50, P171; WATT NF, 1972, J NERV MENT DIS, V155, P42, DOI 10.1097/00005053-197207000-00006; WATT NF, 1978, ARCH GEN PSYCHIAT, V35, P160; WEINTRAUB S, 1978, J ABNORM CHILD PSYCH, V6, P461, DOI 10.1007/BF00926056; WERRY JS, 1991, J AM ACAD CHILD PSY, V30, P457, DOI 10.1097/00004583-199105000-00017; ZEITLIN H, 1986, MAUDSLEY MONOGRAPH, V29; ZUBIN J, 1977, J ABNORM PSYCHOL, V86, P103, DOI 10.1037/0021-843X.86.2.103	65	19	20	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1018-8827	1435-165X		EUR CHILD ADOLES PSY	Eur. Child Adolesc. Psych.	MAR	2005	14	2					83	94		10.1007/s00787-005-0436-0			12	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	910RI	WOS:000227949500004	15793687				2021-06-18	
J	Yoon, SJ; Lee, JH; Kim, ST; Chun, MH				Yoon, SJ; Lee, JH; Kim, ST; Chun, MH			Evaluation of traumatic brain injured patients in correlation with functional status by localized H-1-MR spectroscopy	CLINICAL REHABILITATION			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; DIFFUSE AXONAL INJURY; HEAD-INJURY; METABOLITE	Objective: To determine whether proton magnetic resonance spectroscopy (H-1-MRS) could be a useful tool for detecting microscopic diffuse axonal injury to evaluate the functional status of patients with traumatic brain injury (TBI). Design: A comparative study. Setting: An inpatient rehabilitation unit in Korea. Subjects: We examined eight adult patients who had severe TBI approximately five months before. Fourteen normal controls were employed for comparison. Main measures: Image-guided localized in vivo H-1-MRS was performed in the parietal white matter and occipital grey matter regions in brain in which no definite abnormalities in MR imaging were found at the time of H-1-MRS examination. We evaluated functional status for all patients with the Functional Independence Measure (FIM) on the same day as the H-1-MRS examination and compared the results. Results: In the parietal white matter, the [N-acetyl aspartate/creatine] ratios were significantly lower, and the [choline/creatine] and [myo-inositol/creatine] ratios were significantly higher than those of normal controls. Significant correlations of the [N-acetyl aspartate/creatine] and [myo-inositol/creatine] ratios in the parietal white matter with FIM scores were observed (p < 0.05). Conclusions: A spectral feature of the decreased [N-acetyl aspartate/creatine] and increased [choline/creatine] and [myo-inositol/creatine] ratios in parietal white matter may be a marker for diffuse axonal injury in patients with TBI and has a significant correlation with the functional status of the patients. Localized H-1-MRS has the potential to be used for detecting diffuse axonal injury in vivo in TBI patients, which can be used to guide evaluation of the functional status of TBI patients receiving rehabilitation.	Univ Ulsan, Coll Med, Asan Med Ctr, Dept Rehabil Med, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, NMR Lab, Seoul 138736, South Korea	Chun, MH (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Rehabil Med, 388-1 Poongnap Dong, Seoul 138736, South Korea.	mhchun@amc.seoul.kr	lee, jung hee/H-8107-2018				ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chan YL, 1999, J MAGN RESON IMAGING, V10, P130, DOI 10.1002/(SICI)1522-2586(199908)10:2<130::AID-JMRI4>3.0.CO;2-R; Chang L, 1996, LIFE SCI, V58, P2049, DOI 10.1016/0024-3205(96)00197-X; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRAHAM GD, 1993, STROKE, V24, P1891, DOI 10.1161/01.STR.24.12.1891; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; RANGO M, 1995, MAGNET RESON MED, V33, P595, DOI 10.1002/mrm.1910330503; ROSS B, 1994, MAGN RESON QUART, V10, P191; Saunders DE, 1999, JMRI-J MAGN RESON IM, V9, P711, DOI 10.1002/(SICI)1522-2586(199905)9:5<711::AID-JMRI14>3.0.CO;2-3; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1996, J NEUROCHEM, V66, P2477	22	19	24	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	MAR	2005	19	2					209	215		10.1191/0269215505cr813oa			7	Rehabilitation	Rehabilitation	901TY	WOS:000227306000012	15759537				2021-06-18	
J	Chapman, SS; Ewing, CB; Mozzoni, MP				Chapman, SS; Ewing, CB; Mozzoni, MP			Precision teaching and fluency training across cognitive, physical, and academic tasks in children with traumatic brain injury: A multiple baseline study	BEHAVIORAL INTERVENTIONS			English	Article								Children with traumatic brain injuries present significant challenges in terms of interrupted development and loss of previously mastered skills. The sequelae of pediatric brain injury develop in time whereas injury to an adult brain tends to create static deficits. Children with brain injuries present unique problems in their ability to form enduring memories of verbal material and performance strategies. Precision teaching and fluency training methodologies present teachers with powerful tools to capitalize upon over learning as a method of improving persistence of a new repertoire. In this series of studies precision teaching and fluency training were used across academic, communicative, and physical skill repertoires, to demonstrate the utility, efficiency, and efficacy of these methodologies. Significant improvements were reached in all functional target areas. By utilizing data-based decision methods therapists can rapidly assess and adjust treatment to keep clients progressing. In this age of limited length of stay within the therapeutic treatment environment fast and effective treatment is a mandate. Copyright (C) 2005 John Wiley Sons, Ltd.	Univ Nevada, Reno, NV 89557 USA; Timber Ridge Ranch, Little Rock, AR USA	Mozzoni, MP (corresponding author), Timber Ridge Grp Inc, 4500 W Commercial Dr, N Little Rock, AR 72116 USA.	mikeaba@ix.netcom.com					Binder C, 1996, BEHAV ANALYST, V19, P163, DOI 10.1007/BF03393163; Hartnedy SL, 2005, BEHAV INTERVENT, V20, P27, DOI 10.1002/bin.167; Haughton E.C., 1980, J PRECISION TEACHING, V1, P2; JOHNSON KR, 1994, BEHAVIOR ANALYSIS IN EDUCATION, P173; KOENIG CH, 1980, CLASSROOM LEARNING S; Kubina R. M., 2000, BEHAV SOCIAL ISSUES, V10, P83; Kubina RM, 2000, BEHAV INTERVENT, V15, P189; Lindsley OR, 1995, J PRECIS TEACH CELER, V13, P2; McGreevy P, 1983, TEACHING LEARNING PL; Merbitz CT, 2000, BEHAV INTERVENT, V15, P169, DOI 10.1002/1099-078X(200007/09)15:3<169::AID-BIN54>3.0.CO;2-5; PENNYPACKER HS, 1972, HDB STANDARD CELERAT; *REG RES CTR, 1971, DIAGN MATH INT; WHITE OR, 1986, EXCEPT CHILDREN, V52, P522, DOI 10.1177/001440298605200605	13	19	19	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1072-0847	1099-078X		BEHAV INTERVENT	Behav. Intervent.	FEB	2005	20	1					37	49		10.1002/bin.168			13	Psychology, Clinical	Psychology	899IR	WOS:000227138600005					2021-06-18	
J	Solbakk, AK; Reinvang, I; Svebak, S; Nielsen, CS; Sundet, K				Solbakk, AK; Reinvang, I; Svebak, S; Nielsen, CS; Sundet, K			Attention to affective pictures in closed head injury: Event-related brain potentials and cardiac responses	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD; DEFICITS; CORTEX; P300; COMPLAINTS; COMPONENT; AROUSAL; INDEXES; TASK	We examined whether closed head injury patients show altered patterns of selective attention to stimulus categories that naturally evoke differential responses in healthy people. Self-reported rating and electrophysiological (event-related potentials [ERPs], heart rate [HR]) responses to affective pictures were studied in patients with mild head injury (n = 20; CT/MRI negative), in patients with predominantly frontal brain lesions (n = 12; CT/MRI confirmed), and in healthy controls (n = 20). Affective valence similarly modulated HR and ERP responses in all groups, but group differences occurred that were independent of picture valence. The attenuation of P3-slow wave amplitudes in the mild head injury group indicates a reduction in the engagement of attentional resources to the task. In contrast, the general enhancement of ERP amplitudes at occipital sites in the group with primarily frontal brain injury may reflect disinhibition of input at sensory receptive areas, possibly due to a deficit in top-down modulation performed by anterior control systems.	Univ Oslo, Dept Psychol, N-0317 Blindern, Norway; Univ Oslo, Rikshosp, Dept Psychosomat & Behav Med, N-0316 Oslo, Norway; Norwegian Univ Sci & Technol, MTFS, Dept Neurosci, N-7034 Trondheim, Norway	Solbakk, AK (corresponding author), Univ Oslo, Dept Psychol, PB 1094, N-0317 Blindern, Norway.	a.k.solbakk@psykologi.uio.no					Barcelo F, 2000, NAT NEUROSCI, V3, P399; Belin P, 1998, J NEUROSCI, V18, P6388; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Butcher J. N., 1989, MMPI2 MINNESOTA MULT; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, P269; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Coull JT, 1998, J NEUROSCI, V18, P7426; *CSEA NIMH, 1995, INT AFF PICT SYST; Cuthbert BN, 2000, BIOL PSYCHOL, V52, P95, DOI 10.1016/S0301-0511(99)00044-7; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Gaetz M, 2000, BRAIN INJURY, V14, P815; Hartikainen KA, 2001, BRAIN COGNITION, V47, P339; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Herrmann CS, 2001, NEUROSCI BIOBEHAV R, V25, P465, DOI 10.1016/S0149-7634(01)00027-6; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KNIGHT RT, 1989, BRAIN RES, V504, P338, DOI 10.1016/0006-8993(89)91381-4; Knight RT, 1997, J COGNITIVE NEUROSCI, V9, P75, DOI 10.1162/jocn.1997.9.1.75; Knight RT, 1999, ACTA PSYCHOL, V101, P159, DOI 10.1016/S0001-6918(99)00004-9; Kok A, 1997, BIOL PSYCHOL, V45, P19, DOI 10.1016/S0301-0511(96)05221-0; Lane RD, 1997, NEUROPSYCHOLOGIA, V35, P1437, DOI 10.1016/S0028-3932(97)00070-5; Lang P., 1995, INT AFFECTIVE PICTUR; Lang PJ, 1997, ATTENTION AND ORIENTING: SENSORY AND MOTIVATIONAL PROCESSES, P97; Lang PJ, 1998, PSYCHOPHYSIOLOGY, V35, P199, DOI 10.1017/S0048577298001991; Lees-Haley PR, 2003, ARCH CLIN NEUROPSYCH, V18, P585; LEVIN HS, 1987, NEUROBEHAVIORAL RECO, P221; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; Naatanen R., 1992, ATTENTION BRAIN FUNC; NIELSEN CS, 1997, READPEAK DATA PROGRA; Palomba D, 1997, INT J PSYCHOPHYSIOL, V27, P55, DOI 10.1016/S0167-8760(97)00751-4; POSNER MI, 1995, BEHAV BRAIN SCI, V18, P327, DOI 10.1017/S0140525X0003870X; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Reinvang I, 1999, NEUROPSYCHOL REV, V9, P231, DOI 10.1023/A:1021638723486; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rule RR, 2002, COGN AFFECT BEHAV NE, V2, P264, DOI 10.3758/CABN.2.3.264; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; YAMAGUCHI S, 1990, BRAIN RES, V521, P281, DOI 10.1016/0006-8993(90)91553-S	52	19	19	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2005	27	2					205	223		10.1080/13803390490515739			19	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	908NP	WOS:000227794000005	15903151				2021-06-18	
J	Lew, HL; Poole, JH; Chiang, JYP; Lee, EH; Date, ES; Warden, D				Lew, HL; Poole, JH; Chiang, JYP; Lee, EH; Date, ES; Warden, D			Event-related potential in facial affect recognition: Potential clinical utility in patients with traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						affect recognition; brain injury; cognition; electroencephalograph; emotional processing; event-related potential; social perception	EMOTIONAL EXPRESSION; P300; STIMULI; LATENCY; TIME; TASK	Traumatic brain injury (TBI) frequently leads to deficits in social behavior Prior research suggests that such deficits may result from impaired perception of basic social Cues. However. these social-emotional deficits have not been studied eelectrophysiologically. We measured the P300 event-related potential (ERP), which has been shown to be a sensitive index of cognitive efficiency, in 13 patients with a history of moderate to severe TBI and in 13 healthy controls. The P300 response was measured during detection of 30 pictures of angry faces (rare target) randomly distributed among 120 neutral faces (frequent nontarget). Compared to control subjects, the TBI group's P300 responses were significantly delayed in latency (p = 0.002) and lower in amplitude (p = 0.003). TBI patients also showed slower reaction times and reduced accuracy when manually signaling their detection of angry faces. Coefficients of variation (CVs) for the facial P300 response compared faborably to those of many standard clinical assays, Suggesting. potential clinical utility. For this study, we demonstrated the feasibility of studying TBI patients P300 responses during the recognition of facial affect. Compared to controls. TBI patients showed significantly impaired electrophysiological and behavioral responses while attempting to detect affective facial cues. Additional studies are required for clinicians to determine whether this measure is related to patients' psychosocial function in the community.	VA Palo Alto Hlth Care Syst, PM&R Serv, Palo Alto, CA 94304 USA; Def & Vet Brain Injury Ctr, Palo Alto, CA USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA	Lew, HL (corresponding author), VA Palo Alto Hlth Care Syst, PM&R Serv, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.	henry.lew@med.va.gov					Birch DG, 2002, ARCH OPHTHALMOL-CHIC, V120, P1045; Campanella S, 2002, BIOL PSYCHOL, V59, P171, DOI 10.1016/S0301-0511(02)00005-4; Eger E, 2003, NEUROPSYCHOLOGIA, V41, P808, DOI 10.1016/S0028-3932(02)00287-7; Ekman P., 1976, PICTURES FACIAL AFFE; Espino DV, 2004, J AM GERIATR SOC, V52, P822, DOI 10.1111/j.1532-5415.2004.52226.x; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Ilan AB, 1999, CLIN NEUROPHYSIOL, V110, P367; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Krolak-Salmon P, 2001, EUR J NEUROSCI, V13, P987, DOI 10.1046/j.0953-816x.2001.01454.x; Kubu CS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P451; LANG SF, 1990, J CLIN EXP NEUROPSYC, V12, P946, DOI 10.1080/01688639008401033; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Lew HL, 2002, AM J PHYS MED REHAB, V81, P524, DOI 10.1097/00002060-200207000-00011; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Morita Y, 2001, NEUROSCI RES, V41, P89, DOI 10.1016/S0168-0102(01)00248-6; NISHIMURA N, 1995, PSYCHIAT CLIN NEUROS, V49, P79, DOI 10.1111/j.1440-1819.1995.tb01863.x; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; Polich J., 1997, ELECTROENCEPHALOGRAP, V104, P228, DOI DOI 10.1016/S0168-5597(97)96139-6; Viggiano MP, 1996, J CLIN EXP NEUROPSYC, V18, P631, DOI 10.1080/01688639608408288	23	19	20	0	5	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.	JAN-FEB	2005	42	1					29	34		10.1682/JRRD.2004.05.0056			6	Rehabilitation	Rehabilitation	914DL	WOS:000228205100006	15742247				2021-06-18	
J	Marklund, N; Keck, C; Hoover, R; Soltesz, K; Millard, M; LeBold, D; Spangler, Z; Banning, A; Benson, J; McIntosh, TK				Marklund, N; Keck, C; Hoover, R; Soltesz, K; Millard, M; LeBold, D; Spangler, Z; Banning, A; Benson, J; McIntosh, TK			Administration of monoclonal antibodies neutralizing the inflammatory mediators tumor necrosis factor alpha and interleukin-6 does not attenuate acute behavioral deficits following experimental traumatic brain injury in the rat	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						traumatic brain injury; lateral fluid percussion; tumor necrosis factor (TNF)-alpha; interleukin (IL)-6; Morris water maze; neuroscore; rotating pole; cerebral edema; inflammation	CLOSED-HEAD INJURY; CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; PLATELET-ACTIVATING-FACTOR; GROWTH-FACTOR PRODUCTION; FOCAL CEREBRAL-ISCHEMIA; FLUID-PERCUSSION MODEL; NEURONAL CELL-DEATH; KAPPA-B ACTIVATION; TNF-ALPHA	Purpose: Although many previous studies have indicated that the acute inflammatory response following traumatic brain injury (TBI) is detrimental, inflammation may also positively influence outcome in the more chronic post-injury recovery period. We evaluated the effects of monoclonal antibodies (mAB), neutralizing either IL-6 (IL-6 mAB) or TNF-alpha (TNF mAB), administered intracerebroventricularly (i.c.v) on acute neurobehavioral outcome following TBI. Methods: Male Sprague-Dawley rats (n = 173) were anesthetized (sodium pentobarbital, 60 mg/kg) and subjected to lateral fluid percussion (FP) brain injury of moderate severity (n = 123) or sham injury (n = 50). Beginning 1 It post-injury, TNF mAB (n = 41, of which 25 were brain-injured) or IL-6 mAB (n = 42, of which 25 were brain-injured) at a concentration of 2 mg/mL was infused i.c.v ipsilateral to the injury for 48 hours. Vehicle-treated animals (control IgG; n = 43, of which 26 were brain-injured) served as controls. In Study 1, cognitive function was evaluated in the Morris Water Maze (MWM) followed by evaluation of regional cerebral edema at 48 h post-injury. In Study 2, animals were evaluated for neurological motor function and post-injury learning in the MWM at one week post-injury. Results: FP brain injury caused significant cognitive (p < 0.05) and neurological motor (p < 0.05) deficits and increased regional brain water content in the injured hemisphere. Treatment with either TNF- or IL-6-mAB had no effect on neurological motor, cognitive function or brain edema during the first post-injury week. Conclusions: Evaluation of anti-inflammatory mABs on more chronic behavioral deficits appears warranted.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Labraty, Philadelphia, PA 19104 USA; Centocor Inc, Radnor, PA 19087 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Labraty, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu		Marklund, Niklas/0000-0002-9797-5626	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40978, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS040978, P50NS008803] Funding Source: NIH RePORTER		Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bjugstad KB, 2000, J NEUROVIROL, V6, P478, DOI 10.3109/13550280009091948; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Campbell IL, 1998, NEUROIMMUNOMODULAT, V5, P126, DOI 10.1159/000026329; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Carlson NG, 1999, J IMMUNOL, V163, P3963; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; CHENEY JA, 2001, J CEREB BLOOD FLOW M, V21, P403; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Farkas G, 1998, NEUROSCI LETT, V242, P147, DOI 10.1016/S0304-3940(98)00060-3; Fiedler M, 2002, PROTEIN ENG, V15, P931, DOI 10.1093/protein/15.11.931; GORDON HM, 1992, J IMMUNOL, V148, P4021; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hallenbeck JM, 2002, NAT MED, V8, P1363, DOI 10.1038/nm1202-1363; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hisahara S, 1997, J NEUROCHEM, V69, P10; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Ichiyama T, 2001, BRAIN RES, V911, P56, DOI 10.1016/S0006-8993(01)02672-5; KARKAR AM, 1998, J AM SOC NEPHROL, V9, P478; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; LaFleur M, 1996, J EXP MED, V184, P2311; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MARKLUND N, 2004, 34 ANN M SAN DIEG CA; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Pulliam L, 1998, J NEUROSCI RES, V54, P530, DOI 10.1002/(SICI)1097-4547(19981115)54:4<530::AID-JNR10>3.0.CO;2-1; Qiu ZH, 1998, J NEUROSCI, V18, P10445; Rhodes JKJ, 2002, NEUROSCI LETT, V335, P1, DOI 10.1016/S0304-3940(02)00811-X; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Spikes S E, 1996, Contemp Top Lab Anim Sci, V35, P53; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TERADA LS, 1992, INFLAMMATION, V16, P13, DOI 10.1007/BF00917511; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Westmoreland SV, 1996, J NEUROVIROL, V2, P118, DOI 10.3109/13550289609146545; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; ZABEL P, 1989, LANCET, V2, P1474; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zou LL, 2002, J CEREBR BLOOD F MET, V22, P959, DOI 10.1097/00004647-200208000-00007	98	19	22	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2005	23	1					31	42					12	Neurosciences	Neurosciences & Neurology	944HG	WOS:000230417200004	15846030				2021-06-18	
J	Arciniegas, DB; Frey, KL; Anderson, CA; Brousseau, KM; Harris, SN				Arciniegas, DB; Frey, KL; Anderson, CA; Brousseau, KM; Harris, SN			Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; CARBON-MONOXIDE ASPHYXIA; POSTANOXIC ENCEPHALOPATHY; DEMYELINATION; ARYLSULFATASE; LEUKOENCEPHALOPATHY; PSEUDODEFICIENCY; SEQUELAE	Delayed post-hypoxic encephalopathy is an uncommon but potentially debilitating consequence of hypoxic-ischemic brain injury. This condition is characterized by delayed neurological deterioration days-to-weeks after an initial partial or complete recovery from hypoxic-ischemic brain injury. The course of recovery from this condition is highly variable, ranging from rapid and fatal progression over several weeks to delayed but occasionally complete recovery. There are no reports describing neuro-rehabilitative, including neuropharmacologic, interventions for persons with persistent neurological and/or neurobehavioural deficits following delayed post-hypoxic encephalopathy. This study describes the case of a 24-year old male who developed delayed post-hypoxic encephalopathy following an unintentional methadone and diazepam overdose and who demonstrated cognitive and neurobehavioural improvements during treatment with amantadine HCl hydrochloride in a single-case, open-label design. A brief review of the literature regarding this condition, its treatment and suggestions for further study are presented.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Psychiat,Neuropsychiat Serv, Denver, CO 80262 USA; Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA; Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO USA	Arciniegas, DB (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Psychiat,Neuropsychiat Serv, Campus Box C268-68,4200 E 9th Ave, Denver, CO 80262 USA.	david.arciniegas@uchsu.edu	Arciniegas, David/A-3792-2009				Barker RA, 1999, J NEUROL, V246, P1103, DOI 10.1007/s004150050523; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; COURVILLE C B, 1955, Bull Los Angel Neuro Soc, V20, P9; COURVILLE CB, 1957, J NERV MENT DIS, V125, P534, DOI 10.1097/00005053-195710000-00007; COURVILLE CB, 1953, CONTRIUTIONS STUDY C; DEUTSCH H, 1917, JB PSYCHIAT, V37, P237; DOOLING EC, 1976, ARCH NEUROL-CHICAGO, V33, P196, DOI 10.1001/archneur.1976.00500030052011; GAMPER E, 1937, ARCH PSYCHIAT NERVEN, V106, P774; Ginsberg M D, 1979, Adv Neurol, V26, P21; GINSBERG MD, 1976, ARCH NEUROL-CHICAGO, V33, P5, DOI 10.1001/archneur.1976.00500010007002; GINSBERG MD, 1974, ARCH NEUROL-CHICAGO, V30, P202, DOI 10.1001/archneur.1974.00490330010002; Gottfried JA, 1997, NEUROLOGY, V49, P1400, DOI 10.1212/WNL.49.5.1400; Grinker RR, 1926, J NERV MENT DIS, V64, P18, DOI 10.1097/00005053-192607000-00003; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; LEE MH, 1978, J KOREAN NEUROPSYCHI, V15, P374; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MEIGS JW, 1939, ARCH IND HYGIENE, V6, P344; MERIWETHER LS, 1955, ARCH NEURO PSYCHIATR, V73, P286, DOI 10.1001/archneurpsyc.1955.02330090032003; MEYER J E, 1961, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V202, P113, DOI 10.1007/BF00356094; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; PLUM F, 1962, ARCH INTERN MED, V110, P56; PROTASS LM, 1971, ANN INTERN MED, V74, P738, DOI 10.7326/0003-4819-74-5-738; RICHARDSON JC, 1959, ARCH NEUROL-CHICAGO, V1, P178, DOI 10.1001/archneur.1959.03840020052007; SCHWEDENBERG TH, 1959, J NEUROPATH EXP NEUR, V18, P597, DOI 10.1097/00005072-195910000-00012; Shillito FH, 1936, J AMER MED ASSOC, V106, P669; SOHLBERG MM, 1986, ATTENTION PROCESS TR; ULE G, 1958, Arztl Wochensch, V13, P1038; WEINBERGER LM, 1994, NEUROLOGY, V44, P152, DOI 10.1212/WNL.44.1.152; WILSON B, 1989, REVERMEAD BEHAV MEMO	31	19	20	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2004	18	12					1309	1318		10.1080/02699050410001720130			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	871BW	WOS:000225105300011	15666573				2021-06-18	
J	Wiese, H; Stude, P; Nebel, K; Osenberg, D; Ischebeck, W; Stolke, D; Diener, HC; Keidel, M				Wiese, H; Stude, P; Nebel, K; Osenberg, D; Ischebeck, W; Stolke, D; Diener, HC; Keidel, M			Recovery of movement-related potentials in the temporal course after prefrontal traumatic brain injury: a follow-up study	CLINICAL NEUROPHYSIOLOGY			English	Article						traumatic brain injury; frontal lobe; EEG; Bereitschaftspotential; movement-related potential; recovery	SUPPLEMENTARY MOTOR AREA; EXTERNALLY TRIGGERED MOVEMENTS; VOLUNTARY MOVEMENT; FINGER MOVEMENTS; CEREBRAL-CORTEX; CORTICAL AREAS; ACTIVATION; READINESS; SCALP; CONNECTIONS	Objective: The movement-related potential (MRP) is an EEG measure related to self-initiated movements, consisting of the Bereitschaftspotential (BP), the negative slope, and the motor potential. Since in a former study the BP was reduced in acute prefrontal traumatic brain injury (TBI) patients, the present study examined the MRPs' course in follow-up examinations. Methods: Right index finger MRPs of 22 patients with contusions of the prefrontal cortex were recorded 12, 26, and 52 weeks after TBI and compared to controls. Results: Within the patient group, a significant increase of the BP in the temporal course after TBI was observed. MRPs 12 and 26 weeks after TBI did not differ significantly from the control group. One year after TBI, significantly enhanced BPs were found. Conclusions: In the temporal course after prefrontal TBI, a recovery of the initially reduced BP was observed. The enhanced BP areas 1 year after TBI might represent the need for increased cognitive resources during movement preparation, supporting a recovered, but less effective neuronal network. Significance: The present study represents the first longitudinal follow-up study of MRPs after prefrontal brain lesion. The observed changes reflect the plastic capacity of the brain, reorganizing the neuronal network function. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Univ Duisburg Essen, Dept Neurol, D-45122 Essen, Germany; Klin Holthausen, Hattingen, Germany; Univ Duisburg Essen, Dept Neurosurg, D-45122 Essen, Germany; Dist Hosp Bayeruth, Dept Neurol, Bayreuth, Germany; Dist Hosp Bayeruth, Dept Neurorehabil, Bayreuth, Germany	Wiese, H (corresponding author), Univ Duisburg Essen, Dept Neurol, Hufelandstr 55, D-45122 Essen, Germany.	holger.wiese@uni-essen.de	Diener, Hans-Christoph/AAF-7275-2019; Wiese, Holger/M-5281-2014	Wiese, Holger/0000-0003-4928-0771			Ball T, 1999, NEUROIMAGE, V10, P682, DOI 10.1006/nimg.1999.0507; BARBAS H, 1987, J COMP NEUROL, V256, P211, DOI 10.1002/cne.902560203; BATES JF, 1993, J COMP NEUROL, V336, P211, DOI 10.1002/cne.903360205; BIRBAUMER N, 1990, PHYSIOL REV, V70, P1, DOI 10.1152/physrev.1990.70.1.1; BRUNIA CHM, 1980, BIOL PSYCHOL, V11, P181, DOI 10.1016/0301-0511(80)90054-X; BRUNIA CHM, 1981, BIOL PSYCHOL, V13, P261; Cui RQ, 1999, NEUROIMAGE, V9, P124, DOI 10.1006/nimg.1998.0388; Cunnington R, 2003, NEUROIMAGE, V20, P404, DOI 10.1016/S1053-8119(03)00291-X; Cunnington R, 2002, NEUROIMAGE, V15, P373, DOI 10.1006/nimg.2001.0976; DEECKE L, 1969, EXP BRAIN RES, V7, P158; DEECKE L, 1987, J NEUROL NEUROSUR PS, V50, P1430, DOI 10.1136/jnnp.50.11.1430; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; Deiber MP, 1998, NEUROIMAGE, V7, P73, DOI 10.1006/nimg.1997.0314; Deiber MP, 1999, J NEUROPHYSIOL, V81, P3065; DICK JPR, 1987, ELECTROEN CLIN NEURO, V66, P263, DOI 10.1016/0013-4694(87)90075-7; Erdler M, 2000, NEUROIMAGE, V11, P697, DOI 10.1006/nimg.2000.0579; Fallgatter AJ, 2001, CLIN NEUROPHYSIOL, V112, P198, DOI 10.1016/S1388-2457(00)00505-8; Garavan H, 2003, NEUROIMAGE, V20, P1132, DOI 10.1016/S1053-8119(03)00334-3; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Green Joseph B, 2003, Top Stroke Rehabil, V10, P1; Hanakawa T, 2003, J NEUROPHYSIOL, V89, P989, DOI 10.1152/jn.00132.2002; HOLM S, 1979, SCAND J STAT, V6, P65; Humberstone M, 1997, ANN NEUROL, V42, P632, DOI 10.1002/ana.410420414; IKEDA A, 1995, ELECTROEN CLIN NEURO, V95, P323, DOI 10.1016/0013-4694(95)00086-E; IKEDA A, 1992, BRAIN, V115, P1017, DOI 10.1093/brain/115.4.1017; IRLE E, 1987, BRAIN RES REV, V12, P307, DOI 10.1016/0165-0173(87)90003-8; Jahanshahi M, 2001, NEUROCASE, V7, P495, DOI 10.1093/neucas/7.6.495; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; Jahanshahi M., 2003, BEREITSCHAFTSPOTENTI, P1, DOI [10.1007/978-1-4615-0189-3_1, DOI 10.1007/978-1-4615-0189-3]; Jenkins IH, 2000, BRAIN, V123, P1216, DOI 10.1093/brain/123.6.1216; Johnson SH, 2002, NEUROIMAGE, V17, P1693, DOI 10.1006/nimg.2002.1265; Kahneman D., 1973, ATTENTION EFFORT; KELLER I, 1990, ELECTROEN CLIN NEURO, V76, P351, DOI 10.1016/0013-4694(90)90036-J; Knosche T, 1996, ELECTROEN CLIN NEURO, V99, P183, DOI 10.1016/0013-4694(96)95648-5; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; Kropp P, 2000, APPL PSYCHOPHYS BIOF, V25, P33, DOI 10.1023/A:1009533405695; Lee KM, 1999, NEUROIMAGE, V9, P117, DOI 10.1006/nimg.1998.0393; Loose R, 2003, HUM BRAIN MAPP, V18, P249, DOI 10.1002/hbm.10082; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; LUPPINO G, 1993, J COMP NEUROL, V338, P114, DOI 10.1002/cne.903380109; MCCALLUM WC, 1993, NATO ADV SCI INST SE, V254, P1; NATIV A, 1991, PHYS THER, V71, P48, DOI 10.1093/ptj/71.1.48; NESHIGE R, 1988, BRAIN, V111, P719; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Pucak ML, 1996, J COMP NEUROL, V376, P614, DOI 10.1002/(SICI)1096-9861(19961223)376:4<614::AID-CNE9>3.0.CO;2-4; Rektor I, 2002, CLIN NEUROPHYSIOL, V113, P1998, DOI 10.1016/S1388-2457(02)00286-9; REMY P, 1994, ANN NEUROL, V36, P19, DOI 10.1002/ana.410360107; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; ROCKSTOHR B, 1989, SLOW CORTICAL POTENT; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; SHIBASAKI H, 1993, BRAIN, V116, P1387, DOI 10.1093/brain/116.6.1387; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; SINGH J, 1990, NEUROSCI LETT, V119, P27, DOI 10.1016/0304-3940(90)90747-W; SINGH J, 1990, BRAIN RES, V531, P45, DOI 10.1016/0006-8993(90)90756-2; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373; Toma K, 2003, BEREITSCHAFTSPOTENTI, P113; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Weeks RA, 2001, NEUROIMAGE, V14, P219, DOI 10.1006/nimg.2001.0780; Weilke F, 2001, J NEUROPHYSIOL, V85, P1858; Wessel K, 1997, J NEUROIMAGING, V7, P145, DOI 10.1111/jon199773145; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Wildgruber D, 1997, NEUROSCI LETT, V227, P161, DOI 10.1016/S0304-3940(97)00329-7; Zimmermann P., 1994, TESTBATTERIE AUFMERK	64	19	19	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	DEC	2004	115	12					2677	2692		10.1016/j.clinph.2004.06.015			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	877AQ	WOS:000225540600002	15546776				2021-06-18	
J	Bor-Seng-Shu, E; Teixeira, MJ; Hirsch, R; de Andrade, AF; Marino, R				Bor-Seng-Shu, E; Teixeira, MJ; Hirsch, R; de Andrade, AF; Marino, R			Transcranial doppler sonography in two patients who underwent decompressive craniectomy for traumatic brain swelling - Report of two cases	ARQUIVOS DE NEURO-PSIQUIATRIA			English	Article						brain swelling; cerebral hemodynamics; decompressive craniectomy; head injury; intracranial hypertension; transcranial Doppler sonography	CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; FLOW VELOCITY; HEAD-INJURY; ULTRASONOGRAPHY; MANAGEMENT; VASOSPASM; ULTRASOUND; DIAGNOSIS; CHILDREN	The role of decompressive craniectomy in the treatment of severe posttraumatic cerebral swelling remains quite a controversial issue. To the best of our knowledge, there is no study demonstrating the effect of decompressive craniectomy on cerebral blood flow (CBF) velocity by means of transcranial Doppler sonography (TCD). We present two patients who developed traumatic brain swelling and uncontrollable intracranial hypertension with coma and signs of transtentorial herniation. One patient underwent bifrontal, while the second, unilateral, frontotemporoparietal decompressive craniectomy with dural expansion. In both patients, TCD examinations were performed immediately before and after surgery to study the cerebral hemodynamic changes related to the operations. Pre and postoperative TCD examinations demonstrated a significant increase in blood flow velocity in the intracranial arteries in both subjects. In conclusion, our cases suggest that decompressive craniectomy with dural expansion may result in elevation of CBF velocity in patients with massive brain swelling. The increase in CBF velocity appears to occur not only in the decompressed hemisphere, but also on the opposite side.	Univ Sao Paulo, Sch Med, Hosp Clin, Div Neurosurg, Sao Paulo, Brazil	Bor-Seng-Shu, E (corresponding author), Rua Loefgreen 1272, BR-04040001 Sao Paulo, Brazil.	edsonshu@hotmail.com	Teixeira, Manoel J/E-3110-2012; BOR-SENG-SHU, EDSON/AAC-9762-2019; BOR-SENG-SHU, EDSON/H-7784-2013	BOR-SENG-SHU, EDSON/0000-0002-6713-8974; BOR-SENG-SHU, EDSON/0000-0002-6713-8974			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Babikian VL, 2000, J NEUROIMAGING, V10, P101, DOI 10.1111/jon2000102101; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Csokay A, 2002, SURG NEUROL, V57, P126, DOI 10.1016/S0090-3019(01)00686-3; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASSLER W, 1988, J NEUROSURG, V68, P745; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; KLINGELHOFER J, 1991, J NEUROSURG, V75, P752, DOI 10.3171/jns.1991.75.5.0752; KUNZE E, 1998, ACTA NEUROCHIR SUPP, V71, pS16; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Martin N A, 1994, Neurosurg Clin N Am, V5, P607; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; MUIZELAAR JP, 1984, ADV NEUROTRAUMATOLOG, P92; Munch E, 2000, NEUROSURGERY, V47, P315; Newell D W, 1994, Neurosurg Clin N Am, V5, P619; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RINALDI A, 1990, ACTA NEUROCHIR SUPP, V51, pS394; Schmidt B, 1997, STROKE, V28, P2465, DOI 10.1161/01.STR.28.12.2465; Sloan MA, 1996, NEUROSONOLOGY, P156; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Whitfield PC, 2001, NEUROSURGERY, V49, P225, DOI 10.1097/00006123-200107000-00042; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	34	19	19	0	1	ASSOC ARQUIVOS NEURO- PSIQUIATRIA	SAO PAULO SP	PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL	0004-282X	1678-4227		ARQ NEURO-PSIQUIAT	Arq. Neuro-Psiquiatr.	SEP	2004	62	3A					715	721		10.1590/S0004-282X2004000400028			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	853AV	WOS:000223799400028	15334237	DOAJ Gold			2021-06-18	
J	Kirsch, NL; Shenton, M; Spirl, E; Simpson, R; LoPresti, E; Schreckenghost, D				Kirsch, NL; Shenton, M; Spirl, E; Simpson, R; LoPresti, E; Schreckenghost, D			An assistive-technology intervention for verbose speech after traumatic brain injury - A single case study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assistive technology; cognition disorders; handheld computers; Internet; rehabilitation; traumatic brain injury	MEMORY AID; REHABILITATION; PARTICIPATION; INDIVIDUALS; IMPAIRMENTS; SYSTEMS; AMNESIA; NORMS; HOME	Objective: To assess an assistive-technology intervention for neurobehavioral change, coordinated with a Web-based data recording system. Participant: Male, mid-thirties, with a complex history, having verbose speech subsequent to traumatic brain injury. Design: BAB' single-case. Intervention and Measures: The intervention (B and B' trials) was a digital recording of the participant's voice, stating "be brief," delivered at fixed intervals by a personal digital assistant. Utterance start and stop times were monitored with a wireless, Web-enabled device and were recorded in a server-side database. Results: Utterance frequency did not change. However, the total utterance time was reduced during B trials, attributable to the reduced frequency of lengthier utterances. Conclusions: The target behavior was modified successfully. The participant adopted a specific cue-appropriate strategy. Since a variety of alternative response strategies may be required of a person, given a range of context-specific social practices and community settings, the importance of context-sensitive assistive technology cue repertoires is discussed.	Univ Michigan Hlth Syst, Div Rehabil Psychol & Neuropsychol, Ann Arbor, MI 48108 USA; Univ Michigan Hlth Syst, Adult Neurorehabil Day Program, Ann Arbor, MI 48108 USA; Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA; AT Sci, Pittsburgh, PA USA; Metrica Inc, Houston, TX USA	Kirsch, NL (corresponding author), Univ Michigan Hlth Syst, Div Rehabil Psychol & Neuropsychol, Ann Arbor, MI 48108 USA.	nlkirsch@umich.edu	Simpson, Richard/G-5683-2015; Shenton, Martha/V-8780-2019	Simpson, Richard/0000-0002-6306-9393; 			Bergman M M, 2000, Appl Neuropsychol, V7, P76, DOI 10.1207/S15324826AN0702_2; Bergman MM, 2002, J HEAD TRAUMA REHAB, V17, P431, DOI 10.1097/00001199-200210000-00005; BROWNTRIOLO D, 2001, ASSISTIVE TECHNOLOYG, P31; Buhler C, 2001, INT J HUM-COMPUT ST, V55, P645, DOI 10.1006/ijhc.2001.0489; CARMIENS, MAPS MEMORY AIDING P; Cole E, 1999, NEUROREHABILITATION, V12, P39; Cole E, 1994, NeuroRehabilitation, V4, P174, DOI 10.3233/NRE-1994-4308; Cole E., 1990, SIGCHI Bulletin, V22, P28; Cooper M, 1996, MED ENG PHYS, V18, P176, DOI 10.1016/1350-4533(95)00071-2; CROSSON B, 1998, J HEAD TRAUMA REHAB, V4, P46; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P906, DOI 10.1076/jcen.20.6.906.1104; FLANNERY M, 1997, USING AVAILABLE TECH, P517; Flannery M A, 1997, Pediatr Rehabil, V1, P239; FORTA B, 2003, MACROMEDIA COLDFUSIO; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GLISKY EL, 1992, J HEAD TRAUMA REHAB, V7, P1; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK, 1999, J CLIN EXP NEUROPSYC, V21, P571, DOI 10.1076/jcen.21.4.572.882; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; HOMER A, 1997, INSTANT HTML; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; KIME S, 1995, BRAIN INJURY, V10, P17; Kirsch NL, 2004, REHABIL PSYCHOL, V49, P200, DOI 10.1037/0090-5550.49.3.200; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; Kittel A, 2002, DISABIL REHABIL, V24, P106, DOI 10.1080/09638280110066785; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; LOPRESTI EF, 1997, ELECT VOCATIONAL PEO, P514; Maguire M, 2001, INT J HUM-COMPUT ST, V55, P587, DOI 10.1006/ijhc.2001.0503; MIHAILIDIS A, 2000, TECHNOLOGY DISABILIT, V12, P23; OSSORIO PG, 1997, ESSAYS CLIN TOPICS C, V2, P168; Pape TLB, 2002, DISABIL REHABIL, V24, P5, DOI 10.1080/09638280110066235; Phillips B, 1993, Assist Technol, V5, P36; Rialle V, 2002, TELEMED J E-HEALTH, V8, P395, DOI 10.1089/15305620260507530; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Scherer MJ, 1996, DISABIL REHABIL, V18, P439, DOI 10.3109/09638289609165907; Stickel MS, 2002, DISABIL REHABIL, V24, P115, DOI 10.1080/09638280110066794; Tang P, 2000, J TELEMED TELECARE, V6, P8, DOI 10.1258/1357633001933871; van den Broek MD, 2000, BRAIN INJURY, V14, P455; White GW, 2002, REHABIL PSYCHOL, V47, P438, DOI 10.1037//0090-5550.47.4.438; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; WILSON BA, 2002, REBABIL PSYCHOL, V44, P284; WILTIN P, 2000, BEGINNING JAVASCRIPT; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	51	19	19	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2004	19	5					366	377		10.1097/00001199-200409000-00002			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858UB	WOS:000224216300002	15597028				2021-06-18	
J	Wingrave, JM; Sribnick, EA; Wilford, GG; Matzelle, DD; Mou, JA; Ray, SK; Hogan, EL; Banik, NL				Wingrave, JM; Sribnick, EA; Wilford, GG; Matzelle, DD; Mou, JA; Ray, SK; Hogan, EL; Banik, NL			Higher calpastatin levels correlate with resistance to calpain-mediated proteolysis and neuronal apoptosis in juvenile rats after spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						calpain; calpastatin; juvenile; neuronal apoptosis; secondary injury; spinal cord injury	ACTIVATED NEUTRAL PROTEINASE; TRAUMATIC BRAIN-INJURY; CELL-DEATH; NERVOUS-SYSTEM; LYMPHOID-CELLS; IMPACT TRAUMA; EXPRESSION; LESION; DISEASE; DEGRADATION	While the average age for patients admitted with spinal cord injury is 32 years, patients under the age of 16 account for 5% of spinal cord injured persons. For these younger patients, an increased mortality up to 24 h post-injury has been reported, however, survivors may regain more function than their adult counterparts, suggesting that age may play a role in injury tolerance. While the use of growth factors as a therapy for spinal cord injury is well researched, the response of the developing cord to secondary injury has not been thoroughly investigated. Following spinal cord injury, Ca2+ influx can activate enzymes such as calpain, a Ca2+ -dependent protease, which plays a role in the pathogenesis of spinal cord injury in rats. The present investigation revealed that following spinal cord injury, calpain upregulation was significantly less (15.3%) in the 21-day-old rats than in either 45-day-old (70%) or 90-day-old (99.6%) rats, as shown by Western blot and in situ immunofluorescent studies. Expression of the endogenous calpain inhibitor, calpastatin, was significantly higher in juvenile rats than adult rats. juvenile rats with spinal cord injury also showed a reduced Bax:Bcl-2 ratio (4:1 vs. 6:1), reduced caspase-3 staining, reduced myelin loss (3% vs. 18%), and less neuronal DNA damage, as compared to older rats. These results suggest that increased calpastatin levels found in juvenile rats muted calpain activity and neuronal apoptosis, following spinal cord injury.	Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA	Banik, NL (corresponding author), 96 Jonathan Lucas St,Ste 309, Charleston, SC 29425 USA.	banikn1@musc.edu	Sribnick, Eric/AAH-6693-2020		NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA091460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045967, R01NS031622, R01NS038146, R01NS041088] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 91460] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 08716] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38146, NS 41088, NS 45967, NS 31622] Funding Source: Medline		Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; BALENTINE JD, 1978, LAB INVEST, V39, P236; Banik N L, 1984, Cent Nerv Syst Trauma, V1, P131; Bizat N, 2003, J NEUROSCI, V23, P5020; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; CHAKERES DW, 1987, AM J NEURORADIOL, V8, P5; CHAKRABARTI AK, 1988, J NEUROSCI RES, V20, P351, DOI 10.1002/jnr.490200309; CHAKRABARTI AK, 1993, DEV BRAIN RES, V71, P107, DOI 10.1016/0165-3806(93)90111-M; Cifu DX, 1999, J NEUROTRAUM, V16, P805, DOI 10.1089/neu.1999.16.805; Curt A, 1998, ARCH PHYS MED REHAB, V79, P81, DOI 10.1016/S0003-9993(98)90213-1; DESHPANDE RV, 1995, J NEUROSCI RES, V42, P259, DOI 10.1002/jnr.490420214; DESHPANDE RV, 1995, J BIOL CHEM, V270, P2497, DOI 10.1074/jbc.270.6.2497; DICKMAN CA, 1989, PEDIATR NEUROSCI, V15, P237, DOI 10.1159/000120476; DOHRMANN GJ, 1975, J TRAUMA, V15, P1003, DOI 10.1097/00005373-197511000-00011; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; ESCANDON E, 1994, J NEUROSCI, V14, P2054; Falci S, 1997, J NEUROTRAUM, V14, P875, DOI 10.1089/neu.1997.14.875; Ghirnikar RS, 2000, J NEUROSCI RES, V59, P63, DOI 10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.0.CO;2-W; Green JB, 1998, NEUROLOGY, V50, P1115, DOI 10.1212/WNL.50.4.1115; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HAJNAL JV, 1995, CLIN RADIOL, V50, P1, DOI 10.1016/S0009-9260(05)82956-3; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; HUBBARD DD, 1974, CLIN ORTHOP RELAT R, V100, P56; KALIL K, 1979, SCIENCE, V205, P1158, DOI 10.1126/science.472734; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kotlyar M, 2002, NEUROCHEM RES, V27, P1133, DOI 10.1023/A:1020969208033; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; LI ZH, 1995, BRAIN RES, V697, P112; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; NELSON E, 1977, ARCH NEUROL-CHICAGO, V34, P332, DOI 10.1001/archneur.1977.00500180026005; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Park Il-Kwon, 2002, J Vet Sci, V3, P239; Pollard ME, 2003, SPINE, V28, P33, DOI 10.1097/00007632-200301010-00009; Ray SK, 2000, BRAIN RES PROTOC, V5, P305, DOI 10.1016/S1385-299X(00)00027-1; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2001, ANN NY ACAD SCI, V939, P436; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sasaki S, 1978, Adv Neurol, V20, P423; SASAKI S, 1982, NEUROSURGERY, V10, P360, DOI 10.1227/00006123-198203000-00011; Schaecher K, 2002, J NEUROIMMUNOL, V129, P1, DOI 10.1016/S0165-5728(02)00142-X; Schellinger PD, 2001, SPINE, V26, P314, DOI 10.1097/00007632-200102010-00019; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Shields DC, 2000, J NEUROSCI RES, V61, P146; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; vonEuler M, 1996, EXP NEUROL, V137, P242, DOI 10.1006/exnr.1996.0023; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wingrave JM, 2004, EXP NEUROL, V187, P529, DOI 10.1016/j.expneurol.2004.02.001; Yamakawa H, 2001, NEUROL RES, V23, P522, DOI 10.1179/016164101101198776; YOUNG W, 1980, J NEUROSURG, V52, P473, DOI 10.3171/jns.1980.52.4.0473; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355	60	19	20	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1240	1254		10.1089/0897715041953894			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900012	15453993				2021-06-18	
J	Goethals, I; Audenaert, K; Jacobs, F; Lannoo, E; Van de Wiele, C; Ham, H; Otte, A; Oostra, K; Dierckx, R				Goethals, I; Audenaert, K; Jacobs, F; Lannoo, E; Van de Wiele, C; Ham, H; Otte, A; Oostra, K; Dierckx, R			Cognitive neuroactivation using SPECT and the Stroop Colored Word test in patients with diffuse brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral perfusion; cognitive activation; diffuse brain injury; single photon emission computed tomography	CLOSED-HEAD-INJURY; PREFRONTAL ACTIVATION PROBE; CEREBRAL-BLOOD-FLOW; NEUROPSYCHOLOGICAL RECOVERY; TECHNETIUM-99M-HMPAO SPECT; INTERFERENCE TASK; COUNTING STROOP; FRONTAL-LOBE; PERFORMANCE; VALIDATION	Psychomotor slowing in patients with diffuse brain injury frequently underlies impaired cognitive performance on neuropsychological tests, for example, the Stroop Colored Word test. The aim of the present study was to determine the neural basis associated with performance on the Stroop interference subtask in patients with diffuse brain injury. We hypothesized that patients would be slower than healthy controls, and that this would be associated with brain activations other than those seen in healthy subjects. Brain perfusion, using a split-dose activation paradigm with single photon emission tomography (SPECT) and the Stroop test, was assessed in 9 patients with diffuse brain injury. The Stroop interference score was calculated as a behavioral parameter, and functional imaging data were analyzed with statistical parametrical mapping (SPM99) to determine significant voxel-wise differences of activation between the control and the activation condition. Patients were impaired on the interference subtask of the Stroop test. Comparison of the SPECT data obtained during the activation condition with those obtained during the control condition by means of SPM showed significant activations in the left inferior parietal lobe, the right anterior cingulate extending into the right middle frontal gyrus and the right caudate, and the left posterior cingulate cortex. Patients with diffuse brain injury were slower than healthy controls on the interference subtask of the Stroop test, suggesting difficulty with resistance to distractions This finding was associated with activation effects in posterior (mainly parietal) brain areas in addition with activation of previously observed anterior (mainly anterior cingulate) brain regions.	Ghent Univ Hosp, Poliklin 7, Div Nucl Med, B-9000 Ghent, Belgium; Ghent Univ Hosp, Dept Psychiat & Med Psychol, B-9000 Ghent, Belgium; Ghent Univ Hosp, Ctr Locomotor & Neurol Rehab, B-9000 Ghent, Belgium	Goethals, I (corresponding author), Ghent Univ Hosp, Poliklin 7, Div Nucl Med, De Pintelaan 185, B-9000 Ghent, Belgium.	ingeborg.goethals@ugent.be	Oostra, Kristine/AAI-7317-2020	Otte, Andreas/0000-0002-6290-6786			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Asikainen I, 1999, EUR J NEUROL, V6, P179, DOI 10.1111/j.1468-1331.1999.tb00011.x; Audenaert K, 2001, NUCL MED COMMUN, V22, P135, DOI 10.1097/00006231-200102000-00004; Audenaert K, 2000, EUR J NUCL MED, V27, P1800, DOI 10.1007/s002590000351; BENCH CJ, 1993, NEUROPSYCHOLOGIA, V31, P907, DOI 10.1016/0028-3932(93)90147-R; Brown GG, 1999, J INT NEUROPSYCH SOC, V5, P308, DOI 10.1017/S1355617799544020; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Carter CS, 1995, NEUROIMAGE, V2, P264, DOI 10.1006/nimg.1995.1034; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DAMASIO AR, 1979, BRAIN LANG, V7, P74, DOI 10.1016/0093-934X(79)90007-5; DAVID AS, 1992, NEUROPSYCHOLOGIA, V30, P161, DOI 10.1016/0028-3932(92)90025-H; Derbyshire SWG, 1998, EXP BRAIN RES, V118, P52, DOI 10.1007/s002210050254; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DUNBAR K, 1984, J EXP PSYCHOL HUMAN, V10, P622, DOI 10.1037/0096-1523.10.5.622; FUSTER JM, 1997, PREFRONTAL CORTEX AN; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; George M S, 1994, Hum Brain Mapp, V1, P194, DOI 10.1002/hbm.460010305; Goethals I, 2002, J NUCL MED, V43, P1426; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Gruber SA, 2002, NEUROIMAGE, V16, P349, DOI 10.1006/nimg.2002.1089; Hammes J., 1971, STROOP KLEUR WOORDTE; ICHISE M, 1994, J NUCL MED, V35, P217; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lannoo E, 1997, PSYCHOL BELG, V37, P141; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P171; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LINDSAY DS, 1994, J EXP PSYCHOL HUMAN, V20, P219, DOI 10.1037/0096-1523.20.2.219; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; PRAYER L, 1993, ACTA RADIOL, V34, P593; ROPER SN, 1991, J NUCL MED, V32, P1684; SILVER SM, 1992, AM PSYCHIAT TXB NEUR, P363; Stamatakis EA, 1999, NEUROIMAGE, V10, P397, DOI 10.1006/nimg.1999.0477; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; TAYLOR SF, 1994, NEUROPSYCHOLOGIA, V32, P249, DOI 10.1016/0028-3932(94)90010-8; Taylor SF, 1997, NEUROIMAGE, V6, P81, DOI 10.1006/nimg.1997.0285; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Van Laere K, 2001, EUR J NUCL MED, V28, P873, DOI 10.1007/s002590100549; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VENDRELL P, 1995, NEUROPSYCHOLOGIA, V33, P341, DOI 10.1016/0028-3932(94)00116-7; Whalen PJ, 1998, BIOL PSYCHIAT, V44, P1219, DOI 10.1016/S0006-3223(98)00251-0	53	19	20	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2004	21	8					1059	1069		10.1089/0897715041651051			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	846AK	WOS:000223286800008	15319005				2021-06-18	
J	Metz, M; Kross, M; Abt, P; Bankey, P; Koniaris, LG				Metz, M; Kross, M; Abt, P; Bankey, P; Koniaris, LG			Tree stand falls: A persistent cause of sports injury	SOUTHERN MEDICAL JOURNAL			English	Article						deer tree stands; injury; public health	TRAUMA; EXPERIENCE	Objective: Tree stand falls are a well-known cause of hunting-related injury. Spine and brain injuries associated with these falls result in a significant incidence of permanent disability. Prior studies indicate that hunting tree stand injuries are largely preventable with the proper use of safety belts; however, compliance with safety belt use is variable. The purposes of this study were to determine 1) current compliance with safety belt use, 2) alterations in the spectrum of injury, and 3) causes of the falls. Methods: From January 1996 to October 2001, 51 tree stand-related injuries referred to either of two regional trauma centers or their region's medical examiner's office were reviewed. Data had been recorded in each hospital's trauma registry, and the registries were searched for falls. Medical records were reviewed for additional data retrospectively, with an emphasis on determining the use of safety belts, and mechanisms contributing to the fall. Results: Fifty-one cases of tree stand-associated injuries were identified. These injuries all occurred in men, with a mean age of 42.6 years (range, 22-69 years). Alcohol use was present in 10% of patients and in two of the three deaths. The mean Injury Severity Score was 18.1 (range, 2-75). The most common injuries were spinal fractures (51% of series) and extremity fractures (41% of series). Closed head injuries were identified in 24% and lung injuries were identified in 22% of patients. Abdominal visceral injuries were present in 8% and genitourinary injuries were present in 4%. Three patients died. In addition to injury from the fall, a significant number (six patients [12%]) had additional morbidity from exposure. Only two patients reported the use of a safety belt (4% of series). There were no cases of gunshot wounds in this review, either self-inflicted or hunter-related. The chief reasons reported for these falls were errors in placement that resulted in structural failure of the stand, or errors made while climbing into or out of the stand (50% of falls). Conclusion: Devastating spine and brain injuries continue to occur after falls from tree stands during recreational hunting when safety belts are not used. Our results suggest a continuing need for the education of hunters concerning safe tree stand hunting practices, including proper methods of stand placement, assessment of tree branch strength, avoidance of fatigue and alcohol, anticipation of firearm recoil, and proper methods of stand entrance and exit. Trauma prevention programs directed toward heightened public awareness of these injuries during hunting season are still needed.	Miami Univ, Sch Med, DeWitt Daughtry Dept Surg 310T, Miami, FL 33156 USA; Univ Rochester, Sch Med & Dent, Dept Surg, Rochester, NY USA; Washington Cty Hosp, Dept Surg, Hagerstown, MD USA	Koniaris, LG (corresponding author), Miami Univ, Sch Med, DeWitt Daughtry Dept Surg 310T, 1475 NW 12th St, Miami, FL 33156 USA.	lkoniaris@med.miami.edu	Abt, Peter/AAD-6856-2019				Brandes SB, 1999, J TRAUMA, V47, P643, DOI 10.1097/00005373-199910000-00007; *CDCP, 1989, MMWR-MORBID MORTAL W, V38, P697; Crites B M, 1998, J South Orthop Assoc, V7, P241; Gates RL, 2002, J TRAUMA, V53, P705, DOI 10.1097/00005373-200210000-00014; Goodacre S, 1999, J TRAUMA, V46, P1055, DOI 10.1097/00005373-199906000-00014; Kennedy RL, 2001, J TRAUMA, V51, P717, DOI 10.1097/00005373-200110000-00016; Lawrence D W, 1996, J La State Med Soc, V148, P77; Morey AF, 2001, J TRAUMA, V51, P683, DOI 10.1097/00005373-200110000-00010; Price C, 1994, J Okla State Med Assoc, V87, P270; Thomas B, 1997, J TRAUMA, V42, P384, DOI 10.1097/00005373-199703000-00004; URQUHART CK, 1991, SOUTHERN MED J, V84, P686, DOI 10.1097/00007611-199106000-00003; Wilson S, 2001, INJURY, V32, P525, DOI 10.1016/S0020-1383(00)00199-6	12	19	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0038-4348	1541-8243		SOUTH MED J	South.Med.J.	AUG	2004	97	8					715	719		10.1097/00007611-200408000-00003			5	Medicine, General & Internal	General & Internal Medicine	847BB	WOS:000223362600003	15352662				2021-06-18	
J	Corbo, J; Tripathi, P				Corbo, J; Tripathi, P			Delayed presentation of diffuse axonal injury: A case report	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; FAT-EMBOLISM SYNDROME; HEAD-INJURY; MR; CT	This report highlights a case of delayed onset of diffuse axonal Injury in the apparent absence of direct head trauma. This case questions the appropriate observation period for patients with signs of diffuse axonal injury presenting after a high-velocity crash.	Albert Einstein Coll Med, Dept Emergency Med, Jacobi Med Ctr, Bronx, NY 10462 USA	Corbo, J (corresponding author), Albert Einstein Coll Med, Dept Emergency Med, Jacobi Med Ctr, 1400 Pelham Pkwy S,Room 1W20, Bronx, NY 10462 USA.	jillcorbo@aol.com					Georgopoulos D, 2003, CHEST, V123, P982, DOI 10.1378/chest.123.4.982; Gieron MA, 1998, PEDIATR NEUROL, V19, P382, DOI 10.1016/S0887-8994(98)00072-1; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Johnson MJ, 1996, ORTHOPEDICS, V19, P41; KAMENAR E, 1980, STROKE, V11, P477, DOI 10.1161/01.STR.11.5.477; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mullins MD, 2000, ARCH INTERN MED, V160, P293, DOI 10.1001/archinte.160.3.293; Neumar RW, 2002, ANN EMERG MED, V39, P342, DOI 10.1067/mem.2002.122007; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	11	19	19	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUL	2004	44	1					57	60		10.1016/j.annemergmed.2003.11.010			4	Emergency Medicine	Emergency Medicine	835DO	WOS:000222460700008	15226709				2021-06-18	
J	Fee, DB; Sewell, DL; Andresen, K; Jacques, TJ; Piaskowski, S; Barger, BA; Hart, MN; Fabry, Z				Fee, DB; Sewell, DL; Andresen, K; Jacques, TJ; Piaskowski, S; Barger, BA; Hart, MN; Fabry, Z			Traumatic brain injury increases TGF beta RII expression on endothelial cells	BRAIN RESEARCH			English	Article						traumatic cerebral injury; TGF beta receptor; SMAD protein	CENTRAL-NERVOUS-SYSTEM; CEREBRAL MICROVESSELS; SIGNAL-TRANSDUCTION; IN-VITRO; RECEPTORS; ACTIVATION; PROTEINS; CULTURES	Transforming growth factor beta (TGFbeta) modulates a variety of growth related functions following traumatic injury. The cellular response to TGFbeta is predominantly mediated through TGFbeta receptor I (TGFbetaRI) and receptor II (TGFbetaRII) on the cell surface and SMAD proteins intracellularly. We investigated the expression of TGFbeta receptors in the acute and chronic phases of a traumatic cerebral injury (TCI) by immunohistochemistry and in cultures of murine brain microvascular endothelial (EN) cells using cytofluorimetry. Here, we report that TGFbetaRII expression significantly increases on brain endothelial cells in the chronic phase of TCI. SMAD3 and SMAD4 protein expression were also upregulated suggesting the activation of TGFbeta receptor intracellular signaling. When TGFbetaRI and TGFbetaRII expression was studied in in vitro cultures of murine brain microvessel EN cells, TGFbetaRII showed increased expression on proliferating cells that are incorporating BrdU. These data show a differential expression of TGFbetaRI and TGFbetaRII on brain microvessel EN cells in the acute and chronic phases of TO that might be associated with EN proliferation following injury. (C) 2004 Elsevier B.V. All rights reserved.	Univ Wisconsin, Hosp & Clin, Dept Pathol, Madison, WI 53706 USA; Univ Wisconsin, Hosp & Clin, Dept Neurol, Madison, WI USA; Univ Iowa, Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA	Fabry, Z (corresponding author), Univ Wisconsin, Hosp & Clin, Dept Pathol, 1300 Univ Ave,6130 MSC, Madison, WI 53706 USA.	zfabry@facstaff.wisc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037570] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570] Funding Source: NIH RePORTER		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1972, LAB INVEST, V26, P376; CANCILLA PA, 1979, LAB INVEST, V40, P74; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; Cowin AJ, 2001, EUR J DERMATOL, V11, P424; De Groot CJA, 1999, J NEUROPATH EXP NEUR, V58, P174, DOI 10.1097/00005072-199902000-00007; DeBault L E, 1980, Adv Exp Med Biol, V131, P69; DEBAULT LE, 1979, IN VITRO CELL DEV B, V15, P473; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DOREDUFFY P, 1994, MOL CHEM NEUROPATHOL, V22, P161, DOI 10.1007/BF03160103; FABRY Z, 1995, J IMMUNOL, V155, P325; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Grammas P, 2002, AM J PATHOL, V160, P1583, DOI 10.1016/S0002-9440(10)61105-4; HART MN, 1987, J NEUROPATH EXP NEUR, V46, P141, DOI 10.1097/00005072-198703000-00003; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; KAPLAN MM, 1972, GASTROENTEROLOGY, V62, P452; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MOORE SA, 1988, AM J PHYSIOL, V254, P37; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Ngo M, 2001, PLAST RECONSTR SURG, V108, P1260, DOI 10.1097/00006534-200110000-00025; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; SAHAGUN G, 1989, AM J PATHOL, V134, P1227; Stark B, 2001, BRAIN RES, V913, P47, DOI 10.1016/S0006-8993(01)02757-3; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Vivien D, 1998, J NEUROCHEM, V70, P2296; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	33	19	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 25	2004	1012	1-2					52	59		10.1016/j.brainres.2004.03.028			8	Neurosciences	Neurosciences & Neurology	829QA	WOS:000222063500006	15158160				2021-06-18	
J	Kozlowski, DA; Nahed, BV; Hovda, DA; Lee, SM				Kozlowski, DA; Nahed, BV; Hovda, DA; Lee, SM			Paradoxical effects of cortical impact injury on environmentally enriched rats	JOURNAL OF NEUROTRAUMA			English	Article						contusion; enriched environment; motor coordination; rats; traumatic brain injury	FACTOR MESSENGER-RNA; CEREBRAL-CORTEX; SPATIAL MEMORY; BRAIN-INJURY; LESIONS; HIPPOCAMPUS; COMPLEXITY; RECOVERY; EXPRESSION; INCREASES	Animals housed in an enriched environment develop thicker cortices, with increased numbers of dendrites, synapses, blood vessels, and glial cells. This study examines the responses of adult rats, developmentally reared in an enriched environment, to traumatic brain injury. Rats were placed in an enriched environment for 15 days, starting on postnatal day 21. Following enrichment, they were placed in standard vivarium conditions until adulthood. At 3 months of age, enriched and age-matched control rats received a mild unilateral controlled cortical impact and were allowed to recover for 41 days. During this time, they were examined for motor coordination deficits and for preferences in forelimb use. Results demonstrate that enriched animals had a larger contusion cavity and a greater initial deficit in forelimb use. However, this deficit quickly diminished in comparison to that seen in non-enriched injured rats. The deficit in motor coordination recovered more quickly in enriched rats, 1 week sooner than in controls. These data suggest that the response of enriched animals to brain injury results in more marked neurodegeneration and acute behavioral dysfunction, with a higher capacity for compensation and recovery.	Univ Calif Los Angeles, Sch Med, Brain Injury Res Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Surg Neurosurg, Los Angeles, CA USA	Kozlowski, DA (corresponding author), De Paul Univ, Dept Biol Sci, 2325 N Clifton, Chicago, IL 60614 USA.	dkozlows@depaul.edu	Nahed, Brian/E-4239-2014	Nahed, Brian/0000-0001-8537-106X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS37303] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER		Belayev A, 2003, BRAIN RES, V964, P121, DOI 10.1016/S0006-8993(02)04089-1; DALRYMPLEALFORD JC, 1984, BEHAV NEUROSCI, V98, P23, DOI 10.1037/0735-7044.98.1.23; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; FINGER S, 1978, DEV PSYCHOBIOL, V11, P5, DOI 10.1002/dev.420110105; Galani R, 1997, NEUROBIOL LEARN MEM, V67, P43, DOI 10.1006/nlme.1996.3745; GONZALEZLIMA F, 1994, DEV PSYCHOBIOL, V27, P343, DOI 10.1002/dev.420270603; Greenough W. T., 1992, Brain Dysfunction, V5, P129; Hebb DO., 1949, ORG BEHAV NEUROPSYCH; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; HOVDA DA, 1996, NEUROTRAUMA, P1459; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; STEIN DG, 1983, BEHAV NEURAL BIOL, V37, P185, DOI 10.1016/S0163-1047(83)91216-5; STUMMER W, 1995, STROKE, V26, P138; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; WILL B, 1992, ADV EXP MED BIOL, V325, P79; Young D, 1999, NAT MED, V5, P448; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3	28	19	20	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					513	519		10.1089/089771504774129856			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900003	15165360				2021-06-18	
J	Phillips, VL; Greenspan, AI; Stringer, AY; Stroble, AK; Lehtonen, S				Phillips, VL; Greenspan, AI; Stringer, AY; Stroble, AK; Lehtonen, S			Severity of injury and service utilization following traumatic brain injury - The first 3 months	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						model systems; service utilization; TBI	REHABILITATION; CARE	Objective: To describe the madical and rehabilitation service use of model systems by brain injured participants 1 to 3 months postdischarge from inpatient rehabilitation. Design: Prospective follow-up study. Setting: Georgis Model Brain Injury System (GAMBIS). Participants: Seventy- three GAMBIS subjects consnting to participate in the utilization substudy. Main Outcome Measures: Receipt of services and intensity of service use. Analysis: Chi-square analysis of receipt of services by severity of injury. Results: The likelihood of service use did not vary with severity of injury. Data suggest that intensity of service use was a function of injury severity. Conclusions: Subjects with mild and moderate injuries were as likely to use a range of medical and rehabilitation services during the 3-month discharge period as those with severe injuries. Traditional rehabilitation services, such as physical therapy, were far more likely to be used, than nontradional services such as psychological counseling, in spite of the high level of cognitive and social disability associated with traumatic brain injury.	Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA	Phillips, VL (corresponding author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.	vpphiloi@sph.emory.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A 980028] Funding Source: Medline		Batavia AI, 2001, ARCH PHYS MED REHAB, V82, P546, DOI 10.1053/apmr.2001.20829; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; CHESTNUT RM, 1999, HEAD TRAUMA REHABIL, V14, P277; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Duan N, 1983, J EC BUSINESS STATIS, V1, P115, DOI [10.1080/07350015.1983.10509330, DOI 10.2307/1391852]; Greenspan A I, 1989, Md Med J, V38, P239; Greenspan AI, 2000, BRAIN INJURY, V14, P417; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wheatley B, 1997, HEALTH CARE MANAGE R, V22, P25	17	19	19	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2004	19	3					217	225		10.1097/00001199-200405000-00003			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826JB	WOS:000221824300003	15247844				2021-06-18	
J	Sawauchi, S; Marmarou, A; Beaumont, A; Signoretti, S; Fukui, S				Sawauchi, S; Marmarou, A; Beaumont, A; Signoretti, S; Fukui, S			Acute subdural hematoma associated with diffuse brain injury and hypoxemia in the rat: Effect of surgical evacuation of the hematoma	JOURNAL OF NEUROTRAUMA			English	Article						acute subdural hematoma; brain edema; cerebral blood flow; diffuse brain injury; hypoxemia; intracranial pressure; surgical evacuation	SEVERE HEAD-INJURY; COMATOSE PATIENTS; COMPUTERIZED-TOMOGRAPHY; MANAGEMENT; MORTALITY; VOLUME; MODEL	The aim of this study was to assess the effect of rapid or delayed surgical evacuation on the physiological consequence and brain edema formation in a rat model of acute subdural hematoma (SDH) coupled with either diffuse brain injury (DBI) or hypoxemia. The SDH was made by an autologous blood injection, while DBI was induced using the impact acceleration model (mild, 450 g/1 m; severe, 450 g/2 m). Physiological parameters measured included intracranial pressure (ICP), mean arterial blood pressure (MABP), cerebral blood flow (CBF), and brain tissue water content. At I h (rapid evacuation) or 4 h (delayed evacuation) after the SDH induction, surgical evacuation following a craniotomy was performed using saline irrigation and forceps. The study consisted of three different series, including 400 muL of SDH alone (Series 1), SDH400 + mild DBI (Series 2), and SDH300 + severe DBI + 20 min hypoxemia (Series 3). The hypoxemia was added in Group 3 to produce a steadily increasing ICP. In Series 1 and 2, all rats were randomized into the three following groups: non-, rapid, and delayed evacuation; Series 3 had two groups: non- and rapid evacuation. In Series 1, the surgical evacuation showed no beneficial effects on the brain edema formation assessed at 5 h post-injury. In Series 2, the rapid, but not delayed, evacuation significantly reduced both the increased ICP level and brain water content. The additional insult of hypoxemia (Series 3) resulted in a progressive ICP elevation, persistently depressed CBF, and severe brain swelling. Under this situation, the rapid evacuation exacerbated brain edema. These results have clinical implications for the management of severe traumatic SDH, especially its operative indication and timing.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980508, Richmond, VA 23298 USA.	marmarou@abic.vcu.edu	Signoretti, stefano/AAL-5631-2020; Beaumont, Andrew/AAJ-7457-2020	Signoretti, stefano/0000-0002-8086-1622; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R56NS019235, R01NS019235, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-19235, NS-12587] Funding Source: Medline		CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CROCE MA, 1994, J TRAUMA, V36, P820, DOI 10.1097/00005373-199406000-00012; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412	16	19	20	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					563	573		10.1089/089771504774129892			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900007	15165364				2021-06-18	
J	Kinuya, K; Kakuda, K; Nobata, K; Sakai, S; Yamamoto, K; Itoh, S; Kinuya, S				Kinuya, K; Kakuda, K; Nobata, K; Sakai, S; Yamamoto, K; Itoh, S; Kinuya, S			Role of brain perfusion single-photon emission tomography in traumatic head injury	NUCLEAR MEDICINE COMMUNICATIONS			English	Article						traumatic head injury; X-ray computerized tomography; single-photon emission tomography; magnetic resonance imaging; Tc-99-HMPAO	CEREBRAL-BLOOD-FLOW; TECHNETIUM-99M-HMPAO SPECT; MILD; CONSCIOUSNESS; CT	This investigation examined the role of brain perfusion single-photon emission tomography (SPET) in traumatic head injury in 35 patients. The results were compared with those of X-ray computerized tomography (CT) and magnetic resonance imaging (MRI). CT and MRI detected brain contusions in seven patients, subarachnoid haemorrhage in one patient and both in nine patients. In 16 of the 17 subjects (94%), SPET with technetium-99m-hexamethylpropyleneamine oxime (Tc-99m-HMPAO) revealed CT/MRI-negative abnormalities, such as hypoperfusion in the contre-coup region, frontal hypoperfusion related to personality change and cerebellar hypoperfusion associated with vertigo. In two patients presenting with diffuse axonal injury in the brainstem, hypoperfusion in the frontal cortex on the affected side was observed on SPET. SPET demonstrated hypoperfusion in the adjacent cortex, with no abnormality on either CT or MRI, in six of seven patients exhibiting acute epidural haematoma. SPET failed to provide additional information in two of five patients with acute subdural haematoma and in one of two patients displaying chronic subdural haematoma. In four of nine patients with post-traumatic amnesia, SPET detected hypoperfusion in the temporal lobe, with no abnormality on either CT or MRI. In five of eight patients with vertigo, SPET detected hypoperfusion in the morphologically normal cerebellum. In seven cases involving personality change, frontal hypoperfusion was observed in four; moreover, a markedly non-homogeneous pattern was evident in the remaining three. Overall, SPET afforded additional information in 26 patients (74%). CT possesses an advantage with respect to the detection of haemorrhagic lesions. MRI provides more precise information regarding contusions and axonal injury. Frequently, SPET may tie the only examination to reveal perfusion abnormalities which are related to symptoms in the absence of other objective findings, such as post-traumatic amnesia, vertigo or personality change. (C) 2004 Lippincott Williams Wilkins.	Tonami Gen Hosp, Dept Nucl Med, Tonami 9391395, Japan; Tonami Gen Hosp, Dept Radiol, Tonami 9391395, Japan; Tonami Gen Hosp, Dept Neurosurg, Tonami 9391395, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Biotracer Med, Kanazawa, Ishikawa 920, Japan	Kinuya, K (corresponding author), Tonami Gen Hosp, Dept Nucl Med, Shintomi Cho 1-61, Tonami 9391395, Japan.	dinky@dg.dion.ne.jp					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cantagallo A, 1999, BRAIN INJURY, V13, P219, DOI 10.1080/026990599121593; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; Chang CC, 1998, EUR J NUCL MED, V25, P1330, DOI 10.1007/s002590050303; DellaCorte F, 1997, ACTA NEUROCHIR, V139, P636; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; Goshen E, 1996, NUCL MED COMMUN, V17, P418, DOI 10.1097/00006231-199605000-00011; GRAY BG, 1992, J NUCL MED, V33, P52; ICHISE M, 1994, J NUCL MED, V35, P217; ISAKA Y, 1992, J NUCL MED, V33, P246; Kesler SR, 2000, BRAIN INJURY, V14, P851; MAESHIMA S, 1995, J NEUROL, V242, P613, DOI 10.1007/BF00866909; Mamelak M, 2000, NEUROPSY NEUROPSY BE, V13, P125; MATSUDA H, 1992, EUR J NUCL MED, V19, P195; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; PROVENZALE J, 1992, J NUCL MED, V33, P248; Shiina G, 1998, AM J NEURORADIOL, V19, P297; SILVERMAN IE, 1993, J NUCL MED, V34, P1447; TIKOFSKY RS, 1994, J NUCL MED, V35, P227; Venneri A, 1998, BRAIN INJURY, V12, P605, DOI 10.1080/026990598122368	22	19	20	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0143-3636	1473-5628		NUCL MED COMMUN	Nucl. Med. Commun.	APR	2004	25	4					333	337		10.1097/00006231-200404000-00004			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	815ZR	WOS:000221080700004	15097806				2021-06-18	
J	Morgan, A; Ward, E; Murdoch, B				Morgan, A; Ward, E; Murdoch, B			Clinical progression and outcome of dysphagia following paediatric traumatic brain injury: a prospective study	BRAIN INJURY			English	Article							HEAD-INJURY; REHABILITATION	Objectives : To provide a preliminary clinical profile of the resolution and outcomes of oral-motor impairment and swallowing function in a group of paediatric dysphagia patients post-traumatic brain injury (TBI). To document the level of cognitive impairment parallel to the return to oral intake, and to investigate the correlation between the resolution of impaired swallow function versus the resolution of oral-motor impairment and cognitive impairment. Participants : Thirteen children admitted to an acute care setting for TBI. Main outcome measures : A series of oral-motor (Verbal Motor Production Assessment for Children, Frenchay Dysarthria Assessment, Schedule for Oral Motor Assessment) and swallowing (Paramatta Hospital's Assessment for Dysphagia) assessments, an outcome measure for swallowing (Royal Brisbane Hospital's Outcome Measure for Swallowing), and a cognitive rating scale (Rancho Level of Cognitive Functioning Scale). Results : Across the patient group, oral-motor deficits resolved to normal status between 3 and 11 weeks post-referral (and at an average of 12 weeks post-injury) and swallowing function and resolution to normal diet status were achieved by 3-11 weeks post-referral (and at an average of 12 weeks post-injury). The resolution of dysphagia and the resolution of oral-motor impairment and cognitive impairment were all highly correlated. Conclusion : The provision of a preliminary profile of oral-motor functioning and dysphagia resolution, and data on the linear relationship between swallowing impairment and cognition, will provide baseline information on the course of rehabilitation of dysphagia in the paediatric population post-TBI. Such data will contribute to more informed service provision and rehabilitation planning for paediatric patients post-TBI.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld, Australia	Morgan, A (corresponding author), Inst Child Hlth, Dev Cognit Neurosci Sci, 30 Guilford St, London WC1N, England.		Murdoch, Bruce E/C-1397-2012; Ward, Elizabeth/F-9652-2010; Morgan, Angela/J-5235-2017	Ward, Elizabeth/0000-0002-2680-8978; Morgan, Angela/0000-0003-1147-7405			Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; Christensen J R, 1989, Dysphagia, V3, P131, DOI 10.1007/BF02407131; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Eker C, 2000, BRAIN INJURY, V14, P605; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Gisel E G, 1998, Int J Orofacial Myology, V24, P27; Gisel EG, 1996, DYSPHAGIA, V11, P48, DOI 10.1007/BF00385800; Gisel Erika G., 1994, Dysphagia, V9, P180, DOI 10.1007/BF00341263; Hagen C., 1972, LEVELS COGNITIVE FUN; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; HANSWORTH DS, 1997, J NEUROSCIENCE NURSI, V29, P156; Hayden D.A., 1999, VERBAL MOTOR PRODUCT; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mcilvoy L, 2001, J Neurosci Nurs, V33, P72; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Morgan A, 2003, J HEAD TRAUMA REHAB, V18, P239, DOI 10.1097/00001199-200305000-00002; Morgan AT, 2001, ASIA PACIFIC J SPEEC, V6, P9; Morris S E, 1989, Dysphagia, V3, P135, DOI 10.1007/BF02407132; REILLY S, 1995, DYSPHAGIA, V10, P177, DOI 10.1007/BF00260975; Rowe LA, 1999, J HEAD TRAUMA REHAB, V14, P497, DOI 10.1097/00001199-199910000-00010; STARR S, 1998, FEEDING ASSESSMENT R, V2; Ward E, 1999, ASIA PACIFIC J SPEEC, V4, P109, DOI DOI 10.1179/136132899805577051; *WESTM HOSP COMM H, 1998, PARR HOSP ASS DYSPH; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; Ylvisaker M, 1989, J HEAD TRAUMA REHAB, V4, P51; YLVISAKER M, 1986, MANAGEMENT HEAD INJU; YORKSTON KM, 1989, J HEAD TRAUMA REHAB, V4, P52	30	19	20	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2004	18	4					359	376		10.1080/02699050310001617424			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	765VB	WOS:000188304100003	14742150				2021-06-18	
J	Wartenberg, KE; Patsalides, A; Yepes, MS				Wartenberg, KE; Patsalides, A; Yepes, MS			Is magnetic resonance spectroscopy superior to conventional diagnostic tools in hypoxic-ischemic encephalopathy?	JOURNAL OF NEUROIMAGING			English	Article						hypoxic-ischemic encephalopathy; MR spectroscopy; hypoxic brain injury; global ischemia; prognosis in hypoxic coma	PERSISTENT VEGETATIVE STATE; TRAUMATIC BRAIN-INJURY; EVOKED-POTENTIALS; MEDICAL ASPECTS; COMA; MR; INVOLVEMENT; PREDICTION; MECHANISMS; LESIONS	Anoxic brain injury carries a poor prognosis. Therefore, a diagnostic tool sensitive enough to predict its outcome is needed. The authors describe the case of a 51-year-old woman who suffered cardiorespiratory arrest, Electroencephalography, somatosensory evoked potentials, and magnetic resonance imaging did not prove to be useful in establishing a definitive prognosis. Magnetic resonance spectroscopy demonstrated the presence of significant neuronal loss in the cortex and cerebellum and was the only diagnostic procedure closely associated with this patient's prognosis.	Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ Hosp, Dept Neuroradiol, Washington, DC 20007 USA	Yepes, MS (corresponding author), Georgetown Univ, Dept Neurol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	yepesm@aol.com					Arbelaez A, 1999, AM J NEURORADIOL, V20, P999; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Baba Y, 1998, J COMPUT ASSIST TOMO, V22, P976, DOI 10.1097/00004728-199811000-00024; Centonze D, 2001, PROG NEUROBIOL, V63, P687, DOI 10.1016/S0301-0082(00)00037-X; Falini A, 1998, AM J NEURORADIOL, V19, P648; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Frucht S, 2000, MOVEMENT DISORD, V15, P1; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Genovese E, 2000, AM J NEURORADIOL, V21, P845; Guerit JM, 2000, ACTA NEUROL BELG, V100, P229; Hossmann KA, 1999, ADV EXP MED BIOL, V474, P155; Malisza KL, 1998, BIOCHEM CELL BIOL, V76, P487, DOI 10.1139/bcb-76-2-3-487; Neumar RW, 2000, ANN EMERG MED, V36, P483, DOI 10.1067/mem.2000.110995; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; Rupright J, 1996, ARCH PHYS MED REHAB, V77, P1205, DOI 10.1016/S0003-9993(96)90150-1; SAFAR P, 1978, CRIT CARE MED, V6, P215, DOI 10.1097/00003246-197807000-00003; TAKAHASHI S, 1993, RADIOLOGY, V189, P449, DOI 10.1148/radiology.189.2.8210374; WEISSENBORN K, 1995, METAB BRAIN DIS, V10, P219, DOI 10.1007/BF02081027; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zandbergen EGJ, 2000, J CLIN NEUROPHYSIOL, V17, P498, DOI 10.1097/00004691-200009000-00008; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076	22	19	19	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284	1552-6569		J NEUROIMAGING	J. Neuroimaging	APR	2004	14	2					180	186		10.1177/1051228403259514			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	876DA	WOS:000225474900016	15095566				2021-06-18	
J	Dixon, MR; Falcomata, TS				Dixon, MR; Falcomata, TS			Preference for progressive delays and concurrent physical therapy exercise in an adult with acquired brain injury	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article						brain injury; impulsivity; physical therapy; self-control	SELF-CONTROL; REINFORCEMENT; CHILDREN	The purpose of this study was to increase self-control and engagement in a physical therapy task (head holding) for a man with acquired traumatic brain injury. Once impulsivity was observed (i.e., repeated impulsive choices), an experimental condition was introduced that consisted of choices between a small immediate reinforcer, a large fixed-delay reinforcer, and a large progressive-delay reinforcer. The participant showed a preference for the progressive-delay option, even when the duration of the delay exceeded that of the fixed delay. The results have implications for establishing optimal choice making and teaching life-enhancing skills.	So Illinois Univ, Behav Analtsis & Therapy Program, Carbondale, IL 62901 USA	Dixon, MR (corresponding author), So Illinois Univ, Behav Analtsis & Therapy Program, Carbondale, IL 62901 USA.	mdixon@siu.edu					DeLeon IG, 1996, J APPL BEHAV ANAL, V29, P519, DOI 10.1901/jaba.1996.29-519; Dixon MR, 2003, J APPL BEHAV ANAL, V36, P371, DOI 10.1901/jaba.2003.36-371; Dixon MR, 2001, J APPL BEHAV ANAL, V34, P491, DOI 10.1901/jaba.2001.34-491; Dixon MR, 2000, J APPL BEHAV ANAL, V33, P611, DOI 10.1901/jaba.2000.33-611; Stromer R, 2000, J APPL BEHAV ANAL, V33, P359, DOI 10.1901/jaba.2000.33-359; Vollmer TR, 1999, J APPL BEHAV ANAL, V32, P451, DOI 10.1901/jaba.1999.32-451	6	19	19	0	4	JOURNAL APPL BEHAV ANAL	LAWRENCE	DEPT HUMAN DEVELOPMENT, UNIV KANSAS, LAWRENCE, KS 66045 USA	0021-8855			J APPL BEHAV ANAL	J. Appl. Behav. Anal.	SPR	2004	37	1					101	105		10.1901/jaba.2004.37-101			5	Psychology, Clinical	Psychology	808CG	WOS:000220546600013	15154223	Bronze, Green Published			2021-06-18	
J	Wang, Q; Wang, Z; Zhu, PF; Jiang, JX				Wang, Q; Wang, Z; Zhu, PF; Jiang, JX			Alterations of myelin basic protein and ultrastructure in the limbic system at the early stage of trauma-related stress disorder in dogs	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						myelin basic protein (MBP); ultrastructure; trauma; stress disorder; cerebrospinal fluid (CSF); limbic system	MISSILE EXTREMITY IMPACT; PRESSURE WAVE INJURIES; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; PIGS; EXPRESSION; MARKERS; LIGHT	Background: The secondary injury and related complications after trauma are still the focus of trauma research. However, whether the remote effects on the central nervous system could be induced by high-energy missile extremity impact remains unclear. Also, the possible biomarker for brain damage in traumatic stress disorder has not been determined. Methods: Forty-two healthy adult dogs were divided into three groups: the control group (n = 12), the high-speed trauma group (n = 15), and the low-speed trauma group (n = 15). Bilateral thighs of dogs were wounded with a smoothbore 6.2-mm rifle at a speed of 1,368 m/s (1.03-g steel bullet) for the high-speed trauma group and 625 m/s for the low-speed trauma group. The expression of myelin basic protein (MBP) in cerebrospinal fluid (CSF), hypothalamus and hippocampus of the limbic system, and temporoparietal cortex was investigated by enzyme-linked immunosorbent assay and dot-blot analysis. Also, the ultrastructure of the above areas was observed with light and electron microscopy. Results: Neuronal degeneration and nerve fiber demyelination were seen in the hypothalamus and hippocampus in the high-speed trauma group at 8 hours after impact. The MBP level was markedly increased in the CSF (p < 0.01) in the two trauma groups, in the hypothalamus of the low-speed trauma group (p < 0.05), and in both the hypothalamus and the hippocampus of the high-speed trauma group (p < 0.01). The expression of MBP mRNA was also significantly enhanced in these areas at the same time. The increase of MBP content in the CSF was positively correlated with the elevation of MBP concentration in the hypothalamus and hippocampus. Conclusion: The hypothalamus and hippocampus of the limbic system in the central nervous system are vulnerable to damage after high-energy missile extremity impact, indicating that it might be one of the important pathologic bases involved in the development of trauma-related complications. Meanwhile, the MBP level in the CSF may be a sensitive biological indicator for brain damage at the early stage of trauma-related stress disorder.	Third Mil Med Univ, Daping Hosp, Dept 4, Inst Surg Res, Chongqing 400042, Peoples R China	Wang, Q (corresponding author), Third Mil Med Univ, Daping Hosp, Dept 4, Inst Surg Res, Chongqing 400042, Peoples R China.	wqs832001@sina.com					Danzer SC, 2002, J NEUROSCI, V22, P9754; de Vries J, 2001, J NEUROL NEUROSUR PS, V71, P671, DOI 10.1136/jnnp.71.5.671; Fackler ML, 1996, ANN EMERG MED, V28, P194, DOI 10.1016/S0196-0644(96)70062-8; Gustafsson U., 1997, Annals Academy of Medicine Singapore, V26, P22; GUSTAFSSON U, 1988, ANN ACAD MED SINGAP, V28, P3; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Hull AM, 2002, BRIT J PSYCHIAT, V181, P102; Jin Y, 2002, EXP NEUROL, V177, P265, DOI 10.1006/exnr.2002.7980; Lanius RA, 2001, AM J PSYCHIAT, V158, P1920, DOI 10.1176/appi.ajp.158.11.1920; Lathe R, 2001, J ENDOCRINOL, V169, P205, DOI 10.1677/joe.0.1690205; Marshall RD, 2002, PSYCHIAT RES, V110, P219, DOI 10.1016/S0165-1781(02)00126-9; Massaro AR, 1998, MULT SCLER J, V4, P1; Michalowska-Wender G, 2001, FOLIA NEUROPATHOL, V39, P1; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Ohta M, 2000, CLIN CHEM, V46, P1326; Petrovich GD, 2001, BRAIN RES REV, V38, P247, DOI 10.1016/S0165-0173(01)00080-7; Reindl M, 1999, BRAIN, V122, P2047, DOI 10.1093/brain/122.11.2047; Sarchielli P, 2002, J NEUROIMMUNOL, V132, P180, DOI 10.1016/S0165-5728(02)00319-3; SCHANTZ B, 1982, ACTA CHIR SCAND, P159; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1990, J TRAUMA, V30, P281, DOI 10.1097/00005373-199003000-00006; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Wang JZ, 1997, RARE METAL MAT ENG, V26, P54; Wrathall JR, 1998, J NEUROSCI, V18, P8780; Xiang XY, 2001, J VIROL METHODS, V94, P129, DOI 10.1016/S0166-0934(01)00284-1; Zhang XH, 2002, NEURON, V36, P675, DOI 10.1016/S0896-6273(02)01023-1	28	19	22	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2004	56	3					604	610		10.1097/01.TA.0000058122.57737.0E			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	808CM	WOS:000220547200029	15128132				2021-06-18	
J	Mitchell, P; Tseng, M; Mendelow, AD				Mitchell, P; Tseng, M; Mendelow, AD			Decompressive craniectomy with lattice duraplasty	ACTA NEUROCHIRURGICA			English	Article						decompressive craniectomy; dura; duraplasty	TRAUMATIC BRAIN INJURY	A method of opening dura for decompressive craniectomies is described. Numerous cuts intersecting in a lattice pattern allow the dura to expand in a gradual and controlled manner minimising the chances of cortical laceration or venous kinking on the craniectomy edge.	Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Mitchell, P (corresponding author), Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	patrick.mitchell@ncl.ac.uk					Alves OL, 2003, ACTA NEUROCHIR, V145, P583, DOI 10.1007/s00701-003-0055-9; Csokay A, 2001, NEUROSURG REV, V24, P209, DOI 10.1007/s101430100158; Csokay A, 2001, ACTA NEUROCHIR, V143, P173, DOI 10.1007/s007010170125; Schneider GH, 2002, ACT NEUR S, V81, P77; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110	6	19	25	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	FEB	2004	146	2					159	160		10.1007/s00701-003-0186-z			2	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	773NB	WOS:000188928900020	14963748				2021-06-18	
J	Dosemeci, L; Yilmaz, M; Cengiz, M; Dora, B; Ramazanoglu, A				Dosemeci, L; Yilmaz, M; Cengiz, M; Dora, B; Ramazanoglu, A			Brain death and donor management in the intensive care unit: Experiences over the last 3 years	TRANSPLANTATION PROCEEDINGS			English	Article; Proceedings Paper	Joint Meeting of the Turkish-Transplantation-Society and Eurotransplant	JUN 25-27, 2003	ANKARA, TURKEY	Turkish Transplantat Soc, Eurotransplant				We sought to examine the frequency of brain death in the ICU, the donation rate, and the problems encountered during donor management between the years of January 2000, the date we began treating patients with neurologic pathologies and traumatic brain injury, and March 2003. Between January 2000 and March 2003, 134 patients diagnosed with brain death in our ICU were studied prospectively for the reason of brain death, the time between admission to ICU, and the diagnosis of brain death, the frequency of diabetes insipidus, the inotrope requirement, hypothermia, electrolyte imbalance, arrhythmia, and cardiac arrest. Among the approximately 2600 patients admitted to the general 24-bed ICU, 940 had cerebral injuries. In this group, the mortality rate was 33.5% (315 out of 940 patients) including brain-dead patients. Donor care was performed in 94 patients with organs suitable for transplantation out of 134 brain-dead patients. Fifty (53.2%) out of 94 patients became organ donors. The donor ratio was 12 per million-population per year as a mean value of the study period, which was approximately 10 times higher than the average ratio in Turkey. Although we observed many life-threatening problems during donor management, none of these patients died or had acute organ dysfunction.	Akdeniz Univ Hosp, Dept Anesthesiol & Intens Care, Antalya, Turkey	Dosemeci, L (corresponding author), Akdeniz Univ Hosp, Dept Anesthesiol & Intens Care, Dumlupinar Bulvar,Kampus Alani,B Blok, Antalya, Turkey.	leventege@yahoo.com	Dora, Babur/C-1053-2016; Yilmaz, Murat/I-6629-2017				MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; POWNER DJ, 2000, TXB CRITICAL CARE, P1894; TROPPMANN C, 1999, INTENS CARE MED, P2184; 2001, ORGANS TISSUES, V3, P143	4	19	21	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	JAN-FEB	2004	36	1					20	21		10.1016/j.transproceed.2003.11.050			2	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	770YC	WOS:000188758100005	15013289				2021-06-18	
J	Formisano, R; Voogt, RD; Buzzi, MG; Vinicola, V; Penta, F; Peppe, A; Stanzione, P				Formisano, R; Voogt, RD; Buzzi, MG; Vinicola, V; Penta, F; Peppe, A; Stanzione, P			Time interval of oral feeding recovery as a prognostic factor in severe traumatic brain injury	BRAIN INJURY			English	Article							KLUVER-BUCY-SYNDROME; HEAD-INJURY; ACUTE PREDICTORS; IMPROVEMENT; AMNESIA; RETURN	Primary objectives : To assess the outcome of severe traumatic brain injury at least 1 year after trauma, in relation to some early clinical prognostic factors occurring during coma recovery. Research design : Retrospective study conducted at the post-coma unit of a rehabilitation hospital. Methods and procedures : A total of 43 patients were included. All of the patients sustained severe traumatic brain injury and prolonged coma, i.e. coma lasting at least 15 days. Outcome was assessed by means of Glasgow Coma Scale, Barthel Index and Mini Mental State 1 year after trauma, in relation to some early clinical prognostic factors occurring during coma recovery. Main outcomes and results : At the 1 year follow-up, a statistically significant correlation was found with both the Glasgow Outcome Scale and the Barthel Index for the time interval from brain injury to recovery of the following clinical variables: optical fixation, ability to obey commands, spontaneous motor activity and first safe oral feeding. Psychomotor agitation and bulimia were also favourable prognostic factors for the final outcome. Conclusions : In the present study, first safe oral feeding during coma recovery represents the clinical feature that better predicts the final outcome of patients with severe traumatic brain injury and prolonged coma.	IRCCS, Fdn Santa Lucia, I-00179 Rome, Italy; Robert Voogt & Associates, Virginia Beach, VA USA; Univ Roma Tor Vergata, Neurol Clin, I-00173 Rome, Italy	Formisano, R (corresponding author), IRCCS, Fdn Santa Lucia, Via Ardeatina 306, I-00179 Rome, Italy.	r.formisano@hsantalucia.it	Buzzi, Maria Gabriella/K-5468-2016	Buzzi, Maria Gabriella/0000-0003-1307-8707			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARTHEL L, 1965, MD STATE MED J, V14, P61; Bates JB, 1997, J NEUROPSYCH CLIN N, V9, P626, DOI 10.1176/jnp.9.4.626; BRICOLO A, 1968, ACTA NEUROL SCAND, V44, P512, DOI 10.1111/j.1600-0404.1968.tb05589.x; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Childs A, 1987, Brain Inj, V1, P49, DOI 10.3109/02699058709034444; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; ESPERSEN JO, 1982, ACTA NEUROCHIR, V65, P81, DOI 10.1007/BF01405444; Finch M, 1997, BRAIN INJURY, V11, P713, DOI 10.1080/026990597123089; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORMISANO R, 1995, ACTA NEUROL SCAND, V91, P54; FROWEIN RA, 1989, ADV NEUROSURG, V17, P36; GERSTENBRAND F, 1983, NEUROSCI BIOBEHAV R, V7, P413, DOI 10.1016/0149-7634(83)90047-7; Goscinski I, 1997, ACTA NEUROCHIR, V139, P303, DOI 10.1007/BF01808825; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; OVERGAARD J, 1973, LANCET, V2, P631; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; RICHARD KE, 1989, ADV NEUROSURG, V17, P81; RITWENDEN FJ, 1998, CLIN REHABILATION, V12, P53; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; STALHAMMAR JE, 1980, ACTA NEUROCHIR, V90, P73; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	36	19	20	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2004	18	1					103	109		10.1080/0269905031000149470			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	749PB	WOS:000186928200007	14660239				2021-06-18	
J	Landry, SH; Swank, P				Landry, SH; Swank, P			Social competence in young children with inflicted traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							SHAKEN-BABY SYNDROME; BIRTH-WEIGHT CHILDREN; CLOSED-HEAD INJURY; 1ST 2 YEARS; PHYSICAL ABUSE; EMOTIONAL EXPRESSION; SOCIOECONOMIC-STATUS; MALTREATED CHILDREN; PRACTICAL SCALE; IMPACT SYNDROME	As infants develop skills that allow for increasing independence in social and cognitive domains, they acquire the ability to identify goals, sequence behaviors to carry out goals, and to flexibly use strategies for attaining goals in both social and independent play contexts. Little is known about how brain injury in young children may disrupt the precursors to such executive processes. In this study, we examined social and cognitive competence in 25 infants ages 3 to 23 months who sustained moderate to severe traumatic brain injury (TBI) secondary to physical abuse and in 22 healthy community comparison children. Children with TBI were evaluated an average of 1.6 months after the injury. A toy-centered activity with the examiner was used to capture joint attention and social behavior and an exploratory toy play situation was used to measure independent goal-directed play. The inflicted TBI group showed significant reduction in both social and cognitive domains relative to the comparison group. Canonical correlation analyses disclosed that inflicted TBI was associated with reduction in (a) initiation of social interactions, (b) responsiveness to interactions initiated by the examiner, (c) positive affect, and (d) compliance. The groups performed comparably on indexes of gestural and verbal communication and for the occurrence of negative affect. Joint attention was an area of vulnerability for the TBI group in both social initiation and response contexts. Although general cognitive and motor scores were lower in the inflicted TBI group, the complexity of independent toy play did not differ across groups. Early brain injury causes significant disruption in behaviors regulating initiation and responsiveness in social contexts. Longitudinal follow-up will characterize the long-term consequences of early disruption in joint attention and other behaviors on the development of social and cognitive precursors to executive processes.	Univ Texas, Hlth Sci Ctr, Div Dev Pediat, Houston, TX 77030 USA; FSD Data Serv, Houston, TX USA	Landry, SH (corresponding author), Univ Texas, Hlth Sci Ctr, Div Dev Pediat, 7400 Fannin,Suite 2300, Houston, TX 77030 USA.	susan.h.landry@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 29462-07] Funding Source: Medline		ABER JL, 1987, DEV PSYCHOL, V23, P406, DOI 10.1037/0012-1649.23.3.406; ADAMS KM, 1985, J CLIN EXP NEUROPSYC, V7, P445, DOI 10.1080/01688638508401276; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; APPELBAUM AS, 1977, J ABNORM CHILD PSYCH, V5, P417, DOI 10.1007/BF00915089; BARAHAL RM, 1981, J CONSULT CLIN PSYCH, V49, P508, DOI 10.1037/0022-006X.49.4.508; Barkley R. A., 1997, ADHD NATURE SELF CON; Bayley N., 2006, BAYLEY SCALES INFANT; Block JH, 1980, MINNESOTA S CHILD PS, V13, P39; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRADLEY RH, 1995, J PEDIATR PSYCHOL, V20, P347, DOI 10.1093/jpepsy/20.3.347; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Bruner Jerome S., 1982, SOCIAL INTERCHANGE I, P23; BULLOCK M, 1988, CHILD DEV, V59, P664, DOI 10.2307/1130566; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CAMRAS LA, 1983, J CLIN CHILD PSYCHOL, V12, P325, DOI 10.1207/s15374424jccp1203_16; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; CICCHETTI D, 1994, DEV PSYCHOPATHOL, V6, P533, DOI 10.1017/S0954579400004673; CICCHETTI D, 1987, NEW DIR CHILD ADOLES, V36, P47; Darwish D, 2001, CHILD ABUSE NEGLECT, V25, P13, DOI 10.1016/S0145-2134(00)00228-3; De Bellis MD, 2001, DEV PSYCHOPATHOL, V13, P539, DOI 10.1017/S0954579401003078; DENEKLA MB, 1996, ATTENTION MEMORY EXE, P263; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; *DIV INJ CONTR CTR, 1969, AM J DIS CHILD, V144, P627; DODGE KA, 1995, J ABNORM PSYCHOL, V104, P632, DOI 10.1037/0021-843X.104.4.632; DODGE KA, 1990, SCIENCE, V250, P1678, DOI 10.1126/science.2270481; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Dunham P.J., 1995, JOINT ATTENTION ITS, P29; DURING SM, 1991, J CLIN CHILD PSYCHOL, V20, P132, DOI 10.1207/s15374424jccp2002_4; Eisenberg N, 1997, CHILD DEV, V68, P642, DOI 10.2307/1132116; ELMER E, 1977, PEDIATRICS, V59, P273; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; FENSON L, 1976, CHILD DEV, V47, P232; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; Fleiss J., 1986, DESIGN ANAL CLIN EXP; FRICK T, 1978, REV EDUC RES, V48, P157, DOI 10.3102/00346543048001157; GAENSBAUER TJ, 1982, J AM ACAD CHILD PSY, V21, P163, DOI 10.1016/S0002-7138(09)60915-8; GAENSBAUER TJ, 1981, DEV NEUROPSYCHOL, V20, P673; GARNER PW, 1991, INFANT BEHAV DEV, V14, P489, DOI 10.1016/0163-6383(91)90035-Q; GOLDSON E, 1978, AM J DIS CHILD, V132, P790, DOI 10.1001/archpedi.1978.02120330062016; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Green MB, 1998, J HIGH ENERGY PHYS; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HERRENKOHL EC, 1995, CHILD ABUSE NEGLECT, V19, P191, DOI 10.1016/0145-2134(94)00116-C; Hinshaw SP, 1997, CHILD DEV, V68, P880, DOI 10.1111/j.1467-8624.1997.tb01968.x; HOFFMANPLOTKIN D, 1984, CHILD DEV, V55, P794, DOI 10.1111/j.1467-8624.1984.tb03816.x; HOLMBERG MC, 1980, CHILD DEV, V51, P448; JENNETT B, 1975, LANCET, V1, P480; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; KOPP CB, 1982, DEV PSYCHOL, V18, P199, DOI 10.1037/0012-1649.18.2.199; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KUCZYNSKI L, 1990, DEV PSYCHOL, V26, P398, DOI 10.1037/0012-1649.26.3.398; Landry SH, 1997, J CLIN EXP NEUROPSYC, V19, P261, DOI 10.1080/01688639708403856; LANDRY SH, 1990, CHILD DEV, V61, P1605, DOI 10.2307/1130768; Landry SH, 1998, CHILD DEV, V69, P105, DOI 10.2307/1132074; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Landry SH, 2000, CHILD DEV, V71, P358, DOI 10.1111/1467-8624.00150; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; LEUNG EHL, 1981, DEV PSYCHOL, V17, P215, DOI 10.1037/0012-1649.17.2.215; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LYONS TJ, 1993, PEDIATRICS, V92, P125; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Masten AS, 1999, DEV PSYCHOPATHOL, V11, P143, DOI 10.1017/S0954579499001996; Maughan A, 2002, CHILD DEV, V73, P1525, DOI 10.1111/1467-8624.00488; MITCHELL SK, 1979, PSYCHOL BULL, V86, P376, DOI 10.1037/0033-2909.86.2.376; OKUN A, 1994, DEV PSYCHOPATHOL, V6, P77, DOI 10.1017/S0954579400005897; PARPAL M, 1985, CHILD DEV, V56, P1326, DOI 10.2307/1130247; PLUNKETT JW, 1989, INFANT MENT HEALTH J, V10, P117, DOI 10.1002/1097-0355(198922)10:2<117::AID-IMHJ2280100205>3.0.CO;2-B; ROGOSCH FA, 1995, DEV PSYCHOPATHOL, V7, P591, DOI 10.1017/S0954579400006738; SALZINGER S, 1993, CHILD DEV, V64, P169, DOI 10.1111/j.1467-8624.1993.tb02902.x; SCAIFE M, 1975, NATURE, V253, P265, DOI 10.1038/253265a0; Siegler R. S., 1978, CHILDRENS THINKING W, P3; Sroufe L. A., 1995, DEV PSYCHOPATHOL, V1, P581; TEASDALE G, 1974, LANCET, V2, P81; Toth SL, 1996, J CONSULT CLIN PSYCH, V64, P32, DOI 10.1037/0022-006X.64.1.32; TRICKETT PK, 1991, DEV PSYCHOL, V27, P148, DOI 10.1037/0012-1649.27.1.148; VONDRA JI, 1990, CHILD ABUSE NEGLECT, V14, P525, DOI 10.1016/0145-2134(90)90101-X; WERTSCH JV, 1979, HUM DEV, V22, P1, DOI 10.1159/000272425; ZAHNWAXLER C, 1995, DEV PSYCHOPATHOL, V7, P27, DOI 10.1017/S0954579400006325	91	19	19	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	26	3					707	733		10.1207/s15326942dn2603_4			27	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	876KQ	WOS:000225496100004	15525566				2021-06-18	
J	Lee, CY; Yim, MB; Kim, IM; Son, EI; Kim, DW				Lee, CY; Yim, MB; Kim, IM; Son, EI; Kim, DW			Traumatic aneurysm of the supraclinoid internal carotid artery and an associated carotid-cavernous fistula: vascular reconstruction performed using intravascular implantation of stents and coils - Case report	JOURNAL OF NEUROSURGERY			English	Article						traumatic aneurysm; carotid-cavernous fistula; intravascular stent; coil embolization	TECHNICAL CASE-REPORT; INTRACRANIAL ANEURYSMS; FALSE ANEURYSM; SINUS FISTULA; EMBOLIZATION; OCCLUSION; REPAIR; PLACEMENT; EVOLUTION; GRAFTS	This report documents the treatment of a traumatic aneurysm of the supraclinoid internal carotid artery (ICA) that was associated with a carotid-cavernous fistula (CCF), which appeared following closed head trauma. This life-threatening lesion, which is very rare, required aggressive management achieved using intravascular stents and coils. A 19-year-old man presented with severe traumatic intracerebral and subarachnoid hematoma after he had suffered a severe closed head injury in a motor vehicle accident. Cerebral angiography performed 11 days after the injury demonstrated a traumatic aneurysm and severe narrowing of the right supraclinoid ICA, which was consistent with a dissection-induced stenosis associated with a direct CCF. Both lesions were successfully obliterated with preservation of the parent artery by using stents in conjunction with coils. Follow-up angiography obtained 7 months postoperatively revealed persistent obliteration of the aneurysm and CCF as well as patency of the parent artery. The patient remained asymptomatic during the clinical follow-up period of 14 months. Endovascular treatment involving the use of a stent combined with coils appears to be a feasible, minimally invasive option for treatment of this hard-to-treat lesion.	Keimyung Univ, Sch Med, Dept Neurosurg, Brain Res Inst, Jung Gu 700712, Daegu, South Korea	Yim, MB (corresponding author), Keimyung Univ, Sch Med, Dept Neurosurg, Brain Res Inst, 194 Dongsan Dong, Jung Gu 700712, Daegu, South Korea.	y760111@dsmc.or.kr					ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; Baskaya MK, 1996, NEUROL RES, V18, P135; Bendok BR, 1999, NEUROSURGERY, V45, P367, DOI 10.1097/00006123-199908000-00032; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BOUSQUET C, 1989, SURG NEUROL, V31, P319, DOI 10.1016/0090-3019(89)90059-1; DEBRUN GM, 1988, NEUROSURGERY, V22, P285, DOI 10.1227/00006123-198802000-00001; Dorros G, 1998, AM J NEURORADIOL, V19, P392; ENOMOTO H, 1984, NEUROSURGERY, V15, P700, DOI 10.1227/00006123-198411000-00011; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; Funahashi K, 1977, No Shinkei Geka, V5, P619; GEREMIA G, 1994, AM J NEURORADIOL, V15, P1223; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HALBACH VV, 1988, AM J NEURORADIOL, V9, P741; HANDA J., 1967, ACTA NEURO CHIR, V17, P161; Higashida RT, 1997, J NEUROSURG, V87, P944, DOI 10.3171/jns.1997.87.6.0944; JAKOBSSON KE, 1984, ACTA NEUROCHIR, V71, P91, DOI 10.1007/BF01401153; KOMIYAMA M, 1991, SURG NEUROL, V36, P126, DOI 10.1016/0090-3019(91)90230-7; Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020; Link J, 1996, RADIOLOGY, V200, P397, DOI 10.1148/radiology.200.2.8685332; LISTER JR, 1979, NEUROSURGERY, V5, P473; Lylyk P, 1998, NEUROSURGERY, V43, P385, DOI 10.1097/00006123-199808000-00132; MARIN ML, 1993, J VASC SURG, V18, P299, DOI 10.1016/0741-5214(93)90611-O; MASANA Y, 1992, J NEUROSURG, V76, P524, DOI 10.3171/jns.1992.76.3.0524; MASE M, 1995, NEUROSURGERY, V37, P832, DOI 10.1227/00006123-199510000-00032; MULLAN S, 1979, J NEUROSURG, V50, P131, DOI 10.3171/jns.1979.50.2.0131; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PARKINSON D, 1973, J NEUROSURG, V38, P99, DOI 10.3171/jns.1973.38.1.0099; Parodi JC, 1996, WORLD J SURG, V20, P655, DOI 10.1007/s002689900100; POZZATI E, 1982, J NEUROSURG, V57, P418, DOI 10.3171/jns.1982.57.3.0418; PROLO DJ, 1971, J NEUROSURG, V35, P237, DOI 10.3171/jns.1971.35.2.0237; REDDY SVR, 1981, J NEUROSURG, V55, P813, DOI 10.3171/jns.1981.55.5.0813; Saito Kiyoshi, 1995, Neurologia Medico-Chirurgica, V35, P886, DOI 10.2176/nmc.35.886; Saito Ryoichi, 1992, Neurological Surgery, V20, P973; SALCMAN M, 1985, NEUROSURGERY, V16, P218; SALMON JH, 1968, J THORAC CARDIOV SUR, V56, P28, DOI 10.1016/S0022-5223(19)42868-7; Sekhar LN, 1999, NEUROSURGERY, V44, P1207, DOI 10.1097/00006123-199906000-00028; Siniluoto T, 1997, AM J NEURORADIOL, V18, P519; STEINMETZ H, 1988, SURG NEUROL, V30, P305, DOI 10.1016/0090-3019(88)90304-7; WAGA S, 1978, SURG NEUROL, V9, P367; Waga S, 1979, No Shinkei Geka, V7, P933; WAKHLOO A, 1996, CIRCULATION S, V94, P1; YONAS H, 1980, NEUROSURGERY, V7, P499, DOI 10.1227/00006123-198011000-00016	42	19	20	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2004	100	1					115	119		10.3171/jns.2004.100.1.0115			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	761YQ	WOS:000187943400018	14743921				2021-06-18	
J	Levine, NB; Tanaka, T; Jones, BV; Crone, KR				Levine, NB; Tanaka, T; Jones, BV; Crone, KR			Minimally invasive management of a traumatic artery aneurysm resulting from shaken baby syndrome	PEDIATRIC NEUROSURGERY			English	Article						traumatic aneurysms; pericallosal artery; posttraumatic obstructive hydrocephalus; third ventriculostomy; coiling	INTRACRANIAL ANEURYSMS; CHILDHOOD	Based on our review of the literature, we present the first use of coiling in an infant with a traumatic artery aneurysm that resulted from shaken baby syndrome. Computed tomography (CT) scans showed a skull fracture, hemorrhagic subdural collections, multiple parenchymal contusions, and intraventricular and subarachnoid hemorrhages in a 3-week-old infant who presented with lethargy, poor feeding, and seizure. These multiple injuries were consistent with shaken baby syndrome. After closed-head injury medical management, including subdural taps, the baby was discharged home. When increasing seizures and hydrocephalus developed 8 months later, CT angiographic scans showed a pseudoaneurysm of the anterior cerebral artery. We successfully occluded the aneurysm with pushable coils placed via a microcatheter and treated the obstructive hydrocephalus with endoscopic third ventriculostomy. We show that minimally invasive radiological and surgical techniques may be effective in managing the sequelae of trauma in children. Copyright (C) 2004 S. Karger AG, Basel.	Univ Cincinnati, Coll Med, Dept Neurosurg, Neurosci Inst,Editorial Off, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp Med Ctr, Dept Neurosurg, Cincinnati, OH USA	Crone, KR (corresponding author), Univ Cincinnati, Coll Med, Dept Neurosurg, Neurosci Inst,Editorial Off, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	editor@mayfieldclinic.com		Tanaka, Tomoko/0000-0003-0897-8217			BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; Jones BV, 2002, AM J NEURORADIOL, V23, P1145; Lam CH, 1996, NEUROSURGERY, V39, P1252, DOI 10.1097/00006123-199612000-00041; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125; YAZBAK PA, 1995, PEDIATR NEUROSURG, V22, P15, DOI 10.1159/000121294	6	19	19	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2004	40	3					128	131		10.1159/000079855			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	869XK	WOS:000225017700006	15367803				2021-06-18	
J	Poirrier, ALML; Ngosso-Tetanye, I; Mouchamps, M; Misson, JP				Poirrier, ALML; Ngosso-Tetanye, I; Mouchamps, M; Misson, JP			Spontaneous arachnoid cyst rupture in a previously asymptomatic child: a case report	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						arachnoid cyst; subdural hygroma; intracranial hypertension; cerebrospinal fluid derivation	MIDDLE CRANIAL FOSSA; EXPERIENCE; VALVE	Arachnoid cysts are benign congenital cavities arising in the subarachnoid space. Non-traumatic subdural effusion of cerebrospinal fluid is a rare complication requiring surgical treatment. Case Report: A 15-year-old boy was admitted to the hospital because of symptoms related to acute intracranial hypertension (headache and vomiting). The cerebral CT-scan revealed a subdural hygroma adjoining a voluminous Sylvian arachnoid cyst. Two arachnoid cysts were incidentally discovered 11 years before this dramatic complication. Moreover, the patient had suffered a cerebral concussion 2 years earlier, but interestingly did not develop cystic hemorrhage or rupture, contrary to numerous cases previously described in the literature. The location of the cysts and their regular follow-up did not allow foreseeing a cystic rupture. Hygroma evacuation was first performed after which a subdural peritoneal. shunting, using a programmable opening pressure valve, was implanted. Spontaneous rupture into the subdural space represents an unusual complication of arachnoid cysts. Clinical aspects, radiographic findings, pathogenesis and surgical management are described. It is important to point out that subdural hygroma or haematoma should never be excluded in the absence of trauma history, even in the case of small non-progressive cysts regularly supervised. (C) 2004 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	Univ Liege, Dept Neuropediat, CHR Citadelle, B-4000 Liege, Belgium	Misson, JP (corresponding author), Univ Liege, Dept Neuropediat, CHR Citadelle, 12E Ligne Blvd,1, B-4000 Liege, Belgium.	jeanpaul.misson@skynet.be		Poirrier, Anne-Lise/0000-0002-1247-2334			Albuquerque FC, 1997, NEUROSURGERY, V41, P951, DOI 10.1097/00006123-199710000-00036; Arai H, 1996, NEUROSURGERY, V39, P1108, DOI 10.1097/00006123-199612000-00007; Cayli SR, 2000, BRIT J NEUROSURG, V14, P568, DOI 10.1080/02688690050206738; Di Rocco C, 2003, SURG NEUROL, V60, P211, DOI 10.1016/S0090-3019(03)00064-8; Dodd RL, 2002, PEDIATR NEUROSURG, V37, P152, DOI 10.1159/000064394; Germano A, 2003, CHILD NERV SYST, V19, P166, DOI 10.1007/s00381-002-0702-0; Gosalakkal JA, 2002, PEDIATR NEUROL, V26, P93, DOI 10.1016/S0887-8994(01)00329-0; Kang JK, 2000, CHILD NERV SYST, V16, P111, DOI 10.1007/s003810050024; Mazurkiewicz-Beldzinska Maria, 2002, Med Sci Monit, V8, pCR462; Mori K, 2002, J NEUROTRAUM, V19, P1017, DOI 10.1089/089771502760341938; Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010; Wester K, 1999, NEUROSURGERY, V45, P775, DOI 10.1097/00006123-199910000-00008; Yamauchi T, 1999, ACTA NEUROCHIR, V141, P537, DOI 10.1007/s007010050338; Zemack G, 2000, J NEUROSURG, V92, P941, DOI 10.3171/jns.2000.92.6.0941	14	19	20	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.		2004	8	5					247	251		10.1016/j.ejpn.2004.04.005			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	856CP	WOS:000224021500003	15341907				2021-06-18	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			Recovery and predictors of intellectual ability two years following paediatric traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; CHILDREN; SEQUELAE; COHORT; SEVERITY; ADOLESCENTS; CHILDHOOD; AGE	While a number of research papers have reported findings on intellectual skills following traumatic brain injury (TBI), only limited studies have monitored the recovery of these skills over time. The present study examined intellectual skills in a group of 70 children who had sustained a mild, moderate, or severe traumatic brain injury (TBI). Results showed that, while the severe TBI group exhibited greatest recovery of intellectual ability over 24 months, they continued to perform more poorly than children who had sustained a mild and moderate injury. Further, domain-specific Index Scores, derived from intellectual measures, provided additional insight regarding the development and/or recovery of specific cognitive areas following TBI. Best predictor of intellectual outcome was socio-economic status.	Royal Childrens Hosp, Melbourne, Vic, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	catroppc@cryptic.rch.unimelb.edu.au					Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; ANDERSON V, 2001, J CLIN EXPT NEUROPSY; ANDERSON V, 2001, IN PRESS DEV NEU DEC; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2000, BRAIN INJURY, V14, P679; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Daniel A. E., 1983, POWER PRIVILEGE PRES; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HOLMESBERNSTEIN J, 1990, NEUROMETHODS, V17, P311, DOI DOI 10.1385/0896031330; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Morse S, 1999, Pediatr Rehabil, V3, P139; Ong LC, 1998, J PAEDIATR CHILD H, V34, P363, DOI 10.1046/j.1440-1754.1998.00239.x; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Wechsler D., 1991, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	41	19	19	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	DEC	2003	13	5					517	536		10.1080/09602010343000084			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	742PB	WOS:000186525500002					2021-06-18	
J	Bhambhani, Y; Rowland, G; Farag, M				Bhambhani, Y; Rowland, G; Farag, M			Reliability of peak cardiorespiratory responses in patients with moderate to severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	48th Annual Meeting of the American-College-of-Sports-Medicine	MAY-JUN -, 2001	BALTIMORE, MD	Amer Coll Sports Med		brain injuries; exercise; rehabilitation	EXERCISE; DEPRESSION; CAPACITY	Objective: To examine the test-retest reliability of acute physiologic responses in patients with traumatic brain injury (TBI). Design: Repeated measures within I week. Setting: Brain injury rehabilitation program and community rehabilitation hospital. Participants: Thirty-six inpatients or their legal guardians. Interventions: Each patient performed a symptom-limited incremental cycle ergometer test to voluntary fatigue on 2 separate occasions within I week. Main Outcome Measures: Peak values of power output and cardiorespiratory responses measured with a metabolic cart interfaced with an electrocardiogram. Results: Intraclass correlations between the 2 trials were as follows: power output, .96; absolute oxygen uptake,.98; relative oxygen uptake,.97; heart rate,.82; ventilation rate,.96; and respiratory exchange ratio,.81. Bland-Altman plots showed that all data points were within the 95% confidence limits of the mean value of the 2 trials for each variable. Conclusions: The reliability of the peak cardiorespiratory responses during non-weight-bearing exercise was high in patients with TBI in a controlled laboratory setting. Therefore, aerobic exercise programs can be accurately prescribed, and changes resulting from such interventions can be confidently evaluated in this population.	Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada; Alberta Hosp Ponoka, Brain Injury Rehabil Prov Program, Ponoka, AB, Canada	Bhambhani, Y (corresponding author), Univ Alberta, Fac Rehabil Med, Rm 373,Corbett Hall, Edmonton, AB T6G 2G4, Canada.	yagesh.bhambhani@ualberta.ca					*AM COLL SPORTS ME, 2001, GUID EX TEST PRESCR; [Anonymous], 1990, Med Sci Sports Exerc, V22, P265; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Bhambhani Y, 1985, Can J Appl Sport Sci, V10, P44; BHAMBHANI Y, 1994, CAN J APPL PHYSIOL, V19, P49, DOI 10.1139/h94-003; BHAMBHANI YN, 1991, ARCH PHYS MED REHAB, V72, P559; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; GOWLAND C, 1994, BRAIN INJURY REHABIL, P102; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greenleaf J E, 1982, Exerc Sport Sci Rev, V10, P84; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Keller A, 2001, SPINE, V26, P771, DOI 10.1097/00007632-200104010-00017; Keppel G., 1973, DESIGN ANAL RES HDB, V3rd; King ML, 1997, BRAIN INJURY, V11, P445; MCARDLE WD, 2001, EXERCISE PHYSIOLOGYE; MCLEAN KP, 2002, ACSM RESOURCES CLIN, P98; *NIH, 1998, NIH CONS STAT REH PE; NOVACK TA, 1988, REHABIL COUNS BULL, V31, P313; Puente-Maestu L, 2001, EUR J APPL PHYSIOL, V85, P434, DOI 10.1007/s004210100486; Saltin B, 1968, CIRCULATION       S7, V38, pVII1, DOI DOI 10.1161/01; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; TAYLOR HL, 1955, J APPL PHYSIOL, V8, P73; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US DEP HHS, 1996, PHYS ACT HLTH REP SU, P15250; Vitale AE, 1996, BRAIN INJURY, V10, P367, DOI 10.1080/026990596124377; VITALE AE, 1995, PERCEPT MOTOR SKILL, V80, P57, DOI 10.2466/pms.1995.80.1.57; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Wasserman K., 1994, PRINCIPLES EXERCISE; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; Wiercisiewski DR, 1998, J HEAD TRAUMA REHAB, V13, P28, DOI 10.1097/00001199-199802000-00006	40	19	19	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2003	84	11					1629	1636		10.1053/S0003-9993(03)00343-5			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	741PR	WOS:000186466900009	14639562				2021-06-18	
J	Grados, MA				Grados, MA			Obsessive-compulsive disorder after traumatic brain injury	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; PSYCHIATRIC-DISORDERS; FOLLOW-UP; ADOLESCENTS; CHILDREN; PHARMACOTHERAPY; PREVALENCE; DISABILITY	Traumatic brain injury (TBI) neuropsychiatric sequelae are a significant cause of morbidity in TBI victims. Among the recognized sequelae are anxiety, obsessions, compulsions and obsessive-compulsive disorder (OCD). This review addresses the emergence of OCD and OCD symptoms after TBI with an emphasis on neural circuits that underlie OCD symptom expression that may be affected by the injury. Current studies suggest that post-TBI emergent psychopathology, including OCD, is influenced by underlying sub-clinical diathesis, brain injury lesions sites, environmental stressors and the rehabilitation process. Pre-morbid status can be obtained by structured psychiatric interviews, and TBI brain lesions can be defined with advanced neuroimaging techniques. This information along with the management of family and environmental stressors and the enhanced clinical identification of symptoms of anxiety and OCD can be used in the rehabilitation process to improve prognosis after TBI.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Grados, MA (corresponding author), 3901 Greenspring Ave,2nd Floor, Baltimore, MD 21211 USA.			Grados, Marco/0000-0002-6189-6264	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066284] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH066284-01] Funding Source: Medline		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; [Anonymous], 1980, DIAGN STAT MAN MENT, V3; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FLAMENT MF, 1988, J AM ACAD CHILD PSY, V27, P764, DOI 10.1097/00004583-198811000-00018; Gamazo-Garran P, 2002, J CHILD ADOL PSYCHOP, V12, P259, DOI 10.1089/104454602760386950; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Grados M, 1999, CHILD ADOL PSYCH CL, V8, P617; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Heyman I, 2003, INT REV PSYCHIATR, V15, P178, DOI 10.1080/0954026021000046146; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; HILLBOM E, 1960, Acta Psychiatr Scand Suppl, V35, P1; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; HOLLINGSWORTH CE, 1980, J AM ACAD CHILD PSY, V19, P134, DOI 10.1016/S0002-7138(09)60658-0; INSEL TR, 1992, PSYCHIAT CLIN N AM, V15, P813; JENIKE M, 1984, J AFFECT DISORDERS, V2, P359; JOSEPH R, 1993, NAKED NEURON; Kant R, 1996, BRAIN INJURY, V10, P55; KARNO M, 1988, ARCH GEN PSYCHIAT, V45, P1094, DOI 10.1001/archpsyc.1988.01800360042006; Kim KW, 2002, J NEUROPSYCH CLIN N, V14, P88, DOI 10.1176/appi.neuropsych.14.1.88; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LISHMAN WA, 1973, ORGANIC PSYCHIAT; Luria A. R., 1969, HDB CLINICAL NEUROLO, V2, P725; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Rosenberg DR, 1997, J PSYCHIATR NEUROSCI, V22, P29; Sachdev P, 2001, AUST NZ J PSYCHIAT, V35, P684, DOI 10.1080/0004867010060519; Sagan C., 1977, DRAGONS EDEN; SCHILDER P, 1938, AM J PSYCHIAT, V94, P1414; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Stein J, 2002, TXB ANXIETY DISORDER, P43; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; Szeszko PR, 1999, ARCH GEN PSYCHIAT, V56, P913, DOI 10.1001/archpsyc.56.10.913; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN PH, 1993, ACTA PSYCHIAT SCAND, V88, P212, DOI 10.1111/j.1600-0447.1993.tb03441.x; VALLENIBASILE LA, 1994, J AM ACAD CHILD PSY, V33, P782, DOI 10.1097/00004583-199407000-00002; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; ZOHAR AH, 1992, J AM ACAD CHILD PSY, V31, P1057, DOI 10.1097/00004583-199211000-00010	47	19	19	0	8	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0954-0261			INT REV PSYCHIATR	Int. Rev. Psych.	NOV	2003	15	4					350	358		10.1080/09540260310001606737			9	Psychiatry	Psychiatry	739UD	WOS:000186364100007	15276956				2021-06-18	
J	Kerr, ME; Kamboh, ML; Yookyung, K; Kraus, MF; Puccio, AM; DeKosky, ST; Marion, DW				Kerr, ME; Kamboh, ML; Yookyung, K; Kraus, MF; Puccio, AM; DeKosky, ST; Marion, DW			Relationship between apoE4 allele and excitatory amino acid levels after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; excitatory amino acids; apolipoprotein; neuromonitoring; cerebrospinal fluid; cerebral ischemia; high-performance liquid chromatography	E-DEFICIENT MICE; CORTICAL EXTRACELLULAR LEVELS; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; HEAD-INJURY; CEREBRAL-ISCHEMIA; EPSILON-4 ALLELE; GLUTAMATE; RELEASE	Objective; Apolipoprotein E isoform (B) has been posited to affect outcomes after central nervous system injury. This project sought to determine the relationship between the apoE4 allele and the recovery of amino acid neurotransmitters (aspartate, glutamate, and lactate/pyruvate ratio [UP]) following a traumatic brain injury (TBI) after controlling for patient characteristics. Design: This prospective clinical study examined neurotransmitters and UP within the cerebrospinal fluid and compared the trends by apoE genotypes. Setting: Adults with TBI were recruited from a neurotraurna intensive care unit within a trauma 1 university medical center. Patients: Ninety-one patients were enrolled into the study after a severe TBI (Glasgow Coma Scale [GCS] score, less than or equal to8). Cerebrospinal fluid was serially sampled from a ventriculostomy every 4 hrs for the first 24 hrs and every 6 hrs for 25-120 hrs after injury. Measurements and Main Results: Hierarchical linear modeling analyses were used to compare the change of glutamate, aspartate, and UP over time by the presence or absence of the apoE4 allele, with GCS score, sex, race, and therapeutic hypothermias included as covariates. There was a significant apoE4 allele group effect on both the linear and quadratic slopes in aspartate. In glutamate, the rate of change in glutamate was statistically related to GCS score. There was no significant difference in the glutamate response over time by the presence of the apoE4 allele. There was a significant difference in the change in UP across time, with faster recovery when the apoE4 allele was absent. Conclusions: Recovery of aspartate and UP differed depending on the presence of the apoE4 allele. Patients with the allele had significant increased and sustained levels of aspartate and UP after TBI. Changes in glutamate were related to severity of illness and were independent of the presence of the apoE4 allele.	Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA	Kerr, ME (corresponding author), Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, 3811 Ohara St, Pittsburgh, PA 15213 USA.		Marion, Donald/AAR-5749-2021	DeKosky, Steven/0000-0003-3743-2758; Kamboh, M. Ilyas/0000-0002-3453-1438	NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR04301] Funding Source: Medline		ASSMANN G, 1984, CLIN CHEM, V30, P641; BRYK AS, 1992, HIERARCHIAL LINEAR M; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; CHOI DW, 1990, J NEUROSCI, V10, P2493; De Sarno P, 1998, EXP NEUROL, V152, P123, DOI 10.1006/exnr.1998.6825; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Graham DI, 1996, ACT NEUR S, V66, P96; Gross R, 1997, JAMA-J AM MED ASSOC, V278, P2143, DOI 10.1001/jama.1997.03550240033025; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; HARTMANN H, 1994, BIOCHEM BIOPH RES CO, V200, P1185, DOI 10.1006/bbrc.1994.1576; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; KAMBOH MI, 1995, ATHEROSCLEROSIS, V112, P145, DOI 10.1016/0021-9150(94)05409-C; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kimelberg H K, 1987, Cent Nerv Syst Trauma, V4, P3; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1989, MOL CHEM NEUROPATHOL, V11, P1, DOI 10.1007/BF03160036; Klunk WE, 1998, NEUROBIOL AGING, V19, P511, DOI 10.1016/S0197-4580(98)00105-5; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Lendon CL, 2000, EUR J NEUROSCI, V12, P2235, DOI 10.1046/j.1460-9568.2000.00113.x; Little T.D., 2000, MODELING LONGITUDINA; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MessmerJoudrier S, 1996, EUR J NEUROSCI, V8, P2652, DOI 10.1111/j.1460-9568.1996.tb01560.x; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Overmyer M, 1999, DEMENT GERIATR COGN, V10, P252, DOI 10.1159/000017128; OYAMA F, 1995, MOL BRAIN RES, V29, P92, DOI 10.1016/0169-328X(94)00233-5; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Petegnief V, 2001, NEUROSCIENCE, V104, P223, DOI 10.1016/S0306-4522(01)00046-X; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Rao VLR, 1998, J NEUROCHEM, V70, P2020; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SELKOE DJ, 1991, NATURE, V354, P432, DOI 10.1038/354432a0; SELKOE DJ, 1991, SCI AM, V265, P40, DOI 10.1038/scientificamerican1191-68; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Shimokata H, 2000, J Epidemiol, V10, pS46; UTERMANN G, 1980, AM J HUM GENET, V32, P339; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; WARDELL MR, 1982, J LIPID RES, V23, P1174; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	53	19	23	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2003	31	9					2371	2379		10.1097/01.CCM.0000080484.72004.C4			9	Critical Care Medicine	General & Internal Medicine	721BL	WOS:000185297100016	14501969				2021-06-18	
J	Vanderluit, JL; McPhail, LT; Fernandes, KJL; Kobayashi, NR; Tetzlaff, W				Vanderluit, JL; McPhail, LT; Fernandes, KJL; Kobayashi, NR; Tetzlaff, W			In vivo application of mitochondrial pore inhibitors blocks the induction of apoptosis in axotomized neonatal facial motoneurons	CELL DEATH AND DIFFERENTIATION			English	Article						facial; motoneurons; apoptosis; cell death; caspase-3; axotomy	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; TRAUMATIC BRAIN-INJURY; ADENINE-NUCLEOTIDE TRANSLOCATOR; TRANSIENT CEREBRAL-ISCHEMIA; D-ASPARTATE RECEPTORS; CELL-DEATH; NEURONAL DEATH; BAX TRANSLOCATION; CYCLOSPORINE-A	Axotomy induces apoptosis in motoneurons of neonatal rodents. To identify the key players in motoneuron apoptosis, we assessed the progression of apoptosis at 4 h intervals following facial motoneuron axotomy. The mitochondrial release of cytochrome c, caspase-3 activation and nuclear condensation were first observed in the motoneuron cell bodies 16 h postaxotomy. In vivo application of inhibitors of the mitochondrial permeability transition pore, Bongkrekic acid and cyclosporin A prevented cytochrome c release as well as caspase-3 activation and attenuated motoneuron apoptosis. Similarly, in vivo application of RU360, an inhibitor of the mitochondrial calcium uniporter, also protected axotomized motoneurons from apoptosis. Taken together, our results show that cytochrome c release and subsequent caspase-3 activation are critical events that precipitate the apoptotic death of axotomized neonatal motoneurons in vivo. In addition, these results provide evidence that application of mitochondrial pore inhibitors in vivo can block the induction of apoptosis following motoneuron axotomy.	Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, ICORD, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Surg, Vancouver, BC V6T 1Z4, Canada	Tetzlaff, W (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.		Tetzlaff, Wolfram/AAY-4430-2020				Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; BROEKEMEIER KM, 1994, MOL CELL BIOCHEM, V139, P33, DOI 10.1007/BF00944201; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Casanovas A, 1996, NEUROSCIENCE, V71, P313, DOI 10.1016/0306-4522(95)00461-0; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; DeBilbao F, 1996, NEUROSCIENCE, V71, P1111, DOI 10.1016/0306-4522(95)00505-6; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; GREENSMITH L, 1994, DEV BRAIN RES, V81, P162, DOI 10.1016/0165-3806(94)90302-6; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hamburger V, 1934, J EXP ZOOL, V68, P449, DOI 10.1002/jez.1400680305; IWASAKI Y, 1995, J NEUROL SCI, V134, P21, DOI 10.1016/0022-510X(95)00217-6; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kikuchi M, 2000, J NEUROSCI, V20, P5037; KLINGENBERG M, 1970, BIOCHEM BIOPH RES CO, V39, P344, DOI 10.1016/0006-291X(70)90582-6; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAUQUIN GJM, 1976, BIOCHEMISTRY-US, V15, P2316, DOI 10.1021/bi00656a011; Lawson SJ, 1998, NEUROSCIENCE, V87, P337, DOI 10.1016/S0306-4522(98)00120-1; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; LOWRIE MB, 1992, TRENDS NEUROSCI, V15, P80, DOI 10.1016/0166-2236(92)90014-Y; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MENTIS GZ, 1993, NEUROSCIENCE, V54, P283, DOI 10.1016/0306-4522(93)90253-C; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tapia R, 1997, NEUROCHEM INT, V30, P137, DOI 10.1016/S0197-0186(96)00056-3; Tong JXX, 1997, J NEUROCYTOL, V26, P339, DOI 10.1023/A:1018508819191; Vanderluit JL, 2000, EUR J NEUROSCI, V12, P3469, DOI 10.1046/j.1460-9568.2000.00241.x; Velasco I, 2000, J NEUROSCI RES, V60, P543, DOI 10.1002/(SICI)1097-4547(20000515)60:4<543::AID-JNR13>3.0.CO;2-Z; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Ziv NE, 1995, J NEUROPHYSIOL, V74, P2625	57	19	20	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047			CELL DEATH DIFFER	Cell Death Differ.	SEP	2003	10	9					969	976		10.1038/sj.cdd.4401258			8	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	717FE	WOS:000185075100005	12934071	Bronze			2021-06-18	
J	Page, S; Levine, P				Page, S; Levine, P			Forced use after TBI: promoting plasticity and function through practice	BRAIN INJURY			English	Article							CONSTRAINT-INDUCED THERAPY; INDUCED MOVEMENT THERAPY; UPPER-LIMB FUNCTION; UPPER-EXTREMITY; PHYSICAL REHABILITATION; INTERRATER RELIABILITY; STROKE PATIENTS; INJURY	Objective: To review the literature supporting, and determine the efficacy of, modified constraint-induced therapy ( mCIT) in improving more affected upper limb use and function in patients with traumatic brain injury ( TBI). Design: Multiple-baseline, pre-post, case series. Setting: Outpatient clinic. Patients: Three patients with TBI occurring >1 year ago and exhibiting stable upper limb hemiparesis and learned non-use. Intervention: Patients participated in 10 sessions of 30 minute, structured physical and occupational therapy, emphasizing more affected arm use in valued, functional activities, three times/week for 10 weeks and using shaping techniques. Their less affected upper limbs were also restrained 5 days/week during 5 hours identified as times of frequent use during the same 10-week period. Main outcome measures: The Action Research Arm Test (ARA), Wolf Motor Function Test (WMFT) and Motor Activity Log ( MAL). Results: Following intervention, subjects exhibited improvements > 2.0 in their amount and quality of more affected limb use, as measured by the MAL. Subjects 1, 2 and 3 also displayed functional improvements on the ARA (14.0, 5.5 and 6.0, respectively), improvements in ratings of WMFT task performance (1.15, 1.7 and 1.35, respectively) and diminished time needed to perform all WMFT tasks. Conclusions: mCIT is a promising approach by which improved more affected limb use and function can be realized following TBI.	Univ Cincinnati, Coll Med, Dept Phys Med & Rehabil, Cincinnati, OH 45267 USA	Page, S (corresponding author), Univ Cincinnati, Coll Med, Dept Phys Med & Rehabil, 202 Goodman Dr,Suite 275, Cincinnati, OH 45267 USA.	stephen.page@uc.edu	LEVINE, PETER/AAS-2067-2020				Blanton S, 1999, PHYS THER, V79, P847, DOI 10.1093/ptj/79.9.847; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BRINKMANN JR, 1979, PHYS THER, V59, P859; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Classen J, 1998, J NEUROPHYSIOL, V79, P1117; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; JR Anderson., 1981, COGNITIVE SKILLS THE, P1; KEITH RA, 1987, SOC SCI MED, V24, P529, DOI 10.1016/0277-9536(87)90342-X; Liepert J, 1999, EXP BRAIN RES, V125, P435, DOI 10.1007/s002210050700; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Lincoln NB, 1996, STROKE, V27, P18, DOI 10.1161/01.STR.27.1.18; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Mackey F, 1996, ARCH PHYS MED REHAB, V77, P1066, DOI 10.1016/S0003-9993(96)90070-2; Miller T.R., 1995, DATABOOK NONFATAL IN; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Page SJ, 2002, ARCH PHYS MED REHAB, V83, P286, DOI 10.1053/apmr.2002.28007; Page SJ, 2002, AM J PHYS MED REHAB, V81, P870, DOI 10.1097/00002060-200211000-00013; Page SJ, 2002, CLIN REHABIL, V16, P55, DOI 10.1191/0269215502cr473oa; Page SJ, 2001, J REHABIL RES DEV, V38, P583; Reynolds WE, 2001, J HEAD TRAUMA REHAB, V16, P34, DOI 10.1097/00001199-200102000-00006; SCHAUMBURG S, 1999, ANN M AM C REH MED O; Taub E, 1999, J REHABIL RES DEV, V36, pVII; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 1999, J REHABIL RES DEV, V36, P237; Taub E., 1976, NEURAL CONTROL LOCOM, P676; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Wallen MA, 2001, ARCH PHYS MED REHAB, V82, P642, DOI 10.1053/apmr.2001.22620; WINSTEIN CJ, 2001, J STROKE CEREBROVASC, V10, P197; Wolf S L, 1997, Top Stroke Rehabil, V3, pv, DOI 10.1080/10749357.1997.11754125; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	34	19	20	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2003	17	8					675	684		10.1080/0269905031000107160			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500005	12850952				2021-06-18	
J	Thornton, K				Thornton, K			The electrophysiological effects of a brain injury on auditory memory functioning - The QEEG correlates of impaired memory	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						QEEG; auditory memory; brain damage; memory; electrophysiology	CLOSED-HEAD-INJURY; EEG	The effect of a brain injury on the quantitative EEG (QEEG) variables during an auditory memory activation condition was examined with 56 normal subjects and 85 mild traumatic brain-injured (MTBI) subjects. An analysis was conducted on the different response patterns of the two groups, the variables which were correlated with memory performance in the brain-injured group, and the variables which predicted the memory score for the combined two groups (normal and brain injured). The three conditions included the input task, the immediate recall, and the delayed recall task. The consistent effect of a brain injury was a lowering of the connectivity patterns in the betal and beta2 frequencies (phase and coherences) and increases predominantly in the relative power of beta1 (13-32 Hz), which were correlated with the differences in recall. There is a subtle shift to right hemisphere/right temporal functioning and employment of the higher beta1 and beta2 frequencies (phase and coherence) in the response pattern of the MTBI subject. Memory functioning is predominantly positively correlated with connection activity (phase and coherence) and negatively correlated with beta activation at specific locations. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	Ctr Hlth Psychol, S Plainfield, NJ 07080 USA	Thornton, K (corresponding author), Ctr Hlth Psychol, Ste 2A,2509 Pk Ave, S Plainfield, NJ 07080 USA.			thornton, kirtley/0000-0002-3303-4747			HOOSHMAND H, 1989, CLIN ELECTROENCEPHAL, V20, P235, DOI 10.1177/155005948902000411; HUGHES JR, 1999, IN PRESS J NEUROPSYC; Moran John E., 1993, Brain Topography, V5, P229, DOI 10.1007/BF01128990; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; PAULSON MJ, 1970, J CLIN PSYCHOL, V26, P453, DOI 10.1002/1097-4679(197010)26:4<453::AID-JCLP2270260415>3.0.CO;2-V; PRICHEP L S, 1992, Brain Topography, V4, P249, DOI 10.1007/BF01135562; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; TABANO MT, 1988, ELECTROENCEPHALOGRAP, V70, P185; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; THATCHER RW, 1989, ELECTROENCEPHALOGRAP, V73, P10; THORNTON K, 2001, J NEUROTHERAPY, V4, P45; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; THORNTON KE, 1999, J NEUROTHERAPY   FAL, P1	13	19	19	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2003	18	4					363	378	PII S0887-6177(02)00139-7	10.1016/S0887-6177(02)00139-7			16	Psychology, Clinical; Psychology	Psychology	678GA	WOS:000182857100003	14591452				2021-06-18	
J	Edwards, MJ; McNeil, JE; Greenwood, RJ				Edwards, MJ; McNeil, JE; Greenwood, RJ			Process and outcome during early inpatient rehabilitation after brain injury	DISABILITY AND REHABILITATION			English	Article								Purpose: To describe aspects of process and outcome during early inpatient rehabilitation of younger adults after single incident brain injury. Method: Analysis of a database of 290 patients discharged from an inner-city hospital based inpatient unit for younger adults after single incident neurological events, over a 5-year period. Results: Analysis showed a stable case-mix of patients over the 5 years surveyed with a preponderance of young male patients after traumatic brain injury. Improvements in patients' disability and dependency, measured by the Barthel Index and Functional Independence Measure, were recorded in the majority of patients. The ethnic diversity of the patients, reflecting the multi-cultural nature of the catchment population, did not appear to affect rehabilitation outcome. Failure to record improvement in 15% of patients was related to the floor and ceiling effects of the instruments. A useful regression equation was produced relating length of stay to Barthel score on admission. Conclusions: These data demonstrate the changes that occur during early inpatient rehabilitation after single incident brain injury. They explore clinical indicators of dependency and outcome, and aspects of resource utilization that characterize our service. Publication of data of this sort, from this and other units, should encourage the development and improvement of current rehabilitation service delivery after brain injury.	Homerton Hosp, Reg Neurol Rehabil Unit, London, England	Greenwood, RJ (corresponding author), Homerton Hosp, Reg Neurol Rehabil Unit, London, England.	Richard.Greenwood@homerton.nhs.uk	Edwards, Mark J/F-1052-2012	Edwards, Mark J/0000-0002-8283-9015			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Clark Luther T., 1999, American Journal of Medicine, V107, p22S; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Crombie I., 1993, AUDIT HDB IMPROVING; Haigh R, 2001, J REHABIL MED, V33, P273; *INT WORK PART STR, 1999, NAT CLIN GUID STROK; King JT, 1997, NEUROIMAG CLIN N AM, V7, P659; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MAHONEY F I, 1965, Md State Med J, V14, P61; McMillan T. M., 1993, CLIN REHABIL, V7, P346; McNeil JE, 1999, NEUROPSYCHOL REHABIL, V9, P321, DOI 10.1080/096020199389400; Mountney L, 2000, CLIN REHABIL, V14, P111; Novak S., 1996, CLIN REHABIL, V10, P128; RONDINELLI RD, 1991, ARCH PHYS MED REHAB, V72, P447; *ROYAL COLL SURG E, 1999, REP WORK PART MAN PA; SCHYVE PM, 1990, MEASURING OUTCOMES M; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SORYAL I, 1992, CLIN REHABIL, V6, P103; *STAT U NY BUFF, 1993, GUID UN DAT SYST MED; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; STINEMAN MG, 1998, CRIT REV PHYS REHABI, V10, P319; *STROK UN TRIAL CO, 1999, COCHR LIB; Tesio L, 1996, DISABIL REHABIL, V18, P502, DOI 10.3109/09638289609166036; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008	25	19	21	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	APR 22	2003	25	8					405	410		10.1080/0963828031000062642			6	Rehabilitation	Rehabilitation	683KN	WOS:000183147400005	12745950				2021-06-18	
J	Bleich, S; Wilhelm, J; Graesel, E; Degner, D; Sperling, W; Rossner, V; Javaheripour, K; Kornhuber, J				Bleich, S; Wilhelm, J; Graesel, E; Degner, D; Sperling, W; Rossner, V; Javaheripour, K; Kornhuber, J			Apolipoprotein E epsilon 4 is associated with hippocampal volume reduction in females with alcoholism	JOURNAL OF NEURAL TRANSMISSION			English	Article						alcoholism; apolipoprotein E epsilon 4 allele; hippocampal volume; brain shrinkage	TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; E GENOTYPE; ALLELE DISTRIBUTION; CEREBRAL-CORTEX; E POLYMORPHISM; ATROPHY; NEURONS; SUSCEPTIBILITY; DEFICITS	There is evidence that a higher incidence of diverse neurodegenerative diseases is associated with the apolipoprotein E epsilon4 allele (ApoE4). Most recently it has been found that the ApoE4 allele is specifically related to an accelerated hippocampal atrophy in patients with Alzheimer's disease. Therefore, the aim of the present study was to investigate the association between ApoE4 genotypes and brain hippocampal volume reduction in alcoholics by using volumetric high-resolution MR imaging. In the present study, female alcoholics with the ApoE4 genotype were found to have significantly smaller hippocampal volumes than those not carrying an 84 allele (ANOVA, p < 0.05), whereas no differences in hippocampal volume were seen in male alcoholics. Since hippocampal volume reduction is lately discussed to be proportional to brain atrophy, we propose that the alcohol-related brain atrophy in patients suffering from chronic alcoholism, is more pronounced in female carriers of the apoE epsilon4 allele. These findings indicate a genetic disposition for alcohol related brain atrophy in female carrying the ApoE4 genotype, which may also explain why female alcoholics are more susceptible to alcohol-induced brain damage.	Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, D-91054 Erlangen, Germany; Univ Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany; Univ Gottingen, Dept Neuroradiol, Gottingen, Germany	Kornhuber, J (corresponding author), Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, Schwabachanlage 6-10, D-91054 Erlangen, Germany.		Roessner, Veit/AAQ-8760-2020; Bleich, Stefan/ABC-1796-2020; Kornhuber, Johannes/B-9613-2014; Roessner, Veit/A-6876-2009	Kornhuber, Johannes/0000-0002-8096-3987; 			Agartz I, 1999, ARCH GEN PSYCHIAT, V56, P356, DOI 10.1001/archpsyc.56.4.356; AMOUYEL P, 1994, LANCET, V344, P1315, DOI 10.1016/S0140-6736(94)90691-2; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Bleich S, 2000, ALCOHOL ALCOHOLISM, V35, P351, DOI 10.1093/alcalc/35.4.351; Bretsky PM, 1999, ALZ DIS ASSOC DIS, V13, P216, DOI 10.1097/00002093-199910000-00007; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DELAMONTE SM, 1988, ARCH NEUROL-CHICAGO, V45, P990, DOI 10.1001/archneur.1988.00520330076013; Durany N, 2000, PSYCHIAT GENET, V10, P73, DOI 10.1097/00041444-200010020-00003; Duvernoy H.M., 1998, HUMAN HIPPOCAMPUS FU; FERRER I, 1984, NEUROPATH APPL NEURO, V10, P245, DOI 10.1111/j.1365-2990.1984.tb00357.x; FOX JH, 1976, JAMA-J AM MED ASSOC, V236, P365, DOI 10.1001/jama.236.4.365; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HARPER C, 1987, BRIT MED J, V294, P534, DOI 10.1136/bmj.294.6571.534; HARPER C, 1989, J NEUROL SCI, V92, P81, DOI 10.1016/0022-510X(89)90177-9; HARPER CG, 1990, ALCOHOL ALCOHOLISM, V25, P207, DOI 10.1093/oxfordjournals.alcalc.a044994; Harrington CR, 1995, NEUROSCI LETT, V202, P101, DOI 10.1016/0304-3940(95)12218-4; JERNIGAN TL, 1991, ALCOHOL CLIN EXP RES, V15, P418, DOI 10.1111/j.1530-0277.1991.tb00540.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalman J, 2000, NEUROBIOL AGING, V21, P555, DOI 10.1016/S0197-4580(00)00150-0; KORSAKOFF SS, 1887, VESTNIK PSICHIATRII, V4, P2; KRIL JJ, 1993, J NEUROPATH EXP NEUR, V52, P586, DOI 10.1097/00005072-199311000-00005; Laakso MP, 2000, BEHAV BRAIN RES, V109, P177, DOI 10.1016/S0166-4328(99)00172-2; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mori E, 2002, ANN NEUROL, V51, P209, DOI 10.1002/ana.10093; Muramatsu T, 1997, J NEURAL TRANSM, V104, P913, DOI 10.1007/BF01285559; MURAMATSU T, 1994, ANN NEUROL, V36, P797, DOI 10.1002/ana.410360519; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; PAYAMI H, 1993, LANCET, V342, P738; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RIIKONEN RS, 1994, PEDIATR NEUROL, V11, P332, DOI 10.1016/0887-8994(94)90012-4; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHNEIDER JA, 1995, ANN NEUROL, V38, P131, DOI 10.1002/ana.410380122; SULLIVAN EV, 1995, ALCOHOL CLIN EXP RES, V19, P110, DOI 10.1111/j.1530-0277.1995.tb01478.x; TORVIK A, 1982, J NEUROL SCI, V56, P233, DOI 10.1016/0022-510X(82)90145-9; TSAI GC, 1995, AM J PSYCHIAT, V152, P332; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wernicke C., 1881, LEHRBUCH GEHIRNKRANK	41	19	19	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0300-9564			J NEURAL TRANSM	J. Neural Transm.	APR	2003	110	4					401	411		10.1007/s00702-002-0789-1			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	666NB	WOS:000182182400007	12658367				2021-06-18	
J	Buhre, W; Heinzel, FR; Grund, S; Sonntag, H; Weyland, A				Buhre, W; Heinzel, FR; Grund, S; Sonntag, H; Weyland, A			Extrapolation to zero-flow pressure in cerebral arteries to estimate intracranial pressure	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain, blood flow; brain, intracranial pressure; head, injury	CRITICAL CLOSING PRESSURE; PERFUSION-PRESSURE; CIRCULATION; HYPERTENSION; VELOCITY; INJURY	Background. Cerebral perfusion pressure (CPP) is commonly calculated from the difference between arterial blood pressure (AP) and intracranial pressure (ICP). ICP can be considered the effective downstream pressure of the cerebral circulation. Consequently, cerebral circulatory arrest would occur when AP equals ICP. Estimation of AP for zero-flow pressure (ZFP) may thus allow estimation of ICP. We estimated ZFP from cerebral pressure-flow velocity relationships so that ICP could be measured by transcranial Doppler sonography. Methods. We studied 20 mechanically ventilated patients with severe head injury, in whom ICP was monitored by epidural pressure transducers. AP was measured with a radial artery cannula. Blood flow velocity in the middle cerebral artery (V-MCA) ipsilateral to the site of ICP measurement was measured with a 2 MHz transcranial Doppler probe. All data were recorded by a microcomputer from analogue-digital converters. ZFP was extrapolated by regression analysis of AP-V-MCA plots and compared with simultaneous measurements of ICP. Results. ZFP estimated from AP-V-MCA plots was linearly related to ICP over a wide range of values (r=0.93). There was no systematic difference between ZFP and ICP. Limit of agreement (2 sd) was 15.2 mm Hg. Short-term variations in ICP were closely followed by changes in ZFP. Conclusion. Extrapolation of cerebral ZFP from instantaneous AP-V-MCA relationships enables detection of severely elevated ICP and may be a useful and less invasive method for CPP monitoring than other methods.	Univ Klinikum RWTH Aachen, Anasthesiol Klin, D-52074 Aachen, Germany; Univ Essen Gesamthsch Klinikum, Inst Pathophysiol, D-4300 Essen, Germany; Univ Gottingen, Zentrum Anaesthesiol Rettungs & Intens Med, D-3400 Gottingen, Germany; Anasthesiol Klin, Oldenburg, Germany; Operat Intens Med Stadt Kliniken, Oldenburg, Germany	Buhre, W (corresponding author), Univ Klinikum RWTH Aachen, Anasthesiol Klin, Pauwelsstr 30, D-52074 Aachen, Germany.		Buhre, Wolfgang/X-9192-2018	Heinzel, Frank R./0000-0002-4529-5282			AASLID R, 1986, NEURORADIOLOGY, V28, P11, DOI 10.1007/BF00341759; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DEWEY RC, 1976, AM J SURG, V131, P338, DOI 10.1016/0002-9610(76)90128-8; EARLY CB, 1974, J NEUROSURG, V41, P590, DOI 10.3171/jns.1974.41.5.0590; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KLOCKE FJ, 1985, CIRC RES, V56, P310, DOI 10.1161/01.RES.56.3.310; Lang E W, 1995, New Horiz, V3, P400; Lannoo E, 1998, INTENS CARE MED, V24, P236, DOI 10.1007/s001340050556; MELOT C, 1995, AM J PHYSIOL-HEART C, V268, pH817; Nanto S, 1996, ANGIOLOGY, V47, P115, DOI 10.1177/000331979604700202; PANERAI RB, 1995, NEUROPEDIATRICS, V26, P168, DOI 10.1055/s-2007-979748; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thees C, 2002, ANESTHESIOLOGY, V96, P595, DOI 10.1097/00000542-200203000-00014; Weyland A, 2000, J NEUROSURG ANESTH, V12, P210, DOI 10.1097/00008506-200007000-00002; WEYLAND A, 1994, ANESTHESIOLOGY, V81, P1401, DOI 10.1097/00000542-199412000-00015	18	19	20	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	MAR	2003	90	3					291	295		10.1093/bja/aeg073			5	Anesthesiology	Anesthesiology	652ZG	WOS:000181410300005	12594138	Bronze			2021-06-18	
J	Eames, P; Wood, RL				Eames, P; Wood, RL			Episodic disorders of behaviour and affect after acquired brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							AGGRESSIVE-BEHAVIOR; DYSCONTROL; CARBAMAZEPINE; PROPRANOLOL; OUTBURSTS; EPILEPSY	Psychological disorders that follow traumatic brain injury are possibly more complex and diverse than those associated with other forms of "brain damage". These may include organic aggressive, or organic affective syndromes that are episodic in nature and therefore require a more specific diagnosis, a different classification, and a different approach to treatment. Consequently, it is necessary for clinicians to learn to distinguish between "primary" psychiatric illnesses and those disorders of behavioural control and mood that stem specifically from brain injury. There is relatively little in the clinical literature that explains the relationship between variable states of behaviour, mood or temperament, and clinical disorders that may have long-term implications for patient management. This concept paper therefore addresses abnormalities of mood and behaviour that are episodic in character and are not recognisably included in the DSM and ICD classifications of psychological or psychiatric disorders.	Univ Coll Swansea, Dept Psychol, Swansea SA2 8PP, W Glam, Wales; Beechwood House Brain Injury Rehabil Unit, Pontypool, Wales	Wood, RL (corresponding author), Univ Coll Swansea, Dept Psychol, Singleon Pk, Swansea SA2 8PP, W Glam, Wales.						ADAMEC RE, 1990, BIOL PSYCHIAT, V27, P249, DOI 10.1016/0006-3223(90)90001-I; ADAMEC RE, 1978, LIMBIC MECHANISMS CO, P405; ALDERMAN N, 2000, NEUROBEHAVIOURAL DIS; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANGST J, 1994, J CLIN PSYCHIAT, V55, P3; BACHYRITA G, 1971, AM J PSYCHIAT, V127, P1473, DOI 10.1176/ajp.127.11.1473; BACON C, 1982, BRIT J CLIN SOCIAL P, V2, P16; BLECK TP, 1990, CLIN NEUROPHARMACOL, V13, P121, DOI 10.1097/00002826-199004000-00002; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BRODSKY L, 1978, 2 WORLD C BIOL PSYCH; CORRIGAN PW, 1993, HOSP COMMUNITY PSYCH, V44, P125; Demark J, 2002, BRAIN INJURY, V16, P91, DOI 10.1080/02699050110102059; DEVINSKY O, 1984, AM J PSYCHIAT, V141, P651; Eames P. G., 1990, NEUROBEHAVIOURAL SEQ; ELLIOTT FA, 1982, J NERV MENT DIS, V170, P680, DOI 10.1097/00005053-198211000-00007; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; Fava M, 1997, PSYCHIAT CLIN N AM, V20, P427, DOI 10.1016/S0193-953X(05)70321-X; FREDERIKSEN LW, 1981, VIOLENT BEHAV SOCIAL, P265; GLENN MB, 1989, AM J PHYS MED REHAB, V68, P221, DOI 10.1097/00002060-198910000-00004; HARPER M, 1962, COMPR PSYCHIAT, V3, P129; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; HOOPER R S, 1945, J Ment Sci, V91, P458; KAPLAN K, 1899, P ROY SOC MED, V2, P458; KOCH G, 1987, ARCH NEUROL-CHICAGO, V44, P578, DOI 10.1001/archneur.1987.00520180004003; Kraepelin, 1921, MANIC DEPRESSIVE INS; Letterman L, 1999, PHARMACOTHERAPY, V19, P565, DOI 10.1592/phco.19.8.565.31521; LEWIN J, 1992, BRIT J PSYCHIAT, V161, P261, DOI 10.1192/bjp.161.2.261; MAHCESTER D, 2000, NEUROBEHAVIOURAL DIS; MALETZKY BM, 1973, DIS NERV SYST, V34, P178; MATTES JA, 1986, J NERV MENT DIS, V174, P464, DOI 10.1097/00005053-198608000-00004; MATTES JA, 1984, PSYCHOPHARMACOL BULL, V20, P98; MONROE RR, 1989, COMPR PSYCHIAT, V30, P489, DOI 10.1016/0010-440X(89)90078-3; MONROE RR, 1982, J NERV MENT DIS, V170, P711, DOI 10.1097/00005053-198212000-00001; Monroe RR, 1970, EPISODIC BEHAV DISOR; MONROE RR, 1986, LIMBIC SYSTEM FUNCTI, P251; MONROE RR, 1978, BRAIN DYSFUNCTION AG, P105; Morikawa M, 2000, Nihon Shinkei Seishin Yakurigaku Zasshi, V20, P149; NOVACO RW, 1975, ANGER CONTROL DEV DE; ONEILL H, 1999, MANAGING ANGER; Penfield W., 1961, EPILEPSIA, V2, P109; PINEL JPJ, 1977, SCIENCE, V197, P1088, DOI 10.1126/science.560719; POND DA, 1957, J INDIAN MED PROFESS, V3, P1441; POST RM, 1985, PSYCHIAT J U OTTAWA, V10, P205; SACHDEO RC, 1987, LANCET, V1, P1432; SILVER JM, 1987, PSYCHIAT ANN, V17, P367, DOI 10.3928/0048-5713-19870601-06; Silver Jonathan M., 1994, P313; STEIN G, 1992, BRIT J PSYCHIAT, V161, P167, DOI 10.1192/bjp.161.2.167; STONE JL, 1986, BIOL PSYCHIAT, V21, P208, DOI 10.1016/0006-3223(86)90148-4; Tariot PN, 1998, AM J PSYCHIAT, V155, P54, DOI 10.1176/ajp.155.1.54; Wood R, 2000, NEUROBEHAVIOURAL DIS; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Wroblewski BA, 1997, BRAIN INJURY, V11, P37, DOI 10.1080/026990597123791; Young J L, 1994, Bull Am Acad Psychiatry Law, V22, P53	54	19	19	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		241	258		10.1080/09602010244000435			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500013	21854336				2021-06-18	
J	Setkowicz, Z; Janeczko, K				Setkowicz, Z; Janeczko, K			Long-term changes in susceptibility to pilocarpine-induced status epilepticus following neocortical injuries in the rat at different developmental stages	EPILEPSY RESEARCH			English	Article						developing brain; mechanical injury; seizure susceptibility; pilocarpine model of epilepsy	TRAUMATIC BRAIN INJURY; TEMPORAL-LOBE EPILEPSY; AGE-DEPENDENT CHANGES; SEIZURE SUSCEPTIBILITY; IMMATURE RAT; PROLIFERATIVE RESPONSE; CEREBRAL HEMISPHERE; NERVOUS-SYSTEM; GAP-JUNCTIONS; NEONATAL RAT	In the brain, injury-induced gliosis and axonal sprouting have been regarded as age-dependent repairing processes with, unfortunately, epileptogenic effects. The present study examines whether brains injured at different developmental stages become more or less susceptible to experimentally-induced status epilepticus. In 6- and 30-day-old Wistar rats (P6s and P30s, respectively), a mechanical injury was performed in the cortex of the left cerebral hemisphere. On postnatal day 60, all the animals and naive controls received single intraperitoneally pilocarpine injections to evoke status epilepticus. During a 6-h period following the injection, the animals were observed continuously and motor manifestations of seizure activity were recorded and rated. Seven days after pilocarpine injection, the animals were perfused and their body and brain weights recorded. When compared to controls, P6s showed neither significant variations in their epileptic behavior nor in brain and body weights. In relation to controls and to P6s, P30s presented an extremely high mortality, a significant loss of body weight and much longer-lasting seizures of much higher intensity. The data provide evidence that the long-term variations in susceptibility to experimentally-induced status epilepticus are determined by differences in the brain response to injury at different stages of postnatal development. (C) 2003 Elsevier Science B.V. All rights reserved.	Jagiellonian Univ, Dept Neuroanat, Inst Zool, PL-30060 Krakow, Poland	Janeczko, K (corresponding author), Jagiellonian Univ, Dept Neuroanat, Inst Zool, Ingardena 6, PL-30060 Krakow, Poland.			Janeczko, Krzysztof/0000-0002-9544-918X; Setkowicz, Zuzanna/0000-0002-7213-8194			Acarin L, 2001, Prog Brain Res, V132, P375; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Carlen PL, 2000, BRAIN RES REV, V32, P235, DOI 10.1016/S0165-0173(99)00084-3; CASSEL JC, 1987, EXP NEUROL, V97, P564, DOI 10.1016/0014-4886(87)90114-2; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; DORETTO MC, 1995, PHYSIOL BEHAV, V58, P273, DOI 10.1016/0031-9384(95)00050-S; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Fernandes MJD, 1999, J CEREBR BLOOD F MET, V19, P195; Fonseca CG, 2002, BRAIN RES, V929, P105, DOI 10.1016/S0006-8993(01)03289-9; Golarai G, 2001, J NEUROSCI, V21, P8523; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Jacobs KM, 2000, EPILEPSIA, V41, pS153, DOI 10.1111/j.1528-1157.2000.tb01574.x; JANECZKO K, 1994, INT J DEV NEUROSCI, V12, P431, DOI 10.1016/0736-5748(94)90027-2; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; JENSEN FE, 1992, EPILEPSIA, V33, P971, DOI 10.1111/j.1528-1157.1992.tb01746.x; Koh S, 1999, NEUROLOGY, V53, P915, DOI 10.1212/WNL.53.5.915; KOLASA K, 1992, PHARMACOL BIOCHEM BE, V41, P99, DOI 10.1016/0091-3057(92)90066-O; Kolb B, 1998, BEHAV BRAIN RES, V91, P127, DOI 10.1016/S0166-4328(97)00112-5; LOSCHER W, 1995, BRAIN RES, V697, P197, DOI 10.1016/0006-8993(95)00843-F; MAROSI M, 1994, EPILEPSY RES, V19, P63, DOI 10.1016/0920-1211(94)90089-2; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; MOSHE SL, 1985, BRAIN RES, V337, P368, DOI 10.1016/0006-8993(85)90077-0; Nehlig A, 2002, EPILEPSY RES, V51, P189, DOI 10.1016/S0920-1211(02)00125-0; OKADA R, 1984, DEV BRAIN RES, V15, P177, DOI 10.1016/0165-3806(84)90095-6; Priel MR, 1996, EPILEPSY RES, V26, P115, DOI 10.1016/S0920-1211(96)00047-2; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1219; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Rice DC, 2000, ENVIRON HEALTH PERSP, V108, P405, DOI 10.2307/3454528; ROMIJN HJ, 1994, EPILEPSY RES, V17, P31, DOI 10.1016/0920-1211(94)90077-9; Rozental R, 2000, BRAIN RES REV, V32, P11, DOI 10.1016/S0165-0173(99)00095-8; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Sankar R, 1998, J NEUROSCI, V18, P8382; Schmid R, 1999, NEUROLOGY, V53, P1754, DOI 10.1212/WNL.53.8.1754; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Towfighi J, 1997, DEV BRAIN RES, V100, P149, DOI 10.1016/S0165-3806(97)00036-9; TURSKI L, 1989, SYNAPSE, V3, P154, DOI 10.1002/syn.890030207; Wong M, 2001, DEV BRAIN RES, V128, P113, DOI 10.1016/S0165-3806(01)00149-3; XIA Y, 1995, BRAIN RES, V675, P224, DOI 10.1016/0006-8993(95)00079-6	45	19	22	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	MAR	2003	53	3					216	224		10.1016/S0920-1211(03)00029-9			9	Clinical Neurology	Neurosciences & Neurology	674KH	WOS:000182635600006	12694930				2021-06-18	
J	Woischneck, D; Klein, S; Reissberg, S; Peters, B; Avenarius, S; Gunther, G; Firsching, R				Woischneck, D; Klein, S; Reissberg, S; Peters, B; Avenarius, S; Gunther, G; Firsching, R			Prognosis of brain stem lesion in children with head injury	CHILDS NERVOUS SYSTEM			English	Article						head injury; children; magnetic resonance imaging; brain stem lesion	EVOKED-POTENTIALS	Introduction: Traumatic brain stem lesions (tBSL) in children are thought to be a rare phenomenon. This prospective study analyzed the frequency and significance of such lesions on early magnetic resonance imaging (MRI) after severe head injury, since CT fails to demonstrate these lesions. Methods: In 30 consecutive children comatose after head injuries, MRI was performed within 8 days of the injury. Results: The incidence of tBSL was 60%. When the lesion affected the pons or caudal portions of medulla oblongata bilaterally, mortality was 100%. The presence of tBSL significantly correlated with the duration of coma and the categories of outcome, as indicated by the Glasgow Outcome Score. The frequency and the distribution of tBSL in children were similar to adults. Conclusion: Magnetic resonance imaging appears to be of high predictive value after severe pediatric head injuries.	Otto Von Guericke Univ, Neurochirurg Klin, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Radiol Diagnost Klin, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Biomed & Med Stat, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Klin Allgemeine Padiatrie & Neonatol, D-39120 Magdeburg, Germany	Woischneck, D (corresponding author), Otto Von Guericke Univ, Neurochirurg Klin, Leipziger Str 44, D-39120 Magdeburg, Germany.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ALEXANDER E, 1982, SURG NEUROL, V17, P107, DOI 10.1016/S0090-3019(82)80031-1; BERNARDI B, 1993, TOP MAGN RESON IMAG, V5, P161; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; FIRSCHING R, 1990, NEUROSURG REV, V13, P141, DOI 10.1007/BF00383655; FROWEIN RA, 1976, ACTA NEUROCHIR, V34, P1; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; JENNETT B, 1975, LANCET, V1, P81; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Nieuwenhuys R., 1985, CHEMOARCHITECTURE BR; Stein H, 1996, ZBL CHIR, V121, P985; Wijdicks EFM, 1997, NEUROLOGY, V48, P1456, DOI 10.1212/WNL.48.5.1456	19	19	19	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	MAR	2003	19	3					174	178		10.1007/s00381-002-0703-z			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	670LV	WOS:000182410600008	12644869				2021-06-18	
J	Whyte, J; Hart, T; Bode, RK; Malec, JF				Whyte, J; Hart, T; Bode, RK; Malec, JF			The Moss Attention Rating Scale for traumatic brain injury: Initial psychometric assessment	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						attention; brain injuries; rehabilitation	HEAD-INJURY; WORKING-MEMORY; TASK; METHYLPHENIDATE; BEHAVIOR	Objective: To examine the psychometric properties of the Moss Attention Rating Scale (MARS), a new observational rating scale for attention-related behaviors in traumatic brain injury (TBI). Design: Prospective observational study. Setting: Eight acute inpatient rehabilitation facilities that are part of the Traumatic Brain Injury Model Systems program. Participants: Two hundred twenty-eight patients with TBI requiring acute inpatient rehabilitation treatment. Interventions: Not applicable. Main Outcome Measures: Rasch analysis on the 53-item MARS (45 attention items, 8 control items) as rated separately by the treating occupational therapist and physical therapist. Results: The MARS appeared to measure a single dimension and demonstrated good person separation (5.69) and reliability (.97). In post hoc assessment, misfitting attention items may not have required attention and control items that fit the dimension may have required at least rudimentary attention. Occupational therapists rated patients as slightly less attentive than did physical therapists. Overall, the scale was well targeted to an acute inpatient rehabilitation population. Conclusions: Our results provide: preliminary support for the viability of developing an observational attention rating scale for use in inpatient TBI rehabilitation. Further research will need to explore the existence of subdimensions and provide further validation with reference to other neuropsychologic measures of attention and knowledge of lesion severity and localization.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Mayo Clin & Mayo Grad Sch Med, Rochester, MN USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474			Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; Hinshaw SP, 1999, DIAGNOSTIC ASSESSMENT IN CHILD AND ADOLESCENT PSYCHOPATHOLOGY, P91; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Linacre J. M., 1989, MANY FACET RASCH MEA; LINACRE JM, 2001, FACETS RASCH ANAL CO; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mehta MA, 2000, J NEUROSCI, V20; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Rasch G., 1980, PROBABILISTIC MODELS; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Whyte J, 1998, REHABILITATION MED P, P1191; WHYTE J, 1998, P 5 INT ASS STUD TRA, P154; Whyte J., 1997, PROMISE OUTCOMES RES, P43; WILLIAMS JM, 1987, COGNITIVE BEHAV RATI; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wright B. D., 1982, RATING SCALE ANAL RA; WRIGHT BD, 2001, WINSTEPS RASCH ANAL	29	19	19	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					268	276		10.1053/apmr.2003.50108			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700018	12601660				2021-06-18	
J	Bayir, H; Kochanek, TM; Liu, SX; Arroyo, A; Osipov, A; Jiang, TF; Wisniewski, S; Adelson, PD; Graham, SH; Kagan, VE				Bayir, H; Kochanek, TM; Liu, SX; Arroyo, A; Osipov, A; Jiang, TF; Wisniewski, S; Adelson, PD; Graham, SH; Kagan, VE			Increased S-nitrosothiols and S-nitrosoalbumin in cerebrospinal fluid after severe traumatic brain injury in infants and children: Indirect association with intracranial pressure	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						nitric oxide; nitrosative stress; oxidative stress; head injury; ascorbate; DAF-2	NITRIC-OXIDE SYNTHASE; ANTIPLATELET PROPERTIES; PLATELET-AGGREGATION; OXIDATIVE STRESS; MICE DEFICIENT; SMOOTH-MUSCLE; ALBUMIN; INHIBITION; PLASMA; NITROSOGLUTATHIONE	Nitric oxide (NO) is implicated in both secondary damage and recovery after traumatic brain injury (TBI). Transfer of NO groups to cysteine sulfhydryls on proteins produces S-nitrosothiols (RSNO). S-nitrosothiols may be neuroprotective after TBI by nitrosylation of N-methyl-D-aspartate receptor and caspases. S-nitrosothiols release NO on decomposition for which endogenous reductants (i.e., ascorbate) are essential, and ascorbate is depleted in cerebrospinal fluid (CSF) after pediatric TBI. This study examined the presence and decomposition of RSNO in CSF and the association between CSF RSNO level and physiologic parameters after severe TBI. Cerebrospinal fluid samples (n = 72) were obtained from 48 infants and children on days I to 3 after severe TBI (Glasgow Coma Scale score < 8) and 18 controls. Cerebrospinal fluid RSNO levels assessed by fluorometric assay peaked on day 3 versus control (1.42 +/- 0.11 mu mol/L vs. 0.86 +/- 0.04, P < 0.05). S-nitrosoalbumin levels were also higher after TBI (n = 8, 0.99 +/- 0.09 mumol/L on day 3 vs. n = 6, 0.42 +/- 0.02 in controls, P < 0.05). S-nitrosoalbumin decomposition was decreased after TbI. Multivariate analysis showed an inverse relation between CSF RSNO and intracranial pressure and a direct relation with barbiturate treatment. Using a novel assay, the presence of RSNO and S-nitrosoalbumin in human CSF, an similar to 1.7-fold increase after TBI, and an association with low intracranial pressure are reported, supporting a possible neuroprotective role for RSNO. The increase in RSNO may result from increased NO production and/or decreased RSNO decomposition.	Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth & Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Kagan, VE (corresponding author), Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth & Pharmacol, 3343 Forbes Ave, Pittsburgh, PA 15213 USA.	kagan@pitt.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL64145] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P01NS030318, P20NS030318] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; AMANO M, 1994, J CARDIOVASC PHARM, V24, P860, DOI 10.1097/00005344-199424060-00002; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Boje KMK, 2000, J PHARMACOL EXP THER, V293, P545; Bullock MR, 1996, J NEUROTRAUM, V13, P667; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; DAWSON TM, 1994, PROG BRAIN RES, V103, P365; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Gaston B, 1998, BIOCHEM BIOPH RES CO, V253, P899, DOI 10.1006/bbrc.1998.9865; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gluckman TL, 2000, J TOXICOL ENV HEAL A, V61, P9, DOI 10.1080/00984100050116753; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; Hogg N, 1999, ANAL BIOCHEM, V272, P257, DOI 10.1006/abio.1999.4199; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ILLI OE, 1983, HELV PAEDIATR ACTA, V38, P323; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; Johnson MA, 2001, J BIOL CHEM, V276, P39872, DOI 10.1074/jbc.M102781200; Jourd'heuil D, 2000, FREE RADICAL BIO MED, V28, P409, DOI 10.1016/S0891-5849(99)00257-9; KashibaIwatsuki M, 1997, ARCH BIOCHEM BIOPHYS, V345, P237, DOI 10.1006/abbi.1997.0258; Kastenbauer S, 1999, J INFECT DIS, V180, P1164, DOI 10.1086/315048; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; Kelm M, 1999, BBA-BIOENERGETICS, V1411, P273, DOI 10.1016/S0005-2728(99)00020-1; Kluge I, 1997, J NEUROCHEM, V69, P2599; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2001, PEDIATR CLIN N AM, V48, P661, DOI 10.1016/S0031-3955(05)70333-3; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Konorev EA, 2000, FREE RADICAL BIO MED, V28, P1671, DOI 10.1016/S0891-5849(00)00281-1; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MELLION BT, 1983, MOL PHARMACOL, V23, P653; MORRIS SL, 1981, J BACTERIOL, V148, P465, DOI 10.1128/JB.148.2.465-471.1981; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; PARK JW, 1988, BIOCHEM BIOPH RES CO, V152, P916, DOI 10.1016/S0006-291X(88)80127-X; Pfeiffer S, 1998, ANAL BIOCHEM, V258, P68, DOI 10.1006/abio.1998.2562; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Schulz JB, 1995, J NEUROSCI, V15, P8419; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; TOMITA H, 1994, ACTA NEUROCHIR, P547; TRAVIS J, 1976, BIOCHEM J, V157, P301, DOI 10.1042/bj1570301; Tyurin VA, 2002, METHOD ENZYMOL, V352, P347; Tyurin VA, 2001, CIRC RES, V88, P1210, DOI 10.1161/hh1101.092179; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu AM, 2000, HYPERTENSION, V36, P291, DOI 10.1161/01.HYP.36.2.291	71	19	20	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2003	23	1					51	61		10.1097/01.WCB.0000040399.30600.E3			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	629LW	WOS:000180052000006	12500091	Bronze			2021-06-18	
J	Godfrey, HPD; Harnett, MA; Knight, RG; Marsh, NV; Kesel, DA; Partridge, FM; Robertson, RH				Godfrey, HPD; Harnett, MA; Knight, RG; Marsh, NV; Kesel, DA; Partridge, FM; Robertson, RH			Assessing distress in caregivers of people with a traumatic brain injury (TBI): a psychometric study of the Head Injury Behaviour Scale	BRAIN INJURY			English	Article							SELF-AWARENESS; FAMILY; REHABILITATION; PERSONALITY; STRESS; ADULTS	This study examined the psychometric properties of the Head Injury Behaviour Scale (HIBS) using responses from 242 caregivers. The HIBS is a 20-item, scale describing common behavioural problems following traumatic brain injury (TBI), which are typical of dysexecutive syndrome. A principal components analysis was conducted on caregiver distress ratings for the 20 items comprising the HIBS and produced a two-factor solution with 10 items loading on each factor. Consequently, two sub-scales were derived and labelled Emotional Regulation and Behavioural Regulation. The sub-scales were found to have good internal-consistency reliability. It is suggested that the Emotional Regulation sub-scale assesses behaviours reflecting impaired emotional control, occurring during interactions with caregivers. The Behavioural Regulation sub-scale assesses problems typical of dysexecutive syndrome, but which carry less emotional valence for caregivers. The clinical implications of these findings are discussed and normative data provided for the two sub-scales.	Univ Otago, Dept Psychol, Dunedin, New Zealand; Univ Teesside, Sch Hlth & Social Care, Middlesbrough, Tees Valley, England; Community Treatment Ctr Acquired Brain Damage, Glasgow, Lanark, Scotland; Psychol Associates, Dunedin, New Zealand	Knight, RG (corresponding author), Univ Otago, Dept Psychol, POB 56, Dunedin, New Zealand.	rknight@psy.otago.ac.nz	Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432; Fountain, Mairead/0000-0003-0575-5368			Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1984, CLOSE HEAD INJURY PS; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GODFREY HPD, 1987, NEW ZEAL J PSYCHOL, V16, P49; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Jennett B, 1981, MANAGEMENT HEAD INJU; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; Man D, 1999, BRAIN INJURY, V13, P433, DOI 10.1080/026990599121485; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Minnes P, 2000, BRAIN INJURY, V14, P737; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PLATT S, 1983, SOCIAL BEHAV ASSESSM; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; ROBERTSON RH, 2002, UNPUB EVALUATION SOC; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P88, DOI 10.1097/00001199-199608000-00011; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Smith L.M., 1995, FAMILY SUPPORT PROGR	28	19	19	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	5					427	435		10.1080/0269905031000066201			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	660MQ	WOS:000181837300006	12745714				2021-06-18	
J	Johnstone, B; Mount, D; Gaines, T; Goldfader, P; Bounds, T; Pitts, O				Johnstone, B; Mount, D; Gaines, T; Goldfader, P; Bounds, T; Pitts, O			Race differences in a sample of vocational rehabilitation clients with traumatic brain injury	BRAIN INJURY			English	Article								Objective : To evaluate race differences in demographics, injury severity, and vocational outcomes for persons with TBI. Participants : Seventy-five individuals with TBI (13 African American, 62 Caucasian) who requested services from the Missouri Division of Vocational Rehabilitation (VR) over a 2-year period. Measures : Demographics (i.e. age, race, level of education), injury severity (i.e. LOC, PTA, length of hospitalization, neuropsychological test scores), VR services provided (e.g. transportation, maintenance, on-the-job training, etc.), and VR outcomes (successfully vs unsuccessfully employed; cost per case). Procedure : All participants completed a standard neuropsychological evaluation and completed VR services (i.e. were followed from enrolment to case closure). Hypotheses : African Americans and Caucasians would not differ in demographics or injury severity, although fewer African Americans would be successfully employed through DVR. Analyses : Chi-squares and non-parametric MANOVAs to evaluate race differences in terms of demographics, injury severity, vocational services provided and vocational outcomes. Results : As hypothesized, there were few race differences in demographics or injury severity, although African Americans received significantly more transportation services (62 vs 21%). Contrary to hypotheses, there was no difference in the number of successfully employed African Americans (23%) vs Caucasians (18%). Conclusions : African Americans and Caucasians with TBI achieve similar vocational successes if they receive state VR services.	Univ Missouri, Columbia, MO USA; Div Vocat Rehabil, Jefferson City, MO USA; Div Vocat Rehabil, St Charles, MO USA	Johnstone, B (corresponding author), Dept Hlth Psychol, DC046-46, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Arnold B. R., 1994, ASSESSMENT, V1, P239, DOI [10.1177/107319119400100303., DOI 10.1177/107319119400100303]; Belgrave FZ, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P585, DOI 10.1037/10361-028; BOUNDS T, IN PRESS NEUROREHABI; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burnett DM, 2000, BRAIN INJURY, V14, P713; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DEFILIPPIS NA, 1991, MANUAL BOOKLET CATEG; GOODALL P, 1994, J HEAD TRAUMA REHAB, V9, P61; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; HURT GD, 2000, NEUROPSYCHOLOGICAL M, P215; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; JOHNSTONE B, IN PRESS ARCH PHYSIC; *KESSL MED REH RES, 2000, TRAUM BRAIN INJ MOD; KLOVE H, CLIN NEUROPSYCHOLOGY, P211; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SEELMAN KD, 1998, PLEN SESS TIDE 3 C A; *US BUR CENS, 2000, STAT COUNT QUICK FAC; Wechsler D., 1997, ADM SCORING MANUAL; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST	30	19	19	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	2					95	104		10.1080/0269905021000010212			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LL	WOS:000180284700001	12519638				2021-06-18	
J	Gauggel, S; Hoop, M; Werner, K				Gauggel, S; Hoop, M; Werner, K			Assigned versus self-set goals and their impact on the performance of brain-damaged patients	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE LESIONS; IMPAIRED AWARENESS; REACTION-TIME; INJURY; PARTICIPATION; ANOSOGNOSIA; VALIDITY; FLUENCY; DESIGN; TASK	The purpose of this study was to investigate the role played by goal difficulty and goal origin (i.e., self-set vs. assigned) on the performance of patients with brain injuries in a simple arithmetic task. Eighty-seven patients with either cerebral vascular accidents or traumatic brain injuries were investigated. Patients were randomly assigned to one of three conditions: (1) one in which a specific, high goal was assigned. (2) one in which a "do your best" goal was given. and (3) one in which a personal goal has to be stated. The results indicate that both goal difficulty and goal origin had an influence on performance. Assigned difficult goals lead to better performance than assigned easy goals. Self-setting a goal did not increase performance to the same level than the assignment of a difficult goal. This lower performance increase with self-set goals can he explained by the fact that participants selected goals which were not as difficult as the assigned difficult goal. Self-set goals were attained by most of the patients and only 1 patient showed a high discrepancy between self-set goal and actual performance. These findings suggest that goal origin and goal difficulty are important moderators in the goal setting process. Furthermore, patients with brain injuries do not necessarily set unrealistic high goals.	Univ Technol Chemnitz, Dept Psychol, D-09107 Chemnitz, Germany	Gauggel, S (corresponding author), Univ Technol Chemnitz, Dept Psychol, D-09107 Chemnitz, Germany.			Gauggel, Siegfried/0000-0002-2742-4917			Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Austin JT, 1996, PSYCHOL BULL, V120, P338, DOI 10.1037/0033-2909.120.3.338; Baldo JV, 1998, NEUROPSYCHOLOGY, V12, P259, DOI 10.1037/0894-4105.12.2.259; BANDURA A, 1991, ORGAN BEHAV HUM DEC, V50, P248, DOI 10.1016/0749-5978(91)90022-L; Becker Edwin D., 1996, ENCY NUCL MAGNETIC R, V1, P1; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; Brown T, 2001, AM POETRY REV, V30, P50; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; EARLEY PC, 1985, ORGAN BEHAV HUM DEC, V36, P378, DOI 10.1016/0749-5978(85)90006-8; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gauggel S, 2000, J HEAD TRAUMA REHAB, V15, P710, DOI 10.1097/00001199-200002000-00009; Gauggel S, 2002, ARCH CLIN NEUROPSYCH, V17, P283, DOI 10.1016/S0887-6177(01)00113-5; Gauggel S, 2001, J CLIN EXP NEUROPSYC, V23, P351, DOI 10.1076/jcen.23.3.351.1178; Gauggel S, 2001, NEUROPSYCHOL REHABIL, V11, P33, DOI 10.1080/09602010042000150; Gauggel S, 2000, NEUROPSYCHOLOGY, V14, P125; GAUGGEL S, 1998, NEUROPSYCHOLOGISCHE; HINSZ VB, 1995, J APPL SOC PSYCHOL, V25, P965, DOI 10.1111/j.1559-1816.1995.tb02385.x; HINSZ VB, 1991, J APPL SOC PSYCHOL, V22, P1296; HOLLENBECK JR, 1987, ORGAN BEHAV HUM DEC, V40, P392, DOI 10.1016/0749-5978(87)90023-9; HOLLENBECK JR, 1989, J APPL PSYCHOL, V74, P951, DOI 10.1037/0021-9010.74.6.951; Horn W, 1983, LEISTUNGSPRUFSYSTEM; HSU LM, 1989, J CONSULT CLIN PSYCH, V57, P131, DOI 10.1037/0022-006X.57.1.131; HUCK SW, 1975, PSYCHOL BULL, V82, P511, DOI 10.1037/h0076767; LATHAM GP, 1982, PERS PSYCHOL, V35, P399, DOI 10.1111/j.1744-6570.1982.tb02204.x; LATHAM GP, 1988, J APPL PSYCHOL, V73, P753, DOI 10.1037/0021-9010.73.4.753; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Locke E.A., 1990, THEORY GOAL SETTING; LOCKE EA, 1991, ORGAN BEHAV HUM DEC, V50, P288, DOI 10.1016/0749-5978(91)90023-M; NAYLOR JC, 1984, RES ORGAN BEHAV, V6, P95; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Schefft BK, 1997, CLIN NEUROPSYCHOLOGY, P237; Schwarzer R., 1994, DIAGNOSTICA, V40, P105; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P93; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STEVENS JP, 1990, INTERMEDIATE STAT; STRECHER VJ, 1995, HEALTH EDUC QUART, V22, P190, DOI 10.1177/109019819502200207; Sturm W, 1983, DIAGNOSTICA, V29, P346; VILKKI J, 1994, NEUROPSYCHOLOGIA, V32, P1257, DOI 10.1016/0028-3932(94)90107-4; VILKKI J, 1991, CORTEX, V27, P203, DOI 10.1016/S0010-9452(13)80124-4	44	19	19	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2002	24	8					1070	1080		10.1076/jcen.24.8.1070.8377			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	642HA	WOS:000180797100008	12650232				2021-06-18	
J	Jako, P				Jako, P			Safety measures in amateur boxing	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CONCUSSION; SPORTS		Int Amateur Boxing Assoc, H-1053 Budapest, Hungary	Jako, P (corresponding author), Int Amateur Boxing Assoc, Veress Palne 33, H-1053 Budapest, Hungary.						Allanson-Winn R. G., 1897, BOXING; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; CANTU RC, 1995, BOXING MED, P11; JAKO P, 2000, HUNGARIAN REV SPORTS, V61, P173; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784	8	19	19	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	DEC	2002	36	6					394	395		10.1136/bjsm.36.6.394			2	Sport Sciences	Sport Sciences	625BD	WOS:000179796200003	12453832	Green Published, Bronze			2021-06-18	
J	Luo, J; Li, N; Robinson, JP; Shi, R				Luo, J; Li, N; Robinson, JP; Shi, R			The increase of reactive oxygen species and their inhibition in an isolated guinea pig spinal cord compression model	SPINAL CORD			English	Article						spinal cord injury; reactive oxygen species (ROS); in vitro; ascorbic acid; hypothermia; flow cytometry	NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; SUPEROXIDE PRODUCTION; MODERATE HYPOTHERMIA; POLYETHYLENE-GLYCOL; CEREBRAL-ISCHEMIA; ASCORBIC-ACID; CNS INJURY; DAMAGE; BRAIN	Study design: In vitro studies using isolated guinea pig spinal cord. Objectives: To develop an alternative model using isolated guinea pig spinal cord, which can be used to screen antioxidants for in vivo SCI treatment. Setting: Department of Basic Medical Sciences, Purdue University, West Lafayette, Indiana, USA. Methods: The compression injury was induced by a constant-displacement of 5-s compression of spinal cord using a modified forceps possessing a spacer. Reactive oxygen species (ROS) were evaluated using three distinct methods: fluorescence microscopy, lipid peroxidation assay, and flow cytometry. Results: The injury-mediated ROS increases are comparable with other in vivo studies and consistent with our previous observation using a similar injury model and measured with electrophysiological and anatomical technique. Further, ascorbic acid, hypothermia, or the combination of both significantly suppressed superoxide and lipid peroxidation. The combination treatment was the most effective when compared with ascorbic acid or hypothermia alone. Conclusion: This in vitro model has the advantage of replicating some of the in vivo conditions while gaining the ability to control the experimental conditions. This in vitro model is suitable to study the mechanisms of ROS generation and degradation and can also be used to critically evaluate the effective suppressor of ROS in the contents of spinal cord traumatic injury.	Purdue Univ, Sch Vet Med, Dept Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Cytometry Labs, W Lafayette, IN USA	Shi, R (corresponding author), Purdue Univ, Sch Vet Med, Dept Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA.		Robinson, Joseph/AAA-1001-2020; Robinson, Joseph P/K-8492-2012; Luo, Jian/B-8449-2014	Robinson, Joseph/0000-0001-8383-3240; Luo, Jian/0000-0002-2064-8467			Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ASANO T, 1995, J NEUROTRAUM, V12, P993; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; De Zwart LL, 1999, FREE RADICAL BIO MED, V26, P202, DOI 10.1016/S0891-5849(98)00196-8; Dietrich WD, 1996, ADV NEUROL, V71, P177; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1992, J NEUROTRAUM, V9, P169, DOI 10.1089/neu.1992.9.169; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GROGAN WM, 1990, GUIDE FLOW CYTOMETRY; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; IWASA K, 1989, FREE RADICAL BIO MED, V6, P599, DOI 10.1016/0891-5849(89)90067-1; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; LAM DKC, 1986, Q J EXP PHYSIOL CMS, V71, P483, DOI 10.1113/expphysiol.1986.sp003007; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; May JM, 1999, FASEB J, V13, P995; Mu XJ, 2000, BRAIN RES, V870, P66, DOI 10.1016/S0006-8993(00)02402-1; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Povlishock J T, 1992, Hum Cell, V5, P345; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; ROBINSON JP, 1993, HDB FLOW CYTOMETRY M; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Springer JE, 1997, J NEUROCHEM, V68, P2469; Taoka Y, 1998, BRAIN RES, V799, P264, DOI 10.1016/S0006-8993(98)00459-4; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660	45	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393			SPINAL CORD	Spinal Cord	DEC	2002	40	12					656	665		10.1038/sj.sc.3101363			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	625QF	WOS:000179826600007	12483500	Bronze			2021-06-18	
J	MacKay, DG; James, LE				MacKay, DG; James, LE			Aging, retrograde amnesia, and the binding problem for phonology and orthography: A longitudinal study of "hippocampal amnesic" HM	AGING NEUROPSYCHOLOGY AND COGNITION			English	Article							CLOSED-HEAD-INJURY; OLDER ADULTS; TEMPORAL-LOBE; THEORETICAL IMPLICATIONS; LANGUAGE PRODUCTION; NEURONAL-ACTIVITY; EXPLICIT MEMORY; WORD RETRIEVAL; SYSTEM; AGE	This study develops and tests a theory of aging and long-term retrograde amnesia (RA) that extends to word retrieval, including the seemingly simple retrieval task of reading isolated words. Under the theory, transmission deficits due to aging, nonrecent use of connections, and infrequent use of connections over the lifespan cause mild and reversible RA in normals but severe and irreversible RA in amnesics who cannot readily form new connections to replace nonfunctioning ones. Consistent with this theory, "hippocampal amnesic" H.M. exhibited little or no retrieval deficit relative to memory-normal controls in reading short, moderately high frequency words at ages 60 or 71 but exhibited accelerated age-linked declines for low frequency words that were unrelated to cerebellar function, working memory capacity, practice effects, speed-accuracy trade-off, and sensory or attentional deficits.	Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA	MacKay, DG (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	mackay@psych.ucla.edu					ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; Atkinson R. C., 1968, PSYCHOL LEARN MOTIV, V2, P89, DOI [10.1016/S0079-7421(08)60422-3, DOI 10.1016/S0079-7421(08)60422-3]; BALOTA DA, 1993, J MEM LANG, V32, P573, DOI 10.1006/jmla.1993.1029; Bock K, 1996, PSYCHON B REV, V3, P395, DOI 10.3758/BF03214545; Burke DM, 1997, PHILOS T R SOC B, V352, P1845, DOI 10.1098/rstb.1997.0170; BURKE DM, 1991, J MEM LANG, V30, P542, DOI 10.1016/0749-596X(91)90026-G; CARPENTER GA, 1993, TRENDS NEUROSCI, V16, P131, DOI 10.1016/0166-2236(93)90118-6; Cohen N.J., 1993, MEMORY AMNESIA HIPPO; COLTHEART M, 1993, PSYCHOL REV, V100, P589, DOI 10.1037/0033-295X.100.4.589; Corkin S, 1997, J NEUROSCI, V17, P3964; CORKIN S, 1984, SEMIN NEUROL, V4, P249, DOI 10.1055/s-2008-1041556; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Francis W. N., 1982, FREQUENCY ANAL ENGLI; FREED DM, 1987, NEUROPSYCHOLOGIA, V25, P461, DOI 10.1016/0028-3932(87)90071-6; GABRIELI JDE, 1988, BRAIN COGNITION, V7, P157, DOI 10.1016/0278-2626(88)90027-9; Goodglass H., 1997, ANOMIA NEUROANATOMIC, P3; GORDON WC, 1989, LEARNING MEMORY; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GRAFMAN J, 1996, BASIC APPL MEMORY TH, P259; Halgren E, 1991, Hippocampus, V1, P153, DOI 10.1002/hipo.450010204; Helmuth LI, 1997, LEARN MEMORY, V3, P456, DOI 10.1101/lm.3.6.456; HODGES JR, 1995, HDB MEMORY DISORDERS, P81; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; James LE, 2000, J EXP PSYCHOL LEARN, V26, P1378, DOI 10.1037//0278-7393.26.6.1378; James LE, 2001, PSYCHOL SCI, V12, P485, DOI 10.1111/1467-9280.00390; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; Kempermann G, 1998, NERVENARZT, V69, P851, DOI 10.1007/s001150050353; Kesner RP, 1998, PSYCHON B REV, V5, P585, DOI 10.3758/BF03208836; Kintsch W., 1998, COMPREHENSION PARADI; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; LACKNER JR, 1974, NEUROPSYCHOLOGIA, V12, P199, DOI 10.1016/0028-3932(74)90005-0; LAVER GD, 1993, PSYCHOL AGING, V8, P34, DOI 10.1037/0882-7974.8.1.34; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; Loftus M, 2000, EXP NEUROL, V163, P180, DOI 10.1006/exnr.2000.7361; MacKay D. G., 1990, RELATIONSHIPS PERCEP, P269; MacKay D. G., 1987, ORG PERCEPTION ACTIO; MacKay DG, 1998, J MEM LANG, V38, P28, DOI 10.1006/jmla.1997.2544; MACKAY DG, 1982, PSYCHOL REV, V89, P483, DOI 10.1037/0033-295X.89.5.483; MacKay DG, 1998, J COGNITIVE NEUROSCI, V10, P377, DOI 10.1162/089892998562807; MacKay DG, 1998, PSYCHOL AGING, V13, P647, DOI 10.1037/0882-7974.13.4.647; MacKay DG, 2001, BRAIN LANG, V78, P265, DOI 10.1006/brln.2001.2470; MacKay DG, 2001, LANG COGNITIVE PROC, V16, P419, DOI 10.1080/01690960042000102; MacKay DG, 1999, PSYCHOL AGING, V14, P3, DOI 10.1037/0882-7974.14.1.3; MACKAY DG, 1992, CONSCIOUS COGN, V1, P199, DOI 10.1016/1053-8100(92)90061-E; MACKAY DG, 1990, AGING COGNITION KNOW, P281, DOI DOI 10.1016/S0166-4115(08)60159-4; MACKAY DG, 2000, ANN M COGN NEUR SOC; Mackay Donald G., 1996, P251; MARSLENWILSON W, 1970, UNPUB BIOGRAPHICAL I, P1; MARSLENWILSON WD, 1975, NEUROPSYCHOLOGIA, V13, P353, DOI 10.1016/0028-3932(75)90013-5; MASSARO DW, 1978, VISIBLE LANG, V12, P3; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCCLELLAND JL, 1985, MEMORY DYSFUNCTIONS, V444, P1; METCALFE J, 1992, J COGNITIVE NEUROSCI, V4, P289, DOI 10.1162/jocn.1992.4.3.289; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; Milner B, 1975, Adv Neurol, V8, P299; Morris RGM, 1999, CURR BIOL, V9, pR890; MULLER RU, 1987, J NEUROSCI, V9, P4101; Murre JMJ, 1996, HIPPOCAMPUS, V6, P675, DOI 10.1002/(SICI)1098-1063(1996)6:6<675::AID-HIPO10>3.0.CO;2-Y; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; Ogden J. A., 1991, MEMORY MECH TRIBUTE, P195; OMARA SM, 1994, J NEUROSCI, V14, P6511; PARKIN AJ, 1996, CLASSIC CASES NEUROP; PASHLER H, 1996, MEMORY, P4; Postle BR, 1998, NEUROPSYCHOLOGIA, V36, P421, DOI 10.1016/S0028-3932(97)00155-3; Rastle K, 2000, J MEM LANG, V42, P342, DOI 10.1006/jmla.1999.2687; RINGO JL, 1994, J NEUROPHYSIOL, V71, P1285; SAFFRAN E M, 1990, P137; Santiago J, 2000, LANG COGNITIVE PROC, V15, P1, DOI 10.1080/016909600386101; SCHACTER D L, 1990, P543; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHANKS D, 1996, COGNITIVE SCI INTRO, P276; SQUIRE LR, 1987, MEMORY BRAIN; Sternberg R.J., 1985, HUMAN ABILITIES INFO; STRATTON RP, 1975, BEHAV RES METH INSTR, V7, P1, DOI 10.3758/BF03201278; Tulving E, 1983, ELEMENTS EPISODIC ME; White KK, 2002, PSYCHOL AGING, V17, P226, DOI 10.1037//0882-7974.17.2.226; WICKELGREN WA, 1979, PSYCHOL REV, V86, P44, DOI 10.1037/0033-295X.86.1.44; WICKELGREN WA, 1968, NEUROPSYCHOLOGIA, V6, P235, DOI 10.1016/0028-3932(68)90022-5; WICKELGREN WA, 1975, SHORT TERM MEMORY, P41; WILKINSON A, 1978, Age and Ageing, V7, P151, DOI 10.1093/ageing/7.3.151; WILSON FAW, 1990, BEHAV BRAIN RES, V40, P7, DOI 10.1016/0166-4328(90)90038-G; WILSON FAW, 1994, BEHAV BRAIN SCI, V17, P499, DOI 10.1017/S0140525X00035676; 1949, WEBSTERS NEW COLL DI	85	19	19	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1382-5585	1744-4128		AGING NEUROPSYCHOL C	Aging Neuropsychol. Cogn.	DEC	2002	9	4					298	333		10.1076/anec.9.4.298.8774			36	Psychology, Developmental; Psychology, Experimental	Psychology	641XT	WOS:000180772900005					2021-06-18	
J	Stander, S; Bone, HG; Machens, HG; Aberle, T; Burchard, W; Prien, T; Luger, TA; Metze, D				Stander, S; Bone, HG; Machens, HG; Aberle, T; Burchard, W; Prien, T; Luger, TA; Metze, D			Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals	CELL AND TISSUE RESEARCH			English	Article						hydroxyethyl starch; pruritus; nerve fibers; blood-brain barrier; placental barrier; rat (Sprague Dawley); sheep	CLOSED-HEAD TRAUMA; RETICULOENDOTHELIAL SYSTEM; LONG-TERM; PERSISTENT PRURITUS; REPERFUSION INJURY; CELL-DEATH; ALBUMIN; HEMODILUTION; HES; HETASTARCH	Therapy with hydroxyethyl starch (HES) is associated with a high incidence of persistent pruritus due to HES storage in cutaneous nerves. Up to now it has been unknown if HES also accumulates in the extracutaneous peripheral or central nervous system. To study this, five rats including one pregnant one were infused with a single dose (34-150 mg) of HES (70/200/450 kDa molecular weight) conjugated with fluorescein isothiocyanate (FITC). In addition, four sheep were infused with a cumulative dosage of 30 g, 120 g, and 420 g HES (200 kDa), respectively. After 7-13 days, biopsies from the adult rats, four fetal rats and sheep were taken from various organs. The specimens were analyzed by light, electron, and confocal laser scanning microscopy. Typical HES storage vacuoles were found in macrophages of the skin, liver, spleen, lung, and kidney. HES storage in healthy animals was not associated with signs of either inflammation or apoptosis contrary to a previously described animal hemorrhagic shock model. Beyond that, fetus biopsies did not show any storage phenomenon, confirming that HES does not cross the placental barrier. Deposits of HES could be detected in Schwann cells of cutaneous nerve fibers as well as in perineural and endo-neural cells of sciatic nerve in one rat (HES 450 kDa) and three of four sheep. No HES storage was found in the central nervous system. Our findings clearly demonstrate that storage of HES is detectable only in small peripheral nerves, suggesting a cutaneous origin of the HES-induced pruritus.	Univ Munster, Dept Anesthesiol & Intens Care Med, Munster, Germany; Hannover Med Sch, Clin Plast Hand & Reconstruct Surg, D-3000 Hannover, Germany; Univ Freiburg, Inst Macromol Chem, D-7800 Freiburg, Germany; Univ Munster, Dept Dermatol, D-4400 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Munster, Germany	Stander, S (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-4400 Munster, Germany.	sonja.staender@uni-muenster.de		Stander, Sonja/0000-0003-3612-7786			Belder de A. N., 1973, CARBOHYD POLYM, V2, P375, DOI DOI 10.1016/S0008-6215(00)81824-8; Chi OZ, 1996, ANESTH ANALG, V83, P336, DOI 10.1097/00000539-199608000-00023; Chorny I, 1999, J NEUROSURG ANESTH, V11, P273, DOI 10.1097/00008506-199910000-00008; Chrysomali E, 1997, ORAL SURG ORAL MED O, V83, P272, DOI 10.1016/S1079-2104(97)90016-0; Eilig I, 2001, ANESTH ANALG, V92, P669, DOI 10.1213/00000539-200103000-00023; Forster H, 1999, INFUSIONSTHERAPIE, V26, P45; FORSTER H, 1989, HYDROXYETHYLSTARKE A, P15; Gall H, 1996, DERMATOLOGY, V192, P222, DOI 10.1159/000246370; GALL H, 1993, HAUTARZT, V44, P713; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HEILMANN L, 1989, Z GEBURTSH PERINATOL, V193, P219; HEILMANN L, 1991, INFUSIONSTHERAPIE, V18, P236; HULSE JD, 1983, DRUG INTEL CLIN PHAR, V17, P334, DOI 10.1177/106002808301700503; JURECKA W, 1993, ARCH DERMATOL RES, V285, P13, DOI 10.1007/BF00370817; KARINEN J, 1994, BRIT J ANAESTH, V73, P751, DOI 10.1093/bja/73.6.751; KIESEWETTER H, 1990, J INTERN MED, V227, P107, DOI 10.1111/j.1365-2796.1990.tb00127.x; Kimme P, 2001, ACTA ANAESTH SCAND, V45, P686, DOI 10.1034/j.1399-6576.2001.045006686.x; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAFT D, 1992, EUR SURG RES, V24, P138, DOI 10.1159/000129200; LENZ G, 1986, ANAESTHESIST, V35, P423; LEUNIG A, 1995, LARYNGO RHINO OTOL, V74, P135, DOI 10.1055/s-2007-997706; MESSMER K, 1986, EUR SURG RES, V18, P254, DOI 10.1159/000128533; Metze D, 1997, BRIT J DERMATOL, V136, P553, DOI 10.1046/j.1365-2133.1997.d01-1234.x; Murphy M, 2001, BRIT J DERMATOL, V144, P973, DOI 10.1046/j.1365-2133.2001.04184.x; PARKER NE, 1982, BRIT MED J, V284, P385, DOI 10.1136/bmj.284.6313.385-a; PARTH E, 1992, EUR SURG RES, V24, P13, DOI 10.1159/000129184; RICHTER W, 1983, HDB EXPT PHARM, V63, P581; SAKAKI T, 1990, NEUROSURGERY, V27, P268, DOI 10.1227/00006123-199008000-00016; SALING P, 1990, PERINATALE MED, P233; SCHELL RM, 1992, ANESTHESIOLOGY, V77, P86, DOI 10.1097/00000542-199207000-00013; Schmelz M, 2001, NAT NEUROSCI, V4, P9, DOI 10.1038/82956; SHATNEY CH, 1984, CIRC SHOCK, V13, P21; Sirtl C, 1999, BRIT J ANAESTH, V82, P510; Stander S, 2001, CELL TISSUE RES, V304, P261, DOI 10.1007/s004410000324; Subrato D, 2000, J TRAUMA, V49, P47, DOI 10.1097/00005373-200007000-00007; SZEIMIES RM, 1994, BRIT J DERMATOL, V131, P380, DOI 10.1111/j.1365-2133.1994.tb08529.x; Thompson J.B.J., 1979, T AM CRYSTALLOGRAPHI, V15, P1; UNGER M, 1990, PERINATALE MED, P235; WHITE KL, 1986, DRUG CHEM TOXICOL, V9, P305, DOI 10.3109/01480548608998282; ZIKRIA BA, 1989, CRIT CARE MED, V17, P1306, DOI 10.1097/00003246-198912000-00012	40	19	19	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	DEC	2002	310	3					279	287		10.1007/s00441-002-0644-6			9	Cell Biology	Cell Biology	628XQ	WOS:000180021700003	12457226				2021-06-18	
J	Ai, JL; Baker, A				Ai, JL; Baker, A			Presynaptic hyperexcitability at cerebellar synapses in traumatic injury rat	NEUROSCIENCE LETTERS			English	Article						cerebellum; neurotransmission; presynaptic; hyperexcitability; trauma brain injury	BRAIN INJURY; HIPPOCAMPUS; MOVEMENT	Neurotransmission in rat cerebellum following fluid percussion injury (FPI) was studied by extracellular recording method. An increased amplitude of population spikes from presynaptic mossy fibers was detected at 3 days after FPI. However, there were no differences at 1 h, 1 day, 1 week or 2 weeks after FPI compared to naive controls. An enhanced amplitude of the population spikes, as well as the after hyperpolarization component from presynaptic response of the parallel fibers, was seen in the groups at 3 days and 1 week post FPI, but not in other groups. These results indicate a presynaptic hyperexcitation was induced by FPI within a specific time window. This hyperexcitability may contribute to the reported loss of Purkinje cells after FPI. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Toronto, St Michaels Hosp, Trauma Brain Injury Lab, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada	Ai, JL (corresponding author), Univ Toronto, St Michaels Hosp, Trauma Brain Injury Lab, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada.			AI, JINGLU/0000-0001-7414-0207			Armano S, 2000, J NEUROSCI, V20, P5208, DOI 10.1523/JNEUROSCI.20-14-05208.2000; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GILMAN S, 1994, ANN NEUROL, V35, P3, DOI 10.1002/ana.410350103; Ito M, 2001, PHYSIOL REV, V81, P1143; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Thach WT, 1998, NEUROBIOL LEARN MEM, V70, P177, DOI 10.1006/nlme.1998.3846; Tian GF, 2000, J NEUROPHYSIOL, V83, P1830; vandenPol AN, 1996, J NEUROSCI, V16, P4283	17	19	20	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	NOV 8	2002	332	3					155	158	PII S0304-3940(02)00945-X	10.1016/S0304-3940(02)00945-X			4	Neurosciences	Neurosciences & Neurology	611JL	WOS:000179013300002	12399004				2021-06-18	
J	Heinius, G; Wladis, A; Hahn, RG; Kjellstrom, BT				Heinius, G; Wladis, A; Hahn, RG; Kjellstrom, BT			Induced hypothermia and rewarming after hemorrhagic shock	JOURNAL OF SURGICAL RESEARCH			English	Article						pig : shock; hypovolemia; temperature; coagulation.	TOTAL HIP-ARTHROPLASTY; BLOOD-LOSS; MILD HYPOTHERMIA; THROMBELASTOGRAPHY; COAGULATION; INJURY; TRAUMA; COAGULOPATHY	Background. Recent patient and animal studies have shown protective effects of hypothermia (HT) in traumatic brain injury and hemorrhagic shock. We have demonstrated a reduced stress level and a lack of additive hemodynamic effects of HT. The present work was undertaken to evaluate whether these effects persist during and after rewarming. Methods. Pigs were quickly exsanguinated of 40% of their individually calculated blood volume and randomized to HT (32.5degreesC) or normothermia (controls). After 30 min of HT, rewarming to baseline temperature was initiated. All animals were followed for 7 h. Thrombolelastography was used to evaluate blood coagulation. Results. HT did not aggravate the hemodynamic signs of hemorrhagic shock. HT decreased the oxygen uptake, however, which reduced the oxygen extraction ratio to the prehemorrhage level (P < 0.05). Serum levels of potassium were transiently stabilized by cooling. Coagulation was slower, but blood clot strength was normal. HT also delayed fibrinolysis (P < 0.05). Rewarming reversed all physiological changes induced by HT including those involving the coagulation system. Conclusion. HT produced few hemodynamic effects in the presence of hemorrhagic shock, but created a surplus of oxygen in the core circulation. Blood clotting was delayed by HT. (C) 2002 Elsevier Science (USA).	Karolinska Inst, Soder Hosp, Dept Surg, SE-11883 Stockholm, Sweden; Karolinska Inst, Soder Hosp, Dept Anesthesiol, SE-11883 Stockholm, Sweden; Swedish Def Res Agcy, Div Human Sci, Dept Expt Traumatol, Stockholm, Sweden	Heinius, G (corresponding author), Karolinska Inst, Soder Hosp, Dept Surg, SE-11883 Stockholm, Sweden.		Wladis, Andreas/AAJ-7844-2020	Wladis, Andreas/0000-0003-4377-0892; Heinius, Goran/0000-0002-4647-3773; Hahn, Robert/0000-0002-1528-3803			BERNABEI AF, 1992, J TRAUMA, V33, P835, DOI 10.1097/00005373-199212000-00007; DOUNING LK, 1995, ANESTH ANALG, V81, P608, DOI 10.1097/00000539-199509000-00033; HAHN RG, 1987, ACTA ANAESTH SCAND, V31, P572, DOI 10.1111/j.1399-6576.1987.tb02623.x; HANNON JP, 1985, AM J PHYSIOL, V248, pR293; Johansson T, 1999, ACTA ANAESTH SCAND, V43, P1005, DOI 10.1034/j.1399-6576.1999.431006.x; Johnson KB, 1996, SHOCK, V6, P223, DOI 10.1097/00024382-199609000-00012; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; Kettner SC, 1998, BRIT J ANAESTH, V80, P313; MALLETT SV, 1992, BRIT J ANAESTH, V69, P307, DOI 10.1093/bja/69.3.307; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; OBrien PJ, 1997, LAB ANIM SCI, V47, P486; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; Riddez L, 1999, Prehosp Disaster Med, V14, P87; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; TISHERMAN SA, 1998, TRAUMA MANUAL, P394; TUMAN KJ, 1987, ANESTH ANALG, V66, P856; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; WILSON RF, 1996, MANAGEMENT TRAUMA PI, P777; Wladis A, 2002, SHOCK, V17, P120, DOI 10.1097/00024382-200202000-00007; Wladis A, 2001, SHOCK, V15, P60, DOI 10.1097/00024382-200115010-00010; Yamakage M, 1998, CAN J ANAESTH, V45, P993, DOI 10.1007/BF03012308	22	19	21	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	NOV	2002	108	1					7	13		10.1006/jsre.2002.6470			7	Surgery	Surgery	620HM	WOS:000179528000002	12443709				2021-06-18	
J	Weber, JT; Rzigalinski, BA; Ellis, EF				Weber, JT; Rzigalinski, BA; Ellis, EF			Calcium responses to caffeine and muscarinic receptor agonists are altered in traumatically injured neurons	JOURNAL OF NEUROTRAUMA			English	Article						calcium imaging; calcium stores; cortical neurons; inositol (1,4,5)-trisphosphate; intracellular free calcium; in vitro; traumatic brain injury	EXPERIMENTAL BRAIN INJURY; STRETCH-INDUCED INJURY; CORTICAL-NEURONS; PHOSPHOLIPASE-C; STORES; CELLS; ASTROCYTES; RELEASE; RAT; TRISPHOSPHATE	A fundamental mechanism that is believed to contribute to neuronal injury and death following traumatic brain injury (TBI) is a disruption in cellular calcium homeostasis. Of primary importance to these homeostatic mechanisms are intracellular calcium stores located on the endoplasmic reticulum. These intracellular stores play an important role in maintaining normal levels of calcium and calcium-mediated signaling through these stores is critical to several physiological processes in neurons. Using an in vitro model of stretch-induced traumatic injury and fura-2 digital calcium imaging, we investigated alterations in calcium-induced calcium release (CICR) and inositol (1,4,5)trisphosphate (IP3)-linked signaling through intracellular calcium stores in populations of cultured rat cortical neurons. Caffeine, which stimulates CICR, produced a rapid elevation of intracellular free calcium ([Ca2+](i)) in 70% of uninjured neurons. Fifteen min after injury the population of caffeine-responsive neurons was reduced to 30%. The IP3-linked muscarinic acetylcholine receptor agonists, CDD-0097 HCl and McN-A-343, produced elevations in [Ca2+], in 91% and 70% of uninjured neurons, respectively. Following injury the population of responders was reduced to 19% and 26%, respectively. Differential responses to agonists were also noted after injury, in which the majority of neurons within a given culture well were unresponsive to agonists while others elicited a normal elevation of calcium. These results suggest disruptions in intracellular calcium store-mediated signaling and altered calcium signaling population dynamics following injury. These alterations could affect normal neurotransmission in the brain and may contribute to some of the pathology of TBI.	Erasmus Univ, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Weber, JT (corresponding author), Erasmus Univ, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040490, R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214, NS-40490] Funding Source: Medline		Ahmed S. M., 2000, Journal of Neurotrauma, V17, P957; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRORSON JR, 1991, J NEUROSCI, V11, P4024; Choi S, 1996, J NEUROSCI, V16, P36; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P405; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IRVING AJ, 1992, J PHYSIOL-LONDON, V456, P667, DOI 10.1113/jphysiol.1992.sp019360; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Messer WS, 1997, J MED CHEM, V40, P1230, DOI 10.1021/jm960467d; MICHELETTI R, 1990, J PHARMACOL EXP THER, V253, P310; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rose CR, 2001, NEURON, V31, P519, DOI 10.1016/S0896-6273(01)00402-0; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sanderson MJ, 1996, NEWS PHYSIOL SCI, V11, P262, DOI 10.1152/physiologyonline.1996.11.6.262; Schreiber D., 1995, P 1995 INT RES C BIO, P233; SHMIGOL A, 1994, PFLUG ARCH EUR J PHY, V426, P174, DOI 10.1007/BF00374686; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TRUMP BF, 1996, SCI PRACTICE ACUTE M, V4, P139; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WILLAN RL, 1990, MULTIPURPOSE TREE SP, V2, P11; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	40	19	19	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1433	1443		10.1089/089771502320914660			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500004	12490008				2021-06-18	
J	Mobbs, RJ; Yang, MO				Mobbs, RJ; Yang, MO			The dangers of diagnostic laparoscopy in the head injured patient	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						ICP; laparoscopy; head injury	INTRACRANIAL-PRESSURE; INTRAABDOMINAL PRESSURE; PNEUMOPERITONEUM	Pneumoperitoneum during laparoscopy has been known to result in a rise in intracranial pressure (ICP) in experimental studies. There are no reports of the effect of pneumoperitoneum during diagnostic laparoscopy in patients suffering closed head injuries. We present the case of a 39 year old male with a closed head injury. Diagnostic laparoscopy was performed while intracranial pressure was monitored. ICP increased from 9 mmHg to over 60 mmHg within 10 min of pneumoperitoneum. Laparoscopy was terminated and the ICP returned to normal levels within 35 min. The authors recommend that pneumoperitoneum laparoscopy should not be used in the trauma setting where head injury is suspected. (C) 2002 Published by Elsevier Science Ltd.	Univ New S Wales, Sydney, NSW 2033, Australia	Mobbs, RJ (corresponding author), 3 Wansey Rd, Randwick, NSW 2031, Australia.		Mobbs, Ralph/G-5254-2014	Mobbs, Ralph/0000-0001-6542-6836			Ben-Haim M, 2000, J SURG RES, V91, P101, DOI 10.1006/jsre.2000.5903; ESTEMCDONALD JR, 1995, ARCH SURG-CHICAGO, V130, P362; Halverson AL, 1999, SURG ENDOSC-ULTRAS, V13, P797, DOI 10.1007/s004649901102; JOSEPHS LG, 1994, J TRAUMA, V36, P815, DOI 10.1097/00005373-199406000-00011; Moncure M, 1999, AM SURGEON, V65, P168; Rosenthal RJ, 1998, J AM COLL SURGEONS, V187, P32, DOI 10.1016/S1072-7515(98)00126-4; Rosenthal RJ, 1997, SURG ENDOSC, V11, P376, DOI 10.1007/s004649900367; Schob OM, 1996, AM J SURG, V172, P248, DOI 10.1016/S0002-9610(96)00101-8; Uzzo RG, 1997, UROLOGY, V49, P753, DOI 10.1016/S0090-4295(97)00233-1	9	19	19	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	SEP	2002	9	5					592	593		10.1054/jocn.2001.1070			2	Clinical Neurology; Neurosciences	Neurosciences & Neurology	609YL	WOS:000178933900024	12383425				2021-06-18	
J	Yunoki, M; Nishio, S; Ukita, N; Anzivino, MJ; Lee, KS				Yunoki, M; Nishio, S; Ukita, N; Anzivino, MJ; Lee, KS			Characteristics of hypothermic preconditioning influencing the induction of delayed ischemic tolerance	JOURNAL OF NEUROSURGERY			English	Article						hypothermia; neuronal tolerance; neuroprotection; preconditioning; rat	TRAUMATIC BRAIN-INJURY; GERBIL HIPPOCAMPUS; SPREADING DEPRESSION; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; GLOBAL-ISCHEMIA; NITRIC-OXIDE; DAMAGE; PRETREATMENT; NEUROPROTECTION	Object. A brief period of hypothermia has recently been shown to induce delayed tolerance to ischemic brain injury. This form of tolerance is initiated several hours after hypothermic preconditioning (HPC) and persists for a few days. Hypothermia-induced tolerance could provide a means for limiting cellular injury during predictable periods of ischemia, such as those that occur during many surgical procedures. The purpose of this study was to characterize the parameters of HPC that regulate the induction of delayed tolerance. Methods. The general design of the experiments was to perform HPC or a sham procedure on adult Sprague-Dawley rats. Twenty-four hours later, the animals were subjected to a transient period of ischemia induced by a 1-hour period of three-vessel occlusion. Infarct volume was assessed 24 hours postischemia. In the first series of experiments, the depth of global (that is, whole-body) HPC was set at 25.5, 28.5, or 31.5degreesC. and the duration of HPC was fixed at 20 minutes. In the second series of experiments, the duration of global HPC was set at 20, 60, 120, or 180 minutes. and the depth of HPC was set at 33 or 34.5degreesC. In the third series of experiments, focal HPC was administered by selectively cooling the head to achieve a cortical temperature of 28.5 or 31.5degreesC for 20 minutes, with the duration of HPC fixed at 20 minutes. The magnitude of tolerance induced by HPC was dependent on the depth and duration of the hypothermic stimulus. The parameters of hypothermia that are capable of inducing tolerance are similar to, or less severe than, those already in clinical use during intraoperative procedures. Focal cooling was as effective as global cooling for eliciting tolerance, indicating that it is possible to establish tolerance while limiting the potential complications of systemic hypothermia. Conclusions. The results of these experiments indicate that HPC may provide an effective and safe means for limiting cellular injury resulting from predictable periods of central nervous system ischemia.	Univ Virginia, Hlth Sci Ctr, Dept Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Neurol Surg, Charlottesville, VA 22908 USA	Lee, KS (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Neurosci, Box 801392,MR4 Annex, Charlottesville, VA 22908 USA.	ksl3h@virginia.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038918] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38918] Funding Source: Medline		Caprioli J, 1996, INVEST OPHTH VIS SCI, V37, P2376; Centeno JM, 1999, BRAIN RES, V836, P62, DOI 10.1016/S0006-8993(99)01610-8; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; CHOPP M, 1992, STROKE, V23, P104, DOI 10.1161/01.STR.23.1.104; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; GIDDAY JM, 1994, NEUROSCI LETT, V168, P221, DOI 10.1016/0304-3940(94)90455-3; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Hiraide T, 2001, BRAIN RES, V910, P94, DOI 10.1016/S0006-8993(01)02647-6; HIRAMATSU K, 1993, ACTA NEUROCHIR, V120, P66, DOI 10.1007/BF02001472; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kapinya K, 2000, BRAIN RES, V872, P282, DOI 10.1016/S0006-8993(00)02503-8; KATO H, 1992, BRAIN RES BULL, V29, P559, DOI 10.1016/0361-9230(92)90123-F; KATO H, 1995, NEUROSCI LETT, V189, P13, DOI 10.1016/0304-3940(95)11437-2; KATO H, 1991, BRAIN RES, V553, P238, DOI 10.1016/0006-8993(91)90831-F; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; KAWAHARA N, 1995, NEUROL RES, V17, P9, DOI 10.1080/01616412.1995.11740281; Kawahara N, 1997, NEUROSCI RES, V29, P37, DOI 10.1016/S0168-0102(97)00069-2; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; KULUZ JW, 1992, STROKE, V23, P1792, DOI 10.1161/01.STR.23.12.1792; Leben J, 1997, ANN NY ACAD SCI, V813, P807, DOI 10.1111/j.1749-6632.1997.tb51785.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MOURITZEN CV, 1966, J THORAC CARDIOV SUR, V51, P585, DOI 10.1016/S0022-5223(19)43326-6; NAKATA N, 1993, NEUROREPORT, V4, P695, DOI 10.1097/00001756-199306000-00023; Nandagopal K, 2001, J PHARMACOL EXP THER, V297, P474; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; NISHI S, 1993, BRAIN RES, V615, P281, DOI 10.1016/0006-8993(93)90039-P; Nishio S, 2000, J NEUROSURG, V93, P845, DOI 10.3171/jns.2000.93.5.0845; Nishio S, 1999, ANN NY ACAD SCI, V890, P26, DOI 10.1111/j.1749-6632.1999.tb07978.x; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; Reshef A, 2000, NEUROREPORT, V11, P463, DOI 10.1097/00001756-200002280-00007; Riepe MW, 1997, MOL CELL BIOCHEM, V174, P249, DOI 10.1023/A:1006820927262; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; SCHUBERT A, 1997, J NEUROSURG ANESTHES, V7, P139; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIMAZAKI K, 1994, NEUROSCI RES, V20, P95, DOI 10.1016/0168-0102(94)90026-4; SOMMER C, 1995, BRAIN PATHOL, V5, P135, DOI 10.1111/j.1750-3639.1995.tb00587.x; Sugino T, 2000, NEUROSCI LETT, V278, P101, DOI 10.1016/S0304-3940(99)00906-4; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; Tauskela JS, 1999, BRAIN RES, V827, P143, DOI 10.1016/S0006-8993(99)01322-0; Tomasevic G, 1999, MOL BRAIN RES, V70, P304, DOI 10.1016/S0169-328X(99)00146-1; Toyoda T, 1997, NEUROREPORT, V8, P847, DOI 10.1097/00001756-199703030-00008; Wada K, 1996, BRAIN RES, V740, P15; Wada S, 2000, MAR BIOTECHNOL, V2, P285, DOI 10.1007/s101260000006; Yanamoto H, 1998, BRAIN RES, V784, P239, DOI 10.1016/S0006-8993(97)01344-9; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004	48	19	20	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2002	97	3					650	657		10.3171/jns.2002.97.3.0650			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	593JA	WOS:000177986400020	12296650				2021-06-18	
J	Wang, CX; Reece, C; Wrathall, JR; Shuaib, A; Olschowka, JA; Hao, CH				Wang, CX; Reece, C; Wrathall, JR; Shuaib, A; Olschowka, JA; Hao, CH			Expression of tumor necrosis factor alpha and its mRNA in the spinal cord following a weight-drop injury	NEUROREPORT			English	Article						bioassay; contusion; cytokine; polymerase chain reaction	TRAUMATIC INJURY; GENE-EXPRESSION; RAT; INFLAMMATION; CYTOKINES; BRAIN; INTERLEUKIN-1-BETA; ASTROCYTES; INCREASE; PROTEIN	The effect of traumatic spinal cord injury (SCI) on the expression of tumor necrosis factor (TNFalpha) and its mRNA was examined. Quantitative reverse transcription polymerase chain reaction assay showed TNFalpha mRNA level increased > 20-fold at the lesion site by 1 h after the injury compared to that in uninjured controls. The TNFalpha mRNA level was still significantly higher than in the controls 72 h after the injury TNFalpha mRNA in the samples collected immediately caudal to the lesion site was also increased. Levels of TNFalpha protein, determined by a cytotoxic bioassay, were also significantly increased at the lesion site. The TNFalpha protein level was maximal 1 and 8 h after the injury and still significantly higher than in the controls 24 h post-injury. The present results demonstrate that TNFalpha is rapidly induced in the spinal cord after the injury, and it may play a significant role in secondary events in SCI.	Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Georgetown Univ, Dept Cell Biol, Washington, DC 20057 USA; Univ Rochester, Dept Neurobiol & Anat, Rochester, NY 14627 USA	Wang, CX (corresponding author), Univ Alberta, Dept Med, Room 533 HMRC, Edmonton, AB T6G 2S2, Canada.						BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; ENG LF, 1992, PROG BRAIN RES, V94, P353; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FORSTER E, 1992, BIOTECHNIQUES, V16, P8; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; HEREMANS H, 1992, EUR J IMMUNOL, V22, P2395, DOI 10.1002/eji.1830220932; LOTZ M, 1996, CELLULAR RESPONSES C, P47; Merrill E, 1996, CYTOKINES CNS, P151; METHA VK, 1994, EUR J ENDOCRINOL, V130, P208; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NUTTIN B, 1994, ACTA NEUROL BELG, V94, P64; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1994, NEUROREPORT, V5, P585, DOI 10.1097/00001756-199401000-00013; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; YOSHIDA K, 1992, J NEUROCHEM, V59, P919, DOI 10.1111/j.1471-4159.1992.tb08331.x	24	19	22	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	AUG 7	2002	13	11					1391	1393		10.1097/00001756-200208070-00008			3	Neurosciences	Neurosciences & Neurology	593GU	WOS:000177983300004	12167759				2021-06-18	
J	Kulkarni, M; Armstead, WM				Kulkarni, M; Armstead, WM			Relationship between NOC/oFQ, dynorphin, and COX-2 activation in impaired NMDA cerebrovasodilation after brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral circulation; excitatory amino acids; newborn; opioids; oxygen free radicals	NOCICEPTIN/ORPHANIN FQ; CEREBRAL-CIRCULATION; HEAD-INJURY; ORPHANIN-FQ; CYCLOOXYGENASE-2; EXPRESSION; RELEASE; RAT; CONTRIBUTES; RECEPTOR	Previous studies have observed that the recently described endogenous opioid, nociceptin/orphanin FQ (NOC/oFQ), contributes to impairment of N-methyl-D-aspartate (NMDA)-induced cerebrovasodilation following fluid percussion brain injury (FPI) via a cyclooxygenase (COX)-dependent generation of superoxide anion (O-2(-)). This study was designed to investigate the relationship between NOC/oFQ, another opioid, dynorphin, and activation of the COX-2 isoform of the enzyme in such impaired dilation to NMDA after FPI in piglets equipped with a closed cranial window. Superoxide dismutase (SOD)-inhibitable nitroblue tetrazolium (NBT) reduction was determined as an index of O-2(-) generation. Under non-brain injury conditions, NOC/oFQ (10(-10) M), the CSF concentration observed after FPI, increased CSF dynorphin, while the NOC/oFQ antagonist [F/G] NOC/oFQ (1-13) NH2 attenuated the stimulated release of dynorphin following FPI (34 +/- 3 and 97 +/- 6 vs. 36 +/- 3 and 68 +/- 8 pg/mol for CSF dynorphin before and after FPI in untreated and NOC/oFQ antagonist-pretreated animals). FPI increased SOD-inhibitable NBT reduction, but pretreatment with norbinaltorphimine, a dynorphin antagonist, or NS398, a COX-2 inhibitor, blunted such reduction (1 +/- 1 vs. 19 +/- 3 vs. 4 +/- 1 vs. 4 +/- 1 pmol/mm(2) for control, FPI, FPI-norbinaltorphimine and FPI-NS398, respectively). Under non-brain injury conditions, dynorphin, in a concentration observed in CSF after FPI, also increased SOD-inhibitable NBT reduction, which was blunted by NS398. NMDA-induced pial artery dilation was reversed to vasoconstriction following FPI, but pretreatment with norbinaltorphimine or NS398 partially protected such responses (9 +/- 1 and 16 +/- 1, control; -8 +/- 1 and -13 +/- 2, FPI; 6 +/- 1 and 12 +/- 1% FPI-norbinaltorphimine for NMDA 10(-8), 10(-6) M, respectively). These data show that NOC/oFQ modulates the CSF release of dynorphin after FPI. These data also show that dynorphin contributes to O-2(-) generation after FPI via COX-2 activation. These data additionally indicate that dynorphin and COX-2 activation contribute to impairment of NMDA pial artery dilation after FPI. Finally, these data suggest that NOC/oFQ impairs NMDA dilation postinsult via the sequential release of dynorphin, activation of COX-2, and generation of O-2(-).	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.						Armstead WM, 2000, AM J PHYSIOL-HEART C, V279, pH2188; Armstead WM, 2000, J NEUROTRAUM, V17, P751, DOI 10.1089/neu.2000.17.751; ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; Armstead WM, 1997, P SOC EXP BIOL MED, V214, P210; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FATAKI N, 1994, PROSTAGLANDINS, V47, P55; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gintzler AR, 1997, EUR J PHARMACOL, V325, P29, DOI 10.1016/S0014-2999(97)00103-9; Gong C, 2001, BRAIN RES, V901, P38, DOI 10.1016/S0006-8993(01)02186-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kaufman AE, 1996, IEEE T VIS COMPUT GR, V2, P1; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; Lapchak PA, 2001, STROKE, V32, P1220, DOI 10.1161/01.STR.32.5.1220; Leffler CW, 1993, REGULATION CEREBRAL, P297; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Niwa K, 2001, CIRC RES, V88, P600, DOI 10.1161/01.RES.88.6.600; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	33	19	22	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					965	973		10.1089/089771502320317113			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800006	12225656				2021-06-18	
J	Haan, JM; Kramer, ME; Scalea, TM				Haan, JM; Kramer, ME; Scalea, TM			Pattern of injury from personal watercraft	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Meeting of the Southeastern-Surgical-Congress	FEB 01-05, 2002	NASHVILLE, TENNESSEE				JET-SKI ACCIDENT	Injury from personal watercraft has continued to increase. Prior attempts to delineate patterns of injury and relative frequencies have yielded varied results. We retrospectively reviewed Trauma Registry data and charts of all patients who suffered personal watercraft injury treated at the R. Adams Cowley Shock Trauma Center between August 1996 and January 2001. Patient demographics included mechanism of injury, injuries sustained, and outcomes. Attempts were made to correlate events around the injury and injury pattern. During the study period 24 patients were treated. Mechanisms consisted of direct collision, fails from the watercraft, handlebar straddle injuries, axial loading, and hydrostatic jet injury. Traumatic brain injury was most common occurring in 54 per cent of patients. Spinal injury was also common occurring in 29 per cent of patients. Axial loading from falls while wave jumping seemed to correlate with skeletal injury. Thoracolumbar spine injury were often skeletally unstable requiring either brace or operative fixation. Inexperience and reckless behavior were found to be the greatest contributing factors. Substance abuse did not influence injury.	Univ Maryland, Dept Surg Crit Care, Baltimore, MD 21231 USA	Haan, JM (corresponding author), Univ Maryland, Dept Surg Crit Care, 22 S Greene St, Baltimore, MD 21231 USA.						Branche CM, 1997, JAMA-J AM MED ASSOC, V278, P663, DOI 10.1001/jama.278.8.663; Francis R A, 1994, Mo Med, V91, P241; HAEFNER HK, 1991, OBSTET GYNECOL, V78, P986; HAMMAN BL, 1993, J PEDIATR SURG, V28, P920, DOI 10.1016/0022-3468(93)90697-J; Jones C S, 1997, J Ark Med Soc, V94, P111; Morrison DM, 1998, J TRAUMA, V45, P816, DOI 10.1097/00005373-199810000-00037; Philpott JM, 1999, J TRAUMA, V47, P385, DOI 10.1097/00005373-199908000-00031; SCALEA T, 1986, J TRAUMA, V26, P706, DOI 10.1097/00005373-198608000-00005; Shatz DV, 1998, J TRAUMA, V44, P198, DOI 10.1097/00005373-199801000-00029; SODERSTROM C, RECENT ARTICLE EPIDE; Swinburn EEL, 1996, MED J AUSTRALIA, V165, P606, DOI 10.5694/j.1326-5377.1996.tb138662.x; Tyler B C, 1997, N C Med J, V58, P284; WEIN P, 1990, AUST NZ J OBSTET GYN, V30, P384, DOI 10.1111/j.1479-828X.1990.tb02038.x; White MW, 1999, AM SURGEON, V65, P865	14	19	19	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	JUL	2002	68	7					624	627					4	Surgery	Surgery	573AN	WOS:000176807300014	12132746				2021-06-18	
J	Hatcher, JP; Virley, D; Hadingham, SJ; Roberts, J; Hunter, AJ; Parsons, AA				Hatcher, JP; Virley, D; Hadingham, SJ; Roberts, J; Hunter, AJ; Parsons, AA			The behavioural effect of middle cerebral artery occlusion on apolipoprotein-E deficient mice	BEHAVIOURAL BRAIN RESEARCH			English	Article						apolipoprotein-E; MCAO; behaviour; mouse	CLOSED-HEAD INJURY; COGNITIVE DEFICITS; GLOBAL-ISCHEMIA; PROTEIN; BRAINS; MOUSE	The behavioural effects of middle cerebral artery occlusion (MCAO) in apoliprotein-E deficient (Apo-E KO) mice were investigated using a modified SHIRPA protocol and compared with effects in wild type littermate controls. The MCA was permanently occluded by insertion of an intraluminal filament to its origin on the Circle of Willis and behavioural reponses were observed 24 It later. MCAO treatment caused a range or changes in the wild type mice whereas, few differences were observed in the Apo-E KO mice in the behavioural observation. In the rotarod task, MCAO operated wild type mice showed a significant reduction in performance compared with sham-operated and non-operated animals. In contrast, both sham and MCAO operated Apo-E KO mice showed significant impairment compared with non-operated controls. A significant reduction in performance was also observed in sham-operated Apo-E KO compared with sham-operated wild type mice. In locomotor activity tests, no significant reduction in activity was observed between non-operated and sham-operated wild type controls, whereas a significant reduction was found between sham operated and MCAO operated mice. In the Apo-E KO mice, both sham and MCAO-operated animals showed a reduction in locomotor activity compared with non-operated mice. Furthermore, Apo-E KO MCAO mice showed a worsened deficit in locomotor activity, which was significantly correlated with exacerbated cortical lesion volume, unlike wild-type MCAO mice. This study shows that Apo-E KO animals demonstrate an impaired functional recovery post surgery which may be further compounded by post experimental stroke and also demonstrates the utility of the SHIRPA test system for investigating behavioural changes in functional outcome post stroke. (C) 2002 Elsevier Science B.V. All rights reserved.	GlaxoSmithKline, Neurol CEDD, Harlow CM19 5AW, Essex, England	Hatcher, JP (corresponding author), GlaxoSmithKline, Neurol CEDD, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.						Ali SM, 1996, MOL BRAIN RES, V38, P37, DOI 10.1016/0169-328X(95)00301-8; Bart RD, 1998, NEUROREPORT, V9, P2615, DOI 10.1097/00001756-199808030-00035; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; FULLERTON SM, 1999, SOC NEUR ABSTR, V25, P542; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KOIZUMI J, 1996, JPN J STROKE, V8, P1; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; OBRIEN MD, 1979, STROKE, V10, P623, DOI 10.1161/01.STR.10.6.623; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; SLOOTER AJ, 1997, JAMA-J AM MED ASSOC, V227, P818; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhou Y, 1998, BRAIN RES, V788, P151, DOI 10.1016/S0006-8993(97)01533-3	28	19	22	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	APR 1	2002	131	1-2					139	149	PII S0166-4328(01)00377-1	10.1016/S0166-4328(01)00377-1			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	537UD	WOS:000174777200015	11844581				2021-06-18	
J	Krum, JM; Phillips, TM; Rosenstein, JM				Krum, JM; Phillips, TM; Rosenstein, JM			Changes in astroglial GLT-1 expression after neural transplantation or stab wounds	EXPERIMENTAL NEUROLOGY			English	Article						glutamate transporters; gliosis; neural grafting; nestin; GFAP; immunoaffinity chromatography	GLUTAMATE TRANSPORTER GLT-1; TRAUMATIC BRAIN INJURY; FIBRILLARY ACIDIC PROTEIN; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; INDUCED AXONAL INJURY; MOUSE SPINAL-CORD; NEOCORTICAL TRANSPLANTS; REACTIVE ASTROCYTES; NERVOUS-SYSTEM	Uncontrolled release of glutamate from damaged brain initiates events that result in excitotoxic neuronal death. Glutamate uptake by specialized astroglial transporters is essential for control of extracellular glutamate levels. Many studies have demonstrated a reduction in astrocytic GLT-1 expression after different forms of injury. Because extensive neuronal death does not occur after direct cortical stab wounds and viable developing neurons populate fetal CNS grafts, we hypothesized that reactive astroglia associated with these procedures might maintain or up-regulate GLT-1. We examined the temporal and spatial distribution of GLT-1, GFAP and nestin proteins by confocal double-label immunohistochemistry combined with a new methodology in which precise brain areas are microdissected and analyzed for protein content by immunoaffinity chromatography. In stab wounds, GLT-1 protein content did not change compared to normal cortex, as determined by direct protein measurements; GLT-1 colocalized with nestin- and GFAP(+) astroglia adjacent to the lesion. In contrast, host reactive astroglia adjacent to grafts significantly upregulated GLT-1 by 3 days postoperative. The GFAP protein analysis suggests that increased GLT-1 is not the result of greater numbers of activated astroglia around grafts, but that developing graft tissue influences adjacent host astroglia to upregulate GLT-1. GLT-1 protein within grafts was rapidly accelerated to mature levels by just three days, and was expressed by the nestin(+) cell population. These data, which demonstrate immunoexpression of GLT-1 protein combined with a new method for protein measurement in situ indicate that, in contrast to other injury models, astroglial GLT-1 is upregulated or maintained following invasive CNS procedures. (C) 2002 Elsevier Science (USA).	George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	Krum, JM (corresponding author), George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38128, NS39282] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039282, R01NS038128] Funding Source: NIH RePORTER		Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; BABASHAK JV, 1988, J CHROMATOGR, V444, P21, DOI 10.1016/S0021-9673(01)94005-1; BarPeled O, 1997, J NEUROCHEM, V69, P2571; Bender AS, 1997, J NEUROCHEM, V69, pS241; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chan H, 1999, NEUROCHEM RES, V24, P1397, DOI 10.1023/A:1022532623281; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1994, PROG BRAIN RES, V100, P47; CHOI DW, 1987, J NEUROSCI, V7, P357; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; DAS GD, 1980, AM J ANAT, V158, P135, DOI 10.1002/aja.1001580204; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FONSECA M, 1988, EXP BRAIN RES, V69, P387; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Furuta A, 1997, J NEUROSCI, V17, P8363; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; GINSBERG SD, 1995, J NEUROCHEM, V65, P2800; Ginsberg SD, 1996, J NEUROCHEM, V67, P1208; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HOHMANN CF, 1988, BRAIN RES, V448, P53, DOI 10.1016/0006-8993(88)91101-8; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; KRUM JM, 1989, EXP NEUROL, V103, P203, DOI 10.1016/0014-4886(89)90044-7; KRUM JM, 1988, J COMP NEUROL, V271, P331, DOI 10.1002/cne.902710304; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; Lievens JC, 2000, J NEUROCHEM, V74, P909, DOI 10.1046/j.1471-4159.2000.0740909.x; McAdoo DJ, 2000, BRAIN RES, V865, P283, DOI 10.1016/S0006-8993(00)02296-4; MURPHY TH, 1990, FASEB J, V4, P1624; Northington FJ, 1999, J NEUROBIOL, V39, P515; Ottersen OP, 1996, J CHEM NEUROANAT, V12, P1, DOI 10.1016/S0891-0618(96)00178-0; PHILLIPS TM, 1994, J CHROMATOGR B, V662, P307, DOI 10.1016/0378-4347(94)00190-1; PHILLIPS TM, 1994, J CHROMATOGR B, V656, P259, DOI 10.1016/0378-4347(94)00036-0; PHILLIPS TM, 1993, LC GC-MAG SEP SCI, V11, P36; Phillips TM, 1998, J CHROMATOGR B, V715, P55, DOI 10.1016/S0378-4347(97)00675-0; PHILLIPS TM, 1992, ANAL TECHNIQUES IMMU; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; Roettger V, 1996, NEUROSCIENCE, V75, P677, DOI 10.1016/0306-4522(96)00314-4; ROSEN GD, 1994, DEV BRAIN RES, V82, P127, DOI 10.1016/0165-3806(94)90155-4; ROSENBERG PA, 1990, NEUROSCI LETT, V116, P399; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; ROSENSTEIN JM, 1995, EXP NEUROL, V133, P1, DOI 10.1006/exnr.1995.1001; ROSENSTEIN JM, 1993, EXP NEUROL, V124, P208, DOI 10.1006/exnr.1993.1191; Rosenstein JM, 1996, CELL TRANSPLANT, V5, P233, DOI 10.1016/0963-6897(95)02031-4; ROSENSTEIN JM, 1995, CELL TRANSPLANT, V4, P83, DOI 10.1016/0963-6897(94)00041-H; ROSENSTEIN JM, 1989, BRAIN RES, V476, P110, DOI 10.1016/0006-8993(89)91542-4; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Schmitt A, 1996, NEUROSCIENCE, V71, P989, DOI 10.1016/0306-4522(95)00477-7; SCHULZ MK, 1993, EXP BRAIN RES, V96, P480; Shibata T, 1997, J NEUROSCI, V17, P9212; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; Sutherland ML, 1996, J NEUROSCI, V16, P2191; Swanson RA, 1997, J NEUROSCI, V17, P932; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TORP R, 1995, EXP BRAIN RES, V103, P51; Velardo M. J., 1999, Society for Neuroscience Abstracts, V25, P524; Yamada K, 1998, J NEUROSCI, V18, P5706; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306	79	19	19	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	APR	2002	174	2					137	149		10.1006/exnr.2002.7867			13	Neurosciences	Neurosciences & Neurology	541PM	WOS:000174993000002	11922656				2021-06-18	
J	Wilson, DJ; Swaboda, JL				Wilson, DJ; Swaboda, JL			Partial weight-bearing gait retraining for persons following traumatic brain injury: preliminary report and proposed assessment scale	BRAIN INJURY			English	Article							COMMUNITY INTEGRATION QUESTIONNAIRE; NONAMBULATORY HEMIPARETIC PATIENTS; FUNCTIONAL ASSESSMENT MEASURE; REHABILITATION PROGRAM; SUPPORT; RELIABILITY; RECOVERY	The objectives of this investigation were to (1) document the recovery patterns of walking ability in two patients recovering from traumatic brain injury receiving partial weight-bearing gait retraining, and (2) introduce a new assessment scale of gait progress for patients receiving partial weight support therapy. The two patients were categorized as acute (< 6 months) and chronic (> 2 years) injury. Each patient received extensive in-patient rehabilitation, including physical therapy designed with twice-weekly partial body support gait training. The subjects made improvements in all measured indicators of gait ability (i.e. muscle strength, spasticity, standing balance). However, assessment of their improvement using standard assessment scales showed little progress. The newly devised Missouri Assisted Gait (MAG) scale, which includes developmental components of gait ability measured dramatic gains. This added precision of measurement was useful in communicating progress to both patients and providers.	SW Missouri State Univ, Dept Hlth Phys Educ & Recreat, Springfield, MO 65804 USA; Healthsouth, Howard A Rusk Rehabil Ctr, Columbia, MO USA	Wilson, DJ (corresponding author), SW Missouri State Univ, Dept Hlth Phys Educ & Recreat, 121C McDonald Arena,901 S Natl Ave, Springfield, MO 65804 USA.						Alcott D, 1997, DISABIL REHABIL, V19, P355, DOI 10.3109/09638289709166551; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DOBKIN BH, 1993, WESTERN J MED, V159, P56; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; GRILLNER S, 1995, SCIENCE, V288, P143; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HESSE S, 1994, ARCH PHYS MED REHAB, V75, P1087, DOI 10.1016/0003-9993(94)90083-3; HESSE SA, 1994, STROKE, V25, P1999, DOI 10.1161/01.STR.25.10.1999; KERRIGAN DC, 1994, AM J PHYS MED REHAB, V73, P421, DOI 10.1097/00002060-199411000-00007; LEMON R, 1988, TRENDS NEUROSCI, V11, P501, DOI 10.1016/0166-2236(88)90012-4; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MCPHERSON K, IN PRESS DISABILITY; NORMAN KE, 1995, ARCH PHYS MED REHAB, V76, P772, DOI 10.1016/S0003-9993(95)80533-8; RINEHART MA, 1990, REHABILITATION ADULT; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SEEFELDT VS, 1972, M AM ASS HLTH PHYS E; SHIRLEY MM, 1931, 1 2 YEARS STUDY 22 B, V1; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610	21	19	19	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2002	16	3					259	268		10.1080/02699050110103922			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800007	11874617				2021-06-18	
J	Gallyas, F; Farkas, O; Mazlo, M				Gallyas, F; Farkas, O; Mazlo, M			Traumatic compaction of the axonal cytoskeleton induces argyrophilia: histological and theoretical importance	ACTA NEUROPATHOLOGICA			English	Article						head injury; axonal pathology; cytoskeletal compaction; silver staining; electron microscopy	LIGHT MICROSCOPIC RESPONSE; CONCUSSIVE HEAD-INJURY; NEURONAL SOMATA; DARK NEURONS; RAT; DENDRITES; TISSUE	It was earlier established that one of the primary morphopathological consequences of experimental traumatic brain injury is a dramatic reduction in the distances between the neurofilaments (cytoskeletal compaction) inside a number of axon segments that appear to be randomly distributed among normal axons in an otherwise undamaged parenchymal environment. The present results demonstrate that the cytoskeletal compaction instantly induces argyrophilia, thereby rendering possible selective visualisation of the affected axon segments for light microscopy through use of a special silver staining method. On combination of this method with electron microscopy, it was revealed that the cytoskeletal compaction is completed in much shorter times and extends to much longer axon segments than previously assumed.	Univ Pecs, Fac Med, Dept Neurosurg, H-7623 Pecs, Hungary; Univ Pecs, Fac Med, Cent Elect Microscop Lab, H-7623 Pecs, Hungary	Gallyas, F (corresponding author), Univ Pecs, Fac Med, Dept Neurosurg, Ret Utca 2, H-7623 Pecs, Hungary.		Gallyas, Ferenc/C-5450-2009				Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; GALLYAS F, 1993, J NEUROSCI METH, V50, P159, DOI 10.1016/0165-0270(93)90004-B; GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P57; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAYAT MA, 1981, FIXATION ELECT MICRO, P176; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Newman GR, 1998, J PATHOL, V186, P119; ONKOWO DO, 1999, NEUROREPORT, V10, P353; ONKOWO DO, 1998, BRAIN RES, V784, P1; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PETTUS EH, 1996, BRAIN RES, V772, P1; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410	21	19	20	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JAN	2002	103	1					36	42		10.1007/s004010100424			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	510AY	WOS:000173187600005	11837745				2021-06-18	
J	Cazalis, F; Azouvi, P; Sirigu, A; Agar, N; Burnod, Y				Cazalis, F; Azouvi, P; Sirigu, A; Agar, N; Burnod, Y			Script knowledge after severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						script; executive functions; traumatic brain injury	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; FRONTAL-LOBE; MENTAL REPRESENTATION; STRATEGY APPLICATION; WORKING-MEMORY; DAMAGE; LESIONS; IMPAIRMENTS; DEFICITS	Severe diffuse traumatic brain injury (TBI) may impair the performance of daily-life complex activities. The aim of the present study was to assess whether these difficulties are related to a representational impairment of action knowledge. Two tasks requiring the manipulation of scripts were used. The first (script reconstitution) required subjects to sort cards describing actions belonging to 4 different scripts, presented in a random order. The second (script generation) required subjects to generate actions belonging to a given script. The results showed that TBI patients had preserved access to goal representation and action knowledge. However, they demonstrated (1) significant impairments when they had to deal with simultaneous competing sources of information and (2) a lack of inhibitory control on routine overlearned skills. Patients' performance was significantly correlated with behavioral modifications in everyday life. These data suggest that action impairment in severe TBI patients cannot be attributed to an impairment of action knowledge per se. As previously suggested by Schwartz et al., a restriction of limited-capacity processing resources may account for the observed deficits.	Univ Paris 05, Hop Raymond Poincare, Dept Neurol Rehabil, Serv Reduc Neurol, F-92380 Garches, France; INSERM, U483, F-75654 Paris 13, France; CNRS, Inst Cognit Sci, Bron, France	Azouvi, P (corresponding author), Univ Paris 05, Hop Raymond Poincare, Dept Neurol Rehabil, Serv Reduc Neurol, F-92380 Garches, France.		Sirigu, Angela/L-4683-2017				Allain P, 1999, J CLIN EXP NEUROPSYC, V21, P643, DOI 10.1076/jcen.21.5.643.871; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; BOWER GH, 1979, COGNITIVE PSYCHOL, V11, P177, DOI 10.1016/0010-0285(79)90009-4; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Grafman J., 1994, HANDB NEUR, V9, P187; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Reason J.T., 1984, VARIETIES ATTENTION, P515; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SCHANK R, 1982, DYNAMIC MEMORY THEOR; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Sirigu A, 1996, CORTEX, V32, P297, DOI 10.1016/S0010-9452(96)80052-9; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wickens C.D., 1984, VARIETIES ATTENTION, P63, DOI 10.1038/s41598-020-80452-5; Wilson BA, 1996, BEHAV ASSESSMENT DYS	39	19	22	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2001	7	7					795	804		10.1017/S1355617701777028			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	496YV	WOS:000172426700002	11771622	Green Published			2021-06-18	
J	Weinstein, CS; Fucetola, R; Mollica, R				Weinstein, CS; Fucetola, R; Mollica, R			Neuropsychological issues in the assessment of refugees and victims of mass violence	NEUROPSYCHOLOGY REVIEW			English	Article						neuropsychology refugees/victims; mass violence	POSTTRAUMATIC-STRESS-DISORDER; WAR; TRAUMA; SURVIVORS; SEQUELAE; PRISONER; DEFICITS; TORTURE; MEMORY; PTSD	Brain injury, stressor severity, depression, premorbid vulnerabilities, and PTSD are frequently intertwined in trauma populations. This interaction is further complicated when the neuropsychologist evaluates refugees from other cultures. In addition, the observed psychiatric symptoms reported in refugees and victims of mass violence may in fact not be the primary features of PTSD and depression but psychiatric symptoms secondary to the effects of traumatic brain injury. This paper reviews the occurrence of starvation, torture, beatings, imprisonment, and other head injury experiences in refugee and POW populations to alert treators to the presence of chronic and persistent neuropsychiatric morbidity, with implications for psychosocial adjustment. The concept of fixed neural loss may also interact with environmental and emotional stresses, and a model of neuropsychological abnormalities triggered by traumatic events and influenced by subsequent stress will also be considered. Neuropsychologists working with refugees play an important role in assessing the possibility of traumatic brain injury with tools that are relatively culture-fair.	Harvard Univ, Dept Psychiat, Sch Med, Beth Israel Deaconess Hosp, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO USA; Harvard Univ, Sch Med, Harvard Refugee & Trauma Program, Boston, MA 02115 USA	Weinstein, CS (corresponding author), Harvard Univ, Dept Psychiat, Sch Med, Beth Israel Deaconess Hosp, East Campus,Rabb Bldg,2nd Floor, Boston, MA 02115 USA.						Adams JH, 1992, GREENFIELDS NEUROPAT; ADAMS KM, 2000, M INT NEUR SOC DENV; Allden K, 1996, AM J PUBLIC HEALTH, V86, P1561, DOI 10.2105/AJPH.86.11.1561; [Anonymous], 1994, JAMA, V272, P391; Ardila A., 1992, HDB NEUROPSYCHOLOGIC, P181; Axelrod BN, 2000, CLIN NEUROPSYCHOL, V14, P344, DOI 10.1076/1385-4046(200008)14:3;1-P;FT344; Axelrod BN, 1997, J NEUROPSYCH CLIN N, V9, P23; Barona A., 1991, SCHOOL PSYCHOL INT, V12, P119, DOI [10.1177/0143034391121010, DOI 10.1177/0143034391121010]; Bieliauskas LA, 2000, CLIN NEUROPSYCHOL, V14, P341, DOI 10.1076/1385-4046(200008)14:3;1-P;FT341; BREMNER JD, 1995, J TRAUMA STRESS, V8, P527, DOI 10.1007/BF02102888; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brown L., 1990, TEST NONVERBAL INTEL; BROWN R, 1977, COGNITION, V5, P73, DOI 10.1016/0010-0277(77)90018-X; CASSIDAY KL, 1992, J TRAUMA STRESS, V5, P627, DOI 10.1007/BF00979230; CHRISTENSEN AL, 1998, J INT NEUROPSYCH SOC, V4, P212; CHRISTIANSON SA, 1984, SCAND J PSYCHOL, V25, P147, DOI 10.1111/j.1467-9450.1984.tb01007.x; CHRISTIANSON SA, 1991, COGNITION EMOTION, V5, P81, DOI 10.1080/02699939108411027; DELIA LF, 1996, TRAILS TEST PROFESSI; DEVAUGES V, 1990, BEHAV BRAIN RES, V39, P19, DOI 10.1016/0166-4328(90)90118-X; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Dougherty D, 1997, HARVARD REV PSYCHIAT, V5, P138, DOI 10.3109/10673229709000299; Drevets WC, 1998, ANNU REV MED, V49, P341, DOI 10.1146/annurev.med.49.1.341; EITENGER L, 1964, CONCENTRATION CAMP S; EITENGER L, 1973, MORTALITY MORBIDITY; FRIEDMAN MJ, 1989, J TRAUMATIC, V4, P67; FULD PA, 1982, FULD OBJECT MEMORY E; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; Goodglass H., 1983, ASSESSMENT APHASIA R; Gorst-Unsworth C, 1998, BRIT J PSYCHIAT, V172, P90, DOI 10.1192/bjp.172.1.90; GRONVIK O, 1962, J NEUROPSYCHIATRY, V4, P50; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; Hom J, 1997, ARCH CLIN NEUROPSYCH, V12, P531, DOI 10.1016/S0887-6177(97)00035-8; HOUGEN HP, 1988, FORENSIC SCI INT, V36, P153, DOI 10.1016/0379-0738(88)90229-0; JENSEN TS, 1982, NEW ENGL J MED, V307, P1341; Kaplan E., 1991, WECHSLER ADULT INTEL; KEITEL MA, 1996, HDB MULTICULTURAL AS, P29; KING DA, 1996, NEUROPSYCHOLOGICAL A, P22; Kizer K. W., 1995, Morbidity and Mortality Weekly Report, V44, P443; KLOVE H, 1974, CLIN NEUROPSYCHOLOGY; Krystal JH, 1995, MEMORY DISTORTION, P150; KRYSTAL JH, 1989, BEHAV THER, V20, P177, DOI 10.1016/S0005-7894(89)80068-1; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; LINDEM K, 2001, J INT NEUROPSYCH SOC, V7, P723; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; MACLEOD C, 1988, Q J EXP PSYCHOL-A, V40, P653, DOI 10.1080/14640748808402292; Manly JJ, 1998, J INT NEUROPSYCH SOC, V4, P291, DOI 10.1017/S1355617798002914; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; MCGAUGH JL, 1989, ANNU REV NEUROSCI, V12, P255, DOI 10.1146/annurev.ne.12.030189.001351; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MESULAM MM, 1985, PRINCIPLES BEHAVIORA, P86; Mollica RF, 1997, J AM ACAD CHILD PSY, V36, P1098, DOI 10.1097/00004583-199708000-00017; Mollica RF, 1998, BRIT J PSYCHIAT, V173, P482, DOI 10.1192/bjp.173.6.482; MOLLICA RF, 1997, J NERVOUS MENTAL S1, V180, P111; Nell V., 2000, CROSS CULTURAL NEURO; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PALUMBO C, 2001, J INT NEUROPSYCH SOC, V7, P723; PEREZARCE P, 1998, ECOLOGICAL VALIDITY, P283; PRIEBE S, 1997, J NERV MENT DIS, V185, P34; REITAN RM, 1969, UNPUB MANUAL ADM NEU; Rey A, 1941, EXAMEN CLIN PSYCHOL; Rosenstein LD, 1999, ARCH CLIN NEUROPSYCH, V14, P359, DOI 10.1016/S0887-6177(98)00026-2; Sack WH, 1997, J AM ACAD CHILD PSY, V36, P49, DOI 10.1097/00004583-199701000-00017; SAPOLSKY R, 1995, J NEUROSCI, V5, P1227; SAPOLSKY R, 1992, STRSS AGING BRAIN ME; SAPOLSKY RM, 1994, WHY ZEBRAS DONT GET, P172; SATZ P, 1997, 105 ANN CONV AM PSYC; Schacter D. L., 1995, MEMORY DISTORTION MI; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238; Shepherd I, 1999, J INT NEUROPSYCH SOC, V5, P83, DOI 10.1017/S1355617799511119; Shiang J, 1998, CLIN PSYCHOL-SCI PR, V5, P182, DOI 10.1111/j.1468-2850.1998.tb00143.x; Shimamura AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION; Silove D, 1997, BRIT J PSYCHIAT, V170, P351, DOI 10.1192/bjp.170.4.351; Sinnerbrink I, 1997, J PSYCHOL, V131, P463, DOI 10.1080/00223989709603533; Sue S., 1994, HDB PSYCHOTHERAPY BE, V4th ed, P783; Sulway MR, 1996, NEUROLOGY, V46, P650, DOI 10.1212/WNL.46.3.650; SUTKER PB, 1990, PSYCHOL REP, V66, P912, DOI 10.2466/PR0.66.3.912-914; SUTKER PB, 1993, AM J PSYCHIAT, V150, P240; SUTKER PB, 1990, J PERS ASSESS, V54, P170, DOI 10.1207/s15327752jpa5401&2_17; SUTKER PB, 1989, J PSYCHOPATHOL BEHAV, V11, P185, DOI 10.1007/BF00960479; SUTKER PB, 1990, J CONSULT CLIN PSYCH, V58, P323, DOI 10.1037/0022-006X.58.3.323; THYGESEN P, 1970, DAN MED BULL, V17, P65; VANDERKOLK B, 1985, BIOL PSYCHIAT, V20, P314, DOI 10.1016/0006-3223(85)90061-7; VASTERLING J, 2001, J INT NEUROPSYCH SOC, V7, P155; Vasterling JJ, 1997, ASSESSMENT, V4, P51, DOI 10.1177/107319119700400107; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; VEGA WA, 1991, ANNU REV SOCIOL, V17, P351, DOI 10.1146/annurev.so.17.080191.002031; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; WAGENAAR WA, 1990, APPL COGNITIVE PSYCH, V4, P77, DOI 10.1002/acp.2350040202; WOLFE J, 1991, PSYCHOL ASSESSMENT J, V4, P573; Wolfson D., 1993, HALSTEAD REITAN NEUR	98	19	19	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1040-7308	1573-6660		NEUROPSYCHOL REV	Neuropsychol. Rev.	SEP	2001	11	3					131	141		10.1023/A:1016650623996			11	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	508TV	WOS:000173106400002	11795840				2021-06-18	
J	Koestler, J; Keshavarz, R				Koestler, J; Keshavarz, R			Penetrating head injury in children: A case report and review of the literature	JOURNAL OF EMERGENCY MEDICINE			English	Article							MAGNETIC-RESONANCE ANGIOGRAPHY; TRAUMATIC BRAIN INJURY; POSTTRAUMATIC SEIZURES; CRANIOCEREBRAL INJURY; SUBARACHNOID HEMORRHAGE; EPIDEMIOLOGY; PREVENTION; CHILDHOOD; SCALE	Head trauma is exceedingly common in children, but rarely presents as a penetrating injury to the skull. Most of the recommendations on evaluation, management, and follow-up of Such injuries are based on the adult literature. We report a case of penetrating head injury from a tapered metal object in a 4-year old child. (C) 2001 Elsevier Science Inc.	Mt Sinai Sch Med, Dept Internal Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA	Koestler, J (corresponding author), Mt Sinai Sch Med, Dept Internal Med, 1 Gustave L Levy Pl,Box 1512, New York, NY 10029 USA.						ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; Cushing H, 1918, Br Med J, V1, P221; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DOMINGO Z, 1994, PEDIATR NEUROSURG, V21, P45, DOI 10.1159/000120813; DUFFY GP, 1969, BRIT J SURG, V56, P685, DOI 10.1002/bjs.1800560912; DUJOVNY M, 1975, J TRAUMA, V15, P981, DOI 10.1097/00005373-197511000-00007; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Geller E, 1997, PEDIATR RADIOL, V27, P790, DOI 10.1007/s002470050234; Glasier CM, 1997, CLIN NEUROSCI, V4, P153; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; James CA, 1997, CLIN NEUROSCI, V4, P137; JENNETT B, 1977, LANCET, V1, P878; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KENNEDY CR, 1986, J HEAD TRAUMA REHAB, V1, P66; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KUHL DA, 1990, DICP ANN PHARMAC, V24, P277, DOI 10.1177/106002809002400314; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Mayberg MR, 1998, NEUROSURG CLIN N AM, V9, P615; MCKICKEN DB, 1986, ANN EMERG MED, V15, P274; MILLER CF, 1977, SURG NEUROL, V7, P95; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; REGEV E, 1990, INJURY, V21, P414, DOI 10.1016/0020-1383(90)90138-K; RIVARA FP, 1994, PEDIATR ANN, V23, P12, DOI 10.3928/0090-4481-19940101-06; RIVERA F, 1987, PEDIATRICS, P579; RUGGIERI PM, 1992, CARDIOVASC INTER RAD, V15, P71, DOI 10.1007/BF02733902; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; SOTIROPOULOS SV, 1990, AM J DIS CHILD, V144, P980, DOI 10.1001/archpedi.1990.02150330040018; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; TAY JS, 1987, PEDIATRICS, V79, P261; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801	37	19	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	AUG	2001	21	2					145	150		10.1016/S0736-4679(01)00363-8			6	Emergency Medicine	Emergency Medicine	460UQ	WOS:000170327300007	11489404				2021-06-18	
J	Laforce, R; Martin-MacLeod, L				Laforce, R; Martin-MacLeod, L			Symptom cluster associated with mild traumatic brain injury in university students	PERCEPTUAL AND MOTOR SKILLS			English	Article							HEAD-INJURY; POSTCONCUSSION SYNDROME; COLLEGE-STUDENTS; PREVALENCE; QUESTIONNAIRE; POPULATION; SAMPLE	There is growing recognition that even a minor blow to the head can have serious consequences on physical, cognitive, behavioral, and social well-being. Previous studies have indicated that such changes may in turn have a dramatic effect on the ability of university students to carry out their studies. This survey measured the prevalence of mild traumatic brain injury in a nonclinical population of 1,075 university students from all disciplines. In addition to surveying the nature, cause, and sex distribution, it further investigated the relationships between the physical, cognitive, behavioral, and social repercussions of the incidents. Results replicated earlier findings and indicated a prevalence rate of mild traumatic brain injury of 34.9% (n = 375). Moreover. significant correlations were found among the physical, cognitive, behavioral, and social changes reported by the students, suggesting a cluster of symptoms associated with such incidents, Altogether, these results suggest that even currently enrolled and active university students may face unique and subtle challenges related to a mild traumatic brain injury.	Univ New Brunswick, Dept Psychol, St John, NB E2L 4L5, Canada	Laforce, R (corresponding author), Univ New Brunswick, Dept Psychol, POB 5050, St John, NB E2L 4L5, Canada.			Laforce, Robert Jr/0000-0002-2031-490X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Chan K M, 1984, Br J Sports Med, V18, P195; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CROVITZ HF, 1992, CORTEX, V28, P509, DOI 10.1016/S0010-9452(13)80160-8; FABIANO RJ, 1998, BRAIN INJURY, V14, P9; FITZGERALD DC, 1995, ARCH PHYS MED REHAB, V76, P1017, DOI 10.1016/S0003-9993(95)81041-2; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; HOLMES CB, 1991, PERCEPT MOTOR SKILL, V73, P497, DOI 10.2466/PMS.73.5.497-498; HOLMES CB, 1990, J POSTSECONDARY ED D, V8, P142; Hux D, 1998, BRAIN INJURY, V12, P667; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Klonoff PS, 1998, CLIN NEUROPSYCHOL, V12, P31, DOI 10.1076/clin.12.1.31.1732; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MCBEATH JG, 1994, HEADACHE, V3, P148; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; POWELL BD, 1995, PERCEPT MOTOR SKILL, V81, P227, DOI 10.2466/pms.1995.81.1.227; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Triplett G, 1996, PERCEPT MOTOR SKILL, V83, P1344, DOI 10.2466/pms.1996.83.3f.1344; VARNEY NR, 1991, NEUROPSYCHOLOGY LAW, P24	29	19	19	0	1	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807 USA	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	AUG	2001	93	1					281	288		10.2466/PMS.93.5.281-288			8	Psychology, Experimental	Psychology	484BF	WOS:000171669800043	11693696				2021-06-18	
J	Linan, E; O'Dell, MW; Pierce, JM				Linan, E; O'Dell, MW; Pierce, JM			Continuous passive motion in the management of heterotopic ossification in a brain injured patient	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						heterotopic ossification; continuous passive motion; traumatic brain injury; physical therapy	BONE-FORMATION	We report a man admitted to inpatient rehabilitation 6 wk after traumatic brain injury, who presented with bilateral knee heterotopic ossification. In addition to conventional physical therapy, we applied a continuous passive motion device during 4 wk increasing the range of motion of the knees. On the basis of the limited current literature and this case, we suggest that the use of continuous passive motion devices for heterotopic ossification may be effective and safe and should be the subject of further study.	Long Isl Jewish Med Ctr, Dept Phys Med & Rehabil, New Hyde Pk, NY 11040 USA; Southside Hosp, Reg Ctr Brain Injury Rehabil, Bay Shore, NY USA	Linan, E (corresponding author), Long Isl Jewish Med Ctr, Dept Phys Med & Rehabil, 270-05 76th Ave CH-005, New Hyde Pk, NY 11040 USA.						DELISA JA, 1998, REHABILITATION MED; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P133; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; GARLAND DE, 1983, CLIN ORTHOP RELAT R, V176, P197; GOLDBERG MA, 1977, ARCH INTERN MED, V137, P619, DOI 10.1001/archinte.137.5.619; HAMMOND FM, 1997, PHYS MED REH CLIN N, V8, P667; JENSEN LL, 1987, AM J PHYS MED REHAB, V66, P351; Keenan MAE, 1996, J HEAD TRAUMA REHAB, V11, P8, DOI 10.1097/00001199-199608000-00004; MCINNES J, 1992, JAMA-J AM MED ASSOC, V268, P1423, DOI 10.1001/jama.268.11.1423; MICHELSSON JE, 1983, CLIN ORTHOP RELAT R, P265; NADLER SF, 1993, AM J PHYS MED REHAB, V72, P162, DOI 10.1097/00002060-199306000-00011; Norkin CC, 1995, MEASUREMENT JOINT MO; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; RUSK H A, 1971, REHABILITATION MED; Salter RB, 1996, HAND CLIN, V12, P1; SALTER RB, 1980, J BONE JOINT SURG AM, V62, P1232, DOI 10.2106/00004623-198062080-00002; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; vanSusante JLC, 1996, ACTA ORTHOP SCAND, V67, P450, DOI 10.3109/17453679608996666; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P410	22	19	22	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2001	80	8					614	617		10.1097/00002060-200108000-00013			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	454BR	WOS:000169953000011	11475483				2021-06-18	
J	Cronin, AF				Cronin, AF			Traumatic brain injury in children: Issues in community function	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						child, exceptional; head injury occupational therapy; school based occupational therapy	HEAD-INJURIES; REHABILITATION; STUDENTS; SEQUELAE; INTERVENTION; ADOLESCENTS; TRANSITION; REENTRY; SCHOOL; MILD	The pathology and sequelae of pediatric traumatic brain injury (TBI) differ from those of the adult TBI population. In childhood TBI, cognitive impairment and secondary delays are often overlooked in the referral and intervention process. Although TBI is the leading cause of acquired dis ability in childhood, most children with TBI are discharged from acute care to home with little or no rehabilitation. This literature review provides current information germane to the occupational therapist on sequence and functional limitations that may exist or develop after TBI in children. Further, method by which these deficits can be addressed within the context of Individuals With Disabilities Education Act guidelines are described. Children with a history of TBI should be screened regularly because some cognitive problems emerge years after the injury as developmental demand on the child increase In this article school-based therapists are urged to look beyond a child's motor limitations to address the cognitive and neuropsychological problems typical of this population.	W Virginia Univ, Morgantown, WV 26505 USA	Cronin, AF (corresponding author), W Virginia Univ, Morgantown, WV 26505 USA.	acronin@hsc.wvu.edu					Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Berker E, 1996, INT J NEUROSCI, V85, P195, DOI 10.3109/00207459608986683; Blasier D, 1989, Orthop Rev, V18, P350; BLASKEY J, 1999, DECISION MAKING PEDI, P84; Blosser J, 1997, J HEAD TRAUMA REHAB, V12, P21, DOI 10.1097/00001199-199704000-00004; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bruce D A, 1990, Curr Probl Pediatr, V20, P61; CARNEY J, 1990, Pediatrician, V17, P222; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DAmato RC, 1996, J LEARN DISABIL, V29, P670, DOI 10.1177/002221949602900611; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; HUMPHRY R, 1996, OCCUPATIONAL THERAPY, P67; JENNETT B, 1975, LANCET, V1, P480; JOHNSTON MV, 1995, BRAIN DEV-JPN, V17, P301, DOI 10.1016/0387-7604(95)00079-Q; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; LAZAR MF, 1995, J HEAD TRAUMA REHAB, V10, P55, DOI 10.1097/00001199-199510000-00007; LOWENTHAL B, 1998, INFANT TODDLER INTER, V8, P377; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MILLER L, 1991, COGNITIVE REHABILITA, V9, P16; Moseley AM, 1997, PHYS THER, V77, P240, DOI 10.1093/ptj/77.3.240; Nuismer BA, 1997, AM J OCCUP THER, V51, P538, DOI 10.5014/ajot.51.7.538; Pang D, 1985, HEAD INJURY REHABILI, P3; Parkin AE., 1996, AUSTR OCCUPATIONAL T, V43, P133; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PORR S, 1999, PEDIAT THERAPY SYSTE, P525; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prosser R, 1996, J Hand Ther, V9, P378; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; Scott A.D., 1995, OCCUPATIONAL THERAPY, P705; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; TEASDALE G, 1974, LANCET, V2, P81; VESSEY, 1997, PEDIAT NURSING, V23, P507; WALLECK C, 1994, NEUROSCIENCE NURSING, P324; WARREN M, 1991, OCCUPATIONAL THERAPY, P634; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015; WINKLER P, 1995, NEUROLOGICAL REHABIL, P421	50	19	20	0	7	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JUL-AUG	2001	55	4					377	384		10.5014/ajot.55.4.377			8	Rehabilitation	Rehabilitation	454BJ	WOS:000169952300003	11723981				2021-06-18	
J	Saleh, SS; Fuortes, L; Vaughn, T; Bauer, EP				Saleh, SS; Fuortes, L; Vaughn, T; Bauer, EP			Epidemiology of occupational injuries and illnesses in a university population: A focus on age and gender differences	AMERICAN JOURNAL OF INDUSTRIAL MEDICINE			English	Article						occupational injuries; cause of injury; nature of injury; gender; age	WORKERS-COMPENSATION; UNITED-STATES; INDUSTRY; RATES; COSTS	Background Occupational injuries and illnesses are a major preventable public health problem. Methods This study evaluated the incidence, nature, and cause of awarded workers' compensation claims for a large state university and teaching hospital. Rates and types of injury weve compared across age and gender. Results Rates of injury varied over twofold with age, with those 16-25 having the lowest rates of injury and those 36-45 having the highest rates. Claims rates were 1.36-fold higher for women than men. Women had higher rates for injury resulting from lifting, falling noxious exposures, repetitive motion, and carpal tunnel syndrome. Similarly women had significantly higher rates of claims for pain, sprains, bruises, bums, concussion, and inhalation injury; with lower rates of cuts, ligament injury, and jammed joints. Conclusions These group differences suggest the need to examine age and gender job distributions and relevant ergonomic and environmental causative factors. Am. J. Ind. Med. 39:581-586, 2001. (C) 2001 Wiley-Liss, Inc.	Univ Iowa, Coll Publ Hlth, Dept Hlth Policy & Management, Iowa City, IA 52242 USA; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA	Saleh, SS (corresponding author), Univ Iowa, Coll Publ Hlth, Dept Hlth Policy & Management, 2700 SB, Iowa City, IA 52242 USA.						BERNACKI EJ, 1996, J OCCUP ENVIRON MED, V38, P1019; CHEADLE A, 1994, AM J PUBLIC HEALTH, V84, P190, DOI 10.2105/AJPH.84.2.190; Choi BCK, 1996, J OCCUP ENVIRON MED, V38, P379, DOI 10.1097/00043764-199604000-00016; FUORTES LJ, 1990, AM J IND MED, V18, P211, DOI 10.1002/ajim.4700180213; Gluck JV, 1998, SPINE, V23, P1572, DOI 10.1097/00007632-199807150-00013; Goldsmith DF, 1998, OCCUP MED, V13, P389; Henry K, 1995, Minn Med, V78, P41; Khuder SA, 1999, J OCCUP ENVIRON MED, V41, P53, DOI 10.1097/00043764-199901000-00009; Kraus JF, 1997, AM J EPIDEMIOL, V146, P637; Leigh JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/archinte.157.14.1557; MARKOWITZ S, 1992, ENV OCCUPATIONAL MED, P19; MCCURDY SA, 1989, AM J IND MED, V15, P499, DOI 10.1002/ajim.4700150503; Miller TR, 1995, ACCIDENT ANAL PREV, V27, P741, DOI 10.1016/0001-4575(95)00022-4; MITCHELL OS, 1988, MON LABOR REV, V111, P8; MONT D, 1999, WORKERS COMPENSATION; ROEGGE D, 1992, 29 ANN SUMM EMPL BEN, V1, P42; Vergara A E, 1998, Int J Occup Environ Health, V4, P199; WEBSTER S, 1993, SITES, V26, P2; ZWERLING C, 1993, AM J EPIDEMIOL, V138, P46, DOI 10.1093/oxfordjournals.aje.a116776	19	19	19	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0271-3586			AM J IND MED	Am. J. Ind. Med.	JUN	2001	39	6					581	586		10.1002/ajim.1057			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	438DF	WOS:000169037900006	11385642				2021-06-18	
J	Guyot, LL; Kazmierczak, CD; Diaz, FG				Guyot, LL; Kazmierczak, CD; Diaz, FG			Vascular injury in neurotrauma	NEUROLOGICAL RESEARCH			English	Article						traumatic aneurysm; pseudoaneurysm; dissection; cavernous-carotid fistula	CAROTID-ARTERY DISSECTION; VERTEBRAL ARTERY; CAVERNOUS FISTULAS; TRAUMATIC ANEURYSMS; ANGIOGRAPHY; MANAGEMENT; DIAGNOSIS; HEAD; NECK; CLASSIFICATION	Traumatic vascular lesions can occur after severe or even the most mild of head and cervical trauma. The initial evaluation of the injured patient must be thorough and the clinical suspicion of vascular injury must be highly suspected based on the mechanism of injury. Traumatic vascular injuries can be broadly classified into traumatic aneurysms, dissections and occlusions and fistulae of the carotid or vertebral arteries. The current management and treatment options of each condition are discussed.	Wayne State Univ, Detroit Med Ctr, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Detroit Med Ctr, Dept Radiol, Detroit, MI 48201 USA	Guyot, LL (corresponding author), Wayne State Univ, Dept Neurol Surg, 4201 St Antoine 6E-UHC, Detroit, MI 48201 USA.						AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; ACHTEREEKTE HAM, 1994, SURG NEUROL, V42, P240, DOI 10.1016/0090-3019(94)90270-4; Ahmadi J, 1996, NEUROSURGERY, VII, P2821; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biousse V, 1998, ARCH NEUROL-CHICAGO, V55, P715, DOI 10.1001/archneur.55.5.715; BIOUSSE V, 1995, STROKE, V26, P235, DOI 10.1161/01.STR.26.2.235; Debehnke Daniel J., 1994, Journal of Emergency Medicine, V12, P27, DOI 10.1016/0736-4679(94)90008-6; DEBRUN G, 1981, J NEUROSURG, V55, P678, DOI 10.3171/jns.1981.55.5.0678; DEBRUN GM, 1988, NEUROSURGERY, V22, P285, DOI 10.1227/00006123-198802000-00001; DeOcampo J, 1997, J NEUROIMAGING, V7, P187, DOI 10.1111/jon199773187; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; Eachempati SR, 1998, J TRAUMA, V45, P997, DOI 10.1097/00005373-199812000-00004; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FISHER CM, 1982, HEADACHE, V22, P60, DOI 10.1111/j.1526-4610.1982.hed2202060.x; Glauser Jonathan, 1994, Journal of Emergency Medicine, V12, P307, DOI 10.1016/0736-4679(94)90271-2; GOLUEKE P, 1987, J TRAUMA, V27, P856, DOI 10.1097/00005373-198708000-00003; GUGTOWSKI NJ, 1992, J NEUROL NEUROSUR PS, V55, P841; GUIBERT, 1895, ANN OCUL, V113, P314; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HALBACH VV, 1993, J NEUROSURG, V79, P183, DOI 10.3171/jns.1993.79.2.0183; HANUS SH, 1977, ARCH NEUROL-CHICAGO, V34, P574, DOI 10.1001/archneur.1977.00500210076015; HART RG, 1988, NEUROLOGY, V38, P987, DOI 10.1212/WNL.38.6.987; HERR RD, 1992, ANN EMERG MED, V21, P88, DOI 10.1016/S0196-0644(05)82248-6; HINSE P, 1991, J NEUROL NEUROSUR PS, V54, P863, DOI 10.1136/jnnp.54.10.863; HOFFMANN M, 1993, STROKE, V24, P815, DOI 10.1161/01.STR.24.6.815; Hong MK, 1997, AM J CARDIOL, V79, P538, DOI 10.1016/S0002-9149(96)00808-9; LEVY C, 1994, RADIOLOGY, V190, P97, DOI 10.1148/radiology.190.1.8259436; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; LEWIS AI, 1995, NEUROSURGERY, V36, P239, DOI 10.1227/00006123-199502000-00001; Liu AY, 1999, NEUROSURGERY, V45, P1368, DOI 10.1097/00006123-199912000-00022; Lucas C, 1998, STROKE, V29, P2646, DOI 10.1161/01.STR.29.12.2646; MAS JL, 1987, J NEUROL, V234, P237; Millman B, 1994, Ear Nose Throat J, V73, P408; PRABHU VC, 1994, SURG NEUROL, V42, P245, DOI 10.1016/0090-3019(94)90271-2; Sclafani AP, 1996, LARYNGOSCOPE, V106, P168, DOI 10.1097/00005537-199602000-00012; SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125; STEINKE W, 1990, NEURORADIOLOGY, V32, P502, DOI 10.1007/BF02426464; STEINKE W, 1994, STROKE, V25, P998, DOI 10.1161/01.STR.25.5.998; TRAMO MJ, 1985, STROKE, V16, P1039, DOI 10.1161/01.STR.16.6.1039; TULYAPRONCHOTE R, 1994, NEUROLOGY, V44, P1379; Uzan M, 1998, NEUROSURGERY, V43, P1314, DOI 10.1097/00006123-199812000-00024; Wallick Kristin, 1997, Journal of Emergency Medicine, V15, P23, DOI 10.1016/S0736-4679(96)00239-9; Zetterling M, 2000, ACTA NEUROL SCAND, V101, P1, DOI 10.1034/j.1600-0404.2000.00001.x	45	19	20	0	0	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					291	296		10.1179/016164101101198442			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	422DX	WOS:000168104200022	11320609				2021-06-18	
J	Stibick, DL; Feeney, DM				Stibick, DL; Feeney, DM			Enduring vulnerability to transient reinstatement of hemiplegia by prazosin after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						alpha(1) noradrenergic receptors; brain injury; noradrenaline; prazosin; reinstatement; trauma	SENSORIMOTOR CORTEX CONTUSION; CORTICAL INJURY; RAT-BRAIN; AMPHETAMINE; RECOVERY; MOTOR; NEURONS; NOREPINEPHRINE; ORGANIZATION; RECEPTORS	A single dose of an alpha (1)-noradrenergic antagonist transiently reinstates hemiplegia after recovery from brain injury, which suggests that noradrenaline (NA) is required to maintain recovery. No systematic studies have determined the postinjury duration of this vulnerability. This study used a within-subject, dose-response design to determine whether prazosin (PRAZ), an alpha (1)-NA antagonist, or propranolol (PROP), a beta -NA antagonist, would continue to reinstate hemiplegia over time after recovery from weight-drop traumatic brain injury (TBI), PRAZ transiently reinstated hemiplegia as measured by beam walk (BW) score in a dose-dependent manner, with the same degree of symptom reinstatement at 1, 3, 6, and 12 months post-TBI, Between-animal variability in reinstatement of hemiplegia by PRAZ was predicted by severity of deficits in BW ability 24 h after TBI, In contrast, PRAZ did not reinstate tactile placing deficits at 1 month post-TBI suggesting a different mechanism of maintaining recovery for each task. Reinstatement of symptoms are not due to sedation. Only TBI rats receiving PRAZ, not high, sedating doses of PROP or saline (SAL), showed return of hemiplegia, These data indicate that vulnerability to transient reinstatement of hemiplegia on some tasks endures long after functional recovery from TBI.	Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA	Feeney, DM (corresponding author), Univ New Mexico, Dept Psychol, Logan Hall, Albuquerque, NM 87131 USA.	feeney@unm.edu					BOGEN J, 1975, J NEUROBIOL, V6, P125, DOI 10.1002/neu.480060115; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1983, THESIS U NEW MEXICO; BRAILOWSKY S, 1987, NEUROBIOL AGING, V8, P441, DOI 10.1016/0197-4580(87)90039-X; BROWN AW, 1979, ANN NEUROL, V5, P127, DOI 10.1002/ana.410050206; COHEN Z, 1986, INT J COLOR DIS, V1, P2; DERYCK M, 1992, BRAIN RES, V573, P44; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1983, FED PROC, V42, P1157; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1989, J NEUROTRAUM, V6, P209; FEENEY DM, 1995, J NEUR ABSTR, V21, P495; FEENEY DM, 1998, CEREBROVASC DIS, P620; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; Goldstein LB, 1998, RESTORATIVE NEUROLOGY, P241; GOLDSTEIN LB, 1988, NEUROLOGY, V38, P1806, DOI 10.1212/WNL.38.11.1806; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HOFFMAN B B, 1990, P221; HOVDA DA, 1983, SOC NEUR ABSTR, V9, P1002; HOVDA DA, 1996, NEUROTRAUMA, P1459; KLUVER H, 1976, HISTOLOGICAL PROCESS, P39; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; RUTLEDGE CO, 1970, J PHARMACOL EXP THER, V171, P188; SAPORTA S, 1977, J COMP NEUROL, V174, P187, DOI 10.1002/cne.901740202; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; SHENOY AK, 1979, LIFE SCI, V24, P255, DOI 10.1016/0024-3205(79)90227-3; STEWART J, 1987, CALCULUS, P440; STIBICK DL, 1998, P 5 INT WORLD C BIOM; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1994, NEUROLOGICAL REHABIL, P469; SUTTON RL, 1995, CENTRAL NERVOUS SYST, P497; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TANIGUCHI T, 1988, LIFE SCI, V42, P2341, DOI 10.1016/0024-3205(88)90187-7; Tracey David J., 1995, P689; WEISEND M P, 1989, Society for Neuroscience Abstracts, V15, P69; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; WILSON KM, 1991, J NEUROCHEM, V56, P953, DOI 10.1111/j.1471-4159.1991.tb02014.x; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	51	19	19	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					303	312		10.1089/08977150151070955			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000007	11284550				2021-06-18	
J	Santa Maria, MP; Pinkston, JB; Miller, SR; Gouvier, WD				Santa Maria, MP; Pinkston, JB; Miller, SR; Gouvier, WD			Stability of postconcussion symptomatology differs between high and low responders and by gender but not by mild head injury status	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							SEX-DIFFERENCES; BASE RATES; SYMPTOMS; DEPRESSION; CONCUSSION; STRESS	A large sample of undergraduates (N = 2.326) was screened for general health. The screen discretely included items assessing postconcussion symptomatology and neurologic history. A subsample of experiment-blind participants whose self-reported postconcussion symptom levels were > 0.5 SD below the screening sample mean (low symptomatic; n = 45) or > 0.5 SD above the screening sample mean thigh symptomatic: n = 53) were re-evaluated for postconcussion symptomatology 3 to 90 days later. The sample included 50 participants who reported history of mild head injury (MHI) and 48 controls. MHI was defined as loss of consciousness of less than or equal to 20 minutes within the past 10 years, but no more recent than 3 months. Persons with history of > 1 head injury or with other neurologic history were not included in the study. The stability of postconcussion symptoms differed by high symptomatic versus low symptomatic presentation thigh symptomatic presentation was more variable) and by gender (females were more variable), but not by actual history of MHI. Sex differences in self-reported postconcussion symptomatology are consistent with gender-related differences in reporting of other physical and psychological symptoms. In addition to demonstrating differences in the stability of self-reported postconcussion symptomatology, the current study provides normative test-retest data for the Postconcussion Symptom Checklist for extreme responders by gender and MHI status. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA	Santa Maria, MP (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurol, 100 High St,D-6, Buffalo, NY 14203 USA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Compas BE, 1997, J CONSULT CLIN PSYCH, V65, P617, DOI 10.1037/0022-006X.65.4.617; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; FRANK E, 1988, AM J PSYCHIAT, V145, P41; Frieze I. H., 1978, WOMEN SEX ROLES SOCI; Gater R, 1998, ARCH GEN PSYCHIAT, V55, P405, DOI 10.1001/archpsyc.55.5.405; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldberg D.P, 1972, DETECTION PSYCHIAT I; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HannaPladdy B, 1997, ARCH CLIN NEUROPSYCH, V12, P329; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kibby M Y, 1997, Appl Neuropsychol, V4, P34, DOI 10.1207/s15324826an0401_4; KING DA, 1982, J PERS SOC PSYCHOL, V42, P963, DOI 10.1037/0022-3514.42.5.963; Kornstein SG, 1997, J CLIN PSYCHIAT, V58, P12; Kroenke K, 1998, PSYCHOSOM MED, V60, P150, DOI 10.1097/00006842-199803000-00006; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; NOLENHOEKSEMA S, 1987, PSYCHOL BULL, V101, P259, DOI 10.1037/0033-2909.101.2.259; PHILLIPS DL, 1969, AM SOCIOL REV, V34, P58, DOI 10.2307/2092787; PINKSTON JB, 2000, IN PRESS BRAIN COGNI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; WEISSMAN MM, 1977, ARCH GEN PSYCHIAT, V34, P98; WOOD F, 1984, INT J PSYCHIAT MED, V14, P277; YOUNG MA, 1990, J NERV MENT DIS, V178, P200, DOI 10.1097/00005053-199003000-00008	29	19	19	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2001	16	2					133	140					8	Psychology, Clinical; Psychology	Psychology	415JB	WOS:000167716900002	14590181				2021-06-18	
J	Foster, M; Fleming, J; Tilse, C; Rosenman, L				Foster, M; Fleming, J; Tilse, C; Rosenman, L			Referral to post-acute care following traumatic brain injury (TBI) in the Australian context	BRAIN INJURY			English	Article							HEAD-INJURY; REHABILITATION; CHILDREN	The study aimed to describe the types of care allocated at the end of acute care to people diagnosed with TBI and to identify the factors associated with variations in referral to care. A retrospective analysis of medical records of 61 patients was conducted based on a sample from two hospitals. While 60.7% of the study sample were referred to formal rehabilitation care, this was primarily non-inpatient rehabilitation care (32.8%). Discriminant analysis was used to determine medical and non-medical predictors of referral. Results indicated that place of treatment and age contribute to group differences and were significant in separating the inpatient rehabilitation group from the non-inpatient and no rehabilitation groups. Review by a rehabilitation physician was associated with referral to inpatient rehabilitation but was not adequate to explain referral to non-inpatient rehabilitation. An in-depth exploration of post-acute referral is warranted to improve policy and practice in relation to continuity of care following TBI.	Univ Queensland, Sch Social Work & Social Policy, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia; Univ Queensland, Fac Social & Behav Sci, Brisbane, Qld 4072, Australia	Foster, M (corresponding author), Univ Queensland, Sch Social Work & Social Policy, Brisbane, Qld 4072, Australia.		Tilse, Cheryl/A-1266-2008; Fleming, Jennifer M/B-4436-2011; Tilse, Cheryl/AAH-2155-2019	Tilse, Cheryl/0000-0001-5596-9132; 			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; *AUSTR FAC REH MED, 1997, REH 21 CENT VIS VICT; CAPLAN A, 1987, HASTINGS CTR REP S, P1; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COULTON CJ, 1988, SOC WORK HEALTH CARE, V13, P19, DOI 10.1300/J010v13n04_03; DEMBOVY M, 1996, BRAIN INJURY, V11, P305; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; FORTUNE N, 1999, 15 AIHW DIS; GILES GM, 1994, AM J OCCUP THER, V48, P199, DOI 10.5014/ajot.48.3.199; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Hoenig H, 1996, ARCH PHYS MED REHAB, V77, P58, DOI 10.1016/S0003-9993(96)90221-X; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Mooney GH, 1997, MED J AUSTRALIA, V166, P575, DOI 10.5694/j.1326-5377.1997.tb123266.x; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tabachnick BG, 2013, USING MULTIVARIATE S; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	23	19	20	0	2	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2000	14	12					1035	1045					11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	380YW	WOS:000165736100001	11147576				2021-06-18	
J	Hortobagyi, T; Hortobagyi, S; Gorlach, C; Harkany, T; Benbyo, Z; Gorogh, T; Nagel, W; Wahl, M				Hortobagyi, T; Hortobagyi, S; Gorlach, C; Harkany, T; Benbyo, Z; Gorogh, T; Nagel, W; Wahl, M			A novel brain trauma model in the mouse: effects of dexamethasone treatment	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Article						brain swelling; cold lesion; dexamethasone; mouse; oedema therapy	LATERAL FLUID-PERCUSSION; COLD-INJURY; CEREBRAL-CORTEX; EDEMA; MICE; RAT; BARRIER; NECROSIS; LESION	We describe a novel methodological approach for inducing cold lesion in the mouse as a model of human cortical contusion trauma. To validate its reproducibility and reliability, dexamethasone (Dxm) was repeatedly applied to demonstrate possible antioedematous drug effects. Following tho induction of anaesthesia with halothane, the dura was exposed via trephination. Using a micromanipulator a pre-cooled (-78 degreesC) copper cylinder, 3 mm in diameter, was pressed down to a depth of 1 mm onto the dura fur 30 s under microscopic control. The body temperature was held constant at 37 degreesC throughout the procedure. Blood pressure (BP), measured by a modified photosensor-monitored tail-cuff method, and acid-base status were not significantly different when analysed before and after cold lesion and prior to sacrifice. However, there was a marginal mixed respiratory and metabolic acidosis. The antioedematous action of Dxm was studied in four standard pre and post-treatment paradigms: 2x0.5 mg/kg (II), 2x12,5 mg/kg (III) and 4x6.25 mg/kg (IV: 3x pre-, 1x post-treatment; V: 1x pre-, 3x post-treatment). Physiological saline injections served as controls. High doses of Dxm (III-V) significantly attenuated the cold-lesion-induced loss of body mass. Dxm treatment also resulted in a reduction of brain water content (III; P<0.05), and brain swelling (IV; P<0.05) in the lesioned hemisphere, relative to controls. In conclusion, we have characterized a novel cold lesion model in the mouse to mimic traumatic brain injury and the beneficial effect of Dxm treatment on the extent of brain oedema.	Univ Munich, Dept Physiol, D-80336 Munich, Germany; Univ Groningen, Dept Anim Physiol, NL-9750 AA Haren, Netherlands; Semmelweis Univ, Inst Human Physiol & Clin Expt Res, H-1446 Budapest, Hungary; Univ Kiel, Dept Otorhinolaryngol Head & Neck Surg, Oncol Mol Lab, D-24105 Kiel, Germany	Hortobagyi, T (corresponding author), Univ Munich, Dept Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.	hortobagyi@lrz.uni-muenchen.de	Benyo, Zoltan/C-9184-2009	Benyo, Zoltan/0000-0001-6015-0359			Abraham I, 1997, J NEUROENDOCRINOL, V9, P713, DOI 10.1046/j.1365-2826.1997.00634.x; Bertorelli R, 1998, NEUROSCI LETT, V246, P41, DOI 10.1016/S0304-3940(98)00221-3; Biros MH, 1996, AM J EMERG MED, V14, P27, DOI 10.1016/S0735-6757(96)90008-X; De Kloet ER, 1997, Stress, V2, P13; ERISKAT J, 1994, ACTA NEUROCHIR, P425; FOLGER S, 1991, P 25 INT S BIOL MOD, P9; HEDLEYWHYTE ET, 1986, ANN NEUROL, V19, P373, DOI 10.1002/ana.410190411; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HORTOBAGYI T, 2000, PFLUGERS ARCH S, V439, pR437; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KLATZO I, 1972, STEROIDS BRAIN EDEMA, P1; Kostron H, 1990, Adv Neurol, V52, P289; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meinig G, 1990, Adv Neurol, V52, P295; Michel C, 1999, PHYSIOL BEHAV, V68, P145, DOI 10.1016/S0031-9384(99)00159-6; Minet-Quinard R, 2000, JPEN-PARENTER ENTER, V24, P30, DOI 10.1177/014860710002400130; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P880, DOI 10.1097/00005072-199608000-00003; Nakata H, 1990, Adv Neurol, V52, P335; OLSON JJ, 1987, J NEUROPATH EXP NEUR, V46, P682, DOI 10.1097/00005072-198711000-00007; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; SCHILLING L, 1994, ACTA NEUROCHIR, P79; Steinbach JP, 1999, NEUROPATH APPL NEURO, V25, P468; Tajima A, 1990, Adv Neurol, V52, P343; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; VONANDRIANWERBU.U, 1992, THESIS U MUNICH; Wahl M., 1999, Acta Physiologica Hungarica, V86, P155	30	19	19	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0031-6768	1432-2013		PFLUG ARCH EUR J PHY	Pflugers Arch.	DEC	2000	441	2-3					409	415		10.1007/s004240000441			7	Physiology	Physiology	389BX	WOS:000166219700030	11211129				2021-06-18	
J	McCunn, M; Mirvis, S; Reynolds, HN; Cottingham, C				McCunn, M; Mirvis, S; Reynolds, HN; Cottingham, C			Physician utilization of a portable computed tomography scanner in the intensive care unit	CRITICAL CARE MEDICINE			English	Article						CT scan; portable CT; mobile CT; trauma; diagnostic studies in critical illness; survey; unexpected findings; occult disease	CRITICALLY ILL PATIENTS; INTRAHOSPITAL TRANSPORT; COMPLICATIONS	Objective: To determine the utilization of a portable computed tamography (CT) scanner for critically ill adult patients in an intensive care unit (ICU). Design: survey study and retrospective review. Subjects: Critical care attending staff and fellows and neurosurgery residents. Setting: A university hospital and Level I trauma center with a multitrauma ICU, a neurotrauma ICU, and a neurosurgical ICU. Interventions: We surveyed all physicians who ordered portable CT scans from December 1996 through June 1998. Ordering physicians included critical care attending staff and fellows (anesthesiology, surgery, internal medicine) and neurosurgery residents. Physicians who no longer worked at the institution were contacted by mail or fax. Radiology records were reviewed to determine the actual number and type of scans performed. Measurements and Main Results:The survey response was 100%. Most physicians reported ordering portable head CT scans (97%), followed by chest CT (88%), abdominal CT (78%), and pelvic CT (34%) scans. Analysis of the actual number of scans performed correlated with these reports (511 head, 115 chest, 88 abdomen, and 87 pelvis). The indication for portable CT scans (as opposed to a "fixed" or "stationary" scans) cited most often was patient severity of illness (77%). Patients an extracarporeal support (93%), those with cardiovascular instability (70%), followed by those with respiratory instability (57%) and neurologic instability (40%) were deemed tao ill to transport. If the portable CT scanner was unavailable, however, most physicians (67%) ordered a fixed helical CT scan and the patient was transported to the radiology suite, regardless of medical condition. Conclusions: Access to a portable CT scanner impacts the physician ordering patterns for ICU patients. We found that 100% of surveyed physicians used the portable CT scanner for critically ill patients when the patient was unstable. If the diagnostic study was deemed medically necessary, and the portable scanner was unavailable, most surveyed physicians ordered a "fixed" helical scan and the patient was transported by an experienced transport team for the study. The portable CT offered an alternative and potentially safer means of obtaining diagnostic studies.	Univ Maryland, Sch Med, Dept Crit Care, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Radiol, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA	McCunn, M (corresponding author), Univ Maryland, Sch Med, Dept Crit Care, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.						BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; HURST JM, 1992, J TRAUMA, V33, P582, DOI 10.1097/00005373-199210000-00015; INDECK M, 1988, J TRAUMA, V28, P1020, DOI 10.1097/00005373-198807000-00018; INSEL J, 1986, CRIT CARE MED, V14, P539, DOI 10.1097/00003246-198606000-00004; JASTREMSKI MS, 1993, CRIT CARE MED, V21, P931; MIRVIS S, 1997, EMERG RADIOL, P1; MIRVIS SE, 1987, AM J ROENTGENOL, V148, P685, DOI 10.2214/ajr.148.4.685; SMITH I, 1990, CRIT CARE MED, V18, P278, DOI 10.1097/00003246-199003000-00006; SZEM JW, 1995, CRIT CARE MED, V23, P1660, DOI 10.1097/00003246-199510000-00009; TAYLOR JO, 1970, LANCET, V2, P1205; WALLEN E, 1995, CRIT CARE MED, V23, P1588, DOI 10.1097/00003246-199509000-00020; WEG JG, 1989, CHEST, V96, P631, DOI 10.1378/chest.96.3.631	12	19	21	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	DEC	2000	28	12					3808	3813		10.1097/00003246-200012000-00008			6	Critical Care Medicine	General & Internal Medicine	388NB	WOS:000166186200005	11153618				2021-06-18	
J	Alessandri, B; AL-Samsam, R; Corwin, F; Fatouros, P; Young, HF; Bullock, RM				Alessandri, B; AL-Samsam, R; Corwin, F; Fatouros, P; Young, HF; Bullock, RM			Acute and late changes in N-acetyl-aspartate following diffuse axonal injury in rats: An MRI spectroscopy and microdialysis study	NEUROLOGICAL RESEARCH			English	Article						proton nuclear magnetic resonance spectroscopy (H-1-NMR); microdialysis; N-acetyl-aspartate; traumatic brain injury; weight drop injury; neuronal death; rat; halothane anesthesia; brain	MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; HYPOXIA-ISCHEMIA; ACETYLASPARTATE; LESIONS; DISEASE; MODEL; LOBE	N-acetyl-aspartate (NAA) measured by proton nuclear magnetic resonance spectroscopy (H-1-NMR) has been used as a marker of neuronal injury in many cerebral pathologies. Therefore, we evaluate the roles of microdialysis vs. H-1-NMR as techniques to assess NAA (NAA(d); NAA/Creatine ratio) in the living brain, and compare the results with whole brain NAA (NAA(w)) analyzed by HPLC after diffuse traumatic brain injury (TBI). Acute (4 h post-injury survival) and late (48 h survival) changes were studied in a sham-operated group (Sham, n = 4), and two injured groups (TBI/4h, n = 8; TBI/48h, n = 7). Baseline NAAd was 8.17 +/- 1 muM, and there was no significant difference between groups. There was only a small (twice of control), but transient increase in NAAd in the TBI/4 h group after trauma. Baseline NAA/Cr ratio was 1.35 +/- 0.2, which did not change significantly between baseline, 1, 2, 3, 4 and 48 h or between groups after TBI. Whole brain NAA, (baseline 8.5 +/- 0.5 mmol kg(-1) wet weight) did not differ significantly between groups before and after TBI. Diffuse TBI did not produce long-term changes in NAA, assessed by three different methods. These results may indicate that NAA is not a sensitive marker of the severity of diffuse axonal damage. However, further studies are needed to evaluate whether confounding factors such as microdialysis probe, voxel position and non-regional tissue homogenization might have influenced our data.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Pediat Crit Care, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Radiol, Richmond, VA 23298 USA	Bullock, RM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980631,MCV Stn Box, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Al-Samsam R, 1999, CRIT CARE MED, V27, pA104, DOI 10.1097/00003246-199901001-00265; ALSAMASAM R, 1998, J NEUROTRAUM, V15, pA9; ALSAMASAM R, 1999, IN PRESS J NEUROTRAU; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; BERLINGUET L, 1996, CAN J BIOCHEM, V44, P783; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CENDES F, 1994, ANN NEUROL, V35, P211, DOI 10.1002/ana.410350213; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; DI X, 1999, 11 INT S BRAIN OED M, P65; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GIDEON P, 1992, STROKE, V23, P1566, DOI 10.1161/01.STR.23.11.1566; Harms L, 1997, J NEUROL NEUROSUR PS, V62, P27, DOI 10.1136/jnnp.62.1.27; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOATS RA, 1994, MAGNET RESON MED, V32, P110, DOI 10.1002/mrm.1910320115; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; PEDEN CJ, 1993, DEV MED CHILD NEUROL, V35, P502; Penrice J, 1996, PEDIATR RES, V40, P6, DOI 10.1203/00006450-199607000-00002; Penrice J, 1997, PEDIATR RES, V41, P443, DOI 10.1203/00006450-199703000-00024; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; Sager TN, 1997, J NEUROCHEM, V68, P675; SHIINO A, 1993, SURG NEUROL, V39, P143, DOI 10.1016/0090-3019(93)90093-G; SIGNORETTI S, 1999, J NEUROTRAUM, V16, P990; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; TAYLOR DL, 1994, J NEUROCHEM, V62, P2349; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; TSUCHIDA E, 1999, IN PRESS J NEUROTRAU; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	38	19	21	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	2000	22	7					705	712					8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	373LH	WOS:000165290600010	11091977				2021-06-18	
J	Feinstein, A; Hershkop, S; Jardine, A; Ouchterlony, D				Feinstein, A; Hershkop, S; Jardine, A; Ouchterlony, D			The prevalence and neuropsychiatric correlates of posttraumatic stress symptoms following mild traumatic brain injury	BRAIN AND COGNITION			English	Article							DISORDER; PREDICTORS	The prevalence of posttraumatic stress disorder (PTSD) symptomatology was investigated in 57 patients with mild traumatic brain injury (TBI) approximately one month after injury (mean = 44; SD = 26 days). Symptoms of varying severity were present in 84% of the sample. Patients with a premorbid psychiatric diagnosis, substance abuse, physical complaints, and those involved in litigation were more likely to endorse PTSD symptoms. A comparison of patients with and without PTSD symptoms demonstrated that the latter were significantly more anxious and depressed both on subjective and objective measures of pychopathology. The study demonstrates that PTSD symptoms are frequently present early in the recovery phase of mild TBI and are associated with significant psychiatric comorbidity. (C) 2000 Academic Press.	Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON, Canada	Feinstein, A (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON, Canada.		Jardine, Alan/L-5770-2019				BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106	5	19	19	1	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	OCT	2000	44	1					78	82					5	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	358FJ	WOS:000089547300020					2021-06-18	
J	Pelletier, PM; Alfano, DP				Pelletier, PM; Alfano, DP			Depression, social support, and family coping following traumatic brain injury	BRAIN AND COGNITION			English	Article							CAREGIVERS	Relationships among variables related to patients' psychological functioning and family coping following traumatic brain injury (TBI) were investigated in a sample of 13 matched pairs of patients and family members. Patient depression and perceived stress were examined in relation to perceived social support from family/friends, family coping, and perceived family stress. Greater perceived social support from family was related to lower reported levels of patient depression and perceived stress. Family coping style was also related to patient perceived stress and depression. Family stress due to greater patient physical limitations was related to lower patient depression and perceived stress. The findings of this study clearly suggest an important link between family environment and patient functioning following TBI which has implications For intervention with patients and families. (C) 2000 Academic Press.	London Hlth Sci Ctr, London, ON, Canada; Univ Regina, Regina, SK S4S 0A2, Canada	Pelletier, PM (corresponding author), London Hlth Sci Ctr, London, ON, Canada.						FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Pelletier P M, 1994, Appl Neuropsychol, V1, P38, DOI 10.1207/s15324826an0101&2_8; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548	5	19	20	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	OCT	2000	44	1					45	49					5	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	358FJ	WOS:000089547300012					2021-06-18	
J	Verma, A				Verma, A			Opportunities for neuroprotection in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						apoptosis; CNS trauma; inhibitory transmitters; neuroprotection	SPINAL-CORD INJURY; FOCAL CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; POLY(ADP-RIBOSE) POLYMERASE; CYCLOSPORINE-A; IMPAIRED MITOCHONDRIAL; LIPID-PEROXIDATION; DENTATE GYRUS; NITRIC-OXIDE; HEAD-INJURY	Traumatic injury of the brain in man is normally followed by little or no recovery of function by the lesioned tissue. Neuroprotective strategies employed in the acute period after traumatic CNS injury attempt to use pharmacological tools to reduce the progressive secondary injury processes that follow after the initial lesion occurs to limit overall tissue damage. Results from experimental animal studies using a variety of drugs that modulate neurotransmitter function, scavenge free radicals, or interfere with cell death cascades point toward many new opportunities for pharmacological intervention in the acute and subacute period after traumatic brain injury.	Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Verma, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA.						ABEL MS, 1992, J NEUROCHEM, V58, P740, DOI 10.1111/j.1471-4159.1992.tb09780.x; ALBERS GW, 1995, STROKE, V26, P254, DOI 10.1161/01.STR.26.2.254; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; Cookson MR, 1998, J NEUROCHEM, V70, P501; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; ENDERS M, 1997, J CEREB BLOOD FLOW M, V17, P1143; Faden A I, 1997, Adv Neurol, V72, P377; FAGG GE, 1983, NEUROSCIENCE, V9, P701, DOI 10.1016/0306-4522(83)90263-4; FAVIT A, 1999, SOC NEUR; FISHER M, 1995, EUR NEUROL, V35, P3, DOI 10.1159/000117082; Ford R W, 1985, Cent Nerv Syst Trauma, V2, P9; GERBER AM, 1980, NEUROSURGERY, V7, P472, DOI 10.1227/00006123-198011000-00009; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Haghighi SS, 1996, NEUROL RES, V18, P509; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HARRISON NL, 1985, BRIT J PHARMACOL, V84, P381, DOI 10.1111/j.1476-5381.1985.tb12922.x; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; INGLIS FM, 1990, ACT NEUR S, V51, P277; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kass GEN, 1999, ENVIRON HEALTH PERSP, V107, P25, DOI 10.2307/3434469; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; Koura SS, 1998, ACT NEUR S, V71, P244; Kuhn HG, 1996, J NEUROSCI, V16, P2027; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Lee KS, 1997, ANN NY ACAD SCI, V825, P95, DOI 10.1111/j.1749-6632.1997.tb48419.x; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; Lyden PD, 1997, INT REV NEUROBIOL, V40, P233; Mao JR, 1997, PAIN, V72, P355, DOI 10.1016/S0304-3959(97)00063-8; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; Peters Gary R., 1996, Stroke, V27, P195; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Rosenberg LJ, 1999, J NEUROSCI, V19, P464; Ross IB, 1991, J NEUROTRAUM, V8, P229, DOI 10.1089/neu.1991.8.229; Schubert P, 1997, ANN NY ACAD SCI, V825, P1, DOI 10.1111/j.1749-6632.1997.tb48409.x; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; STRAND R, 1993, 7 NORD M CER DIS, P37; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; Urushitani M, 1998, ANN NEUROL, V44, P796, DOI 10.1002/ana.410440514; WAHLGREN NG, 1995, STROKE THERAPY, P315; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Winkler T, 1997, ACT NEUR S, V70, P216; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; YOUNG W, 1992, J NEUROTRAUM, V9, pS9	63	19	20	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1149	1161		10.1097/00001199-200010000-00008			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800008	10970935				2021-06-18	
J	Zafonte, RD; Lexell, J; Cullen, N				Zafonte, RD; Lexell, J; Cullen, N			Possible applications for dopaminergic agents following traumatic brain injury: Part 1	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							LEVODOPA; PERGOLIDE; APHASIA; AGONIST		Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; UPMC Hlth Syst, Clin Rehabil Serv, Pittsburgh, PA 15260 USA; Univ Lund Hosp, Dept Rehabil Med, Brain Injury Unit, S-22185 Lund, Sweden; Univ Toronto, Toronto, ON, Canada; Toronto Rehabil Program, Neurorehab Program, Toronto, ON, Canada	Zafonte, RD (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.			Cullen, Nora/0000-0001-6359-9418; Lexell, Jan/0000-0001-5294-3332			ALBERT ML, 1988, NEUROLOGY, V38, P877, DOI 10.1212/WNL.38.6.877; Barbier P, 1997, J NEURAL TRANSM, V104, P867, DOI 10.1007/BF01285554; DOBKIN BH, 1993, ANN NEUROL, V33, P313, DOI 10.1002/ana.410330315; Durif F, 1999, DRUG AGING, V14, P337, DOI 10.2165/00002512-199914050-00002; Gupta SR, 1995, NEUROLOGY, V45, P2170, DOI 10.1212/WNL.45.12.2170; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; KRAUS M, 1887, BRIAN INJURY, V11, P455; Kulisevsky J, 1996, BRAIN, V119, P2121, DOI 10.1093/brain/119.6.2121; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Shaunak S, 1999, J NEUROL NEUROSUR PS, V66, P79, DOI 10.1136/jnnp.66.1.79; Tang YP, 1997, BEHAV BRAIN RES, V83, P189, DOI 10.1016/S0166-4328(97)86067-6	12	19	20	0	2	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1179	1182		10.1097/00001199-200010000-00014			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800014	10970937				2021-06-18	
J	Duncan, MA; Dowd, N; Rawluk, D; Cunningham, AJ				Duncan, MA; Dowd, N; Rawluk, D; Cunningham, AJ			Traumatic bilateral internal carotid artery dissection following airbag deployment in a patient with fibromuscular dysplasia	BRITISH JOURNAL OF ANAESTHESIA			English	Article						complications, accidents; complications, trauma; complications, fibromuscular dysplasia; arteries, carotid		This case describes a 39-yr-old male, presenting with left hemiplegia after a road traffic accident involving frontal deceleration and airbag deployment. Brain computerized tomography (CT) scan revealed a right parietal lobe infarct. Contrast angiography demonstrated bilateral internal carotid artery dissection and fibromuscular dysplasia. The patient was treated with systemic heparinization. Neurological improvement, evidenced by full return of touch sensation, proprioception and nociception began 10 days after the injury. To our knowledge, this is the first case report of carotid artery dissection associated with airbag deployment. Forced neck extension in such settings may result in carotid artery dissection because of shear force injury at the junction of the extracranial and intrapetrous segments of the vessel. Clinicians should consider carotid artery injury when deterioration in neurological status occurs after airbag deployment, We propose that the risk of carotid artery dissection was increased by the presence of fibromuscular dysplasia.	Beaumont Hosp, Dept Anaesthesia Intens Care Med & Neurosurg, Dublin 9, Ireland	Duncan, MA (corresponding author), Beaumont Hosp, Dept Anaesthesia Intens Care Med & Neurosurg, Beaumont Rd, Dublin 9, Ireland.						BIOUSSE V, 1995, STROKE, V26, P235, DOI 10.1161/01.STR.26.2.235; Eachempati SR, 1998, J TRAUMA, V44, P406, DOI 10.1097/00005373-199802000-00035; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; HACKE W, 1995, INTENS CARE MED, V21, P856, DOI 10.1007/BF01700973; Hart R G, 1983, Neurol Clin, V1, P155; Maxeiner H, 1997, J TRAUMA, V42, P1148, DOI 10.1097/00005373-199706000-00029; Mikhail J N, 1997, J Emerg Nurs, V23, P439, DOI 10.1016/S0099-1767(97)90138-0; MOKRI B, 1986, ANN NEUROL, V19, P126, DOI 10.1002/ana.410190204; Perez J, 1996, ANN EMERG MED, V28, P722, DOI 10.1016/S0196-0644(96)70099-9; PERRY MO, 1995, VASCULAR SURG, P705; PORTER JM, 1993, VASCULAR SURG COMPRE, P108; Schievink WI, 1996, CLIN NEUROPATHOL, V15, P2	12	19	19	1	2	PROF SCI PUBL	LONDON	TAVISTOCK HOUSE EAST, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	SEP	2000	85	3					476	478		10.1093/bja/85.3.476			3	Anesthesiology	Anesthesiology	351UL	WOS:000089176500027	11103196				2021-06-18	
J	Schretlen, DJ				Schretlen, DJ			Do neurocognitive ability and personality traits account for different aspects of psychosocial outcome after traumatic brain injury?	REHABILITATION PSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; PREDICTORS; COMA; ADJUSTMENT; VALIDITY; SEQUELAE; SCALE	Objective: To examine the contributions of demographic, injury, cognitive, and personality characteristics to psychosocial outcome 8 years after traumatic brain injury (TBI). Design: Multiple regression analyses were used to estimate the variance explained by putative "predictors" of psychosocial outcome. Participants: Thirty-nine TBI survivors and 39 family member informants. On the basis of Glasgow Coma Scale scores and Accident Injury Severity (head) ratings, the patients' brain injuries ranged from mild to critical in severity. Main Outcome Measures: One self-report measure combined putative markers of social role engagement, such as marital status and earned income. Another, based on informant ratings using the Katz Adjustment Scale, was conceptualized as reflecting behavioral adjustment. Results: Whereas cognitive functioning explained significant unique variation in social role engagement, it did not account for variance in behavioral adjustment. Conversely, whereas 3 personality trait ratings explained significant incremental variance in behavioral stability, only 1 did the same with respect to social role engagement. Conclusions: Social role engagement and behavioral adjustment appear to represent 2 related but distinguishable aspects of TBI outcome that are associated with different patient characteristics.	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA	Schretlen, DJ (corresponding author), Johns Hopkins Hosp, 600 N Wolfe St,Meyer 218, Baltimore, MD 21287 USA.						*ASS ADV AUT MED, 1980, ABBR INJ SCAL 1980 R; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Costa P. T, 1985, NEO PERSONALITY INVE; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Goran DA, 1997, ARCH CLIN NEUROPSYCH, V12, P691, DOI 10.1016/S0887-6177(97)00004-8; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hathaway S. R., 1989, MINNESOTA MULTIPHASI; Heaton R., 1981, MANUAL WISCONSIN CAR; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; JENNETT B, 1975, LANCET, V1, P480; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KEYL PM, 2000, UNPUB CAN BRIEF NEUR; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Schretlen D, 2000, J ABNORM PSYCHOL, V109, P134, DOI 10.1037/0021-843X.109.1.134; Schretlen D, 1997, BRIEF TEST ATTENTION; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Spreen O., 1998, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wechsler, 1981, WAIS R MANUAL; Wong TM, 1999, ARCH CLIN NEUROPSYCH, V14, P728; Zachary R., 1986, SHIPLEY I LIVING SCA	40	19	19	1	6	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2000	45	3					260	273		10.1037/0090-5550.45.3.260			14	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	338BZ	WOS:000088399400003					2021-06-18	
J	Vinall, PE; Kramer, MS; Heinel, LA; Rosenwasser, RH				Vinall, PE; Kramer, MS; Heinel, LA; Rosenwasser, RH			Temporal changes in sensitivity of rats to cerebral ischemic insult	JOURNAL OF NEUROSURGERY			English	Article						cerebral infarction; circadian rhythm; middle cerebral artery occlusion; brain swelling; rat	PERMANENT FOCAL ISCHEMIA; TRAUMATIC BRAIN INJURY; MILD HYPOTHERMIA; INFLAMMATORY RESPONSE; CIRCADIAN VARIATION; INFARCT SIZE; MODEL; TEMPERATURE; RHYTHMS; ONSET	Object. Experimental rat models are often used to study cerebral ischemia, yet rats are nocturnal animals that have activity cycles that are the opposite of those of humans. In the following study the authors examined the circadian rhythm of sensitivity to an ischemic insult in rats by using an intraluminal thread technique to produce reversible middle cerebral artery occlusion. Methods. Ischemia (2 hours of blockage followed by 22 hours of reperfusion) was induced in rats according to the 24-hour clock at either 100, 400, 700, 1000, 1300, 1600, 1900, or 2200 hours (11-14 rats per time period). The rat brains were removed, coronally sectioned, stained with 3,3,5-triphenyltetrazolium chloride and analyzed using commercially available software. Analysis of variance and cosinor-rhythmometry statistical tests were used for analysis of data. The time of day when the ischemic infarct was induced had a significant (p = 0.011) influence on the volume of the lesion. The volume of total brain infarct produced at 400 hours (7.65 +/- 1.31%) was more than three times greater than the volume produced at 1600 hours (2.1 +/- 0.34%). Cosinor-rhythm analysis indicated a peak occurrence of infarct volume at 6:02 (95% confidence interval 5:49-6:16). The size of the infarct correlated with core body temperature rhythms, which varied by 1.3 +/- 0.62 degrees C (mean +/- standard deviation). Conclusions. Circadian rhythms, as well as the reversed natural body rhythms of the rat compared with humans, should be considered when extrapolating data to human or other animal studies. Temporal rhythms may also provide information concerning the cascading disease processes associated with cerebral ischemia.	Thomas Jefferson Univ, Dept Neurosurg, Field Lab Cerebrovasc Res, Philadelphia, PA 19107 USA; Penn Hosp, Neurosci Res Inst, Philadelphia, PA 19107 USA	Heinel, LA (corresponding author), Thomas Jefferson Univ, Dept Neurosurg, Field Lab Cerebrovasc Res, 305 Coll Bldg,1025 Walnut St, Philadelphia, PA 19107 USA.	Lynn.Heinel@mail.tju.edu	ROSENWASSER, ROBERT H/L-2482-2014				AHLERSOVA E, 1986, PHYSIOL BOHEMOSLOV, V35, P233; ARONOWSKI J, 1994, STROKE, V25, P2235, DOI 10.1161/01.STR.25.11.2235; BAKER CJ, 1995, NEUROSURGERY, V36, P994, DOI 10.1227/00006123-199505000-00016; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; BRUGUEROLLE B, 1994, BIOL RHYTHMS CLIN LA, P114; BUCHAN AM, 1992, STROKE, V23, P273, DOI 10.1161/01.STR.23.2.273; BUREAU JP, 1991, INT J TISSUE REACT, V13, P203; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CICCIARELLO R, 1993, CHILD NERV SYST, V9, P25, DOI 10.1007/BF00301931; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; COHEN M, 1978, THROMB RES, V12, P965, DOI 10.1016/0049-3848(78)90052-X; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; FOX G, 1993, STROKE, V24, P2087, DOI 10.1161/01.STR.24.12.2087; FRAZZINI VI, 1994, NEUROSURGERY, V34, P1040, DOI 10.1227/00006123-199406000-00013; Ginsberg MD, 1996, ARCH NEUROL-CHICAGO, V53, P1065, DOI 10.1001/archneur.1996.00550100151024; HALBERG F, 1969, ANNU REV PHYSIOL, V31, P675, DOI 10.1146/annurev.ph.31.030169.003331; KADER A, 1992, NEUROSURGERY, V31, P1056, DOI 10.1227/00006123-199212000-00011; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; KUSUMOTO K, 1992, BRAIN RES, V576, P147, DOI 10.1016/0006-8993(92)90621-F; LABRECQUE G, 1995, PHARMACOL THERAPEUT, V66, P285, DOI 10.1016/0163-7258(94)00082-E; LABRECQUE G, 1988, ANN REV CHRONOPHARMA, V5, P445; LEMMER B, 1974, N-S ARCH PHARMACOL, V282, P75, DOI 10.1007/BF00647404; LEMMER B, 1994, BIOL RHYTHMS CLIN LA, P418; LEMMER B, 1989, CHRONOPHARMACOLOGY C, P252; LEVI F, 1991, ANN NY ACAD SCI, V618, P312, DOI 10.1111/j.1749-6632.1991.tb27251.x; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Manev H, 1996, FASEB J, V10, P1546; Manev H, 1998, J Stroke Cerebrovasc Dis, V7, P165, DOI 10.1016/S1052-3057(98)80002-5; MARSHALL J, 1977, STROKE, V8, P230, DOI 10.1161/01.STR.8.2.230; MARSHALL SB, 1956, ARCH SURG-CHICAGO, V72, P98; MASUKAWA T, 1993, JPN J PHARMACOL, V61, P197, DOI 10.1254/jjp.61.197; MINEMATSU S, 1995, EXP ANIM TOKYO, V44, P223, DOI 10.1538/expanim.44.223; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Park CK, 1998, ACT NEUR S, V71, P225; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; SCHEVING LE, 1967, ANAT REC, V157, P657, DOI 10.1002/ar.1091570411; SLOAN MA, 1992, STROKE, V23, P1420, DOI 10.1161/01.STR.23.10.1420; SMOLENSKY MH, 1976, CHRONOBIOLOGIA, V3, P337; Soares HD, 1995, J NEUROSCI, V15, P8223; SOLOMON GD, 1992, CLEV CLIN J MED, V59, P326, DOI 10.3949/ccjm.59.3.326; SOULBAN G, 1989, LIFE SCI, V45, P2485, DOI 10.1016/0024-3205(89)90015-5; THOMAS G, 1986, J PHARM PHARMACOL, V38, P936, DOI 10.1111/j.2042-7158.1986.tb03390.x; TONI D, 1991, CHRONOBIOL INT, V8, P321, DOI 10.3109/07420529109059168; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8	48	19	19	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2000	93	1					82	89		10.3171/jns.2000.93.1.0082			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	327UW	WOS:000087813100012	10883909				2021-06-18	
J	Saternus, KS; Kernbach-Wighton, G; Oehmichen, M				Saternus, KS; Kernbach-Wighton, G; Oehmichen, M			The shaking trauma in infants - kinetic chains	FORENSIC SCIENCE INTERNATIONAL			English	Article						shaking trauma; kinetic chains; periosteal sign (bleeding); shoulder; cervical spine	CHILD-ABUSE; INJURIES	The findings in three children who died as a consequence of shaking and those in another child who survived are presented. In the three fatal cases, a combination of anatomical lesions were identified at autopsy which appear to indicate the sites where kinetic energy related to the shaking episodes had been applied thus enabling the sequence of events resulting in the fatal head injury to be elucidated. Such patterns of injuries involved the upper limb, the shoulder, the brachial nerve plexus and the muscles close to the scapula; hemorrhages were present at the insertions of the sternocleidomastoid muscles due to hyperextension trauma (the so-called periosteal sign) and in the transition zone between the cervical and thoracic spine and extradural hematomas. Characteristic lesions due to traction were also found in the legs. All three children with lethal shaking trauma died from a subdural hematoma only a few hours after the event. The surviving child had persistant hypoxic damage of the brain following on massive cerebral edema. All the children showed a discrepancy between the lack of identifiable external lesions and severe internal ones. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Univ Gottingen, Inst Legal Med, D-37073 Gottingen, Germany; Univ Lubeck, Inst Legal Med, D-23562 Lubeck, Germany	Saternus, KS (corresponding author), Univ Gottingen, Inst Legal Med, Windausweg 2, D-37073 Gottingen, Germany.						ADEBAHR G, 1982, AKT NEUROPAD, V4, P146; AMBERG R, 1993, ZBL RECHTSMED, V40, P229; AMBERG R, 1994, ZBL RECHTSMED, V42, P453; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AJR, V56, P167; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Horisberger B, 1997, INT J LEGAL MED, V110, P73, DOI 10.1007/s004140050034; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Oehmichen M, 1997, RES LEG MED, V17, P203; POUNDER DJ, 1997, AM J FOREN MED PATH, V18, P322; Saternus K.-S., 1992, PLOTZLICHE KINDSTOD, P11; SCHNEIDER V, 1979, MUNCHEN MED WOCHEN, V121, P171; Southall DP, 1997, PEDIATRICS, V100, P735, DOI 10.1542/peds.100.5.735; Thomsen TK, 1997, FORENSIC SCI INT, V90, P223, DOI 10.1016/S0379-0738(97)00166-7; UNTERHARNSCHEID.F, 1993, SPEZIELLE PATHOLOGIS, V13; UNTERHARNSCHEIDT F, 1969, ACTA NEUROPATHOL, V12, P200, DOI 10.1007/BF00692508; Voigt G E, 1968, Dtsch Z Gesamte Gerichtl Med, V64, P9, DOI 10.1007/BF00585127	20	19	20	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	APR 10	2000	109	3					203	213		10.1016/S0379-0738(00)00144-4			11	Medicine, Legal	Legal Medicine	302FK	WOS:000086354900004	10725656				2021-06-18	
J	Denney, RL; Wynkoop, TF				Denney, RL; Wynkoop, TF			Clinical neuropsychology in the criminal forensic setting	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						competency; criminal; dangerousness; forensic; sanity; traumatic brain injury	CHRONIC COCAINE ABUSE; MENTAL DISORDER; VIOLENCE; MEMORY; PREDICTIONS; DEFICITS; HEALTH; MURDER	This article reviews the application of clinical neuropsychology to criminal court proceedings, a complex, underserved, yet growing area of neuropsychological practice. The authors write from the perspective that the audience is primarily neurorehabilitation clinicians with limited experience In criminal matters. Discussions on the theoretical differences between clinical and forensic work, the forensic evaluation process with conceptual model, historical and current perspectives on criminal competencies and responsibility, prediction of dangerousness, and professional and ethical issues often encountered in criminal neuropsychology are provided.	US Med Ctr Fed Prisoners, Springfield, MO 65807 USA; Bowling Green State Univ, Clin Affiliate Fac, Court Diagnost & Treatment Ctr, Toledo, OH USA; Forest Inst Profess Psychol, Springfield, MO 65807 USA	Denney, RL (corresponding author), US Med Ctr Fed Prisoners, 1900 W Sunshine, Springfield, MO 65807 USA.	rdenney@bop.gov					*AM PSYCH ASS, 1992, AM PSYCHOL, V47, P1597, DOI DOI 10.1037/0003-066X.47.12.1597; [Anonymous], 1990, BLACKS LAW DICT; BENSON DF, 1997, BEHAV NEUROLOGY NEUR, P401; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BORUM R, 1995, PROF PSYCHOL-RES PR, V26, P465, DOI 10.1037/0735-7028.26.5.465; Brown L., 1982, TEST NONVERBAL INTEL; CERCY SP, 1997, CLIN ASSESSMENT MALI; CLARK CR, 1987, HDB FORENSIC PSYCHOL, P352; Denney R. L., 1999, J FORENSIC NEUROPSYC, V1, P29, DOI 10.1300/J151v01n02_04; Denney R. L., 1999, J FORENSIC NEUROPSYC, V1, P5; Denney RL, 1996, ARCH CLIN NEUROPSYCH, V11, P589, DOI 10.1016/0887-6177(95)00042-9; DENNEY RL, 1995, CLIN NEUROPSYCHOL, V9, P227; Dickens S. E., 1992, STRUCTURED INTERVIEW; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Everington C., 1992, COMPETENCE ASSESSMEN; Frederick R.I., 1997, VALIDITY INDICATOR P; FREDERICK RI, 1995, B AM ACAD PSYCH LAW, V23, P231; Frederick RI, 1998, CLIN NEUROPSYCHOL, V12, P193, DOI 10.1076/clin.12.2.193.2006; FREDERICK RI, IN PRESS ARCH CLIN N; FREDERICK RI, 1993, ANN CONV AM PSYCH AS; GIULIANO AJ, 1997, CRIT ISS NE, P1; GOLDING SL, 1991, LAW HUMAN BEHAV, V15, P655; GOLDING SL, 1990, INT J LAW PSYCHIAT, V13, P281, DOI 10.1016/0160-2527(90)90023-V; Gouvier WD, 1998, CRIT ISS NE, P55; GRISSO T, 1992, LAW HUMAN BEHAV, V16, P621, DOI 10.1007/BF01884019; Grisso T., 1986, EVALUATING COMPETENC; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; HALL HV, 1988, INT J CLIN NEUROPSYC, V10, P113; Hartman DE, 1988, NEUROPSYCHOLOGICAL T; Haughton P M, 1979, Br J Audiol, V13, P135, DOI 10.3109/03005367909078888; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HEINRICHS RW, 1989, BIOL PSYCHIAT, V25, P174, DOI 10.1016/0006-3223(89)90161-3; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Hoge SK, 1997, LAW HUMAN BEHAV, V21, P141, DOI 10.1023/A:1024826312495; LEWIS DO, 1989, J AM ACAD CHILD PSY, V28, P431, DOI 10.1097/00004583-198905000-00022; LEWIS DO, 1985, AM J PSYCHIAT, V142, P1161; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; MARTELL DA, 1992, LAW HUMAN BEHAV, V16, P313, DOI 10.1007/BF01044772; MCGARRY AL, 1973, COMPETENCY STAND TRI; Melton G. B., 1997, PSYCHOL EVALUATIONS; MILLS VM, 1997, NEUROLOGICAL REHABIL; MITTENBERG W, 1993, ARCH CLIN NEUROPSYCH, V8, P477, DOI 10.1016/0887-6177(93)90048-6; MONAHAN J, 1992, AM PSYCHOL, V47, P511, DOI 10.1037/0003-066X.47.4.511; Monahan J, 1994, VIOLENCE MENTAL DISO; MOSSMAN D, 1994, J CONSULT CLIN PSYCH, V62, P783, DOI 10.1037/0022-006X.62.4.783; MRAD D, 1996, ISS FOR ASS S FED BU; Nestor PG, 1997, J AM ACAD PSYCHIATRY, V25, P161; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; Parente R., 1996, RETRAINING COGNITION; PIACENTE GJ, 1986, PSYCHIAT CLIN N AM, V9, P329; Pirozzolo F. J., 1991, NEUROPSYCHOLOGY LAW, P1; Raine A., 1993, PSYCHOPATHOLOGY CRIM; REHKOPF DG, 1997, CRIT ISS NE, P135; REISNER R, 1990, LAW MENTAL HLTH SYST; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Reynolds CR, 1998, CRIT ISS NE, P261; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Rogers R, 1997, CLIN ASSESSMENT MALI, P373; SAKS MJ, 1990, LAW HUMAN BEHAV, V14, P291, DOI 10.1007/BF01068158; SCHREINER L, 1956, AM J PHYSIOL, V184, P486; SCHRETLEN DJ, 1988, CLIN PSYCHOL REV, V8, P451, DOI 10.1016/0272-7358(88)90074-8; SHAPIRO DL, 1991, FORENSIC PSYCHOL ASS; Shapiro DL, 1999, CRIMINAL RESPONSIBIL; SOHLBERG MM, 1989, INTRO COGNITIVE BEHA; Steadman H. J., 1993, HINCKLEY EVALUATING; STEADMAN HJ, 1988, LAW HUMAN BEHAV, V12, P91, DOI 10.1007/BF01064276; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; THEODOR LH, 1973, J ABNORM PSYCHOL, V82, P552, DOI 10.1037/h0035362; TONKONOGY TM, 1991, J NEUROPSYCHIAT, V3, P189; VOLAVKA J, 1992, J FORENSIC SCI, V37, P237; WASHTON AM, 1984, PSYCHIAT ANN, V14, P733, DOI 10.3928/0048-5713-19841001-09; WILDMAN R, 1980, GEORGIA COURT COMPET; WONG MTH, 1994, ACTA PSYCHIAT SCAND, V90, P97, DOI 10.1111/j.1600-0447.1994.tb01562.x; Wynkoop TF, 1999, CLIN NEUROPSYCHOL, V13, P220; WYNKOOP TF, 1994, ADV MED PSYCHOTHER, V7, P181; Zachary R., 1986, SHIPLEY I LIVING SCA; 1982, TANAKH NEW TRANSLATI	80	19	20	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2000	15	2					804	828		10.1097/00001199-200004000-00005			25	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	305FY	WOS:000086529800005	10739969				2021-06-18	
J	Ricker, JH; Zafonte, RD				Ricker, JH; Zafonte, RD			Functional neuroimaging and quantitative electroencephalography in adult traumatic head injury: Clinical applications and interpretive cautions	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; head injury; neuroimaging; positron emission tomography; single photon emission computed tomography	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; BRAIN INJURY; COMPUTED-TOMOGRAPHY; RETROGRADE-AMNESIA; SPECT; MILD; EEG; PERFUSION; METABOLISM	Functional neuroimaging and quantitative electroencephalographic procedures are being used increasingly in brain injury research and clinical care. These procedures are also seeing increased use in the context of forensic evaluations, particularly in cases of mild head trauma. This article provides an overview of the use of procedures such as positron emission tomography, single photon emission computed tomography, and quantitative electroencephalogram in adults. Also discussed are the clinical limitations of each procedure within the context of myriad interpretive confounds that can interfere with accurate differential diagnosis of mild head trauma.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA	Ricker, JH (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.			Ricker, Joseph/0000-0003-3415-991X			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; ADAMS BL, 1993, J PSYCHIATR NEUROSCI, V18, P109; Altrocchi PH, 1996, NEUROLOGY, V46, P278; Amen D G, 1996, Ann Clin Psychiatry, V8, P129, DOI 10.3109/10401239609147750; [Anonymous], 1996, NEUROLOGY, V47, P592; BARON JC, 1995, REV NEUROL, V151, P511; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; CHERTKOW H, 1994, LOCALIZATION NEUROIM, P151; DellaCorte F, 1997, ACTA NEUROCHIR, V139, P636; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Dupont RM, 1996, PSYCHIAT RES-NEUROIM, V67, P99, DOI 10.1016/0925-4927(96)02769-2; FONTAINE A, 1996, P AUST BRAIN INJ SOC, V1, P98; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Goncalves J M, 1992, Acta Neurochir Suppl (Wien), V55, P11; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HARTHSONE M, 1994, FUNCTIONAL BRAIN IMA, P101; Herscovitch Peter, 1996, P89; HERTZMAN M, 1990, AM J PSYCHIAT, V147, P255; HOLMAN BL, 1992, J NUCL MED, V33, P1888; ICHISE M, 1994, J NUCL MED, V35, P217; IIDAKA T, 1995, CLIN PSYCHIATR, V37, P951; JACOBS A, 1994, J NUCL MED, V35, P942; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; JUNI JE, 1994, J NUCL MED, V35, P1891; KRYSTAL JH, 1995, AM J DRUG ALCOHOL AB, V21, P47, DOI 10.3109/00952999509095229; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LAZARUS A, 1989, J CLIN PSYCHIAT, V50, P475; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; LOUTFI ISSA, 1995, INVEST RADIOL, V30, P588, DOI 10.1097/00004424-199510000-00004; MAMPUNZA S, 1995, ACTA NEUROL BELG, V95, P164; MASDEU JC, 1995, J NEUROIMAGING, V5, pS14, DOI 10.1111/jon19955s1s14; Matousek M, 1996, ACTA ANAESTH SCAND, V40, P824, DOI 10.1111/j.1399-6576.1996.tb04540.x; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; MILLER S, 1992, S AFR J PHILOS, V11, P1; MODELL JG, 1995, J NEUROPSYCH CLIN N, V7, P15; Mozley PD, 1996, J NUCL MED, V37, P1965; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; PAULMAN RG, 1990, BIOL PSYCHIAT, V27, P377, DOI 10.1016/0006-3223(90)90549-H; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; READ SL, 1995, J AM GERIATR SOC, V43, P1243, DOI 10.1111/j.1532-5415.1995.tb07400.x; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; Ricker J, 1998, CLIN NEUROPSYCHOL, V12, P279; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; SACKEIM HA, 1990, ARCH GEN PSYCHIAT, V47, P60; SIRONI V, 1983, ADV NEUROTRAUMATOLOG, P329; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Uchiyama Mayuki, 1997, Nippon Acta Radiologica, V57, P41; Umile EM, 1998, BRAIN INJURY, V12, P577; WOOD F, 1991, READ WRIT, V3, P379, DOI 10.1007/BF00354969; ZHANG JJ, 1994, CLIN NUCL MED, V19, P789, DOI 10.1097/00003072-199409000-00009	57	19	19	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2000	15	2					859	868		10.1097/00001199-200004000-00007			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	305FY	WOS:000086529800007	10739971				2021-06-18	
J	Dowler, RN; Bush, BA; Novack, TA; Jackson, WT				Dowler, RN; Bush, BA; Novack, TA; Jackson, WT			Cognitive orientation in rehabilitation and neuropsychological outcome after traumatic brain injury	BRAIN INJURY			English	Article							SCALE	This study evaluated the ability of the Orientation Log (O-Log) to predict cognitive outcome at rehabilitation discharge, as well as future neuropsychological outcome. The hypothesis was that patients who demonstrated better orientation upon admission would achieve superior functional cognitive outcome at discharge and on subsequent neuropsychological assessment. Sixty individuals receiving inpatient rehabilitation following a new-onset TBI participated Orientation data was collected using the O-Log during morning bedside rounds. Outcome data was collected at 6 and 12 months post-injury. Significant correlations were found between the O-log and measures of memory, executive functioning, basic verbal skills, and estimated intellectual ability. When compared to the other predictor variables, step-wise multiple regression analyses revealed that the minimum O-Log score was the primary significant predictor of performance on six neuropsychological and functional outcome measures. Results of this study suggest that evaluating orientation with the O-Log during acute rehabilitation may reflect level of injury severity and aid in predicting cognitive outcome.	Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL 35233 USA	Novack, TA (corresponding author), Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, 1717 6th Ave S, Birmingham, AL 35233 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [403641] Funding Source: Medline		Benton A.L., 1983, CONTRIBUTIONS NEUROP; DELIS D, 1987, CALIFORNIA VERBAL LE; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KAPLAN E, 1983, BOSTON NAMING; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; SILVERSTEIN AB, 1982, J CONSULT CLIN PSYCH, V50, P415, DOI 10.1037/0022-006X.50.3.415; *STAT U NEW YORK B, 1993, GUID UN SET MED REH; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	14	19	19	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					117	123		10.1080/026990500120781			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000002	10695568				2021-06-18	
J	Abraham, KE; Brewer, KL; McGinty, JF				Abraham, KE; Brewer, KL; McGinty, JF			Opioid peptide messenger RNA expression is increased at spinal and supraspinal levels following excitotoxic spinal cord injury	NEUROSCIENCE			English	Article						dynorphin; enkephalin; excitotoxicity; pain; quisqualic acid; spinal cord injury	DORSAL HORN NEURONS; TRAUMATIC INJURY; PERIPHERAL INFLAMMATION; INSITU HYBRIDIZATION; RADIOIMMUNOASSAY TECHNIQUE; INTRASPINAL INJECTIONS; CEREBRAL-CORTEX; QUISQUALIC ACID; RAT-BRAIN; DYNORPHIN	Spinal cord injury in rats is known to cause anatomical, physiological and molecular changes within the spinal cord. These changes may account for behavioral syndromes that appear following spinal cord injury, syndromes believed to be related to the clinical condition of chronic pain. Intraspinal injection of quisqualic acid produces an excitotoxic injury with pathological characteristics similar to those associated with ischemic and traumatic spinal cord injury. In addition, recent studies have demonstrated changes in blood flow, neuronal excitability and gene expression in the brain following excitotoxic injury, indicating that behavioral changes may result from modification of neuronal substrates at supraspinal levels of the neuraxis. Because changes in spinal opioid peptide expression have been demonstrated in models of traumatic spinal cord injury and chronic pain, the present study investigated messenger RNA expression of the opioid peptides, preproenkephalin and preprodynorphin, at spinal and supraspinal levels following excitotoxic spinal cord injury. Male, Long-Evans rats were given three intraspinal injections of quisqualic acid (total 1.2 mu l, 125 mM). After one, three, five, seven or 10 days, animals were killed and quantitative in situ hybridization performed on regions of the spinal cord surrounding the lesion site, as well as whole-brain sections through various levels of the thalamus. Preproenkephalin and preprodynorphin expression was increased in spinal cord areas adjacent to the site of quisqualic injection and in cortical regions associated with nociceptive function, preproenkephalin in the cingulate cortex and preprodynorphin in the parietal cortex, both ipsilaterally and contralaterally at various time-points following injury. These results further our knowledge of the secondary events that occur following spinal cord injury, specifically implicating supraspinal opioid systems in the CNS response to spinal cord injury. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	E Carolina Univ, Sch Med, Dept Emergency Med, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA	Brewer, KL (corresponding author), E Carolina Univ, Sch Med, Dept Emergency Med, Greenville, NC 27858 USA.	brewerk@mail.ecu.edu			NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA003982] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA03982] Funding Source: Medline		ALVAREZBOLADO G, 1990, J COMP NEUROL, V300, P287, DOI 10.1002/cne.903000302; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bethea JR, 1998, J NEUROSCI, V18, P3251; Brewer K. L., 1997, Society for Neuroscience Abstracts, V23, P438; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; DAVIDOFF G, 1987, PAIN, V29, P39, DOI 10.1016/0304-3959(87)90176-X; DRAISCI G, 1991, BRAIN RES, V560, P186, DOI 10.1016/0006-8993(91)91231-O; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1985, REGUL PEPTIDES, V11, P35, DOI 10.1016/0167-0115(85)90029-1; GAUMANN DM, 1990, NEUROSCIENCE, V39, P761, DOI 10.1016/0306-4522(90)90259-7; HAO JX, 1991, PAIN, V45, P175, DOI 10.1016/0304-3959(91)90186-2; HARLAN RE, 1987, J COMP NEUROL, V258, P159, DOI 10.1002/cne.902580202; HELTON TE, 1993, MOL CELL NEUROSCI, V4, P319, DOI 10.1006/mcne.1993.1042; Hurd YL, 1996, NEUROSCIENCE, V72, P767, DOI 10.1016/0306-4522(96)00002-4; Kenshalo DR, 1991, CEREBRAL CORTEX, V9; KOSTERLITZ HW, 1985, PROC R SOC SER B-BIO, V225, P27, DOI 10.1098/rspb.1985.0048; LENZ FA, 1990, PAIN, V5, P493; LEVITT M, 1985, BRAIN RES REV, V10, P247, DOI 10.1016/0165-0173(85)90027-X; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; LONG JB, 1989, BRAIN RES, V497, P155, DOI 10.1016/0006-8993(89)90982-7; MCGINTY JF, 1984, J NEUROSCI, V4, P1104; MELZACK R, 1968, P423; MELZACK R, 1978, PAIN, V4, P195, DOI 10.1016/0304-3959(77)90133-6; Morrow TJ, 2000, EXP NEUROL, V161, P220, DOI 10.1006/exnr.1999.7246; NOGUCHI K, 1992, NEUROSCIENCE, V46, P561, DOI 10.1016/0306-4522(92)90144-Q; NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169-328X(91)90065-6; Olsson Y, 1995, PROG BRAIN RES, V104, P381; PRZEWLOCKI R, 1988, MOL BRAIN RES, V4, P37, DOI 10.1016/0169-328X(88)90016-2; REEP RL, 1982, NEUROSCIENCE, V7, P1265, DOI 10.1016/0306-4522(82)91133-2; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; Ruda MA, 1995, PROG BRAIN RES, V104, P349; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; SHARMA HS, 1992, NEUROSCI RES, V14, P195; SHARMA HS, 1994, REG PEPT S, V1, pS91; SIDDALL P, 1995, NEUROREPORT, V6, P1241, DOI 10.1097/00001756-199506090-00003; Siddall PJ, 1997, SPINAL CORD, V35, P69, DOI 10.1038/sj.sc.3100365; SMITH AP, 1988, ANNU REV PHARMACOL, V28, P123, DOI 10.1146/annurev.pa.28.040188.001011; SMITH DB, 1993, NUCLEIC ACIDS RES, V21, P359, DOI 10.1093/nar/21.2.359; Tachibana T, 1998, J NEUROTRAUM, V15, P485, DOI 10.1089/neu.1998.15.485; TASKER RR, 1991, SYMP PAIN R, P31; TUNKS E, 1986, MANAGEMENT SPINAL CO, P180; Vogt BA, 1993, NEUROBIOLOGY CINGULA, P313; WANG JQ, 1995, J PHARMACOL EXP THER, V273, P909; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yezierski RP, 1996, PAIN, V68, P185, DOI 10.1016/S0304-3959(96)03178-8; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; YEZIERSKI RP, 1993, NEUROSCI LETT, V157, P115, DOI 10.1016/0304-3940(93)90656-6; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445; ZELTSER R, 1994, PROG PAIN RES MANAG, V3, P295	52	19	20	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2000	99	1					189	197		10.1016/S0306-4522(00)00150-0			9	Neurosciences	Neurosciences & Neurology	343GA	WOS:000088692300018	10924963				2021-06-18	
J	Crimmins, DW; Palmer, JD				Crimmins, DW; Palmer, JD			Snapshot view of emergency neurosurgical head injury care in Great Britain and Ireland	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; transfer; intensive care unit; resources for healthcare	MANAGEMENT; GUIDELINES; RESUSCITATION; HEMATOMA	Objectives-To study the availability of neurosurgical intensive care for the traumatically brain injured in all 36 neurosurgical centres in the United Kingdom and Ireland receiving head injuries, the response times to referral, and the advice given to the referring hospitals. Methods-Telephone survey of receiving neurosurgeons regarding their bed status and their advice on three hypothetical case scenarios. Outcome measures included response times for an acute head injury to be accepted to a neurosurgical centre; the intensive care bed status; variations in advice given to the referring hospitals with regard to ventilation, use of mannitol, steroids, anticonvulsants, and antibiotics. Results-There were 43 neurosurgical intensive care beds available for an There were 1.8 beds available/million of the population for nonventilated patients, 0.64 beds available/million for ventilated patients, and 0.55 beds available/million for ventilated paediatric patients. London had a shortage of beds with 0.19 adult beds for ventilation/million north of the Thames and 0.14 adult beds for ventilation/million south of the Thames. The median response time for a patient with an extradural haematoma to be accepted for transfer was 6 minutes and 89% of such a referral was accepted within 30 minutes. Clinically significant delays in receiving referrals (over 30 minutes) occurred in four units. Practices regarding the use of hyperventilation, mannitol, anticonvulsants, and antibiotics showed little conformity and in some cases were against the available evidence and advice given by published guidelines. Conclusions-There is a severe shortage of available emergency neurosurgical beds especially in the south east of England. The lack of immediately available neurosurgical intensive care beds ventilated patients, 0.64 beds available England. The lack of immediately available neurosurgical intensive care beds results in delays of transfer that could adversely affect the outcome of surgery for traumatic intracranial haematoma. Advice given to the referring units by the receiving doctors is very variable.	Univ London, Natl Hosp Neurol & Neurosurg, Inst Neurol, Dept Neurosurg, London WC1N 3BG, England	Palmer, JD (corresponding author), Derriford Hosp, Dept Neurosurg, Plymouth PL6 8DH, Devon, England.						*AM COLL SURG COMM, 1993, ATLS COURS MAN; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; BRIGGS M, 1984, BRIT MED J, V288, P983; BROCKLEHURST G, 1987, BRIT MED J, V294, P345, DOI 10.1136/bmj.294.6568.345; BRYDEN JS, 1983, BRIT MED J, V286, P1791, DOI 10.1136/bmj.286.6380.1791; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock MR, 1996, J NEUROTRAUM, V13, P731; CAIRNS HWB, 1947, NOTES NEUROSURGICAL; DUNN LT, 1994, ANN ROY COLL SURG, V76, P353; GENTLEMAN D, 1993, BRIT MED J, V307, P547, DOI 10.1136/bmj.307.6903.547; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GENTLEMAN D, 1981, LANCET, V2, P853; JEFFREYS RV, 1981, LANCET, V2, P459; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kirkpatrick PJ, 1996, J NEUROL NEUROSUR PS, V60, P131, DOI 10.1136/jnnp.60.2.131; Kirkpatrick PJ, 1997, J NEUROL NEUROSUR PS, V62, P109, DOI 10.1136/jnnp.62.2.109; LAMBERT SM, 1993, INJURY, V24, P333, DOI 10.1016/0020-1383(93)90058-E; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marsh H, 1989, Br J Neurosurg, V3, P13, DOI 10.3109/02688698909001021; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; *POP EST UN OFF NA, 1994, POP VIT STAT UK; *ROYAL COLL SURG E, 1986, WORK PART HEAD INJ; *SOC BRIT NEUR SUR, 1993, SAF NEUR MAINT DEV H; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; *US BUR CENS, 1996, CENS POP IR 1996, V1; VYVYAN HAL, 1991, ANAESTHESIA, V46, P728, DOI 10.1111/j.1365-2044.1991.tb09766.x	28	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2000	68	1					8	13		10.1136/jnnp.68.1.8			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	270AL	WOS:000084513200005	10601392	Green Published, Bronze			2021-06-18	
J	Kolakowsky-Hayner, SA; Kreutzer, JS; Miner, KD				Kolakowsky-Hayner, SA; Kreutzer, JS; Miner, KD			Validation of the Service Obstacles Scale for the traumatic brain injury population	NEUROREHABILITATION			English	Article						service obstacles; traumatic brain injury; family needs; life quality	FAMILY NEEDS; RELATIVES; LIFE	Traumatic brain injury is a leading cause of death and disability iii the United States. Limited access to specialized medical and rehabilitation services has been linked to poor outcomes. Literature provides little guidance for assessment of service obstacles and satisfaction with community resources. The present investigation describes the development of a specialized scale to evaluate caregivers' perceptions of brain injury services in the community. Results indicate good internal consistency and criterion-related validity of the Service Obstacles Scale. Lack of money for services and lack of adequate community resources were the greatest concerns voiced by respondents, while lack of transportation was the least problematic. Comparisons are made with regard to family needs and respondents' post-injury life quality. Implications for future research are discussed.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kolakowsky-Hayner, SA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909			BARNES BL, 1997, INDIAN J PSYCHOMETRY, V26, P1; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUNTING K, 1997, RATIONAL DISABILITY; Campbell C H, 1988, Rehabil Nurs, V13, P320; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Engli M, 1993, J Neurosci Nurs, V25, P78; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MARWITZ JH, SERVICE OBSTACLES SC; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; MOLTER NC, 1979, HEART LUNG, V8, P332; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; 2000, J HEAD TRAUMA REHABI, V15, P750	25	19	19	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2000	14	3					151	158					8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357PD	WOS:000089509300004					2021-06-18	
J	Koyfman, L; Kaplanski, J; Artru, AA; Talmor, D; Rubin, M; Shapira, Y				Koyfman, L; Kaplanski, J; Artru, AA; Talmor, D; Rubin, M; Shapira, Y			Inhibition of cyclooxygenase 2 by nimesulide decreases prostaglandin E2 formation but does not alter brain edema or clinical recovery after closed head injury in rats	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						head injury; inflammatory reaction; prostaglandins; nimesulide; cyclooxygenase inhibitors; cerebral cortex	CEREBRAL-ISCHEMIA; GENE-EXPRESSION; NEURONS; TRAUMA; ACID; METHYLPREDNISOLONE; INDOMETHACIN; INDUCTION; TISSUE; DEATH	Recently, the enzyme cyclooxygenase (COX) has been recognized to exist as constitutive (COX-1) and inducible isoforms (COX-2). In previous studies, drugs chat were inhibitors of both COX-1 and COX-2 failed to decrease brain edema formation or improve Neurological Severity Score (NSS) after closed head trauma (CHT), although some did decrease prostaglandin-E2 (PGE2) formation. The present study examined whether or not a specific inhibitor of COX-2 (nimesulide) exerts a beneficial effect after CHT in rats. Halothane-anesthetized rats (n = 8 in each group) were randomly assigned to one of four groups: surgery, no CHT, no drug (group 1); surgery, no CHT, nimesulide 30 mg/kg intraperitoneally (IP) (group 2); surgery, CHT, no drug (group 3); and surgery, CHT, nimesulide 30 mg/kg IP (group 4). NSS was determined at 1 and 24 h, and brain tissue PGE2 concentration and water content were determined after killing at 24 h. Treatment with nimesulide did not improve NSS (NSS at 24 h = 11 +/- 6 [median +/- range] in group 3 and 12 +/- 4 in group 4) or edema formation (brain water content at 24 h = 84.3 +/- 1.8% [mean +/- SD] in group 3 and 83.8 +/- 1.9% in group 4). However, nimesulide did decrease cortical and hypothalamic PGE? formation by 41% and 47%, respectively during the first hour of incubation after brain tissue sampling. The authors conclude that although nimesulide does reduce tissue PGE2 formation, it does not exert a beneficial effect on brain tissue edema or functional activity after CHT in rats.	Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA; Ben Gurion Univ Negev, Soroka Med Ctr, Fac Hlth Sci, Div Anesthesiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Soroka Med Ctr, Fac Hlth Sci, Dept Clin Pharmacol, IL-84105 Beer Sheva, Israel	Artru, AA (corresponding author), Univ Washington, Sch Med, Dept Anesthesiol, Box 356540, Seattle, WA 98195 USA.						BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; CHAN PH, 1983, ANN NEUROL, V13, P625, DOI 10.1002/ana.410130608; DANON A, 1983, J PHARM PHARMACOL, V35, P576, DOI 10.1111/j.2042-7158.1983.tb04336.x; DAVIS R, 1994, DRUGS, V48, P431, DOI 10.2165/00003495-199448030-00008; Deininger MH, 1999, J NEUROIMMUNOL, V95, P202, DOI 10.1016/S0165-5728(98)00257-4; Dumont I, 1998, AM J PHYSIOL-REG I, V275, pR1812; Fiebich BL, 1998, J NEUROIMMUNOL, V92, P170, DOI 10.1016/S0165-5728(98)00201-X; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hara K, 1998, NEUROSCI LETT, V256, P53, DOI 10.1016/S0304-3940(98)00755-1; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hirata T, 1997, LIFE SCI, V61, P1603, DOI 10.1016/S0024-3205(97)00739-X; Ho L, 1998, J NEUROIMMUNOL, V89, P142, DOI 10.1016/S0165-5728(98)00132-5; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; IANNOTTI F, 1981, STROKE, V12, P301, DOI 10.1161/01.STR.12.3.301; KAPLANSKI J, 1992, SYMP PHARMA, V7, P33; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Knapp DJ, 1999, ALCOHOL CLIN EXP RES, V23, P633, DOI 10.1097/00000374-199904000-00010; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; MILDE LN, 1998, CLIN NEUROANAESTHESI, P177; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nogawa S, 1997, J NEUROSCI, V17, P2746; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Saper CB, 1998, ANN NY ACAD SCI, V856, P90, DOI 10.1111/j.1749-6632.1998.tb08317.x; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1993, EUR J ANAESTH, V10, P155; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1989, PROSTAG LEUKOTR ESS, V36, P49, DOI 10.1016/0952-3278(89)90162-2; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; Shapira Y, 1998, J NEUROSURG ANESTH, V10, P94, DOI 10.1097/00008506-199804000-00005; Sharma Sangeeta, 1997, Indian Journal of Experimental Biology, V35, P1025; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Sigthorsson G, 1998, SCAND J GASTROENTERO, V33, P728; Taniguchi Y, 1997, EUR J PHARMACOL, V330, P221, DOI 10.1016/S0014-2999(97)00183-0; Vellucci SV, 1998, NEUROPEPTIDES, V32, P439, DOI 10.1016/S0143-4179(98)90069-5; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X	42	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2000	12	1					44	50		10.1097/00008506-200001000-00009			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	270PT	WOS:000084545200009	10636620				2021-06-18	
J	Ferstl, EC; Guthke, T; von Cramon, DY				Ferstl, EC; Guthke, T; von Cramon, DY			Change of perspective in discourse comprehension: Encoding and retrieval processes after brain injury	BRAIN AND LANGUAGE			English	Article							CLOSED HEAD-INJURY; FRONTAL-LOBE; INDIVIDUAL-DIFFERENCES; TEXT COMPREHENSION; WORKING-MEMORY; LANGUAGE; DEFICITS; BEHAVIOR; DAMAGE; ORGANIZATION	Damage to frontal areas has been associated with nonaphasic language disturbances in which word and sentence level processes remain largely intact but text level processes are impaired. Most studies providing evidence for these language deficits have concentrated on text production. To study text comprehension of nonaphasic patients, we adopted the paradigm of Anderson and Pichert (1978) that was developed to separate encoding from retrieval processes. Subjects read a story under one of two alternative perspectives and subsequently recalled it. After this first recall, they were instructed to now adopt the second perspective and to recall the story once more. Twenty-four brain injured patients participated. Each patient's lesion was evaluated with respect to the involvement of right- and/or left-frontal regions. Seven patients showed unilateral left-frontal lesions, five patients unilateral right-frontal lesions, four patients had bilateral frontal damage, and the lesions of the remaining eight patients did not involve frontal areas. The only factor predicting behavioral results was the presence of a left-frontal lesion. For patients without frontal lesions and patients with unilateral right-frontal lesions, we replicated previously reported results. Encoding relevant information was recalled better than other information. Furthermore, the switch of perspective aided recall of perspective relevant information during the second recall. In contrast, patients with left-frontal or bilateral frontal lesions could not make use of the perspective instructions. While they showed comparable recall performance, as well as sensitivity to the relative ease of information, neither the encoding instructions nor the switch instructions had an impact an the recall patterns. These results suggest that left-frontal damage leads to an impairment of goal directed text processing skills. (C) 1999 Academic Press.	Max Planck Inst Cognit Neurosci, D-04103 Leipzig, Germany; Univ Leipzig, D-7010 Leipzig, Germany	Ferstl, EC (corresponding author), Max Planck Inst Cognit Neurosci, Stephanstr 1 A, D-04103 Leipzig, Germany.	ferstl@cns.mpg.de					ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; ANDERSON RC, 1978, J VERB LEARN VERB BE, V17, P1, DOI 10.1016/S0022-5371(78)90485-1; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; BAILLET SD, 1986, DISCOURSE PROCESS, V9, P247, DOI 10.1080/01638538609544643; Beeman M., 1998, RIGHT HEMISPHERE LAN; Bloom R. L., 1994, DISCOURSE ANAL APPL; BORLAND R, 1985, DISCOURSE PROCESS, V8, P305, DOI 10.1080/01638538509544619; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROOKSHIRE RH, 1984, BRAIN LANG, V21, P21, DOI 10.1016/0093-934X(84)90033-6; Brownell H. H., 1995, HDB NEUROLOGICAL SPE, P325; Caplan D., 1992, LANGUAGE STRUCTURE P; CHAPMAN SB, 1995, HDB NEUROLOGICAL SPE, P387; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DELIS D, 1987, CALIFORNIA VERBAL LE; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; deZubicaray G, 1996, CLIN NEUROPSYCHOL, V10, P245, DOI 10.1080/13854049608406687; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; FUSTER JM, 1988, PREFRONTAL CORTEX; GERMANI MJ, 1992, BRAIN LANG, V42, P308, DOI 10.1016/0093-934X(92)90103-L; Glindemann R, 1995, SPRACHE-STIMME-GEHOR, V19, P1; Goldberg T E, 1990, J Neuropsychiatry Clin Neurosci, V2, P165; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HAUT M W, 1990, Brain Injury, V4, P281, DOI 10.3109/02699059009026178; Hess T. M., 1992, J GERONTOL, V47, P52, DOI [10.1093/ geronj/ 47.1. P52, DOI 10.1093/GERONJ/47.1.P52]; Horn W, 1983, LEISTUNGSPRUFSYSTEM; HOUGH MS, 1990, BRAIN LANG, V38, P253, DOI 10.1016/0093-934X(90)90114-V; HUBER W, 1984, ADV NEUROLOGY, V42; Joanette Y., 1990, DISCOURSE ABILITY BR; Johnson-Laird PN., 1983, MENTAL MODELS; Kaczmarek B. L. J., 1987, FRONTAL LOBES REVISI, P225; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; KARDASH CAM, 1988, J EDUC PSYCHOL, V80, P324, DOI 10.1037/0022-0663.80.3.324; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; KINTSCH W, 1990, J MEM LANG, V29, P133, DOI 10.1016/0749-596X(90)90069-C; KINTSCH W, 1988, PSYCHOL REV, V95, P163, DOI 10.1037/0033-295X.95.2.163; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; KIRSHNER HS, 1995, HDB NEUROLOGICAL SPE; LEESAMMONS WH, 1991, J EXP PSYCHOL LEARN, V17, P1074, DOI 10.1037/0278-7393.17.6.1074; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NEWSOME GL, 1986, J READING BEHAV, V18, P117, DOI 10.1080/10862968609547560; Nicholas L.E., 1995, AM J SPEECH LANGUAGE, V4, P69, DOI [10.1044/1058-0360.0403.69, DOI 10.1044/1058-0360.0403.69]; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; PICHERT JW, 1977, J EDUC PSYCHOL, V69, P309, DOI 10.1037/0022-0663.69.4.309; PIERCE RS, 1988, APHASIOLOGY, V2, P577, DOI 10.1080/02687038808248968; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Snow P, 1997, BRAIN INJURY, V11, P409; STACHOWIAK FJ, 1977, BRAIN LANG, V4, P177, DOI 10.1016/0093-934X(77)90016-5; Stemmer B, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P329; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1987, FRONTAL LOBES REVIS; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; Van Dijk T.A., 1983, STRATEGIES DISCOURSE; WALLESCH CW, 1983, ARCH PSYCHIAT NERVEN, V233, P279, DOI 10.1007/BF00345798; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zimmermann P., 1992, TESTBATTERIE AUFMERK	64	19	20	0	5	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	DEC	1999	70	3					385	420		10.1006/brln.1999.2151			36	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	263YK	WOS:000084152700005	10600227				2021-06-18	
J	Hak, DJ; Goulet, JA				Hak, DJ; Goulet, JA			Severity of injuries associated with traumatic hip dislocation as a result of motor vehicle collisions	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						hip dislocation; multiple trauma	AIRBAG; ACCIDENTS; CRASHES	Background: Previous reports have shown a high rate of associated injuries in patients who sustain traumatic hip dislocation. Since these earlier reports appeared, improvements have been made in passenger safety systems and the rate of restraint usage has increased. The purpose of this study was to review the associated injuries present in a current series of patients who sustained traumatic hip dislocation as a result of motor vehicle collisions. Methods: We retrospectively reviewed our trauma registry and identified 66 patients who sustained traumatic hip dislocation as a result of motor vehicle collisions. Thirty patients (45%) were restrained and 36 (55%) were unrestrained. Airbags were known to have deployed in 14 cases. Results: The incidence of associated injuries was 95% (63 patients), Orthopedic injuries alone were seen in 22 patients (33%), whereas associated injuries were seen in 44 patients (67%), Abdominal injuries were present in 10 patients (15%), thoracic injuries were present in 14 patients (21%), closed head injuries were present in 16 patients (24%), and craniofacial injuries were present in 14 patients (21%). Acetabular fractures were seen in 46 patients (70%), femoral head fractures were identified in 9 patients (14%), and other extremity fractures occurred in 26 patients (39%), The average Injury Severity Score for all patients was 17.4 (range, 9-59), The average Injury Severity Score of the restrained patients was not statistically different from that of the unrestrained patients (p = 0.491). Conclusion: Although improvements in automotive safety features and restraint usage have occurred since previous reports appeared, there continues to be a high rate of severe injuries associated with traumatic hip dislocation that occur in motor vehicle collisions, We believe that all patients who sustain traumatic hip dislocation warrant a general surgery trauma evaluation to rule out any potential associated injuries.	Univ Michigan, Sect Orthopaed Surg, Ann Arbor, MI 48109 USA	Hak, DJ (corresponding author), 2914G Taubman Ctr, Sect Orthopaed Surg, Ann Arbor, MI 48105 USA.						BRAV EA, 1962, J BONE JOINT SURG AM, V44, P1115, DOI 10.2106/00004623-196244060-00007; BURGESS AR, 1995, J TRAUMA, V38, P509, DOI 10.1097/00005373-199504000-00008; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; HOUGAARD K, 1987, J BONE JOINT SURG AM, V69A, P679, DOI 10.2106/00004623-198769050-00007; JACOB JR, 1987, CLIN ORTHOP RELAT R, P249; Kuner EH, 1996, INJURY, V27, P185, DOI 10.1016/0020-1383(95)00211-1; Loo GT, 1996, J TRAUMA, V41, P935, DOI 10.1097/00005373-199612000-00001; PIETRAFESA CA, 1983, JAMA-J AM MED ASSOC, V249, P3342; ROEDER LF, 1980, CLIN ORTHOP RELAT R, P121; ROSENTHAL RE, 1979, J TRAUMA, V19, P572, DOI 10.1097/00005373-197908000-00005; SHIM SS, 1979, CLIN ORTHOP RELAT R, V140, P155; SURACI AJ, 1986, J TRAUMA, V26, P458, DOI 10.1097/00005373-198605000-00008; Sutyak JP, 1997, SOUTHERN MED J, V90, P915, DOI 10.1097/00007611-199709000-00011; VIANO DC, 1995, J TRAUMA, V38, P538, DOI 10.1097/00005373-199504000-00013; YANG RS, 1991, CLIN ORTHOP RELAT R, P218	15	19	20	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	1999	47	1					60	63		10.1097/00005373-199907000-00014			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	216ZQ	WOS:000081474700012	10421188				2021-06-18	
J	Kroppenstedt, SN; Stroop, R; Kern, M; Thomale, UW; Schneider, GH; Unterberg, AW				Kroppenstedt, SN; Stroop, R; Kern, M; Thomale, UW; Schneider, GH; Unterberg, AW			Lubeluzole following traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact injury; lubeluzole; neuroprotection; nitric oxide synthase pathway; traumatic brain injury	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; SODIUM-CHANNEL BLOCKER; NEUROLOGICAL FUNCTION; STROKE; NEUROPROTECTION; PROTECTION; GLUTAMATE; MODEL	Lubeluzole, a novel nitric oxide synthase (NOS) pathway modulator, was shown to be neuroprotective in cerebral ischemia as studied in animal models and clinical trials. The present study investigated the effect of lubeluzole on contusion volume and brain edema following traumatic brain injury. Sprague-Dawley rats (n = 36) were subjected to cortical impact injury. Lubeluzole (0.8 mg/kg i.v.; n = 18) or a corresponding volume of vehicle (n = 18) was injected 15 and 75 minutes following trauma. Animals were sacrificed 24 hours following trauma. Contusion volume was measured planimetrically from coronal slices stained with hematoxylin and eosin. In this group, T-2-weighted magnetic resonance imaging (MRI) was also performed 90 minutes and 6 and 24 hours after trauma. Hemispheric swelling and water content were determined gravimetrically 24 hours after trauma. In this group, intracranial pressure (ICP), mean arterial blood pressure (MABP), and cerebral perfusion pressure (CPP) were monitored for 30 minutes before sacrifice. Lubeluzole did not reduce contusion volume, hemispheric swelling, or water content. ICP, MABP, and the resulting CPP did not differ between treated and untreated rats 24 hours after injury. T-2-weighted MRI revealed a higher volume of edema at 90 minutes after trauma in treated rats. However, at 6 and 24 hours after trauma, no significant difference was discernible. Under these experimental conditions, lubeluzole fails to exert beneficial effects following experimental traumatic brain injury (TBI).	Humboldt Univ, Charite, Dept Neurosurg, D-13353 Berlin, Germany	Kroppenstedt, SN (corresponding author), Humboldt Univ, Charite, Dept Neurosurg, Augustenburger Pl 1,Campus Virchow, D-13353 Berlin, Germany.						Aronowski J, 1996, STROKE, V27, P1571, DOI 10.1161/01.STR.27.9.1571; Ashton D, 1997, BRAIN RES, V745, P210, DOI 10.1016/S0006-8993(96)01094-3; Beaumont A, 1998, ACT NEUR S, V71, P149; BULLOCK R, 1996, NEUROTRAUMA, P375; Busse R, 1997, BRAIN PATHOL, V7, P1377; CARREAU A, 1994, EUR J PHARMACOL, V256, P241, DOI 10.1016/0014-2999(94)90549-5; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DAWSON DA, 1994, CEREBROVAS BRAIN MET, V6, P299; DeRyck M, 1996, J PHARMACOL EXP THER, V279, P748; DeRyck M, 1997, CEREBROVASC DIS, V7, P18, DOI 10.1159/000108239; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; Diener HC, 1998, CEREBROVASC DIS, V8, P172, DOI 10.1159/000015847; Diener HC, 1996, STROKE, V27, P76, DOI 10.1161/01.STR.27.1.76; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; GROTTA J, 1997, STROKE, V12, P2338; Grotta JC, 1997, CEREBROVASC DIS, V7, P31, DOI 10.1159/000108240; Haseldonckx M, 1997, STROKE, V28, P428, DOI 10.1161/01.STR.28.2.428; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LEE SM, 1997, J CEREB BLOOD FLOW S, V17, P592; Lesage A. S., 1994, Society for Neuroscience Abstracts, V20, P185; Lesage AS, 1996, J PHARMACOL EXP THER, V279, P759; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Maiese K, 1997, J NEUROCHEM, V68, P710; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mori T, 1998, ACT NEUR S, V71, P120; MURAMATSU H, 1996, CEREBROVASC DIS S2, V6, P49; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; RATZMANN IB, 1997, EUR J PHARMACOL, V320, P2; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Scheller DKA, 1997, EUR J PHARMACOL, V338, P243, DOI 10.1016/S0014-2999(97)81927-9; Stroop R, 1998, ACT NEUR S, V71, P303; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; THOMALE UW, 1997, ZENTRALBL NEUROCHI S, V55; Unterberg AW, 1997, ACT NEUR S, V70, P106; VANDERLINDEN A, 1996, P 4 SCI M SOC MAGN R, P503; VANREEMPTS J, 1996, P 10 INT BRAIN ED S; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	45	19	19	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1999	16	7					629	637		10.1089/neu.1999.16.629			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	220EN	WOS:000081651700007	10447074				2021-06-18	
J	Swaine, BR; Pless, IB; Friedman, DS; Montes, JL				Swaine, BR; Pless, IB; Friedman, DS; Montes, JL			Using the measure of processes of care with parents of children hospitalized for head injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						head injury; rehabilitation; satisfaction	TRAUMATIC BRAIN INJURY; PATIENT SATISFACTION; MEDICAL-CARE; COMA; REHABILITATION; QUESTIONNAIRE; VALIDATION; FAMILIES; SYSTEM; SCALE	Despite recommendations that rehabilitation programs adopt family/patient satisfaction as an outcome measure, few studies have addressed satisfaction with services for children with head injury. This report describes our use of the Measure of Processes of Care (MPOC) to document the perceptions of care of parents whose children were hospitalized with a head injury and to compare parental perceptions of care with those of the service providers (n = 16). The MPOC is a self-administered questionnaire consisting of 56 items, each of which is included in one of five care-giving scales: (1) enabling and partnership; (2) providing general information; (3) providing specific information about the child; (4) coordinated and comprehensive care; (5) respectful and supportive care. The MPOC was mailed to parents of children with a head injury who were consecutively admitted to a pediatric trauma center during a 5-mo period. The results, based on the responses of 73 parents (response rate, 59.3%), revealed that the needs of these parents are being met to varying degrees. Mean scores for the five scales ranged from 4.6 to 6.4 and from 5.9 to 6.6 for parents and providers, respectively. Significant differences between the groups were found for two scales: providing general and specific information. Because of the low percentage of valid responses for three of the five scales, the MPOC appears to be an inappropriate tool for use with parents of children with mild head injury (89%) in the acute care setting. The MPOC, however, is applicable for parents of children who are more severely injured (e.g., average hospital stay, 9 days) and is informative for rehabilitation service providers.	Univ Montreal, Ecole Readaptat, Fac Med, Montreal, PQ H3T 1A8, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Biostat & Epidemiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 2T5, Canada; McGill Montreal Childrens Hosp, Res Inst, Montreal, PQ, Canada; Montreal Childrens Hosp, Neurotrauma Program, Montreal, PQ, Canada; Montreal Childrens Hosp, Dept Neurosurg, Montreal, PQ, Canada	Swaine, BR (corresponding author), Univ Montreal, Ecole Readaptat, Fac Med, 2375 Cote St Catherine Rd, Montreal, PQ H3T 1A8, Canada.						*AM AC FAM PHYS, 1994, AM FAM PHYSICIAN, V50, P807; American Speech and Hearing Association, 1995, ASHA S14, V37, P23; BRESLAU N, 1982, MED CARE, V20, P347, DOI 10.1097/00005650-198204000-00001; Cleary P D, 1989, QRB Qual Rev Bull, V15, P172; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; Elliott-Burke TL., 1997, J REHABIL OUTCOMES M, V1, P18; *EM MED SERV CHILD, 1995, INF FAM POSS LONG TE; GADDIS GM, 1994, ANN EMERG MED, V23, P75, DOI 10.1016/S0196-0644(94)70012-5; GASTON L, 1992, EVAL PROGRAM PLANN, V15, P227, DOI 10.1016/0149-7189(92)90085-9; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Johnston MV, 1997, ARCH PHYS MED REHAB, V78, pS1, DOI 10.1016/S0003-9993(97)90148-9; King G, 1995, MEASURE PROCESSES CA; King SM, 1996, DEV MED CHILD NEUROL, V38, P757, DOI 10.1111/j.1469-8749.1996.tb15110.x; Kosciulek JF, 1997, J REHABIL, V63, P5; Larsen D L, 1979, Eval Program Plann, V2, P197, DOI 10.1016/0149-7189(79)90094-6; LASH M, 1995, REHAB UPDATE     FAL; LASH M, 1996, REHAB UPDATE     WIN; LEWIS CC, 1986, MED CARE, V24, P209, DOI 10.1097/00005650-198603000-00003; Lucke JF, 1996, ANN EMERG MED, V28, P408, DOI 10.1016/S0196-0644(96)70006-9; MCCOMAS J, 1995, AM J OCCUP THER, V49, P980, DOI 10.5014/ajot.49.10.980; MCCORDIE WR, 1991, BRAIN INJURY, V5, P43; MERRITT KL, 1990, PSYCHOL REP, V67, P129, DOI 10.2466/PR0.67.5.129-130; MOSELEY A, 1995, BRAIN INJURY, V9, P355, DOI 10.3109/02699059509005775; MURPHY DL, 1991, BEACH CTR FAMILIES D; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Osberg JS, 1997, NEUROREHABILITATION, V9, P149, DOI 10.3233/NRE-1997-9206; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; PETERS AV, 1994, B MED LIBR ASSOC, V82, P153; ROSENBAUM PL, 1992, DEV MED CHILD NEUROL, V34, P103; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rydman RJ, 1997, ANN EMERG MED, V29, P109, DOI 10.1016/S0196-0644(97)70316-0; Streiner DL, 1989, HLTH MEASUREMENT SCA; TEASDALE G, 1974, LANCET, V2, P81; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008; Zastowny T R, 1995, Qual Manag Health Care, V3, P50	36	19	19	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1999	78	4					323	329		10.1097/00002060-199907000-00006			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	216AP	WOS:000081418600005	10418837				2021-06-18	
J	Capitani, E; Laiacona, M; Barbarotto, R; Cossa, FM				Capitani, E; Laiacona, M; Barbarotto, R; Cossa, FM			How can we evaluate interference in attentional tests? A study based on bi-variate non-parametric tolerance limits	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; DEFICITS	In attentional tasks a basic performance is often contrasted with the same task administered with some additional load, defined here as "interference". However, it is questionable how interference should be quantified. The raw difference between the interference-loaded ("complex") task and the basic task is marred by measurement artefacts. There are alternative ways, but the choice of which solution to employ appears arbitrary. Bivariate non-parametric tolerance limits were introduced as they retain the information linked to the bivariate nature of the observation, and in this study we compared the different approaches for evaluating interference using real data from 209 normal participants who performed Visual Reaction Times (basic and go / no-go) and the Stroop Test. Our analysis indicated that, among the univariate indices, the use of the complex score covaried for the basic score yields the most satisfactory evaluation of interference; however, its use can be decided only after data inspection. Bivariate non-parametric tolerance limits offer advantages in terms of generality of use.	Univ Milan, S Paolo Hosp, Clin Nervous Dis, I-20122 Milan, Italy; S Maugeri Fdn, Dept Neurol, Neuropsychol Unit, Clin Lavoro & Riabilitaz, Veruno, Novara, Italy; Ist Disabili Psich Villa S Ambrogio, Ist Fatebenefratelli, Milan, Italy	Capitani, E (corresponding author), Osped S Paolo, Neurol Clin, Via di Rudini 8, I-20142 Milan, Italy.						ACKERMANN H, 1985, MEHRDIMENSIONALE NIC; Capitani E, 1997, J CLIN EXP NEUROPSYC, V19, P795, DOI 10.1080/01688639708403761; FRASER DAS, 1953, ANN MATH STAT, V24, P44, DOI 10.1214/aoms/1177729081; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; MURPHY RB, 1948, ANN MATH STAT, V19, P79; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Uttl B, 1997, J CLIN EXP NEUROPSYC, V19, P405, DOI 10.1080/01688639708403869; Venturini R., 1983, COLOR WORD TEST TEST; Wald A, 1943, ANN MATH STAT, V14, P45, DOI 10.1214/aoms/1177731491; Wilks SS, 1941, ANN MATH STAT, V12, P91, DOI 10.1214/aoms/1177731788	11	19	19	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1999	21	2					216	228		10.1076/jcen.21.2.216.934			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	226CL	WOS:000082002700006	10425518				2021-06-18	
J	Moorthi, S; Schneider, WN; Dombovy, ML				Moorthi, S; Schneider, WN; Dombovy, ML			Rehabilitation outcomes in encephalitis - a retrospective study 1990-1997	BRAIN INJURY			English	Article							HERPES-SIMPLEX ENCEPHALITIS; RAPID RECOVERY	Background: Encephalitis is an uncommon clinical entity compared to traumatic brain injury, and stroke. Many encephalitis survivors have disabling seqeulae. There is scant information in the literature addressing outcome following inpatient rehabilitation for encephalitis. Further, it is unclear which of these patients will benefit from acute in-patient rehabilitation. Purpose: The purposes of this study are to (1) describe the outcome following in-patient rehabilitation in a cohort of patients with encephalitis, and (2) develop preliminary; criteria to guide the selection of patients with encephalitis who may benefit from inpatient rehabilitation. Method: The demographic, clinical, functional (functional independence measure-FIM) and neuropsychological data were retrospectively abstracted for eight subjects with a clinical diagnosis of encephalitic aged 5 to 75 years, who were admitted to a brain injury rehabilitation unit between 1990 and 1997. Results: In the eight subjects, the mean age was 38 years, mean acute hospital stay (ALOS) was 40.3 days, and mean rehabilitation length of stay (RLOS) was 75.9 days. Mean admission FIM (AFIM) was 40.1, mean discharge FIM (DFIM) was 69.9. Mean FIM gain was 29.8 and mean FIM efficiency was 0.39. Adult subjects with an AFIM > 30 at 5 weeks from onset of illness (n = 4) had a FIM LOS efficiency of 0.64 and all four were discharged home. None of the adult subjects with an AFIM < 30 at 5 weeks from onset of illness (n = 3, FIM efficiency = 0.14) were discharged home. A child with an AFIM < 30 (n = 1) had a FIM LOS efficiency of 1.24, made good recovery and was discharged home. FIM LOS efficiency of 0.64 in encephalitis is less, as compared to traumatic brain injury (TBI -1.27) and stroke (1.06). Conclusions: The results of this study showed that, although subjects with encephalitis make functional gains in rehabilitation, the rate of recovery varies and is generally less than that for TBI and stroke. The study also suggests chat FIM scores can he used for screening adult patients after encephalitis for admission to inpatient rehabilitation. Adult patients with an AFIM > 30, 3 weeks post onset of illness are likely to make reasonable progress and be discharged home. If replicated, these results suggest that despite low AFIM scores at 5 weeks from onset of illness (AFIM < 30), children may still make good progress and should be given a trial of in-patient rehabilitation.	Univ Rochester, Dept Phys Med & Rehabil, Rochester, NY USA; Univ Rochester, Dept Neurol, Rochester, NY USA; Unity Hlth Syst, Dept Phys Med & Rehabil, Rochester, NY USA	Dombovy, ML (corresponding author), Univ Rochester, St Marys Hosp, 89 Genesee St, Rochester, NY 14611 USA.						BALE JF, 1996, CLIN NEUROLOGY, V2, P1; Dombovy ML, 1998, BRAIN INJURY, V12, P443, DOI 10.1080/026990598122412; EARNEST MP, 1971, NEUROLOGY, V21, P969, DOI 10.1212/WNL.21.9.969; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FIELDER RC, 1996, AM J PHYSICAL MED RE, V75, P125; FIELDER RC, 1998, AM J PHYS MED REHABI, V77, P69; Gutierrez KM, 1998, POSTGRAD MED, V103, P123, DOI 10.3810/pgm.1998.03.413; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Hokkanen L, 1997, J NEUROL NEUROSUR PS, V63, P222, DOI 10.1136/jnnp.63.2.222; Johnson RT, 1996, CLIN INFECT DIS, V23, P219, DOI 10.1093/clinids/23.2.219; Kolski H, 1998, CLIN INFECT DIS, V26, P398, DOI 10.1086/516301; LOWERY PW, 1997, J LAB CLIN MED, V129, P405; Marton R, 1996, ACTA NEUROL SCAND, V93, P149; McCarthy D., 1972, MCCARTHY SCALES CHIL; McGrath N, 1997, J NEUROL NEUROSUR PS, V63, P321, DOI 10.1136/jnnp.63.3.321; *NO CAL NEUR GROUP, 1995, NEUR COGN STAT EX NC; Partington J., 1949, PSYCHOL SERVICE CTR, V1, P9; Reitan RM., 1985, HALSTEAD REITAN NEUR; Tong CYW, 1997, LANCET, V349, P470, DOI 10.1016/S0140-6736(96)09320-8; Wechsler D., 1987, WECHSLER MEMORY SCAL; WHITLEY RJ, 1989, JAMA-J AM MED ASSOC, V262, P24; Zifroni A, 1997, LANCET, V349, P1328, DOI 10.1016/S0140-6736(05)62546-9	23	19	19	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1999	13	2					139	146		10.1080/026990599121809			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	167HQ	WOS:000078626800007	10079959				2021-06-18	
J	Panizzon, KL; Shin, D; Frautschy, S; Wallis, RA				Panizzon, KL; Shin, D; Frautschy, S; Wallis, RA			Neuroprotection with Bcl-2(20-34) peptide against trauma	NEUROREPORT			English	Article						AMPA; apoptosis; Bcl-2; cerebral ischemia; hypoxia; nitric oxide; NMDA; slice; traumatic brain injury	ADP-RIBOSYLATION; NITRIC-OXIDE; BCL-2; ISCHEMIA; INJURY; APOPTOSIS; BAX; HIPPOCAMPUS; INHIBITORS; NEURONS	WE tested the neuroprotective potential of the Bcl-2(20-34) peptide sequence in hippocampal slices. Treatment with Bcl-2 after fluid percussion trauma significantly improved recovery of CA1 antidromic PS to a mean of 92% +/- 1 of initial amplitude, compared with only 16% +/- 2 in unmedicated slices. The EC50 for trauma protection was 84 mu M Bcl-2(20-34). Protection with Bcl-2(20-34) also extended to long-term potentiation. No protection was seen with the reverse sequence of Bcl-2(20-34). Treatment with Bcl-2(20-34) also protected against hypoxic damage, with treated slices recovering to 98% +/- 2, while unmedicated slices recovered to 14% +/- 2. Similar protection was seen against AMPA, NMDA and nitric oxide. These findings indicate that Bcl-2(20-34) provides specific neuroprotection against acute CA1 neuronal injury. (C) 1998 Lippincott Williams & Wilkins.	Sepulveda VAMC, Sepulveda, CA 91343 USA; Univ Calif Los Angeles, Sch Med, Neuronal Injury Lab, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Geriatr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90024 USA	Wallis, RA (corresponding author), Sepulveda VAMC, 111-N1,16111 Plummer St, Sepulveda, CA 91343 USA.			Frautschy, Sally A./0000-0003-0194-0363			Bonfoco E, 1996, NEUROREPORT, V8, P273, DOI 10.1097/00001756-199612200-00054; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Chen J, 1996, J NEUROCHEM, V67, P64; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Long C J, 1983, Psychiatr Med, V1, P35; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WALLIS RA, 1993, NEUROREPORT, V5, P245; WALLIS RA, 1993, EUR J PHARMACOL, V238, P165, DOI 10.1016/0014-2999(93)90844-8; White MJ, 1997, ANN NEUROL, V42, P580, DOI 10.1002/ana.410420408; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	25	19	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	DEC 21	1998	9	18					4131	4136		10.1097/00001756-199812210-00024			6	Neurosciences	Neurosciences & Neurology	158QY	WOS:000078128400028	9926861				2021-06-18	
J	Barnfield, TV; Leathem, JM				Barnfield, TV; Leathem, JM			Neuropsychological outcomes of traumatic brain injury and substance abuse in a New Zealand prison population	BRAIN INJURY			English	Article							CHRONIC COCAINE ABUSERS; HEAD-INJURY; FOLLOW-UP; IMPAIRMENT; DEFICITS; INTOXICATION; PERFORMANCE; PERSONALITY; SEQUELAE; RECOVERY	Fifty subjects with a history of traumatic brain injury (TBI) and/or substance use, completed neuro psychological measures of shea and long term verbal and visual memory, information processing, motor speed and co-ordination, executive functioning, and malingering. AU subjects; performed below norms on tests of verbal memory and verbal abstract thinking, but overall no differences were found due to either severity of TBI or level of substance use. Maori subjects obtained the lowest scores on tests of verbal ability, but also reported higher rates of TBI and substance use, which is presumed to account for this result. In conclusion, prison populations seem to have disproportionately high rates of TBI, recurrent TBI, and substance use, compared to the general population. Further, there are a group of individuals who have experienced both TBI and substance abuse, with associated impairments in verbal memory and learning, abstract thinking, and who report problems with general memory and socialization. These difficulties may affect functioning both in prison and following release.	Massey Univ, Dept Psychol, Palmerston North, New Zealand; Hutt Valley Hlth, Adult Mental Hlth Serv, Lower Hutt, New Zealand	Leathem, JM (corresponding author), Massey Univ, Dept Psychol, POB 11-222, Palmerston North, New Zealand.						*ACC REH COMP INS, 1993, ACC INJ STAT 1992; ADAMS J, 1992, DRUG STAT 1992; ARDILA A, 1991, INT J NEUROSCI, V57, P73, DOI 10.3109/00207459109150348; BARNFIELD TV, BRAIN INJURY, V12, P455; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENTON R, 1988, ROYAL COMMISSION S 2, V3; BERGMAN H, 1989, BRIT J ADDICT, V84, P547; BERRY J, 1993, DRUG ALCOHOL DEPEN, V32, P231, DOI 10.1016/0376-8716(93)90087-7; BLACK S, 1993, DRUGS NZ SURVEY; BOND MR, 1986, NEUROPSYCHOLOGICAL A; BOWDEN SC, 1994, NEUROPSYCHOLOGY CLIN; BRAYBROOK B, 1992, CENSUS PRISON INMATE; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; BROWNING MD, 1992, ALCOHOL HEALTH RES W, V16, P280; BRUN P, 1975, AM J PSYCHIAT, V132, P397; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; CARLIN AS, 1991, FORENSIC NEUROPSYCHO, P99; CASSIDY JW, 1990, J HEAD TRAUMA REHAB, V5, P83; COSGROVE J, 1991, J CLIN PSYCHOL, V47, P159, DOI 10.1002/1097-4679(199101)47:1<159::AID-JCLP2270470125>3.0.CO;2-O; CROSSON B, 1987, CLIN NEUROPSYCHOLOGI, V1, P355; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EAMES P, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P134; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; ELMER O, 1985, ACTA CHIR SCAND, V151, P305; Ennis J., 1987, TU TANGATA, V36, P21; Fishbein D. H., 1990, CRIME BIOL SOCIAL MO; FRANCESCHI M, 1984, J NEUROL NEUROSUR PS, V47, P1134, DOI 10.1136/jnnp.47.10.1134; GANDOSSY RP, 1980, DRUGS CRIME SURVEY A; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; GODFREY HPD, NZ J PSYCHOL, V16, P49; GRANT I, 1977, DRUG ALCOHOL DEPEN, V2, P91, DOI 10.1016/0376-8716(77)90010-2; GREER BG, 1986, J REHABILITATION JAN, P34; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gronwall Dorothy, 1990, HEAD INJURY FACTS GU; Gualtari CT, 1991, BRAIN INJURY, V5, P219; GUERRA D, 1987, DRUG ALCOHOL DEPEN, V20, P261, DOI 10.1016/0376-8716(87)90036-6; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; HARLOW CW, 1991, DRUGS JAIL INMATES 1; HASIN DS, 1987, COMPR PSYCHIAT, V28, P520, DOI 10.1016/0010-440X(87)90018-6; HORMES JT, 1986, NEUROLOGY, V36, P698, DOI 10.1212/WNL.36.5.698; JOHNSON DA, 1993, BRAIN INJURY, V7, P491, DOI 10.3109/02699059309008176; JONES GA, 1989, ALCOHOL HEALTH RES W, V13, P105; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kaplan H.I., 1991, SYNOPSIS PSYCHIAT BE; KOIB B, 1990, FUNDAMENTALS HUMAN N; LANGLEY M J, 1990, Brain Injury, V4, P77, DOI 10.3109/02699059009026151; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LOBERG T, 1986, NEUROPSYCHOLOGICAL A; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MEEK PS, 1989, J PSYCHOACTIVE DRUGS, V21, P153, DOI 10.1080/02791072.1989.10472155; MENDHIRATTA SS, 1988, BRIT J ADDICT, V83, P749; MILLER L, 1992, INT J LAW PSYCHIAT, V15, P303, DOI 10.1016/0160-2527(92)90005-L; Morse P, 1992, CLIN SYNDROMES ADULT, P85; NORRIS M, 1909, OFFENDING NZ TRENDS; NOVACK TA, 1988, REHABIL COUNS BULL, V31, P313; OMALLEY S, 1992, AM J DRUG ALCOHOL AB, V18, P131, DOI 10.3109/00952999208992826; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; PAGE JB, 1988, J PSYCHOACTIVE DRUGS, V20, P57, DOI 10.1080/02791072.1988.10524372; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1991, AWARENESS DEFICIT BR, P116; REY A, 1968, EPREUVES MNESIQUES A; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RICHARDS M, 1992, J SUBST ABUSE TREAT, V9, P371, DOI 10.1016/0740-5472(92)90033-K; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; SACHDEV PS, 1989, PSYCHOL MED, V19, P959, DOI 10.1017/S0033291700005687; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Schafer J, 1994, NEUROPSYCHOLOGY, V8, P100, DOI 10.1037/0894-4105.8.1.100; SELBY MJ, IN PRESS ARCH CLIN N, V10; Shorr J., 1992, NEUROPSYCHOLOGY, V6, P43, DOI DOI 10.1037/0894-4105.6.1.43; SPICER P, 1993, CONVICTION SENTENCIN; Spreen O., 1991, COMPENDIUM NEUROPSYC; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; SWEENEY JA, 1989, J CLIN PSYCHOL, V45, P346, DOI 10.1002/1097-4679(198903)45:2<346::AID-JCLP2270450227>3.0.CO;2-L; TARTER RE, 1986, ALCOHOL CLIN EXP RES, V10, P128, DOI 10.1111/j.1530-0277.1986.tb05059.x; TEASDALE G, 1974, LANCET, V2, P81; *US DEP JUST, 1983, BUR JUST STAT B; Waldegrave C., 1985, AUSTR NZ J FAMILY TH, V6, P197; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WYLLIE A, 1989, DRINKING NZ SURVEY 1; ZIELINSKI R, IN PRESS ARCH CLIN N	87	19	19	0	11	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1998	12	11					951	962		10.1080/026990598122007			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	143NR	WOS:000077262300004	9839028				2021-06-18	
J	Harbrecht, BG; Moraca, RJ; Saul, M; Courcoulas, AP				Harbrecht, BG; Moraca, RJ; Saul, M; Courcoulas, AP			Percutaneous endoscopic gastrostomy reduces total hospital costs in head injured patients	AMERICAN JOURNAL OF SURGERY			English	Article							COMPLICATIONS	BACKGROUND: Gastrostomies provide reliable long-term enteral access in patients with traumatic brain injuries. The impact of technique of gastrostomy on total hospital cost is not known. METHODS: A retrospective analysis of patients who sustained head trauma and required gastrostomies for long-term enteral access between 1 July 1990 and 1 July 1996 was performed. RESULTS: The patients who received percutaneous endoscopic gastrostomies (PEG) were similar to patients who received Stamm gastrostomies (OPEN) with respect to age, injury severity score, mechanism of injury, associated injuries, complication rates, and deaths. Total hospital costs ($ x 10(3)) were lower for patients who had PEGs placed in the intensive care unit (78.2 +/- 37.4) or endoscopy suite (71.9 +/- 37.7) compared with PEGs placed in the operating room (122.4 +/- 75.7) or OPEN gastrostomies (119.8 +/- 65.1). CONCLUSIONS: In head-injured patients, PEGs are a reliable method of obtaining long-term enteral access with a complication rate equivalent to Stamm gastrostomies. If performed in either the intensive care unit or the endoscopy suite, PEGs are associated with significantly reduced total hospital costs. (C) 1998 by Excerpta Medica, Inc.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; Univ Pittsburgh, Dept Biomed Infomat, Pittsburgh, PA USA	Harbrecht, BG (corresponding author), Univ Pittsburgh, Presbyterian Univ Hosp A1010, 200 Lothrop St, Pittsburgh, PA 15213 USA.						Carrillo EH, 1997, SURG ENDOSC, V11, P1068, DOI 10.1007/s004649900531; Chowdhury MA, 1996, J GASTROEN HEPATOL, V11, P835, DOI 10.1111/j.1440-1746.1996.tb00089.x; DAMELIO LF, 1992, J TRAUMA, V33, P435; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; Lowe JB, 1997, AM J SURG, V174, P624, DOI 10.1016/S0002-9610(97)00177-3; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; SHELLITO PC, 1985, ANN SURG, V201, P180, DOI 10.1097/00000658-198502000-00008; STIEGMANN GV, 1990, GASTROINTEST ENDOSC, V36, P1, DOI 10.1016/S0016-5107(90)70911-X; WEBSTER MW, 1975, ARCH SURG-CHICAGO, V110, P658	11	19	20	0	0	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011 USA	0002-9610			AM J SURG	Am. J. Surg.	OCT	1998	176	4					311	314		10.1016/S0002-9610(98)00206-2			4	Surgery	Surgery	135DL	WOS:000076785500004	9817245				2021-06-18	
J	Hogg, S; Perron, C; Barneoud, P; Sanger, DJ; Moser, PC				Hogg, S; Perron, C; Barneoud, P; Sanger, DJ; Moser, PC			Neuroprotective effect of eliprodil: Attenuation of a conditioned freezing deficit induced by traumatic injury of the right parietal cortex in the rat	JOURNAL OF NEUROTRAUMA			English	Article						conditioned emotional response; conditioned fear response; neuroprotection; NMDA receptor antagonist; traumatic brain injury	RECEPTOR ANTAGONIST ELIPRODIL; GLOBAL CEREBRAL-ISCHEMIA; BRAIN INJURY; NMDA RECEPTOR; CA2+ CHANNELS; CORTICAL-NEURONS; POLYAMINE SITE; ANIMAL-MODELS; IFENPRODIL; SL-82.0715	We have previously demonstrated that a lateral fluid percussion-induced traumatic lesion of the right parietal cortex can lead to a deficit in a conditioned freezing response and that this deficit can be attenuated by both pre- and postlesion administration of the NMDA receptor antagonist dizocilpine. In the present study, we investigated the effects of eliprodil, a noncompetitive NMDA receptor antagonist acting at the polyamine modulatory site, which also acts as a Ca2+ channel blocker, on the trauma-induced conditioned freezing deficit, Eliprodil produced a 50% reduction in this deficit when administered as three 1 mg/kg injections i.v. at 15 min, 6 h, and 24 h following the lesion. Approximately the same degree of protection was afforded when 2 x 1.5 mg/kg were administered 6 and 24 h and equally at 12 and 24 h after surgery (56% and 59%, respectively). A single treatment (3 mg/kg) at 24 h was ineffective against the deficit. The protection afforded with treatment at 6 and 24 h after lesion was dose dependent, with a minimal active dose of 2 x 0.75 mg/kg, These data complement those previously published on the ability of eliprodil to reduce lesion volume following traumatic brain injury and show, in addition, that the neuroprotective effect has functional consequences.	Synthelabo Rech, F-92500 Rueil Malmaison, France; Synthelabo Rech, Bagneux, France	Moser, PC (corresponding author), Synthelabo Rech, 10 Rue Carrieres, F-92500 Rueil Malmaison, France.			Moser, Paul/0000-0002-6887-3508			Avenet P, 1997, NEUROSCI LETT, V223, P133, DOI 10.1016/S0304-3940(97)13422-X; Bath CP, 1996, EUR J PHARMACOL, V299, P103, DOI 10.1016/0014-2999(95)00846-2; BENAVIDES J, 1990, BRAIN RES, V522, P275, DOI 10.1016/0006-8993(90)91472-S; BENAVIDES J, 1992, J PHARMACOL EXP THER, V260, P896; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BITON B, 1994, EUR J PHARMACOL, V257, P297, DOI 10.1016/0014-2999(94)90142-2; Biton B, 1995, EUR J PHARMACOL, V294, P91, DOI 10.1016/0014-2999(95)00511-0; CARTER C, 1989, EUR J PHARMACOL, V164, P611, DOI 10.1016/0014-2999(89)90275-6; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; DECOSTER MA, 1995, BRAIN RES, V671, P45, DOI 10.1016/0006-8993(94)01294-R; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DUVAL D, 1992, NEUROSCI LETT, V137, P193, DOI 10.1016/0304-3940(92)90402-S; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Novack TA, 1996, J CLIN EXP NEUROPSYC, V18, P685, DOI 10.1080/01688639608408292; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paxinos G., 1982, RAT BRAIN STEREOTAXI; POIGNET H, 1992, BRAIN RES, V596, P320, DOI 10.1016/0006-8993(92)91565-V; PONCELET M, 1993, NEUROPHARMACOLOGY, V32, P605, DOI 10.1016/0028-3908(93)90057-A; SANGER DJ, 1991, PSYCHOPHARMACOLOGY, V104, P27, DOI 10.1007/BF02244550; SCATTON B, 1994, DIRECT ALLOSTERIC CO, P139; SHALABY IA, 1992, J PHARMACOL EXP THER, V260, P925; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q	38	19	19	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1998	15	7					545	553		10.1089/neu.1998.15.545			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZY374	WOS:000074614700008	9674557				2021-06-18	
J	Popovich, PG; Whitacre, CC; Stokes, BT				Popovich, PG; Whitacre, CC; Stokes, BT			Is spinal cord injury an autoimmune disorder?	NEUROSCIENTIST			English	Article						T-lymphocyte; autoimmunity; CNS injury; microglia; demyelination; neuroimmunology	CENTRAL-NERVOUS-SYSTEM; BASIC-PROTEIN; MULTIPLE-SCLEROSIS; T-CELLS; LYMPHOCYTES; MYELIN; ENCEPHALOMYELITIS; REGENERATION; INHIBITION; DISEASE	Cross-talk between cells of the nervous and immune systems is an emerging concept in neurotrauma research. Previously, neuroimmunological approaches in brain and spinal cord injury have focused on the functional consequences of macrophage and microglial activation. These cells constitute the natural, or innate, branch of CNS immunity and respond to injury or infection in a nonspecific fashion. Recent evidence, however, has shown that T-lymphocytes may also play a significant role in spinal cord injury. Once activated, T-and B-lymphocytes orchestrate the complex functions of the inflammatory response. Acquired immunity is readily induced against "non-self," or foreign, antigens, although "self-reactive" lymphocytes are present in normal individuals, providing the potential for the onset of autoimmunity. Trauma to or infection in the CNS may release "self" antigens normally sequestered behind the blood-brain barrier that can trigger lymphocyte activation. This article addresses the potential pathological and physiological implications of lymphocyte activation induced by traumatic spinal cord injury.	Ohio State Univ, Coll Med & Publ Hlth, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Spinal Cord Injury Res Ctr, Columbus, OH 43210 USA			Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395			APPEL SH, 1994, J NEUROL SCI, V124, P14, DOI 10.1016/0022-510X(94)90171-6; BERRY M, 1974, BRIT MED BULL, V30, P135, DOI 10.1093/oxfordjournals.bmb.a071183; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; CROSS AH, 1990, LAB INVEST, V63, P162; CRUSE JM, 1992, IMMUNOL RES, V11, P104, DOI 10.1007/BF02918615; Ehrlich P, 1900, P R SOC            B, V66, P424, DOI DOI 10.1098/RSPL.1899.0121; Falcone M, 1997, J EXP MED, V185, P901, DOI 10.1084/jem.185.5.901; FERINGA ER, 1975, ARCH NEUROL-CHICAGO, V32, P676, DOI 10.1001/archneur.1975.00490520046007; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GUTH L, 1994, EXP NEUROL, V126, P76, DOI 10.1006/exnr.1994.1043; HARLINGBERG CJ, 1991, J NEUROIMMUNOL, V35, P45, DOI 10.1016/0165-5728(91)90160-9; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HORNER PJ, 1994, NEURAL TRANSPLANTATI, P119; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; MARTIN R, 1995, CRIT REV CL LAB SCI, V32, P121, DOI 10.3109/10408369509084683; MILLER DJ, 1995, J NEUROSCI RES, V41, P291, DOI 10.1002/jnr.490410302; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; PALLADINI G, 1987, EXP NEUROL, V95, P639, DOI 10.1016/0014-4886(87)90305-0; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Prochazka M, 1971, Int Surg, V55, P322; RAINE CS, 1984, LAB INVEST, V50, P608; Ramirez F, 1996, J IMMUNOL, V156, P2406; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; SHALIT F, 1995, CLIN IMMUNOL IMMUNOP, V75, P246, DOI 10.1006/clin.1995.1078; Stefan J, 1971, Int Surg, V55, P316; THEOFILOPOULOS AN, 1993, MOL PATHOLOGY AUTOIM, V1, P1; Whitacre CC, 1996, CLIN IMMUNOL IMMUNOP, V80, pS31, DOI 10.1006/clin.1996.0139; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; YAROM Y, 1983, NATURE, V303, P246, DOI 10.1038/303246a0	36	19	19	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1073-8584			NEUROSCIENTIST	Neuroscientist	MAR	1998	4	2					71	76		10.1177/107385849800400203			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ZC578	WOS:000072594700010					2021-06-18	
J	Urenjak, J; Obrenovitch, TP				Urenjak, J; Obrenovitch, TP			Neuroprotection - rationale for pharmacological modulation of Na+-channels	AMINO ACIDS			English	Article; Proceedings Paper	Satellite on Neurobiology at the 5th International Congress on Amino Acids	AUG 25-29, 1997	CHALKIDIKI, GREECE	Sandoz Res Inst Berne LTD, Berne, Switzerland, Lomberg Chem Fabrik Gmbh, Byk Gulden, Konstanz, Germany, Pfizer Ltd, Kent, England, Pharmacia & Upjohn Co, Kalamazoo, MI, Boehringer Ingelheim, Ingelheim am Rhein, Germany, Merz & Co, Frankfurt am Main, Germany, Astra Arcus AB, Sodertalje, Sweden		neuroprotection; Na+-channels; Na+-channel blockers; ischaemia; energy deprivation; traumatic brain injury	GLUTAMATE RELEASE INHIBITOR; DEPENDENT SODIUM-CHANNELS; GLOBAL CEREBRAL-ISCHEMIA; RAT HIPPOCAMPAL-NEURONS; EXCITATORY AMINO-ACIDS; CNS WHITE-MATTER; BRAIN INJURY; BLOCKER TETRODOTOXIN; ANTIEPILEPTIC DRUG; LOCAL-ANESTHETICS	The primary factor detrimental to neurons in neurological disorders associated with deficient oxygen supply or mitochondrial dysfunction is insufficient ATP production relative to their requirement. As a large part of the energy consumed by brain cells is used for maintenance of the Na+ gradient across the cellular membrane, reduction of energy demand by downmodulation of voltage-gated Na+-channels is a rational strategy for neuroprotection. In addition, preservation of the inward Na+ gradient may be beneficial because it is an essential driving force for vital ion exchanges and transport mechanisms such as Ca2+ homeostasis and neurotransmitter uptake.	Pfizer Cent Res, Discovery Biol, Sandwich, Kent, England; Inst Neurol, Dept Neurochem, London, England	Urenjak, J (corresponding author), Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England.						AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992; Ames Adelbert Iii, 1997, P17; Artru F, 1991, Agressologie, V32, P439; ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; BOENING JA, 1989, NEUROSCIENCE, V33, P263, DOI 10.1016/0306-4522(89)90205-4; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; CHERUBINI E, 1989, J NEUROPHYSIOL, V62, P882; CHEUNG H, 1992, EPILEPSY RES, V13, P107; CUMMINS TR, 1994, J NEUROPHYSIOL, V71, P1052; DARGENT B, 1990, P NATL ACAD SCI USA, V87, P5907, DOI 10.1073/pnas.87.15.5907; Douglas S. M., 1996, Society for Neuroscience Abstracts, V22, P230; EDWARDS RA, 1989, AM J PHYSIOL, V257, pR1354; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; EVANS DE, 1984, J NEUROSURG, V60, P257, DOI 10.3171/jns.1984.60.2.0257; FERN R, 1993, J PHARMACOL EXP THER, V266, P1549; FRIEDMAN JE, 1994, BRAIN RES, V641, P57, DOI 10.1016/0006-8993(94)91815-5; GILLAND E, 1994, DEV BRAIN RES, V83, P79, DOI 10.1016/0165-3806(94)90181-3; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAKIM A M, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P115; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HOEHN K, 1993, NEURON, V10, P543, DOI 10.1016/0896-6273(93)90341-N; KEMPSKI O, 1988, NEUROCHEM PATHOL, V9, P109; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LANG DG, 1993, J PHARMACOL EXP THER, V266, P829; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; LEKIEFFRE D, 1993, NEUROSCIENCE, V56, P93, DOI 10.1016/0306-4522(93)90565-W; LUCAS LF, 1989, J NEUROSCI METH, V28, P47, DOI 10.1016/0165-0270(89)90008-3; Lysko P. G., 1993, Society for Neuroscience Abstracts, V19, P286; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; MESSENHEIMER JA, 1995, EPILEPSIA, V36, pS87, DOI 10.1111/j.1528-1157.1995.tb06002.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OBRENOVITCH TP, 1990, J NEUROPHYSIOL, V64, P1125; OBRENOVITCH TP, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P97; OBRENOVITCH TP, 1997, REV CONTEMP PHARMACO, V8, P227; OBRENOVITCH TP, 1997, NEUROPROTECTIVE AGEN, P109; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PEREZPINZON MA, 1992, AM J PHYSIOL, V262, pR712; PRENEN GHM, 1988, EXP NEUROL, V99, P118, DOI 10.1016/0014-4886(88)90132-X; RASOOL N, 1990, STROKE, V21, P929, DOI 10.1161/01.STR.21.6.929; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; Schulz JB, 1996, NEUROSCIENCE, V71, P1043, DOI 10.1016/0306-4522(95)00527-7; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; SKILLING SR, 1988, J NEUROCHEM, V51, P127, DOI 10.1111/j.1471-4159.1988.tb04845.x; SMITH SE, 1995, STROKE, V26, P117, DOI 10.1161/01.STR.26.1.117; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; SPETZLER R F, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P212; STYS PK, 1992, J NEUROSCI, V12, P430; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TAYLOR CP, 1993, TRENDS NEUROSCI, V16, P455, DOI 10.1016/0166-2236(93)90077-Y; Urenjak J, 1996, PHARMACOL REV, V48, P21; URENJAK J, 1991, PHARMACOLOGY, V43, P26, DOI 10.1159/000138824; VORNOV JJ, 1994, STROKE, V25, P457, DOI 10.1161/01.STR.25.2.457; WAXMAN SG, 1994, BRAIN RES, V644, P197, DOI 10.1016/0006-8993(94)91680-2; WIARD RP, 1995, STROKE, V26, P466, DOI 10.1161/01.STR.26.3.466; XIA Y, 1994, J COMP NEUROL, V345, P279, DOI 10.1002/cne.903450209; XIA Y, 1993, J COMP NEUROL, V330, P363, DOI 10.1002/cne.903300307; Xie XM, 1996, NEUROSCIENCE, V73, P951, DOI 10.1016/0306-4522(96)00092-9; XIE XM, 1995, PFLUG ARCH EUR J PHY, V430, P437, DOI 10.1007/BF00373920; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; YAMASAKI Y, 1991, NEUROSCI LETT, V121, P251, DOI 10.1016/0304-3940(91)90697-R; YOUNG AMJ, 1990, J NEUROCHEM, V55, P1060, DOI 10.1111/j.1471-4159.1990.tb04597.x	67	19	19	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0939-4451			AMINO ACIDS	Amino Acids		1998	14	1-3					151	158		10.1007/BF01345256			8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	YU287	WOS:000071701500024	9871455				2021-06-18	
J	Soblosky, JS; Colgin, LL; Chorney-Lane, D; Davidson, JF; Carey, ME				Soblosky, JS; Colgin, LL; Chorney-Lane, D; Davidson, JF; Carey, ME			Some functional recovery and behavioral sparing occurs independent of task-specific practice after injury to the rat's sensorimotor cortex	BEHAVIOURAL BRAIN RESEARCH			English	Article						behavioral compensation; recovery; sensorimotor cortex; traumatic brain injury; forelimb deficit; task-specific practice; hindlimb deficit; rat	TRAUMATIC BRAIN INJURY; MOTOR CORTEX; ADULT-RATS; NEOCORTICAL DAMAGE; NEURONAL INJURY; LESIONS; AMPHETAMINE; MEMORY; ORGANIZATION; PLASTICITY	These experiments on rats evaluated whether recovery of competence in certain motor tests could be enhanced by practice begun soon after traumatic brain injury (TBI). Before TBI, rats were pre-trained to cross a flat and a pegged beam. Anesthetized animals received a right sensorimotor cortex TBI. One group began task-specific testing (flat and pegged beams) on day 1 after injury and repeated 13 times in 35 days by which time functional recovery occurred. Paw preference was evaluated eight times during the 35 day period, beginning the third day after injury. A second group of injured rats remained in their home cage without any testing for 35 days after injury. From day 35 they were tested 13 times over the next 35 days on both beam tests and eight times on the paw preference test. At day 35 those rats that remained in their home cage without testing (task-specific practice) performed as well on the flat beam as the rats that began testing 1 day after injury. By day 37, their third test day, the untested rats performed as well as the tested rats on the pegged beam. Paw preference was the same in both groups of rats. These results were compared to sham-operated controls. Post-injury performance as measured by these tests indicated that most of the recovery occurred without task-specific practice. However, task-specific practice was necessary to achieve optimum performance on both beam tests. This implies that neural reorganization occurred independent of any practice. Task specific practice served to 'fine tune' the rat's performance after 35 days. (C) 1997 Elsevier Science B.V.	Louisiana State Univ, Med Ctr, Dept Neurosurg, Neurotrauma Res Lab, New Orleans, LA 70112 USA	Soblosky, JS (corresponding author), Louisiana State Univ, Med Ctr, Dept Neurosurg, Neurotrauma Res Lab, 1542 Tulane Ave, New Orleans, LA 70112 USA.	JSOBLO@lsumc.edu		Lane, Diane/0000-0001-7313-557X; Colgin, Laura/0000-0002-4853-8913			BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; CHEN S, 1990, BRAIN RES, V520, P103, DOI 10.1016/0006-8993(90)91695-D; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GOLDSTEIN LB, 1993, NEUROSCI PROTOCOLS, P1; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; PELLEGRINO I, 1979, STEREOTAXIC ATLAS RA; ROSE FD, 1993, BEHAV BRAIN RES, V56, P93, DOI 10.1016/0166-4328(93)90025-L; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SOBLOSKY JS, UNPUB LADDER BEAM CA; STEPHENS J, 1986, Society for Neuroscience Abstracts, V12, P1285; STEPHENS J, 1987, PHYS THER, V67, P769; SZELE FG, 1995, J NEUROSCI, V15, P4429; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519	32	19	20	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC	1997	89	1-2					51	59		10.1016/S0166-4328(97)00049-1			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	YT189	WOS:000071574400003	9475614				2021-06-18	
J	Brulot, MM; Strauss, E; Spellacy, F				Brulot, MM; Strauss, E; Spellacy, F			Validity of the Minnesota multiphasic personality inventory-2 correction factors for use with patients with suspected head injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMA PATIENTS; MMPI-2; PSYCHOPATHOLOGY; COMPLAINTS; SYMPTOMS; SEQUELAE; SCALES	The clinical scales of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) are thought to be artificially inflated in patients with closed head injury (CHI). Correction factors have been proposed (e.g,. Alfano, Paniak, & Finlayson, 1993; Artzy, 1994; Gass, 1991b) by comparing item endorsement of various populations and selecting items unique to the CHI population. The present study assessed the validity of the correction factors by relating these to indices of head- injury severity and to scores on standard neuropsychological measures. Results revealed no significant associations between the correction factors and duration of loss of consciousness (LOC) and posttraumatic amnesia (PTA). In addition, no significant associations were found between correction factors and performance on neuropsychological tests. Significant correlations were found, however, between correction factors and the MMPI-2 depression content scale. These results suggest that the correction factors proposed for interpreting MMPI-2 protocols of head-injured individuals may be more sensitive to depression than to closed head injury.	Univ Victoria, Dept Psychol, Victoria, BC V8V 3P5, Canada	Brulot, MM (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8V 3P5, Canada.						Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; ARTZY G, 1994, THESIS U VICTORIA BR; Ben-Porath Y. S., 1991, PSYCHOL ASSESSMENT J, V3, P634; BENPORATH YS, 1993, J PERS ASSESS, V61, P557, DOI 10.1207/s15327752jpa6103_12; Benton A. L, 1989, MILD HEAD INJURY, P3; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOONE DE, 1994, PSYCHOL REP, V74, P159, DOI 10.2466/pr0.1994.74.1.159; Brickenkamp R., 1981, TEST D2 AUFMERKSAMKE, V7th; BROOKS N, 1984, CLOSED HEAD INJURY P, P44; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURTON LA, 1994, J NEUROLOGICAL REHAB, V8, P63, DOI DOI 10.1177/136140969400800202; BUTCHER JN, 1992, CAN PSYCHOL, V33, P61, DOI 10.1037/h0078693; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CRIPE LI, 1989, REHABIL PSYCHOL, V34, P93; DIKMEN S, 1974, PERCEPT MOTOR SKILL, V39, P831, DOI 10.2466/pms.1974.39.2.831; DIKMEN SS, 1989, MILD HEAD INJURY, P229; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GASS CS, 1992, ARCH CLIN NEUROPSYCH, V7, P17, DOI 10.1016/0887-6177(92)90015-F; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, J CLIN PSYCHOL, V47, P100, DOI 10.1002/1097-4679(199101)47:1<100::AID-JCLP2270470116>3.0.CO;2-H; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; Graham JR, 1993, MMPI 2 ASSESSING PER; GRAVES RE, 1985, REY VISUAL DESIGN LE; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hathaway S. R., 1989, MINNESOTA MULTIPHASI; KARLSEN B, 1984, STANFORD DIAGNOSTIC; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; OHARA C, 1988, COGNITIVE REHABILITA, V6, P26; OJILE JR, 1995, ANN M INT NEUR SOC S; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; Partington J., 1949, PSYCHOL SERVICE CTR, V1, P9; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; POPE KS, 1993, MMPI MMPI 2 MMPI A C; Regard M, 1981, THESIS U VICTORIA BR; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Reitan RM, 1997, CLIN NEUROPSYCHOL, V11, P69, DOI 10.1080/13854049708407031; REITAN RM, 1969, UNPUB MANUAL ADM NEU; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Smith A., 1982, SYMBOL DIGIT MODALIT; SPEARBASSETT S, 1990, J PEDIATR PSYCHOL, V15, P225; Spreen O., 1977, NEUROSENSORY CTR COM; Tiffin J., 1968, PURDUE PEGBOARD EXAM; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Western Psychological Services, 1983, HOOP VIS ORG TEST VO; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	61	19	19	0	2	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV	1997	11	4					391	401		10.1080/13854049708400468			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	136GW	WOS:000076851900006					2021-06-18	
J	Nilsson, F; Nilsson, T; Edvinsson, L; Bjorkman, S; Nordstrom, CH				Nilsson, F; Nilsson, T; Edvinsson, L; Bjorkman, S; Nordstrom, CH			Effects of dihydroergotamine and sumatriptan on isolated human cerebral and peripheral arteries and veins	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						human; cerebral arteries; cerebral veins; dihydroergotamine; sumatriptan; in vitro	SEVERE HEAD-INJURY; EXPERIMENTAL INTRACRANIAL HYPERTENSION; TRAUMATIC BRAIN-LESIONS; BLOOD-FLOW; 5-HT1-LIKE RECEPTOR; HEALTHY-SUBJECTS; BASILAR ARTERY; 5-HYDROXYTRYPTAMINE; INDOMETHACIN; VASOCONSTRICTION	Background: Pharmacological cerebral vasoconstriction has recently been suggested as treatment for patients with increased intracranial pressure (ICP) after severe traumatic brain lesions. Hypothetically, a moderate constriction of precapillary resistance vessels might be advantageous since it decreases intracapillary blood pressure, and a contraction of cerebral veins might effectively reduce intracranial blood volume and ICP. This report examines the in vitro effects of two vasoconstrictors, dihydroergotamine (DHE) and sumatriptan, which may be considered for treatment of increased ICP. Methods: The reactivity of isolated small human cerebral, subcutaneous and omental arteries and veins were studied during exposure to different concentrations of DHE and sumatriptan. Results: Both sumatriptan and DHE induced concentration-dependent contractions in human cerebral arteries and veins and 50% of maximum contractions were obtained at significantly lower concentrations of DHE than of sumatriptan. The maximum contraction of cerebral arteries was significantly higher with sumatriptan than with DHE. Both drugs caused contractions of subcutaneous arteries at concentrations of 10(-7)-10(-6)M, which is within the therapeutic concentration range of sumatriptan, while no effect was obtained in omental vessels. Conclusions: Both DHE and sumatriptan cause contraction of isolated human cortical arteries and veins at very low concentrations. The differences observed between the two drugs may be explained by the fact that DHE is an or-adrenergic as well as a 5-HT agonist while sumatriptan acts specifically on 5-HT receptors. The study supports the hypothesis underlying the use of DHE for the treatment of increased ICP in patients with severe traumatic brain lesions.	MALMO UNIV HOSP,DEPT ANAESTHESIA & INTENS CARE & EXPT RES,MALMO,SWEDEN; MALMO UNIV HOSP,HOSP PHARM,MALMO,SWEDEN; UNIV LUND HOSP,DEPT INTERNAL MED,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN				Edvinsson, Lars/0000-0002-1805-1346			ANDERSEN AR, 1987, STROKE, V18, P120, DOI 10.1161/01.STR.18.1.120; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; AUER LM, 1984, CEREBRAL VENOUS SYST, P169; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; CONNOR HE, 1989, BRIT J PHARMACOL, V96, P379, DOI 10.1111/j.1476-5381.1989.tb11828.x; CUNNINGHAM M, 1984, BRIT J SURG, V71, P829, DOI 10.1002/bjs.1800711106; EDVINSSON L, 1971, ACTA PHYSIOL SCAND, V83, P42, DOI 10.1111/j.1748-1716.1971.tb05049.x; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P253; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P354; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FENIUK W, 1989, BRIT J PHARMACOL, V96, P83, DOI 10.1111/j.1476-5381.1989.tb11787.x; FOWLER PA, 1991, EUR NEUROL, V31, P291, DOI 10.1159/000116756; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; HACHINSKI V, 1978, STROKE, V9, P594, DOI 10.1161/01.STR.9.6.594; HARDEBO JE, 1987, J CEREBR BLOOD F MET, V7, P612, DOI 10.1038/jcbfm.1987.113; HOGESTATT ED, 1983, ACTA PHYSIOL SCAND, V117, P49, DOI 10.1111/j.1748-1716.1983.tb07178.x; HOYER D, 1994, PHARMACOL REV, V46, P157; HUMPHREY PPA, 1991, TRENDS PHARMACOL SCI, V12, P444, DOI 10.1016/0165-6147(91)90630-B; JANSEN I, 1993, ACTA PHYSIOL SCAND, V147, P141, DOI 10.1111/j.1748-1716.1993.tb09483.x; JANSEN I, 1992, CEPHALALGIA, V12, P202, DOI 10.1046/j.1468-2982.1992.1204202.x; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; LEE TJF, 1994, AM J PHYSIOL, V266, pH1000; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MCCARTHY BG, 1989, HEADACHE, V29, P420, DOI 10.1111/j.1526-4610.1989.hed2907420.x; MELLANDER S, 1970, CLIN SCI, V39, P183, DOI 10.1042/cs0390183; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1994, INTENS CARE MED, V20, P249, DOI 10.1007/BF01708957; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MULLER H, 1988, PHARMACOLOGY, V37, P248, DOI 10.1159/000138473; NILSSON F, 1995, ANESTHESIOLOGY, V83, P1283, DOI 10.1097/00000542-199512000-00019; Nilsson F, 1996, ACTA ANAESTH SCAND, V40, P612, DOI 10.1111/j.1399-6576.1996.tb04497.x; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P916, DOI 10.1111/j.1399-6576.1995.tb04198.x; OWMAN CH, 1983, CEREBRAL VEINS, P203; PARSONS AA, 1989, BRIT J PHARMACOL, V96, P434, DOI 10.1111/j.1476-5381.1989.tb11835.x; RORARIUS M, 1985, ANN CLIN RES, V17, P306; SAYAMA I, 1983, CEREBRAL VEINS, P273; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SCHUTTA HS, 1968, BRAIN, V91, P281, DOI 10.1093/brain/91.2.281; WALSHE JJ, 1979, ANN INTERN MED, V91, P47, DOI 10.7326/0003-4819-91-1-47; Wennmalm A, 1984, Arch Toxicol Suppl, V7, P350; WYSS PA, 1991, EUR J CLIN PHARMACOL, V41, P597, DOI 10.1007/BF00314992; YADA K, 1973, J NEUROSURG, V39, P723, DOI 10.3171/jns.1973.39.6.0723	49	19	20	0	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	1997	41	10					1257	1262		10.1111/j.1399-6576.1997.tb04641.x			6	Anesthesiology	Anesthesiology	YJ915	WOS:A1997YJ91500005	9422289				2021-06-18	
J	Raskin, SA				Raskin, SA			The relationship between sexual abuse and mild traumatic brain injury	BRAIN INJURY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; URINARY CATECHOLAMINE EXCRETION; HEAD-INJURY; SCALE; NORADRENALINE; CONCUSSION; SURVIVORS; SYMPTOMS	It remains unclear why some individuals with mild traumatic brain injury (MTBI) complain of cognitive deficits many months after the injury. Given neuropathological changes associated with prolonged stress, such as occurs with repeated sexual abuse (SA), it seems possible that individuals who experienced SA might be predisposed to greater deficits after MTBI. Four groups of subjects were administered measures of cognitive and emotional functioning. These groups were those with MTBI (n = 10), those with a history of SA (n = 10), those with both MTBI and SA (n = 10), and normal control (NC) subjects (n = 10). Copared to the NC subjects, those with MTBI demonstrated deficits in working memory, those with SA demonstrated deficits in executive functioning, and those with both MTBI and SA demonstrated the greatest number of deficits which were in working memory, executive functioning and memory. Tests of anxiety, depression and post-traumatic stress disorder, while demonstrating significant symptoms in all clinical groups, did not correlate with the neuropsychological tests that differentiated the groups.	TRINITY COLL, PROGRAM NEUROSCI, HARTFORD, CT 06106 USA	Raskin, SA (corresponding author), TRINITY COLL, DEPT PSYCHOL, LIFE SCI CTR, HARTFORD, CT 06106 USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			BECK A, 1997, BECK ANXIETY INVENTO; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; Blake D., 1990, CLIN ADM PTSD SCALE; BLANCHARD H, 1986, J NERV MENT DIS, V174, P727; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; DAVIDOFF DA, 1988, COGNITIVE REHABILITA, V6, P8; DEBELLIS MD, 1994, J AM ACAD CHILD PSY, V33, P320, DOI 10.1097/00004583-199403000-00004; DELIS D, 1983, CALIFORNIA VERBAL LE; Derogatis L.R., 1983, SCL 90 R; DINKLAGE D, 1993, 21 ANN M INT NEUR SO; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; FADEN A, SCIENCE, V244, P798; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; Gill T., 1990, J TRAUMA STRESS, V3, P29, DOI DOI 10.1002/JTS.2490030104; GLAVIN GB, 1985, NEUROSCI BIOBEHAV R, V9, P233, DOI 10.1016/0149-7634(85)90048-X; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KAY T, 1992, REHABILITATION POST, P109; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V48, P556; LYETH BG, 1992, J NEUROTRAUMA S2, V9, P463; MATEER CA, 1992, PHYSICAL MED REHABIL, V6, P143; McNair DM, 1981, EITS MANUAL PROFILE; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; MOORE A, 1993, 21 ANN M INT NEUR SO; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; RASKIN S, 1994, INT NEUR SOC ANG FRA; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; SANDEL ME, 1990, ARCH PHYS MED REHAB, V71, P523; SAPORTA JA, 1993, CLIN PRAC, V27, P101; SARNO JE, 1973, ARCH PHYS MED REHAB, V54, P214; SHERMAN AD, 1980, BEHAV NEURAL BIOL, V30, P119, DOI 10.1016/S0163-1047(80)91005-5; Shipley W., 1939, SHIPLEY I LIVING SCA; SIMSON PE, 1988, NEUROPSYCHOPHARMACOL, V1, P287; Smith A., 1973, SYMBOL DIGIT MODALIT; SOHLBERG M, 1989, ATTENTION PROCESS TE; SUTKER PB, 1995, NEUROPSYCHOLOGY, V9, P118, DOI 10.1037/0894-4105.9.1.118; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TSUDA A, 1985, BEHAV NEUROSCI, V99, P802; VANDERKOLK B, 1985, BIOL PSYCHIAT, V20, P314, DOI 10.1016/0006-3223(85)90061-7; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; YEHUDA R, 1992, J NERV MENT DIS, V180, P321, DOI 10.1097/00005053-199205000-00006; YEHUDA R, 1995, AM J PSYCHIAT, V152, P982	53	19	19	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1997	11	8					587	603		10.1080/026990597123287			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XL930	WOS:A1997XL93000004	9251867				2021-06-18	
J	Bostrom, L				Bostrom, L			Injury panorama and medical consequences for 1158 persons assaulted in the central part of Stockholm, Sweden	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article							VIOLENCE; BLUNT	This retrospective study describes assaults, type of trauma, injury panorama, the abbreviated injury scale score and medical consequences for 1158 assaulted persons. All patients were examined by surgeons at the Emergency Department, Sabbatsberg's hospital, Stockholm, Sweden, which is open around the clock. The police were not notified. The study group included all assaulted patients who attended and were examined at the Emergency Department from 1 April 1992 to 31 March 1993: 84% men and 16% women. Their median age was 25 years (range 13-86 years). Sixty-eight percent arrived at the Emergency Department between 11 p.m. and 4 a.m. In 44% the hospital staff registered in the case notes that the victims were drunk. Blunt trauma of low-energy type predominated, 44% were hit by fists and 30% by kicks. Penetrating trauma occurred in 10% of the assaults (knife 8%), and a combination of blunt and/or cutting trauma (bottle/glass) in 10%. Eighty-two percent of the victims suffered an injury to the head, resulting in concussion in 116 cases, 4 skull fractures, 1 intracerebral contusion, 74 fractures of nose bones, 17 fractures of other face bones, and 6 mandible fractures. Two persons died because of knifestab wounds. Eighty-two percent of the victims had minor injuries, and 16% had moderate injuries according to the score on the Abbreviated Injury Scale (AIS). The present study shows that assault in the central part of Stockholm, Sweden, is mainly a problem involving young men, especially late in the evening, and that many of the victims are drunk. Injuries to the head due to low-energy trauma are the most common (hit by fists and kicks), but severe injuries seldom occur.		Bostrom, L (corresponding author), KAROLINSKA INST,SODER HOSP,DEPT SURG,S-11883 STOCKHOLM,SWEDEN.						ASSOCIATION OF THE EUROPEAN SELF MEDICATION INDUSTRY. AESGP, 1990, ABBR INJ SCAL, P1; Bostrom L, 1994, Lakartidningen, V91, P3801; Bostrom L, 1994, Lakartidningen, V91, P3981; BROWN CRS, 1993, INJURY, V24, P25, DOI 10.1016/0020-1383(93)90077-J; CESARE J, 1990, J TRAUMA, V30, P176, DOI 10.1097/00005373-199002000-00007; DYSTING M, 1993, FACE STREET VIOLENCE, P1; GROLEAU GA, 1993, J TRAUMA, V34, P366, DOI 10.1097/00005373-199303000-00010; LAYTON S, 1994, INJURY, V25, P523, DOI 10.1016/0020-1383(94)90094-9; Lenke L., 1990, ALCOHOL CRIMINAL VIO; LIDBERG L, 1994, LAKARTIDNINGEN, V92, P2739; MURDOCH D, 1990, INT J ADDICT, V25, P1065, DOI 10.3109/10826089009058873; ORD RA, 1995, J ORAL MAXIL SURG, V53, P514, DOI 10.1016/0278-2391(95)90061-6; SHEPHERD JP, 1990, J ROY SOC MED, V83, P75, DOI 10.1177/014107689008300206; VANGELDERMALSEN AA, 1993, J TROP MED HYG, V96, P93; Wilhelmson B, 1994, Lakartidningen, V91, P4792	15	19	20	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0936-8051			ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	JUL	1997	116	6-7					315	320					6	Orthopedics; Surgery	Orthopedics; Surgery	XM777	WOS:A1997XM77700001	9266031				2021-06-18	
J	SchmitterEdgecombe, M; Rogers, WA				SchmitterEdgecombe, M; Rogers, WA			Automatic process development following severe closed head injury	NEUROPSYCHOLOGY			English	Article							PERFORMANCE; SEARCH; MEMORY; CATEGORY; CONSISTENCY; SKILL; TASK	Automatic process development was investigated in a closed head injury (CHI) population. Ten severe CHI participants (>1 year postinjury) and 10 matched controls completed consistent mapping (CM) and varied mapping (VM) semantic-category memory search tasks. In VM search, despite a similar pattern of serial memory search, the CHI participants responded slower than controls and exhibited slower memory search rates throughout practice (1,800 trials). In CM search, after extensive practice (1,800 trials) both groups showed the performance characteristics indicative of automatic process development, that is, near-zero slopes and large reductions in response times. However, the CHI participants were slower to automatize the task. These results indicate that for memory-based search tasks the effects of a CHI may slow down the speed with which automatic processes develop but that CHI participants can acquire and use automatic processes in task performance.	UNIV GEORGIA,DEPT PSYCHOL,ATHENS,GA 30602	SchmitterEdgecombe, M (corresponding author), WASHINGTON STATE UNIV,DEPT PSYCHOL,BOX 644820,PULLMAN,WA 99164, USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG07654] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [G42658S1] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG007654] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; CATTELL RB, 1973, HDB INDIVIDUAL GROUP; CLARK JL, 1994, P HUM FACT ERG SOC 3; COLLEN A, 1975, J EXP PSYCHOL-HUM L, V1, P629; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; Fisk A. D., 1991, MULTIPLE TASK PERFOR, P415; FISK AD, 1992, COGNITIVE APPROACHES TO AUTOMATED INSTRUCTION, P171; FISK AD, 1992, HUM FACTORS, V34, P693, DOI 10.1177/001872089203400604; FISK AD, 1991, HUM FACTORS, V33, P267; FISK AD, 1988, HUM FACTORS, V30, P703, DOI 10.1177/001872088803000606; FISK AD, 1983, J EXP PSYCHOL LEARN, V9, P177, DOI 10.1037/0278-7393.9.2.177; FISK AD, 1987, HUMAN FACTORS PSYCHO, P159; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; JR Anderson., 1981, COGNITIVE SKILLS THE, P1; Kaplan E., 1987, MANUAL CALIFORNIA VE; KRAMER AF, 1990, J EXP PSYCHOL HUMAN, V16, P505; KRAMER AF, 1991, PSYCHOPHYSIOLOGY, V28, P425, DOI 10.1111/j.1469-8986.1991.tb00726.x; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LOGAN GD, 1985, CAN J PSYCHOL, V39, P367, DOI 10.1037/h0080066; MERRILL E. C., 1990, INT REV RES MENT RET, V16, P51; Miller E, 1970, Cortex, V6, P121; ROGERS WA, 1994, J EXP PSYCHOL LEARN, V20, P710, DOI 10.1037/0278-7393.20.3.710; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SCHNEIDER W, 1988, BEHAV RES METH INSTR, V20, P206, DOI 10.3758/BF03203833; SCHNEIDER W, 1984, J EXP PSYCHOL LEARN, V10, P1; SCHNEIDER W, 1982, PERCEPT PSYCHOPHYS, V31, P160, DOI 10.3758/BF03206216; Schneider W., 1985, ATTENTION PERFORM, P475; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SHIFFRIN RM, 1988, STEVENS HDB EXPT PSY, V1, P739; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; STRAYER DL, 1994, PSYCHOL AGING, V9, P589, DOI 10.1037/0882-7974.9.4.589; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WHALEY CJ, 1993, HUM FACTORS, V35, P639	48	19	19	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	APR	1997	11	2					296	308		10.1037/0894-4105.11.2.296			13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	WT569	WOS:A1997WT56900013	9110336				2021-06-18	
J	Max, JE; Dunisch, DL				Max, JE; Dunisch, DL			Traumatic brain injury in a child psychiatry outpatient clinic: A controlled study	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children and adolescents; psychiatric outpatients	HEAD-INJURIES; SEQUELAE	Objective: To demonstrate the similarity of children with a history of traumatic brain injury (TBI), particularly mild TBI, to matched children without such a history, within a child psychiatry outpatient clinic. Method: This is a chart review of patients presenting to a child psychiatry outpatient clinic over a 3-year period. Children with TBI were matched by age, sex, race, and social class to children with no history of TBI. Axis I and II diagnoses, use of special education services, and IQ scores were compared. Results: Seventy-four (5.6%) of 1,333 consecutive clinic cases had a definite TBI. Of these, 64 were mild. Only 3 of 59 comparisons that were made between TBI and control subjects were significant. A developmental communication disorder cluster was significantly more frequent in the TBI group. Autism and a pervasive developmental disorder cluster were significantly more frequent in the control group. Conclusion: In a child psychiatry clinic, patients with a history of TBI are virtually indistinguishable from matched children without TBI. Caution should be exercised before attributing the child's problems, especially long-term problems, to the TBI unless the injury was severe or the child is exhibiting related phobic or posttraumatic stress symptomatology.	UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242							American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GILLBERG C, 1995, CLIN CHILD NEUROPSYC, P274; HARRINGTON JA, 1958, J MENT SCI, V104, P1205; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; MARTINI DR, 1992, SCI P 39 ANN M AM AC, V8; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MAX JE, IN PRESS J NERV MENT; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; *SPSS, 1993, SPSS WIND PROOF STAT; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81	23	19	19	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAR	1997	36	3					404	411		10.1097/00004583-199703000-00020			8	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	WK274	WOS:A1997WK27400020	9055522				2021-06-18	
J	Osberg, JS; Brooke, MM; Baryza, MJ; Rowe, K; Lash, M; Kahn, P				Osberg, JS; Brooke, MM; Baryza, MJ; Rowe, K; Lash, M; Kahn, P			Impact of childhood brain injury on work and family finances	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; CHILDREN; TRAUMA; MORBIDITY; VIOLENCE	Parents of children who suffer brain injuries are often surprised by the extent to which work and family finances are disrupted In this paper, work and financial problems are described, predictors are identified, and ways to minimize problems are discussed. Eighty-two children treated at two Massachusetts trauma centres were given an extensive battery of medical, functional and psychosocial tests during hospitalization. At 1 and 6 months post-discharge they were retested and their parents were surveyed about work and financial difficulties. Trouble maintaining regular work schedules and injury-related financial problems were common. At highest risk for work and financial problems were families of children with severe injuries who had four to nine impairments, along with children hospitalized >2 weeks who were not discharged to home. Surprisingly, families with HMO coverage reported significantly fewer financial problems, and this relationshp was not due to differences in socioeconomic status or injury severity. Health-care providers need to pay more attention to the potential impact of injury on work and family finances. Providers can help at-risk families muster child-care services, deal effectively with employers and insurance companies, and plan for the future.	TUFTS UNIV, SCH MED, DEPT PHYS MED & REHABIL, BOSTON, MA 02111 USA; SHRINERS BURN INST, BOSTON, MA 02114 USA	Osberg, JS (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT PHYS MED & REHABIL, 750 WASHINGTON ST, 75K-R, BOSTON, MA 02111 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR102330] Funding Source: Medline		*AM PSYCH ASS, 1994, DSM3R683 AM PSYCH AS; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BACHYRITA, 1989, COMPREHENSIVE NEUROL, V2; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; DEJONG G, 1983, SCI AM, V248, P40, DOI 10.1038/scientificamerican0683-40; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; Greenspan A I, 1989, Md Med J, V38, P239; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; HORN L, 1992, PHYS MED REHABILITAT, P475; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KRAUS JF, 1987, PEDIATRICS, V79, P501; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; Livingston MG., 1990, REHABILITATION ADULT, P225; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; OSBERG JS, 1988, AM J PHYS MED REHAB, V67, P66, DOI 10.1097/00002060-198804000-00006; OSBERG JS, 1996, IN PRESS PEDIATRICS; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pope AM, 1991, DISABILITY AM NATL A; RESNICK C, 1993, SOC WORK HEALTH CARE, V18, P49, DOI 10.1300/J010v18n02_03; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; ROSENTHAL M, 1989, COMPREHENSIVE NEUROL, V2, P191; ROSENTHAL M, 1990, REHABILITATION ADULT; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHUMAN D, 1994, KAN L REV, V43, P39; SHALALA DE, 1993, HEALTH AFFAIR, V12, P30, DOI 10.1377/hlthaff.12.4.30; STEIN REK, 1985, TABLE DOCUMENTING PS; Testani-Dufour L, 1992, J Neurosci Nurs, V24, P317; WALKER B, 1992, J NATL MED ASSOC, V84, P490	35	19	19	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1997	11	1					11	24					14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300002	9012548				2021-06-18	
J	DAmato, RC; Rothlisberg, BA				DAmato, RC; Rothlisberg, BA			How education should respond to students with traumatic brain injury	JOURNAL OF LEARNING DISABILITIES			English	Article							LEARNING-DISABILITIES; TRANSITION; CHILDREN	This article focuses on the educational implications of traumatic brain injury (TBI). It details the conceptual issues surrounding TBI and discusses how assessment of this group differs from that of other groups with disabilities. Finally, the article offers suggestions for an integrated intervention approach based on the idea of bringing order to the life experiences of these students. The S. O. S. (Structure, Organization, and Strategy) Approach offers a framework from which to consider the variable needs of these learners.	BALL STATE UNIV,MA EDS PROGRAM SCH PSYCHOL,MUNCIE,IN 47306	DAmato, RC (corresponding author), UNIV NO COLORADO,SCH PSYCHOL PROGRAM,PPSY DIV,CLIN NEUROPSYCHOL LAB,MCKEE 248,GREELEY,CO 80639, USA.						ADAMS L, 1991, GUIDELINES PAPER TRA; BEGALI V, 1994, ED DIMENSIONS ACQUIR, P453; Bigler E. D., 1989, HDB CLIN CHILD NEURO, P557; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; Blosser JL, 1991, J HEAD TRAUMA REHAB, V6, P73; BLOSSER JL, 1994, ED DIMENSIONS ACQUIR, P413; Bruce D., 1990, REHABILITATION ADULT, P521; Cohen S. B., 1986, J HEAD TRAUMA REHAB, V1, P22; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; D'Amato R. C., 1990, SCHOOL PSYCHOL QUART, V5, P141; DAMATO RC, 1987, PROFESSIONAL SCH PSY, V2, P93; DAMATO RC, IN PRESS HDB CLIN CH; DAMATO RC, 1991, ANN M NAT ASS SCH PS; DAMATO RC, 1992, PSYCHOL PERSPECTIVES; DEAN RS, 1990, HDB PSYCHOL ED ASSES, P371; Deaton A., 1990, TRAUMATIC BRAIN INJU, P231; DENNIS M, 1992, TOP LANG DISORD, V13, P66, DOI 10.1097/00011363-199211000-00008; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FLETCHER JM, 1984, J CLIN NEUROPSYCHOL, V6, P39, DOI 10.1080/01688638408401195; Gaddes W.H., 1994, LEARNING DISABILITIE; GRAY JW, 1989, HDB CLIN CHILD NEURO, P397; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; HAMMILL D, 1991, DETROIT TESTS LEARNI; HARRINGTON DE, 1990, REHABILITATION ADULT, P476; HARTLAGE LC, 1983, J LEARN DISABIL, V16, P521, DOI 10.1177/002221948301600904; HILL RB, 1994, UNPUB INTERACTION TE; HYND GW, 1988, PEDIAT NEUROPSYCHOLO; Jaffe K. M., 1990, REHABILITATION ADULT, P539; Kaufman A. S., 1979, INTELLIGENT TESTING; Kaufman A. S., 1990, ASSESSING ADOLESCENT; KAUFMAN AS, 1979, J RES DEV EDUC, V12, P96; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEU PW, 1994, ANN M NAT ASS SCH PS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; *LOS AM RES ED I, 1990, RANCH LOS AM SCAL CO; *MED EC DAT, 1993, PDR FAM GUID PRESCR; MERRELL KW, 1994, ASSESSMENT BEHAV SOC; POSTHILL SM, 1991, J LEARN DISABIL, V24, P619, DOI 10.1177/002221949102401005; PRIGATANO GP, 1990, TRAUMATIC BRAIN INJU, P273; REIFF HB, 1992, LEARN DISABILITY Q, V15, P237, DOI 10.2307/1511316; REYNOLDS CR, 1989, HDB CLIN CHILD NEURO; ROJEWSKI JW, 1992, LEARN DISABILITY Q, V15, P135, DOI 10.2307/1511015; Rosen CD, 1986, HEAD TRAUMA ED REINT; Russell N, 1993, LANG SPEECH HEAR SER, V24, P67; RUTTER M, 1983, DEV NEUROPSYCHIATRY; SACHS PR, 1993, REHABIL PSYCHOL, V38, P87, DOI 10.1037/h0080294; SATTLER JM, 1992, ASSESSMENT CHILDRENS; Savage RC, 1987, J HEAD TRAUMA REHAB, V2, P1; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; SCAHS PR, 1991, TREATING FAMILIES BR; SCUCCIMARRA DJ, 1990, J LEARN DISABIL, V23, P213, DOI 10.1177/002221949002300403; SOAR RS, 1979, RES TEACHING CONCEPT, P271; TAYLOR HG, 1987, DEV NEUROPSYCHOL, V3, P153, DOI 10.1080/87565648709540371; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1985, NEUROPSYCHOLOGY INDI, P271; TELZROW CF, 1990, TRAUMATIC BRAIN INJU, P251; *UT TBI TASK FORC, 1994, UT TRAUM BRAIN INJ T; WEDDING D, 1986, HDB CLIN BEHAV NEURO; WHITTEN JC, 1992, PSYCHOL PERSPECTIVES, P112; YLVISAKER M, 1990, REHABILITATION ADULT, P521	61	19	19	0	4	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1996	29	6					670	683		10.1177/002221949602900611			14	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	VU234	WOS:A1996VU23400011	8942311				2021-06-18	
J	Burg, JS; McGuire, LM; Burright, RG; Donovick, PJ				Burg, JS; McGuire, LM; Burright, RG; Donovick, PJ			Prevalence of traumatic brain injury in an inpatient psychiatric population	JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS			English	Article						traumatic brain injury; psychiatric patients; neuropsychology; Head Injury Questionnaire; health psychology	HEAD-INJURY; SEQUELAE	This study investigated the prevalence of traumatic brain injury (TBI) in an inpatient psychiatric population. We hypothesized increased prevalence of TBI relative to the general population due to a variety of risk factors observed in psychiatric patients. One hundred (mean age=34) psychiatric inpatients completed the revised Head Injury Questionnaire. Chart review of 17 subjects reporting injuries established whether injuries were documented in medical records. Sixty-eight percent of this psychiatric population reported one or more injuries in which they were unconscious or dazed This number is higher than the prevalence in the general population. Injuries were generally of mild to moderate severity; multiple injuries were common. Chart review of 17 subjects reporting TBI indicated that histories of TBI had not been noted in the medical record. Finally, 63% of TBI subjects reported that their injury predated the onset of their psychiatric symptoms These results suggest a possible role of TBI in psychiatric symptomatology, and have implications for psychiatric treatment in this population.	SUNY BINGHAMTON,DEPT PSYCHOL,ENVIRONM NEUROPSYCHOL LAB,BINGHAMTON,NY 13902; UNITED HLTH SERV,DEPT PSYCHIAT & NEUROSCI,BINGHAMTON,NY							CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; Kraus Jess F., 1994, P3; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; Robinson Robert G., 1994, P219; SEGALOWITZ SJ, 1993, M INT NEUR SOC GALV; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Taylor Craig A., 1994, P81; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	10	19	19	0	3	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	1068-9583			J CLIN PSYCHOL MED S	J. Clin. Psychol. Med. Settings	SEP	1996	3	3					243	251		10.1007/BF01993910			9	Psychology, Clinical	Psychology	VJ512	WOS:A1996VJ51200006	24226761				2021-06-18	
J	Stein, SC				Stein, SC			Management of minor closed head injury	NEUROSURGERY QUARTERLY			English	Article						head injury; intracranial hematoma; cranial computed tomography	TRAUMATIC INTRACRANIAL HEMATOMA; BRAIN INJURY; COMPUTED-TOMOGRAPHY; CLINICAL INDICATORS; MODERATE; MILD; CHILDREN; CT; RISK; ADMISSION	The literature on the diagnosis and treatment of minor closed head injury (CHI) in the computed tomography (CT) scan era was reviewed. Working definitions were developed for the categories of minor CHI (minimal, mild, and moderate), and the natural history of each category was reviewed. The risks of intracranial complications and surgical lesions were calculated for each category. For minimal CHI, they are almost no risks, for mild CHI, the risks are 15% and 2.5%, respectively. Patients with moderate CHI can expect an intracranial lesion rate of 30%; 8% require neurosurgical intervention. Additional evidence was documented from the literature to allow comparisons among various treatment options with reference to clinical outcomes. It is concluded that most patients with minimal CHI can be safely discharged from the Emergency Department (ED) unless risk factors, which might indicate the need for CT scanning or hospitalization, are present. Those having mild CHI should have urgent CT scanning; patients in whom the scan is normal can be safely discharged from the ED. Moderate CHI requires both hospital admission and urgent CT scanning. Based on the natural history evidence of similar risk in children and adolescents, the same recommendations are made in the pediatric age group with minor CHI. Cost factors and the public health impact of this management scheme are discussed.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,COOPER HOSP,MED CTR,DEPT SURG,CAMDEN,NJ 08103							ANDERSON DW, 1983, NEUROEPIDEMIOLOGY, V2, P70; Bailey B. N., 1989, TXB HEAD INJURY, P308; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; CHAN KH, 1990, CHILD NERV SYST, V6, P27, DOI 10.1007/BF00262262; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DERSHEWITZ RA, 1983, PEDIATRICS, V72, P602; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; EISENBERG HM, 1989, MILD MODERATE HEAD I, P95; GODANO U, 1992, CHILD NERV SYST, V8, P136, DOI 10.1007/BF00298269; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANGFITT TW, 1981, CLIN NEUROSURG, V29, P353; LIGUORI G, 1989, CHILD NERV SYST, V5, P160, DOI 10.1007/BF00272119; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; MIKHAIL MG, 1992, AM J EMERG MED, V10, P24, DOI 10.1016/0735-6757(92)90119-I; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MILLER JD, 1989, MILD MODERATE HEAD I, P117; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; PITTS LH, 1989, MILD MODERATE HEAD I, P107; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIVERA F, 1987, PEDIATRICS, V80, P579; ROS S P, 1989, Pediatric Emergency Care, V5, P216, DOI 10.1097/00006565-198912000-00003; ROS SP, 1992, PEDIATR EMERG CARE, V8, P328, DOI 10.1097/00006565-199212000-00005; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; SAINSBURY CPQ, 1984, ARCH DIS CHILD, V59, P856, DOI 10.1136/adc.59.9.856; Schafermeyer Robert, 1993, Emergency Medicine Clinics of North America, V11, P187; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE G, 1989, MILD MODERATE HEAD I, P227; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TEPAS JJ, 1989, J PEDIATR SURG, V24, P156, DOI 10.1016/S0022-3468(89)80237-4; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZIMMERMAN RA, 1981, J NEURORADIOLOGY, V8, P257	49	19	19	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	1050-6438			NEUROSURG QUART	Neurosurg. Q.	JUN	1996	6	2					108	115		10.1097/00013414-199606000-00004			8	Neurosciences; Surgery	Neurosciences & Neurology; Surgery	UL555	WOS:A1996UL55500004					2021-06-18	
J	Wetter, MW; Deitsch, SE				Wetter, MW; Deitsch, SE			Faking specific disorders and temporal response consistency on the MMPI-2	PSYCHOLOGICAL ASSESSMENT			English	Article							COLLEGE-STUDENTS	The ability of persons faking posttraumatic stress disorder (PTSD) or closed-head injury (CHI) to respond consistently across serial testings on the Minnesota Multiphasic Personality Inventory-2 (MMPI-2; J. Butcher, W. Dahlstrom, J. Graham, A. Tellegen, & B. Kaemmer, 1989) was investigated. Results showed that individuals faking PTSD obtained 2-week test-retest reliability scores comparable to individuals completing the MMPI-2 with standard instructions; individuals faking CHI obtained reliability coefficients significantly lower than individuals faking PTSD. A 3 X 2 (Response Style X Time) analysis of variance indicated that individuals faking a disorder obtained significantly elevated scores on validity scales sensitive to overreporting; no main effect for time was found. Results suggest that test-takers faking specific disorders can describe symptoms consistently on repeated testing and that type of disorder may affect temporal response consistency.		Wetter, MW (corresponding author), UNIV KENTUCKY,DEPT PSYCHOL,KASTLE HALL,LEXINGTON,KY 40506, USA.						ARBISI PA, 1993, 28 ANN S REC DEV MMP; BALDINGER B, 1995, TRIAL, V31, P56; BEE C, 1994, TRIAL, V30, P54; Butcher J.N., 1989, MANUAL RESTANDARIZED; BUTCHER JN, 1990, J PERS ASSESS, V54, P1, DOI 10.1207/s15327752jpa5401&2_1; Cullum C, 1991, FORENSIC NEUROPSYCHO, P141; Dickens S. E., 1992, STRUCTURED INTERVIEW; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GOUGH HG, 1947, J ABNORM SOC PSYCH, V42, P215, DOI 10.1037/h0063295; Graham JR, 1993, MMPI 2 ASSESSING PER; Lamb DG, 1994, PSYCHOL ASSESSMENT, V6, P8; Lees-Haley P. R., 1992, AM J FORENSIC PSYCH, V10, P25; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; MATZ PA, 1992, J CLIN PSYCHOL, V48, P330, DOI 10.1002/1097-4679(199205)48:3<330::AID-JCLP2270480310>3.0.CO;2-3; PLATT J, 1986, AM J FORENSIC PSYCH, V4, P29; POPE KS, 1993, MMPI MMPI 2 MMPI A C; ROGERS R, 1993, J PERS ASSESS, V60, P215, DOI 10.1207/s15327752jpa6002_1; ROGERS R, 1988, CLIN ASSESSMENT MALI, P309; SCHRETLEN D, 1992, PSYCHOL ASSESSMENT, V4, P77; SCHRETLEN DJ, 1988, CLIN PSYCHOL REV, V8, P451, DOI 10.1016/0272-7358(88)90074-8; Wetter M. W., 1993, PSYCHOL ASSESSMENT, V5, P317; ZIELINSKI JJ, 1994, CLIN PSYCHOL-SCI PR, V1, P169, DOI 10.1111/j.1468-2850.1994.tb00018.x; ZISKIN J, 1988, COPING PSYCHIAT PSYC, V2	23	19	19	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	MAR	1996	8	1					39	47					9	Psychology, Clinical	Psychology	UB448	WOS:A1996UB44800006					2021-06-18	
J	Boswell, WC; Boyd, CR; Schaffner, D; Williams, JS; Frantz, E				Boswell, WC; Boyd, CR; Schaffner, D; Williams, JS; Frantz, E			Prevention of pediatric mortality from trauma: Are current measures adequate?	SOUTHERN MEDICAL JOURNAL			English	Article							ALL-TERRAIN VEHICLES; INJURY SEVERITY; HEAD-INJURIES; BICYCLISTS; VICTORIA; CHILD; CARE	Trauma accounts for nearly half of pediatric deaths in the United States. We reviewed all pediatric trauma-related deaths that occurred over a 5-year period at two Georgia trauma centers to determine the number of trauma deaths in children, mechanism of injury, cause of death, and compliance with safety standards. Of the 69 fatalities, 31 were caused by motor vehicle accidents. Twenty-five of these victims (81%) were unrestrained; 17 were 4 years old or less, and only 1 of them was restrained in a car seat. Pedestrian versus vehicle accidents resulted in 19 deaths, 10 of the victims being 4 years old or less. Bicycle versus vehicle accidents resulted in 4 deaths, 2 of them due to closed head injury; none of the victims wore headgear. Ah-terrain vehicle accidents resulted in 2 deaths from massive head injury; neither victim wore a helmet. One death occurred from bicycle handlebar injury; 12 deaths resulted from causes other than vehicle accidents. Major causes of pediatric fatalities were motor vehicle accidents (45%), pedestrian-vehicle accidents (28%), and bicycle accidents (6%). This study indicates that when safety measures such as restraint systems, helmets, or proper supervision are ignored, children may die as a result of trauma.	MEM MED CTR,DEPT SURG EDUC,SAVANNAH,GA 31403; MEM MED CTR,TRAUMA SERV,SAVANNAH,GA 31403; SCOTTISH RITE CHILDRENS MED CTR,DEPT SURG,ATLANTA,GA							BROWNE GJ, 1987, PREVENTION COALITION, P65; CYNECKI MJ, 1984, DOT HS806676 PUBL; EVANS L, 1987, J TRAUMA, V27, P746, DOI 10.1097/00005373-198707000-00009; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; FRIEDMAN R, 1988, LARYNGOSCOPE, V98, P1251; GOLLADAY ES, 1985, J TRAUMA, V25, P232, DOI 10.1097/00005373-198503000-00012; HAMILTON SM, 1991, J TRAUMA, V31, P951, DOI 10.1097/00005373-199107000-00011; MCDERMOTT FT, 1982, MED J AUSTRALIA, V2, P30, DOI 10.5694/j.1326-5377.1982.tb124205.x; ORSAY EM, 1988, JAMA-J AM MED ASSOC, V260, P3598, DOI 10.1001/jama.260.24.3598; PAULSON JA, 1981, CLIN PEDIATR, V20, P285, DOI 10.1177/000992288102000409; PETERSON TD, 1991, AM FAM PHYSICIAN, V44, P1307; POLLACK CV, 1990, J TRAUMA, V30, P888, DOI 10.1097/00005373-199007000-00021; SHELNESS A, 1983, SAE CHILD INJURY RES, P207; SHERG RG, 1991, DEC P NAT C CHILD PA; SMITH SM, 1986, JAMA-J AM MED ASSOC, V255, P2454, DOI 10.1001/jama.255.18.2454; SPAITE DW, 1991, J TRAUMA, V31, P1510, DOI 10.1097/00005373-199111000-00008; STEVENS WS, 1986, J PEDIATR-US, V109, P25, DOI 10.1016/S0022-3476(86)80566-2; WAGENAAR AC, 1987, J TRAUMA, V27, P726, DOI 10.1097/00005373-198707000-00006; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; 1990, GOVT OFFICE HIGHWAY; 1987, JAMA-J AM MED ASSOC, V257, P3334	21	19	20	0	2	SOUTHERN MEDICAL ASSN	BIRMINGHAM	35 LAKESHORE DR PO BOX 190088, BIRMINGHAM, AL 35219	0038-4348			SOUTHERN MED J	South.Med.J.	FEB	1996	89	2					218	220		10.1097/00007611-199602000-00012			3	Medicine, General & Internal	General & Internal Medicine	TU577	WOS:A1996TU57700012	8578354				2021-06-18	
J	ALLISON, SC; ABRAHAM, LD				ALLISON, SC; ABRAHAM, LD			CORRELATION OF QUANTITATIVE MEASURES WITH THE MODIFIED ASHWORTH SCALE IN THE ASSESSMENT OF PLANTAR FLEXOR SPASTICITY IN PATIENTS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROLOGY			English	Article						SPASTICITY; ANKLE; REFLEX; VIBRATION; ASHWORTH SCALE	PRESYNAPTIC INHIBITION; HYPERTONIA; MECHANISMS; BACLOFEN; REFLEXES; GAIT	This study of plantar flexor spasticity describes relationships among a traditional qualitative spasticity scale, three potential quantitative spasticity measures and a measure of voluntary ankle muscle function. Thirty-four volunteer adult patients with traumatic brain injuries participated. There were 28 males and 6 females; the mean age was 30.3 years. A battery of five randomly sequenced tests was performed for each subject on one ankle. Tests were: modified Ashworth scale (MAS) scoring; H-reflex testing with and without Achilles tendon vibration; H-reflex testing with and without dorsiflexor contraction; reflex threshold angle and timed toe tapping (TTT). Twenty-six subjects returned to have the second ankle tested, resulting in 60 ankles for the analyses. Spearman's coefficients for correlation of quantitative spasticity measures with MAS scores ranged from 0.39 to 0.49 with associated probabilities less than or equal to 0.002. Pearson coefficients for correlation of quantitative spasticity measures with TTT scores were lower but also significant (P less than or equal to 0.07). Multiple correlation for the set of quantitative measures yielded R = 0.614 (P < 0.001) with MAS scores and R = 0.365 (P = 0.045) with TTT scores. These findings reveal statistically significant relationships of low to moderate strength among potential quantitative spasticity measures, a traditional qualitative spasticity scale and a simple measure of voluntary ankle muscle function. Understanding these relationships is an essential part of the ongoing search for quantitative spasticity measures.	BAYLOR UNIV,ACAD HLTH SCI,GRAD PROGRAM PHYS THERAPY,FT SAM HOUSTON,TX 78234; UNIV TEXAS,DEPT KINESIOL & HLTH EDUC,AUSTIN,TX 78712							ALLISON SC, IN PRESS RELIABILITY; BOHANNON RW, 1987, ARCH PHYS MED REHAB, V68, P777; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOORMAN GI, 1992, ABSTR SOC NEUROSCI, V18, P1408; CRONE C, 1987, J PHYSIOL-LONDON, V389, P163, DOI 10.1113/jphysiol.1987.sp016652; GILLIES JD, 1969, J PHYSIOL-LONDON, V205, P329, DOI 10.1113/jphysiol.1969.sp008968; GIULIANI C, 1988, NEUROL REP, V12, P4; Guilford J. P., 1956, FUNDAMENTAL STATISTI; Hagbarth K.-E., 1973, NEW DEV ELECTROMYOGR, V3, P428; HUGENHOLTZ H, 1992, CAN J NEUROL SCI, V19, P188, DOI 10.1017/S0317167100042244; Hugon M., 1973, NEW DEVELOPMENTS ELE, P277; ILES JF, 1986, J NEUROL NEUROSUR PS, V49, P937, DOI 10.1136/jnnp.49.8.937; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; LANCE JW, 1973, NEW DEVELOPMENTS ELE, V3, P444; LANDAU WM, 1974, ARCH NEUROL-CHICAGO, V31, P217; LATASH ML, 1993, HUMAN KINETICS; LEONARD CT, 1990, DEV MED CHILD NEUROL, V32, P974; LEVIN MF, 1993, J NEUROL, V240, P63, DOI 10.1007/BF00858718; MILANOV I, 1992, J NEUROL, V239, P287; MILANOV IG, 1992, ACTA NEUROL SCAND, V85, P305; NANCE PW, 1989, PARAPLEGIA, V27, P296, DOI 10.1038/sc.1989.44; PIERROTDESEILLI.E, 1990, NEW TRENDS ADV TECHN, P264; ROSE SA, 1991, PHYS THER, V71, P961, DOI 10.1093/ptj/71.12.961; SAHRMANN SA, 1977, ANN NEUROL, V2, P460, DOI 10.1002/ana.410020604; Sloan R L, 1992, Int J Rehabil Res, V15, P158, DOI 10.1097/00004356-199206000-00009	26	19	20	2	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0340-5354			J NEUROL	J. Neurol.	OCT	1995	242	10					699	706		10.1007/BF00866923			8	Clinical Neurology	Neurosciences & Neurology	RZ790	WOS:A1995RZ79000015	8568534				2021-06-18	
J	FLAKOLL, PJ; WENTZEL, LS; HYMAN, SA				FLAKOLL, PJ; WENTZEL, LS; HYMAN, SA			PROTEIN AND GLUCOSE-METABOLISM DURING ISOLATED CLOSED-HEAD INJURY	AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM			English	Article						PROTEOLYSIS; PROTEIN SYNTHESIS; AMINO ACID OXIDATION; GLUCOSE PRODUCTION; HEAD TRAUMA; INSULIN RESISTANCE	AMINO-ACIDS; HYPERGLYCEMIA; INSULIN; PROTEOLYSIS; HUMANS; TRAUMA	Patients with isolated closed-head injuries are characterized by excessive nitrogen loss, hyperglycemia, and increased caloric demand. However, the relative contributions of specific metabolic events such as protein breakdown and synthesis or glucose production and utilization to the physiological changes prevalent during isolated closed-head injury remains unestablished. By use of isotopic dilutions of L-[1-C-13]leucine and D-[3-H-3]glucose, components of protein and glucose metabolism were examined in patients with isolated closed-head injury (n = 7). Normal overnight-fasted volunteers (n = 8) were also studied as a reference point for comparison. Despite prevailing hyperinsulinemia (29 +/- 5 mu U/ml), head-injured patients had elevated plasma leucine concentrations (183 +/- 22 vs. 144 +/- 8 mu mol/l), whole body proteolysis (331 +/- 44 vs. 150 +/- 7 mg . kg(-1). h(-1)), protein synthesis (248 +/- 38 vs. 126 +/- 11 mg . kg(-1). h(-1)), and amino acid oxidation (84 +/- 11 vs. 23 +/- 3 mg . kg(-1). h(-1)). Therefore nitrogen loss normally associated with isolated closed-head injury is primarily due to an increase in the rate of whole body proteolysis, with a greater proportion of the resultant amino acids being oxidized for energy. Furthermore, head-injured patients were hyperglycemic (6.7 +/- 0.3 mu mol/l) with increased rates of glucose turnover (an estimate of production and utilization) compared with the controls (4.0 +/- 0.7 vs. 2.5 +/- 0.2 mg . kg(-1). min(-1)). Hence, these data suggest that head injury, even in the absence of peripheral trauma, induces a physiological state of accelerated metabolism associated with resistance to insulin action.	VANDERBILT UNIV, MED CTR, DEPT BIOCHEM & ANESTHESIOL, NASHVILLE, TN 37232 USA	FLAKOLL, PJ (corresponding author), VANDERBILT UNIV, MED CTR, DEPT SURG, 750 MRB, NASHVILLE, TN 37232 USA.				NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK-26657, DK-20593, DK-43290] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R29DK043290, P60DK020593, P30DK026657] Funding Source: NIH RePORTER		ALDEN PB, 1987, J TRAUMA, V27, P1039, DOI 10.1097/00005373-198709000-00014; ALLSOP JR, 1978, J APPL PHYSIOL, V45, P137; ANTON AH, 1962, J PHARMACOL EXP THER, V138, P306; Bergmeyer H.U, 1971, METHODS ENZYMATIC AN, V1; BOREL MJ, 1993, FRONTIERS ENDOCRINOL, P149; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; DEUTSCHMAN CS, 1987, WORLD J SURG, V11, P182, DOI 10.1007/BF01656401; DRUCKER D, 1985, CRIT CARE MED, V13, P477, DOI 10.1097/00003246-198506000-00007; FLAKOLL PJ, 1993, AM J PHYSIOL, V265, pE715; FLAKOLL PJ, 1994, METABOLISM, V43, P1509, DOI 10.1016/0026-0495(94)90009-4; FLAKOLL PJ, 1989, AM J PHYSIOL, V257, pE839; FREXESSTEED M, 1990, AM J PHYSIOL, V258, pE907; FUKAGAWA NK, 1989, AM J PHYSIOL, V256, pE288; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; JEEVANANDAM P, 1994, AM J PHYSIOL, V266, pE366; JENNET B, 1978, LANCET, V1, P878; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; MATTHEWS DE, 1990, AM J PHYSIOL, V258, pE948; MCCALLISTER B, 1983, J SURG RES, V35, P426, DOI 10.1016/0022-4804(83)90033-1; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; NAIR KS, 1983, DIABETOLOGIA, V25, P400, DOI 10.1007/BF00282518; Ott L, 1990, Nutr Clin Pract, V5, P68, DOI 10.1177/011542659000500268; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; RIZZA RA, 1981, AM J PHYSIOL, V240, pE630; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROBERTSON CS, 1988, J TRAUMA, V28, P1523, DOI 10.1097/00005373-198811000-00002; ROSENBLATT J, 1988, AM J PHYSIOL, V254, pE526; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SHIMAZU T, 1981, DIABETOLOGIA, V20, P343, DOI 10.1007/BF00254502; SNEDECOR GW, 1967, STATISTICIAL METHODS; SUDO M, 1991, AM J PHYSIOL, V261, pE298; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355	37	19	20	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0193-1849			AM J PHYSIOL-ENDOC M	Am. J. Physiol.-Endocrinol. Metab.	OCT	1995	269	4					E636	E641					6	Endocrinology & Metabolism; Physiology	Endocrinology & Metabolism; Physiology	TA573	WOS:A1995TA57300005	7485475				2021-06-18	
J	LAZAR, MF; MENALDINO, S				LAZAR, MF; MENALDINO, S			COGNITIVE OUTCOME AND BEHAVIORAL-ADJUSTMENT IN CHILDREN FOLLOWING TRAUMATIC BRAIN INJURY - A DEVELOPMENTAL PERSPECTIVE	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED HEAD-INJURY; SEQUELAE; ADOLESCENTS; DAMAGE; MOTOR	The study of long-term cognitive outcome following traumatic brain injury in children is important in guiding educational planning. It is critical to examine outcome from a developmental perspective to allow appreciation of the interaction between recovery processes and the significant maturational changes that take place during childhood. Behavioral adjustment and adaptive functioning are additional important variables to include in consideration of outcome. Methodologically sound longitudinal studies, more investigations that include preschoolers and adolescents, and studies that follow children as they make the transition into adulthood would enhance school planning and guide policy planning in education and health care management.	UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; MOSSREHAB HOSP,DRUCKER BRAIN INJURY CTR,PHILADELPHIA,PA	LAZAR, MF (corresponding author), UNIV PENN,SCH MED,DEPT PEDIAT PSYCHOL,CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA 19104, USA.						ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BERNSTEIN JH, 1990, NEUROMETHODS, V17; BLAZYK S, 1983, SOC WORK HEALTH CARE, V8, P55, DOI 10.1300/J010v08n04_05; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DEPOMPEI R, 1991, NEUROREHABILITATION, V1, P29; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; EWINGCOBBS L, 1985, HEAD INJURY REHABILI; FINGER S, 1991, DEV NEUROPSYCHOL, V7, P261, DOI 10.1080/87565649109540494; Fletcher J, 1987, NEUROBEHAVIORAL RECO; FLETCHER J, 1988, HDB PEDIATRIC PSYCHO; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; HANSON SL, 1992, PHYSICAL MED REHABIL, V6, P483; HOLMES JM, 1987, HDB COGNITIVE SOCIAL, V2; JACOBSON MS, 1986, PEDIATRICS, V77, P236; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; Lehr E, 1990, PSYCHOL MANAGEMENT T; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1984, AGING RECOVERY FUNCT; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; MILTON SB, 1991, J HEAD TRAUMA REHAB, V6, P35; MOORE CM, 1994, 22ND ANN M INT NEUR; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROSS B, 1991, PHYS MED REHABIL CLI, V2, P781; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; YLVISAKER M, 1989, MILD MODERATE HEAD I	41	19	20	0	2	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1995	10	5					55	63		10.1097/00001199-199510000-00007			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RY617	WOS:A1995RY61700007					2021-06-18	
J	WILDBURGER, R; ZARKOVIC, N; EGGER, G; PETEK, W; MEINITZER, A; BOROVIC, S; ZARKOVIC, K; LI, LB; STIPANCIC, I; TRBOJEVICCEPE, M; CVORISCEC, D; DOKO, M				WILDBURGER, R; ZARKOVIC, N; EGGER, G; PETEK, W; MEINITZER, A; BOROVIC, S; ZARKOVIC, K; LI, LB; STIPANCIC, I; TRBOJEVICCEPE, M; CVORISCEC, D; DOKO, M			COMPARISON OF THE VALUES OF BASIC FIBROBLAST GROWTH-FACTOR DETERMINED BY AN IMMUNOASSAY IN THE SERA OF PATIENTS WITH TRAUMATIC BRAIN INJURY AND ENHANCED OSTEOGENESIS AND THE EFFECTS OF THE SAME SERA ON THE FIBROBLAST GROWTH IN-VITRO	EUROPEAN JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY			English	Article							HEAD-INJURY; AFFINITY-CHROMATOGRAPHY; HEPARIN-SEPHAROSE; PITUITARY; INVITRO; CALLUS; FGF	In patients with severe traumatic brain injury, the early healing of fractures is accompanied by hypertrophic callus formation or heterotopic ossifications, which might even result in ankylosis of the affected joints. Analysis of the sera of patients with traumatic brain injury revealed post-traumatic dynamic changes of basic fibroblast growth factor immunoreactivity, similar to those observed during fracture healing associated with enhanced osteogenesis. The aim of this study was to determine whether such changes in basic fibroblast growth factor concentrations could be related to the phenomenon of enhanced osteogenesis. Basic fibroblast growth factor immunoreactivity was determined (using an IEMA kit) in the sera of patients with traumatic brain injury and bone fractures (n = 8) and in the sera of patients with either traumatic brain injury alone (n = 10) or bone fractures alone (n = 7), and the effects of these sera on L929 fibroblast growth were analysed in vitro. The results did not prove a causative relationship between the changes of basic fibroblast growth factor immunoreactivity and in vitro growth promoting effects of the sera. However, it is apparent that, in addition to changes in the growth-promoting activity and basic fibroblast growth factor concentration of serum, other as yet unknown post-traumatic changes can cause enhanced osteogenesis.	GRAZ UNIV,TRAUMATOL CLIN,GRAZ,AUSTRIA; RUDJER BOSKOVIC INST,ZAGREB,CROATIA; GRAZ UNIV,INST GEN & EXPTL PATHOL,GRAZ,AUSTRIA; GRAZ UNIV,SURG CLIN,CLIN CHEM LAB,GRAZ,AUSTRIA; CTR HOSP CTR REBRO,INST NEUROPATHOL,ZAGREB,CROATIA; UNIV TRADIT CHINESE MED,DEPT EXPTL NEUROSCI,BEIJING,PEOPLES R CHINA; GEN HOSP,DEPT SURG,ZAGREB,CROATIA; UNIV CLIN REBRO,CLIN INST LAB DIAGNOSIS,ZAGREB,CROATIA; CLIN HOSP SISTERS MERCY,DEPT SURG,ZAGREB,CROATIA			Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CANALIS E, 1988, TRIANGLE, V27, P11; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; FINKLESTEIN SP, 1990, STROKE, V21, P122; FRAUTSCHY SA, 1991, BRAIN RES, V12, P291; GAUTHIER T, 1987, BIOCHEM BIOPH RES CO, V145, P775, DOI 10.1016/0006-291X(87)91032-1; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; KATO Y, 1985, J CELL BIOL, V100, P477, DOI 10.1083/jcb.100.2.477; LOGAN A, 1992, J NEUROSCI, V12, P3828; MAZUE G, 1992, TOXICOL LETT, V38, P64; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RIVA MA, 1992, MOL BRAIN RES, V15, P311, DOI 10.1016/0169-328X(92)90123-S; RODAN SB, 1992, CYTOKINES BONE METAB, P115; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; WILDBURGER R, 1992, ZBL CHIR, V117, P515; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4	25	19	20	0	0	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0939-4974			EUR J CLIN CHEM CLIN	Eur. J. Clin. Chem. Clin. Biochem.	OCT	1995	33	10					693	698					6	Biochemistry & Molecular Biology; Medical Laboratory Technology	Biochemistry & Molecular Biology; Medical Laboratory Technology	TE478	WOS:A1995TE47800005	8608189				2021-06-18	
J	POURCHER, E; BARUCH, P; BOUCHARD, RH; FILTEAU, MJ; BERGERON, D				POURCHER, E; BARUCH, P; BOUCHARD, RH; FILTEAU, MJ; BERGERON, D			NEUROLEPTIC ASSOCIATED TARDIVE DYSKINESIAS IN YOUNG-PEOPLE WITH PSYCHOSES	BRITISH JOURNAL OF PSYCHIATRY			English	Article; Proceedings Paper	2nd International Congress of the Movement-Disorder-Society	JUN, 1994	MUNICH, GERMANY	Movement Disorder Soc			SCHIZOPHRENIA; DYSFUNCTION	Background. Apart from ageing, the factors associated with vulnerability to the emergence of tardive dyskinesia are poorly defined. Method. Risk factors associated with the presence of a chronic choreic or dystonic disorder were assessed in a cross-sectional comparison of anamnestic and clinical data in a homogeneous group of 64 young psychotic patients (under 40 years of age) on chronic low to moderate doses of neuroleptics. Results. Dyskinetic subjects presented more indirect indicators of occult brain damage, such as a perinatal event or traumatic brain injuries in infancy and early childhood; neurological examination showed more anomalies in dyskinetic patients than in non-dyskinetics, with a higher prevalence of facial release reflexes. Conclusion. These data may support the hypothesis that occult acquired brain damage is important in the genesis of this 'drug-induced' disorder.	UNIV LAVAL ROBERT GIFFARD,CTR RECH,BEAUPORT,PQ,CANADA							American Psychiatric Association, 1987, DIAGN STAT MAN MENT; CHOUINARD G, 1982, AM J PSYCHIAT, V139, P312; CHOUINARD G, 1986, PSYCHOPHARMACOL BULL, V22, P259; Guy W, 1976, ECDEU ASSESSMENT MAN, P534; JUNCOS JL, 1989, ANN NEUROL, V25, P473, DOI 10.1002/ana.410250509; KANE JM, 1984, PSYCHOPHARMACOL BULL, V20, P39; KING DJ, 1991, BRIT J PSYCHIAT, V158, P770, DOI 10.1192/bjp.158.6.770; MCCREADIE RG, 1992, BRIT J PSYCHIAT, V161, P799; OCALLAGHAN E, 1990, BRIT J PSYCHIAT, V157, P578, DOI 10.1192/bjp.157.4.578; SCHOOLER NR, 1982, ARCH GEN PSYCHIAT, V39, P486; WADDINGTON JL, 1987, ARCH GEN PSYCHIAT, V44, P907; WEGNER JT, 1985, ARCH GEN PSYCHIAT, V42, P860; YASSA R, 1985, CAN J PSYCHIAT, V30, P344, DOI 10.1177/070674378503000508; YOUSSEF HA, 1988, BIOL PSYCHIAT, V23, P791, DOI 10.1016/0006-3223(88)90067-4	14	19	19	0	0	ROYAL COLLEGE OF PSYCHIATRISTS	LONDON	BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON, ENGLAND SW1X 8PG	0007-1250			BRIT J PSYCHIAT	Br. J. Psychiatry	JUN	1995	166						768	772		10.1192/bjp.166.6.768			5	Psychiatry	Psychiatry	RF270	WOS:A1995RF27000012	7663825				2021-06-18	
J	HAYES, RL; YANG, K; WHITSON, JS; XUE, JJ; KAMPFL, A; MU, XS; ZHAO, X; FAUSTINELLA, F; CLIFTON, GL				HAYES, RL; YANG, K; WHITSON, JS; XUE, JJ; KAMPFL, A; MU, XS; ZHAO, X; FAUSTINELLA, F; CLIFTON, GL			RESCUE OF INJURY-INDUCED NEUROFILAMENT LOSS BY BDNF GENE TRANSFECTION IN PRIMARY SEPTOHIPPOCAMPAL CELL-CULTURES	NEUROSCIENCE LETTERS			English	Article						GENE TRANSFER; LIPOSOME; BDNF; SEPTOHIPPOCAMPAL CELL CULTURE; NEURAL INJURY; NEUROFILAMENT	TRAUMATIC BRAIN INJURY; NERVE GROWTH-FACTOR; ANTIBODIES; INVIVO; VECTOR	We employed primary septo-hippocampal cell cultures to determine the ability of liposome-mediated BDNF gene transfection to facilitate recovery of neurofilament loss caused by depolarization injury. After BDNF gene transfection in uninjured cultures, RT-PCR and immunohistochemical staining confirmed increases in BDNF mRNA and protein in transfected cells. Three days after depolarization injury, Western blot and immunohistochemical analyses detected significant loss of neurofilament proteins in non-transfected cultures, while BDNF transfection produced marked increases in neurofilament proteins following either pre-injury transfection or transfection 24 h following injury. Immunohistochemical studies also detected enhanced immunolabeling of BDNF and total neurofilament protein (phosphorylated and non-phosphorylated) in injured neurons following BDNF transfection or administration of exogenous BDNF protein, compared to untransfected, injured controls.		HAYES, RL (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT NEUROSURG, 6431 FANNIN ST, HOUSTON, TX 77030 USA.						BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; CLARK EA, 1991, J NEUROCHEM, V57, P802, DOI 10.1111/j.1471-4159.1991.tb08222.x; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; FANG XJ, 1989, HEPATOLOGY, V10, P781; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GIORDANO T, 1991, EXP CELL RES, V992, P993; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEFTI F, 1986, J NEUROSCI, V6, P2155; HORWITZ M S, 1990, P1679; HUG P, 1991, BIOCHIM BIOPHYS ACTA, V1097, P1, DOI 10.1016/0925-4439(91)90016-3; IP NY, 1993, J NEUROSCI, V13, P3394; JOHNSON PA, 1992, MOL BRAIN RES, V12, P95, DOI 10.1016/0169-328X(92)90072-J; KAMPFL AW, 1994, SOC NEUR ABSTR; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LI AP, 1992, IN VITRO CELL DEV-AN, V28A, P373; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; ROESSLER BJ, 1994, NEUROSCI LETT, V167, P5, DOI 10.1016/0304-3940(94)91015-4; SAATMAN KE, 1994, SOC NEUR ABSTR; SHAW G, 1986, EUR J CELL BIOL, V42, P1; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAFT WC, UNPUB J NEUROTRAUMA; THOMPSON TA, 1993, IN VITRO CELL DEV-AN, V29, P165, DOI 10.1007/BF02630949; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITSON JS, UNPUB J NEUROSCI; WHITSON JS, SOC NEUR ABSTR; WOLF D, 1988, MOL BIOL MED, V5, P43; YANG K, 1994, NEUROSCI LETT, V182, P287, DOI 10.1016/0304-3940(94)90818-4; YANG K, 1994, NEUROSCI LETT, V182, P291, DOI 10.1016/0304-3940(94)90819-2	32	19	19	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 19	1995	191	1-2					121	125		10.1016/0304-3940(95)11561-X			5	Neurosciences	Neurosciences & Neurology	RA274	WOS:A1995RA27400030	7544881				2021-06-18	
J	ALDIN, ASN; MUBAIDIN, A; WRIEKAT, AL; ALQAM, M				ALDIN, ASN; MUBAIDIN, A; WRIEKAT, AL; ALQAM, M			RISK-FACTORS OF ASEPTIC INTRACRANIAL VENOUS OCCLUSIVE DISEASE	ACTA NEUROLOGICA SCANDINAVICA			English	Article						ASEPTIC INTRACRANIAL VENOUS OCCLUSIVE DISEASE; DURAL SINUS THROMBOSIS; SUPERIOR SAGITTAL SINUS THROMBOSIS; BEHCETS DISEASE; PUERPERIUM; THROMBOPHELIA; FAMILIAL MEDITERRANEAN FEVER	SAGITTAL SINUS THROMBOSIS; PROTEIN-S DEFICIENCY; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CLOSED HEAD-INJURY; DURAL SINUS; BEHCETS-DISEASE; CLINICAL COURSE; SUPERIOR; DIAGNOSIS; PATIENT	Introduction - Risk factors for aseptic intracranial venous occlusive disease are varied but only few epidemiologic studies were performed to verify the relative importance of particular factors. Patients and methods - A 2-year hospital-based prospective study was conducted in two hospitals to identify the clinical characteristics and risk factors of patients with confirmed aseptic intracranial venous occlusive disease. Results - 21 patients were identified, representing 0.9% of the total neurological admissions. Men were more commonly affected than women; 81% of the patients presented in a clinical picture indistinguishable from idiopathic intracranial hypertension. Risk factors included Behcet's disease in 4, the puerperium in 3, thrombophelia in 3, familial Mediterranean fever in 2, malignancies in 1, lupus anticoagulant in 1, and the contraceptive pill in 1. Conclusion - Aseptic intracranial venous occlusive disease proved to be not rare in Arabs. It should be considered seriously in the differential diagnosis of idiopathic intracranial hypertension, particularly in males. Several risk factors were incriminated.	KING HUSSEIN MED CTR,AMMAN,JORDAN	ALDIN, ASN (corresponding author), JORDAN UNIV HOSP,POB 13046,AMMAN,JORDAN.						ALFARO A, 1992, J NEUROL NEUROSUR PS, V55, P412, DOI 10.1136/jnnp.55.5.412; ALKAWI MZ, 1992, J TROP GEOGR NEUROL, V2, P49; BANSAL BC, 1980, JPN HEART J, V21, P171; BARNES BD, 1983, NEUROLOGY, V33, P508, DOI 10.1212/WNL.33.4.508; BORER H, 1991, SCHWEIZ MED WSCHR, V121, P788; CHAUDHURI R, 1992, J COMPUT ASSIST TOMO, V16, P30, DOI 10.1097/00004728-199201000-00006; COCHRAN FB, 1990, AM J MED GENET, V35, P519, DOI 10.1002/ajmg.1320350415; CROS D, 1990, STROKE, V21, P632; ELRAMAHI KM, 1991, J NEUROL NEUROSUR PS, V54, P826, DOI 10.1136/jnnp.54.9.826; ESKRIDGE JM, 1991, J VASC INT RADIOL, V22, P89; FELDENZER JA, 1987, STROKE, V18, P656, DOI 10.1161/01.STR.18.3.656; FURUTA M, 1991, Nippon Ganka Gakkai Zasshi, V95, P199; GARCIAMONCO JC, 1991, NEUROLOGY, V41, P1324, DOI 10.1212/WNL.41.8.1324; GILMAN JK, 1983, SOUTHERN MED J, V76, P658; GREEN D, 1992, NEUROLOGY, V42, P1029, DOI 10.1212/WNL.42.5.1029; HAMMANS SR, 1989, J NEUROL NEUROSUR PS, V52, P287, DOI 10.1136/jnnp.52.2.287; HEISTINGER M, 1992, ANN HEMATOL, V64, P105, DOI 10.1007/BF01715355; HESSELBROCK R, 1985, NEUROSURGERY, V16, P825, DOI 10.1227/00006123-198506000-00017; HICKEY WF, 1982, AM J MED, V73, P740; HORST A, 1991, SCHWEIZ MED WSCHR, V121, P1601; HUSS GP, 1992, NERVENARZT, V63, P352; Iijima S, 1980, Rinsho Shinkeigaku, V20, P333; KOBAYASHI S, 1980, CLIN NEUROL, V20, P904; KONISHI Y, 1987, PEDIATR NEUROL, V3, P222, DOI 10.1016/0887-8994(87)90022-1; Mohamed A, 1991, Clin Exp Neurol, V28, P23; MORIYAMA E, 1992, Neurologia Medico-Chirurgica, V32, P232, DOI 10.2176/nmc.32.232; MURAMATSU S, 1990, THROMB RES, V57, P593, DOI 10.1016/0049-3848(90)90076-O; MURPHY MF, 1983, BRIT MED J, V287, P1344, DOI 10.1136/bmj.287.6402.1344; OJEDA VJ, 1982, MED J AUSTRALIA, V2, P584, DOI 10.5694/j.1326-5377.1982.tb132581.x; OMARDEEN F, 1992, W INDIAN MED J, V41, P31; PATCHELL RA, 1986, NEUROLOGY, V36, P745, DOI 10.1212/WNL.36.6.745; PRATS JM, 1992, NEUROLOGY, V42, P2303, DOI 10.1212/WNL.42.12.2303-a; ROOS KL, 1990, OBSTET GYNECOL, V76, P492; SACCO RL, 1987, ANN NEUROL, V22, P115; SASAKI A, 1991, Neurologia Medico-Chirurgica, V31, P978, DOI 10.2176/nmc.31.978; SCOTT EB, 1992, AM J PHYS MED REHAB, V71, P119, DOI 10.1097/00002060-199204000-00011; SHIOZAWA Z, 1986, ANN NEUROL, V20, P272, DOI 10.1002/ana.410200216; SHIOZAWA Z, 1985, J NEUROL, V232, P280, DOI 10.1007/BF00313866; SHIOZAWA Z, 1982, ANN NEUROL, V12, P578, DOI 10.1002/ana.410120613; Shiozawa Z, 1982, Rinsho Shinkeigaku, V22, P815; STEPHENS PH, 1991, BRIT J ANAESTH, V67, P476, DOI 10.1093/bja/67.4.476; STERN JM, 1989, S AFR MED J, V75, P243; STRINGER WL, 1983, NEUROSURGERY, V12, P95; Takashima S, 1988, Rinsho Shinkeigaku, V28, P812; THRON A, 1986, J NEUROL, V233, P283, DOI 10.1007/BF00314160; Ueda T, 1982, No To Shinkei, V34, P349; Usui Y, 1986, Rinsho Hoshasen, V31, P413; WATANABE M, 1992, PLANT CELL PHYSIOL, V33, P343; YONEKURA S, 1991, JPN J MED, V30, P175	49	19	19	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	DEC	1994	90	6					412	416					5	Clinical Neurology	Neurosciences & Neurology	PW675	WOS:A1994PW67500007	7892760				2021-06-18	
J	DESMOND, DW; TATEMICHI, TK; FIGUEROA, M; GROPEN, TI; STERN, Y				DESMOND, DW; TATEMICHI, TK; FIGUEROA, M; GROPEN, TI; STERN, Y			DISORIENTATION FOLLOWING STROKE - FREQUENCY, COURSE, AND CLINICAL CORRELATES	JOURNAL OF NEUROLOGY			English	Article						DISORIENTATION; STROKE; DEMENTIA; MEMORY; ATTENTION	CLOSED-HEAD-INJURY; DEMENTIA; MEMORY; ALZHEIMERS; LANGUAGE; DISEASE; COHORT	To investigate the frequency, course, and clinical correlates of disorientation following stroke, we administered the Mini-Mental State Examination orientation subtest to 177 alert patients 7-10 days and 3 months after stroke and 240 stroke-free nondemented subjects. Disorientation was defined as a score less than or equal to 8/10. Seventy-two (40.7%) of the patients were disoriented 7-10 days after stroke and 39 patients (22.0% of the sample) remained disoriented 3 months later. A logistic regression analysis determined that persistent disorientation was significantly related to stroke status [odds ratio (OR)=5.8], after adjusting for memory and attentional deficits and demographic variables. Among stroke patients, disorientation was associated with severe hemispheral stroke syndromes (OR=7.7), but not infarct location or vascular risk factor history, after adjusting for memory and attentional deficits and demographic variables. Sensitivity and specificity analyses determined that disorientation was an inaccurate marker for dementia or deficits in memory or attention, while intact orientation was associated with a low probability of dementia or memory dysfunction in most patients but not preserved attention. We conclude that disorientation is common and persistent following stroke and associated with severe hemispheral stroke syndromes but not infarct location. While disorientation is a poor marker for dementia or deficits in memory or attention, intact orientation should suggest that cognitive functions are likely to be preserved.	NEUROL INST,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY; COLUMBIA UNIV,COLL PHYS & SURG,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY				Desmond, David/0000-0002-6961-5658; Stern, Yaakov/0000-0001-7542-3241	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01-AG07232] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS01635, R01-NS26179] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001635, R01NS026179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG007232] Funding Source: NIH RePORTER		BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; DESMOND D W, 1992, Neurology, V42, P426; DESMOND DW, 1993, ARCH NEUROL-CHICAGO, V50, P162, DOI 10.1001/archneur.1993.00540020040015; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; GOTTLIEB G, 1965, J COMP PHYSIOL PSYCH, V60, P368, DOI 10.1037/h0022555; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HALLIDAY AM, 1968, BRIT J PSYCHIAT, V114, P997, DOI 10.1192/bjp.114.513.997; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; HUBER SJ, 1989, ARCH NEUROL-CHICAGO, V46, P1287, DOI 10.1001/archneur.1989.00520480029015; HUNTER R, 1989, PSYCHOL MED, V19, P847, DOI 10.1017/S0033291700005560; KOPELMAN MD, 1986, BRIT J PSYCHIAT, V148, P517, DOI 10.1192/bjp.148.5.517; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MAHURIN RK, 1991, J GERONTOL, V46, pP58, DOI 10.1093/geronj/46.2.P58; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; TATEMICHI TK, 1992, NEUROLOGY, V42, P1185, DOI 10.1212/WNL.42.6.1185; THASE ME, 1982, J MENT DEFIC RES, V26, P239; VALENTINE M, 1968, BRIT J PSYCHIAT, V114, P989, DOI 10.1192/bjp.114.513.989; Wade D T, 1989, Int Disabil Stud, V11, P34	20	19	19	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0340-5354			J NEUROL	J. Neurol.	OCT	1994	241	10					585	591		10.1007/BF00920621			7	Clinical Neurology	Neurosciences & Neurology	PL348	WOS:A1994PL34800003	7836961				2021-06-18	
J	NORWOOD, S; MYERS, MB				NORWOOD, S; MYERS, MB			OUTCOMES FOLLOWING INJURY IN A PREDOMINANTLY RURAL-POPULATION-BASED TRAUMA CENTER	ARCHIVES OF SURGERY			English	Article							VOLUME; CARE; MORTALITY; IMPACT; SYSTEM	Objective: To determine the incidence, severity, and outcomes of injury in patients treated in a rural-based level I trauma center and to compare the outcomes with a nationally indexed patient population-the Major Trauma Outcome Study. Design: Retrospective evaluation of trauma registry data. Setting: State of Illinois designated level I trauma center located in Urbana. Patients: A total of 2246 trauma patients admitted from August 1989 through August 1992, with a mortality cohort of 158 patients. There were 1735 patients (77%) with Injury Severity Scores less than or equal to 19 and 511 patients (23%) with more severe injuries (Injury Severity Scores greater than or equal to 20). Main Outcome Measures: Mortality rates using the TRISS method, the Major Trauma Outcome Study, and final patient dispositions. Results: The overall mortality rate, excluding those patients who were pronounced dead on arrival, was 125/2213 (5.6%). Eighty-six (69%) of these 125 patients had neurological Abbreviated Injury Scores of 3 or greater, with neurotrauma being a major contributer to their deaths. The m-statistic was 0.99 and the z-statistic was -3.30 for the entire group. The observed probability of survival met or exceeded the expected probability of survival when compared with the Major Trauma Outcome Study in all categories. Conclusion: Acceptable mortality rates compared with the Major Trauma Outcome Study can be achieved in a rural-community-based level I trauma center despite relatively small numbers of critically injured patients. Such outcomes may assist in justifying resource allocation for trauma centers in rural areas.	CARLE FDN HOSP,URBANA,IL	NORWOOD, S (corresponding author), E TEXAS MED CTR,TRAUMA SERV,1021 E IDEL ST,POB 7677,TYLER,TX 75711, USA.						BAKER CC, 1986, ANN EMERG MED, V18, P1389; BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; BAKER SP, 1984, INJURY FACT BOOK; BLAISDELL FW, 1989, ARCH SURG-CHICAGO, V124, P1122; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CONN AK, 1989, EMERG CARE Q, V5, P75; EXPOSITO TJ, 1991, ADV TRAUMA CRITICAL, V6, P115; FLORA JD, 1978, J TRAUMA, V18, P701, DOI 10.1097/00005373-197810000-00003; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MARTIN GD, 1990, J TRAUMA, V30, P1014, DOI 10.1097/00005373-199008000-00011; MCCLAIN PW, 1990, TRAUMA REGISTRY USER; RINKER CF, 1989, AM J SURG, V158, P548, DOI 10.1016/0002-9610(89)90189-X; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; SHATNEY CH, 1993, J TRAUMA, V35, P171; SMITH RF, 1990, J TRAUMA, V30, P1066, DOI 10.1097/00005373-199009000-00002; WADDELL TK, 1991, J TRAUMA, V31, P958, DOI 10.1097/00005373-199107000-00012; WENNEKER WW, 1990, AM J SURG, V160, P655, DOI 10.1016/S0002-9610(05)80768-8; ZUCKLICK LC, 1991, ARCH SURG-CHICAGO, V126, P1427; 1984, MONTHLY VITAL STAT R, V32, P13; 1993, RESOURCES OPTIMAL CA, P7; 1979, ACS B 63, V8, P43	22	19	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	AUG	1994	129	8					800	805					6	Surgery	Surgery	PB266	WOS:A1994PB26600003	8048848				2021-06-18	
J	KAGAN, RJ; BAKER, RJ				KAGAN, RJ; BAKER, RJ			THE IMPACT OF THE VOLUME OF NEUROTRAUMA EXPERIENCE ON MORTALITY AFTER HEAD-INJURY	AMERICAN SURGEON			English	Article							TRAUMA; COUNTY	The volume of neurotrauma experience and mortality after head injury were evaluated in 4667 patients admitted to 10 Level I trauma centers. The hospitals were divided into three groups based on the number of severely head-injured patients admitted each month. The mean number of patients admitted each month to Hospital Groups 1, 2, and 3 with a Glasgow Coma Scale (GCS) score >10 was 100.0, 18.2, and 10.6. Mortality was significantly lower for patients admitted to Group 1 than for those admitted to Group 2 or 3; however, the difference between Groups 2 and 3 was not significant. The mean number of admissions with a GCS score less-than-or-equal-to 10 was 8.3, 6.5, and 2.8, and mortality rates were 26.7 per cent, 36.5 per cent, and 41.4 per cent, respectively. Mortality for Group 1 patients was significantly lower than for those in Groups 2 or 3. Patient age also had a profound impact on survival among all hospital groups. We conclude that the volume of neurotrauma experience correlates with mortality after head injury.	CHICAGO DEPT PUBL HLTH,DEPT SURG,CHICAGO,IL; JEFFERSON MED COLL,DEPT SURG,WILMINGTON,DE; MED CTR,DELAWARE,DEPT SURG,WILMINGTON,DE	KAGAN, RJ (corresponding author), UNIV CINCINNATI,COLL MED,DEPT SURG,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.						ANNEGERS JF, 1979, CENTRAL NERVOUS SYST, P1; BOWERS SA, 1980, NEUROSURGERY, V6, P237; CALES RH, 1984, ANN EMERG MED, V13, P15; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; GARNICK DW, 1989, JAMA-J AM MED ASSOC, V262, P547, DOI 10.1001/jama.262.4.547; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; JANE JA, 1982, CLIN NEUR, V29, P346; JENNETT B, 1978, INJURY, V10, P31; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KLAUBER MR, 1985, J NEUROSURG, V62, P508; LILLEHEI KO, 1985, ANN EMERG MED, V14, P789, DOI 10.1016/S0196-0644(85)80059-7; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; WEST JG, 1983, ARCH SURG-CHICAGO, V118, P740	19	19	19	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	JUN	1994	60	6					394	400					7	Surgery	Surgery	NN591	WOS:A1994NN59100005	8198326				2021-06-18	
J	NEISTADT, ME				NEISTADT, ME			A MEAL PREPARATION TREATMENT PROTOCOL FOR ADULTS WITH BRAIN INJURY	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						ACTIVITIES OF DAILY LIVING; BRAIN INJURIES; INDEPENDENT LIVING SKILLS	OCCUPATIONAL-THERAPY; PERCEPTUAL DEFICITS	Adults with acquired brain injury often demonstrate dysfunction in meal preparation due to deficits in component cognitive-perceptual skills. Although occupational therapy for these clients routinely includes meal preparation training, there are no protocols in the occupational therapy literature to help structure that activity to address clients' cognitive-perceptual deficits. This paper describes a meal preparation treatment protocol based on cognitive-perceptual information processing theory that has been pilot tested in a treatment outcome study with adult men with traumatic or anoxic acquired brain injury. In that study, the group of 23 subjects treated with this meal preparation protcol showed significant improvement in their meal preparation skill, as measured by the Rabideau Kitchen Evaluation-Revised (RKE-R), a test of meal preparation skill, and in their cognitive-perceptual skill, as measured by the WAIS-R Block Design Test. The treatment protocol includes descriptions of the structure, grading, and cuing methods for light meal preparation activities.		NEISTADT, ME (corresponding author), UNIV NEW HAMPSHIRE,SCH HLTH & HUMAN SERV,DEPT OCCUPAT THERAPY,DURHAM,NH 03824, USA.						ABREU BC, 1987, AM J OCCUP THER, V41, P439, DOI 10.5014/ajot.41.7.439; BEN-YISHAY Y, 1970, Journal of Abnormal Psychology, V76, P378, DOI 10.1037/h0030404; Ben-Yishay Y, 1974, Cortex, V10, P121; BENYISHAY Y, 1970, J ABNORM PSYCHOL, V75, P248, DOI 10.1037/h0029368; FLEISHMAN EA, 1963, J EXP PSYCHOL, V66, P6, DOI 10.1037/h0046677; Hopkins H. L., 1993, WILLARD SPACKMANS OC; KANTOWITZ BH, 1980, THEOR LEARN, P332; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; NEISTADT ME, 1990, AM J OCCUP THER, V44, P299, DOI 10.5014/ajot.44.4.299; NEISTADT ME, 1992, OCCUP THER J RES, V12, P242, DOI 10.1177/153944929201200404; NEISTADT ME, 1993, AM J OCCUP THER, V47, P154, DOI 10.5014/ajot.47.2.154; NEISTADT ME, 1992, AM J OCCUP THER, V46, P141, DOI 10.5014/ajot.46.2.141; NEISTADT ME, 1988, AM J OCCUP THER, V42, P434, DOI 10.5014/ajot.42.7.434; NEISTADT ME, 1994, AM J OCCUP THER, V48, P62, DOI 10.5014/ajot.48.1.62; NEISTADT ME, 1989, AM J OCCUP THER, V43, P448, DOI 10.5014/ajot.43.7.448; NEISTADT ME, 1991, OCCUPATIONAL THERAPY; Pedretti LW, 1990, OCCUPATIONAL THERAPY; RABIDEAU GM, 1986, THESIS TUFTS U MEDFO; Singer R. N., 1985, QUEST, V37, P103, DOI [10.1080/00336297.1985.10483824, DOI 10.1080/00336297.1985.10483824]; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505; Trombly CA, 1989, OCCUPATIONAL THERAPY; ZOLTAN B, 1986, PERCEPTUAL COGNITIVE	22	19	19	0	4	AMER OCCUPATION THERAPY ASSN	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	MAY	1994	48	5					431	438		10.5014/ajot.48.5.431			8	Rehabilitation	Rehabilitation	NF247	WOS:A1994NF24700006	8042686				2021-06-18	
J	ADESUNKANMI, K; OYELAMI, OA				ADESUNKANMI, K; OYELAMI, OA			THE PATTERN AND OUTCOME OF BURN INJURIES AT WESLEY-GUILD-HOSPITAL, ILESHA, NIGERIA - A REVIEW OF 156 CASES	JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article						BURN INJURIES; PATTERN AND OUTCOME	INFECTION; PATIENT; HONEY; UNIT	A review of 156 patients with burn injuries admitted over a 5-year period (January 1988-December 1992) at Wesley Guild Hospital, Ilesha, was undertaken. The male:female ratio was 1.6:1. About 70% of the cases were between 1 and 10 years of age (mean 9 years). Scalds were responsible for 50.6% of the cases while naked flames, including kerosine explosion and burns at road traffic accidents, were responsible for 43.5%. Seventy-one per cent were due to domestic accidents. The burns were categorized as major in 70% of cases. The trunk accounted for 56.4% of anatomical areas involved, upper limbs 51.3%, lower limbs 48%, while head and neck accounted for 28.8%. Open dressings were used in 70.5% of the cases, combined open and closed dressings in 22.4% and closed dressings in 10.3%. In about 90% of cases, silver sulphadiazine was used as a topical antimicrobial agent while natural honey was used on the rest. Wound infection was the commonest complication occurring in 24.4%, while mortality was recorded in 7.7% of cases.	OBAFEMI AWOLOWO UNIV, COLL HLTH SCI, DEPT PAEDIAT, IFE, NIGERIA	ADESUNKANMI, K (corresponding author), OBAFEMI AWOLOWO UNIV, COLL HLTH SCI, DEPT SURG, IFE, NIGERIA.						AKHTAR M, 1981, BURNS, V7, P1; BANERJEE AK, 1991, BRIT J SURG, V78, P248, DOI 10.1002/bjs.1800780240; BANG RL, 1988, BURNS, V14, P194, DOI 10.1016/0305-4179(88)90038-1; BURKE JF, 1991, ARCH SURG-CHICAGO, V126, P677; CHAURASIA AR, 1982, BURNS, V9, P184; CIOFFI WG, 1991, ARCH SURG-CHICAGO, V126, P74; DEMLING RH, 1985, NEW ENGL J MED, V313, P1389, DOI 10.1056/NEJM198511283132205; EFEM SEE, 1988, BRIT J SURG, V75, P679, DOI 10.1002/bjs.1800750718; HEGAZY MM, 1991, ANN SAUDI MED, V11, P255, DOI 10.5144/0256-4947.1991.255; MCMANUS AT, 1985, ARCH SURG-CHICAGO, V120, P217; MUIR IFK, 1978, CURRENT SURGICAL PRA, V2, P230; Oluwasanmi J O, 1969, Br J Plast Surg, V22, P216, DOI 10.1016/S0007-1226(69)80110-4; OLUWASANMI JO, 1989, PRINCIPLE PRACTICE S, P160; OLUWASANMI JO, 1979, PLASTIC SURGERY TROP, P44; PRUITT BA, 1990, BRIT J SURG, V77, P1081, DOI 10.1002/bjs.1800771002; PURDUE GF, 1985, J TRAUMA, V25, P216, DOI 10.1097/00005373-198503000-00008; SOWEMIMO GOA, 1982, BURNS, V9, P280; SUBRAHMANYAM M, 1991, BRIT J SURG, V78, P497, DOI 10.1002/bjs.1800780435	18	19	19	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-5304			J TROP MED HYG	J. Trop. Med. Hyg.	APR	1994	97	2					108	112					5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	NF895	WOS:A1994NF89500009	8170000				2021-06-18	
J	GALSKI, T; PALASZ, J; BRUNO, RL; WALKER, JE				GALSKI, T; PALASZ, J; BRUNO, RL; WALKER, JE			PREDICTING PHYSICAL AND VERBAL AGGRESSION ON A BRAIN TRAUMA UNIT	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MINI-MENTAL STATE; CLOSED HEAD-INJURY; PRACTICAL SCALE; RELIABILITY; DEMENTIA; ORIENTATION; INSTRUMENTS; IMPAIRMENT; PHENYTOIN		UMDNJ, NEW JERSEY MED SCH, NEWARK, NJ USA	GALSKI, T (corresponding author), KESSLER INST REHABIL, BRAIN INJURY PROGRAM, 240 CENT AVE, E ORANGE, NJ 07018 USA.						ANTHONY JC, 1982, PSYCHOL MED, V12, P397, DOI 10.1017/S0033291700046730; BIRD HR, 1987, J NERV MENT DIS, V175, P731, DOI 10.1097/00005053-198712000-00005; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Brooks D N, 1979, Int Rehabil Med, V1, P160; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DICK JPR, 1984, J NEUROL NEUROSUR PS, V47, P496, DOI 10.1136/jnnp.47.5.496; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; FILLENBAUM GG, 1987, ARCH NEUROL-CHICAGO, V44, P924, DOI 10.1001/archneur.1987.00520210026014; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Holland N J, 1988, Rehabil Nurs, V13, P244; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Johnston M. V., 1992, NEUROREHABILITATION, V2, P72; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; LESHER EL, 1986, J CONSULT CLIN PSYCH, V54, P726, DOI 10.1037/0022-006X.54.5.726; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; MCCULLA MM, 1989, ARCH NEUROL-CHICAGO, V46, P1210, DOI 10.1001/archneur.1989.00520470070029; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Ozuna J, 1985, J Neurosurg Nurs, V17, P66; PRUITT AW, 1985, PEDIATRICS, V76, P644; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; WILLIAMS JM, 1987, COGNITIVE BEHAVIOR R; ZILLMER EA, 1989, STAFF RES PHYS, V35, P79	32	19	19	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1994	75	4					380	383		10.1016/0003-9993(94)90158-9			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	NH535	WOS:A1994NH53500002	8172494				2021-06-18	
J	KLUGER, Y; JAROSZ, D; PAUL, DB; TOWNSEND, RN; DIAMOND, DL				KLUGER, Y; JAROSZ, D; PAUL, DB; TOWNSEND, RN; DIAMOND, DL			DIVING INJURIES - A PREVENTABLE CATASTROPHE	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							CORD INJURY	During a 5-year period from January 1987 through January 1992, 58 patients were admitted to the Allegheny General Hospital trauma center for non-scuba, non-suicidal diving injuries. There were 46 men and 12 women (mean age, 23 years). Forty-five patients were injured in swimming pools. Twenty-two patients had blood alcohol levels >100 mg/dL. Cervical spine injury was the most common pathologic entity encountered in this group of patients. Closed head injury, pelvic fracture, thoracic vertebral fracture, and rib fractures were other injuries identified. Some patients had multiple organ failure syndrome. Aquatic recreational activities carry a risk for injury that is preventable. The mechanism, clinical data, and complications of 58 patients are presented and the importance of prevention is discussed.	ALLEGHENY GEN HOSP,TRAUMA INTENS CARE UNIT,PITTSBURGH,PA 15212	KLUGER, Y (corresponding author), ALLEGHENY GEN HOSP,DIV GEN SURG,320 E N AVE,PITTSBURGH,PA 15212, USA.						Albrand O W, 1975, Surg Neurol, V4, P461; Albrand O W, 1976, Am J Sports Med, V4, P107, DOI 10.1177/036354657600400303; BAILES JE, 1990, SURG NEUROL, V34, P155, DOI 10.1016/0090-3019(90)90064-V; FIFE D, 1986, SPINE, V11, P2, DOI 10.1097/00007632-198601000-00002; KEWALRAMANI LS, 1975, J TRAUMA, V15, P130, DOI 10.1097/00005373-197502000-00005; KIWERSKI J, 1980, PARAPLEGIA, V18, P101, DOI 10.1038/sc.1980.16; LEDSOME JR, 1981, AM REV RESPIR DIS, V124, P41; RAYMOND CA, 1988, JAMA-J AM MED ASSOC, V260, P1199; RICHARDS RN, 1973, PHYSICIAN SPORTSMED, V1, P63; SCHER AT, 1981, S AFR MED J, V59, P603; 1992, THINK 1ST PROGRAM	11	19	19	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1994	36	3					349	351		10.1097/00005373-199403000-00011			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	NC960	WOS:A1994NC96000011	8145314				2021-06-18	
J	SOUSTIEL, JF; HAFNER, H; GUILBURD, JN; ZAAROOR, M; LEVI, L; FEINSOD, M				SOUSTIEL, JF; HAFNER, H; GUILBURD, JN; ZAAROOR, M; LEVI, L; FEINSOD, M			A PHYSIOLOGICAL COMA SCALE - GRADING OF COMA BY COMBINED USE OF BRAIN-STEM TRIGEMINAL AND AUDITORY-EVOKED POTENTIALS AND THE GLASGOW COMA SCALE	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						COMA; BRAIN-STEM EVOKED POTENTIALS; OUTCOME PROGNOSIS	SEVERE HEAD-INJURY; CENTRAL SOMATOSENSORY CONDUCTION; POST-TRAUMATIC COMA; PREDICTION; PRESSURE; DAMAGE; DEATH	Forty-five comatose patients were prospectively studied by means of clinical examination and evoked potentials. In each patient, clinical data included Glasgow Coma Scale (GCS) score, age, pupillary response to light, corneal reflex, and eye movements. Neurophysiological evaluation was based on brain-stem trigeminal evoked potentials (BTEPs) and brain-stem auditory evoked potentials (BAEPs). For each physiological test, a progressive grading system was designed. This system was based on the evaluation of central conduction times along the trigeminal and the auditory pathways within the brain-stem. The accuracy of the clinical and the neurophysiological indicants in predicting ''favorable'' or ''unfavorable'' outcome was assessed singly and in combination. Of the clinical indicants, the GCS provided the most accurate prognosis (80%). Similar results were provided by the BAEP and the BTEP, with significant improvement in the confidence of outcome prediction. No significant difference in the accuracy of outcome predictions could be found between combined clinical data and neurophysiological data. However, the combination of clinical and neurophysiological data markedly increased both the accuracy and the confidence of outcome prediction, reaching 86% correct predictions at the over 90% confidence level with only 2% false pessimistic errors. According to these findings, a clinical-physiological coma scale, the trigeminal-auditory Glasgow (Coma Scale) score (TAG score) was designed. The TAG score demonstrated the highest accuracy at each confidence level as compared to other single indicants. We concluded that the TAG score may improve the evaluation of deep comatose patients and assist the physician in the management of such patients.	TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,HAIFA,ISRAEL	SOUSTIEL, JF (corresponding author), TECHNION ISRAEL INST TECHNOL,RAMBAM MED CTR,DEPT NEUROSURG,POB 9602,IL-31096 HAIFA,ISRAEL.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BUCHNER H, 1988, ELECTROEN CLIN NEURO, V69, P14, DOI 10.1016/0013-4694(88)90031-4; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CORDOBES F, 1985, ACTA NEUROCHIR WIEN, V81, P27; FACCO E, 1985, ELECTROEN CLIN NEURO, V62, P332, DOI 10.1016/0168-5597(85)90041-3; FERBERT A, 1990, BRAIN, V113, P49, DOI 10.1093/brain/113.1.49; GANES T, 1988, ELECTROEN CLIN NEURO, V69, P6, DOI 10.1016/0013-4694(88)90030-2; GARCIALARREA L, 1987, ELECTROEN CLIN NEURO, V68, P446, DOI 10.1016/0168-5597(87)90056-6; GARCIALARREA L, 1992, J NEUROL NEUROSUR PS, V55, P792, DOI 10.1136/jnnp.55.9.792; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1977, LANCET, V1, P480; JENNETT B, 1981, MANAGEMENT HEAD INJU, P317; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MCCORMICK WF, 1985, NEUROSURGERY, V2, P1544; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; SOUSTIEL JF, 1991, ELECTROEN CLIN NEURO, V80, P119, DOI 10.1016/0168-5597(91)90149-R; TEASDALE G, 1974, LANCET, V2, P81	23	19	23	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	NOV	1993	87	5					277	283		10.1016/0013-4694(93)90180-4			7	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	MJ399	WOS:A1993MJ39900002	7693438				2021-06-18	
J	SPENCE, SE; GODFREY, HPD; KNIGHT, RG; BISHARA, SN				SPENCE, SE; GODFREY, HPD; KNIGHT, RG; BISHARA, SN			1ST IMPRESSIONS COUNT - A CONTROLLED INVESTIGATION OF SOCIAL SKILL FOLLOWING CLOSED-HEAD INJURY	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							VERBAL IMPAIRMENT; RELATIVES	This study examined social skills in 14 closed head injured (CHI) patients who were assessed at four months post-injury and compared with 19 orthopaedic control (OC) patients. Social skills deficits were found to be more common in the CHI patients, of whom over half were classified as socially unskilled. CHI patients displayed poorer social skills in the earlier (but not later) part of an extended social interaction, indicating that they make a poor first impression. It is suggested that poor initial impression formation skills may be one reason why CHI patients fail to establish and maintain friendships. Implications of these findings for patient management are discussed. Close others of CHI patients reported higher levels of mood disturbance. Higher levels of close other hostility were associated with social skills deficits in CHI patients.	UNIV OTAGO, DEPT PSYCHOL, CTR COMMUNITY COUNSELLING, POB 56, DUNEDIN, NEW ZEALAND; UNIV OTAGO, DEPT SURG, DUNEDIN, NEW ZEALAND							Argyle M., 1985, ANATOMY RELATIONSHIP; Benton AL, 1978, MULTILINGUAL APHASIA; ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Goodglass H., 1972, ASSESSMENT APHASIA R; GORDON WP, 1987, BRAIN LANG, V31, P1, DOI 10.1016/0093-934X(87)90056-3; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Nelson H., 1982, NATIONAL ADULT READI; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ROSENBERRY T L, 1980, Neurochemistry International, V2, P135, DOI 10.1016/0197-0186(80)90020-0; RUSSELL WR, 1961, TRAUMATIC AMNESIAS; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1988, SCAND J REHABIL MED, P55; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; SARNO MT, 1987, APHASIOLOGY, V1, P331; SILVERSTEIN AB, 1982, J CONSULT CLIN PSYCH, V50, P415, DOI 10.1037/0022-006X.50.3.415; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; ZUCKERMAN M, 1985, MULTIPLE AFFECT ADJE	25	19	19	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0144-6657	2044-8260		BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	SEP	1993	32		3				309	318		10.1111/j.2044-8260.1993.tb01061.x			10	Psychology, Clinical	Psychology	LZ987	WOS:A1993LZ98700006	8251961				2021-06-18	
J	REID, DB; KELLY, MP				REID, DB; KELLY, MP			WECHSLER MEMORY SCALE-REVISED IN CLOSED HEAD-INJURY	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							BRAIN-DAMAGE; SEQUELAE	This study was undertaken to determine the ability of the Wechsler Memory Scale-Revised (WMS-R) to differentiate a group of closed head injury patients from a group of controls and determine how injury severity and attentional deficits are associated with WMS-R performance. The relationship of WMS-R performance to everyday memory also was assessed. The head injured group performed more poorly than controls on all five WMS-R indices and exhibited greater impairments on tasks that measure retention. In the original sample only the Visual Memory Index correlated with injury severity; in a larger sample, all four memory indices correlated modestly with injury severity. Patients who performed more poorly on the WMS-R also received poorer ratings on an independent assessment of everyday memory.	UNIV MARYLAND,MONTEBELLO HOSP,SCH MED,2201 ARGONNE DR,BALTIMORE,MD 21218; WRIGHT STATE UNIV,DAYTON,OH 45435							BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Butters N., 1988, CLIN NEUROPSYCHOL, V2, P133; CHELUNE GJ, 1988, CLIN NEUROPSYCHOL, V2, P121, DOI DOI 10.1080/13854048808520095; CROSSEN JR, 1988, CLIN NEUROPSYCHOL, V2, P393; Erikson R.C., 1977, PSYCHOL BULL, V84, P1130; Fisher J., 1988, CLIN NEUROPSYCHOL, V2; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1980, 9TH ANN M INT NEUR S; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KNIGHT RG, 1984, J CONSULT CLIN PSYCH, V52, P769; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWIN W, 1968, BMJ-BRIT MED J, V1, P465, DOI 10.1136/bmj.1.5590.465; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PRIGATANO GP, 1978, J CLIN PSYCHOL, V34, P816, DOI 10.1002/1097-4679(197810)34:4<816::AID-JCLP2270340402>3.0.CO;2-Q; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V39, P133; Ryan J. J., 1988, CLIN NEUROPSYCHOL, V2, P173; Seretny M L, 1986, Arch Clin Neuropsychol, V1, P5, DOI 10.1016/0887-6177(86)90021-1; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1990, NEUROPSYCHOLOGY EVER, P169; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Walsh K.W, 1978, NEUROPSYCHOLOGY; Wechsler D., 1987, WMS R WECHSLER MEMOR; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	30	19	19	0	3	CLINICAL PSYCHOLOGY PUBL CO	BRANDON	4 CONANT SQUARE, BRANDON, VT 05733	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	MAR	1993	49	2					245	254		10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1			10	Psychology, Clinical	Psychology	KZ345	WOS:A1993KZ34500017	8486808				2021-06-18	
J	WAALAND, PK; BURNS, C; COCKRELL, J				WAALAND, PK; BURNS, C; COCKRELL, J			EVALUATION OF NEEDS OF HIGH-INCOME AND LOW-INCOME FAMILIES FOLLOWING PEDIATRIC TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							HEAD-INJURIES; CHILDREN; SEQUELAE; ILL	This paper assesses the needs of high- and low-income caregivers shortly after the traumatic brain injury of their child. The Family Needs Questionnaire [1], developed to assess the priorities and satisfaction of needs among family members, was administered to 49 caregivers. Surprisingly, caregivers from both groups displayed similar patterns of priorities and rated their most important needs as met. Caregivers' most important needs included clear information, therapy input, and understanding from professionals and classroom teachers. Personal needs, family support, and fixture patient-related concerns were devalued by both groups. These results are discussed as having implications for identification of high-risk families, treatment goals, and community reintegration needs.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,CTR REHABIL RES & TRAINING,CHILDRENS NEUROL SERV,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,CHILDRENS HOSP,RICHMOND,VA 23298							Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FARBER B, 1959, MONOGRAPHS SOC RES C, V21; FLETCHER JM, IN PRESS J CONSULTIN; GARDNER RA, 1973, FAMILY BOOK MINIMAL; HELM DT, 1986, J AUTISM DEV DISORD, V16, P1, DOI 10.1007/BF01531574; KALSBEEK WD, 1980, J NEUROSURG, V53, P819; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; Kreutzer J.S., 1990, COMMUNITY INTEGR TRA, P249; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MARCUS LM, 1984, EFFECTS AUTISM FAMIL, P311; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINNEY B, 1987, J PEDIATR PSYCHOL, V12, P133; MOLTER NC, 1979, HEART LUNG, V8, P332; POLINKO PR, 1985, HEAD INJURY REHABILI, P91; Rosen CD, 1986, HEAD TRAUMA ED REINT; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; SAVAGE R, 1985, SURVEY TRAUMATICALLY, P1; WAALAND P, 1991, JUN POSTGR COURS REH; WAALAND PK, 1990, COMMUNITY INTEGRATIO, P225; WALLANDER JL, 1989, J PEDIATR PSYCHOL, V14, P157, DOI 10.1093/jpepsy/14.2.157; WEINRAUB M, 1977, HUM DEV, V20, P31, DOI 10.1159/000271546	26	19	19	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR-APR	1993	7	2					135	146		10.3109/02699059309008167			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	KZ726	WOS:A1993KZ72600005	8453412				2021-06-18	
J	ZWIL, AS; MCALLISTER, TW; COHEN, I; HALPERN, LR				ZWIL, AS; MCALLISTER, TW; COHEN, I; HALPERN, LR			ULTRA-RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER FOLLOWING A CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							BRAIN INJURY; SECONDARY MANIA; LITHIUM-CARBONATE; ILLNESS; TRAUMA	A young adult with no prior history of affective disease suffered the onset of a rapid cycling bipolar illness, marginally responsive to psychotropic medications, following a mild closed-head injury, and persisting after the cognitive effects of the injury had resolved. A concurrence of findings on the neurological examination, neurobehavioural examination, SPECT scan, EEG and neuropsychological test battery suggested the presence of a diffuse cerebral injury with a predominance of left frontotemporal findings. This case demonstrates that a severe and disabling mood disorder may follow a mild head injury, and that its course may be independent of cognitive impairment and recovery.	THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PSYCHIAT & HUMAN BEHAV,PHILADELPHIA,PA 19107; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PSYCHIAT,HANOVER,NH 03756; NEW HAMPSHIRE HOSP,CONCORD,NH; BRYN MAWR HOSP,DEPT PSYCHIAT,BRYN MAWR,PA; UNIV PENN,DEPT PSYCHIAT,PHILADELPHIA,PA 19104							ALARCON RD, 1985, COMPR PSYCHIAT, V26, P522, DOI 10.1016/0010-440X(85)90019-7; BRACKEN P, 1987, BRIT J PSYCHIAT, V150, P690, DOI 10.1192/bjp.150.5.690; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; COHN CK, 1977, DIS NERV SYST, V38, P630; CUMMINGS JL, 1986, PSYCHIAT CLIN N AM, V9, P293; DUNNER DL, 1974, ARCH GEN PSYCHIAT, V30, P229; DUNNER DL, 1977, COMPR PSYCHIAT, V18, P561, DOI 10.1016/S0010-440X(97)90006-7; FLORHENRY P, 1983, BIOL PSYCHIAT, V18, P1045; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; JENNER FA, 1967, BRIT J PSYCHIAT, V113, P895, DOI 10.1192/bjp.113.501.895; KRAUTHAMMER C, 1978, ARCH GEN PSYCHIAT, V35, P1333; MCALLISTER TW, IN PRESS PSYCHIATRIC; NIZAMIE SH, 1988, ACTA PSYCHIAT SCAND, V77, P637, DOI 10.1111/j.1600-0447.1988.tb05181.x; PANG D, 1989, ASSESSMENT BEHAV CON, P1; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; RIESS H, 1987, J CLIN PSYCHIAT, V48, P29; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; SINANAN K, 1984, BRIT J PSYCHIAT, V144, P330, DOI 10.1192/bjp.144.3.330; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; STARKSTEIN SE, 1988, J NERV MENT DIS, V176, P87, DOI 10.1097/00005053-198802000-00004; STEWART JT, 1988, J CLIN PSYCHIAT, V49, P74; YATHAM LN, 1988, ACTA PSYCHIAT SCAND, V77, P359, DOI 10.1111/j.1600-0447.1988.tb05135.x; ZWIL AS, 1990, BIOL PSYCHAITRY, V27, pA55; 1987, DIAGNOSTIC STATISTIC	27	19	19	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR-APR	1993	7	2					147	152		10.3109/02699059309008168			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	KZ726	WOS:A1993KZ72600006	8095835				2021-06-18	
J	HARIRI, RJ; GHAJAR, JBG; BAHRAMIAN, K; SHARIF, S; BARIE, PS				HARIRI, RJ; GHAJAR, JBG; BAHRAMIAN, K; SHARIF, S; BARIE, PS			ALTERATIONS IN INTRACRANIAL-PRESSURE AND CEREBRAL BLOOD-VOLUME IN ENDOTOXEMIA	SURGERY GYNECOLOGY & OBSTETRICS			English	Article							TRAUMATIC BRAIN INJURY; OXYGEN-CONSUMPTION; SEPSIS SYNDROME; SEPTIC SHOCK; FLOW; PH; METABOLISM; DIAMETER; DOGS; RAT	Marked deterioration of neurologic function accompanies organ dysfunction in systemic sepsis. Although previous hypotheses have suggested that cerebral hypoperfusion, anoxia or progressive edema of the brain may be causative, the pathogenesis remains unknown. Patients with sepsis with stable or supported hemodynamics and adequate oxygenation may manifest confusion, stupor or coma. Recent evidence has demonstrated that the brain is the source of many classical mediators of inflammation after various forms of injury. These mediators, including the leukotrienes, have pronounced effect on cerebrovascular function. Endotoxin is known to stimulate the release of arachidonate from cell membranes, the rate limiting step in leukotriene synthesis. The current studies were performed to test the hypothesis that neurologic dysfunction associated with endotoxemia is characterized by alterations in cerebrovascular permeability or vasomotor function manifested by intracranial hypertension, or both. We studied the response of miniature swine to experimental endotoxemic shock and compared this response with hemorrhagic hypotension. We observed a dramatic elevation of intracranial pressure in swine subjected to endotoxemic shock, despite arterial hypotension. Moreover, estimation of cerebral blood volume (CBV) by reflectance infrared photoplethysmography demonstrated a dramatic increase in CBV, which corresponded to this elevation in intracranial pressure. However, cerebral cortical oxygen saturation was significantly reduced despite this net increase in CBV, indicative of an increase in the venous volume of the brain, while arterial volume remained the same or decreased from baseline levels. Oxygen extraction across the brain decreased during this same period compared with baseline and control values. These results demonstrate that endotoxemia is associated with the development of intracranial hypertension and an increase in CBV secondary to elevation of cerebrovascular venous volume coupled with reduced oxygen extraction across the brain. This evidence of cerebrovascular dysfunction probably represents blood flow maldistribution, similar to that seen in other organs with sepsis, suggesting a cause for altered neurologic function in systemic sepsis.		HARIRI, RJ (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT SURG,DIV NEUROSURG,AITKEN NEUROSURG LAB,1300 YORK AVE,NEW YORK,NY 10021, USA.		Barie, Philip/AAN-8811-2020				ARCHIE JP, 1977, ANN SURG, V186, P171, DOI 10.1097/00000658-197708000-00008; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BONE RC, 1989, CRIT CARE MED, V17, P398; BOWTON DL, 1989, CRIT CARE MED, V17, P399, DOI 10.1097/00003246-198905000-00004; BRYAN WJ, 1977, P SOC EXP BIOL MED, V156, P205; DAHN MS, 1987, SURGERY, V101, P69; DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806; EKSTROMJODAL B, 1982, ACTA ANAESTH SCAND, V26, P163, DOI 10.1111/j.1399-6576.1982.tb01746.x; ELLMAN H, 1984, CRIT CARE MED, V12, P629, DOI 10.1097/00003246-198408000-00004; FISH RE, 1986, CIRC SHOCK, V18, P267; FREUND HR, 1978, ANN SURG, V188, P423, DOI 10.1097/00000658-197809000-00017; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; HARADA J, 1991, J NEUROSURG, V75, P103, DOI 10.3171/jns.1991.75.1.0103; HARIRI RJ, 1989, J TRAUMA, V29, P1203, DOI 10.1097/00005373-198909000-00003; HARIRI RJ, 1990, STROKE S, V21, P81; HARIRI RJ, UNPUB; HINSHAW LB, 1970, ARCH SURG-CHICAGO, V100, P600; JEPPSSON B, 1981, AM J SURG, V141, P136, DOI 10.1016/0002-9610(81)90026-X; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; KUSCHINSKY W, 1972, CIRC RES, V31, P240, DOI 10.1161/01.RES.31.2.240; LAW WR, 1985, CIRC SHOCK, V15, P49; LEFER AM, 1989, CIRC SHOCK, V27, P3; LIU MS, 1988, J SURG RES, V45, P472, DOI 10.1016/0022-4804(88)90198-9; MENDELOW AD, 1981, STROKE, V12, P58, DOI 10.1161/01.STR.12.1.58; MENDELSON Y, 1988, MED INSTRUM, V22, P167; MENDELSON Y, 1983, ADV EXP MED BIOL, V159, P93; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; PULSINELLI WA, 1982, ANN NEUROL, V11, P499, DOI 10.1002/ana.410110510; SHEPARD SR, 1990, ACT NEUR S, V51, P58; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SMITH EF, 1988, CIRC SHOCK, V25, P21; WAHL M, 1970, PFLUG ARCH EUR J PHY, V316, P152, DOI 10.1007/BF00586483; WYATT JS, 1986, LANCET, V2, P1063, DOI 10.1016/S0140-6736(86)90467-8; YOSHIYA I, 1980, MED BIOL ENG COMPUT, V18, P27, DOI 10.1007/BF02442476; 1990, CURRENT TRENDS INCRE, V39, P31	37	19	19	0	0	FRANKLIN H MARTIN FOUNDATION	CHICAGO	55 E ERIE ST, CHICAGO, IL 60611	0039-6087			SURG GYNECOL OBSTET	Surg. Gynecol. Obstet.	FEB	1993	176	2					155	166					12	Obstetrics & Gynecology; Surgery	Obstetrics & Gynecology; Surgery	KK498	WOS:A1993KK49800010	8421804				2021-06-18	
J	MCBURNEY, RN; DALY, D; FISCHER, JB; HU, LY; SUBBARAO, K; KNAPP, AG; KOBAYASHI, K; MARGOLIN, L; REDDY, NL; GOLDIN, SM				MCBURNEY, RN; DALY, D; FISCHER, JB; HU, LY; SUBBARAO, K; KNAPP, AG; KOBAYASHI, K; MARGOLIN, L; REDDY, NL; GOLDIN, SM			NEW CNS-SPECIFIC CALCIUM-ANTAGONISTS	JOURNAL OF NEUROTRAUMA			English	Article							TRANSMITTER RELEASE; SUPERFUSION SYSTEM; VERTEBRATE CELLS; CHANNELS; INHIBITION; RECEPTOR; BRAIN; CONE	Ischemic insults to the brain in stroke or traumatic brain injury produce excessive release of glutamate from depolarized nerve terminals. This excessive glutamate release in turn stimulates massive calcium entry into nerve cells, activating a biochemical cascade that results in cell death. A major pathway of calcium entry into depolarized nerve cells is through voltage-sensitive, high threshold calcium channels. A large fraction of this calcium entry is mediated through "R-type" calcium channels, channels resistant to blockage by dihydropyridine calcium antagonists such as nimodipine. A newly discovered compound derived from spider venom, CNS 2103, antagonizes both R-type channels and dihydropyridine-sensitive ("L-type") calcium channels. This broad spectrum of action, coupled with selectivity for calcium channels over other classes of voltage-sensitive and ligand-gated ion channels, makes CNS 2103 an interesting lead for development of drugs to treat ischemic brain injury. Activation of presynaptic ("N-type") calcium channels in nerve terminals is a primary cause of excessive neurotransmitter release in brain ischemia. Prevention of glutamate release by blockade of N-type channels in glutamatergic nerve terminals may, at an early stage in the pathophysiological cascade, abort the process leading to nerve cell death. Cambridge NeuroScience has developed a novel rapid kinetic approach for monitoring glutamate release from brain nerve terminals in vitro, and this has led to CNS 1145, a substituted guanidine that selectively blocks a kinetic component of calcium-dependent glutamate release mediated by persistent depolarization. Additional evidence suggests that CNS 1145 antagonizes presynaptic N-type calcium channels, and this may account at least in part for its ability to block glutamate release.		MCBURNEY, RN (corresponding author), CAMBRIDGE NEUROSCI INC, 1 KENDALL SQ, BLDG 700, CAMBRIDGE, MA 02139 USA.		Subbarao, Krishna/X-3870-2019	Subbarao, Krishna/0000-0002-2075-1835			[Anonymous], 1990, Lancet, V336, P1205; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; HILLE B, 1984, IONIC CHANNELS EXCIT, P226; JANIS RA, 1991, CALCIUM CHANNELS THE, P197; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P194; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KEANA JFW, 1989, P NATL ACAD SCI USA, V86, P5631, DOI 10.1073/pnas.86.14.5631; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.neuro.14.1.379; MAZZO DJ, 1983, ANAL PROFILE DRUG SU, V15, P1; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; NACHSHEN DA, 1985, J PHYSIOL-LONDON, V361, P251, DOI 10.1113/jphysiol.1985.sp015644; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; RITCHIE JM, 1977, REV PHYSIOL BIOCH P, V79, P1, DOI 10.1007/BFb0037088; SCOTT RH, 1990, MOL PHARMACOL, V38, P711; SEABROOK GR, 1989, BRIT J PHARMACOL, V97, P1125, DOI 10.1111/j.1476-5381.1989.tb12570.x; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SUSZKIW JB, 1986, J NEUROSCI, V6, P1349; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TSUBOKAWA M, 1991, ABST SOC NEUR ANN M, V17, P1161; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; TURNER TJ, 1989, BIOCHEMISTRY-US, V28, P586, DOI 10.1021/bi00428a026	31	19	20	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1992	9			2			S531	S543					13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HU819	WOS:A1992HU81900010	1319500				2021-06-18	
J	HORVAT, JC				HORVAT, JC			TRANSPLANTS OF FETAL NEURAL TISSUE AND AUTOLOGOUS PERIPHERAL-NERVES IN AN ATTEMPT TO REPAIR SPINAL-CORD INJURIES IN THE ADULT-RAT - AN OVERALL VIEW	PARAPLEGIA			English	Article						SPINAL CORD INJURY; TRANSPLANTATION; FETAL NEURAL TISSUE; PERIPHERAL NERVE AUTOGRAFTS; ADULT RAT; EXPERIMENTAL RESEARCH		Embryonic neurons and autologous peripheral nerve segments constitute selected materials for studying central nervous system plasticity and repair in adult mammals. Transplanted to the brain or the spinal cord, the former are possible substitutes designed to replace lost or deficient host neurons while the latter have useful stimulating and guiding effects upon axonal regrowth from surviving axotomized neurons. Consequently, these techniques give rise to interesting prospects for short and medium range fundamental research as well as for possible medium and long-term clinical applications. From a basic viewpoint, utilisation of such transplants is designed to study the survival, the morphological and biochemical differentiation, the reafferentation, the expression of potentialities for plasticity, axomal growth or regeneration, synaptogenesis, of host as well as of transplanted embryonic neurons. From a clinical viewpoint these studies should attempt at finding solutions to counteract the effects of severe traumatic or neurodegenerative lesions of the brain and of the spinal cord which until now appear quite refractory to therapeutic approaches.		HORVAT, JC (corresponding author), DESCARTES UNIV 45,NEUROBIOL RENE LAB,RUE ST PERES,F-75270 PARIS 06,FRANCE.							0	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0031-1758			PARAPLEGIA	Paraplegia	JUN	1991	29	5					299	308		10.1038/sc.1991.44			10	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	FR564	WOS:A1991FR56400003	1886729	Bronze			2021-06-18	
J	MEYER, CA; MIRVIS, SE; WOLF, AL; THOMPSON, RK; GUTIERREZ, MA				MEYER, CA; MIRVIS, SE; WOLF, AL; THOMPSON, RK; GUTIERREZ, MA			ACUTE TRAUMATIC MIDBRAIN HEMORRHAGE - EXPERIMENTAL AND CLINICAL OBSERVATIONS WITH CT	RADIOLOGY			English	Article						BRAIN, CT; BRAIN, HEMORRHAGE; BRAIN, INFARCTION; BRAIN, INJURIES; MENINGES, INJURIES	BRAIN-STEM HEMORRHAGE; DIFFUSE AXONAL INJURY; COMPUTERIZED-TOMOGRAPHY; HEAD TRAUMA; MR; LESIONS; SCANS	Traumatic brain stem hemorrhage (TBH) after blunt head impact is an uncommon injury and has historically been associated with high mortality. Retrospective clinical review identified 64 patients with TBH admitted during a 5-year period. Complete imaging and clinical records for 45 of these patients demonstrated that TBH could be categorized into three groups. The most frequent site of hemorrhage, in 31 (69%) of 45 patients (group 1), was the midline rostral anterior brain stem, posterior to the interpeduncular cistern, and this injury was associated with a 71% survival rate. This pattern was also associated with a predominantly anterior site of head and/or face impact. Eight (18%) patients (group 2) had miscellaneous foci of acute brain stem hemorrhage, with seven (88%) surviving. Six (13%) patients (group 3) had brain stem hemorrhage associated with transtentorial herniation and brain stem compression, with 100% mortality. Experimental findings in a canine model and clinical results indicate that the anterior rostral midbrain is a common site of TBH and appears to arise from sudden craniocaudal displacement of the brain at impact. Survival is unexpectedly high with this location of traumatic midbrain hemorrhage.	MARYLAND INST EMERGENCY MED SERV SYST,DEPT RADIOL,22 S GREENE ST,BALTIMORE,MD 21202; MARYLAND INST EMERGENCY MED SERV SYST,DEPT NEUROSURG,BALTIMORE,MD 21202; WALTER REED ARMY MED CTR,DEPT RADIOL,WASHINGTON,DC 20307; UNIV MARYLAND,MED CTR,DIV NEUROSURG,BALTIMORE,MD 21201							ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; CARDOBES F, 1986, ACTA NEUROCHIR, V81, P27; CLIFTON GL, 1983, CLIN NEUROSCIENCES, V2, P1269; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; COPE DN, 1990, KRUSENS HDB PHYSICAL, P1217; CROMPTON MR, 1971, LANCET, V1, P669; ESPERSEN JO, 1981, ACTA NEUROCHIR, V56, P201, DOI 10.1007/BF01407231; FRENCH BN, 1977, SURG NEUROL, V7, P171; FREYTAG E, 1963, ARCH PATHOL, V75, P402; FRIEDE RL, 1966, NEUROLOGY, V16, P1210, DOI 10.1212/WNL.16.12.1210; GALYON DD, 1988, PEDIATR NEUROSCI, V14, P272, DOI 10.1159/000120403; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HASSLER O, 1967, NEUROLOGY, V17, P368, DOI 10.1212/WNL.17.4.368; JACOBS L, 1976, NEUROLOGY, V26, P1111, DOI 10.1212/WNL.26.12.1111; KLINTWOR.GK, 1965, AM J PATHOL, V47, P525; LINDENBERG R, 1955, J NEUROPATH EXP NEUR, V14, P223, DOI 10.1097/00005072-195507000-00001; LINDENBERG R, 1966, CLIN NEUROSURG, V12, P129; MARGOLIS MT, 1974, RADIOLOGY SKULL BRAI, V2; ROPPER AH, 1985, ANN NEUROL, V18, P80, DOI 10.1002/ana.410180114; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; THOMPSON RK, 1988, NEUROSURGERY, V22, P629, DOI 10.1227/00006123-198804000-00002; THOMPSON RK, 1988, NEUROSURGERY, V22, P623, DOI 10.1227/00006123-198804000-00001; TOMINSON BE, 1970, J CLIN PATHOL S4, V23, P154; TSAI FY, 1980, AM J ROENTGENOL, V134, P717, DOI 10.2214/ajr.134.4.717; WEINTRAUB CM, 1960, BRIT J SURG, V48, P62, DOI 10.1002/bjs.18004820711; YEAKLEY JW, 1986, RADIOLOGY, V158, P699, DOI 10.1148/radiology.158.3.3945742; ZUCCARELLO M, 1983, ACTA NEUROCHIR, V67, P103, DOI 10.1007/BF01401670	31	19	20	0	0	RADIOLOGICAL SOC NORTH AMER	EASTON	20TH AND NORTHAMPTON STS, EASTON, PA 18042	0033-8419			RADIOLOGY	Radiology	JUN	1991	179	3					813	818		10.1148/radiology.179.3.2027997			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	FM910	WOS:A1991FM91000045	2027997				2021-06-18	
J	OGAWA, T				OGAWA, T			BLADDER DEFORMITIES IN PATIENTS WITH NEUROGENIC BLADDER DYSFUNCTION	UROLOGIA INTERNATIONALIS			English	Article						NEUROGENIC BLADDER DYSFUNCTION; BLADDER DEFORMITY		231 patients with neurogenic bladder dysfunction were evaluated for bladder deformities. Bladder deformity implies bladder trabeculation and deformity of bladder shape such as pine tree shape. Bladder deformity was judged radiographically at maximum cystometric capacity and classified into grade 0 (none), grade I (mild), grade II (moderate) and grade III (severe). Upper urinary tract deterioration (hydronephrosis and/or reflux) was found in 2% of grade 0, 8% of grade I, 52% of grade II and 62% of grade III. I suggested that bladder deformity was one of the risk factors for upper tract deterioration. High grade deformity (grade II and III) was found more frequently in traumatic spinal cord injury and spinal dysraphism than brain disease. Most patients with low compliance bladder had high grade bladder deformity. The management program including clean intermittent catheterization was effective in preventing bladder deformities.		OGAWA, T (corresponding author), WAKAYAMA ROHSAI HOSP,DEPT UROL,WAKAYAMA,JAPAN.							0	19	19	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0042-1138			UROL INT	Urol.Int.		1991	47			1			59	62		10.1159/000282252			4	Urology & Nephrology	Urology & Nephrology	GD446	WOS:A1991GD44600016	1949379				2021-06-18	
J	RIEGER, H; PENNIG, D; KLEIN, W; GRUNERT, J				RIEGER, H; PENNIG, D; KLEIN, W; GRUNERT, J			TRAUMATIC DISLOCATION OF THE HIP IN YOUNG-CHILDREN	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article								Traumatic dislocation of the hip joint is an uncommon injury in children. The present report on this traumatic emergency is based on the authors' own observations of three cases and a review of the literature. The main problem is the possible development of avascular necrosis of the femoral head. The crucial therapeutic intervention to avoid this seious complication seems to be immediate, usually closed, reduction under general anaesthesia. A management protocol is presented.		RIEGER, H (corresponding author), UNIV MUNSTER,UNFALL & HANDCHIRURG KLIN & POLIKLIN,JUNGEBLODTPL 1,W-4400 MUNSTER,GERMANY.						BRUG E, 1974, MUNCHEN MED WOCHEN, V116, P315; BRUNNER C, 1988, Z KINDERCHIR, V43, P174; CHUNG SMK, 1976, J BONE JOINT SURG AM, V58, P961, DOI 10.2106/00004623-197658070-00011; FINESCHI G, 1956, Arch Orthop Unfallchir, V48, P225, DOI 10.1007/BF00418688; FINKE W, 1976, ZENTRALBL CHIR, V101, P177; FUNK FJ, 1962, J BONE JOINT SURG AM, V44, P1135, DOI 10.2106/00004623-196244060-00008; GLASS A, 1961, J BONE JOINT SURG BR, V43, P29; HELBING G, 1986, PRAXIS ORTHOPADIE, P310; HIPP E, 1986, LEHBRUCH ORTHOPADIE, V3, P344; JONASCH E, 1981, LEBENSJAHR, P84; JUNGBLUTH KH, 1978, BG SCHRIFTENREIHE, P69; LUGGER LJ, 1974, ZBL CHIR, V99, P340; OFFIERSKI CM, 1981, J BONE JOINT SURG BR, V63, P194; PIGGOT J, 1961, J BONE JOINT SURG BR, V43, P38; REEEINHARDT R, 1975, BG SCHRIFTENREIHE, P177; RITTER G, 1984, UNFALLHEILKUNDE, V87, P24; SEILER JG, 1989, J BONE JOINT SURG AM, V671, P28; SLAVIK M, 1986, ARCH ORTHOP TRAUM SU, V104, P385, DOI 10.1007/BF00454438; TRUETA J, 1957, J BONE JOINT SURG BR, V39, P358; VONLAER L, 1986, FRAKTUREN LUXATIONEN, P142; Weigand H, 1979, Hefte Unfallheilkd, P239; 1988, J BONE JOINT SURG AM, V50, P79	22	19	21	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0936-8051			ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.		1991	110	2					114	117		10.1007/BF00393886			4	Orthopedics; Surgery	Orthopedics; Surgery	EZ001	WOS:A1991EZ00100011	2015133				2021-06-18	
J	JACKSON, RD; MYSIW, WJ				JACKSON, RD; MYSIW, WJ			ABNORMAL CORTISOL DYNAMICS AFTER TRAUMATIC BRAIN INJURY - LACK OF UTILITY IN PREDICTING AGITATION OR THERAPEUTIC RESPONSE TO TRICYCLIC ANTIDEPRESSANTS	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article									OHIO STATE UNIV,DEPT MED,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT PHYS MED,COLUMBUS,OH 43210			Mysiw, Walter/E-3724-2011		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR 0034] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000034] Funding Source: NIH RePORTER		ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2; BOOTH BJ, 1980, REHABILITATION HEAD; CARROLL BJ, 1986, J CLIN PSYCHIAT, V47, P10; CARROLL BJ, 1982, PHARMACOPSYCHIATRIA, V15, P19, DOI 10.1055/s-2007-1019504; COCCARO EF, 1984, J CLIN PSYCHIAT, V45, P382; CORRIGAN JD, IN PRESS ARCH PHYS M; COYLE JT, 1986, DIS NERV SYST, P880; DAVIS JM, 1985, COMPREHENSIVE TXB PS, V4, P1513; GWIRTSMAN H, 1982, J CLIN PSYCHIAT, V43, P321; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; JENNETT B, 1981, MANAGEMENT HEAD INJU, P23; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KLEIN HE, 1984, BRIT J PSYCHIAT, V145, P591, DOI 10.1192/bjp.145.6.591; KLEIN HE, 1984, ACTA PSYCHIAT SCAND, V70, P239, DOI 10.1111/j.1600-0447.1984.tb01204.x; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Liddle GW, 1981, TXB ENDOCRINOLOGY, P249; LYNCH WJ, 1982, COGNITIVE REHABILITA, P63; MALKMUS D, 1980, REBHABILITATION HEAD; MANDEL P, 1979, PSYCHOPHARMACOLOGY A, P95; MASON JW, 1965, ARCH GEN PSYCHIAT, V13, P1; Mysiw W.J., 1987, J HEAD TRAUMA REHAB, V2, P34, DOI [10.1097/00001199-198712000-00007, DOI 10.1097/00001199-198712000-00007]; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; NELSON WH, 1982, ARCH GEN PSYCHIAT, V39, P1033; SCHILDKRAUT JJ, 1985, COMPREHENSIVE TX PSY, V4, P769; TREXLER L, 1982, COGNITIVE REHABILITA, P173; VANWOERKOM TCA, 1974, LANCET, P812; ZUNG WWK, 1984, J CLIN PSYCHIAT, V45, P437; 1982, WORKING BRAIN INJURE	28	19	19	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	1989	68	1					18	23		10.1097/00002060-198902000-00006			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	T5779	WOS:A1989T577900006	2644950				2021-06-18	
J	BRAUN, CMJ; DAIGNEAULT, S; CHAMPAGNE, D				BRAUN, CMJ; DAIGNEAULT, S; CHAMPAGNE, D			INFORMATION-PROCESSING DEFICITS AS INDEXED BY REACTION-TIME PARAMETERS IN SEVERE CLOSED HEAD-INJURY	INTERNATIONAL JOURNAL OF CLINICAL NEUROPSYCHOLOGY			English	Article										BRAUN, CMJ (corresponding author), UNIV QUEBEC, DEPT PSYCHOL, CP 8888, SUCC A, MONTREAL H3C 3P8, QUEBEC, CANADA.						ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS; BENTON AL, 1957, J ABNORM SOC PSYCH, V54, P109, DOI 10.1037/h0047176; BENTON AL, 1962, J NERV MENT DIS, V135, P415; BLACKBURN H L, 1955, Confin Neurol, V15, P327; BOHANNON WE, 1983, PSYCHIAT RES, V9, P17, DOI 10.1016/0165-1781(83)90084-7; BRACY OL, 1984, USING COMPUTERS CLIN, P257; BRACY OL, 1986, COGNITIVE REHABILITA, V4, P10; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; BRAUN C, 1987, COGNITIVE REHABILITA, V5, P44; BRAUN C, 1987, P CLIN APHASIOLOGY C; BRAUN C, 1985, REV MODIFICATION COM, V15, P176; BRAUN CMJ, 1987, J CLIN EXP NEUROPSYC, V9, P48; BRAUN CMJ, 1988, J NEUROLOGICAL REHAB, V2, P109; Brooks N., 1984, CLOSED HEAD INJURY P; BROUWER WH, 1984, COMMUNICATION; BROUWER WH, 1984, 13TH P ANN INS M SAN; BRUHN P, 1977, CORTEX, V13, P373, DOI 10.1016/S0010-9452(77)80018-X; Bruhn P, 1971, Cortex, V7, P278; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; DEE HL, 1971, ACTA PSYCHIAT SCAND, V47, P315, DOI 10.1111/j.1600-0447.1971.tb02217.x; DENCKER SJ, 1958, ACTA PSYCHIATRICA NE, V33, P120; Dirken J. M., 1972, FUNCTIONAL AGE IND W; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FERRIS S, 1976, J AM GERIATR SOC, V24, P529, DOI 10.1111/j.1532-5415.1976.tb03277.x; GOLDSTEIN K, 1942, EFFECTS BRAIN DAMAGE; Green D., 1966, SIGNAL DETECTION THE; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HANNAY H J, 1982, Journal of Clinical Neuropsychology, V4, P117; KLENSCH H, 1983, FORT NEUROL PSYCHIAT, V41, P575; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LITTLE MM, 1985, EVIDENCE SPECIFIC AT; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; Miller E, 1970, Cortex, V6, P121; NORMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236; PIROZZOLO FJ, 1981, NEUROBIOL AGING, V2, P113, DOI 10.1016/0197-4580(81)90008-7; POSNER MI, 1987, NEUROPSYCHOLOGIA, V25, P135, DOI 10.1016/0028-3932(87)90049-2; Posner MI., 1978, CHRONOMETRIC EXPLORA; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Ruesch J, 1944, J NEUROSURG, V1, P243, DOI 10.3171/jns.1944.1.4.0243; SAVINO PJ, 1980, NEUROLOGY, V30, P963, DOI 10.1212/WNL.30.9.963; THOMAS C, 1977, THESIS OXFORD U; TOGLIA JU, 1979, LATE EFFECTS HEAD IN, P72; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1978, REACTION TIME ATTENT; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P83	49	19	19	0	1	MELNIC PRESS INC	MADISON	PO BOX 6216, MADISON, WI 53716 USA	0197-3681			INT J CLIN NEUROPSYC			1989	11	4					167	176					10	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	CC367	WOS:A1989CC36700003					2021-06-18	
J	SAHGAL, V; HEINEMANN, A				SAHGAL, V; HEINEMANN, A			RECOVERY OF FUNCTION DURING INPATIENT REHABILITATION FOR MODERATE TRAUMATIC BRAIN INJURY	SCANDINAVIAN JOURNAL OF REHABILITATION MEDICINE			English	Article										SAHGAL, V (corresponding author), REHABIL INST CHICAGO,BRAIN TRAUMA PROGRAM,345 E SUPER ST,CHICAGO,IL 60611, USA.		Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326				0	19	19	0	2	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5505			SCAND J REHABIL MED	Scand. J. Rehabil. Med.		1989	21	2					71	79					9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AB880	WOS:A1989AB88000002	2749197				2021-06-18	
J	SAUNDERS, CE; COTA, R; BARTON, CA				SAUNDERS, CE; COTA, R; BARTON, CA			RELIABILITY OF HOME OBSERVATION FOR VICTIMS OF MILD CLOSED-HEAD INJURY	ANNALS OF EMERGENCY MEDICINE			English	Article										SAUNDERS, CE (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT SURG,NASHVILLE,TN 37232, USA.							0	19	20	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	FEB	1986	15	2					160	163		10.1016/S0196-0644(86)80012-9			4	Emergency Medicine	Emergency Medicine	AYW03	WOS:A1986AYW0300010	3946858				2021-06-18	
J	MCLEAN, JM; WRIGHT, RM; HENDERSON, JP; LISTER, JR				MCLEAN, JM; WRIGHT, RM; HENDERSON, JP; LISTER, JR			VERTEBRAL ARTERY RUPTURE ASSOCIATED WITH CLOSED HEAD-INJURY - REPORT OF 2 CASES	JOURNAL OF NEUROSURGERY			English	Article									ST FRANCIS MED CTR, DEPT RADIOL, PEORIA, IL USA	MCLEAN, JM (corresponding author), UNIV ILLINOIS, COLL MED, DEPT NEUROSCI, 530 NE GLEN OAK AVE, PEORIA, IL 61656 USA.						BLADIN P F, 1975, Proceedings of the Australian Association of Neurologists, V12, P35; CARPENTER S, 1961, J NEUROSURG, V18, P849, DOI 10.3171/jns.1961.18.6.0849; CONTOSTAVLOS D L, 1971, Journal of Forensic Sciences, V16, P40; DAVIDSON KC, 1975, RADIOLOGY, V115, P651, DOI 10.1148/15.3.651; DAVIS JM, 1983, NEURORADIOLOGY, V25, P55, DOI 10.1007/BF00333294; DEKLEYN A, 1933, DTSCH Z NERVENHEILKD, V132, P157; FIELDING JW, 1957, J BONE JOINT SURG AM, V39, P1280, DOI 10.2106/00004623-195739060-00005; FORD R, 1956, J FORENSIC SCI, V1, P117; FRAENCKEL P, 1927, DTSCH Z GES GERICHTL, V10, P193; FREYTAG E, 1963, ARCH PATHOL, V75, P402; FRITZ E, 1935, BEITR GERICHTL MED, V13, P22; GERLACH L, 1984, BEITR MORPHOL, V1, P104; GURDJIAN ES, 1963, J NEUROSURG, V20, P418, DOI 10.3171/jns.1963.20.5.0418; HARBITZ F, 1933, NORSK MAG LAEGEVID, V94, P241; HENKE W, 1863, HDB ANATOMIE MECHANI; Hinz P, 1968, Arch Orthop Unfallchir, V64, P268, DOI 10.1007/BF02171264; HOLZER J, 1955, DTSCH Z GERICHTL MED, V44, P422; KRAULAND W, 1949, Schweiz Z Pathol Bakteriol, V12, P113; KRAULAND W, 1949, BEITR GERICHTL MED, V18, P24; MANT AK, 1972, J FORENSIC SCI SOC, V12, P567; MUNCK W, 1926, HOSPITAL STIDENDE, V69, P149; NEWBARR FD, 1958, J FORENSIC SCI, V3, P174; PAUL GA, 1980, J NEUROSURG, V53, P101, DOI 10.3171/jns.1980.53.1.0101; Schmidt H, 1942, BEITR PATHOL ANAT AL, V107, P256; SCHMITT HP, 1976, SCHWEIZ ARCH NEUROL, V119, P363; Schneider R C, 1972, Clin Neurosurg, V19, P312; SELECKI BR, 1969, MED J AUSTRALIA, V1, P1012, DOI 10.5694/j.1326-5377.1969.tb49865.x; Simonsen J, 1967, J Forensic Med, V14, P146; SIX EG, 1981, J NEUROSURG, V54, P814, DOI 10.3171/jns.1981.54.6.0814; TATLOW WFT, 1957, NEUROLOGY, V7, P331, DOI 10.1212/WNL.7.5.331; THORNSTEDT H, 1960, Dtsch Z Gesamte Gerichtl Med, V50, P254, DOI 10.1007/BF00586083; TOOLE JF, 1960, ARCH NEUROL-CHICAGO, V2, P616, DOI 10.1001/archneur.1960.03840120022003; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WHITE AA, 1978, CLIN BIOMECHANICS SP, pCH2; WOLFF K, 1928, DTSCH Z GES GERICHTL, V11, P464; YATES PO, 1959, ARCH DIS CHILD, V34, P436, DOI 10.1136/adc.34.177.436	36	19	19	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.		1985	62	1					135	138		10.3171/jns.1985.62.1.0135			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TX749	WOS:A1985TX74900021	3964845				2021-06-18	
J	WEST, M; LABELLA, FS; HAVLICEK, V; PARKINSON, D				WEST, M; LABELLA, FS; HAVLICEK, V; PARKINSON, D			CEREBRAL CONCUSSION IN RATS RAPIDLY INDUCES HYPOTHALAMIC-SPECIFIC EFFECTS ON OPIATE AND CHOLINERGIC RECEPTORS	BRAIN RESEARCH			English	Article									UNIV MANITOBA,FAC MED,DEPT PHARMACOL & THERAPEUT,WINNIPEG R3E 0W3,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,DEPT NEUROL SURG,WINNIPEG R3E 0W3,MANITOBA,CANADA	WEST, M (corresponding author), UNIV MANITOBA,FAC MED,DEPT PHYSIOL,WINNIPEG R3E 0W3,MANITOBA,CANADA.						BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; CHOW E, 1979, BRIT J PHARMACOL, V67, P345, DOI 10.1111/j.1476-5381.1979.tb08686.x; CREESE I, 1977, EUR J PHARMACOL, V46, P377, DOI 10.1016/0014-2999(77)90232-1; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P591, DOI 10.1001/archneurpsyc.1952.02320230017002; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GROAT RA, 1950, NEUROPATH EXP NEUROL, V9, P150; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P386; JOSEPH PD, 1971, BRAIN RES, V26, P15; MARTIN JB, 1977, CLIN NEUROENDOCRINOL, P247; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; PARKINSON D, 1976, MAYO CLIN P, V52, P492; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Ranson SW, 1939, ARCH NEURO PSYCHIATR, V41, P1; RIPPERGER EA, 1975, HDB CLIN NEUROLOGY, V23, P91; SELLIER K, 1966, 3RD P INT C NEUR SUR, P87; SHAH KR, 1981, CANAD FED BIOL SOC M; Shetter A G, 1979, Adv Neurol, V22, P5; STALHAMMAR D, 1975, ACTA NEUROL SCAND, V52, P27; THOMAS LM, 1967, J NEUROSURG, V26, P316, DOI 10.3171/jns.1967.26.3.0316; TOWER DB, 1966, HEAD INJURY, P448; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725	29	19	19	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.		1981	225	2					271	277		10.1016/0006-8993(81)90835-0			7	Neurosciences	Neurosciences & Neurology	MR196	WOS:A1981MR19600004	6272930				2021-06-18	
J	LYNCH, S; YARNELL, PR				LYNCH, S; YARNELL, PR			RETROGRADE-AMNESIA - DELAYED FORGETTING AFTER CONCUSSION	AMERICAN JOURNAL OF PSYCHOLOGY			English	Article									UNIV CALIF,DAVIS,CA 95616; UNIV COLORADO,BOULDER,CO 80304							MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351	1	19	19	0	1	UNIV ILLINOIS PRESS	CHAMPAIGN	1325 S OAK ST, CHAMPAIGN, IL 61820	0002-9556			AM J PSYCHOL	Am. J. Psychol.		1973	86	3					643	645		10.2307/1421950			3	Psychology, Multidisciplinary	Psychology	S1630	WOS:A1973S163000016	4780127				2021-06-18	
J	Symonds, CP				Symonds, CP			Disturbance of cerebral function in concussion	LANCET			English	Article																Russell W Ritchie, 1934, Edinb Med J, V41, P129; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Symonds CP, 1932, LANCET, V1, P820; Trotter W, 1925, LANCET, V2, P953; TROTTER W, 1923, SYSTEM SURG, V3, P464	5	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet		1935	1						486	488					3	Medicine, General & Internal	General & Internal Medicine	V9599	WOS:000188727600178					2021-06-18	
J	McDonald, SJ; Sharkey, JM; Sun, M; Kaukas, LM; Shultz, SR; Turner, RJ; Leonard, AV; Brady, RD; Corrigan, F				McDonald, Stuart J.; Sharkey, Jessica M.; Sun, Mujun; Kaukas, Lola M.; Shultz, Sandy R.; Turner, Renee J.; Leonard, Anna, V; Brady, Rhys D.; Corrigan, Frances			Beyond the Brain: Peripheral Interactions after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autonomic dysfunction; infection; inflammation; polytrauma; traumatic brain injury	ENHANCED PULMONARY INFLAMMATION; BONE-MINERAL DENSITY; ACUTE KIDNEY INJURY; HETEROTOPIC OSSIFICATION; RISK-FACTORS; SPINAL-CORD; SODIUM SELENATE; HYPERPHOSPHORYLATED TAU; LUNG INJURY; MOUSE MODEL	Traumatic brain injury (TBI) is a leading cause of death and disability, and there are currently no pharmacological treatments known to improve patient outcomes. Unquestionably, contributing toward a lack of effective treatments is the highly complex and heterogenous nature of TBI. In this review, we highlight the recent surge of research that has demonstrated various central interactions with the periphery as a potential major contributor toward this heterogeneity and, in particular, the breadth of research from Australia. We describe the growing evidence of how extracranial factors, such as polytrauma and infection, can significantly alter TBI neuropathology. In addition, we highlight how dysregulation of the autonomic nervous system and the systemic inflammatory response induced by TBI can have profound pathophysiological effects on peripheral organs, such as the heart, lung, gastrointestinal tract, liver, kidney, spleen, and bone. Collectively, this review firmly establishes TBI as a systemic condition. Further, the central and peripheral interactions that can occur after TBI must be further explored and accounted for in the ongoing search for effective treatments.	[McDonald, Stuart J.; Sun, Mujun; Shultz, Sandy R.; Brady, Rhys D.] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia; [McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic, Australia; [Sharkey, Jessica M.; Turner, Renee J.; Leonard, Anna, V] Univ Adelaide, Fac Hlth & Med Sci, Adelaide Med Sch, Discipline Anat & Pathol, Adelaide, SA, Australia; [Kaukas, Lola M.; Corrigan, Frances] Univ South Australia, Sch Hlth Sci, Adelaide, SA, Australia; [Shultz, Sandy R.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia	McDonald, SJ (corresponding author), Monash Univ, Dept Neurosci, Alfred Ctr, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	stuart.mcdonald@monash.edu		Sun, Mujun/0000-0002-9923-9913; McDonald, Stuart/0000-0001-5190-3179; Corrigan, Frances/0000-0001-6150-8893	Neurosurgical Research Foundation; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [APP1145483]	This work was supported by funding from the Neurosurgical Research Foundation and the National Health and Medical Research Council (APP1145483).	Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Abdel-Haq R, 2019, J EXP MED, V216, P41, DOI 10.1084/jem.20180794; Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Ahmed M, 2015, BRIT J NEUROSURG, V29, P544, DOI 10.3109/02688697.2015.1016892; Ajmo CT, 2009, EXP NEUROL, V218, P47, DOI 10.1016/j.expneurol.2009.03.044; Alfieri KA, 2012, BONE JOINT RES, V1, P174, DOI 10.1302/2046-3758.18.2000102; Alharfi IM, 2014, J NEUROTRAUM, V31, P452, DOI [10.1089/NEU.2013.2904, 10.1089/neu.2013.2904]; Almangour W, 2016, ANN PHYS REHABIL MED, V59, P263, DOI 10.1016/j.rehab.2016.03.009; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andres-Hernando A, 2012, NEPHROL DIAL TRANSPL, V27, P4339, DOI 10.1093/ndt/gfs256; Avlonitis VS, 2005, AM J TRANSPLANT, V5, P684, DOI 10.1111/j.1600-6143.2005.00755.x; AYALA A, 1991, AM J PHYSIOL, V260, pR167; BALDA MS, 1992, YALE J BIOL MED, V65, P725; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Baumann A, 2007, ACTA ANAESTH SCAND, V51, P447, DOI 10.1111/j.1399-6576.2007.01276.x; Beaupre GS, 2006, AM J PHYS MED REHAB, V85, P464, DOI 10.1097/01.phm.0000214275.69286.7a; Bishop S, 2017, BRAIN INJURY, V31, P247, DOI 10.1080/02699052.2016.1226385; Blomster LV, 2013, EXP NEUROL, V247, P226, DOI 10.1016/j.expneurol.2013.05.002; Brady RD, 2016, J MUSCULOSKEL NEURON, V16, P369; Brady RD, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115263; Brady RD, 2018, BONE, V109, P35, DOI 10.1016/j.bone.2017.05.015; Brady RD, 2016, SCI REP-UK, V6, DOI 10.1038/srep34491; Brown S, 2011, BRAIN INJURY, V25, P453, DOI 10.3109/02699052.2011.556581; Calsavara AJC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22754-3; Campos MM, 2000, NEUROPEPTIDES, V34, P314, DOI 10.1054/npep.2000.0823; Carabotti M, 2015, ANN GASTROENTEROL, V28, P203; Chalidis B, 2007, J NEUROTRAUM, V24, P1675, DOI 10.1089/neu.2007.0342; Cheng LK, 2010, WIRES SYST BIOL MED, V2, P65, DOI 10.1002/wsbm.19; Chmielewski C., 2003, NEPHROL NURS J, V30, P191; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; Civiletti F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42147-4; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Corrigan F, 2017, BRAIN BEHAV IMMUN, V64, P124, DOI 10.1016/j.bbi.2017.04.006; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Davydow DS, 2013, AM J GERIAT PSYCHIAT, V21, P887, DOI 10.1016/j.jagp.2013.01.017; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Dijkstra-Kersten SMA, 2020, J CRIT CARE, V55, P171, DOI 10.1016/j.jcrc.2019.11.006; Dobson JL, 2017, AM J PHYSIOL-REG I, V312, pR575, DOI 10.1152/ajpregu.00499.2016; Dong TT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0663-y; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; Freeman WD, 2015, NEUROCRIT CARE, V22, P173, DOI 10.1007/s12028-015-0119-8; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P59; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; Genet F, 2015, J PATHOL, V236, P229, DOI 10.1002/path.4519; Genet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016632; Gonzalvo R, 2007, CRIT CARE, V11, DOI 10.1186/cc5930; Gregory T, 2012, BJA EDUC, V12, P67, DOI 10.1093/bjaceaccp/mkr058; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE-08-0568; Harrison FE, 2009, BEHAV BRAIN RES, V198, P247, DOI 10.1016/j.bbr.2008.10.015; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Ho CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190683; Hofman M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/204842; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Houlden A, 2016, BRAIN BEHAV IMMUN, V57, P10, DOI 10.1016/j.bbi.2016.04.003; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Junger WG, 2013, SHOCK, V40, P366, DOI 10.1097/SHK.0000000000000038; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; Kinsey GR, 2008, NEPHRON EXP NEPHROL, V109, pE102, DOI 10.1159/000142934; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Kondo H, 2013, AM J PHYSIOL-ENDOC M, V304, pE507, DOI 10.1152/ajpendo.00191.2012; Kong XD, 2014, NEUROSCI BULL, V30, P903, DOI 10.1007/s12264-014-1481-9; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Koutsoukou Antonia, 2016, World J Crit Care Med, V5, P65, DOI 10.5492/wjccm.v5.i1.65; Krishnamoorthy V, 2017, NEUROCRIT CARE, V26, P379, DOI 10.1007/s12028-016-0335-x; Kristensen E, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/294965; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Li H, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13260; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li N, 2011, NEUROCRIT CARE, V14, P377, DOI 10.1007/s12028-011-9511-1; Liao DH, 2009, WORLD J GASTROENTERO, V15, P169, DOI 10.3748/wjg.15.169; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Locher RJ, 2015, J MUSCULOSKEL NEURON, V15, P309; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Ma EL, 2017, BRAIN BEHAV IMMUN, V66, P56, DOI 10.1016/j.bbi.2017.06.018; Ma QQ, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1434-3; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matsumoto T, 1997, J LEUKOCYTE BIOL, V62, P581; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Moore EM, 2010, RENAL FAILURE, V32, P1060, DOI 10.3109/0886022X.2010.510234; Morioka K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48126-z; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; Mrakovcic-Sutic I, 2010, SCAND J IMMUNOL, V72, P57, DOI 10.1111/j.1365-3083.2010.02407.x; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; MUELLER M, 1991, J BONE MINER RES, V6, P401; Nagao M, 2011, P NATL ACAD SCI USA, V108, P17767, DOI 10.1073/pnas.1109402108; Navarro Solano J., 2009, INT J IMMUNOPATHOL S, V22, P13; Nicholson SE, 2019, SHOCK, V52, P240, DOI 10.1097/SHK.0000000000001211; Nicolls MR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010259; Nizamutdinov D, 2017, SCI REP-UK, V7, DOI 10.1038/srep40112; Nongnuch A, 2014, CRIT CARE, V18, DOI 10.1186/cc13907; O'Leary R, 2011, BJA EDUC, V11, P87, DOI 10.1093/bjaceaccp/mkr006; Olsen AB, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12121; Oppl B, 2014, J BONE MINER RES, V29, P1096, DOI 10.1002/jbmr.2122; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Park Chang-Yong, 2016, Korean J Neurotrauma, V12, P89, DOI 10.13004/kjnt.2016.12.2.89; Pavlov VA, 2015, IMMUNOL RES, V63, P38, DOI 10.1007/s12026-015-8718-1; Pelosi P., 2002, RESP FAILURE BRAIN I; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890; Prescott HC, 2019, AM J RESP CRIT CARE, V200, P972, DOI 10.1164/rccm.201812-2383CP; Probst C, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/136020; Purkayastha S, 2019, BRAIN INJURY, V33, P1129, DOI 10.1080/02699052.2019.1631488; Rael LT, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-57; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Reed Mary L, 2013, Front Endocrinol (Lausanne), V4, P64, DOI 10.3389/fendo.2013.00064; Reznik JE, 2014, J MUSCULOSKEL NEURON, V14, P19; Rizoli SB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1620-6; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Rosas-Ballina M, 2009, NEURON, V64, P28, DOI 10.1016/j.neuron.2009.09.039; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Russo M.V., 2018, J IMMUNOL, V200, P108; Sahbaie P, 2018, J PAIN, V19, P1392, DOI 10.1016/j.jpain.2018.06.004; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; SCHRAUFNAGEL DE, 1993, AM REV RESPIR DIS, V148, P477, DOI 10.1164/ajrccm/148.2.477; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Shahidi B, 2018, J NEUROTRAUM, V35, P398, DOI 10.1089/neu.2017.5172; Sharma R, 2019, BRAIN BEHAV IMMUN, V79, P63, DOI 10.1016/j.bbi.2019.04.034; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Singleton Q, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010063; Skrabal CA, 2005, J SURG RES, V123, P118, DOI 10.1016/j.jss.2004.07.245; Skrifvars MB, 2019, ACTA ANAESTH SCAND, V63, P200, DOI 10.1111/aas.13244; Skrifvars MB, 2017, J TRAUMA ACUTE CARE, V83, P449, DOI 10.1097/TA.0000000000001594; Smith E, 2016, IRISH J MED SCI, V185, P473, DOI 10.1007/s11845-016-1399-5; Smith EM, 2009, ARCH PHYS MED REHAB, V90, P1127, DOI 10.1016/j.apmr.2008.09.578; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; Smithason S, 2013, ACTA NEUROCHIR SUPPL, V115, P253, DOI 10.1007/978-3-7091-1192-5_45; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Sonneville R, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-15; Sun B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128214; Sun MJ, 2018, BRAIN BEHAV IMMUN, V69, P618, DOI 10.1016/j.bbi.2018.01.007; Sun MJ, 2017, BRAIN BEHAV IMMUN, V66, P359, DOI 10.1016/j.bbi.2017.08.005; Suto Y, 2019, J NEUROTRAUM, V36, P609, DOI 10.1089/neu.2018.5812; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; THEODORE J, 1975, LANCET, V2, P749; Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI 10.1056/NEJMra1608077; Torossian F, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96034; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Treangen TJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02757; Tsitsilonis S, 2015, INJURY, V46, P661, DOI 10.1016/j.injury.2015.01.044; Turner Ryan C, 2017, Neuroimmunol Neuroinflamm, V4, P6, DOI 10.20517/2347-8659.2016.40; Valencic L, 2015, SANAMED, V10, P185, DOI [10.5937/sanamed1503185V, DOI 10.5937/SANAMED1503185V]; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Villapol S, 2015, AM J PATHOL, V185, P2641, DOI 10.1016/j.ajpath.2015.06.016; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang L, 2011, CHIN J TRAUMATOL, V14, P7, DOI 10.3760/cma.j.issn.1008-1275.2011.01.002; Wang Y, 2017, J NEUROL SCI, V381, P82, DOI 10.1016/j.jns.2017.08.279; Wang YB, 2011, WORLD J GASTROENTERO, V17, P657, DOI 10.3748/wjg.v17.i5.657; Weckbach S, 2013, J TRAUMA ACUTE CARE, V74, P489, DOI 10.1097/TA.0b013e31827d5f1b; Weckbach S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/890816; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Wicker E, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5967816; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wu S, 2006, EXP NEUROL, V200, P245, DOI 10.1016/j.expneurol.2006.01.027; Yang L, 2016, SCAND J IMMUNOL, V83, P26, DOI 10.1111/sji.12393; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhou ZW, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.827; Zhuang YF, 2013, ASIAN PAC J TROP MED, V6, P383, DOI 10.1016/S1995-7645(13)60043-7; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	185	18	19	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2020	37	5					770	781		10.1089/neu.2019.6885			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LD0OA	WOS:000525731200007	32041478				2021-06-18	
J	Drake, SA; Holcomb, JB; Yang, YJ; Thetford, C; Myers, L; Brock, M; Wolf, DA; Cron, S; Persse, D; McCarthy, J; Kao, LL; Todd, SR; Naik-Mathuria, BJ; Cox, C; Kitagawa, R; Sandberg, G; Wade, CE				Drake, Stacy A.; Holcomb, John B.; Yang, Yijiong; Thetford, Caitlin; Myers, Lauren; Brock, Morgan; Wolf, Dwayne A.; Cron, Stanley; Persse, David; McCarthy, James; Kao, Lillian; Todd, S. Rob; Naik-Mathuria, Bindi J.; Cox, Charles; Kitagawa, Ryan; Sandberg, Glenn; Wade, Charles E.			Establishing a Regional Trauma Preventable/Potentially Preventable Death Rate	ANNALS OF SURGERY			English	Article						trauma preventable death rate; trauma surgery; trauma system research; trauma system; trauma	POSITION STATEMENT; NATIONAL ACADEMIES; INJURY SEVERITY; MEDICINE REPORT; SYSTEM; CARE; EPIDEMIOLOGY; MILITARY; TRENDS; TOURNIQUET	Objective: To establish a trauma preventable/potentially preventable death rate (PPPDR) within a heavily populated county in Texas. The National Academies of Sciences estimated the trauma preventable death rate in the United States to be 20%, issued a call for zero preventable deaths, while acknowledging that an accurate preventable death rate was lacking. In this absence, effective strategies to improve quality of care across trauma systems will remain difficult. Methods: A retrospective review of death-related records that occurred during 2014 in Harris County, TX, a diverse population of 4.4 million. Patient demographics, mechanism of injury, cause, timing, and location of deaths were assessed. Deaths were categorized using uniform criteria and recorded as preventable, potentially preventable or nonpreventable. Results: Of 1848 deaths, 85% had an autopsy and 99.7% were assigned a level of preventability, resulting in a trauma PPPDR of 36.2%. Sex, age, and race/ethnicity varied across preventability categories (P< 0.01). Of 847 prehospital deaths, 758 (89.5%) were nonpreventable. Among 89 prehospital preventable/potentially preventable (P/PP) deaths, hemorrhage accounted for 55.1%. Of the 657 initial acute care setting deaths, 292 (44.4%) were P/PP; of these, hemorrhage, sepsis, and traumatic brain injury accounted for 73.3%. Of 339 deaths occurring after initial hospitalization, 287 (84.7%) were P/PP, of these 117 resulted from sepsis and 31 from pulmonary thromboembolism, accounted for 51.6%. Conclusions: The trauma PPPDR was almost double that estimated by the National Academies of Sciences. Data regarding P/PP deaths offers opportunity to target research, prevention, intervention, and treatment corresponding to all phases of the trauma system.	[Drake, Stacy A.; Yang, Yijiong; Thetford, Caitlin; Cron, Stanley] Univ Texas Hlth Sci Ctr Houston, Cizak Sch Nursing, Houston, TX 77030 USA; [Drake, Stacy A.; Holcomb, John B.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA; [Holcomb, John B.; McCarthy, James; Kao, Lillian; Cox, Charles; Kitagawa, Ryan; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, McGovern Sch Med, Houston, TX 77030 USA; [Thetford, Caitlin] Houston Methodist Hosp, Houston, TX 77030 USA; [Myers, Lauren; Naik-Mathuria, Bindi J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Brock, Morgan] Lyndon B Johnson Gen Hosp, Houston, TX USA; [Wolf, Dwayne A.; Sandberg, Glenn] Harris Cty Inst Forens Sci, Houston, TX USA; [Persse, David] Dept Hlth & Human Serv City Houston, Houston, TX USA; [McCarthy, James] Mem Hermann Hosp, Houston, TX USA; [Todd, S. Rob; Naik-Mathuria, Bindi J.] Baylor Coll Med, Houston, TX 77030 USA	Drake, SA (corresponding author), Univ Texas Hlth Sci Ctr Houston, 6901 Bertner Ave 593, Houston, TX 77030 USA.	Stacy.A.Drake@uth.tmc.edu		holcomb, john/0000-0001-8312-9157	internal PARTNERS Grant from UTHEALTH; Center for Translational Injury Research (CeTIR) from UTHEALTH	The study was in part funded from grants received from an internal PARTNERS Grant and Center for Translational Injury Research (CeTIR) both from UTHEALTH.	ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Boman H, 1999, EUR J SURG, V165, P828; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CDC, 2014, CDC NAT HLTH REP LEA; Chang MH, 2016, J PUBLIC HEALTH MAN, V22, pS13, DOI 10.1097/PHH.0000000000000267; Davis JS, 2014, J TRAUMA ACUTE CARE, V77, P213, DOI 10.1097/TA.0000000000000292; Drake Stacy A, 2017, Trauma Surg Acute Care Open, V2, pe000106, DOI 10.1136/tsaco-2017-000106; Dwyer-Lindgren L, 2018, JAMA-J AM MED ASSOC, V319, P1013, DOI 10.1001/jama.2018.0900; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Falconer JA, 2010, NEW ZEAL MED J, V123, P11; Hanzlick R, 1997, ARCH PATHOL LAB MED, V121, P377; Hartnett T., 2010, CONSENSUS ORIENTED D; Hicks CW, 2015, ANN SURG, V262, P179, DOI 10.1097/SLA.0000000000000809; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Jacobs LM, 2017, J AM COLL SURGEONS, V224, P1084, DOI 10.1016/j.jamcollsurg.2017.02.013; Janak JC, 2018, JAMA SURG, V153, P367, DOI 10.1001/jamasurg.2017.6105; Jenkins DH, 2016, J TRAUMA ACUTE CARE, V81, P819, DOI 10.1097/TA.0000000000001217; Jenkins DH, 2016, J TRAUMA ACUTE CARE, V81, P816, DOI 10.1097/TA.0000000000001218; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kleber C, 2013, WORLD J SURG, V37, P1154, DOI 10.1007/s00268-013-1964-2; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Kwon AM, 2014, EUR J TRAUMA EMERG S, V40, P279, DOI 10.1007/s00068-013-0364-5; Losonczy LI, 2014, J HEALTH CARE POOR U, V25, P308, DOI 10.1353/hpu.2014.0021; Maio RF, 1996, J TRAUMA, V41, P83, DOI 10.1097/00005373-199607000-00013; Martin M, 2009, J TRAUMA, V66, pS51, DOI 10.1097/TA.0b013e31819d86ad; National Academies of Sciences [NAS], 2016, NAT TRAUM CAR SYST I; Navarro S, 2014, WORLD J SURG, V38, P2273, DOI 10.1007/s00268-014-2587-y; NCIPC (National Center for Injury Prevention and Control), 2015, WISQARSTM FAT INJ RE; Oyeniyi BT, 2017, INJURY, V48, P5, DOI 10.1016/j.injury.2016.10.037; Rogers FB, 1997, ARCH SURG-CHICAGO, V132, P376; Sampalis JS, 1995, J TRAUMA, V39, P1029, DOI 10.1097/00005373-199512000-00002; Sanddal TL, 2011, J TRAUMA, V70, P970, DOI 10.1097/TA.0b013e3181fec9ba; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Scerbo MH, 2017, J TRAUMA ACUTE CARE, V83, P1165, DOI 10.1097/TA.0000000000001666; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Staudenmayer K, 2016, AM SURGEON, V82, P356; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Teixeira PGR, 2018, J AM COLL SURGEONS, V226, P769, DOI 10.1016/j.jamcollsurg.2018.01.047; Zafar SN, 2015, J TRAUMA ACUTE CARE, V78, P852, DOI 10.1097/TA.0000000000000557	42	18	18	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	FEB	2020	271	2					375	382		10.1097/SLA.0000000000002999			8	Surgery	Surgery	NC5ZL	WOS:000561296300031	30067544				2021-06-18	
J	Kodali, M; Castro, OW; Kim, DK; Thomas, A; Shuai, B; Attaluri, S; Upadhya, R; Gitai, D; Madhu, LN; Prockop, DJ; Shetty, AK				Kodali, Maheedhar; Castro, Olagide W.; Kim, Dong-Ki; Thomas, Alicia; Shuai, Bing; Attaluri, Sahithi; Upadhya, Raghavendra; Gitai, Daniel; Madhu, Leelavathi N.; Prockop, Darwin J.; Shetty, Ashok K.			Intranasally Administered Human MSC-Derived Extracellular Vesicles Pervasively Incorporate into Neurons and Microglia in both Intact and Status Epilepticus Injured Forebrain	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						brain injury; exosomes; extracellular vesicles; intranasal administration; mesenchymal stem cells; microglia; microvesicles; status epilepticus; transport of extracellular vesicles	SPONTANEOUS SEIZURES; ABNORMAL NEUROGENESIS; STROMAL CELLS; OLD-AGE; EXOSOMES; MODEL; BRAIN; NEURODEGENERATION; INFLAMMATION; IMPAIRMENTS	Extracellular vesicles (EVs) derived from human bone marrow mesenchymal stem cells (hMSCs) have great promise as biologics to treat neurological and neurodegenerative conditions due to their robust antiinflammatory and neuroprotective properties. Besides, intranasal (IN) administration of EVs has caught much attention because the procedure is noninvasive, amenable for repetitive dispensation, and leads to a quick penetration of EVs into multiple regions of the forebrain. Nonetheless, it is unknown whether brain injury-induced signals are essential for the entry of IN-administered EVs into different brain regions. Therefore, in this study, we investigated the distribution of IN-administered hMSC-derived EVs into neurons and microglia in the intact and status epilepticus (SE) injured rat forebrain. Ten billion EVs labeled with PKH26 were dispensed unilaterally into the left nostril of naive rats, and rats that experienced two hours of kainate-induced SE. Six hours later, PKH26 + EVs were quantified from multiple forebrain regions using serial brain sections processed for different neural cell markers and confocal microscopy. Remarkably, EVs were seen bilaterally in virtually all regions of intact and SE-injured forebrain. The percentage of neurons incorporating EVs were comparable for most forebrain regions. However, in animals that underwent SE, a higher percentage of neurons incorporated EVs in the hippocampal CA1 subfield and the entorhinal cortex, the regions that typically display neurodegeneration after SE. In contrast, the incorporation of EVs by microglia was highly comparable in every region of the forebrain measured. Thus, unilateral IN administration of EVs is efficient for delivering EVs bilaterally into neurons and microglia in multiple regions in the intact or injured forebrain. Furthermore, incorporation of EVs by neurons is higher in areas of brain injury, implying that injury-related signals likely play a role in targeting of EVs into neurons, which may be beneficial for EV therapy in various neurodegenerative conditions including traumatic brain injury, stroke, multiple sclerosis, and Alzheimer's disease.	[Kodali, Maheedhar; Kim, Dong-Ki; Thomas, Alicia; Shuai, Bing; Attaluri, Sahithi; Upadhya, Raghavendra; Madhu, Leelavathi N.; Prockop, Darwin J.; Shetty, Ashok K.] Texas A&M Univ, Dept Mol & Cellular Med, Inst Regenerat Med, 1114 TAMU, College Stn, TX 77842 USA; [Castro, Olagide W.; Gitai, Daniel] Univ Fed Alagoas, Hlth Sci Ctr, BR-57072900 Maceio, Alagoas, Brazil	Shetty, AK (corresponding author), Texas A&M Univ, Dept Mol & Cellular Med, Inst Regenerat Med, 1114 TAMU, College Stn, TX 77842 USA.	kodali@tamu.edu; olagidewww@gmail.com; biodon2003@msn.com; aliciathomas65@gmail.com; shuai@medicine.tamhsc.edu; sahithi.attaluri@tamu.edu; sacraghu@tamu.edu; danielgitai@gmail.com; lnmadhu802@tamu.edu; prockop@tamu.edu; akskrs@tamu.edu	Gitai, Daniel LG/A-7982-2019; Castro, Olagide/ABA-6708-2020; Madhu, Leelavathi N/AAP-2764-2021; Shetty, Ashok K/A-2428-2008; da Saude, Programa Ciencias/ABF-1705-2020; Castro, Olagide/C-6781-2015	Gitai, Daniel LG/0000-0001-7056-2373; Castro, Olagide/0000-0002-1874-509X; Madhu, Leelavathi N/0000-0002-5850-1786; Shetty, Ashok K/0000-0001-5049-6671; Castro, Olagide/0000-0002-1874-509X	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS106907-01]; State of Texas (Emerging Technology Fund); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Government of Brazil; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS106907] Funding Source: NIH RePORTER	This work was supported by grants from the National Institute of Neurological Disorders and Stroke (1R01NS106907-01 to A.K.S. and D.J.P.) and the State of Texas (Emerging Technology Fund to A.K.S.). Olagide Castro and Daniel Gitai were supported by Visiting Scientist Awards from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Government of Brazil.	Dabrowska S, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1571-8; Drexel M, 2012, NEUROPHARMACOLOGY, V63, P806, DOI 10.1016/j.neuropharm.2012.06.009; Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600-0854.2010.01041.x; Fitzner D, 2011, J CELL SCI, V124, P447, DOI 10.1242/jcs.074088; Flamant S, 2016, RADIAT RES, V186, P203, DOI 10.1667/RR14482.1; Fruhbeis C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00182; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Haney MJ, 2015, J CONTROL RELEASE, V207, P18, DOI 10.1016/j.jconrel.2015.03.033; Hannafon BN, 2013, INT J MOL SCI, V14, P14240, DOI 10.3390/ijms140714240; Hattiangady B, 2012, STEM CELL TRANSL MED, V1, P696, DOI 10.5966/sctm.2012-0050; Hattiangady B, 2011, AGING DIS, V2, P1; Hemphill M, 2020, J NEUROTRAUM, V37, P2424, DOI 10.1089/neu.2018.6220; Johnston Miles, 2004, Cerebrospinal Fluid Res, V1, P2, DOI 10.1186/1743-8454-1-2; Kalani A, 2016, INT J BIOCHEM CELL B, V79, P360, DOI 10.1016/j.biocel.2016.09.002; Katsu M, 2019, NEUROSCI LETT, V708, DOI 10.1016/j.neulet.2019.03.048; Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600-0854.2009.00878.x; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kodali M, 2018, BRAIN BEHAV IMMUN, V69, P499, DOI 10.1016/j.bbi.2018.01.009; Kumar SS, 2006, J NEUROSCI, V26, P4613, DOI 10.1523/JNEUROSCI.0064-06.2006; Loerke D, 2009, PLOS BIOL, V7, P628, DOI 10.1371/journal.pbio.1000057; Long Q, 2017, P NATL ACAD SCI USA, V114, pE3536, DOI 10.1073/pnas.1703920114; Lu YH, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00209; Madhu LN, 2019, BRAIN BEHAV IMMUN, V81, P430, DOI 10.1016/j.bbi.2019.06.040; Malloci M, 2019, ANTIOXID REDOX SIGN, V30, P813, DOI 10.1089/ars.2017.7265; Mendt M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99263; Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509-510; Mishra V, 2015, SCI REP-UK, V5, DOI 10.1038/srep17807; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Morad G, 2019, ACS NANO, V13, P13853, DOI 10.1021/acsnano.9b04397; Park KS, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1398-3; Pelassa I, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00091; Rao MS, 2006, J NEUROSCI RES, V83, P1088, DOI 10.1002/jnr.20802; Rao MS, 2008, HIPPOCAMPUS, V18, P931, DOI 10.1002/hipo.20449; Rao MS, 2007, NEUROBIOL DIS, V27, P117, DOI 10.1016/j.nbd.2007.03.016; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Riazifar M, 2019, ACS NANO, V13, P6670, DOI 10.1021/acsnano.9b01004; Saman S, 2012, J BIOL CHEM, V287, P3842, DOI 10.1074/jbc.M111.277061; Shetty AK, 1999, J COMP NEUROL, V414, P238, DOI 10.1002/(SICI)1096-9861(19991115)414:2<238::AID-CNE7>3.0.CO;2-A; Shetty AK, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101389; Shi M, 2014, ACTA NEUROPATHOL, V128, P639, DOI 10.1007/s00401-014-1314-y; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Upadhya D, 2019, CURR PHARM DESIGN, V25, P3500, DOI 10.2174/1381612825666191014164950; Upadhya Dinesh, 2019, Epilepsy Behav, P106499, DOI 10.1016/j.yebeh.2019.106499; Upadhya D, 2019, AGING DIS, V10, P915, DOI 10.14336/AD.2019.0720; Upadhya D, 2019, P NATL ACAD SCI USA, V116, P287, DOI 10.1073/pnas.1814185115; Vogel A, 2018, EBIOMEDICINE, V38, P273, DOI 10.1016/j.ebiom.2018.11.026; Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood-2014-03-562439; Wang SS, 2018, J ALZHEIMERS DIS, V61, P1005, DOI 10.3233/JAD-170848; Webb RL, 2018, TRANSL STROKE RES, V9, P530, DOI 10.1007/s12975-017-0599-2; Webb RL, 2018, STROKE, V49, P1248, DOI 10.1161/STROKEAHA.117.020353; Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316; Winston Charisse N, 2016, Alzheimers Dement (Amst), V3, P63, DOI 10.1016/j.dadm.2016.04.001; Zakharov Andrei, 2004, Lymphat Res Biol, V2, P139, DOI 10.1089/1539685042564372; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164	56	18	18	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	JAN 1	2020	21	1							181	10.3390/ijms21010181			15	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	KO2KF	WOS:000515378000181	31888012	DOAJ Gold, Green Published			2021-06-18	
J	Griffin, AD; Turtzo, LC; Parikh, GY; Tolpygo, A; Lodato, Z; Moses, AD; Nair, G; Perl, DP; Edwards, NA; Dardzinski, BJ; Armstrong, RC; Ray-Chaudhury, A; Mitra, PP; Latour, LL				Griffin, Allison D.; Turtzo, L. Christine; Parikh, Gunjan Y.; Tolpygo, Alexander; Lodato, Zachary; Moses, Anita D.; Nair, Govind; Perl, Daniel P.; Edwards, Nancy A.; Dardzinski, Bernard J.; Armstrong, Regina C.; Ray-Chaudhury, Abhik; Mitra, Partha P.; Latour, Lawrence L.			Traumatic microbleeds suggest vascular injury and predict disability in traumatic brain injury	BRAIN			English	Article						radiological-pathological analysis; MRI biomarkers of traumatic brain injury; traumatic vascular injury; traumatic microbleeds; mild traumatic brain injury	DIFFUSE AXONAL INJURY; LONG-TERM DISABILITY; CEREBRAL MICROBLEEDS; UNITED-STATES; HEAD-INJURY; LESIONS; MICROHEMORRHAGES; CHILDREN; RECOVERY; DISEASE	Traumatic microbleeds are small foci of hypointensity seen on T-2*-weighted MRI in patients following head trauma that have previously been considered a marker of axonal injury. The linear appearance and location of some traumatic microbleeds suggests a vascular origin. The aims of this study were to: (i) identify and characterize traumatic microbleeds in patients with acute traumatic brain injury; (ii) determine whether appearance of traumatic microbleeds predict clinical outcome; and (iii) describe the pathology underlying traumatic microbleeds in an index patient. Patients presenting to the emergency department following acute head trauma who received a head CT were enrolled within 48 h of injury and received a research MRI. Disability was defined using Glasgow Outcome Scale-Extended <= 6 at follow-up. All magnetic resonance images were interpreted prospectively and were used for subsequent analysis of traumatic microbleeds. Lesions on T-2* MRI were stratified based on 'linear' streak-like or 'punctate' petechial-appearing traumatic microbleeds. The brain of an enrolled subject imaged acutely was procured following death for evaluation of traumatic microbleeds using MRI targeted pathology methods. Of the 439 patients enrolled over 78 months, 31% (134/439) had evidence of punctate and/or linear traumatic microbleeds on MRI. Severity of injury, mechanism of injury, and CT findings were associated with traumatic microbleeds on MRI. The presence of traumatic microbleeds was an independent predictor of disability (P < 0.05; odds ratio = 2.5). No differences were found between patients with punctate versus linear appearing microbleeds. Post-mortem imaging and histology revealed traumatic microbleed co-localization with iron-laden macrophages, predominately seen in perivascular space. Evidence of axonal injury was not observed in co-localized histopathological sections. Traumatic microbleeds were prevalent in the population studied and predictive of worse outcome. The source of traumatic microbleed signal on MRI appeared to be iron-laden macrophages in the perivascular space tracking a network of injured vessels. While axonal injury in association with traumatic microbleeds cannot be excluded, recognizing traumatic microbleeds as a form of traumatic vascular injury may aid in identifying patients who could benefit from new therapies targeting the injured vasculature and secondary injury to parenchyma.	[Griffin, Allison D.; Lodato, Zachary; Moses, Anita D.; Perl, Daniel P.; Dardzinski, Bernard J.; Armstrong, Regina C.; Latour, Lawrence L.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Griffin, Allison D.; Turtzo, L. Christine; Moses, Anita D.; Latour, Lawrence L.] Natl Inst Neurol Disorders & Stroke, Acute Cerebrovasular Diagnost Unit, Bethesda, MD USA; [Parikh, Gunjan Y.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma, Baltimore, MD 21201 USA; [Parikh, Gunjan Y.] Univ Maryland, Sch Med, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Baltimore, MD 21201 USA; [Tolpygo, Alexander; Lodato, Zachary; Mitra, Partha P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Nair, Govind; Latour, Lawrence L.] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA; [Perl, Daniel P.; Dardzinski, Bernard J.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Edwards, Nancy A.; Ray-Chaudhury, Abhik] Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, Bethesda, MD USA	Latour, LL (corresponding author), Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA.; Latour, LL (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.	LatourL@ninds.nih.gov	Latour, Larry/AAH-5663-2021; Parikh, Gunjan/AAS-1375-2020	Latour, Larry/0000-0001-6160-5263; Parikh, Gunjan/0000-0002-8447-1349; Griffin, Allison/0000-0001-7055-068X	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Crick-Clay Professorship; Mathers Foundation; Intramural Research Programs at the NIH Clinical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work was supported by the Department of Defense in the Center for Neuroscience and Regenerative Medicine, the Intramural Research Programs at the NIH Clinical Center and NINDS, the Crick-Clay Professorship and the Mathers Foundation. The contents of this article are solely the responsibility of the authors and do not represent the official views of the Department of Defense or the Center for Neuroscience and Regenerative Medicine.	Absinta M, 2014, J NEUROPATH EXP NEUR, V73, P780, DOI 10.1097/NEN.0000000000000096; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Conijn MMA, 2011, AM J NEURORADIOL, V32, P1043, DOI 10.3174/ajnr.A2450; Cota MR, 2019, J NEUROTRAUM, V36, P1335, DOI 10.1089/neu.2018.5772; Fisher M, 2010, STROKE, V41, P2782, DOI 10.1161/STROKEAHA.110.593657; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Huang YL, 2015, J NEUROL NEUROPHYSIO, V6, P321; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Izzy S, 2017, NEUROCRIT CARE, V27, P199, DOI 10.1007/s12028-017-0399-2; Keene CD, 2018, ACTA NEUROPATHOL, V135, P303, DOI 10.1007/s00401-017-1801-z; Kenney K, 2018, ANN CLIN TRANSL NEUR, V5, P418, DOI 10.1002/acn3.541; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Lawrence TP, 2017, NEUROSCI LETT, V655, P143, DOI 10.1016/j.neulet.2017.06.046; Lee B, 2018, INT J MIGR HEALTH SO, V14, P1, DOI 10.1108/IJMHSC-01-2016-0003; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Loftus TJ, 2016, SHOCK, V46, P341, DOI 10.1097/SHK.0000000000000636; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mizuma A, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00467; Naka H, 2004, AM J NEURORADIOL, V25, P714; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pinskiy V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0102363; Ramos-Cejudo J, 2018, EBIOMEDICINE, V28, P21, DOI 10.1016/j.ebiom.2018.01.021; Ricciardi MC, 2017, J NEUROTRAUM, V34, P23, DOI 10.1089/neu.2015.4338; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Tatsumi S, 2008, CEREBROVASC DIS, V26, P142, DOI 10.1159/000139661; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Toth A, 2016, NEUROSCI LETT, V617, P207, DOI 10.1016/j.neulet.2016.02.028; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; van Veluw SJ, 2015, JOVE-J VIS EXP, DOI 10.3791/53125; van Veluw SJ, 2013, J CEREBR BLOOD F MET, V33, P322, DOI 10.1038/jcbfm.2012.196; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang RL, 2006, J NEUROSCI RES, V83, P1213, DOI 10.1002/jnr.20813	50	18	18	2	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2019	142		11				3550	3564		10.1093/brain/awz290			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JY3MS	WOS:000504323200031	31608359	Green Published, Bronze			2021-06-18	
J	Winston, CN; Romero, HK; Ellisman, M; Nauss, S; Julovich, DA; Conger, T; Hall, JR; Campana, W; O'Bryant, SE; Nievergelt, CM; Baker, DG; Risbrough, VB; Rissman, RA				Winston, Charisse N.; Romero, Haylie K.; Ellisman, Maya; Nauss, Sophie; Julovich, David A.; Conger, Tori; Hall, James R.; Campana, Wendy; O'Bryant, Sid E.; Nievergelt, Caroline M.; Baker, Dewleen G.; Risbrough, Victoria B.; Rissman, Robert A.			Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; neuronal exosomes; astrocytes; amyloid; tau	ALZHEIMERS-DISEASE; COLLABORATING CENTER; NEUROFILAMENT LIGHT; SYNAPTIC PROTEINS; AMYLOID-BETA; TASK-FORCE; TAU; BIOMARKERS; DEPLOYMENT; ASSOCIATION	Mild traumatic brain injury (mTBI) disproportionately affects military service members and is very difficult to diagnose. To-date, there is currently no blood-based, diagnostic biomarker for mTBI cases with persistent post concussive symptoms. To examine the potential of neuronally-derived (NDE) and astrocytic-derived (ADE) exosome cargo proteins as biomarkers of chronic mTBI in younger adults, we examined plasma exosomes from a prospective longitudinal study of combat-related risk and resilience, marine resiliency study II (MRSII). After return from a combat-deployment participants were interviewed to assess TBI exposure while on deployment. Plasma exosomes from military service members with mTBI (mean age, 21.7 years, n = 19, avg. days since injury 151), and age-matched, controls (deployed service members who did not endorse a deployment-related TBI or a pre-deployment history of TBI; mean age, 21.95 years, n = 20) were precipitated and enriched against a neuronal adhesion protein, L1-CAM, and an astrocyte marker, glutamine aspartate transporter (GLAST) using magnetic beads to immunocapture the proteins and subsequently selected by fluorescent activated cell sorting (FACS). Extracted protein cargo from NDE and ADE preparations were quantified for protein levels implicated in TBI neuropathology by standard ELISAs and on the ultra-sensitive single molecule assay (Simoa) platform. Plasma NDE and ADE levels of A beta 42 were significantly higher while plasma NDE and ADE levels of the postsynaptic protein, neurogranin (NRGN) were significantly lower in participants endorsing mTBI exposure compared to controls with no TBI history. Plasma NDE and ADE levels of A beta 40, total tau, and neurofilament light (NFL), P-T181-tau, P-S396-tau were either undetectable or not significantly different between the two groups. In an effort to understand the pathogenetic potential of NDE and ADE cargo proteins, neuron-like cultures were treated with NDE and ADE preparations from TBI and non-TBI groups. Lastly, we determined that plasma NDE but not ADE cargo proteins from mTBI samples were found to be toxic to neuron-like recipient cells in vitro. These data support the presence of markers of neurodegeneration in NDEs of mTBI and suggest that these NDEs can be used as tools to identify pathogenic mechanisms of TBI.	[Winston, Charisse N.; Ellisman, Maya; Nauss, Sophie; Rissman, Robert A.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Romero, Haylie K.; Campana, Wendy] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Julovich, David A.; Conger, Tori; Hall, James R.; O'Bryant, Sid E.] Univ North Texas Hlth Sci Ctr, Inst Translat Res, Dept Pharmacol & Neurosci, Ft Worth, TX USA; [Campana, Wendy; Rissman, Robert A.] VA San Diego Healthcare Syst, La Jolla, CA 92161 USA; [Nievergelt, Caroline M.; Baker, Dewleen G.; Risbrough, Victoria B.] Ctr Excellence Stress & Mental Hlth, La Jolla, CA 92161 USA; [Nievergelt, Caroline M.; Baker, Dewleen G.; Risbrough, Victoria B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA	Rissman, RA (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.; Rissman, RA (corresponding author), VA San Diego Healthcare Syst, La Jolla, CA 92161 USA.; Risbrough, VB (corresponding author), Ctr Excellence Stress & Mental Hlth, La Jolla, CA 92161 USA.; Risbrough, VB (corresponding author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.	vrisbrough@ucsd.edu; rrissman@ucsd.edu			National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG057459, AG057469, AG051848, AG018440, ADRC P50 AG005131]; VA Merit Awards [BX003040, BX004312, RX002484]; Department of DefenseUnited States Department of Defense [W81XWH1810761, P50 MH096889-06]; VA Center of Excellence for Stress and Mental Health; Flow Cytometry Core at the San Diego Center for AIDS Research [P30 AI036214]; VA San Diego Health Care SystemUS Department of Veterans Affairs; San Diego Veterans Medical Research Foundation; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG018440, R56AG057469] Funding Source: NIH RePORTER	This study was supported by grants AG057459, AG057469, AG051848, AG018440, and ADRC P50 AG005131 from the National Institute on Aging, and VA Merit Awards BX003040 and BX004312 to RR and VA Merit Award BX004312, Department of Defense W81XWH1810761, P50 MH096889-06 to VR, VA Merit Award RX002484 to WC, and the VA Center of Excellence for Stress and Mental Health funding to VR, CN, and DB. This work was performed with the support of the Flow Cytometry Core at the San Diego Center for AIDS Research (P30 AI036214), the VA San Diego Health Care System, and the San Diego Veterans Medical Research Foundation.	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Baker DG, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110134; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Eme R, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7050046; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gill J, 2018, BRAIN INJURY, V32, P1277, DOI 10.1080/02699052.2018.1471738; Glenn DE, 2017, DEPRESS ANXIETY, V34, P723, DOI 10.1002/da.22642; Goetzl EJ, 2019, FASEB J, V33, P5082, DOI 10.1096/fj.201802319R; Goetzl EJ, 2018, ANN NEUROL, V83, P544, DOI 10.1002/ana.25172; Goetzl EJ, 2018, FASEB J, V32, P888, DOI 10.1096/fj.201700731R; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2016, FASEB J, V30, P3853, DOI 10.1096/fj.201600756R; Goetzl L, 2018, ANN CLIN TRANSL NEUR, V5, P4, DOI 10.1002/acn3.499; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hamlett ED, 2017, ALZHEIMERS DEMENT, V13, P541, DOI 10.1016/j.jalz.2016.08.012; Helmick K, 2006, DEFENSE VETERANS BRA; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kawata K, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00239; Kenney Kimbra, 2018, Brain Inj, V32, P1276, DOI 10.1080/02699052.2018.1483530; Kim C, 2015, CELL REP, V13, P771, DOI 10.1016/j.celrep.2015.09.044; Kim HJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97105; Kochanek PM, 1998, SEMIN CLIN NEUROPSYC, P176; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lee RR, 2014, PROG NEUROL SURG, V28, P94, DOI 10.1159/000358768; Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006; Lin YS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35766-w; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; Moore TM, 2017, J PSYCHIATR RES, V95, P121, DOI 10.1016/j.jpsychires.2017.08.013; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ngolab J, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0445-5; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prince C, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080105; Putz U, 2008, J BIOL CHEM, V283, P32621, DOI 10.1074/jbc.M804120200; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Reilly P, 2017, NEUROBIOL DIS, V106, P222, DOI 10.1016/j.nbd.2017.06.005; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Salat DH, 2017, BRAIN INJURY, V31, P1204, DOI 10.1080/02699052.2017.1327672; Shahim P, 2018, NEUROLOGY, V90, pE1780, DOI 10.1212/WNL.0000000000005518; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shin SS, 2017, BRAIN IMAGING BEHAV, V11, P591, DOI 10.1007/s11682-017-9684-0; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Vogt D, 2013, J TRAUMA STRESS, V26, P710, DOI 10.1002/jts.21868; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; Wakida NM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196153; Winston Charisse N, 2019, Alzheimers Dement (Amst), V11, P61, DOI 10.1016/j.dadm.2018.11.002; Winston CN, 2018, J ALZHEIMERS DIS, V66, P971, DOI 10.3233/JAD-180302; Winston Charisse N, 2016, Alzheimers Dement (Amst), V3, P63, DOI 10.1016/j.dadm.2016.04.001; Xiong Y, 2018, CHIN J TRAUMATOL, V21, P137, DOI 10.1016/j.cjtee.2018.02.003; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	70	18	19	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-453X		FRONT NEUROSCI-SWITZ	Front. Neurosci.	OCT 2	2019	13								1005	10.3389/fnins.2019.01005			14	Neurosciences	Neurosciences & Neurology	JO4RN	WOS:000497567100001	31680797	DOAJ Gold, Green Published			2021-06-18	
J	Webster, KM; Shultz, SR; Ozturk, E; Dill, LK; Sun, M; Casillas-Espinosa, P; Jones, NC; Crack, PJ; O'Brien, TJ; Semple, BD				Webster, Kyria M.; Shultz, Sandy R.; Ozturk, Ezgi; Dill, Larissa K.; Sun, Mujun; Casillas-Espinosa, Pablo; Jones, Nigel C.; Crack, Peter J.; O'Brien, Terence J.; Semple, Bridgette D.			Targeting high-mobility group box protein 1 (HMGB1) in pediatric traumatic brain injury: Chronic neuroinflammatory, behavioral, and epileptogenic consequences	EXPERIMENTAL NEUROLOGY			English	Article						High-mobility group box protein-1 (HMGB1); Glycyrrhizin; Inflammation; Post-traumatic epilepsy; Seizures; Pediatric; Neurotrauma; Traumatic brain injury; Behavior	EARLY POSTTRAUMATIC SEIZURES; CONTROLLED CORTICAL IMPACT; TEMPORAL-LOBE EPILEPSY; QUALITY-OF-LIFE; TERM-FOLLOW-UP; GLYCYRRHIZIC ACID; INTERLEUKIN-1 RECEPTOR; BARRIER PERMEABILITY; SOCIAL-RECOGNITION; HEAD TRAUMA	High mobility group box protein-1 (HMGB1) has been implicated as a key mediator of neuroinflammation and neurodegeneration in a range of neurological conditions including traumatic brain injury (TBI) and epilepsy. To date, however, most studies have examined only acute outcomes, and the adult brain. We have recently demonstrated HMGB1 release after experimental TBI in the pediatric mouse. This study therefore examined the chronic consequences of acute HMGB1 inhibition in the same model, to test the hypothesis that HMGB1 is a pivotal mediator of neuropathological, neurobehavioral, and epilepsy outcomes in pediatric TBI. HMGB1 was inhibited by treatment with 50 mg/kg i.p. Glycyrrhizin (Gly), compared to vehicle controls, commencing 1 h prior to moderate TBI or sham surgery in post-natal day 21 mice. We first demonstrated that Gly reduced brain HMGB1 levels and brain edema at an acute time point of 3 days post-injury. Subsequent analysis over a chronic time course found that pediatric TBI resulted in short-term spatial memory and motor learning deficits alongside an apparent increase in hippocampal microglial reactivity, which was prevented in Gly-treated TBI mice. In contrast, Gly treatment did not reduce the severity of evoked seizures, the proportion of animals exhibiting chronic spontaneous seizure activity, or cortical tissue loss. Together, our findings contribute to a growing appreciation for HMGB1's role in neuropathology and associated behavioral outcomes after TBI. However, further work is needed to fully elucidate the contribution of HMGB1 to epileptogenesis in this context.	[Webster, Kyria M.; Shultz, Sandy R.; Jones, Nigel C.; O'Brien, Terence J.; Semple, Bridgette D.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Parkville, Vic, Australia; [Shultz, Sandy R.; Ozturk, Ezgi; Dill, Larissa K.; Sun, Mujun; Casillas-Espinosa, Pablo; Jones, Nigel C.; O'Brien, Terence J.; Semple, Bridgette D.] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia; [Shultz, Sandy R.; Ozturk, Ezgi; Dill, Larissa K.; Jones, Nigel C.; O'Brien, Terence J.] Alfred Hlth, Dept Neurol, Prahran, Vic, Australia; [Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic, Australia	Semple, BD (corresponding author), Monash Univ, Dept Neurosci, Alfred Ctr, Level 6,99 Commercial Rd, Prahran, Vic 3004, Australia.	kyria.webster@genesearch.com.au; sandy.shultz@monash.edu; ezgi.ozturk@monash.edu; larissa.dill@monash.edu; mujun.sun@monash.edu; Pablo.casillas-espinosa@monash.edu; nigel.jones@monash.edu; pcrack@unimelb.edu.au; Terence.obrien@monash.edu; Bridgette.Semple@monash.edu	Crack, Peter/ABE-2065-2020	Crack, Peter/0000-0002-5030-0330; O'Brien, Terence/0000-0002-7198-8621; Sun, Mujun/0000-0002-9923-9913	National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia	The authors acknowledge funding support from the National Health and Medical Research Council of Australia (NHMRC) in the form of Project Grants and Career Development Fellowships to BDS and SRS. The authors also thank the Biomedical Histology Facility at the University of Melbourne, and Monash Histology Platform, Monash University at the Alfred Hospital.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Akao T, 2000, BIOL PHARM BULL, V23, P1418, DOI 10.1248/bpb.23.1418; Akman T, 2015, INFLAMMATION, V38, P1581, DOI 10.1007/s10753-015-0133-1; Alcaraz C, 1990, J Vet Diagn Invest, V2, P191; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Arase Y, 1997, CANCER, V79, P1494, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Balosso S, 2014, ANTIOXID REDOX SIGN, V21, P1726, DOI 10.1089/ars.2013.5349; Bannerman DM, 2001, EXP BRAIN RES, V138, P100, DOI 10.1007/s002210100687; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Chen XD, 2019, EXP NEUROL, V311, P1, DOI 10.1016/j.expneurol.2018.09.007; Chhor V, 2017, BRAIN BEHAV IMMUN, V63, P197, DOI 10.1016/j.bbi.2016.11.001; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Costello DA, 2011, J NEUROSCI, V31, P3871, DOI 10.1523/JNEUROSCI.6676-10.2011; Crespel A, 2002, BRAIN RES, V952, P159, DOI 10.1016/S0006-8993(02)03050-0; David Y, 2009, J NEUROSCI, V29, P10588, DOI 10.1523/JNEUROSCI.2323-09.2009; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; Descotes J, 2009, MABS, V1, P104, DOI 10.4161/mabs.1.2.7909; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Gao TL, 2018, BIOCHEM BIOPH RES CO, V497, P430, DOI 10.1016/j.bbrc.2018.02.102; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; Gu XJ, 2014, CHIN J TRAUMATOL, V17, P1, DOI 10.3760/cma.j.issn.1008-1275.2014.01.001; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Hayakawa K, 2012, P NATL ACAD SCI USA, V109, P7505, DOI 10.1073/pnas.1121146109; Heinemann U, 2012, GLIA, V60, P1251, DOI 10.1002/glia.22311; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Iori V, 2013, NEUROBIOL DIS, V58, P102, DOI 10.1016/j.nbd.2013.03.006; Jacewicz M, 2009, FOLIA NEUROPATHOL, V47, P321; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Keret A, 2017, J NEUROSURG-PEDIATR, V20, P64, DOI 10.3171/2017.2.PEDS16585; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kieslich M, 2001, DISABIL REHABIL, V23, P665; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Langlois J. A., 2000, DIVISION ACUTE CARE; Larkin M, 2016, CUREUS, V8, DOI 10.7759/cureus.744; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Li D, 2015, NEUROSCI LETT, V609, P109, DOI 10.1016/j.neulet.2015.10.035; Li YJ, 2019, J PHARM PHARMACOL, V71, P390, DOI 10.1111/jphp.13040; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; Luo L, 2014, CELL MOL NEUROBIOL, V34, P987, DOI 10.1007/s10571-014-0075-4; Luo Lidan, 2013, Exp Neurobiol, V22, P107, DOI 10.5607/en.2013.22.2.107; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maaswinkel H, 1996, PHYSIOL BEHAV, V60, P55, DOI 10.1016/0031-9384(95)02233-3; Maroso M, 2011, J INTERN MED, V270, P319, DOI 10.1111/j.1365-2796.2011.02431.x; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Mazarati A, 2011, EXP NEUROL, V232, P143, DOI 10.1016/j.expneurol.2011.08.012; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Morganti-Kossmann MC, 2019, ACTA NEUROPATHOL, V137, P731, DOI 10.1007/s00401-018-1944-6; Musumeci D, 2014, PHARMACOL THERAPEUT, V141, P347, DOI 10.1016/j.pharmthera.2013.11.001; Nehlig A, 1996, EPILEPSY RES, V26, P93, DOI 10.1016/S0920-1211(96)00045-9; Ohnishi M, 2014, NEUROCHEM INT, V75, P32, DOI 10.1016/j.neuint.2014.05.007; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Okuma Y, 2019, WORLD NEUROSURG, V122, pE864, DOI 10.1016/j.wneu.2018.10.164; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Pang HG, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4569521; Passalacqua M, 1998, NEUROSCIENCE, V82, P1021; Paudel YN, 2019, J NEUROCHEM, V151, P542, DOI 10.1111/jnc.14663; Ploeger B, 2001, DRUG METAB REV, V33, P125, DOI 10.1081/DMR-100104400; Potts Mathew B, 2006, NeuroRx, V3, P143; Raible DJ, 2015, EXP NEUROL, V271, P445, DOI 10.1016/j.expneurol.2015.07.001; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Riazi K, 2010, EPILEPSY RES, V89, P34, DOI 10.1016/j.eplepsyres.2009.09.004; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schoderboeck L, 2009, NEUROBIOL DIS, V35, P368, DOI 10.1016/j.nbd.2009.05.026; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Semple BD, 2017, J NEUROSCI, V37, P7864, DOI 10.1523/JNEUROSCI.0982-17.2017; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI 10.1016/j.nbd.2014.12.003; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Sha YG, 2008, J IMMUNOL, V180, P2531, DOI 10.4049/jimmunol.180.4.2531; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Sun MJ, 2017, BRAIN BEHAV IMMUN, V66, P359, DOI 10.1016/j.bbi.2017.08.005; Sun Q, 2013, MED HYPOTHESES, V81, P681, DOI 10.1016/j.mehy.2013.07.026; Tabuchi M, 2012, CELL MOL NEUROBIOL, V32, P1139, DOI 10.1007/s10571-012-9839-x; Tarr AJ, 2011, BEHAV BRAIN RES, V217, P481, DOI 10.1016/j.bbr.2010.10.036; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Webster KM, 2019, J COMP NEUROL, V527, P1102, DOI 10.1002/cne.24589; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; YAMAMURA Y, 1995, BIOL PHARM BULL, V18, P337, DOI 10.1248/bpb.18.337; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Yang LJ, 2018, CELL PHYSIOL BIOCHEM, V46, P2532, DOI 10.1159/000489659; Zhang J, 2016, J NEUROPATH EXP NEUR, V75, P527, DOI 10.1093/jnen/nlw030; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334	117	18	18	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2019	320								112979	10.1016/j.expneurol.2019.112979			14	Neurosciences	Neurosciences & Neurology	IU2OR	WOS:000483420200016	31229637				2021-06-18	
J	Xiao, X; Jiang, YJ; Liang, WB; Wang, YY; Cao, SQ; Yan, H; Gao, LB; Zhang, L				Xiao, Xiao; Jiang, Youjing; Liang, Weibo; Wang, Yanyun; Cao, Shuqiang; Yan, He; Gao, Linbo; Zhang, Lin			miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2	MOLECULAR BRAIN			English	Article						Traumatic brain injury (TBI); Ferroptosis; miR-212-5p; Prostaglandin endoperoxide synthase-2 (Ptgs2)	DOWN-REGULATION; EXPRESSION; MECHANISMS; PROMOTES; INACTIVATION; METABOLISM; MONOCYTES; OXIDATION; RETENTION; MICRORNAS	Ferroptosis, a newly discovered form of iron-dependent regulated cell death, has been implicated in traumatic brain injury (TBI). MiR-212-5p has previously been reported to be downregulated in extracellular vesicles following TBI. To investigate whether miR-212-5p is involved in the ferroptotic neuronal death in TBI mice, we first examined the accumulation of malondialdehyde (MDA) and ferrous ion, and the expression of ferroptosis-related molecules at 6 h, 12 h, 24 h, 48 h and 72 h following controlled cortical impact (CCI) in mice. There was a significant upregulation in the expression of Gpx4 and Acsl4 at 6 h, Slc7a11 from 12 h to 72 h, and Nox2 and Sat1 from 6 h to 72 h post injury. Similarly, an upregulation in the expression of Gpx4 at 6 h, Nox2 from 6 h to 72 h, xCT from 12 h to 72 h, and Sat1 at 72 h after CCI was observed at the protein level. Interestingly, MDA and ferrous ion were increased whereas miR-212-5p was decreased in the CCI group compared to the sham group. Furthermore, we found that overexpression of miR-212-5p attenuated ferroptosis while downregulation of miR-212-5p promoted ferroptotic cell death partially by targeting prostaglandin-endoperoxide synthase-2 (Ptgs2) in HT-22 and Neuro-2a cell lines. In addition, administration of miR-212-5p in CCI mice significantly improved learning and spatial memory. Collectively, these findings indicate that miR-212-5p may protect against ferroptotic neuronal death in CCI mice partially by targeting Ptgs2.	[Xiao, Xiao; Jiang, Youjing; Liang, Weibo; Cao, Shuqiang; Zhang, Lin] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Forens Genet, Chengdu 610041, Sichuan, Peoples R China; [Wang, Yanyun; Gao, Linbo; Zhang, Lin] Sichuan Univ, Ctr Translat Med, Key Lab Birth Defects & Related Dis Women & Child, Lab Mol Translat Med,Minist Educ,West China Univ, Chengdu, Sichuan, Peoples R China; [Yan, He] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Forens Pathol, Chengdu, Sichuan, Peoples R China	Zhang, L (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Forens Genet, Chengdu 610041, Sichuan, Peoples R China.; Gao, LB; Zhang, L (corresponding author), Sichuan Univ, Ctr Translat Med, Key Lab Birth Defects & Related Dis Women & Child, Lab Mol Translat Med,Minist Educ,West China Univ, Chengdu, Sichuan, Peoples R China.	gaolinboscu@163.com; zhanglin@scu.edu.cn	liang, weibo/G-8456-2011	liang, weibo/0000-0002-8487-3575	Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2018SCUH0053]; Science and Technology Major Projects of Sichuan Province of China [2017SZDZX0013]; Science and Technology Support Program of Sichuan Province of China [2016SZ0013]	This work was supported by the Fundamental Research Funds for the Central Universities (No. 2018SCUH0053), the Science and Technology Major Projects of Sichuan Province of China (No.2017SZDZX0013), and the Science and Technology Support Program of Sichuan Province of China (No.2016SZ0013).	Amadio P, 2017, THROMB HAEMOSTASIS, V117, P1486, DOI 10.1160/TH16-12-0968; Aten S, 2016, RNA DIS, V3, pe1375; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Becker RE, 2018, ALZHEIMERS DEMENT, V14, P431, DOI 10.1016/j.jalz.2017.11.007; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bretscher P, 2015, EMBO MOL MED, V7, P593, DOI 10.15252/emmm.201404702; Burek M, 2019, TRANSL STROKE RES, V10, P672, DOI 10.1007/s12975-018-0683-2; Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1; Chen W, 2019, BIOMATERIALS, V192, P590, DOI 10.1016/j.biomaterials.2018.11.035; Cheng PC, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002332; Dean Dana D, 2017, Curr Protoc Neurosci, V81, DOI 10.1002/cpns.37; del Rey MQ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00238; Devos D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39739-5; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI 10.1016/S1474-4422(18)30499-X; Fiedler SD, 2008, BIOL REPROD, V79, P1030, DOI 10.1095/biolreprod.108.069690; Fricker M, 2018, PHYSIOL REV, V98, P813, DOI 10.1152/physrev.00011.2017; Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95; Garcia-Concejo A, 2018, BBA-GEN SUBJECTS, V1862, P2605, DOI 10.1016/j.bbagen.2018.07.001; Gaschler MM, 2018, ACS CHEM BIOL, V13, P1013, DOI 10.1021/acschembio.8b00199; Guiney SJ, 2017, NEUROCHEM INT, V104, P34, DOI 10.1016/j.neuint.2017.01.004; Guo YJ, 2017, J MOL ENDOCRINOL, V59, P205, DOI 10.1530/JME-16-0179; Hambright WS, 2017, REDOX BIOL, V12, P8, DOI 10.1016/j.redox.2017.01.021; Hansen KF, 2016, LEARN MEMORY, V23, P61, DOI 10.1101/lm.039578.115; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; He J, 2016, J ENVIRON SCI-CHINA, V39, P97, DOI 10.1016/j.jes.2015.12.003; Hernandez-Rapp J, 2016, SCI REP-UK, V6, DOI 10.1038/srep30953; Hernandez-Rapp J, 2015, BEHAV BRAIN RES, V287, P15, DOI 10.1016/j.bbr.2015.03.032; Hirschhorn T, 2019, FREE RADICAL BIO MED, V133, P130, DOI 10.1016/j.freeradbiomed.2018.09.043; Hu C, 2019, J CELL PHYSIOL, V234, P7090, DOI 10.1002/jcp.27463; Hua X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09636-w; Iaccarino C, 2018, J NEUROSURG SCI, V62, P765, DOI 10.23736/S0390-5616.16.03721-8; Ilmaniemi S, 2019, J EPIDEMIOL COMMUN H, V73, P451, DOI 10.1136/jech-2018-211960; Jiang Yi-na, 2018, Chinese Pharmacological Bulletin, V34, P166, DOI 10.3969/j.issn.1001-1978.2018.02.005; Kang R, 2017, CURR PATHOBIOL REP, V5, P153, DOI 10.1007/s40139-017-0139-5; Keller RF, 2017, IEEE T NANOBIOSCI, V16, P843, DOI 10.1109/TNB.2017.2776841; Kenny EM, 2019, CRIT CARE MED, V47, P410, DOI 10.1097/CCM.0000000000003555; Kong ZY, 2019, BIOMED PHARMACOTHER, V109, P2043, DOI 10.1016/j.biopha.2018.11.030; Lane DJR, 2018, J ALZHEIMERS DIS, V64, pS379, DOI 10.3233/JAD-179944; Lee YS, 2018, MOL CANCER RES, V16, P1073, DOI 10.1158/1541-7786.MCR-18-0055; Li Q, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90777; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu XP, 2016, CELL CHEM BIOL, V23, P1217, DOI 10.1016/j.chembiol.2016.08.009; Lu L, 2013, INT J BIOCHEM CELL B, V45, P2530, DOI 10.1016/j.biocel.2013.08.007; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Magtanong L, 2019, DEV NEUROSCI-BASEL, V40, P382, DOI 10.1159/000496922; Majdan M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002331; Mendoza-Viveros L, 2017, CELL REP, V19, P505, DOI 10.1016/j.celrep.2017.03.057; Mohamed AZ, 2019, EUR J NUCL MED MOL I, V46, P1139, DOI 10.1007/s00259-018-4241-7; Pan YB, 2017, NEUROSCIENCE, V367, P189, DOI 10.1016/j.neuroscience.2017.10.046; Pichler S, 2017, NEUROBIOL AGING, V50, DOI 10.1016/j.neurobiolaging.2016.09.019; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Shang J, 2015, MOL ENDOCRINOL, V29, P1243, DOI 10.1210/me.2014-1335; Smith PY, 2015, HUM MOL GENET, V24, P6721, DOI 10.1093/hmg/ddv377; Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Sui XB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01371; Sun DD, 2017, CELL MOL NEUROBIOL, V37, P1349, DOI 10.1007/s10571-017-0484-2; Sun SF, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00381; Ved R, 2018, J NEUROL, V265, P1241, DOI 10.1007/s00415-018-8855-2; Wanet A, 2012, NUCLEIC ACIDS RES, V40, P4742, DOI 10.1093/nar/gks151; Wang CY, 2017, J NEUROCHEM, V143, P112, DOI 10.1111/jnc.14138; Wang Y, 2017, NEUROBIOL AGING, V51, P156, DOI 10.1016/j.neurobiolaging.2016.12.015; Weigelt K, 2013, BRAIN BEHAV IMMUN, V29, P147, DOI 10.1016/j.bbi.2012.12.018; Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Wu YN, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00115; Xiao JJ, 2016, J CELL MOL MED, V20, P204, DOI 10.1111/jcmm.12733; Xie BS, 2019, CNS NEUROSCI THER, V25, P465, DOI 10.1111/cns.13069; Zhang ZL, 2018, AUTOPHAGY, V14, P2083, DOI 10.1080/15548627.2018.1503146	73	18	19	1	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1756-6606		MOL BRAIN	Mol. Brain	SEP 18	2019	12	1							78	10.1186/s13041-019-0501-0			12	Neurosciences	Neurosciences & Neurology	IZ3YM	WOS:000487021500001	31533781	DOAJ Gold, Green Published			2021-06-18	
J	Gorgoraptis, N; Li, LM; Whittington, A; Zimmerman, KA; Maclean, LM; McLeod, C; Ross, E; Heslegrave, A; Zetterberg, H; Passchier, J; Matthews, PM; Gunn, RN; McMillan, TM; Sharp, DJ				Gorgoraptis, Nikos; Li, Lucia M.; Whittington, Alex; Zimmerman, Karl A.; Maclean, Linda M.; McLeod, Claire; Ross, Ewan; Heslegrave, Amanda; Zetterberg, Henrik; Passchier, Jan; Matthews, Paul M.; Gunn, Roger N.; McMillan, Tom M.; Sharp, David J.			In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury	SCIENCE TRANSLATIONAL MEDICINE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; AMYLOID-BETA ACCUMULATION; VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; HEAD-INJURY; NEUROPATHOLOGICAL CRITERIA; COGNITIVE IMPAIRMENT; HYDROLASE L1; MOUSE MODEL	Traumatic brain injury (TBI) can trigger progressive neurodegeneration, with tau pathology seen years after a single moderate-severe TBI. Identifying this type of posttraumatic pathology in vivo might help to understand the role of tau pathology in TBI pathophysiology. We used flortaucipir positron emission tomography (PET) to investigate whether tau pathology is present many years after a single TBI in humans. We examined PET data in relation to markers of neurodegeneration in the cerebrospinal fluid (CSF), structural magnetic resonance imaging measures, and cognitive performance. Cerebral flortaucipir binding was variable, with many participants with TBI showing increases in cortical and white matter regions. At the group level, flortaucipir binding was increased in the right occipital cortex in TBI when compared to healthy controls. Flortaucipir binding was associated with increased total tau, phosphorylated tau, and ubiquitin carboxyl-terminal hydrolase L1 CSF concentrations, as well as with reduced fractional anisotropy and white matter tissue density in TBI. Apolipoprotein E (APOE) epsilon 4 genotype affected the relationship between flortaucipir binding and time since injury, CSF beta amyloid 1-42 (A beta 42) concentration, white matter tissue density, and longitudinal Mini-Mental State Examination scores in TBI. The results demonstrate that tau PET is a promising approach to investigating progressive neurodegeneration associated with tauopathy after TBI.	[Gorgoraptis, Nikos; Li, Lucia M.; Whittington, Alex; Zimmerman, Karl A.; Ross, Ewan; Matthews, Paul M.; Gunn, Roger N.; Sharp, David J.] Imperial Coll London, Dept Brain Sci, London W12 0NN, England; [Whittington, Alex; Passchier, Jan; Gunn, Roger N.] Invicro London, London W12 0NN, England; [Maclean, Linda M.; McLeod, Claire; McMillan, Tom M.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland; [Heslegrave, Amanda; Zetterberg, Henrik] UCL, UK Dementia Res Inst, London WC1N 3BG, England; [Heslegrave, Amanda; Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England; [Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, S-43180 Molndal, Sweden; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-41345 Molndal, Sweden; [Matthews, Paul M.; Sharp, David J.] Imperial Coll London, UK Dementia Res Inst, London W12 0NN, England; [Sharp, David J.] Imperial Coll London, Royal British Leg Ctr Blast Injury Studies, London, England	Sharp, DJ (corresponding author), Imperial Coll London, Dept Brain Sci, London W12 0NN, England.; Sharp, DJ (corresponding author), Imperial Coll London, UK Dementia Res Inst, London W12 0NN, England.; Sharp, DJ (corresponding author), Imperial Coll London, Royal British Leg Ctr Blast Injury Studies, London, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Zimmerman, Karl/AAL-4988-2020	Zimmerman, Karl/0000-0003-1239-3414; Ross, Ewan/0000-0002-5983-526X; Heslegrave, Amanda/0000-0002-7290-6405; Whittington, Alex/0000-0001-8768-3366; Gunn, Roger/0000-0003-1181-5769; Gorgoraptis, Nikos/0000-0002-2588-9235	Medical Research Council (MRC) UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/L022141/1]; NIHR Research Professorship [NIHR-RP-011-048]; UK Dementia Research Institute	This project was funded by the Medical Research Council (MRC) UK grant number MR/L022141/1 (to D.J.S.). D.J.S. was supported by an NIHR Research Professorship (NIHR-RP-011-048). This work was supported by the UK Dementia Research Institute. Infrastructure was supported by the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre.	Aerts MB, 2011, MOVEMENT DISORD, V26, P169, DOI 10.1002/mds.23341; Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Bilguvar K, 2013, P NATL ACAD SCI USA, V110, P3489, DOI 10.1073/pnas.1222732110; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dickstein DL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.175; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Harada R, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010007; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lee CM, 2018, J ALZHEIMERS DIS, V62, P1691, DOI 10.3233/JAD-170840; Li LZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002028; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Makaretz SJ, 2018, J NEUROL NEUROSUR PS, V89, P1024, DOI 10.1136/jnnp-2017-316409; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marquie M, 2017, ANN NEUROL, V81, P117, DOI 10.1002/ana.24844; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mechelli A, 2005, CURR MED IMAGING, V1, P105, DOI 10.2174/1573405054038726; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Noda K, 2006, NEUROPATHOLOGY, V26, P508, DOI 10.1111/j.1440-1789.2006.00722.x; Ohrfelt A, 2016, DEMENT GER COGN D EX, V6, P283, DOI 10.1159/000447239; Ossenkoppele R, 2016, BRAIN, V139, P1551, DOI 10.1093/brain/aww027; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Passamonti L, 2017, BRAIN, V140, P781, DOI 10.1093/brain/aww340; Pereira JMS, 2010, NEUROIMAGE, V49, P2205, DOI 10.1016/j.neuroimage.2009.10.068; Polymenidou M, 2012, J EXP MED, V209, P889, DOI 10.1084/jem.20120741; R Core Team, 2014, R LANG ENV STAT COMP; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ripolles P, 2012, NEUROIMAGE, V60, P1296, DOI 10.1016/j.neuroimage.2012.01.094; Sander K, 2016, ALZHEIMERS DEMENT, V12, P1116, DOI 10.1016/j.jalz.2016.01.003; Schwarz AJ, 2016, BRAIN, V139, P1539, DOI 10.1093/brain/aww023; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shi Y, 2017, NATURE, V549, P523, DOI 10.1038/nature24016; Smith DH, 2019, NAT REV NEUROL, V15, P179, DOI 10.1038/s41582-018-0114-8; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith R, 2016, BRAIN, V139, P2372, DOI 10.1093/brain/aww163; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Spillantini MG, 2013, LANCET NEUROL, V12, P609, DOI 10.1016/S1474-4422(13)70090-5; Stern RA, 2019, NEW ENGL J MED, V380, P1716, DOI 10.1056/NEJMoa1900757; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Tosun D, 2017, BRAIN, V140, P1499, DOI 10.1093/brain/awx046; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; Vermeiren C, 2018, MOVEMENT DISORD, V33, P273, DOI 10.1002/mds.27271; Wang L, 2016, JAMA NEUROL, V73, P1070, DOI 10.1001/jamaneurol.2016.2078; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xia CJ, 2017, JAMA NEUROL, V74, P427, DOI 10.1001/jamaneurol.2016.5755; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784	82	18	18	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	SEP 4	2019	11	508							eaaw1993	10.1126/scitranslmed.aaw1993			14	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	IV6VQ	WOS:000484406300002	31484787	Green Accepted			2021-06-18	
J	Edwards, G; Zhao, J; Dash, PK; Soto, C; Moreno-Gonzalez, I				Edwards, George, III; Zhao, Jing; Dash, Pramod K.; Soto, Claudio; Moreno-Gonzalez, Ines			Traumatic Brain Injury Induces Tau Aggregation and Spreading	JOURNAL OF NEUROTRAUMA			English	Article; Early Access						Alzheimer disease; chronic traumatic encephalopathy; risk factor; tau aggregation; traumatic brain injury	ALZHEIMERS-DISEASE; AMYLOID-BETA; MOUSE MODEL; PROTEIN; PATHOLOGY; PROGRESSION; MECHANISMS; TAUOPATHY; STRAINS; MICE	The misfolding and aggregation of tau protein into neurofibrillary tangles is the main underlying hallmark of tauopathies. Most tauopathies have a sporadic origin and can be associated with multiple risk factors. Traumatic brain injury (TBI) has been suggested as a risk factor for tauopathies by triggering disease onset and facilitating its progression. Several studies indicate that TBI seems to be a risk factor to development of Alzheimer disease and chronic traumatic encephalopathy, because there is a relationship of TBI severity and propensity to development of these illnesses. In this study, we evaluated whether moderate to severe TBI can trigger the initial formation of pathological tau that would induce the development of the pathology throughout the brain. To this end, we subjected tau transgenic mice to TBI and assessed tau phosphorylation and aggregation pattern to create a spatial heat map of tau deposition and spreading in the brain. Our results suggest that brain injured tau transgenic mice have an accelerated tau pathology in different brain regions that increases over time compared with sham mice. The appearance of pathological tau occurs in regions distant to the injury area that are connected synaptically, suggesting dissemination of tau aggregates. Overall, this work posits TBI as a risk factor for tauopathies through the induction of tau hyperphosphorylation and aggregation.	[Edwards, George, III; Soto, Claudio; Moreno-Gonzalez, Ines] Univ Texas Hlth Sci Ctr Houston, Mitchell Ctr Alzheimers Dis & Related Brain Disor, Dept Neurol, Houston, TX 77030 USA; [Zhao, Jing; Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Moreno-Gonzalez, Ines] Univ Malaga, Fac Ciencias, Networking Res Ctr Neurodegenerat Dis CIBERNED, Dept Cell Biol, Malaga, Spain	Moreno-Gonzalez, I (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurol, 6431 Fannin St,R456, Houston, TX 77030 USA.	Ines.M.Gonzalez@uth.tmc.edu	Moreno-Gonzalez, Ines/AAA-2222-2019; Moreno-Gonzalez, Ines/AAO-1694-2021	Moreno-Gonzalez, Ines/0000-0003-3875-0889; Edwards III, George/0000-0001-8795-5851	Department of Defense Peer Reviewed Alzheimer's Research Program Convergence Science Research Award [AZ160106, AZ160082]; Alzheimer's Association New Investigator Research Grant [NIRG-394284]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS103499]; University of Texas System-Neuroscience and Neurotechnology Research Institute UTBrain seed grant program	This work was partially funded by Department of Defense Peer Reviewed Alzheimer's Research Program Convergence Science Research Award grant AZ160106 to IMG and AZ160082 to CS; Alzheimer's Association New Investigator Research Grant NIRG-394284 to IMG; The University of Texas System-Neuroscience and Neurotechnology Research Institute UTBrain seed grant program to CS, and NIH-NINDS grant F31NS103499 to GE3.	Ahmed Z, 2014, ACTA NEUROPATHOL, V127, P667, DOI 10.1007/s00401-014-1254-6; Arendt T, 2016, BRAIN RES BULL, V126, P238, DOI 10.1016/j.brainresbull.2016.08.018; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Braak H, 2012, CURR OPIN NEUROL, V25, P708, DOI 10.1097/WCO.0b013e32835a3432; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Brendel M, 2016, J NUCL MED, V57, P792, DOI 10.2967/jnumed.115.163493; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; CORIA F, 1994, REV NEUROSCIENCE, V5, P275; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duran-Aniotz C, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-76; Duran-Aniotz C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089014; Edwards G, 2017, BIOCHEM BIOPH RES CO, V483, P1137, DOI 10.1016/j.bbrc.2016.07.123; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Frost B, 2009, PRION, V3, P74, DOI 10.4161/pri.3.2.8754; Furman JL, 2017, ACTA NEUROPATHOL, V133, P91, DOI 10.1007/s00401-016-1644-z; Gilbert M, 2014, INT PSYCHOGERIATR, V26, P1593, DOI 10.1017/S1041610214000842; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gotz J, 2001, BRAIN RES REV, V35, P266, DOI 10.1016/S0165-0173(01)00055-8; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Holmes BB, 2014, P NATL ACAD SCI USA, V111, pE4376, DOI 10.1073/pnas.1411649111; Holmes BB, 2014, J BIOL CHEM, V289, P19855, DOI 10.1074/jbc.R114.549295; Hoover BR, 2010, NEURON, V68, P1067, DOI 10.1016/j.neuron.2010.11.030; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Hurtado DE, 2010, AM J PATHOL, V177, P1977, DOI 10.2353/ajpath.2010.100346; Hyman BT, 2005, BBA-MOL BASIS DIS, V1739, P150, DOI 10.1016/j.bbadis.2004.06.015; Iba M, 2015, ACTA NEUROPATHOL, V130, P349, DOI 10.1007/s00401-015-1458-4; Iba M, 2013, J NEUROSCI, V33, P1024, DOI 10.1523/JNEUROSCI.2642-12.2013; Jankowsky JL, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0231-7; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Kaufman SK, 2016, NEURON, V92, P796, DOI 10.1016/j.neuron.2016.09.055; Kriegel J., 2018, COLD SPRING HARB PER, V8; Lasagna-Reeves CA, 2012, SCI REP-UK, V2, DOI 10.1038/srep00700; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lv QS, 2014, J NEUROL SCI, V345, P48, DOI 10.1016/j.jns.2014.06.037; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mendez MF, 2015, J ALZHEIMERS DIS, V47, P985, DOI 10.3233/JAD-143207; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Morales R, 2015, VIRUS RES, V207, P106, DOI 10.1016/j.virusres.2014.12.031; Morales R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003537; Moreno-Gonzalez I, 2017, MOL PSYCHIATR, V22, P1327, DOI 10.1038/mp.2016.230; Moreno-Gonzalez I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2494; Moreno-Gonzalez I, 2011, SEMIN CELL DEV BIOL, V22, P482, DOI 10.1016/j.semcdb.2011.04.002; Moreno-Gonzalez I, 2009, J ALZHEIMERS DIS, V18, P755, DOI 10.3233/JAD-2009-1192; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Sanders DW, 2014, NEURON, V82, P1271, DOI 10.1016/j.neuron.2014.04.047; Sawmiller D, 2014, INT J MOL SCI, V15, P895, DOI 10.3390/ijms15010895; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Sohn PD, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0109-0; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Soto C, 2012, CELL, V149, P968, DOI 10.1016/j.cell.2012.05.007; Stancu IC, 2015, ACTA NEUROPATHOL, V129, P875, DOI 10.1007/s00401-015-1413-4; Sundman M.H., 2014, J ALZHEIMERS DIS PAR, P4; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Vandrovcova J, 2010, CURR ALZHEIMER RES, V7, P726, DOI 10.2174/156720510793611619; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Walker LC, 2016, ANNU REV GENET, V50, P329, DOI 10.1146/annurev-genet-120215-034943; Walker LC, 2013, JAMA NEUROL, V70, P304, DOI 10.1001/jamaneurol.2013.1453; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhao J, 2018, J NEUROTRAUM, V35, P362, DOI 10.1089/neu.2017.5102	70	18	18	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma												10.1089/neu.2018.6348		AUG 2019	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	IT7PX	WOS:000483069300001	31317824	Other Gold, Green Published			2021-06-18	
J	Nitta, ME; Savitz, J; Nelson, LD; Teague, TK; Hoelzle, JB; McCrea, MA; Meier, TB				Nitta, Morgan E.; Savitz, Jonathan; Nelson, Lindsay D.; Teague, T. Kent; Hoelzle, James B.; McCrea, Michael A.; Meier, Timothy B.			Acute elevation of serum inflammatory markers predicts symptom recovery after concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; C-REACTIVE PROTEIN; BLOOD; SPORT; IL-6; INTERLEUKIN-1-BETA; EXPRESSION; SEVERITY; CYTOKINE	Objective To test the hypothesis that acute elevations in serum inflammatory markers predict symptom recovery after sport-related concussion (SRC). Methods High school and collegiate football players (n = 857) were prospectively enrolled. Forty-one athletes with concussion and 43 matched control athletes met inclusion criteria. Serum levels of interleukin (IL)-6, IL-1 beta, IL-10, tumor necrosis factor, C-reactive protein, interferon-gamma, and IL-1 receptor antagonist and Sport Concussion Assessment Tool, 3rd edition (SCAT3) symptom severity scores were collected at a preinjury baseline, 6 and 24-48 hours postinjury, and approximately 8, 15, and 45 days following concussion. The number of days that athletes were symptomatic following SRC (i.e., duration of symptoms) was the primary outcome variable. Results IL-6 and IL-1RA were significantly elevated in athletes with concussion at 6 hours relative to preinjury and other postinjury visits, as well as compared to controls (ps <= 0.001). IL-6 and IL-1RA significantly discriminated concussed from control athletes at 6 hours postconcussion (IL-6 area under receiver operating characteristic curve 0.79 [95% confidence interval (CI) 0.65-0.92], IL-1RA AUC 0.79 [95% CI 0.67-0.90]). Further, IL-6 levels at 6 hours post-concussion were significantly associated with the duration of symptoms (hazard ratio for symptom recovery = 0.61 [95% CI 0.38-0.96], p = 0.031). Conclusions Results support the potential utility of IL-6 and IL-1RA as serum biomarkers of SRC and demonstrate the potential of these markers in identifying athletes at risk for prolonged recovery after SRC. Classification of evidence This study provides Class III evidence that serum levels of IL-6 and IL-1RA 6 hours postconcussion significantly discriminated concussed from control athletes.	[Nitta, Morgan E.; Nelson, Lindsay D.; McCrea, Michael A.; Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Meier, Timothy B.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; [Meier, Timothy B.] Med Coll Wisconsin, Dept Biomed Engn, Milwaukee, WI 53226 USA; [Nitta, Morgan E.; Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [Savitz, Jonathan] Laureate Inst Brain Res, Tulsa, OK USA; [Savitz, Jonathan] Univ Tulsa, Oxley Coll Hlth Sci, Tulsa, OK 74104 USA; [Teague, T. Kent] Univ Oklahoma, Sch Community Med, Dept Surg, Norman, OK 73019 USA; [Teague, T. Kent] Univ Oklahoma, Sch Community Med, Dept Psychiat, Norman, OK 73019 USA; [Teague, T. Kent] Univ Oklahoma, Coll Pharm, Dept Pharmaceut Sci, Norman, OK 73019 USA; [Teague, T. Kent] Oklahoma State Univ, Dept Biochem & Microbiol, Ctr Hlth Sci, Tulsa, OK USA	Meier, TB (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.; Meier, TB (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.; Meier, TB (corresponding author), Med Coll Wisconsin, Dept Biomed Engn, Milwaukee, WI 53226 USA.	tmeier@mcw.edu	Savitz, Jonathan/C-3088-2009; Teague, T. Kent/A-2527-2008	Savitz, Jonathan/0000-0001-8143-182X; Teague, T. Kent/0000-0002-4680-5440	Department of Defense Broad Agency Announcement for Extramural Medical Research [W81XWH-14-1-0561]; National Institute of Neurological Disorders and Stroke of the NIH [R21NS099789]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS102225]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM121312]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH113871]; National Center for Advancing Translational Sciences, NIH [UL1TR001436]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM121312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH113871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS099789, R01NS102225] Funding Source: NIH RePORTER	Supported by the Department of Defense Broad Agency Announcement for Extramural Medical Research through award number W81XWH-14-1-0561, National Institute of Neurological Disorders and Stroke of the NIH under award number R21NS099789, and National Institute of Neurological Disorders and Stroke under award number R01NS102225. The National Institute of General Medical Sciences (P20GM121312) and the National Institute of Mental Health (R21MH113871) also provided support for this project. The REDCap electronic database and the Adult Translational Research Unit used for this project were supported by the National Center for Advancing Translational Sciences, NIH, award number UL1TR001436.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928; Gill J, 2017, BRAIN BEHAV IMMUN, V65, P90, DOI 10.1016/j.bbi.2017.02.015; Gill J, 2016, J HEAD TRAUMA REHAB, V31, P269, DOI 10.1097/HTR.0000000000000191; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kasapis C, 2005, J AM COLL CARDIOL, V45, P1563, DOI 10.1016/j.jacc.2004.12.077; Lagerstedt L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193278; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2017, J NEUROTRAUM, V34, P3134, DOI 10.1089/neu.2017.5046; Merchant-Borna K, 2016, J NEUROTRAUM, V33, P1576, DOI 10.1089/neu.2015.4191; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Palomo J, 2015, CYTOKINE, V76, P25, DOI 10.1016/j.cyto.2015.06.017; Raheja A, 2016, J NEUROSURG, V125, P631, DOI 10.3171/2015.6.JNS15674; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Singh R, 2016, J NEUROL NEUROSUR PS, V87, P670, DOI 10.1136/jnnp-2015-311369; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Wechsler D., 2001, WECHSLER TEST ADULT; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zeiler FA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00331	34	18	18	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 30	2019	93	5					E497	E507		10.1212/WNL.0000000000007864			11	Clinical Neurology	Neurosciences & Neurology	IQ5LX	WOS:000480795200008	31270219	Green Published			2021-06-18	
J	Abeare, C; Messa, I; Whitfield, C; Zuccato, B; Casey, J; Rykulski, N; Erdodi, L				Abeare, Christopher; Messa, Isabelle; Whitfield, Cameron; Zuccato, Brandon; Casey, Joseph; Rykulski, Nicholas; Erdodi, Laszlo			Performance Validity in Collegiate Football Athletes at Baseline Neurocognitive Testing	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						baseline testing; concussion; ImPACT; neurocognitive testing; performance validity; sport neuropsychology	SPORT-RELATED CONCUSSION; RECOGNITION MEMORY TEST; COMPLEX IDEATIONAL MATERIAL; TRAUMATIC BRAIN-INJURY; DIGIT SPAN; CLASSIFICATION ACCURACY; INVALID PERFORMANCE; AMERICAN ACADEMY; RESPONSE BIAS; TEST-SCORES	Objective: To assess the prevalence of invalid performance on baseline neurocognitive testing using embedded measures within computerized tests and individually administered neuropsychological measures, and to examine the influence of incentive status and performance validity on neuropsychological test scores. Setting: Sport-related concussion management program at a regionally accredited university. Participants: A total of 83 collegiate football athletes completing their preseason baseline assessment within the University's concussion management program and a control group of 140 nonathlete students. Design: Cross-sectional design based on differential incentive status: motivated to do poorly to return to play more quickly after sustaining a concussion (athletes) versus motivated to do well due to incentivizing performance (students). Main Measures: Immediate Post-Concussion and Cognitive Testing (ImPACT), performance validity tests, and measures of cognitive ability. Results: Half of the athletes failed at least 1 embedded validity indicator within ImPACT (51.8%), and the traditional neuropsychological tests (49.4%), with large effects for performance validity on cognitive test scores (d: 0.62-1.35), incentive status (athletes vs students; d: 0.36-1.15), and the combination of both factors (d: 1.07-2.20) on measures of attention and processing speed. Conclusion: Invalid performance on baseline assessment is common (50%), consistent across instruments (ImPACT or neuropsychological tests) and settings (one-on-one or group administration), increases as a function of incentive status (risk ratios: 1.3-4.0) and results in gross underestimates of the athletes' true ability level, complicating the clinical interpretation of the postinjury evaluation and potentially leading to premature return to play.	[Abeare, Christopher; Messa, Isabelle; Whitfield, Cameron; Zuccato, Brandon; Casey, Joseph; Erdodi, Laszlo] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Rykulski, Nicholas] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA	Abeare, C (corresponding author), Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada.	cabeare@uwindsor.ca		Abeare, Christopher/0000-0002-7163-7434	HSSRG Grant from the University of Windsor	This research was supported in part by an HSSRG Grant from the University of Windsor awarded to C. Abeare. We thank the students who were involved in the Sport-Related Concussion Centre and assisted with baseline testing.	Abeare CA, 2018, JAMA NEUROL, V75, P697, DOI 10.1001/jamaneurol.2018.0031; Abeare CA, 2017, J CLIN EXP NEUROPSYC, V39, P738, DOI 10.1080/13803395.2016.1259396; An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT., 1989, MILD HEAD INJURY, P257; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P755, DOI 10.1037/pas0000525; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Gaudet CE, 2017, CLIN NEUROPSYCHOL, V31, P43, DOI 10.1080/13854046.2016.1220622; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2004, MEDICAL SYMPTOMS VAL; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Higgins KL, 2017, ARCH CLIN NEUROPSYCH, V32, P259, DOI 10.1093/arclin/acw108; HIGGINS KM, 2017, AOTEAROA NZ SOCIAL C, V16, P1, DOI DOI 10.1007/978-3-319-43893-1_1; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Hurtubise JL, 2017, PSYCHOL INJ LAW, V10, P121, DOI 10.1007/s12207-017-9287-5; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Kerr ZY, 2015, J ATHL TRAINING, V50, P1174, DOI 10.4085/1062-6050-50.11.11; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Larrabee, 2012, FORENSIC NEUROPSYCHO, P116; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Lovell MR., 2000, IMPACT IMMEDIATE POS; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; McCrory P, 2009, J ATHL TRAINING, P36; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Rabinowitz AR, 2016, J CLIN EXP NEUROPSYC, V38, P599, DOI 10.1080/13803395.2015.1123224; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Rey A., 1964, CLIN EXAMINATION PSY; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Roth R.M., 2017, PSYCHOL NEUROSCI, V10, DOI [https//doi.org/10.1037/pne0000103, DOI 10.1037/PNE0000103]; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V27, P1262; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; WARRINGTON EK, 1984, MANUAL RECOGNITION M; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Wechsler D., 2009, ADV CLIN SOLUTIONS W; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Young G, 2015, PSYCHOL INJ LAW, V8, P188, DOI 10.1007/s12207-015-9232-4	70	18	18	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2019	34	4					E20	E31		10.1097/HTR.0000000000000451			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	IQ4XH	WOS:000480754400003	30499932				2021-06-18	
J	Kim, T; Chelluboina, B; Chokkalla, AK; Vemuganti, R				Kim, TaeHee; Chelluboina, Bharath; Chokkalla, Anil K.; Vemuganti, Raghu			Age and sex differences in the pathophysiology of acute CNS injury	NEUROCHEMISTRY INTERNATIONAL			English	Article							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; ESTROGEN REPLACEMENT THERAPY; FOCAL CEREBRAL-ISCHEMIA; KAPPA-B ACTIVATION; EXPERIMENTAL STROKE; INFLAMMATORY CYTOKINES; UNITED-STATES; FEMALE RATS; GENDER	Despite the immeasurable burden on patients and families, no effective therapies to protect the CNS after an acute injury are available yet. Furthermore, the underlying mechanisms that promote neuronal death and functional deficits after injury remain to be poorly understood. The prevalence, age of onset, pathophysiology, and symptomatology of many CNS insults differ significantly between males and females. In the case of stroke, younger males tend to show a higher risk than younger females, while this trend reverses with age. Accumulating evidence from preclinical studies have shown that sex hormones play a crucial role in providing neuroprotection following ischemic stroke and other acute CNS injuries. Estrogen, in particular, exerts a neuroprotective effect by modulating the immune responses after injury. In addition, there exists a sexual dimorphism in cell death pathways between males and females that are independent of hormones. Meanwhile, recent studies suggest that microRNAs are critically involved in the sex-specific mechanisms of cell death. This review discusses the current knowledge on the contribution of sex and age to outcome after stroke. Implication of the interplay between these two factors on other CNS injuries (spinal cord injury and traumatic brain injury) from the experimental evidence were also discussed.	[Kim, TaeHee; Chelluboina, Bharath; Chokkalla, Anil K.; Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA; [Chokkalla, Anil K.; Vemuganti, Raghu] Univ Wisconsin, Cellular & Mol Pathol Program, Madison, WI 53792 USA; [Vemuganti, Raghu] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA	Vemuganti, R (corresponding author), Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA.	vemuganti@neurosurgery.wisc.edu	Kim, TaeHee/AAS-5541-2020	Kim, TaeHee/0000-0002-1980-7774; Chelluboina, Bharath/0000-0001-8834-6484	U.S. Department of Veterans Affairs Merit Review GrantUS Department of Veterans Affairs [I01 BX002985]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS101960, RO1 N5099531, RO1 NS109459]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS109459, R01NS099531, R01NS101960] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002985] Funding Source: NIH RePORTER	This work was supported, in part, by the U.S. Department of Veterans Affairs Merit Review Grant (I01 BX002985) and NIH grants RO1 NS101960, RO1 N5099531, RO1 NS109459. Figures were created using the Servier Medical Art image bank with appropriate modifications.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Barber PA, 2001, NEUROLOGY, V56, P1015, DOI 10.1212/WNL.56.8.1015; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Biswas RK, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0211-y; Boehme AK, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00500; Boutin H, 2001, J NEUROSCI, V21, P5528; Broughton BRS, 2014, STROKE, V45, P835, DOI 10.1161/STROKEAHA.113.001499; Broughton BRS, 2013, NEUROSIGNALS, V21, P229, DOI 10.1159/000338019; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Cai M, 2014, NEUROSCI LETT, V558, P115, DOI 10.1016/j.neulet.2013.11.007; Carrasquilla GD, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002445; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Chan WM, 2013, TRANSL STROKE RES, V4, P447, DOI 10.1007/s12975-012-0249-7; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Chen YY, 2016, ARCH PHYS MED REHAB, V97, P1610, DOI 10.1016/j.apmr.2016.03.017; Chiappetta O, 2007, INT REV NEUROBIOL, V82, P357, DOI 10.1016/S0074-7742(07)82019-8; Chu MC, 2003, HUM REPROD, V18, P1570, DOI 10.1093/humrep/deg330; Cole JA, 2007, OBSTET GYNECOL, V109, P339, DOI 10.1097/01.AOG.0000250968.82370.04; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; DiNapoli VA, 2008, NEUROBIOL AGING, V29, P753, DOI 10.1016/j.neurobiolaging.2006.12.007; DiNapoli VA, 2006, J NEUROSCI METH, V154, P233, DOI 10.1016/j.jneumeth.2005.12.026; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Edwards P, 2005, LANCET, V365, P1957; Fang Jing, 2012, Morbidity and Mortality Weekly Report, V61, P379; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Fee DB, 2007, BRAIN RES, V1137, P146, DOI 10.1016/j.brainres.2006.12.024; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Galea J, 2013, J INFLAMM RES, V6, P121, DOI 10.2147/JIR.S35629; Gordon KB, 2005, BRAIN RES, V1036, P155, DOI 10.1016/j.brainres.2004.12.052; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Herman P, 2018, J NEUROTRAUM, V35, P1819, DOI 10.1089/neu.2017.5519; Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Kim TH, 2015, CNS NEUROSCI THER, V21, P327, DOI 10.1111/cns.12346; Kleindorfer DO, 2010, STROKE, V41, P1326, DOI 10.1161/STROKEAHA.109.575043; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Laliberte F, 2011, MENOPAUSE, V18, P1052, DOI 10.1097/gme.0b013e3182175e5c; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lang JT, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-33; Ley EJ, 2013, J TRAUMA ACUTE CARE, V75, P682, DOI 10.1097/TA.0b013e31829d024f; Li H, 2005, ANN NEUROL, V58, P317, DOI 10.1002/ana.20538; Lin CW, 2016, NEUROSCI BULL, V32, P137, DOI 10.1007/s12264-016-0017-x; Liu FD, 2011, STROKE, V42, P1090, DOI 10.1161/STROKEAHA.110.594861; Liu FD, 2009, STROKE, V40, P1842, DOI 10.1161/STROKEAHA.108.538686; Lokkegaard E, 2017, STROKE, V48, P2266, DOI 10.1161/STROKEAHA.117.017132; Low PC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4450; Lu D, 2016, BIOCHEM BIOPH RES CO, V477, P209, DOI 10.1016/j.bbrc.2016.06.044; Lusardi TA, 2014, FRONT MOL NEUROSCI, V7, DOI [10.3389/fnmo1.2014.00011, 10.3389/fnmol.2014.00011]; Madsen TE, 2015, STROKE, V46, P717, DOI 10.1161/STROKEAHA.114.006737; Manwani B, 2015, J CEREBR BLOOD F MET, V35, P221, DOI 10.1038/jcbfm.2014.186; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; McCullough LD, 2016, AGING-US, V8, P1432, DOI 10.18632/aging.100997; Murphy AJ, 2010, J IMMUNOL, V184, P5029, DOI 10.4049/jimmunol.0903463; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Nadkarni S, 2013, CURR OPIN PHARMACOL, V13, P576, DOI 10.1016/j.coph.2013.05.007; Niemeier JP, 2013, NEUROPSYCHOL REHABIL, V23, P363, DOI 10.1080/09602011.2012.761944; Nys GMS, 2006, J NEUROL SCI, V247, P149, DOI 10.1016/j.jns.2006.04.005; Ouyang YB, 2012, NEUROBIOL DIS, V45, P555, DOI 10.1016/j.nbd.2011.09.012; Petrone AB, 2014, AGING DIS, V5, P340, DOI 10.14336/AD.2014.0500340; Poynter B, 2009, PSYCHOSOMATICS, V50, P563, DOI 10.1176/appi.psy.50.6.563; Rahnama M, 2002, B VET I PULAWY, V46, P273; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Rosen CL, 2005, J NEUROSURG, V103, P687, DOI 10.3171/jns.2005.103.4.0687; Santizo RA, 2002, BRAIN RES, V956, P86, DOI 10.1016/S0006-8993(02)03484-4; Sealy-Jefferson S, 2012, GENDER MED, V9, P121, DOI 10.1016/j.genm.2012.02.002; Selvamani A, 2017, NEUROCHEM INT, V107, P168, DOI 10.1016/j.neuint.2016.10.008; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Seshadri S, 2006, STROKE, V37, P345, DOI 10.1161/01.STR.0000199613.38911.b2; Sharma S, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/2042-6410-5-3; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Spani CB, 2018, FRONT NEUROENDOCRIN, V50, P52, DOI 10.1016/j.yfrne.2018.03.006; Spinal cord injury (SCI), 2016, J SPINAL CORD MED, V39, P493, DOI [10.1080/10790268.2016.1210925, DOI 10.1080/10790268.2016.1210925]; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Stary CM, 2017, MOL CELL NEUROSCI, V82, P118, DOI 10.1016/j.mcn.2017.05.004; Strom JO, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-22; Strom JO, 2011, INT J MOL SCI, V12, P1533, DOI 10.3390/ijms12031533; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Turtzo LC, 2011, J NEUROSCI, V31, P13255, DOI 10.1523/JNEUROSCI.0621-11.2011; Vagnerova K, 2010, NEUROSCIENCE, V166, P476, DOI 10.1016/j.neuroscience.2009.12.041; Vannucci SJ, 2001, J CEREBR BLOOD F MET, V21, P52, DOI 10.1097/00004647-200101000-00007; Vega T, 2009, J STROKE CEREBROVASC, V18, P11, DOI 10.1016/j.jstrokecerebrovasdis.2008.06.010; von Leden RE, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0933-3; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xing DQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036890; Xu J, 2015, NCHS DATA BRIEF, V2016, P1, DOI DOI 10.1056/NEJM184002260220306; Yanhong Li, 2007, Neural Regeneration Research, V2, P471; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Zahuranec DB, 2014, NEUROLOGY, V82, P2180, DOI 10.1212/WNL.0000000000000519; Zhao TZ, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.449; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	112	18	18	1	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUL	2019	127						22	28		10.1016/j.neuint.2019.01.012			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	IH2LY	WOS:000474327500004	30654116	Green Accepted			2021-06-18	
J	Negah, SS; Oliazadeh, P; Jahan-Abad, AJ; Eshaghabadi, A; Samini, F; Ghasemi, S; Asghari, A; Gorji, A				Negah, Sajad Sahab; Oliazadeh, Pardis; Jahan-Abad, Ali Jahanbazi; Eshaghabadi, Arezou; Samini, Fariborz; Ghasemi, Sepideh; Asghari, Amir; Gorji, Ali			Transplantation of human meningioma stem cells loaded on a self-assembling peptide nanoscaffold containing IKVAV improves traumatic brain injury in rats	ACTA BIOMATERIALIA			English	Article						Human stem cells; Brain injury; Cell damage; Cell death; Neuroinflammation	NEURAL STEM/PROGENITOR CELLS; SYNTHETIC PEPTIDE; A-CHAIN; HYDROGEL; DIFFERENTIATION; PROLIFERATION; BIOCOMPATIBILITY; INVOLVEMENT; MIGRATION; RECOVERY	Traumatic brain injury (TBI) can result in permanent brain function impairment due to the poor regenerative ability of neural tissue. Tissue engineering has appeared as a promising approach to promote nerve regeneration and to ameliorate brain damage. The present study was designed to investigate the effect of transplantation of the human meningioma stem-like cells (hMgSCs) seeded in a promising three-dimensional scaffold (RADA4GGSIKVAV; R-GSIK) on the functional recovery of the brain and neuroinflammatory responses following TBI in rats. After induction of TBI, hMgSCs seeded in R-GS1K was transplanted within the injury site and its effect was compared to several control groups. Application of hMgSCs with R-GSIK improved functional recovery after TBI. A significant higher number of hMgSCs was observed in the brain when transplanted with R-GSIK scaffold compared to the control groups. Application of hMgSCs seeded in R-GSIK significantly decreased the lesion volume, reactive gliosis, and apoptosis at the injury site. Furthermore, treatment with hMgSCs seeded in R-GSIK significantly inhibited the expression of Toll-like receptor 4 and its downstream signaling molecules, including interleukin-1 beta and tumor necrosis factor. These data revealed the potential for hMgSCs seeded in R-GS1K to improve the functional recovery of the brain after TBI; possibly via amelioration of inflammatory responses. Statement of significance Tissue engineered scaffolds that mimic the natural extracellular matrix of the brain may modulate stem cell fate and contribute to tissue repair following traumatic brain injury (TB!). Among several scaffolds, self-assembly peptide nanofiber scaffolds markedly promotes cellular behaviors, including cell survival and differentiation. We developed a novel three-dimensional scaffold (RADAI6GGSIKVAV; R-GSIK). Transplantation of the human meningioma stem-like cells seeded in R-GS1K in an animal model of TB1 significantly improved functional recovery of the brain, possibly via enhancement of stem cell survival as well as reduction of the lesion volume, inflammatory process, and reactive gliosis at the injury site. R-GSII( is a suitable microenvironment for human stem cells and could be a potential biomaterial for the reconstruction of the injured brain after TBI. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Negah, Sajad Sahab; Oliazadeh, Pardis; Gorji, Ali] Mashhad Univ Med Sci, Dept Neurosci, Fac Med, Mashhad, Razavi Khorasan, Iran; [Negah, Sajad Sahab; Oliazadeh, Pardis; Gorji, Ali] Mashhad Univ Med Sci, Neurosci Res Ctr, Mashhad, Razavi Khorasan, Iran; [Negah, Sajad Sahab; Jahan-Abad, Ali Jahanbazi; Eshaghabadi, Arezou; Ghasemi, Sepideh; Gorji, Ali] Khatam Alanbia Hosp, Shefa Neurosci Res Ctr, Tehran, Iran; [Samini, Fariborz] Mashhad Univ Med Sci, Dept Neurosurg, Fac Med, Mashhad, Razavi Khorasan, Iran; [Asghari, Amir] Mashhad Univ Med Sci, Devis Neurocognit Sci Psychiat & Behav Sci Res Ct, Mashhad, Razavi Khorasan, Iran; [Gorji, Ali] Westfalische Wilhelms Univ Munster, Dept Neurosurg, Munster, Germany; [Gorji, Ali] Westfalische Wilhelms Univ Munster, Dept Neurol, Munster, Germany; [Gorji, Ali] Westfalische Wilhelms Univ Munster, Epilepsy Res Ctr, Domagkstr 11, D-48149 Munster, Germany	Gorji, A (corresponding author), Westfalische Wilhelms Univ Munster, Epilepsy Res Ctr, Domagkstr 11, D-48149 Munster, Germany.	gorjial@uni-muenster.de	Negah, Sajad Sahab/AAQ-5852-2020	Gorji, Ali/0000-0002-4557-3270; Jahanbazi Jahanabad, Ali/0000-0001-8629-7762	Iran National Science Foundation (INSF)Iran National Science Foundation (INSF); National Institute for Medical Research (NIMAD) [964650]; German Academic Exchange Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD) [57348208, 57403633]	This study was supported by the Iran National Science Foundation (INSF), National Institute for Medical Research (NIMAD; 964650), and the German Academic Exchange Service (DAAD; 57348208 and 57403633) to AG.	Agius E, 1996, NEUROSCIENCE, V71, P773, DOI 10.1016/0306-4522(95)00447-5; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Aligholi H, 2016, BRAIN RES, V1642, P197, DOI 10.1016/j.brainres.2016.03.043; Aligholi H, 2014, J NEUROSCI METH, V225, P81, DOI 10.1016/j.jneumeth.2013.12.008; Cavalcanti BN, 2013, DENT MATER, V29, P97, DOI 10.1016/j.dental.2012.08.002; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Chronopoulou L, 2012, SOFT MATTER, V8, P5784, DOI 10.1039/c2sm25528f; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Cui GH, 2016, MOL NEUROBIOL, V53, P1108, DOI 10.1007/s12035-014-9069-y; Daadi MM, 2010, STROKE, V41, P516, DOI 10.1161/STROKEAHA.109.573691; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dolecek TA, 2015, CANCER-AM CANCER SOC, V121, P2400, DOI 10.1002/cncr.29379; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Farrukh A, 2017, STEM CELL REP, V9, P1432, DOI 10.1016/j.stemcr.2017.09.002; Feng Y, 2017, CELL MOL NEUROBIOL, V37, P155, DOI 10.1007/s10571-016-0356-1; Francis NL, 2016, ACS BIOMATER SCI ENG, V2, P1030, DOI 10.1021/acsbiomaterials.6b00156; Glushakova OY, 2018, J NEUROTRAUM, V35, P157, DOI 10.1089/neu.2017.4999; Gong L, 2018, EXP THER MED, V15, P620, DOI 10.3892/etm.2017.5439; Goto S, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00022; Guo JS, 2009, NANOMED-NANOTECHNOL, V5, P345, DOI 10.1016/j.nano.2008.12.001; Hassannejad Z., 2018, INJURY; Hu DZ, 2012, J NEURO-ONCOL, V106, P505, DOI 10.1007/s11060-011-0705-3; Hueng DY, 2011, J NEURO-ONCOL, V104, P45, DOI 10.1007/s11060-010-0469-1; Iwasaki M, 2014, BIOMATERIALS, V35, P2617, DOI 10.1016/j.biomaterials.2013.12.019; Jahan-Abad A. J., 2017, MOL NEUROBIOL, P1; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jiang H, 2017, CANCER IMMUNOL IMMUN, V66, P1037, DOI 10.1007/s00262-017-2003-1; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Koss KM, 2016, ACTA BIOMATER, V35, P127, DOI 10.1016/j.actbio.2016.02.001; Leung GKK, 2012, METHOD ENZYMOL, V508, P177, DOI 10.1016/B978-0-12-391860-4.00009-4; Li C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43834; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Lim HY, 2013, INT J ONCOL, V43, P1260, DOI 10.3892/ijo.2013.2053; Liu Y, 2013, ACTA BIOMATER, V9, P8075, DOI 10.1016/j.actbio.2013.06.001; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Ludwig PE, 2018, NEURAL REGEN RES, V13, P7, DOI 10.4103/1673-5374.224361; Marshall LF, 2000, HEAD INJURY RECENT P; Meng XE, 2016, MED SCI MONITOR, V22, P284, DOI 10.12659/MSM.894148; Moradi F, 2012, J NEUROSCI RES, V90, P2335, DOI 10.1002/jnr.23120; Negah S. S., 2018, MOL NEUROBIOL, P1; Negah SS, 2018, CELL TISSUE RES, V371, P223, DOI 10.1007/s00441-017-2717-6; Negah SS, 2017, MOL NEUROBIOL, V54, P8050, DOI 10.1007/s12035-016-0295-3; Negah SS, 2016, IRAN J BASIC MED SCI, V19, P1271, DOI 10.22038/ijbms.2016.7907; Pan LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104335; Ramos-Cabrer P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012779; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Su N., 2019, BIOMACROMOLECULES; Tang HL, 2012, INT J MOL SCI, V13, P6424, DOI 10.3390/ijms13056424; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; Theocharidis U, 2014, PROG BRAIN RES, V214, P3, DOI 10.1016/B978-0-444-63486-3.00001-3; Thonhoff JR, 2008, BRAIN RES, V1187, P42, DOI 10.1016/j.brainres.2007.10.046; Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008; Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001; Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038; Xiong LL, 2018, MOL NEUROBIOL, V55, P2696, DOI 10.1007/s12035-017-0551-1; Yang YH, 2015, ACTA BIOMATER, V21, P55, DOI 10.1016/j.actbio.2015.04.031; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang SC, 2008, PHILOS T R SOC B, V363, P87, DOI 10.1098/rstb.2006.2014; Zhang XM, 2018, CELL PHYSIOL BIOCHEM, V45, P258, DOI 10.1159/000486772; Zou ZW, 2014, J BIOMED MATER RES A, V102, P1286, DOI 10.1002/jbm.a.34804	67	18	18	3	33	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JUL 1	2019	92						132	144		10.1016/j.actbio.2019.05.010			13	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	IF8ZC	WOS:000473380800011	31075516				2021-06-18	
J	Younger, D; Murugan, M; Rao, KVR; Wu, LJ; Chandra, N				Younger, Daniel; Murugan, Madhuvika; Rao, Kakulavarapu V. Rama; Wu, Long-Jun; Chandra, Namas			Microglia Receptors in Animal Models of Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Microglia; Brain injury; Receptors	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; METABOTROPIC GLUTAMATE RECEPTORS; TOLL-LIKE RECEPTORS; PPAR-GAMMA AGONIST; VASOACTIVE-INTESTINAL-PEPTIDE; IMPROVES FUNCTIONAL RECOVERY; CONTROLLED CORTICAL IMPACT; PROLIFERATOR-ACTIVATED RECEPTORS; OUTWARD POTASSIUM CURRENTS	Microglia have been implicated as a key mediator of chronic inflammation following traumatic brain injury (TBI). The animal models of TBI vary significantly based on the type of brain injury (focal versus diffuse). This has made it extremely difficult to assess the role of microglia and the window of microglia activation. Hence, the focus of this review is to summarize the time course ofmicroglia activation in various animal models of TBI. The review explores the repertoire of secondary injurymechanisms such as aberrant neurotransmitter release, oxidative stress, blood-brain barrier disruption, and production of pro-inflammatory cytokines that follow microglia activation. Since receptors act as sensors for activation, we highlight certain microglia receptors that have been implicated in TBI pathology, including fractalkine receptor (CX3CR1), purinergic receptor (P2Y12R), Toll-like receptor (TLR4), scavenger receptors, tumor necrosis factor receptor (TNF-1R), interleukin receptor (IL-1R), complement receptors, and peroxisome proliferator-activated receptor (PPAR). In addition to describing their downstream signaling pathways in TBI, we describe the functional consequences of their activation and the implication in behavioral outcomes. Taken together, this review will provide a holistic view of the role of microglia and its receptors in TBI based on animal studies.	[Younger, Daniel; Murugan, Madhuvika; Rao, Kakulavarapu V. Rama; Chandra, Namas] New Jersey Inst Technol, Dept Bioengn, 111 Lock St,Room105 CHEN Bldg, Newark, NJ 07102 USA; [Wu, Long-Jun] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Chandra, N (corresponding author), New Jersey Inst Technol, Dept Bioengn, 111 Lock St,Room105 CHEN Bldg, Newark, NJ 07102 USA.	namas.chandra@njit.edu	Murugan, Madhuvika/AAZ-8533-2020; Wu, Long-Jun/AAK-7113-2020	Wu, Long-Jun/0000-0001-8019-3380; Murugan, Madhuvika/0000-0002-0706-0730	US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-15-1-0303]; New Jersey Commission for Brain Injury Research [CBIR17PIL020]; Rutgers Brain Health Institute [BHI-RUN-NJIT-2016]	This work was supported by funding from the US Army Medical Research and Material Command (W81XWH-15-1-0303), New Jersey Commission for Brain Injury Research (CBIR17PIL020), and Rutgers Brain Health Institute (BHI-RUN-NJIT-2016).	ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Abe N, 2018, GLIA; Andre R, 2005, J NEUROCHEM, V95, P324, DOI 10.1111/j.1471-4159.2005.03364.x; Avignone E, 2008, J NEUROSCI, V28, P9133, DOI 10.1523/JNEUROSCI.1820-08.2008; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; BADER MF, 1994, GLIA, V11, P336, DOI 10.1002/glia.440110406; Balcaitis S, 2003, NEUROREPORT, V14, P2373, DOI 10.1097/00001756-200312190-00017; Ballerini P, 2005, INT J IMMUNOPATH PH, V18, P255, DOI 10.1177/039463200501800208; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Barger SW, 2001, J NEUROCHEM, V76, P846, DOI 10.1046/j.1471-4159.2001.00075.x; Basrai HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153418; Basu A, 2002, J NEUROSCI, V22, P6071; Bate C, 2005, J NEUROIMMUNOL, V170, P62, DOI 10.1016/j.jneuroim.2005.08.021; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bernardino ALF, 2008, INFECT IMMUN, V76, P4385, DOI 10.1128/IAI.00394-08; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Biber K, 1999, J NEUROCHEM, V72, P1671, DOI 10.1046/j.1471-4159.1999.721671.x; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Boddeke EWGH, 1999, EUR J PHARMACOL, V374, P309, DOI 10.1016/S0014-2999(99)00307-6; Boddeke EWGM, 1999, J NEUROIMMUNOL, V98, P176, DOI 10.1016/S0165-5728(99)00096-X; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Bollmann L, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00363; Bordey A, 2003, EUR J NEUROSCI, V18, P2893, DOI 10.1111/j.1460-9568.2003.03021.x; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Bu W, 2016, FRONT NEUROSCI, V10, P17; Butchi NB, 2010, GLIA, V58, P650, DOI 10.1002/glia.20952; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Butovsky O, 2007, MOL CELL NEUROSCI, V35, P490, DOI 10.1016/j.mcn.2007.04.009; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Cabral GA, 2005, J LEUKOCYTE BIOL, V78, P1192, DOI 10.1189/jlb.0405216; Cao Q, 2008, GLIA, V56, P1224, DOI 10.1002/glia.20692; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Cavaliere F, 2005, NEUROSCIENCE, V136, P615, DOI 10.1016/j.neuroscience.2005.04.038; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cervantes JL, 2012, CELL MOL IMMUNOL, V9, P434, DOI 10.1038/cmi.2012.38; Chang CZ, 2015, WORLD NEUROSURG, V84, P954, DOI 10.1016/j.wneu.2015.05.075; Chao CC, 1996, P NATL ACAD SCI USA, V93, P8051, DOI 10.1073/pnas.93.15.8051; Charles KJ, 2003, MOL CELL NEUROSCI, V24, P214, DOI 10.1016/S1044-7431(03)00162-3; Chattopadhyay N, 1999, J NEUROCHEM, V72, P1915, DOI 10.1046/j.1471-4159.1999.0721915.x; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen KQ, 2006, J BIOL CHEM, V281, P3651, DOI 10.1074/jbc.M508125200; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Christensen RN, 2006, J NEUROSCI RES, V84, P170, DOI 10.1002/jnr.20865; Clark AK, 2007, P NATL ACAD SCI USA, V104, P10655, DOI 10.1073/pnas.0610811104; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cowell RM, 2006, J NEUROIMMUNOL, V173, P155, DOI 10.1016/j.jneuroim.2006.01.005; Crehan H, 2012, INT J ALZHEIMERS DIS, V2012, P983640, DOI [DOI 10.1155/2012/983640, 10.1155/2012/983640]; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; CUNNINGHAM ET, 1993, IMMUNOL TODAY, V14, P171; Dalpke AH, 2002, J IMMUNOL, V168, P4854, DOI 10.4049/jimmunol.168.10.4854; De Simone R, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-4; del Puerto A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00197; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Delgado M, 2003, FASEB J, V17, P1922, DOI 10.1096/fj.02-1029fje; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Deselms H, 2016, J NEUROSCI METH, V272, P69, DOI 10.1016/j.jneumeth.2016.02.002; DING AH, 1988, J IMMUNOL, V141, P2407; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBRENIS K, 1995, BRAIN RES, V686, P239, DOI 10.1016/0006-8993(95)00452-V; Dong H, 2016, CELL MOL NEUROBIOL, V36, P639, DOI 10.1007/s10571-015-0244-0; Drouin-Ouellet J, 2011, GLIA, V59, P188, DOI 10.1002/glia.21086; Duncan JA, 2009, J IMMUNOL, V182, P6460, DOI 10.4049/jimmunol.0802696; Ebert S, 2005, J NEUROIMMUNOL, V159, P87, DOI 10.1016/j.jneuroim.2004.10.005; Ekmark-Lewen S, 2016, EUR J NEUROSCI, V43, P1016, DOI 10.1111/ejn.13190; El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Esen N, 2006, J IMMUNOL, V176, P6802, DOI 10.4049/jimmunol.176.11.6802; Eyo UB, 2015, J NEUROSCI, V35, P2417, DOI 10.1523/JNEUROSCI.3279-14.2015; Facchinetti F, 2003, GLIA, V41, P161, DOI 10.1002/glia.10177; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Fang F, 2010, FASEB J, V24, P1043, DOI 10.1096/fj.09-139634; Farber K, 2005, MOL CELL NEUROSCI, V29, P128, DOI 10.1016/j.mcn.2005.01.003; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Febinger HY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0386-5; Feindt J, 1998, MOL BRAIN RES, V60, P228, DOI 10.1016/S0169-328X(98)00184-3; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2; Fujita H, 1998, NEUROSCI LETT, V242, P37, DOI 10.1016/S0304-3940(98)00003-2; Fujita R, 2008, J NEUROCHEM, V107, P152, DOI 10.1111/j.1471-4159.2008.05599.x; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Garrett MC, 2009, BRAIN RES, V1298, P171, DOI 10.1016/j.brainres.2009.04.047; Gasque P, 1998, J IMMUNOL, V160, P3543; Gekker G, 2006, INT IMMUNOPHARMACOL, V6, P1029, DOI 10.1016/j.intimp.2005.12.005; Geurts JJG, 2003, BRAIN, V126, P1755, DOI 10.1093/brain/awg179; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gonzalez P, 2009, J NEUROPATH EXP NEUR, V68, P391, DOI 10.1097/NEN.0b013e31819dca30; Gonzalez-Rey E, 2008, BRAIN BEHAV IMMUN, V22, P35, DOI 10.1016/j.bbi.2007.07.004; Gottlieb M, 1997, J CEREBR BLOOD F MET, V17, P290, DOI 10.1097/00004647-199703000-00006; Grandbarbe L, 2007, GLIA, V55, P1519, DOI 10.1002/glia.20553; Gu N, 2016, BRAIN BEHAV IMMUN, V55, P82, DOI 10.1016/j.bbi.2015.11.007; Gyoneva S, 2015, J NEUROINFLAMM, V12, P12; Hagino Y, 2004, GLIA, V47, P68, DOI 10.1002/glia.20034; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hajishengallis G, 2007, J IMMUNOL, V179, P2359, DOI 10.4049/jimmunol.179.4.2359; Hall AA, 2009, GLIA, V57, P744, DOI 10.1002/glia.20802; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hammad A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1066-z; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; Hanamsagar R, 2011, J NEUROCHEM, V119, P736, DOI 10.1111/j.1471-4159.2011.07481.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanisch UK, 1997, J BIOL CHEM, V272, P28853, DOI 10.1074/jbc.272.46.28853; Hanisch UK, 2001, EUR J IMMUNOL, V31, P2104, DOI 10.1002/1521-4141(200107)31:7<2104::AID-IMMU2104>3.0.CO;2-3; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Harry GJ, 2008, J NEUROCHEM, V106, P281, DOI 10.1111/j.1471-4159.2008.05382.x; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hausler KG, 2002, EUR J NEUROSCI, V16, P2113, DOI 10.1046/j.1460-9568.2002.02287.x; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heese K, 1997, NEUROSCI LETT, V231, P83, DOI 10.1016/S0304-3940(97)00545-4; Hellewell SC, 2013, J NEUROINFLAMM, V10, P21; Hidetoshi T.-S., 2012, WILEY INTERDISCIP RE, V1, P493, DOI DOI 10.1002/WMTS.46; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Horvath RJ, 2009, J NEUROSCI, V29, P998, DOI 10.1523/JNEUROSCI.4595-08.2009; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Huang EYK, 2014, BEHAV BRAIN RES, V267, P156, DOI 10.1016/j.bbr.2014.03.033; Huang Z, 2007, NEUROSCI LETT, V417, P160, DOI 10.1016/j.neulet.2007.01.086; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667; Ifuku M, 2007, J NEUROSCI, V27, P13065, DOI 10.1523/JNEUROSCI.3467-07.2007; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Ilschner S, 1996, NEUROSCIENCE, V73, P1109, DOI 10.1016/0306-4522(96)00107-8; Israel I, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0604-9; Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kabadi SV, 2015, J CEREBR BLOOD F MET, V35, P2010, DOI 10.1038/jcbfm.2015.165; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kato G, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0004-16.2016; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kelso ML, 2014, CURR PHARM DESIGN, V20, P4284; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kielian T, 2002, J NEUROIMMUNOL, V130, P86, DOI 10.1016/S0165-5728(02)00216-3; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Koizumi S, 2013, GLIA, V61, P47, DOI 10.1002/glia.22358; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kraft AD, 2009, NEUROTOXICOLOGY, V30, P785, DOI 10.1016/j.neuro.2009.07.001; Kuhn SA, 2004, MOL CELL NEUROSCI, V25, P312, DOI 10.1016/j.mcn.2003.10.023; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kuno R, 2005, J NEUROIMMUNOL, V162, P89, DOI 10.1016/j.jneuroim.2005.01.015; Kuriakose M, 2018, J NEUROTRAUMA; Kust BM, 1999, GLIA, V25, P120; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Lai JP, 2000, NEUROSCIENCE, V101, P1137, DOI 10.1016/S0306-4522(00)00398-5; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Lehnardt S, 2006, J IMMUNOL, V177, P583, DOI 10.4049/jimmunol.177.1.583; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Light AR, 2006, NEURON GLIA BIOL, V2, P125, DOI 10.1017/S1740925X05000323; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Link VM, 2015, COLD SH Q B, V80, P213, DOI 10.1101/sqb.2015.80.027367; Liu C, 2014, ONCOL LETT, V8, P2747, DOI 10.3892/ol.2014.2575; Liu GJ, 2006, MOL PHARMACOL, V70, P851, DOI 10.1124/mol.105.021436; Liu GJ, 2009, EUR J NEUROSCI, V29, P1108, DOI 10.1111/j.1460-9568.2009.06659.x; Liu H, 2016, BIOCHEM BIOPH RES CO, V472, P648, DOI 10.1016/j.bbrc.2016.03.003; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu J, 2009, INVEST OPHTH VIS SCI, V50, P1408, DOI 10.1167/iovs.08-2398; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lou NH, 2016, P NATL ACAD SCI USA, V113, P1074, DOI 10.1073/pnas.1520398113; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Madry C, 2018, NEURON, V97, P299, DOI 10.1016/j.neuron.2017.12.002; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mastroeni D, 2009, NEUROBIOL AGING, V30, P1805, DOI 10.1016/j.neurobiolaging.2008.01.001; McIntosh TK, 1996, LAB INVEST, V74, P315; McLarnon JG, 1999, NEUROSCI LETT, V263, P9, DOI 10.1016/S0304-3940(99)00082-8; McMullan SM, 2012, ASN NEURO, V4, P323, DOI 10.1042/AN20120044; McNamee EN, 2010, EUR J PHARMACOL, V626, P219, DOI 10.1016/j.ejphar.2009.09.054; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Means TK, 2009, J EXP MED, V206, P637, DOI 10.1084/jem.20082109; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Mitrasinovic OM, 2003, NEUROBIOL AGING, V24, P807, DOI 10.1016/S0197-4580(02)00237-3; Mitrasinovic OM, 2003, NEUROSCI LETT, V344, P185, DOI 10.1016/S0304-3940(03)00474-9; Mitrasinovic OM, 2002, J BIOL CHEM, V277, P29889, DOI 10.1074/jbc.M200868200; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Miyoshi M, 2008, EUR J NEUROSCI, V27, P343, DOI 10.1111/j.1460-9568.2007.06014.x; Mizoguchi Y, 2009, J IMMUNOL, V183, P7778, DOI 10.4049/jimmunol.0901326; Moller T, 1997, NEUROREPORT, V8, P2127; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Moller T, 1997, J NEUROSCI, V17, P615; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Moore CS, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000106; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mori K, 2002, NEUROPHARMACOLOGY, V43, P1026, DOI 10.1016/S0028-3908(02)00211-3; Mori M, 1996, J NEUROSCI, V16, P3590; Morrison H, 2017, SCI REP, V7, P12; Murugan M, 2011, GLIA, V59, P521, DOI 10.1002/glia.21121; Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x; Navone SE, 2018, OSTEOARTHR CARTILAGE, V26, P978, DOI 10.1016/j.joca.2018.04.013; Neher MD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-95; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noda M, 2004, NEUROCHEM INT, V45, P437, DOI 10.1016/j.neuint.2003.07.007; Noda M, 2000, J NEUROSCI, V20, P251, DOI 10.1523/JNEUROSCI.20-01-00251.2000; Noda M, 2003, LIFE SCI, V72, P1573, DOI 10.1016/S0024-3205(02)02449-9; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; Noda M, 2007, J NEUROCHEM, V101, P397, DOI 10.1111/j.1471-4159.2006.04339.x; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; Ock J, 2007, J NEUROSCI RES, V85, P1989, DOI 10.1002/jnr.21322; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Petitto JN, 2003, J NEUROIMMUNOL, V134, P95, DOI 10.1016/S0165-5728(02)00422-8; Pilipovic K, 2015, PROG NEURO-PSYCHOPH, V59, P8, DOI 10.1016/j.pnpbp.2015.01.003; Pinteaux E, 2002, J NEUROCHEM, V83, P754, DOI 10.1046/j.1471-4159.2002.01184.x; Pinteaux-Jones F, 2008, J NEUROCHEM, V106, P442, DOI 10.1111/j.1471-4159.2008.05426.x; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Prinz M, 1999, J NEUROPATH EXP NEUR, V58, P1078, DOI 10.1097/00005072-199910000-00006; Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Qin LY, 2005, GLIA, V52, P78, DOI 10.1002/glia.20225; Qu BG, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43059; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Ransohoff RM, 2011, NAT NEUROSCI, V14, P1098, DOI 10.1038/nn.2917; Rao KVR, J NEUROTRAUMA, V14; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rappert A, 2002, J IMMUNOL, V168, P3221, DOI 10.4049/jimmunol.168.7.3221; Rasley A, 2002, GLIA, V37, P258, DOI 10.1002/glia.10034; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Robson MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150068; Rock RB, 2008, J NEUROIMMUNE PHARM, V3, P143, DOI 10.1007/s11481-007-9098-7; SAKAI N, 1995, J NEUROCHEM, V65, P895; Sankarapandi S, 1998, ARCH BIOCHEM BIOPHYS, V353, P312, DOI 10.1006/abbi.1998.0658; Sasaki Y, 2003, GLIA, V44, P242, DOI 10.1002/glia.10293; Sattayaprasert P, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-11; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; SAWADA M, 1995, J NEUROCHEM, V64, P1973; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639; Shi FS, 2013, J NEUROIMMUNOL, V260, P121, DOI 10.1016/j.jneuroim.2013.04.016; Shimizu E, 2008, J IMMUNOL, V181, P6503, DOI 10.4049/jimmunol.181.9.6503; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sieger D, 2012, DEV CELL, V22, P1138, DOI 10.1016/j.devcel.2012.04.012; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Sipe GO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10905; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stankovic ND, 2016, ACTA NEUROPATHOL, V131, P347, DOI 10.1007/s00401-015-1524-y; Stavridis S, 2005, HISTOCHEM CELL BIOL, V123, P377, DOI 10.1007/s00418-004-0743-4; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Stohwasser R, 2000, GLIA, V29, P355, DOI 10.1002/(SICI)1098-1136(20000215)29:4<355::AID-GLIA6>3.3.CO;2-W; Suuronen T, 2006, NEUROCHEM INT, V49, P610, DOI 10.1016/j.neuint.2006.05.001; Suzuki T, 2006, J NEUROSCI RES, V83, P1461, DOI 10.1002/jnr.20850; Swiatkowski P, 2016, NEUROSCIENCE, V318, P22, DOI 10.1016/j.neuroscience.2016.01.008; Syed MM, 2007, J NEUROCHEM, V103, P1461, DOI 10.1111/j.1471-4159.2007.04838.x; Tanaka J, 1997, GLIA, V20, P23, DOI 10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.0.CO;2-6; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor DL, 2002, J NEUROCHEM, V82, P1179, DOI 10.1046/j.1471-4159.2002.01062.x; Taylor DL, 2005, J NEUROSCI, V25, P2952, DOI 10.1523/JNEUROSCI.4456-04.2005; Taylor DL, 2003, J NEUROSCI, V23, P2150; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Town T, 2006, J IMMUNOL, V176, P3804, DOI 10.4049/jimmunol.176.6.3804; Tozaki-Saitoh H, 2017, J NEUROCHEM, V141, P100, DOI 10.1111/jnc.13968; Trahanas DM, 2015, SHOCK, V43, P255, DOI 10.1097/SHK.0000000000000291; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Rossum D, 2008, GLIA, V56, P271, DOI 10.1002/glia.20611; Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003; Venneti S, 2007, EXP NEUROL, V207, P118, DOI 10.1016/j.expneurol.2007.06.003; Visentin S, 2006, Purinergic Signal, V2, P605, DOI 10.1007/s11302-006-9023-1; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; Wang JW, 2012, BRAIN RES, V1464, P73, DOI 10.1016/j.brainres.2012.05.014; Wang WY, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.49; Wang X, 1999, BRAIN RES, V842, P159, DOI 10.1016/S0006-8993(99)01849-1; Wang XJ, 2007, J NEUROIMMUNE PHARM, V2, P259, DOI 10.1007/s11481-007-9075-1; Warden A, 2016, SCI REP, V6, P15; Weber DJ, 2015, ANTIOXID REDOX SIGN, V23, P1316, DOI 10.1089/ars.2015.6299; Weber DJ, 2014, SCI TRANSL MED, V6, P252; Wen L, 2018, J NEUROTRAUM, V35, P2330, DOI 10.1089/neu.2017.5540; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilkinson B, 2006, J BIOL CHEM, V281, P20842, DOI 10.1074/jbc.M600627200; Wilkinson Kim, 2012, Int J Alzheimers Dis, V2012, P489456, DOI 10.1155/2012/489456; Woo MS, 2016, J BIOL CHEM, V291, P23654, DOI 10.1074/jbc.M116.750018; Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034; Xiang ZH, 2005, GLIA, V52, P119, DOI 10.1002/glia.20227; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V277, P268, DOI 10.1016/j.expneurol.2016.01.010; Xu PF, 2015, BRAIN BEHAV IMMUN, V50, P87, DOI 10.1016/j.bbi.2015.06.020; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yang SX, 2006, J CEREBR BLOOD F MET, V26, P1490, DOI 10.1038/sj.jcbfm.9600305; Yao XL, 2017, J NEUROIMMUNOL, V310, P38, DOI 10.1016/j.jneuroim.2017.06.006; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zhang Z, 2006, CELL MOL LIFE SCI, V63, P2901, DOI 10.1007/s00018-006-6189-1; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhang ZY, 2007, ACTA NEUROPATHOL, V113, P675, DOI 10.1007/s00401-007-0195-8; Zhao X, 2018, DEV NEUROBIOY; Zhuang ZY, 2007, BRAIN BEHAV IMMUN, V21, P642, DOI 10.1016/j.bbi.2006.11.003; Ziebell JM, 2012, J NEUROINFLAMM, V9, P11; Zuiderwijk-Sick EA, 2007, GLIA, V55, P1589, DOI 10.1002/glia.20572	367	18	19	0	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUL	2019	56	7					5202	5228		10.1007/s12035-018-1428-7			27	Neurosciences	Neurosciences & Neurology	IT8VJ	WOS:000483159700046	30554385				2021-06-18	
J	Wettervik, TS; Howells, T; Enblad, P; Lewen, A				Wettervik, Teodor Svedung; Howells, Timothy; Enblad, Per; Lewen, Anders			Temporal Neurophysiological Dynamics in Traumatic Brain Injury: Role of Pressure Reactivity and Optimal Cerebral Perfusion Pressure for Predicting Outcome	JOURNAL OF NEUROTRAUMA			English	Article						cerebral autoregulation; CPPopt; neurointensive care; traumatic brain injury	NEUROINTENSIVE CARE MANAGEMENT; DECOMPRESSIVE CRANIECTOMY; CEREBROVASCULAR REACTIVITY; INTRACRANIAL-PRESSURE; AUTOREGULATION; THRESHOLDS; GUIDELINES	Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and the pressure reactivity index (PRx) have been shown to correlate with outcome after traumatic brain injury (TBI), but their temporal evolution is less studied. Optimal CPP (CPPopt; i.e., the CPP with the lowest [optimal] PRx value) has been proposed as a dynamic, individualized CPP target. Our aim was to map the temporal course of these parameters and their relation to outcome, in particular the extent and impact of CPP insults based both on fixed CPP thresholds and on divergence from CPPopt. Data from 362 TBI patients with ICP-monitoring treated at the neurointensive care unit of Uppsala University Hospital, Uppsala, Sweden, between 2008-2016 were retrospectively analyzed for the temporal course of ICP, mean arterial blood pressure, CPP, PRx, PRx55-15 (a variant of PRx), and CPPopt the first 10 days post-injury. PRx and PRx55-15 showed significantly lower/better values for those with favorable outcome, most pronounced on Days 2 to 5. PRx55-15 gave better separation between the two groups. In the univariate analysis, CPP insults (both fixed and CPPopt-thresholds) were significantly correlated with outcome on these days. Multi-variate logistic regression showed that age, Glasgow Coma Score Motor, pupillary abnormality at admission, CPP > CPPopt, and PRx55-15 were significant independent outcome predictors. PRx was significant when PRx55-15 was excluded. High PRx55-15 and high grade of monitoring time with CPP > CPPopt, but not the traditional fixed CPP thresholds, were strong predictors for worse clinical outcome. The study supports the concept that CPPopt is an important parameter in TBI management.	[Wettervik, Teodor Svedung; Howells, Timothy; Enblad, Per; Lewen, Anders] Uppsala Univ, Uppsala Univ Hosp, Dept Neurosci, Sect Neurosurg, Uppsala, Sweden	Wettervik, TS (corresponding author), Uppsala Univ, Sect Neurosurg, Dept Neurosci, SE-75185 Uppsala, Sweden.	teodor.svedung-wettervik@neuro.uu.se	Wettervik, Teodor Mikael Svedung/S-5356-2017				Adams H, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002353; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Donnelly J, 2017, CRIT CARE MED, V45, P1464, DOI 10.1097/CCM.0000000000002575; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Fischerstrom A, 2014, ACTA NEUROCHIR, V156, P177, DOI 10.1007/s00701-013-1932-5; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Howells T, 2018, CRIT CARE MED, V46, pe235, DOI 10.1097/CCM.0000000000002930; Howells T, 2017, J CLIN MONIT COMPUT, V31, P469, DOI 10.1007/s10877-016-9863-3; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Nyholm L, 2013, UPSALA J MED SCI, V118, P169, DOI 10.3109/03009734.2013.806616; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Wettervik TS, 2018, ACTA NEUROCHIR, V160, P229, DOI 10.1007/s00701-017-3418-3; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	34	18	18	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2019	36	11					1818	1827		10.1089/neu.2018.6157			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	IB1EQ	WOS:000470007600012	30595128				2021-06-18	
J	Hossain, I; Mohammadian, M; Takala, RSK; Tenovuo, O; Lagerstedt, L; Ala-Seppala, H; Frantzen, J; van Gils, M; Hutchinson, P; Katila, AJ; Maanpaa, HR; Menon, DK; Newcombe, VF; Tallus, J; Hrusovsky, K; Wilson, DH; Blennow, K; Sanchez, JC; Zetterberg, H; Posti, JP				Hossain, Iftakher; Mohammadian, Mehrbod; Takala, Riikka S. K.; Tenovuo, Olli; Lagerstedt, Linnea; Ala-Seppala, Henna; Frantzen, Janek; van Gils, Mark; Hutchinson, Peter; Katila, Ari J.; Maanpaa, Henna-Riikka; Menon, David K.; Newcombe, Virginia F.; Tallus, Jussi; Hrusovsky, Kevin; Wilson, David H.; Blennow, Kaj; Sanchez, Jean-Charles; Zetterberg, Henrik; Posti, Jussi P.			Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						GFAP; NF-L; outcome; traumatic brain injury	C-TERMINAL HYDROLASE-L1; HEAD-INJURY; CEREBROSPINAL-FLUID; SERUM; S100B; BIOMARKERS; BLOOD; DAMAGE; DIAGNOSIS; SEVERITY	The purpose of this study was to correlate the early levels of glial fibrillary acidic protein (GFAP) and neurofilament light protein (NF-L) with outcome in patients with mild traumatic brain injury (mTBI). A total of 107 patients with mTBI (Glasgow Coma Scale >= 13) who had blood samples for GFAP and NF-L available within 24 h of arrival were included. Patients with mTBI were divided into computed tomography (CT)-positive and CT-negative groups. Glasgow Outcome Scale-Extended (GOSE) was used to assess the outcome. Outcomes were defined as complete (GOSE 8) versus incomplete (GOSE <8), and favorable (GOSE 5-8) versus unfavorable (GOSE 1-4). GFAP and NF-L concentrations in blood were measured using ultrasensitive single molecule array technology. Patients with incomplete recovery had significantly higher levels of NF-L compared with those with complete recovery (p = 0.005). The levels of GFAP and NF-L were significantly higher in patients with unfavorable outcome than in patients with favorable outcome (p = 0.002 for GFAP and p < 0.001 for NF-L). For predicting favorable outcome, the area under the receiver operating characteristic curve for GFAP and NF-L was 0.755 and 0.826, respectively. In a multi-variate logistic regression model, the level of NF-L was still a significant predictor for complete recovery (odds ratio [OR] = 1.008; 95% confidence interval [CI], 1.000-1.016). Moreover, the level of NF-L was a significant predictor for complete recovery in CT-positive patients (OR = 1.009; 95% CI, 1.001-1.016). The early levels of GFAP and NF-L are significantly correlated with the outcome in patients with mTBI. The level of NF-L within 24 h from arrival has a significant predictive value in mTBI also in a multi-variate model.	[Hossain, Iftakher; Frantzen, Janek; Maanpaa, Henna-Riikka; Posti, Jussi P.] Turku Univ Hosp, Dept Neurosurg, Turku, Finland; [Hossain, Iftakher; Mohammadian, Mehrbod; Takala, Riikka S. K.; Tenovuo, Olli; Ala-Seppala, Henna; Katila, Ari J.; Maanpaa, Henna-Riikka; Tallus, Jussi; Posti, Jussi P.] Turku Univ Hosp, Turku Brain Injury Ctr, Turku, Finland; [Tallus, Jussi] Turku Univ Hosp, Dept Radiol, Turku, Finland; [Hossain, Iftakher; Mohammadian, Mehrbod; Tenovuo, Olli; Ala-Seppala, Henna; Frantzen, Janek; Maanpaa, Henna-Riikka; Tallus, Jussi; Posti, Jussi P.] Univ Turku, Dept Neurol, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Turku Univ Hosp, Perioperat Serv Intens Care Med & Pain Management, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Univ Turku, Turku, Finland; [Lagerstedt, Linnea; Sanchez, Jean-Charles] Univ Geneva, Fac Med, Dept Human Prot Sci, Geneva, Switzerland; [van Gils, Mark] VTT Tech Res Ctr Finland Ltd, Tampere, Finland; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge, England; [Menon, David K.; Newcombe, Virginia F.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England; [Hrusovsky, Kevin; Wilson, David H.] Quanterix Corp, Lexington, MA USA; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, Queen Sq, London, England	Hossain, I (corresponding author), Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, FI-20521 Turku, Finland.	ifthos@utu.fi	Mohammadian, Mehrbod/AAH-1018-2019; Posti, Jussi P./Y-2908-2019	Mohammadian, Mehrbod/0000-0002-6851-7511; Posti, Jussi P./0000-0002-5925-5193; van Gils, Mark/0000-0002-0029-1771; Newcombe, Virginia/0000-0001-6044-9035; Ala-Seppala, Henna/0000-0002-1577-3028			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bogoslovsky T, 2016, DIAGNOSTICS, V6, DOI 10.3390/diagnostics6040037; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Halford J, 2017, J CEREBR BLOOD F MET, V37, P3278, DOI 10.1177/0271678X17724681; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Mercier E, 2018, J NEUROTRAUM, V35, P609, DOI 10.1089/neu.2017.5013; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Missler U, 1999, CLIN CHEM, V45, P138; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mondello S, 2021, J NEUROTRAUM, V38, P1086, DOI 10.1089/neu.2017.5182; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Robin X., 2013, TL PROTEOMICS, V1, P57, DOI [10.1016/j.trprot.2013.04.003, DOI 10.1016/J.TRPROT.2013.04.003]; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Skillback T, 2014, NEUROLOGY, V83, P1945, DOI 10.1212/WNL.0000000000001015; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00300; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zetterberg H, 2016, JAMA NEUROL, V73, P60, DOI 10.1001/jamaneurol.2015.3037; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	47	18	19	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2019	36	10					1551	1560		10.1089/neu.2018.5952			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HX7CZ	WOS:000467562900007	30489229				2021-06-18	
J	Morales-Gomez, JA; Garcia-Estrada, E; Leos-Bortoni, JE; Delgado-Brito, M; Flores-Huerta, LE; De la Cruz-Arriaga, AA; Torres-Diaz, LJ; de Leon, ARMP				Morales-Gomez, Jesus A.; Garcia-Estrada, Everardo; Leos-Bortoni, Jorge E.; Delgado-Brito, Miriam; Flores-Huerta, Luis E.; De la Cruz-Arriaga, Adriana A.; Torres-Diaz, Luis J.; Martinez-Ponce de Leon, Angel R.			Cranioplasty with a low-cost customized polymethylmethacrylate implant using a desktop 3D printer	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; custom polymethylmethacrylate mold; 3D printing; surgical technique	PATIENT-SPECIFIC IMPLANTS; POLYETHER ETHER KETONE; LARGE CRANIAL DEFECTS; BONE FLAP; METHACRYLATE CRANIOPLASTY; ACRYLIC CRANIOPLASTY; PMMA CRANIOPLASTY; RECONSTRUCTION	OBJECTIVE Cranioplasty implants should be widely available, low in cost, and customized or easy to mold during surgery. Although autologous bone remains the first choice for repair, it cannot always be used due to infection, fragmentation, bone resorption, or other causes, which led to use of synthetic alternatives. The most frequently used allogenic material for cranial reconstructions with long-term results is polymethylmethacrylate (PMMA). Three-dimensional printing technology has allowed the production of increasingly popular customized, prefabricated implants. The authors describe their method and experience with a customized PMMA prosthesis using a precise and reliable low-cost implant that can be customized at any institution with open-source or low-cost software and desktop 3D printers. METHODS A review of 22 consecutive patients undergoing CT-based, low-cost, customized PMMA cranioplasty over a 1-year period at a university teaching hospital was performed. Preoperative data included patient sex and age; CT modeling parameters, including the surface area of the implant (defect); reason for craniectomy; date(s) of injury and/or resections; the complexity of the defect; and associated comorbidities. Postoperative data included morbiditiy and complications, such as implant exposure, infection, hematoma, seroma, implant failure, and seizures; the cost of the implant; and cosmetic outcome. RESULTS Indications for the primary craniectomy were traumatic brain injury (16, 73%), tumor resection (3, 14%), infection (1, 4%), and vascular (2, 9%). The median interval between previous surgery and PMMA cranioplasty was 12 months. The operation time ranged from 90 to 150 minutes (mean 126 minutes). The average cranial defect measured 65.16 cm(2) (range 29.31-131.06 cm(2)). During the recovery period, there was no sign of infection, implant rejection, or wound dehiscence, and none of the implants had to be removed over a follow-up ranging from 1 to 6 months. The aesthetic appearance of all patients was significantly improved, and the implant fit was excellent. CONCLUSIONS The use of a customized PMMA was associated with excellent patient, family, and surgeon satisfaction at follow-up at a fraction of the cost associated with commercially available implants. This technique could be an attractive option to all patients undergoing cranioplasty.	[Morales-Gomez, Jesus A.; Garcia-Estrada, Everardo; Leos-Bortoni, Jorge E.; Delgado-Brito, Miriam; Flores-Huerta, Luis E.; De la Cruz-Arriaga, Adriana A.; Torres-Diaz, Luis J.; Martinez-Ponce de Leon, Angel R.] Hosp Univ Dr Jose Eleuterio Gonzalez, Dept Neurosurg, Monterrey, Nuevo Leon, Mexico	Morales-Gomez, JA (corresponding author), Hosp Univ Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo Leon, Mexico.	jesus.moralesg@uanl.mx	Garcia-Estrada, Everardo/AAA-7401-2019	Garcia-Estrada, Everardo/0000-0002-8773-1230			Akan M, 2011, J CRANIOFAC SURG, V22, P1236, DOI 10.1097/SCS.0b013e31821c0f34; Anchieta MVM, 2016, INT J COMPUT ASS RAD, V11, P1919, DOI 10.1007/s11548-016-1415-2; Bauermeister AJ, 2016, ANN PLAS SURG, V77, P569, DOI 10.1097/SAP.0000000000000671; Bhargava D, 2010, ACTA NEUROCHIR, V152, P173, DOI 10.1007/s00701-009-0394-2; BONFIELD CM, 2014, NEUROSURG FOCUS, V36; Brandicourt P, 2017, WORLD NEUROSURG, V105, P783, DOI 10.1016/j.wneu.2017.04.049; Caro-Osorio Enrique, 2013, Surg Neurol Int, V4, P136, DOI 10.4103/2152-7806.119535; Chae MP, 2015, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00025; Eppley BL, 2005, J CRANIOFAC SURG, V16, P140, DOI 10.1097/00001665-200501000-00028; Feroze AH, 2015, J NEUROSURG, V123, P1098, DOI 10.3171/2014.11.JNS14622; Fiaschi P, 2016, J NEUROSURG-PEDIATR, V17, P705, DOI 10.3171/2015.10.PEDS15489; Fischer CM, 2012, NEUROL RES, V34, P281, DOI 10.1179/1743132812Y.0000000007; Gurdjian ES, 1943, SURGERY, V14, P876; Hanasono MM, 2009, ANN PLAS SURG, V62, P653, DOI 10.1097/SAP.0b013e318184abc7; Harris DA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13560; Huang GJ, 2015, J CRANIOFAC SURG, V26, P68, DOI 10.1097/SCS.0000000000001315; Jaberi J, 2013, J ORAL MAXIL SURG, V71, pE81, DOI 10.1016/j.joms.2012.09.023; Kung WM, 2012, BRAIN INJURY, V26, P1737, DOI 10.3109/02699052.2012.698361; Lethaus B, 2014, J CRANIO MAXILL SURG, V42, P1948, DOI 10.1016/j.jcms.2014.08.006; Manrique OJ, 2015, J CRANIOFAC SURG, V26, P663, DOI 10.1097/SCS.0000000000001443; Marbacher S, 2013, WORLD NEUROSURG, V79, P124, DOI 10.1016/j.wneu.2011.05.057; Marbacher S, 2012, NEUROSURG REV, V35, P527, DOI 10.1007/s10143-012-0376-3; Naftulin JS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136198; O'Reilly EB, 2015, J PLAST RECONSTR AES, V68, P329, DOI 10.1016/j.bjps.2014.11.001; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenthal G, 2014, NEUROSURGERY, V75, P523, DOI 10.1227/NEU.0000000000000477; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Sharavanan GM, 2015, J MAXILLOFAC ORAL SU, V14, P378, DOI 10.1007/s12663-014-0670-4; Tan ETW, 2016, J NEUROSURG, V124, P1531, DOI 10.3171/2015.5.JNS15119; Unterhofer C, 2017, NEUROL NEUROCHIR POL, V51, P214, DOI 10.1016/j.pjnns.2017.02.007; Werndle MC, 2012, CLIN NEUROL NEUROSUR, V114, P962, DOI 10.1016/j.clineuro.2012.02.019; 2017, WORLD NEUROSURG, V105, P971; 2013, J NEUROSCI RURAL PRA, V4, P471	33	18	18	1	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2019	130	5					1721	1727		10.3171/2017.12.JNS172574			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HW0VW	WOS:000466401100037	29905512	Bronze			2021-06-18	
J	Belardo, C; Iannotta, M; Boccella, S; Rubino, RC; Ricciardi, F; Infantino, R; Pieretti, G; Stella, L; Paino, S; Marabese, I; Maisto, R; Luongo, L; Maione, S; Guida, F				Belardo, Carmela; Iannotta, Monica; Boccella, Serena; Rubino, Rosamaria Cristina; Ricciardi, Flavia; Infantino, Rosmara; Pieretti, Gorizio; Stella, Luigi; Paino, Salvatore; Marabese, Ida; Maisto, Rosa; Luongo, Livio; Maione, Sabatino; Guida, Francesca			Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury	FRONTIERS IN PHARMACOLOGY			English	Article						cannabidiol; traumatic brain injury; pain; behavior; microdialysis	IN-VITRO; PAIN; NEUROPROTECTION; INHIBITION; MICE	Neurological dysfunctions are the most impactful and persistent consequences of traumatic brain injury (TBI). Indeed, previous reports suggest that an association between TBI and chronic pain syndromes, as well anxio-depressive behaviors, tends to be more common in patients with mild forms of TBI. At present, no effective treatment options are available for these symptoms. In the present study, we used a weight drop mild TBI mouse model to investigate the effect of a commercially available 10% Cannabidiol (CBD) oil on both the sensorial and neuropsychiatric dysfunctions associated with mild TBI through behavioral and biomolecular approaches. TBI mice developed chronic pain associated with anxious and aggressive behavior, followed by a late depressive-like behavior and impaired social interaction. Such behaviors were related with specific changes in neurotransmitters release at cortical levels. CBD oral treatment restored the behavioral alterations and partially normalized the cortical biochemical changes. In conclusion, our data show some of the brain modifications probably responsible for the behavioral phenotype associated with TBI and suggest the CBD as a pharmacological tool to improve neurological dysfunctions caused by the trauma.	[Belardo, Carmela; Iannotta, Monica; Boccella, Serena; Ricciardi, Flavia; Infantino, Rosmara; Paino, Salvatore; Marabese, Ida; Maisto, Rosa; Luongo, Livio; Maione, Sabatino; Guida, Francesca] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy; [Rubino, Rosamaria Cristina] Enecta S l, Bologna, Italy; [Pieretti, Gorizio] Univ Campania Luigi Vanvitelli, Dept Plast Surg, Naples, Italy; [Stella, Luigi] Drug Addict Unit SerT, Naples, Italy	Maione, S; Guida, F (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.	sabatino.maione@unicampania.it; franc.guida@gmail.com	pieretti, gorizio/AAJ-8216-2020	pieretti, gorizio/0000-0002-0326-8438; Maione, Sabatino/0000-0003-3850-6704; Infantino, Rosmara/0000-0003-1266-6881	Department of Experimental Medicine of Universisty of Campania	We thank Enecta Group for providing Cannabidiol. We also thank the Department of Experimental Medicine of Universisty of Campania for publication fees.	Apps R, 2015, NAT REV NEUROSCI, V16, P642, DOI 10.1038/nrn4028; Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; Aspide R, 1998, BEHAV BRAIN RES, V95, P123, DOI 10.1016/S0166-4328(97)00217-9; Boccella S, 2019, NEUROBIOL DIS, V121, P106, DOI 10.1016/j.nbd.2018.09.023; Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103; Castillo A, 2010, NEUROBIOL DIS, V37, P434, DOI 10.1016/j.nbd.2009.10.023; D'Aniello A, 2017, NEUROSCI LETT, V651, P151, DOI 10.1016/j.neulet.2017.04.041; De Gregorio D, 2019, PAIN, V160, P136, DOI 10.1097/j.pain.0000000000001386; Feliciano DP, 2014, NEUROSCI LETT, V583, P55, DOI 10.1016/j.neulet.2014.09.030; Fernandez-Ruiz J, 2013, BRIT J CLIN PHARMACO, V75, P323, DOI 10.1111/j.1365-2125.2012.04341.x; Giordano C, 2012, CEREB CORTEX, V22, P2495, DOI 10.1093/cercor/bhr328; Guida F, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0139-5; Guida F, 2017, RECEPT SER, P15, DOI 10.1007/978-3-319-56170-7_2; Guida F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00095; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hayakawa K, 2007, J NEUROCHEM, V102, P1488, DOI 10.1111/j.1471-4159.2007.04565.x; Hayakawa K, 2010, PHARMACEUTICALS, V3, P2197, DOI 10.3390/ph3072197; Lastres-Becker I, 2005, NEUROBIOL DIS, V19, P96, DOI 10.1016/j.nbd.2004.11.009; Lever C, 2006, REV NEUROSCIENCE, V17, P111; Liu JJ, 2019, NEUROIMMUNOMODULAT, V26, P102, DOI 10.1159/000495467; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Luongo L, 2013, NEUROPHARMACOLOGY, V66, P317, DOI 10.1016/j.neuropharm.2012.05.047; Mayeux J, 2017, J NEUROTRAUM, V34, P436, DOI 10.1089/neu.2016.4452; Palazzo E, 2015, PAIN, V156, P1060, DOI 10.1097/j.pain.0000000000000150; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Schonhofen P, 2018, CNS DRUGS, V32, P697, DOI 10.1007/s40263-018-0550-4; Schurman LD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00069; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Vialou V, 2014, J NEUROSCI, V34, P3878, DOI 10.1523/JNEUROSCI.1787-13.2014; Vigano D, 2009, INT J NEUROPSYCHOPH, V12, P599, DOI 10.1017/S1461145708009371; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	32	18	18	1	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	APR 16	2019	10								352	10.3389/fphar.2019.00352			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	HT5IQ	WOS:000464597500001	31040777	DOAJ Gold, Green Published			2021-06-18	
